PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gilbert, MM; Beam, CK; Robinson, BS; Moberg, KH				Gilbert, M. Melissa; Beam, Carolyn K.; Robinson, Brian S.; Moberg, Kenneth H.			Genetic Interactions between the Drosophila Tumor Suppressor Gene ept and the stat92E Transcription Factor	PLOS ONE			English	Article								Background: Tumor Susceptibility Gene-101 (TSG101) promotes the endocytic degradation of transmembrane proteins and is implicated as a mutational target in cancer, yet the effect of TSG101 loss on cell proliferation in vertebrates is uncertain. By contrast, Drosophila epithelial tissues lacking the TSG101 ortholog erupted (ept) develop as enlarged undifferentiated tumors, indicating that the gene can have anti-growth properties in a simple metazoan. A full understanding of pathways deregulated by loss of Drosophila ept will aid in understanding potential links between mammalian TSG101 and growth control. Principal Findings: We have taken a genetic approach to the identification of pathways required for excess growth of Drosophila eye-antennal imaginal discs lacking ept. We find that this phenotype is very sensitive to the genetic dose of stat92E, the transcriptional effector of the Jak-Stat signaling pathway, and that this pathway undergoes strong activation in ept mutant cells. Genetic evidence indicates that stat92E contributes to cell cycle deregulation and excess cell size phenotypes that are observed among ept mutant cells. In addition, autonomous Stat92E hyper-activation is associated with altered tissue architecture in ept tumors and an effect on expression of the apical polarity determinant crumbs. Conclusions: These findings identify ept as a cell-autonomous inhibitor of the Jak-Stat pathway and suggest that excess Jak-Stat signaling makes a significant contribution to proliferative and tissue architectural phenotypes that occur in ept mutant tissues.			Gilbert, MM (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.	kmoberg@cellbio.emory.edu	Moberg, Ken/J-4849-2017	Moberg, Ken/0000-0002-9820-5543; Gilbert-Ross, Melissa/0000-0002-1960-8302	NATIONAL CANCER INSTITUTE [R01CA123368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169, T32GM008490, F32GM077898] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA123368-01, R01 CA123368-03, R01 CA123368-04, R01 CA123368, R01 CA123368-05, R01 CA123368-02] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169, F32-GM077898, T32 GM008490, F32 GM077898] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach EA, 2003, GENETICS, V165, P1149; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chao JL, 2004, DEVELOPMENT, V131, P3839, DOI 10.1242/dev.01258; CHOU TB, 1993, DEVELOPMENT, V119, P1359; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Devergne O, 2007, J CELL SCI, V120, P3457, DOI 10.1242/jcs.005926; Ghiglione C, 2002, DEVELOPMENT, V129, P5437, DOI 10.1242/dev.00116; Gilbert MM, 2005, MECH DEVELOP, V122, P939, DOI 10.1016/j.mod.2005.03.004; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KIM BY, 2007, BIOCH BIOPHYS RES CO; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Lee MP, 1997, CANCER RES, V57, P3131; Li JH, 2003, MECH DEVELOP, V120, P1455, DOI 10.1016/j.mod.2003.09.004; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Lovegrove B, 2006, CURR BIOL, V16, P2206, DOI 10.1016/j.cub.2006.09.029; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Luo H, 2002, MOL GENET GENOMICS, V267, P57, DOI 10.1007/s00438-001-0632-7; Malerod L, 2007, TRAFFIC, V8, P1617, DOI 10.1111/j.1600-0854.2007.00630.x; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Mortimer NT, 2007, DEV BIOL, V312, P560, DOI 10.1016/j.ydbio.2007.10.002; Muller P, 2005, NATURE, V436, P871, DOI 10.1038/nature03869; Oh KB, 2007, ONCOGENE, V26, P5950, DOI 10.1038/sj.onc.1210401; Pignoni F, 1997, DEVELOPMENT, V124, P271; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; RAIBORG C, 2007, EXP CELL RES; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Stuffers S., 2008, EXP CELL RES; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Tsai YC, 2004, GENESIS, V39, P141, DOI 10.1002/gene.20035; Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Wang Q, 1998, ONCOGENE, V16, P677, DOI 10.1038/sj.onc.1201563; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Young TW, 2007, MOL CELL PROTEOMICS, V6, P294, DOI 10.1074/mcp.M600305-MCP200; Young TW, 2007, CLIN CANCER RES, V13, P3848, DOI 10.1158/1078-0432.CCR-07-0337; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482	58	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7083	10.1371/journal.pone.0007083	http://dx.doi.org/10.1371/journal.pone.0007083			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787055	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290100002
J	Horowitz-Kraus, T; Breznitz, Z				Horowitz-Kraus, Tzipi; Breznitz, Zvia			Can the Error Detection Mechanism Benefit from Training the Working Memory? A Comparison between Dyslexics and Controls - An ERP Study	PLOS ONE			English	Article							SHORT-TERM-MEMORY; NEURAL PLASTICITY; WORD RECOGNITION; BRAIN PLASTICITY; ADULT DYSLEXICS; CRITICAL PERIOD; SYSTEM; COMPREHENSION; ACQUISITION; PERFORMANCE	Background: Based on the relationship between working memory and error detection, we investigated the capacity of adult dyslexic readers' working memory to change as a result of training, and the impact of training on the error detection mechanism. Methodology: 27 dyslexics and 34 controls, all university students, participated in the study. ERP methodology and behavioral measures were employed prior to, immediately after, and 6 months after training. The CogniFit Personal Coach Program, which consists of 24 sessions of direct training of working memory skills, was used. Findings: Both groups of readers gained from the training program but the dyslexic readers gained significantly more. In the dyslexic group, digit span increased from 9.84 +/- 63.15 to 10.79 +/- 3.03. Working memory training significantly increased the number of words per minute read correctly by 14.73%. Adult brain activity changed as a result of training, evidenced by an increase in both working memory capacity and the amplitude of the Error-related Negativity (ERN) component (24.71%). When ERN amplitudes increased, the percentage of errors on the Sternberg tests decreased. Conclusions: We suggest that by expanding the working memory capacity, larger units of information are retained in the system, enabling more effective error detection. The crucial functioning of the central-executive as a sub-component of the working memory is also discussed.			Horowitz-Kraus, T (corresponding author), Univ Haifa, Edmond J Safra Brain Res Ctr Study Learning Disab, Fac Educ, IL-31999 Haifa, Israel.	Thorvitz@construct.haifa.ac.il						ACKERMAN PT, 1993, J LEARN DISABIL, V26, P597, DOI 10.1177/002221949302600910; [Anonymous], 2002, READING WRITING INTE, DOI DOI 10.1023/A:1013872422108; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A.D., 1974, MOTIV ADV RES THEORY, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; BERNSTEIN PS, 1995, J EXP PSYCHOL HUMAN, V21, P1312, DOI 10.1037/0096-1523.21.6.1312; Bitan T, 2005, COGNITIVE BRAIN RES, V25, P90, DOI 10.1016/j.cogbrainres.2005.04.014; Breznitz Z, 2003, BRAIN LANG, V85, P486, DOI 10.1016/S0093-934X(03)00071-3; BREZNITZ Z, 2006, FLUENCY READING SYCH; Brickenkamp R., 1981, TEST D2 AUFMERK SANK; British Psychological Society, 1999, DYSL LIT PSYCH ASS; Callan DE, 2003, NEUROIMAGE, V19, P113, DOI 10.1016/S1053-8119(03)00020-X; CARRIER LM, 1995, J EXP PSYCHOL LEARN, V21, P1339, DOI 10.1037/0278-7393.21.5.1339; Chard DJ, 2002, J LEARN DISABIL-US, V35, P386, DOI 10.1177/00222194020350050101; *COGNIFIT LTD, 2008, COGNIFIT PERS COACH; COHEN RL, 1984, J LEARN DISABIL, V17, P218, DOI 10.1177/002221948401700406; Cowan N, 1999, MODELS WORKING MEMOR, P62, DOI [10.1017/CBO9781139174909.006, DOI 10.1017/CBO9781139174909.006]; *CTR PSYCH TESTS, 1994, OR SIL COMPR T UNPUB; de Jong PF, 1998, J EXP CHILD PSYCHOL, V70, P75, DOI 10.1006/jecp.1998.2451; Dorfberger S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000240; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; FERMAN S, 2009, J NEUROLING IN PRESS; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Harrison RV, 2005, DEV PSYCHOBIOL, V46, P252, DOI 10.1002/dev.20052; Helland T, 2004, J CLIN EXP NEUROPSYC, V26, P31, DOI 10.1076/jcen.26.1.31.23935; Helmstaedter C, 2002, ANN NEUROL, V52, P89, DOI 10.1002/ana.10260; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Hochman EY, 2005, MEM COGNITION, V33, P635, DOI 10.3758/BF03195330; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Horowitz-Kraus T, 2008, CLIN NEUROPHYSIOL, V119, P2238, DOI 10.1016/j.clinph.2008.06.009; Jolicoeur P, 1998, COGNITIVE PSYCHOL, V36, P138, DOI 10.1006/cogp.1998.0684; JORM AF, 1983, BRIT J PSYCHOL, V74, P311, DOI 10.1111/j.2044-8295.1983.tb01865.x; KARNI A, 1995, LANCET, V345, P395, DOI 10.1016/S0140-6736(95)90386-0; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Karni A, 1996, COGNITIVE BRAIN RES, V5, P39, DOI 10.1016/S0926-6410(96)00039-0; Karni A, 1997, CURR OPIN NEUROBIOL, V7, P530, DOI 10.1016/S0959-4388(97)80033-5; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Korman M, 2003, P NATL ACAD SCI USA, V100, P12492, DOI 10.1073/pnas.2035019100; Landerl K, 1997, COGNITION, V63, P315, DOI 10.1016/S0010-0277(97)00005-X; MATAL Battery, 2007, DIAGN BATT ASS LEARN; Meyer MS, 1999, ANN DYSLEXIA, V49, P283, DOI 10.1007/s11881-999-0027-8; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Miltner WHR, 1997, J COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Pailing PE, 2004, BRAIN COGNITION, V56, P215, DOI 10.1016/j.bandc.2004.06.005; Palmer S., 2000, J RES READ, V23, P28, DOI DOI 10.1111/1467-9817.00100; Papanicolaou AC, 2001, J CHILD NEUROL, V16, P241; PATTERSON JV, 1991, ELECTROEN CLIN NEURO, V78, P424, DOI 10.1016/0013-4694(91)90060-H; Poldrack RA, 2001, BRAIN, V124, P67, DOI 10.1093/brain/124.1.67; Raven J.C., 1960, GUIDE STANDARD PROGR; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Roodenrys S, 2001, READ WRIT, V14, P379, DOI 10.1023/A:1011123406884; Russeler J, 2003, NEUROSCI RES, V47, P233, DOI 10.1016/S0168-0102(03)00212-8; SHIRAN A, 2009, THESIS U HAIFA ISRAE; Smith-Spark JH, 2007, MEMORY, V15, P34, DOI 10.1080/09658210601043384; Smith-Spark JH, 2003, EUR J COGN PSYCHOL, V15, P567, DOI 10.1080/09541440340000024; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Swanson HL, 2000, INTELLIGENCE, V28, P1, DOI 10.1016/S0160-2896(99)00025-2; THOMSON ME, 1978, J RES READ, V1, P7; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091; Wechsler D., 1997, WECHSLER ADULT INTEL; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI 10.1037/0033-295x.111.4.931	65	65	67	2	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7141	10.1371/journal.pone.0007141	http://dx.doi.org/10.1371/journal.pone.0007141			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	498WL	19779625	gold, Green Published, Green Submitted			2022-12-27	WOS:000270176200003
J	Lee, HG; Chen, Q; Wolfram, JA; Richardson, SL; Liner, A; Siedlak, SL; Zhu, XW; Ziats, NP; Fujioka, H; Felsher, DW; Castellani, RJ; Valencik, ML; McDonald, JA; Hoit, BD; Lesnefsky, EJ; Smith, MA				Lee, Hyoung-gon; Chen, Qun; Wolfram, Julie A.; Richardson, Sandy L.; Liner, Anna; Siedlak, Sandra L.; Zhu, Xiongwei; Ziats, Nicholas P.; Fujioka, Hisashi; Felsher, Dean W.; Castellani, Rudy J.; Valencik, Maria L.; McDonald, John A.; Hoit, Brian D.; Lesnefsky, Edward J.; Smith, Mark A.			Cell Cycle Re-Entry and Mitochondrial Defects in Myc-Mediated Hypertrophic Cardiomyopathy and Heart Failure	PLOS ONE			English	Article								While considerable evidence supports the causal relationship between increases in c-Myc (Myc) and cardiomyopathy as a part of a "fetal re-expression'' pattern, the functional role of Myc in mechanisms of cardiomyopathy remains unclear. To address this, we developed a bitransgenic mouse that inducibly expresses Myc under the control of the cardiomyocyte-specific MHC promoter. In adult mice the induction of Myc expression in cardiomyocytes in the heart led to the development of severe hypertrophic cardiomyopathy followed by ventricular dysfunction and ultimately death from congestive heart failure. Mechanistically, following Myc activation, cell cycle markers and other indices of DNA replication were significantly increased suggesting that cell cycle-related events might be a primary mechanism of cardiac dysfunction. Furthermore, pathological alterations at the cellular level included alterations in mitochondrial function with dysregulation of mitochondrial biogenesis and defects in electron transport chain complexes I and III. These data are consistent with the known role of Myc in several different pathways including cell cycle activation, mitochondrial proliferation, and apoptosis, and indicate that Myc activation in cardiomyocytes is an important regulator of downstream pathological sequelae. Moreover, our findings indicate that the induction of Myc in cardiomyocytes is sufficient to cause cardiomyopathy and heart failure, and that sustained induction of Myc, leading to cell cycle re-entry in adult cardiomyocytes, represents a maladaptive response for the mature heart.			Lee, HG (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.	hyoung-gon.lee@case.edu; mark.smith@case.edu	Chen, Qun/HGD-0868-2022; Zhu, Xiongwei/A-9629-2009; Smith, Mark A/A-9053-2009; Castellani, Rudy J/A-9555-2009; Lee, Hyoung-gon/A-9637-2009	Zhu, Xiongwei/0000-0003-2092-6508; 	NATIONAL INSTITUTE ON AGING [R01AG028679, P01AG015885, R21AG031364] Funding Source: NIH RePORTER; NIA NIH HHS [R21 AG031364, P01 AG015885, R01 AG028679, AG028679, AG031364, AG15885] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barrick CJ, 2007, AM J PHYSIOL-HEART C, V292, pH2119, DOI 10.1152/ajpheart.00816.2006; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; BUCHWALD A, 1990, EUR HEART J, V11, P509, DOI 10.1093/oxfordjournals.eurheartj.a059743; Cash AD, 2003, AM J PATHOL, V162, P1623, DOI 10.1016/S0002-9440(10)64296-4; Chen Q, 2008, AM J PHYSIOL-CELL PH, V294, pC460, DOI 10.1152/ajpcell.00211.2007; Dang CV, 1999, MOL CELL BIOL, V19, P1; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hayashi M, 2005, MOL VIS, V11, P201; HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kai H, 1998, CIRC RES, V83, P594, DOI 10.1161/01.RES.83.6.594; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P37, DOI 10.1006/jmcc.2000.1273; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G; Lucas DT, 2003, AM J PHYSIOL-HEART C, V284, pH575, DOI 10.1152/ajpheart.00619.2002; Marin-Garcia J, 1999, CARDIOVASC PATHOL, V8, P217, DOI 10.1016/S1054-8807(99)00010-1; MarinGarcia J, 1996, BIOCHEM MOL BIOL INT, V40, P487; Morgan EE, 2004, AM J PHYSIOL-HEART C, V287, pH2049, DOI 10.1152/ajpheart.00393.2004; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; POLLACK PS, 1994, J CELL BIOCHEM, V54, P78, DOI 10.1002/jcb.240540109; Quigley AF, 2000, J CARD FAIL, V6, P47, DOI 10.1016/S1071-9164(00)00011-7; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; REISS K, 1993, AM J PHYSIOL, V264, pH760, DOI 10.1152/ajpheart.1993.264.3.H760; ROBBINS RJ, 1992, AM J PHYSIOL, V262, pH590, DOI 10.1152/ajpheart.1992.262.2.H590; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Sihag S, 2009, J MOL CELL CARDIOL, V46, P201, DOI 10.1016/j.yjmcc.2008.10.025; Suzuki M, 2002, CIRCULATION, V105, P1824, DOI 10.1161/01.CIR.0000014926.32463.89; Valencik ML, 2001, TRANSGENIC RES, V10, P269, DOI 10.1023/A:1016601928465; Van Coster R, 2000, ACTA NEUROL BELG, V100, P156; Xiao GS, 2001, CIRC RES, V89, P1122, DOI 10.1161/hh2401.100742; Zhong WG, 2006, EMBO J, V25, P3869, DOI 10.1038/sj.emboj.7601252; Zhu XW, 2004, J NEUROCHEM, V89, P1233, DOI 10.1111/j.1471-4159.2004.02416.x	42	37	39	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7172	10.1371/journal.pone.0007172	http://dx.doi.org/10.1371/journal.pone.0007172			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779629	Green Published, gold, Green Submitted			2022-12-27	WOS:000270176200013
J	Al-Chalabi, A; Durr, A; Wood, NW; Parkinson, MH; Camuzat, A; Hulot, JS; Morrison, KE; Renton, A; Sussmuth, SD; Landwehrmeyer, BG; Ludolph, A; Agid, Y; Brice, A; Leigh, PN; Bensimon, G				Al-Chalabi, Ammar; Duerr, Alexandra; Wood, Nicholas W.; Parkinson, Michael H.; Camuzat, Agnes; Hulot, Jean-Sebastien; Morrison, Karen E.; Renton, Alan; Sussmuth, Sigurd D.; Landwehrmeyer, Bernhard G.; Ludolph, Albert; Agid, Yves; Brice, Alexis; Leigh, P. Nigel; Bensimon, Gilbert		NNIPPS Genetic Study Grp	Genetic Variants of the alpha-Synuclein Gene SNCA Are Associated with Multiple System Atrophy	PLOS ONE			English	Article								Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by parkinsonism, cerebellar ataxia and autonomic dysfunction. Pathogenic mechanisms remain obscure but the neuropathological hallmark is the presence of alpha-synuclein-immunoreactive glial cytoplasmic inclusions. Genetic variants of the alpha-synuclein gene, SNCA, are thus strong candidates for genetic association with MSA. One follow-up to a genome-wide association of Parkinson's disease has identified association of a SNP in SNCA with MSA. Methodology/Findings: We evaluated 32 SNPs in the SNCA gene in a European population of 239 cases and 617 controls recruited as part of the Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) study. We used 161 independently collected samples for replication. Two SNCA SNPs showed association with MSA: rs3822086 (P = 0.0044), and rs3775444 (P = 0.012), although only the first survived correction for multiple testing. In the MSA-C subgroup the association strengthened despite more than halving the number of cases: rs3822086 P = 0.0024, OR 2.153, (95% CI 1.3-3.6); rs3775444 P = 0.0017, OR 4.386 (95% CI 1.6-11.7). A 7-SNP haplotype incorporating three SNPs either side of rs3822086 strengthened the association with MSA-C further (best haplotype, P = 8.7 x 10(-4)). The association with rs3822086 was replicated in the independent samples (P = 0.035). Conclusions/Significance: We report a genetic association between MSA and alpha-synuclein which has replicated in independent samples. The strongest association is with the cerebellar subtype of MSA.			Al-Chalabi, A (corresponding author), Kings Coll London, Inst Psychiat, MRC, Dept Clin Neurosci,Ctr Neurodegenerat Res, London WC2R 2LS, England.	ammar@iop.kcl.ac.uk	Landwehrmeyer, Georg Bernhard/AHB-4443-2022; Al-Chalabi, Ammar/E-5361-2010; brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009; Leigh, Peter/AAD-5638-2019; Wood, Nicholas W/C-2505-2009; Hulot, Jean-Sébastien/A-2278-2016	Landwehrmeyer, Georg Bernhard/0000-0003-3375-790X; Al-Chalabi, Ammar/0000-0002-4924-7712; brice, alexis/0000-0002-0941-3990; Wood, Nicholas W/0000-0002-9500-3348; Hulot, Jean-Sébastien/0000-0001-5463-6117; Renton, Alan E./0000-0001-6702-8268; Morrison, Karen Elaine/0000-0003-0216-5717	Medical Research Council [G0400017] Funding Source: Medline; Parkinson&apos;s UK [J-0804] Funding Source: Medline; Parkinson&quot;s UK [J-0804] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Parkinson&apos;s UK(Parkinson&apos;s UK); Parkinson&quot;s UK(Parkinson&apos;s UK)		Bensimon G, 2009, BRAIN, V132, P156, DOI 10.1093/brain/awn291; Cairns NJ, 1997, NEUROSCI LETT, V221, P161, DOI 10.1016/S0304-3940(96)13316-4; Chiba-Falek O, 2003, HUM GENET, V113, P426, DOI 10.1007/s00439-003-1002-9; Cho S, 2003, AM J MED GENET A, V120A, P234, DOI 10.1002/ajmg.a.20194; Combarros O, 2003, MOVEMENT DISORD, V18, P1385, DOI 10.1002/mds.10540; COSTA C, 1992, REV NEUROL, V148, P274; Furiya Y, 2005, MOL BRAIN RES, V138, P178, DOI 10.1016/j.molbrainres.2005.04.011; Gilman S, 2008, NEUROLOGY, V71, P670, DOI 10.1212/01.wnl.0000324625.00404.15; Hara K, 2007, ARCH NEUROL-CHICAGO, V64, P545, DOI 10.1001/archneur.64.4.545; Infante J, 2005, J NEUROL SCI, V228, P11, DOI 10.1016/j.jns.2004.09.023; LEWIS P, 1964, BRAIN, V87, P719, DOI 10.1093/brain/87.4.719; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Mellick GD, 2005, NEUROSCI LETT, V375, P112, DOI 10.1016/j.neulet.2004.10.078; Morris HR, 2000, NEUROLOGY, V55, P1918, DOI 10.1212/WNL.55.12.1918; NAKAZATO Y, 1990, J NEUROPATH EXP NEUR, V49, P521, DOI 10.1097/00005072-199009000-00007; Nishimura M, 2005, MOVEMENT DISORD, V20, P1031, DOI 10.1002/mds.20491; Nishimura M, 2002, MOVEMENT DISORD, V17, P808, DOI 10.1002/mds.10124; Ozawa T, 2006, J NEUROL NEUROSUR PS, V77, P464, DOI 10.1136/jnnp.2005.073528; Ozawa T, 1999, NEUROSCI LETT, V270, P110, DOI 10.1016/S0304-3940(99)00475-9; Pals P, 2004, ANN NEUROL, V56, P591, DOI 10.1002/ana.20268; PLANTEBORDENEUVE V, 1995, MOVEMENT DISORD, V10, P277, DOI 10.1002/mds.870100307; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Scholz SW, 2009, ANN NEUROL, V65, P610, DOI 10.1002/ana.21685; Soma H, 2006, J NEUROL SCI, V240, P107, DOI 10.1016/j.jns.2005.09.003; Soma H, 2008, MOVEMENT DISORD, V23, P1161, DOI 10.1002/mds.22046; Wullner U, 2004, J NEUROL NEUROSUR PS, V75, P924, DOI 10.1136/jnnp.2003.025155; Yabe I, 2006, J NEUROL SCI, V249, P115, DOI 10.1016/j.jns.2006.05.064	27	114	115	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7114	10.1371/journal.pone.0007114	http://dx.doi.org/10.1371/journal.pone.0007114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771175	gold, Green Published, Green Accepted			2022-12-27	WOS:000270154400010
J	Baumann, O; Greenlee, MW				Baumann, Oliver; Greenlee, Mark W.			Effects of Attention to Auditory Motion on Cortical Activations during Smooth Pursuit Eye Tracking	PLOS ONE			English	Article							EVENT-RELATED FMRI; SPATIAL ATTENTION; TARGET SELECTION; MOVEMENTS; SCHIZOPHRENIA; PERCEPTION; CORTEX; FIELD; TASK; HUMANS	Background: In contrast to traditional views that consider smooth pursuit as a relatively automatic process, evidence has been reported for the importance of attention for accurate pursuit performance. However, the exact role that attention might play in the maintenance of pursuit remains unclear. Methodology/Principal Findings: We analysed the neuronal activity associated with healthy subjects executing smooth pursuit eye movements (SPEM) during concurrent attentive tracking of a moving sound source, which was either in-phase or in antiphase to the executed eye movements. Assuming that attentional resources must be allocated to the moving sound source, the simultaneous execution of SPEM and auditory tracking in diverging directions should result in increased load on common attentional resources. By using an auditory stimulus as a distractor rather then a visual stimulus we guaranteed that cortical activity cannot be caused by conflicts between two simultaneous visual motion stimuli. Our results revealed that the smooth pursuit task with divided attention led to significantly higher activations bilaterally in the posterior parietal cortex and lateral and medial frontal cortex, presumably containing the parietal, frontal and supplementary eye fields respectively. Conclusions: The additional cortical activation in these areas is apparently due to the process of dividing attention between the execution of SPEM and the covert tracking of the auditory target. On the other hand, even though attention had to be divided the attentional resources did not seem to be exhausted, since the identification of the direction of the auditory target and the quality of SPEM were unaffected by the congruence between visual and auditory motion stimuli. Finally, we found that this form of task-related attention modulated not only the cortical pursuit network in general but also affected modality specific and supramodal attention regions.			Baumann, O (corresponding author), Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia.	o.baumann@uq.edu.au	Baumann, Oliver/C-8296-2009; Greenlee, Mark/M-6414-2018	Greenlee, Mark/0000-0003-2305-9286; Lauwereyns, Jan/0000-0003-0551-2550; Baumann, Oliver/0000-0003-3976-5855				ACKER W, 1978, BRIT J SOC CLIN PSYC, V17, P173, DOI 10.1111/j.2044-8260.1978.tb00261.x; Baumann O, 2007, EXP BRAIN RES, V181, P237, DOI 10.1007/s00221-007-0922-3; Baumann O, 2007, CEREB CORTEX, V17, P1433, DOI 10.1093/cercor/bhl055; Baumgart F, 1999, NATURE, V400, P724, DOI 10.1038/23390; Belin P, 1999, NEUROIMAGE, V10, P417, DOI 10.1006/nimg.1999.0480; Berman RA, 1999, HUM BRAIN MAPP, V8, P209, DOI 10.1002/(SICI)1097-0193(1999)8:4<209::AID-HBM5>3.0.CO;2-0; Berryhill ME, 2006, J NEUROPHYSIOL, V96, P461, DOI 10.1152/jn.00152.2006; Bon L, 1997, EXP BRAIN RES, V113, P180, DOI 10.1007/BF02454156; Boucher L, 2004, J PHYSIOL-PARIS, V98, P235, DOI 10.1016/j.jphysparis.2004.03.010; Chen Y, 1999, ARCH GEN PSYCHIAT, V56, P155, DOI 10.1001/archpsyc.56.2.155; Colonius H, 2001, PERCEPT PSYCHOPHYS, V63, P126, DOI 10.3758/BF03200508; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Coull JT, 1998, NEUROIMAGE, V8, P176, DOI 10.1006/nimg.1998.0354; Culham JC, 1998, J NEUROPHYSIOL, V80, P2657, DOI 10.1152/jn.1998.80.5.2657; Deubel H, 1996, VISION RES, V36, P1827, DOI 10.1016/0042-6989(95)00294-4; Driver J, 1998, PHILOS T R SOC B, V353, P1319, DOI 10.1098/rstb.1998.0286; FERRERA VP, 1995, J NEUROSCI, V15, P7472; Findlay JM, 1999, BEHAV BRAIN SCI, V22, P661, DOI 10.1017/S0140525X99002150; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; Hall DA, 1999, HUM BRAIN MAPP, V7, P213, DOI 10.1002/(SICI)1097-0193(1999)7:3<213::AID-HBM5>3.0.CO;2-N; Husain M, 2003, NAT NEUROSCI, V6, P117, DOI 10.1038/nn1005; Hutton S, 1998, NEUROLOGY, V50, P604, DOI 10.1212/WNL.50.3.604; Hutton SB, 2005, EXP BRAIN RES, V163, P306, DOI 10.1007/s00221-004-2171-z; Johnson JA, 2006, NEUROIMAGE, V31, P1673, DOI 10.1016/j.neuroimage.2006.02.026; Jovicich J, 2001, J COGNITIVE NEUROSCI, V13, P1048, DOI 10.1162/089892901753294347; Kathmann N, 1999, PSYCHOPHYSIOLOGY, V36, P158, DOI 10.1017/S0048577299981167; Kimmig H, 1999, EXP BRAIN RES, V126, P443, DOI 10.1007/s002210050751; Knox PC, 2002, PROG BRAIN RES, V140, P211; Kustov AA, 1996, NATURE, V384, P74, DOI 10.1038/384074a0; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LIPTON RB, 1980, PERCEPT MOTOR SKILL, V50, P159; Muri RM, 1996, J NEUROL NEUROSUR PS, V60, P445, DOI 10.1136/jnnp.60.4.445; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Ohlendorf S, 2007, EUR J NEUROSCI, V26, P2096, DOI 10.1111/j.1460-9568.2007.05824.x; Ortuno F, 2002, NEUROIMAGE, V17, P411, DOI 10.1006/nimg.2002.1168; Pack C, 2001, J COGNITIVE NEUROSCI, V13, P102, DOI 10.1162/089892901564207; Petit L, 1999, J NEUROPHYSIOL, V82, P463, DOI 10.1152/jn.1999.82.1.463; Posner M I, 1992, Curr Opin Neurobiol, V2, P165, DOI 10.1016/0959-4388(92)90006-7; Recanzone GH, 2000, J NEUROPHYSIOL, V83, P777, DOI 10.1152/jn.2000.83.2.777; RIZZOLATTI G, 1987, NEUROPSYCHOLOGIA, V25, P31, DOI 10.1016/0028-3932(87)90041-8; Rosano C, 2002, CEREB CORTEX, V12, P107, DOI 10.1093/cercor/12.2.107; Saygin AP, 2008, CEREB CORTEX, V18, P2158, DOI 10.1093/cercor/bhm242; Schmid A, 2001, NEUROREPORT, V12, P1409, DOI 10.1097/00001756-200105250-00023; Schulz KP, 2004, AM J PSYCHIAT, V161, P1650, DOI 10.1176/appi.ajp.161.9.1650; SHELIGA BM, 1994, EXP BRAIN RES, V98, P507; SHELIGA BM, 1995, EXP BRAIN RES, V105, P261; SHEPHERD M, 1986, Q J EXP PSYCHOL-A, V38, P475, DOI 10.1080/14640748608401609; Stuve TA, 1997, PSYCHOL MED, V27, P143, DOI 10.1017/S0033291796004230; Tanabe J, 2002, NEUROIMAGE, V17, P1315, DOI 10.1006/nimg.2002.1263; VANGELDER P, 1995, VISION RES, V35, P667, DOI 10.1016/0042-6989(94)00161-E; WYATT HJ, 1987, VISION RES, V27, P1565, DOI 10.1016/0042-6989(87)90165-9	52	8	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7110	10.1371/journal.pone.0007110	http://dx.doi.org/10.1371/journal.pone.0007110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	498PN	19771159	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400008
J	Ye, BC; Zhang, Y; Yu, H; Yu, WB; Liu, BH; Yin, BC; Yin, CY; Li, YY; Chu, J; Zhang, SL				Ye, Bang-Ce; Zhang, Yan; Yu, Hui; Yu, Wen-Bang; Liu, Bao-Hong; Yin, Bin-Cheng; Yin, Chun-Yun; Li, Yuan-Yuan; Chu, Ju; Zhang, Si-Liang			Time-Resolved Transcriptome Analysis of Bacillus subtilis Responding to Valine, Glutamate, and Glutamine	PLOS ONE			English	Article							GENERAL STRESS-RESPONSE; AMINO-ACIDS; EXPRESSION; SIGMA(W); OPERON; CODY; BIOSYNTHESIS; SPORULATION; CHEMOTAXIS; MUTATION	Microorganisms can restructure their transcriptional output to adapt to environmental conditions by sensing endogenous metabolite pools. In this paper, an Agilent customized microarray representing 4,106 genes was used to study temporal transcript profiles of Bacillus subtilis in response to valine, glutamate and glutamine pulses over 24 h. A total of 673, 835, and 1135 amino-acid-regulated genes were identified having significantly changed expression at one or more time points in response to valine, glutamate, and glutamine, respectively, including genes involved in cell wall, cellular import, metabolism of amino-acids and nucleotides, transcriptional regulation, flagellar motility, chemotaxis, phage proteins, sporulation, and many genes of unknown function. Different amino acid treatments were compared in terms of both the global temporal profiles and the 5-minute quick regulations, and between-experiment differential genes were identified. The highlighted genes were analyzed based on diverse sources of gene functions using a variety of computational tools, including T-profiler analysis, and hierarchical clustering. The results revealed the common and distinct modes of action of these three amino acids, and should help to elucidate the specific signaling mechanism of each amino acid as an effector.			Ye, BC (corresponding author), E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Lab Biosyst & Microanal, Shanghai 200237, Peoples R China.	bcye@ecust.edu.cn; yyli@scbit.org	Yu, Hui/B-3787-2018					ABRAHAM LS, 2007, NATURE REV MICROBIOL, V5, P917; ABRAHAM LS, 2008, MOL MICROBIOL, V68, P242; Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; AGUSTINO MA, 2006, TRENDS MICROBIOL, V14, P22; ALEX TB, 2008, J BACTERIOL, V190, P1751; Altabe SG, 2003, J BACTERIOL, V185, P3228, DOI 10.1128/JB.185.10.3228-3231.2003; ANDREAS GL, 2006, MOL CELL, V24, P1; ANNE G, 2008, BMC SYSTEMS BIOL, V2, P20; ASWIN SNS, 2006, CURR OPIN MICROBIOL, V9, P511; Barrick JE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r239; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergara F, 2003, J BACTERIOL, V185, P3118, DOI 10.1128/JB.185.10.3118-3126.2003; Boorsma A, 2005, NUCLEIC ACIDS RES, V33, pW592, DOI 10.1093/nar/gki484; Brauer MJ, 2008, MOL BIOL CELL, V19, P352, DOI 10.1091/mbc.E07-08-0779; Budde I, 2006, MICROBIOL-SGM, V152, P831, DOI 10.1099/mic.0.28530-0; Cao M, 2002, J MOL BIOL, V316, P443, DOI 10.1006/jmbi.2001.5372; Debarbouille M, 1999, J BACTERIOL, V181, P2059, DOI 10.1128/JB.181.7.2059-2066.1999; DEJONG MH, 1977, ARCH MICROBIOL, V113, P153, DOI 10.1007/BF00428596; Diaz M, 2005, MICROBIOL-SGM, V151, P2583, DOI 10.1099/mic.0.27983-0; ERIC G, 2001, MOL MICROBIOL, V40, P1227; Esteban A, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-201; FABIAN MC, 2008, J BACTERIOL, V190, P3557; FABIAN MC, 2006, CURR OPIN MICROBIOL, P167; Fisher SH, 2008, P NATL ACAD SCI USA, V105, P1014, DOI 10.1073/pnas.0709949105; GEORGE MS, 2006, MICROBIOL MOL BIOL R, V70, P253; Gollnick P, 2005, ANNU REV GENET, V39, P47, DOI 10.1146/annurev.genet.39.073003.093745; GREGORY TS, 2007, MICROBIOLOGY, V153, P4123; HANS PF, 2004, GENOME RES, V14, P90; Hecker M, 2007, ANNU REV MICROBIOL, V61, P215, DOI 10.1146/annurev.micro.61.080706.093445; HELADIA S, 2007, FEBS LETT, V581, P3499; Huang XJ, 1998, J BACTERIOL, V180, P3765, DOI 10.1128/JB.180.15.3765-3770.1998; Ito M, 2005, J MOL BIOL, V352, P396, DOI 10.1016/j.jmb.2005.07.030; Jenkins AH, 2007, NAT CHEM BIOL, V3, P492, DOI 10.1038/nchembio.2007.13; JENNIFER MA, 2006, J BACTERIOL, V188, P5273; KATHRIN D, 1998, J BACTERIOL, V180, P6674; KAZUO K, 2001, J BACTERIOL, V183, P7365; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KYLE NE, 2005, J BACTERIOL, V187, P4042; LARISA EC, 2004, J BIOL CHEM, V279, P39340; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lulko AT, 2007, J MOL MICROB BIOTECH, V12, P82, DOI 10.1159/000096463; Matsuoka H, 2007, J BIOL CHEM, V282, P5180, DOI 10.1074/jbc.M606831200; Mirel DB, 2000, J BACTERIOL, V182, P3055, DOI 10.1128/JB.182.11.3055-3062.2000; MITSUO O, 2002, J BACTERIOL, V184, P2344; ORDAL GW, 1977, J BACTERIOL, V129, P151, DOI 10.1128/JB.129.1.151-155.1977; PIERRE B, 2005, J BACTERIOL, V187, P6019; Piggot PJ, 2004, CURR OPIN MICROBIOL, V7, P579, DOI 10.1016/j.mib.2004.10.001; Price CW, 2001, MOL MICROBIOL, V41, P757, DOI 10.1046/j.1365-2958.2001.02534.x; ROBERT PS, 2004, MOL MICROBIOL, V53, P599; SARATH CJ, 2007, J MOL BIOL, V368, P263; Serganov A, 2007, NAT REV GENET, V8, P776, DOI 10.1038/nrg2172; SERGINE E, 2006, J BACTERIOL, V188, P2184; Serizawa M, 2005, BIOSCI BIOTECH BIOCH, V69, P2155, DOI 10.1271/bbb.69.2155; Serror P, 1996, J BACTERIOL, V178, P5910, DOI 10.1128/jb.178.20.5910-5915.1996; SHADIA Z, 2009, MOL SYSTEMS BIOL, V5, P245; SHASHI C, 2009, J BACTERIOL, V191, P2362; SHIGEO T, 2005, MOL MICROBIOL, V56, P1560; TAKENORI S, 2005, J BACTERIOL, V187, P4813; Terahara N, 2006, J BACTERIOL, V188, P2701, DOI 10.1128/JB.188.7.2701-2705.2006; Terahara N, 2008, P NATL ACAD SCI USA, V105, P14359, DOI 10.1073/pnas.0802106105; Tojo S, 2004, J BACTERIOL, V186, P7971, DOI 10.1128/JB.186.23.7971-7979.2004; Tseng CL, 2008, J BACTERIOL, V190, P1561, DOI 10.1128/JB.01497-07; ULRIKE M, 2002, J BACTERIOL, V184, P4288; VANDERDRIFT C, 1974, ARCH MICROBIOL, V96, P83, DOI 10.1007/BF00590165; Wang LJ, 2007, J BACTERIOL, V189, P8467, DOI 10.1128/JB.01285-07; Wiegert T, 2001, MOL MICROBIOL, V41, P59, DOI 10.1046/j.1365-2958.2001.02489.x; Winkler WC, 2005, ANNU REV MICROBIOL, V59, P487, DOI 10.1146/annurev.micro.59.030804.121336; Wray LV, 1997, J BACTERIOL, V179, P5494, DOI 10.1128/jb.179.17.5494-5501.1997; Yang YH, 2001, PROC SPIE, V4266, P141, DOI 10.1117/12.427982; Zakrzewska A, 2005, EUKARYOT CELL, V4, P703, DOI 10.1128/EC.4.4.703-715.2005; Zaman S, 2008, ANNU REV GENET, V42, P27, DOI 10.1146/annurev.genet.41.110306.130206; ZOLTAN P, 2002, MICROBIOLOGY, V148, P1593	72	16	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7073	10.1371/journal.pone.0007073	http://dx.doi.org/10.1371/journal.pone.0007073			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763274	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970400010
J	Okamoto, N; Chantangsi, C; Horak, A; Leander, BS; Keeling, PJ				Okamoto, Noriko; Chantangsi, Chitchai; Horak, Ales; Leander, Brian S.; Keeling, Patrick J.			Molecular Phylogeny and Description of the Novel Katablepharid Roombia truncata gen. et sp nov., and Establishment of the Hacrobia Taxon nov	PLOS ONE			English	Article							FLAGELLATES PROTISTA; ALGAL GROUP; MARINE; PHYLUM; ULTRASTRUCTURE; DIVERSITY; PLASTIDS; ORIGIN; TREE; DINOFLAGELLATE	Background: Photosynthetic eukaryotes with a secondary plastid of red algal origin (cryptophytes, haptophytes, stramenopiles, dinoflagellates, and apicomplexans) are hypothesized to share a single origin of plastid acquisition according to Chromalveolate hypothesis. Recent phylogenomic analyses suggest that photosynthetic "chromalveolates'' form a large clade with inclusion of several non-photosynthetic protist lineages. Katablepharids are one such non-photosynthetic lineage closely related to cryptophytes. Despite their evolutionary and ecological importance, katablepharids are poorly investigated. Methodology/Principal Findings: Here, we report a newly discovered flagellate, Roombia truncata gen. et sp. nov., that is related to katablepharids, but is morphologically distinct from othermembers of the group in the following ways: ( 1) two flagella emerge from a papilla-like subapical protrusion, ( 2) conspicuous ejectisomes are aligned in multiple (5-11) rows, ( 3) each ejectisome increases in size towards the posterior end of the rows, and ( 4) upon feeding, a part of cytoplasm elastically stretch to engulf whole prey cell. Molecular phylogenies inferred from Hsp90, SSU rDNA, and LSU rDNA sequences consistently and strongly show R. truncata as the sister lineage to all other katablepharids, including lineages known only from environmental sequence surveys. A close association between katablepharids and cryptophytes was also recovered in most analyses. Katablepharids and cryptophytes are together part of a larger, more inclusive, group that also contains haptophytes, telonemids, centrohelids and perhaps biliphytes. The monophyly of this group is supported by several different molecular phylogenetic datasets and one shared lateral gene transfer; therefore, we formally establish this diverse clade as the "Hacrobia.'' Conclusions/Significance: Our discovery of R. truncata not only expands our knowledge in the less studied flagellate group, but provide a better understanding of phylogenetic relationship and evolutionary view of plastid acquisition/losses of Hacrobia. Being an ancestral to all katablepharids, and readily cultivable, R. truncata is a good candidate for multiple gene analyses that will contribute to future phylogenetic studies of Hacrobia.			Okamoto, N (corresponding author), Univ British Columbia, Dept Bot, Vancouver, BC, Canada.	pkeeling@interchange.ubc.ca	Horak, Ales/H-6723-2012; Okamoto, Noriko/J-6570-2012	Horak, Ales/0000-0002-3364-7383; Okamoto, Noriko/0000-0001-5493-8051; Keeling, Patrick/0000-0002-7644-0745				Auer B, 2001, FRESHWATER BIOL, V46, P959, DOI 10.1046/j.1365-2427.2001.00730.x; Barlow SB, 2002, HYDROBIOLOGIA, V473, P129, DOI 10.1023/A:1016585818665; Brandt SM, 2000, ESTUAR COAST SHELF S, V51, P91, DOI 10.1006/ecss.2000.0607; Braun EL, 2008, J PHYCOL, V44, P2, DOI 10.1111/j.1529-8817.2007.00432.x; BURKI F, 2009, EARLY EVOLU IN PRESS; Burki F, 2008, BIOL LETTERS, V4, P366, DOI 10.1098/rsbl.2008.0224; Burki F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000790; Cavalier-Smith T, 2004, SYST ASSOC SPEC VOL, P75; Clay B, 1999, PROTIST, V150, P43, DOI 10.1016/S1434-4610(99)70008-8; Cleven EJ, 2001, AQUAT MICROB ECOL, V23, P147, DOI 10.3354/ame023147; Cuvelier ML, 2008, ENVIRON MICROBIOL, V10, P1621, DOI 10.1111/j.1462-2920.2008.01580.x; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; Grauvogel C, 2007, J MOL EVOL, V65, P725, DOI 10.1007/s00239-007-9053-5; Hackett JD, 2007, MOL BIOL EVOL, V24, P1702, DOI 10.1093/molbev/msm089; Hall TA., 1999, NUCL ACIDS S SERIES, V41, P95; Hampl V, 2009, P NATL ACAD SCI USA, V106, P3859, DOI 10.1073/pnas.0807880106; Harper JT, 2005, INT J SYST EVOL MICR, V55, P487, DOI 10.1099/ijs.0.63216-0; Harper JT, 2003, MOL BIOL EVOL, V20, P1730, DOI 10.1093/molbev/msg195; Hoppenrath M, 2006, J EUKARYOT MICROBIOL, V53, P327, DOI 10.1111/j.1550-7408.2006.00110.x; Katoh K, 2008, BRIEF BIOINFORM, V9, P286, DOI 10.1093/bib/bbn013; Katoh K, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-212; Keeling PJ, 2009, J EUKARYOT MICROBIOL, V56, P1, DOI 10.1111/j.1550-7408.2008.00371.x; Keeling PJ, 2005, TRENDS ECOL EVOL, V20, P670, DOI 10.1016/j.tree.2005.09.005; Kim E, 2006, MOL BIOL EVOL, V23, P2455, DOI 10.1093/molbev/msl120; Klaveness D, 2005, INT J SYST EVOL MICR, V55, P2595, DOI 10.1099/ijs.0.63652-0; KUGRENS P, 1987, J PHYCOL, V23, P511; KUGRENS P, 1994, PROTOPLASMA, V181, P164, DOI 10.1007/BF01666394; LARSEN J, 1990, J NAT HIST, V24, P801, DOI 10.1080/00222939000770571; LEE RE, 1991, J PHYCOL, V27, P725, DOI 10.1111/j.0022-3646.1991.00725.x; Lee WJ, 2000, J NAT HIST, V34, P483, DOI 10.1080/002229300299435; Matsuzaki M, 2008, MOL BIOL EVOL, V25, P1167, DOI 10.1093/molbev/msn064; Not F, 2007, ENVIRON MICROBIOL, V9, P1233, DOI 10.1111/j.1462-2920.2007.01247.x; Not F, 2007, SCIENCE, V315, P253, DOI 10.1126/science.1136264; Okamoto N, 2005, SCIENCE, V310, P287, DOI 10.1126/science.1116125; Okamoto N, 2005, PROTIST, V156, P163, DOI 10.1016/j.protis.2004.12.003; Okamoto N, 2006, PROTIST, V157, P401, DOI 10.1016/j.protis.2006.05.011; Patron NJ, 2007, CURR BIOL, V17, P887, DOI 10.1016/j.cub.2007.03.069; Patron NJ, 2004, EUKARYOT CELL, V3, P1169, DOI 10.1128/EC.3.5.1169-1175.2004; Reyes-Prieto A, 2008, CURR BIOL, V18, P956, DOI 10.1016/j.cub.2008.05.042; Rice DW, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-31; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Shalchian-Tabrizi K, 2006, P ROY SOC B-BIOL SCI, V273, P1833, DOI 10.1098/rspb.2006.3515; Shalchian-Tabrizi K, 2007, PROTIST, V158, P173, DOI 10.1016/j.protis.2006.10.003; Sherr EB, 2002, ANTON LEEUW INT J G, V81, P293, DOI 10.1023/A:1020591307260; Shimodaira H, 2001, BIOINFORMATICS, V17, P1246, DOI 10.1093/bioinformatics/17.12.1246; Shimodaira H, 2002, SYST BIOL, V51, P492, DOI 10.1080/10635150290069913; SKUJA H., 1939, ACTA HORTI BOT UNIV LATVIENSIS, V11/12, P41; Slamovits CH, 2008, MOL BIOL EVOL, V25, P1297, DOI 10.1093/molbev/msn075; Slapeta J, 2006, PROTIST, V157, P7, DOI 10.1016/j.protis.2005.11.004; Sommer MS, 2007, MOL BIOL EVOL, V24, P918, DOI 10.1093/molbev/msm008; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Swofford D, 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/J.0014-3820.2002.TB00191.X; Teles-Grilo ML, 2007, EUR J PROTISTOL, V43, P163, DOI 10.1016/j.ejop.2007.02.002; Vaulot D, 2008, FEMS MICROBIOL REV, V32, P795, DOI 10.1111/j.1574-6976.2008.00121.x; VORS N, 1992, EUR J PROTISTOL, V28, P369, DOI 10.1016/S0932-4739(11)80001-5; Yoon HS, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-14	56	82	86	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7080	10.1371/journal.pone.0007080	http://dx.doi.org/10.1371/journal.pone.0007080			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759916	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970200010
J	Deniaud, E; Baguet, J; Chalard, R; Blanquier, B; Brinza, L; Meunier, J; Michallet, MC; Laugraud, A; Ah-Soon, C; Wierinckx, A; Castellazzi, M; Lachuer, J; Gautier, C; Marvel, J; Leverrier, Y				Deniaud, Emmanuelle; Baguet, Joel; Chalard, Roxane; Blanquier, Bariza; Brinza, Lilia; Meunier, Julien; Michallet, Marie-Cecile; Laugraud, Aurelie; Ah-Soon, Claudette; Wierinckx, Anne; Castellazzi, Marc; Lachuer, Joel; Gautier, Christian; Marvel, Jacqueline; Leverrier, Yann			Overexpression of Transcription Factor Sp1 Leads to Gene Expression Perturbations and Cell Cycle Inhibition	PLOS ONE			English	Article								Background: The ubiquitous transcription factor Sp1 regulates the expression of a vast number of genes involved in many cellular functions ranging from differentiation to proliferation and apoptosis. Sp1 expression levels show a dramatic increase during transformation and this could play a critical role for tumour development or maintenance. Although Sp1 deregulation might be beneficial for tumour cells, its overexpression induces apoptosis of untransformed cells. Here we further characterised the functional and transcriptional responses of untransformed cells following Sp1 overexpression. Methodology and Principal Findings: We made use of wild-type and DNA-binding-deficient Sp1 to demonstrate that the induction of apoptosis by Sp1 is dependent on its capacity to bind DNA. Genome-wide expression profiling identified genes involved in cancer, cell death and cell cycle as being enriched among differentially expressed genes following Sp1 overexpression. In silico search to determine the presence of Sp1 binding sites in the promoter region of modulated genes was conducted. Genes that contained Sp1 binding sites in their promoters were enriched among down-regulated genes. The endogenous sp1 gene is one of the most down-regulated suggesting a negative feedback loop induced by overexpressed Sp1. In contrast, genes containing Sp1 binding sites in their promoters were not enriched among up-regulated genes. These results suggest that the transcriptional response involves both direct Sp1-driven transcription and indirect mechanisms. Finally, we show that Sp1 overexpression led to a modified expression of G1/S transition regulatory genes such as the down-regulation of cyclin D2 and the up-regulation of cyclin G2 and cdkn2c/p18 expression. The biological significance of these modifications was confirmed by showing that the cells accumulated in the G1 phase of the cell cycle before the onset of apoptosis. Conclusion: This study shows that the binding to DNA of overexpressed Sp1 induces an inhibition of cell cycle progression that precedes apoptosis and a transcriptional response targeting genes containing Sp1 binding sites in their promoter or not suggesting both direct Sp1-driven transcription and indirect mechanisms.			Deniaud, E (corresponding author), INSERM, U851, F-69008 Lyon, France.	jacqueline.marvel@inserm.fr; yann.leverrier@inserm.fr	Wierinckx, Anne/AAF-5233-2021; LEVERRIER, Yann/M-3767-2014; meunier, julien/ABE-1435-2020; marvel, jacqueline/H-8638-2014	Wierinckx, Anne/0000-0002-0186-6645; LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; lachuer, joel/0000-0002-5209-5094				Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chamboredon S, 2005, ONCOGENE, V24, P2547, DOI 10.1038/sj.onc.1208489; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Deniaud E, 2006, ONCOGENE, V25, P7096, DOI 10.1038/sj.onc.1209696; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; He SH, 2005, MOL BIOL CELL, V16, P4073, DOI 10.1091/mbc.e05-05-0388; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jiang NY, 2008, CANCER EPIDEM BIOMAR, V17, P1648, DOI 10.1158/1055-9965.EPI-07-2791; Kavurma MM, 2003, J BIOL CHEM, V278, P32537, DOI 10.1074/jbc.M305650200; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lou Z, 2005, CANCER RES, V65, P1007; Marcais A, 2006, EUR J IMMUNOL, V36, P2745, DOI 10.1002/eji.200636259; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Song J, 2001, J BIOL CHEM, V276, P30429, DOI 10.1074/jbc.M103968200; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; van den Abbeele A, 2007, CANCER LETT, V255, P57, DOI 10.1016/j.canlet.2007.03.023; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yuan P, 2007, CANCER-AM CANCER SOC, V110, P2682, DOI 10.1002/cncr.23092; Zannetti A, 2000, CANCER RES, V60, P1546	44	66	68	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7035	10.1371/journal.pone.0007035	http://dx.doi.org/10.1371/journal.pone.0007035			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753117	gold, Green Submitted, Green Published			2022-12-27	WOS:000269796500018
J	Martin-Subero, JI; Ammerpohl, O; Bibikova, M; Wickham-Garcia, E; Agirre, X; Alvarez, S; Bruggemann, M; Bug, S; Calasanz, MJ; Deckert, M; Dreyling, M; Du, MQ; Durig, J; Dyer, MJS; Fan, JB; Gesk, S; Hansmann, ML; Harder, L; Hartmann, S; Klapper, W; Kuppers, R; Montesinos-Rongen, M; Nagel, I; Pott, C; Richter, J; Roman-Gomez, J; Seifert, M; Stein, H; Suela, J; Trumper, L; Vater, I; Prosper, F; Haferlach, C; Cigudosa, JC; Siebert, R				Martin-Subero, Jose I.; Ammerpohl, Ole; Bibikova, Marina; Wickham-Garcia, Eliza; Agirre, Xabier; Alvarez, Sara; Brueggemann, Monika; Bug, Stefanie; Calasanz, Maria J.; Deckert, Martina; Dreyling, Martin; Du, Ming Q.; Duerig, Jan; Dyer, Martin J. S.; Fan, Jian-Bing; Gesk, Stefan; Hansmann, Martin-Leo; Harder, Lana; Hartmann, Sylvia; Klapper, Wolfram; Kueppers, Ralf; Montesinos-Rongen, Manuel; Nagel, Inga; Pott, Christiane; Richter, Julia; Roman-Gomez, Jose; Seifert, Marc; Stein, Harald; Suela, Javier; Truemper, Lorenz; Vater, Inga; Prosper, Felipe; Haferlach, Claudia; Cigudosa, Juan Cruz; Siebert, Reiner			A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms	PLOS ONE			English	Article								Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities, and comprehensive studies are required. Methodology/Principal Findings: Here, we report for the first time a microarray-based DNA methylation study of 767 genes in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as well as 37 samples from different cell types of the hematopoietic system. Using appropriate controls of B-, T-, or myeloid cellular origin, we identified a total of 220 genes hypermethylated in at least one HN entity. In general, promoter hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center mature B- cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-associated DNA hypermethylation. We also observed a significant correlation between the number of hypermethylated and hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias. Most of the genes becoming hypermethylated contained promoters with high CpG content, and a significant fraction of them are targets of the polycomb repressor complex. Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression. Conclusions/Significance: We have characterized the DNA methylation profile of a wide range of different HNs entities. As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes-DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1-that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies. These might therefore play an important role in the development of different HNs.			Martin-Subero, JI (corresponding author), Univ Kiel, Inst Human Genet, Kiel, Germany.	jimartin@idibell.cat; rsiebert@medgen.uni-kiel.de	Agirre, Xabier/ABE-4110-2020; Brüggemann, Monika/M-8150-2013; Hartmann, Sylvia/AAJ-4376-2021; Klapper, Wolfram/D-2516-2010; SUELA, JAVIER/K-3968-2016; Ammerpohl, Ole/G-2691-2010; Klapper, Wolfram/S-6314-2016; Seifert, Marc/N-5602-2015; Siebert, Reiner/A-8049-2010; Calasanz, MJ/R-5813-2016; Prosper, Felipe/H-6859-2017; Deckert, Martina/P-2842-2016; Dyer, Martin/F-2691-2014	Brüggemann, Monika/0000-0001-5514-5010; Seifert, Marc/0000-0001-9453-369X; Calasanz, MJ/0000-0002-0374-3008; Prosper, Felipe/0000-0001-6115-8790; Du, Ming-Qing/0000-0002-1017-5045; Montesinos-Rongen, Manuel/0000-0003-4724-5526; Martin-Subero, Jose Ignacio/0000-0001-8809-5195; Kuppers, Ralf/0000-0002-6691-7191; Dyer, Martin/0000-0002-5033-2236	Medical Research Council [MC_U132670597] Funding Source: Medline; MRC [MC_U132670597] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Al-Moundhri MS, 2009, J CLIN GASTROENTEROL, V43, P152, DOI 10.1097/MCG.0b013e31815853fa; Baiocchi OCG, 2008, LEUKEMIA LYMPHOMA, V49, P2031, DOI 10.1080/10428190802517799; Bennett LB, 2009, GENE CHROMOSOME CANC, V48, P828, DOI 10.1002/gcc.20687; Bermudez-Morales VH, 2008, CANCER INVEST, V26, P1037, DOI 10.1080/07357900802112693; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Boultwood J, 2007, BRIT J HAEMATOL, V138, P3, DOI 10.1111/j.1365-2141.2007.06604.x; Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008-5472.CAN-06-1215; Dolloff NG, 2005, ONCOGENE, V24, P6848, DOI 10.1038/sj.onc.1208815; Durig J, 2007, LEUKEMIA, V21, P2153, DOI 10.1038/sj.leu.2404877; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Feng YX, 2008, CANCER LETT, V270, P250, DOI 10.1016/j.canlet.2008.05.013; Figueroa ME, 2009, BLOOD, V113, P2795, DOI 10.1182/blood-2008-08-172387; Figueroa ME, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001882; Ford CE, 2007, BRIT J CANCER, V96, P808, DOI 10.1038/sj.bjc.6603614; Galinsky VL, 2003, BIOINFORMATICS, V19, P1832, DOI 10.1093/bioinformatics/btg260; Galinsky VL, 2003, BIOINFORMATICS, V19, P1824, DOI 10.1093/bioinformatics/btg259; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Garcia-Manero G, 2008, CURR OPIN ONCOL, V20, P705, DOI 10.1097/CCO.0b013e328313699c; Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376; Gronbaek K, 2008, MODERN PATHOL, V21, P632, DOI 10.1038/modpathol.2008.27; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Jiang Y, 2009, BLOOD, V113, P1315, DOI 10.1182/blood-2008-06-163246; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56; Killian JK, 2009, CANCER RES, V69, P758, DOI 10.1158/0008-5472.CAN-08-2984; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lehmann U, 2004, ANN HEMATOL, V83, P137, DOI 10.1007/s00277-003-0798-7; Lind H, 2005, LUNG CANCER, V50, P285, DOI 10.1016/j.lungcan.2005.07.003; Lurje G, 2009, PHARMACOGENET GENOM, V19, P95, DOI 10.1097/FPC.0b013e32831a9ad1; Martin-Subero JI, 2009, BLOOD, V113, P2488, DOI 10.1182/blood-2008-04-152900; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Muste A, 2009, CYTOKINE, V45, P8, DOI 10.1016/j.cyto.2008.10.019; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; ORIAIN C, 2009, LEUKEMIA; Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18; Pirooznia M, 2007, BIOINFORMATION, V1, P420, DOI 10.6026/97320630001420; Raaphorst FM, 2001, J IMMUNOL, V166, P5925, DOI 10.4049/jimmunol.166.10.5925; Rahmatpanah FB, 2006, LEUKEMIA, V20, P1855, DOI 10.1038/sj.leu.2404345; Roman-Gomez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; San Jose-Eneriz E, 2006, BRIT J HAEMATOL, V134, P137, DOI 10.1111/j.1365-2141.2006.06131.x; Sato N, 2003, CANCER RES, V63, P4158; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Scholz C, 2005, ANN HEMATOL, V84, P236, DOI 10.1007/s00277-004-0969-1; Shimada K, 2008, CANCER SCI, V99, P39, DOI 10.1111/j.1349-7006.2007.00655.x; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Swerdlow SH, 2008, WHO CLASSIFICATION T; Taylor JME, 2001, LEUKEMIA, V15, P583, DOI 10.1038/sj.leu.2402080; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Vairaktaris E, 2008, J CANCER RES CLIN, V134, P821, DOI 10.1007/s00432-008-0360-z; van Galen JC, 2004, EUR J IMMUNOL, V34, P1870, DOI 10.1002/eji.200424985; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Wehler TC, 2008, ONCOL REP, V19, P697; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wilczynski SP, 2005, HUM PATHOL, V36, P242, DOI 10.1016/j.humpath.2004.11.009; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441	65	102	106	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6986	10.1371/journal.pone.0006986	http://dx.doi.org/10.1371/journal.pone.0006986			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750229	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696600015
J	Wang, W; Wang, W; Mei, XP; Huang, J; Wei, YY; Wang, YY; Wu, SX; Li, YQ				Wang, Wei; Wang, Wen; Mei, Xiaopeng; Huang, Jing; Wei, Yanyan; Wang, Yayun; Wu, Shengxi; Li, Yunqing			Crosstalk between Spinal Astrocytes and Neurons in Nerve Injury-Induced Neuropathic Pain	PLOS ONE			English	Article								Emerging research implicates the participation of spinal dorsal horn (SDH) neurons and astrocytes in nerve injury-induced neuropathic pain. However, the crosstalk between spinal astrocytes and neurons in neuropathic pain is not clear. Using a lumbar 5 (L5) spinal nerve ligation (SNL) pain model, we testified our hypothesis that SDH neurons and astrocytes reciprocally regulate each other to maintain the persistent neuropathic pain states. Glial fibrillary acidic protein (GFAP) was used as the astrocytic specific marker and Fos, protein of the protooncogene c-fos, was used as a marker for activated neurons. SNL induced a significant mechanical allodynia as well as activated SDH neurons indicated by the Fos expression at the early phase and activated astrocytes with the increased expression of GFAP during the late phase of pain, respectively. Intrathecal administration of c-fos antisense oligodeoxynucleotides (ASO) or astroglial toxin L-alpha-aminoadipate (L-AA) reversed the mechanical allodynia, respectively. Immunofluorescent histochemistry revealed that intrathecal administration of c-fos ASO significantly suppressed activation of not only neurons but also astrocytes induced by SNL. Meanwhile, L-AA shortened the duration of neuronal activation by SNL. Our data offers evidence that neuronal and astrocytic activations are closely related with the maintenance of neuropathic pain through a reciprocal "crosstalk''. The current study suggests that neuronal and non-neuronal elements should be taken integrally into consideration for nociceptive transmission, and that the intervention of such interaction may offer some novel pain therapeutic strategies.			Wang, W (corresponding author), Fourth Mil Med Univ, Dept Anat Histol & Embryol, KK Leung Brain Res Ctr, Xian 710032, Peoples R China.	shengxi@fmmu.edu.cn; deptanat@fmmu.edu.cn	王, 亚云/AAJ-7271-2020; 王, 亚/GXM-4793-2022	wang, yayun/0000-0002-0397-0390				Abbadie C, 2005, TRENDS IMMUNOL, V26, P529, DOI 10.1016/j.it.2005.08.001; BULLITT E, 1990, J COMP NEUROL, V296, P517, DOI 10.1002/cne.902960402; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen T, 2003, J ANAT, V203, P579, DOI 10.1046/j.1469-7580.2003.00242.x; Chen Y, 2005, PAIN, V119, P38, DOI 10.1016/j.pain.2005.09.007; Coggeshall RE, 2005, PROG NEUROBIOL, V77, P299, DOI 10.1016/j.pneurobio.2005.11.002; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Feng YP, 2002, NEUROSIGNALS, V11, P151, DOI 10.1159/000065056; Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007; HUCK S, 1984, J NEUROSCI, V4, P2650; Ikeda H, 2007, EUR J NEUROSCI, V25, P1297, DOI 10.1111/j.1460-9568.2007.05386.x; Inoue K, 2006, PHARMACOL THERAPEUT, V109, P210, DOI 10.1016/j.pharmthera.2005.07.001; Inoue K, 2007, J NEUROCHEM, V102, P1447, DOI 10.1111/j.1471-4159.2007.04824.x; IVANUSIC JJ, 2008, EUR J PAIN; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; Khurgel M, 1996, GLIA, V16, P351, DOI 10.1002/(SICI)1098-1136(199604)16:4<351::AID-GLIA7>3.0.CO;2-2; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Li A, 2007, NEUROREPORT, V18, P495, DOI 10.1097/WNR.0b013e3280586839; Mika J, 2008, PHARMACOL REP, V60, P297; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632-200405150-00006; Qin M, 2006, NEUROSCI RES, V55, P442, DOI 10.1016/j.neures.2006.04.017; Rodriguez MJ, 2004, J NEUROSCI RES, V77, P344, DOI 10.1002/jnr.20177; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Shan S, 2007, PAIN, V129, P64, DOI 10.1016/j.pain.2006.09.035; Suter MR, 2007, NEURON GLIA BIOL, V3, P255, DOI 10.1017/S1740925X08000100; Svensson CI, 2005, NEUROPEPTIDES, V39, P485, DOI 10.1016/j.npep.2005.08.002; TABER KH, 2008, J NEUROPSYCHIATRY CL, V20, P129; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Terayama R, 2008, NEUROSCIENCE, V153, P1245, DOI 10.1016/j.neuroscience.2008.03.041; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Viviani B, 2003, J NEUROSCI, V23, P8692; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wang H., 2003, International Journal of Fuzzy Systems, V5, P106; Wang W, 2008, ANAT REC, V291, P513, DOI 10.1002/ar.20673; Wang YY, 2006, NEUROSCIENCE, V139, P1083, DOI 10.1016/j.neuroscience.2006.01.011; Wang YY, 2003, BIOCHEM BIOPH RES CO, V309, P631, DOI 10.1016/j.bbrc.2003.08.046; Watkins LR, 2007, BRAIN BEHAV IMMUN, V21, P131, DOI 10.1016/j.bbi.2006.10.011; Watkins LR, 2001, PAIN, V93, P201, DOI 10.1016/S0304-3959(01)00359-1; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wu SX, 2002, NEUROSIGNALS, V11, P224, DOI 10.1159/000065430; Zhang RX, 2008, PAIN, V135, P232, DOI 10.1016/j.pain.2007.05.023; Zhang RX, 1998, BRAIN RES, V795, P282, DOI 10.1016/S0006-8993(98)00300-X; Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	49	81	84	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6973	10.1371/journal.pone.0006973	http://dx.doi.org/10.1371/journal.pone.0006973			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759893	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696600012
J	Yakob, L; Yan, GY				Yakob, Laith; Yan, Guiyun			Modeling the Effects of Integrating Larval Habitat Source Reduction and Insecticide Treated Nets for Malaria Control	PLOS ONE			English	Article							CONTROLLING AQUATIC STAGES; ANOPHELES-GAMBIAE; BED NETS; SPATIAL-DISTRIBUTION; MOSQUITO NETS; BEHAVIOR; MORTALITY; CHILDREN; TRANSMISSION; DYNAMICS	Integrated vector management for malaria control has received a lot of recent interest. Attacking multiple points in the transmission cycle is hoped to act synergistically and improve upon current single-tool interventions based on the use of insecticide-treated bed nets (ITNs). In the present study, we theoretically examined the application of larval habitat source reduction with ITNs in reducing malaria transmission. We selected this type of environmental management to complement ITNs because of a potential secondary mode of action that both control strategies share. In addition to increasing vector mortality, ITNs reduce the rate at which female mosquitoes locate human hosts for blood feeding, thereby extending their gonotrophic cycle. Similarly, while reducing adult vector emergence and abundance, source reduction of larval habitats may prolong the cycle duration by extending delays in locating oviposition sites. We found, however, that source reduction of larval habitats only operates through this secondary mode of action when habitat density is below a critical threshold. Hence, we illustrate how this strategy becomes increasingly effective when larval habitats are limited. We also demonstrate that habitat source reduction is better suited to human populations of higher density and in the presence of insecticide resistance or when the insecticidal properties of ITNs are depleted.			Yakob, L (corresponding author), Univ Calif Irvine, Program Publ Hlth, Irvine, CA 92717 USA.	lyakob@uci.edu	Yakob, Laith/B-1059-2012; Yakob, Laith/AAD-4521-2019	Yakob, Laith/0000-0001-8639-4511	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050243] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI050243] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afrane YA, 2005, J MED ENTOMOL, V42, P974, DOI 10.1603/0022-2585(2005)042[0974:EOMCCB]2.0.CO;2; Afrane YA, 2006, AM J TROP MED HYG, V74, P772, DOI 10.4269/ajtmh.2006.74.772; ArredondoJimenez JI, 1997, MED VET ENTOMOL, V11, P87, DOI 10.1111/j.1365-2915.1997.tb00294.x; Beier JC, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S4; Binka FN, 1998, AM J TROP MED HYG, V59, P80, DOI 10.4269/ajtmh.1998.59.80; Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0; Chitnis Nakul, 2008, Journal of Biological Dynamics, V2, P259, DOI 10.1080/17513750701769857; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Donnelly MJ, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-12; DYE C, 1986, T ROY SOC TROP MED H, V80, P69, DOI 10.1016/0035-9203(86)90199-9; Eisele TP, 2009, AM J TROP MED HYG, V80, P209, DOI 10.4269/ajtmh.2009.80.209; Fillinger U, 2004, TROP MED INT HEALTH, V9, P1274, DOI 10.1111/j.1365-3156.2004.01335.x; GILROY AB, 1948, MALARIA CONTROL COAS; Gimnig JE, 2003, AM J TROP MED HYG, V68, P115, DOI 10.4269/ajtmh.2003.68.115; GOSONIU L, 2008, BMC PUBLIC HEALTH, V8, DOI DOI 10.1186/1471-2458-1188-1356; Gu WD, 2005, AM J TROP MED HYG, V73, P546, DOI 10.4269/ajtmh.2005.73.546; Gu WD, 2008, AM J TROP MED HYG, V78, P2, DOI 10.4269/ajtmh.2008.78.2; Gu WD, 2006, P NATL ACAD SCI USA, V103, P17560, DOI 10.1073/pnas.0608452103; Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052; Hii JLK, 2001, T ROY SOC TROP MED H, V95, P7, DOI 10.1016/S0035-9203(01)90315-3; Kachur SP, 1999, TROP MED INT HEALTH, V4, P728, DOI 10.1046/j.1365-3156.1999.00481.x; Killeen GF, 2007, PLOS MED, V4, P1246, DOI 10.1371/journal.pmed.0040229; Killeen GF, 2007, T ROY SOC TROP MED H, V101, P867, DOI 10.1016/j.trstmh.2007.04.022; Killeen GF, 2006, AM J TROP MED HYG, V74, P517, DOI 10.4269/ajtmh.2006.74.517; Killeen GF, 2004, AM J TROP MED HYG, V71, P87, DOI 10.4269/ajtmh.2004.71.2_suppl.0700087; Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486; Korenromp EL, 2003, TROP MED INT HEALTH, V8, P693, DOI 10.1046/j.1365-3156.2003.01084.x; Le Menach A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-23; Le Menach A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-10; Lengeler C, 2004, B WORLD HEALTH ORGAN, V82, P84; LINES JD, 1987, MED VET ENTOMOL, V1, P37, DOI 10.1111/j.1365-2915.1987.tb00321.x; MACDONALD G, 1968, B WORLD HEALTH ORGAN, V38, P743; Majambere S, 2008, AM J TROP MED HYG, V79, P19, DOI 10.4269/ajtmh.2008.79.19; Pates HV, 2001, B ENTOMOL RES, V91, P289, DOI 10.1079/BER200198; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23, DOI 10.4269/ajtmh.2003.68.23; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Saul A, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-32; Schellenberg JA, 2002, T ROY SOC TROP MED H, V96, P368, DOI 10.1016/S0035-9203(02)90361-5; Smith DL, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-13; Smith T, 2006, AM J TROP MED HYG, V75, P56, DOI 10.4269/ajtmh.2006.75.56; Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131; Thomson MC, 2006, NATURE, V439, P576, DOI 10.1038/nature04503; Utzinger J, 2001, TROP MED INT HEALTH, V6, P677, DOI 10.1046/j.1365-3156.2001.00769.x; WHO, 2004, WHO GLOB STRAT FRAM; Zhou G, 2004, P NATL ACAD SCI USA, V101, P2375, DOI 10.1073/pnas.0308714100; Zhou G, 2007, AM J TROP MED HYG, V77, P29, DOI 10.4269/ajtmh.2007.77.29	46	31	32	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6921	10.1371/journal.pone.0006921	http://dx.doi.org/10.1371/journal.pone.0006921			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742312	Green Published, Green Accepted, gold			2022-12-27	WOS:000269622500006
J	van Hal, SJ; Foo, H; Blyth, CC; McPhie, K; Armstrong, P; Sintchenko, V; Dwyer, DE				van Hal, Sebastiaan J.; Foo, Hong; Blyth, Christopher C.; McPhie, Kenneth; Armstrong, Paul; Sintchenko, Vitali; Dwyer, Dominic E.			Influenza Outbreak during Sydney World Youth Day 2008: The Utility of Laboratory Testing and Case Definitions on Mass Gathering Outbreak Containment	PLOS ONE			English	Article								Background: Influenza causes annual epidemics and often results in extensive outbreaks in closed communities. To minimize transmission, a range of interventions have been suggested. For these to be effective, an accurate and timely diagnosis of influenza is required. This is confirmed by a positive laboratory test result in an individual whose symptoms are consistent with a predefined clinical case definition. However, the utility of these clinical case definitions and laboratory testing in mass gathering outbreaks remains unknown. Methods and Results: An influenza outbreak was identified during World Youth Day 2008 in Sydney. From the data collected on pilgrims presenting to a single clinic, a Markov model was developed and validated against the actual epidemic curve. Simulations were performed to examine the utility of different clinical case definitions and laboratory testing strategies for containment of influenza outbreaks. Clinical case definitions were found to have the greatest impact on averting further cases with no added benefit when combined with any laboratory test. Although nucleic acid testing (NAT) demonstrated higher utility than indirect immunofluorescence antigen or on-site point-of-care testing, this effect was lost when laboratory NAT turnaround times was included. The main benefit of laboratory confirmation was limited to identification of true influenza cases amenable to interventions such as antiviral therapy. Conclusions: Continuous re-evaluation of case definitions and laboratory testing strategies are essential for effective management of influenza outbreaks during mass gatherings.			van Hal, SJ (corresponding author), Westmead Hosp, Ctr Infect Dis & Microbiol, Inst Clin Pathol & Med Res, Sydney, NSW, Australia.	vanhal@gotalk.net.au	Blyth, Christopher/ABG-8231-2020; Ali, Mohammad/E-2365-2017	Blyth, Christopher/0000-0003-2017-0683; Ali, Mohammad/0000-0003-1410-388X; Sintchenko, Vitali/0000-0002-9261-3650; van Hal, Sebastiaan/0000-0001-5852-4155				Bellei N, 2003, J VIROL METHODS, V109, P85, DOI 10.1016/S0166-0934(03)00050-8; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Brotherton JML, 2003, EPIDEMIOL INFECT, V130, P263, DOI 10.1017/S0950268802008166; *CDC, 2009, OV INFL SURV US; Ellis JS, 1997, J CLIN MICROBIOL, V35, P2076, DOI 10.1128/JCM.35.8.2076-2082.1997; Ellis JS, 2002, REV MED VIROL, V12, P375, DOI 10.1002/rmv.370; ELVEBACK LR, 1976, AM J EPIDEMIOL, V103, P152, DOI 10.1093/oxfordjournals.aje.a112213; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Fizzell J, 2008, MED J AUSTRALIA, V189, P633, DOI 10.5694/j.1326-5377.2008.tb02222.x; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; GLEZEN WP, 1978, NEW ENGL J MED, V298, P587, DOI 10.1056/NEJM197803162981103; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; Grassly NC, 2008, NAT REV MICROBIOL, V6, P477, DOI 10.1038/nrmicro1845; Gundlapalli AV, 2006, EMERG INFECT DIS, V12, P144, DOI 10.3201/eid1201.050645; Halloran ME, 2002, VACCINE, V20, P3254; Herrmann B, 2001, J CLIN MICROBIOL, V39, P134, DOI 10.1128/JCM.39.1.134-138.2001; Hui DS, 2008, THORAX, V63, P690, DOI 10.1136/thx.2007.090951; Laurel VL, 2001, CLIN INFECT DIS, V32, P1639, DOI 10.1086/320513; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; McVernon J, 2007, INFLUENZA OTHER RESP, V1, P43, DOI 10.1111/j.1750-2659.2007.00008.x; Mitchell R, 2006, Can Commun Dis Rep, V32, P257; MONTO AS, 1985, AM J EPIDEMIOL, V121, P811, DOI 10.1093/oxfordjournals.aje.a114052; *NEW S WAL DEP HLT, 2006, NSW HLTH INT INFL PA; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; Ohmit SE, 2006, CLIN INFECT DIS, V43, P564, DOI 10.1086/506352; Pachucki Constance T, 2005, Curr Infect Dis Rep, V7, P187, DOI 10.1007/s11908-005-0033-x; Peltola V, 2005, CLIN INFECT DIS, V41, P1198, DOI 10.1086/444508; Petric M, 2006, J INFECT DIS, V194, pS98, DOI 10.1086/507554; Playford EG, 2002, PATHOLOGY, V34, P115, DOI 10.1080/003130201201117909; Rashid H, 2008, LANCET INFECT DIS, V8, P526, DOI 10.1016/S1473-3099(08)70186-5; Rodriguez WJ, 2002, PEDIATR INFECT DIS J, V21, P193, DOI 10.1097/00006454-200203000-00006; Rothberg MB, 2003, J GEN INTERN MED, V18, P808, DOI 10.1046/j.1525-1497.2003.20822.x; Rothberg MB, 2003, ANN INTERN MED, V139, P321, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00007; Schweiger B, 2000, J CLIN MICROBIOL, V38, P1552, DOI 10.1128/JCM.38.4.1552-1558.2000; Siddiqui MR, 2008, EMERG INFECT DIS, V14, P267, DOI 10.3201/eid1402.070478; Thursky K, 2003, J CLIN VIROL, V27, P170, DOI 10.1016/S1386-6532(02)00172-5; Vynnycky E, 2007, INT J EPIDEMIOL, V36, P881, DOI 10.1093/ije/dym071; World Health Organization (WHO), 2005, WHO GLOB INFL PREP P; Zambon M, 2001, ARCH INTERN MED, V161, P2116, DOI 10.1001/archinte.161.17.2116; 2008, AUSTR HLTH MANAGEMEN	41	18	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6620	10.1371/journal.pone.0006620	http://dx.doi.org/10.1371/journal.pone.0006620			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727401	Green Published, Green Submitted, gold			2022-12-27	WOS:000269522900002
J	Nishiura, H; Klinkenberg, D; Roberts, M; Heesterbeek, JAP				Nishiura, Hiroshi; Klinkenberg, Don; Roberts, Mick; Heesterbeek, Johan A. P.			Early Epidemiological Assessment of the Virulence of Emerging Infectious Diseases: A Case Study of an Influenza Pandemic	PLOS ONE			English	Article							ACUTE-RESPIRATORY-SYNDROME; CASE-FATALITY RATIO	Background: The case fatality ratio (CFR), the ratio of deaths from an infectious disease to the number of cases, provides an assessment of virulence. Calculation of the ratio of the cumulative number of deaths to cases during the course of an epidemic tends to result in a biased CFR. The present study develops a simple method to obtain an unbiased estimate of confirmed CFR (cCFR), using only the confirmed cases as the denominator, at an early stage of epidemic, even when there have been only a few deaths. Methodology/Principal Findings: Our method adjusts the biased cCFR by a factor of underestimation which is informed by the time from symptom onset to death. We first examine the approach by analyzing an outbreak of severe acute respiratory syndrome in Hong Kong (2003) with known unbiased cCFR estimate, and then investigate published epidemiological datasets of novel swine-origin influenza A (H1N1) virus infection in the USA and Canada (2009). Because observation of a few deaths alone does not permit estimating the distribution of the time from onset to death, the uncertainty is addressed by means of sensitivity analysis. The maximum likelihood estimate of the unbiased cCFR for influenza may lie in the range of 0.16-4.48% within the assumed parameter space for a factor of underestimation. The estimates for influenza suggest that the virulence is comparable to the early estimate in Mexico. Even when there have been no deaths, our model permits estimating a conservative upper bound of the cCFR. Conclusions: Although one has to keep in mind that the cCFR for an entire population is vulnerable to its variations among sub-populations and underdiagnosis, our method is useful for assessing virulence at the early stage of an epidemic and for informing policy makers and the public.			Nishiura, H (corresponding author), Univ Utrecht, Utrecht, Netherlands.	h.nishiura@uu.nl	Roberts, Mick/Q-7277-2019; Nishiura, Hiroshi/D-1426-2011	Roberts, Mick/0000-0003-2693-5093; Heesterbeek, Hans/0000-0001-8537-6418; Nishiura, Hiroshi/0000-0003-0941-8537; Klinkenberg, Don/0000-0002-9449-6873				Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P453; Brundage JF, 2008, EMERG INFECT DIS, V14, P1193, DOI 10.3201/eid1408.071313; Butler D, 2009, NATURE, V458, P1082, DOI 10.1038/4581082a; Butler D, 2009, NATURE, V459, P14, DOI 10.1038/459014a; Cameron AR, 1998, PREV VET MED, V34, P1, DOI 10.1016/S0167-5877(97)00081-0; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P521; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; de Wit E, 2008, VACCINE, V26, pD54, DOI 10.1016/j.vaccine.2008.07.072; Diekmann O., 2000, MATH EPIDEMIOLOGY IN; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Fineberg HV, 2009, SCIENCE, V324, P987, DOI 10.1126/science.1176297; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Galvani AP, 2003, EMERG INFECT DIS, V9, P991; Garske T, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2840; Ghani AC, 2005, AM J EPIDEMIOL, V162, P479, DOI 10.1093/aje/kwi230; Jewell NP, 2007, STAT MED, V26, P1982, DOI 10.1002/sim.2691; Lipsitch M, 2009, NEW ENGL J MED, V361, P112, DOI 10.1056/NEJMp0904380; Ma JL, 2008, B MATH BIOL, V70, P118, DOI 10.1007/s11538-007-9243-8; Nicholson KG, 1998, TXB INFLUENZA, P219; Nishiura H, 2009, EUROSURVEILLANCE, V14; Nishiura H, 2007, THEOR BIOL MED MODEL, V4, DOI 10.1186/1742-4682-4-20; *PUBL HLTH AG CAN, 2009, H1N1 FLU VIR HUM SWI; *TIME, 2009, MEX MYST WHY IS SWIN; Venette RC, 2002, ANNU REV ENTOMOL, V47, P143, DOI 10.1146/annurev.ento.47.091201.145147; WHO, 2009, EP PAND AL RESP EPR	25	75	77	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6852	10.1371/journal.pone.0006852	http://dx.doi.org/10.1371/journal.pone.0006852			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718434	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415900021
J	Rajan, SS; Sokal, DC				Rajan, Suja S.; Sokal, David C.			Comparison of Projected and Actual Outcomes of the HIV/AIDS Epidemic in Malawi, 1990-2000	PLOS ONE			English	Article							IMPACT; AIDS	Background: In 1992 Liomba et al used HIV-AIDS prevalence data from 1980 to 1990 and projected the adult HIV prevalence and the impact of AIDS for the years 1991 to 2000, under high and low HIV incidence scenarios, using EpiModel, DemProj and the AIDS Impact Model. This report compares the actual outcomes of the HIV-AIDS epidemic in Malawi from 1991 to 2000 with projections made by Liomba et al. Methods and Findings: Due to the lack of data on rural HIV prevalence in 1992, the prevalence estimates for the years 1980 to 1990 used by Liomba et al were higher than the now published prevalence. We re-estimated the projections for 1991 to 2000 based on more recent estimates of 1980 to 1990 HIV-AIDS prevalence using the Spectrum modeling software, and compared the old and new projections with the actual epidemic figures reported by NAC. The original projections made by Liomba et al and the adjusted projections made in this report are both very similar to the observed course of the AIDS epidemic reported by National AIDS Commission. Unfortunately for Malawi the epidemic seems to have followed the high scenario of HIV incidence. Conclusion: The course of the epidemic in Malawi and the social and economic devastation caused by it, despite the presence of reasonably good projections and prevention recommendations by Liomba et al, highlights the need for better co-ordination between research and practice. It also emphasizes the need to examine the difficulties faced by countries like Malawi to act more rapidly and implement effective prevention measures in the face of an epidemic.			Rajan, SS (corresponding author), Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA.	Dsokal@fhi.org		Rajan, Suja/0000-0001-9558-3146				[Anonymous], 2004, 2004 REP GLOB AIDS E; *AV, 2008, HIV AIDS THAIL; *AV, 2008, HIV AIDS UG; Bernstein RS, 1998, INTERFACES, V28, P101, DOI 10.1287/inte.28.3.101; Brown T, 2006, SEX TRANSM INFECT, V82, pIII34, DOI 10.1136/sti.2006.020230; CHIN J, 1991, B WORLD HEALTH ORGAN, V69, P399; Chirwa I, 1995, Aidscaptions, V2, P40; EGERO B, 2001, HIV AIDS WORLD TODAY, P1; Fulcher Christopher L, 2003, AMIA Annu Symp Proc, P1064; *FUT GROUP, 2007, SPECTR SOFTW; GARBO J, 2000, SE ASIAS URGENT CALL; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; *HLTH RES CTR DEP, 2005, HLTH MAN INF SYST; LIMOBA G, 1992, PREVENTING AIDS MALA; Mhone C S, 1996, AIDS Anal Afr, V6, P16; *NAT AIDS COMM, 2003, HIV AIDS MAL EST PRE; Needham D, 1996, CAN MED ASSOC J, V155, P91; OWENS C, 1991, ASIAN WALL STREET J, V13, P4; Pervilhac C, 2005, AIDS, V19, pS53, DOI 10.1097/01.aids.0000172877.13004.c0; UNAIDS, 2005, AIDS EP UPD; *UNAIDS, 2007, AIDS EP UPD; UNAIDS/WHO, 2004, MAL EP FACT SHEETS H; *UNICEF, 2005, MAL COUNTR STAT; *US AG INT DEV, 2005, HLTH PROF MAL HIV AI; *US AG INT DEV, 2006, ISS BRIEF STRAT INF; *US BUR CENS, 2007, COUNTR SUMM MAL; Walden VM, 1999, HEALTH EDUC RES, V14, P545, DOI 10.1093/her/14.4.545; World Bank, 2005, WORLD BANK COUNTRY, P1, DOI 10.1596/978-0-8213-6226-6; *WORLD BANK, 2009, MAL DAT PROF WORLD D	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6806	10.1371/journal.pone.0006806	http://dx.doi.org/10.1371/journal.pone.0006806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710919	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415600018
J	Dubreuil, P; Letard, S; Ciufolini, M; Gros, L; Humbert, M; Casteran, N; Borge, L; Hajem, B; Lermet, A; Sippl, W; Voisset, E; Arock, M; Auclair, C; Leventhal, PS; Mansfield, CD; Moussy, A; Hermine, O				Dubreuil, Patrice; Letard, Sebastien; Ciufolini, Marco; Gros, Laurent; Humbert, Martine; Casteran, Nathalie; Borge, Laurence; Hajem, Berengere; Lermet, Anne; Sippl, Wolfgang; Voisset, Edwige; Arock, Michel; Auclair, Christian; Leventhal, Phillip S.; Mansfield, Colin D.; Moussy, Alain; Hermine, Olivier			Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT	PLOS ONE			English	Article								Background: The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT. Methodology/Principal Findings: In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC(50)) of 200 +/- 40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC(50) of 150 +/- 80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant. Conclusions: Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.			Dubreuil, P (corresponding author), Ctr Reference Mastocytoses, Ctr Rech Cancerol Marseille Signalisat Hematopoie, INSERM, U891, Marseille, France.	patrice.dubreuil@inserm.fr; olivier.hermine@nck.aphp.fr	Voisset, Edwige/GSE-5113-2022; Dubreuil, Patrice/V-4816-2019; Sippl, Wolfgang/P-5944-2014; Hermine, Olivier/Q-7072-2018; Voisset, Edwige/AAM-3503-2021; dubreuil, patrice/F-5346-2011	Voisset, Edwige/0000-0002-0943-4847; Dubreuil, Patrice/0000-0003-1155-1150; Sippl, Wolfgang/0000-0002-5985-9261; Voisset, Edwige/0000-0002-0943-4847; dubreuil, patrice/0000-0003-1155-1150; Hermine, Olivier/0000-0003-2574-3874; LETARD, Sebastien/0000-0002-6508-7376				Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; Atwell S, 2004, J BIOL CHEM, V279, P55827, DOI 10.1074/jbc.M409792200; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood-2004-10-3967; Fernandez A, 2007, J CLIN INVEST, V117, P4044, DOI 10.1172/JCI32373; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Gabillot-Carre M, 2006, BLOOD, V108, P1065, DOI 10.1182/blood-2005-06-2433; Hahn KA, 2008, J VET INTERN MED, V22, P1301, DOI 10.1111/j.1939-1676.2008.0190.x; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; MEININGER CJ, 1992, BLOOD, V79, P958; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Nagar B, 2002, CANCER RES, V62, P4236; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; Reber L, 2006, EUR J PHARMACOL, V533, P327, DOI 10.1016/j.ejphar.2005.12.067; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Royer B, 2001, J ALLERGY CLIN IMMUN, V108, P80, DOI 10.1067/mai.2001.115753; Rubin BP, 2006, LAB INVEST, V86, P981, DOI 10.1038/labinvest.3700466; Shchemelinin I, 2006, FOLIA BIOL-PRAGUE, V52, P137; Small D, 2006, FLT3 MUTATIONS BIOL, P178; Testa U, 2008, DRUG FUTURE, V33, P161, DOI 10.1358/dof.2008.033.02.1164207; Tsujimura T, 1996, BLOOD, V87, P273; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; Wang RX, 2003, J MED CHEM, V46, P2287, DOI 10.1021/jm0203783; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269; 1996, J OFFICIEL      0602, P8167; GLEEVEC PHARM REV	37	280	297	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7258	10.1371/journal.pone.0007258	http://dx.doi.org/10.1371/journal.pone.0007258			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789626	Green Submitted, Green Published, gold			2022-12-27	WOS:000270354100017
J	Ma, CH; Kachroo, AH; Macieszak, A; Chen, TY; Guga, P; Jayaram, M				Ma, Chien-Hui; Kachroo, Aashiq H.; Macieszak, Anna; Chen, Tzu-Yang; Guga, Piotr; Jayaram, Makkuni			Reactions of Cre with Methylphosphonate DNA: Similarities and Contrasts with Flp and Vaccinia Topoisomerase	PLOS ONE			English	Article								Background: Reactions of vaccinia topoisomerase and the tyrosine site-specific recombinase Flp with methylphosphonate (MeP) substituted DNA substrates, have provided important insights into the electrostatic features of the strand cleavage and strand joining steps catalyzed by them. A conserved arginine residue in the catalytic pentad, Arg-223 in topoisomerase and Arg-308 in Flp, is not essential for stabilizing the MeP transition state. Topoisomerase or its R223A variant promotes cleavage of the MeP bond by the active site nucleophile Tyr-274, followed by the rapid hydrolysis of the MeP-tyrosyl intermediate. Flp(R308A), but not wild type Flp, mediates direct hydrolysis of the activated MeP bond. These findings are consistent with a potential role for phosphate electrostatics and active site electrostatics in protecting DNA relaxation and site-specific recombination, respectively, against abortive hydrolysis. Methodology/Principal Findings: We have examined the effects of DNA containing MeP substitution in the Flp related Cre recombination system. Neutralizing the negative charge at the scissile position does not render the tyrosyl intermediate formed by Cre susceptible to rapid hydrolysis. Furthermore, combining the active site R292A mutation in Cre (equivalent to the R223A and R308A mutations in topoisomerase and Flp, respectively) with MeP substitution does not lead to direct hydrolysis of the scissile MeP bond in DNA. Whereas Cre follows the topoisomerase paradigm during the strand cleavage step, it follows the Flp paradigm during the strand joining step. Conclusions/Significance: Collectively, the Cre, Flp and topoisomerase results highlight the contribution of conserved electrostatic complementarity between substrate and active site towards transition state stabilization during site-specific recombination and DNA relaxation. They have potential implications for how transesterification reactions in nucleic acids are protected against undesirable abortive side reactions. Such protective mechanisms are significant, given the very real threat of hydrolytic genome damage or disruption of RNA processing due to the cellular abundance and nucleophilicity of water.			Ma, CH (corresponding author), Univ Texas Austin, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.	Jayaram@icmb.utexas.edu	Kachroo, Aashiq/Z-2505-2019; Kachroo, Aashiq/C-3714-2009; Guga, Piotr J/Y-5582-2018	Kachroo, Aashiq/0000-0001-9770-778X; Kachroo, Aashiq/0000-0001-9770-778X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM035654, R01 GM035654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL KL, 1979, NUCLEIC ACIDS RES, V6, P3009, DOI 10.1093/nar/6.9.3009; An S, 2008, NUCLEIC ACIDS RES, V36, P2514, DOI 10.1093/nar/gkn063; Belfort Marlene, 2002, P761; CECH TR, 1983, CELL, V34, P713, DOI 10.1016/0092-8674(83)90527-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Conway AB, 2003, J MOL BIOL, V326, P425, DOI 10.1016/S0022-2836(02)01370-0; Craig N. L., 2002, MOBILE DNA, P3; Dash C, 2008, NUCLEIC ACIDS RES, V36, P6363, DOI 10.1093/nar/gkn678; Dertinger D, 2001, RNA, V7, P622, DOI 10.1017/S1355838201002217; Ghosh K, 2002, METHODS, V28, P374, DOI 10.1016/S1046-2023(02)00244-X; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Jayaram M, 2004, PROG NUCLEIC ACID RE, V77, P127, DOI 10.1016/S0079-6603(04)77004-X; Jayaram M., 2002, MOBILE DNA, P192; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; LEE J, 1993, J BIOL CHEM, V268, P17564; Lee J, 1996, J MOL BIOL, V257, P532, DOI 10.1006/jmbi.1996.0183; Ma CH, 2009, EMBO J, V28, P1745, DOI 10.1038/emboj.2009.131; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; Mizuuchi Kiyoshi, 2002, P12; NOBLE SA, 1984, NUCLEIC ACIDS RES, V12, P3387, DOI 10.1093/nar/12.7.3387; Parker JB, 2008, BIOCHEMISTRY-US, V47, P8614, DOI 10.1021/bi800854g; PRITCHARD CE, 1994, NUCLEIC ACIDS RES, V22, P2592, DOI 10.1093/nar/22.13.2592; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rice P. A., 2002, MOBILE DNA, P219; Rosati O, 2002, BIOCHEM BIOPH RES CO, V295, P198, DOI 10.1016/S0006-291X(02)00645-9; San AK, 2001, J BIOL CHEM, V276, P46612, DOI 10.1074/jbc.M106492200; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; Tian LG, 2005, STRUCTURE, V13, P513, DOI 10.1016/j.str.2005.02.001; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Woods KC, 2001, J MOL BIOL, V313, P49, DOI 10.1006/jmbi.2001.5012; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6	33	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7248	10.1371/journal.pone.0007248	http://dx.doi.org/10.1371/journal.pone.0007248			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789629	Green Published, gold, Green Submitted			2022-12-27	WOS:000270354100013
J	Gibson, NJ; Tolbert, LP; Oland, LA				Gibson, Nicholas J.; Tolbert, Leslie P.; Oland, Lynne A.			Roles of Specific Membrane Lipid Domains in EGF Receptor Activation and Cell Adhesion Molecule Stabilization in a Developing Olfactory System	PLOS ONE			English	Article							MOTH MANDUCA-SEXTA; EPIDERMAL-GROWTH-FACTOR; DETERGENT-RESISTANT MEMBRANES; DEAFFERENTED ANTENNAL LOBES; SENSORY AXON GUIDANCE; LABIAL PIT ORGAN; FASCICLIN-II; NERVOUS-SYSTEM; GLIAL-CELLS; IMMUNOGLOBULIN SUPERFAMILY	Background: Reciprocal interactions between glial cells and olfactory receptor neurons (ORNs) cause ORN axons entering the brain to sort, to fasciculate into bundles destined for specific glomeruli, and to form stable protoglomeruli in the developing olfactory system of an experimentally advantageous animal species, the moth Manduca sexta. Epidermal growth factor receptors (EGFRs) and the cell adhesion molecules (IgCAMs) neuroglian and fasciclin II are known to be important players in these processes. Methodology/Principal Findings: We report in situ and cell-culture studies that suggest a role for glycosphingolipid-rich membrane subdomains in neuron-glia interactions. Disruption of these subdomains by the use of methyl-beta-cyclodextrin results in loss of EGFR activation, depletion of fasciclin II in ORN axons, and loss of neuroglian stabilization in the membrane. At the cellular level, disruption leads to aberrant ORN axon trajectories, small antennal lobes, abnormal arrays of olfactory glomerul, and loss of normal glial cell migration. Conclusions/Significance: We propose that glycosphingolipid-rich membrane subdomains (possible membrane rafts or platforms) are essential for IgCAM-mediated EGFR activation and for anchoring of neuroglian to the cytoskeleton, both required for normal extension and sorting of ORN axons.			Gibson, NJ (corresponding author), Univ Arizona, Arizona Res Labs, Div Neurobiol, Tucson, AZ 85721 USA.	njgibson@neurobio.arizona.edu			NIDCD NIH HHS [R01 DC004598, DC004598, DC008597, R01 DC008597] Funding Source: Medline; NINDS NIH HHS [P01-NS28495, P01 NS028495] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004598, R01DC008597] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Abeytunga DTU, 2004, J LIPID RES, V45, P1221, DOI 10.1194/jlr.M300392-JLR200; Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Allende D, 2004, TRENDS BIOCHEM SCI, V29, P325, DOI 10.1016/j.tibs.2004.04.002; Baumann PM, 1996, J COMP NEUROL, V373, P118; Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boiko T, 2007, J NEUROSCI, V27, P590, DOI 10.1523/JNEUROSCI.4302-06.2007; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown DA, 2006, PHYSIOLOGY, V21, P430, DOI 10.1152/physiol.00032.2006; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Chang MC, 2006, MOL CELL NEUROSCI, V31, P525, DOI 10.1016/j.mcn.2005.11.006; Chen CL, 1997, DEV BIOL, V181, P1, DOI 10.1006/dbio.1996.8437; Cheng L, 2005, J NEUROSCI, V25, P395, DOI 10.1523/JNEUROSCI.4097-04.2005; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Dickson TC, 2002, J CELL BIOL, V157, P1105, DOI 10.1083/jcb.200111076; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; Falk J, 2004, MOL BIOL CELL, V15, P4695, DOI 10.1091/mbc.E04-03-0171; Forni JJ, 2004, MOL CELL NEUROSCI, V26, P282, DOI 10.1016/j.mcn.2004.02.003; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Garcia-Alonso L, 2000, NEURON, V28, P741, DOI 10.1016/S0896-6273(00)00150-1; Gibson NJ, 2006, J COMP NEUROL, V495, P554, DOI 10.1002/cne.20890; Gibson NJ, 2001, DEV BIOL, V240, P326, DOI 10.1006/dbio.2001.0463; Gibson NJ, 2004, J COMP NEUROL, V476, P1, DOI 10.1002/cne.20178; Gil OD, 2003, J CELL BIOL, V162, P719, DOI 10.1083/jcb.200211011; Godenschwege TA, 2006, CURR BIOL, V16, P12, DOI 10.1016/j.cub.2005.11.062; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Hall SG, 1997, J NEUROBIOL, V32, P325, DOI 10.1002/(SICI)1097-4695(199703)32:3<325::AID-NEU6>3.3.CO;2-N; Hamlin JA, 2004, J COMP NEUROL, V474, P438, DOI 10.1002/cne.20133; HARPER JR, 1991, J NEUROCHEM, V56, P797, DOI 10.1111/j.1471-4159.1991.tb01994.x; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HAYASHI JH, 1990, J NEUROSCI, V10, P848; Herincs Z, 2005, J CELL SCI, V118, P1687, DOI 10.1242/jcs.02296; Hering H, 2003, J NEUROSCI, V23, P3262; Higgins MR, 2002, DEV BIOL, V244, P134, DOI 10.1006/dbio.2002.0583; HILDEBRAND JG, 1979, P NATL ACAD SCI USA, V76, P499, DOI 10.1073/pnas.76.1.499; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Hou QM, 2008, MOL CELL NEUROSCI, V38, P213, DOI 10.1016/j.mcn.2008.02.010; Huetteroth W, 2005, CELL TISSUE RES, V319, P513, DOI 10.1007/s00441-004-1016-1; Islam R, 2004, MOL BIOL CELL, V15, P2003, DOI 10.1091/mbc.e03-05-0333; Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7; Jefford G, 2000, J BIOL CHEM, V275, P27726; Jenkins SM, 2001, J CELL SCI, V114, P3823; Jhaveri D, 2000, DEV BIOL, V226, P73, DOI 10.1006/dbio.2000.9855; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Kent KS, 1999, J NEUROBIOL, V40, P28, DOI 10.1002/(SICI)1097-4695(199907)40:1<28::AID-NEU3>3.0.CO;2-E; KENT KS, 1986, CELL TISSUE RES, V245, P237; KENT KS, 1985, THESIS HARVARD U; Kiryushko D, 2004, ANN NY ACAD SCI, V1014, P140, DOI 10.1196/annals.1294.015; Kizhatil K, 2002, J NEUROSCI, V22, P7948; Kristiansen LV, 2005, MOL CELL NEUROSCI, V28, P141, DOI 10.1016/j.mcn.2004.09.003; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Ma L, 2003, J NEUROSCI, V23, P3164; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; McIntosh TJ, 2006, ANNU REV BIOPH BIOM, V35, P177, DOI 10.1146/annurev.biophys.35.040405.102022; McIntosh TJ, 2003, BIOPHYS J, V85, P1656, DOI 10.1016/S0006-3495(03)74595-0; Mintz CD, 2003, J COMP NEUROL, V464, P438, DOI 10.1002/cne.10809; MIRAGALL F, 1989, DEV BIOL, V135, P272, DOI 10.1016/0012-1606(89)90179-6; Moores CA, 2004, MOL CELL, V14, P833, DOI 10.1016/j.molcel.2004.06.009; MORTON DB, 1985, J COMP PHYSIOL A, V157, P423, DOI 10.1007/BF00615142; Nakai Y, 2002, J CELL BIOL, V159, P1097, DOI 10.1083/jcb.200209077; Nardi JB, 2006, DEV COMP IMMUNOL, V30, P447, DOI 10.1016/j.dci.2005.06.026; NARDI JB, 1993, DEVELOPMENT, V118, P967; NARDI JB, 1994, DEV DYNAM, V199, P315, DOI 10.1002/aja.1001990406; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Nishimura K, 2003, J CELL BIOL, V163, P1077, DOI 10.1083/jcb.200303060; OLAND LA, 1988, J NEUROSCI, V8, P353; Oland LA, 1998, J COMP NEUROL, V398, P119; OLAND LA, 1989, GLIA, V2, P10, DOI 10.1002/glia.440020103; OLAND LA, 1987, J COMP NEUROL, V255, P196, DOI 10.1002/cne.902550204; OLAND LA, 1990, J NEUROSCI, V10, P2096; Oland LA, 1996, J NEUROBIOL, V30, P92; Oland LA, 2003, ANNU REV ENTOMOL, V48, P89, DOI 10.1146/annurev.ento.48.091801.112654; Oland LA, 1996, J NEUROSCI METH, V69, P103, DOI 10.1016/S0165-0270(96)00025-8; Oland LA, 1999, CELL TISSUE RES, V297, P527, DOI 10.1007/s004410051379; Oland LA, 1998, J NEUROBIOL, V36, P41, DOI 10.1002/(SICI)1097-4695(199807)36:1<41::AID-NEU4>3.0.CO;2-A; Parker RJ, 2006, SEMIN CELL DEV BIOL, V17, P66, DOI 10.1016/j.semcdb.2005.11.012; Parker RJ, 2004, BIOCHEM CELL BIOL, V82, P694, DOI 10.1139/O04-119; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; Ridyard MS, 2003, J BIOL CHEM, V278, P13803, DOI 10.1074/jbc.M210245200; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; ROSPARS JP, 1992, CELL TISSUE RES, V270, P205, DOI 10.1007/BF00328007; Rospars JP, 2000, CHEM SENSES, V25, P119, DOI 10.1093/chemse/25.2.119; Rossler W, 1999, J NEUROSCI, V19, P9865; SANES JR, 1976, DEV BIOL, V51, P282, DOI 10.1016/0012-1606(76)90144-5; SANES JR, 1977, BRAIN RES, V119, P389, DOI 10.1016/0006-8993(77)90318-3; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Schaefer AW, 2002, J CELL BIOL, V157, P1223, DOI 10.1083/jcb.200203024; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Sepp KJ, 2003, J NEUROSCI, V23, P8221; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sinakevitch I, 2001, J COMP NEUROL, V439, P352, DOI 10.1002/cne.1355; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Takebayashi M, 2004, SYNAPSE, V53, P90, DOI 10.1002/syn.20041; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TOLBERT LP, 1990, J COMP NEUROL, V298, P69, DOI 10.1002/cne.902980106; TOLBERT LP, 1981, PROC R SOC SER B-BIO, V213, P279, DOI 10.1098/rspb.1981.0067; TOLBERT LP, 1983, J NEUROSCI, V3, P1158; Tolbert LP, 2004, PROG NEUROBIOL, V73, P73, DOI 10.1016/j.pneurobio.2004.04.004; Treloar H, 1997, J NEUROBIOL, V32, P643, DOI 10.1002/(SICI)1097-4695(19970620)32:7<643::AID-NEU1>3.0.CO;2-4; Treloar HB, 1999, J COMP NEUROL, V413, P289; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Tucker ES, 2004, J COMP NEUROL, V472, P478, DOI 10.1002/cne.20058; Tucker ES, 2003, DEV BIOL, V260, P9, DOI 10.1016/S0012-1606(03)00207-0; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Whittard JD, 2006, MOL BIOL CELL, V17, P2696, DOI 10.1091/mbc.E06-01-0090; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17789; Wisco D, 2003, J CELL BIOL, V162, P1317, DOI 10.1083/jcb.200307069; Wong RWC, 2004, CYTOKINE GROWTH F R, V15, P147, DOI 10.1016/j.cytogfr.2004.01.004; Wright JW, 1999, DEVELOPMENT, V126, P3217; Yang XL, 2004, LIFE SCI, V75, P2495, DOI 10.1016/j.lfs.2004.04.036; Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026	137	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7222	10.1371/journal.pone.0007222	http://dx.doi.org/10.1371/journal.pone.0007222			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787046	Green Submitted, Green Published, gold			2022-12-27	WOS:000270290100019
J	Villani, AC; Lemire, M; Louis, E; Silverberg, MS; Collette, C; Fortin, G; Nimmo, ER; Renaud, Y; Brunet, S; Libioulle, C; Belaiche, J; Bitton, A; Gaudet, D; Cohen, A; Langelier, D; Rioux, JD; Arnott, IDR; Wild, GE; Rutgeerts, P; Satsangi, J; Vermeire, S; Hudson, TJ; Franchimont, D				Villani, Alexandra-Chloe; Lemire, Mathieu; Louis, Edouard; Silverberg, Mark S.; Collette, Catherine; Fortin, Genevieve; Nimmo, Elaine R.; Renaud, Yannick; Brunet, Sebastien; Libioulle, Cecile; Belaiche, Jacques; Bitton, Alain; Gaudet, Daniel; Cohen, Albert; Langelier, Diane; Rioux, John D.; Arnott, Ian D. R.; Wild, Gary E.; Rutgeerts, Paul; Satsangi, Jack; Vermeire, Severine; Hudson, Thomas J.; Franchimont, Denis			Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; SUSCEPTIBILITY LOCI; FLIP-FLOP; PYRIN; MUTATIONS; EXPRESSION; CONTRIBUTE; INTERACTS; CASPASE-1	Background and Aims: The familial Mediterranean fever (FMF) gene (MEFV) encodes pyrin, a major regulator of the inflammasome platform controlling caspase-1 activation and IL-1 beta processing. Pyrin has been shown to interact with the gene product of NLRP3, NALP3/cryopyrin, also an important active member of the inflammasome. The NLRP3 region was recently reported to be associated with Crohn's disease (CD) susceptibility. We therefore sought to evaluate MEFV as an inflammatory bowel disease (IBD) susceptibility gene. Methodology and Results: MEFV colonic mucosal gene expression was significantly increased in experimental colitis mice models (TNBS p < 0.0003; DSS p < 0.006), in biopsies from CD (p < 0.02) and severe ulcerative colitis (UC) patients (p < 0.008). Comprehensive genetic screening of the MEFV region in the Belgian exploratory sample set (440 CD trios, 137 UC trios, 239 CD cases, 96 UC cases, and 107 healthy controls) identified SNPs located in the MEFV 59 haplotype block that were significantly associated with UC (rs224217; p = 0.003; A allele frequency: 56% cases, 45% controls), while no CD associations were observed. Sequencing and subsequent genotyping of variants located in this associated haplotype block identified three synonymous variants (D102D/rs224225, G138G/rs224224, A165A/rs224223) and one non-synonymous variant (R202Q/rs224222) located in MEFV exon 2 that were significantly associated with UC (rs224222: p = 0.0005; A allele frequency: 32% in cases, 23% in controls). No consistent associations were observed in additional Canadian (256 CD trios, 91 UC trios) and Scottish (495 UC, 370 controls) sample sets. We note that rs224222 showed marginal association (p = 0.012; G allele frequency: 82% in cases, 70% in controls) in the Canadian sample, but with a different risk allele. None of the NLRP3 common variants were associated with UC in the Belgian-Canadian UC samples and no significant interactions were observed between NLRP3 and MEFV that could explain the observed flip-flop of the rs224222 risk allele. Conclusion: The differences in association levels observed between the sample sets may be a consequence of distinct founder effects or of the relative small sample size of the cohorts evaluated in this study. However, the results suggest that common variants in the MEFV region do not contribute to CD and UC susceptibility.			Villani, AC (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Dept Gastroenterol, Montreal, PQ H3G 1A4, Canada.	alexandra-chloe.villani@mail.mcgill.ca	Rioux, John D/A-9599-2015; Silverberg, Mark/B-4183-2008	Rioux, John D/0000-0001-7560-8326; Vermeire, Severine/0000-0001-9942-3019	Medical Research Council [G0600329, G0800759, G0800675] Funding Source: Medline; NIAID NIH HHS [AI065687, P01 AI065687, U19 AI067152, AI067152] Funding Source: Medline; NIDDK NIH HHS [DK062432, R01 DK064869, DK064869, U01 DK062432, DK624230] Funding Source: Medline; Wellcome Trust [072789/Z/03/Z] Funding Source: Medline; Chief Scientist Office [CZB/4/540] Funding Source: Medline; MRC [G0600329, G0800675, G0800759] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067152, P01AI065687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064869, U01DK062432] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust); Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 1997, CELL, V90, P797; Aldea A, 2004, HUM MUTAT, V23, P399, DOI 10.1002/humu.9229; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Bell PA, 2002, BIOTECHNIQUES, P70; Bernot A, 1998, HUM MOL GENET, V7, P1317, DOI 10.1093/hmg/7.8.1317; Bernot A, 1997, NAT GENET, V17, P25; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cattan D, 2000, LANCET, V355, P378, DOI 10.1016/S0140-6736(99)02134-0; Chae JJ, 2008, BLOOD, V112, P1794, DOI 10.1182/blood-2008-01-134932; Chae JJ, 2006, P NATL ACAD SCI USA, V103, P9982, DOI 10.1073/pnas.0602081103; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Day TG, 2008, ARTHRITIS RHEUM-US, V58, P2142, DOI 10.1002/art.23604; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Fidder H, 2005, AM J GASTROENTEROL, V100, P338, DOI 10.1111/j.1572-0241.2005.40810.x; Fidder HH, 2002, MEDICINE, V81, P411, DOI 10.1097/00005792-200211000-00001; Fisher SA, 2008, NAT GENET, V40, P710, DOI 10.1038/ng.145; Franke A, 2008, NAT GENET, V40, P713, DOI 10.1038/ng.148; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Giaglis S, 2006, DIGEST DIS SCI, V51, P687, DOI 10.1007/s10620-006-3192-1; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Hsu TM, 2001, BIOTECHNIQUES, V31, P560, DOI 10.2144/01313rr01; Karban A, 2005, GENES IMMUN, V6, P134, DOI 10.1038/sj.gene.6364156; Kramer M, 2006, J LEUKOCYTE BIOL, V79, P860, DOI 10.1189/jlb.0805484; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; Lichtenberger GS, 2004, INFLAMM BOWEL DIS, V10, pS58, DOI 10.1097/00054725-200402001-00012; Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; McDermott MF, 2004, TRENDS IMMUNOL, V25, P457, DOI 10.1016/j.it.2004.07.007; Milhavet F, 2008, HUM MUTAT, V29, P803, DOI 10.1002/humu.20720; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Papin S, 2007, CELL DEATH DIFFER, V14, P1457, DOI 10.1038/sj.cdd.4402142; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Plevy SE, 1997, J IMMUNOL, V159, P6276; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Sari S, 2008, EUR J PEDIATR, V167, P391, DOI 10.1007/s00431-007-0508-x; SILVERBERG MS, 2005, CAN J GASTROENTEROL, V5, P36; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Villani AC, 2009, NAT GENET, V41, P71, DOI 10.1038/ng.285; Whitcombe D, 1998, CLIN CHEM, V44, P918; Zaykin DV, 2008, AM J HUM GENET, V82, P794, DOI 10.1016/j.ajhg.2008.02.001	54	41	41	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7154	10.1371/journal.pone.0007154	http://dx.doi.org/10.1371/journal.pone.0007154			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784369	Green Published, gold			2022-12-27	WOS:000270290000003
J	Armougom, F; Henry, M; Vialettes, B; Raccah, D; Raoult, D				Armougom, Fabrice; Henry, Mireille; Vialettes, Bernard; Raccah, Denis; Raoult, Didier			Monitoring Bacterial Community of Human Gut Microbiota Reveals an Increase in Lactobacillus in Obese Patients and Methanogens in Anorexic Patients	PLOS ONE			English	Article							DIVERSITY; THERAPY	Background: Studies of the bacterial communities of the gut microbiota have revealed a shift in the ratio of Firmicutes and Bacteroidetes in obese patients. Determining the variations of microbial communities in feces may be beneficial for the identification of specific profiles in patients with abnormal weights. The roles of the archaeon Methanobrevibacter smithii and Lactobacillus species have not been described in these studies. Methods and Findings: We developed an efficient and robust real-time PCR tool that includes a plasmid-based internal control and allows for quantification of the bacterial divisions Bacteroidetes, Firmicutes, and Lactobacillus as well as the methanogen M. smithii. We applied this technique to the feces of 20 obese subjects, 9 patients with anorexia nervosa, and 20 normal-weight healthy controls. Our results confirmed a reduction in the Bacteroidetes community in obese patients (p<0.01). We found a significantly higher Lactobacillus species concentration in obese patients than in lean controls (p = 0.0197) or anorexic patients (p = 0.0332). The M. smithii concentration was much higher in anorexic patients than in the lean population (p = 0.0171). Conclusions: Lactobacillus species are widely used as growth promoters in the farm industry and are now linked to obesity in humans. The study of the bacterial flora in anorexic patients revealed an increase in M. smithii. This increase might represent an adaptive use of nutrients in this population.			Armougom, F (corresponding author), Univ Mediterranee, Fac Med, IRD 3R198, URMITE UMR CNRS 6236, Marseille, France.	didier.raoult@gmail.com	RAOULT, Didier/A-8434-2008	RAOULT, Didier/0000-0002-0633-5974				Armougom F, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-576; Charrel RN, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-21; Cole JR, 2007, NUCLEIC ACIDS RES, V35, pD169, DOI 10.1093/nar/gkl889; DiBaise JK, 2008, MAYO CLIN PROC, V83, P460, DOI 10.4065/83.4.460; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; FIEDOREK SC, 1990, J PEDIATR GASTR NUTR, V10, P473, DOI 10.1097/00005176-199005000-00010; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Huse SM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000255; Kanamori Y, 2004, J PEDIATR SURG, V39, P1686, DOI 10.1016/j.jpedsurg.2004.07.013; Khan M, 2007, BRIT POULTRY SCI, V48, P732, DOI 10.1080/00071660701716222; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; McKenna P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040020; Menard JP, 2008, CLIN INFECT DIS, V47, P33, DOI 10.1086/588661; MILLER TL, 1986, SYST APPL MICROBIOL, V7, P223; Rajilic-Stojanovic M, 2007, ENVIRON MICROBIOL, V9, P2125, DOI 10.1111/j.1462-2920.2007.01369.x; Raoult D, 2008, EUR J CLIN MICROBIOL, V27, P631, DOI 10.1007/s10096-008-0490-x; Rozen S, 2000, Methods Mol Biol, V132, P365; Samuel BS, 2006, P NATL ACAD SCI USA, V103, P10011, DOI 10.1073/pnas.0602187103; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Uchida K, 2007, PEDIATR SURG INT, V23, P243, DOI 10.1007/s00383-006-1866-6; Walker A, 2006, NAT REV MICROBIOL, V4, P572, DOI 10.1038/nrmicro1483; Walker A, 2007, NAT REV MICROBIOL, V5, P572, DOI 10.1038/nrmicro1720; WEAVER GA, 1986, GUT, V27, P698, DOI 10.1136/gut.27.6.698; Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106	27	574	610	1	123	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7125	10.1371/journal.pone.0007125	http://dx.doi.org/10.1371/journal.pone.0007125			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774074	Green Published, gold, Green Submitted			2022-12-27	WOS:000270160900010
J	Olivier, P; Fontaine, RH; Loron, G; Van Steenwinckel, J; Biran, V; Massonneau, V; Kaindl, A; Dalous, J; Charriaut-Marlangue, C; Aigrot, MS; Pansiot, J; Verney, C; Gressens, P; Baud, O				Olivier, Paul; Fontaine, Romain H.; Loron, Gauthier; Van Steenwinckel, Juliette; Biran, Valerie; Massonneau, Veronique; Kaindl, Angela; Dalous, Jeremie; Charriaut-Marlangue, Christiane; Aigrot, Marie-Stephane; Pansiot, Julien; Verney, Catherine; Gressens, Pierre; Baud, Olivier			Melatonin Promotes Oligodendroglial Maturation of Injured White Matter in Neonatal Rats	PLOS ONE			English	Article								Objective: To investigate the effects of melatonin treatment in a rat model of white matter damage (WMD) in the developing brain. Additionally, we aim to delineate the cellular mechanisms of melatonin effect on the oligodendroglial cell lineage. Methods: A unilateral ligation of the uterine artery in pregnant rat at the embryonic day 17 induces fetal hypoxia and subsequent growth restriction (GR) in neonatal pups. GR and control pups received a daily intra-peritoneal injection of melatonin from birth to post-natal day (P) 3. Results: Melatonin administration was associated with a dramatic decrease in microglial activation and astroglial reaction compared to untreated GR pups. At P14, melatonin prevented white matter myelination defects with an increased number of mature oligodendrocytes (APC-immunoreactive) in treated GR pups. Conversely, melatonin was not found to be associated with an increased density of total oligodendrocytes (Olig2-immunoreactive), suggesting that melatonin is able to promote oligodendrocyte maturation but not proliferation. These effects appear to be melatonin-receptor dependent and were reproduced in vitro. Interpretation: These data suggest that melatonin has a strong protective effect on developing damaged white matter through decreased microglial activation and oligodendroglial maturation leading to a normalization of the myelination process. Consequently, melatonin should be a considered as an effective neuroprotective candidate not only in perinatal brain damage but also in inflammatory and demyelinating diseases observed in adults.			Olivier, P (corresponding author), Hop Robert Debre, INSERM, AVENIR, R05230HS, F-75019 Paris, France.	olivier.baud@rdb.aphp.fr	Biran, Valerie/GQY-8192-2022; , CHARRIAUT-MARLANGUE/H-3249-2019; gressens, pierre/M-7557-2017	gressens, pierre/0000-0002-0909-4221; Van Steenwinckel, Juliette/0000-0003-3463-4856; Kaindl, Angela/0000-0001-9454-206X; LORON, Gauthier/0000-0001-9536-9510; Fontaine, Romain/0000-0003-4574-9165				Baud O, 2004, J NEUROSCI, V24, P1531, DOI 10.1523/JNEUROSCI.3989-03.2004; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Borlongan CV, 2000, NEUROREPORT, V11, P923, DOI 10.1097/00001756-200004070-00005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Fontaine RH, 2008, P NATL ACAD SCI USA, V105, P16779, DOI 10.1073/pnas.0803004105; Haynes RL, 2005, BRAIN PATHOL, V15, P225; HETIER E, 1988, J NEUROSCI RES, V21, P391, DOI 10.1002/jnr.490210230; Husson I, 2002, ANN NEUROL, V51, P82, DOI 10.1002/ana.10072; Ishimura R, 2002, TOXICOL APPL PHARM, V185, P197, DOI 10.1006/taap.2002.9539; Jacobsson B, 2008, BJOG-INT J OBSTET GY, V115, P1250, DOI 10.1111/j.1471-0528.2008.01827.x; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Martin V, 2002, J PINEAL RES, V33, P204, DOI 10.1034/j.1600-079X.2002.02113.x; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mesples B, 2005, NEUROBIOL DIS, V18, P193, DOI 10.1016/j.nbd.2004.09.018; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; NAVE KA, 1994, J NEUROSCI RES, V38, P607, DOI 10.1002/jnr.490380602; Olivier P, 2005, J NEUROPATH EXP NEUR, V64, P998, DOI 10.1097/01.jnen.0000187052.81889.57; Olivier P, 2007, NEUROBIOL DIS, V26, P253, DOI 10.1016/j.nbd.2007.01.001; Padilla-Gomes NF, 2007, ACTA PAEDIATR, V96, P1582, DOI 10.1111/j.1651-2227.2007.00496.x; Pei Z, 2003, J PINEAL RES, V34, P194, DOI 10.1034/j.1600-079X.2003.00026.x; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; Riccio P, 2000, J NEUROSCI RES, V59, P513, DOI 10.1002/(SICI)1097-4547(20000215)59:4<513::AID-JNR6>3.0.CO;2-M; ROSENBLUTH J, 1980, J COMP NEUROL, V194, P639, DOI 10.1002/cne.901940310; Schober ME, 2009, AM J PHYSIOL-REG I, V296, pR681, DOI 10.1152/ajpregu.90396.2008; Sun FY, 2002, J PINEAL RES, V33, P48, DOI 10.1034/j.1600-079X.2002.01891.x; Tahraoui SL, 2001, BRAIN PATHOL, V11, P56; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Welin AK, 2007, PEDIATR RES, V61, P153, DOI 10.1203/01.pdr.0000252546.20451.1a; Zhou JF, 2008, J PINEAL RES, V45, P157, DOI 10.1111/j.1600-079X.2008.00570.x	36	91	94	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7128	10.1371/journal.pone.0007128	http://dx.doi.org/10.1371/journal.pone.0007128			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771167	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400018
J	Hester, ME; Song, S; Miranda, CJ; Eagle, A; Schwartz, PH; Kaspar, BK				Hester, Mark E.; Song, SungWon; Miranda, Carlos J.; Eagle, Amy; Schwartz, Phillip H.; Kaspar, Brian K.			Two Factor Reprogramming of Human Neural Stem Cells into Pluripotency	PLOS ONE			English	Article							PROGENITOR CELLS; SOMATIC-CELLS; SELF-RENEWAL; FIBROBLASTS; GENERATION; MOUSE; EXPRESSION; INDUCTION; CIRCUITRY; SURVIVAL	Background: Reprogramming human somatic cells to pluripotency represents a valuable resource for the development of vitro based models for human disease and holds tremendous potential for deriving patient-specific pluripotent stem cells. Recently, mouse neural stem cells (NSCs) have been shown capable of reprogramming into a pluripotent state by forced expression of Oct3/4 and Klf4; however it has been unknown whether this same strategy could apply to human NSCs, which would result in more relevant pluripotent stem cells for modeling human disease. Methodology and Principal Findings: Here, we show that OCT3/4 and KLF4 are indeed sufficient to induce pluripotency from human NSCs within a two week time frame and are molecularly indistinguishable from human ES cells. Furthermore, human NSC-derived pluripotent stem cells can differentiate into all three germ lineages both in vitro and in vivo. Conclusions/Significance: We propose that human NSCs represent an attractive source of cells for producing human iPS cells since they only require two factors, obviating the need for c-MYC, for induction into pluripotency. Thus, in vitro human disease models could be generated from iPS cells derived from human NSCs.			Hester, ME (corresponding author), Nationwide Childrens Res Inst, Res Inst, Columbus, OH 44408 USA.	Brian.Kaspar@pediatrics.ohio-state.edu	Hester, Mark/AAY-8611-2020; Kaspar, Brian/E-3349-2011; Miranda, Carlos/B-7885-2008	Miranda, Carlos/0000-0001-8208-7100	NINDS NIH HHS [R01 NS064492, 1R01NS064492-01A1, R01 NS064492-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064492] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; BANITO A, 2009, GENES DEV; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cai JL, 2002, DEV BIOL, V251, P221, DOI 10.1006/dbio.2002.0828; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Darr H, 2006, REGEN MED, V1, P317, DOI 10.2217/17460751.1.3.317; Eminli S, 2008, STEM CELLS, V26, P2467, DOI 10.1634/stemcells.2008-0317; HONG H, 2009, NATURE; Hotta A, 2008, J CELL BIOCHEM, V105, P940, DOI 10.1002/jcb.21912; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698; KAWAMURA T, 2009, NATURE; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Lewitzky M, 2007, CURR OPIN BIOTECH, V18, P467, DOI 10.1016/j.copbio.2007.09.007; LI H, 2009, NATURE; Li XY, 2008, STEM CELLS DEV, V17, P1079, DOI 10.1089/scd.2007.0247; Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; MARION RM, 2009, NATURE; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Nandan MO, 2009, HISTOL HISTOPATHOL, V24, P1343, DOI 10.14670/HH-24.1343; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Stadtfeld M, 2008, CURR BIOL, V18, P890, DOI 10.1016/j.cub.2008.05.010; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TOHYAMA T, 1992, LAB INVEST, V66, P303; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; UTIKAL J, 2009, NATURE; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	38	53	56	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7044	10.1371/journal.pone.0007044	http://dx.doi.org/10.1371/journal.pone.0007044			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763260	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970400004
J	Masia, L; Casadio, M; Sandini, G; Morasso, P				Masia, Lorenzo; Casadio, Maura; Sandini, Giulio; Morasso, Pietro			Eye-Hand Coordination during Dynamic Visuomotor Rotations	PLOS ONE			English	Article							SENSORIMOTOR ADAPTATION; INTERNAL-MODEL; TRANSFORMATIONS; DIRECTION; POSITION; REPRESENTATIONS; LOCALIZATION; MECHANISMS; VISION; MUSCLE	Background: for many technology-driven visuomotor tasks such as tele-surgery, human operators face situations in which the frames of reference for vision and action are misaligned and need to be compensated in order to perform the tasks with the necessary precision. The cognitive mechanisms for the selection of appropriate frames of reference are still not fully understood. This study investigated the effect of changing visual and kinesthetic frames of reference during wrist pointing, simulating activities typical for tele-operations. Methods: using a robotic manipulandum, subjects had to perform center-out pointing movements to visual targets presented on a computer screen, by coordinating wrist flexion/extension with abduction/adduction. We compared movements in which the frames of reference were aligned (unperturbed condition) with movements performed under different combinations of visual/kinesthetic dynamic perturbations. The visual frame of reference was centered to the computer screen, while the kinesthetic frame was centered around the wrist joint. Both frames changed their orientation dynamically (angular velocity = 36 degrees/s) with respect to the head-centered frame of reference (the eyes). Perturbations were either unimodal (visual or kinesthetic), or bimodal (visual+kinesthetic). As expected, pointing performance was best in the unperturbed condition. The spatial pointing error dramatically worsened during both unimodal and most bimodal conditions. However, in the bimodal condition, in which both disturbances were in phase, adaptation was very fast and kinematic performance indicators approached the values of the unperturbed condition. Conclusions: this result suggests that subjects learned to exploit an "affordance" made available by the invariant phase relation between the visual and kinesthetic frames. It seems that after detecting such invariance, subjects used the kinesthetic input as an informative signal rather than a disturbance, in order to compensate the visual rotation without going through the lengthy process of building an internal adaptation model. Practical implications are discussed as regards the design of advanced, high-performance man-machine interfaces.			Masia, L (corresponding author), Italian Inst Technol, Dept Robot Brain & Cognit Sci, Genoa, Italy.	lorenzo.masia@iit.it	MASIA, LORENZO/D-9385-2014; Casadio, Maura/AAH-2861-2022; Casadio, Maura/AFM-0496-2022	Sandini, Giulio/0000-0003-3324-985X				Abeele S, 2001, EXP BRAIN RES, V140, P407, DOI 10.1007/s002210100846; Abeele S, 2001, EXP BRAIN RES, V139, P248, DOI 10.1007/s002210100768; ANDERSON R, 1980, TECHNIQUE USE SURG T; Baugh LA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005484; BERNOTAT R, 1970, ERGONOMICS, V13, P353; Bock O, 2008, HUM MOVEMENT SCI, V27, P383, DOI 10.1016/j.humov.2008.01.001; BREEDVELD P, 2002, MINIM INVASIV THER, V10, P155; BRIAN P, 2004, P IEEE INT C ROB AUT; Brown LE, 2003, J NEUROPHYSIOL, V90, P3105, DOI 10.1152/jn.00013.2003; Congedo M, 2006, PRESENCE-TELEOP VIRT, V15, P353, DOI 10.1162/pres.15.3.353; CUNNINGHAM HA, 1989, J EXP PSYCHOL HUMAN, V15, P493, DOI 10.1037/0096-1523.15.3.493; CUNNINGHAM HA, 1990, BIOL CYBERN, V64, P117, DOI 10.1007/BF02331340; Cuschieri A, 1992, OPERATIVE MANUAL END; DIZIO P, 1993, J NEUROPHYSIOL, V70, P1578, DOI 10.1152/jn.1993.70.4.1578; ELLIS SR, 1993, SID 93 DIGEST, P487; GHILARDI MF, 1995, J NEUROPHYSIOL, V73, P2535, DOI 10.1152/jn.1995.73.6.2535; Girgenrath M, 2008, EXP BRAIN RES, V184, P561, DOI 10.1007/s00221-007-1124-8; Groen J, 1998, PRESENCE-TELEOP VIRT, V7, P429, DOI 10.1162/105474698565839; Kakei S, 2003, NEUROSCI RES, V46, P1, DOI 10.1016/S0168-0102(03)00031-2; Kakei S, 2001, NAT NEUROSCI, V4, P1020, DOI 10.1038/nn726; Kakei S, 1999, SCIENCE, V285, P2136, DOI 10.1126/science.285.5436.2136; KIM WS, 1987, IEEE T SYST MAN CYB, V17, P61, DOI 10.1109/TSMC.1987.289333; KITAZAWA S, 1995, J NEUROSCI, V15, P7644; KOHLER, 1964, FORMATION TRANSFORMA; Krakauer JW, 2009, ADV EXP MED BIOL, V629, P405, DOI 10.1007/978-0-387-77064-2_21; Krakauer JW, 2000, J NEUROSCI, V20, P8916, DOI 10.1523/jneurosci.20-23-08916.2000; Krakauer JW, 2005, J NEUROSCI, V25, P473, DOI 10.1523/JNEUROSCI.4218-04.2005; LACKNER JR, 1979, AVIAT SPACE ENVIR MD, V50, P346; Pennel I, 2003, J MOTOR BEHAV, V35, P274, DOI 10.1080/00222890309602140; Pennel I, 2002, ERGONOMICS, V45, P1047, DOI 10.1080/00140130210166906; PICK HL, 1969, J EXP PSYCHOL, V80, P125, DOI 10.1037/h0027111; Sainburg RL, 2003, J NEUROPHYSIOL, V89, P401, DOI 10.1152/jn.00243.2002; Shadmehr R., 2005, COMPUTATIONAL NEUROB; Soechting J F, 1991, Exerc Sport Sci Rev, V19, P389; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P595, DOI 10.1152/jn.1989.62.2.595; Stratton G.M., 1897, PSYCHOL REV, V4, P341, DOI [DOI 10.1037/H0075482, 10.1037/h0075482]; Tendick F., 1993, PRESENCETELEOP VIRT, V2, P66, DOI [DOI 10.1162/PRES.1993.2.1.66, 10.1162/pres.1993.2.1.66]; VANLAER E, 1970, PERCEPT MOTOR SKILL, V30, P723, DOI 10.2466/pms.1970.30.3.723; Vindras P, 1998, J EXP PSYCHOL HUMAN, V24, P569, DOI 10.1037/0096-1523.24.2.569; WARREN DH, 1979, PERCEPTION, V8, P323, DOI 10.1068/p080323; WARREN DH, 1971, J EXP PSYCHOL, V90, P206, DOI 10.1037/h0031545; WARREN DH, 1978, J EXP PSYCHOL HUMAN, V4, P302, DOI 10.1037/0096-1523.4.2.302; Wentink M, 2002, SURG ENDOSC, V16, P1533, DOI 10.1007/s00464-001-9214-3; Wigmore V, 2002, J EXP PSYCHOL HUMAN, V28, P447, DOI 10.1037//0096-1523.28.2.447; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	48	48	49	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7004	10.1371/journal.pone.0007004	http://dx.doi.org/10.1371/journal.pone.0007004			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	494FO	19753120	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796500003
J	Rizk, ML; Liao, JC				Rizk, Matthew L.; Liao, James C.			Ensemble Modeling for Aromatic Production in Escherichia coli	PLOS ONE			English	Article								Ensemble Modeling (EM) is a recently developed method for metabolic modeling, particularly for utilizing the effect of enzyme tuning data on the production of a specific compound to refine the model. This approach is used here to investigate the production of aromatic products in Escherichia coli. Instead of using dynamic metabolite data to fit a model, the EM approach uses phenotypic data (effects of enzyme overexpression or knockouts on the steady state production rate) to screen possible models. These data are routinely generated during strain design. An ensemble of models is constructed that all reach the same steady state and are based on the same mechanistic framework at the elementary reaction level. The behavior of the models spans the kinetics allowable by thermodynamics. Then by using existing data from the literature for the overexpression of genes coding for transketolase (Tkt), transaldolase (Tal), and phosphoenolpyruvate synthase (Pps) to screen the ensemble, we arrive at a set of models that properly describes the known enzyme overexpression phenotypes. This subset of models becomes more predictive as additional data are used to refine the models. The final ensemble of models demonstrates the characteristic of the cell that Tkt is the first rate controlling step, and correctly predicts that only after Tkt is overexpressed does an increase in Pps increase the production rate of aromatics. This work demonstrates that EM is able to capture the result of enzyme overexpression on aromatic producing bacteria by successfully utilizing routinely generated enzyme tuning data to guide model learning.			Rizk, ML (corresponding author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90024 USA.	liaoj@seas.ucla.edu		Liao, James/0000-0002-4580-7276	NIGMS NIH HHS [01GM076143, R01 GM076143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alper H, 2005, P NATL ACAD SCI USA, V102, P12678, DOI 10.1073/pnas.0504604102; Alper H, 2005, NAT BIOTECHNOL, V23, P612, DOI 10.1038/nbt1083; ANTONIEWICZ MR, 2006, METAB ENG A IN PRESS; Baez JL, 2001, BIOTECHNOL BIOENG, V73, P530, DOI 10.1002/bit.1088; Berry A, 1996, TRENDS BIOTECHNOL, V14, P250, DOI 10.1016/0167-7799(96)10033-0; Bongaerts J, 2001, METAB ENG, V3, P289, DOI 10.1006/mben.2001.0196; CHAO YP, 1993, J BACTERIOL, V175, P6939, DOI 10.1128/jb.175.21.6939-6944.1993; CONTADOR CA, 2009, METAB ENG; Cook P. F., 2007, ENZYME KINETICS MECH; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, DOI 10.1016/C2013-0-04130-8; DRATHS KM, 1992, J AM CHEM SOC, V114, P3956, DOI 10.1021/ja00036a050; Farmer WR, 2001, BIOTECHNOL PROGR, V17, P57, DOI 10.1021/bp000137t; Flores N, 1996, NAT BIOTECHNOL, V14, P620, DOI 10.1038/nbt0596-620; Goldberg RN, 2004, BIOINFORMATICS, V20, P2874, DOI 10.1093/bioinformatics/bth314; Gosset G, 1996, J IND MICROBIOL, V17, P47, DOI 10.1007/BF01570148; Heijnen JJ, 2004, METAB ENG, V6, P391, DOI 10.1016/j.ymben.2004.07.002; Henry CS, 2007, BIOPHYS J, V92, P1792, DOI 10.1529/biophysj.106.093138; Henry CS, 2006, BIOPHYS J, V90, P1453, DOI 10.1529/biophysj.105.071720; Ikeda Masato, 2003, Adv Biochem Eng Biotechnol, V79, P1; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KELL DB, 1986, FEMS MICROBIOL LETT, V39, P305, DOI 10.1016/0378-1097(86)90020-0; Kholodenko BN, 1998, BIOTECHNOL BIOENG, V59, P239, DOI 10.1002/(SICI)1097-0290(19980720)59:2&lt;239::AID-BIT11&gt;3.0.CO;2-9; LIAO JC, 1993, BIOTECHNOL PROGR, V9, P221, DOI 10.1021/bp00021a001; Lu JL, 1997, BIOTECHNOL BIOENG, V53, P132, DOI 10.1002/(SICI)1097-0290(19970120)53:2<132::AID-BIT2>3.0.CO;2-P; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; PATNAIK R, 1994, APPL ENVIRON MICROB, V60, P3903, DOI 10.1128/AEM.60.11.3903-3908.1994; PATNAIK R, 1995, BIOTECHNOL BIOENG, V46, P361, DOI 10.1002/bit.260460409; Rizk ML, 2009, J TAIWAN INST CHEM E, V40, P595, DOI 10.1016/j.jtice.2009.05.003; Schellenberger J, 2009, J BIOL CHEM, V284, P5457, DOI 10.1074/jbc.R800048200; Sriram G, 2004, PLANT PHYSIOL, V136, P3043, DOI 10.1104/pp.104.050625; Sriram G, 2004, METAB ENG, V6, P116, DOI 10.1016/j.ymben.2004.02.003; Tran LM, 2008, BIOPHYS J, V95, P5606, DOI 10.1529/biophysj.108.135442; Visser D, 2002, METAB ENG, V4, P114, DOI 10.1006/mben.2001.0216; Wang LQ, 2006, METAB ENG, V8, P142, DOI 10.1016/j.ymben.2005.11.002; Wang LQ, 2004, BIOPHYS J, V87, P3750, DOI 10.1529/biophysj.104.048090; Yang TH, 2005, COMPUT BIOL CHEM, V29, P121, DOI 10.1016/j.compbiolchem.2005.02.005; Yang TH, 2004, METAB ENG, V6, P256, DOI 10.1016/j.ymben.2004.02.002	37	40	41	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6903	10.1371/journal.pone.0006903	http://dx.doi.org/10.1371/journal.pone.0006903			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730732	gold, Green Published, Green Submitted			2022-12-27	WOS:000269622100008
J	Klinghoffer, RA; Frazier, J; Annis, J; Berndt, JD; Roberts, BS; Arthur, WT; Lacson, R; Zhang, XD; Ferrer, M; Moon, RT; Cleary, MA				Klinghoffer, Richard A.; Frazier, Jason; Annis, James; Berndt, Jason D.; Roberts, Brian S.; Arthur, William T.; Lacson, Raul; Zhang, Xiaohua Douglas; Ferrer, Marc; Moon, Randall T.; Cleary, Michele A.			A Lentivirus-Mediated Genetic Screen Identifies Dihydrofolate Reductase (DHFR) as a Modulator of beta-Catenin/GSK3 Signaling	PLOS ONE			English	Article							BETA-CATENIN; HIT SELECTION; MELANOMA; PATHWAY; QUALITY; TUMORS; CELLS	The multi-protein beta-catenin destruction complex tightly regulates beta-catenin protein levels by shuttling beta-catenin to the proteasome. Glycogen synthase kinase 3 beta (GSK3 beta), a key serine/threonine kinase in the destruction complex, is responsible for several phosphorylation events that mark beta-catenin for ubiquitination and subsequent degradation. Because modulation of both beta-catenin and GSK3 beta activity may have important implications for treating disease, a complete understanding of the mechanisms that regulate the beta-catenin/GSK3 beta interaction is warranted. We screened an arrayed lentivirus library expressing small hairpin RNAs (shRNAs) targeting 5,201 human druggable genes for silencing events that activate a beta-catenin pathway reporter (BAR) in synergy with 6-bromoindirubin-3'oxime (BIO), a specific inhibitor of GSK3 beta. Top screen hits included shRNAs targeting dihydrofolate reductase (DHFR), the target of the anti-inflammatory compound methotrexate. Exposure of cells to BIO plus methotrexate resulted in potent synergistic activation of BAR activity, reduction of beta-catenin phosphorylation at GSK3-specific sites, and accumulation of nuclear beta-catenin. Furthermore, the observed synergy correlated with inhibitory phosphorylation of GSK3 beta and was neutralized upon inhibition of phosphatidyl inositol 3-kinase (PI3K). Linking these observations to inflammation, we also observed synergistic inhibition of lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines (TNF alpha, IL-6, and IL-12), and increased production of the anti-inflammatory cytokine IL-10 in peripheral blood mononuclear cells exposed to GSK3 inhibitors and methotrexate. Our data establish DHFR as a novel modulator of beta-catenin and GSK3 signaling and raise several implications for clinical use of combined methotrexate and GSK3 inhibitors as treatment for inflammatory disease.			Klinghoffer, RA (corresponding author), Rosetta Inpharmat LLC, Seattle, WA USA.	richard_klinghoffer@merck.com	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Zhang, Xiaohua Douglas/0000-0002-2486-7931				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Bartz SR, 2006, MOL CELL BIOL, V26, P9377, DOI 10.1128/MCB.01229-06; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Buchbinder R, 2008, ARTHRIT RHEUM-ARTHR, V59, P794, DOI 10.1002/art.23716; Carter M, 2005, P NATL ACAD SCI USA, V102, P12843, DOI 10.1073/pnas.0501963102; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CRONSTEIN BN, 1992, INFLAMMATION, V16, P411, DOI 10.1007/BF00918968; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Jaszewski R, 2004, CANCER LETT, V206, P27, DOI 10.1016/j.canlet.2003.10.027; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klinghoffer RA, 2008, ASSAY DRUG DEV TECHN, V6, P105, DOI 10.1089/adt.2007.106; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu ZH, 2007, J NUTR, V137, P2701, DOI 10.1093/jn/137.12.2701; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Orth AP, 2004, EXPERT OPIN THER TAR, V8, P587, DOI 10.1517/14728222.8.6.587; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Strimmer K, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-303; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Zhang XHD, 2006, PHARMACOGENOMICS, V7, P299, DOI 10.2217/14622416.7.3.299; Zhang XHD, 2008, J BIOMOL SCREEN, V13, P378, DOI 10.1177/1087057108317145; Zhang XHD, 2008, J BIOMOL SCREEN, V13, P363, DOI 10.1177/1087057108317062; Zhang XD, 2007, J BIOMOL SCREEN, V12, P645, DOI 10.1177/1087057107300645; Zhang XD, 2007, J BIOMOL SCREEN, V12, P497, DOI 10.1177/1087057107300646; Zhang XHD, 2009, BIOINFORMATICS, V25, P841, DOI 10.1093/bioinformatics/btp082	33	16	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6892	10.1371/journal.pone.0006892	http://dx.doi.org/10.1371/journal.pone.0006892			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727391	gold, Green Published, Green Submitted			2022-12-27	WOS:000269522900021
J	Lamba, S; Felicioni, L; Buttitta, F; Bleeker, FE; Malatesta, S; Corbo, V; Scarpa, A; Rodolfo, M; Knowles, M; Frattini, M; Marchetti, A; Bardelli, A				Lamba, Simona; Felicioni, Lara; Buttitta, Fiamma; Bleeker, Fonnet E.; Malatesta, Sara; Corbo, Vincenzo; Scarpa, Aldo; Rodolfo, Monica; Knowles, Margaret; Frattini, Milo; Marchetti, Antonio; Bardelli, Alberto			Mutational Profile of GNAQ(Q209) in Human Tumors	PLOS ONE			English	Article								Background: Frequent somatic mutations have recently been identified in the ras-like domain of the heterotrimeric G protein alpha-subunit (GNAQ) in blue naevi 83%, malignant blue naevi (50%) and ocular melanoma of the uvea (46%). The mutations exclusively affect codon 209 and result in GNAQ constitutive activation which, in turn, acts as a dominant oncogene. Methodology: To assess if the mutations are present in other tumor types we performed a systematic mutational profile of the GNAQ exon 5 in a panel of 922 neoplasms, including glioblastoma, gastrointestinal stromal tumors (GIST), acute myeloid leukemia (AML), blue naevi, skin melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas. Principal Findings: We detected the previously reported mutations in 6/13 (46%) blue naevi. Changes affecting Q209 were not found in any of the other tumors. Our data indicate that the occurrence of GNAQ mutations display a unique pattern being present in a subset of melanocytic tumors but not in malignancies of glial, epithelial and stromal origin analyzed in this study.			Lamba, S (corresponding author), Univ Torino, Med Sch Candiolo TO, Sch Med, Inst Canc Res & Treatment,Lab Mol Genet, Turin, Italy.	a.bardelli@unito.it	rodolfo, monica/H-2671-2012; scarpa, aldo/K-6832-2016; BARDELLI, Alberto/J-9721-2018; Corbo, Vincenzo/J-7754-2016	rodolfo, monica/0000-0002-9196-0298; scarpa, aldo/0000-0003-1678-739X; Lamba, Simona Elena/0000-0003-3207-1594; BARDELLI, Alberto/0000-0003-1647-5070; Corbo, Vincenzo/0000-0002-6340-8009; Knowles, Margaret/0000-0002-9363-8657	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; KATHERINE L, 2005, BIOCH CELL BIOL, V83, P1; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Saldanha G, 2004, INT J CANCER, V111, P705, DOI 10.1002/ijc.20325; SHIN MK, 1999, NATURE DEV BIOL, P162; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586	9	56	57	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6833	10.1371/journal.pone.0006833	http://dx.doi.org/10.1371/journal.pone.0006833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718445	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415900006
J	Masuda, A; Aou, S				Masuda, Akira; Aou, Shuji			Social Transmission of Avoidance Behavior under Situational Change in Learned and Unlearned Rats	PLOS ONE			English	Article							FOOD PREFERENCES; NORWAY RATS; RATTUS-NORVEGICUS; DISCRIMINATION; CHIMPANZEES; AVERSIONS; VIGILANCE; EXPOSURE; PREDATOR; STIMULI	Background: Rats receive information from other conspecifics by observation or other types of social interaction. Such social interaction may contribute to the effective adaptation to changes of environment such as situational switching. Learning to avoid dangerous places or objects rapidly occurs with even a single conditioning session, and the conditioned memory tends to be sustained over long periods. The avoidance is important for adaptation, but the details of the conditions under which the social transmission of avoidance is formed are unknown. We demonstrate that the previous experience of avoidance learning is important for the formation of behaviors for social transmission of avoidance and that the experienced rats adapt to a change of situation determined by the presence or absence of aversive stimuli. We systematically investigated social influence on avoidance behavior using a passive avoidance test in a light/dark two-compartment apparatus. Methodology/Principal Findings: Rats were divided into two groups, one receiving foot shocks and another with no aversive experience in a dark compartment. Experienced and inexperienced rats were further divided into subjects and partners. In Experiment 1, each subject experienced (1) interaction with an experienced partner, (2) interaction with an inexperienced partner, or (3) no interaction. In Experiment 2, each subject experienced interaction with a partner that received a shock. The entering latency to a light compartment was measured. The avoidance behavior of experienced rats was inhibited by interaction with inexperienced or experienced partners in a safely-changed situation. The avoidance of experienced rats was reinstated in a dangerously-changed situation by interaction with shocked rats. In contrast, the inexperienced rats were not affected by any social circumstances. Conclusions/Significance: These results suggest that transmitted information among rats can be updated under a situational change and that the previous experience is crucial for social enhancement and inhibition of avoidance behavior in rats.			Masuda, A (corresponding author), Kyushu Inst Technol, Dept Brain Sci & Engn, Kitakyushu, Fukuoka 804, Japan.	aou@brain.kyutech.ac.jp	Masuda, Akira/G-1164-2011; Masuda, Akira/AAU-2391-2020	Masuda, Akira/0000-0002-8659-6356				BAUM M, 1969, J COMP PHYSIOL PSYCH, V67, P83, DOI 10.1037/h0026664; Biro D, 2003, ANIM COGN, V6, P213, DOI 10.1007/s10071-003-0183-x; Blaisdell AP, 2006, SCIENCE, V311, P1020, DOI 10.1126/science.1121872; BLANCHARD RJ, 1991, PHYSIOL BEHAV, V50, P967, DOI 10.1016/0031-9384(91)90423-L; Brown GE, 2003, FISH FISH, V4, P227, DOI 10.1046/j.1467-2979.2003.00132.x; Carlier P, 2006, BEHAV BRAIN RES, V174, P125, DOI 10.1016/j.bbr.2006.07.014; COOK M, 1985, J ABNORM PSYCHOL, V94, P591, DOI 10.1037/0021-843X.94.4.591; DEVRY J, 1993, EUR J PHARMACOL, V249, P331, DOI 10.1016/0014-2999(93)90530-U; ELGAR MA, 1989, BIOL REV, V64, P13, DOI 10.1111/j.1469-185X.1989.tb00636.x; ELGAR MA, 1984, BEHAVIOUR, V90, P215, DOI 10.1163/156853984X00146; Fletcher ML, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0005.2002; GALEF BG, 1988, PHYSIOL BEHAV, V42, P119, DOI 10.1016/0031-9384(88)90285-5; GALEF BG, 1986, J COMP PSYCHOL, V100, P432, DOI 10.1037/0735-7036.100.4.432; Galef BG, 2001, ANIM BEHAV, V62, P41, DOI 10.1006/anbe.2000.1721; Galef BG, 2005, BIOSCIENCE, V55, P489, DOI 10.1641/0006-3568(2005)055[0489:SLIAES]2.0.CO;2; GALEF BG, 1985, ANIM LEARN BEHAV, V13, P25, DOI 10.3758/BF03213361; GALEF BG, 1983, J COMP PSYCHOL, V97, P358, DOI 10.1037/0735-7036.97.4.358; Galef BG, 2003, LEARN BEHAV, V31, P160; GALEF BG, 1990, ANIM LEARN BEHAV, V18, P199, DOI 10.3758/BF03205259; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Goubert L, 2005, PAIN, V118, P285, DOI 10.1016/j.pain.2005.10.025; HALL D, 1995, NEUROBIOL LEARN MEM, V63, P229, DOI 10.1006/nlme.1995.1027; HEYES CM, 1992, Q J EXP PSYCHOL-B, V45, P229; HEYES CM, 1990, Q J EXP PSYCHOL-B, V42, P59; HIKAMI K, 1990, J COMP PSYCHOL, V104, P233, DOI 10.1037/0735-7036.104.3.233; Hirata S, 2000, J COMP PSYCHOL, V114, P291, DOI 10.1037/0735-7036.114.3.291; Kiyokawa Y, 2004, BEHAV NEUROSCI, V118, P798, DOI 10.1037/0735-7044.118.4.798; Kiyokawa Y, 2007, EUR J NEUROSCI, V26, P3606, DOI 10.1111/j.1460-9568.2007.05969.x; Knapska E, 2006, P NATL ACAD SCI USA, V103, P3858, DOI 10.1073/pnas.0511302103; Li W, 2008, SCIENCE, V319, P1842, DOI 10.1126/science.1152837; LIMA SL, 1990, CAN J ZOOL, V68, P619, DOI 10.1139/z90-092; LORE R, 1971, ANIM BEHAV, V19, P112, DOI 10.1016/S0003-3472(71)80143-4; MACKAYSIM A, 1981, PHYSIOL BEHAV, V27, P511, DOI 10.1016/0031-9384(81)90340-1; Magurran AE, 1996, P ROY SOC B-BIOL SCI, V263, P1551, DOI 10.1098/rspb.1996.0227; Mowrer OH, 1947, HARVARD EDUC REV, V17, P102; Murphy RA, 2008, SCIENCE, V319, P1849, DOI 10.1126/science.1151564; RIESS D, 1972, J EXP ANAL BEHAV, V18, P181, DOI 10.1901/jeab.1972.18-181; von Frisch K, 1938, NATURWISSENSCHAFTEN, V26, P601; White DJ, 1998, ANIM LEARN BEHAV, V26, P433, DOI 10.3758/BF03199236; Wilson DA, 2003, J NEUROPHYSIOL, V90, P65, DOI 10.1152/jn.00133.2003; ZENTALL TR, 1972, SCIENCE, V178, P1220, DOI 10.1126/science.178.4066.1220	41	24	24	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6794	10.1371/journal.pone.0006794	http://dx.doi.org/10.1371/journal.pone.0006794			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489JE	19710921	gold, Green Published, Green Submitted			2022-12-27	WOS:000269415600008
J	Sung, MH; Salvatore, L; De Lorenzi, R; Indrawan, A; Pasparakis, M; Hager, GL; Bianchi, ME; Agresti, A				Sung, Myong-Hee; Salvatore, Luigi; De Lorenzi, Rossana; Indrawan, Anindya; Pasparakis, Manolis; Hager, Gordon L.; Bianchi, Marco E.; Agresti, Alessandra			Sustained Oscillations of NF-kappa B Produce Distinct Genome Scanning and Gene Expression Profiles	PLOS ONE			English	Article							IN-SILICO; GLUCOCORTICOID-RECEPTOR; TEMPORAL CONTROL; DYNAMICS; TRANSCRIPTION; CHROMATIN; PATHWAY; BINDING	NF-kappa B is a prototypic stress-responsive transcription factor that acts within a complex regulatory network. The signaling dynamics of endogenous NF-kappa B in single cells remain poorly understood. To examine real time dynamics in living cells, we monitored NF-kappa B activities at multiple timescales using GFP-p65 knock-in mouse embryonic fibroblasts. Oscillations in NFkB were sustained in most cells, with several cycles of transient nuclear translocation after TNF-alpha stimulation. Mathematical modeling suggests that NF-kappa B oscillations are selected over other non-oscillatory dynamics by fine-tuning the relative strengths of feedback loops like I kappa B alpha. The ability of NF-kappa B to scan and interact with the genome in vivo remained remarkably constant from early to late cycles, as observed by fluorescence recovery after photobleaching (FRAP). Perturbation of long-term NF-kappa B oscillations interfered with its short-term interaction with chromatin and balanced transcriptional output, as predicted by the mathematical model. We propose that negative feedback loops do not simply terminate signaling, but rather promote oscillations of NF-kappa B in the nucleus, and these oscillations are functionally advantageous.			Sung, MH (corresponding author), NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA.	sungm@mail.nih.gov; agresti.alessandra@hsr.it	Bianchi, Marco Emilio/K-3417-2018; Pasparakis, Manolis/N-4350-2019; Agresti, Alessandra/K-5228-2016; Agresti, Alessandra/Q-4394-2019; Pasparakis, Manolis/H-9292-2017; Sung, Myong-Hee/AAC-7316-2020	Bianchi, Marco Emilio/0000-0002-5329-6445; Pasparakis, Manolis/0000-0002-9870-0966; Agresti, Alessandra/0000-0001-5006-9506; Agresti, Alessandra/0000-0001-5006-9506; Pasparakis, Manolis/0000-0002-9870-0966; Sung, Myong-Hee/0000-0002-9739-8558	Intramural NIH HHS Funding Source: Medline; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; NATIONAL CANCER INSTITUTE [ZIABC005450] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barken D, 2005, SCIENCE, V308, DOI 10.1126/science.1107904; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Braeckmans K, 2007, BIOPHYS J, V92, P2172, DOI 10.1529/biophysj.106.099838; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Cheong R, 2006, J BIOL CHEM, V281, P2945, DOI 10.1074/jbc.M510085200; Cheong R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.30; De Lorenzi R, 2009, GENESIS, V47, P323, DOI 10.1002/dvg.20468; Dundr M, 2007, J CELL BIOL, V179, P1095, DOI 10.1083/jcb.200710058; Geva-Zatorsky N, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100068; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Ihekwaba AEC, 2007, FEBS J, V274, P1678, DOI 10.1111/j.1742-4658.2007.05713.x; Kearns JD, 2006, J CELL BIOL, V173, P659, DOI 10.1083/jcb.200510155; Lassot I, 2007, MOL CELL, V25, P369, DOI 10.1016/j.molcel.2006.12.020; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Schaaf MJM, 2006, J BIOL CHEM, V281, P22409, DOI 10.1074/jbc.M511086200; Sillitoe K, 2007, BIOCHEM SOC T, V35, P263, DOI 10.1042/BST0350263; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Sung MH, 2004, MOL PHARMACOL, V66, P70, DOI 10.1124/mol.66.1.70; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zi ZK, 2005, FEBS LETT, V579, P1101, DOI 10.1016/j.febslet.2005.01.009	30	86	86	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7163	10.1371/journal.pone.0007163	http://dx.doi.org/10.1371/journal.pone.0007163			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787057	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290100005
J	Jimenez, AP; Mohamed, MK; Eldin, NS; Abou Seif, H; El Aidi, S; Sultan, Y; Elsaid, N; Rekacewicz, C; El-Hoseiny, M; El-Daly, M; Abdel-Hamid, M; Fontanet, A				Jimenez, Adela Paez; Mohamed, Mostafa K.; Eldin, Noha Sharaf; Abou Seif, Hasnaa; El Aidi, Said; Sultan, Yehia; Elsaid, Nasr; Rekacewicz, Claire; El-Hoseiny, Mostafa; El-Daly, May; Abdel-Hamid, Mohamed; Fontanet, Arnaud			Injection Drug Use Is a Risk Factor for HCV Infection in Urban Egypt	PLOS ONE			English	Article							HEPATITIS-C-VIRUS; VOLUNTEER BLOOD-DONORS; SEXUAL TRANSMISSION; NILE DELTA; COMMUNITY; SPREAD; EPIDEMIOLOGY; POPULATION; PREVALENCE; ROUTES	Objective: To identify current risk factors for hepatitis C virus (HCV) transmission in Greater Cairo. Design and Setting: A 1: 1 matched case-control study was conducted comparing incident acute symptomatic hepatitis C patients in two "fever'' hospitals of Greater Cairo with two control groups: household members of the cases and acute hepatitis A patients diagnosed at the same hospitals. Controls were matched on the same age and sex to cases and were all anti-HCV antibody negative. Iatrogenic, community and household exposures to HCV in the one to six months before symptoms onset for cases, and date of interview for controls, were exhaustively assessed. Results: From 2002 to 2007, 94 definite acute symptomatic HCV cases and 188 controls were enrolled in the study. In multivariate analysis, intravenous injections (OR = 5.0; 95% CI = 1.2-20.2), medical stitches (OR = 4.2; 95% CI = 1.6-11.3), injection drug use (IDU) (OR = 7.9; 95% CI = 1.4-43.5), recent marriage (OR = 3.3; 95% CI = 1.1-9.9) and illiteracy (OR = 3.9; 95% CI = 1.8-8.5) were independently associated with an increased HCV risk. Conclusion: In urban Cairo, invasive health care procedures remain a source of HCV transmission and IDU is an emerging risk factor. Strict application of standard precautions during health care is a priority. Implementation of comprehensive infection prevention programs for IDU should be considered.			Jimenez, AP (corresponding author), Inst Pasteur, Emerging Dis Epidemiol Unit, Paris, France.	adelapaez@yahoo.com	mohamed, mostafa/AFE-7371-2022; El-Daly, Mai/C-4704-2013	mohamed, mostafa/0000-0002-1421-2667; PAEZ JIMENEZ, Adela/0000-0002-8653-610X; El-Daly, Mai/0000-0002-3864-523X; , arnaud/0000-0002-5239-6110				Aaron S, 2008, CLIN INFECT DIS, V47, P931, DOI 10.1086/591699; Abdel-Aziz F, 2000, HEPATOLOGY, V32, P111, DOI 10.1053/jhep.2000.8438; Abdel-Hamid M, 1997, J Hum Virol, V1, P58; Abdel-Hamid M, 2007, J GEN VIROL, V88, P1526, DOI 10.1099/vir.0.82626-0; Akhtar S, 2004, J VIRAL HEPATITIS, V11, P527, DOI 10.1111/j.1365-2893.2004.00518.x; Alavian SM, 2002, J GASTROEN HEPATOL, V17, P1092, DOI 10.1046/j.1440-1746.2002.02843.x; Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436; Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389; Arafa N, 2005, J HEPATOL, V43, P418, DOI 10.1016/j.jhep.2005.03.021; Bari A, 2001, TROP MED INT HEALTH, V6, P732, DOI 10.1046/j.1365-3156.2001.00779.x; Brandao Ajacio B M, 2002, BMC Gastroenterol, V2, P18, DOI 10.1186/1471-230X-2-18; Brewer DD, 2006, J INFECT DIS, V194, P764, DOI 10.1086/505585; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Edlin BR, 2006, CLIN INFECT DIS, V42, P673, DOI 10.1086/499960; El Gaafary MM, 2005, J MED VIROL, V76, P520, DOI 10.1002/jmv.20392; el-Sadawy Mahmoud, 2004, J Egypt Soc Parasitol, V34, P367; ELDIN NIS, 2000, PLOS ONE, V3; Esteban JI, 2008, J HEPATOL, V48, P148, DOI 10.1016/j.jhep.2007.07.033; Fabris P, 2008, CURR PHARM DESIGN, V14, P1661, DOI 10.2174/138161208784746789; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; Garten RJ, 2004, INT J EPIDEMIOL, V33, P182, DOI 10.1093/ije/dyh019; Gates JA, 2004, J URBAN HEALTH, V81, P448, DOI 10.1093/jurban/jth129; Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1053/jhep.1997.v26.pm0009328327; Habib M, 2001, HEPATOLOGY, V33, P248, DOI 10.1053/jhep.2001.20797; Hagan H, 2004, EPIDEMIOLOGY, V15, P543, DOI 10.1097/01.ede.0000135170.54913.9d; Hajiani E, 2006, WORLD J GASTROENTERO, V12, P4884; Karmochkine M, 2006, J VIRAL HEPATITIS, V13, P775, DOI 10.1111/j.1365-2893.2006.00742.x; Magder LS, 2005, INT J EPIDEMIOL, V34, P160, DOI 10.1093/ije/dyh370; Maheshwari A, 2008, LANCET, V372, P321, DOI 10.1016/S0140-6736(08)61116-2; Mariano A, 2004, J MED VIROL, V74, P216, DOI 10.1002/jmv.20182; Marzouk D, 2007, GUT, V56, P1105, DOI 10.1136/gut.2006.091983; McMahon James M, 2004, Ann Clin Microbiol Antimicrob, V3, P6, DOI 10.1186/1476-0711-3-6; Medhat A, 2002, AM J TROP MED HYG, V66, P633, DOI 10.4269/ajtmh.2002.66.633; Mohamed MK, 2005, HEPATOLOGY, V42, P683, DOI 10.1002/hep.20811; Murphy EL, 2000, HEPATOLOGY, V31, P756, DOI 10.1002/hep.510310329; Nafeh MA, 2000, AM J TROP MED HYG, V63, P236, DOI 10.4269/ajtmh.2000.63.236; PLANCOULAINE S, 2008, GUT; Stoszek SK, 2006, T ROY SOC TROP MED H, V100, P102, DOI 10.1016/j.trstmh.2005.05.021; Tahan V, 2005, AM J GASTROENTEROL, V100, P821, DOI 10.1111/j.1572-0241.2005.40879.x; Talaat M, 2006, AM J INFECT CONTROL, V34, P193, DOI 10.1016/j.ajic.2005.05.028; Thaikruea L, 2004, TRANSFUSION, V44, P1433, DOI 10.1111/j.1537-2995.2004.04073.x; Todd CS, 2007, EMERG INFECT DIS, V13, P1327, DOI 10.3201/eid1309.070036; Vandelli C, 2004, AM J GASTROENTEROL, V99, P855, DOI 10.1111/j.1572-0241.2004.04150.x; Yazdanpanah Y, 2005, CLIN INFECT DIS, V41, P1423, DOI 10.1086/497131; Zakaria S, 2007, CLIN INFECT DIS, V44, pE30, DOI 10.1086/511074	45	40	41	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7193	10.1371/journal.pone.0007193	http://dx.doi.org/10.1371/journal.pone.0007193			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784363	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290000010
J	Shu, N; Liu, Y; Li, J; Li, YH; Yu, CS; Jiang, TZ				Shu, Ni; Liu, Yong; Li, Jun; Li, Yonghui; Yu, Chunshui; Jiang, Tianzi			Altered Anatomical Network in Early Blindness Revealed by Diffusion Tensor Tractography	PLOS ONE			English	Article							BRAIN STRUCTURAL NETWORKS; CROSS-MODAL PLASTICITY; PRIMARY VISUAL-CORTEX; SMALL-WORLD; FUNCTIONAL CONNECTIVITY; WHITE-MATTER; ACTIVATION PATTERNS; CORTICAL THICKNESS; POSTCENTRAL GYRUS; NEURAL SYSTEMS	The topological architecture of the cerebral anatomical network reflects the structural organization of the human brain. Recently, topological measures based on graph theory have provided new approaches for quantifying large-scale anatomical networks. Diffusion MRI studies have revealed the efficient small-world properties and modular structure of the anatomical network in normal subjects. However, no previous study has used diffusion MRI to reveal changes in the brain anatomical network in early blindness. Here, we utilized diffusion tensor imaging to construct binary anatomical networks for 17 early blind subjects and 17 age- and gender-matched sighted controls. We established the existence of structural connections between any pair of the 90 cortical and sub-cortical regions using deterministic tractography. Compared with controls, early blind subjects showed a decreased degree of connectivity, a reduced global efficiency, and an increased characteristic path length in their brain anatomical network, especially in the visual cortex. Moreover, we revealed some regions with motor or somatosensory function have increased connections with other brain regions in the early blind, which suggested experience-dependent compensatory plasticity. This study is the first to show alterations in the topological properties of the anatomical network in early blindness. From the results, we suggest that analyzing the brain's anatomical network obtained using diffusion MRI data provides new insights into the understanding of the brain's re-organization in the specific population with early visual deprivation.			Shu, N (corresponding author), Chinese Acad Sci, Inst Automat, Natl Lab Pattern Recognit, LIAMA Ctr Computat Med, Beijing, Peoples R China.	chunshuiyu@yahoo.cn; jiangtz@nlpr.ia.ac.cn	Shu, Ni/B-9583-2014; QIN, WEN/F-3783-2015; Jiang, Tianzi/I-4256-2012; Li, Yonghui/G-8539-2012; Liu, Yong/F-2682-2011	QIN, WEN/0000-0002-9121-8296; Jiang, Tianzi/0000-0001-9531-291X; Liu, Yong/0000-0002-1862-3121; Yu, Chunshui/0000-0001-5648-5199				Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Amedi A, 2003, NAT NEUROSCI, V6, P758, DOI 10.1038/nn1072; Amunts K, 1999, J COMP NEUROL, V412, P319, DOI 10.1002/(SICI)1096-9861(19990920)412:2<319::AID-CNE10>3.0.CO;2-7; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182; Bassettt DS, 2006, P NATL ACAD SCI USA, V103, P19518, DOI 10.1073/pnas.0606005103; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bolam JP, 2000, J ANAT, V196, P527, DOI 10.1046/j.1469-7580.2000.19640527.x; Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; Bullmore E, 2009, NAT REV NEUROSCI, V10, DOI 10.1038/nrn2618; Burns GAPC, 2000, PHILOS T R SOC B, V355, P55, DOI 10.1098/rstb.2000.0549; Burton H, 2006, HUM BRAIN MAPP, V27, P325, DOI 10.1002/hbm.20188; Burton H, 2002, J NEUROPHYSIOL, V87, P589, DOI 10.1152/jn.00285.2001; CARLSON M, 1981, BRAIN RES, V204, P424, DOI 10.1016/0006-8993(81)90602-8; Charpier S, 1997, P NATL ACAD SCI USA, V94, P7036, DOI 10.1073/pnas.94.13.7036; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Costa LD, 2007, ADV PHYS, V56, P167, DOI 10.1080/00018730601170527; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; Friman O, 2006, IEEE T MED IMAGING, V25, P965, DOI 10.1109/TMI.2006.877093; FROMM C, 1984, EXP BRAIN RES, V54, P177; Gerfen CR, 2000, TRENDS NEUROSCI, V23, pS64, DOI 10.1016/S1471-1931(00)00019-7; Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799; Gizewski ER, 2003, NEUROIMAGE, V19, P968, DOI 10.1016/S1053-8119(03)00114-9; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000597; He Y, 2008, J NEUROSCI, V28, P4756, DOI 10.1523/JNEUROSCI.0141-08.2008; He Y, 2007, CEREB CORTEX, V17, P2407, DOI 10.1093/cercor/bhl149; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; HONEY CJ, 2009, P NATL ACAD SCI US; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hubel D H, 1978, Harvey Lect, V72, P1; Humphries MD, 2006, P ROY SOC B-BIOL SCI, V273, P503, DOI 10.1098/rspb.2005.3354; Iturria-Medina Y, 2007, NEUROIMAGE, V36, P645, DOI 10.1016/j.neuroimage.2007.02.012; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Jiang JF, 2009, J NEUROSCI, V29, P2205, DOI 10.1523/JNEUROSCI.5451-08.2009; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005; Kujala T, 2005, NEUROSCI LETT, V379, P127, DOI 10.1016/j.neulet.2004.12.070; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Liu Y, 2007, BRAIN, V130, P2085, DOI 10.1093/brain/awm121; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Noppeney U, 2005, CURR BIOL, V15, pR488, DOI 10.1016/j.cub.2005.06.053; Nucifora PGP, 2007, RADIOLOGY, V245, P367, DOI 10.1148/radiol.2452060445; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pan WJ, 2007, NEUROIMAGE, V37, P212, DOI 10.1016/j.neuroimage.2007.05.014; Parker GJM, 2002, IEEE T MED IMAGING, V21, P505, DOI 10.1109/TMI.2002.1009386; Parvizi J, 2006, P NATL ACAD SCI USA, V103, P1563, DOI 10.1073/pnas.0507729103; Ptito Maurice, 2005, Journal of Integrative Neuroscience, V4, P479, DOI 10.1142/S0219635205000951; Rodrigo S, 2007, AM J NEURORADIOL, V28, P1526, DOI 10.3174/ajnr.A0584; Sadato N, 1998, BRAIN, V121, P1213, DOI 10.1093/brain/121.7.1213; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; Scannell JW, 1999, CEREB CORTEX, V9, P277, DOI 10.1093/cercor/9.3.277; Sengpiel F, 2002, CURR BIOL, V12, pR818, DOI 10.1016/S0960-9822(02)01318-0; Shimony JS, 2006, CEREB CORTEX, V16, P1653, DOI 10.1093/cercor/bhj102; Shu N, 2009, HUM BRAIN MAPP, V30, P220, DOI 10.1002/hbm.20507; Sporns O, 2000, CEREB CORTEX, V10, P127, DOI 10.1093/cercor/10.2.127; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O, 2004, NEUROINFORMATICS, V2, P145, DOI 10.1385/NI:2:2:145; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2004, NEUROSCI LETT, V355, P25, DOI 10.1016/j.neulet.2003.10.063; Stephan KE, 2001, PHILOS T ROY SOC B, V356, P1159, DOI 10.1098/rstb.2001.0908; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; WANG J, 2008, HUM BRAIN MAPP; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Weeks R, 2000, J NEUROSCI, V20, P2664; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Wittenberg GF, 2004, EUR J NEUROSCI, V20, P1923, DOI 10.1111/j.1460-9568.2004.03630.x; YOUNG MP, 1993, P ROY SOC B-BIOL SCI, V252, P13, DOI 10.1098/rspb.1993.0040; Yu CS, 2008, HUM BRAIN MAPP, V29, P533, DOI 10.1002/hbm.20420; Yu CS, 2007, NEUROIMAGE, V36, P411, DOI 10.1016/j.neuroimage.2007.03.003; ZALESKY A, 2009, IEEE T MED IMAGING	96	110	114	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7228	10.1371/journal.pone.0007228	http://dx.doi.org/10.1371/journal.pone.0007228			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784379	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290000019
J	An, DD; Apidianakis, Y; Boechat, AL; Baldini, RL; Goumnerov, BC; Rahme, LG				An, Dingding; Apidianakis, Yiorgos; Boechat, Ana Laura; Baldini, Regina L.; Goumnerov, Boyan C.; Rahme, Laurence G.			The Pathogenic Properties of a Novel and Conserved Gene Product, KerV, in Proteobacteria	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA PATHOGENESIS; TRANSPOSON MUTANT LIBRARY; III SECRETION; BACTERIAL; HOST; PROTEIN; DNA; METHYLGLYOXAL; REPLICATION; MECHANISMS	Identification of novel virulence factors is essential for understanding bacterial pathogenesis and designing antibacterial strategies. In this study, we uncover such a factor, termed KerV, in Proteobacteria. Experiments carried out in a variety of eukaryotic host infection models revealed that the virulence of a Pseudomonas aeruginosa kerV null mutant was compromised when it interacted with amoebae, plants, flies, and mice. Bioinformatics analyses indicated that KerV is a hypothetical methyltransferase and is well-conserved across numerous Proteobacteria, including both well-known and emerging pathogens (e.g., virulent Burkholderia, Escherichia, Shigella, Vibrio, Salmonella, Yersinia and Brucella species). Furthermore, among the 197 kerV orthologs analyzed in this study, about 89% reside in a defined genomic neighborhood, which also possesses essential DNA replication and repair genes and detoxification gene. Finally, infection of Drosophila melanogaster with null mutants demonstrated that KerV orthologs are also crucial in Vibrio cholerae and Yersinia pseudotuberculosis pathogenesis. Our findings suggested that KerV has a novel and broad significance as a virulence factor in pathogenic Proteobacteria and it might serve as a new target for antibiotic drug design.			An, DD (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.	rahme@molbio.mgh.harvard.edu	Baldini, Regina L/C-4035-2012; Apidianakis, Yiorgos/ABF-7464-2020; Borges, Ana Laura/AAQ-4158-2020	Baldini, Regina L/0000-0003-4349-6352; Apidianakis, Yiorgos/0000-0002-7465-3560; 				Apidianakis Y, 2005, P NATL ACAD SCI USA, V102, P2573, DOI 10.1073/pnas.0409588102; Blow NS, 2005, PLOS PATHOG, V1, P92, DOI 10.1371/journal.ppat.0010008; BOLIN I, 1982, INFECT IMMUN, V37, P506; Braun V, 2001, INT J MED MICROBIOL, V291, P67, DOI 10.1078/1438-4221-00103; Cai H, 2001, BIOCHEMISTRY-US, V40, P2210, DOI 10.1021/bi0022902; Cameron DE, 2008, P NATL ACAD SCI USA, V105, P8736, DOI 10.1073/pnas.0803281105; Cegelski L, 2008, NAT REV MICROBIOL, V6, P17, DOI 10.1038/nrmicro1818; Clatworthy AE, 2009, INFECT IMMUN, V77, P1293, DOI 10.1128/IAI.01181-08; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cosson P, 2002, J BACTERIOL, V184, P3027, DOI 10.1128/JB.184.11.3027-3033.2002; D'Argenio DA, 2001, J BACTERIOL, V183, P1466, DOI 10.1128/JB.183.4.1466-1471.2001; Derbise A, 2003, FEMS IMMUNOL MED MIC, V38, P113, DOI 10.1016/S0928-8244(03)00181-0; Deziel E, 2005, MOL MICROBIOL, V55, P998, DOI 10.1111/j.1365-2958.2004.04448.x; FINK RB, 1993, PSEUDOMONAS AERUGINO; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hogan DA, 2002, SCIENCE, V296, P2229, DOI 10.1126/science.1070784; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KANAYA S, 1984, P NATL ACAD SCI-BIOL, V81, P3447, DOI 10.1073/pnas.81.11.3447; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Liberati NT, 2006, P NATL ACAD SCI USA, V103, P2833, DOI 10.1073/pnas.0511100103; Mahajan-Miklos S, 2000, MOL MICROBIOL, V37, P981, DOI 10.1046/j.1365-2958.2000.02056.x; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Murata-Kamiya N, 2000, MUTAT RES-GEN TOX EN, V468, P173, DOI 10.1016/S1383-5718(00)00044-9; OGAWA T, 1984, P NATL ACAD SCI-BIOL, V81, P1040, DOI 10.1073/pnas.81.4.1040; Parsek MR, 2000, P NATL ACAD SCI USA, V97, P8789, DOI 10.1073/pnas.97.16.8789; Preston GM, 2007, CELL HOST MICROBE, V2, P291, DOI 10.1016/j.chom.2007.10.004; Pukatzki S, 2002, P NATL ACAD SCI USA, V99, P3159, DOI 10.1073/pnas.052704399; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rahme LG, 1997, P NATL ACAD SCI USA, V94, P13245, DOI 10.1073/pnas.94.24.13245; Rahme LG, 2000, P NATL ACAD SCI USA, V97, P8815, DOI 10.1073/pnas.97.16.8815; Rietsch A, 2006, MOL MICROBIOL, V59, P807, DOI 10.1111/j.1365-2958.2005.04990.x; Robins E V, 1989, Crit Care Nurs Clin North Am, V1, P767; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Starkey M, 2009, NAT PROTOC, V4, P117, DOI 10.1038/nprot.2008.224; Stevens Emily J., 1994, Journal of Burn Care and Rehabilitation, V15, P232, DOI 10.1097/00004630-199405000-00005; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; Tan MW, 1999, P NATL ACAD SCI USA, V96, P2408, DOI 10.1073/pnas.96.5.2408; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; von Bodman SB, 2003, ANNU REV PHYTOPATHOL, V41, P455, DOI 10.1146/annurev.phyto.41.052002.095652; Waldor MK., 1996, ENTERIC INFECT IMMUN, P37, DOI [10.1007/978-1-4899-0313-6_3, DOI 10.1007/978-1-4899-0313-6_3]; Williams P, 2000, PHILOS T R SOC B, V355, P667, DOI 10.1098/rstb.2000.0607; Wion D, 2006, NAT REV MICROBIOL, V4, P183, DOI 10.1038/nrmicro1350	48	12	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7167	10.1371/journal.pone.0007167	http://dx.doi.org/10.1371/journal.pone.0007167			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779606	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200010
J	Suda, Y; Rodriguez, RK; Coluccio, AE; Neiman, AM				Suda, Yasuyuki; Rodriguez, Rachael K.; Coluccio, Alison E.; Neiman, Aaron M.			A Screen for Spore Wall Permeability Mutants Identifies a Secreted Protease Required for Proper Spore Wall Assembly	PLOS ONE			English	Article								The ascospores of Saccharomyces cerevisiae are surrounded by a complex wall that protects the spores from environmental stresses. The outermost layer of the spore wall is composed of a polymer that contains the cross-linked amino acid dityrosine. This dityrosine layer is important for stress resistance of the spore. This work reports that the dityrosine layer acts as a barrier blocking the diffusion of soluble proteins out of the spore wall into the cytoplasm of the ascus. Diffusion of a fluorescent protein out of the spore wall was used as an assay to screen for mutants affecting spore wall permeability. One of the genes identified in this screen, OSW3 (RRT12/YCR045c), encodes a subtilisin-family protease localized to the spore wall. Mutation of the active site serine of Osw3 results in spores with permeable walls, indicating that the catalytic activity of Osw3 is necessary for proper construction of the dityrosine layer. These results indicate that dityrosine promotes stress resistance by acting as a protective shell around the spore. OSW3 and other OSW genes identified in this screen are strong candidates to encode enzymes involved in assembly of this protective dityrosine coat.			Suda, Y (corresponding author), RIKEN Adv Sci Inst, Mol Membrane Biol Lab, Saitama, Japan.	Aaron.Neiman@sunysb.edu	Suda, Yasuyuki/AAH-5065-2020; Suda, Yasuyuki/D-3870-2017	Suda, Yasuyuki/0000-0001-8725-8001; Suda, Yasuyuki/0000-0001-8725-8001; Neiman, Aaron/0000-0002-6600-6996	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072540] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM072540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen MR, 2008, GENETICS, V179, P1179, DOI 10.1534/genetics.108.089250; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, J BIOL CHEM, V265, P15118; BRIZA P, 1988, J BIOL CHEM, V263, P11569; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; Byrne KP, 2005, GENOME RES, V15, P1456, DOI 10.1101/gr.3672305; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; Christodoulidou A, 1999, FEBS LETT, V460, P275, DOI 10.1016/S0014-5793(99)01334-4; Christodoulidou A, 1996, J BIOL CHEM, V271, P31420, DOI 10.1074/jbc.271.49.31420; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Coluccio A, 2004, EUKARYOT CELL, V3, P1464, DOI 10.1128/EC.3.6.1464-1475.2004; Coluccio A, 2004, MICROBIOL-SGM, V150, P3189, DOI 10.1099/mic.0.27253-0; Coluccio AE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002873; Diamond AE, 2009, MOL BIOL CELL, V20, P134, DOI 10.1091/mbc.E08-06-0615; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hontz RD, 2009, GENETICS, V182, P105, DOI 10.1534/genetics.108.100313; Ishihara S, 2007, EUKARYOT CELL, V6, P143, DOI 10.1128/EC.00200-06; Jang YK, 1999, MOL CELL BIOL, V19, P7630; Kalebina TS, 2003, ANTON LEEUW INT J G, V84, P179, DOI 10.1023/A:1026034123673; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KREGERVANRIJ NJW, 1978, ARCH MICROBIOL, V117, P73, DOI 10.1007/BF00689354; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Li J, 2007, GENETICS, V175, P143, DOI 10.1534/genetics.106.066381; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Melo NR, 2008, ANTIMICROB AGENTS CH, V52, P3718, DOI 10.1128/AAC.00446-08; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; MUTHUKUMAR G, 1993, J BACTERIOL, V175, P386, DOI 10.1128/JB.175.2.386-394.1993; Neiman AM, 2000, GENETICS, V155, P1643; Neiman AM, 2005, MICROBIOL MOL BIOL R, V69, P565, DOI 10.1128/MMBR.69.4.565-584.2005; PAMMER M, 1992, YEAST, V8, P1089, DOI 10.1002/yea.320081211; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Ragni E, 2007, EUKARYOT CELL, V6, P302, DOI 10.1128/EC.00321-06; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rose MD., 1990, METHODS YEAST GENETI; SANSEGUNDO P, 1993, J BACTERIOL, V175, P3823, DOI 10.1128/JB.175.12.3823-3837.1993; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIKORSKI RS, 1989, GENETICS, V122, P19; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; VANDEVEN WJM, 1991, ENZYME, V45, P257, DOI 10.1159/000468900	40	33	41	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7184	10.1371/journal.pone.0007184	http://dx.doi.org/10.1371/journal.pone.0007184			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779569	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200017
J	Alonso-Camino, V; Sanchez-Martin, D; Compte, M; Sanz, L; Alvarez-Vallina, L				Alonso-Camino, Vanesa; Sanchez-Martin, David; Compte, Marta; Sanz, Laura; Alvarez-Vallina, Luis			Lymphocyte Display: A Novel Antibody Selection Platform Based on T Cell Activation	PLOS ONE			English	Article								Since their onset, display technologies have proven useful for the selection of antibodies against a variety of targets; however, most of the antibodies selected with the currently available platforms need to be further modified for their use in humans, and are restricted to accessible antigens. Furthermore, these platforms are not well suited for in vivo selections. We present here a novel cell based antibody display platform, which takes advantage of the functional capabilities of T lymphocytes. The display of antibodies on the surface of T lymphocytes, as a part of a chimeric-immune receptor (CIR) mediating signaling, may ideally link the antigen-antibody interaction to a demonstrable change in T cell phenotype, due to subsequent expression of the early T cell activation marker CD69. In this proof-of-concept, an in vitro selection was carried out using a human T cell line lentiviral-transduced to express a tumor-specific CIR on the surface, against a human tumor cell line expressing the carcinoembryonic antigen. Based on an effective interaction between the CIR and the tumor antigen, we demonstrated that combining CIR-mediated activation with FACS sorting of CD69(+) T cells, it is possible to isolate binders to tumor specific cell surface antigen, with an enrichment factor of at least 10(3)-fold after two rounds, resulting in a homogeneous population of T cells expressing tumor-specific CIRs.			Alonso-Camino, V (corresponding author), Hosp Univ Puerta Hierro, Mol Immunol Unit, Madrid, Spain.	lalvarezv.hpth@salud.madrid.org	Alvarez-Vallina, Luis/ABD-2431-2020; Álvarez-Vallina, Luis/A-2032-2010; Sanz, Laura/F-8542-2010; Alvarez-Vallina, Luis/A-2033-2010; Compte Grau, Marta/H-5873-2012; Sánchez-Martín, David/C-9927-2013	Alvarez-Vallina, Luis/0000-0003-3053-6757; Sanz, Laura/0000-0002-3119-3218; Sánchez-Martín, David/0000-0002-2712-4762; Compte Grau, Marta/0000-0002-7138-9266				Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Alvarez-Vallina L, 2000, CANCER GENE THER, V7, P526, DOI 10.1038/sj.cgt.7700128; Alvarez-Vallina L., 2001, Current Gene Therapy, V1, P385, DOI 10.2174/1566523013348418; AlvarezVallina L, 1996, EUR J IMMUNOL, V26, P2304, DOI 10.1002/eji.1830261006; Beerli RR, 2008, P NATL ACAD SCI USA, V105, P14336, DOI 10.1073/pnas.0805942105; Blanco B, 2002, CANCER GENE THER, V9, P275, DOI 10.1038/sj.cgt.7700438; Buchholz CJ, 1998, NAT BIOTECHNOL, V16, P951, DOI 10.1038/nbt1098-951; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; Compte M, 2007, CANCER GENE THER, V14, P380, DOI 10.1038/sj.cgt.7701021; Finney HM, 1998, J IMMUNOL, V161, P2791; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; HEFTA LJF, 1992, CANCER RES, V52, P5647; Ho M, 2006, P NATL ACAD SCI USA, V103, P9637, DOI 10.1073/pnas.0603653103; Hoogenboom HR, 2005, NAT BIOTECHNOL, V23, P1105, DOI 10.1038/nbt1126; Khare PD, 2003, VIROLOGY, V315, P313, DOI 10.1016/S0042-6822(03)00530-0; Paillard F, 1998, HUM GENE THER, V9, P2307, DOI 10.1089/hum.1998.9.16-2307; Pizzato M, 1999, J VIROL, V73, P8599, DOI 10.1128/JVI.73.10.8599-8611.1999; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; Sanz L, 2004, TRENDS IMMUNOL, V25, P85, DOI 10.1016/j.it.2003.12.001; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1985, SCIENCE, V14, P228; Taube R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003181; Urban JH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni033; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Wolkowicz R, 2005, J BIOL CHEM, V280, P15195, DOI 10.1074/jbc.M500254200; Zhang LL, 2006, CANCER RES, V66, P5696, DOI 10.1158/0008-5472.CAN-05-3876	26	15	17	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7174	10.1371/journal.pone.0007174	http://dx.doi.org/10.1371/journal.pone.0007174			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777065	Green Published, Green Submitted, gold			2022-12-27	WOS:000270164600010
J	Paccagnini, D; Sieswerda, L; Rosu, V; Masala, S; Pacifico, A; Gazouli, M; Ikonomopoulos, J; Ahmed, N; Zanetti, S; Sechi, LA				Paccagnini, Daniela; Sieswerda, Lee; Rosu, Valentina; Masala, Speranza; Pacifico, Adolfo; Gazouli, Maria; Ikonomopoulos, John; Ahmed, Niyaz; Zanetti, Stefania; Sechi, Leonardo A.			Linking Chronic Infection and Autoimmune Diseases: Mycobacterium avium Subspecies paratuberculosis, SLC11A1 Polymorphisms and Type-1 Diabetes Mellitus	PLOS ONE			English	Article								Background: The etiology of type 1 diabetes mellitus (T1DM) is still unknown; numerous studies are performed to unravel the environmental factors involved in triggering the disease. SLC11A1 is a membrane transporter that is expressed in late endosomes of antigen presenting cells involved in the immunopathogenic events leading to T1DM. Mycobacterium avium subsp. paratuberculosis (MAP) has been reported to be a possible trigger in the development of T1DM. Methodology/Principal Findings: Fifty nine T1DM patients and 79 healthy controls were genotyped for 9 polymorphisms of SLC11A1 gene, and screened for the presence of MAP by PCR. Differences in genotype frequency were evaluated for both T1DM patients and controls. We found a polymorphism in the SLC11A1 gene (274C/T) associated to type 1 diabetic patients and not to controls. The presence of MAP DNA was also significantly associated with T1DM patients and not with controls. Conclusions/Significance: The 274C/T SCL11A1 polymorphism was found to be associated with T1DM as well as the presence of MAP DNA in blood. Since MAP persists within macrophages and it is also processed by dendritic cells, further studies are necessary to evaluate if mutant forms of SLC11A1 alter the processing or presentation of MAP antigens triggering thereby an autoimmune response in T1DM patients.			Paccagnini, D (corresponding author), Sez Microbiol Clin & Sperimentale, Dipartimento Sci Biomed, Sassari, Italy.	sechila@uniss.it	Ahmed, Niyaz/D-2589-2010; Gazouli, Maria/I-2572-2018; Sechi, Leonardo Antonio/Y-3109-2018; Gazouli, Maria/W-6245-2019	Ahmed, Niyaz/0000-0001-6425-7583; Gazouli, Maria/0000-0002-3295-6811; Gazouli, Maria/0000-0002-3295-6811; Masala, Speranza/0000-0003-4943-9164; sechi, leonardo antonio/0000-0003-0566-2049				Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830; Akerblom HK, 2002, AM J MED GENET, V115, P18, DOI 10.1002/ajmg.10340; Alter-Koltunoff M, 2003, J BIOL CHEM, V278, P44025, DOI 10.1074/jbc.M307954200; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Bellamy R, 2003, GENES IMMUN, V4, P4, DOI 10.1038/sj.gene.6363915; Blackwell JM, 2003, IMMUNOL LETT, V85, P197, DOI 10.1016/S0165-2478(02)00231-6; Blackwell JM, 1999, IMMUNOL LETT, V65, P73, DOI 10.1016/S0165-2478(98)00127-8; BLACKWELL JM, 1995, MOL MED, V1, P194, DOI 10.1007/BF03401567; Canonne-Hergaux F, 1999, P ASSOC AM PHYSICIAN, V111, P283, DOI 10.1046/j.1525-1381.1999.99236.x; Chacon O, 2004, ANNU REV MICROBIOL, V58, P329, DOI 10.1146/annurev.micro.58.030603.123726; Comabella M, 2004, MULT SCLER J, V10, P618, DOI 10.1191/1352458504ms1097oa; Dai YD, 2009, DIABETES, V58, P156, DOI 10.2337/db07-1608; Daneman D, 2006, LANCET, V367, P847, DOI 10.1016/S0140-6736(06)68341-4; Dow CT, 2006, MED HYPOTHESES, V67, P782, DOI 10.1016/j.mehy.2006.04.029; Ferreira FR, 2004, INT J LEPROSY, V72, P457, DOI 10.1489/1544-581X(2004)72&lt;457:STLMBC&gt;2.0.CO;2; Guarner F, 2006, NAT CLIN PRACT GASTR, V3, P275, DOI 10.1038/ncpgasthep0471; Hofmeister A, 1997, SURGERY, V122, P173, DOI 10.1016/S0039-6060(97)90006-4; Jin J, 2009, CLIN INFECT DIS, V48, P733, DOI 10.1086/597034; Kissler S, 2006, NAT GENET, V38, P479, DOI 10.1038/ng1766; Knip M, 2005, DIABETES, V54, pS125, DOI 10.2337/diabetes.54.suppl_2.S125; Litherland SA, 2005, J IMMUNOL, V175, P4561, DOI 10.4049/jimmunol.175.7.4561; Nishino M, 2005, METABOLISM, V54, P628, DOI 10.1016/j.metabol.2004.12.006; O'Keeffe M, 2005, INT IMMUNOL, V17, P307, DOI 10.1093/intimm/dxh210; Piganelli JD, 1998, DIABETES, V47, P1212, DOI 10.2337/diabetes.47.8.1212; Polymeros D, 2006, GASTROENTEROLOGY, V131, P85, DOI 10.1053/j.gastro.2006.04.021; Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9; ROSU V, 2008, ANN CLIN MICROBIOL A, V22, P7; Rosu V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004386; Sechi LA, 2005, AM J GASTROENTEROL, V100, P1529, DOI 10.1111/j.1572-0241.2005.41415.x; Sechi LA, 2008, CLIN VACCINE IMMUNOL, V15, P320, DOI 10.1128/CVI.00381-07; Sechi LA, 2008, CLIN INFECT DIS, V46, P148, DOI 10.1086/524084; Sechi LA, 2006, WORLD J GASTROENTERO, V12, P7161, DOI 10.3748/wjg.v12.i44.7161; Takahashi K, 2004, TISSUE ANTIGENS, V63, P231, DOI 10.1111/j.1399-0039.2004.000172.x; Yang YS, 2000, J KOREAN MED SCI, V15, P83, DOI 10.3346/jkms.2000.15.1.83; Yen JH, 2006, IMMUNOL LETT, V102, P91, DOI 10.1016/j.imlet.2005.07.008	35	40	40	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7109	10.1371/journal.pone.0007109	http://dx.doi.org/10.1371/journal.pone.0007109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768110	gold, Green Published, Green Submitted			2022-12-27	WOS:000270154000009
J	Molina-Luna, K; Pekanovic, A; Rohrich, S; Hertler, B; Schubring-Giese, M; Rioult-Pedotti, MS; Luft, AR				Molina-Luna, Katiuska; Pekanovic, Ana; Roehrich, Sebastian; Hertler, Benjamin; Schubring-Giese, Maximilian; Rioult-Pedotti, Mengia-Seraina; Luft, Andreas R.			Dopamine in Motor Cortex Is Necessary for Skill Learning and Synaptic Plasticity	PLOS ONE			English	Article								Preliminary evidence indicates that dopamine given by mouth facilitates the learning of motor skills and improves the recovery of movement after stroke. The mechanism of these phenomena is unknown. Here, we describe a mechanism by demonstrating in rat that dopaminergic terminals and receptors in primary motor cortex (M1) enable motor skill learning and enhance M1 synaptic plasticity. Elimination of dopaminergic terminals in M1 specifically impaired motor skill acquisition, which was restored upon DA substitution. Execution of a previously acquired skill was unaffected. Reversible blockade of M1 D1 and D2 receptors temporarily impaired skill acquisition but not execution, and reduced long-term potentiation (LTP) within M1, a form of synaptic plasticity critically involved in skill learning. These findings identify a behavioral and functional role of dopaminergic signaling in M1. DA in M1 optimizes the learning of a novel motor skill.			Molina-Luna, K (corresponding author), Univ Zurich, Dept Neurol, Zurich, Switzerland.	andreas.luft@usz.ch	Rioult-Pedotti, Mengia-Seraina/AAF-1377-2021	Lauwereyns, Jan/0000-0003-0551-2550				Asanuma H, 1997, NEUROREPORT, V8, pR1; Awenowicz PW, 2002, J NEUROPHYSIOL, V88, P3439, DOI 10.1152/jn.00078.2002; BOYSON SJ, 1986, J NEUROSCI, V6, P3177; Buitrago MM, 2004, BEHAV BRAIN RES, V155, P249, DOI 10.1016/j.bbr.2004.04.025; Buitrago MM, 2004, NEUROBIOL LEARN MEM, V81, P211, DOI 10.1016/j.nlm.2004.01.001; CALABRESI P, 1992, J NEUROSCI, V12, P4224; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; DAWSON TM, 1986, J NEUROSCI, V6, P2352; DESCARRIES L, 1987, NEUROSCIENCE, V21, P807, DOI 10.1016/0306-4522(87)90038-8; DEUTCH AY, 1986, NEUROSCI LETT, V71, P257, DOI 10.1016/0304-3940(86)90630-0; Doyon J, 2008, CURR OPIN NEUROL, V21, P478, DOI 10.1097/WCO.0b013e328304b6a3; FAULL RLM, 1968, J COMP NEUROL, V132, P73, DOI 10.1002/cne.901320104; Fleming SM, 2005, BEHAV BRAIN RES, V156, P201, DOI 10.1016/j.bbr.2004.05.024; Floel A, 2005, NEUROLOGY, V65, P472, DOI 10.1212/01.wnl.0000172340.56307.5e; Floel A, 2005, ANN NEUROL, V58, P121, DOI 10.1002/ana.20536; GASPAR P, 1995, EUR J NEUROSCI, V7, P1050, DOI 10.1111/j.1460-9568.1995.tb01092.x; Gurden H, 1999, NEUROSCIENCE, V94, P1019, DOI 10.1016/S0306-4522(99)00395-4; Harms KJ, 2008, J NEUROSCI, V28, P5686, DOI 10.1523/JNEUROSCI.0584-08.2008; Hess G, 1996, ACTA NEUROBIOL EXP, V56, P863; Hess G, 1996, J NEUROPHYSIOL, V75, P1765, DOI 10.1152/jn.1996.75.5.1765; Huang YY, 2004, P NATL ACAD SCI USA, V101, P3236, DOI 10.1073/pnas.0308280101; HUNTLEY GW, 1992, MOL BRAIN RES, V15, P181, DOI 10.1016/0169-328X(92)90107-M; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Ioffe M E, 2004, Neurosci Behav Physiol, V34, P5, DOI 10.1023/B:NEAB.0000003241.12053.47; IRIKI A, 1989, SCIENCE, V245, P1385, DOI 10.1126/science.2551038; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; LEWIS DA, 1987, J NEUROSCI, V7, P279; LIDOW MS, 1989, P NATL ACAD SCI USA, V86, P6412, DOI 10.1073/pnas.86.16.6412; Luft AR, 2009, INT J DEV NEUROSCI, V27, P415, DOI 10.1016/j.ijdevneu.2009.05.004; Luft AR, 2008, STROKE, V39, P3341, DOI 10.1161/STROKEAHA.108.527531; Luft AR, 2004, J NEUROSCI, V24, P6515, DOI 10.1523/JNEUROSCI.1034-04.2004; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; MCENTEE WJ, 1987, YALE J BIOL MED, V60, P187; MIKLYAEVA EI, 1994, J NEUROSCI, V14, P7148; Molina-Luna K, 2007, J NEUROSCI METH, V161, P118, DOI 10.1016/j.jneumeth.2006.10.025; Nagai T, 2007, LEARN MEMORY, V14, P117, DOI 10.1101/lm.461407; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Otani S, 2003, CEREB CORTEX, V13, P1251, DOI 10.1093/cercor/bhg092; PAVLIDES C, 1993, J NEUROPHYSIOL, V70, P733, DOI 10.1152/jn.1993.70.2.733; Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040; Pleger B, 2004, CLIN NEUROPHYSIOL, V115, P2157, DOI 10.1016/j.clinph.2004.04.015; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rioult-Pedotti MS, 2007, J NEUROPHYSIOL, V98, P3688, DOI 10.1152/jn.00164.2007; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; SAKAMOTO T, 1989, BRAIN RES, V503, P258, DOI 10.1016/0006-8993(89)91672-7; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; TEYLER TJ, 1994, HIPPOCAMPUS, V4, P623, DOI 10.1002/hipo.450040602; Ueki Y, 2006, ANN NEUROL, V59, P60, DOI 10.1002/ana.20692; Whishaw IQ, 2007, NEUROSCIENCE, V146, P86, DOI 10.1016/j.neuroscience.2007.01.034; Wolters EC, 2000, ADV RES NEURODEGENER, V8, P291	55	218	219	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7082	10.1371/journal.pone.0007082	http://dx.doi.org/10.1371/journal.pone.0007082			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759902	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970200012
J	Vire, B; de Walque, S; Restouin, A; Olive, D; Van Lint, C; Collette, Y				Vire, Berengere; de Walque, Stephane; Restouin, Audrey; Olive, Daniel; Van Lint, Carine; Collette, Yves			Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions	PLOS ONE			English	Article								Histone deacetylase inhibitors (HDACi) have demonstrated promising therapeutic potential in clinical trials for hematological malignancies. HDACi, such as SAHA/Vorinostat, Trichostatin A, and MS-275 were found to induce apoptosis of leukemic blasts through activation of the death receptor pathway and transcriptional induction of the Tumor Necrosis Factor (TNF)-related pro-apoptotic family members, TRAIL and FasL. The impact of HDACi on TNF-related costimulatory molecules such as 4-1BB ligand (4-1BBL/TNFSF9) is however not known. Following exposure to SAHA/Vorinostat, Trichostatin A, and MS-275, transcript levels were determined by real time PCR in Jurkat, Raji and U937 cells. Treatment with HDACi up-regulated TNFSF9 gene expression in the three leukemia cell lines, yet to different extend and with distinct kinetics, which did not require de novo protein synthesis and was not associated with DNAse I hypersensitive chromatin remodeling. Transcriptional activity of TNFSF9 promoter-luciferase constructs was induced up to 12 fold by HDACi, and implication of Sp1/Sp3 transcription factors binding to functional GC-box elements was evidenced by reporter gene assays, site-directed mutagenesis, and electrophoretic mobility shift assays. Functionality of modulated target genes was assessed in allogeneic mixed leukocyte reaction experiments. MS-275- and to a lesser extent Trichostatin A- and SAHA-treated Raji cells significantly up regulated T lymphocytes proliferation which was reduced by about 50% by a 4-1BB blocking recombinant protein, while MS-275- but neither Trichostatin A- nor SAHA-treated cells up-regulated IFN gamma secretion by T lymphocytes. Our results identify 4-1BBL/4-1BB as a downstream target of HDACi, especially of MS-275 anti-leukemia action in vitro. Thus, HDACi such as MS-275 displaying dual TNF-dependent proapoptotic and costimulatory activities might be favored for inclusion in HDACi-based anti-cancer therapeutic strategies.			Vire, B (corresponding author), INSERM, Ctr Rech Cancerol Marseille, U891, F-13258 Marseille, France.	collette@marseille.inserm.fr	COLLETTE, Yves/F-2270-2013	COLLETTE, Yves/0000-0001-5359-7099				Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Bhuiyan MPI, 2006, BIOORGAN MED CHEM, V14, P3438, DOI 10.1016/j.bmc.2005.12.063; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butler LM, 2000, CANCER RES, V60, P5165; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Castellano R, 2006, J BIOL CHEM, V281, P14719, DOI 10.1074/jbc.M602373200; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Fallarino F, 1999, J IMMUNOL, V163, P4109; Glaser KB, 2003, MOL CANCER THER, V2, P151; Glick RD, 1999, CANCER RES, V59, P4392; Gramaglia I, 2000, EUR J IMMUNOL, V30, P392, DOI 10.1002/1521-4141(200002)30:2<392::AID-IMMU392>3.0.CO;2-H; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jaboin J, 2002, CANCER RES, V62, P6108; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kim S, 2006, BIOCHEM BIOPH RES CO, V342, P1168, DOI 10.1016/j.bbrc.2006.02.081; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Liu F, 2006, MOL BIOL CELL, V17, P585, DOI 10.1091/mbc.E05-08-0775; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Mariadason JM, 2000, CANCER RES, V60, P4561; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nakajima C, 2001, CANCER RES, V61, P3399; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Suske G, 2000, Methods Mol Biol, V130, P175; Takahashi C, 1999, J IMMUNOL, V162, P5037; Uno T, 2006, NAT MED, V12, P693, DOI 10.1038/nm1405; VanLint C, 1996, GENE EXPRESSION, V5, P245; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Vigushin DM, 2004, CURR CANCER DRUG TAR, V4, P205, DOI 10.2174/1568009043481560; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wilcox RA, 2002, CANCER RES, V62, P4413; Wilcox RA, 2002, J IMMUNOL, V169, P4230, DOI 10.4049/jimmunol.169.8.4230; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; Wilcox RA, 2002, J IMMUNOL, V168, P4262, DOI 10.4049/jimmunol.168.9.4262; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004	65	13	13	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7085	10.1371/journal.pone.0007085	http://dx.doi.org/10.1371/journal.pone.0007085			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759901	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970200014
J	Fardin, P; Ognibene, M; Vanni, C; De Santanna, A; Varesio, L; Eva, A				Fardin, Paolo; Ognibene, Marzia; Vanni, Cristina; De Santanna, Amleto; Varesio, Luigi; Eva, Alessandra			Induction of Epithelial Mesenchimal Transition and Vasculogenesis in the Lenses of Dbl Oncogene Transgenic Mice	PLOS ONE			English	Article							TO-MESENCHYMAL TRANSITION; NF-KAPPA-B; RHO-GTPASES; TUMOR PROGRESSION; GENE-EXPRESSION; E-CADHERIN; METALLOTHIONEIN; TRANSCRIPTION; HYPOXIA; TARGET	Background: The Dbl family of proteins represents a large group of proto-oncogenes involved in cell growth regulation. The numerous domains that are present in many Dbl family proteins suggest that they act to integrate multiple inputs in complicated signaling networks involving the Rho GTPases. Alterations of the normal function of these proteins lead to pathological processes such as developmental disorders and neoplastic transformation. We generated transgenic mice introducing the cDNA of Dbl oncogene linked to the metallothionein promoter into the germ line of FVB mice and found that onco-Dbl expression in mouse lenses affected proliferation, migration and differentiation of lens epithelial cells. Results: We used high density oligonucleotide microarray to define the transcriptional profile induced by Dbl in the lenses of 2 days, 2 weeks, and 6 weeks old transgenic mice. We observed modulation of genes encoding proteins promoting epithelial-mesenchymal transition (EMT), such as down-regulation of epithelial cell markers and up-regulation of fibroblast markers. Genes encoding proteins involved in the positive regulation of apoptosis were markedly down regulated while anti-apoptotic genes were strongly up-regulated. Finally, several genes encoding proteins involved in the process of angiogenesis were up-regulated. These observations were validated by histological and immunohistochemical examination of the transgenic lenses where vascularization can be readily observed. Conclusion: Onco-Dbl expression in mouse lens correlated with modulation of genes involved in the regulation of EMT, apoptosis and vasculogenesis leading to disruption of the lens architecture, epithelial cell proliferation, and aberrant angiogenesis. We conclude that onco-Dbl has a potentially important, previously unreported, capacity to dramatically alter epithelial cell migration, replication, polarization and differentiation and to induce vascularization of an epithelial tissue.			Fardin, P (corresponding author), Ist Giannina Gaslini, Mol Biol Lab, I-16148 Genoa, Italy.	alessandraeva@ospedale-gaslini.ge.it	Ognibene, Marzia/AAA-7275-2020; varesio, luigi/J-8261-2016; Eva, Alessandra/J-8268-2016	Ognibene, Marzia/0000-0003-3698-9319; varesio, luigi/0000-0001-5659-2218; Eva, Alessandra/0000-0003-2949-078X	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Alonso-Magdalena P, 2009, P NATL ACAD SCI USA, V106, P2859, DOI 10.1073/pnas.0812666106; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Balzac F, 2005, J CELL SCI, V118, P4765, DOI 10.1242/jcs.02584; Banh A, 2006, INVEST OPHTH VIS SCI, V47, P3450, DOI 10.1167/iovs.05-1208; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CHIU ST, 2009, CARCINOGENESIS; Conti I, 2004, SEMIN CANCER BIOL, V14, P149, DOI 10.1016/j.semcancer.2003.10.009; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; EVA A, 1991, NEW BIOL, V3, P158; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Ghoul A, 2009, CANCER RES, V69, P4260, DOI 10.1158/0008-5472.CAN-08-2837; Hirsch E, 2002, MOL CELL BIOL, V22, P3140, DOI 10.1128/MCB.22.9.3140-3148.2002; Hu K, 2008, FRONT BIOSCI, V13, P5174, DOI 10.2741/3073; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kojima I, 2009, KIDNEY INT, V75, P268, DOI 10.1038/ki.2008.488; Lee EH, 2002, MOL VIS, V8, P235; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; LOW MJ, 1985, CELL, V41, P211, DOI 10.1016/0092-8674(85)90075-3; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Marcantonio JM, 2003, EXP EYE RES, V77, P339, DOI 10.1016/S0014-4835(03)00125-8; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Murphy BJ, 1999, CANCER RES, V59, P1315; Murphy BJ, 2008, MOL CANCER RES, V6, P483, DOI 10.1158/1541-7786.MCR-07-0341; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Nieto MA, 2001, MECH DEVELOP, V105, P27, DOI 10.1016/S0925-4773(01)00394-X; Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846; Orlichenko LS, 2008, CLIN EXP METASTAS, V25, P593, DOI 10.1007/s10585-008-9143-9; Perng MD, 2007, EXP CELL RES, V313, P2180, DOI 10.1016/j.yexcr.2007.04.005; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Przybylo JA, 2007, INT J BIOCHEM CELL B, V39, P1082, DOI 10.1016/j.biocel.2007.03.002; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Robson EJD, 2006, DIFFERENTIATION, V74, P254, DOI 10.1111/j.1432-0436.2006.00075.x; Rodgers RJ, 2000, MOL CELL ENDOCRINOL, V163, P73, DOI 10.1016/S0303-7207(00)00219-7; RON D, 1989, ONCOGENE, V4, P1067; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; ROZEN R, 2000, PRIMER 3 WWW GEN USE, P365; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Sharma MC, 2007, CURR PHARM DESIGN, V13, P3568, DOI 10.2174/138161207782794167; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; Waldmann J, 2008, BRIT J CANCER, V99, P1900, DOI 10.1038/sj.bjc.6604755; Wang B, 2008, BIOCHEM BIOPH RES CO, V368, P88, DOI 10.1016/j.bbrc.2008.01.036; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Xu YF, 2009, J NEPHROL, V22, P403; Yoo HJ, 2009, EXP MOL MED, V41, P102, DOI 10.3858/emm.2009.41.2.013; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106; Zhang HJ, 2005, CELL BIOL INT, V29, P213, DOI 10.1016/j.cellbi.2004.12.007	65	3	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7058	10.1371/journal.pone.0007058	http://dx.doi.org/10.1371/journal.pone.0007058			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19759912	gold, Green Published, Green Submitted			2022-12-27	WOS:000269970000021
J	Mileti, E; Matteoli, G; Iliev, ID; Rescigno, M				Mileti, Erika; Matteoli, Gianluca; Iliev, Iliyan D.; Rescigno, Maria			Comparison of the Immunomodulatory Properties of Three Probiotic Strains of Lactobacilli Using Complex Culture Systems: Prediction for In Vivo Efficacy	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; TOLL-LIKE RECEPTOR-4; EXPERIMENTAL COLITIS; DENDRITIC CELLS; ULCERATIVE-COLITIS; INTESTINAL INFLAMMATION; COLONIC INFLAMMATION; IMMUNE HOMEOSTASIS; PARACASEI B21060; EPITHELIAL-CELLS	Background: While the use of probiotics to treat or prevent inflammatory bowel disease (IBD) has been proposed, to this point the clinical benefits have been limited. In this report we analyzed the immunological activity of three strains of Lactobacillus to predict their in vivo efficacy in protecting against experimental colitis. Methodology/Principal Findings: We compared the immunological properties of Lactobacillus plantarum NCIMB8826, L. rhamnosus GG (LGG), L. paracasei B21060 and pathogenic Salmonella typhimurium (SL1344). We studied the stimulatory effects of these different strains upon dendritic cells (DCs) either directly by co-culture or indirectly via conditioning of an epithelial intermediary. Furthermore, we characterized the effects of these strains in vivo using a Dextran sulphate sodium (DSS) model of colitis. We found that the three strains exhibited different abilities to induce inflammatory cytokine production by DCs with L. plantarum being the most effective followed by LGG and L. paracasei. L. paracasei minimally induced the release of cytokines, while it also inhibited the potential of DCs to both produce inflammatory cytokines (IL-12 and TNF-alpha) and to drive Th1 T cells in response to Salmonella. This effect on DCs was found under both direct and indirect stimulatory conditions - i.e. mediated by epithelial cells - and was dependent upon an as yet unidentified soluble mediator. When tested in vivo, L. plantarum and LGG exacerbated the development of DSS-induced colitis and caused the death of treated mice, while, conversely L. paracasei was protective. Conclusions: We describe a new property of probiotics to either directly or indirectly inhibit DC activation by inflammatory bacteria. Moreover, some immunostimulatory probiotics not only failed to protect against colitis, they actually amplified the disease progression. In conclusion, caution must be exercised when choosing a probiotic strain to treat IBD.			Mileti, E (corresponding author), European Inst Oncol, Dept Expt Oncol, Milan, Italy.	maria.rescigno@ifom-ieo-campus.it	Mileti, Erika/AAR-7801-2020; Rescigno, Maria/J-9704-2012	Mileti, Erika/0000-0003-0425-5169; Rescigno, Maria/0000-0002-6464-509X; Matteoli, Gianluca/0000-0002-2902-4976				Abe K, 2007, P NATL ACAD SCI USA, V104, P17022, DOI 10.1073/pnas.0708469104; Amit-Romach E, 2008, DIS COLON RECTUM, V51, P1828, DOI 10.1007/s10350-008-9394-1; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Boirivant M, 2007, CURR OPIN GASTROEN, V23, P679, DOI 10.1097/MOG.0b013e3282f0cffc; Bousvaros A, 2005, INFLAMM BOWEL DIS, V11, P833, DOI 10.1097/01.MIB.0000175905.00212.2c; Carroll IM, 2007, AM J PHYSIOL-GASTR L, V293, pG729, DOI 10.1152/ajpgi.00132.2007; Castagliuolo I, 2005, FEMS IMMUNOL MED MIC, V43, P197, DOI 10.1016/j.femsim.2004.08.011; Chen LL, 2009, WORLD J GASTROENTERO, V15, P321, DOI 10.3748/wjg.15.321; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Chung YW, 2008, CLIN EXP IMMUNOL, V151, P182, DOI 10.1111/j.1365-2249.2007.03549.x; COOPER HS, 1993, LAB INVEST, V69, P238; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; Daniel C, 2006, APPL ENVIRON MICROB, V72, P5799, DOI 10.1128/AEM.00109-06; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; Elson CO, 2005, IMMUNOL REV, V206, P260, DOI 10.1111/j.0105-2896.2005.00291.x; FAO/WHO, 2001, FAO WHO EXP CONS EV; Feighery LM, 2008, DIGEST DIS SCI, V53, P2495, DOI 10.1007/s10620-007-0157-y; Fitzpatrick LR, 2008, BRIT J NUTR, V100, P530, DOI 10.1017/S0007114508930373; Foligne B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000313; Foligne B, 2007, WORLD J GASTROENTERO, V13, P236, DOI 10.3748/wjg.v13.i2.236; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Fukuda M, 2002, INT J MOL MED, V9, P65; Garrett WS, 2007, CELL, V131, P33, DOI 10.1016/j.cell.2007.08.017; Gaudier E, 2005, J NUTR, V135, P2753; Geier MS, 2007, INT J FOOD MICROBIOL, V114, P267, DOI 10.1016/j.ijfoodmicro.2006.09.018; Grabig A, 2006, INFECT IMMUN, V74, P4075, DOI 10.1128/IAI.01449-05; Herias MV, 2005, INT J FOOD MICROBIOL, V103, P143, DOI 10.1016/j.ijfoodmicro.2004.11.032; Iliev ID, 2009, MUCOSAL IMMUNOL, V2, P340, DOI 10.1038/mi.2009.13; ILIEV ID, 2009, GUT; Isaacs K, 2008, INFLAMM BOWEL DIS, V14, P1597, DOI 10.1002/ibd.20465; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kamada A, 2005, INFLAMM BOWEL DIS, V11, P455, DOI 10.1097/01.MIB.0000158158.55955.de; Kennedy RJ, 2000, SCAND J GASTROENTERO, V35, P1266, DOI 10.1080/003655200453601; Konstantinov SR, 2008, P NATL ACAD SCI USA, V105, P19474, DOI 10.1073/pnas.0810305105; Kumar NSN, 2008, J GASTROEN HEPATOL, V23, P1834, DOI 10.1111/j.1440-1746.2008.05723.x; Lee J, 2008, SEMIN IMMUNOPATHOL, V30, P3, DOI 10.1007/s00281-007-0099-7; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Llopis M, 2005, GUT, V54, P955, DOI 10.1136/gut.2004.056101; Matsumoto S, 2005, CLIN EXP IMMUNOL, V140, P417, DOI 10.1111/j.1365-2249.2005.02790.x; McCarthy J, 2003, GUT, V52, P975, DOI 10.1136/gut.52.7.975; Mennigen R, 2009, AM J PHYSIOL-GASTR L, V296, pG1140, DOI 10.1152/ajpgi.90534.2008; Morelli L, 2006, DIGEST LIVER DIS, V38, P894, DOI 10.1016/j.dld.2006.07.010; Morelli L, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-11; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; O'Mahony L, 2001, ALIMENT PHARM THER, V15, P1219, DOI 10.1046/j.1365-2036.2001.01027.x; Osman N, 2008, DIGEST DIS SCI, V53, P2464, DOI 10.1007/s10620-007-0174-x; Peluso I, 2007, INFECT IMMUN, V75, P1730, DOI 10.1128/IAI.01172-06; Peran L, 2007, J APPL MICROBIOL, V103, P836, DOI 10.1111/j.1365-2672.2007.03302.x; Peran L, 2007, BRIT J NUTR, V97, P96, DOI 10.1017/S0007114507257770; Peran L, 2006, INT J COLORECTAL DIS, V21, P737, DOI 10.1007/s00384-005-0773-y; Prantera C, 2002, GUT, V51, P405, DOI 10.1136/gut.51.3.405; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; RESCIGNO M, 2008, CURR OPIN IMMUNOL; Rescigno M, 2008, CURR DRUG TARGETS, V9, P395, DOI 10.2174/138945008784221125; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schultz M, 2004, CLIN DIAGN LAB IMMUN, V11, P372, DOI 10.1128/CDLI.11.2.372-378.2004; Schultz M, 2002, INFLAMM BOWEL DIS, V8, P71, DOI 10.1097/00054725-200203000-00001; Selvam R, 2009, INDIAN J BIOCHEM BIO, V46, P79; Sengul N, 2006, DIS COLON RECTUM, V49, P250, DOI 10.1007/s10350-005-0267-6; Shibolet O, 2002, INFLAMM BOWEL DIS, V8, P399, DOI 10.1097/00054725-200211000-00004; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Soo I, 2008, CAN J GASTROENTEROL, V22, P237, DOI 10.1155/2008/520383; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Swidsinski A, 2007, GUT, V56, P343, DOI 10.1136/gut.2006.098160; Szajewska H, 2001, J PEDIATR-US, V138, P361, DOI 10.1067/mpd.2001.111321; van Baarlen P, 2009, P NATL ACAD SCI USA, V106, P2371, DOI 10.1073/pnas.0809919106; Vanderpool C, 2008, INFLAMM BOWEL DIS, V14, P1585, DOI 10.1002/ibd.20525; Zournpopoulou G, 2008, INT J FOOD MICROBIOL, V121, P18, DOI 10.1016/j.ijfoodmicro.2007.10.013; Zwolinska-Wcislo M, 2009, J PHYSIOL PHARMACOL, V60, P107	75	190	202	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7056	10.1371/journal.pone.0007056	http://dx.doi.org/10.1371/journal.pone.0007056			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756155	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970000020
J	Yamamoto, K; Tanaka, S; Kobayashi, H; Kozima, H; Hashiya, K				Yamamoto, Kentaro; Tanaka, Saori; Kobayashi, Hiromi; Kozima, Hideki; Hashiya, Kazuhide			A Non-Humanoid Robot in the "Uncanny Valley": Experimental Analysis of the Reaction to Behavioral Contingency in 2-3 Year Old Children	PLOS ONE			English	Article							SOCIAL CONTINGENCY; INFANTS; RECOGNITION; PREFERENCE	Infants' sensitivity to social or behavioral contingency has been examined in the field of developmental psychology and behavioral sciences, mainly using a double video paradigm or a still face paradigm. These studies have shown that infants distinguish other individuals' contingent behaviors from non-contingent ones. The present experiment systematically examined if this ability extends to the detection of non-humanoids' contingent actions in a communicative context. We examined two-to three-year-olds' understanding of contingent actions produced by a non-humanoid robot. The robot either responded contingently to the actions of the participants (contingent condition) or programmatically reproduced the same sequence of actions to another participant (non-contingent condition). The results revealed that the participants exhibited different patterns of response depending on whether or not the robot responded contingently. It was also found that the participants did not respond positively to the contingent actions of the robot in the earlier periods of the experimental sessions. This might reflect the conflict between the non-humanlike appearance of the robot and its humanlike contingent actions, which presumably led the children to experience the uncanny valley effect.			Yamamoto, K (corresponding author), Kyushu Univ, Grad Sch Human Environm Studies, Fukuoka 812, Japan.	yama-ken@kyudai.jp; hashiya@mindless.com	Yamamoto, Kentaro/AFO-9654-2022		Grants-in-Aid for Scientific Research [21330154] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Arita A, 2005, COGNITION, V95, pB49, DOI 10.1016/j.cognition.2004.08.001; Bigelow AE, 1999, INFANT BEHAV DEV, V22, P367, DOI 10.1016/S0163-6383(99)00016-8; Cohen L. B., 1975, INFANT PERCEPTION SE, P347, DOI 10.1016/B978-0-12-178601-4.50011-6; de Haan M, 2002, J COGNITIVE NEUROSCI, V14, P199, DOI 10.1162/089892902317236849; ELLSWORTH CP, 1993, DEV PSYCHOL, V29, P63, DOI 10.1037/0012-1649.29.1.63; FUJITA K, 1987, PRIMATES, V28, P353, DOI 10.1007/BF02381018; GUSELLA JL, 1988, CHILD DEV, V59, P1111; Hains SMJ, 1996, INFANT BEHAV DEV, V19, P49, DOI 10.1016/S0163-6383(96)90043-0; Johnson SC, 2001, COGNITIVE DEV, V16, P637, DOI 10.1016/S0885-2014(01)00043-0; Johnson S, 1998, DEVELOPMENTAL SCI, V1, P233, DOI 10.1111/1467-7687.00036; Kozima H., 2006, MOBILE ROBOTS NEW AP, P269; Kozima H, 2009, INT J SOC ROBOT, V1, P3, DOI 10.1007/s12369-008-0009-8; MacDorman KF, 2009, COMPUT HUM BEHAV, V25, P695, DOI 10.1016/j.chb.2008.12.026; Meltzoff A.N., 2005, PERSPECTIVES IMITATI, V2, P55; Meltzoff A. N., 2001, INTENTIONS INTENTION, P171; Meltzoff AN, 2007, DEVELOPMENTAL SCI, V10, P126, DOI 10.1111/j.1467-7687.2007.00574.x; Mori M., 1970, ENERGY, V7, P33, DOI DOI 10.1109/MRA.2012.2192811; MURRAY L., 1985, SOCIAL PERCEPTION IN, P177; Nadel J, 1999, DEVELOPMENTAL SCI, V2, P164, DOI 10.1111/1467-7687.00065; Plenderleith M, 2005, BIOL LETT-UK, V1, P411, DOI 10.1098/rsbl.2005.0355; RYAN TA, 1960, PSYCHOL BULL, V57, P318, DOI 10.1037/h0044320; Sanefuji W, 2006, INFANT BEHAV DEV, V29, P584, DOI 10.1016/j.infbeh.2006.07.007; Sanefuji W, 2008, INFANT BEHAV DEV, V31, P624, DOI 10.1016/j.infbeh.2008.07.003; Stormark KM, 2004, INFANT BEHAV DEV, V27, P195, DOI 10.1016/j.infbeh.2003.09.004; Striano T, 2004, CHILD DEV, V75, P468, DOI 10.1111/j.1467-8624.2004.00687.x; Tanaka F, 2007, P NATL ACAD SCI USA, V104, P17954, DOI 10.1073/pnas.0707769104; TODA S, 1993, DEV PSYCHOL, V29, P532, DOI 10.1037/0012-1649.29.3.532; TRONICK E, 1978, J AM ACAD CHILD PSY, V17, P1, DOI 10.1016/S0002-7138(09)62273-1; Whaling CS, 1997, P NATL ACAD SCI USA, V94, P12694, DOI 10.1073/pnas.94.23.12694; [No title captured]	30	8	8	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e6974	10.1371/journal.pone.0006974	http://dx.doi.org/10.1371/journal.pone.0006974			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	496KE	19759818	Green Published, gold			2022-12-27	WOS:000269970000004
J	Crispi, S; Calogero, RA; Santini, M; Mellone, P; Vincenzi, B; Citro, G; Vicidomini, G; Fasano, S; Meccariello, R; Cobellis, G; Menegozzo, S; Pierantoni, R; Facciolo, F; Baldi, A; Menegozzo, M				Crispi, Stefania; Calogero, Raffaele A.; Santini, Mario; Mellone, Pasquale; Vincenzi, Bruno; Citro, Gennaro; Vicidomini, Giovanni; Fasano, Silvia; Meccariello, Rosaria; Cobellis, Gilda; Menegozzo, Simona; Pierantoni, Riccardo; Facciolo, Francesco; Baldi, Alfonso; Menegozzo, Massimo			Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target	PLOS ONE			English	Article							HUMAN-MALIGNANT MESOTHELIOMA; LEUCINE-ZIPPER KINASE; BREAST-CANCER CELLS; PROGNOSTIC-FACTORS; MICROARRAY DATA; GROWTH-FACTOR; LUNG-CANCER; CYCLIN B1; AURORA-A; OVEREXPRESSION	Background: The goal of our study was to molecularly dissect mesothelioma tumour pathways by mean of microarray technologies in order to identify new tumour biomarkers that could be used as early diagnostic markers and possibly as specific molecular therapeutic targets. Methodology: We performed Affymetrix HGU133A plus 2.0 microarray analysis, containing probes for about 39,000 human transcripts, comparing 9 human pleural mesotheliomas with 4 normal pleural specimens. Stringent statistical feature selection detected a set of differentially expressed genes that have been further evaluated to identify potential biomarkers to be used in early diagnostics. Selected genes were confirmed by RT-PCR. As reported by other mesothelioma profiling studies, most of genes are involved in G2/M transition. Our list contains several genes previously described as prognostic classifier. Furthermore, we found novel genes, never associated before to mesotheliom that could be involved in tumour progression. Notable is the identification of MMP-14, a member of matrix metalloproteinase family. In a cohort of 70 mesothelioma patients, we found by a multivariate Cox regression analysis, that the only parameter influencing overall survival was expression of MMP14. The calculated relative risk of death in MM patients with low MMP14 expression was significantly lower than patients with high MMp14 expression (P = 0.002). Conclusions: Based on the results provided, this molecule could be viewed as a new and effective therapeutic target to test for the cure of mesothelioma.			Crispi, S (corresponding author), Inst Genet & Biophys, Gene Express Core Human Mol Genet Lab, Naples, Italy.	crispi@igb.cnr.it	SANTINI, Mario/AAE-9516-2022; SANTINI, Mario/AFE-1150-2022; Baldi, Alfonso/ABG-2397-2021; SANTINI, Mario/AAE-9589-2022; Calogero, Raffaele/K-9428-2019; SANTINI, Mario/AFE-6002-2022	SANTINI, Mario/0000-0003-1162-7805; SANTINI, Mario/0000-0003-1162-7805; SANTINI, Mario/0000-0003-1162-7805; Calogero, Raffaele/0000-0002-2848-628X; SANTINI, Mario/0000-0003-1162-7805; Meccariello, Rosaria/0000-0003-2174-1118; FASANO, SILVIA/0000-0002-4716-6142; Crispi, Stefania/0000-0002-7566-1554; COBELLIS, Gilda/0000-0001-5884-9208; VICIDOMINI, Giovanni/0000-0002-1002-6090; PIERANTONI, Riccardo/0000-0001-8246-2177; Baldi, Alfonso/0000-0002-8693-3842; Vincenzi, Bruno/0000-0001-8222-9025; Facciolo, Francesco/0000-0002-7137-8946				Arrossi AV, 2008, AM J CLIN PATHOL, V130, P754, DOI 10.1309/AJCPHV33LJTVDGJJ; BALDI F, 2007, MESOTHELIOMA BENCH S, P279; Ball AR, 2002, MOL CELL BIOL, V22, P5769, DOI 10.1128/MCB.22.16.5769-5781.2002; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07; Chao JI, 2007, MOL CANCER THER, V6, P3039, DOI 10.1158/1535-7163.MCT-07-0281; Che G, 2006, NEOPLASMA, V53, P530; COGNETTI F, 2007, MESOTHELIOMA BENCH S, P347; Corson TW, 2007, CLIN CANCER RES, V13, P3229, DOI 10.1158/1078-0432.CCR-07-0393; Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giet R, 1999, J CELL SCI, V112, P3591; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Gordon GJ, 2007, J PATHOL, V211, P439, DOI 10.1002/path.2120; Gordon GJ, 2008, CANCER CHEMOTH PHARM, V61, P549, DOI 10.1007/s00280-007-0500-1; Gordon GJ, 2005, AM J PATHOL, V166, P1827, DOI 10.1016/S0002-9440(10)62492-3; Gordon GJ, 2002, CANCER RES, V62, P4963; Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HUGHES JM, 1986, AM REV RESPIR DIS, V133, P5, DOI 10.1164/arrd.1986.133.1.5; Ishikawa K, 2008, BRIT J CANCER, V98, P1824, DOI 10.1038/sj.bjc.6604379; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kaiser LR, 1999, J THORAC CARDIOV SUR, V117, P63; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; Lafleur MA, 2003, FEBS LETT, V553, P457, DOI 10.1016/S0014-5793(03)01094-9; Lassmann S, 2007, CLIN CANCER RES, V13, P4083, DOI 10.1158/1078-0432.CCR-06-2775; Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650; Liu ZW, 2001, INT J CANCER, V91, P638, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1102>3.0.CO;2-Y; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Melendez-Zajgla J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-85; MENEGOZZO M, 2007, MESOTHELIOMA BENCH S, P25; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; Nakano I, 2008, J NEUROSCI RES, V86, P48, DOI 10.1002/jnr.21471; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nymark P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-62; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Segawa T, 2008, BIOCHEM BIOPH RES CO, V369, P915, DOI 10.1016/j.bbrc.2008.02.114; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Song YM, 2008, CARCINOGENESIS, V29, P307, DOI 10.1093/carcin/bgm269; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Spugnini EP, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-58; Spugnini EP, 2006, CLIN CANCER RES, V12, P6133, DOI 10.1158/1078-0432.CCR-06-1056; Spugnini EP, 2006, INT J BIOCHEM CELL B, V38, P2000, DOI 10.1016/j.biocel.2006.07.002; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Sugarbaker DJ, 1999, J THORAC CARDIOV SUR, V117, P54, DOI 10.1016/S0022-5223(99)70469-1; Suzuki T, 2007, CANCER SCI, V98, P644, DOI 10.1111/j.1349-7006.2007.00444.x; Tang JB, 2006, P NATL ACAD SCI USA, V103, P11964, DOI 10.1073/pnas.0604987103; Tomek S, 2003, CURR OPIN ONCOL, V15, P148, DOI 10.1097/00001622-200303000-00006; Tsou AP, 2003, ONCOGENE, V22, P298, DOI 10.1038/sj.onc.1206129; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; VONHEYDEBRECK A, 2004, BIOCONDUCTOR PROJECT, V7; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; Westfall P.H., 1993, RESAMPLING BASED MUL, V279; Wilde A, 2006, J CELL BIOL, V173, P829, DOI 10.1083/jcb.200605150; Wittmann BM, 2003, CANCER RES, V63, P5151; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; WU Z, 2004, P 8 C RES COMP MOL B, P98; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yamamoto Y, 2007, CANCER GENET CYTOGEN, V174, P42, DOI 10.1016/j.cancergencyto.2006.11.012; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903	78	65	66	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7016	10.1371/journal.pone.0007016	http://dx.doi.org/10.1371/journal.pone.0007016			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753302	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796500007
J	Smith, MV; Boyd, WA; Kissling, GE; Rice, JR; Snyder, DW; Portier, CJ; Freedman, JH				Smith, Marjolein V.; Boyd, Windy A.; Kissling, Grace E.; Rice, Julie R.; Snyder, Daniel W.; Portier, Christopher J.; Freedman, Jonathan H.			A Discrete Time Model for the Analysis of Medium-Throughput C. elegans Growth Data	PLOS ONE			English	Article								Background: As part of a program to predict the toxicity of environmental agents on human health using alternative methods, several in vivo high- and medium-throughput assays are being developed that use C. elegans as a model organism. C. elegans-based toxicological assays utilize the COPAS Biosort flow sorting system that can rapidly measure size, extinction (EXT) and time-of-flight (TOF), of individual nematodes. The use of this technology requires the development of mathematical and statistical tools to properly analyze the large volumes of biological data. Methodology/Principal Findings: Findings A Markov model was developed that predicts the growth of populations of C. elegans. The model was developed using observations from a 60 h growth study in which five cohorts of 300 nematodes each were aspirated and measured every 12 h. Frequency distributions of log(EXT) measurements that were made when loading C. elegans L1 larvae into 96 well plates (t = 0 h) were used by the model to predict the frequency distributions of the same set of nematodes when measured at 12 h intervals. The model prediction coincided well with the biological observations confirming the validity of the model. The model was also applied to log(TOF) measurements following an adaptation. The adaptation accounted for variability in TOF measurements associated with potential curling or shortening of the nematodes as they passed through the flow cell of the Biosort. By providing accurate estimates of frequencies of EXT or TOF measurements following varying growth periods, the model was able to estimate growth rates. Best model fits showed that C. elegans did not grow at a constant exponential rate. Growth was best described with three different rates. Microscopic observations indicated that the points where the growth rates changed corresponded to specific developmental events: the L1/L2 molt and the start of oogenesis in young adult C. elegans. Conclusions: Quantitative analysis of COPAS Biosort measurements of C. elegans growth has been hampered by the lack of a mathematical model. In addition, extraneous matter and the inability to assign specific measurements to specific nematodes made it difficult to estimate growth rates. The present model addresses these problems through a population-based Markov model.			Smith, MV (corresponding author), SRA Int, Durham, NC USA.	freedma1@niehs.nih.gov	Portier, Christopher J/A-3160-2010	Portier, Christopher J/0000-0002-0954-0279; Boyd, Windy/0000-0003-3803-3716	Intramural NIH HHS [Z01 ES102046] Funding Source: Medline; PHS HHS [GS-00F-0003L] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES045004, ZIAES102046, ZIAES048002, Z01ES102046] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhat U. N., 1984, ELEMENTS APPL STOCHA, V2nd; Boyd W.A., 2009, NEUROTOXICOL TERATOL; BRENNER S, 1974, GENETICS, V77, P71; BYERLY L, 1976, DEV BIOL, V51, P23, DOI 10.1016/0012-1606(76)90119-6; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Collins FS, 2008, SCIENCE, V319, P906, DOI 10.1126/science.1154619; Hall DH., 2008, C ELEGANS ATLAS; Khanna N, 1997, ARCH ENVIRON CON TOX, V32, P110, DOI 10.1007/s002449900162; Knight CG, 2002, EVOL DEV, V4, P16, DOI 10.1046/j.1525-142x.2002.01058.x; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Peterson RT, 2008, NEUROTOXICOLOGY, V29, P546, DOI 10.1016/j.neuro.2008.04.006; Pulak Rock, 2006, V351, P275; Tzur A, 2009, SCIENCE, V325, P167, DOI 10.1126/science.1174294; WILLIAMS PL, 1988, TOXICOL IND HEALTH, V4, P469, DOI 10.1177/074823378800400406; Wood WB, 1988, NEMATODE CAENORHABDI, P1	15	16	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7018	10.1371/journal.pone.0007018	http://dx.doi.org/10.1371/journal.pone.0007018			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753303	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796500009
J	Herrou, J; Debrie, AS; Willery, E; Renaud-Mongenie, G; Locht, C; Mooi, F; Jacob-Dubuisson, F; Antoine, R				Herrou, Julien; Debrie, Anne-Sophie; Willery, Eve; Renaud-Mongenie, Genevieve; Locht, Camille; Mooi, Frits; Jacob-Dubuisson, Francoise; Antoine, Rudy			Molecular Evolution of the Two-Component System BvgAS Involved in Virulence Regulation in Bordetella	PLOS ONE			English	Article								The whooping cough agent Bordetella pertussis is closely related to Bordetella bronchiseptica, which is responsible for chronic respiratory infections in various mammals and is occasionally found in humans, and to Bordetella parapertussis, one lineage of which causes mild whooping cough in humans and the other ovine respiratory infections. All three species produce similar sets of virulence factors that are co-regulated by the two-component system BvgAS. We characterized the molecular diversity of BvgAS in Bordetella by sequencing the two genes from a large number of diverse isolates. The response regulator BvgA is virtually invariant, indicating strong functional constraints. In contrast, the multi-domain sensor kinase BvgS has evolved into two different types. The pertussis type is found in B. pertussis and in a lineage of essentially human-associated B. bronchiseptica, while the bronchiseptica type is associated with the majority of B. bronchiseptica and both ovine and human B. parapertussis. BvgS is monomorphic in B. pertussis, suggesting optimal adaptation or a recent population bottleneck. The degree of diversity of the bronchiseptica type BvgS is markedly different between domains, indicating distinct evolutionary pressures. Thus, absolute conservation of the putative solute-binding cavities of the two periplasmic Venus Fly Trap (VFT) domains suggests that common signals are perceived in all three species, while the external surfaces of these domains vary more extensively. Co-evolution of the surfaces of the two VFT domains in each type and domain swapping experiments indicate that signal transduction in the periplasmic region may be type-specific. The two distinct evolutionary solutions for BvgS confirm that B. pertussis has emerged from a specific B. bronchiseptica lineage. The invariant regions of BvgS point to essential parts for its molecular mechanism, while the variable regions may indicate adaptations to different lifestyles. The repertoire of BvgS sequences will pave the way for functional analyses of this prototypic system.			Herrou, J (corresponding author), INSERM, U629, Lille, France.	francoise.jacob@ibl.fr	Antoine, Rudy/CAH-6653-2022; Jacob-Dubuisson, Françoise/F-1610-2018; Antoine, Rudy/L-1630-2018; Locht, Camille/L-3516-2018	Antoine, Rudy/0000-0002-7369-0626; Jacob-Dubuisson, Françoise/0000-0002-5102-1704; Antoine, Rudy/0000-0002-7369-0626; Locht, Camille/0000-0001-7295-7336; Herrou, Julien/0000-0002-8585-8043; Debrie, Anne-Sophie/0000-0003-0570-4413				Antoine R, 2000, J BACTERIOL, V182, P5902, DOI 10.1128/JB.182.20.5902-5905.2000; Antoine R, 2005, J MOL BIOL, V351, P799, DOI 10.1016/j.jmb.2005.05.071; ARICO B, 1987, MOL MICROBIOL, V1, P301, DOI 10.1111/j.1365-2958.1987.tb01936.x; BEIER D, 1995, J MOL BIOL, V248, P596, DOI 10.1006/jmbi.1995.0245; Beier D, 2006, CURR OPIN MICROBIOL, V9, P143, DOI 10.1016/j.mib.2006.01.005; Bekker Martijn, 2006, Science Progress, V89, P213, DOI 10.3184/003685006783238308; Bock A, 2002, EUR J BIOCHEM, V269, P3479, DOI 10.1046/j.1432-1033.2002.03029.x; COOTE JG, 1991, J GEN MICROBIOL, V137, P2493, DOI 10.1099/00221287-137-11-2493; Coote JG, 2001, ADV MICROB PHYSIOL, V44, P141, DOI 10.1016/S0065-2911(01)44013-6; Cotter PA, 1997, MOL MICROBIOL, V24, P671, DOI 10.1046/j.1365-2958.1997.3821741.x; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; CULLINANE LC, 1987, NEW ZEAL VET J, V35, P175, DOI 10.1080/00480169.1987.35433; Cummings CA, 2006, J BACTERIOL, V188, P1775, DOI 10.1128/JB.188.5.1775-1785.2006; Cummings CA, 2004, J BACTERIOL, V186, P1484, DOI 10.1128/JB.186.5.1484-1492.2004; Deora R, 2002, J BACTERIOL, V184, P6942, DOI 10.1128/JB.184.24.6942-6951.2002; Deora R, 2001, MOL MICROBIOL, V40, P669, DOI 10.1046/j.1365-2958.2001.02415.x; deTejada GM, 1996, MOL MICROBIOL, V22, P895, DOI 10.1046/j.1365-2958.1996.01538.x; Diavatopoulos DA, 2005, PLOS PATHOG, V1, P373, DOI 10.1371/journal.ooat.0010045; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Felder CB, 1999, AAPS PHARMSCI, V1; GOODNOW RA, 1980, MICROBIOL REV, V44, P722, DOI 10.1128/MMBR.44.4.722-738.1980; GOYARD S, 1995, RES MICROBIOL, V146, P363, DOI 10.1016/0923-2508(96)80282-8; Hewlett EL, 1997, PEDIATR INFECT DIS J, V16, pS78, DOI 10.1097/00006454-199704001-00002; IMAIZUMI A, 1983, J CLIN MICROBIOL, V17, P781, DOI 10.1128/JCM.17.5.781-786.1983; Jones AM, 2005, MOL MICROBIOL, V58, P700, DOI 10.1111/j.1365-2958.2005.04875.x; Lacey BW, 1960, J HYG, V31, P423; LINNEMANN CC, 1977, AM J DIS CHILD, V131, P560, DOI 10.1001/archpedi.1977.02120180074014; MANETTI R, 1994, GENE, V150, P123, DOI 10.1016/0378-1119(94)90870-2; Mascher T, 2006, MICROBIOL MOL BIOL R, V70, P910, DOI 10.1128/MMBR.00020-06; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; Merkel TJ, 1998, J BACTERIOL, V180, P1682, DOI 10.1128/JB.180.7.1682-1690.1998; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; MUSSER JM, 1986, J BACTERIOL, V166, P230, DOI 10.1128/jb.166.1.230-237.1986; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; PORTER JF, 1993, FEMS MICROBIOL LETT, V110, P33, DOI 10.1111/j.1574-6968.1993.tb06291.x; PORTER JF, 1991, APPL ENVIRON MICROB, V57, P1202, DOI 10.1128/AEM.57.4.1202-1206.1991; Porter JF, 1996, FEMS MICROBIOL LETT, V135, P131, DOI 10.1111/j.1574-6968.1996.tb07977.x; PORTER JF, 1994, MICROBIOL-SGM, V140, P255, DOI 10.1099/13500872-140-2-255; Preston A, 2004, NAT REV MICROBIOL, V2, P379, DOI 10.1038/nrmicro886; PRUGNOLA A, 1995, MICROBIOL-UK, V141, P2529, DOI 10.1099/13500872-141-10-2529; STIBITZ S, 1986, GENE, V50, P133, DOI 10.1016/0378-1119(86)90318-5; Stibitz S, 2007, BORDETELLA MOL MICRO, P47; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Szurmant H, 2007, CURR OPIN STRUC BIOL, V17, P706, DOI 10.1016/j.sbi.2007.08.019; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; VanderZee A, 1997, J BACTERIOL, V179, P6609, DOI 10.1128/jb.179.21.6609-6617.1997; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; WOOLFREY BF, 1991, CLIN MICROBIOL REV, V4, P243, DOI 10.1128/CMR.4.3.243-255.1991; Xu OP, 2003, STRUCTURE, V11, P1569, DOI 10.1016/j.str.2003.10.016; Zhao XD, 2008, J MOL BIOL, V375, P1141, DOI 10.1016/j.jmb.2007.11.045	53	26	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6996	10.1371/journal.pone.0006996	http://dx.doi.org/10.1371/journal.pone.0006996			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750014	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796300012
J	Murton, AJ; Alamdari, N; Gardiner, SM; Constantin-Teodosiu, D; Layfield, R; Bennett, T; Greenhaff, PL				Murton, Andrew J.; Alamdari, Nima; Gardiner, Sheila M.; Constantin-Teodosiu, Dumitru; Layfield, Robert; Bennett, Terence; Greenhaff, Paul L.			Effects of Endotoxaemia on Protein Metabolism in Rat Fast-Twitch Skeletal Muscle and Myocardium	PLOS ONE			English	Article								Background: It is unclear if the rat myocardium undergoes the same rapid reductions in protein content that are classically observed in fast-twitch skeletal muscle during endotoxaemia. Methodology/Principal Findings: To investigate this further, and to determine if there is any divergence in the response of skeletal muscle and myocardium in the mechanisms that are thought to be largely responsible for eliciting changes in protein content, Sprague Dawley rats were implanted with vascular catheters and administered lipopolysaccharide (LPS; 150 mu g kg(-1) h(-1)) intravenously for 2 h, 6 h or 24 h (saline administered control animals were also included), after which the extensor digitorum longus (EDL) and myocardium were removed under terminal anaesthesia. The protein-to-DNA ratio, a marker of protein content, was significantly reduced in the EDL following 24 h LPS administration (23%; P<0.05), but was no different from controls in the myocardium. At the same time point, a significant increase in MAFbx/atrogin-1 and MuRF1 mRNA (3.76+/-0.7- and 19.5+/-61.9 fold increase vs. controls, respectively; P<0.05), in addition to protein levels of alpha 1-3, 5-7 subunits of the 20S proteasome, were observed in EDL but not myocardium. In contrast, elevations in phosphorylation of p70 S6K residues Thr(421)/Ser(424), and 4E-BP1 residues Thr(37)/Thr(46) (P<0.05), consistent with an elevation in translation initiation, were seen exclusively in the myocardium of LPS-treated animals. Conclusions/Significance: In summary, these findings suggest that the myocardium does not undergo the same catabolic response as skeletal muscle during early endotoxaemia, partly due to the absence of transcriptional and signalling events in the myocardium typically associated with increased muscle proteolysis and the suppression of protein synthesis.			Murton, AJ (corresponding author), Univ Nottingham, Sch Biomed Sci, Queens Med Ctr, Ctr Integrated Syst Biol & Med, Nottingham NG7 2RD, England.	andrew.murton@nottingham.ac.uk		Layfield, Robert/0000-0003-0702-3259; Murton, Andrew/0000-0002-9474-9113; Greenhaff, Paul/0000-0003-4403-0490	BBSRC [BB/G011435/1] Funding Source: UKRI; MRC [G0401644] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/G011435/1] Funding Source: Medline; Medical Research Council [G0401644] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams V, 2008, EUR J CARDIOV PREV R, V15, P293, DOI 10.1097/HJR.0b013e3282f3ec43; Adams V, 2007, CARDIOVASC RES, V73, P120, DOI 10.1016/j.cardiores.2006.10.026; BLAIR R, 1980, PHARMACOL BIOCHEM BE, V12, P463, DOI 10.1016/0091-3057(80)90055-6; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boluyt MO, 2004, CARDIOVASC DRUG THER, V18, P257, DOI 10.1023/B:CARD.0000041245.61136.56; Constantin D, 2007, J PHYSIOL-LONDON, V583, P381, DOI 10.1113/jphysiol.2007.135459; Crossland H, 2008, J PHYSIOL-LONDON, V586, P5589, DOI 10.1113/jphysiol.2008.160150; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Eliasson J, 2006, AM J PHYSIOL-ENDOC M, V291, pE1197, DOI 10.1152/ajpendo.00141.2006; Favier FB, 2008, PFLUG ARCH EUR J PHY, V456, P587, DOI 10.1007/s00424-007-0423-z; Fischer D, 2000, BIOCHEM BIOPH RES CO, V270, P215, DOI 10.1006/bbrc.2000.2398; Frost RA, 2007, AM J PHYSIOL-ENDOC M, V292, pE501, DOI 10.1152/ajpendo.00359.2006; Gamrin L, 1996, CRIT CARE MED, V24, P575, DOI 10.1097/00003246-199604000-00005; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; Gardiner SM, 2005, AM J PHYSIOL-HEART C, V288, pH2280, DOI 10.1152/ajpheart.00851.2004; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Janssen SPM, 2005, CIRCULATION, V111, P996, DOI 10.1161/01.CIR.0000156469.96135.0D; Jones SW, 2004, FASEB J, V18, P1025, DOI 10.1096/fj.03-1228fje; Kim SJ, 2008, J APPL PHYSIOL, V105, P1246, DOI 10.1152/japplphysiol.90668.2008; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; Lang CH, 2002, AM J PHYSIOL-ENDOC M, V282, pE336, DOI 10.1152/ajpendo.00366.2001; Lang CH, 2000, AM J PHYSIOL-ENDOC M, V278, pE1133, DOI 10.1152/ajpendo.2000.278.6.E1133; Lang CH, 2007, AM J PHYSIOL-ENDOC M, V293, pE453, DOI 10.1152/ajpendo.00204.2007; Lang CH, 2007, METABOLISM, V56, P49, DOI 10.1016/j.metabol.2006.08.025; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Minnaard R, 2005, MUSCLE NERVE, V31, P339, DOI 10.1002/mus.20268; MUNRO HN, 1966, ANALYST, V91, P78, DOI 10.1039/an9669100078; Nader GA, 2002, CLIN ORTHOP RELAT R, pS178, DOI 10.1097/01.blo.0000031979.92980.2e; O'Leary MJ, 2002, SHOCK, V18, P265, DOI 10.1097/00024382-200209000-00011; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Smart N, 2006, CARDIOVASC RES, V69, P164, DOI 10.1016/j.cardiores.2005.08.017; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tsutamoto T, 1998, J AM COLL CARDIOL, V31, P391, DOI 10.1016/S0735-1097(97)00494-4; Vary TC, 1998, MOL CELL BIOCHEM, V178, P81, DOI 10.1023/A:1006826331115; Vary TC, 2002, AM J PHYSIOL-ENDOC M, V283, pE1032, DOI 10.1152/ajpendo.00171.2002; VARY TC, 1992, AM J PHYSIOL, V262, pC1513, DOI 10.1152/ajpcell.1992.262.6.C1513; WALLER J, 1995, BRIT J PHARMACOL, V116, P2487, DOI 10.1111/j.1476-5381.1995.tb15100.x; WALLER J, 1994, BRIT J PHARMACOL, V112, P1057, DOI 10.1111/j.1476-5381.1994.tb13190.x; Williams A, 1998, AM J PHYSIOL-REG I, V275, pR1983, DOI 10.1152/ajpregu.1998.275.6.R1983; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2	44	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6945	10.1371/journal.pone.0006945	http://dx.doi.org/10.1371/journal.pone.0006945			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759896	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796300003
J	Rosenberg, E; Ben-Shmuel, A; Shalev, O; Sinay, R; Cowman, A; Pollack, Y				Rosenberg, Elli; Ben-Shmuel, Amir; Shalev, Oshrit; Sinay, Rosa; Cowman, Alan; Pollack, Yaakov			Differential, Positional-Dependent Transcriptional Response of Antigenic Variation (var) Genes to Biological Stress in Plasmodium falciparum	PLOS ONE			English	Article							MALARIA PARASITE; VIRULENCE GENES; EXPRESSION; SEQUENCE; REGIONS	1% of the genes of the human malaria causing agent Plasmodium falciparum belong to the heterogeneous var gene family which encodes P. falciparum erythrocyte membrane protein 1 (PFEMP1). This protein mediates part of the pathogenesis of the disease by causing adherence of infected erythrocytes (IE) to the host endothelium. At any given time, only one copy of the family is expressed on the IE surface. The cues which regulate the allelic exclusion of these genes are not known. We show the existence of a differential expression pattern of these genes upon exposure to biological stress in relation to their positional placement on the chromosome expression of centrally located var genes is induced while sub-telomeric copies of the family are repressed - this phenomenon orchestrated by the histone deacetylase pfsir2. Moreover, stress was found to cause a switch in the pattern of the expressed var genes thus acting as a regulatory cue. By using pharmacological compounds which putatively affect pfsir2 activity, distinct changes of var gene expression patterns were achieved which may have therapeutic ramifications. As disease severity is partly associated with expression of particular var gene subtypes, manipulation of the IE environment may serve as a mechanism to direct transcription towards less virulent genes.	[Rosenberg, Elli; Ben-Shmuel, Amir; Shalev, Oshrit; Sinay, Rosa; Pollack, Yaakov] Ben Gurion Univ Negev, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; [Cowman, Alan] Walter & Eliza Hall Inst Med Res, Dept Infect & Immun, Melbourne, Vic 3050, Australia	Ben Gurion University; Walter & Eliza Hall Institute	Rosenberg, E (corresponding author), Ben Gurion Univ Negev, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.	polak@bgu.ac.il	Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004	Ben-Gurion University Research Fund [89331501]; Toman Fund [31020513]	Ben-Gurion University Research Fund; Toman Fund	This study was partially supported by the Ben-Gurion University Research Fund (number 89331501) and the Toman Fund (number 31020513). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; Calderwood MS, 2003, J BIOL CHEM, V278, P34125, DOI 10.1074/jbc.M213065200; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Cooke BM, 2006, J CELL BIOL, V172, P899, DOI 10.1083/jcb.200509122; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Dyer M, 2000, PARASITOL TODAY, V16, P102, DOI 10.1016/S0169-4758(99)01608-7; Dzikowski R, 2006, PLOS PATHOG, V2, P184, DOI 10.1371/journal.ppat.0020022; Eason DD, 2004, SEMIN IMMUNOL, V16, P215, DOI 10.1016/j.smim.2004.08.001; Fernandez V, 2002, MOL BIOCHEM PARASIT, V121, P195, DOI 10.1016/S0166-6851(02)00038-5; Frank M, 2007, MOL MICROBIOL, V64, P1486, DOI 10.1111/j.1365-2958.2007.05736.x; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; French JB, 2008, BIOCHEMISTRY-US, V47, P10227, DOI 10.1021/bi800767t; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274; Kaestli M, 2006, J INFECT DIS, V193, P1567, DOI 10.1086/503776; Kambere MB, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-S3-S2; Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x; Kyes S, 2007, MOL MICROBIOL, V63, P1237, DOI 10.1111/j.1365-2958.2007.05587.x; Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lopez-Rubio JJ, 2007, MOL MICROBIOL, V66, P1296, DOI 10.1111/j.1365-2958.2007.06009.x; Marti M, 2005, J CELL BIOL, V171, P587, DOI 10.1083/jcb.200508051; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Oakley MSM, 2007, INFECT IMMUN, V75, P2012, DOI 10.1128/IAI.01236-06; Peters JM, 2007, J INFECT DIS, V195, P748, DOI 10.1086/511436; Ralph SA, 2005, CURR OPIN MICROBIOL, V8, P434, DOI 10.1016/j.mib.2005.06.007; Ralph SA, 2005, P NATL ACAD SCI USA, V102, P5414, DOI 10.1073/pnas.0408883102; Rosenberg E, 2006, J BIOL CHEM, V281, P27039, DOI 10.1074/jbc.M601686200; ROUMANN M, 2006, INFECT IMMUN, V74, P3904; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134; Sharp S, 2006, EUKARYOT CELL, V5, P1206, DOI 10.1128/EC.00029-06; Tonkin CJ, 2009, PLOS BIOL, V7, P771, DOI 10.1371/journal.pbio.1000084; Voss TS, 2006, NATURE, V439, P1004, DOI 10.1038/nature04407; WAN G, 2002, QJM, V95, P285; Waterkeyn JG, 2000, EMBO J, V19, P2813, DOI 10.1093/emboj/19.12.2813; WOOD JG, 2001, NATURE, V480, P686	41	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6991	10.1371/journal.pone.0006991	http://dx.doi.org/10.1371/journal.pone.0006991			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V11YM	19730749	Green Published, gold			2022-12-27	WOS:000207566900001
J	Granstedt, AE; Szpara, ML; Kuhn, B; Wang, SSH; Enquist, LW				Granstedt, Andrea E.; Szpara, Moriah L.; Kuhn, Bernd; Wang, Samuel S. -H.; Enquist, Lynn W.			Fluorescence-Based Monitoring of In Vivo Neural Activity Using a Circuit-Tracing Pseudorabies Virus	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; LIVING MICE; PREGANGLIONIC NEURONS; RAT; PROTEIN; INFECTION; SENSOR; CELLS; TOOLS; VITRO	The study of coordinated activity in neuronal circuits has been challenging without a method to simultaneously report activity and connectivity. Here we present the first use of pseudorabies virus (PRV), which spreads through synaptically connected neurons, to express a fluorescent calcium indicator protein and monitor neuronal activity in a living animal. Fluorescence signals were proportional to action potential number and could reliably detect single action potentials in vitro. With two-photon imaging in vivo, we observed both spontaneous and stimulated activity in neurons of infected murine peripheral autonomic submandibular ganglia (SMG). We optically recorded the SMG response in the salivary circuit to direct electrical stimulation of the presynaptic axons and to physiologically relevant sensory stimulation of the oral cavity. During a time window of 48 hours after inoculation, few spontaneous transients occurred. By 72 hours, we identified more frequent and prolonged spontaneous calcium transients, suggestive of neuronal or tissue responses to infection that influence calcium signaling. Our work establishes in vivo investigation of physiological neuronal circuit activity and subsequent effects of infection with single cell resolution.			Granstedt, AE (corresponding author), Princeton Univ, Dept Mol Biol, Inst Neurosci, Princeton, NJ 08544 USA.	lenquist@princeton.edu	Szpara, Moriah L./I-2287-2019; Kuhn, Bernd/N-1132-2014	Szpara, Moriah L./0000-0001-9859-1678; Kuhn, Bernd/0000-0002-6852-2433	NINDS NIH HHS [R01 NS045193, R37 NS033506, NS045193, NS060699, R01 NS060699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060699, R01NS045193, R37NS033506] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akerboom J, 2009, J BIOL CHEM, V284, P6455, DOI 10.1074/jbc.M807657200; Aston-Jones G, 2000, J NEUROSCI METH, V103, P51, DOI 10.1016/S0165-0270(00)00295-8; Banfield BW, 2003, J VIROL, V77, P10106, DOI 10.1128/JVI.77.18.10106-10112.2003; Bartsch T, 1996, NEUROSCI LETT, V214, P143, DOI 10.1016/0304-3940(96)12910-4; Boldogkoi Z, 2009, NAT METHODS, V6, P127, DOI [10.1038/NMETH.1292, 10.1038/nmeth.1292]; Brittle EE, 2004, J VIROL, V78, P12951, DOI 10.1128/JVI.78.23.12951-12963.2004; Card J P, 2001, Curr Protoc Neurosci, VChapter 1, DOI 10.1002/0471142301.ns0105s09; Curanovic D, 2009, CURR PROTOC CELL BIO; Demmin GL, 2001, J VIROL, V75, P10856, DOI 10.1128/JVI.75.22.10856-10869.2001; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Diez-Garcia J, 2007, NEUROIMAGE, V34, P859, DOI 10.1016/j.neuroimage.2006.10.021; Ekstrand MI, 2008, TRENDS MOL MED, V14, P134, DOI 10.1016/j.molmed.2007.12.008; Feierbach B, 2006, PLOS PATHOG, V2, P763, DOI 10.1371/journal.ppat.0020085; Heim N, 2004, J BIOL CHEM, V279, P14280, DOI 10.1074/jbc.M312751200; Hendel T, 2008, J NEUROSCI, V28, P7399, DOI 10.1523/JNEUROSCI.1038-08.2008; Hoogland TM, 2009, P NATL ACAD SCI USA, V106, P3496, DOI 10.1073/pnas.0809269106; JANSEN ASP, 1992, BRAIN RES, V572, P253, DOI 10.1016/0006-8993(92)90479-S; Kim JS, 1999, J VIROL, V73, P9521, DOI 10.1128/JVI.73.11.9521-9531.1999; LICHTMAN JW, 1977, J PHYSIOL-LONDON, V273, P155, DOI 10.1113/jphysiol.1977.sp012087; Loewy AD, 1998, NEUROSCI BIOBEHAV R, V22, P679, DOI 10.1016/S0149-7634(98)00006-2; Luker KE, 2006, VIROLOGY, V347, P286, DOI 10.1016/j.virol.2005.12.016; Luo L, 2008, NEURON, V57, P634, DOI 10.1016/j.neuron.2008.01.002; Mank M, 2008, NAT METHODS, V5, P805, DOI 10.1038/NMETH.1243; MATSUO R, 1989, JPN J PHYSIOL, V39, P349, DOI 10.2170/jjphysiol.39.349; McCann CM, 2008, NAT NEUROSCI, V11, P807, DOI 10.1038/nn.2145; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Ohkura M, 2005, ANAL CHEM, V77, P5861, DOI 10.1021/ac0506837; POMEROY SL, 1988, J CELL BIOL, V107, P1167, DOI 10.1083/jcb.107.3.1167; PURVES D, 1987, SCIENCE, V238, P1122, DOI 10.1126/science.3685967; PURVES D, 1987, J NEUROSCI, V7, P1492; Rassnick S, 1998, J VIROL, V72, P9181, DOI 10.1128/JVI.72.11.9181-9191.1998; RINAMAN L, 1993, J NEUROSCI, V13, P685; Smith BN, 2000, P NATL ACAD SCI USA, V97, P9264, DOI 10.1073/pnas.97.16.9264; Song CK, 2005, VIRUS RES, V111, P235, DOI 10.1016/j.virusres.2005.04.012; SUZUKI T, 1981, Bulletin of Tokyo Dental College, V22, P183; SUZUKI T, 1978, J NEUROBIOL, V9, P367, DOI 10.1002/neu.480090504; Toth IE, 1999, J AUTONOM NERV SYST, V77, P45, DOI 10.1016/S0165-1838(99)00032-6; Wallace DJ, 2008, NAT METHODS, V5, P797, DOI 10.1038/NMETH.1242; Wang Q, 2008, STRUCTURE, V16, P1817, DOI 10.1016/j.str.2008.10.008; Wouterlood FG, 2002, NETWORK-COMP NEURAL, V13, P327, DOI 10.1088/0954-898X/13/3/305; Yang C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-4	41	29	31	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6923	10.1371/journal.pone.0006923	http://dx.doi.org/10.1371/journal.pone.0006923			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742327	gold, Green Submitted, Green Published			2022-12-27	WOS:000269622500008
J	Haddow, AD; Jones, CJ; Odoi, A				Haddow, Andrew D.; Jones, Carl J.; Odoi, Agricola			Assessing Risk in Focal Arboviral Infections: Are We Missing the Big or Little Picture?	PLOS ONE			English	Article								Background: Focal arboviral infections affecting a subset of the overall population present an often overlooked set of challenges in the assessment and reporting of risk and the detection of spatial patterns. Our objective was to assess the variation in risk when using different at-risk populations and geographic scales for the calculation of incidence risk and the detection of geographic hot-spots of infection. We explored these variations using a pediatric arbovirus, La Crosse virus (LACV), as our model. Methods and Findings: Descriptive and cluster analyses were performed on probable and confirmed cases of LACV infections reported to the Tennessee Department of Health from 1997 to 2006, using three at-risk populations (the total population, the population 18 years and younger, and the population 15 years and younger) and at two geographic levels (county and census tract) to assess the variation in incidence risk and to investigate evidence of clustering using both global and local spatial statistics. We determined that the most appropriate at-risk population to calculate incidence risk and to assess the evidence of clustering was the population 15 years and younger. Based on our findings, the most appropriate geographical level to conduct spatial analyses and report incidence risk is the census tract level. The incidence risk in the population 15 years and younger at the county level ranged from 0 to 226.5 per 100,000 persons (median 41.5) in those counties reporting cases (n = 14) and at the census tract level it ranged from 50.9 to 673.9 per 100,000 persons (median 126.7) in those census tracts reporting cases (n = 51). To our knowledge, this is the highest reported incidence risk for this population at the county level for Tennessee and at the census tract level nationally. Conclusion: The results of this study indicate the possibility of missing disease clusters resulting from performing incidence risk investigations of focal diseases using inappropriate at-risk populations and/or at large geographic scales. Improved disease surveillance and health planning will result through the use of well defined at-risk populations and the use of appropriate geographic scales for the analysis and reporting of diseases. The finding of a high incidence risk of LACV infections in eastern Tennessee demonstrates that the vast majority of these infections continue to be under-diagnosed and/or underreported in this region. Persistent prevention and surveillance efforts will be required to reduce exposure to infectious vectors and to detect new cases of infection in this region. Application of this study's observations in future investigations will enhance the quantification of incidence risk and the identification of high-risk groups within the population.			Haddow, AD (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX USA.	adhaddow@gmail.com	Odoi, Agricola/I-9532-2019; Haddow, Andrew/C-5902-2008; Haddow, Andrew/A-7507-2011	Odoi, Agricola/0000-0001-5050-6737; Haddow, Andrew/0000-0002-8957-2608; 				ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x; Anselin L, 2003, GEODA VERSION 0 95I; BALFOUR HH, 1973, PEDIATRICS, V52, P680; Bennett RS, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-25; BERNARDINELLI L, 1992, STAT MED, V11, P983, DOI 10.1002/sim.4780110802; Bithell JF, 2000, STAT MED, V19, P2203, DOI 10.1002/1097-0258(20000915/30)19:17/18<2203::AID-SIM564>3.0.CO;2-U; CALISHER CH, 1994, CLIN MICROBIOL REV, V7, P89, DOI 10.1128/CMR.7.1.89-116.1994; *CDCP, 2004, NAT CTR PUBL HLTH IN; Chun R W, 1983, Prog Clin Biol Res, V123, P193; CLARK CG, 1983, AM J TROP MED HYG, V32, P838, DOI 10.4269/ajtmh.1983.32.838; Erwin PC, 2002, AM J EPIDEMIOL, V155, P1060, DOI 10.1093/aje/155.11.1060; ESRI, 2006, ARCVIEW GIS VERS 9 2; GAULD LW, 1979, J MENT DEFIC RES, V23, P63; GRIMSTAD P, 1988, ARBOVIRUSES EPIDEMIO, V49, P99; GRIMSTAD PR, 1984, AM J EPIDEMIOL, V119, P913, DOI 10.1093/oxfordjournals.aje.a113814; Haddow AD, 2009, J VECTOR ECOL, V34, P70, DOI [10.1111/j.1948-7134.2009.00009.x, 10.3376/038.034.0109]; Haddow AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006145; HAINING R, 1998, GIS HLTH; Jones TF, 2000, CLIN INFECT DIS, V31, P1284, DOI 10.1086/317458; Jones TF, 1999, CLIN INFECT DIS, V28, P93, DOI 10.1086/515087; Kappus K D, 1983, Prog Clin Biol Res, V123, P31; KAPPUS KD, 1982, AM J TROP MED HYG, V31, P556, DOI 10.4269/ajtmh.1982.31.556; KSIAZEK TG, 1977, AM J TROP MED HYG, V26, P815, DOI 10.4269/ajtmh.1977.26.815; McJunkin JE, 1998, INFECT DIS CLIN N AM, V12, P83, DOI 10.1016/S0891-5520(05)70410-4; McJunkin JE, 2001, NEW ENGL J MED, V344, P801, DOI 10.1056/NEJM200103153441103; MONATH TPC, 1970, AM J EPIDEMIOL, V92, P40, DOI 10.1093/oxfordjournals.aje.a121178; MORAN PAP, 1950, BIOMETRIKA, V37, P17, DOI 10.1093/biomet/37.1-2.17; MOULTON DW, 1971, AM J TROP MED HYG, V20, P474, DOI 10.4269/ajtmh.1971.20.474; Odoi Agricola, 2003, Int J Health Geogr, V2, P5, DOI 10.1186/1476-072X-2-5; Openshaw S., 1984, CATMOG 38; Ozonoff A, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-52; PANTUWATANA S, 1974, AM J TROP MED HYG, V23, P246; Reimann CA, 2008, AM J TROP MED HYG, V79, P974, DOI 10.4269/ajtmh.2008.79.974; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rust RS, 1999, J CHILD NEUROL, V14, P1, DOI 10.1177/088307389901400101; SNOW J, 1885, MODE COMMUNICATION; STAINES A, 2000, SPATIAL EPIDEMIOLOGY, P13; *STATA CORP, 2007, INT STATA VERS 10 0; THOMPSON WH, 1977, SCIENCE, V196, P530, DOI 10.1126/science.850794; Tsai T F, 1991, Infect Dis Clin North Am, V5, P73; *US CENS BUR, 2000, DEC CENS AM FACT FIN; *US CENS BUR GEOGR, 2000, CART BOUND FIL DESCR; US Census Bureau, 2008, CART BOUND FIL; Utz JT, 2003, AM J TROP MED HYG, V69, P509, DOI 10.4269/ajtmh.2003.69.509; WATTS DM, 1973, SCIENCE, V182, P1140, DOI 10.1126/science.182.4117.1140; WATTS DM, 1972, J MED ENTOMOL, V9, P125, DOI 10.1093/jmedent/9.2.125	46	15	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6954	10.1371/journal.pone.0006954	http://dx.doi.org/10.1371/journal.pone.0006954			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742311	gold, Green Published			2022-12-27	WOS:000269622500017
J	van der Lelij, P; Godthelp, BC; van Zon, W; van Gosliga, D; Oostra, AB; Steltenpool, J; de Groot, J; Scheper, RJ; Wolthuis, RM; Waisfisz, Q; Darroudi, F; Joenje, H; de Winter, JP				van der Lelij, Petra; Godthelp, Barbara C.; van Zon, Wouter; van Gosliga, Djoke; Oostra, Anneke B.; Steltenpool, Jurgen; de Groot, Jan; Scheper, Rik J.; Wolthuis, Rob M.; Waisfisz, Quinten; Darroudi, Firouz; Joenje, Hans; de Winter, Johan P.			The Cellular Phenotype of Roberts Syndrome Fibroblasts as Revealed by Ectopic Expression of ESCO2	PLOS ONE			English	Article							SISTER-CHROMATID COHESION; FANCONI-ANEMIA; SYNDROME CELLS; NUCLEAR FOCI; DNA-DAMAGE; S-PHASE; PROTEIN; ECO1; RECOMBINATION; ESTABLISHMENT	Cohesion between sister chromatids is essential for faithful chromosome segregation. In budding yeast, the acetyltransferase Eco1/Ctf7 establishes cohesion during DNA replication in S phase and in response to DNA double strand breaks in G2/M phase. In humans two Eco1 orthologs exist: ESCO1 and ESCO2. Both proteins are required for proper sister chromatid cohesion, but their exact function is unclear at present. Since ESCO2 has been identified as the gene defective in the rare autosomal recessive cohesinopathy Roberts syndrome (RBS), cells from RBS patients can be used to elucidate the role of ESCO2. We investigated for the first time RBS cells in comparison to isogenic controls that stably express V5- or GFP-tagged ESCO2. We show that the sister chromatid cohesion defect in the transfected cell lines is rescued and suggest that ESCO2 is regulated by proteasomal degradation in a cell cycle-dependent manner. In comparison to the corrected cells ABS cells were hypersensitive to the DNA-damaging agents mitomycin C, camptothecin and etoposide, while no particular sensitivity to UV, ionizing radiation, hydroxyurea or aphidicolin was found. The cohesion defect of RBS cells and their hypersensitivity to DNA-damaging agents were not corrected by a patient-derived ESCO2 acetyltransferase mutant (W539G), indicating that the acetyltransferase activity of ESCO2 is essential for its function. In contrast to a previous study on cells from patients with Cornelia de Lange syndrome, another cohesinopathy, RBS cells failed to exhibit excessive chromosome aberrations after irradiation in G2 phase of the cell cycle. Our results point at an S phase-specific role for ESCO2 in the maintenance of genome stability.	[van der Lelij, Petra; van Gosliga, Djoke; Oostra, Anneke B.; Steltenpool, Jurgen; Waisfisz, Quinten; Joenje, Hans; de Winter, Johan P.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [Godthelp, Barbara C.; Darroudi, Firouz] Leiden Univ, Med Ctr, Dept Toxicogenet, Leiden, Netherlands; [van Zon, Wouter; Wolthuis, Rob M.] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [de Groot, Jan; Scheper, Rik J.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	van der Lelij, P (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.	j.dewinter@vumc.nl		van der Lelij, Petra/0000-0002-7461-9645; Waisfisz, Quinten/0000-0002-7384-9182; Wolthuis, Rob/0000-0002-3109-1588				Ben-Shahar TR, 2008, SCIENCE, V321, P563, DOI 10.1126/science.1157774; CHEN GL, 1984, J BIOL CHEM, V259, P3560; GIOSK R, 2000, MOL CELL, V5, P243; Gordillo M, 2008, HUM MOL GENET, V17, P2172, DOI 10.1093/hmg/ddn116; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Heidinger-Pauli JM, 2009, MOL CELL, V34, P311, DOI 10.1016/j.molcel.2009.04.008; Hou FJ, 2005, MOL BIOL CELL, V16, P3908, DOI 10.1091/mbc.E04-12-1063; Lengronne A, 2006, MOL CELL, V23, P787, DOI 10.1016/j.molcel.2006.08.018; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Schule B, 2005, AM J HUM GENET, V77, P1117, DOI 10.1086/498695; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Strom L, 2007, SCIENCE, V317, P242, DOI 10.1126/science.1140649; Unal E, 2007, SCIENCE, V317, P245, DOI 10.1126/science.1140637; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Unal E, 2008, SCIENCE, V321, P566, DOI 10.1126/science.1157880; van de Vrugt HJ, 2002, GENES CELLS, V7, P333, DOI 10.1046/j.1365-2443.2002.00518.x; VANDENBERG DJ, 1993, SOMAT CELL MOLEC GEN, V19, P377; VANDENBERG DJ, 1993, AM J MED GENET, V47, P1104, DOI 10.1002/ajmg.1320470735; Vega H, 2005, NAT GENET, V37, P468, DOI 10.1038/ng1548; Vrouwe MG, 2007, HUM MOL GENET, V16, P1478, DOI 10.1093/hmg/ddm098; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Zhang JL, 2008, MOL CELL, V31, P143, DOI 10.1016/j.molcel.2008.06.006	29	51	52	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6936	10.1371/journal.pone.0006936	http://dx.doi.org/10.1371/journal.pone.0006936			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V11YL	19738907	Green Published, gold, Green Submitted			2022-12-27	WOS:000207566800001
J	Morand, PC; Drab, M; Rajalingam, K; Nassif, X; Meyer, TF				Morand, Philippe C.; Drab, Marek; Rajalingam, Krishnaraj; Nassif, Xavier; Meyer, Thomas F.			Neisseria meningitidis Differentially Controls Host Cell Motility through PilC1 and PilC2 Components of Type IV Pili	PLOS ONE			English	Article								Neisseria meningitidis is a strictly human pathogen that has two facets since asymptomatic carriage can unpredictably turn into fulminant forms of infection. Meningococcal pathogenesis relies on the ability of the bacteria to break host epithelial or endothelial cellular barriers. Highly restrictive, yet poorly understood, mechanisms allow meningococcal adhesion to cells of only human origin. Adhesion of encapsulated and virulent meningococci to human cells relies on the expression of bacterial type four pili (T4P) that trigger intense host cell signalling. Among the components of the meningococcal T4P, the concomitantly expressed PilC1 and PilC2 proteins regulate pili exposure at the bacterial surface, and until now, PilC1 was believed to be specifically responsible for T4P-mediated meningococcal adhesion to human cells. Contrary to previous reports, we show that, like PilC1, the meningococcal PilC2 component is capable of mediating adhesion to human ME180 epithelial cells, with cortical plaque formation and F-actin condensation. However, PilC1 and PilC2 promote different effects on infected cells. Cellular tracking analysis revealed that PilC1-expressing meningococci caused a severe reduction in the motility of infected cells, which was not the case when cells were infected with PilC2-expressing strains. The amount of both total and phosphorylated forms of EGFR was dramatically reduced in cells upon PilC1-mediated infection. In contrast, PilC2-mediated infection did not notably affect the EGFR pathway, and these specificities were shared among unrelated meningococcal strains. These results suggest that meningococci have evolved a highly discriminative tool for differential adhesion in specific microenvironments where different cell types are present. Moreover, the fine-tuning of cellular control through the combined action of two concomitantly expressed, but distinctly regulated, T4P-associated variants of the same molecule (i.e. PilC1 and PilC2) brings a new model to light for the analysis of the interplay between pathogenic bacteria and human host cells.			Morand, PC (corresponding author), Max Planck Inst Infect Biol, Dept Mol Biol, Berlin, Germany.	philippe.morand@cch.aphp.fr	Meyer, Thomas F. F/J-2485-2013; Rajalingam, krishnaraj/D-3081-2011; Morand, Philippe/C-1213-2016; Drab, Marek/AAQ-1892-2020; Drab, Marek/J-5196-2013	Meyer, Thomas F. F/0000-0002-6120-8679; Morand, Philippe/0000-0003-0306-8759; Drab, Marek/0000-0002-2771-1692				Caugant DA, 2008, INFECT GENET EVOL, V8, P558, DOI 10.1016/j.meegid.2008.04.002; Coureuil M, 2009, SCIENCE, V325, P83, DOI 10.1126/science.1173196; Gill DB, 2005, CELL MICROBIOL, V7, P1672, DOI 10.1111/j.1462-5822.2005.00584.x; Higashi DL, 2007, INFECT IMMUN, V75, P4743, DOI 10.1128/IAI.00687-07; Hoffmann I, 2001, J CELL BIOL, V155, P133, DOI 10.1083/jcb.200106148; Jones A, 2007, FASEB J, V21, P345, DOI 10.1096/fj.06-6675com; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; JONSSON AB, 1995, MICROBIOL-SGM, V141, P2367, DOI 10.1099/13500872-141-10-2367; Kallstrom H, 1998, J BIOL CHEM, V273, P21777, DOI 10.1074/jbc.273.34.21777; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; Lambotin M, 2005, J CELL SCI, V118, P3805, DOI 10.1242/jcs.02514; Merz AJ, 1999, MOL MICROBIOL, V32, P1316, DOI 10.1046/j.1365-2958.1999.01459.x; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Miller KE, 2006, AM FAM PHYSICIAN, V73, P1779; Morand PC, 2004, EMBO J, V23, P2009, DOI 10.1038/sj.emboj.7600200; Morand PC, 2001, MOL MICROBIOL, V40, P846, DOI 10.1046/j.1365-2958.2001.02452.x; Nassif X, 1999, MOL MICROBIOL, V32, P1124, DOI 10.1046/j.1365-2958.1999.01416.x; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; Nassif X, 1999, CURR OPIN MICROBIOL, V2, P71, DOI 10.1016/S1369-5274(99)80012-5; Neil RB, 2009, MICROBES INFECT, V11, P281, DOI 10.1016/j.micinf.2008.12.001; Opitz D, 2009, CHEMPHYSCHEM, V10, P1614, DOI 10.1002/cphc.200800654; Otsuki Y, 2003, PROG HISTOCHEM CYTO, V38, P275, DOI 10.1016/S0079-6336(03)80002-5; Pron B, 1997, J INFECT DIS, V176, P1285, DOI 10.1086/514124; Pujol C, 1997, INFECT IMMUN, V65, P4836, DOI 10.1128/IAI.65.11.4836-4842.1997; Rahman M, 1997, MOL MICROBIOL, V25, P11, DOI 10.1046/j.1365-2958.1997.4601823.x; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; RUDEL T, 1995, P NATL ACAD SCI USA, V92, P7986, DOI 10.1073/pnas.92.17.7986; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; RUDEL T, 1995, MOL MICROBIOL, V17, P1057, DOI 10.1111/j.1365-2958.1995.mmi_17061057.x; Ryll RR, 1997, MOL MICROBIOL, V23, P879, DOI 10.1046/j.1365-2958.1997.2631630.x; Scheuerpflug I, 1999, INFECT IMMUN, V67, P834, DOI 10.1128/IAI.67.2.834-843.1999; Schweitzer KM, 1997, LAB INVEST, V76, P25; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Snyder LAS, 2005, PLASMID, V54, P191, DOI 10.1016/j.plasmid.2005.04.005; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; Taha MK, 1998, MOL MICROBIOL, V28, P1153, DOI 10.1046/j.1365-2958.1998.00876.x; Tinsley CR, 1996, P NATL ACAD SCI USA, V93, P11109, DOI 10.1073/pnas.93.20.11109; Virji M, 2009, NAT REV MICROBIOL, V7, P274, DOI 10.1038/nrmicro2097; Yazdankhah SP, 2004, J MED MICROBIOL, V53, P821, DOI 10.1099/jmm.0.45529-0	41	25	25	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6834	10.1371/journal.pone.0006834	http://dx.doi.org/10.1371/journal.pone.0006834			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718432	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900007
J	Tomasi, D; Wang, GJ; Wang, RL; Backus, W; Geliebter, A; Telang, F; Jayne, MC; Wong, C; Fowler, JS; Volkow, ND				Tomasi, Dardo; Wang, Gene-Jack; Wang, Ruiliang; Backus, Walter; Geliebter, Allan; Telang, Frank; Jayne, Millar C.; Wong, Christopher; Fowler, Joanna S.; Volkow, Nora D.			Association of Body Mass and Brain Activation during Gastric Distention: Implications for Obesity	PLOS ONE			English	Article								Background: Gastric distention (GD), as it occurs during meal ingestion, signals a full stomach and it is one of the key mechanisms controlling food intake. Previous studies on GD showed lower activation of the amygdala for subjects with higher body mass index (BMI). Since obese subjects have dopaminergic deficits that correlate negatively with BMI and the amygdala is innervated by dopamine neurons, we hypothesized that BMI would correlate negatively with activation not just in the amygdala but also in other dopaminergic brain regions (midbrain and hypothalamus). Methodology/Principal Findings: We used functional magnetic resonance imaging (fMRI) to evaluate brain activation during GD in 24 healthy subjects with BMI range of 20-39 kg/m(2). Using multiple regression and cross-correlation analyses based on a family-wise error corrected threshold P = 0.05, we show that during slow GD to maximum volumes of 500 ml and 700 ml subjects with increased BMI had increased activation in cerebellum and left posterior insula, and decreased activation of dopaminergic (amygdala, midbrain, hypothalamus, thalamus) and serotonergic (pons) brain regions and anterior insula, regions that were functionally interconnected with one another. Conclusions: The negative correlation between BMI and BOLD responses to gastric distention in dopaminergic (midbrain, hypothalamus, amygdala, thalamus) and serotonergic (pons) brain regions is consistent with disruption of dopaminergic and serotonergic signaling in obesity. In contrast the positive correlation between BMI and BOLD responses in posterior insula and cerebellum suggests an opposing mechanism that promotes food intake in obese subjects that may underlie their ability to consume at once large food volumes despite increasing gastric distention.			Tomasi, D (corresponding author), NIAAA, NIH, Bethesda, MD USA.	tomasi@bnl.gov	Tomasi, Dardo/J-2127-2015		NCRR NIH HHS [M01 RR010710, 5-M01-RR-10710] Funding Source: Medline; NIAAA NIH HHS [Y1AA3009, R01 AA009481, R01AA09481] Funding Source: Medline; NIDA NIH HHS [R01DA006278, R01 DA006891, R01DA006891, R01 DA006278] Funding Source: Medline; NIDDK NIH HHS [R56 DK080153-01A1, R01 DK054318-02, R01 DK080153-04, R01 DK080153-01A2, R01 DK080153-03, R01 DK080153, R56 DK080153, R01 DK054318-03, R01 DK054318, R01 DK080153-02, R01 DK054318-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK080153, R01DK054318, R01DK080153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006278, R01DA006891] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aguirre GK, 1998, NEUROIMAGE, V8, P302, DOI 10.1006/nimg.1998.0367; Baicy K, 2007, P NATL ACAD SCI USA, V104, P18276, DOI 10.1073/pnas.0706481104; Balcioglu A, 1998, INT J OBESITY, V22, P325, DOI 10.1038/sj.ijo.0800589; Caparelli EC, 2008, BIOMED SIGNAL PROCES, V3, P107, DOI 10.1016/j.bspc.2007.11.003; Caparelli EC, 2003, NEUROIMAGE, V20, P1411, DOI 10.1016/S1053-8119(03)00339-2; Carlini VP, 2004, BIOCHEM BIOPH RES CO, V313, P635, DOI 10.1016/j.bbrc.2003.11.150; Cerf-Ducastel B, 2001, CHEM SENSES, V26, P625, DOI 10.1093/chemse/26.6.625; Cheung S, 1998, BRAIN RES, V808, P174, DOI 10.1016/S0006-8993(98)00809-9; Craig AD, 2006, J COMP NEUROL, V499, P953, DOI 10.1002/cne.21155; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Craig AD, 2005, TRENDS COGN SCI, V9, P566, DOI 10.1016/j.tics.2005.10.005; DelParigi A, 2004, INT J OBESITY, V28, P370, DOI 10.1038/sj.ijo.0802558; DIETRICHS E, 1986, BRAIN RES, V364, P241, DOI 10.1016/0006-8993(86)90836-X; DIETRICHS E, 1984, SCIENCE, V223, P591, DOI 10.1126/science.6198719; Erritzoe D, 2009, NEUROIMAGE, V46, P23, DOI 10.1016/j.neuroimage.2009.01.050; Fiset P, 1999, J NEUROSCI, V19, P5506; Frank GKW, 2008, NEUROIMAGE, V39, P1559, DOI 10.1016/j.neuroimage.2007.10.061; Frankle WG, 2004, J NUCL MED, V45, P682; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; Garcia-Cabezas MA, 2007, NEUROIMAGE, V34, P965, DOI 10.1016/j.neuroimage.2006.07.032; Gautier JF, 2001, OBES RES, V9, P676, DOI 10.1038/oby.2001.92; Gautier JF, 2000, DIABETES, V49, P838, DOI 10.2337/diabetes.49.5.838; Gavrilescu M, 2002, NEUROIMAGE, V17, P532, DOI 10.1006/nimg.2002.1226; GELIEBTER A, 1988, AM J CLIN NUTR, V48, P592, DOI 10.1093/ajcn/48.3.592; Govindaiah G, 2005, J NEUROPHYSIOL, V94, P3708, DOI 10.1152/jn.00583.2005; HAINES DE, 1984, BRAIN BEHAV EVOLUT, V24, P198, DOI 10.1159/000121317; Heimer L., 1994, HUMAN BRAIN SPINAL C; Heisler LK, 2003, ANN NY ACAD SCI, V994, P169, DOI 10.1111/j.1749-6632.2003.tb03177.x; HENKE PG, 1991, DIGEST DIS SCI, V36, P1633, DOI 10.1007/BF01296409; Hennig J, 2001, MAGNET RESON MED, V46, P6, DOI 10.1002/mrm.1153; HOUPT KA, 1982, NEUROSCI BIOBEHAV R, V6, P145; Killgore WDS, 2003, NEUROIMAGE, V19, P1381, DOI 10.1016/S1053-8119(03)00191-5; King BM, 2006, AM J PHYSIOL-REG I, V291, pR1201, DOI 10.1152/ajpregu.00199.2006; Krowicki ZK, 1997, J PHARMACOL EXP THER, V282, P14; Ladabaum U, 2001, GASTROENTEROLOGY, V120, P369, DOI 10.1053/gast.2001.21201; Ladabaum U, 2007, NEUROIMAGE, V34, P724, DOI 10.1016/j.neuroimage.2006.07.033; LEE JH, 1995, MAGN RESON MED, V34, P308, DOI 10.1002/mrm.1910340305; Liu YJ, 2000, NATURE, V405, P1058, DOI 10.1038/35016590; Lu CL, 2004, NEUROGASTROENT MOTIL, V16, P575, DOI 10.1111/j.1365-2982.2004.00562.x; MAEDA T, 1994, MICROSC RES TECHNIQ, V29, P211, DOI 10.1002/jemt.1070290306; MAHLER P, 1993, PHYSIOL BEHAV, V54, P1063, DOI 10.1016/0031-9384(93)90325-A; Matharu MS, 2006, ANN NEUROL, V59, P535, DOI 10.1002/ana.20763; Matsuda M, 1999, DIABETES, V48, P1801, DOI 10.2337/diabetes.48.9.1801; Miranda MI, 2002, P NATL ACAD SCI USA, V99, P11417, DOI 10.1073/pnas.182200499; Monckton JE, 2002, J NEUROPHYSIOL, V87, P2124, DOI 10.1152/jn.00650.2001; Morton GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026; Munsch T, 2005, EUR J NEUROSCI, V21, P290, DOI 10.1111/j.1460-9568.2004.03842.x; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; Petrovich GD, 2003, ANN NY ACAD SCI, V985, P251; Petrovich GD, 2002, J NEUROSCI, V22, P8748; Price JL, 2003, ANN NY ACAD SCI, V985, P50; Rollins BL, 2000, AM J PHYSIOL-REG I, V279, pR1348, DOI 10.1152/ajpregu.2000.279.4.R1348; Rolls ET, 2007, P NUTR SOC, V66, P96, DOI 10.1017/S0029665107005332; Rothemund Y, 2007, NEUROIMAGE, V37, P410, DOI 10.1016/j.neuroimage.2007.05.008; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Sherwood L., 1997, HUMAN PHYSL CELLS SY; Sobel N, 1998, J NEUROSCI, V18, P8990; Stice E, 2008, J ABNORM PSYCHOL, V117, P924, DOI 10.1037/a0013600; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; TACHE Y, 1995, PEPTIDES, V16, P431, DOI 10.1016/0196-9781(94)00212-O; Tataranni PA, 1999, P NATL ACAD SCI USA, V96, P4569, DOI 10.1073/pnas.96.8.4569; Tecott LH, 2007, CELL METAB, V6, P352, DOI 10.1016/j.cmet.2007.09.012; Tomasi D, 2005, NEUROIMAGE, V27, P377, DOI 10.1016/j.neuroimage.2005.04.010; Van Oudenhove L, 2008, NEUROGASTROENT MOTIL, V20, P479, DOI 10.1111/j.1365-2982.2007.01045.x; VOLKOW ND, 1995, NEUROPSYCHOPHARMACOL, V12, P123, DOI 10.1038/sj.npp.1380246; Wang GJ, 2008, NEUROIMAGE, V39, P1824, DOI 10.1016/j.neuroimage.2007.11.008; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Zhao YQ, 2001, NEUROREPORT, V12, P2939, DOI 10.1097/00001756-200109170-00037; Zhou LG, 2005, PEPTIDES, V26, P1728, DOI 10.1016/j.peptides.2004.12.028; Zhu JN, 2006, J NEUROSCI RES, V84, P1597, DOI 10.1002/jnr.21059; Zhu JN, 2006, BRAIN RES REV, V52, P93, DOI 10.1016/j.brainresrev.2006.01.003	73	39	39	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6847	10.1371/journal.pone.0006847	http://dx.doi.org/10.1371/journal.pone.0006847			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718256	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900019
J	Zhou, L; Choi, HY; Li, WP; Xu, F; Herz, J				Zhou, Li; Choi, Hong Y.; Li, Wei-Ping; Xu, Fang; Herz, Joachim			LRP1 Controls cPLA(2) Phosphorylation, ABCA1 Expression and Cellular Cholesterol Export	PLOS ONE			English	Article								Background: ATP-binding cassette transporter A1 mediates apolipoprotein AI-dependent efflux of cholesterol and thereby removes cholesterol from peripheral tissues. ABCA1 expression is tightly regulated and deficiency of this cholesterol transporter results in cholesterol accumulation within cells. Low-density lipoprotein receptor-related protein 1 (LRP1) participates in lipid metabolism and energy homeostasis by endocytosis of apolipoprotein E-containing lipoproteins and modulation of cellular proliferation signals. Methods and Principal Findings: In the present study, we demonstrate a new role for LRP1 in reverse cholesterol transport. Absence of LRP1 expression results in increased PDGFR beta signaling and sequential activation of the mitogen-activated protein kinase signaling pathway, which increases phosphorylation of cytosolic phospholipase A(2) (cPLA(2)). Phosphorylated and activated cPLA(2) releases arachidonic acid from the phospholipid pool. Overproduction of arachidonic acid suppresses the activation of LXR/RXR heterodimers bound to the promoter of LXR regulated genes such as ABCA1, resulting in greatly reduced ABCA1 expression. Conclusions and Significance: LRP1 regulates LXR-mediated gene transcription and participates in reverse cholesterol transport by controlling cPLA(2) activation and ABCA1 expression. LRP1 thus functions as a physiological integrator of cellular lipid homeostasis with signals that regulate cellular proliferation and vascular wall integrity.			Zhou, L (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA.	joachim.herz@utsouthwestern.edu	黎, 伟/GXM-4040-2022; li, wj/HGD-7322-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63762, P01 HL020948, HL20948, R37 HL063762, R01 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Boucher P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000448; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brunham LR, 2009, ARTERIOSCL THROM VAS, V29, P548, DOI 10.1161/ATVBAHA.108.182303; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clarke F. H., 1995, J CONVEX ANAL, V2, P117; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOFMANN SM, 2007, J CLIN INVEST; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Newton CS, 2005, J BIOL CHEM, V280, P27872, DOI 10.1074/jbc.M505410200; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Oram JF, 2002, TRENDS MOL MED, V8, P168, DOI 10.1016/S1471-4914(02)02289-X; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; Schmitz G, 2005, BBA-MOL CELL BIOL L, V1735, P1, DOI 10.1016/j.bbalip.2005.04.004; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Srivastava N, 2002, MOL CELL BIOCHEM, V237, P155, DOI 10.1023/A:1016506221047; Takayama Y, 2005, J BIOL CHEM, V280, P18504, DOI 10.1074/jbc.M410265200; Terrand J, 2009, J BIOL CHEM, V284, P381, DOI 10.1074/jbc.M806538200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102; Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883; ZHOU YTL, 2009, LRP1 REGULATES UNPUB	49	32	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6853	10.1371/journal.pone.0006853	http://dx.doi.org/10.1371/journal.pone.0006853			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718435	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900022
J	Distler, U; Souady, J; Huelsewig, M; Drmic-Hofman, I; Haier, J; Friedrich, AW; Karch, H; Senninger, N; Dreisewerd, K; Berkenkamp, S; Schmidt, MA; Peter-Katalinic, J; Muthing, J				Distler, Ute; Souady, Jamal; Huelsewig, Marcel; Drmic-Hofman, Irena; Haier, Joerg; Friedrich, Alexander W.; Karch, Helge; Senninger, Norbert; Dreisewerd, Klaus; Berkenkamp, Stefan; Schmidt, M. Alexander; Peter-Katalinic, Jasna; Muething, Johannes			Shiga Toxin Receptor Gb3Cer/CD77: Tumor-Association and Promising Therapeutic Target in Pancreas and Colon Cancer	PLOS ONE			English	Article								Background: Despite progress in adjuvant chemotherapy in the recent decades, pancreatic and colon cancers remain common causes of death worldwide. Bacterial toxins, which specifically bind to cell surface-exposed glycosphingolipids, are a potential novel therapy. We determined the expression of globotriaosylceramide (Gb3Cer/CD77), the Shiga toxin receptor, in human pancreatic and colon adenocarcinomas. Methodology/Principal Findings: Tissue lipid extracts of matched pairs of cancerous and adjacent normal tissue from 21 pancreatic and 16 colon cancer patients were investigated with thin-layer chromatography overlay assay combined with a novel mass spectrometry approach. Gb3Cer/CD77 was localized by immunofluorescence microscopy of cryosections from malignant and corresponding healthy tissue samples. 62% of pancreatic and 81% of colon adenocarcinomas showed increased Gb3Cer/CD77 expression, whereas 38% and 19% of malignant pancreas and colon tissue, respectively, did not, indicating an association of this marker with neoplastic transformation. Also, Gb3Cer/CD77 was associated with poor differentiation (G>2) in pancreatic cancer (P = 0.039). Mass spectrometric analysis evidenced enhanced expression of Gb3Cer/CD77 with long (C24) and short chain fatty acids (C16) in malignant tissues and pointed to the presence of hydroxylated fatty acid lipoforms, which are proposed to be important for receptor targeting. They could be detected in 86% of pancreatic and about 19% of colon adenocarcinomas. Immunohistology of tissue cryosections indicated tumor-association of these receptors. Conclusions/Significance: Enhanced expression of Gb3Cer/CD77 in most pancreatic and colon adenocarcinomas prompts consideration of Shiga toxin, its B-subunit or B-subunit-derivatives as novel therapeutic strategies for the treatment of these challenging malignancies.			Distler, U (corresponding author), Univ Munster, Inst Hyg, Munster, Germany.	jm@uni-muenster.de	Friedrich, Alex/ABG-9823-2020; Drmic Hofman, Irena/D-5026-2017; Dreisewerd, Klaus/K-3884-2015	Drmic Hofman, Irena/0000-0002-4986-9589; Dreisewerd, Klaus/0000-0002-7619-808X; Distler, Ute/0000-0002-8031-6384				Andre Thierry, 2004, Clin Colorectal Cancer, V4 Suppl 1, pS22; Bielaszewska M, 2006, CLIN INFECT DIS, V43, P1160, DOI 10.1086/508195; Binnington B, 2002, NEUROCHEM RES, V27, P807, DOI 10.1023/A:1020261125008; Chester MA, 1999, GLYCOCONJUGATE J, V16, P1; Chu KU, 2000, CANCER, V88, P1828, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1828::AID-CNCR11>3.3.CO;2-6; Distler U, 2008, MOL CANCER THER, V7, P2464, DOI 10.1158/1535-7163.MCT-08-0353; Distler U, 2008, ANAL CHEM, V80, P1835, DOI 10.1021/ac702071x; Dobrindt U, 2005, INT J MED MICROBIOL, V295, P357, DOI 10.1016/j.ijmm.2005.07.009; Durrant LG, 2006, CANCER RES, V66, P5901, DOI 10.1158/0008-5472.CAN-05-3812; Falguieres T, 2008, MOL CANCER THER, V7, P2498, DOI 10.1158/1535-7163.MCT-08-0430; FARKASHIMSLEY H, 1995, P NATL ACAD SCI USA, V92, P6996, DOI 10.1073/pnas.92.15.6996; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Fredman P, 2003, BIODRUGS, V17, P155, DOI 10.2165/00063030-200317030-00002; Gehrmann M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001925; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Hakomori S, 1996, CANCER RES, V56, P5309; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; Janssen KP, 2006, CANCER RES, V66, P7230, DOI 10.1158/0008-5472.CAN-06-0631; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Johannes L, 2005, GENE THER, V12, P1360, DOI 10.1038/sj.gt.3302557; Kannagi R, 2008, BBA-GEN SUBJECTS, V1780, P525, DOI 10.1016/j.bbagen.2007.10.007; Kaper JB, 2008, P NATL ACAD SCI USA, V105, P4535, DOI 10.1073/pnas.0801435105; Karch H, 2005, INT J MED MICROBIOL, V295, P405, DOI 10.1016/j.ijmm.2005.06.009; KIARASH A, 1994, J BIOL CHEM, V269, P11138; Kiguchi K, 2006, CANCER SCI, V97, P1321, DOI 10.1111/j.1349-7006.2006.00326.x; Kovbasnjuk O, 2005, P NATL ACAD SCI USA, V102, P19087, DOI 10.1073/pnas.0506474102; Kovbasnjuk Olga, 2005, Gastroenterology, V129, P1354, DOI 10.1053/j.gastro.2005.08.032; LaCasse EC, 1999, BLOOD, V94, P2901; Lencer WI, 2005, BBA-MOL CELL RES, V1746, P314, DOI 10.1016/j.bbamcr.2005.07.007; Levery SB, 2005, METHOD ENZYMOL, V405, P300, DOI 10.1016/S0076-6879(05)05012-3; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; Lingwood CA, 1999, BIOSCIENCE REP, V19, P345, DOI 10.1023/A:1020299819637; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f; Meisen I, 2005, RAPID COMMUN MASS SP, V19, P3659, DOI 10.1002/rcm.2241; Miller-Podraza H, 2005, J BIOL CHEM, V280, P19695, DOI 10.1074/jbc.M412688200; Muthing J, 2009, THROMB HAEMOSTASIS, V101, P252, DOI 10.1160/TH08-05-0317; Muthing J, 2004, FASEB J, V18, P103, DOI 10.1096/fj.04-2494fje; Muthing J, 1999, GLYCOBIOLOGY, V9, P459, DOI 10.1093/glycob/9.5.459; Muthing J, 1998, METH MOL B, V76, P183; PETRIC M, 1987, FEMS MICROBIOL LETT, V41, P63; Romer W, 2007, NATURE, V450, P670, DOI 10.1038/nature05996; Roque-Navarro L, 2008, MOL CANCER THER, V7, P2033, DOI 10.1158/1535-7163.MCT-08-0222; Salhia B, 2002, NEOPLASIA, V4, P304, DOI 10.1038/sj.neo.7900243; Sandvig K, 2001, TOXICON, V39, P1629, DOI 10.1016/S0041-0101(01)00150-7; Schweppe CH, 2008, GLYCOCONJUGATE J, V25, P291, DOI 10.1007/s10719-007-9091-7; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith DC, 2004, SEMIN CELL DEV BIOL, V15, P397, DOI 10.1016/j.semcdb.2004.03.005; SMITH HW, 1971, J MED MICROBIOL, V4, P301, DOI 10.1099/00222615-4-3-301; SOBIN LH, 2002, INT UNION CANC UICC, P272; Sonnino S, 2006, CHEM REV, V106, P2111, DOI 10.1021/cr0100446; Stirpe F, 2006, CELL MOL LIFE SCI, V63, P1850, DOI 10.1007/s00018-006-6078-7; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Thies A, 2008, BRIT J CANCER, V98, P106, DOI 10.1038/sj.bjc.6604106; Wilkinson N, 2008, GASTROENTEROL CLIN N, V37, P253, DOI 10.1016/j.gtc.2007.12.012; YANG HJ, 1971, J BIOL CHEM, V246, P1192; Yin J, 2006, CANCER RES, V66, P2937, DOI 10.1158/0008-5472.CAN-05-2615; Yu M, 2005, INFECT IMMUN, V73, P2524, DOI 10.1128/IAI.73.4.2524-2532.2005	58	65	68	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6813	10.1371/journal.pone.0006813	http://dx.doi.org/10.1371/journal.pone.0006813			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714252	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415800003
J	Rakhshandehroo, M; Hooiveld, G; Muller, M; Kersten, S				Rakhshandehroo, Maryam; Hooiveld, Guido; Muller, Michael; Kersten, Sander			Comparative Analysis of Gene Regulation by the Transcription Factor PPAR alpha between Mouse and Human	PLOS ONE			English	Article								Background: Studies in mice have shown that PPAR alpha is an important regulator of hepatic lipid metabolism and the acute phase response. However, little information is available on the role of PPARa in human liver. Here we set out to compare the function of PPARa in mouse and human hepatocytes via analysis of target gene regulation. Methodology/Principal Findings: Primary hepatocytes from 6 human and 6 mouse donors were treated with PPARa agonist Wy14643 and gene expression profiling was performed using Affymetrix GeneChips followed by a systems biology analysis. Baseline PPARa expression was similar in human and mouse hepatocytes. Depending on species and time of exposure, Wy14643 significantly induced the expression of 362-672 genes. Surprisingly minor overlap was observed between the Wy14643-regulated genes from mouse and human, although more substantial overlap was observed at the pathway level. Xenobiotics metabolism and apolipoprotein synthesis were specifically regulated by PPARa in human hepatocytes, whereas glycolysis-gluconeogenesis was regulated specifically in mouse hepatocytes. Most of the genes commonly regulated in mouse and human were involved in lipid metabolism and many represented known PPARa targets, including CPT1A, HMGCS2, FABP1, ACSL1, and ADFP. Several genes were identified that were specifically induced by PPARa in human (MBL2, ALAS1, CYP1A1, TSKU) or mouse (Fbp2, lgals4, Cd36, Ucp2, Pxmp4). Furthermore, several putative novel PPARa targets were identified that were commonly regulated in both species, including CREB3L3, KLF10, KLF11 and MAP3K8. Conclusions/Significance: Our results suggest that PPARa activation has a major impact on gene regulation in human hepatocytes. Importantly, the role of PPARa as master regulator of hepatic lipid metabolism is generally well-conserved between mouse and human. Overall, however, PPARa regulates a mostly divergent set of genes in mouse and human hepatocytes.			Rakhshandehroo, M (corresponding author), Top Inst TI Food & Nutr, Nutrigenom Consortium, Wageningen, Netherlands.	sander.kersten@wur.nl	Muller, Michael/B-5795-2008; Hooiveld, Guido JEJ/F-4912-2010; Muller, Michael/M-5724-2019; Kersten, Sander/A-1116-2011	Muller, Michael/0000-0002-5930-9905; Hooiveld, Guido JEJ/0000-0003-1954-3542; Muller, Michael/0000-0002-5930-9905; Kersten, Sander/0000-0003-4488-7734				Ammerschlaeger M, 2004, TOXICOL SCI, V78, P229, DOI 10.1093/toxsci/kfh071; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bandsma RHJ, 2004, J BIOL CHEM, V279, P8930, DOI 10.1074/jbc.M310067200; Barbier O, 2004, TRENDS ENDOCRIN MET, V15, P324, DOI 10.1016/j.tem.2004.07.007; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Bunger M, 2007, BBA-MOL CELL BIOL L, V1771, P1046, DOI 10.1016/j.bbalip.2007.05.004; Cheung C, 2004, CANCER RES, V64, P3849, DOI 10.1158/0008-5472.CAN-04-0322; Corton JC, 2000, MUTAT RES-FUND MOL M, V448, P139, DOI 10.1016/S0027-5107(99)00232-8; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Fernandez-Miranda C, 2008, DIGEST LIVER DIS, V40, P200, DOI 10.1016/j.dld.2007.10.002; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Guo L, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S18; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Heuvel JPV, 2003, TOXICOL APPL PHARM, V188, P185, DOI 10.1016/S0041-008X(03)00015-2; Holden PR, 1999, J MOL ENDOCRINOL, V22, P1, DOI 10.1677/jme.0.0220001; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2008, PPAR RES, V2008, DOI 10.1155/2008/132960; Khan SA, 2003, J NUTR BIOCHEM, V14, P554, DOI 10.1016/S0955-2863(03)00098-6; Klaunig JE, 2003, CRIT REV TOXICOL, V33, P655, DOI 10.1080/713608372; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lee HK, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-269; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Ohta K, 2006, DEVELOPMENT, V133, P3777, DOI 10.1242/dev.02579; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Patel DD, 2001, J LIPID RES, V42, P328; Patsouris D, 2004, J CLIN INVEST, V114, P94, DOI 10.1172/JC1200420468; Petersen SV, 2001, MOL IMMUNOL, V38, P133; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Rakhshandehroo M, 2007, PPAR RES, V2007, DOI 10.1155/2007/26839; Reddy JK, 2001, AM J PHYSIOL-GASTR L, V281, pG1333, DOI 10.1152/ajpgi.2001.281.6.G1333; Richert L, 2003, TOXICOL APPL PHARM, V191, P130, DOI 10.1016/S0041-008X(03)00231-X; Sanderson LM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001681; Schoonjans K, 1996, J LIPID RES, V37, P907; Seree E, 2004, GASTROENTEROLOGY, V127, P1436, DOI 10.1053/j.gastro.2004.08.023; Stienstra R, 2007, ENDOCRINOLOGY, V148, P2753, DOI 10.1210/en.2007-0014; Subramaniam M, 2007, J CELL BIOCHEM, V102, P539, DOI 10.1002/jcb.21492; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tien ES, 2003, CANCER RES, V63, P5767; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; Yang Y, 2006, PHARMACOGENOMICS, V7, P177, DOI 10.2217/14622416.7.2.177; Yu ST, 2001, J BIOL CHEM, V276, P42485, DOI 10.1074/jbc.M106480200; Zandbergen F, 2005, BIOCHEM J, V392, P313, DOI 10.1042/BJ20050636; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040	56	216	224	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6796	10.1371/journal.pone.0006796	http://dx.doi.org/10.1371/journal.pone.0006796			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710929	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415600010
J	Mazzone, PJ; Marchi, N; Fazio, V; Taylor, JM; Masaryk, T; Bury, L; Mekhail, T; Janigro, D				Mazzone, Peter J.; Marchi, Nicola; Fazio, Vince; Taylor, J. Michael; Masaryk, Thomas; Bury, Luke; Mekhail, Tarek; Janigro, Damir			Small Vessel Ischemic Disease of the Brain and Brain Metastases in Lung Cancer Patients	PLOS ONE			English	Article							WHITE-MATTER LESIONS; LONGER SURVIVAL; PATHOGENESIS; BARRIER; RISK; MRI	Background: Brain metastases occur commonly in patients with lung cancer. Small vessel ischemic disease is frequently found when imaging the brain to detect metastases. We aimed to determine if the presence of small vessel ischemic disease (SVID) of the brain is protective against the development of brain metastases in lung cancer patients. Methodology/Principal Findings: A retrospective cohort of 523 patients with biopsy confirmed lung cancer who had received magnetic resonance imaging of the brain as part of their standard initial staging evaluation was reviewed. Information collected included demographics, comorbidities, details of the lung cancer, and the presence of SVID of the brain. A portion of the cohort had the degree of SVID graded. The primary outcome measure was the portion of study subjects with and without SVID of the brain who had evidence of brain metastases at the time of initial staging of their lung cancer. 109 patients (20.8%) had evidence of brain metastases at presentation and 345 (66.0%) had evidence of SVID. 13.9% of those with SVID and 34.3% of those without SVID presented with brain metastases (p<0.0001). In a model including age, diabetes mellitus, hypertension, hyperlipidemia, and tobacco use, SVID of the brain was found to be the only protective factor against the development of brain metastases, with an OR of 0.31 (0.20, 0.48; p<0.001). The grade of SVID was higher in those without brain metastases. Conclusions/Significance: These findings suggest that vascular changes in the brain are protective against the development of brain metastases in lung cancer patients.			Mazzone, PJ (corresponding author), Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.	mazzonp@ccf.org	Marchi, Nicola/J-8607-2016; Mazzone, Peter/AAW-5401-2021	Marchi, Nicola/0000-0001-9124-0226; Mazzone, Peter/0000-0003-2121-0595; Janigro, Damir/0000-0003-2165-5826	NINDS NIH HHS [R01NS049514, R01 NS049514] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049514] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boiten J, 1996, NEUROLOGY, V47, P1109, DOI 10.1212/WNL.47.4.1109; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; BRANTZAWADZKI M, 1985, AM J NEURORADIOL, V6, P675; De Giorgio R, 2000, ARCH INTERN MED, V160, P2217, DOI 10.1001/archinte.160.14.2217; FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351, DOI 10.2214/ajr.149.2.351; Fokas E, 2007, CANCER METAST REV, V26, P705, DOI 10.1007/s10555-007-9088-5; Gerstner ER, 2007, J CLIN ONCOL, V25, P2306, DOI 10.1200/JCO.2006.10.0677; Grant G.A., 2004, YOUMANS NEUROLOGICAL, P153; HAIK BG, 1987, ANN OPHTHALMOL, V19, P218; Hanbali A, 2007, ARCH INTERN MED, V167, P513, DOI 10.1001/archinte.167.5.513-a; Hodi FS, 2008, NAT CLIN PRACT ONCOL, V5, P557, DOI 10.1038/ncponc1183; Lodder J, 1993, Adv Neurol, V62, P213; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Marchi N, 2008, CANCER, V112, P1313, DOI 10.1002/cncr.23314; Marchi N, 2009, EPILEPSIA, V50, P664, DOI 10.1111/j.1528-1167.2008.01989.x; Mazzone P, 2007, NEUROLOGY INTERNAL M, P139; McCarthy BJ, 2002, NEURO-ONCOLOGY, V4, P134, DOI 10.1093/neuonc/4.2.134; O'Brien JT, 2003, LANCET NEUROL, V2, P89, DOI 10.1016/S1474-4422(03)00305-3; Pantoni L, 1997, STROKE, V28, P652, DOI 10.1161/01.STR.28.3.652; Prins ND, 2004, ARCH NEUROL-CHICAGO, V61, P1531, DOI 10.1001/archneur.61.10.1531; Prins ND, 2005, BRAIN, V128, P2034, DOI 10.1093/brain/awh553; Satoh H, 2001, ARCH INTERN MED, V161, P485, DOI 10.1001/archinte.161.3.485; Seymour K, 1999, BRIT J SURG, V86, P1237, DOI 10.1046/j.1365-2168.1999.01228.x; Silvestri GA, 2007, CHEST, V132, p178S, DOI 10.1378/chest.07-1360; Tosoni A, 2004, CRIT REV ONCOL HEMAT, V52, P199, DOI 10.1016/j.critrevonc.2004.08.006; van Dijk EJ, 2005, CIRCULATION, V112, P900, DOI 10.1161/CIRCULATIONAHA.104.506337; VANSWIETEN JC, 1991, BRAIN, V114, P761; Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; 2005, CANC FACTS FIGURES 2	30	16	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7242	10.1371/journal.pone.0007242	http://dx.doi.org/10.1371/journal.pone.0007242			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789633	Green Published, Green Submitted, gold			2022-12-27	WOS:000270354100010
J	Kumar, AA; Bhaskar, E; Shantha, GPS; Swaminathan, P; Abraham, G				Kumar, Anita A.; Bhaskar, Emmanuel; Shantha, Ghanshyam Palamaner Subash; Swaminathan, Porchelvan; Abraham, Georgi			Rhabdomyolysis in Community Acquired Bacterial Sepsis - A Retrospective Cohort Study	PLOS ONE			English	Article								Background and Objectives: Rhabdomyolysis is often associated with sepsis and gram positive bacterial pathogens are reported to be the most frequent cause of sepsis induced rhabdomyolysis. We report the pattern of infecting bacterial pathogens and associated causal factors in a South-Indian cohort. Design, Setting, Participants & Measurements: Retrospective cohort study of adult patients with community acquired bacterial sepsis complicated by rhabdomyolysis from March 2003-August 2008. Rhabdomyolysis was defined as serum creatine kinase >2000 IU/L. The study population was divided into group-I (sepsis with gram positive pathogens), group-II (sepsis with gram negative pathogens) and group-III (culture negative sepsis). Results: 103 patients (group I-15, group II-34 and group III-54) formed the study cohort. Mean age was 55 years and two-third had diabetes. Mean creatine kinase was 7114 IU/L and mean serum creatinine on admission was 2.4 mg/dl. Causative pathogen of sepsis was identified in 47.5%. Gram negative pathogens were more frequently (33%) associated with rhabdomyolysis than gram positive pathogens (14.5%). Lung was the commonest foci of sepsis (38.8%). 78.6% of the study population had one or more additional causal factor for rhabdomyolysis like statin intake, chronic alcoholism, hypokalemia, hypernatremia and hypophosphatemia. Mortality was 59%. Conclusions: Gram negative bacterial pathogens were more frequently associated with rhabdomyolysis than gram positive pathogens. Rhabdomyolysis in patients with sepsis is multifactorial and is associated with high mortality.			Kumar, AA (corresponding author), Sri Ramachandra Univ, Dept Gen Med, Madras, Tamil Nadu, India.	drpssghanshyam@yahoo.co.in	Bhaskar, Emmanuel/ABG-2158-2020	Bhaskar, Emmanuel/0000-0002-3524-641X				Allison RC, 2003, AM J MED SCI, V326, P79, DOI 10.1097/00000441-200308000-00005; ASAO K, 1995, INTERNAL MED, V34, P785, DOI 10.2169/internalmedicine.34.785; BANDO T, 1994, INTERNAL MED, V33, P454, DOI 10.2169/internalmedicine.33.454; BARACOS V, 1983, NEW ENGL J MED, V308, P553, DOI 10.1056/NEJM198303103081002; Betrosian A, 1999, INTENS CARE MED, V25, P469, DOI 10.1007/s001340050882; Brown CVR, 2004, J TRAUMA, V56, P1191, DOI 10.1097/01.TA.0000130761.78627.10; Byrd RP, 1998, RESP MED, V92, P359, DOI 10.1016/S0954-6111(98)90123-8; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; CADNAPAPHORNCHAI P, 1980, AM J MED SCI, V280, P66, DOI 10.1097/00000441-198009000-00001; CARON F, 1994, REV MED INTERNE, V15, P240, DOI 10.1016/S0248-8663(94)80027-8; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Evans M, 2002, CURR OPIN LIPIDOL, V13, P415, DOI 10.1097/00041433-200208000-00009; FERGUSON ER, 1984, AM J PHYSIOL, V246, pF700, DOI 10.1152/ajprenal.1984.246.5.F700; Fernandez WG, 2005, AM J EMERG MED, V23, P1, DOI 10.1016/j.ajem.2004.09.025; Funada H, 1996, INTERNAL MED, V35, P36, DOI 10.2169/internalmedicine.35.36; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; Garcia M Carmina C, 2002, Tenn Med, V95, P67; GROSSMAN RA, 1974, NEW ENGL J MED, V291, P807, DOI 10.1056/NEJM197410172911601; Huerta-Alardin AL, 2005, CRIT CARE, V9, P158, DOI 10.1186/cc2978; KNOCHEL JP, 1982, AM J MED, V72, P521, DOI 10.1016/0002-9343(82)90522-8; KNOCHEL JP, 1975, ANN NY ACAD SCI, V252, P274, DOI 10.1111/j.1749-6632.1975.tb19168.x; Morton SE, 2001, SOUTH MED J, V94, P67, DOI 10.1097/00007611-200194010-00013; Ojukwu IC, 2001, SCAND J INFECT DIS, V33, P227, DOI 10.1080/00365540151060969; Qiu LL, 2004, J AM BOARD FAM PRACT, V17, P54, DOI 10.3122/jabfm.17.1.54; Shih KY, 2002, J FORMOS MED ASSOC, V101, P429; Singh U, 1996, CLIN INFECT DIS, V22, P642, DOI 10.1093/clinids/22.4.642; SMITH LH, 1976, WESTERN J MED, V125, P298; Teramoto S, 1997, Nihon Ronen Igakkai Zasshi, V34, P49; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; TURNER MC, 1987, CLIN PEDIATR, V26, P189, DOI 10.1177/000992288702600408; van Deuren M, 1998, CLIN INFECT DIS, V26, P214, DOI 10.1086/517026; VEENSTRA J, 1994, NEPHROL DIAL TRANSPL, V9, P637, DOI 10.1093/ndt/9.6.637; Visweswaran P, 1999, CRIT CARE CLIN, V15, P415, DOI 10.1016/S0749-0704(05)70061-0; WARD MM, 1988, ARCH INTERN MED, V148, P1553, DOI 10.1001/archinte.148.7.1553; WU AW, 1990, WESTERN J MED, V152, P716	35	20	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7182	10.1371/journal.pone.0007182	http://dx.doi.org/10.1371/journal.pone.0007182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787056	Green Submitted, Green Published, gold			2022-12-27	WOS:000270290100009
J	Markakis, EA; Sasaki, M; Lankford, KL; Kocsis, JD				Markakis, Eleni A.; Sasaki, Masanori; Lankford, Karen L.; Kocsis, Jeffery D.			Convergence of Cells from the Progenitor Fraction of Adult Olfactory Bulb Tissue to Remyelinating Glia in Demyelinating Spinal Cord Lesions	PLOS ONE			English	Article								Background: Progenitor cells isolated from adult brain tissue are important tools for experimental studies of remyelination. Cells harvested from neurogenic regions in the adult brain such as the subependymal zone have demonstrated remyelination potential. Multipotent cells from the progenitor fraction have been isolated from the adult olfactory bulb ( OB) but their potential to remyelinate has not been studied. Methodology/Principal Findings: We used the buoyant density gradient centrifugation method to isolate the progenitor fraction and harvest self-renewing multipotent neural cells grown in monolayers from the adult green-fluorescent protein (GFP) transgenic rat OB. OB tissue was mechanically and chemically dissociated and the resultant cell suspension fractionated on a Percoll gradient. The progenitor fraction was isolated and these cells were plated in growth media with serum for 24 hrs. Cells were then propagated in N2 supplemented serum-free media containing b-FGF. Cells at passage 4 (P4) were introduced into a demyelinated spinal cord lesion. The GFP(+) cells survived and integrated into the lesion, and extensive remyelination was observed in plastic sections. Immunohistochemistry revealed GFP(+) cells in the spinal cord to be glial fibrillary acidic protein (GFAP), neuronal nuclei (NeuN), and neurofilament negative. The GFP(+) cells were found among primarily P0(+) myelin profiles, although some myelin basic protein (MBP) profiles were present. Immuno-electron microscopy for GFP revealed GFP(+) cell bodies adjacent to and surrounding peripheral-type myelin rings. Conclusions/Significance: We report that neural cells from the progenitor fraction of the adult rat OB grown in monolayers can be expanded for several passages in culture and that upon transplantation into a demyelinated spinal cord lesion provide extensive remyelination without ectopic neuronal differentiation.			Markakis, EA (corresponding author), Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA.	eleni.markakis@yale.edu	Sasaki, Masanori/B-3246-2008	Sasaki, Masanori/0000-0001-7961-9698	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043432] Funding Source: NIH RePORTER; NCI NIH HHS [CA1009A10] Funding Source: Medline; NINDS NIH HHS [R01 NS043432, NS43432] Funding Source: Medline; CSR NIH HHS [RG4028] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CSR NIH HHS		Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; Akiyama Y, 2004, NEURON GLIA BIOL, V1, P47, DOI 10.1017/s1740925x04000079; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2000, Prog Brain Res, V127, P1; Au WW, 2002, J COMP NEUROL, V446, P68, DOI 10.1002/cne.10182; Babu H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000388; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; BAYER SA, 1983, EXP BRAIN RES, V50, P329; Blakemore WF, 2008, CURR TOP MICROBIOL, V318, P193; BLAKEMORE WF, 1978, ACTA NEUROPATHOL, V42, P105, DOI 10.1007/BF00690975; CHUAH MI, 1993, BRAIN RES, V601, P213, DOI 10.1016/0006-8993(93)91713-3; Craig CG, 1996, J NEUROSCI, V16, P2649; Doetsch F, 1997, J NEUROSCI, V17, P5046; DOUCETTE JR, 1984, ANAT REC, V210, P385, DOI 10.1002/ar.1092100214; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GRACA DL, 1986, NEUROPATH APPL NEURO, V12, P593, DOI 10.1111/j.1365-2990.1986.tb00162.x; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hardison JL, 2006, EXP NEUROL, V197, P420, DOI 10.1016/j.expneurol.2005.10.016; Honmou O, 1996, J NEUROSCI, V16, P3199; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Lankford KL, 2008, GLIA, V56, P1664, DOI 10.1002/glia.20718; Liu ZP, 2003, J COMP NEUROL, V459, P368, DOI 10.1002/cne.10664; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; Markakis EA, 1999, J COMP NEUROL, V406, P449; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Petreanu L, 2002, J NEUROSCI, V22, P6106; RAMONCUETO A, 1992, NEUROSCIENCE, V47, P213, DOI 10.1016/0306-4522(92)90134-N; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sasaki M, 2006, GLIA, V53, P352, DOI 10.1002/glia.20285; Sasaki M, 2006, J NEUROSCI, V26, P1803, DOI 10.1523/JNEUROSCI.3611-05.2006; Sasaki M, 2004, J NEUROSCI, V24, P8485, DOI 10.1523/JNEUROSCI.1998-04.2004; Sasaki M, 2007, PROG BRAIN RES, V161, P419, DOI 10.1016/S0079-6123(06)61030-3; Talbott JF, 2006, GLIA, V54, P147, DOI 10.1002/glia.20369; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Westergaard E, 1970, THESIS U AARHUS DENM	48	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7260	10.1371/journal.pone.0007260	http://dx.doi.org/10.1371/journal.pone.0007260			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787061	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100026
J	Heja, L; Barabas, P; Nyitrai, G; Kekesi, KA; Lasztoczi, B; Toke, O; Tarkanyi, G; Madsen, K; Schousboe, A; Dobolyi, A; Palkovits, M; Kardos, J				Heja, Laszlo; Barabas, Peter; Nyitrai, Gabriella; Kekesi, Katalin A.; Lasztoczi, Balint; Toke, Orsolya; Tarkanyi, Gabor; Madsen, Karsten; Schousboe, Arne; Dobolyi, Arpad; Palkovits, Miklos; Kardos, Julianna			Glutamate Uptake Triggers Transporter-Mediated GABA Release from Astrocytes	PLOS ONE			English	Article							NEURONAL DAMAGE; MOLECULAR REGULATION; HIPPOCAMPAL; GLU; INHIBITION; EXPRESSION; SEIZURES; EQUILIBRIUM; CONTRIBUTES; COEXISTENCE	Background: Glutamate (Glu) and c-aminobutyric acid (GABA) transporters play important roles in regulating neuronal activity. Glu is removed from the extracellular space dominantly by glial transporters. In contrast, GABA is mainly taken up by neurons. However, the glial GABA transporter subtypes share their localization with the Glu transporters and their expression is confined to the same subpopulation of astrocytes, raising the possibility of cooperation between Glu and GABA transport processes. Methodology/Principal Findings: Here we used diverse biological models both in vitro and in vivo to explore the interplay between these processes. We found that removal of Glu by astrocytic transporters triggers an elevation in the extracellular level of GABA. This coupling between excitatory and inhibitory signaling was found to be independent of Glu receptor-mediated depolarization, external presence of Ca2+ and glutamate decarboxylase activity. It was abolished in the presence of non-transportable blockers of glial Glu or GABA transporters, suggesting that the concerted action of these transporters underlies the process. Conclusions/Significance: Our results suggest that activation of Glu transporters results in GABA release through reversal of glial GABA transporters. This transporter-mediated interplay represents a direct link between inhibitory and excitatory neurotransmission and may function as a negative feedback combating intense excitation in pathological conditions such as epilepsy or ischemia.			Heja, L (corresponding author), Hungarian Acad Sci, Inst Biomol Chem, Chem Res Ctr, Dept Neurochem, Budapest, Hungary.	heja@chemres.hu	Tarkanyi, Gabor/A-7766-2009; Dobolyi, Arpad/AAE-5913-2020; Barabas, Peter/AAL-5650-2020; Kékesi, Katalin Adrienna A/H-3484-2017; Palkovits, Miklos/F-2707-2013	Barabas, Peter/0000-0002-8166-3476; Kékesi, Katalin Adrienna A/0000-0003-3042-4878; Palkovits, Miklos/0000-0003-0578-0387; Toke, Orsolya/0000-0002-1741-1573; Schousboe, Arne/0000-0001-9600-402X; Heja, Laszlo/0000-0002-0035-7005				Angulo MC, 2008, PROG NEUROBIOL, V86, P297, DOI 10.1016/j.pneurobio.2008.08.002; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Barabas P, 2002, J NEUROSCI RES, V67, P149, DOI 10.1002/jnr.10117; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Bonanno G, 2006, CURR TOP MED CHEM, V6, P979, DOI 10.2174/156802606777323746; BORDEN LA, 1994, EUR J PHARM-MOLEC PH, V269, P219, DOI 10.1016/0922-4106(94)90089-2; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Derchansky M, 2004, HIPPOCAMPUS, V14, P935, DOI 10.1002/hipo.20007; Diamond JS, 1997, J NEUROSCI, V17, P4672; Doi T, 2005, MOL BRAIN RES, V142, P91, DOI 10.1016/j.molbrainres.2005.09.010; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Dzubay JA, 1999, J NEUROSCI, V19, P5265; Gutierrez R, 2006, CURR TOP MED CHEM, V6, P975, DOI 10.2174/156802606777323692; Heja L, 2006, CURR TOP MED CHEM, V6, P989, DOI 10.2174/156802606777323656; Hertz L., 1989, DISSECTION TISSUE CU, P105; Hoogland G, 2004, J NEUROSCI RES, V76, P881, DOI 10.1002/jnr.20128; JUHASZ G, 1989, J NEUROSCI METH, V29, P131, DOI 10.1016/0165-0270(89)90024-1; KARDOS J, 1991, BIOCHEM PHARMACOL, V41, P1141, DOI 10.1016/0006-2952(91)90652-L; Kekesi KA, 2000, NEUROCHEM INT, V37, P171, DOI 10.1016/S0197-0186(00)00020-6; Khan GM, 1999, EUR J PHARMACOL, V373, P153, DOI 10.1016/S0014-2999(99)00209-5; Kinney GA, 2005, J NEUROPHYSIOL, V94, P4533, DOI 10.1152/jn.00420.2005; Kinney GA, 2002, J NEUROPHYSIOL, V88, P2899, DOI 10.1152/jn.00037.2002; Kovacs R, 2009, J NEUROSCI, V29, P8565, DOI 10.1523/JNEUROSCI.5698-08.2009; Kozlov AS, 2006, P NATL ACAD SCI USA, V103, P10058, DOI 10.1073/pnas.0603741103; Lasztoczi B, 2004, EUR J NEUROSCI, V19, P1361, DOI 10.1111/j.1460-9568.2004.03231.x; LASZTOCZI B, 2009, J NEUROPHYS IN PRESS; Lee TS, 2006, ACTA NEUROPATHOL, V111, P351, DOI 10.1007/s00401-005-0017-9; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Liang SL, 2006, J NEUROSCI, V26, P8537, DOI 10.1523/JNEUROSCI.0329-06.2006; Liu QY, 2000, J NEUROPHYSIOL, V84, P1392, DOI 10.1152/jn.2000.84.3.1392; Massieu L, 1997, J NEUROCHEM, V69, P1151; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; Matthias K, 2003, J NEUROSCI, V23, P1750; MODY I, 1987, J NEUROPHYSIOL, V57, P869, DOI 10.1152/jn.1987.57.3.869; Montiel T, 2005, NEUROSCIENCE, V133, P667, DOI 10.1016/j.neuroscience.2004.11.020; Moussa CEH, 2007, J NEUROSCI RES, V85, P342, DOI 10.1002/jnr.21108; Munera A, 2001, J NEUROPHYSIOL, V86, P2571, DOI 10.1152/jn.2001.86.5.2571; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Nyitrai G, 2006, CURR TOP MED CHEM, V6, P935, DOI 10.2174/156802606777323674; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; Paillart C, 2003, J NEUROSCI, V23, P4092; Plachez C, 2004, NEUROCHEM INT, V45, P1113, DOI 10.1016/j.neuint.2004.03.030; Richards DA, 1996, NEUROCHEM RES, V21, P135, DOI 10.1007/BF02529130; Richerson GB, 2003, J NEUROPHYSIOL, V90, P1363, DOI 10.1152/jn.00317.2003; Schousboe A, 2003, NEUROCHEM RES, V28, P347, DOI 10.1023/A:1022397704922; SCHOUSBOE A, 1977, NEUROCHEM RES, V2, P217, DOI 10.1007/BF00964098; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; SIHRA TS, 1987, J NEUROCHEM, V49, P261, DOI 10.1111/j.1471-4159.1987.tb03424.x; Somogyi J, 2006, CURR TOP MED CHEM, V6, P969, DOI 10.2174/156802606777323737; Soudijn W, 2000, CURR MED CHEM, V7, P1063, DOI 10.2174/0929867003374363; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Ueda Y, 2007, BRAIN RES, V1151, P55, DOI 10.1016/j.brainres.2007.03.021; Wu YM, 2007, NEURON, V56, P851, DOI 10.1016/j.neuron.2007.10.021; Wu YM, 2006, J NEUROPHYSIOL, V96, P2425, DOI 10.1152/jn.00545.2006; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	56	90	93	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7153	10.1371/journal.pone.0007153	http://dx.doi.org/10.1371/journal.pone.0007153			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777062	Green Published, gold, Green Submitted			2022-12-27	WOS:000270164600005
J	Cantu, D; Schaack, J; Patel, M				Cantu, David; Schaack, Jerome; Patel, Manisha			Oxidative Inactivation of Mitochondrial Aconitase Results in Iron and H2O2-Mediated Neurotoxicity in Rat Primary Mesencephalic Cultures	PLOS ONE			English	Article								Background: Mitochondrial oxidative stress is a contributing factor in the etiology of numerous neuronal disorders. However, the precise mechanism(s) by which mitochondrial reactive oxygen species (ROS) modify cellular targets to induce the death of neurons remains unknown. The goal of this study was to determine if oxidative inactivation of mitochondrial aconitase (m-aconitase) resulted in the release of redox-active iron (Fe2+) and hydrogen peroxide (H2O2) and whether this contributes to cell death. Methodology/Principal Findings: Incubation of rat primary mesencephalic cultures with the redox cycling herbicide paraquat (PQ(2+)) resulted in increased production of H2O2 and Fe2+ at times preceding cell death. To confirm the role of maconitase as a source of Fenton reagents and death, we overexpressed m-aconitase using an adenoviral construct thereby increasing the target available for inactivation by ROS. Co-labeling studies identified astrocytes as the predominant cell type expressing transduced m-aconitase although neurons were identified as the primary cell type dying. Oxidative inactivation of m-aconitase overexpressing cultures resulted in exacerbation of H2O2 production, Fe2+ accumulation and increased neuronal death. Increased cell death in m-aconitase overexpressing cultures was attenuated by addition of catalase and/or a cell permeable iron chelator suggesting that neuronal death occurred in part via astrocyte-derived H2O2. Conclusions: These results suggest a role of ROS-sensitive m-aconitase as a source of Fe2+ and H2O2 and as a contributing factor to neurotoxicity.			Cantu, D (corresponding author), Univ Colorado Denver, Neurosci Program, Anschutz Med Campus, Aurora, CO USA.	manisha.patel@ucdenver.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039587, R01NS045748] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS039587, NS045748, R01 NS045748, NS039587-S1, NS039587, R01 NS045748-05A1, P30 NS041854-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andres-Mateos E, 2007, P NATL ACAD SCI USA, V104, P14807, DOI 10.1073/pnas.0703219104; Baron M, 2007, BIOCHEM SOC T, V35, P1228, DOI 10.1042/BST0351228; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; DEXTER DT, 1987, LANCET, V2, P1219; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Grammatopoulos TN, 2005, BRAIN RES, V1045, P64, DOI 10.1016/j.brainres.2005.03.038; Hirsch EC, 2005, PARKINSONISM RELAT D, V11, pS9, DOI 10.1016/j.parkreldis.2004.10.013; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kaur D, 2004, AGEING RES REV, V3, P327, DOI 10.1016/j.arr.2004.01.003; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; Lian XY, 2004, EPILEPSY RES, V60, P41, DOI 10.1016/j.eplepsyres.2004.05.003; Liang LP, 2004, J NEUROCHEM, V90, P1076, DOI 10.1111/j.1471-4159.2004.02567.x; Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029; LIANG LP, 2008, J NEUROSCI IN PRESS; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; Longo VD, 2000, J NEUROCHEM, V75, P1977, DOI 10.1046/j.1471-4159.2000.0751977.x; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Murakami K, 1997, BIOCHEM MOL BIOL INT, V41, P481; Park LCH, 2001, J NEUROSCI RES, V66, P1028, DOI 10.1002/jnr.10062; Patel M, 2003, NEUROSCIENCE, V118, P431, DOI 10.1016/S0306-4522(02)00979-X; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Petrat F, 2002, BIOCHEM J, V362, P137, DOI 10.1042/0264-6021:3620137; SCHAPIRA AHV, 1993, BIOCHEM SOC T, V21, P367, DOI 10.1042/bst0210367; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Tretter L, 2005, PHILOS T R SOC B, V360, P2335, DOI 10.1098/rstb.2005.1764; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; Vielhaber S, 2008, EPILEPSIA, V49, P40, DOI 10.1111/j.1528-1167.2007.01280.x; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	45	107	112	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7095	10.1371/journal.pone.0007095	http://dx.doi.org/10.1371/journal.pone.0007095			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763183	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970400019
J	Almberg, ES; Mech, LD; Smith, DW; Sheldon, JW; Crabtree, RL				Almberg, Emily S.; Mech, L. David; Smith, Douglas W.; Sheldon, Jennifer W.; Crabtree, Robert L.			A Serological Survey of Infectious Disease in Yellowstone National Park's Canid Community	PLOS ONE			English	Article								Background: Gray wolves (Canis lupus) were reintroduced into Yellowstone National Park (YNP) after a >70 year absence, and as part of recovery efforts, the population has been closely monitored. In 1999 and 2005, pup survival was significantly reduced, suggestive of disease outbreaks. Methodology/Principal Findings: We analyzed sympatric wolf, coyote (Canis latrans), and red fox (Vulpes vulpes) serologic data from YNP, spanning 1991-2007, to identify long-term patterns of pathogen exposure, identify associated risk factors, and examine evidence for disease-induced mortality among wolves for which there were survival data. We found high, constant exposure to canine parvovirus (wolf seroprevalence: 100%; coyote: 94%), canine adenovirus-1 ( wolf pups [0.5-0.9 yr]: 91%, adults [> 1 yr]: 96%; coyote juveniles [0.5-1.5 yrs]: 18%, adults [>= 1.6 yrs]: 83%), and canine herpesvirus ( wolf: 87%; coyote juveniles: 23%, young adults [1.6-4.9 yrs]: 51%, old adults [>= 5 yrs]: 87%) suggesting that these pathogens were enzootic within YNP wolves and coyotes. An average of 50% of wolves exhibited exposure to the protozoan parasite, Neospora caninum, although individuals' odds of exposure tended to increase with age and was temporally variable. Wolf, coyote, and fox exposure to canine distemper virus (CDV) was temporally variable, with evidence for distinct multi-host outbreaks in 1999 and 2005, and perhaps a smaller, isolated outbreak among wolves in the interior of YNP in 2002. The years of high wolf-pup mortality in 1999 and 2005 in the northern region of the park were correlated with peaks in CDV seroprevalence, suggesting that CDV contributed to the observed mortality. Conclusions/Significance: Of the pathogens we examined, none appear to jeopardize the long-term population of canids in YNP. However, CDV appears capable of causing short-term population declines. Additional information on how and where CDV is maintained and the frequency with which future epizootics might be expected might be useful for future management of the Northern Rocky Mountain wolf population.			Almberg, ES (corresponding author), Univ Minnesota, Dept Nat Resources Sci & Management, St Paul, MN 55108 USA.	almb0001@umn.edu						ALEXANDER KA, 1994, J WILDLIFE DIS, V30, P481, DOI 10.7589/0090-3558-30.4.481; ALMBERG E, 2009, THESIS U MINNESOTA G, P21; Altizer S, 2003, ANNU REV ECOL EVOL S, V34, P517, DOI 10.1146/annurev.ecolsys.34.030102.151725; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; APPEL M, 1973, AM J VET RES, V34, P1459; Bangs EE, 1996, WILDLIFE SOC B, V24, P402; Bangs EE, 1998, WILDLIFE SOC B, V26, P785; Barker Ian K., 2001, P131, DOI 10.1002/9780470344880.ch6; Basso W, 2001, J PARASITOL, V87, P612, DOI 10.1645/0022-3395(2001)087[0612:FIONCF]2.0.CO;2; Bates D., 2008, LME4 LINEAR MIXED EF; Biek R, 2006, J WILDLIFE DIS, V42, P606, DOI 10.7589/0090-3558-42.3.606; BITTEGEKO SBPR, 1995, J AM ANIM HOSP ASSOC, V31, P42, DOI 10.5326/15473317-31-1-42; Bjorkman C, 1999, INT J PARASITOL, V29, P1497, DOI 10.1016/S0020-7519(99)00115-0; Burnham K. P., 2002, MODEL SELECTION MULT, V2nd; CARMICHAEL LE, 1980, AM J VET RES, V41, P784; CARMICHAEL LE, 1970, J AM VET MED ASSOC, V156, P1714; Choate JR, 1998, J MAMMAL, V79, P1416; CHOQUETTE L P E, 1974, Journal of Wildlife Diseases, V10, P321; Cleaveland S., 2002, P139; Clifford DL, 2006, BIOL CONSERV, V131, P230, DOI 10.1016/j.biocon.2006.04.029; Cypher BL, 1998, J WILDLIFE DIS, V34, P259, DOI 10.7589/0090-3558-34.2.259; Deem SL, 2005, J ZOO WILDLIFE MED, V36, P192, DOI 10.1638/04-076.1; Dubey JP, 1999, INT J PARASITOL, V29, P1709, DOI 10.1016/S0020-7519(99)00142-3; Dubey JP, 2005, J PARASITOL, V91, P1217, DOI 10.1645/GE-576R.1; DUBEY JP, 1988, J AM VET MED ASSOC, V192, P1269; DUBIELZIG RR, 1979, VET PATHOL, V16, P268, DOI 10.1177/030098587901600216; Funk SM, 2001, CONSERV BIOL SER, V5, P443; Gannon WL, 2007, J MAMMAL, V88, P809, DOI 10.1644/06-MAMM-F-185R1.1; GESE EM, 1991, J WILDLIFE DIS, V27, P320, DOI 10.7589/0090-3558-27.2.320; Gese EM, 1997, J WILDLIFE DIS, V33, P47, DOI 10.7589/0090-3558-33.1.47; Gier H. T., 1968, AGR EXPT STATION B, P393; Gipson PS, 2000, J WILDLIFE MANAGE, V64, P752, DOI 10.2307/3802745; Gondim LFP, 2004, INT J PARASITOL, V34, P159, DOI 10.1016/j.ijpara.2004.01.001; GORDON JC, 1986, AM J VET RES, V47, P1464; GORHAM JR, 1966, J AM VET MED ASSOC, V149, P610; GREEN JS, 1984, J WILDLIFE DIS, V20, P6, DOI 10.7589/0090-3558-20.1.6; Greene C, 2006, INFECT DIS DOG CAT, P41; Greene C.E., 2006, INFECT DIS DOG CAT; Grinder M, 2001, J WILDLIFE DIS, V37, P312, DOI 10.7589/0090-3558-37.2.312; GUO W, 1986, J AM VET MED ASSOC, V189, P1099; Haydon DT, 2006, NATURE, V443, P692, DOI 10.1038/nature05177; HEIDEJORGENSEN MP, 1992, J APPL ECOL, V29, P99, DOI 10.2307/2404353; Houston D.B., 1982, NO YELLOWSTONE ELK E; JOHNSON MR, 1994, J WILDLIFE DIS, V30, P270, DOI 10.7589/0090-3558-30.2.270; Junge RE, 2007, J ZOO WILDLIFE MED, V38, P18, DOI 10.1638/05-123.1; Lachish S, 2007, J ANIM ECOL, V76, P926, DOI 10.1111/j.1365-2656.2007.01272.x; Laurenson K, 1998, ANIM CONSERV, V1, P273, DOI 10.1111/j.1469-1795.1998.tb00038.x; Lindsay DS, 1999, VET PARASITOL, V82, P327, DOI 10.1016/S0304-4017(99)00054-0; MCCALLUM H, 1995, TRENDS ECOL EVOL, V10, P190, DOI 10.1016/S0169-5347(00)89050-3; Mech LD, 2008, J WILDLIFE DIS, V44, P824, DOI 10.7589/0090-3558-44.4.824; MECH LD, 1993, J WILDLIFE DIS, V29, P330, DOI 10.7589/0090-3558-29.2.330; Munson L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002545; Murray DL, 1999, ANIM CONSERV, V2, P241, DOI 10.1111/j.1469-1795.1999.tb00070.x; Nunn CL, 2006, INFECT DIS PRIMATES; Packer C, 1999, J ANIM ECOL, V68, P1161, DOI 10.1046/j.1365-2656.1999.00360.x; Parrish C R, 1990, Adv Virus Res, V38, P403; Peterson RO, 1998, J MAMMAL, V79, P828, DOI 10.2307/1383091; POLLOCK RVH, 1982, J AM VET MED ASSOC, V180, P37; R Core Team, 2018, R LANG ENV STAT COMP; Rijsewijk FAM, 1999, VET MICROBIOL, V65, P1, DOI 10.1016/S0378-1135(98)00285-5; Smith Douglas W., 2007, Yellowstone Science, V15, P17; Smith Douglas W., 2009, P92, DOI 10.1002/9781444312034.ch5; Smith DW, 2004, J WILDLIFE MANAGE, V68, P153, DOI 10.2193/0022-541X(2004)068[0153:WPSAEO]2.0.CO;2; SMITH DW, 2008, YCR200801 NAT PARK S; STEPHENSON RO, 1982, J WILDLIFE DIS, V18, P419, DOI 10.7589/0090-3558-18.4.419; THORNE E T, 1988, Conservation Biology, V2, P66, DOI 10.1111/j.1523-1739.1988.tb00336.x; TRAINER DO, 1968, J WILDLIFE MANAGE, V32, P981, DOI 10.2307/3799581; Vianna MCB, 2005, VET PARASITOL, V129, P253, DOI 10.1016/j.vetpar.2004.02.031; Williams Elizabeth S., 2001, P50; Woods Leslie W., 2001, P202, DOI 10.1002/9780470344880.ch9; *YELL NAT PARK DIV, 2008, YELL RES ISS; ZARNKE RL, 1987, J WILDLIFE DIS, V23, P77, DOI 10.7589/0090-3558-23.1.77	72	64	64	6	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7042	10.1371/journal.pone.0007042	http://dx.doi.org/10.1371/journal.pone.0007042			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756151	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970000011
J	Davies, V; Vaughan, K; Damle, R; Peters, B; Sette, A				Davies, Vince; Vaughan, Kerrie; Damle, Rohini; Peters, Bjoern; Sette, Alessandro			Classification of the Universe of Immune Epitope Literature: Representation and Knowledge Gaps	PLOS ONE			English	Article							GLOBAL HEALTH; DISEASE; BURDEN	Background: A significant fraction of the more than 18 million scientific articles currently indexed in the PubMed database are related to immune responses to various agents, including infectious microbes, autoantigens, allergens, transplants, cancer antigens and others. The Immune Epitope Database (IEDB) is an online repository that catalogs immune epitope reactivity data derived from articles listed in the National Library of Medicine PubMed database. The IEDB is maintained and continually updated by monitoring PubMed for new, potentially relevant references. Methodology: Herein we detail the classification of all epitope-specific literature in over 100 different immunological domains representing Infectious Diseases and Microbes, Autoimmunity, Allergy, Transplantation and Cancer. The relative number of references in each category reflects past and present areas of research on immune reactivities. In addition to describing the overall landscape of data distribution, this particular characterization of the epitope reference data also allows for the exploration of possible correlations with global disease morbidity and mortality data. Conclusions/Significance: While in most cases diseases associated with high morbidity and mortality rates were amongst the most studied, a number of high impact diseases such as dengue, Schistosoma, HSV-2, B. pertussis and Chlamydia trachoma, were found to have very little coverage. The data analyzed in this fashion represents the first estimate of how reported immunological data corresponds to disease-related morbidity and mortality, and confirms significant discrepancies in the overall research foci versus disease burden, thus identifying important gaps to be pursued by future research. These findings may also provide a justification for redirecting a portion of research funds into some of the underfunded, critical disease areas.			Davies, V (corresponding author), La Jolla Inst Allergy & Immunol, La Jolla, CA USA.	kvaughan@liai.org	Sette, Alessandro/AFO-8916-2022		PHS HHS [HHSN2662004000 0 6C] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 2004, TOP 10 CAUS DEATH; Assarsson E, 2008, J VIROL, V82, P12241, DOI 10.1128/JVI.01563-08; Blythe Martin J, 2007, Immunome Res, V3, P10, DOI 10.1186/1745-7580-3-10; Bui HH, 2007, P NATL ACAD SCI USA, V104, P246, DOI 10.1073/pnas.0609330104; Enserink M, 2009, SCIENCE, V323, P700, DOI 10.1126/science.323.5915.700; Flory JH, 2004, PHILOS PUBLIC AFF, V32, P36, DOI 10.1111/j.1467-6486.2004.00004.x; McKenna MT, 2009, ANN EPIDEMIOL, V19, P212, DOI 10.1016/j.annepidem.2008.11.005; Sathiamurthy Muthuraman, 2005, Immunome Res, V1, P2, DOI 10.1186/1745-7580-1-2; Stuckler D, 2008, LANCET, V372, P1563, DOI 10.1016/S0140-6736(08)61656-6; Vaughan K, 2009, PARASITE IMMUNOL, V31, P78, DOI 10.1111/j.1365-3024.2008.01077.x; Vita R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-341; Wang P, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-269; 2000, W J MED, V173, P9	13	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6948	10.1371/journal.pone.0006948	http://dx.doi.org/10.1371/journal.pone.0006948			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19774228	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796300005
J	Lipsitch, M; Lajous, M; O'Hagan, JJ; Cohen, T; Miller, JC; Goldstein, E; Danon, L; Wallinga, J; Riley, S; Dowell, SF; Reed, C; McCarron, M				Lipsitch, Marc; Lajous, Martin; O'Hagan, Justin J.; Cohen, Ted; Miller, Joel C.; Goldstein, Edward; Danon, Leon; Wallinga, Jacco; Riley, Steven; Dowell, Scott F.; Reed, Carrie; McCarron, Meg			Use of Cumulative Incidence of Novel Influenza A/H1N1 in Foreign Travelers to Estimate Lower Bounds on Cumulative Incidence in Mexico	PLOS ONE			English	Article								Background: An accurate estimate of the total number of cases and severity of illness of an emerging infectious disease is required both to define the burden of the epidemic and to determine the severity of disease. When a novel pathogen first appears, affected individuals with severe symptoms are more likely to be diagnosed. Accordingly, the total number of cases will be underestimated and disease severity overestimated. This problem is manifest in the current epidemic of novel influenza A/H1N1. Methods and Results: We used a simple approach to leverage measures of incident influenza A/H1N1 among a relatively small and well observed group of US, UK, Spanish and Canadian travelers who had visited Mexico to estimate the incidence among a much larger and less well surveyed population of Mexican residents. We estimate that a minimum of 113,000 to 375,000 cases of novel influenza A/H1N1 have occurred in Mexicans during the month of April, 2009. Such an estimate serves as a lower bound because it does not account for underreporting of cases in travelers or for nonrandom mixing between Mexican residents and visitors, which together could increase the estimates by more than an order of magnitude. Conclusions: We find that the number of cases in Mexican residents may exceed the number of confirmed cases by two to three orders of magnitude. While the extent of disease spread is greater than previously appreciated, our estimate suggests that severe disease is uncommon since the total number of cases is likely to be much larger than those of confirmed cases.			Lipsitch, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	mlipsitc@hsph.harvard.edu	Wallinga, Jacco/C-4382-2018; Miller, Joel C./C-4229-2015; Danon, Leon/J-6324-2012; Danon, Leon/AFV-8758-2022	Wallinga, Jacco/0000-0003-1725-5627; Miller, Joel C./0000-0003-4426-0405; Danon, Leon/0000-0002-7076-1871; Danon, Leon/0000-0002-7076-1871; Lipsitch, Marc/0000-0003-1504-9213; Riley, Steven/0000-0001-7904-4804; Cohen, Ted/0000-0002-8091-7198	FIC NIH HHS [R01 TW008246-01, R01 TW008246] Funding Source: Medline; NIGMS NIH HHS [5U01GM076497, U01 GM076497] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW008246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM076497] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490; Brundage JF, 2008, EMERG INFECT DIS, V14, P1193, DOI 10.3201/eid1408.071313; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Ghani AC, 2005, AM J EPIDEMIOL, V162, P479, DOI 10.1093/aje/kwi230; Halloran ME, 2008, P NATL ACAD SCI USA, V105, P4639, DOI 10.1073/pnas.0706849105; Kuri-Morales P, 2006, SALUD PUBLICA MEXICO, V48, P379, DOI 10.1590/S0036-36342006000500004; Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6; *MEX MIN TOUR, 2006, TUR INT 2001 2005, P12; *MIN SAL MEX DIR G, 2009, B DIAR MIN SAL MEX, V14; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; Surveillance group for New Influenza A/H1N1 Virus Investigation in Italy, 2009, EUROSURVEILLANCE, V14; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; *YP YANK I, 2008, NAT LEIS TRAV MON	13	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6895	10.1371/journal.pone.0006895	http://dx.doi.org/10.1371/journal.pone.0006895			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742302	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622500002
J	Sorensen, RB; Berge-Hansen, L; Junker, N; Hansen, CA; Hadrup, SR; Schumacher, TNM; Svane, IM; Becker, JC; Straten, PT; Andersen, MH				Sorensen, Rikke Baek; Berge-Hansen, Linda; Junker, Niels; Hansen, Christina Aaen; Hadrup, Sine Reker; Schumacher, Ton N. M.; Svane, Inge Marie; Becker, Juergen C.; Straten, Per Thor; Andersen, Mads Hald			The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase	PLOS ONE			English	Article								Background: The enzyme indoleamine 2,3-dioxygenase (IDO) exerts an well established immunosuppressive function in cancer. IDO is expressed within the tumor itself as well as in antigen-presenting cells in tumor-draining lymph nodes, where it promotes the establishment of peripheral immune tolerance to tumor antigens. In the present study, we tested the notion whether IDO itself may be subject to immune responses. Methods and Findings: The presence of naturally occurring IDO-specific CD8 T cells in cancer patients was determined by MHC/peptide stainings as well as ELISPOT. Antigen specific cytotoxic T lymphocytes (CTL) from the peripheral blood of cancer patients were cloned and expanded. The functional capacity of the established CTL clones was examined by chrome release assays. The study unveiled spontaneous cytotoxic T-cell reactivity against IDO in peripheral blood as well as in the tumor microenvironment of different cancer patients. We demonstrate that these IDO reactive T cells are indeed peptide specific, cytotoxic effector cells. Hence, IDO reactive T cells are able to recognize and kill tumor cells including directly isolated AML blasts as well as IDO-expressing dendritic cells, i.e. one of the major immune suppressive cell populations. Conclusion: IDO may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies. Furthermore, as emerging evidence suggests that IDO constitutes a significant counter-regulatory mechanism induced by pro-inflammatory signals, IDO-based immunotherapy holds the promise to boost anti-cancer immunotherapy in general.			Sorensen, RB (corresponding author), Herlev Univ Hosp, Dept Hematol, CCIT, DK-2730 Herlev, Denmark.	mahaan01@heh.regionh.dk	Schumacher, Ton/Y-2432-2019; Junker, Niels/M-8683-2018; Hadrup, Sine Reker/P-3388-2014	Schumacher, Ton/0000-0003-0517-8804; Hadrup, Sine Reker/0000-0002-5937-4344; Svane, Inge Marie/0000-0002-9451-6037; thor Straten, Per/0000-0002-4731-4969; Andersen, Mads Hald/0000-0002-2914-9605; Junker, Niels/0000-0001-8348-9363				Andersen MH, 2001, CANCER RES, V61, P869; Andersen MH, 2000, TISSUE ANTIGENS, V55, P519, DOI 10.1034/j.1399-0039.2000.550603.x; Andersen MH, 1999, TISSUE ANTIGENS, V54, P185, DOI 10.1034/j.1399-0039.1999.540210.x; Andersen MH, 1999, J IMMUNOL, V163, P3812; Baban B, 2005, INT IMMUNOL, V17, P909, DOI 10.1093/intimm/dxh271; Bauer TM, 2005, TRANSPL INT, V18, P95, DOI 10.1111/j.1432-2277.2004.00031.x; Boasso A, 2007, BLOOD, V109, P3351, DOI 10.1182/blood-2006-07-034785; Chamuleau MED, 2008, HAEMATOL-HEMATOL J, V93, P1894, DOI 10.3324/haematol.13113; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Grohmann U, 2003, J EXP MED, V198, P153, DOI 10.1084/jem.20030633; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Herr W, 1999, P NATL ACAD SCI USA, V96, P12033, DOI 10.1073/pnas.96.21.12033; Keilholz U, 2002, J IMMUNOTHER, V25, P97, DOI 10.1097/00002371-200203000-00001; Kuball J, 2005, IMMUNITY, V22, P117, DOI 10.1016/j.immuni.2004.12.005; Kuball J, 2007, BLOOD, V109, P2331, DOI 10.1182/blood-2006-05-023069; Lee KH, 1998, J IMMUNOL, V161, P4183; LEHMANN F, 1995, EUR J IMMUNOL, V25, P340, DOI 10.1002/eji.1830250206; Lob S, 2008, BLOOD, V111, P2152, DOI 10.1182/blood-2007-10-116111; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; McCutcheon M, 1997, J IMMUNOL METHODS, V210, P149, DOI 10.1016/S0022-1759(97)00182-8; Miki T, 2001, TRANSPLANT P, V33, P129, DOI 10.1016/S0041-1345(00)02792-5; Morgan RA, 2003, J IMMUNOL, V171, P3287, DOI 10.4049/jimmunol.171.6.3287; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Morris E, 2006, BLOOD REV, V20, P61, DOI 10.1016/j.blre.2005.05.001; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Nguyen XD, 2002, TRANSFUSION, V42, P428, DOI 10.1046/j.1525-1438.2002.00067.x; Okamoto A, 2005, CLIN CANCER RES, V11, P6030, DOI 10.1158/1078-0432.CCR-04-2671; Pawelec G, 2006, CANCER IMMUNOL IMMUN, V55, P623, DOI 10.1007/s00262-005-0117-3; Pawelec G, 1997, CRIT REV ONCOGENESIS, V8, P111, DOI 10.1615/CritRevOncog.v8.i2-3.10; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; POPOV A, 2007, J MOL MED; Rammensee HG, 1995, CURR BIOL, V5, P35, DOI DOI 10.1016/S0960-9822(95)00011-X; Riker A, 1999, SURGERY, V126, P112, DOI 10.1067/msy.1999.98739; Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121; Scheibenbogen C, 2002, INT J CANCER, V98, P409, DOI 10.1002/ijc.10205; Scheler M, 2007, AM J PATHOL, V171, P1936, DOI 10.2353/ajpath.2007.070281; Schmidt SM, 2003, BLOOD, V102, P571, DOI 10.1182/blood-2002-08-2554; Sharma MD, 2007, J CLIN INVEST, V117, P2570, DOI 10.1172/JCI31911; Straten PT, 1999, J IMMUNOL, V163, P443; Thebault P, 2007, AM J TRANSPLANT, V7, P2472, DOI 10.1111/j.1600-6143.2007.01960.x; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Wang ZG, 1998, CANCER RES, V58, P2149; Weinlich G, 2007, DERMATOLOGY, V214, P8, DOI 10.1159/000096906; Wills MR, 2002, J IMMUNOL, V168, P5455, DOI 10.4049/jimmunol.168.11.5455; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	50	59	64	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6910	10.1371/journal.pone.0006910	http://dx.doi.org/10.1371/journal.pone.0006910			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738905	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300007
J	Michno, K; Knight, D; Campussano, JM; van de Hoef, D; Boulianne, GL				Michno, Kinga; Knight, David; Campussano, Jorge M.; van de Hoef, Diana; Boulianne, Gabrielle L.			Intracellular Calcium Deficits in Drosophila Cholinergic Neurons Expressing Wild Type or FAD-Mutant Presenilin	PLOS ONE			English	Article								Much of our current understanding about neurodegenerative diseases can be attributed to the study of inherited forms of these disorders. For example, mutations in the presenilin 1 and 2 genes have been linked to early onset familial forms of Alzheimer's disease ( FAD). Using the Drosophila central nervous system as a model we have investigated the role of presenilin in one of the earliest cellular defects associated with Alzheimer's disease, intracellular calcium deregulation. We show that expression of either wild type or FAD-mutant presenilin in Drosophila CNS neurons has no impact on resting calcium levels but does give rise to deficits in intracellular calcium stores. Furthermore, we show that a loss-of-function mutation in calmodulin, a key regulator of intracellular calcium, can suppress presenilin-induced deficits in calcium stores. Our data support a model whereby presenilin plays a role in regulating intracellular calcium stores and demonstrate that Drosophila can be used to study the link between presenilin and calcium deregulation.			Michno, K (corresponding author), Hosp Sick Children, Program Dev & Stem Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	gboul@sickkids.ca	Campusano, Jorge M/CAF-8833-2022; Campusano, Jorge M/A-1592-2014; Knight, David/U-4162-2017	Campusano, Jorge M/0000-0001-5254-8340; Campusano, Jorge M/0000-0001-5254-8340; 				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ahn EY, 2004, J BIOL CHEM, V279, P5661, DOI 10.1074/jbc.M311040200; Amtul Z, 2002, NEUROBIOL DIS, V9, P269, DOI 10.1006/nbdi.2001.0473; Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Baumeister R, 1997, Genes Funct, V1, P149; Boulianne GL, 1997, NEUROREPORT, V8, P1025, DOI 10.1097/00001756-199703030-00041; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Cai CX, 2006, J BIOL CHEM, V281, P16649, DOI 10.1074/jbc.M512026200; Campusano JM, 2007, DEV NEUROBIOL, V67, P1520, DOI 10.1002/dneu.20527; Chen Q, 2008, J NEUROSCI RES, V86, P1615, DOI 10.1002/jnr.21601; Cheung KH, 2008, NEURON, V58, P871, DOI 10.1016/j.neuron.2008.04.015; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Dermaut B, 2004, ANN NEUROL, V55, P617, DOI 10.1002/ana.20083; Etcheberrigaray R, 1998, NEUROBIOL DIS, V5, P37, DOI 10.1006/nbdi.1998.0176; GEULA C, 1989, NEUROSCIENCE, V33, P469, DOI 10.1016/0306-4522(89)90399-0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Guo YQ, 1999, J NEUROSCI, V19, P8435; Harvie PD, 1998, GENETICS, V149, P217; Hayrapetyan V, 2008, CELL CALCIUM, V44, P507, DOI 10.1016/j.ceca.2008.03.004; Heiman RG, 1996, P NATL ACAD SCI USA, V93, P2420, DOI 10.1073/pnas.93.6.2420; Kasri NN, 2006, CELL CALCIUM, V40, P41, DOI 10.1016/j.ceca.2006.03.005; Knight D, 2007, DEV NEUROBIOL, V67, P1598, DOI 10.1002/dneu.20532; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2001, NEUROBIOL DIS, V8, P469, DOI 10.1006/nbdi.2001.0382; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; Lu YS, 2007, FASEB J, V21, P2368, DOI 10.1096/fj.06-6380com; Maezawa I, 2002, PATHOL INT, V52, P551, DOI 10.1046/j.1440-1827.2002.01398.x; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; O'Day DH, 2004, BIOCHEM BIOPH RES CO, V320, P1051, DOI 10.1016/j.bbrc.2004.06.070; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Periz G, 1999, EMBO J, V18, P5983, DOI 10.1093/emboj/18.21.5983; Raux G, 2000, NEUROLOGY, V55, P1577, DOI 10.1212/WNL.55.10.1577; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rybalchenko V, 2008, INT J BIOCHEM CELL B, V40, P84, DOI 10.1016/j.biocel.2007.06.023; Salvaterra Paul M., 2001, Gene Expression Patterns, V1, P73, DOI 10.1016/S1567-133X(01)00011-4; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Seidner GA, 2006, CURR BIOL, V16, P1026, DOI 10.1016/j.cub.2006.04.004; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sicaeros Beatriz, 2007, J Vis Exp, P200, DOI 10.3791/200; Smith IF, 2002, BRAIN RES, V949, P105, DOI 10.1016/S0006-8993(02)02970-0; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Stutzmann GE, 2007, ANN NY ACAD SCI, V1097, P265, DOI 10.1196/annals.1379.025; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; VANDEHOEF D, 2009, GENESIS IN PRESS; Wang B, 2003, GENETICS, V165, P1255; Ye YH, 1999, J CELL BIOL, V146, P1351, DOI 10.1083/jcb.146.6.1351; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yeromin AV, 2004, J GEN PHYSIOL, V123, P167, DOI 10.1085/jgp.200308982; Zatti G, 2004, NEUROBIOL DIS, V15, P269, DOI 10.1016/j.nbd.2003.11.002; Zatti G, 2006, CELL CALCIUM, V39, P539, DOI 10.1016/j.ceca.2006.03.002; Zhu JS, 2004, EXP CELL RES, V300, P440, DOI 10.1016/j.yexcr.2004.07.020	54	20	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6904	10.1371/journal.pone.0006904	http://dx.doi.org/10.1371/journal.pone.0006904			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730737	Green Published, gold			2022-12-27	WOS:000269622100009
J	Ma, K; Xiao, R; Tseng, HT; Shan, L; Fu, LN; Moore, DD				Ma, Ke; Xiao, Rui; Tseng, Hsiu-Ting; Shan, Lu; Fu, Loning; Moore, David D.			Circadian Dysregulation Disrupts Bile Acid Homeostasis	PLOS ONE			English	Article							FARNESOID-X-RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; NEGATIVE FEEDBACK-REGULATION; NUCLEAR RECEPTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE; GENE-EXPRESSION; PERIPHERAL-TISSUES; LIVER; CLOCK; TRANSCRIPTION	Background: Bile acids are potentially toxic compounds and their levels of hepatic production, uptake and export are tightly regulated by many inputs, including circadian rhythm. We tested the impact of disrupting the peripheral circadian clock on integral steps of bile acid homeostasis. Methodology/Principal Findings: Both restricted feeding, which phase shifts peripheral clocks, and genetic ablation in Per1(-/-)/Per2(-/-) (PERDKO) mice disrupted normal bile acid control and resulted in hepatic cholestasis. Restricted feeding caused a dramatic, transient elevation in hepatic bile acid levels that was associated with activation of the xenobiotic receptors CAR and PXR and elevated serum aspartate aminotransferase (AST), indicative of liver damage. In the PERDKO mice, serum bile acid levels were elevated and the circadian expression of key bile acid synthesis and transport genes, including Cyp7A1 and NTCP, was lost. This was associated with blunted expression of a primary clock output, the transcription factor DBP, which transactivates the promoters of both genes. Conclusions/Significance: We conclude that disruption of the circadian clock results in dysregulation of bile acid homeostasis that mimics cholestatic disease.			Ma, K (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	moore@bcm.edu		Shan, Lu/0000-0003-2334-9216	NIDDK NIH HHS [R01 DK068804, DK068804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez L, 2004, HUM MOL GENET, V13, P2451, DOI 10.1093/hmg/ddh261; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; ANGELIN B, 1982, J CLIN INVEST, V70, P724, DOI 10.1172/JCI110668; Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Challet E, 2003, BIOL CHEM, V384, P711, DOI 10.1515/BC.2003.079; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; CRESTANI M, 1995, J LIPID RES, V36, P2419; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Duez H, 2008, GASTROENTEROLOGY, V135, P689, DOI 10.1053/j.gastro.2008.05.035; EDWARDS PA, 1972, J LIPID RES, V13, P396; Eloranta JJ, 2006, MOL ENDOCRINOL, V20, P65, DOI 10.1210/me.2005-0159; Escobar C, 1998, AM J PHYSIOL-REG I, V274, pR1309, DOI 10.1152/ajpregu.1998.274.5.R1309; Gachon F, 2004, CHROMOSOMA, V113, P103, DOI 10.1007/s00412-004-0296-2; Gachon F, 2006, CELL METAB, V4, P25, DOI 10.1016/j.cmet.2006.04.015; GIELEN J, 1975, EUR J BIOCHEM, V55, P41, DOI 10.1111/j.1432-1033.1975.tb02136.x; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Hara R, 2001, GENES CELLS, V6, P269, DOI 10.1046/j.1365-2443.2001.00419.x; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; KAI MH, 1995, J LIPID RES, V36, P367; Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kudo T, 2008, AM J PHYSIOL-ENDOC M, V294, pE120, DOI 10.1152/ajpendo.00061.2007; Kullak-Ublick GA, 2004, GASTROENTEROLOGY, V126, P322, DOI 10.1053/j.gastro.2003.06.005; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lundasen T, 2006, J INTERN MED, V260, P530, DOI 10.1111/j.1365-2796.2006.01731.x; Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604; MITROPOULOS KA, 1976, BIOCHEM J, V160, P49, DOI 10.1042/bj1600049; MOOREEDE MC, 1985, ANNU REV MED, V36, P607, DOI 10.1146/annurev.me.36.020185.003135; Mukai M, 2002, DIGEST DIS SCI, V47, P549, DOI 10.1023/A:1017959801493; Nakamura K, 1998, IND HEALTH, V36, P218, DOI 10.2486/indhealth.36.218; NAKANO A, 1990, AM J PHYSIOL, V258, pG653, DOI 10.1152/ajpgi.1990.258.5.G653; Noshiro M, 2007, J BIOL RHYTHM, V22, P299, DOI 10.1177/0748730407302461; Oishi K, 2004, BIOCHEM BIOPH RES CO, V317, P330, DOI 10.1016/j.bbrc.2004.03.055; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; REEVES SL, 2004, NUTR FOOD SCI, V34, P5; Ripperger JA, 2000, GENE DEV, V14, P679; Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Satoh Y, 2006, AM J PHYSIOL-REG I, V290, pR1276, DOI 10.1152/ajpregu.00775.2005; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; SHAPIRO DJ, 1971, J BIOL CHEM, V246, P3210; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Sorrentino P, 2005, DIGEST DIS SCI, V50, P1130, DOI 10.1007/s10620-005-2719-1; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; THIIS-EVENSEN E, 1958, Ind Med Surg, V27, P493; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; WUARIN J, 1992, J CELL SCI, P123; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Zhang J, 2004, J BIOL CHEM, V279, P49517, DOI 10.1074/jbc.M409041200; Zhang YQ, 2006, P NATL ACAD SCI USA, V103, P1006, DOI 10.1073/pnas.0506982103; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	62	85	89	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6843	10.1371/journal.pone.0006843	http://dx.doi.org/10.1371/journal.pone.0006843			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718444	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900016
J	Lutgers, HL; Gerrits, EG; Sluiter, WJ; Ubink-Veltmaat, LJ; Landman, GWD; Links, TP; Gans, ROB; Smit, AJ; Bilo, HJG				Lutgers, Helen L.; Gerrits, Esther G.; Sluiter, Wim J.; Ubink-Veltmaat, Lielith J.; Landman, Gijs W. D.; Links, Thera P.; Gans, Reinold O. B.; Smit, Andries J.; Bilo, Henk J. G.			Life Expectancy in a Large Cohort of Type 2 Diabetes Patients Treated in Primary Care (ZODIAC-10)	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; MORTALITY; MELLITUS; POPULATION; FRAMINGHAM; OUTCOMES; TRENDS; ATORVASTATIN; PREVALENCE	Background: Most longitudinal studies showed increased relative mortality in individuals with type 2 diabetes mellitus until now. As a result of major changes in treatment regimes over the past years, with more stringent goals for metabolic control and cardiovascular risk management, improvement of life expectancy should be expected. In our study, we aimed to assess present-day life expectancy of type 2 diabetes patients in an ongoing cohort study. Methodology and Principal Findings: We included 973 primary care type 2 diabetes patients in a prospective cohort study, who were all participating in a shared care project in The Netherlands. Vital status was assessed from May 2001 till May 2007. Main outcome measurement was life expectancy assessed by transforming actual survival time to standardised survival time allowing adjustment for the baseline mortality rate of the general population. At baseline, mean age was 66 years, mean HbA(1c) 7.0%. During a median follow-up of 5.4 years, 165 patients died (78 from cardiovascular causes), and 17 patients were lost to follow-up. There were no differences in life expectancy in subjects with type 2 diabetes compared to life expectancy in the general population. In multivariate Cox regression analyses, concentrating on the endpoints 'all-cause' and cardiovascular mortality, a history of cardiovascular disease: hazard ratio (HR) 1.71 (95% confidence interval (CI) 1.23-2.37), and HR 2.59 (95% CI 1.56-4.28); and albuminuria: HR 1.72 (95% CI 1.26-2.35), and HR 1.83 (95% CI 1.17-2.89), respectively, were significant predictors, whereas smoking, HbA(1c), systolic blood pressure and diabetes duration were not. Conclusions: This study shows a normal life expectancy in a cohort of subjects with type 2 diabetes patients in primary care when compared to the general population. A history of cardiovascular disease and albuminuria, however, increased the risk of a reduction of life expectancy. These results show that, in a shared care environment, a normal life expectancy is achievable in type 2 diabetes patients.			Lutgers, HL (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9713 AV Groningen, Netherlands.	e.g.gerrits@isala.nl	Landman, Gijs/AAJ-5540-2021	Landman, Gijs/0000-0002-6852-6450; Gans, Reinold/0000-0001-5481-2387				Clarke PM, 2004, DIABETOLOGIA, V47, P1747, DOI 10.1007/s00125-004-1527-z; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Dale CA, 2008, BRIT MED J, V337, P1; Fox CS, 2007, CIRCULATION, V115, P1544, DOI 10.1161/CIRCULATIONAHA.106.658948; Fox CS, 2006, CIRCULATION, V113, P2914, DOI 10.1161/CIRCULATIONAHA.106.613828; Franco OH, 2007, ARCH INTERN MED, V167, P1145, DOI 10.1001/archinte.167.11.1145; Gregg EW, 2007, ANN INTERN MED, V147, P149, DOI 10.7326/0003-4819-147-3-200708070-00167; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; Links TP, 2005, ENDOCR-RELAT CANCER, V12, P273, DOI 10.1677/erc.1.00892; Lipscombe LL, 2007, LANCET, V369, P750, DOI 10.1016/S0140-6736(07)60361-4; Lutgers HL, 2006, DIABETES CARE, V29, P2654, DOI 10.2337/dc05-2173; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; Roper NA, 2002, DIABETES CARE, V25, P43, DOI 10.2337/diacare.25.1.43; Roper NA, 2001, BRIT MED J, V322, P1389, DOI 10.1136/bmj.322.7299.1389; Rutten G.E.H.M., 2006, HUIS WETEN, V49, P137; Sever PS, 2005, DIABETES CARE, V28, P1151, DOI 10.2337/diacare.28.5.1151; Tan HH, 2004, DIABETES CARE, V27, P2797, DOI 10.2337/diacare.27.12.2797; Tierney EF, 2004, DIABETES CARE, V27, P2723, DOI 10.2337/diacare.27.11.2723; Ubink-Veltmaat LJ, 2003, EUR J EPIDEMIOL, V18, P793, DOI 10.1023/A:1025369623365; Ubink-Vetmaat LJ, 2005, NETH J MED, V63, P103	23	50	50	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6817	10.1371/journal.pone.0006817	http://dx.doi.org/10.1371/journal.pone.0006817			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714245	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415800007
J	Pang, YP; Ekstrom, F; Polsinelli, GA; Gao, Y; Rana, S; Hua, DH; Andersson, B; Andersson, PO; Peng, L; Singh, SK; Mishra, RK; Zhu, KY; Fallon, AM; Ragsdale, DW; Brimijoin, S				Pang, Yuan-Ping; Ekstrom, Fredrik; Polsinelli, Gregory A.; Gao, Yang; Rana, Sandeep; Hua, Duy H.; Andersson, Bjorn; Andersson, Per Ola; Peng, Lei; Singh, Sanjay K.; Mishra, Rajesh K.; Zhu, Kun Yan; Fallon, Ann M.; Ragsdale, David W.; Brimijoin, Stephen			Selective and Irreversible Inhibitors of Mosquito Acetylcholinesterases for Controlling Malaria and Other Mosquito-Borne Diseases	PLOS ONE			English	Article							INVERTEBRATE ACETYLCHOLINESTERASE; ORGANOPHOSPHATE RESISTANCE; SULFHYDRYL-REAGENTS; TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURES; ALPHA-LACTALBUMIN; CHOLINESTERASE; GENE; INSENSITIVITY; INACTIVATION	New insecticides are urgently needed because resistance to current insecticides allows resurgence of disease-transmitting mosquitoes while concerns for human toxicity from current compounds are growing. We previously reported the finding of a free cysteine (Cys) residue at the entrance of the active site of acetylcholinesterase (AChE) in some insects but not in mammals, birds, and fish. These insects have two AChE genes (AP and AO), and only AP-AChE carries the Cys residue. Most of these insects are disease vectors such as the African malaria mosquito (Anopheles gambiae sensu stricto) or crop pests such as aphids. Recently we reported a Cys-targeting small molecule that irreversibly inhibited all AChE activity extracted from aphids while an identical exposure caused no effect on the human AChE. Full inhibition of AChE in aphids indicates that AP-AChE contributes most of the enzymatic activity and suggests that the Cys residue might serve as a target for developing better aphicides. It is therefore worth investigating whether the Cys-targeting strategy is applicable to mosquitocides. Herein, we report that, under conditions that spare the human AChE, a methanethiosulfonate-containing molecule at 6 mu M irreversibly inhibited 95% of the AChE activity extracted from An. gambiae s. str. and > 80% of the activity from the yellow fever mosquito (Aedes aegypti L.) or the northern house mosquito (Culex pipiens L.) that is a vector of St. Louis encephalitis. This type of inhibition is fast (similar to 30 min) and due to conjugation of the inhibitor to the active-site Cys of mosquito AP-AChE, according to our observed reactivation of the methanethiosulfonate-inhibited AChE by 2-mercaptoethanol. We also note that our sulfhydryl agents partially and irreversibly inhibited the human AChE after prolonged exposure (> 4 hr). This slow inhibition is due to partial enzyme denaturation by the inhibitor and/or micelles of the inhibitor, according to our studies using atomic force microscopy, circular dichroism spectroscopy, X-ray crystallography, time-resolved fluorescence spectroscopy, and liquid chromatography triple quadrupole mass spectrometry. These results support our view that the mosquito-specific Cys is a viable target for developing new mosquitocides to control disease vectors and to alleviate resistance problems with reduced toxicity toward non-target species.			Pang, YP (corresponding author), Mayo Clin, Rochester, MN 55905 USA.	pang@mayo.edu; fredrik.ekstrom@foi.se; brimijoi@mayo.edu	Rana, Sandeep/N-1579-2019	Pang, Yuan-Ping/0000-0003-0838-2560; Zhu, Kun Yan/0000-0001-9372-8030	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070864] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI070864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baek JH, 2005, PESTIC BIOCHEM PHYS, V81, P164, DOI 10.1016/j.pestbp.2004.12.003; Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; BRIMIJOIN S, 1979, MOL PHARMACOL, V15, P641; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carlier PR, 2008, CHEM-BIOL INTERACT, V175, P368, DOI 10.1016/j.cbi.2008.04.037; Ekstrom F, 2006, BIOCHEMISTRY-US, V45, P74, DOI 10.1021/bi051286t; Ekstrom FJ, 2007, CLIN PHARMACOL THER, V82, P282, DOI 10.1038/sj.clpt.6100151; Ekstrom F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005957; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FIALKA JJ, 2006, WALL STREET J W 0525; FLEISHER JH, 1967, J PHARMACOL EXP THER, V156, P345; Frisch M J, 1999, GAUSSIAN 98 REVISION; Gao JR, 2002, PESTIC BIOCHEM PHYS, V73, P164, DOI 10.1016/S0048-3575(02)00105-0; Gao JR, 2002, INSECT BIOCHEM MOLEC, V32, P765, DOI 10.1016/S0965-1748(01)00159-X; Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202; Hamer GL, 2009, AM J TROP MED HYG, V80, P268, DOI 10.4269/ajtmh.2009.80.268; Hammond PI, 2003, J PHARMACOL EXP THER, V307, P190, DOI 10.1124/jpet.103.053405; Hong HS, 2009, J NEUROCHEM, V108, P1097, DOI 10.1111/j.1471-4159.2008.05866.x; Hornberg A, 2007, BIOCHEMISTRY-US, V46, P4815, DOI 10.1021/bi0621361; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kono Y, 2006, PESTIC BIOCHEM PHYS, V85, P123, DOI 10.1016/j.pestbp.2005.12.002; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Mamiya A, 1997, APPL ENTOMOL ZOOL, V32, P37, DOI 10.1303/aez.32.37; Millard CB, 2003, PROTEIN SCI, V12, P2337, DOI 10.1110/ps.03110703; MONATH TP, 1987, AM J TROP MED HYG, V37, pS40, DOI 10.4269/ajtmh.1987.37.40S; Morrison AC, 2008, PLOS MED, V5, P362, DOI 10.1371/journal.pmed.0050068; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otzen DE, 2009, J COLLOID INTERF SCI, V329, P273, DOI 10.1016/j.jcis.2008.10.021; Pang YP, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000058; Pang YP, 2007, BIOORG MED CHEM LETT, V17, P197, DOI 10.1016/j.bmcl.2006.09.073; Pang YP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004349; Pezzementi Leo, 2006, Invertebrate Neuroscience, V6, P47, DOI 10.1007/s10158-006-0017-z; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; Rowland M, 2008, CHEM-BIOL INTERACT, V175, P73, DOI 10.1016/j.cbi.2008.02.006; Shin I, 1997, P NATL ACAD SCI USA, V94, P2848, DOI 10.1073/pnas.94.7.2848; Shin I, 2002, PROTEIN SCI, V11, P2022, DOI 10.1110/ps.0205102; SMITH DJ, 1974, J BIOL CHEM, V249, P3317; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Viseu MI, 2007, BIOPHYS J, V93, P3601, DOI 10.1529/biophysj.106.101667; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Warr GG, 2000, CURR OPIN COLLOID IN, V5, P88, DOI 10.1016/S1359-0294(00)00038-8; Weik M, 2002, J SYNCHROTRON RADIAT, V9, P342, DOI 10.1107/S0909049502014589; Weill M, 2002, P ROY SOC B-BIOL SCI, V269, P2007, DOI 10.1098/rspb.2002.2122; WILSON IB, 1962, J BIOL CHEM, V237, P1323	52	28	29	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6851	10.1371/journal.pone.0006851	http://dx.doi.org/10.1371/journal.pone.0006851			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714254	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415800016
J	Christley, S; Nie, Q; Xie, XH				Christley, Scott; Nie, Qing; Xie, Xiaohui			Incorporating Existing Network Information into Gene Network Inference	PLOS ONE			English	Article							PLURIPOTENT STEM-CELLS; REGULATORY NETWORKS; TRANSCRIPTIONAL NETWORK; COMPOUND-MODE; SELF-RENEWAL; MICROARRAY; GENERATION; INTEGRATION; SIMULATION; ALGORITHM	One methodology that has met success to infer gene networks from gene expression data is based upon ordinary differential equations (ODE). However new types of data continue to be produced, so it is worthwhile to investigate how to integrate these new data types into the inference procedure. One such data is physical interactions between transcription factors and the genes they regulate as measured by ChIP-chip or ChIP-seq experiments. These interactions can be incorporated into the gene network inference procedure as a priori network information. In this article, we extend the ODE methodology into a general optimization framework that incorporates existing network information in combination with regularization parameters that encourage network sparsity. We provide theoretical results proving convergence of the estimator for our method and show the corresponding probabilistic interpretation also converges. We demonstrate our method on simulated network data and show that existing network information improves performance, overcomes the lack of observations, and performs well even when some of the existing network information is incorrect. We further apply our method to the core regulatory network of embryonic stem cells utilizing predicted interactions from two studies as existing network information. We show that including the prior network information constructs a more closely representative regulatory network versus when no information is provided.			Christley, S (corresponding author), Univ Calif Irvine, Dept Math, Irvine, CA 92717 USA.	scott.christley@uci.edu		Xie, Xiaohui/0000-0002-5479-6345	NIGMS NIH HHS [R01 GM67247, P50 GM76516, R01 GM075309, R01 GM067247, P50 GM076516, R01 GM75309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM076516, R01GM075309, R01GM067247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE O, 2006, ICML, P89, DOI DOI 10.1145/1143844.1143856; Bansal M, 2006, BIOINFORMATICS, V22, P815, DOI 10.1093/bioinformatics/btl003; Bansal M, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100120; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bonneau R, 2008, NAT CHEM BIOL, V4, P658, DOI 10.1038/nchembio.122; Bonneau R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-r36; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chen YL, 2007, PLOS COMPUT BIOL, V3, P602, DOI 10.1371/journal.pcbi.0030063; De Jong H, 2002, J COMPUT BIOL, V9, P67, DOI 10.1089/10665270252833208; Donohoe ME, 2009, NATURE, V460, P128, DOI 10.1038/nature08098; Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067; Faith JJ, 2007, PLOS BIOL, V5, P54, DOI 10.1371/journal.pbio.0050008; Friedman J., 2008, REGULARIZATION PATHS; Friedman J, 2008, BIOSTATISTICS, V9, P432, DOI 10.1093/biostatistics/kxm045; Friedman N, 2004, SCIENCE, V303, P799, DOI 10.1126/science.1094068; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Gilbert D, 2006, BRIEF BIOINFORM, V7, P339, DOI 10.1093/bib/bbl043; Gustafsson M, 2005, IEEE ACM T COMPUT BI, V2, P254, DOI 10.1109/TCBB.2005.35; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038/nrg2522; KENNARD RW, 2000, RIDGE REGRESSION BIA, P80; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Li H, 2008, BIOINFORMATICS, V24, P1874, DOI 10.1093/bioinformatics/btn332; Li XY, 2008, PLOS BIOL, V6, P365, DOI 10.1371/journal.pbio.0060027; Mardis ER, 2007, NAT METHODS, V4, P613, DOI 10.1038/nmeth0807-613; Margolin AA, 2006, NAT PROTOC, V1, P663, DOI 10.1038/nprot.2006.106; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mordelet F, 2008, BIOINFORMATICS, V24, pI76, DOI 10.1093/bioinformatics/btn273; Mukherjee S, 2008, P NATL ACAD SCI USA, V105, P14313, DOI 10.1073/pnas.0802272105; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Segal E, 2008, NATURE, V451, P535, DOI 10.1038/nature06496; Sharov AA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-269; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tamada Y, 2003, BIOINFORMATICS, V19, pII227, DOI 10.1093/bioinformatics/btg1082; Tan K, 2008, GENOMICS, V91, P219, DOI 10.1016/j.ygeno.2007.11.005; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tseng P, 2001, J OPTIMIZ THEORY APP, V109, P475, DOI 10.1023/A:1017501703105; Tsubooka N, 2009, GENES CELLS, V14, P683, DOI 10.1111/j.1365-2443.2009.01301.x; Wang Y, 2006, BIOINFORMATICS, V22, P2413, DOI 10.1093/bioinformatics/btl396; Werhli Adriano V., 2008, Journal of Bioinformatics and Computational Biology, V6, P543, DOI 10.1142/S0219720008003539; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang XF, 2008, J BIOL CHEM, V283, P35825, DOI 10.1074/jbc.M803481200; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	51	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6799	10.1371/journal.pone.0006799	http://dx.doi.org/10.1371/journal.pone.0006799			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710931	Green Published, gold			2022-12-27	WOS:000269415600013
J	Leendertse, M; Willems, RJL; Giebelen, IAJ; Roelofs, JJTH; Top, J; Bonten, MJM; van der Poll, T				Leendertse, Masja; Willems, Rob J. L.; Giebelen, Ida A. J.; Roelofs, Joris J. T. H.; Top, Janetta; Bonten, Marc J. M.; van der Poll, Tom			Intestinal Colonization with Enterococcus faecium Does Not Influence Pulmonary Defense against Pseudomonas aeruginosa in Mice	PLOS ONE			English	Article							VANCOMYCIN-RESISTANT ENTEROCOCCUS; GASTROINTESTINAL-TRACT FLORA; IMMUNE FUNCTIONS; RISK-FACTORS; INFECTION; IMPAIRS; SF68; GUT; SUPPLEMENTATION; BACTERIA	Background: Enterococci, and especially multiresistant Enterococcus faecium, are increasingly found colonizing hospitalized patients. This increased prevalence of colonization is not only associated with an increased prevalence of infections caused by enterococci, but also by infections with other nosocomial pathogens. In this study we investigated the causality of this observed relationship, by determining the influence of intestinal colonization with E. faecium on pulmonary defense against Pseudomonas aeruginosa. Methodology/Principal Findings: Three groups of mice were tested; 2 groups of mice were pre-treated with vancomycin, of which one group was subsequently treated by oral gavage of vancomycin-resistant E. faecium (VRE). The third group did not receive any pre-treatment. P. aeruginosa pneumonia was induced in all mice. Vancomycin treatment resulted in intestinal gram-negative bacterial overgrowth and VRE treatment resulted in colonization throughout the intestines. All 3 groups of mice were able to clear P. aeruginosa from the lungs and circulation, with comparable lung cytokine responses and lung damage. Mice treated with vancomycin without VRE colonization displayed modestly increased plasma levels of TNF-alpha and IL-10. Conclusion: Overgrowth of E. faecium and/or gram-negative bacteria does not impact importantly on pulmonary defense against P. aeruginosa pneumonia.			Leendertse, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.leendertse@amc.uva.nl	Willems, Rob JL/E-3681-2010	Willems, Rob JL/0000-0002-7370-0812; Roelofs, Joris/0000-0001-9595-6571; Top, Janetta/0000-0002-4620-8128				Benyacoub J, 2003, J NUTR, V133, P1158, DOI 10.1093/jn/133.4.1158; Bonten M J, 2001, Lancet Infect Dis, V1, P314, DOI 10.1016/S1473-3099(01)00145-1; Bonten MJM, 1998, ARCH INTERN MED, V158, P1127, DOI 10.1001/archinte.158.10.1127; Caballero-Granado FJ, 2001, EUR J CLIN MICROBIOL, V20, P83, DOI 10.1007/s100960000429; de Regt MJA, 2008, J ANTIMICROB CHEMOTH, V62, P1401, DOI 10.1093/jac/dkn390; DEITCH EA, 1991, SURGERY, V109, P269; DEITCH EA, 1987, ARCH SURG-CHICAGO, V122, P1019; DiazGranados CA, 2005, J INFECT DIS, V191, P588, DOI 10.1086/427512; Donskey CJ, 2003, INFECT CONT HOSP EP, V24, P242, DOI 10.1086/502207; Guo WD, 2002, J TRAUMA, V52, P1178, DOI 10.1097/00005373-200206000-00026; Guo WD, 1995, AM J PHYSIOL-GASTR L, V269, pG827, DOI 10.1152/ajpgi.1995.269.6.G827; Harris AD, 2004, INFECT CONT HOSP EP, V25, P105, DOI 10.1086/502358; Isolauri E, 2001, AM J CLIN NUTR, V73, p444S, DOI 10.1093/ajcn/73.2.444s; LEENDERTSE M, 2009, J INFECT DIS; MARSHALL JC, 1988, SURGERY, V104, P404; MARSHALL JC, 1988, ARCH SURG-CHICAGO, V123, P1465; Munford RS, 2001, AM J RESP CRIT CARE, V163, P316, DOI 10.1164/ajrccm.163.2.2007102; Nieuwenhuijzen GAP, 1996, EUR J SURG, V162, P259; Ostendorf U, 2006, CURR OPIN INFECT DIS, V19, P327, DOI 10.1097/01.qco.0000235158.40184.28; Renckens R, 2008, CRIT CARE MED, V36, P580, DOI 10.1097/01.CCM.0B013E3181620652; Safdar N, 2002, ANN INTERN MED, V136, P834, DOI 10.7326/0003-4819-136-11-200206040-00013; Scharek L, 2005, VET IMMUNOL IMMUNOP, V105, P151, DOI 10.1016/j.vetimm.2004.12.022; Scharek L, 2007, ARCH ANIM NUTR, V61, P223, DOI 10.1080/17450390701431540; Schultz MJ, 2003, INFECT IMMUN, V71, P1630, DOI 10.1128/IAI.71.4.1630-1634.2003; Top J, 2007, CLIN MICROBIOL INFEC, V13, P316, DOI 10.1111/j.1469-0691.2006.01631.x; Top J, 2004, J CLIN MICROBIOL, V42, P4503, DOI 10.1128/JCM.42.10.4503-4511.2004; Treitman AN, 2005, J CLIN MICROBIOL, V43, P462, DOI 10.1128/JCM.43.1.462-463.2005; Veir JK, 2007, VET THER, V8, P229; Whitman MS, 1996, ANTIMICROB AGENTS CH, V40, P1526, DOI 10.1128/AAC.40.6.1526; Willems RJL, 2005, EMERG INFECT DIS, V11, P821, DOI 10.3201/1106.041204; INFECT CONTROL HOSP, V165, P105	31	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6775	10.1371/journal.pone.0006775	http://dx.doi.org/10.1371/journal.pone.0006775			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710930	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415600003
J	Tan, J; Lu, J; Huang, W; Dong, ZX; Kong, CF; Li, L; Gao, LN; Guo, JH; Huang, BQ				Tan, Jiang; Lu, Jun; Huang, Wei; Dong, Zhixiong; Kong, Chenfei; Li, Lin; Gao, Lina; Guo, Jianhua; Huang, Baiqu			Genome-Wide Analysis of Histone H3 Lysine9 Modifications in Human Mesenchymal Stem Cell Osteogenic Differentiation	PLOS ONE			English	Article								Mesenchymal stem cells (MSCs) possess self-renewal and multi-lineage differentiation potentials. It has been established that epigenetic mechanisms such as histone modifications could be critical for determining the fate of stem cells. In this study, full human genome promoter microarrays and expression microarrays were used to explore the roles of histone modifications (H3K9Ac and H3K9Me2) upon the induction of MSC osteogenic differentiation. Our results revealed that the enrichment of H3K9Ac was decreased globally at the gene promoters, whereas the number of promoters enriched with H3K9Me2 was increased evidently upon osteogenic induction. By a combined analysis of data from both ChIP-on-chip and expression microarrays, a number of differentially expressed genes regulated by H3K9Ac and/or H3K9Me2 were identified, implicating their roles in several biological events, such as cell cycle withdraw and cytoskeleton reconstruction that were essential to differentiation process. In addition, our results showed that the vitamin D receptor played a trans-repression role via alternations of H3K9Ac and H3K9Me2 upon MSC osteogenic differentiation. Data from this study suggested that gene activation and silencing controlled by changes of H3K9Ac and H3K9Me2, respectively, were crucial to MSC osteogenic differentiation.			Tan, J (corresponding author), NE Normal Univ, Inst Cytol & Genet, Minist Educ, Key Lab Mol Epigenet, Changchun, Peoples R China.	jhguo@nenu.edu.cn; huangbq705@nenu.edu.cn						Agarwal N, 2007, NUCLEIC ACIDS RES, V35, P5402, DOI 10.1093/nar/gkm599; Alekseyenko AA, 2006, GENE DEV, V20, P848, DOI 10.1101/gad.1400206; Bannister AJ, 2004, METHOD ENZYMOL, V376, P269; Boquest AC, 2005, MOL BIOL CELL, V16, P1131, DOI 10.1091/mbc.E04-10-0949; Boquest AC, 2006, STEM CELL REV, V2, P319, DOI 10.1007/BF02698059; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Brero A, 2005, J CELL BIOL, V169, P733, DOI 10.1083/jcb.200502062; Caplan A I, 1995, Connect Tissue Res, V31, pS9, DOI 10.3109/03008209509116826; Caplan AI, 2000, CLIN ORTHOP RELAT R, pS67; Chemnitz JM, 2006, CANCER RES, V66, P1114, DOI 10.1158/0008-5472.CAN-05-3252; CHEN YD, 1997, J BIOMEDICAL OPTICS, V4, P11; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Dai B, 2007, STEM CELLS, V25, P2567, DOI 10.1634/stemcells.2007-0131; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853; Gamble MJ, 2007, CELL, V128, P433, DOI 10.1016/j.cell.2007.01.017; Gerami-Naini B, 2004, ENDOCRINOLOGY, V145, P1517, DOI 10.1210/en.2003-1241; Gibbons FD, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r96; Guo Y, 2005, J VIROL, V79, P14392, DOI 10.1128/JVI.79.22.14392-14403.2005; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003-1014; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Kato S, 2007, J STEROID BIOCHEM, V103, P372, DOI 10.1016/j.jsbmb.2006.12.038; Khulan B, 2006, GENOME RES, V16, P1046, DOI 10.1101/gr.5273806; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lanzuolo C, 2007, CELL MOL LIFE SCI, V64, P1043, DOI 10.1007/s00018-007-6420-8; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Ma YL, 2006, STEM CELLS, V24, P315, DOI 10.1634/stemcells.2005-0046; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Medina M, 2000, GENOMICS, V63, P157, DOI 10.1006/geno.1999.6090; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Rasmussen Theodore P, 2003, Reprod Biol Endocrinol, V1, P100, DOI 10.1186/1477-7827-1-100; Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sabbattini P, 2007, EMBO J, V26, P4657, DOI 10.1038/sj.emboj.7601875; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; van Steensel B, 2005, NAT GENET, V37, pS18, DOI 10.1038/ng1559; Yeakley JM, 2002, NAT BIOTECHNOL, V20, P353, DOI 10.1038/nbt0402-353; Yuan WH, 2007, J BIOL CHEM, V282, P29821, DOI 10.1074/jbc.M705495200	55	45	51	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6792	10.1371/journal.pone.0006792	http://dx.doi.org/10.1371/journal.pone.0006792			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710927	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415600006
J	Prokunina-Olsson, L; Kaplan, LM; Schadt, EE; Collins, FS				Prokunina-Olsson, Ludmila; Kaplan, Lee M.; Schadt, Eric E.; Collins, Francis S.			Alternative Splicing of TCF7L2 Gene in Omental and Subcutaneous Adipose Tissue and Risk of Type 2 Diabetes	PLOS ONE			English	Article								Background: Single nucleotide polymorphisms (SNPs) rs7903146 and rs12255372 located within TCF7L2 gene have been identified as the strongest common genetic risk factors for development of type 2 diabetes (T2D). We hypothesized that these genetic variants might increase the risk of T2D through regulation of alternative splicing or expression level of TCF7L2 in human adipose tissue. Methodology/Principal Findings: Expression of 13 assays detecting alternatively spliced forms of TCF7L2 was measured by quantitative reverse-transcriptase PCR (qRT-PCR) in paired biopsies of omental and subcutaneous adipose tissue from 159 obese individuals (BMI 54.6+/212.2 kg/m(2)). TCF7L2 expression in both types of adipose tissue was not associated with SNPs rs7903146 and rs12255372, T2D status and blood levels of glucose or glycosylated hemoglobin (HbA1c). Expression of assays "ex12-13", "ex12-14" and "ex13-13a" detecting C-terminal alternative exons of TCF7L2 was higher in subcutaneous compared to omental adipose tissue by 1.46 fold (p=6.5x10(-15)), 1.41 fold (p=1.4x10(-9)) and 1.26 fold (p=4.7x10(-6)) in the control group and by 1.86 fold (p=1.7x10(-4)), 1.77 fold (p=7.3x10(-4)) and 1.58 fold (p=6.1x10(-4)) in the T2D group. A pathway enrichment analysis on transcripts significantly co-expressed with TCF7L2 in a microarray set combined with individual expression assays, suggested tissue-specific roles of TCF7L2 splicing forms in regulation of transcription, signal transduction and cell adhesion. Conclusions: Expression of TCF7L2 alternatively spliced forms may have different functional roles in omental and subcutaneous adipose tissue but is not associated with SNPs rs7903146 and rs12255372 or T2D status.			Prokunina-Olsson, L (corresponding author), NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.	prokuninal@mail.nih.gov	Prokunina-Olsson, Ludmila/A-8240-2019; Prokunina-Olsson, Ludmila/V-7960-2019	Prokunina-Olsson, Ludmila/0000-0002-9622-2091; Prokunina-Olsson, Ludmila/0000-0002-9622-2091	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [P30 DK040561, P30 DK040561-14] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cauchi S, 2008, OBESITY, V16, P476, DOI 10.1038/oby.2007.77; Cauchi S, 2006, DIABETES, V55, P3189, DOI 10.2337/db06-0692; Cauchi S, 2006, DIABETES, V55, P2903, DOI 10.2337/db06-0474; Elbein SC, 2007, DIABETOLOGIA, V50, P1621, DOI 10.1007/s00125-007-0717-x; Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153; Florez JC, 2006, NEW ENGL J MED, V355, P241, DOI 10.1056/NEJMoa062418; Graham RR, 2006, NAT GENET, V38, P550, DOI 10.1038/ng1782; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Groves CJ, 2006, DIABETES, V55, P2640, DOI 10.2337/db06-0355; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kovacs P, 2008, METABOLISM, V57, P1227, DOI 10.1016/j.metabol.2008.04.016; Lyssenko V, 2007, J CLIN INVEST, V117, P2155, DOI 10.1172/JCI30706; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miranda PJ, 2005, AM HEART J, V149, P33, DOI 10.1016/j.ahj.2004.07.013; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; OSMARK P, 2009, DIABETOLOGIA; PROKUNINAOLSSON L, 2009, HUM MOL GENET; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Saxena R, 2006, DIABETES, V55, P2890, DOI 10.2337/db06-0381; Scott LJ, 2006, DIABETES, V55, P2649, DOI 10.2337/db06-0341; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; WEGNER L, 2008, J CLIN ENDOCRINOL ME; ZHANG W, 2008, HUM GENET; ZHONG H, 2009, PLOS BIOL IN PRESS	26	32	32	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7231	10.1371/journal.pone.0007231	http://dx.doi.org/10.1371/journal.pone.0007231			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789636	Green Published, gold, Green Submitted			2022-12-27	WOS:000270354100005
J	Wei, W; Huang, J; Hao, YJ; Zou, HF; Wang, HW; Zhao, JY; Liu, XY; Zhang, WK; Ma, B; Zhang, JS; Chen, SY				Wei, Wei; Huang, Jian; Hao, Yu-Jun; Zou, Hong-Feng; Wang, Hui-Wen; Zhao, Jing-Yun; Liu, Xue-Yi; Zhang, Wan-Ke; Ma, Biao; Zhang, Jin-Song; Chen, Shou-Yi			Soybean GmPHD-Type Transcription Regulators Improve Stress Tolerance in Transgenic Arabidopsis Plants	PLOS ONE			English	Article								Background: Soybean [Glycine max ( L.) Merr.] is one of the most important crops for oil and protein resource. Improvement of stress tolerance will be beneficial for soybean seed production. Principal Findings: Six GmPHD genes encoding Alfin1-type PHD finger protein were identified and their expressions differentially responded to drought, salt, cold and ABA treatments. The six GmPHDs were nuclear proteins and showed ability to bind the cis-element "GTGGAG". The N-terminal domain of GmPHD played a major role in DNA binding. Using a protoplast assay system, we find that GmPHD1 to GmPHD5 had transcriptional suppression activity whereas GmPHD6 did not have. In yeast assay, the GmPHD6 can form homodimer and heterodimer with the other GmPHDs except GmPHD2. The N-terminal plus the variable regions but not the PHD-finger is required for the dimerization. Transgenic Arabidopsis plants overexpressing the GmPHD2 showed salt tolerance when compared with the wild type plants. This tolerance was likely achieved by diminishing the oxidative stress through regulation of downstream genes. Significance: These results provide important clues for soybean stress tolerance through manipulation of PHD-type transcription regulator.			Wei, W (corresponding author), Chinese Acad Sci, Plant Gene Res Ctr, Natl Key Lab Plant Genom, Inst Genet & Dev Biol, Beijing, Peoples R China.	jszhang@genetics.ac.cn; sychen@genetics.ac.cn			NIAAA NIH HHS [R01 AA021402] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Abe H, 2003, PLANT CELL, V15, P63, DOI 10.1105/tpc.006130; Anderson M, 2002, DEV GENES EVOL, V212, P107, DOI 10.1007/s00427-002-0213-8; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bastola DR, 1998, PLANT MOL BIOL, V38, P1123, DOI 10.1023/A:1006081926699; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bottomley MJ, 2005, J BIOL CHEM, V280, P11505, DOI 10.1074/jbc.M413959200; Cao WH, 2007, PLANT PHYSIOL, V143, P707, DOI 10.1104/pp.106.094292; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Sanchez MD, 2009, P NATL ACAD SCI USA, V106, P2065, DOI 10.1073/pnas.0811093106; Eulgem T, 2007, PLANT J, V49, P829, DOI 10.1111/j.1365-313X.2006.02999.x; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Gao L, 2008, PLANT MOL BIOL, V67, P125, DOI 10.1007/s11103-008-9306-8; Goto E, 2003, J BIOL CHEM, V278, P14657, DOI 10.1074/jbc.M211285200; Greb T, 2007, CURR BIOL, V17, P73, DOI 10.1016/j.cub.2006.11.052; Halbach T, 2000, NUCLEIC ACIDS RES, V28, P3542, DOI 10.1093/nar/28.18.3542; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; He XJ, 2005, PLANT J, V44, P903, DOI 10.1111/j.1365-313X.2005.02575.x; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Kant P, 2007, PLANT PHYSIOL, V145, P814, DOI 10.1104/pp.107.099895; Kasuga M, 1999, NAT BIOTECHNOL, V17, P287, DOI 10.1038/7036; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lee WY, 2009, PLANT J, V58, P511, DOI 10.1111/j.1365-313X.2009.03795.x; Liao Y, 2008, CELL RES, V18, P1047, DOI 10.1038/cr.2008.280; Liao Y, 2008, PLANTA, V228, P225, DOI 10.1007/s00425-008-0731-3; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MAEHLY AC, 1954, METHOD BIOCHEM ANAL, V1, P357; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Mittler R, 2004, TRENDS PLANT SCI, V9, P490, DOI 10.1016/j.tplants.2004.08.009; Novillo F, 2004, P NATL ACAD SCI USA, V101, P3985, DOI 10.1073/pnas.0303029101; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pineiro M, 2003, PLANT CELL, V15, P1552, DOI 10.1105/tpc.012153; Reddy TV, 2003, DEVELOPMENT, V130, P5975, DOI 10.1242/dev.00827; Saiga S, 2008, DEVELOPMENT, V135, P1751, DOI 10.1242/dev.014993; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sebastian J, 2009, PLANT J, V59, P1, DOI 10.1111/j.1365-313X.2009.03845.x; Seki M, 2003, CURR OPIN BIOTECH, V14, P194, DOI 10.1016/S0958-1669(03)00030-2; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sung SB, 2004, NATURE, V427, P159, DOI 10.1038/nature02195; Sung SB, 2006, GENE DEV, V20, P3244, DOI 10.1101/gad.1493306; Thomas CL, 2009, PLANT J, V59, P426, DOI 10.1111/j.1365-313X.2009.03874.x; Townsley FM, 2004, J BIOL CHEM, V279, P5177, DOI 10.1074/jbc.M309722200; Tripoulas N, 1996, GENETICS, V143, P913; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Wang YJ, 2005, PLANTA, V221, P831, DOI 10.1007/s00425-005-1496-6; Wang YJ, 2003, THEOR APPL GENET, V107, P1402, DOI 10.1007/s00122-003-1378-x; Wilson ZA, 2001, PLANT J, V28, P27, DOI 10.1046/j.1365-313X.2001.01125.x; Winicov I, 2004, PLANTA, V219, P925, DOI 10.1007/s00425-004-1296-4; Winicov I, 1999, PLANT PHYSIOL, V120, P473, DOI 10.1104/pp.120.2.473; Winicov I, 2000, PLANTA, V210, P416, DOI 10.1007/PL00008150; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xie C, 2003, PLANT J, V33, P385, DOI 10.1046/j.1365-313X.2003.01631.x; Yang XH, 2003, PLANT CELL, V15, P1281, DOI 10.1105/tpc.010447; Yochum GS, 2001, MOL CELL BIOL, V21, P4110, DOI 10.1128/MCB.21.13.4110-4118.2001; Zhou QY, 2008, PLANT BIOTECHNOL J, V6, P486, DOI 10.1111/j.1467-7652.2008.00336.x; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329	64	75	88	3	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7209	10.1371/journal.pone.0007209	http://dx.doi.org/10.1371/journal.pone.0007209			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789627	gold, Green Submitted, Green Published			2022-12-27	WOS:000270354100001
J	McGarvey, PB; Huang, HZ; Mazumder, R; Zhang, J; Chen, YX; Zhang, CD; Cammer, S; Will, R; Odle, M; Sobral, B; Moore, M; Wu, CH				McGarvey, Peter B.; Huang, Hongzhan; Mazumder, Raja; Zhang, Jian; Chen, Yongxing; Zhang, Chengdong; Cammer, Stephen; Will, Rebecca; Odle, Margie; Sobral, Bruno; Moore, Margaret; Wu, Cathy H.			Systems Integration of Biodefense Omics Data for Analysis of Pathogen-Host Interactions and Identification of Potential Targets	PLOS ONE			English	Article							MODEL ORGANISM DATABASE; VACCINIA-VIRUS; INTRACELLULAR MATURE; BACILLUS-ANTHRACIS; PROTEIN INTERACTIONS; MEMBRANE-PROTEIN; ENVELOPE PROTEIN; GENE-EXPRESSION; IN-VITRO; PROTEOMICS	The NIAID (National Institute for Allergy and Infectious Diseases) Biodefense Proteomics program aims to identify targets for potential vaccines, therapeutics, and diagnostics for agents of concern in bioterrorism, including bacterial, parasitic, and viral pathogens. The program includes seven Proteomics Research Centers, generating diverse types of pathogen-host data, including mass spectrometry, microarray transcriptional profiles, protein interactions, protein structures and biological reagents. The Biodefense Resource Center (www.proteomicsresource.org) has developed a bioinformatics framework, employing a protein-centric approach to integrate and support mining and analysis of the large and heterogeneous data. Underlying this approach is a data warehouse with comprehensive protein + gene identifier and name mappings and annotations extracted from over 100 molecular databases. Value-added annotations are provided for key proteins from experimental findings using controlled vocabulary. The availability of pathogen and host omics data in an integrated framework allows global analysis of the data and comparisons across different experiments and organisms, as illustrated in several case studies presented here. (1) The identification of a hypothetical protein with differential gene and protein expressions in two host systems (mouse macrophage and human HeLa cells) infected by different bacterial (Bacillus anthracis and Salmonella typhimurium) and viral (orthopox) pathogens suggesting that this protein can be prioritized for additional analysis and functional characterization. (2) The analysis of a vaccinia-human protein interaction network supplemented with protein accumulation levels led to the identification of human Keratin, type II cytoskeletal 4 protein as a potential therapeutic target. (3) Comparison of complete genomes from pathogenic variants coupled with experimental information on complete proteomes allowed the identification and prioritization of ten potential diagnostic targets from Bacillus anthracis. The integrative analysis across data sets from multiple centers can reveal potential functional significance and hidden relationships between pathogen and host proteins, thereby providing a systems approach to basic understanding of pathogenicity and target identification.			McGarvey, PB (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA.	pbm9@georgetown.edu; wuc@georgetown.edu	Crozier, Laura B./A-4821-2010; McGarvey, Peter/AAE-9351-2019; Sobral, Bruno/GVU-7637-2022; Chen, YX/G-3937-2010	Sobral, Bruno/0000-0003-3908-577X; Wu, Cathy/0000-0001-6379-8601; McGarvey, Peter/0000-0002-8312-6017; Mazumder, Raja/0000-0001-8823-9945	NIAID NIH HHS [HHSN266200400061C] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alcami A, 1998, J IMMUNOL, V160, P624; Alexeyenko A, 2009, GENOME RES, V19, P1107, DOI 10.1101/gr.087528.108; *AM ONL, 2003, CALL PERS LIB CPL VE; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bader JS, 2004, NAT BIOTECHNOL, V22, P78, DOI 10.1038/nbt924; Bairoch A, 2008, NUCLEIC ACIDS RES, V36, pD190, DOI 10.1093/nar/gkm895; Bergman NH, 2007, INFECT IMMUN, V75, P3434, DOI 10.1128/IAI.01345-06; Bergman NH, 2006, J BACTERIOL, V188, P6092, DOI 10.1128/JB.00723-06; Bienkowska JR, 2003, PROTEIN ENG, V16, P897, DOI 10.1093/protein/gzg130; Blake JA, 2002, NUCLEIC ACIDS RES, V30, P113, DOI 10.1093/nar/30.1.113; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Brown E, 2006, J VIROL, V80, P9455, DOI 10.1128/JVI.01149-06; Canchaya C, 2004, MOL MICROBIOL, V53, P9, DOI 10.1111/j.1365-2958.2004.04113.x; Chisholm RL, 2006, NUCLEIC ACIDS RES, V34, pD423, DOI 10.1093/nar/gkj090; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Craig R, 2004, J PROTEOME RES, V3, P1234, DOI 10.1021/pr049882h; DALLO S, 1987, VIROLOGY, V159, P423, DOI 10.1016/0042-6822(87)90481-8; Deane CM, 2002, MOL CELL PROTEOMICS, V1, P349, DOI 10.1074/mcp.M100037-MCP200; Deng Minghua, 2003, Pac Symp Biocomput, P140; Deutsch EW, 2008, EMBO REP, V9, P429, DOI 10.1038/embor.2008.56; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; GONG S, 1990, VIROLOGY, V178, P81, DOI 10.1016/0042-6822(90)90381-Z; Grigoriev A, 2001, NUCLEIC ACIDS RES, V29, P3513, DOI 10.1093/nar/29.17.3513; Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hermjakob H, 2006, PROTEOMICS, P34, DOI 10.1002/pmic.200600537; Ho Y, 2005, J MOL BIOL, V349, P1060, DOI 10.1016/j.jmb.2005.04.024; Hood Leroy, 2008, Briefings in Functional Genomics & Proteomics, V7, P239, DOI 10.1093/bfgp/eln027; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; HUANG H, 2004, DATA SCI J, V3, P163; Hutchens MA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000153; Hwang D, 2005, P NATL ACAD SCI USA, V102, P17296, DOI 10.1073/pnas.0508647102; Hwang D, 2005, P NATL ACAD SCI USA, V102, P17302, DOI 10.1073/pnas.0508649102; *INF RETR LTD, 2009, NUCL ACIDS RES DAT I; Jones JM, 2008, CYTOKINE, V43, P220, DOI 10.1016/j.cyto.2008.05.016; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Leinonen R, 2004, BIOINFORMATICS, V20, P3236, DOI 10.1093/bioinformatics/bth191; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Lin CL, 2000, J VIROL, V74, P3353, DOI 10.1128/JVI.74.7.3353-3365.2000; Lu ZY, 2007, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2007, P269; Manes NP, 2008, J PROTEOME RES, V7, P960, DOI 10.1021/pr070432+; Mathew JP, 2007, PLOS COMPUT BIOL, V3, P153, DOI 10.1371/journal.pcbi.0030012; Mazumder R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-279; McCoy SL, 2005, J IMMUNOL, V174, P3006, DOI 10.4049/jimmunol.174.5.3006; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; Nichols RJ, 2008, J VIROL, V82, P10247, DOI 10.1128/JVI.01035-08; Norbeck AD, 2005, J AM SOC MASS SPECTR, V16, P1239, DOI 10.1016/j.jasms.2005.05.009; Orchard S, 2008, BRIEF BIOINFORM, V9, P166, DOI 10.1093/bib/bbm061; Orchard S, 2005, PROTEOMICS, V5, P3552, DOI 10.1002/pmic.200500626; Passalacqua KD, 2007, J BACTERIOL, V189, P3996, DOI 10.1128/JB.00185-07; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P224, DOI 10.1093/nar/gkg076; Rolfs A, 2008, P NATL ACAD SCI USA, V105, P4364, DOI 10.1073/pnas.0712049105; Samen U, 2007, INFECT IMMUN, V75, P5405, DOI 10.1128/IAI.00717-07; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sheeley DM, 2005, J PROTEOME RES, V4, P1114, DOI 10.1021/pr050066z; Spellman PT, 2002, GENOME BIOL, V3; Sprague J, 2006, NUCLEIC ACIDS RES, V34, pD581, DOI 10.1093/nar/gkj086; Suthram S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-360; Suzek BE, 2007, BIOINFORMATICS, V23, P1282, DOI 10.1093/bioinformatics/btm098; Taylor CF, 2007, NAT BIOTECHNOL, V25, P887, DOI 10.1038/nbt1329; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; Vermeer PD, 2007, J VIROL, V81, P9891, DOI 10.1128/JVI.00601-07; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Walsh EJ, 2004, J BIOL CHEM, V279, P50691, DOI 10.1074/jbc.M408713200; Wienkoop S, 2008, MOL CELL PROTEOMICS, V7, P1725, DOI 10.1074/mcp.M700273-MCP200; Wu CH, 2004, COMPUT BIOL CHEM, V28, P87, DOI 10.1016/j.compbiolchem.2003.10.003; Yeung Natalie, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0813s23; Zhang C, 2008, NUCLEIC ACIDS RES, V36, pD884, DOI 10.1093/nar/gkm903	69	16	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7162	10.1371/journal.pone.0007162	http://dx.doi.org/10.1371/journal.pone.0007162			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779614	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200009
J	Mukherjee, J; Webster, N; Llewellyn, LE				Mukherjee, Joydeep; Webster, Nicole; Llewellyn, Lyndon E.			Purification and Characterization of a Collagenolytic Enzyme from a Pathogen of the Great Barrier Reef Sponge, Rhopaloeides odorabile	PLOS ONE			English	Article							NUCLEOTIDE-SEQUENCE; COLLAGENASE; DISEASE; GENE; PROTEASE; CLONING; AGENT	Background: In recent years there has been a global increase in reports of disease affecting marine sponges. While disease outbreaks have the potential to seriously impact on the survival of sponge populations, the ecology of the marine environment and the health of associated invertebrates, our understanding of sponge disease is extremely limited. Methodology/Principal Findings: A collagenolytic enzyme suspected to enhance pathogenicity of bacterial strain NW4327 against the sponge Rhopaloeides odorabile was purified using combinations of size exclusion and anion exchange chromatography. After achieving a 77-fold increase in specific activity, continued purification decreased the yield to 21-fold with 7.2% recovery (specific activity 2575 collagen degrading units mg 21 protein) possibly due to removal of co-factors. SDS-PAGE of the partially pure enzyme showed two proteins weighing approximately 116 and 45 kDa with the heavier band being similar to reported molecular weights of collagenases from Clostridium and marine Vibrios. The enzyme degraded tissue fibres of several sponge genera suggesting that NW4327 could be deleterious to other sponge species. Activity towards casein and bird feather keratin indicates that the partially purified collagenase is either a non-selective protease able to digest collagen or is contaminated with non-specific proteases. Enzyme activity was highest at pH 5 (the internal pH of R. odorabile) and 30 degrees C (the average ambient seawater temperature). Activity under partially anaerobic conditions also supports the role of this enzyme in the degradation of the spongin tissue. Cultivation of NW4327 in the presence of collagen increased production of collagenase by 30%. Enhanced enzyme activity when NW4327 was cultivated in media formulated in sterile natural seawater indicates the presence of other factors that influence enzyme synthesis. Conclusions/Significance: Several aspects of the sponge disease etiology were revealed, particularly the strong correlation with the internal tissue chemistry and environmental temperature. This research provides a platform for further investigations into the virulence mechanisms of sponge pathogens.			Mukherjee, J (corresponding author), Jadavpur Univ, Sch Environm Studies, Kolkata, India.	L.Llewellyn@aims.gov.au	Webster, Nicole S/G-4980-2011; Llewellyn, Lyndon E/F-6030-2011	Webster, Nicole S/0000-0002-4753-5278; Llewellyn, Lyndon E/0000-0003-1680-1796				Bell PJL, 2003, J AM CHEM SOC, V125, P9304, DOI 10.1021/ja035496+; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK TD, 1977, APPL ENVIRON MICROB, V33, P254, DOI 10.1128/AEM.33.2.254-256.1977; Cervino JM, 2006, MAR ECOL PROG SER, V324, P139, DOI 10.3354/meps324139; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; Corriero G., 1996, THALASSIA SALENT, V22, P51; Demina NS, 1996, MICROBIOLOGY+, V65, P661; DOI E, 1981, ANAL BIOCHEM, V118, P173, DOI 10.1016/0003-2697(81)90175-5; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; GAMMILL ER, 2005, DIS THREATENS CARIBB; Heinemann S, 2007, BIOMACROMOLECULES, V8, P3452, DOI 10.1021/bm700574y; Juarez ZE, 1999, INFECT IMMUN, V67, P271, DOI 10.1128/IAI.67.1.271-278.1999; Kang SI, 2005, BIOTECHNOL BIOPROC E, V10, P593, DOI 10.1007/BF02932300; Kim BJ, 1998, J MICROBIOL BIOTECHN, V8, P245; Lough JM, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034634; Martinek N, 2007, J DENT RES, V86, P296, DOI 10.1177/154405910708600402; MATSUSHITA O, 1994, J BACTERIOL, V176, P149, DOI 10.1128/JB.176.1.149-156.1994; MERKEL JR, 1975, APPL MICROBIOL, V29, P145, DOI 10.1128/AEM.29.2.145-151.1975; MERKEL JR, 1978, BIOCHEMISTRY-US, V17, P2857, DOI 10.1021/bi00607a025; Nagano H, 2000, BIOSCI BIOTECH BIOCH, V64, P181, DOI 10.1271/bbb.64.181; Olson JB, 2006, DIS AQUAT ORGAN, V71, P163, DOI 10.3354/dao071163; Petrova DH, 2006, J BASIC MICROB, V46, P275, DOI 10.1002/jobm.200510063; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; TAKEUCHI H, 1992, BIOCHEM J, V281, P703, DOI 10.1042/bj2810703; Webster NS, 2007, ENVIRON MICROBIOL, V9, P1363, DOI 10.1111/j.1462-2920.2007.01303.x; Webster NS, 2002, MAR ECOL PROG SER, V232, P305, DOI 10.3354/meps232305; WEBSTER NS, 2000, THESIS J COOK U TOWN; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	29	23	23	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7177	10.1371/journal.pone.0007177	http://dx.doi.org/10.1371/journal.pone.0007177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777058	Green Submitted, Green Published, gold			2022-12-27	WOS:000270164600013
J	Publio, R; Oliveira, RF; Roque, AC				Publio, Rodrigo; Oliveira, Rodrigo F.; Roque, Antonio C.			A Computational Study on the Role of Gap Junctions and Rod I-h Conductance in the Enhancement of the Dynamic Range of the Retina	PLOS ONE			English	Article								Recent works suggest that one of the roles of gap junctions in sensory systems is to enhance their dynamic range by avoiding early saturation in the first processing stages. In this work, we use a minimal conductance-based model of the ON rod pathways in the vertebrate retina to study the effects of electrical synaptic coupling via gap junctions among rods and among AII amacrine cells on the dynamic range of the retina. The model is also used to study the effects of the maximum conductance of rod hyperpolarization activated current I-h on the dynamic range of the retina, allowing a study of the interrelations between this intrinsic membrane parameter with those two retina connectivity characteristics. Our results show that for realistic values of I-h conductance the dynamic range is enhanced by rod-rod coupling, and that AII-AII coupling is less relevant to dynamic range amplification in comparison with receptor coupling. Furthermore, a plot of the retina output response versus input intensity for the optimal parameter configuration is well fitted by a power law with exponent similar to 0.5. The results are consistent with predictions of more theoretical works and suggest that the earliest expression of gap junctions along the rod pathways, together with appropriate values of rod I-h conductance, has the highest impact on vertebrate retina dynamic range enhancement.			Publio, R (corresponding author), Okinawa Inst Sci & Technol, Computat Neurosci Unit, Okinawa, Japan.	publio@oist.jp	Oliveira, Rodrigo Freire/Q-7155-2018; Roque, Antonio C./C-2316-2011	Oliveira, Rodrigo Freire/0000-0003-0312-1839; Roque, Antonio C./0000-0003-1260-4840; Oliveira, Rodrigo/0000-0002-3414-3339	NIAAA NIH HHS [R01-AA16022, R01 AA016022] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA016022] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAYLOR DA, 1984, J PHYSIOL-LONDON, V354, P203, DOI 10.1113/jphysiol.1984.sp015372; BEGGS JM, 2003, J NEUROSCI, V487, P441; Berntson A, 2004, VISUAL NEUROSCI, V21, P913, DOI 10.1017/S095252380421611X; BOOS R, 1993, J NEUROSCI, V13, P2874; Carnevale T.N., 2006, NEURON BOOK; Copelli M, 2005, NEUROCOMPUTING, V65, P691, DOI 10.1016/j.neucom.2004.10.099; Copelli M, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.060901; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; FOHLMEISTER J, 1997, J NEUROPHYSIOL, V78, P1395; Furtado LS, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.011907; Hennig MH, 2009, J NEUROSCI, V29, P1077, DOI 10.1523/JNEUROSCI.4880-08.2009; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hornstein EP, 2005, J NEUROSCI, V25, P11201, DOI 10.1523/JNEUROSCI.3416-05.2005; Jacoby RA, 2001, VISUAL NEUROSCI, V18, P703, DOI 10.1017/S0952523801185044; JONES G, 1995, J PHYSL, V487, P11167; Kamiyama Y, 1996, VISION RES, V36, P4059, DOI 10.1016/S0042-6989(96)00178-2; KANEKO A, 1989, J PHYSIOL-LONDON, V410, P613, DOI 10.1113/jphysiol.1989.sp017551; Kinouchi O, 2006, NAT PHYS, V2, P348, DOI 10.1038/nphys289; Kitzbichler MG, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000314; Kourennyi DE, 2004, J NEUROPHYSIOL, V92, P477, DOI 10.1152/jn.00606.2003; Lagnado L, 2003, CURR BIOL, V13, pR631, DOI 10.1016/S0960-9822(03)00566-9; Li W, 2004, NAT NEUROSCI, V7, P751, DOI 10.1038/nn1275; Liu XD, 2004, ANN BIOMED ENG, V32, P1428, DOI 10.1114/B:ABME.0000042230.99614.8d; MAO BQ, 2003, VISION RES, V83, P2756; Mukai S, 2002, JPN J PHARMACOL, V89, P44, DOI 10.1254/jjp.89.44; Mulloney B, 2003, J NEUROSCI, V23, P5953; Ogura T, 2003, VISION RES, V43, P2019, DOI 10.1016/S0042-6989(03)00309-2; Petrides A, 2008, J COMP NEUROL, V507, P1653, DOI 10.1002/cne.21617; Publio R, 2006, NEUROCOMPUTING, V69, P1020, DOI 10.1016/j.neucom.2005.12.037; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; RODIECK RW, 1988, COMP PRIMATE BIOL, V41, P203; SHEW WL, 2009, ARXIV09060527; Sikora MA, 2005, J NEUROSCI METH, V145, P47, DOI 10.1016/j.jneumeth.2004.11.023; SMITH RG, 1995, VISUAL NEUROSCI, V12, P851, DOI 10.1017/S095252380000941X; STERLING P, 1988, J NEUROSCI, V8, P623; Stevens SS, 1975, PSYCHOPHYSICS INTRO, pxiv; TESSIERLAVIGNE M, 1988, PROC R SOC SER B-BIO, V234, P171, DOI 10.1098/rspb.1988.0043; Usui S, 1996, VISION RES, V36, P4069, DOI 10.1016/S0042-6989(96)00179-4; Vardi N, 1996, VISION RES, V36, P3743, DOI 10.1016/0042-6989(96)00098-3; Veruki ML, 2009, J NEUROPHYSIOL, V101, P2339, DOI 10.1152/jn.00112.2009; Veruki ML, 2008, J NEUROPHYSIOL, V100, P3305, DOI 10.1152/jn.90957.2008; Volgyi B, 2004, J NEUROSCI, V24, P11182, DOI 10.1523/JNEUROSCI.3096-04.2004; von Gersdorff H, 2001, NEURON, V29, P7, DOI 10.1016/S0896-6273(01)00175-1; YUPING M, 2003, J NEUROPHYSIOL, V90, P3479; Zhang J, 2005, J PHYSIOL-LONDON, V564, P849, DOI 10.1113/jphysiol.2005.082859	48	39	41	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e6970	10.1371/journal.pone.0006970	http://dx.doi.org/10.1371/journal.pone.0006970			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777063	Green Submitted, Green Published, gold			2022-12-27	WOS:000270164600002
J	Wyatt, HDM; Tsang, AR; Lobb, DA; Beattie, TL				Wyatt, Haley D. M.; Tsang, Allison R.; Lobb, Deirdre A.; Beattie, Tara L.			Human Telomerase Reverse Transcriptase (hTERT) Q169 Is Essential for Telomerase Function In Vitro and In Vivo	PLOS ONE			English	Article							REPEAT ADDITION PROCESSIVITY; ACTIVE HUMAN TELOMERASE; N-TERMINAL DOMAIN; TETRAHYMENA TELOMERASE; PRIMER SPECIFICITY; YEAST TELOMERASE; IMMORTAL CELLS; ANCHOR SITE; RNA; DNA	Background: Telomerase is a reverse transcriptase that maintains the telomeres of linear chromosomes and preserves genomic integrity. The core components are a catalytic protein subunit, the telomerase reverse transcriptase (TERT), and an RNA subunit, the telomerase RNA (TR). Telomerase is unique in its ability to catalyze processive DNA synthesis, which is facilitated by telomere-specific DNA-binding domains in TERT called anchor sites. A conserved glutamine residue in the TERT N-terminus is important for anchor site interactions in lower eukaryotes. The significance of this residue in higher eukaryotes, however, has not been investigated. Methodology/Principal Findings: To understand the significance of this residue in higher eukaryotes, we performed site-directed mutagenesis on human TERT (hTERT) Q169 to create neutral (Q169A), conservative (Q169N), and non-conservative (Q169D) mutant proteins. We show that these mutations severely compromise telomerase activity in vitro and in vivo. The functional defects are not due to abrogated interactions with hTR or telomeric ssDNA. However, substitution of hTERT Q169 dramatically impaired the ability of telomerase to incorporate nucleotides at the second position of the template. Furthermore, Q169 mutagenesis altered the relative strength of hTERT-telomeric ssDNA interactions, which identifies Q169 as a novel residue in hTERT required for optimal primer binding. Proteolysis experiments indicate that Q169 substitution alters the protease-sensitivity of the hTERT N-terminus, indicating that a conformational change in this region of hTERT is likely critical for catalytic function. Conclusions/Significance: We provide the first detailed evidence regarding the biochemical and cellular roles of an evolutionarily-conserved Gln residue in higher eukaryotes. Collectively, our results indicate that Q169 is needed to maintain the hTERT N-terminus in a conformation that is necessary for optimal enzyme-primer interactions and nucleotide incorporation. We show that Q169 is critical for the structure and function of human telomerase, thereby identifying a novel residue in hTERT that may be amenable to therapeutic intervention.			Wyatt, HDM (corresponding author), Univ Calgary, So Alberta Canc Res Inst, Calgary, AB, Canada.	tbeattie@ucalgary.ca						Autexier C, 2006, ANNU REV BIOCHEM, V75, P493, DOI 10.1146/annurev.biochem.75.103004.142412; Bailey SM, 2006, NUCLEIC ACIDS RES, V34, P2408, DOI 10.1093/nar/gkl303; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; Cramer P, 2004, CURR OPIN GENET DEV, V14, P218, DOI 10.1016/j.gde.2004.01.003; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Finger SN, 2008, NUCLEIC ACIDS RES, V36, P1260, DOI 10.1093/nar/gkm866; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Friedman KL, 2003, MOL BIOL CELL, V14, P1, DOI 10.1091/mbc.E02-06-0327; GARCIA CK, 2007, NUCL ACIDS RES; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hardy CD, 2001, J BIOL CHEM, V276, P4863, DOI 10.1074/jbc.M005158200; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huard S, 2003, NUCLEIC ACIDS RES, V31, P4059, DOI 10.1093/nar/gkg437; Jacobs SA, 2006, NAT STRUCT MOL BIOL, V13, P218, DOI 10.1038/nsmb1054; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; Lue NF, 2007, NUCLEIC ACIDS RES, V35, P5213, DOI 10.1093/nar/gkm531; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Romi E, 2007, P NATL ACAD SCI USA, V104, P8791, DOI 10.1073/pnas.0703157104; Rouda S, 2007, STRUCTURE, V15, P1403, DOI 10.1016/j.str.2007.09.007; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Theimer CA, 2006, CURR OPIN STRUC BIOL, V16, P307, DOI 10.1016/j.sbi.2006.05.005; Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wyatt HDM, 2007, MOL CELL BIOL, V27, P3226, DOI 10.1128/MCB.02368-06; Zaug AJ, 2008, NAT STRUCT MOL BIOL, V15, P871, DOI 10.1038/nsmb.1462; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	49	23	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7176	10.1371/journal.pone.0007176	http://dx.doi.org/10.1371/journal.pone.0007176			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777057	gold, Green Published, Green Submitted			2022-12-27	WOS:000270164600012
J	Battur, B; Boldbaatar, D; Umemiya-Shirafuji, R; Liao, M; Battsetseg, B; Taylor, D; Baymbaa, B; Fujisaki, K				Battur, Banzragch; Boldbaatar, Damdinsuren; Umemiya-Shirafuji, Rika; Liao, Min; Battsetseg, Badgar; Taylor, Demar; Baymbaa, Badarch; Fujisaki, Kozo			LKR/SDH Plays Important Roles throughout the Tick Life Cycle Including a Long Starvation Period	PLOS ONE			English	Article							LYSINE-KETOGLUTARATE REDUCTASE; AMINOADIPIC SEMIALDEHYDE SYNTHASE; SACCHAROPINE DEHYDROGENASE; PIPECOLIC ACID; CATABOLISM; PURIFICATION; METABOLISM; STRESS; DEGRADATION; GLUTAMATE	Background: Lysine-ketoglutarate reductase/saccharopine dehydrogenase (LKR/SDH) is a bifunctional enzyme catalyzing the first two steps of lysine catabolism in plants and mammals. However, to date, the properties of the lysine degradation pathway and biological functions of LKR/SDH have been very little described in arthropods such as ticks. Methodology/Principal Findings: We isolated and characterized the gene encoding lysine-ketoglutarate reductase (LKR, EC 1.5.1.8) and saccharopine dehydrogenase (SDH, EC 1.5.1.9) from a tick, Haemaphysalis longicornis, cDNA library that encodes a bifunctional polypeptide bearing domains similar to the plant and mammalian LKR/SDH enzymes. Expression of LKR/SDH was detected in all developmental stages, indicating an important role throughout the tick life cycle, including a long period of starvation after detachment from the host. The LKR/SDH mRNA transcripts were more abundant in unfed and starved ticks than in fed and engorged ticks, suggesting that tick LKR/SDH are important for the starved tick. Gene silencing of LKR/SDH by RNAi indicated that the tick LKR/SDH plays an integral role in the osmotic regulation of water balance and development of eggs in ovary of engorged females. Conclusions/Significance: Transcription analysis and gene silencing of LKR/SDH indicated that tick LKR/SDH enzyme plays not only important roles in egg production, reproduction and development of the tick, but also in carbon, nitrogen and water balance, crucial physiological processes for the survival of ticks. This is the first report on the role of LKR/SDH in osmotic regulation in animals including vertebrate and arthropods.			Battur, B (corresponding author), Kagoshima Univ, Fac Agr, Dept Frontier Vet Med, Lab Emerging Infect Dis, Kagoshima 890, Japan.	tick@ms.kagoshima-u.ac.jp	Battsetseg, Badgar/AAA-5498-2021; Umemiya-Shirafuji, Rika/AFT-5139-2022; Banzragch, Battur/ABI-7875-2020	Battsetseg, Badgar/0000-0001-6731-9639; Umemiya-Shirafuji, Rika/0000-0001-7641-5526; Banzragch, Battur/0000-0002-2573-8031; Damdinsuren, Boldbaatar/0000-0002-0541-3766				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMEEN M, 1987, BIOCHEM INT, V14, P589; Anderson JF, 2008, INFECT DIS CLIN N AM, V22, P195, DOI 10.1016/j.idc.2007.12.006; Anger K, 1998, INVERTEBR REPROD DEV, V33, P159, DOI 10.1080/07924259.1998.9652629; Azevedo RA, 2001, AMINO ACIDS, V20, P261, DOI 10.1007/s007260170043; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; BLEMINGS KP, 1994, J NUTR, V124, P1215, DOI 10.1093/jn/124.8.1215; BOOTH T F, 1985, Experimental and Applied Acarology, V1, P165, DOI 10.1007/BF01270595; Cakouros D, 2008, J CELL BIOL, V182, P481, DOI 10.1083/jcb.200712169; Deleu C, 1999, PLANT CELL ENVIRON, V22, P979, DOI 10.1046/j.1365-3040.1999.00471.x; Epelbaum S, 1997, PLANT MOL BIOL, V35, P735, DOI 10.1023/A:1005808923191; FORSBERG NE, 1986, NUTR RES, V6, P191, DOI 10.1016/S0271-5317(86)80122-1; FOSTER AR, 1993, NUTR RES, V13, P1433, DOI 10.1016/S0271-5317(05)80792-4; FUENTE JL, 2007, TREPAR, V622, P1; FUJISAKI K, 1994, PARASITOL TODAY, V10, P31, DOI 10.1016/0169-4758(94)90355-7; FUJISAKI K, 1978, NATL I ANIM HEALTH Q, V18, P27; Galili G, 2001, CURR OPIN PLANT BIOL, V4, P261, DOI 10.1016/S1369-5266(00)00170-9; GALUN R, 1965, SCIENCE, V147, P166, DOI 10.1126/science.147.3654.166; Gaziola SA, 1997, EUR J BIOCHEM, V247, P364, DOI 10.1111/j.1432-1033.1997.00364.x; GIACOBINI E, 1980, CELL MOL BIOL, V26, P135; GoncalvesButruille M, 1996, PLANT PHYSIOL, V110, P765, DOI 10.1104/pp.110.3.765; Haond C, 1999, PHYSIOL BIOCHEM ZOOL, V72, P534, DOI 10.1086/316692; Hatta T, 2006, INT J PARASITOL, V36, P1123, DOI 10.1016/j.ijpara.2006.05.010; HIGASHINO K, 1971, ARCH BIOCHEM BIOPHYS, V142, P606, DOI 10.1016/0003-9861(71)90525-X; HOOGSTRAAL H, 1985, ADV PARASIT, V24, P135, DOI 10.1016/S0065-308X(08)60563-1; HUTZLER J, 1975, BIOCHIM BIOPHYS ACTA, V377, P42, DOI 10.1016/0005-2744(75)90284-3; KARCHI H, 1995, PLANT CELL, V7, P1963, DOI 10.1105/tpc.7.11.1963; KARCHI H, 1994, P NATL ACAD SCI USA, V91, P2577, DOI 10.1073/pnas.91.7.2577; Kemper EL, 1999, PLANT CELL, V11, P1981, DOI 10.1105/tpc.11.10.1981; Lees Kristin, 2007, Invertebrate Neuroscience, V7, P183, DOI 10.1007/s10158-007-0060-4; MARKOVITZ PJ, 1984, J BIOL CHEM, V259, P1643; MARKOVITZ PJ, 1987, J BIOL CHEM, V262, P9353; Mazur B, 1999, SCIENCE, V285, P372, DOI 10.1126/science.285.5426.372; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Moulin M, 2006, PLANT PHYSIOL BIOCH, V44, P474, DOI 10.1016/j.plaphy.2006.08.005; Moulin M, 2000, PLANT PHYSIOL BIOCH, V38, P577, DOI 10.1016/S0981-9428(00)00777-4; NEEDHAM GR, 1991, ANNU REV ENTOMOL, V36, P659, DOI 10.1146/annurev.en.36.010191.003303; NODA C, 1978, BIOCHIM BIOPHYS ACTA, V525, P307, DOI 10.1016/0005-2744(78)90225-5; Papes F, 1999, BIOCHEM J, V344, P555, DOI 10.1042/0264-6021:3440555; Papes F, 2001, FEBS LETT, V488, P34, DOI 10.1016/S0014-5793(00)02401-7; PUTNAM SM, 2007, ENTOMOLYGY INSECT PH, pCH22; RAO VV, 1992, COMP BIOCHEM PHYS B, V103, P221, DOI 10.1016/0305-0491(92)90435-T; Ronnestad I, 1999, AQUACULTURE, V177, P201, DOI 10.1016/S0044-8486(99)00082-4; SHINNO H, 1980, BIOCHIM BIOPHYS ACTA, V633, P310, DOI 10.1016/0304-4165(80)90190-7; SONENSHINE DE, 1991, BIOL TICKS, V1, P189; Stepansky A, 2006, AMINO ACIDS, V30, P121, DOI 10.1007/s00726-005-0246-1; Takagi T, 2003, J NEUROSCI RES, V73, P270, DOI 10.1002/jnr.10656; Takagi T, 2001, NEUROSCI LETT, V310, P97, DOI 10.1016/S0304-3940(01)02059-6; Tang GL, 1997, PLANT CELL, V9, P1305, DOI 10.1105/tpc.9.8.1305; Umemiya R, 2007, INSECT BIOCHEM MOLEC, V37, P975, DOI 10.1016/j.ibmb.2007.05.006; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WINGGLESWORTH VB, 1967, PRINCIPLES INSECTS P; Zhu XH, 2000, BIOCHEM J, V351, P215, DOI 10.1042/0264-6021:3510215	53	9	9	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7136	10.1371/journal.pone.0007136	http://dx.doi.org/10.1371/journal.pone.0007136			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774086	Green Published, Green Submitted, gold			2022-12-27	WOS:000270160900014
J	Castillo-Romero, A; Leon-Avila, G; Rangel, AP; Zarate, RC; Tovar, CG; Hernandez, JM				Castillo-Romero, Araceli; Leon-Avila, Gloria; Perez Rangel, Armando; Cortes Zarate, Rafael; Garcia Tovar, Carlos; Manuel Hernandez, Jose			Participation of Actin on Giardia lamblia Growth and Encystation	PLOS ONE			English	Article								Background: Microfilaments play a determinant role in different cell processes such as: motility, cell division, phagocytosis and intracellular transport; however, these structures are poorly understood in the parasite Giardia lamblia. Methodology and Principal Findings: By confocal microscopy using TRITC-phalloidin, we found structured actin distributed in the entire trophozoite, the label stand out at the ventral disc, median body, flagella and around the nuclei. During Giardia encystation, a sequence of morphological changes concurrent to modifications on the distribution of structured actin and in the expression of actin mRNA were observed. To elucidate whether actin participates actively on growth and encystation, cells were treated with Cytochalasin D, Latrunculin A and Jasplakinolide and analyzed by confocal and scanning electron microscopy. All drugs caused a growth reduction ( 27 to 45%) and changes on the distribution of actin. Besides, 60 to 80% of trophozoites treated with the drugs, exhibited damage at the caudal region, alterations in the flagella and wrinkles-like on the plasma membrane. The drugs also altered the cyst-yield and the morphology, scanning electron microscopy revealed diminished cytokinesis, cysts with damages in the wall and alterations in the size and on the intermembranal space. Furthermore, the drugs caused a significant reduction of the intensity of flourescence-labeled CWP1 on ESV and on cyst wall, this was coincident with a reduction of CWP1 gene expression ( 34%). Conclusions and Significance: All our results, indicated an important role of actin in the morphology, growth and encystation and indirectly suggested an actin role in gene expression.			Castillo-Romero, A (corresponding author), CINVESTAV IPN, Dept Biol Celular, Mexico City, DF, Mexico.	manolo@cell.cinvestav.mx	CASTILLO-ROMERO, ARACELI/AAB-5060-2019; Castillo-Romero, Araceli/AAR-8835-2021	CASTILLO-ROMERO, ARACELI/0000-0002-4461-7673; Castillo-Romero, Araceli/0000-0002-4461-7673				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Belmont LD, 1999, J CELL SCI, V112, P1325; BINGHAM AK, 1979, EXP PARASITOL, V47, P284, DOI 10.1016/0014-4894(79)90080-8; Bollen LS, 1996, J IMMUNOL METHODS, V191, P113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; CLEM TR, 1978, J CLIN MICROBIOL, V7, P55; Cordonnier MN, 2001, MOL BIOL CELL, V12, P4013, DOI 10.1091/mbc.12.12.4013; Correa G, 2006, PARASITOL RES, V98, P250, DOI 10.1007/s00436-005-0065-z; CROSSLEY R, 1983, J CELL SCI, V59, P81; CROSSLEY R, 1983, J CELL SCI, V62, P419; Eichinger D, 2001, CURR OPIN MICROBIOL, V4, P421, DOI 10.1016/S1369-5274(00)00229-0; Elmendorf HG, 2003, INT J PARASITOL, V33, P3, DOI 10.1016/S0020-7519(02)00228-X; FEELY DE, 1982, J PARASITOL, V68, P869, DOI 10.2307/3280996; FEELY DE, 1982, EXP PARASITOL, V53, P145, DOI 10.1016/0014-4894(82)90100-X; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; Gadelha APR, 2007, PARASITOL RES, V101, P1401, DOI 10.1007/s00436-007-0661-1; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; GuerreroBarrera AL, 1996, MICROBIOL-SGM, V142, P1133, DOI 10.1099/13500872-142-5-1133; Hernandez Y, 2007, INT J PARASITOL, V37, P21, DOI 10.1016/j.ijpara.2006.09.008; Hernandez-Gonzalez EO, 2000, CELL MOTIL CYTOSKEL, V46, P43, DOI 10.1002/(SICI)1097-0169(200005)46:1&lt;43::AID-CM5&gt;3.0.CO;2-1; HOLBERTON DV, 1981, J CELL SCI, V47, P139; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; JimenezCardoso E, 1997, REV INVEST CLIN, V49, P123; KATELARIS PH, 1995, GUT, V37, P512, DOI 10.1136/gut.37.4.512; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lazaro-Dieguez F, 2006, CELL MOTIL CYTOSKEL, V63, P778, DOI 10.1002/cm.20161; Lovy-Wheeler A, 2007, CELL MOTIL CYTOSKEL, V64, P217, DOI 10.1002/cm.20181; Lujan HD, 2006, MEDICINA-BUENOS AIRE, V66, P70; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; Lujan HD, 1998, PARASITOL TODAY, V14, P446, DOI 10.1016/S0169-4758(98)01333-7; Makioka A, 2001, EXP PARASITOL, V98, P145, DOI 10.1006/expr.2001.4629; Makioka A, 2001, J PARASITOL, V87, P399, DOI 10.1645/0022-3395(2001)087[0399:EOJOTG]2.0.CO;2; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; NARCISI EM, 1994, J PARASITOL, V80, P468, DOI 10.2307/3283419; Nemeth ZH, 2004, J CELL PHYSIOL, V200, P71, DOI 10.1002/jcp.10477; Ocampo J, 2005, TISSUE CELL, V37, P293, DOI 10.1016/j.tice.2005.03.003; Oda T, 2005, BIOPHYS J, V88, P2727, DOI 10.1529/biophysj.104.047753; Pasten-Hidalgo K, 2008, REPRODUCTION, V136, P41, DOI 10.1530/REP-07-0300; Pogliano J, 2008, CURR OPIN CELL BIOL, V20, P19, DOI 10.1016/j.ceb.2007.12.006; REINER DS, 1990, EUR J CELL BIOL, V53, P142; REINER DS, 1989, INFECT IMMUN, V57, P963, DOI 10.1128/IAI.57.3.963-968.1989; Sousa MC, 2001, CLIN DIAGN LAB IMMUN, V8, P258; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Towbin H, 1992, Biotechnology, V24, P145; VANDEKERCKHOVE J, 1985, EMBO J, V4, P2815, DOI 10.1002/j.1460-2075.1985.tb04008.x; Wakatsuki T, 2001, J CELL SCI, V114, P1025; Witteck A, 2003, EXP CELL RES, V287, P106, DOI 10.1016/S0014-4827(03)00129-0; Wolyniak MJ, 2007, EUKARYOT CELL, V6, P1824, DOI 10.1128/EC.00188-07	53	23	23	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7156	10.1371/journal.pone.0007156	http://dx.doi.org/10.1371/journal.pone.0007156			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774081	Green Published, Green Submitted, gold			2022-12-27	WOS:000270160900021
J	Granada, AE; Herzel, H				Granada, Adrian E.; Herzel, Hanspeter			How to Achieve Fast Entrainment? The Timescale to Synchronization	PLOS ONE			English	Article								Entrainment, where oscillators synchronize to an external signal, is ubiquitous in nature. The transient time leading to entrainment plays a major role in many biological processes. Our goal is to unveil the specific dynamics that leads to fast entrainment. By studying a generic model, we characterize the transient time to entrainment and show how it is governed by two basic properties of an oscillator: the radial relaxation time and the phase velocity distribution around the limit cycle. Those two basic properties are inherent in every oscillator. This concept can be applied to many biological systems to predict the average transient time to entrainment or to infer properties of the underlying oscillator from the observed transients. We found that both a sinusoidal oscillator with fast radial relaxation and a spike-like oscillator with slow radial relaxation give rise to fast entrainment. As an example, we discuss the jet-lag experiments in the mammalian circadian pacemaker.			Granada, AE (corresponding author), Humboldt Univ, Inst Theoret Biol, Berlin, Germany.	a.granada@biologie.hu-berlin.de	Granada, Adrian/AAR-3743-2020	Granada, Adrian/0000-0003-0537-9091				Becker-Weimann S, 2004, BIOPHYS J, V87, P3023, DOI 10.1529/biophysj.104.040824; Bernard S, 2007, PLOS COMPUT BIOL, V3, P667, DOI 10.1371/journal.pcbi.0030068; Best JD, 1999, J NEUROSCI, V19, P828; Brown SA, 2008, P NATL ACAD SCI USA, V105, P1602, DOI 10.1073/pnas.0707772105; Cambras T, 2004, J BIOL RHYTHM, V19, P216, DOI 10.1177/0748730404264201; Campbell SR, 2004, IEEE T NEURAL NETWOR, V15, P1027, DOI 10.1109/TNN.2004.833134; Costa G, 2003, OCCUP MED-OXFORD, V53, P83, DOI 10.1093/occmed/kqg045; DETINKO VN, 1976, I SOVIET PHYS J, V19, P1166; Forger DB, 2003, P NATL ACAD SCI USA, V100, P14806, DOI 10.1073/pnas.2036281100; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Garcia-Ojalvo J, 2004, P NATL ACAD SCI USA, V101, P10955, DOI 10.1073/pnas.0307095101; Glass L., 1988, CLOCKS CHAOS RHYTHMS; GOODWIN BRIAN C., 1965, ADVANCE ENZYME REGULAT, V3, P425, DOI 10.1016/0065-2571(65)90067-1; Greenfield MD, 1997, P ROY SOC B-BIOL SCI, V264, P1355, DOI 10.1098/rspb.1997.0188; GUCKENHEIMER J, 1975, J MATH BIOL, V1, P259, DOI 10.1007/BF01273747; HERZEL H, 1995, CHAOS, V5, P30, DOI 10.1063/1.166078; Herzog ED, 2004, J BIOL RHYTHM, V19, P35, DOI 10.1177/0748730403260776; Honma S, 2004, NEUROSCI LETT, V358, P173, DOI 10.1016/j.neulet.2004.01.022; HOPFIELD JJ, 1995, P NATL ACAD SCI USA, V92, P6655, DOI 10.1073/pnas.92.15.6655; HOPPENSTEADT FC, 1982, J MATH BIOL, V15, P339, DOI 10.1007/BF00275692; Izhikevich E., 2007, DYNAMICAL SYSTEMS NE; Josic K., 2006, SCHOLARPEDIA, V1, P1361, DOI DOI 10.4249/SCHOLARPEDIA.1361; Koronovskii AA, 2004, TECH PHYS LETT+, V30, P253, DOI 10.1134/1.1707184; KUNYSZ A, 1995, AM J PHYSIOL-HEART C, V269, pH1153, DOI 10.1152/ajpheart.1995.269.3.H1153; Laje R, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.258104; Leloup JC, 2003, P NATL ACAD SCI USA, V100, P7051, DOI 10.1073/pnas.1132112100; Liu AC, 2007, CELL, V129, P605, DOI 10.1016/j.cell.2007.02.047; Locke JCW, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-22; McMillen D, 2002, P NATL ACAD SCI USA, V99, P679, DOI 10.1073/pnas.022642299; Millar AJ, 2004, J EXP BOT, V55, P277, DOI 10.1093/jxb/erh034; Nagano M, 2003, J NEUROSCI, V23, P6141; Nakamura W, 2005, J NEUROSCI, V25, P5481, DOI 10.1523/JNEUROSCI.0889-05.2005; Quintero JE, 2003, J NEUROSCI, V23, P8070; Rafnsson V, 2001, CANCER CAUSE CONTROL, V12, P95, DOI 10.1023/A:1008983416836; Rand DA, 2004, J ROY SOC INTERFACE, V1, P119, DOI 10.1098/rsif.2004.0014; Ruoff P, 2001, J THEOR BIOL, V209, P29, DOI 10.1006/jtbi.2000.2239; Schmidt MF, 2003, J NEUROPHYSIOL, V90, P3931, DOI 10.1152/jn.00003.2003; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SOMERS D, 1993, BIOL CYBERN, V68, P393, DOI 10.1007/BF00198772; Timme M, 2006, CHAOS, V16, DOI 10.1063/1.2150775; Vansteensel MJ, 2008, BRAIN RES REV, V58, P18, DOI 10.1016/j.brainresrev.2007.10.009; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Winfree A. T., 1980, GEOMETRY BIOL TIME, DOI 10.1007/978-1-4757-3484-3; Woafo P, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.036225; Xiong XH, 2007, PHYSICA A, V385, P689, DOI 10.1016/j.physa.2007.07.003; Yamaguchi S, 2003, SCIENCE, V302, P1408, DOI 10.1126/science.1089287; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682	49	46	46	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7057	10.1371/journal.pone.0007057	http://dx.doi.org/10.1371/journal.pone.0007057			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774087	Green Published, Green Submitted, gold			2022-12-27	WOS:000270160900004
J	Lee, VJ; Tok, MY; Chow, VT; Phua, KH; Ooi, EE; Tambyah, PA; Chen, MI				Lee, Vernon J.; Tok, Mei Yin; Chow, Vincent T.; Phua, Kai Hong; Ooi, Eng Eong; Tambyah, Paul A.; Chen, Mark I.			Economic Analysis of Pandemic Influenza Vaccination Strategies in Singapore	PLOS ONE			English	Article							CROSS-REACTIVE IMMUNITY; H5N1 VACCINE; UNITED-STATES; SPLIT-VIRION; IMMUNOGENICITY; IMMUNIZATION; VIRUSES; SAFETY	Background: All influenza pandemic plans advocate pandemic vaccination. However, few studies have evaluated the cost-effectiveness of different vaccination strategies. This paper compares the economic outcomes of vaccination compared with treatment with antiviral agents alone, in Singapore. Methodology: We analyzed the economic outcomes of pandemic vaccination (immediate vaccination and vaccine stockpiling) compared with treatment-only in Singapore using a decision-based model to perform cost-benefit and cost-effectiveness analyses. We also explored the annual insurance premium (willingness to pay) depending on the perceived risk of the next pandemic occurring. Principal Findings: The treatment-only strategy resulted in 690 deaths, 13,950 hospitalization days, and economic cost of USD$497 million. For immediate vaccination, at vaccine effectiveness of >55%, vaccination was cost-beneficial over treatment-only. Vaccine stockpiling is not cost-effective in most scenarios even with 100% vaccine effectiveness. The annual insurance premium was highest with immediate vaccination, and was lower with increased duration to the next pandemic. The premium was also higher with higher vaccine effectiveness, attack rates, and case-fatality rates. Stockpiling with case-fatality rates of 0.4-0.6% would be cost-beneficial if vaccine effectiveness was >80%; while at case-fatality of >5% stockpiling would be cost-beneficial even if vaccine effectiveness was 20%. High-risk sub-groups warrant higher premiums than low-risk sub-groups. Conclusions: The actual pandemic vaccine effectiveness and lead time is unknown. Vaccine strategy should be based on perception of severity. Immediate vaccination is most cost-effective, but requires vaccines to be available when required. Vaccine stockpiling as insurance against worst-case scenarios is also cost-effective. Research and development is therefore critical to develop and stockpile cheap, readily available effective vaccines.			Lee, VJ (corresponding author), Natl Univ Singapore, Ctr Hlth Serv Res, Singapore 117548, Singapore.	vernonljm@hotmail.com	Chen, Mark/CAG-2949-2022; Chen, Mark/AGC-5338-2022	Chen, Mark/0000-0001-9369-5830; Chen, Mark/0000-0001-9369-5830; Chow, Vincent/0000-0003-2634-6213; Ooi, Eng Eong/0000-0002-0520-1544				Aoki FY, 2003, J ANTIMICROB CHEMOTH, V51, P123, DOI 10.1093/jac/dkg007; Balicer RD, 2005, EMERG INFECT DIS, V11, P1280; Baras B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001401; Bresson JL, 2006, LANCET, V367, P1657, DOI 10.1016/S0140-6736(06)68656-X; Carter NJ, 2008, BIODRUGS, V22, P279, DOI 10.2165/00063030-200822050-00001; *CDCP, 2009, WKLY EPIDEMIOL REC, V84, P185; Chow VTK, 2008, ANN ACAD MED SINGAP, V37, P451; Collin N, 2009, VACCINE, V27, P5184, DOI 10.1016/j.vaccine.2009.06.034; Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121; El Sahlyt HM, 2008, EXPERT REV VACCINES, V7, P241, DOI 10.1586/14760584.7.2.241; Evans D, 2009, J INFECT DIS, V200, P321, DOI 10.1086/603560; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; HADDIX AC, 2002, GUIDE DECISION ANAL; *INFL TEAM ECDC, 2007, EURO SURVEILL, V12; JAMIESON DJ, 2009, LANCET IN PRESS; Lee VJ, 2006, EMERG INFECT DIS, V12, P95; Leroux-Roels I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001665; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Levie K, 2008, J INFECT DIS, V198, P642, DOI 10.1086/590913; Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5; Lipsitch M, 2009, NEW ENGL J MED, V361, P112, DOI 10.1056/NEJMp0904380; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740; Ng TP, 2002, ANN ACAD MED SINGAP, V31, P182; Palache B, 2008, VACCINE, V26, P6232, DOI 10.1016/j.vaccine.2008.07.022; Riley S, 2007, PLOS MED, V4, P1032, DOI 10.1371/journal.pmed.0040218; *SING DEP STAT, KEY STAT; Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948; Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; Turner David, 2003, HEALTH TECHNOL ASSES, V7, P1, DOI DOI 10.3310/HTA7350; Viboud C, 2004, EMERG INFECT DIS, V10, P32, DOI 10.3201/eid1001.020705	32	18	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7108	10.1371/journal.pone.0007108	http://dx.doi.org/10.1371/journal.pone.0007108			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771173	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400007
J	Dawson, MR; Duda, DG; Chae, SS; Fukumura, D; Jain, RK				Dawson, Michelle R.; Duda, Dan G.; Chae, Sung-Suk; Fukumura, Dai; Jain, Rakesh K.			VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR-1; ANGIOGENESIS; TUMORS; PROGRESSION; ANTIBODY; THERAPY; TARGETS; FLT-1	The role of vascular endothelial growth factor receptor 1 (VEGFR1/Flt1) in tumor metastasis remains incompletely characterized. Recent reports suggested that blocking VEGFR1 activity or the interaction with its ligands (VEGF and PlGF) has anti-tumor effects. Moreover, several studies showed that VEGFR1 mediates tumor progression to distant metastasis. All these effects may be exerted indirectly by recruitment of bone marrow-derived cells (BMDCs), such as myeloid cells. We investigated the role of VEGFR1 activity in BMDCs during the pre-metastatic phase, i.e., prior to metastatic nodule formation in mice after surgical removal of the primary tumor. Using pharmacologic blockade or genetic deletion of the tyrosine kinase domain of VEGFR1, we demonstrate that VEGFR1 activity is not required for the infiltration of de novo myeloid BMDCs in the pre-metastatic lungs in two tumor models and in two mouse models. Moreover, in line with emerging clinical observations, we show that blockade of VEGFR1 activity neither prevents nor changes the rate of spontaneous metastasis formation after primary tumor removal. Prevention of metastasis will require further identification and exploration of cellular and molecular pathways that mediate the priming of the metastatic soil.			Dawson, MR (corresponding author), Georgia Inst Technol, Dept Chem & Biomol Engn, Atlanta, GA 30332 USA.	jain@steele.mgh.harvard.edu	Jain, Rakesh K/I-1384-2017; Dawson, Michelle R/Q-7217-2019; Duda, Dan G/H-8523-2014	Jain, Rakesh K/0000-0001-7571-3548; Dawson, Michelle R/0000-0002-2122-4711; Duda, Dan G/0000-0001-7065-8797	NCI NIH HHS [R01 CA096915, T32 CA073479-09, P01 CA080124-07, R01 CA085140-08, T32 CA073479-08, T32 CA073479, R01 CA115767-02, R01 CA126642, R01 CA115767-03, P01CA80124, R01 CA126642-01A1, P01 CA080124-05, R01 CA126642-02, P01 CA080124, R21-CA139168, R01 CA126642-02S1, P01 CA080124-08, R24 CA085140-05, R01 CA085140, R01 CA115767-04, R01 CA085140-07, P01 CA080124-09, T32 CA073479-11, T32 CA073479-12, R24 CA085140, R01 CA085140-09, R01CA85140, P01 CA080124-06A2, T32 CA073479-10, R01 CA115767-01A1, R01CA126642, R01 CA085140-06, R01CA96915, R01 CA115767, P01 CA080124-05S1, R21 CA139168, R01CA115767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096915, T32CA073479, R24CA085140, R01CA126642, R01CA115767, R01CA085140, P01CA080124, R21CA139168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Duda DG, 2006, BLOOD, V107, P2774, DOI 10.1182/blood-2005-08-3210; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; KAMOUN WS, J CLIN ONCO IN PRESS; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Wolmark N, 2009, J CLIN ONCOL, V27; Wu Y, 2006, CLIN CANCER RES, V12, P6573, DOI 10.1158/1078-0432.CCR-06-0831	25	44	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e6525	10.1371/journal.pone.0006525	http://dx.doi.org/10.1371/journal.pone.0006525			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763275	gold, Green Submitted, Green Published			2022-12-27	WOS:000269970400001
J	Dhar, D; Venkataramana, M; Ponnuswamy, A; Das, S				Dhar, Debojyoti; Venkataramana, Musturi; Ponnuswamy, Anand; Das, Saumitra			Role of Polypyrimidine Tract Binding Protein in Mediating Internal Initiation of Translation of Interferon Regulatory Factor 2 RNA	PLOS ONE			English	Article								Background: Earlier we have reported translational control of interferon regulatory factor 2 (IRF2) by internal initiation (Dhar et al, Nucleic Acids Res, 2007). The results implied possible role of IRF2 in controlling the intricate balance of cellular gene expression under stress conditions in general. Here we have investigated the secondary structure of the Internal Ribosome Entry Site of IRF2 RNA and demonstrated the role of PTB protein in ribosome assembly to facilitate internal initiation. Methodology/Principal Findings: We have probed the putative secondary structure of the IRF2 5'UTR RNA using various enzymatic and chemical modification agents to constrain the secondary structure predicted from RNA folding algorithm Mfold. The IRES activity was found to be influenced by the interaction of trans-acting factor, polypyrimidine tract binding protein (PTB). Deletion of 25 nts from the 3'terminus of the 5'untranslated region resulted in reduced binding with PTB protein and also showed significant decrease in IRES activity compared to the wild type. We have also demonstrated putative contact points of PTB on the IRF2-5'UTR using primer extension inhibition assay. Majority of the PTB toe-prints were found to be restricted to the 3'end of the IRES. Additionally, Circular Dichroism (CD) spectra analysis suggested change in the conformation of the RNA upon PTB binding. Further, binding studies using S10 extract from HeLa cells, partially silenced for PTB gene expression, resulted in reduced binding by other trans-acting factors. Finally, we have demonstrated that addition of recombinant PTB enhances ribosome assembly on IRF2 IRES suggesting possible role of PTB in mediating internal initiation of translation of IRF2 RNA. Conclusion/Significance: It appears that PTB binding to multiple sites within IRF2 5'UTR leads to a conformational change in the RNA that facilitate binding of other trans-acting factors to mediate internal initiation of translation.			Dhar, D (corresponding author), Connexios Life Sci, Bangalore, Karnataka, India.	sdas@mcbl.iisc.ernet.in	Dhar, Debojyoti/AAP-3086-2020					Baird SD, 2007, NUCLEIC ACIDS RES, V35, P4664, DOI 10.1093/nar/gkm483; Cho SC, 2005, MOL CELL BIOL, V25, P1283, DOI 10.1128/MCB.25.4.1283-1297.2005; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Dhar D, 2007, NUCLEIC ACIDS RES, V35, P5409, DOI 10.1093/nar/gkm524; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kolupaeva VG, 1996, RNA, V2, P1199; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Schepens B, 2005, NUCLEIC ACIDS RES, V33, P6884, DOI 10.1093/nar/gki1000; Sella O, 1999, MOL CELL BIOL, V19, P5429; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Venkatramana M, 2003, VIRUS RES, V98, P141, DOI 10.1016/j.virusres.2003.09.004; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	21	4	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7049	10.1371/journal.pone.0007049	http://dx.doi.org/10.1371/journal.pone.0007049			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756143	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970000016
J	Okoli, I; Coleman, JJ; Tempakakis, E; An, WF; Holson, E; Wagner, F; Conery, AL; Larkins-Ford, J; Wu, G; Stern, A; Ausubel, FM; Mylonakis, E				Okoli, Ikechukwu; Coleman, Jeffrey J.; Tempakakis, Emmanouil; An, W. Frank; Holson, Edward; Wagner, Florence; Conery, Annie L.; Larkins-Ford, Jonah; Wu, Gang; Stern, Andy; Ausubel, Frederick M.; Mylonakis, Eleftherios			Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay	PLOS ONE			English	Article							IN-VITRO INTERACTIONS; TACROLIMUS FK506; AMPHOTERICIN-B; CALCINEURIN; AGENTS; RESISTANCE; VIRULENCE; SUSCEPTIBILITY; INFECTIONS; SCREEN	Candida albicans, the most common human pathogenic fungus, can establish a persistent lethal infection in the intestine of the microscopic nematode Caenorhabditis elegans. The C. elegans-C. albicans infection model was previously adapted to screen for antifungal compounds. Modifications to this screen have been made to facilitate a high-throughput assay including co-inoculation of nematodes with C. albicans and instrumentation allowing precise dispensing of worms into assay wells, eliminating two labor-intensive steps. This high-throughput method was utilized to screen a library of 3,228 compounds represented by 1,948 bioactive compounds and 1,280 small molecules derived via diversity-oriented synthesis. Nineteen compounds were identified that conferred an increase in C. elegans survival, including most known antifungal compounds within the chemical library. In addition to seven clinically used antifungal compounds, twelve compounds were identified which are not primarily used as antifungal agents, including three immunosuppressive drugs. This assay also allowed the assessment of the relative minimal inhibitory concentration, the effective concentration in vivo, and the toxicity of the compound in a single assay.			Okoli, I (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.	emylonakis@partners.org	Coleman, Jeffrey J/E-2981-2015	Stern, Andrew/0000-0002-8437-2957; Coleman, Jeffrey/0000-0001-8579-1996; Larkins-Ford, Jonah/0000-0001-9123-9508	NCI NIH HHS [N01-CO-12400, N01CO12400] Funding Source: Medline; NIAID NIH HHS [R01 AI072508, R01 AI075286, T32 AI007061] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561, P30 DK040561-14] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072508, T32AI007061, R01AI075286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akins RA, 2005, MED MYCOL, V43, P285, DOI 10.1080/13693780500138971; ARAI T, 1962, J ANTIBIOT, V15, P231; Artal-Sanz Marto, 2006, Biotechnology Journal, V1, P1405, DOI 10.1002/biot.200600176; BACIGALUPO A, 1983, ACTA HAEMATOL-BASEL, V69, P409, DOI 10.1159/000206930; Bader T, 2003, INFECT IMMUN, V71, P5344, DOI 10.1128/IAI.71.9.5344-5354.2003; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; BEGGS WH, 1985, J ANTIMICROB CHEMOTH, V16, P397, DOI 10.1093/jac/16.3.397; Blankenship JR, 2003, EUKARYOT CELL, V2, P422, DOI 10.1128/EC.2.3.422-430.2003; Breger J, 2007, PLOS PATHOG, V3, P168, DOI 10.1371/journal.ppat.0030018; BRENNER S, 1974, GENETICS, V77, P71; BUCHENAUER H, 1977, NETH J PLANT PATHOL, V83, P93, DOI 10.1007/BF03041424; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; CarriloMunoz AJ, 1996, J ANTIMICROB CHEMOTH, V37, P815, DOI 10.1093/jac/37.4.815; Cho BP, 2003, CHEM RES TOXICOL, V16, P285, DOI 10.1021/tx0256679; COCKRELL RS, 1966, BIOCHEMISTRY-US, V5, P2326, DOI 10.1021/bi00871a022; Cruz MC, 2002, EMBO J, V21, P546, DOI 10.1093/emboj/21.4.546; Dannaoui E, 2009, ANTIMICROB AGENTS CH, V53, P3549, DOI 10.1128/AAC.00184-09; Davis D, 2000, INFECT IMMUN, V68, P5953, DOI 10.1128/IAI.68.10.5953-5959.2000; Della Casa V, 2002, ARZNEIMITTELFORSCH, V52, P699; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Espinel-Ingroff A, 2001, MYCOPATHOLOGIA, V150, P101, DOI 10.1023/A:1010954803886; Fox DS, 2001, MOL MICROBIOL, V39, P835, DOI 10.1046/j.1365-2958.2001.02295.x; Francois IEJA, 2005, CURR DRUG TARGETS, V6, P895, DOI 10.2174/138945005774912744; Garcia-Effron G, 2009, ANTIMICROB AGENTS CH, V53, P112, DOI 10.1128/AAC.01162-08; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; High KP, 1997, J INFECT DIS, V175, P222, DOI 10.1093/infdis/175.1.222; Jones TR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-482; Kaletta T, 2006, NAT REV DRUG DISCOV, V5, P387, DOI 10.1038/nrd2031; KANSAL VK, 1986, TETRAHEDRON, V42, P2389, DOI 10.1016/0040-4020(86)80002-3; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; KINASHI H, 1984, J ANTIBIOT, V37, P1333, DOI 10.7164/antibiotics.37.1333; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; Kohler P, 2001, INT J PARASITOL, V31, P336, DOI 10.1016/S0020-7519(01)00131-X; Kontoyiannis DP, 2008, ANTIMICROB AGENTS CH, V52, P735, DOI 10.1128/AAC.00990-07; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Marchetti O, 2000, ANTIMICROB AGENTS CH, V44, P2373, DOI 10.1128/AAC.44.9.2373-2381.2000; MARKING LL, 1994, PROG FISH CULT, V56, P225, DOI 10.1577/1548-8640(1994)056&lt;0225:AFSEOA&gt;2.3.CO;2; MATSUMURA F, 1971, SCIENCE, V173, P49, DOI 10.1126/science.173.3991.49; Miller LG, 2001, CLIN INFECT DIS, V32, P1110, DOI 10.1086/319613; MOLINA JMH, 1992, MYCOPATHOLOGIA, V118, P15, DOI 10.1007/BF00472565; Moy TI, 2009, ACS CHEM BIOL, V4, P527, DOI 10.1021/cb900084v; Moy TI, 2006, P NATL ACAD SCI USA, V103, P10414, DOI 10.1073/pnas.0604055103; Mylonakis E, 2004, MOL MICROBIOL, V54, P407, DOI 10.1111/j.1365-2958.2004.04310.x; Mylonakis E, 2007, PLOS PATHOG, V3, P859, DOI 10.1371/journal.ppat.0030101; Nielsen TE, 2008, ANGEW CHEM INT EDIT, V47, P48, DOI 10.1002/anie.200703073; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARISER DM, 1994, CUTIS, V54, P43; Park CN, 2008, J MICROBIOL BIOTECHN, V18, P880; Park JI, 2005, J BIOL CHEM, V280, P2529, DOI 10.1074/jbc.M407900200; PETROU MA, 1985, J ANTIMICROB CHEMOTH, V16, P169, DOI 10.1093/jac/16.2.169; PFALLER MA, 1989, DIAGN MICR INFEC DIS, V12, P467, DOI 10.1016/0732-8893(89)90079-5; Reedy JL, 2006, ANTIMICROB AGENTS CH, V50, P1573, DOI 10.1128/AAC.50.4.1573-1577.2006; Rentz AM, 1998, CLIN INFECT DIS, V27, P781, DOI 10.1086/514955; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P40, DOI 10.1128/AAC.39.1.40; ROBA J, 1976, EUR J PHARMACOL, V37, P265, DOI 10.1016/0014-2999(76)90034-0; ROBINSON HJ, 1969, TEX REP BIOL MED, VS 27, P537; Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x; SchaferKorting M, 1996, MYCOSES, V39, P329, DOI 10.1111/j.1439-0507.1996.tb00149.x; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Sifri CD, 2005, TRENDS MICROBIOL, V13, P119, DOI 10.1016/j.tim.2005.01.003; Singh N, 2004, TRANSPLANTATION, V77, P795, DOI 10.1097/01.TP.0000117252.75651.D6; Spanakis EK, 2006, CLIN INFECT DIS, V43, P1060, DOI 10.1086/507891; Steinbach WJ, 2004, ANTIMICROB AGENTS CH, V48, P1664, DOI 10.1128/AAC.48.5.1664-1669.2004; Tampakakis E, 2008, NAT PROTOC, V3, P1925, DOI 10.1038/nprot.2008.193; Tang RJ, 2005, INFECT IMMUN, V73, P8219, DOI 10.1128/IAI.73.12.8219-8225.2005; UPADHYAY MP, 1980, BRIT J OPHTHALMOL, V64, P30, DOI 10.1136/bjo.64.1.30; Watanabe H, 2005, J ANTIBIOT, V58, P753, DOI 10.1038/ja.2005.102; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	68	88	98	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7025	10.1371/journal.pone.0007025	http://dx.doi.org/10.1371/journal.pone.0007025			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750012	gold, Green Published			2022-12-27	WOS:000269796300019
J	Zhang, XQ; Rodriguez, ME; Harvill, ET				Zhang, Xuqing; Rodriguez, Maria Eugenia; Harvill, Eric T.			O Antigen Allows B. parapertussis to Evade B. pertussis Vaccine-Induced Immunity by Blocking Binding and Functions of Cross-Reactive Antibodies	PLOS ONE			English	Article							ENABLES BORDETELLA-PARAPERTUSSIS; LOWER RESPIRATORY-TRACT; GAMMA-INTERFERON; NEUTROPHIL RECRUITMENT; WHOLE-CELL; INFECTIONS; BRONCHISEPTICA; EPIDEMIOLOGY; CLEARANCE; RECEPTOR	Although the prevalence of Bordetella parapertussis varies dramatically among studies in different populations with different vaccination regimens, there is broad agreement that whooping cough vaccines, composed only of B. pertussis antigens, provide little if any protection against B. parapertussis. In C57BL/6 mice, a B. pertussis whole-cell vaccine (wP) provided modest protection against B. parapertussis, which was dependent on IFN-gamma. The wP was much more protective against an isogenic B. parapertussis strain lacking O-antigen than its wild-type counterpart. O-antigen inhibited binding of wP-induced antibodies to B. parapertussis, as well as antibody-mediated opsonophagocytosis in vitro and clearance in vivo. aP-induced antibodies also bound better in vitro to the O-antigen mutant than to wild-type B. parapertussis, but aP failed to confer protection against wild-type or O antigen-deficient B. parapertussis in mice. Interestingly, B. parapertussis-specific antibodies provided in addition to either wP or aP were sufficient to very rapidly reduce B. parapertussis numbers in mouse lungs. This study identifies a mechanism by which one pathogen escapes immunity induced by vaccination against a closely related pathogen and may explain why B. parapertussis prevalence varies substantially between populations with different vaccination strategies.			Zhang, XQ (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.	harvill@psu.edu		Harvill, Eric/0000-0001-8893-2133	NIAID NIH HHS [R01 AI053075-03, R01 AI053075-05, R01 AI053075-04, R01 AI053075-01A1, R01 AI053075-02, R01 AI053075] Funding Source: Medline; NIGMS NIH HHS [R01 GM083113, R01 GM083113-01, R01 GM083113-02, GM083113, R01 GM083113-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083113] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; ARICO B, 1987, J BACTERIOL, V169, P2847, DOI 10.1128/jb.169.6.2847-2853.1987; Burns VC, 2003, INFECT IMMUN, V71, P86, DOI 10.1128/IAI.71.1.86-94.2003; Celentano LP, 2005, PEDIATR INFECT DIS J, V24, P761, DOI 10.1097/01.inf.0000177282.53500.77; CHERRY JD, 1988, PEDIATRICS, V81; David S, 2004, VACCINE, V22, P1892, DOI 10.1016/j.vaccine.2003.11.005; de Melker HE, 2006, J INFECTION, V53, P106, DOI 10.1016/j.jinf.2005.10.020; Diavatopoulos DA, 2005, PLOS PATHOG, V1, P373, DOI 10.1371/journal.ooat.0010045; Ellis TN, 2004, IMMUNOLOGY, V112, P2, DOI 10.1111/j.1365-2567.2004.01849.x; Goebel EM, 2008, INFECT IMMUN, V76, P1774, DOI 10.1128/IAI.01629-07; Gopinathan L, 2007, MICROBES INFECT, V9, P442, DOI 10.1016/j.micinf.2007.01.001; Harvill ET, 2000, INFECT IMMUN, V68, P6720, DOI 10.1128/IAI.68.12.6720-6728.2000; He QS, 1998, JAMA-J AM MED ASSOC, V280, P635, DOI 10.1001/jama.280.7.635; Heininger U, 1999, CLIN INFECT DIS, V28, P602, DOI 10.1086/515154; Hoppe JE, 1999, PEDIATR INFECT DIS J, V18, P375, DOI 10.1097/00006454-199904000-00016; KHELEF N, 1993, INFECT IMMUN, V61, P486, DOI 10.1128/IAI.61.2.486-490.1993; Kirimanjeswara GS, 2005, J CLIN INVEST, V115, P3594, DOI 10.1172/JCI24609; Kirimanjeswara GS, 2003, INFECT IMMUN, V71, P1719, DOI 10.1128/IAI.71.4.1719-1724.2003; Liese JG, 2003, ARCH DIS CHILD, V88, P684, DOI 10.1136/adc.88.8.684; Mahon BP, 1997, J EXP MED, V186, P1843, DOI 10.1084/jem.186.11.1843; MARCHITTO KS, 1987, INFECT IMMUN, V55, P497, DOI 10.1128/IAI.55.3.497-501.1987; Mastrantonio P, 1998, J CLIN MICROBIOL, V36, P999, DOI 10.1128/JCM.36.4.999-1002.1998; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Mills K H, 1998, Dev Biol Stand, V95, P31; Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6; Myc A, 1997, CLIN DIAGN LAB IMMUN, V4, P113, DOI 10.1128/CDLI.4.2.113-116.1997; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; Parent MA, 2006, INFECT IMMUN, V74, P3381, DOI 10.1128/IAI.00185-06; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; Pilione MR, 2006, INFECT IMMUN, V74, P1043, DOI 10.1128/IAI.74.2.1043-1049.2006; Pishko EJ, 2004, EUR J IMMUNOL, V34, P184, DOI 10.1002/eji.200324234; Powell KR, 2006, PEDIATRICS, V117, P965, DOI 10.1542/peds.2005-3038; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; REPP R, 1991, BLOOD, V78, P885, DOI 10.1182/blood.V78.4.885.bloodjournal784885; Rodriguez ME, 2001, J IMMUNOL, V167, P6545, DOI 10.4049/jimmunol.167.11.6545; Rodriguez ME, 2001, J IMMUNOL METHODS, V252, P33, DOI 10.1016/S0022-1759(01)00329-5; STAINER DW, 1970, J GEN MICROBIOL, V63, P211, DOI 10.1099/00221287-63-2-211; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; Sun K, 2007, INFECT IMMUN, V75, P1196, DOI 10.1128/IAI.01403-06; van den Akker WMR, 1998, MICROBIOL-SGM, V144, P1527, DOI 10.1099/00221287-144-6-1527; van den Berg BM, 1999, INFECT IMMUN, V67, P1050, DOI 10.1128/IAI.67.3.1050-1055.1999; VONKOENIG CHW, 1988, J CLIN MICROBIOL, V26, P2558, DOI 10.1128/JCM.26.12.2558-2560.1988; VONKONIG CHW, 1995, LANCET, V346, P1326, DOI 10.1016/S0140-6736(95)92343-8; Watanabe Mineo, 2004, Expert Rev Anti Infect Ther, V2, P447, DOI 10.1586/14787210.2.3.447; Weingart CL, 1999, INFECT IMMUN, V67, P4264, DOI 10.1128/IAI.67.8.4264-4267.1999; Willems RJL, 1998, VACCINE, V16, P410, DOI 10.1016/S0264-410X(97)80919-X; Wolfe DN, 2007, INFECT IMMUN, V75, P4972, DOI 10.1128/IAI.00763-07; Wolfe DN, 2007, INFECT IMMUN, V75, P4416, DOI 10.1128/IAI.00412-07; Wolfe DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004280; Wolfe DN, 2005, INFECT IMMUN, V73, P6508, DOI 10.1128/IAI.73.10.6508-6513.2005; 2002, JAMA, V287, P977	52	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6989	10.1371/journal.pone.0006989	http://dx.doi.org/10.1371/journal.pone.0006989			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750010	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796300011
J	Dutta, C; Rhind, N				Dutta, Chaitali; Rhind, Nicholas			The Role of Specific Checkpoint-Induced S-Phase Transcripts in Resistance to Replicative Stress	PLOS ONE			English	Article								Checkpoint activation during S phase modulates transcription. In response to replication arrest, the fission yeast Cds1 checkpoint kinase maintains the normal S-phase transcriptional program by regulating MBF, the S-phase transcription factor. We show that similar regulation occurs in response to DNA damage during S-phase. We test the relative contributions to replication-stress resistance of transcriptional regulation and the two other major checkpoint functions: cell-cycle arrest and fork stabilization. We show that, although transcriptional regulation provides only modest resistance relative to fork stabilization, it contributes significantly to cell survival. Finally, we investigate the roles of two specific transcripts: mik1 and mrc1. These results demonstrate the general importance of checkpoint regulation of G1/S transcription in response to replicative stress and elucidate the specific roles of Mik1 and Mrc1 in the checkpoint.			Dutta, C (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	nick.rhind@umassmed.edu		Rhind, Nicholas/0000-0003-1758-7736	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069957] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069957, R01 GM069957, R01 GM069957-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Baber-Furnari BA, 2000, MOL BIOL CELL, V11, P1; Baum B, 1997, EMBO J, V16, P4676, DOI 10.1093/emboj/16.15.4676; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; Chu ZQ, 2007, MOL BIOL CELL, V18, P1756, DOI 10.1091/mbc.E06-10-0928; de Bruin RAM, 2008, P NATL ACAD SCI USA, V105, P11230, DOI 10.1073/pnas.0801106105; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dutta C, 2008, MOL CELL BIOL, V28, P5977, DOI 10.1128/MCB.00596-08; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Forsburg SL, 2006, YEAST, V23, P173, DOI 10.1002/yea.1347; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Ng SS, 2001, FEBS LETT, V503, P131, DOI 10.1016/S0014-5793(01)02720-X; Nitani N, 2006, GENETICS, V174, P155, DOI 10.1534/genetics.106.060053; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; RUSTICI G, 2004, NAT GENET; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Watson A, 2004, MOL BIOL CELL, V15, P851, DOI 10.1091/mbc.E03-08-0569; Willis N, 2009, MOL BIOL CELL, V20, P819, DOI 10.1091/mbc.E08-08-0798	27	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6944	10.1371/journal.pone.0006944	http://dx.doi.org/10.1371/journal.pone.0006944			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750219	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696600004
J	Paul-Victor, C; Turnbull, LA				Paul-Victor, Cloe; Turnbull, Lindsay A.			The Effect of Growth Conditions on the Seed Size/Number Trade-Off	PLOS ONE			English	Article								Background: If the amount of resources allocated to reproduction (K) is fixed, then an increase in seed mass (S) can only be achieved by a decrease in seed number (n = K/S). Thus, log(n) = log(K)-log(S) producing a slope of -1 when seed mass and number are plotted on log-log axes. However, in comparative studies, empirical support for a slope of -1 is limited and contentious, leading some to question the utility of this concept. Methodology/Principal Findings: First, we show that the expected slope depends on whether genotypes and species producing seeds of different mass are expected to reach the same adult size and that this in turn depends partly on the nature of growth. Second, we present experimental results using a population of recombinant inbred lines (RILs) of Arabidopsis thaliana. When these RILs are grown in large pots with plentiful nutrients, they exhibit a trade-off between seed size and number with a slope of-1.68 (+/- 0.18) on log-log axes. This occurs because of genetic correlations between seed mass and adult size so that, under the right growth conditions, lines producing lighter seeds have the genetic potential to produce larger rosettes and hence a greater total mass of seeds. We re-grew lines in small pots (10 and 40 mm diameter) in a nutrient-poor substrate so that final adult size was heavily restricted by pot size. Conclusions/Significance: Under our growth conditions, small-seeded lines were unable to produce a greater total mass of seeds. Hence a trade-off emerged between seed mass and seed number with a slope of -1.166 +/- 0.319 on log-log axes in 40-mm diameter pots (close to the expected value of -1), although the slope was 0.132 +/- 0.263 in 10 mm diameter pots, demonstrating that the nature of the trade-off is sensitive to the growth conditions.			Paul-Victor, C (corresponding author), Univ Zurich, Inst Environm Sci, Zurich, Switzerland.	lindsayt@uwinst.uzh.ch	Turnbull, Lindsay A./A-2680-2012	Paul-Victor, Cloe/0000-0001-5413-8046				Alonso-Blanco C, 1999, P NATL ACAD SCI USA, V96, P4710, DOI 10.1073/pnas.96.8.4710; Alonso-Blanco C, 1998, GENETICS, V149, P749; Angert AL, 2007, J ECOL, V95, P321, DOI 10.1111/j.1365-2745.2006.01203.x; Cadotte MW, 2007, P ROY SOC B-BIOL SCI, V274, P2739, DOI 10.1098/rspb.2007.0925; Childs DZ, 2003, P ROY SOC B-BIOL SCI, V270, P1829, DOI 10.1098/rspb.2003.2399; Dalling JW, 2002, J ECOL, V90, P557, DOI 10.1046/j.1365-2745.2002.00695.x; Freckleton RP, 2001, FUNCT ECOL, V15, P615, DOI 10.1046/j.0269-8463.2001.00558.x; Gelman A, DATA ANAL USING REGR; HARPER J. L., 1970, Annual review of ecology and systematics., V1, P327, DOI 10.1146/annurev.es.01.110170.001551; Henery ML, 2001, OIKOS, V92, P479, DOI 10.1034/j.1600-0706.2001.920309.x; Hubbell Stephen P., 2001, V32, pi; Hunt R, 1982, PLANT GROWTH ANAL; Kiflawi M, 2006, OIKOS, V113, P168, DOI 10.1111/j.0030-1299.2001.14378.x; KLINKHAMER PGL, 1990, AM NAT, V135, P291, DOI 10.1086/285045; Koelewijn HP, 2005, J ECOL, V93, P373, DOI 10.1111/j.1365-2745.2004.00940.x; KRANNITZ PG, 1991, AM J BOT, V78, P446, DOI 10.2307/2444967; Levine JM, 2002, AM NAT, V160, P452, DOI 10.1086/342073; Lobin W, 1983, ARABID INF SERV, V20, P119; LORD J, 1995, AM NAT, V146, P349, DOI 10.1086/285804; MADDOX GD, 1983, ECOLOGY, V64, P1092, DOI 10.2307/1937819; Maloof JN, 2003, CURR OPIN GENET DEV, V13, P576, DOI 10.1016/j.gde.2003.10.003; MAZER SJ, 1987, AM NAT, V130, P891, DOI 10.1086/284754; Michaels HJ, 1988, EVOL ECOL, V2, P157, DOI 10.1007/BF02067274; MitchellOlds T, 1996, EVOLUTION, V50, P140, DOI [10.2307/2410788, 10.1111/j.1558-5646.1996.tb04480.x]; Moles AT, 2004, J ECOL, V92, P384, DOI 10.1111/j.0022-0477.2004.00880.x; Moles AT, 2005, SCIENCE, V307, P576, DOI 10.1126/science.1104863; Moles AT, 2006, OIKOS, V113, P91, DOI 10.1111/j.0030-1299.2006.14194.x; Pinheiro J, MIXED EFFECTS MODELS; R Core Team, 2020, R LANG ENV STAT COMP; REDEI GP, 1962, GENETICS, V47, P443; REDEI GP, 1992, HEURISTIC GLANCE ARA, P1; Rees M, 1999, AM NAT, V154, P628, DOI 10.1086/303268; REES M, 1995, J ECOL, V83, P857, DOI 10.2307/2261422; Rees M, 2007, J ECOL, V95, P926, DOI 10.1111/j.1365-2745.2007.01277.x; Schamp BS, 2008, J ECOL, V96, P204, DOI 10.1111/j.1365-2745.2007.01328.x; Shimizu KK, 2005, PLANT PHYSIOL, V138, P578, DOI 10.1104/pp.105.061655; SILVERTOWN JW, 1983, AM NAT, V121, P448, DOI 10.1086/284074; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Somerville C, 2002, NAT REV GENET, V3, P883, DOI 10.1038/nrg927; Susko DJ, 2008, BOTANY, V86, P259, DOI 10.1139/B07-137; Turnbull LA, 2008, ECOL LETT, V11, P1037, DOI 10.1111/j.1461-0248.2008.01214.x; Turnbull LA, 2008, ECOLOGY, V89, P1352, DOI 10.1890/07-1531.1; Turnbull LA, 2006, BIOL LETT-UK, V2, P397, DOI 10.1098/rsbl.2006.0476; VENABLE DL, 1992, AM NAT, V140, P287, DOI 10.1086/285413; WEINER J, 1985, ECOLOGY, V66, P743, DOI 10.2307/1940535; Weiner J, 1997, J ECOL, V85, P133, DOI 10.2307/2960645; Weiner J., 1988, PLANT POPULATION ECO, P59; WINN AA, 1988, ECOLOGY, V69, P1537, DOI 10.2307/1941651	48	44	46	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6917	10.1371/journal.pone.0006917	http://dx.doi.org/10.1371/journal.pone.0006917			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746162	Green Submitted, Green Published, gold			2022-12-27	WOS:000269696500001
J	Tiemann, L; Reidt, JH; Esposito, L; Sander, D; Theiss, W; Poppert, H				Tiemann, Laura; Reidt, Jutta Hubertina; Esposito, Lorena; Sander, Dirk; Theiss, Wolfram; Poppert, Holger			Neuropsychological Sequelae of Carotid Angioplasty with Stent Placement: Correlation with Ischemic Lesions in Diffusion Weighted Imaging	PLOS ONE			English	Article							CEREBRAL-ISCHEMIA; CARDIOPULMONARY BYPASS; TRANSCRANIAL DOPPLER; BRAIN-LESIONS; ARTERY; ENDARTERECTOMY; EVENTS; MR; MICROEMBOLI; PERFORMANCE	Background and Purpose: Few studies investigated the neuropsychological outcome after carotid angioplasty with stent placement (CAS), yielding partially inconsistent results. The present investigation evaluated the effect of CAS in patients with high-grade stenosis and assessed the predictive value of ischemic lesion number for postinterventional cognitive deterioration. Methods: 22 patients were tested neuropsychologically before and six weeks after CAS. Cerebral ischemic changes were assessed with diffusion weighted imaging (DWI) prior to and after angioplasty. Results: Pre- to postinterventional cognitive performance improved significantly in terms of verbal memory (t=-2.30; p<0.05), whereas significant deterioration was noted regarding verbal memory span (t=2.31; p<0.05). 8 (36%) persons conformed to the criteria of cognitive improvement. 6 patients (27%) were postinterventionally classified as having deficits. Analysis yielded no statistically significant correlations between lesion quantity and cognitive change. Conclusion: Both improvement and deterioration of cognitive functioning was observed in our collective of patients, leaving the neuropsychological outcome after percutaneous transluminal angioplasty unpredictable in individual cases. The presence of acute ischemic lesions on DWI was found to be not tightly associated with cognitive dysfunction after CAS.			Tiemann, L (corresponding author), Tech Univ Munich, Neurol Klin & Poliklin, Munich, Germany.	tiemann@lrz.tu-muenchen.de		Poppert, Holger/0000-0003-2189-7681; Tiemann, Laura/0000-0002-5261-5459				Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Aschenbrenner S., 2000, REGENSBURGER WORTFLU; Bakker FC, 2000, J NEUROL, V247, P669, DOI 10.1007/s004150070108; Barber PA, 2008, STROKE, V39, P1427, DOI 10.1161/STROKEAHA.107.502989; Barrett Kevin M, 2007, Curr Atheroscler Rep, V9, P333, DOI 10.1007/s11883-007-0041-4; Bendszus M, 1999, LANCET, V354, P1594, DOI 10.1016/S0140-6736(99)07083-X; BENKE T, 1991, ACTA NEUROL SCAND, V83, P378, DOI 10.1111/j.1600-0404.1991.tb03967.x; Crawley F, 1997, STROKE, V28, P2460, DOI 10.1161/01.STR.28.12.2460; Crawley F, 2000, STROKE, V31, P1329, DOI 10.1161/01.STR.31.6.1329; El-Koussy M, 2007, J ENDOVASC THER, V14, P293, DOI 10.1583/06-1990.1; GAUNT ME, 1994, BRIT J SURG, V81, P1435, DOI 10.1002/bjs.1800811009; Greenstein AJ, 2007, J VASC SURG, V46, P1138, DOI 10.1016/j.jvs.2007.08.026; HAMSTER W, 1984, EUR ARCH PSY CLIN N, V234, P69, DOI 10.1007/BF00432886; Hauth EAM, 2005, AM J NEURORADIOL, V26, P2336; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Heyer EJ, 2006, NEUROSURGERY, V58, P474, DOI 10.1227/01.NEU.0000197123.09972.EA; Karaarslan E, 2008, EUR J RADIOL, V65, P402, DOI 10.1016/j.ejrad.2007.04.023; Kastrup A, 2006, STROKE, V37, P2312, DOI 10.1161/01.STR.0000236492.86303.85; KELLY MP, 1980, ARCH NEUROL-CHICAGO, V37, P743, DOI 10.1001/archneur.1980.00500610023002; Kishikawa K, 2003, J NEUROL SCI, V213, P19, DOI 10.1016/S0022-510X(03)00128-X; LEHRL S, 1995, MANUAL ZUM MWT B; Lehrner J, 2005, J CLIN EXP NEUROPSYC, V27, P859, DOI 10.1080/13803390490919083; Louwerse K, 1999, ST HEAL T, V68, P311; Lovblad KO, 1997, ANN NEUROL, V42, P164; Mathias K D, 1999, Adv Surg, V32, P225; Mlekusch W, 2008, CATHETER CARDIO INTE, V71, P114, DOI 10.1002/ccd.21407; Naugle R I, 1986, Arch Clin Neuropsychol, V1, P25, DOI 10.1016/0887-6177(86)90023-5; NEWMAN SP, 2000, BRAIN CARDIAC SURG C, P22; OSWALD WD, 1978, NURNBERGER ALTERSINV; OSWALD WD, 1999, NURNBERGER ALTERSINV; Pelz DM, 2000, CAN MED ASSOC J, V162, P1451; Pinero P, 2006, AM J NEURORADIOL, V27, P1338; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; REITH W, 1995, NEUROLOGY, V45, P172, DOI 10.1212/WNL.45.1.172; Rosenkranz M, 2006, AM J NEURORADIOL, V27, P157; Sader Mark A, 2002, Heart Lung Circ, V11, P95, DOI 10.1046/j.1444-2892.2002.00127.x; Switzer Jeffrey A, 2007, Curr Treat Options Neurol, V9, P451, DOI 10.1007/s11940-007-0046-x; Tedesco MM, 2007, J VASC SURG, V46, P244, DOI 10.1016/j.jvs.2007.04.049; Tewes U, 1991, HDB TESTANWEISUNG; Touze E, 2008, CURR OPIN NEUROL, V21, P56, DOI 10.1097/WCO.0b013e3282f313d2; Turk AS, 2008, AM J NEURORADIOL, V29, P265, DOI 10.3174/ajnr.A0828; van Everdingen KJ, 1998, STROKE, V29, P1783, DOI 10.1161/01.STR.29.9.1783; van Heesewijk HPM, 2002, RADIOLOGY, V224, P361, DOI 10.1148/radiol.2242011302; Witt K, 2007, J NEUROL, V254, P1524, DOI 10.1007/s00415-007-0576-x; Wolf O, 2004, EUR J VASC ENDOVASC, V27, P167, DOI 10.1016/j.ejvs.2003.11.002; Xu GL, 2007, NEUROL RES, V29, P251, DOI 10.1179/016164107X159216	46	20	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e7001	10.1371/journal.pone.0007001	http://dx.doi.org/10.1371/journal.pone.0007001			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746158	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696500011
J	Xie, ZM; Zou, HF; Lei, G; Wei, W; Zhou, QY; Niu, CF; Liao, Y; Tian, AG; Ma, B; Zhang, WK; Zhang, JS; Chen, SY				Xie, Zong-Ming; Zou, Hong-Feng; Lei, Gang; Wei, Wei; Zhou, Qi-Yun; Niu, Can-Fang; Liao, Yong; Tian, Ai-Guo; Ma, Biao; Zhang, Wan-Ke; Zhang, Jin-Song; Chen, Shou-Yi			Soybean Trihelix Transcription Factors GmGT-2A and GmGT-2B Improve Plant Tolerance to Abiotic Stresses in Transgenic Arabidopsis	PLOS ONE			English	Article								Background: Trihelix transcription factors play important roles in light-regulated responses and other developmental processes. However, their functions in abiotic stress response are largely unclear. In this study, we identified two trihelix transcription factor genes GmGT-2A and GmGT-2B from soybean and further characterized their roles in abiotic stress tolerance. Findings: Both genes can be induced by various abiotic stresses, and the encoded proteins were localized in nuclear region. In yeast assay, GmGT-2B but not GmGT-2A exhibits ability of transcriptional activation and dimerization. The N-terminal peptide of 153 residues in GmGT-2B was the minimal activation domain and the middle region between the two trihelices mediated the dimerization of the GmGT-2B. Transactivation activity of the GmGT-2B was also confirmed in plant cells. DNA binding analysis using yeast one-hybrid assay revealed that GmGT-2A could bind to GT-1bx, GT-2bx, mGT-2bx-2 and D1 whereas GmGT-2B could bind to the latter three elements. Overexpression of the GmGT-2A and GmGT-2B improved plant tolerance to salt, freezing and drought stress in transgenic Arabidopsis plants. Moreover, GmGT-2B-transgenic plants had more green seedlings compared to Col-0 under ABA treatment. Many stress-responsive genes were altered in GmGT-2A-and GmGT-2B-transgenic plants. Conclusion: These results indicate that GmGT-2A and GmGT-2B confer stress tolerance through regulation of a common set of genes and specific sets of genes. GmGT-2B also affects ABA sensitivity.			Xie, ZM (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Plant Gene Res Ctr, Natl Key Lab Plant Genom, Beijing, Peoples R China.	jszhang@genetics.ac.cn; sychen@genetics.ac.cn	Tian, AG/E-8177-2010	Tian, Aiguo/0000-0001-5011-6034	NIAAA NIH HHS [R01 AA021402] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA021402] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abe H, 2003, PLANT CELL, V15, P63, DOI 10.1105/tpc.006130; Almeida AM, 2005, EUPHYTICA, V146, P165, DOI 10.1007/s10681-005-7080-0; Arondel V, 2000, PLANT SCI, V157, P1, DOI 10.1016/S0168-9452(00)00232-6; Ayadi M, 2004, FEBS LETT, V562, P147, DOI 10.1016/S0014-5793(04)00222-4; Boxall SF, 2005, PLANT PHYSIOL, V137, P969, DOI 10.1104/pp.104.054577; Brewer PB, 2004, DEVELOPMENT, V131, P4035, DOI 10.1242/dev.01279; Buchel AS, 1996, PLANT MOL BIOL, V30, P493, DOI 10.1007/BF00049327; Chen YH, 2006, PLANT MOL BIOL, V60, P107, DOI 10.1007/s11103-005-2910-y; Cuevas JC, 2008, PLANT PHYSIOL, V148, P1094, DOI 10.1104/pp.108.122945; Davletova S, 2005, PLANT PHYSIOL, V139, P847, DOI 10.1104/pp.105.068254; DEHESH K, 1990, SCIENCE, V250, P1397, DOI 10.1126/science.2255908; FLUHR R, 1986, SCIENCE, V232, P1106, DOI 10.1126/science.232.4754.1106; Gao MJ, 2009, PLANT CELL, V21, P54, DOI 10.1105/tpc.108.061309; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; Gong ZZ, 2001, PLANT PHYSIOL, V126, P363, DOI 10.1104/pp.126.1.363; GREEN PJ, 1987, EMBO J, V6, P2543, DOI 10.1002/j.1460-2075.1987.tb02542.x; He XJ, 2005, PLANT J, V44, P903, DOI 10.1111/j.1365-313X.2005.02575.x; HIRATSUKA K, 1994, PLANT CELL, V6, P1805, DOI 10.1105/tpc.6.12.1805; Hu HH, 2006, P NATL ACAD SCI USA, V103, P12987, DOI 10.1073/pnas.0604882103; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Jin HL, 1999, PLANT MOL BIOL, V41, P577, DOI 10.1023/A:1006319732410; Kaliff M, 2007, MOL PLANT MICROBE IN, V20, P335, DOI 10.1094/MPMI-20-4-0335; Kamei A, 2005, PLANT CELL ENVIRON, V28, P1267, DOI 10.1111/j.1365-3040.2005.01363.x; Kim S, 2004, PLANT PHYSIOL, V136, P3639, DOI 10.1104/pp.104.049189; KUHN RM, 1993, PLANT MOL BIOL, V23, P337, DOI 10.1007/BF00029009; LAWTON MA, 1991, PLANT MOL BIOL, V16, P235, DOI 10.1007/BF00020555; Le Gourrierec J, 1999, PLANT J, V18, P663, DOI 10.1046/j.1365-313x.1999.00482.x; Le Gourrierec J., 2002, GENOME LETT, V1, P77; Leshem Y, 2006, P NATL ACAD SCI USA, V103, P18008, DOI 10.1073/pnas.0604421103; Liao Y, 2008, CELL RES, V18, P1047, DOI 10.1038/cr.2008.280; Liao Y, 2008, PLANTA, V228, P225, DOI 10.1007/s00425-008-0731-3; Lin ZW, 2007, PLANTA, V226, P11, DOI 10.1007/s00425-006-0460-4; Liu JX, 2007, PLANT J, V51, P897, DOI 10.1111/j.1365-313X.2007.03195.x; Llorente F, 2002, PLANT J, V32, P13, DOI 10.1046/j.1365-313X.2002.01398.x; McCarty DR, 2000, CELL, V103, P201, DOI 10.1016/S0092-8674(00)00113-6; Mittler R, 2006, FEBS LETT, V580, P6537, DOI 10.1016/j.febslet.2006.11.002; MIZOGUCHI T, 1995, FEBS LETT, V358, P199, DOI 10.1016/0014-5793(94)01423-X; Nagano Y, 2001, J BIOL CHEM, V276, P22238, DOI 10.1074/jbc.M102474200; Nakashima K, 2006, PHYSIOL PLANTARUM, V126, P62, DOI 10.1111/j.1399-3054.2005.00592.x; Ni M, 1996, PLANT CELL, V8, P1041, DOI 10.1105/tpc.8.6.1041; Nylander M, 2001, PLANT MOL BIOL, V45, P263, DOI 10.1023/A:1006469128280; O'Grady K, 2001, PLANT MOL BIOL, V47, P367, DOI 10.1023/A:1011629307051; Park HC, 2004, PLANT PHYSIOL, V135, P2150, DOI 10.1104/pp.104.041442; PERISIC O, 1992, PLANT CELL, V4, P831, DOI 10.1105/tpc.4.7.831; Priest DM, 2006, PLANT J, V46, P492, DOI 10.1111/j.1365-313X.2006.02701.x; Riano-Pachon DM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-42; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Sakamoto H, 2004, PLANT PHYSIOL, V136, P2734, DOI 10.1104/pp.104.046599; Sakuma Y, 2006, PLANT CELL, V18, P1292, DOI 10.1105/tpc.105.035881; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; Singh KB, 2002, CURR OPIN PLANT BIOL, V5, P430, DOI 10.1016/S1369-5266(02)00289-3; Song CP, 2005, PLANT CELL, V17, P2384, DOI 10.1105/tpc.105.033043; Tan BC, 2003, PLANT J, V35, P44, DOI 10.1046/j.1365-313X.2003.01786.x; Tian AG, 2004, THEOR APPL GENET, V108, P903, DOI 10.1007/s00122-003-1499-2; Umezawa T, 2006, PLANT J, V46, P171, DOI 10.1111/j.1365-313X.2006.02683.X; VILLAIN P, 1994, J BIOL CHEM, V269, P16626; Vogel JT, 2005, PLANT J, V41, P195, DOI 10.1111/j.1365-313X.2004.02288.x; Wang HW, 2007, PLANT J, V52, P716, DOI 10.1111/j.1365-313X.2007.03268.x; Yanagisawa S, 2004, PLANT CELL PHYSIOL, V45, P386, DOI 10.1093/pcp/pch055; Yang CY, 2005, PLANT PHYSIOL, V139, P836, DOI 10.1104/pp.105.065458; Zhang JS, 1999, THEOR APPL GENET, V99, P1006, DOI 10.1007/s001220051408; Zhou DX, 1999, TRENDS PLANT SCI, V4, P210, DOI 10.1016/S1360-1385(99)01418-1; ZHOU DX, 1992, J BIOL CHEM, V267, P23515; Zhou QY, 2008, PLANT BIOTECHNOL J, V6, P486, DOI 10.1111/j.1467-7652.2008.00336.x	65	78	106	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6898	10.1371/journal.pone.0006898	http://dx.doi.org/10.1371/journal.pone.0006898			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730734	Green Submitted, gold, Green Published			2022-12-27	WOS:000269622100004
J	Gur-Wahnon, D; Borovsky, Z; Liebergall, M; Rachmilewitz, J				Gur-Wahnon, Devorah; Borovsky, Zipora; Liebergall, Meir; Rachmilewitz, Jacob			The Induction of APC with a Distinct Tolerogenic Phenotype via Contact-Dependent STAT3 Activation	PLOS ONE			English	Article								Background: Activation of the signal transducer and activator of transcription 3 (STAT3) within antigen presenting cells (APCs) is linked to abnormal APCs differentiation and function. We have previously shown that STAT3 is activated within APC by a novel contact-dependent mechanism, which plays a key role in mediating the immunomodulatory effects of hMSC. In order to better understand the underlying mechanisms that control APC maturation in a contact dependent manner, we extended our observation to tumor cells. Tumors were shown to secrete a variety of tumor-derived factors that activate STAT3 within infiltrating APCs. We now tested whether tumor cells can activate STAT3 within APC using the contact-dependent mechanism, in addition to soluble factors, and compared these two STAT3 activating pathways. Principal Findings: We demonstrate that in addition to tumor-derived secreted factors tumor cells activate STAT3 by a mechanism that is based on cell-cell interaction. We further demonstrate that these two STAT3 activating mechanisms differ in their JAK usage and their susceptibility to JSI-124 inhibition thereby representing two distinct pathways. Significantly, although both pathways activate STAT3, they modulate DCs maturation in a different manner that results in disparate phenotypic outcomes. Whereas the soluble-dependent pathway results in an immature phenotype, the contact-dependent pathway results in an apparently mature phenotype. Albeit their mature-like phenotype these latter cells express the tolerogenic markers ILT3 and ILT4 and possess T cell inhibitory activity. Significance: This data suggests that, in at least certain cellular microenvironments, cell: cell interactions represent a novel way to activate STAT3 signaling, uncouple APC activation events and consequently regulate immunity and tolerance. Significantly, we have now demonstrated that this contact-dependent signaling pathway differs from that mediated by soluble factors and cytokines, inducing disparate phenotypic outcome, suggesting these two mechanisms have different and possibly complementary biological functions.			Gur-Wahnon, D (corresponding author), Hadassah Hebrew Univ, Med Ctr, Goldyne Savad Inst Gene Therapy, Jerusalem, Israel.	rjacob@cc.huji.ac.il						Adler HS, 2007, EUR J DERMATOL, V17, P476; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gur-Wahnon D, 2007, EXP HEMATOL, V35, P426, DOI 10.1016/j.exphem.2006.11.001; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Nefedova Y, 2005, J IMMUNOL, V175, P4338, DOI 10.4049/jimmunol.175.7.4338; Nefedova Y, 2007, CURR CANCER DRUG TAR, V7, P71, DOI 10.2174/156800907780006887; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712; Sato K, 2002, CELL IMMUNOL, V215, P186, DOI 10.1016/S0008-8749(02)00021-7; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Svajger U, 2008, INT IMMUNOPHARMACOL, V8, P997, DOI 10.1016/j.intimp.2008.03.006; Verbovetski I, 2002, J EXP MED, V196, P1553, DOI 10.1084/jem.20020263; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Willimsky G, 2008, J EXP MED, V205, P1687, DOI 10.1084/jem.20072016; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhang B, 2009, BLOOD, V113, P46, DOI 10.1182/blood-2008-04-154138; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	27	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6846	10.1371/journal.pone.0006846	http://dx.doi.org/10.1371/journal.pone.0006846			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718269	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900018
J	Loyola, RD; Oliveira-Santos, LGR; Almeida-Neto, M; Nogueira, DM; Kubota, U; Diniz, JAF; Lewinsohn, TM				Loyola, Rafael Dias; Rodrigues Oliveira-Santos, Luiz Gustavo; Almeida-Neto, Mario; Nogueira, Denise Martins; Kubota, Umberto; Felizola Diniz-Filho, Jose Alexandre; Lewinsohn, Thomas Michael			Integrating Economic Costs and Biological Traits into Global Conservation Priorities for Carnivores	PLOS ONE			English	Article							EXTINCTION RISK; BIODIVERSITY CONSERVATION; ECOREGIONS; POPULATION; BENEFITS; MODELS; AREAS	Background: Prioritization schemes usually highlight species-rich areas, where many species are at imminent risk of extinction. To be ecologically relevant these schemes should also include species biological traits into area-setting methods. Furthermore, in a world of limited funds for conservation, conservation action is constrained by land acquisition costs. Hence, including economic costs into conservation priorities can substantially improve their conservation cost-effectiveness. Methodology/Principal Findings: We examined four global conservation scenarios for carnivores based on the joint mapping of economic costs and species biological traits. These scenarios identify the most cost-effective priority sets of ecoregions, indicating best investment opportunities for safeguarding every carnivore species, and also establish priority sets that can maximize species representation in areas harboring highly vulnerable species. We compared these results with a scenario that minimizes the total number of ecoregions required for conserving all species, irrespective of other factors. We found that cost-effective conservation investments should focus on 41 ecoregions highlighted in the scenario that consider simultaneously both ecoregion vulnerability and economic costs of land acquisition. Ecoregions included in priority sets under these criteria should yield best returns of investments since they harbor species with high extinction risk and have lower mean land cost. Conclusions/Significance: Our study highlights ecoregions of particular importance for the conservation of the world's carnivores defining global conservation priorities in analyses that encompass socioeconomic and life-history factors. We consider the identification of a comprehensive priority-set of areas as a first step towards an in-situ biodiversity maintenance strategy.			Loyola, RD (corresponding author), Univ Fed Goias, Inst Ciencias Biol, Dept Ecol, Goiania, Go, Brazil.	avispa@gmail.com	Loyola, Rafael/A-4425-2008; Loyola, Rafael/S-3978-2019; Diniz-Filho, José Alexandre Felizola/D-9405-2013; Oliveira-Santos, Luiz Gustavo Rodrigues/F-9562-2012; Almeida-Neto, M./A-6389-2009; Lewinsohn, Thomas M/D-5880-2012	Loyola, Rafael/0000-0001-5323-2735; Loyola, Rafael/0000-0001-5323-2735; Diniz-Filho, José Alexandre Felizola/0000-0002-0967-9684; Oliveira-Santos, Luiz Gustavo Rodrigues/0000-0001-9632-5173; Almeida-Neto, M./0000-0002-2161-2968; Lewinsohn, Thomas M/0000-0001-5950-5343				ANDELMAN S, 1999, SITES V 1 0 AN TOOLB; Balmford A, 2003, P NATL ACAD SCI USA, V100, P1046, DOI 10.1073/pnas.0236945100; Becker CG, 2008, BIODIVERS CONSERV, V17, P2297, DOI 10.1007/s10531-007-9298-8; Bode M, 2008, P NATL ACAD SCI USA, V105, P6498, DOI 10.1073/pnas.0710705105; Boyd C, 2008, CONSERV LETT, V1, P37, DOI 10.1111/j.1755-263X.2008.00002.x; Brooks TM, 2006, SCIENCE, V313, P58, DOI 10.1126/science.1127609; BURGESS DN, 2004, TERRESTRIAL ECOREGIO; Carbone C, 2002, SCIENCE, V295, P2273, DOI 10.1126/science.1067994; Cardillo M, 2005, SCIENCE, V309, P1239, DOI 10.1126/science.1116030; Cardillo M, 2006, P NATL ACAD SCI USA, V103, P4157, DOI 10.1073/pnas.0510541103; Cardillo M, 2004, PLOS BIOL, V2, P909, DOI 10.1371/journal.pbio.0020197; Center for International Earth Science Information Network (CIESIN) Columbia University Centro Internacional de Agricultura Tropical (CIAT), 2005, GRIDD POP WORLD GPW; Cowling RM, 2003, BIOL CONSERV, V112, P191, DOI 10.1016/S0006-3207(02)00425-1; Das A, 2006, BIOL CONSERV, V133, P16, DOI 10.1016/j.biocon.2006.05.023; Davis FW, 2006, ECOL SOC, V11; Dinerstein E., 1995, CONSERVATION ASSESSM; Dirzo R., 1991, PLANT ANIMAL INTERAC, P273; Galvan DV, 2008, ANIM CONSERV, V11, P215, DOI 10.1111/j.1469-1795.2008.00171.x; GITTLEMAN JL, 1993, SYM ZOOL S, P65; Gittleman JL, 2001, CONSERV BIOL SER, V5, P1; *INT MON FUND, 2004, INT FIN STAT; Lamoreux JF, 2006, NATURE, V440, P212, DOI 10.1038/nature04291; Laurance WF, 2002, CONSERV BIOL, V16, P605, DOI 10.1046/j.1523-1739.2002.01025.x; LAURANCE WF, 2006, EMERGING THREATS TRO; Loyola RD, 2008, DIVERS DISTRIB, V14, P949, DOI 10.1111/j.1472-4642.2008.00508.x; Loyola RD, 2007, DIVERS DISTRIB, V13, P389, DOI 10.1111/j.1472-4642.2007.00345.x; Loyola RD, 2009, BIODIVERS CONSERV, V18, P2017, DOI 10.1007/s10531-008-9570-6; Loyola RD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002120; Margules CR, 2007, ECOL BIODIVERS CONS, P1; Margules CR, 2000, NATURE, V405, P243, DOI 10.1038/35012251; Mittermeier RA, 2003, P NATL ACAD SCI USA, V100, P10309, DOI 10.1073/pnas.1732458100; Mittermeier Russell A., 2004, P1; Naidoo R, 2006, TRENDS ECOL EVOL, V21, P681, DOI 10.1016/j.tree.2006.10.003; Urbina-Cardona JN, 2008, TROP CONSERV SCI, V1, P417, DOI 10.1177/194008290800100408; Olson DM, 2001, BIOSCIENCE, V51, P933, DOI 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2; Olson DM, 2002, ANN MO BOT GARD, V89, P199, DOI 10.2307/3298564; Possingham Hugh, 2000, P291, DOI 10.1007/0-387-22648-6_17; Pressey RL, 1997, BIOL CONSERV, V80, P207, DOI 10.1016/S0006-3207(96)00045-6; Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234; Rondinini C, 2005, CONSERV BIOL, V19, P1488, DOI 10.1111/j.1523-1739.2005.00204.x; Rondinini C, 2007, CONSERV BIOL, V21, P1455, DOI 10.1111/j.1523-1739.2007.00834.x; Smith RJ, 2006, ORYX, V40, P400, DOI 10.1017/S0030605306001232; Soutullo A, 2008, DIVERS DISTRIB, V14, P604, DOI 10.1111/j.1472-4642.2007.00445.x; Stattersfield A.J., 1998, ENDEMIC BIRD AREAS W, V115, P1089, DOI 10.2307/4089533; Underwood EC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001515; Valenzuela-Galvan D, 2008, BIODIVERS CONSERV, V17, P539, DOI 10.1007/s10531-007-9269-0; Wilson D.E., 1993, TAXONOMIC GEOGRAPHIC, V2nd ed.; *WWF, 2006, WILFINDER ONL DAT SP	48	41	43	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6807	10.1371/journal.pone.0006807	http://dx.doi.org/10.1371/journal.pone.0006807			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710911	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415600019
J	Morris, TJ; Vickers, M; Gluckman, P; Gilmour, S; Affara, N				Morris, Tiffany J.; Vickers, Mark; Gluckman, Peter; Gilmour, Stewart; Affara, Nabeel			Transcriptional Profiling of Rats Subjected to Gestational Undernourishment: Implications for the Developmental Variations in Metabolic Traits	PLOS ONE			English	Article								A link has been established between prenatal nutrition and the development of metabolic and cardiovascular diseases later in life, a process referred to as developmental programming. It has been suggested that the trajectory of development is shifted by alterations in the maternal nutritional state leading to changes in developmental plasticity, in part underpinned by epigenetic changes in gene regulation. However, to date, only candidate gene approaches have been used to assess expression and molecular changes in the offspring of maternally undernourished animals. Furthermore, most work has focused on animals at an age where the programmed phenotype is already manifest and little is known about changes in gene expression in the offspring prior to development of obesity and related metabolic disorders. Gene expression profiles of liver, retroperitoneal white adipose fat, and biceps femoris skeletal muscle tissue from young adult male rats (55 days old) in which nutritional status had been manipulated in utero by maternal undernutrition ( UN) were compared to the profiles of offspring of ad libitum fed mothers serving as the control group (AD) (8 offspring/group). The expression profiles were determined using the Illumina RatRef-12 BeadChip. No significant changes in expression were identified for skeletal muscle or white adipose tissue. However, studies of liver tissue showed 249 differentially expressed genes (143 up regulated, 106 down regulated). Although the animals at day 55 have yet to develop obesity they already show biochemical abnormalities and by day 110 express a phenotype characterized by increased adiposity and altered insulin sensitivity. An analysis of pathways affected suggests that intrauterine programming of UN animals to favor fat as an energy source results in mitochondrial dysfunction which initially affects the postnatal hepatic function and subsequently, via the resultant metabolic changes in other organs leads to the evolution of a phenotype similar to that of the metabolic syndrome.			Morris, TJ (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	tjm42@cam.ac.uk		Vickers, Mark/0000-0003-4876-9356				Barker D J, 2001, Med Health Care Philos, V4, P31, DOI 10.1023/A:1009934412988; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Bateson P, 2001, INT J EPIDEMIOL, V30, P928, DOI 10.1093/ije/30.5.928; BEGINHEICK N, 1994, AM J PHYSIOL, V266, pC1664, DOI 10.1152/ajpcell.1994.266.6.C1664; Bertram C, 2001, ENDOCRINOLOGY, V142, P2841, DOI 10.1210/en.142.7.2841; Bertram CE, 2002, REPRODUCTION, V124, P459, DOI 10.1530/rep.0.1240459; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burcelin R, 2004, J BIOL CHEM, V279, P1108, DOI 10.1074/jbc.M307788200; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; Dahlman I, 2005, DIABETES, V54, P3032, DOI 10.2337/diabetes.54.10.3032; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Drake AJ, 2007, CLIN SCI, V113, P219, DOI 10.1042/CS20070107; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Eisenhaber F, 2001, TRENDS BIOCHEM SCI, V26, P345, DOI 10.1016/S0968-0004(01)01851-5; Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347; Gerecke DR, 2004, MATRIX BIOL, V22, P593, DOI 10.1016/j.matbio.2003.11.004; Gluckman PD, 2005, BIOL NEONATE, V87, P127, DOI 10.1159/000082311; Gluckman PD, 2005, P ROY SOC B-BIOL SCI, V272, P671, DOI 10.1098/rspb.2004.3001; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Gluckman PD, 2007, P NATL ACAD SCI USA, V104, P12796, DOI 10.1073/pnas.0705667104; Gluckman PD, 2005, MATERN CHILD NUTR, V1, P130, DOI 10.1111/j.1740-8709.2005.00020.x; GRANNER D, 1990, J BIOL CHEM, V265, P10173; Gummesson A, 2007, J CLIN ENDOCR METAB, V92, P4759, DOI 10.1210/jc.2007-1136; Haj FG, 2005, J BIOL CHEM, V280, P15038, DOI 10.1074/jbc.M413240200; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Iwahashi H, 2002, DIABETES, V51, P910, DOI 10.2337/diabetes.51.4.910; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; Kmiec Z, 2001, Adv Anat Embryol Cell Biol, V161, pIII; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; KUNOS G, 1987, BIOCHEM PHARMACOL, V36, P1185, DOI 10.1016/0006-2952(87)90068-2; Kurz T, 2005, NATURE, V435, P1257, DOI 10.1038/nature03662; Lam NT, 2006, J MOL ENDOCRINOL, V36, P163, DOI 10.1677/jme.1.01937; Lepreux S, 2004, J HEPATOL, V40, P774, DOI 10.1016/j.jhep.2004.01.008; Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382; Lin SM, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1075; Lisinski I, 2006, BIOCHEM BIOPH RES CO, V344, P1179, DOI 10.1016/j.bbrc.2006.04.017; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; MILANI S, 1994, HEPATOLOGY, V20, P908, DOI 10.1002/hep.1840200420; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Min KW, 2005, BIOCHEM BIOPH RES CO, V334, P867, DOI 10.1016/j.bbrc.2005.06.188; Ozanne SE, 2006, DIABETOLOGIA, V49, P2993, DOI 10.1007/s00125-006-0466-2; Ozanne SE, 2003, J ENDOCRINOL, V177, P235, DOI 10.1677/joe.0.1770235; Ozanne Susan E, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402005240; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Stanhill A, 2006, MOL CELL, V23, P875, DOI 10.1016/j.molcel.2006.07.023; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; Uchio K, 2002, LAB INVEST, V82, P619, DOI 10.1038/labinvest.3780456; Vickers MH, 2008, ENDOCRINOLOGY, V149, P1906, DOI 10.1210/en.2007-0981; Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Vickers MH, 2003, AM J PHYSIOL-REG I, V285, pR271, DOI 10.1152/ajpregu.00051.2003; Wheatcroft SB, 2007, DIABETES, V56, P285, DOI 10.2337/db06-0436; Woodall SM, 1996, J ENDOCRINOL, V150, P231, DOI 10.1677/joe.0.1500231; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225; Ziouzenkova O, 2008, FEBS LETT, V582, P32, DOI 10.1016/j.febslet.2007.11.081	62	31	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7271	10.1371/journal.pone.0007271	http://dx.doi.org/10.1371/journal.pone.0007271			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787071	Green Published, Green Accepted, gold, Green Submitted			2022-12-27	WOS:000270290100030
J	Sontag, CA; Sage, H; Erickson, HP				Sontag, Christopher A.; Sage, Harvey; Erickson, Harold P.			BtubA-BtubB Heterodimer Is an Essential Intermediate in Protofilament Assembly	PLOS ONE			English	Article							TUBULIN; ASSAY; FTSZ	Background: BtubA and BtubB are two tubulin-like genes found in the bacterium Prosthecobacter. Our work and a previous crystal structure suggest that BtubB corresponds to alpha-tubulin and BtubA to beta-tubulin. A 1: 1 mixture of the two proteins assembles into tubulin-like protofilaments, which further aggregate into pairs and bundles. The proteins also form a BtubA/B heterodimer, which appears to be a repeating subunit in the protofilament. Methodology/Principal Findings: We have designed point mutations to disrupt the longitudinal interfaces bonding subunits into protofilaments. The mutants are in two classes, within dimers and between dimers. We have characterized one mutant of each class for BtubA and BtubB. When mixed 1: 1 with a wild type partner, none of the mutants were capable of assembly. An excess of between-dimer mutants could depolymerize preformed wild type polymers, while within-dimer mutants had no activity. Conclusions: An essential first step in assembly of BtubA + BtubB is formation of a heterodimer. An excess of between-dimer mutants depolymerize wild type BtubA/B by sequestering the partner wild type subunit into inactive dimers. Within-dimer mutants cannot form dimers and have no activity.			Sontag, CA (corresponding author), Indiana Univ, Med Sci Program, Bloomington, IN 47405 USA.	h.erickson@cellbio.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066014, R01-GM66014] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caplow M, 2002, MOL BIOL CELL, V13, P2120, DOI 10.1091/mbc.E01-10-0089; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Ingerman E, 2005, METHOD ENZYMOL, V404, P611, DOI 10.1016/S0076-6879(05)04053-X; Jackson AP, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-261; Jenkins C, 2002, P NATL ACAD SCI USA, V99, P17049, DOI 10.1073/pnas.012516899; Laue T.M., 1992, COMPUTER AIDED INTER; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Pilhofer M, 2007, MOL BIOL EVOL, V24, P1439, DOI 10.1093/molbev/msm069; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; SCHLIEPER D, 2005, P NATL ACAD SCI US; Sontag CA, 2005, J CELL BIOL, V169, P233, DOI 10.1083/jcb.200410027; VanBuren V, 2002, P NATL ACAD SCI USA, V99, P6035, DOI 10.1073/pnas.092504999	16	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7253	10.1371/journal.pone.0007253	http://dx.doi.org/10.1371/journal.pone.0007253			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787042	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290100024
J	Gonzalez, S; Flo, M; Margenat, M; Duran, R; Gonzalez-Sapienza, G; Grana, M; Parkinson, J; Maizels, RM; Salinas, G; Alvarez, B; Fernandez, C				Gonzalez, Silvia; Flo, Martin; Margenat, Mariana; Duran, Rosario; Gonzalez-Sapienza, Gualberto; Grana, Martin; Parkinson, John; Maizels, Rick M.; Salinas, Gustavo; Alvarez, Beatriz; Fernandez, Cecilia			A Family of Diverse Kunitz Inhibitors from Echinococcus granulosus Potentially Involved in Host-Parasite Cross-Talk	PLOS ONE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; TISSUE FACTOR; ALPHA-DENDROTOXIN; CRYSTAL-STRUCTURE; BOVINE TRYPSIN; SLOW-BINDING; EVOLUTIONARY; CHYMOTRYPSIN; SITE; GENOME	The cestode Echinococcus granulosus, the agent of hydatidosis/echinococcosis, is remarkably well adapted to its definitive host. However, the molecular mechanisms underlying the successful establishment of larval worms (protoscoleces) in the dog duodenum are unknown. With the aim of identifying molecules participating in the E. granulosus-dog cross-talk, we surveyed the transcriptomes of protoscoleces and protoscoleces treated with pepsin at pH 2. This analysis identified a multigene family of secreted monodomain Kunitz proteins associated mostly with pepsin/H+-treated worms, suggesting that they play a role at the onset of infection. We present the relevant molecular features of eight members of the E. granulosus Kunitz family (EgKU-1 - EgKU-8). Although diverse, the family includes three pairs of close paralogs (EgKU-1/EgKU-4; EgKU-3/EgKU-8; EgKU-6/EgKU-7), which would be the products of recent gene duplications. In addition, we describe the purification of EgKU-1 and EgKU-8 from larval worms, and provide data indicating that some members of the family (notably, EgKU-3 and EgKU-8) are secreted by protoscoleces. Detailed kinetic studies with native EgKU-1 and EgKU-8 highlighted their functional diversity. Like most monodomain Kunitz proteins, EgKU-8 behaved as a slow, tight-binding inhibitor of serine proteases, with global inhibition constants (K-I*) versus trypsins in the picomolar range. In sharp contrast, EgKU-1 did not inhibit any of the assayed peptidases. Interestingly, molecular modeling revealed structural elements associated with activity in Kunitz cation-channel blockers. We propose that this family of inhibitors has the potential to act at the E. granulosus-dog interface and interfere with host physiological processes at the initial stages of infection.			Gonzalez, S (corresponding author), Univ Republica, Catedra Inmunol, Fac Quim, Montevideo, Uruguay.	cfernan@fq.edu.uy	Grana, Martin/R-7245-2019; Durán, Rosario/GQH-8502-2022; Parkinson, John/A-4424-2008	Grana, Martin/0000-0003-1182-8236; Parkinson, John/0000-0001-9815-1189; Alvarez, Beatriz/0000-0001-6911-3132; Salinas, Gustavo/0000-0003-3350-3002; Duran, Rosario/0000-0002-8575-9651; Gonzalez-Sapienza, Gualberto/0000-0003-1824-0611				Aguilar-Diaz H, 2006, PARASITOL INT, V55, pS127, DOI 10.1016/j.parint.2005.11.020; Andreev YA, 2008, J BIOL CHEM, V283, P23914, DOI 10.1074/jbc.M800776200; ARNOUX B, 1995, J MOL BIOL, V246, P609, DOI 10.1006/jmbi.1994.0112; Ascenzi P, 2003, CURR PROTEIN PEPT SC, V4, P231, DOI 10.2174/1389203033487180; Bairoch A, 2009, NUCLEIC ACIDS RES, V37, pD169, DOI 10.1093/nar/gkn664; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bayrhuber M, 2005, J BIOL CHEM, V280, P23766, DOI 10.1074/jbc.C500064200; BELL G, 1987, NATURE, V328, P66, DOI 10.1038/328066a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BROZE GJ, 1987, BLOOD, V69, P150; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Chand HS, 2004, J BIOL CHEM, V279, P17500, DOI 10.1074/jbc.M400802200; Chen CP, 2001, J BIOL CHEM, V276, P45079, DOI 10.1074/jbc.M106182200; Craig PS, 2006, ADV PARASIT, V61, P443, DOI 10.1016/S0065-308X(05)61011-1; Fernandez C, 2002, MOL BIOCHEM PARASIT, V122, P171, DOI 10.1016/S0166-6851(02)00098-1; Fry BG, 2005, GENOME RES, V15, P403, DOI 10.1101/gr.3228405; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; GRECO WR, 1979, J BIOL CHEM, V254, P2104; Harvey AL, 2004, CURR MED CHEM, V11, P3065, DOI 10.2174/0929867043363820; Harvey AL, 2001, TOXICON, V39, P15, DOI 10.1016/S0041-0101(00)00162-8; Hawdon JM, 2003, J PARASITOL, V89, P402, DOI 10.1645/0022-3395(2003)089[0402:MCOANM]2.0.CO;2; Heath D. D., 1995, P183; Heath D. D., 1986, The biology of Echinococcusand hydatid disease, P164; Helland R, 1998, EUR J BIOCHEM, V256, P317, DOI 10.1046/j.1432-1327.1998.2560317.x; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; Kamei S, 1999, THROMB RES, V94, P147, DOI 10.1016/S0049-3848(98)00205-9; Katoh E, 2000, BIOPOLYMERS, V54, P44, DOI 10.1002/(SICI)1097-0282(200007)54:1<44::AID-BIP50>3.0.CO;2-Z; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; Kooyman FNJ, 2009, MOL BIOCHEM PARASIT, V163, P85, DOI 10.1016/j.molbiopara.2008.09.012; Kordis D, 2000, GENE, V261, P43, DOI 10.1016/S0378-1119(00)00490-X; Krowarsch D, 2005, PROTEIN PEPTIDE LETT, V12, P403, DOI 10.2174/0929866054395275; Krowarsch D, 1999, J MOL BIOL, V289, P175, DOI 10.1006/jmbi.1999.2757; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MOSES E, 1983, J MOL BIOL, V170, P765, DOI 10.1016/S0022-2836(83)80130-2; OHLSSON K, 1973, BIOCHIM BIOPHYS ACTA, V317, P328, DOI 10.1016/0005-2795(73)90228-6; Olivera BM, 2006, J BIOL CHEM, V281, P31173, DOI 10.1074/jbc.R600020200; Outzen H, 1996, COMP BIOCHEM PHYS B, V115, P33, DOI 10.1016/0305-0491(96)00081-8; Parkinson J, 2004, BIOINFORMATICS, V20, P1398, DOI 10.1093/bioinformatics/bth101; Parkinson J, 2004, NUCLEIC ACIDS RES, V32, pD427, DOI 10.1093/nar/gkh018; Parkinson J, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-31; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; Rawlings ND, 2008, NUCLEIC ACIDS RES, V36, pD320, DOI 10.1093/nar/gkm954; Robb SMC, 2008, NUCLEIC ACIDS RES, V36, pD599, DOI 10.1093/nar/Gkm684; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; SMALAS AO, 1994, PROTEINS, V20, P149, DOI 10.1002/prot.340200205; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; Smyth J.D., 1989, PHYSL BIOCH CESTODES; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Thompson R. C. A., 1995, P1; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; VINCENT JP, 1973, EUR J BIOCHEM, V38, P365, DOI 10.1111/j.1432-1033.1973.tb03069.x; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; Waritani T, 2001, VET IMMUNOL IMMUNOP, V80, P333, DOI 10.1016/S0165-2427(01)00293-8; Watanabe J, 2007, NUCLEIC ACIDS RES, V35, pD431, DOI 10.1093/nar/gkl1039; Williams J W, 1979, Methods Enzymol, V63, P437; Woodard SL, 2003, BIOTECHNOL APPL BIOC, V38, P123, DOI 10.1042/BA20030026; WU FC, 1955, J BIOL CHEM, V213, P609; Yuan CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003414; Zang XX, 2001, TRENDS BIOCHEM SCI, V26, P191, DOI 10.1016/S0968-0004(00)01761-8	73	32	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7009	10.1371/journal.pone.0007009	http://dx.doi.org/10.1371/journal.pone.0007009			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759914	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970200001
J	Rivas-Caicedo, A; Soldevila, G; Fortoul, TI; Castell-Rodriguez, A; Flores-Romo, L; Garcia-Zepeda, EA				Rivas-Caicedo, Ana; Soldevila, Gloria; Fortoul, Teresa I.; Castell-Rodriguez, Andres; Flores-Romo, Leopoldo; Garcia-Zepeda, Eduardo A.			Jak3 Is Involved in Dendritic Cell Maturation and CCR7-Dependent Migration	PLOS ONE			English	Article								Background: CCR7-mediated signalling is important for dendritic cell maturation and homing to the lymph nodes. We have previously demonstrated that Jak3 participates in the signalling pathway of CCR7 in T lymphocytes. Methodology and Principal Findings: Here, we used Jak3(-/-) mice to analyze the role of Jak3 in CCR7-mediated dendritic cells migration and function. First, we found no differences in the generation of DCs from Jak3(-/-) bone marrow progenitors, when compared to wild type cells. However, phenotypic analysis of the bone marrow derived DCs obtained from Jak3(-/-) mice showed reduced expression of co-stimulatory molecules compared to wild type (Jak3(+/+)). In addition, when we analyzed the migration of Jak3(-/-) and Jak3(+/+) mature DCs in response to CCL19 and CCL21 chemokines, we found that the absence of Jak3 results in impaired chemotactic responses both in vitro and in vivo. Moreover, lymphocyte proliferation and contact hypersensitivity experiments showed that DC-mediated T lymphocyte activation is reduced in the absence of Jak3. Conclusion/Significance: Altogether, our data provide strong evidence that Jak3 is important for DC maturation, migration and function, through a CCR7-mediated signalling pathway.			Rivas-Caicedo, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Mexico City 04510, DF, Mexico.	garciaze@servidor.unam.mx	Fortoul, Teresa I./AAW-3936-2020	Fortoul, Teresa I./0000-0002-3507-1365; Castell-Rodriguez, Andres/0000-0003-2881-2759; Soldevila, Gloria/0000-0003-1539-2548				Andrews DM, 2001, NAT IMMUNOL, V2, P1077, DOI 10.1038/ni724; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Cappello P, 2006, J IMMUNOL, V177, P6143, DOI 10.4049/jimmunol.177.9.6143; Cera MR, 2004, J CLIN INVEST, V114, P729, DOI 10.1172/JCI200421231; DELPRETE A, 2006, BLOOD; Garcia-Zepeda EA, 2007, IMMUNOLOGY, V122, P247, DOI 10.1111/j.1365-2567.2007.02634.x; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Grayson MH, 2007, J IMMUNOL, V179, P1438, DOI 10.4049/jimmunol.179.3.1438; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Idoyaga J, 2007, CANCER IMMUNOL IMMUN, V56, P1237, DOI 10.1007/s00262-006-0275-y; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kabashima K, 2007, AM J PATHOL, V171, P1249, DOI 10.2353/ajpath.2007.070225; Kabashima K, 2007, BIOCHEM BIOPH RES CO, V361, P1012, DOI 10.1016/j.bbrc.2007.07.128; Kaiser A, 2005, J IMMUNOL, V175, P2349, DOI 10.4049/jimmunol.175.4.2349; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Lutz MB, 2002, J IMMUNOL, V169, P3574, DOI 10.4049/jimmunol.169.7.3574; Marsland BJ, 2005, IMMUNITY, V22, P493, DOI 10.1016/j.immuni.2005.02.010; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Mori S, 2001, J EXP MED, V193, P207, DOI 10.1084/jem.193.2.207; Mueller A, 2004, FEBS LETT, V570, P126, DOI 10.1016/j.febslet.2004.04.100; Nishio H, 2001, J ANAT, V198, P581, DOI 10.1046/j.1469-7580.2001.19850581.x; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Scandella E, 2004, BLOOD, V103, P1595, DOI 10.1182/blood-2003-05-1643; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Soldevila G, 2004, IMMUNOLOGY, V112, P191, DOI 10.1111/j.1365-2567.2004.01863.x; SOLDEVILA G, 2007, SIGNAL TRANSDUCTION, V7, P427, DOI DOI 10.1002/SITA.200700144; Stein JV, 2003, BLOOD, V101, P38, DOI 10.1182/blood-2002-03-0841; Stoitzner P, 2002, J INVEST DERMATOL, V118, P117, DOI 10.1046/j.0022-202x.2001.01631.x; Tanabe S, 1997, J IMMUNOL, V159, P905; Van VQ, 2006, EMBO J, V25, P5560, DOI 10.1038/sj.emboj.7601415; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Xu H, 2001, EUR J IMMUNOL, V31, P3085, DOI 10.1002/1521-4141(2001010)31:10<3085::AID-IMMU3085>3.0.CO;2-B; Yamaoka K, 2005, BLOOD, V106, P3227, DOI 10.1182/blood-2005-02-0769; Yao Q, 2007, IMMUNOL LETT, V110, P110, DOI 10.1016/j.imlet.2007.04.007; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	44	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7066	10.1371/journal.pone.0007066	http://dx.doi.org/10.1371/journal.pone.0007066			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759904	gold, Green Published, Green Submitted			2022-12-27	WOS:000269970200004
J	Song, JN; Tan, H; Mahmood, K; Law, RHP; Buckle, AM; Webb, GI; Akutsu, T; Whisstock, JC				Song, Jiangning; Tan, Hao; Mahmood, Khalid; Law, Ruby H. P.; Buckle, Ashley M.; Webb, Geoffrey I.; Akutsu, Tatsuya; Whisstock, James C.			Prodepth: Predict Residue Depth by Support Vector Regression Approach from Protein Sequences Only	PLOS ONE			English	Article								Residue depth (RD) is a solvent exposure measure that complements the information provided by conventional accessible surface area (ASA) and describes to what extent a residue is buried in the protein structure space. Previous studies have established that RD is correlated with several protein properties, such as protein stability, residue conservation and amino acid types. Accurate prediction of RD has many potentially important applications in the field of structural bioinformatics, for example, facilitating the identification of functionally important residues, or residues in the folding nucleus, or enzyme active sites from sequence information. In this work, we introduce an efficient approach that uses support vector regression to quantify the relationship between RD and protein sequence. We systematically investigated eight different sequence encoding schemes including both local and global sequence characteristics and examined their respective prediction performances. For the objective evaluation of our approach, we used 5-fold cross-validation to assess the prediction accuracies and showed that the overall best performance could be achieved with a correlation coefficient (CC) of 0.71 between the observed and predicted RD values and a root mean square error (RMSE) of 1.74, after incorporating the relevant multiple sequence features. The results suggest that residue depth could be reliably predicted solely from protein primary sequences: local sequence environments are the major determinants, while global sequence features could influence the prediction performance marginally. We highlight two examples as a comparison in order to illustrate the applicability of this approach. We also discuss the potential implications of this new structural parameter in the field of protein structure prediction and homology modeling. This method might prove to be a powerful tool for sequence analysis.			Song, JN (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia.	Jiangning.Song@med.monash.edu.au; James.Whisstock@med.monash.edu.au	Buckle, Ashley/P-8366-2016; Webb, Geoff i/R-9967-2017; Webb, Geoffrey/Q-7270-2019; Song, Jiangning/F-9787-2010	Buckle, Ashley/0000-0003-2943-9044; Webb, Geoff i/0000-0001-9963-5169; Webb, Geoffrey/0000-0001-9963-5169; Song, Jiangning/0000-0001-8031-9086; law, ruby/0000-0001-5432-5781; Whisstock, James/0000-0003-4200-5611; Mahmood, Khalid/0000-0003-0980-3646; Akutsu, Tatsuya/0000-0001-9763-797X				Ahmad S, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-33; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bajaj K, 2005, P NATL ACAD SCI USA, V102, P16221, DOI 10.1073/pnas.0505089102; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Bromberg Y, 2007, NUCLEIC ACIDS RES, V35, P3823, DOI 10.1093/nar/gkm238; Chakravarty S, 1999, STRUCT FOLD DES, V7, P723, DOI 10.1016/S0969-2126(99)80097-5; CHANDONIA JM, 1995, PROTEIN SCI, V4, P275; Chen HL, 2005, NUCLEIC ACIDS RES, V33, P3193, DOI 10.1093/nar/gki633; Chen K, 2007, BIOINFORMATICS, V23, P2843, DOI 10.1093/bioinformatics/btm475; Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396; Cheng JL, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-113; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; Coleman RG, 2006, J MOL BIOL, V362, P441, DOI 10.1016/j.jmb.2006.07.022; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DeLano WL, 2002, PYMOL USERS MANUAL; Ferre F, 2005, BIOINFORMATICS, V21, P2336, DOI 10.1093/bioinformatics/bti328; Hamelryck T, 2005, PROTEINS, V59, P38, DOI 10.1002/prot.20379; Ishida T, 2007, NUCLEIC ACIDS RES, V35, pW460, DOI 10.1093/nar/gkm363; Joachims T., 1999, ADV KERNEL METHODS S; Jones DT, 2007, BIOINFORMATICS, V23, P538, DOI 10.1093/bioinformatics/btl677; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kalidas Y, 2008, J STRUCT BIOL, V161, P31, DOI 10.1016/j.jsb.2007.09.005; Kalita MK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002605; Kinjo AR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001963; Kinjo AR, 2005, PROTEINS, V58, P158, DOI 10.1002/prot.20300; Kumar M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-463; Kurgan L, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-226; Kurgan LA, 2008, AMINO ACIDS, V35, P551, DOI 10.1007/s00726-008-0080-3; Lacombe-Harvey ME, 2009, FEBS J, V276, P857, DOI 10.1111/j.1742-4658.2008.06830.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-471; Liu S, 2007, PROTEINS, V68, P636, DOI 10.1002/prot.21459; Liu W, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-182; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nguyen MN, 2006, PROTEINS, V63, P542, DOI 10.1002/prot.20883; Noguchi T, 2003, NUCLEIC ACIDS RES, V31, P492, DOI 10.1093/nar/gkg022; Ofran Y, 2007, PLOS COMPUT BIOL, V3, P1169, DOI 10.1371/journal.pcbi.0030119; Ofran Y, 2007, BIOINFORMATICS, V23, pI347, DOI 10.1093/bioinformatics/btm174; Pintar A, 2003, TRENDS BIOCHEM SCI, V28, P593, DOI 10.1016/j.tibs.2003.09.004; Pintar A, 2003, BIOPHYS J, V84, P2553, DOI 10.1016/S0006-3495(03)75060-7; Pintar A, 2003, BIOINFORMATICS, V19, P313, DOI 10.1093/bioinformatics/19.2.313; Pollastri G, 2001, Bioinformatics, V17 Suppl 1, pS234; Qiu J, 2008, PROTEINS, V71, P1175, DOI 10.1002/prot.21809; Radivojac P, 2007, BIOPHYS J, V92, P1439, DOI 10.1529/biophysj.106.094045; Raghava GPS, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-59; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schlessinger A, 2006, BIOINFORMATICS, V22, P891, DOI 10.1093/bioinformatics/btl032; Schlessinger A, 2007, BIOINFORMATICS, V23, P2376, DOI 10.1093/bioinformatics/btm349; Schlessinger A, 2007, PLOS COMPUT BIOL, V3, P1335, DOI 10.1371/journal.pcbi.0030140; Schlessinger A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004433; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; Schueler-Furman O, 2005, SCIENCE, V310, P638, DOI 10.1126/science.1112160; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Song JN, 2008, BIOINFORMATICS, V24, P1489, DOI 10.1093/bioinformatics/btn222; Song JN, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-425; Song JN, 2007, BIOINFORMATICS, V23, P3147, DOI 10.1093/bioinformatics/btm505; Song JN, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-124; Stout M, 2008, BIOINFORMATICS, V24, P916, DOI 10.1093/bioinformatics/btn050; Vapnik V., 1998, STAT LEARNING THEORY; Vapnik V.N., 1995, NATURE STAT LEARNING; Varrazzo D, 2005, BIOINFORMATICS, V21, P2856, DOI 10.1093/bioinformatics/bti444; Vlahovicek K, 2005, NUCLEIC ACIDS RES, V33, pW252, DOI 10.1093/nar/gki362; Wan J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-463; Wang X, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-32; Wang ZX, 2000, PROTEINS, V38, P165, DOI 10.1002/(SICI)1097-0134(20000201)38:2<165::AID-PROT5>3.0.CO;2-V; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Whisstock JC, 2003, Q REV BIOPHYS, V36, P307, DOI 10.1017/S0033583503003901; Xie D, 2005, NUCLEIC ACIDS RES, V33, pW105, DOI 10.1093/nar/gki359; Yuan Z, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-248; Yuan Z, 2008, PROTEINS, V70, P509, DOI 10.1002/prot.21545; Zhang H, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-388; Zhang W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002325; Zhou HY, 2005, PROTEINS, V58, P321, DOI 10.1002/prot.20308	82	35	35	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7072	10.1371/journal.pone.0007072	http://dx.doi.org/10.1371/journal.pone.0007072			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759917	Green Published, gold			2022-12-27	WOS:000269970200007
J	Hale, CM; Sun, SX; Wirtz, D				Hale, Christopher M.; Sun, Sean X.; Wirtz, Denis			Resolving the Role of Actoymyosin Contractility in Cell Microrheology	PLOS ONE			English	Article								Einstein's original description of Brownian motion established a direct relationship between thermally-excited random forces and the transport properties of a submicron particle in a viscous liquid. Recent work based on reconstituted actin filament networks suggests that nonthermal forces driven by the motor protein myosin II can induce large non-equilibrium fluctuations that dominate the motion of particles in cytoskeletal networks. Here, using high-resolution particle tracking, we find that thermal forces, not myosin-induced fluctuating forces, drive the motion of submicron particles embedded in the cytoskeleton of living cells. These results resolve the roles of myosin II and contractile actomyosin structures in the motion of nanoparticles lodged in the cytoplasm, reveal the biphasic mechanical architecture of adherent cells-stiff contractile stress fibers interdigitating in a network at the cell cortex and a soft actin meshwork in the body of the cell, validate the method of particle tracking-microrheology, and reconcile seemingly disparate atomic force microscopy (AFM) and particle-tracking microrheology measurements of living cells.			Hale, CM (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.	wirtz@jhu.edu	Sun, Sean/M-7208-2019; Wirtz, Denis/A-3257-2010; Hale, Christopher/A-6633-2009; Sun, Sean X/C-6755-2009	Sun, Sean/0000-0002-9077-7088; Hale, Christopher/0000-0002-2360-7759; Sun, Sean X/0000-0002-9077-7088	NCI NIH HHS [R21 CA137686, CA137686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA137686] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Bananis E, 2000, J CELL BIOL, V151, P179, DOI 10.1083/jcb.151.1.179; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bendix PM, 2008, BIOPHYS J, V94, P3126, DOI 10.1529/biophysj.107.117960; Brangwynne CP, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.118104; Brangwynne CP, 2008, J CELL BIOL, V183, P583, DOI 10.1083/jcb.200806149; Brown R., 1828, PHILOS MAG, V4, P161, DOI [10.1080/14786442808674769, DOI 10.1080/14786442808674769]; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; Gittes F, 1997, PHYS REV LETT, V79, P3286, DOI 10.1103/PhysRevLett.79.3286; Haber C, 2000, BIOPHYS J, V79, P1530, DOI 10.1016/S0006-3495(00)76404-6; HOH JH, 1994, J CELL SCI, V107, P1105; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kole TP, 2005, MOL BIOL CELL, V16, P328, DOI 10.1091/mbc.e04-06-0485; Kole TP, 2004, MOL BIOL CELL, V15, P3475, DOI 10.1091/mbc.E04-03-0218; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Le Goff L, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.018101; Lee JSH, 2007, BIOPHYS J, V93, P2542, DOI 10.1529/biophysj.106.102426; Lee JSH, 2006, J CELL SCI, V119, P1760, DOI 10.1242/jcs.02899; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; LUBYPHELPS K, 1986, J CELL BIOL, V102, P2015, DOI 10.1083/jcb.102.6.2015; Mason TG, 1997, PHYS REV LETT, V79, P3282, DOI 10.1103/PhysRevLett.79.3282; MASON TG, 1995, PHYS REV LETT, V74, P1254; Matzke R, 2001, NAT CELL BIOL, V3, P607, DOI 10.1038/35078583; Mizuno D, 2007, SCIENCE, V315, P370, DOI 10.1126/science.1134404; Panorchan P, 2007, METHOD CELL BIOL, V83, P115, DOI 10.1016/S0091-679X(07)83006-8; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; RADMACHER M, 1994, BIOPHYS J, V66, P2159, DOI 10.1016/S0006-3495(94)81011-2; Ramamurthy B, 2004, BIOCHEMISTRY-US, V43, P14832, DOI 10.1021/bi0490284; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Shu S, 2005, P NATL ACAD SCI USA, V102, P1472, DOI 10.1073/pnas.0409528102; Smith DA, 2001, BIOPHYS J, V80, P45, DOI 10.1016/S0006-3495(01)75994-2; Smoluchowski M., 1906, ANN PHYSIK, V326, P756, DOI DOI 10.1002/ANDP.19063261405; Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tseng Y, 2004, J BIOL CHEM, V279, P1819, DOI 10.1074/jbc.M306090200; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; Van Citters KM, 2006, BIOPHYS J, V91, P3946, DOI 10.1529/biophysj.106.091264; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Yam PT, 2007, J CELL BIOL, V178, P1207, DOI 10.1083/jcb.200706012; Yarrow JC, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-5	44	52	52	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7054	10.1371/journal.pone.0007054	http://dx.doi.org/10.1371/journal.pone.0007054			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756147	Green Submitted, gold, Green Published			2022-12-27	WOS:000269970000019
J	Jeffry, JA; Yu, SQ; Sikand, P; Parihar, A; Evans, MS; Premkumar, LS				Jeffry, Joseph A.; Yu, Shuang-Quan; Sikand, Parul; Parihar, Arti; Evans, M. Steven; Premkumar, Louis S.			Selective Targeting of TRPV1 Expressing Sensory Nerve Terminals in the Spinal Cord for Long Lasting Analgesia	PLOS ONE			English	Article								Chronic pain is a major clinical problem and opiates are often the only treatment, but they cause significant problems ranging from sedation to deadly respiratory depression. Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block. Intrathecal administration of RTX to rats in the short-term inhibits nociceptive synaptic transmission, and in the long-term causes a localized, selective ablation of TRPV1-expressing central sensory nerve terminals leading to long lasting analgesia in behavioral models. Since RTX actions are selective for central sensory nerve terminals, other efferent functions of dorsal root ganglion neurons can be preserved. Preventing nociceptive transmission at the level of the spinal cord can be a useful strategy to treat chronic, debilitating and intractable pain.			Jeffry, JA (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA.	lpremkumar@siumed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK065742, R01DK065742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042296] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065742, R56 DK065742, DK065742] Funding Source: Medline; NINDS NIH HHS [NS042296, R01 NS042296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akerman S, 2004, BRIT J PHARMACOL, V142, P1354, DOI 10.1038/sj.bjp.0705896; Apostolidis A, 2005, UROLOGY, V65, P400, DOI 10.1016/j.urology.2004.10.007; Appendino G, 1997, LIFE SCI, V60, P681, DOI 10.1016/S0024-3205(96)00567-X; Baccei ML, 2003, J PHYSIOL-LONDON, V549, P231, DOI 10.1113/jphysiol.2003.040451; Brown DC, 2005, ANESTHESIOLOGY, V103, P1052, DOI 10.1097/00000542-200511000-00020; Cao DS, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-5; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Constantin CE, 2008, J NEUROSCI, V28, P5072, DOI 10.1523/JNEUROSCI.4476-07.2008; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; Dinis P, 2004, BJU INT, V94, P153, DOI 10.1111/j.1464-4096.2004.04855.x; Gavva NR, 2008, PAIN, V136, P202, DOI 10.1016/j.pain.2008.01.024; Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815-04.2005; Giannantoni A, 2004, J UROLOGY, V172, P240, DOI 10.1097/01.ju.0000132152.53532.5d; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; GOSO C, 1993, NEUROSCI LETT, V162, P197, DOI 10.1016/0304-3940(93)90594-B; Gram DX, 2007, EUR J NEUROSCI, V25, P213, DOI 10.1111/j.1460-9568.2006.05261.x; Gram DX, 2005, EUR J PHARMACOL, V509, P211, DOI 10.1016/j.ejphar.2004.12.039; GRUDT TJ, 1994, J NEUROSCI, V14, P1646, DOI 10.1523/JNEUROSCI.14-03-01646.1994; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Immke DC, 2006, SEMIN CELL DEV BIOL, V17, P582, DOI 10.1016/j.semcdb.2006.09.004; JANCSOGABOR A, 1970, J PHYSIOL-LONDON, V208, P449, DOI 10.1113/jphysiol.1970.sp009130; Jones RCW, 2005, J NEUROSCI, V25, P10981, DOI 10.1523/JNEUROSCI.0703-05.2005; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Karai L, 2004, J CLIN INVEST, V113, P1344, DOI 10.1172/JCI200420449; Kim JH, 2003, J SPINAL CORD MED, V26, P358, DOI 10.1080/10790268.2003.11753706; Kissin EY, 2005, ANESTH ANALG, V101, P1433, DOI 10.1213/01.ANE.0000180998.29890.B0; Lauria G, 2006, J PERIPHER NERV SYST, V11, P262, DOI 10.1111/j.1529-8027.2006.0097.x; Lazzeri M, 2004, EUR UROL, V45, P98, DOI 10.1016/S0302-2838(03)00418-4; Lehto SG, 2008, J PHARMACOL EXP THER, V326, P218, DOI 10.1124/jpet.107.132233; Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7; NAGY JI, 1981, BRAIN RES, V211, P497, DOI 10.1016/0006-8993(81)90980-X; Nakatsuka T, 2002, J NEUROSCI, V22, P1228, DOI 10.1523/JNEUROSCI.22-04-01228.2002; Petersen KL, 2002, PAIN, V98, P119, DOI 10.1016/S0304-3959(02)00029-5; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Raisinghani M, 2005, J PHYSIOL-LONDON, V567, P771, DOI 10.1113/jphysiol.2005.087874; Razavi R, 2006, CELL, V127, P1123, DOI 10.1016/j.cell.2006.10.038; RUSSELL LC, 1984, BRAIN RES REV, V8, P165, DOI 10.1016/0165-0173(84)90005-5; RUSSELL LC, 1986, PAIN, V25, P109, DOI 10.1016/0304-3959(86)90013-8; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Sikand P, 2007, J PHYSIOL-LONDON, V581, P631, DOI 10.1113/jphysiol.2006.118620; Strecker T, 2005, CARDIOVASC RES, V65, P405, DOI 10.1016/j.cardiores.2004.10.013; Szabo T, 1999, BRAIN RES, V840, P92, DOI 10.1016/S0006-8993(99)01763-1; SZALLASI A, 1990, LIFE SCI, V47, P1399, DOI 10.1016/0024-3205(90)90518-V; Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280; Varga A, 2005, NEUROSCI LETT, V385, P137, DOI 10.1016/j.neulet.2005.05.015; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544; YAKSH TL, 1979, SCIENCE, V206, P481, DOI 10.1126/science.228392; Yang K, 1998, NEUROSCI LETT, V255, P135, DOI 10.1016/S0304-3940(98)00730-7; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	56	76	78	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7021	10.1371/journal.pone.0007021	http://dx.doi.org/10.1371/journal.pone.0007021			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753113	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796500011
J	Bennett, KL; Romigh, T; Eng, C				Bennett, Kristi L.; Romigh, Todd; Eng, Charis			AP-2 alpha Induces Epigenetic Silencing of Tumor Suppressive Genes and Microsatellite Instability in Head and Neck Squamous Cell Carcinoma	PLOS ONE			English	Article								Background: Activator protein 2 alpha (AP-2 alpha) is involved in a variety of physiological processes. Increased AP-2 alpha expression correlates with progression in various squamous cell carcinomas, and a recent publication found AP-2 alpha to be overexpressed in similar to 70% of Head and Neck Squamous Cell Carcinoma (HNSCC) patient samples. It was found to repress transcription of the tumor suppressor gene C/CAAT Enhancer Binding Protein alpha (C/EBP alpha), and its binding site correlated with upstream methylation of the C/EBP alpha promoter. Therefore, we investigated the potential for AP-2 alpha to target methylation to additional genes that would be relevant to HNSCC pathogenesis. Principal Findings: Stable downregulation of AP-2 alpha stable by shRNA in HNSCC cell lines correlated with decreased methylation of its target genes' regulatory regions. Furthermore, methylation of MLH1 in HNSCC with and without AP-2 alpha downregulation revealed a correlation with microsatellite instability (MSI). ChIP analysis was used to confirm binding of AP-2 alpha and HDAC1/2 to the targets. The effects of HDAC inhibition was assessed using Trichostatin A in a HNSCC cell line, which revealed that AP-2 alpha targets methylation through HDAC recruitment. Conclusions: These findings are significant because they suggest AP-2 alpha plays a role not only in epigenetic silencing, but also in genomic instability. This intensifies the potential level of regulation AP-2 alpha has through transcriptional regulation. Furthermore, these findings have the potential to revolutionize the field of HNSCC therapy, and more generally the field of epigenetic therapy, by targeting a single gene that is involved in the malignant transformation via disrupting DNA repair and cell cycle control.			Bennett, KL (corresponding author), Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA.	engc@ccf.org		Eng, Charis/0000-0002-3693-5145				Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Bennett KL, 2009, INT J CANCER, V124, P1285, DOI 10.1002/ijc.24087; Boland CR, 1998, CANCER RES, V58, P5248; Bosher JM, 1996, ONCOGENE, V13, P1701; Choi HJ, 2008, GLYCOBIOLOGY, V18, P395, DOI 10.1093/glycob/cwn016; Damberg M, 2005, J NEURAL TRANSM, V112, P1281, DOI 10.1007/s00702-005-0325-1; Demokan S, 2006, ANN ONCOL, V17, P995, DOI 10.1093/annonc/mdl048; Dietmaier W, 1997, CANCER RES, V57, P4749; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x; Han CY, 2008, CANCER SCI, V99, P502, DOI 10.1111/j.1349-7006.2007.00718.x; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kawamoto K, 2007, CLIN CANCER RES, V13, P2541, DOI 10.1158/1078-0432.CCR-06-2225; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Leung SY, 1999, CANCER RES, V59, P159; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; McCool KW, 2007, J BIOL CHEM, V282, P6696, DOI 10.1074/jbc.M609519200; Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482; Orso F, 2008, FASEB J, V22, P2702, DOI 10.1096/fj.08-106492; Oyama N, 2002, ARCH DERMATOL RES, V294, P273, DOI 10.1007/s00403-002-0327-x; Provenzano MJ, 2007, EXP MOL PATHOL, V83, P277, DOI 10.1016/j.yexmp.2007.06.001; Schulte JH, 2008, CANCER LETT, V271, P56, DOI 10.1016/j.canlet.2008.05.039; Singh H, 2000, J CELL BIOCHEM, P61; Suyama Eigo, 2002, Nucleic Acids Res Suppl, P247; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Taylor KH, 2007, CANCER RES, V67, P2617, DOI 10.1158/0008-5472.CAN-06-3993; Thibodeau SN, 1998, CANCER RES, V58, P1713; Uramoto H, 2004, J CELL SCI, V117, P5323, DOI 10.1242/jcs.01384; Yu YH, 2002, MOL CARCINOGEN, V34, P172, DOI 10.1002/mc.10062; Zhang GQ, 2004, ENDOCRINOLOGY, V145, P2760, DOI 10.1210/en.2003-1545	35	17	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6931	10.1371/journal.pone.0006931	http://dx.doi.org/10.1371/journal.pone.0006931			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742317	Green Published, gold			2022-12-27	WOS:000269622500010
J	Johnston, JC; Shahidi, NC; Sadatsafavi, M; Fitzgerald, JM				Johnston, James C.; Shahidi, Neal C.; Sadatsafavi, Mohsen; Fitzgerald, J. Mark			Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							PULMONARY TUBERCULOSIS; FOLLOW-UP; STANDARDIZED REGIMENS; MANAGEMENT; TB; CALIFORNIA; PROGRAM	Background: Treatment outcomes for multidrug-resistant Mycobacterium Tuberculosis (MDRTB) are generally poor compared to drug sensitive disease. We sought to estimate treatment outcomes and identify risk factors associated with poor outcomes in patients with MDRTB. Methodology/Principal Findings: We performed a systematic search (to December 2008) to identify trials describing outcomes of patients treated for MDRTB. We pooled appropriate data to estimate WHO-defined outcomes at the end of treatment and follow-up. Where appropriate, pooled covariates were analyzed to identify factors associated with worse outcomes. Among articles identified, 36 met our inclusion criteria, representing 31 treatment programmes from 21 countries. In a pooled analysis, 62% [95% CI 57-67] of patients had successful outcomes, while 13% [9-17] defaulted, 11% [9-13] died, and 2% [1-4] were transferred out. Factors associated with worse outcome included male gender 0.61 (OR for successful outcome) [0.46-0.82], alcohol abuse 0.49 [0.39-0.63], low BMI 0.41[0.23-0.72], smear positivity at diagnosis 0.53 [0.31-0.91], fluoroquinolone resistance 0.45 [0.22-0.91] and the presence of an XDR resistance pattern 0.57 [0.41-0.80]. Factors associated with successful outcome were surgical intervention 1.91 [1.44-2.53], no previous treatment 1.42 [1.05-1.94], and fluoroquinolone use 2.20 [1.19-4.09]. Conclusions/Significance: We have identified several factors associated with poor outcomes where interventions may be targeted. In addition, we have identified high rates of default, which likely contributes to the development and spread of MDRTB.			Johnston, JC (corresponding author), British Columbia Ctr Dis Control, Vancouver, BC, Canada.	johnst22@interchange.ubc.ca	Sadatsafayi, Mohsen/AAZ-1593-2020	Sadatsafayi, Mohsen/0000-0002-0419-7862; Shahidi, Neal/0000-0002-4536-0515				Abba K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006086.pub2; [Anonymous], 2008, GUID PROGR MAN DRUG; Avendano M, 2000, Can Respir J, V7, P383; Banerjee R, 2008, CLIN INFECT DIS, V47, P450, DOI 10.1086/590009; Bartu V, 2003, Cas Lek Cesk, V142, P226; Bashar M, 2001, CHEST, V120, P1514, DOI 10.1378/chest.120.5.1514; Burgos M, 2005, CLIN INFECT DIS, V40, P968, DOI 10.1086/428582; Caminero JA, 2006, INT J TUBERC LUNG D, V10, P829; *CDC, 1991, MMWR-MORBID MORTAL W, V42, P434; *CDC, 1991, MMWR-MORBID MORTAL W, V42, P427; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-1159OC; CHAN ED, 2008, NEW ENGL J MED, P657; Chan ED, 2008, CURR OPIN INFECT DIS, V21, P587, DOI 10.1097/QCO.0b013e328319bce6; Chiang CY, 2006, EUR RESPIR J, V28, P980, DOI 10.1183/09031936.06.00125705; Cox HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001126; Escudero E, 2006, INT J TUBERC LUNG D, V10, P409; Ferrara G, 2005, INT J TUBERC LUNG D, V9, P507; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; GIRLING DJ, 1992, TUBERCLE LUNG DIS, V73, P59; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Granich RM, 2005, JAMA-J AM MED ASSOC, V293, P2732, DOI 10.1001/jama.293.22.2732; Hersi A, 1999, Can Respir J, V6, P155; Holtz TH, 2006, ANN INTERN MED, V144, P650, DOI 10.7326/0003-4819-144-9-200605020-00008; Jeon CY, 2008, CLIN INFECT DIS, V46, P42, DOI 10.1086/524017; Jeon CY, 2008, PLOS MED, V5, P1091, DOI 10.1371/journal.pmed.0050152; Keshavjee S, 2008, LANCET, V372, P1403, DOI 10.1016/S0140-6736(08)61204-0; Kim DH, 2008, AM J RESP CRIT CARE, V178, P1075, DOI 10.1164/rccm.200801-132OC; Kim HR, 2007, CLIN INFECT DIS, V45, P1290, DOI 10.1086/522537; Kim SJ, 1995, TUBERCLE LUNG DIS, V76, P529, DOI 10.1016/0962-8479(95)90529-4; Kwon YS, 2008, CLIN INFECT DIS, V47, P496, DOI 10.1086/590005; Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640; Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1; Masjedi MR, 2008, INT J TUBERC LUNG D, V12, P750; MATHEW TA, 2008, INTEGRATION ALCOHOL; Migliori GB, 2008, EUR RESPIR J, V31, P1155, DOI 10.1183/09031936.00028708; Migliori GB, 2007, EUR RESPIR J, V30, P623, DOI 10.1183/09031936.00077307; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mitnick CD, 2008, NEW ENGL J MED, V359, P563, DOI 10.1056/NEJMoa0800106; Mitnick CD, 2007, PLOS MED, V4, P1730, DOI 10.1371/journal.pmed.0040292; Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2; Narita M, 2001, CHEST, V120, P343, DOI 10.1378/chest.120.2.343; Nathanson E, 2006, EMERG INFECT DIS, V12, P1389, DOI 10.3201/eid1209.051618; O'Riordan P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003173; Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6; PablosMendez A, 1997, AM J PUBLIC HEALTH, V87, P574, DOI 10.2105/AJPH.87.4.574; Palmero DJ, 2004, INT J TUBERC LUNG D, V8, P778; Park SK, 2004, INT J TUBERC LUNG D, V8, P361; Raviglione MC, 2008, NEW ENGL J MED, V359, P636, DOI 10.1056/NEJMe0804906; Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273; Sharma SK, 2006, CHEST, V130, P149, DOI 10.1378/chest.130.1.149; Shean KP, 2008, INT J TUBERC LUNG D, V12, P1182; Shin SS, 2006, INT J TUBERC LUNG D, V10, P402; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; Torun T, 2007, INT J TUBERC LUNG D, V11, P979; Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352; Uffredi ML, 2007, INT J ANTIMICROB AG, V29, P434, DOI 10.1016/j.ijantimicag.2006.11.023; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; Van Deun A, 2004, INT J TUBERC LUNG D, V8, P560; Ward HA, 2005, INT J TUBERC LUNG D, V9, P164; *WHO INT UN TUB LU, 2007, GLOB PROJ ANT DRUG R; World Health Organization, 2007, GLOB MDR TB XDR TB R; Yew WW, 2003, CHEST, V124, P1476, DOI 10.1378/chest.124.4.1476; Yew WW, 2000, CHEST, V117, P744, DOI 10.1378/chest.118.3.744	67	313	328	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6914	10.1371/journal.pone.0006914	http://dx.doi.org/10.1371/journal.pone.0006914			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742330	gold, Green Submitted, Green Published			2022-12-27	WOS:000269622500003
J	Baumann, F; Pahnke, J; Radovanovic, I; Rulicke, T; Bremer, J; Tolnay, M; Aguzzi, A				Baumann, Frank; Pahnke, Jens; Radovanovic, Ivan; Ruelicke, Thomas; Bremer, Juliane; Tolnay, Markus; Aguzzi, Adriano			Functionally Relevant Domains of the Prion Protein Identified In Vivo	PLOS ONE			English	Article							CELLULAR PRION; 3-DIMENSIONAL STRUCTURES; MICE DEFICIENT; NMR STRUCTURE; PRP; DOPPEL; DEGENERATION; LACKING; ATAXIA; TOXICITY	The prion consists essentially of PrPSc, a misfolded and aggregated conformer of the cellular protein PrPC. Whereas PrPC deficient mice are clinically healthy, expression of PrPC variants lacking its central domain (PrP Delta CD), or of the PrP-related protein Dpl, induces lethal neurodegenerative syndromes which are repressed by full-length PrP. Here we tested the structural basis of these syndromes by grafting the amino terminus of PrPC (residues 1-134), or its central domain (residues 90-134), onto Dpl. Further, we constructed a soluble variant of the neurotoxic PrP Delta CD mutant that lacks its glycosyl phosphatidyl inositol (GPI) membrane anchor. Each of these modifications abrogated the pathogenicity of Dpl and PrP Delta CD in transgenic mice. The PrP-Dpl chimeric molecules, but not anchorless PrP Delta CD, ameliorated the disease of mice expressing truncated PrP variants. We conclude that the amino proximal domain of PrP exerts a neurotrophic effect even when grafted onto a distantly related protein, and that GPI-linked membrane anchoring is necessary for both beneficial and deleterious effects of PrP and its variants.			Baumann, F (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano.aguzzi@usz.ch	Bremer, Juliane/AAH-9487-2020; Bremer, Juliane/E-2298-2012; Baumann, Frank/F-7737-2016; Aguzzi, Adriano/A-3351-2008; Pahnke, Jens/G-1757-2010	Pahnke, Jens/0000-0001-7355-4213; Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2005, SCIENCE, V308, P1420, DOI 10.1126/science.1114168; Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Atarashi R, 2003, J BIOL CHEM, V278, P28944, DOI 10.1074/jbc.M303655200; Baumann F, 2007, EMBO J, V26, P538, DOI 10.1038/sj.emboj.7601510; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Behrens A, 2002, EMBO J, V21, P3652, DOI 10.1093/emboj/cdf386; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chacon MA, 2003, MOL PSYCHIATR, V8, P853, DOI [10.1038/sj.mp.4001400, 10.1038/sj.mp.4001414]; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Drisaldi B, 2004, J BIOL CHEM, V279, P55443, DOI 10.1074/jbc.M404794200; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Hornemann S, 2004, EMBO REP, V5, P1159, DOI 10.1038/sj.embor.7400297; Karapetyan YE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005730; Khosravani Houman, 2008, J Gen Physiol, V131, pi5, DOI 10.1085/JGP1316OIA5; Li AM, 2007, EMBO J, V26, P548, DOI 10.1038/sj.emboj.7601507; Luhrs T, 2003, J MOL BIOL, V326, P1549, DOI 10.1016/S0022-2836(02)01471-7; Mattei V, 2004, FEBS LETT, V560, P14, DOI 10.1016/S0014-5793(04)00029-8; Mitteregger G, 2007, BRAIN PATHOL, V17, P174, DOI 10.1111/j.1750-3639.2007.00061.x; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nazor KE, 2007, BBA-MOL BASIS DIS, V1772, P645, DOI 10.1016/j.bbadis.2007.04.004; Nishida N, 1999, LAB INVEST, V79, P689; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Polymenidou M, 2008, VACCINE, V26, P2601, DOI 10.1016/j.vaccine.2008.03.035; Polymenidou M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003872; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Radovanovic I, 2005, J NEUROSCI, V25, P4879, DOI 10.1523/JNEUROSCI.0328-05.2005; Riek R, 2003, CLIN LAB MED, V23, P209, DOI 10.1016/S0272-2712(02)00070-7; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Rulicke T, 2004, METH MOL B, V254, P165; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Toni M, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/69469; Trifilo MJ, 2008, J VIROL, V82, P9890, DOI 10.1128/JVI.00486-08; Trifilo MJ, 2006, SCIENCE, V313, P94, DOI 10.1126/science.1128635; Varela-Nallar L, 2006, BIOL RES, V39, P39, DOI 10.4067/S0716-97602006000100005; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55; Yamaguchi N, 2004, BIOCHEM BIOPH RES CO, V319, P1247, DOI 10.1016/j.bbrc.2004.05.115; Yoshikawa D, 2008, J BIOL CHEM, V283, P24202, DOI 10.1074/jbc.M804212200; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	54	25	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6707	10.1371/journal.pone.0006707	http://dx.doi.org/10.1371/journal.pone.0006707			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738901	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300001
J	Oh, YM; Kim, JK; Choi, Y; Choi, S; Yoo, JY				Oh, Young Min; Kim, Jong Kyoung; Choi, Yongwook; Choi, Seungjin; Yoo, Joo-Yeon			Prediction and Experimental Validation of Novel STAT3 Target Genes in Human Cancer Cells	PLOS ONE			English	Article								The comprehensive identification of functional transcription factor binding sites (TFBSs) is an important step in understanding complex transcriptional regulatory networks. This study presents a motif-based comparative approach, STAT-Finder, for identifying functional DNA binding sites of STAT3 transcription factor. STAT-Finder combines STAT-Scanner, which was designed to predict functional STAT TFBSs with improved sensitivity, and a motif-based alignment to minimize false positive prediction rates. Using two reference sets containing promoter sequences of known STAT3 target genes, STAT-Finder identified functional STAT3 TFBSs with enhanced prediction efficiency and sensitivity relative to other conventional TFBS prediction tools. In addition, STAT-Finder identified novel STAT3 target genes among a group of genes that are over-expressed in human cancer cells. The binding of STAT3 to the predicted TFBSs was also experimentally confirmed through chromatin immunoprecipitation. Our proposed method provides a systematic approach to the prediction of functional TFBSs that can be applied to other TFs.			Oh, YM (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea.	seungjin@postech.ac.kr; jyoo@postech.ac.kr	Kim, Jong Kyoung/AAF-3414-2021; Kim, Jong Kyoung/C-2971-2008	Kim, Jong Kyoung/0000-0002-0257-0547				Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Badis G, 2009, SCIENCE, V324, P1720, DOI 10.1126/science.1162327; Bai Y, 2008, J BIOL CHEM, V283, P6832, DOI 10.1074/jbc.M706021200; Berezikov E, 2004, GENOME RES, V14, P170; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chang LW, 2006, GENOME RES, V16, P405, DOI 10.1101/gr.4303406; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Claverie JM, 1996, COMPUT APPL BIOSCI, V12, P431; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; COFFER P, 1995, ONCOGENE, V10, P985; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Della Gatta G, 2008, GENOME RES, V18, P939, DOI 10.1101/gr.073601.107; Doniger SW, 2007, PLOS COMPUT BIOL, V3, P932, DOI 10.1371/journal.pcbi.0030099; Doniger SW, 2005, GENOME RES, V15, P701, DOI 10.1101/gr.3578205; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Elnitski L, 2006, GENOME RES, V16, P1455, DOI 10.1101/gr.4140006; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Fan SC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001184; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hannenhalli S, 2008, BIOINFORMATICS, V24, P1325, DOI 10.1093/bioinformatics/btn198; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hartner A, 1997, KIDNEY INT, V51, P1754, DOI 10.1038/ki.1997.241; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jensen ST, 2008, J AM STAT ASSOC, V103, P188, DOI 10.1198/016214507000000365; Jiang C, 2007, NUCLEIC ACIDS RES, V35, pD137, DOI 10.1093/nar/gkl1041; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kheradpour P, 2007, GENOME RES, V17, P1919, DOI 10.1101/gr.7090407; King DC, 2005, GENOME RES, V15, P1051, DOI 10.1101/gr.3642605; Kiryu-Seo S, 2008, J BIOL CHEM, V283, P6988, DOI 10.1074/jbc.M707514200; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Liu XD, 2007, AM J RESP CELL MOL, V37, P121, DOI 10.1165/rcmb.2005-0253OC; Marzolf B, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-286; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Palin K, 2006, NAT PROTOC, V1, P368, DOI 10.1038/nprot.2006.56; Pritsker M, 2004, GENOME RES, V14, P99; RAHMANN S, 2003, STAT APPL GENET MOL, V2, DOI DOI 10.2202/1544-6115.1032; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Smit A, 1996, REPEATMASKER OPEN 30; Snyder M, 2008, J BIOL CHEM, V283, P3791, DOI 10.1074/jbc.M706976200; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Spano JP, 2006, EUR J CANCER, V42, P2668, DOI 10.1016/j.ejca.2006.07.006; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; STADEN R, 1989, COMPUT APPL BIOSCI, V5, P89; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Thijs G, 2002, BIOINFORMATICS, V18, P331, DOI 10.1093/bioinformatics/18.2.331; Tomida M, 2008, J CANCER RES CLIN, V134, P551, DOI 10.1007/s00432-007-0318-6; Tompa M, 2005, NAT BIOTECHNOL, V23, P137, DOI 10.1038/nbt1053; Urnov FD, 2003, J CELL BIOCHEM, V88, P684, DOI 10.1002/jcb.10397; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Wray GA, 2003, MOL BIOL EVOL, V20, P1377, DOI 10.1093/molbev/msg140; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Xie XH, 2009, BIOINFORMATICS, V25, P167, DOI 10.1093/bioinformatics/btn605; Yang Y, 2005, J IMMUNOL, V174, P2720, DOI 10.4049/jimmunol.174.5.2720; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200	80	23	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6911	10.1371/journal.pone.0006911	http://dx.doi.org/10.1371/journal.pone.0006911			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730699	Green Submitted, gold, Green Published			2022-12-27	WOS:000269622100014
J	Kurth, A; Straube, M; Kuczka, A; Dunsche, AJ; Meyer, H; Nitsche, A				Kurth, Andreas; Straube, Martin; Kuczka, Annette; Dunsche, Anton Josef; Meyer, Hermann; Nitsche, Andreas			Cowpox Virus Outbreak in Banded Mongooses (Mungos mungo) and Jaguarundis (Herpailurus yagouaroundi) with a Time-Delayed Infection to Humans	PLOS ONE			English	Article								Background: Often described as an extremely rare zoonosis, cowpox virus (CPXV) infections are on the increase in Germany. CPXV is rodent-borne with a broad host range and contains the largest and most complete genome of all poxviruses, including parts with high homology to variola virus (smallpox). So far, most CPXV cases have occurred individually in unvaccinated animals and humans and were caused by genetically distinguishable virus strains. Methodology/Principal Findings: Generalized CPXV infections in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) at a Zoological Garden were observed with a prevalence of the affected animal group of 100% and a mortality of 30%. A subsequent serological investigation of other exotic animal species provided evidence of subclinical cases before the onset of the outbreak. Moreover, a time-delayed human cowpox virus infection caused by the identical virus strain occurred in a different geographical area indicating that handling/feeding food rats might be the common source of infection. Conclusions/Significance: Reports on the increased zoonotic transmission of orthopoxviruses have renewed interest in understanding interactions between these viruses and their hosts. The list of animals known to be susceptible to CPXV is still growing. Thus, the likely existence of unknown CPXV hosts and their distribution may present a risk for other exotic animals but also for the general public, as was shown in this outbreak. Animal breeders and suppliers of food rats represent potential multipliers and distributors of CPXV, in the context of increasingly pan-European trading. Taking the cessation of vaccination against smallpox into account, this situation contributes to the increased incidence of CPXV infections in man, particularly in younger age groups, with more complicated courses of clinical infections.			Kurth, A (corresponding author), Robert Koch Inst, German Consultant Lab Poxviruses, D-1000 Berlin, Germany.	kurtha@rki.de		Nitsche, Andreas/0000-0001-8185-3176				BASSE A, 1964, VERH BER ERKRG ZOOTI, V6, P55; BAXBY D, 1982, J HYG-CAMBRIDGE, V89, P365, DOI 10.1017/S0022172400070935; BAXBY D, 1997, ARCH VIROL         S, V13, P1; Begon M, 1999, P ROY SOC B-BIOL SCI, V266, P1939, DOI 10.1098/rspb.1999.0870; Bennett M, 1997, J COMP PATHOL, V116, P35, DOI 10.1016/S0021-9975(97)80041-2; BIEL SS, 1999, VIRUS CELL CULTURE P, P11; Coras B, 2005, LANCET, V365, P446; EISHUBINGER AM, 1990, LANCET, V336, P880, DOI 10.1016/0140-6736(90)92387-W; Essbauer S., 2007, POXVIRUSES BIRKH USE; Eulenberger K., 2005, Proceedings of the Institute for Zoo and Wildlife Research, Berlin, P77; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; Hentschke J, 1999, TIERAERZTL UMSCHAU, V54, P311; Kik MJL, 2006, VET QUART, V28, P42, DOI 10.1080/01652176.2006.9695206; KUBIN G, 1975, Wiener Tieraerztliche Monatsschrift, V62, P271; Kurth A, 2008, EMERG INFECT DIS, V14, P670, DOI 10.3201/eid1404.070817; Kurth A, 2007, FUTURE VIROL, V2, P467, DOI 10.2217/17460794.2.5.467; MAIBORODA AD, 1982, ACTA VIROL, V26, P288; MARENNIKOVA SS, 1976, ACTA VIROL, V20, P442; MARENNIKOVA SS, 1978, LAB ANIM, V12, P33, DOI 10.1258/002367778780953288; MARENNIKOVA SS, 1977, J INFECT DIS, V135, P358, DOI 10.1093/infdis/135.3.358; Martina BEE, 2006, EMERG INFECT DIS, V12, P1005, DOI 10.3201/eid1206.051513; Matz-Rensing K, 2006, VET PATHOL, V43, P212, DOI 10.1354/vp.43-2-212; Muller T, 1996, J WILDLIFE DIS, V32, P348; NAKANO JH, 1989, DIAGNOSTIC PROCEDURE, P257; Nitsche A, 2004, J CLIN MICROBIOL, V42, P1207, DOI 10.1128/JCM.42.3.1207-1213.2004; Pastoret PP, 2000, REV SCI TECH OIE, V19, P23, DOI 10.20506/rst.19.1.1213; Pelkonen PM, 2003, EMERG INFECT DIS, V9, P1458, DOI 10.3201/eid0911.020814; PILASKI J, 1993, VERH ERKRG ZOOTIERE, V35, P39; Potel K., 1963, Zoologische Garten Leipzig (N F), V27, P1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandvik T, 1998, J CLIN MICROBIOL, V36, P2542, DOI 10.1128/JCM.36.9.2542-2547.1998; Schaudien D, 2007, J COMP PATHOL, V137, P151, DOI 10.1016/j.jcpa.2007.05.007; Schuppel K.F., 1997, VERH BER ERKRG ZOOTI, V38, P259; Wisser J, 2001, VET REC, V149, P244, DOI 10.1136/vr.149.8.244; Wolfs TFW, 2002, EMERG INFECT DIS, V8, P1495, DOI 10.3201/eid0812.020089; Yang G, 2005, J VIROL, V79, P13139, DOI 10.1128/JVI.79.20.13139-13149.2005; ZWART P, 1971, BRIT VET J, V127, P20, DOI 10.1016/S0007-1935(17)37783-7	37	41	41	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6883	10.1371/journal.pone.0006883	http://dx.doi.org/10.1371/journal.pone.0006883			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727399	Green Published, Green Submitted, gold			2022-12-27	WOS:000269522900012
J	Beilharz, TH; Humphreys, DT; Clancy, JL; Thermann, R; Martin, DIK; Hentze, MW; Preiss, T				Beilharz, Traude H.; Humphreys, David T.; Clancy, Jennifer L.; Thermann, Rolf; Martin, David I. K.; Hentze, Matthias W.; Preiss, Thomas			microRNA-Mediated Messenger RNA Deadenylation Contributes to Translational Repression in Mammalian Cells	PLOS ONE			English	Article							PROTEIN-SYNTHESIS; LET-7 MICRORNA; CAENORHABDITIS-ELEGANS; GENE-REGULATION; IN-VITRO; INITIATION; ARGONAUTE; CAP; EXPRESSION; GW182	Animal microRNAs (miRNAs) typically regulate gene expression by binding to partially complementary target sites in the 39 untranslated region (UTR) of messenger RNA (mRNA) reducing its translation and stability. They also commonly induce shortening of the mRNA 39 poly(A) tail, which contributes to their mRNA decay promoting function. The relationship between miRNA-mediated deadenylation and translational repression has been less clear. Using transfection of reporter constructs carrying three imperfectly matching let-7 target sites in the 39 UTR into mammalian cells we observe rapid target mRNA deadenylation that precedes measureable translational repression by endogenous let-7 miRNA. Depleting cells of the argonaute co-factors RCK or TNRC6A can impair let-7-mediated repression despite ongoing mRNA deadenylation, indicating that deadenylation alone is not sufficient to effect full repression. Nevertheless, the magnitude of translational repression by let-7 is diminished when the target reporter lacks a poly(A) tail. Employing an antisense strategy to block deadenylation of target mRNA with poly(A) tail also partially impairs translational repression. On the one hand, these experiments confirm that tail removal by deadenylation is not strictly required for translational repression. On the other hand they show directly that deadenylation can augment miRNA-mediated translational repression in mammalian cells beyond stimulating mRNA decay. Taken together with published work, these results suggest a dual role of deadenylation in miRNA function: it contributes to translational repression as well as mRNA decay and is thus critically involved in establishing the quantitatively appropriate physiological response to miRNAs.			Beilharz, TH (corresponding author), Victor Chang Cardiac Res Inst, Div Mol Genet, Sydney, NSW, Australia.	t.preiss@victorchang.edu.au	Beilharz, Traude/I-1438-2014; Preiss, Thomas/F-7355-2010; Hentze, Matthias W/V-3980-2017; Beilharz, Traude/O-5457-2019	Beilharz, Traude/0000-0002-8942-9502; Preiss, Thomas/0000-0001-6273-784X; Hentze, Matthias W/0000-0002-4023-7876; Beilharz, Traude/0000-0002-8942-9502; Humphreys, David/0000-0003-4140-0089				Amrani N, 2008, NATURE, V453, P1276, DOI 10.1038/nature06974; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Barreau C, 2006, RNA, V12, P1790, DOI 10.1261/rna.191706; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Behm-Ansmant I, 2006, GENE DEV, V20, P1885, DOI 10.1101/gad.1424106; Beilharz TH, 2007, RNA, V13, P982, DOI 10.1261/rna.569407; Beilharz TH, 2009, METHODS, V48, P294, DOI 10.1016/j.ymeth.2009.02.003; Beitzinger M, 2007, RNA BIOL, V4, P76, DOI 10.4161/rna.4.2.4640; Bergamini G, 2000, RNA, V6, P1781, DOI 10.1017/S1355838200001679; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351; Chekulaeva M, 2009, CURR OPIN CELL BIOL, V21, P452, DOI 10.1016/j.ceb.2009.04.009; Chekulaeva M, 2009, RNA, V15, P794, DOI 10.1261/rna.1364909; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Chu CY, 2006, PLOS BIOL, V4, P1122, DOI 10.1371/journal.pbio.0040210; Clancy JL, 2007, METHOD ENZYMOL, V431, P83, DOI 10.1016/S0076-6879(07)31006-9; Ding XC, 2008, CELL CYCLE, V7, P3083, DOI 10.4161/cc.7.19.6778; Ding XC, 2009, EMBO J, V28, P213, DOI 10.1038/emboj.2008.275; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Eulalio A, 2008, NAT STRUCT MOL BIOL, V15, P346, DOI 10.1038/nsmb.1405; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Eulalio A, 2007, GENE DEV, V21, P2558, DOI 10.1101/gad.443107; Eulalio A, 2009, RNA, V15, P1067, DOI 10.1261/rna.1605509; Eulalio A, 2009, RNA, V15, P21, DOI 10.1261/rna.1399509; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Goldstrohm AC, 2008, NAT REV MOL CELL BIO, V9, P337, DOI 10.1038/nrm2370; Gu S, 2009, NAT STRUCT MOL BIOL, V16, P144, DOI 10.1038/nsmb.1552; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; IWASAKI S, 2009, MOL CELL; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Jakymiw A, 2005, NAT CELL BIOL, V7, P1267, DOI 10.1038/ncb1334; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Kiriakidou M, 2007, CELL, V129, P1141, DOI 10.1016/j.cell.2007.05.016; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Kong YW, 2008, P NATL ACAD SCI USA, V105, P8866, DOI 10.1073/pnas.0800650105; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lazzaretti D, 2009, RNA, V15, P1059, DOI 10.1261/rna.1606309; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Liu JD, 2005, NAT CELL BIOL, V7, P1261, DOI 10.1038/ncb1333; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Maroney PA, 2006, NAT STRUCT MOL BIOL, V13, P1102, DOI 10.1038/nsmb1174; Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Meister G, 2005, CURR BIOL, V15, P2149, DOI 10.1016/j.cub.2005.10.048; Mishima Y, 2006, CURR BIOL, V16, P2135, DOI 10.1016/j.cub.2006.08.086; Muckenthaler M, 1997, RNA, V3, P983; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Nissan T, 2008, RNA, V14, P1480, DOI 10.1261/rna.1072808; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Peters L, 2007, MOL CELL, V26, P611, DOI 10.1016/j.molcel.2007.05.001; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Pillai RS, 2004, RNA, V10, P1518, DOI 10.1261/rna.7131604; Preiss T, 2003, BIOESSAYS, V25, P1201, DOI 10.1002/bies.10362; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Standart N, 2007, GENE DEV, V21, P1975, DOI 10.1101/gad.1591507; Thermann R, 2007, NATURE, V447, P875, DOI 10.1038/nature05878; Till S, 2007, NAT STRUCT MOL BIOL, V14, P897, DOI 10.1038/nsmb1302; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wakiyama M, 2007, GENE DEV, V21, P1857, DOI 10.1101/gad.1566707; Wang BB, 2008, P NATL ACAD SCI USA, V105, P5343, DOI 10.1073/pnas.0801102105; Wang BB, 2006, MOL CELL, V22, P553, DOI 10.1016/j.molcel.2006.03.034; Westman B, 2005, RNA, V11, P1505, DOI 10.1261/rna.2132505; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Wu L, 2008, MOL CELL, V29, P1, DOI 10.1016/j.molcel.2007.12.010; Yoshida M, 2006, EMBO J, V25, P1934, DOI 10.1038/sj.emboj.7601079; Zipprich JT, 2009, RNA, V15, P781, DOI 10.1261/rna.1448009	78	74	76	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6783	10.1371/journal.pone.0006783	http://dx.doi.org/10.1371/journal.pone.0006783			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710908	gold, Green Published			2022-12-27	WOS:000269415600004
J	Cuny, C; Nathaus, R; Layer, F; Strommenger, B; Altmann, D; Witte, W				Cuny, Christiane; Nathaus, Rolf; Layer, Franziska; Strommenger, Birgit; Altmann, Doris; Witte, Wolfgang			Nasal Colonization of Humans with Methicillin-Resistant Staphylococcus aureus (MRSA) CC398 with and without Exposure to Pigs	PLOS ONE			English	Article							HIGH-RISK; ST398; TRANSMISSION; CARRIAGE; INFECTIONS; PREVALENCE; ANIMALS; ORIGIN; SPREAD	Background: Studies in several European countries and in North America revealed a frequent nasal colonization of livestock with MRSA CC398 and also in humans with direct professional exposure to colonized animals. The study presented here addresses the question of further transmission to non exposed humans. Methods: After selecting 47 farms with colonized pigs in different regions of Germany we sampled the nares of 113 humans working daily with pigs and of their 116 non exposed family members. The same was performed in 18 veterinarians attending pig farms and in 44 of their non exposed family members. For investigating transmission beyond families we samples the nares of 462 pupils attending a secondary school in a high density pig farming area. MRSA were detected by direct culture on selective agar. The isolates were typed by means of spa-sequence typing and classification of SCCmec elements. For attribution of spa sequence types to clonal lineages as defined by multi locus sequence typing we used the BURP algorithm. Antibiotic susceptibility testing was performed by microbroth dilution assay. Results: At the farms investigated 86% of humans exposed and only 4.3% of their family members were found to carry MRSA exhibiting spa-types corresponding to clonal complex CC398. Nasal colonization was also found in 45% of veterinarians caring for pig farms and in 9% of their non exposed family members. Multivariate analysis revealed that antibiotic usage prior to sampling beard no risk with respect to colonization. From 462 pupils only 3 were found colonized, all 3 were living on pig farms. Conclusion: These results indicate that so far the dissemination of MRSA CC398 to non exposed humans is infrequent and probably does not reach beyond familial communities.			Cuny, C (corresponding author), Wernigerode Branc, Robert Koch Inst, Wernigerode, Germany.	wittew@rki.de		Layer, Franziska/0000-0002-4613-6478				Armand-Lefevre L, 2005, EMERG INFECT DIS, V11, P711, DOI 10.3201/eid1105.040866; Cuny C, 2008, MICROB DRUG RESIST, V14, P307, DOI 10.1089/mdr.2008.0845; Cuny Christiane, 2008, MMW Fortschr Med, V150 Suppl 2, P65; de Neeling AJ, 2007, VET MICROBIOL, V122, P366, DOI 10.1016/j.vetmic.2007.01.027; Declercq P, 2008, INFECTION, V36, P590, DOI 10.1007/s15010-007-7029-4; DENIS O, 2009, EMERG INFECT, V14; Enright MC, 2000, J CLIN MICROBIOL, V38, P1008, DOI 10.1128/JCM.38.3.1008-1015.2000; *GERM I STAND, 2000, MED MICR IMM DIAGN P, P215; GRAVELAND H, 2008, METHICILLIN RESISTAN; Guardabassi L, 2007, VET MICROBIOL, V122, P384, DOI 10.1016/j.vetmic.2007.03.021; Harmsen D, 2003, J CLIN MICROBIOL, V41, P5442, DOI 10.1128/JCM.41.12.5442-5448.2003; Holtfreter S, 2007, J CLIN MICROBIOL, V45, P2669, DOI 10.1128/JCM.00204-07; Huijsdens Xander W, 2006, Ann Clin Microbiol Antimicrob, V5, P26, DOI 10.1186/1476-0711-5-26; Khanna T, 2008, VET MICROBIOL, V128, P298, DOI 10.1016/j.vetmic.2007.10.006; Lewis HC, 2008, EMERG INFECT DIS, V14, P1383, DOI 10.3201/eid1409.071576; Loeffler A, 2005, J ANTIMICROB CHEMOTH, V56, P692, DOI 10.1093/jac/dki312; Lu PL, 2008, NEPHROL DIAL TRANSPL, V23, P1659, DOI 10.1093/ndt/gfm806; Mainous AG, 2006, ANN FAM MED, V4, P132, DOI 10.1370/afm.526; Martineau F, 1998, J CLIN MICROBIOL, V36, P618, DOI 10.1128/JCM.36.3.618-623.1998; Moodley A, 2008, SCAND J WORK ENV HEA, V34, P151, DOI 10.5271/sjweh.1219; MORAN GJ, 2008, J ANTIMICROB CHEMOTH, V62, P1181; Nemati M, 2008, ANTIMICROB AGENTS CH, V52, P3817, DOI 10.1128/AAC.00613-08; *ROBERTKOCH I, 2008, EPIDEMIOLOGISCHES B, V42, P63; Sergio DMB, 2007, J MED MICROBIOL, V56, P1107, DOI 10.1099/jmm.0.47283-0; Simoons-Smit AM, 2000, EUR J CLIN MICROBIOL, V19, P150, DOI 10.1007/s100960050450; Smith TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004258; Strommenger B, 2006, J CLIN MICROBIOL, V44, P2533, DOI 10.1128/JCM.00420-06; Tiemersma EW, 2004, EMERG INFECT DIS, V10, P1627, DOI 10.3201/eid1009.040069; Tristan A, 2007, EMERG INFECT DIS, V13, P594, DOI 10.3201/eid1304.061316; Urth T, 2005, INFECT CONT HOSP EP, V26, P144, DOI 10.1086/502518; van den Broek IVF, 2008, EPIDEMIOL INFECT, V24, P1; van Duijkeren E, 2008, VET MICROBIOL, V126, P383, DOI 10.1016/j.vetmic.2007.07.021; van Loo I, 2007, EMERG INFECT DIS, V13, P1834, DOI 10.3201/eid1312.070384; van Rijen MML, 2008, CLIN INFECT DIS, V46, P261, DOI 10.1086/524672; Wassenberg M W M, 2008, Ned Tijdschr Geneeskd, V152, P2681; WASSENBERG MWM, 2008, 18 EUR C CLIN MICR I; Witte W, 2007, CLIN MICROBIOL INFEC, V13, P408, DOI 10.1111/j.1469-0691.2006.01671.x; Witte W, 2007, EMERG INFECT DIS, V13, P255, DOI 10.3201/eid1302.060924; Wulf M, 2006, EMERG INFECT DIS, V12, P1939	39	167	168	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6800	10.1371/journal.pone.0006800	http://dx.doi.org/10.1371/journal.pone.0006800			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710922	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415600014
J	Bohland, JW; Bokil, H; Allen, CB; Mitra, PP				Bohland, Jason W.; Bokil, Hemant; Allen, Cara B.; Mitra, Partha P.			The Brain Atlas Concordance Problem: Quantitative Comparison of Anatomical Parcellations	PLOS ONE			English	Article							FUNCTIONAL IMAGING DATA; HUMAN CEREBRAL-CORTEX; HUMAN NEOCORTEX; TEMPORAL-LOBE; TALAIRACH; MNI; COORDINATE; SEGMENTATION; LOCALIZATION; ONTOLOGY	Many neuroscientific reports reference discrete macro-anatomical regions of the brain which were delineated according to a brain atlas or parcellation protocol. Currently, however, no widely accepted standards exist for partitioning the cortex and subcortical structures, or for assigning labels to the resulting regions, and many procedures are being actively used. Previous attempts to reconcile neuroanatomical nomenclatures have been largely qualitative, focusing on the development of thesauri or simple semantic mappings between terms. Here we take a fundamentally different approach, discounting the names of regions and instead comparing their definitions as spatial entities in an effort to provide more precise quantitative mappings between anatomical entities as defined by different atlases. We develop an analytical framework for studying this brain atlas concordance problem, and apply these methods in a comparison of eight diverse labeling methods used by the neuroimaging community. These analyses result in conditional probabilities that enable mapping between regions across atlases, which also form the input to graph-based methods for extracting higher-order relationships between sets of regions and to procedures for assessing the global similarity between different parcellations of the same brain. At a global scale, the overall results demonstrate a considerable lack of concordance between available parcellation schemes, falling within chance levels for some atlas pairs. At a finer level, this study reveals spatial relationships between sets of defined regions that are not obviously apparent; these are of high potential interest to researchers faced with the challenge of comparing results that were based on these different anatomical models, particularly when coordinate-based data are not available. The complexity of the spatial overlap patterns revealed points to problems for attempts to reconcile anatomical parcellations and nomenclatures using strictly qualitative and/or categorical methods. Detailed results from this study are made available via an interactive web site at http://obart.info.			Bohland, JW (corresponding author), Boston Univ, Dept Hlth Sci, Sargent Coll, Boston, MA 02215 USA.	jbohland@bu.edu	Bohland, Jason/L-4807-2016	Bohland, Jason/0000-0002-6305-5848; Mitra, Partha/0000-0001-8818-6804	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH084802] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH084802] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anthoney T. R, 1994, NEUROANATOMY NEUROLO; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bezgin G, 2008, NEURAL NETWORKS, V21, P1132, DOI 10.1016/j.neunet.2008.05.010; Bezgin G, 2009, NEUROINFORMATICS, V7, P7, DOI 10.1007/s12021-008-9039-5; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Bowden DM, 2003, NEUROINFORMATICS, V1, P43, DOI 10.1385/NI:1:1:043; BOWDEN DM, 1995, NEUROIMAGE, V2, P63, DOI 10.1006/nimg.1995.1009; Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756; Brodmann K, 1909, VERGLEICHENDE LOKALI; Burns Gully A P C, 2006, J Biomed Discov Collab, V1, P10, DOI 10.1186/1747-5333-1-10; Carmack PS, 2004, NEUROIMAGE, V22, P367, DOI 10.1016/j.neuroimage.2004.01.022; Caviness VS, 1996, J COGNITIVE NEUROSCI, V8, P566, DOI 10.1162/jocn.1996.8.6.566; Chau W, 2005, NEUROIMAGE, V25, P408, DOI 10.1016/j.neuroimage.2004.12.007; Chung F., 1997, SPECTRAL GRAPH THEOR; Crespo-Facorro B, 1999, NEUROIMAGE, V10, P500, DOI 10.1006/nimg.1999.0489; Devlin JT, 2007, NEUROIMAGE, V37, P1033, DOI 10.1016/j.neuroimage.2006.09.055; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; FIEDLER M, 1973, CZECH MATH J, V23, P298; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; HUBERT L, 1985, J CLASSIF, V2, P193, DOI 10.1007/BF01908075; Jaccard P., 1901, B SOC VAUD SCI N, V37, P241, DOI DOI 10.5169/SEALS-266450; Kennedy DN, 1998, CEREB CORTEX, V8, P372, DOI 10.1093/cercor/8.4.372; Kim JJ, 2000, NEUROIMAGE, V11, P271, DOI 10.1006/nimg.2000.0543; Klein A, 2005, NEUROIMAGE, V24, P261, DOI 10.1016/j.neuroimage.2004.09.016; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P115, DOI 10.1007/BF02289694; Laird AR, 2005, NEUROINFORMATICS, V3, P65, DOI 10.1385/NI:3:1:065; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LINDBERG DAB, 1993, METHOD INFORM MED, V32, P281, DOI 10.1055/s-0038-1634945; Marcus DS, 2007, J COGNITIVE NEUROSCI, V19, P1498, DOI 10.1162/jocn.2007.19.9.1498; Muller HM, 2008, NEUROINFORMATICS, V6, P195, DOI 10.1007/s12021-008-9031-0; Muller HM, 2004, PLOS BIOL, V2, P1984, DOI 10.1371/journal.pbio.0020309; Nielsen FA, 2002, HUM BRAIN MAPP, V15, P146, DOI 10.1002/hbm.10012; Nieto-Castanon A, 2003, NEUROIMAGE, V19, P1303, DOI 10.1016/S1053-8119(03)00188-5; PAPADIMITRIOU CH, 1976, COMPUTING, V16, P263, DOI 10.1007/BF02280884; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pohl KM, 2007, IEEE T MED IMAGING, V26, P1201, DOI 10.1109/TMI.2007.901433; Poldrack RA, 2007, SOC COGN AFFECT NEUR, V2, P67, DOI 10.1093/scan/nsm006; RADEMACHER J, 1992, J COGNITIVE NEUROSCI, V4, P352, DOI 10.1162/jocn.1992.4.4.352; Rosse C, 2003, J BIOMED INFORM, V36, P478, DOI 10.1016/j.jbi.2003.11.007; Rubin DL, 2006, OMICS, V10, P185, DOI 10.1089/omi.2006.10.185; Salton G., 1989, AUTOMATIC TEXT PROCE, VVolume 169; Schmahmann JD, 1999, NEUROIMAGE, V10, P233, DOI 10.1006/nimg.1999.0459; Shattuck DW, 2008, NEUROIMAGE, V39, P1064, DOI 10.1016/j.neuroimage.2007.09.031; Stephan KE, 2000, PHILOS T R SOC B, V355, P37, DOI 10.1098/rstb.2000.0548; Swanson L. W., 2003, BRAIN MAPS STRUCTURE; Talairach J., 1988, COPLANAR STEREOTAXIC; Tourville J. A., 2003, CASCNS03022 BOST U; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Van Essen DC, 2007, NEURON, V56, P209, DOI 10.1016/j.neuron.2007.10.015; Van Essen DC, 2005, DATABASING BRAIN DAT, P369; Whitmore I., 1998, TERMINOLOGIA ANATOMI; Wilder BG, 1896, J COMP NEUROL, V6, P216, DOI DOI 10.1002/CNE.910060306	57	102	102	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7200	10.1371/journal.pone.0007200	http://dx.doi.org/10.1371/journal.pone.0007200			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	500HR	19787067	Green Submitted, gold, Green Accepted, Green Published			2022-12-27	WOS:000270290100013
J	Ormond, J; Woodin, MA				Ormond, Jake; Woodin, Melanie A.			Disinhibition Mediates a Form of Hippocampal Long-Term Potentiation in Area CA1	PLOS ONE			English	Article								The hippocampus plays a central role in memory formation in the mammalian brain. Its ability to encode information is thought to depend on the plasticity of synaptic connections between neurons. In the pyramidal neurons constituting the primary hippocampal output to the cortex, located in area CA1, firing of presynaptic CA3 pyramidal neurons produces monosynaptic excitatory postsynaptic potentials (EPSPs) followed rapidly by feedforward (disynaptic) inhibitory postsynaptic potentials (IPSPs). Long-term potentiation (LTP) of the monosynaptic glutamatergic inputs has become the leading model of synaptic plasticity, in part due to its dependence on NMDA receptors (NMDARs), required for spatial and temporal learning in intact animals. Using whole-cell recording in hippocampal slices fromadult rats, we find that the efficacy of synaptic transmission from CA3 to CA1 can be enhanced without the induction of classic LTP at the glutamatergic inputs. Taking care not to directly stimulate inhibitory fibers, we show that the induction of GABAergic plasticity at feedforward inhibitory inputs results in the reduced shunting of excitatory currents, producing a long-term increase in the amplitude of Schaffer collateral-mediated postsynaptic potentials. Like classic LTP, disinhibition-mediated LTP requires NMDAR activation, suggesting a role in types of learning and memory attributed primarily to the former and raising the possibility of a previously unrecognized target for therapeutic intervention in disorders linked to memory deficits, as well as a potentially overlooked site of LTP expression in other areas of the brain.			Ormond, J (corresponding author), Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada.	jake.ormond@utoronto.ca; m.woodin@utoronto.ca	Woodin, Melanie A/A-2761-2008	Woodin, Melanie A/0000-0003-2984-8630				ABRAHAM WC, 1987, J PHYSIOL-LONDON, V394, P367, DOI 10.1113/jphysiol.1987.sp016875; ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; ASZTELY F, 1994, HIPPOCAMPUS, V4, P148, DOI 10.1002/hipo.450040205; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Campanac E, 2008, J NEUROSCI, V28, P8635, DOI 10.1523/JNEUROSCI.1411-08.2008; Chevaleyre V, 2003, NEURON, V38, P461, DOI 10.1016/S0896-6273(03)00235-6; Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; Daoudal G, 2002, P NATL ACAD SCI USA, V99, P14512, DOI 10.1073/pnas.222546399; Fiumelli H, 2005, NEURON, V48, P773, DOI 10.1016/j.neuron.2005.10.025; Fritschy JM, 1998, J COMP NEUROL, V390, P194; Glickfeld LL, 2006, NAT NEUROSCI, V9, P807, DOI 10.1038/nn1688; Gruart A, 2006, J NEUROSCI, V26, P1077, DOI 10.1523/JNEUROSCI.2834-05.2006; Gusev PA, 2001, J NEUROPHYSIOL, V86, P881, DOI 10.1152/jn.2001.86.2.881; Hardie J, 2009, J NEUROSCI, V29, P3233, DOI 10.1523/JNEUROSCI.6000-08.2009; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; HESS G, 1990, NEUROSCIENCE, V37, P61, DOI 10.1016/0306-4522(90)90192-7; Huerta PT, 2000, NEURON, V25, P473, DOI 10.1016/S0896-6273(00)80909-5; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Karnup S, 1999, J PHYSIOL-LONDON, V516, P485, DOI 10.1111/j.1469-7793.1999.0485v.x; Kitamura A, 2008, NEUROSCI RES, V62, P270, DOI 10.1016/j.neures.2008.09.002; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; Marder CP, 2004, J NEUROSCI, V24, P8873, DOI 10.1523/JNEUROSCI.2661-04.2004; Mehta MR, 2000, NEURON, V25, P707, DOI 10.1016/S0896-6273(00)81072-7; Meredith RM, 2003, J NEUROSCI, V23, P11142, DOI 10.1523/jneurosci.23-35-11142.2003; MILES R, 1990, J PHYSIOL-LONDON, V428, P61, DOI 10.1113/jphysiol.1990.sp018200; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nelson SB, 2008, NEURON, V60, P477, DOI 10.1016/j.neuron.2008.10.020; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; O'Neill J, 2008, NAT NEUROSCI, V11, P209, DOI 10.1038/nn2037; ORMOND J, 2006, SOC NEUR ANN M; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 2002, J CELL BIOL, V159, P747, DOI 10.1083/jcb.200209011; SAYER RJ, 1990, J NEUROSCI, V10, P826; Staff NP, 2003, HIPPOCAMPUS, V13, P801, DOI 10.1002/hipo.10129; STELZER A, 1994, P NATL ACAD SCI USA, V91, P3058, DOI 10.1073/pnas.91.8.3058; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Wittenberg GM, 2006, J NEUROSCI, V26, P6610, DOI 10.1523/JNEUROSCI.5388-05.2006; Woodin MA, 2003, NEURON, V39, P807, DOI 10.1016/S0896-6273(03)00507-5	46	36	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7224	10.1371/journal.pone.0007224	http://dx.doi.org/10.1371/journal.pone.0007224			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787049	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100021
J	Rosenblum, M; Deeks, SG; van der Laan, M; Bangsberg, DR				Rosenblum, Michael; Deeks, Steven G.; van der Laan, Mark; Bangsberg, David R.			The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy	PLOS ONE			English	Article							VIRAL SUPPRESSION; INDUCTION THERAPY; INHIBITOR THERAPY; DRUG-RESISTANCE; PLUS EFAVIRENZ; INFECTION; PROTEASE; CD4(+); MAINTENANCE; HOMELESS	Background: We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression would decrease with longer duration of viral suppression. Methodology: Eligible participants were identified from the REACH cohort of marginally housed HIV infected adults in San Francisco. Adherence to antiretroviral therapy was measured through pill counts obtained at unannounced visits by research staff to each participant's usual place of residence. Marginal structural models and targeted maximum likelihood estimation methodologies were used to determine the effect of adherence to antiretroviral therapy on the probability of virologic failure during early and late viral suppression. Principal Findings: A total of 221 subjects were studied (median age 44.1 years; median CD4+ T cell nadir 206 cells/mm(3)). Most subjects were taking the following types of antiretroviral regimens: non-nucleoside reverse transcriptase inhibitor based (37%), ritonavir boosted protease inhibitor based (28%), or unboosted protease inhibitor based (25%). Comparing the probability of failure just after achieving suppression vs. after 12 consecutive months of suppression, there was a statistically significant decrease in the probability of virologic failure for each range of adherence proportions we considered, as long as adherence was greater than 50%. The estimated risk difference, comparing the probability of virologic failure after 1 month vs. after 12 months of continuous viral suppression was 0.47 (95% CI 0.23-0.63) at 50-74% adherence, 0.29 (CI 0.03-0.50) at 75-89% adherence, and 0.36 (CI 0.23-0.48) at 90-100% adherence. Conclusions: The risk of virologic failure for adherence greater than 50% declines with longer duration of continuous suppression. While high adherence is required to maximize the probability of durable viral suppression, the range of adherence capable of sustaining viral suppression is wider after prolonged periods of viral suppression.			Rosenblum, M (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	david_bangsberg@harvard.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, R01MH054907] Funding Source: NIH RePORTER; NCRR NIH HHS [U54 RR023566-01] Funding Source: Medline; NIMH NIH HHS [T32 MH019105, 5 T32 MH-19105-19, R01 MH054907] Funding Source: Medline; PHS HHS [NIAAA 015287, A1074345-01, R01A1074345-01, 54907] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bangsberg DR., 2001, AIDS BEHAV, V5, P275, DOI DOI 10.1023/A:1011396711486; Cameron DW, 2008, J INFECT DIS, V198, P234, DOI 10.1086/589622; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Delfraissy JFO, 2008, AIDS, V22, P385, DOI 10.1097/QAD.0b013e3282f3f16d; Efron Bradley, 1993, INTRO BOOTSTRAP, V57; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595; Mallolas J, 2008, AIDS, V22, P377, DOI 10.1097/QAD.0b013e3282f3db2c; Markowitz M, 2005, JAIDS-J ACQ IMM DEF, V39, P257, DOI 10.1097/01.qai.0000169664.15536.20; Martin M, 2008, AIDS RES HUM RETROV, V24, P1263, DOI 10.1089/aid.2008.0141; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; NEUGEBAUER R, 2002, UC BERKELEY DIVISION; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Petersen ML, 2007, CLIN INFECT DIS, V45, P908, DOI 10.1086/521250; Petersen ML, 2006, JAIDS-J ACQ IMM DEF, V43, pS96, DOI 10.1097/01.qai.0000248344.95135.8d; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; Robertson MJ, 2004, AM J PUBLIC HEALTH, V94, P1207, DOI 10.2105/AJPH.94.7.1207; ROBINS J, 1986, MATH MODELLING, V7, P1393, DOI 10.1016/0270-0255(86)90088-6; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Robins JM, 2001, STAT SINICA, V11, P920; ROBINS JM, 1987, J CHRONIC DIS S2, V40; ROBINS JM, 2000, P AM STAT ASS SECTIO, V69; Robins JM, 1998, 1997 P AM STAT ASS S, P1, DOI DOI 10.1097/EDE.0B013E318245847E; Shuter J, 2008, J ANTIMICROB CHEMOTH, V61, P769, DOI 10.1093/jac/dkn020; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Strain MC, 2003, P NATL ACAD SCI USA, V100, P4819, DOI 10.1073/pnas.0736332100; van der Laan M.J., 2003, UNIFIED METHODS CENS, V5, DOI 10.1007/978-0-387-21700-0; van der Laan MJ, 2006, INT J BIOSTAT, V2, P11, DOI [10.2202/1557-4679.1043, DOI 10.2202/1557-4679.1043]; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455	41	92	92	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7196	10.1371/journal.pone.0007196	http://dx.doi.org/10.1371/journal.pone.0007196			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787058	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100011
J	Raherison, C; Janson, C; Jarvis, D; Burney, P; Cazzoletti, L; de Marco, R; Neukirch, F; Leynaert, B				Raherison, Chantal; Janson, Christer; Jarvis, Deborah; Burney, Peter; Cazzoletti, Lucia; de Marco, Roberto; Neukirch, Francoise; Leynaert, Benedicte			Evolution of Asthma Severity in a Cohort of Young Adults: Is There Any Gender Difference?	PLOS ONE			English	Article								Introduction: Little is known about the distribution of asthma severity in men and women in the general population. The objective of our study was to describe asthma severity and change in severity according to gender in a cohort of adult asthmatics. Methods: Subjects with asthma were identified from random samples of the 22 to 44 year-olds from the general population, screened for asthma from 1991 to 1993 in 48 centers from 22 countries and followed-up during 1998-2002, as part of the European Community Respiratory Health Survey (ECRHS). All participants to follow-up with current asthma at baseline were eligible for the analysis. To assess change over the follow-up, asthma severity at the two surveys was defined using standardized data on respiratory symptoms, lung function and medication according to the Global Initiative for Asthma (GINA) Guidelines. Another quantitative score (Ronchetti) further considering hospitalizations was also analysed. Results: The study included 685 subjects with asthma followed-up over a mean period of 8.65 yr (min 4.3-max 11.7). At baseline, asthma severity according to GINA was distributed as intermittent: 40.7%, 31.7% as mild persistent, 14% as moderate persistent, and 13.5% as severe persistent. Using the Ronchetti score derived classification, the distribution of asthma severity was 58% mild, (intermittent and mild persistent), 25.8% moderate, and 15.4% severe. Whatever the classification, there was no significant difference in the severity distribution between men and women. There was also no gender difference in the severity distribution among incident cases which developed asthma between the two surveys. Men with moderate-to-severe asthma at baseline were more likely than women to have moderate-to-severe asthma at follow-up. Using GINA, 69.2% of men vs. 53.1% of women (p = 0.09) with moderate-to-severe asthma at baseline were still moderate-to-severe at follow-up. Using Ronchetti score, 53.3% of men vs. 36.2% of women (p = 0.03) with moderate-to-severe asthma at baseline were still moderate-to-severe at follow-up. Conclusions: There was no gender difference in asthma severity at the two surveys. However, our findings suggest that asthma severity might be less stable in women than in men.			Raherison, C (corresponding author), Univ Bordeaux 2, Dept Resp Dis Haut Leveque CHU Bordeaux, ISPED, EA 3672, F-33076 Bordeaux, France.	chantal.raherison@chu-bordeaux.fr	Jarvis, Deborah/E-6494-2011; de Marco, Roberto/A-5470-2008; Leynaert, Benedicte/N-5251-2018; Raherison, Chantal/T-3556-2019	Burney, Peter/0000-0001-8635-5678; Leynaert, Benedicte/0000-0001-5045-2492; Jarvis, Deborah/0000-0002-1753-3896	NCRR NIH HHS [#2 S07 RR05521-28] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER; Medical Research Council [G0801056B] Funding Source: researchfish	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		*AM THOR SOC, 1995, AM J RESP CRIT CARE, V152, P1122; [Anonymous], 2003, EUR RESP J, V22, P470; Baraldo S., 2003, EUR RESP MONOGR, V25, P1, DOI [10.1183/1025448x.00025001, DOI 10.1183/1025448X.00025001]; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; European Community Respiratory Health Survey IISC, 2002, EUR RESP J, V20, P1071; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; National Institutes of Health, 1992, INT CONS REP DIAGN T; *NIH, 2004, GLOB STRAT ASTHM MAN; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; Ronchetti R, 1997, EUR RESPIR J, V10, P1248, DOI 10.1183/09031936.97.10061248; Salmeron S, 2001, LANCET, V358, P629, DOI 10.1016/S0140-6736(01)05779-8; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Trawick DR, 2001, CHEST, V119, P115, DOI 10.1378/chest.119.1.115; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Watson L, 2003, EUR RESP MON, V8, P50; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	26	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7146	10.1371/journal.pone.0007146	http://dx.doi.org/10.1371/journal.pone.0007146			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779616	Green Submitted, gold, Green Published			2022-12-27	WOS:000270176200004
J	Koehler, JW; Bolton, M; Rollins, A; Snook, K; Deharo, E; Henson, E; Rogers, L; Martin, LN; Krogstad, DJ; James, MA; Rice, J; Davison, B; Veazey, RS; Prabhu, R; Amedee, AM; Garry, RF; Cogswell, FB				Koehler, Jeffrey W.; Bolton, Michael; Rollins, Amanda; Snook, Kirsten; Deharo, Eileen; Henson, Elizabeth; Rogers, Linda; Martin, Louis N.; Krogstad, Donald J.; James, Mark A.; Rice, Janet; Davison, Billie; Veazey, Ronald S.; Prabhu, Ramesh; Amedee, Angela M.; Garry, Robert F.; Cogswell, Frank B.			Altered Immune Responses in Rhesus Macaques Co-Infected with SIV and Plasmodium cynomolgi: An Animal Model for Coincident AIDS and Relapsing Malaria	PLOS ONE			English	Article								Background: Dual epidemics of the malaria parasite Plasmodium and HIV-1 in sub-Saharan Africa and Asia present a significant risk for co-infection in these overlapping endemic regions. Recent studies of HIV/Plasmodium falciparum co-infection have reported significant interactions of these pathogens, including more rapid CD4+ T cell loss, increased viral load, increased immunosuppression, and increased episodes of clinical malaria. Here, we describe a novel rhesus macaque model for co-infection that supports and expands upon findings in human co-infection studies and can be used to identify interactions between these two pathogens. Methodology/Principal Findings: Five rhesus macaques were infected with P. cynomolgi and, following three parasite relapses, with SIV. Compared to macaques infected with SIV alone, co-infected animals had, as a group, decreased survival time and more rapid declines in markers for SIV progression, including peripheral CD4+ T cells and CD4+/CD8+ T cell ratios. The naive CD4+ T cell pool of the co-infected animals was depleted more rapidly than animals infected with SIV alone. The co-infected animals also failed to generate proliferative responses to parasitemia by CD4+ and CD8+ T cells as well as B cells while also having a less robust anti-parasite and altered anti-SIV antibody response. Conclusions/Significance: These data suggest that infection with both SIV and Plasmodium enhances SIV-induced disease progression and impairs the anti-Plasmodium immune response. These data support findings in HIV/Plasmodium co-infection studies. This animal model can be used to further define impacts of lentivirus and Plasmodium co-infection and guide public health and therapeutic interventions.			Koehler, JW (corresponding author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA.	jeff.koehler@amedd.army.mil		Garry, Robert/0000-0002-5683-3250; Koehler, Jeffrey/0000-0003-3225-6599	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR018229] Funding Source: NIH RePORTER; NCRR NIH HHS [RR018229, R01 RR018229] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abu-Raddad LJ, 2006, SCIENCE, V314, P1603, DOI 10.1126/science.1132338; AMEDEE AM, 1995, J VIROL, V69, P7982, DOI 10.1128/JVI.69.12.7982-7990.1995; Amedee AM, 1996, J MED PRIMATOL, V25, P225, DOI 10.1111/j.1600-0684.1996.tb00020.x; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Cohen C, 2005, CLIN INFECT DIS, V41, P1631, DOI 10.1086/498023; CONWAY MD, 1991, J MED PRIMATOL, V20, P152; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Davison BB, 1998, AM J TROP MED HYG, V59, P189, DOI 10.4269/ajtmh.1998.59.189; Davison BB, 2000, AM J TROP MED HYG, V63, P158, DOI 10.4269/ajtmh.2000.63.158; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Dutta S, 2005, INFECT IMMUN, V73, P5936, DOI 10.1128/IAI.73.9.5936-5944.2005; French N, 2001, AIDS, V15, P899, DOI 10.1097/00002030-200105040-00010; FUJIOKA H, 1994, EXP PARASITOL, V78, P371, DOI 10.1006/expr.1994.1040; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Holterman L, 2000, J GEN VIROL, V81, P1719, DOI 10.1099/0022-1317-81-7-1719; Holterman L, 1999, J GEN VIROL, V80, P3089, DOI 10.1099/0022-1317-80-12-3089; IBIWOYE MO, 1993, J COMP PATHOL, V108, P303, DOI 10.1016/S0021-9975(08)80293-9; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kamya MR, 2006, J INFECT DIS, V193, P9, DOI 10.1086/498577; Kaslow DC, 1996, IMMUNOL LETT, V51, P187, DOI 10.1016/0165-2478(96)02570-9; KAWAI S, 1993, AM J TROP MED HYG, V48, P630, DOI 10.4269/ajtmh.1993.48.630; Kublin JG, 2005, LANCET, V365, P233, DOI 10.1016/S0140-6736(05)17743-5; KUVIN SANFORD F., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P371, DOI 10.1016/0035-9203(62)90007-X; Laufer MK, 2006, J INFECT DIS, V193, P872, DOI 10.1086/500245; Lawn SD, 2001, CLIN MICROBIOL REV, V14, P753, DOI 10.1128/CMR.14.4.753-777.2001; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARTIN LN, 1994, ANTIMICROB AGENTS CH, V38, P1277, DOI 10.1128/AAC.38.6.1277; MEDING SJ, 1991, EUR J IMMUNOL, V21, P1433, DOI 10.1002/eji.1830210616; Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3; Mermin J, 2006, JAIDS-J ACQ IMM DEF, V41, P129, DOI 10.1097/01.qai.0000179427.11789.a7; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; Nishimura Y, 2007, J VIROL, V81, P893, DOI 10.1128/JVI.01635-06; Patnaik P, 2005, J INFECT DIS, V192, P984, DOI 10.1086/432730; Praba-Egge AD, 2002, AM J TROP MED HYG, V67, P586, DOI 10.4269/ajtmh.2002.67.586; Rychert J, 2006, J VIROL, V80, P3721, DOI 10.1128/JVI.80.8.3721-3731.2006; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SCHMIDT LH, 1986, AM J TROP MED HYG, V35, P1077, DOI 10.4269/ajtmh.1986.35.1077; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; SPERBER K, 1995, CLIN THER, V17, P622, DOI 10.1016/0149-2918(95)80039-5; Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311; Tongren JE, 2000, AM J TROP MED HYG, V62, P530, DOI 10.4269/ajtmh.2000.62.530; Trichel AM, 2002, J MED PRIMATOL, V31, P171, DOI 10.1034/j.1600-0684.2002.02003.x; Trichel AM, 1997, J MED PRIMATOL, V26, P3, DOI 10.1111/j.1600-0684.1997.tb00313.x; VASLIN B, 1994, VACCINE, V12, P1132, DOI 10.1016/0264-410X(94)90184-8; Veazey RS, 2000, J VIROL, V74, P11001, DOI 10.1128/JVI.74.23.11001-11007.2000; WATERS AP, 1993, MOL BIOL EVOL, V10, P914; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; 2007, AIDS EPIDEMIC UPDATE	49	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7139	10.1371/journal.pone.0007139	http://dx.doi.org/10.1371/journal.pone.0007139			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774084	gold, Green Published, Green Submitted			2022-12-27	WOS:000270160900016
J	Wiley, JA; Richert, LE; Swain, SD; Harmsen, A; Barnard, DL; Randall, TD; Jutila, M; Douglas, T; Broomell, C; Young, M; Harmsen, A				Wiley, James A.; Richert, Laura E.; Swain, Steve D.; Harmsen, Ann; Barnard, Dale L.; Randall, Troy D.; Jutila, Mark; Douglas, Trevor; Broomell, Chris; Young, Mark; Harmsen, Allen			Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses	PLOS ONE			English	Article								Background: Destruction of the architectural and subsequently the functional integrity of the lung following pulmonary viral infections is attributable to both the extent of pathogen replication and to the host-generated inflammation associated with the recruitment of immune responses. The presence of antigenically disparate pulmonary viruses and the emergence of novel viruses assures the recurrence of lung damage with infection and resolution of each primary viral infection. Thus, there is a need to develop safe broad spectrum immunoprophylactic strategies capable of enhancing protective immune responses in the lung but which limits immune-mediated lung damage. The immunoprophylactic strategy described here utilizes a protein cage nanoparticle (PCN) to significantly accelerate clearance of diverse respiratory viruses after primary infection and also results in a host immune response that causes less lung damage. Methodology/Principal Findings: Mice pre-treated with PCN, independent of any specific viral antigens, were protected against both sub-lethal and lethal doses of two different influenza viruses, a mouse-adapted SARS-coronavirus, or mouse pneumovirus. Treatment with PCN significantly increased survival and was marked by enhanced viral clearance, accelerated induction of viral-specific antibody production, and significant decreases in morbidity and lung damage. The enhanced protection appears to be dependent upon the prior development of inducible bronchus-associated lymphoid tissue (iBALT) in the lung in response to the PCN treatment and to be mediated through CD4+ T cell and B cell dependent mechanisms. Conclusions/Significance: The immunoprophylactic strategy described utilizes an infection-independent induction of naturally occurring iBALT prior to infection by a pulmonary viral pathogen. This strategy non-specifically enhances primary immunity to respiratory viruses and is not restricted by the antigen specificities inherent in typical vaccination strategies. PCN treatment is asymptomatic in its application and importantly, ameliorates the damaging inflammation normally associated with the recruitment of immune responses into the lung.			Wiley, JA (corresponding author), Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA.	jwiley@montana.edu	Douglas, Trevor/GRS-0012-2022; Douglas, Trevor/F-2748-2011	Douglas, Trevor/0000-0002-7882-2704; 	NCRR NIH HHS [P20 RR016455, P20 RR020185, P20-RR16455, P20-RR020185] Funding Source: Medline; NHLBI NIH HHS [R01 HL069409, HL69409] Funding Source: Medline; NIAID NIH HHS [HHSN26620040009C/N01-AI-40009, N01AI40009, AI072689, AI083520, U54-AI065357, R21 AI083520, R01 AI072689, U54 AI065357] Funding Source: Medline; NIBIB NIH HHS [EB005364, R21 EB005364] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185, P20RR016455] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI065357, R21AI083520, R01AI072689, N01AI40009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB005364] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Belshe Robert, 2004, Expert Rev Vaccines, V3, P643, DOI 10.1586/14760584.3.6.643; Carragher DM, 2008, SEMIN IMMUNOL, V20, P26, DOI 10.1016/j.smim.2007.12.004; Chen HD, 2003, AM J PATHOL, V163, P1341, DOI 10.1016/S0002-9440(10)63493-1; Drent M, 1996, EUR RESPIR J, V9, P1736, DOI 10.1183/09031936.96.09081736; Flenniken ML, 2006, CHEM BIOL, V13, P161, DOI 10.1016/j.chembiol.2005.11.007; Humphreys IR, 2003, J EXP MED, V198, P1237, DOI 10.1084/jem.20030351; Karaolis DKR, 2007, INFECT IMMUN, V75, P4942, DOI 10.1128/IAI.01762-06; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Minne A, 2008, VACCINE, V26, P2360, DOI 10.1016/j.vaccine.2008.02.062; Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091; Moyron-Quiroz JE, 2006, IMMUNITY, V25, P643, DOI 10.1016/j.immuni.2006.08.022; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Randall TD, 2008, ANNU REV IMMUNOL, V26, P627, DOI 10.1146/annurev.immunol.26.021607.090257; Rangel-Moreno J, 2006, J CLIN INVEST, V116, P3183, DOI 10.1172/JCI28756; Rosenberg HF, 2008, IMMUNOL LETT, V118, P6, DOI 10.1016/j.imlet.2008.03.013; Treanor J, 2006, VACCINE, V24, P6913, DOI 10.1016/j.vaccine.2006.06.006; Wiley JA, 1999, AM J PATHOL, V154, P919, DOI 10.1016/S0002-9440(10)65339-4; Wiley JA, 2005, J IMMUNOL, V175, P3186, DOI 10.4049/jimmunol.175.5.3186; Wiley JA, 2001, AM J PATHOL, V158, P119, DOI 10.1016/S0002-9440(10)63950-8	19	85	89	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7142	10.1371/journal.pone.0007142	http://dx.doi.org/10.1371/journal.pone.0007142			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774076	gold, Green Published			2022-12-27	WOS:000270160900017
J	Ganesalingam, J; Stahl, D; Wijesekera, L; Galtrey, C; Shaw, CE; Leigh, PN; Al-Chalabi, A				Ganesalingam, Jeban; Stahl, Daniel; Wijesekera, Lokesh; Galtrey, Clare; Shaw, Christopher E.; Leigh, P. Nigel; Al-Chalabi, Ammar			Latent Cluster Analysis of ALS Phenotypes Identifies Prognostically Differing Groups	PLOS ONE			English	Article							MOTOR-NEURON DISEASE; LATERAL-SCLEROSIS; MOLECULAR SIGNATURE; CLINICAL-FEATURES; FLAIL ARM; CLASSIFICATION; DIAGNOSIS; CRITERIA; HISTORY; TRIALS	Background: Amyotrophic lateral sclerosis (ALS) is a degenerative disease predominantly affecting motor neurons and manifesting as several different phenotypes. Whether these phenotypes correspond to different underlying disease processes is unknown. We used latent cluster analysis to identify groupings of clinical variables in an objective and unbiased way to improve phenotyping for clinical and research purposes. Methods: Latent class cluster analysis was applied to a large database consisting of 1467 records of people with ALS, using discrete variables which can be readily determined at the first clinic appointment. The model was tested for clinical relevance by survival analysis of the phenotypic groupings using the Kaplan-Meier method. Results: The best model generated five distinct phenotypic classes that strongly predicted survival (p<0.0001). Eight variables were used for the latent class analysis, but a good estimate of the classification could be obtained using just two variables: site of first symptoms (bulbar or limb) and time from symptom onset to diagnosis (p<0.00001). Conclusion: The five phenotypic classes identified using latent cluster analysis can predict prognosis. They could be used to stratify patients recruited into clinical trials and generating more homogeneous disease groups for genetic, proteomic and risk factor research.			Ganesalingam, J (corresponding author), Kings Coll London, Inst Psychiat, MRC, Ctr Neurodegenerat Res,Dept Clin Neurosci, London WC2R 2LS, England.	ammar@iop.kcl.ac.uk	Leigh, Peter/AAD-5638-2019; Stahl, Daniel/B-9713-2011; Al-Chalabi, Ammar/E-5361-2010	Stahl, Daniel/0000-0001-7987-6619; Al-Chalabi, Ammar/0000-0002-4924-7712; Shaw, Christopher/0000-0003-0251-0146	MRC [G0500289, G0900688] Funding Source: UKRI; Medical Research Council [G0500289, G0900688, G0500289B] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Andersen PM, 1997, BRAIN, V120, P1723, DOI 10.1093/brain/120.10.1723; Beghi E, 2006, BBA-MOL BASIS DIS, V1762, P1150, DOI 10.1016/j.bbadis.2006.09.008; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Dangond F, 2004, PHYSIOL GENOMICS, V16, P229, DOI 10.1152/physiolgenomics.00087.2001; De Carvalho M, 2005, AMYOTROPH LATERAL SC, V6, P202, DOI 10.1080/14660820510011997; de Carvalho M, 2008, CLIN NEUROPHYSIOL, V119, P497, DOI 10.1016/j.clinph.2007.09.143; GILBERT ES, 1968, J AM STAT ASSOC, V63, P1399, DOI 10.2307/2285893; Gruzman A, 2007, P NATL ACAD SCI USA, V104, P12524, DOI 10.1073/pnas.0705044104; Hu MTM, 1998, J NEUROL NEUROSUR PS, V65, P950, DOI 10.1136/jnnp.65.6.950; Katz JS, 1999, NEUROLOGY, V53, P1071, DOI 10.1212/WNL.53.5.1071; Lambrechts D, 2007, TRENDS NEUROSCI, V30, P536, DOI 10.1016/j.tins.2007.07.002; Lazarsfeld P.F., 1968, LATENT STRUCTURE ANA; Lomen-Hoerth C, 2003, NEUROLOGY, V60, P1094, DOI 10.1212/01.WNL.0000055861.95202.8D; McCutcheon AL, 1987, LATENT CLASS ANAL; Miller RG, 1999, J NEUROL SCI, V169, P2, DOI 10.1016/S0022-510X(99)00209-9; MOORE DH, 1973, J AM STAT ASSOC, V68, P399, DOI 10.1080/01621459.1973.10482440; Muthen L, 2007, MUTH N MUTH N; PRINGLE CE, 1992, BRAIN, V115, P495, DOI 10.1093/brain/115.2.495; RAMASWAMY V, 1993, MARKET SCI, V12, P103, DOI 10.1287/mksc.12.1.103; Rosenfeld J, 2006, NEUROLOGY, V66, P624, DOI 10.1212/01.wnl.0000205597.62054.db; Skrondal A., 2004, GEN LATENT VARIABLE; Swash M, 2000, AMYOTROPH LATERAL SC, V1, P105; Tabachnick B.G., 2014, USING MULTIVARIATE S, V6th Ed., P659; Talman P, 2008, AMYOTROPH LATERAL SC, V18, P1; Turner MR, 2002, AMYOTROPH LATERAL SC, V3, P15, DOI 10.1080/146608202317576499; Valdmanis PN, 2008, NEUROLOGY, V70, P144, DOI 10.1212/01.wnl.0000296811.19811.db; Visser J, 2008, NEUROLOGY, V70, P723, DOI 10.1212/01.wnl.0000302187.20239.93; Wijesekera LC, 2009, NEUROLOGY, V72, P1087, DOI 10.1212/01.wnl.0000345041.83406.a2; Zoccolella S, 2005, NEUROL SCI, V26, P330, DOI 10.1007/s10072-005-0501-y; [No title captured]	30	50	52	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7107	10.1371/journal.pone.0007107	http://dx.doi.org/10.1371/journal.pone.0007107			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771164	Green Published, Green Submitted, Green Accepted, gold			2022-12-27	WOS:000270154400006
J	Magold, AI; Cacquevel, M; Fraering, PC				Magold, Alexandra I.; Cacquevel, Matthias; Fraering, Patrick C.			Gene Expression Profiling in Cells with Enhanced gamma-Secretase Activity	PLOS ONE			English	Article								Background: Processing by gamma-secretase of many type-I membrane protein substrates triggers signaling cascades by releasing intracellular domains (ICDs) that, following nuclear translocation, modulate the transcription of different genes regulating a diverse array of cellular and biological processes. Because the list of gamma-secretase substrates is growing quickly and this enzyme is a cancer and Alzheimer's disease therapeutic target, the mapping of gamma-secretase activity susceptible gene transcription is important for sharpening our view of specific affected genes, molecular functions and biological pathways. Methodology/Principal Findings: To identify genes and molecular functions transcriptionally affected by gamma-secretase activity, the cellular transcriptomes of Chinese hamster ovary (CHO) cells with enhanced and inhibited gamma-secretase activity were analyzed and compared by cDNA microarray. The functional clustering by FatiGO of the 1,981 identified genes revealed over- and under-represented groups with multiple activities and functions. Single genes with the most pronounced transcriptional susceptibility to gamma-secretase activity were evaluated by real-time PCR. Among the 21 validated genes, the strikingly decreased transcription of PTPRG and AMN1 and increased transcription of UPP1 potentially support data on cell cycle disturbances relevant to cancer, stem cell and neurodegenerative diseases' research. The mapping of interactions of proteins encoded by the validated genes exclusively relied on evidence-based data and revealed broad effects on Wnt pathway members, including WNT3A and DVL3. Intriguingly, the transcription of TERA, a gene of unknown function, is affected by gamma-secretase activity and was significantly altered in the analyzed human Alzheimer's disease brain cortices. Conclusions/Significance: Investigating the effects of gamma-secretase activity on gene transcription has revealed several affected clusters of molecular functions and, more specifically, 21 genes that hold significant potential			Magold, AI (corresponding author), Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Sch Life Sci, Brain Mind Inst, CH-1015 Lausanne, Switzerland.	Patrick.fraering@epfl.ch		Magold, Alexandra/0000-0001-6979-9584; Fraering, Patrick/0000-0002-5841-5327	NIA NIH HHS [P30 AG028377] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG028377] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe Y, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-27; Abramova N, 2005, DEV BIOL, V283, P269, DOI 10.1016/j.ydbio.2005.03.040; Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9; Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; An L, 2009, NEUROSCI LETT, V452, P277, DOI 10.1016/j.neulet.2009.01.071; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Aoyama K, 2007, STEM CELLS, V25, P2488, DOI 10.1634/stemcells.2007-0102; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Avasarala JR, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-2; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; Beecham GW, 2009, AM J HUM GENET, V84, P35, DOI 10.1016/j.ajhg.2008.12.008; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Brem H, 2007, MOL MED, V13, P30, DOI 10.2119/2006-00054.Brem; Cacquevel M, 2008, J NEUROCHEM, V104, P210, DOI 10.1111/j.1471-4159.2007.05041.x; Cansev M, 2008, ALZHEIMERS DEMENT, V4, pS153, DOI 10.1016/j.jalz.2007.10.005; Castensson A, 2000, GENOME RES, V10, P1219, DOI 10.1101/gr.10.8.1219; Chen JY, 2006, J BIOL CHEM, V281, P11910, DOI 10.1074/jbc.M511920200; Cheung AKL, 2008, CANCER RES, V68, P8137, DOI 10.1158/0008-5472.CAN-08-0904; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Ernst Wolfgang, 2006, Biotechnology Journal, V1, P639, DOI 10.1002/biot.200600010; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Fraering PC, 2007, CURR GENOMICS, V8, P531, DOI 10.2174/138920207783769521; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Frank CF, 2007, TRANSL RES, V149, P211, DOI 10.1016/j.trsl.2006.11.006; GAEDICKE S, 2009, BR J NUTR, P1; Gatti MD, 2007, J BIOSCI BIOENG, V103, P82, DOI 10.1263/jbb.103.82; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Haapasalo A, 2007, J BIOL CHEM, V282, P9063, DOI 10.1074/jbc.M611324200; He X, 2008, NAT CELL BIOL, V10, P11, DOI 10.1038/ncb0108-11; Hulette CM, 1997, ARCH PATHOL LAB MED, V121, P615; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Jin YH, 2009, BBA-MOL CELL RES, V1793, P290, DOI 10.1016/j.bbamcr.2008.10.002; Kamagata E, 2009, BIOCHEM BIOPH RES CO, V379, P691, DOI 10.1016/j.bbrc.2008.12.147; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee JL, 2007, CANCER RES, V67, P2089, DOI 10.1158/0008-5472.CAN-06-3625; Liu Q, 2007, NEURON, V56, P66, DOI 10.1016/j.neuron.2007.08.008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowell S, 2006, PLOS BIOL, V4, P805, DOI 10.1371/journal.pbio.0040121; Luo J, 2008, J NEUROSCI, V28, P3804, DOI 10.1523/JNEUROSCI.0224-08.2008; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Matoba R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000026; McClintock TS, 2008, PHYSIOL GENOMICS, V32, P198, DOI 10.1152/physiolgenomics.00128.2007; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28; Muller T, 2007, MOL BIOL CELL, V18, P201, DOI 10.1091/mbc.E06-04-0283; *NCI NAT, 2009, PATHW INT DAT; Ohlstein B, 2007, SCIENCE, V315, P988, DOI 10.1126/science.1136606; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Opar A, 2008, NAT REV DRUG DISCOV, V7, P717, DOI 10.1038/nrd2676; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pascual A, 2008, NAT NEUROSCI, V11, P755, DOI 10.1038/nn.2136; PAUL T, 2002, PRINCIPLES PRACTICE, P229; Petroziello J, 2004, ONCOGENE, V23, P7734, DOI 10.1038/sj.onc.1207921; Pfenninger KH, 2009, NAT REV NEUROSCI, V10, P251, DOI 10.1038/nrn2593; Pizzorno G, 2002, BBA-MOL BASIS DIS, V1587, P133, DOI 10.1016/S0925-4439(02)00076-5; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Richter K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-75; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; Russell RL, 2001, J BIOL CHEM, V276, P13302, DOI 10.1074/jbc.M008512200; Sahin F, 2005, PANCREAS, V30, P158, DOI 10.1097/01.mpa.0000151581.45156.e4; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Schumann G, 1998, MOL BRAIN RES, V62, P56, DOI 10.1016/S0169-328X(98)00237-X; Scott WK, 2000, AM J HUM GENET, V66, P922, DOI 10.1086/302828; Sharov AA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-269; Sharples RA, 2008, FASEB J, V22, P1469, DOI 10.1096/fj.07-9357com; Shou JY, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1883; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Soulie C, 2004, NEUROSCI LETT, V365, P1, DOI 10.1016/j.neulet.2004.03.090; Sun XL, 2006, FASEB J, V20, P1361, DOI 10.1096/fj.05-5628com; TAKEDA M, 1990, ACTA NEUROL SCAND, V82, P238; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Tang BSF, 2005, J VIROL, V79, P6180, DOI 10.1128/JVI.79.10.6180-6193.2005; Tanimizu N, 2004, J CELL SCI, V117, P3165, DOI 10.1242/jcs.01169; Terrand J, 2009, J BIOL CHEM, V284, P381, DOI 10.1074/jbc.M806538200; Wakabayashi T, 2008, PHYSIOLOGY, V23, P194, DOI 10.1152/physiol.00009.2008; WATANABE SI, 1995, BIOCHEM BIOPH RES CO, V216, P265, DOI 10.1006/bbrc.1995.2619; Whitfield JF, 2004, CELL SIGNAL, V16, P763, DOI 10.1016/j.cellsig.2003.12.002; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yee JC, 2008, BIOTECHNOL BIOENG, V101, P1359, DOI 10.1002/bit.21984; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhou J, 2009, ANNU REV PHYSIOL, V71, P83, DOI 10.1146/annurev.physiol.70.113006.100621; Zurhove K, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164263	92	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e6952	10.1371/journal.pone.0006952	http://dx.doi.org/10.1371/journal.pone.0006952			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763259	gold, Green Published, Green Submitted			2022-12-27	WOS:000269970400002
J	Gustafsson, MCU; Knight, D; Palmer, CNA				Gustafsson, Mattias C. U.; Knight, Deborah; Palmer, Colin N. A.			Ligand Modulated Antagonism of PPAR gamma by Genomic and Non-Genomic Actions of PPAR delta	PLOS ONE			English	Article							PROLIFERATOR-ACTIVATED-RECEPTOR; FATTY-ACID-METABOLISM; PEROXISOME-PROLIFERATOR; CROSS-TALK; NUTRITIONAL REGULATION; TRANSCRIPTION; GENE; LXR; PEROXISOME-PROLIFERATOR-ACTIVATED-RECEPTOR-(PPAR)-ALPHA; IDENTIFICATION	Background: Members of the Peroxisome Proliferator Activated Receptor, PPAR, subfamily of nuclear receptors display complex opposing and overlapping functions and a wide range of pharmacological and molecular genetic tools have been used to dissect their specific functions. Non-agonist bound PPAR delta has been shown to repress PPAR Response Element, PPRE, signalling and several lines of evidence point to the importance of PPAR delta repressive actions in both cardiovascular and cancer biology. Methodology/Principal Findings: In this report we have employed transient transfections and luciferase reporter gene technology to study the repressing effects of PPAR delta and two derivatives thereof. We demonstrate for the first time that the classical dominant negative deletion of the Activation Function 2, AF2, domain of PPAR delta show enhanced repression of PPRE signalling in the presence of a PPAR delta agonist. We propose that the mechanism for the phenomenon is increased RXR heterodimerisation and DNA binding upon ligand binding concomitant with transcriptional co-repressor binding. We also demonstrated ligand-dependent dominant negative action of a DNA non-binding derivative of PPAR delta on PPAR gamma 1 signalling. This activity was abolished upon over-expression of RXR alpha suggesting a role for PPAR/cofactor competition in the absence of DNA binding. Conclusions/Significance: These findings are important in understanding the wide spectrum of molecular interactions in which PPAR delta and PPAR gamma have opposing biological roles and suggest novel paradigms for the design of different functional classes of nuclear receptor antagonist drugs.			Gustafsson, MCU (corresponding author), Lund Univ, Dept Lab Med, Div Med Microbiol, Lund, Sweden.	Mattias.Gustafsson@med.lu.se	Gustafsson, Mattias C. U./A-7451-2010; Palmer, Colin NA/C-7053-2008	Gustafsson, Mattias C. U./0000-0003-3260-0724; Palmer, Colin NA/0000-0002-6415-6560	Medical Research Council [G0000119] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABBOTT BD, 2008, REPROD TOXICOL; Adamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Araki O, 2005, P NATL ACAD SCI USA, V102, P16251, DOI 10.1073/pnas.0508556102; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Matsusue K, 2006, MOL CELL ENDOCRINOL, V256, P23, DOI 10.1016/j.mce.2006.05.005; Michalik L, 2005, MOL ENDOCRINOL, V19, P2335, DOI 10.1210/me.2005-0068; Riserus U, 2008, DIABETES, V57, P332, DOI 10.2337/db07-1318; Sambrook J., 2001, MOL CLONING LAB MANU; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Seedorf U, 2007, BBA-MOL CELL BIOL L, V1771, P1125, DOI 10.1016/j.bbalip.2007.04.017; Shearer BG, 2008, MOL ENDOCRINOL, V22, P523, DOI 10.1210/me.2007-0190; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Sprecher DL, 2007, ARTERIOSCL THROM VAS, V27, P359, DOI 10.1161/01.ATV.0000252790.70572.0c; Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460; Tachibana K, 2008, PPAR RES, V2008, DOI 10.1155/2008/102737; Takahashi S, 2007, ENDOCR J, V54, P347, DOI 10.1507/endocrj.KR-99; Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Ying H, 2007, MOL CELL BIOL, V27, P2359, DOI 10.1128/MCB.02189-06; Yoshikawa T, 2003, MOL ENDOCRINOL, V17, P1240, DOI 10.1210/me.2002-0190	36	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7046	10.1371/journal.pone.0007046	http://dx.doi.org/10.1371/journal.pone.0007046			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756148	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970000013
J	Maaty, WS; Wiedenheft, B; Tarlykov, P; Schaff, N; Heinemann, J; Robison-Cox, J; Valenzuela, J; Dougherty, A; Blum, P; Lawrence, CM; Douglas, T; Young, MJ; Bothner, B				Maaty, Walid S.; Wiedenheft, Blake; Tarlykov, Pavel; Schaff, Nathan; Heinemann, Joshua; Robison-Cox, Jim; Valenzuela, Jacob; Dougherty, Amanda; Blum, Paul; Lawrence, C. Martin; Douglas, Trevor; Young, Mark J.; Bothner, Brian			Something Old, Something New, Something Borrowed; How the Thermoacidophilic Archaeon Sulfolobus solfataricus Responds to Oxidative Stress	PLOS ONE			English	Article							DPS-LIKE PROTEIN; DNA-BINDING PROTEIN; HYDROGEN-PEROXIDE; GENE-EXPRESSION; DESULFOVIBRIO-VULGARIS; SUPEROXIDE-DISMUTASE; PROTEOMICS ANALYSIS; MERCURY RESISTANCE; ESCHERICHIA-COLI; COG DATABASE	To avoid molecular damage of biomolecules due to oxidation, all cells have evolved constitutive and responsive systems to mitigate and repair chemical modifications. Archaea have adapted to some of the most extreme environments known to support life, including highly oxidizing conditions. However, in comparison to bacteria and eukaryotes, relatively little is known about the biology and biochemistry of archaea in response to changing conditions and repair of oxidative damage. In this study transcriptome, proteome, and chemical reactivity analyses of hydrogen peroxide (H2O2) induced oxidative stress in Sulfolobus solfataricus (P2) were conducted. Microarray analysis of mRNA expression showed that 102 transcripts were regulated by at least 1.5 fold, 30 minutes after exposure to 30 mu M H2O2. Parallel proteomic analyses using two-dimensional differential gel electrophoresis (2D-DIGE), monitored more than 800 proteins 30 and 105 minutes after exposure and found that 18 had significant changes in abundance. A recently characterized ferritin-like antioxidant protein, DPSL, was the most highly regulated species of mRNA and protein, in addition to being post-translationally modified. As expected, a number of antioxidant related mRNAs and proteins were differentially regulated. Three of these, DPSL, superoxide dismutase, and peroxiredoxin were shown to interact and likely form a novel supramolecular complex for mitigating oxidative damage. A scheme for the ability of this complex to perform multi-step reactions is presented. Despite the central role played by DPSL, cells maintained a lower level of protection after disruption of the dpsl gene, indicating a level of redundancy in the oxidative stress pathways of S. solfataricus. This work provides the first "omics'' scale assessment of the oxidative stress response for an archeal organism and together with a network analysis using data from previous studies on bacteria and eukaryotes reveals evolutionarily conserved pathways where complex and overlapping defense mechanisms protect against oxygen toxicity.			Maaty, WS (corresponding author), Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA.	bbothner@chemistry.montana.edu	Douglas, Trevor/GRS-0012-2022; Lawrence, C. Martin/AAH-3420-2020; Tarlykov, Pavel/C-2587-2012; Douglas, Trevor/F-2748-2011	Douglas, Trevor/0000-0002-7882-2704; Lawrence, C. Martin/0000-0002-5398-466X; Tarlykov, Pavel/0000-0003-2075-307X; Valenzuela, Jacob/0000-0002-2320-241X	NCRR NIH HHS [P20 RR-020185, P20 RR020185] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Alscher RG, 2002, J EXP BOT, V53, P1331, DOI 10.1093/jexbot/53.372.1331; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berndt C, 2008, BBA-MOL CELL RES, V1783, P641, DOI 10.1016/j.bbamcr.2008.02.003; Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118; Boucher Y, 2003, ANNU REV GENET, V37, P283, DOI 10.1146/annurev.genet.37.050503.084247; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chang RY, 2007, J CELL BIOCHEM, V100, P267, DOI 10.1002/jcb.20969; Chen DR, 2008, MOL BIOL CELL, V19, P308, DOI 10.1091/mbc.E07-08-0735; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Chen E, 2000, EXP CELL RES, V259, P140, DOI 10.1006/excr.2000.4952; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Coulter ED, 1999, BIOCHEM BIOPH RES CO, V255, P317, DOI 10.1006/bbrc.1999.0197; Dabney A, 2004, QVALUE Q VALUE ESTIM; Delany I, 2004, MOL MICROBIOL, V52, P1081, DOI 10.1111/j.1365-2958.2004.04030.x; deMare F, 1996, NAT STRUCT BIOL, V3, P539, DOI 10.1038/nsb0696-539; Eymann C, 2007, PROTEOMICS, V7, P3509, DOI 10.1002/pmic.200700232; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Ferrer-Navarro M, 2006, J PROTEOME RES, V5, P688, DOI 10.1021/pr050340p; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Fricke WF, 2006, J BACTERIOL, V188, P642, DOI 10.1128/JB.188.2.642-658.2006; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gauss GH, 2006, BIOCHEMISTRY-US, V45, P10815, DOI 10.1021/bi060782u; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; GREGORY EM, 1985, ARCH BIOCHEM BIOPHYS, V238, P83, DOI 10.1016/0003-9861(85)90143-2; Gutteridge JMC, 2000, ANN NY ACAD SCI, V899, P136, DOI 10.1111/j.1749-6632.2000.tb06182.x; Hao Q, 2006, MOL PHARMACOL, V69, P1938, DOI 10.1124/mol.105.020115; Hernandez JA, 2007, FEBS LETT, V581, P1351, DOI 10.1016/j.febslet.2007.02.053; Hu YY, 2005, MOL BIOL CELL, V16, P3705, DOI 10.1091/mbc.E05-04-0301; Iguchi T, 2009, IN VIVO, V23, P7; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Janowiak BE, 2005, J BIOL CHEM, V280, P11829, DOI 10.1074/jbc.M414326200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kato S, 2008, ENVIRON MICROBIOL, V10, P893, DOI 10.1111/j.1462-2920.2007.01508.x; Kim SH, 2005, BIOCHEM J, V387, P271, DOI 10.1042/BJ20041053; Kurtz DM, 2006, J INORG BIOCHEM, V100, P679, DOI 10.1016/j.jinorgbio.2005.12.017; Kusch H, 2007, PROTEOMICS, V7, P686, DOI 10.1002/pmic.200600575; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; Li H, 2004, J BACTERIOL, V186, P3331, DOI 10.1128/JB.186.11.3331-3345.2004; Limauro D, 2006, FEBS J, V273, P721, DOI 10.1111/j.1742-4658.2006.05104.x; Limauro D, 2008, FEBS J, V275, P2067, DOI 10.1111/j.1742-4658.2008.06361.x; Liu JF, 2007, ELECTROPHORESIS, V28, P4348, DOI 10.1002/elps.200600696; Lower BH, 2004, J BACTERIOL, V186, P463, DOI 10.1128/JB.186.2.463-472.2004; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Ma MY, 2008, J PROTEOME RES, V7, P4821, DOI 10.1021/pr800392s; Maaty WSA, 2006, J VIROL, V80, P7625, DOI 10.1128/JVI.00522-06; Marchler-Bauer A, 2007, NUCLEIC ACIDS RES, V35, pD237, DOI 10.1093/nar/gkl951; Marles-Wright J, 2008, SCIENCE, V322, P92, DOI 10.1126/science.1159572; Morales MA, 2008, PROTEOMICS, V8, P350, DOI 10.1002/pmic.200700697; Mostertz J, 2004, MICROBIOL-SGM, V150, P497, DOI 10.1099/mic.0.26665-0; Mulder NJ, 2007, NUCLEIC ACIDS RES, V35, pD224, DOI 10.1093/nar/gkl841; Munhoz DC, 2004, J BIOL CHEM, V279, P35219, DOI 10.1074/jbc.M313773200; Mydel P, 2006, PLOS PATHOG, V2, P712, DOI 10.1371/journal.ppat.0020076; Nie L, 2007, CRIT REV BIOTECHNOL, V27, P63, DOI 10.1080/07388550701334212; Nie L, 2006, GENETICS, V174, P2229, DOI 10.1534/genetics.106.065862; Nissom PM, 2006, MOL BIOTECHNOL, V34, P125, DOI 10.1385/MB:34:2:125; NOBLE RW, 1970, J BIOL CHEM, V245, P2409; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Pedone E, 2006, FEBS J, V273, P5407, DOI 10.1111/j.1742-4658.2006.05533.x; Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rabilloud T, 2005, EXPERT REV PROTEOMIC, V2, P949, DOI 10.1586/14789450.2.6.949; RADAK Z, 1995, J APPL PHYSIOL, V79, P129, DOI 10.1152/jappl.1995.79.1.129; Ramsay B, 2006, J INORG BIOCHEM, V100, P1061, DOI 10.1016/j.jinorgbio.2005.12.001; Ray WK, 2005, J BACTERIOL, V187, P4270, DOI 10.1128/JB.187.12.4270-4275.2005; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; ROCHA ER, 1995, J BACTERIOL, V177, P3111, DOI 10.1128/jb.177.11.3111-3119.1995; Rockabrand D, 1998, J BACTERIOL, V180, P846, DOI 10.1128/JB.180.4.846-854.1998; Santos R, 2000, MOL MICROBIOL, V38, P750, DOI 10.1046/j.1365-2958.2000.02178.x; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schelert J, 2004, J BACTERIOL, V186, P427, DOI 10.1128/JB.186.2.427-437.2004; Schelert J, 2006, J BACTERIOL, V188, P7141, DOI 10.1128/JB.00558-06; Schulenberg B, 2004, ELECTROPHORESIS, V25, P2526, DOI 10.1002/elps.200406007; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Su MH, 2005, BIOCHEMISTRY-US, V44, P5572, DOI 10.1021/bi0472705; Sund CJ, 2008, MOL MICROBIOL, V67, P129, DOI 10.1111/j.1365-2958.2007.06031.x; Sztukowska M, 2002, MOL MICROBIOL, V44, P479, DOI 10.1046/j.1365-2958.2002.02892.x; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Vandenbroucke K, 2008, MOL BIOL EVOL, V25, P507, DOI 10.1093/molbev/msm276; Vergauwen B, 2006, J BIOL CHEM, V281, P4380, DOI 10.1074/jbc.M509517200; Vivancos AP, 2006, MOL GENET GENOMICS, V276, P495, DOI 10.1007/s00438-006-0175-z; Weinberg MV, 2004, J BACTERIOL, V186, P7888, DOI 10.1128/JB.186.23.7888-7895.2004; Wiedenheft B, 2005, P NATL ACAD SCI USA, V102, P10551, DOI 10.1073/pnas.0501497102; Williamson AJK, 2008, MOL CELL PROTEOMICS, V7, P459, DOI 10.1074/mcp.M700370-MCP200; Worthington P, 2003, J BACTERIOL, V185, P482, DOI 10.1128/JB.185.2.482-488.2003; Yao F, 2005, J BACTERIOL, V187, P6354, DOI 10.1128/JB.187.18.6354-6362.2005; Zhang WW, 2006, ANTON LEEUW INT J G, V90, P41, DOI 10.1007/s10482-006-9059-9; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	101	60	60	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e6964	10.1371/journal.pone.0006964	http://dx.doi.org/10.1371/journal.pone.0006964			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19759909	gold, Green Published			2022-12-27	WOS:000269970000002
J	Liu, GH; Gerace, L				Liu, Guang-Hui; Gerace, Larry			Sumoylation Regulates Nuclear Localization of Lipin-1 alpha in Neuronal Cells	PLOS ONE			English	Article							ACTIVATED RECEPTOR-GAMMA; PHOSPHATIDATE PHOSPHATASES; SUBCELLULAR-LOCALIZATION; LIPIN; PROTEIN; SUMO; PGC-1-ALPHA; EXPRESSION; PHOSPHORYLATION; LIPODYSTROPHY	Lipin-1 is a protein that has dual functions as a phosphatidic acid phosphohydrolase (PAP) and a nuclear transcriptional coactivator. It remains unknown how the nuclear localization and coactivator functions of lipin-1 are regulated. Here, we show that lipin-1 (including both the alpha and beta isoforms) is modified by sumoylation at two consensus sumoylation sites. We are unable to detect sumoylation of the related proteins lipin-2 and lipin-3. Lipin-1 is sumoylated at relatively high levels in brain, where lipin-1 alpha is the predominant form. In cultured embryonic cortical neurons and SH-SY5Y neuronal cells, ectopically expressed lipin-1 alpha is localized in both the nucleus and the cytoplasm, and the nuclear localization is abrogated by mutating the consensus sumyolation motifs. The sumoylation site mutant of lipin-1 alpha loses the capacity to coactivate the transcriptional (co-) activators PGC-1 alpha and MEF2, consistent with its nuclear exclusion. Thus, these results show that sumoylation facilitates the nuclear localization and transcriptional coactivator behavior of lipin-1 alpha that we observe in cultured neuronal cells, and suggest that lipin-1 alpha may act as a sumoylation-regulated transcriptional coactivator in brain.			Liu, GH (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ghliu@scripps.edu; lgerace@scripps.edu		Liu, Guang-Hui/0000-0001-9289-8177	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028521] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28521, R01 GM028521-27, R01 GM028521] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Donkor J, 2007, J BIOL CHEM, V282, P3450, DOI 10.1074/jbc.M610745200; Du JX, 2008, J BIOL CHEM, V283, P31991, DOI 10.1074/jbc.M803612200; Finck BN, 2006, CELL METAB, V4, P199, DOI 10.1016/j.cmet.2006.08.005; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Fukunaga K, 2006, J BIOL CHEM, V281, P9490, DOI 10.1074/jbc.M512970200; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Grimsey N, 2008, J BIOL CHEM, V283, P29166, DOI 10.1074/jbc.M804278200; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Harris TE, 2007, J BIOL CHEM, V282, P277, DOI 10.1074/jbc.M609537200; Hay RT, 2007, TRENDS CELL BIOL, V17, P370, DOI 10.1016/j.tcb.2007.08.002; HAYRT, 2005, MOL CELL, V18, P1; Higashida K, 2008, BIOCHEM BIOPH RES CO, V374, P587, DOI 10.1016/j.bbrc.2008.07.079; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Khalil MB, 2009, J LIPID RES, V50, P47, DOI 10.1194/jlr.M800204-JLR200; Kim YJ, 2007, P NATL ACAD SCI USA, V104, P6596, DOI 10.1073/pnas.0702099104; Koh YK, 2008, J BIOL CHEM, V283, P34896, DOI 10.1074/jbc.M804007200; Li H, 2008, P NATL ACAD SCI USA, V105, P9397, DOI 10.1073/pnas.0802876105; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Liu GH, 2006, MOL BIOL CELL, V17, P1822, DOI 10.1091/mbc.E05-10-0979; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Nadra K, 2008, GENE DEV, V22, P1647, DOI 10.1101/gad.1638008; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Qu J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001085; Qu J, 2007, NUCLEIC ACIDS RES, V35, P2522, DOI 10.1093/nar/gkl1163; Reue K, 2008, J LIPID RES, V49, P2493, DOI 10.1194/jlr.R800019-JLR200; Reue K, 2008, FEBS LETT, V582, P90, DOI 10.1016/j.febslet.2007.11.014; Reue K, 2009, J LIPID RES, V50, pS109, DOI 10.1194/jlr.R800052-JLR200; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; SINIOSSOGLOU S, 2009, LIPINS LIPIDS NUCL E; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Takeuchi K, 2009, AM J PHYSIOL-ENDOC M, V296, pE1195, DOI 10.1152/ajpendo.90958.2008; Takeuchi M, 2007, GENE, V399, P174, DOI 10.1016/j.gene.2007.05.009; Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004; Weydt P, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-3; Wilson VG., 2005, SCI STKE SIGNAL TRAN, pE32; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200	51	61	65	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7031	10.1371/journal.pone.0007031	http://dx.doi.org/10.1371/journal.pone.0007031			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753306	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796500015
J	Florins, A; Reichert, M; Asquith, B; Bouzar, AB; Jean, G; Francois, C; Jasik, A; Burny, A; Kettmann, R; Willems, L				Florins, Arnaud; Reichert, Michal; Asquith, Becca; Bouzar, Amel-Baya; Jean, Genevieve; Francois, Carole; Jasik, Agnieszka; Burny, Arsene; Kettmann, Richard; Willems, Luc			Earlier Onset of delta-Retrovirus-Induced Leukemia after Splenectomy	PLOS ONE			English	Article								Infection by delta-retroviruses such as human T-lymphotropic virus type 1 (HTLV-1) and bovine leukemia virus (BLV) is mostly asymptomatic. Indeed, only a minority (<5%) of delta-retrovirus infected hosts will develop either lymphoproliferative or neurodegenerative diseases after long latency periods. In fact, the host immune response is believed to tightly control viral replication but this assumption has not been definitely proven in vivo. Here, we provide direct experimental evidence demonstrating that integrity of the spleen is required to control pathogenesis. In the BLV model, we show that asplenia decreases efficiency of the immune response and induces an imbalance in cell dynamics resulting in accelerated onset of leukemia. These observations enlighten a potential threat in splenectomized HTLV-1 carriers and justify a regular preventive evaluation.	[Florins, Arnaud; Bouzar, Amel-Baya; Francois, Carole; Burny, Arsene; Kettmann, Richard; Willems, Luc] Gembloux Agr Univ FUSAGx, Cellular Mol Biol, Gembloux, Belgium; [Reichert, Michal; Jasik, Agnieszka] Natl Vet Res Inst, Pulawy, Poland; [Asquith, Becca] Univ London Imperial Coll Sci Technol & Med, Dept Immunol, London, England; [Jean, Genevieve] Gembloux Agr Univ FUSAGx, Zootechny Unit, Gembloux, Belgium; [Willems, Luc] Univ Liege, Interdisciplinary Cluster Appl Genoprote GIGA, Liege, Belgium	University of Liege; National Veterinary Institute - National Research Institute; Imperial College London; University of Liege; University of Liege	Florins, A (corresponding author), Gembloux Agr Univ FUSAGx, Cellular Mol Biol, Gembloux, Belgium.	florins.a@fsagx.ac.be		Asquith, Becca/0000-0002-5911-3160; Willems, Luc/0000-0002-0563-2213	Medical Research Council [G0601072] Funding Source: Medline; MRC [G0601072] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asquith B, 2006, P R SOC B, V273, P1165, DOI 10.1098/rspb.2005.3432; Cadili A, 2008, AM J MED, V121, P371, DOI 10.1016/j.amjmed.2008.02.014; Chung CT, 1997, INT J RADIAT ONCOL, V37, P405, DOI 10.1016/S0360-3016(96)00498-1; CULLINGFORD GL, 1991, BRIT J SURG, V78, P716, DOI 10.1002/bjs.1800780626; Davidson RN, 2001, CLIN MICROBIOL INFEC, V7, P657, DOI 10.1046/j.1198-743x.2001.00355.x; Debacq C, 2002, P NATL ACAD SCI USA, V99, P10048, DOI 10.1073/pnas.142100999; Debacq C, 2006, J VIROL, V80, P9710, DOI 10.1128/JVI.01022-06; DIETRICH PY, 1994, BLOOD, V84, P1209; Endo Y, 2008, SURG TODAY, V38, P1148, DOI 10.1007/s00595-008-3802-y; Florins A, 2007, FRONT BIOSCI-LANDMRK, V12, P1520, DOI 10.2741/2165; Florins A, 2006, J VIROL, V80, P11998, DOI 10.1128/JVI.01447-06; Fotiadis C, 1999, ANTICANCER RES, V19, P4235; Gillet N, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-18; HULL CC, 1988, ARCH SURG-CHICAGO, V123, P462; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KOTZIN BL, 1980, SCIENCE, V208, P59, DOI 10.1126/science.6965803; LEWIS M, 2005, SPLEEN CONSEQUENCES; LOUGHRAN TP, 1987, BRIT J HAEMATOL, V67, P135, DOI 10.1111/j.1365-2141.1987.tb02316.x; Saji S, 1999, SURG TODAY, V29, P504, DOI 10.1007/BF02482344; Seabrook TJ, 2000, BLOOD, V96, P1180, DOI 10.1182/blood.V96.3.1180.015k24_1180_1183; Suzuki S, 2008, EUR J HAEMATOL, V81, P236, DOI 10.1111/j.1600-0609.2008.01097.x; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428; TURA S, 1993, J CLIN ONCOL, V11, P925, DOI 10.1200/JCO.1993.11.5.925; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993	25	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6943	10.1371/journal.pone.0006943	http://dx.doi.org/10.1371/journal.pone.0006943			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759828	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796300002
J	Sogaard, OS; Lohse, N; Gerstoft, J; Kronborg, G; Ostergaard, L; Pedersen, C; Pedersen, G; Sorensen, HT; Obel, N				Sogaard, Ole S.; Lohse, Nicolai; Gerstoft, Jan; Kronborg, Gitte; Ostergaard, Lars; Pedersen, Court; Pedersen, Gitte; Sorensen, Henrik Toft; Obel, Niels			Mortality after Hospitalization for Pneumonia among Individuals with HIV, 1995-2008: A Danish Cohort Study	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; BACTERIAL PNEUMONIA; ANTIRETROVIRAL THERAPY; OUTCOMES; INFECTION; MORBIDITY; SURVIVAL; DENMARK; DISEASE	Background: HIV-infected persons are at increased risk of pneumonia, even with highly active antiretroviral treatment (HAART). We examined the impact of pneumonia on mortality and identified prognostic factors for death among HIV-infected. Methodology/Principal Findings: In a nationwide, population-based cohort of individuals with HIV, we included persons hospitalized with pneumonia from the Danish National Hospital Registry and obtained mortality data from the Danish Civil Registration System. Comparing individuals with and without pneumonia, we used Poisson regression to estimate relative mortality and logistic regression to examine prognostic factors for death following pneumonia. From January 1, 1995, to July 1, 2008, we observed 699 episodes of first hospitalization for pneumonia among 4,352 HIV patients. Ninety-day mortality after pneumonia decreased from 22.4% (95% confidence interval [CI]: 16.5%-28.9%) in 1995-1996 to 8.4% (95% CI: 6.1%-11.6%) in 2000-2008. Mortality remained elevated for more than a year after hospitalization for pneumonia: adjusted mortality rate ratio 5.38 (95% CI: 4.27-6.78), 1.80 (95% CI: 1.36-2.37), and 1.62 (95% CI: 1.32-2.00) for days 0-90, 91-365, and 366+, respectively. The following variables predicted mortality within 90 days following hospitalization for pneumonia (adjusted Odds Ratios): male sex (3.77, 95% CI: 1.37-10.4), Charlson Comorbidity Index score >= 2 (3.86, 95% CI: 2.19-6.78); no current HAART (3.58, 95% CI: 1.83-6.99); history of AIDS (2.46, 95% CI: 1.40-4.32); age per 10 year increase (1.43, 95% CI: 1.11-1.85); and CD4+ cell count <= 200 (2.52, 95% CI: 1.37-4.65). Conclusions/Significance: The first hospitalization for pneumonia among HIV-infected individuals was associated with elevated risk of death up to more than a year later. Use of HAART decreased the risk, independent of current CD4+ cell count. Prognosis following pneumonia improved over calendar time.			Sogaard, OS (corresponding author), Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark.	olesoega@rm.dk	Sorensen, Henrik Toft/Z-6181-2019; Kronborg, Gitte/E-4757-2010; Lohse, Nicolai/ABE-5884-2020; Søgaard, Ole Schmeltz/AEP-7968-2022; Ostergaard, Lars/AAA-3020-2020; Søgaard, Ole S/P-6058-2016	Sorensen, Henrik Toft/0000-0003-4299-7040; Søgaard, Ole Schmeltz/0000-0001-9107-2023; Ostergaard, Lars/0000-0003-2459-0511; Ostergaard, Lars/0000-0002-7619-605X; Lohse, Nicolai/0000-0001-8403-8759				Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Fine MJ, 1999, ARCH INTERN MED, V159, P970, DOI 10.1001/archinte.159.9.970; Gordin FM, 2008, AM J RESP CRIT CARE, V178, P630, DOI 10.1164/rccm.200804-617OC; Grau I, 2005, ARCH INTERN MED, V165, P1533, DOI 10.1001/archinte.165.13.1533; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kaplan V, 2003, ARCH INTERN MED, V163, P317, DOI 10.1001/archinte.163.3.317; KITAHATA MM, 2009, N ENGL J MED; Kohli R, 2006, CLIN INFECT DIS, V43, P90, DOI 10.1086/504871; Lohse N, 2005, SCAND J INFECT DIS, V37, P338, DOI 10.1080/00365540510031692; Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 2009, CLIN INFECT DIS, V48, P1138, DOI 10.1086/597468; Mortensen EM, 2003, CLIN INFECT DIS, V37, P1617, DOI 10.1086/379712; Mortensen EM, 2002, ARCH INTERN MED, V162, P1059, DOI 10.1001/archinte.162.9.1059; Obel N, 2008, INT J EPIDEMIOL; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; Sogaard OS, 2008, CLIN INFECT DIS, V47, P1345, DOI 10.1086/592692; Thomsen RW, 2006, J INTERN MED, V259, P410, DOI 10.1111/j.1365-2796.2006.01629.x; 1992, MORBIDITY MORTALITY, V41, P1	24	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7022	10.1371/journal.pone.0007022	http://dx.doi.org/10.1371/journal.pone.0007022			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750011	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796300017
J	Chen, H; Contreras, X; Yamaguchi, Y; Handa, H; Peterlin, BM; Guo, S				Chen, Hui; Contreras, Xavier; Yamaguchi, Yuki; Handa, Hiroshi; Peterlin, B. Matija; Guo, Su			Repression of RNA Polymerase II Elongation In Vivo Is Critically Dependent on the C-Terminus of Spt5	PLOS ONE			English	Article							TRANSCRIPTION ELONGATION; P-TEFB; GENE-EXPRESSION; TARGET GENES; PROMOTER; PROTEIN; HSPT5; NELF; DSIF; PHOSPHORYLATION	The stalling of RNA polymerase II (RNAPII) at the promoters of many genes, including developmental regulators, stress-responsive genes, and HIVLTR, suggests transcription elongation as a critical regulatory step in addition to initiation. Spt5, the large subunit of the DRB sensitivity-inducing factor (DSIF), represses or activates RNAPII elongation in vitro. How RNAPII elongation is repressed in vivo is not well understood. Here we report that CTR1 and CTR2CT, the two repeat-containing regions constituting the C-terminus of Spt5, play a redundant role in repressing RNAPII elongation in vivo. First, mis-expression of Spt5 lacking CTR1 or CTR2CT is inconsequential, but mis-expression of Spt5 lacking the entire C-terminus (termed NSpt5) dominantly impairs embryogenesis in zebrafish. Second, NSpt5 de-represses the transcription of hsp70-4 in zebrafish embryos and HIVLTR in cultured human cells, which are repressed at the RNAPII elongation step under non-inducible conditions. Third, NSpt5 directly associates with hsp70-4 chromatin in vivo and increases the occupancy of RNAPII, positive transcription elongation factor b (P-TEFb), histone H3 Lys 4 trimethylation (H3K4Me3), and surprisingly, the negative elongation factor A (NELF-A) at the locus, indicating a direct action of NSpt5 on the elongation repressed locus. Together, these results reveal a dominant activity of NSpt5 to de-repress RNAPII elongation, and suggest that the C-terminus of Spt5 is critical for repressing RNAPII elongation in vivo.			Chen, H (corresponding author), Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.	su.guo@ucsf.edu	contreras, xavier/ABA-3533-2020; Yamaguchi, Yuki/B-9390-2015	contreras, xavier/0000-0003-0748-6923; Yamaguchi, Yuki/0000-0002-0197-614X	NIAID NIH HHS [AI49104, R01 AI049104] Funding Source: Medline; NIGMS NIH HHS [P50 GM082250-02, P50 GM082250] Funding Source: Medline; NINDS NIH HHS [R01 NS042626, NS042626] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM082250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Barboric M, 2005, PLOS BIOL, V3, P200, DOI 10.1371/journal.pbio.0030076; Bucheli ME, 2005, EMBO J, V24, P2150, DOI 10.1038/sj.emboj.7600687; Burckin T, 2005, NAT STRUCT MOL BIOL, V12, P175, DOI 10.1038/nsmb891; Cheng B, 2007, J BIOL CHEM, V282, P21901, DOI 10.1074/jbc.M702936200; Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301; Cooper KL, 2005, DEV DYNAM, V234, P651, DOI 10.1002/dvdy.20584; Cui YJ, 2003, MOL CELL BIOL, V23, P7887, DOI 10.1128/MCB.23.21.7887-7901.2003; Fujinaga K, 2004, MOL CELL BIOL, V24, P787, DOI 10.1128/MCB.24.2.787-795.2004; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; Guo S, 1999, NEURON, V24, P555, DOI 10.1016/S0896-6273(00)81112-5; Guo Su, 1999, Techniques in the Behavioral and Neural Sciences, V13, P166; Halloran MC, 2000, DEVELOPMENT, V127, P1953; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Jennings BH, 2004, CURR BIOL, V14, P1680, DOI 10.1016/j.cub.2004.08.066; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Keegan BR, 2002, DEVELOPMENT, V129, P1623; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Krishnan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003621; Krone PH, 2003, SEMIN CELL DEV BIOL, V14, P267, DOI 10.1016/j.semcdb.2003.09.018; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; Lee CY, 2008, MOL CELL BIOL, V28, P3290, DOI 10.1128/MCB.02224-07; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; MALONE EA, 1993, MOL GEN GENET, V237, P449, DOI 10.1007/BF00279450; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Oven I, 2007, MOL CELL BIOL, V27, P8815, DOI 10.1128/MCB.01085-07; Palangat M, 2005, P NATL ACAD SCI USA, V102, P15036, DOI 10.1073/pnas.0409405102; Pei Y, 2003, J BIOL CHEM, V278, P43346, DOI 10.1074/jbc.M307319200; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Ping Yueh-Hsin, 2004, Retrovirology, V1, P46, DOI 10.1186/1742-4690-1-46; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26	56	24	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6918	10.1371/journal.pone.0006918	http://dx.doi.org/10.1371/journal.pone.0006918			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742326	Green Submitted, gold, Green Published			2022-12-27	WOS:000269622500004
J	Zhou, L; Takayama, Y; Boucher, P; Tallquist, MD; Herz, J				Zhou, Li; Takayama, Yoshiharu; Boucher, Philippe; Tallquist, Michelle D.; Herz, Joachim			LRP1 Regulates Architecture of the Vascular Wall by Controlling PDGFR beta-Dependent Phosphatidylinositol 3-Kinase Activation	PLOS ONE			English	Article							RECEPTOR-RELATED PROTEIN; PHOSPHOLIPASE-C-GAMMA; PHOSPHOINOSITIDE 3-KINASE; MARFAN-SYNDROME; TGF-BETA; GROWTH-INHIBITION; MOUSE MODEL; PATHOGENESIS; CELLS; INVOLVEMENT	Background: Low density lipoprotein receptor-related protein 1 (LRP1) protects against atherosclerosis by regulating the activation of platelet-derived growth factor receptor beta (PDGFR beta) in vascular smooth muscle cells (SMCs). Activated PDGFR beta undergoes tyrosine phosphorylation and subsequently interacts with various signaling molecules, including phosphatidylinositol 3-kinase (PI3K), which binds to the phosphorylated tyrosine 739/750 residues in mice, and thus regulates actin polymerization and cell movement. Methods and Principal Findings: In this study, we found disorganized actin in the form of membrane ruffling and enhanced cell migration in LRP1-deficient (LRP1-/-) SMCs. Marfan syndrome-like phenotypes such as tortuous aortas, disrupted elastic layers and abnormally activated transforming growth factor beta (TGF beta) signaling are present in smooth muscle-specific LRP1 knockout (smLRP1-/-) mice. To investigate the role of LRP1-regulated PI3K activation by PDGFR beta in atherogenesis, we generated a strain of smLRP1-/- mice in which tyrosine 739/750 of the PDGFR beta had been mutated to phenylalanines (PDGFR beta F2/F2). Spontaneous atherosclerosis was significantly reduced in the absence of hypercholesterolemia in these mice compared to smLRP1-/- animals that express wild type PDGFR. Normal actin organization was restored and spontaneous SMC migration as well as PDGF-BB-induced chemotaxis was dramatically reduced, despite continued overactivation of TGF beta signaling, as indicated by high levels of nuclear phospho-Smad2. Conclusions and Significance: Our data suggest that LRP1 regulates actin organization and cell migration by controlling PDGFR beta-dependent activation of PI3K. TGF beta activation alone is not sufficient for the expression of the Marfan-like vascular phenotype. Thus, regulation of PI3 Kinase by PDGFR beta is essential for maintaining vascular integrity, and for the prevention of atherosclerosis as well as Marfan syndrome.			Zhou, L (corresponding author), UT SW Med Ctr, Dept Mol Genet, Dallas, TX USA.	joachim.herz@utsouthwestern.edu	Takayama, Yoshiharu/M-8826-2019; Tallquist, Michelle/AAU-5277-2021; Takayama, Yoshiharu/E-3662-2010	Takayama, Yoshiharu/0000-0003-4532-7114; Tallquist, Michelle/0000-0002-1383-144X; Takayama, Yoshiharu/0000-0003-4532-7114; Boucher, Philippe/0000-0002-3928-9812	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, P01HL020948, R01HL074257, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63762, HL074257, R01 HL074257, P01 HL020948, R37 HL063762, R01 HL063762, HL20948] Funding Source: Medline; NINDS NIH HHS [R01 NS043408, NS43408] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akutsu K, 2007, CIRC J, V71, P1305, DOI 10.1253/circj.71.1305; Arrieumerlou C, 1998, EUR J IMMUNOL, V28, P1877, DOI 10.1002/(SICI)1521-4141(199806)28:06<1877::AID-IMMU1877>3.3.CO;2-9; ARVIDSSON AK, 1992, CELL GROWTH DIFFER, V3, P881; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000448; Brachmann SA, 2005, MOL CELL BIOL, V25, P2593, DOI 10.1128/MCB.25.7.2593-2606.2005; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Heuchel R, 1999, P NATL ACAD SCI USA, V96, P11410, DOI 10.1073/pnas.96.20.11410; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Nataatmadja M, 2006, CIRCULATION, V114, pI371, DOI 10.1161/CIRCULATIONAHA.105.000927; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Ng CM, 2004, J CLIN INVEST, V114, P1586, DOI 10.1172/JCI22715; Okkenhaug K, 2001, Sci STKE, V2001, ppe1; Ramirez F, 2007, CURR OPIN GENET DEV, V17, P252, DOI 10.1016/j.gde.2007.04.006; Robinson PN, 2006, J MED GENET, V43, P769, DOI 10.1136/jmg.2005.039669; Sheehan D.C., 1987, THEORY PRACTICE HIST; Singh KK, 2006, HUM MUTAT, V27, P770, DOI 10.1002/humu.20354; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WILLIAMS JK, 1994, HIGH TEMP CHEM PROCE, V3, P719; WOODS AE, 1995, HISTOPATHOLOGY COMPL; Yu Miao, 2003, Zhonghua Yi Xue Za Zhi, V83, P494; Zhou L, 2003, EXP GERONTOL, V38, P1161, DOI 10.1016/S0531-5565(03)00170-0	39	54	57	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6922	10.1371/journal.pone.0006922	http://dx.doi.org/10.1371/journal.pone.0006922			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742316	Green Submitted, gold, Green Published			2022-12-27	WOS:000269622500007
J	Folegatti, A; de Vignemont, F; Pavani, F; Rossetti, Y; Farne, A				Folegatti, Alessia; de Vignemont, Frederique; Pavani, Francesco; Rossetti, Yves; Farne, Alessandro			Losing One's Hand: Visual-Proprioceptive Conflict Affects Touch Perception	PLOS ONE			English	Article							MULTISENSORY INTEGRATION; RIGHT-HEMISPHERE; REACTION-TIME; BODY; ILLUSION; DISOWNERSHIP; ENHANCEMENT; RECOGNITION; EXTINCTION; OWNERSHIP	Background: While the sense of bodily ownership has now been widely investigated through the rubber hand illusion (RHI), very little is known about the sense of disownership. It has been hypothesized that the RHI also affects the ownership feelings towards the participant's own hand, as if the rubber hand replaced the participant's actual hand. Somatosensory changes observed in the participants' hand while experiencing the RHI have been taken as evidence for disownership of their real hand. Here we propose a theoretical framework to disambiguate whether such somatosensory changes are to be ascribed to the disownership of the real hand or rather to the anomalous visuo-proprioceptive conflict experienced by the participant during the RHI. Methodology/Principal Findings: In experiment 1, reaction times (RTs) to tactile stimuli delivered to the participants' hand slowed down following the establishment of the RHI. In experiment 2, the misalignment of visual and proprioceptive inputs was obtained via prismatic displacement, a situation in which ownership of the seen hand was doubtless. This condition slowed down the participants' tactile RTs. Thus, similar effects on touch perception emerged following RHI and prismatic displacement. Both manipulations also induced a proprioceptive drift, toward the fake hand in the first experiment and toward the visual position of the participants' hand in the second experiment. Conclusions/Significance: These findings reveal that somatosensory alterations in the experimental hand resulting from the RHI result from cross-modal mismatch between the seen and felt position of the hand. As such, they are not necessarily a signature of disownership.			Folegatti, A (corresponding author), INSERM, UMR S Espace & Act 864, F-69500 Bron, France.	Alessia.Folegatti@inserm.fr	Pavani, Francesco/B-4836-2010; FARNE, ALESSANDRO/G-1238-2015; Rossetti, Yves/H-3693-2017	Pavani, Francesco/0000-0003-0426-5578; FARNE, ALESSANDRO/0000-0001-5769-3491; Rossetti, Yves/0000-0001-8867-4496				Aglioti S, 1996, NEUROREPORT, V8, P293, DOI 10.1097/00001756-199612200-00058; Blanke O, 2009, TRENDS COGN SCI, V13, P7, DOI 10.1016/j.tics.2008.10.003; Bottini G, 2002, NEUROREPORT, V13, P249, DOI 10.1097/00001756-200202110-00015; Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; Costantini M, 2007, CONSCIOUS COGN, V16, P229, DOI 10.1016/j.concog.2007.01.001; De Vignemont F, 2007, MIND LANG, V22, P427, DOI 10.1111/j.1468-0017.2007.00315.x; Driver J., 1996, ATTENTION PERFORM, P209; Ehrsson HH, 2007, SCIENCE, V317, P1048, DOI 10.1126/science.1142175; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Frassinetti F, 2008, J COGNITIVE NEUROSCI, V20, P1507, DOI 10.1162/jocn.2008.20067; HOLMES N, 2007, BEHAV BRAIN SCI, V30, P189; Holmes NP, 2004, COGN AFFECT BEHAV NE, V4, P193, DOI 10.3758/CABN.4.2.193; Holmes NP, 2009, BRAIN TOPOGR, V21, P168, DOI 10.1007/s10548-009-0097-2; Holmes NP, 2007, BEHAV BRAIN SCI, V30, P211, DOI 10.1017/S0140525X07001501; HONORE J, 1989, NEUROPSYCHOLOGIA, V27, P367, DOI 10.1016/0028-3932(89)90025-0; HONORE J, 1982, NEUROPSYCHOLOGIA, V20, P727, DOI 10.1016/0028-3932(82)90075-6; Jeannerod M, 2003, BEHAV BRAIN RES, V142, P1, DOI 10.1016/S0166-4328(02)00384-4; Kammers MPM, 2009, NEUROPSYCHOLOGIA, V47, P204, DOI 10.1016/j.neuropsychologia.2008.07.028; Kennett S, 2001, CURR BIOL, V11, P1188, DOI 10.1016/S0960-9822(01)00327-X; LARMANDE P, 1981, REV NEUROL, V137, P285; Lenggenhager B, 2007, SCIENCE, V317, P1096, DOI 10.1126/science.1143439; Lloyd DM, 2007, BRAIN COGNITION, V64, P104, DOI 10.1016/j.bandc.2006.09.013; Longo MR, 2008, COGNITION, V107, P978, DOI 10.1016/j.cognition.2007.12.004; Longo MR, 2008, CONSCIOUS COGN, V17, P1181, DOI 10.1016/j.concog.2008.01.001; Makin TR, 2008, BEHAV BRAIN RES, V191, P1, DOI 10.1016/j.bbr.2008.02.041; Maravita A, 2003, CURR BIOL, V13, pR531, DOI 10.1016/S0960-9822(03)00449-4; Moro V, 2004, NEUROCASE, V10, P437, DOI 10.1080/13554790490894020; Moseley GL, 2008, P NATL ACAD SCI USA, V105, P13169, DOI 10.1073/pnas.0803768105; Pavani F, 2000, PSYCHOL SCI, V11, P353, DOI 10.1111/1467-9280.00270; Pavani F, 2007, PERCEPTION, V36, P1547, DOI 10.1068/p5853; Petkova VI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003832; PIERSON JM, 1991, NEUROPSYCHOLOGIA, V29, P925, DOI 10.1016/0028-3932(91)90056-E; Press C, 2004, EXP BRAIN RES, V154, P238, DOI 10.1007/s00221-003-1651-x; Schutz-Bosbach S, 2009, BRAIN COGNITION, V70, P136, DOI 10.1016/j.bandc.2009.01.006; Tastevin J, 1937, ENCEPHALE, V32, P57; Taylor-Clarke M, 2002, CURR BIOL, V12, P233, DOI 10.1016/S0960-9822(01)00681-9; Tipper SP, 1998, NEUROREPORT, V9, P1741, DOI 10.1097/00001756-199806010-00013; Tsakiris M, 2005, J EXP PSYCHOL HUMAN, V31, P80, DOI 10.1037/0096-1523.31.1.80; Tsakiris M, 2006, CONSCIOUS COGN, V15, P423, DOI 10.1016/j.concog.2005.09.004; Tsakiris M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004040; Uddin LQ, 2005, NEUROIMAGE, V25, P926, DOI 10.1016/j.neuroimage.2004.12.018; Vallar G, 2009, EXP BRAIN RES, V192, P533, DOI 10.1007/s00221-008-1562-y	42	70	70	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6920	10.1371/journal.pone.0006920	http://dx.doi.org/10.1371/journal.pone.0006920			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	491ZH	19738900	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300009
J	Jiang, L; Wang, Q; Yu, Y; Zhao, F; Huang, P; Zeng, R; Qi, RZ; Li, WJ; Liu, Y				Jiang, Lei; Wang, Qiong; Yu, Yue; Zhao, Feng; Huang, Ping; Zeng, Rong; Qi, Robert Z.; Li, Wenjun; Liu, Yong			Leptin Contributes to the Adaptive Responses of Mice to High-Fat Diet Intake through Suppressing the Lipogenic Pathway	PLOS ONE			English	Article							LIPID-METABOLISM; GENE-EXPRESSION; INDUCED OBESITY; ADIPOSE-TISSUE; BODY-WEIGHT; RECEPTOR; PROTEIN; LIVER; CLONING	Background: Leptin is an adipocyte-derived hormone that plays a critical role in energy homeostasis and lipid metabolism. Overnutrition-associated obesity is known to be accompanied by hyperleptinemia. However, the physiological actions of leptin in the metabolic responses to high-fat diet (HFD) intake remain to be completely elucidated. Here we characterized the metabolic features of mice fed high-fat diets and investigated the impact of leptin upon the lipogenic program which was found to be suppressed by HFD feeding through a proteomics approach. Results: When maintained on two types of high-fat diets for up to 16 weeks, mice with a higher fat intake exhibited increased body fat accumulation at a greater pace, developing more severely impaired glucose tolerance. Notably, HFD feeding at 4 weeks elicited the onset of marked hyperleptinemia, prior to the occurrence of apparent insulin resistance and hyperinsulinemia. Proteomic analysis revealed dramatically decreased expression of lipogenic enzymes in the white adipose tissue (WAT) from HFD-fed mice, including ATP-citrate lyase (ACL) and fatty acid synthase (FAS). The expression of ACL and FAS in the liver was similarly suppressed in response to HFD feeding. By contrast, HFD-induced downregulation of hepatic ACL and FAS was significantly attenuated in leptin receptor-deficient db/db mice. Furthermore, in the liver and WAT of wild type animals, intraperitoneal leptin administration was able to directly suppress the expression of these two lipogenic enzymes, accompanied by reduced triglyceride levels both in the liver and serum. Conclusions: These results suggest that leptin contributes to the metabolic responses in adaptation to overnutrition through suppressing the expression of lipogenic enzymes, and that the lipogenic pathway represents a key targeted peripheral component in exerting leptin's liporegulatory actions.			Jiang, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai, Peoples R China.	liuy@sibs.ac.cn		Wang, Qiong/0000-0003-2224-4287; Qi, Robert Zhong/0000-0001-5596-8172; LIU, YONG/0000-0001-7771-4181				Abu-Elheiga L, 2005, P NATL ACAD SCI USA, V102, P12011, DOI 10.1073/pnas.0505714102; Ahren B, 1998, EUR J ENDOCRINOL, V139, P461, DOI 10.1530/eje.0.1390461; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Bassilian S, 2002, AM J PHYSIOL-ENDOC M, V282, pE507, DOI 10.1152/ajpendo.00211.2001; Buettner C, 2008, NAT MED, V14, P667, DOI 10.1038/nm1775; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; de Fourmestraux V, 2004, J BIOL CHEM, V279, P50743, DOI 10.1074/jbc.M408014200; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gallardo N, 2007, ENDOCRINOLOGY, V148, P5604, DOI 10.1210/en.2007-0933; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hick RW, 2006, J IMMUNOL, V177, P169, DOI 10.4049/jimmunol.177.1.169; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Kim S, 2004, GENE, V340, P99, DOI 10.1016/j.gene.2004.06.015; Lee WNP, 2000, AM J PHYSIOL-ENDOC M, V279, pE425, DOI 10.1152/ajpendo.2000.279.2.E425; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Mantzoros CS, 1999, ANN INTERN MED, V130, P671, DOI 10.7326/0003-4819-130-8-199904200-00014; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moraes RC, 2003, ENDOCRINOLOGY, V144, P4773, DOI 10.1210/en.2003-0456; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Prieur X, 2008, ENDOCRINOLOGY, V149, P5432, DOI 10.1210/en.2008-0498; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Sampath H, 2005, ANNU REV NUTR, V25, P317, DOI 10.1146/annurev.nutr.25.051804.101917; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75; SRERE PA, 1959, J BIOL CHEM, V234, P2544; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang Q, 2009, HEPATOLOGY, V49, P1166, DOI 10.1002/hep.22774; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	35	65	70	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6884	10.1371/journal.pone.0006884	http://dx.doi.org/10.1371/journal.pone.0006884			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727392	Green Published, gold, Green Submitted			2022-12-27	WOS:000269522900013
J	Yilmaz, A; Gisslen, M; Spudich, S; Lee, E; Jayewardene, A; Aweeka, F; Price, RW				Yilmaz, Aylin; Gisslen, Magnus; Spudich, Serena; Lee, Evelyn; Jayewardene, Anura; Aweeka, Francesca; Price, Richard W.			Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection	PLOS ONE			English	Article								Introduction: Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in cerebrospinal fluid (CSF) and plasma in subjects receiving antiretroviral treatment regimens containing this drug. Methods: Raltegravir concentrations were determined by liquid chromatography tandem mass spectrometry in 25 paired CSF and plasma samples from 16 HIV-1-infected individuals. The lower limit of quantitation was 2.0 ng/ml for CSF and 10 ng/ml for plasma. Results: Twenty-four of the 25 CSF samples had detectable raltegravir concentrations with a median raltegravir concentration of 18.4 ng/ml (range, <2.0-126.0). The median plasma raltegravir concentration was 448 ng/ml (range, 37-5180). CSF raltegravir concentrations correlated with CSF:plasma albumin ratios and CSF albumin concentrations. Conclusions: Approximately 50% of the CSF specimens exceeded the IC(95) levels reported to inhibit HIV-1 strains without resistance to integrase inhibitors. In addition to contributing to control of systemic HIV-1 infection, raltegravir achieves local inhibitory concentrations in CSF in most, but not all, patients. Blood-brain and blood-CSF barriers likely restrict drug entry, while enhanced permeability of these barriers enhances drug entry.			Yilmaz, A (corresponding author), Univ Gothenburg, Dept Infect Dis, Sahlgrenska Acad, Gothenburg, Sweden.	aylin.yilmaz@gu.se	Gisslen, Magnus/D-7454-2015	Gisslen, Magnus/0000-0002-2357-1020	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH083520] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR024131] Funding Source: Medline; NIMH NIH HHS [R21-MH083520-01, R21 MH083520] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cocohoba J, 2008, CLIN THER, V30, P1747, DOI 10.1016/j.clinthera.2008.10.012; GISSLEN M, 2006, J NEUROIMMU IN PRESS; Iwamoto M, 2008, CLIN PHARMACOL THER, V83, P293, DOI 10.1038/sj.clpt.6100281; Kassahun K, 2007, DRUG METAB DISPOS, V35, P1657, DOI 10.1124/dmd.107.016196; LETENDRE S, 2006, C RETR OPP INF DENV; Monforte AD, 2004, ANN NEUROL, V55, P320, DOI 10.1002/ana.10827; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; Price RW, 2008, J INFECT DIS, V197, pS294, DOI 10.1086/533419; Price RW, 1997, ANN NEUROL, V42, P675, DOI 10.1002/ana.410420502; Sinclair E, 2008, JAIDS-J ACQ IMM DEF, V47, P544, DOI 10.1097/QAI.0b013e318162754f; Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; VARATHARAJAN L, 2009, ANTIVIRAL RES; WENNING L, 2009, CLIN PHARM THER	15	73	75	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6877	10.1371/journal.pone.0006877	http://dx.doi.org/10.1371/journal.pone.0006877			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489XX	19721718	gold, Green Published, Green Submitted			2022-12-27	WOS:000269461100006
J	Green, RM; Gally, F; Keeney, JG; Alper, S; Gao, BF; Han, M; Martin, RJ; Weinberger, AR; Case, SR; Minor, MN; Chu, HW				Green, Rebecca M.; Gally, Fabienne; Keeney, Jonathon G.; Alper, Scott; Gao, Bifeng; Han, Min; Martin, Richard J.; Weinberger, Andrew R.; Case, Stephanie R.; Minor, Maisha N.; Chu, Hong Wei			Impact of Cigarette Smoke Exposure on Innate Immunity: A Caenorhabditis elegans Model	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA INFECTION; FATTY-ACID; EXPRESSION; PATHWAY; PROTEIN; CELLS	Background: Cigarette smoking is the major cause of chronic obstructive pulmonary disease (COPD) and lung cancer. Respiratory bacterial infections have been shown to be involved in the development of COPD along with impaired airway innate immunity. Methodology/Principal Findings: To address the in vivo impact of cigarette smoke (CS) exclusively on host innate defense mechanisms, we took advantage of Caenorhabditis elegans (C. elegans), which has an innate immune system but lacks adaptive immune function. Pseudomonas aeruginosa (PA) clearance from intestines of C. elegans was dampened by CS. Microarray analysis identified 6 candidate genes with a 2-fold or greater reduction after CS exposure, that have a human orthologue, and that may participate in innate immunity. To confirm a role of CS-down-regulated genes in the innate immune response to PA, RNA interference (RNAi) by feeding was carried out in C. elegans to inhibit the gene of interest, followed by PA infection to determine if the gene affected innate immunity. Inhibition of lbp-7, which encodes a lipid binding protein, resulted in increased levels of intestinal PA. Primary human bronchial epithelial cells were shown to express mRNA of human Fatty Acid Binding Protein 5 (FABP-5), the human orthologue of lpb-7. Interestingly, FABP-5 mRNA levels from human smokers with COPD were significantly lower (p = 0.036) than those from smokers without COPD. Furthermore, FABP-5 mRNA levels were up-regulated (7-fold) after bacterial (i.e., Mycoplasma pneumoniae) infection in primary human bronchial epithelial cell culture (air-liquid interface culture). Conclusions: Our results suggest that the C. elegans model offers a novel in vivo approach to specifically study innate immune deficiencies resulting from exposure to cigarette smoke, and that results from the nematode may provide insight into human airway epithelial cell biology and cigarette smoke exposure.			Green, RM (corresponding author), Natl Jewish Hlth, Dept Med, Denver, CO USA.	chuhw@njhealth.org		Green, Rebecca/0000-0001-7319-0755; Gally, Fabienne/0000-0003-0503-7411				Alper S, 2007, MOL CELL BIOL, V27, P5544, DOI 10.1128/MCB.02070-06; Belinda LWC, 2008, MOL IMMUNOL, V45, P1732, DOI 10.1016/j.molimm.2007.09.030; BRENNER S, 1974, GENETICS, V77, P71; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Feng ZY, 2006, CELL, V127, P621, DOI 10.1016/j.cell.2006.09.035; Garcia-Medina R, 2005, INFECT IMMUN, V73, P8298, DOI 10.1128/IAI.73.12.8298-8305.2005; Gravato-Nobre MJ, 2005, CELL MICROBIOL, V7, P741, DOI 10.1111/j.1462-5822.2005.00523.x; Jiang N, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-284; Jones D, 1999, J EXP ZOOL, V284, P147, DOI 10.1002/(SICI)1097-010X(19990701)284:2&lt;147::AID-JEZ4&gt;3.0.CO;2-Z; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Kniazeva M, 2008, GENE DEV, V22, P2102, DOI 10.1101/gad.1692008; Kuijpers ALA, 1997, ACTA DERM-VENEREOL, V77, P14; Lin MC, 2005, WORLD J GASTROENTERO, V11, P7564, DOI 10.3748/wjg.v11.i48.7564; Martin Richard J, 2006, COPD, V3, P3, DOI 10.1080/15412550500493162; Martinez-Solano L, 2008, CLIN INFECT DIS, V47, P1526, DOI 10.1086/593186; Masouye I, 1997, CIRC RES, V81, P297, DOI 10.1161/01.RES.81.3.297; Matta SG, 2007, PSYCHOPHARMACOLOGY, V190, P269, DOI 10.1007/s00213-006-0441-0; Moy TI, 2006, P NATL ACAD SCI USA, V103, P10414, DOI 10.1073/pnas.0604055103; O'Grady EP, 2006, INFECT IMMUN, V74, P5893, DOI 10.1128/IAI.00489-06; Plenefisch J, 2000, MOL BIOCHEM PARASIT, V105, P223, DOI 10.1016/S0166-6851(99)00179-6; Ren Q, 2008, COMP FUNCT GENOM, DOI 10.1155/2008/634283; Tan MW, 1999, P NATL ACAD SCI USA, V96, P2408, DOI 10.1073/pnas.96.5.2408; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; Thaikoottathil JV, 2009, EUR RESPIR J, V33, P835, DOI 10.1183/09031936.00080708; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Triantafilou M, 2004, BIOCHEM SOC T, V32, P636, DOI 10.1042/BST0320636; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Zhu Z, 2007, CANCER RES, V67, P12018, DOI 10.1158/0008-5472.CAN-07-2834	31	31	32	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6860	10.1371/journal.pone.0006860	http://dx.doi.org/10.1371/journal.pone.0006860			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718433	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415900024
J	Tsetsarkin, KA; Mcgee, CE; Volk, SM; Vanlandingham, DL; Weaver, SC; Higgs, S				Tsetsarkin, Konstantin A.; McGee, Charles E.; Volk, Sara M.; Vanlandingham, Dana L.; Weaver, Scott C.; Higgs, Stephen			Epistatic Roles of E2 Glycoprotein Mutations in Adaption of Chikungunya Virus to Aedes Albopictus and Ae. Aegypti Mosquitoes	PLOS ONE			English	Article								Between 2005 and 2007 Chikungunya virus (CHIKV) caused its largest outbreak/epidemic in documented history. An unusual feature of this epidemic is the involvement of Ae. albopictus as a principal vector. Previously we have demonstrated that a single mutation E1-A226V significantly changed the ability of the virus to infect and be transmitted by this vector when expressed in the background of well characterized CHIKV strains LR2006 OPY1 and 37997. However, in the current study we demonstrate that introduction of the E1-A226V mutation into the background of an infectious clone derived from the Ag41855 strain (isolated in Uganda in 1982) does not significantly increase infectivity for Ae. albopictus. In order to elucidate the genetic determinants that affect CHIKV sensitivity to the E1-A226V mutation in Ae. albopictus, the genomes of the LR2006 OPY1 and Ag41855 strains were used for construction of chimeric viruses and viruses with a specific combination of point mutations at selected positions. Based upon the midgut infection rates of the derived viruses in Ae. albopictus and Ae. aegypti mosquitoes, a critical role of the mutations at positions E2-60 and E2-211 on vector infection was revealed. The E2-G60D mutation was an important determinant of CHIKV infectivity for both Ae. albopictus and Ae. aegypti, but only moderately modulated the effect of the E1-A226V mutation in Ae. albopictus. However, the effect of the E2-I211T mutation with respect to mosquito infections was much more specific, strongly modifying the effect of the E1-A226V mutation in Ae. albopictus. In contrast, CHIKV infectivity for Ae. aegypti was not influenced by the E2-1211T mutation. The occurrence of the E2-60G and E2-211I residues among CHIKV isolates was analyzed, revealing a high prevalence of E2-211I among strains belonging to the Eastern/Central/South African (ECSA) clade. This suggests that the E2-211I might be important for adaptation of CHIKV to some particular conditions prevalent in areas occupied by ECSA stains. These newly described determinants of CHIKV mosquito infectivity for Ae. albopictus and Ae. aegypti are of particular importance for studies aimed at the investigation of the detailed mechanisms of CHIKV adaptations to its vector species.			Tsetsarkin, KA (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.	kotsetsa@utmb.edu	Weaver, Scott C/D-6490-2011	Weaver, Scott C/0000-0001-8016-8556	NIAID NIH HHS [R21 AI073389, 1 R21 AI073389] Funding Source: Medline; PHS HHS [T32 A107536] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI073389] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anishchenko M, 2006, P NATL ACAD SCI USA, V103, P4994, DOI 10.1073/pnas.0509961103; Arankalle VA, 2007, J GEN VIROL, V88, P1967, DOI 10.1099/vir.0.82714-0; Arpino C, 2009, REV MED VIROL, V19, P121, DOI 10.1002/rmv.606; BEAMAN JR, 1991, J MED ENTOMOL, V28, P161, DOI 10.1093/jmedent/28.1.161; Benedict MQ, 2007, VECTOR-BORNE ZOONOT, V7, P76, DOI 10.1089/vbz.2006.0562; Bonilauri P, 2008, EMERG INFECT DIS, V14, P852, DOI 10.3201/eid1405.071144; Brault AC, 2002, J VIROL, V76, P6387, DOI 10.1128/JVI.76.12.6387-6392.2002; Brault AC, 2004, P NATL ACAD SCI USA, V101, P11344, DOI 10.1073/pnas.0402905101; BURNESS ATH, 1988, VIROLOGY, V167, P639, DOI 10.1016/S0042-6822(88)90129-8; Cherian SS, 2009, INFECT GENET EVOL, V9, P16, DOI 10.1016/j.meegid.2008.09.004; de Lamballerie X, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-33; Delatte H, 2008, PARASITE, V15, P3, DOI 10.1051/parasite/2008151003; Diallo M, 1999, AM J TROP MED HYG, V60, P281, DOI 10.4269/ajtmh.1999.60.281; Enserink M, 2008, SCIENCE, V320, P864, DOI 10.1126/science.320.5878.864; Enserink M, 2007, SCIENCE, V317, P1485, DOI 10.1126/science.317.5844.1485a; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fernandez Z, 2003, J MED ENTOMOL, V40, P522, DOI 10.1603/0022-2585-40.4.522; Gratz NG, 2004, MED VET ENTOMOL, V18, P215, DOI 10.1111/j.0269-283X.2004.00513.x; Heil ML, 2001, J VIROL, V75, P6303, DOI 10.1128/JVI.75.14.6303-6309.2001; HIGGS S, 1997, MOL BIOL DIS VECTORS, P457; Jupp P. G., 1988, The arboviruses: epidemiology and ecology. Volume II., P137; KERR PJ, 1993, VIROLOGY, V193, P446, DOI 10.1006/viro.1993.1143; Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326; LEVINE B, 1993, J VIROL, V67, P6872, DOI 10.1128/JVI.67.11.6872-6875.1993; Lu YPE, 1999, J VIROL, V73, P4272, DOI 10.1128/JVI.73.5.4272-4278.1999; Mandl CW, 2001, J VIROL, V75, P5627, DOI 10.1128/JVI.75.12.5627-5637.2001; MCCRAE AWR, 1971, T ROY SOC TROP MED H, V65, P152, DOI 10.1016/0035-9203(71)90212-4; McElroy KL, 2006, J GEN VIROL, V87, P2993, DOI 10.1099/vir.0.82023-0; MCINTOSH BM, 1977, S AFR J SCI, V73, P267; McKnight KL, 1996, J VIROL, V70, P1981, DOI 10.1128/JVI.70.3.1981-1989.1996; MITCHELL CJ, 1987, J AM MOSQUITO CONTR, V3, P460; MITCHELL CJ, 1992, SCIENCE, V257, P526, DOI 10.1126/science.1321985; Moutailler S, 2008, VECTOR-BORNE ZOONOT, V8, P749, DOI 10.1089/vbz.2008.0009; Myles KM, 2003, J VIROL, V77, P8872, DOI 10.1128/JVI.77.16.8872-8881.2003; Njenga MK, 2008, J GEN VIROL, V89, P2754, DOI 10.1099/vir.0.2008/005413-0; Pages F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004691; Pierro DJ, 2008, J VIROL, V82, P2966, DOI 10.1128/JVI.02060-07; Pierro DJ, 2007, J GEN VIROL, V88, P1545, DOI 10.1099/vir.0.82577-0; PILITT DR, 1972, J MED ENTOMOL, V9, P334, DOI 10.1093/jmedent/9.4.334; Powers AM, 2000, J GEN VIROL, V81, P471, DOI 10.1099/0022-1317-81-2-471; Reiter P, 2006, LANCET INFECT DIS, V6, P463, DOI 10.1016/S1473-3099(06)70531-X; Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Sardelis MR, 2002, J AM MOSQUITO CONTR, V18, P284; Sardelis MR, 2001, EMERG INFECT DIS, V7, P1018, DOI 10.3201/eid0706.010617; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; SCOTT TW, 1990, J AM MOSQUITO CONTR, V6, P274; Simon F, 2008, MED CLIN N AM, V92, P1323, DOI 10.1016/j.mcna.2008.07.008; Smit JM, 2002, J VIROL, V76, P10128, DOI 10.1128/JVI.76.20.10128-10137.2002; Smit JM, 2001, J VIROL, V75, P11196, DOI 10.1128/JVI.75.22.11196-11204.2001; SMITH TJ, 1995, P NATL ACAD SCI USA, V92, P10648, DOI 10.1073/pnas.92.23.10648; STRAUSS EG, 1991, J VIROL, V65, P4654, DOI 10.1128/JVI.65.9.4654-4664.1991; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Tsetsarkin K, 2006, VECTOR-BORNE ZOONOT, V6, P325, DOI 10.1089/vbz.2006.6.325; Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201; Turell MJ, 2001, J MED ENTOMOL, V38, P130, DOI 10.1603/0022-2585-38.2.130; Vanlandingham DL, 2006, AM J TROP MED HYG, V74, P663, DOI 10.4269/ajtmh.2006.74.663; Vanlandingham DL, 2005, INSECT BIOCHEM MOLEC, V35, P1162, DOI 10.1016/j.ibmb.2005.05.008; Vashishtha M, 1998, J CELL BIOL, V140, P91, DOI 10.1083/jcb.140.1.91; Vazeille M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001168; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WANG KS, 1991, J VIROL, V65, P7037, DOI 10.1128/JVI.65.12.7037-7040.1991; WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P253, DOI 10.1016/0035-9203(58)90084-1; Weng MH, 1997, J MED ENTOMOL, V34, P745, DOI 10.1093/jmedent/34.6.745; Zhang W, 2005, VIROLOGY, V332, P511, DOI 10.1016/j.virol.2004.11.043	65	157	163	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6835	10.1371/journal.pone.0006835	http://dx.doi.org/10.1371/journal.pone.0006835			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718263	gold, Green Published, Green Submitted			2022-12-27	WOS:000269415900008
J	Scholefield, J; Greenberg, LJ; Weinberg, MS; Arbuthnot, PB; Abdelgany, A; Wood, MJA				Scholefield, Janine; Greenberg, L. Jacquie; Weinberg, Marc S.; Arbuthnot, Patrick B.; Abdelgany, Amr; Wood, Matthew J. A.			Design of RNAi Hairpins for Mutation-Specific Silencing of Ataxin-7 and Correction of a SCA7 Phenotype	PLOS ONE			English	Article								Spinocerebellar ataxia type 7 is a polyglutamine disorder caused by an expanded CAG repeat mutation that results in neurodegeneration. Since no treatment exists for this chronic disease, novel therapies such post-transcriptional RNA interference-based gene silencing are under investigation, in particular those that might enable constitutive and tissue-specific silencing, such as expressed hairpins. Given that this method of silencing can be abolished by the presence of nucleotide mismatches against the target RNA, we sought to identify expressed RNA hairpins selective for silencing the mutant ataxin-7 transcript using a linked SNP. By targeting both short and full-length tagged ataxin-7 sequences, we show that mutation-specific selectivity can be obtained with single nucleotide mismatches to the wild-type RNA target incorporated 39 to the centre of the active strand of short hairpin RNAs. The activity of the most effective short hairpin RNA incorporating the nucleotide mismatch at position 16 was further studied in a heterozygous ataxin-7 disease model, demonstrating significantly reduced levels of toxic mutant ataxin-7 protein with decreased mutant protein aggregation and retention of normal wild-type protein in a non-aggregated diffuse cellular distribution. Allele-specific mutant ataxin7 silencing was also obtained with the use of primary microRNA mimics, the most highly effective construct also harbouring the single nucleotide mismatch at position 16, corroborating our earlier findings. Our data provide understanding of RNA interference guide strand anatomy optimised for the allele-specific silencing of a polyglutamine mutation linked SNP and give a basis for the use of allele-specific RNA interference as a viable therapeutic approach for spinocerebellar ataxia 7.			Scholefield, J (corresponding author), Univ Cape Town, Div Human Genet, MRC,Fac Hlth Sci, UCT Human Genet Res Unit,Inst Infect Dis & Mol Me, ZA-7925 Cape Town, South Africa.	matthew.wood@dpag.ox.ac.uk	Weinberg, Marc/B-4669-2009; Wood, Matthew/HDN-1469-2022	Weinberg, Marc/0000-0002-1997-2171; Scholefield, Janine/0000-0001-9610-3976; Wood, Matthew/0000-0002-5436-6011	Medical Research Council [G0500822] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abdelgany A, 2003, HUM MOL GENET, V12, P2637, DOI 10.1093/hmg/ddg280; Alves S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003341; An CI, 2006, RNA, V12, P710, DOI 10.1261/rna.2299306; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Boudreau RL, 2008, RNA, V14, P1834, DOI 10.1261/rna.1062908; Boudreau RL, 2009, MOL THER, V17, P1053, DOI 10.1038/mt.2009.17; Boudreau RL, 2009, MOL THER, V17, P169, DOI 10.1038/mt.2008.231; Bryer A, 2003, J NEUROL SCI, V216, P47, DOI 10.1016/S0022-510X(03)00209-0; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Caplen NJ, 2002, HUM MOL GENET, V11, P175, DOI 10.1093/hmg/11.2.175; Castanotto D, 2002, RNA, V8, P1454, DOI 10.1017/S1355838202021362; Coldwell MJ, 2006, MOL CELL BIOL, V26, P8448, DOI 10.1128/MCB.01248-06; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; Drouet V, 2009, ANN NEUROL, V65, P276, DOI 10.1002/ana.21569; Du Q, 2005, NUCLEIC ACIDS RES, V33, P1671, DOI 10.1093/nar/gki312; Dykxhoorn DM, 2006, P NATL ACAD SCI USA, V103, P5953, DOI 10.1073/pnas.0601309103; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ely A, 2008, MOL THER, V16, P1105, DOI 10.1038/mt.2008.82; Feng XR, 2006, GENE, V371, P68, DOI 10.1016/j.gene.2005.11.006; Garden GA, 2008, CEREBELLUM, V7, P138, DOI 10.1007/s12311-008-0027-y; Giering JC, 2008, MOL THER, V16, P1630, DOI 10.1038/mt.2008.144; Greenberg J, 2006, CLIN GENET, V70, P415, DOI 10.1111/j.1399-0004.2006.00680.x; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Harper SQ, 2005, P NATL ACAD SCI USA, V102, P5820, DOI 10.1073/pnas.0501507102; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Hu JX, 2009, NAT BIOTECHNOL, V27, P478, DOI 10.1038/nbt.1539; Janer A, 2006, J CELL BIOL, V174, P65, DOI 10.1083/jcb.200511045; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Latouche M, 2007, J NEUROSCI, V27, P2483, DOI 10.1523/JNEUROSCI.5453-06.2007; MARTIN JJ, 1994, ACTA NEUROPATHOL, V88, P277; McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105; Miller VM, 2004, NUCLEIC ACIDS RES, V32, P661, DOI 10.1093/nar/gkh208; Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100; Ohnishi Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002248; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Schwarz DS, 2006, PLOS GENET, V2, P1307, DOI 10.1371/journal.pgen.0020140; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shao J, 2007, HUM MOL GENET, V16, pR115, DOI 10.1093/hmg/ddm213; Shao Y, 2007, RNA, V13, P1631, DOI 10.1261/rna.546207; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Thomas PS, 2006, HUM MOL GENET, V15, P2225, DOI 10.1093/hmg/ddl148; Van Raamsdonk JM, 2005, HUM MOL GENET, V14, P1379, DOI 10.1093/hmg/ddi147; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Xia XG, 2006, NEUROBIOL DIS, V23, P578, DOI 10.1016/j.nbd.2006.04.019; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569	50	51	56	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7232	10.1371/journal.pone.0007232	http://dx.doi.org/10.1371/journal.pone.0007232			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789634	Green Published, Green Submitted, gold			2022-12-27	WOS:000270354100006
J	Natesan, SKA; Peacock, L; Leung, KF; Matthews, KR; Gibson, W; Field, MC				Natesan, Senthil Kumar A.; Peacock, Lori; Leung, Ka Fai; Matthews, Keith R.; Gibson, Wendy; Field, Mark C.			The Trypanosome Rab-Related Proteins RabX1 and RabX2 Play No Role in IntraCellular Trafficking but May Be Involved in Fly Infectivity	PLOS ONE			English	Article								Background: Rab GTPases constitute the largest subgroup of the Ras superfamily and are primarily involved in vesicle targeting. The full extent of Rab family function is unexplored. Several divergent Rab-like proteins are known but few have been characterized. In Trypanosoma brucei there are sixteen Rab genes, but RabX1, RabX2 and RabX3 are divergent within canonical sequence regions. Where known, trypanosome Rab functions are broadly conserved when orthologous relationships may be robustly established, but specific functions for RabX1, X2 and X3 have yet to be determined. RabX1 and RabX2 originated via tandem duplication and subcellular localization places RabX1 at the endoplasmic reticulum, while RabX2 is at the Golgi complex, suggesting distinct functions. We wished to determine whether RabX1 and RabX2 are involved in vesicle transport or other cellular processes. Methodology/Principal Findings: Using comparative genomics we find that RabX1 and RabX2 are restricted to trypanosomatids. Gene knockout indicates that RabX1 and RabX2 are non-essential. Simultaneous RNAi knockdown of both RabX1 and RabX2, while partial, was also non-lethal and may suggest non-redundant function, consistent with the distinct locations of the proteins. Analysis of the knockout cell lines unexpectedly failed to uncover a defect in exocytosis, endocytosis or in the morphology or location of multiple markers for the endomembrane system, suggesting that neither RabX1 nor RabX2 has a major role in intracellular transport. However, it was apparent that RabX1 and RabX2 knockout cells displayed somewhat enhanced survival within flies. Conclusions/Significance: RabX1 and RabX2, two members of the trypanosome Rab subfamily, were shown to have no major detectable role in intracellular transport, despite the localization of each gene product to highly specific endomembrane compartments. These data extend the functional scope of Rab proteins in trypanosomes to include non-canonical roles in differentiation-associated processes in protozoa.			Natesan, SKA (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	mcf34@cam.ac.uk	Field, Mark/AAD-6455-2021; Gibson, Wendy/E-4182-2014	Matthews FRS FMedSci FRSE, Professor Keith/0000-0003-0309-9184; Field, Mark/0000-0002-4866-2885	Wellcome Trust [073358, 074242] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ackers JP, 2005, MOL BIOCHEM PARASIT, V141, P89, DOI 10.1016/j.molbiopara.2005.01.017; Alexander DL, 2002, J CELL SCI, V115, P3253; Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; BANGS JD, 1993, J CELL SCI, V105, P1101; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; BARRY JD, 1979, J CELL SCI, V37, P287; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRUN R, 1979, ACTA TROP, V36, P289; Dacks JB, 2009, INT J BIOCHEM CELL B, V41, P330, DOI 10.1016/j.biocel.2008.08.041; Dean S, 2009, NATURE, V459, P213, DOI 10.1038/nature07997; Denny PW, 2002, MOL BIOCHEM PARASIT, V123, P105, DOI 10.1016/S0166-6851(02)00133-0; Dhir V, 2004, MOL BIOCHEM PARASIT, V137, P253, DOI 10.1016/j.molbiopara.2004.06.007; Engstler M, 2007, CELL, V131, P505, DOI 10.1016/j.cell.2007.08.046; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; Field H, 1999, J CELL SCI, V112, P147; Field MC, 2008, TRENDS PARASITOL, V24, P253, DOI 10.1016/j.pt.2008.03.005; Field MC, 2007, ADV EXP MED BIOL, V607, P84; Field MC, 2005, TRENDS PARASITOL, V21, P447, DOI 10.1016/j.pt.2005.08.008; Field MC, 2004, TRAFFIC, V5, P905, DOI 10.1111/j.1600-0854.2004.00234.x; Field MC, 2004, MICROSC MICROANAL, V10, P621, DOI 10.1017/S1431927604040942; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; Hall B, 2004, MOL BIOCHEM PARASIT, V138, P67, DOI 10.1016/j.molbiopara.2004.07.007; Hall BS, 2005, EUKARYOT CELL, V4, P971, DOI 10.1128/EC.4.5.971-980.2005; Hall BS, 2004, J BIOL CHEM, V279, P45047, DOI 10.1074/jbc.M407271200; Hendriks EF, 2005, MOL MICROBIOL, V57, P706, DOI 10.1111/j.1365-2958.2005.04679.x; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; Herder S, 2007, EXP PARASITOL, V117, P111, DOI 10.1016/j.exppara.2007.05.011; HIRUMI H, 1994, PARASITOL TODAY, V10, P80, DOI 10.1016/0169-4758(94)90402-2; Jeffries TR, 2001, J CELL SCI, V114, P2617; Kumar S, 2007, EUKARYOT CELL, V6, P2029, DOI 10.1128/EC.00213-07; Macleod ET, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000239; Matthews KR, 2005, J CELL SCI, V118, P283, DOI 10.1242/jcs.01649; Maudlin I., 1991, Advances in Disease Vector Research, V7, P117; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Morgan GW, 2002, TRENDS PARASITOL, V18, P491, DOI 10.1016/S1471-4922(02)02391-7; Morgan GW, 2001, J CELL SCI, V114, P2605; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Peacock L, 2008, MOL BIOCHEM PARASIT, V160, P100, DOI 10.1016/j.molbiopara.2008.04.009; Quijada L, 2002, NUCLEIC ACIDS RES, V30, P4414, DOI 10.1093/nar/gkf577; Redmond S, 2003, MOL BIOCHEM PARASIT, V128, P115, DOI 10.1016/S0166-6851(03)00045-8; Reuner B, 1997, MOL BIOCHEM PARASIT, V90, P269, DOI 10.1016/S0166-6851(97)00160-6; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Skepper JN, 2000, J MICROSC-OXFORD, V199, P1, DOI 10.1046/j.1365-2818.2000.00704.x; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; Szoor B, 2006, J CELL BIOL, V175, P293, DOI 10.1083/jcb.200605090; Triggs VP, 2003, EUKARYOT CELL, V2, P76, DOI 10.1128/EC.2.1.76-83.2003; Vassella E, 1997, J CELL SCI, V110, P2661; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; Welburn SC, 1999, PARASITOL TODAY, V15, P399, DOI 10.1016/S0169-4758(99)01512-4	55	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7217	10.1371/journal.pone.0007217	http://dx.doi.org/10.1371/journal.pone.0007217			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787065	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290100016
J	Brody, JP				Brody, James P.			Parallel Routes of Human Carcinoma Development: Implications of the Age-Specific Incidence Data	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; BREAST-CANCER; MULTISTAGE CARCINOGENESIS; YOUNG-WOMEN; RACIAL-DIFFERENCES; COLON-CANCER; RISK; MODEL; SUSCEPTIBILITY; EPIDEMIOLOGY	Background: The multi-stage hypothesis suggests that cancers develop through a single defined series of genetic alterations. This hypothesis was first suggested over 50 years ago based upon age-specific incidence data. However, recent molecular studies of tumors indicate that multiple routes exist to the formation of cancer, not a single route. This parallel route hypothesis has not been tested with age-specific incidence data. Methodology/Principal Findings: To test the parallel route hypothesis, I formulated it in terms of a mathematical equation and then tested whether this equation was consistent with age-specific incidence data compiled by the Surveillance Epidemiology and End Results (SEER) cancer registries since 1973. I used the chi-squared goodness of fit test to measure consistency. The age-specific incidence data from most human carcinomas, including those of the colon, lung, prostate, and breast were consistent with the parallel route hypothesis. However, this hypothesis is only consistent if an immune sub-population exists, one that will never develop carcinoma. Furthermore, breast carcinoma has two distinct forms of the disease, and one of these occurs at significantly different rates in different racial groups. Conclusions/Significance: I conclude that the parallel route hypothesis is consistent with the age-specific incidence data only if carcinoma occurs in a distinct sub population, while the multi-stage hypothesis is inconsistent with this data.			Brody, JP (corresponding author), Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92717 USA.	jpbrody@uci.edu		Brody, James/0000-0002-7995-5197	NHGRI NIH HHS [K22 HG000047, T32 HG000047, HG-00047] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG000047, T32HG000047] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anderson WF, 2001, J CLIN ONCOL, V19, P18, DOI 10.1200/JCO.2001.19.1.18; Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Anderson WF, 2006, CANCER EPIDEM BIOMAR, V15, P1899, DOI 10.1158/1055-9965.EPI-06-0191; Anderson WF, 2006, JNCI-J NATL CANCER I, V98, P948, DOI 10.1093/jnci/djj295; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.3.CO;2-T; Colditz GA, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1414; DEWAARD F, 1979, J NATL CANCER I, V63, P549, DOI 10.1093/jnci/63.3.549; Dunckley T, 2007, NEW ENGL J MED, V357, P775, DOI 10.1056/NEJMoa070174; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; FARBER E, 1984, CANCER RES, V44, P4217; Fay MP, 1997, STAT MED, V16, P791; Frank S. A., 2007, DYNAMICS CANC INCIDE; Frank SA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-163; Frank SA, 2004, CURR BIOL, V14, P242, DOI 10.1016/j.cub.2003.12.026; Frank SA, 2003, NATURE, V422, P494, DOI 10.1038/422494a; Heidenreich WF, 2002, RADIAT RES, V158, P607, DOI 10.1667/0033-7587(2002)158[0607:MMATIO]2.0.CO;2; Herrero-Jimenez P, 2000, MUTAT RES-FUND MOL M, V447, P73, DOI 10.1016/S0027-5107(99)00201-8; Herrero-Jimenez P, 1998, MUTAT RES-FUND MOL M, V400, P553, DOI 10.1016/S0027-5107(98)00067-0; Holford Theodore R, 2006, J Natl Cancer Inst Monogr, P19, DOI 10.1093/jncimonographs/lgj016; Houlston RS, 2004, ONCOGENE, V23, P6471, DOI 10.1038/sj.onc.1207951; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Jatoi I, 2003, CANCER-AM CANCER SOC, V98, P894, DOI 10.1002/cncr.11604; Johnson SM, 2002, INT J CANCER, V98, P205, DOI 10.1002/ijc.10197; Jones S., 2008, SCIENCE; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Luebeck EG, 2002, P NATL ACAD SCI USA, V99, P15095, DOI 10.1073/pnas.222118199; Marees T, 2008, J NATL CANCER I, V100, P1771, DOI 10.1093/jnci/djn394; Meza R, 2008, P NATL ACAD SCI USA, V105, P16284, DOI 10.1073/pnas.0801151105; MOOLGAVKAR SH, 1992, J NATL CANCER I, V84, P610, DOI 10.1093/jnci/84.8.610; Moolgavkar SH, 2003, GENE CHROMOSOME CANC, V38, P302, DOI 10.1002/gcc.10264; MOOLGAVKAR SH, 1990, RISK ANAL, V10, P323, DOI 10.1111/j.1539-6924.1990.tb01053.x; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; NORDLING CO, 1953, BRIT J CANCER, V7, P68, DOI 10.1038/bjc.1953.8; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Pfeiffer RM, 2008, JNCI-J NATL CANCER I, V100, P751, DOI 10.1093/jnci/djn112; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Pompei F, 2002, TOXICOL IND HEALTH, V18, P365, DOI 10.1191/0748233702th164oa; *SEER PROGR, 2003, SEERST DAT INC SEER; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Weber-Mangal S, 2003, INT J CANCER, V107, P583, DOI 10.1002/ijc.11460; Weinberg RA., 2002, NEW ENGL J MED, V347, P1593, DOI [DOI 10.1056/NEJMRA021902, 10.1056/NEJMra021902]; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xiong QH, 2001, CANCER, V92, P2523, DOI 10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022	51	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7053	10.1371/journal.pone.0007053	http://dx.doi.org/10.1371/journal.pone.0007053			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774079	Green Published, gold, Green Submitted			2022-12-27	WOS:000270160900003
J	Ahmed, A; Engelberts, MFM; Boer, KR; Ahmed, N; Hartskeerl, RA				Ahmed, Ahmed; Engelberts, Mirjam F. M.; Boer, Kimberly R.; Ahmed, Niyaz; Hartskeerl, Rudy A.			Development and Validation of a Real-Time PCR for Detection of Pathogenic Leptospira Species in Clinical Materials	PLOS ONE			English	Article							POLYMERASE-CHAIN-REACTION; EARLY-DIAGNOSIS; IDENTIFICATION; ASSAY; SEROVAR; GROWTH; SETS	Available serological diagnostics do not allow the confirmation of clinically suspected leptospirosis at the early acute phase of illness. Several conventional and real-time PCRs for the early diagnosis of leptospirosis have been described but these have been incompletely evaluated. We developed a SYBR Green-based real-time PCR targeting secY and validated it according to international guidelines. To determine the analytical specificity, DNA from 56 Leptospira strains belonging to pathogenic, non-pathogenic and intermediate Leptospira spp. as well as 46 other micro-organisms was included in this study. All the pathogenic Leptospira gave a positive reaction. We found no cross-reaction with saprophytic Leptospira and other micro-organisms, implying a high analytical specificity. The analytical sensitivity of the PCR was one copy per reaction from cultured homologous strain M 20 and 1.2 and 1.5 copy for heterologous strains 1342 K and Sarmin, respectively. In spiked serum & blood and kidney tissue the sensitivity was 10 and 20 copies for M 20, 15 and 30 copies for 1342 K and 30 and 50 copies for Sarmin. To determine the diagnostic sensitivity (DSe) and specificity (DSp), clinical blood samples from 26 laboratory-confirmed and 107 negative patients suspected of leptospirosis were enrolled as a prospective consecutive cohort. Based on culture as the gold standard, we found a DSe and DSp of 100% and 93%, respectively. All eight PCR positive samples that had a negative culture seroconverted later on, implying a higher actual DSp. When using culture and serology as the gold standard, the DSe was lower (89%) while the DSp was higher (100%). DSe was 100% in samples collected within the first - for treatment important - 4 days after onset of the illness. Reproducibility and repeatability of the assay, determined by blind testing kidney samples from 20 confirmed positive and 20 negative rodents both appeared 100%. In conclusion we have described for the first time the development of a robust SYBR Green real-time PCR for the detection of pathogenic Leptospira combined with a detailed assessment of its clinical accuracy, thus providing a method for the early diagnosis of leptospirosis with a well-defined satisfactory performance.			Ahmed, A (corresponding author), WHO FAO OIE, Amsterdam, Netherlands.	r.hartskeerl@kit.nl	Ahmed, Niyaz/D-2589-2010	Ahmed, Niyaz/0000-0001-6425-7583				Abdulmawjood A, 2002, MOL CELL PROBE, V16, P335, DOI 10.1006/mcpr.2002.0431; Ahmed Niyaz, 2006, Ann Clin Microbiol Antimicrob, V5, P28, DOI 10.1186/1476-0711-5-28; BAL AE, 1994, J CLIN MICROBIOL, V32, P1894, DOI 10.1128/JCM.32.8.1894-1898.1994; BROWN PD, 1995, J MED MICROBIOL, V43, P110, DOI 10.1099/00222615-43-2-110; Dikken H., 1978, METHOD MICROBIOL, V11, P260; do Oliveira MAA, 2003, J MED MICROBIOL, V52, P127, DOI 10.1099/jmm.0.04923-0; ELLINGHAUSEN HC, 1965, AM J VET RES, V26, P45; Gouvela EL, 2008, EMERG INFECT DIS, V14, P505, DOI 10.3201/eid1403.071064; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; Haake DA, 2000, INFECT IMMUN, V68, P2276, DOI 10.1128/IAI.68.4.2276-2285.2000; Hartskeerl R A, 2006, Indian J Med Microbiol, V24, P309; HARTSKEERL RA, 2008, LCI RICHTLIJNEN INFE, P238; JOHNSON RC, 1967, J BACTERIOL, V94, P27, DOI 10.1128/JB.94.1.27-31.1967; Kawabata H, 2001, MICROBIOL IMMUNOL, V45, P491, DOI 10.1111/j.1348-0421.2001.tb02649.x; Levett PN, 2005, J MED MICROBIOL, V54, P45, DOI 10.1099/jmm.0.45860-0; Louie M, 2000, CAN MED ASSOC J, V163, P301; Matthias MA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000213; Merien F, 2005, FEMS MICROBIOL LETT, V249, P139, DOI 10.1016/j.femsle.2005.06.011; MERIEN F, 1992, J CLIN MICROBIOL, V30, P2219; MERIEN F, 1995, J INFECT DIS, V172, P281, DOI 10.1093/infdis/172.1.281; Nascimento ALTO, 2004, BRAZ J MED BIOL RES, V37, P459, DOI 10.1590/S0100-879X2004000400003; National Center for Biotechnology Information, 2009, BAS LOC AL SEARCH TO; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Palaniappan RUM, 2005, MOL CELL PROBE, V19, P111, DOI 10.1016/j.mcp.2004.10.002; Perolat P, 1998, INT J SYST BACTERIOL, V48, P851, DOI 10.1099/00207713-48-3-851; Post JC, 2000, JAMA-J AM MED ASSOC, V283, P1544, DOI 10.1001/jama.283.12.1544; Priya CG, 2007, J POSTGRAD MED, V53, P236; Reitstetter RE, 2006, FEMS MICROBIOL LETT, V264, P31, DOI 10.1111/j.1574-6968.2006.00431.x; Slack AT, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-95; Smythe LD, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-13; Speelman P, 2008, HARRISONS PRINCIPLES, P1048; *STANDARDS, 2008, STANDARDS REP DIAGN; Stoddard RA, 2009, DIAGN MICR INFEC DIS, V64, P247, DOI 10.1016/j.diagmicrobio.2009.03.014; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; TERPSTRA WJ, 1985, J GEN MICROBIOL, V131, P377; Valverde MD, 2008, INFECT GENET EVOL, V8, P529, DOI 10.1016/j.meegid.2008.02.008; Victoria B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002752; Vinetz JM, 1996, ANN INTERN MED, V125, P794, DOI 10.7326/0003-4819-125-10-199611150-00002; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774; Woo THS, 1997, J CLIN MICROBIOL, V35, P3140, DOI 10.1128/JCM.35.12.3140-3146.1997; World Health Organization, 2003, HUM LEPT GUID DIAGN; *WORLD ORG AN HLTH, 2004, OIE MAN DIAGN TESTS; Yersin C, 1999, TROP MED INT HEALTH, V4, P38, DOI 10.1046/j.1365-3156.1999.00352.x; Zhang Y, 1993, Hua Xi Yi Ke Da Xue Xue Bao, V24, P262; ZUERNER RL, 1995, J CLIN MICROBIOL, V33, P3284, DOI 10.1128/JCM.33.12.3284-3289.1995; Zuerner RL, 2000, FEMS MICROBIOL LETT, V182, P303, DOI 10.1016/S0378-1097(99)00598-4	46	171	175	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7093	10.1371/journal.pone.0007093	http://dx.doi.org/10.1371/journal.pone.0007093			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763264	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970400017
J	Lee, JS; Kim, IS; Kim, JH; Cho, W; Suh, PG; Ryu, SH				Lee, Jun Sung; Kim, Il Shin; Kim, Jung Hwan; Cho, Wonhwa; Suh, Pann-Ghill; Ryu, Sung Ho			Determination of EGFR Endocytosis Kinetic by Auto-Regulatory Association of PLD1 with mu 2	PLOS ONE			English	Article								Background: Upon ligand binding, cell surface signaling receptors are internalized through a process tightly regulated by endocytic proteins and adaptor protein 2 (AP2) to orchestrate them. Although the molecular identities and roles of endocytic proteins are becoming clearer, it is still unclear what determines the receptor endocytosis kinetics which is mainly regulated by the accumulation of endocytic apparatus to the activated receptors. Methodology/Principal Findings: Here we employed the kinetic analysis of endocytosis and adaptor recruitment to show that mu 2, a subunit of AP2 interacts directly with phospholipase D (PLD)1, a receptor-associated signaling protein and this facilitates the membrane recruitment of AP2 and the endocytosis of epidermal growth factor receptor ( EGFR). We also demonstrate that the PLD1-m2 interaction requires the binding of PLD1 with phosphatidic acid, its own product. Conclusions/Significance: These results suggest that the temporal regulation of EGFR endocytosis is achieved by autoregulatory PLD1 which senses the receptor activation and triggers the translocation of AP2 near to the activated receptor.			Lee, JS (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang, Kyungbuk, South Korea.	sungho@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Jung Hwan/0000-0001-8548-4435	NIGMS NIH HHS [R01 GM068849, GM 68849] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068849] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Cremona O, 2001, J CELL SCI, V114, P1041; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gagescu R, 2000, Traffic, V1, P84, DOI 10.1034/j.1600-0854.2000.010112.x; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Han JM, 2002, MOL BIOL CELL, V13, P3976, DOI 10.1091/mbc.E02-02-0100; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Lee CS, 2006, NAT CELL BIOL, V8, P477, DOI 10.1038/ncb1401; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nakano-Kobayashi A, 2007, EMBO J, V26, P1105, DOI 10.1038/sj.emboj.7601573; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Stahelin RV, 2004, J BIOL CHEM, V279, P54918, DOI 10.1074/jbc.M407798200; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wiedemann C, 1998, J NEUROSCI, V18, P5594	25	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7090	10.1371/journal.pone.0007090	http://dx.doi.org/10.1371/journal.pone.0007090			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763255	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970400016
J	Wunschel, D; Webb-Robertson, BJ; Frevert, CW; Skerrett, S; Beagley, N; Willse, A; Colburn, H; Antolick, K				Wunschel, David; Webb-Robertson, Bobbie-Jo; Frevert, Charles W.; Skerrett, Shawn; Beagley, Nat; Willse, Alan; Colburn, Heather; Antolick, Kathryn			Differentiation of Gram-Negative Bacterial Aerosol Exposure Using Detected Markers in Bronchial-Alveolar Lavage Fluid	PLOS ONE			English	Article							TOF MASS-SPECTROMETRY; MALDI-TOF; INFLAMMATORY RESPONSE; IDENTIFICATION; CYTOKINES; DEFENSINS; BREATH; INHALATION; INFECTION; PROTEINS	The identification of biosignatures of aerosol exposure to pathogens has the potential to provide useful diagnostic information. In particular, markers of exposure to different types of respiratory pathogens may yield diverse sets of markers that can be used to differentiate exposure. We examine a mouse model of aerosol exposure to known Gram negative bacterial pathogens, Francisella tularensis novicida and Pseudomonas aeruginosa. Mice were subjected to either a pathogen or control exposure and bronchial alveolar lavage fluid (BALF) was collected at four and twenty four hours post exposure. Small protein and peptide markers within the BALF were detected by matrix assisted laser desorption/ionization (MALDI) mass spectrometry (MS) and analyzed using both exploratory and predictive data analysis methods; principle component analysis and degree of association. The markers detected were successfully used to accurately identify the four hour exposed samples from the control samples. This report demonstrates the potential for small protein and peptide marker profiles to identify aerosol exposure in a short post-exposure time frame.			Wunschel, D (corresponding author), Pacific NW Natl Lab, Richland, WA 99352 USA.	David.Wunschel@pnl.gov	Colburn, Heather/ABC-5136-2021; Wunschel, David/F-3820-2010; Webb-Robertson, Bobbie-Jo/K-8230-2019	Colburn, Heather/0000-0003-0399-4728; Webb-Robertson, Bobbie-Jo/0000-0002-4744-2397	NIAID NIH HHS [U54 AI057141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ardekani Ali M, 2002, Expert Rev Mol Diagn, V2, P312, DOI 10.1586/14737159.2.4.312; Ayabe T, 2001, GASTROENTEROLOGY, V120, pA187, DOI 10.1016/S0016-5085(08)80926-2; Beineke A, 2004, VET IMMUNOL IMMUNOP, V98, P59, DOI 10.1016/j.vetimm.2003.10.002; Devijver P, 1982, PATTERN RECOGNITION; Duenas AI, 2006, INT IMMUNOL, V18, P785, DOI 10.1093/intimm/dxl015; Evans RG, 2006, DIS MANAG HEALTH OUT, V14, P265, DOI 10.2165/00115677-200614050-00002; Fenselau C, 2001, MASS SPECTROM REV, V20, P157, DOI 10.1002/mas.10004; Frevert CW, 1998, FASEB J, V12, pA788; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; Goodman RB, 1998, AM J PHYSIOL-LUNG C, V275, pL87, DOI 10.1152/ajplung.1998.275.1.L87; Greenfield RA, 2002, AM J MED SCI, V323, P299, DOI 10.1097/00000441-200206000-00003; Hager AJ, 2006, MOL MICROBIOL, V62, P227, DOI 10.1111/j.1365-2958.2006.05365.x; Hajjar AM, 2006, INFECT IMMUN, V74, P6730, DOI 10.1128/IAI.00934-06; Holland RD, 1999, ANAL CHEM, V71, P3226, DOI 10.1021/ac990175v; Issaq HJ, 2003, ANAL CHEM, V75, p148A, DOI 10.1021/ac031249c; Jackman J, 2004, J HOPKINS APL TECH D, V25, P6; Jarman KH, 1999, RAPID COMMUN MASS SP, V13, P1586, DOI 10.1002/(SICI)1097-0231(19990815)13:15<1586::AID-RCM680>3.0.CO;2-2; Jarman KH, 2000, ANAL CHEM, V72, P1217, DOI 10.1021/ac990832j; Jin T, 2004, J IMMUNOL, V172, P1169, DOI 10.4049/jimmunol.172.2.1169; Kohn Elise C., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1163; Krader P, 2004, EXTREMOPHILES, V8, P259, DOI 10.1007/s00792-004-0382-7; Kyriacou DN, 2007, CHEST, V131, P489, DOI 10.1378/chest.06-1687; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; Lahteenmaki K, 2001, FEBS LETT, V504, P69, DOI 10.1016/S0014-5793(01)02775-2; Lay JO, 2001, MASS SPECTROM REV, V20, P172, DOI 10.1002/mas.10003; Lee JS, 2005, AM J PHYSIOL-LUNG C, V289, pL731, DOI 10.1152/ajplung.00196.2005; Lembo A, 2008, J IMMUNOL, V180, P7574, DOI 10.4049/jimmunol.180.11.7574; Mandrell R, 2007, MOL CELL PROTEOMICS, V6, P58; Mellmann A, 2007, INT J MED MICROBIOL, V297, P16; Miyoshi S, 2000, MICROBES INFECT, V2, P91, DOI 10.1016/S1286-4579(00)00280-X; Ott RL, 2001, INTRO STAT METHODS D; Prieto D, 2003, J LIQ CHROMATOGR R T, V26, P2315, DOI 10.1081/JLC-120023249; Pusch W, 2007, PHARMACOGENOMICS, V8, P663, DOI 10.2217/14622416.8.6.663; Robroeks CMHHT, 2006, ANN ALLERG ASTHMA IM, V96, P349, DOI 10.1016/S1081-1206(10)61247-1; Sack U, 2006, CYTOM PART A, V69A, P169, DOI 10.1002/cyto.a.20231; SASMANO T, 2004, BIOL MACROPHAGES; Senior BW, 2005, INFECT IMMUN, V73, P1515, DOI 10.1128/IAI.73.3.1515-1522.2005; Skerrett SJ, 2007, AM J PHYSIOL-LUNG C, V292, pL312, DOI 10.1152/ajplung.00250.2006; Smoll J., 2003, Experimental Lung Research, V29, P108; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; Van den Steen PE, 2003, BIOCHEM BIOPH RES CO, V310, P889, DOI 10.1016/j.bbrc.2003.09.098; Visentainer JEL, 2003, EXP HEMATOL, V31, P1044, DOI 10.1016/j.exphem.2003.08.005; West TE, 2008, MICROBES INFECT, V10, P773, DOI 10.1016/j.micinf.2008.04.008; Wunschel SC, 2005, J AM SOC MASS SPECTR, V16, P456, DOI 10.1016/j.jasms.2004.12.004; Zhang H, 2001, AM J PHYSIOL-LUNG C, V280, pL947, DOI 10.1152/ajplung.2001.280.5.L947	45	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7047	10.1371/journal.pone.0007047	http://dx.doi.org/10.1371/journal.pone.0007047			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756149	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970000014
J	Lazarini, F; Mouthon, MA; Gheusi, G; de Chaumont, F; Olivo-Marin, JC; Lamarque, S; Abrous, DN; Boussin, FD; Lledo, PM				Lazarini, Francoise; Mouthon, Marc-Andre; Gheusi, Gilles; de Chaumont, Fabrice; Olivo-Marin, Jean-Christophe; Lamarque, Stephanie; Abrous, Djoher Nora; Boussin, Francois D.; Lledo, Pierre-Marie			Cellular and Behavioral Effects of Cranial Irradiation of the Subventricular Zone in Adult Mice	PLOS ONE			English	Article								Background: In mammals, new neurons are added to the olfactory bulb (OB) throughout life. Most of these new neurons, granule and periglomerular cells originate from the subventricular zone (SVZ) lining the lateral ventricles and migrate via the rostral migratory stream toward the OB. Thousands of new neurons appear each day, but the function of this ongoing neurogenesis remains unclear. Methodology/Principal Findings: In this study, we irradiated adult mice to impair constitutive OB neurogenesis, and explored the functional impacts of this irradiation on the sense of smell. We found that focal irradiation of the SVZ greatly decreased the rate of production of new OB neurons, leaving other brain areas intact. This effect persisted for up to seven months after exposure to 15 Gray. Despite this robust impairment, the thresholds for detecting pure odorant molecules and short-term olfactory memory were not affected by irradiation. Similarly, the ability to distinguish between odorant molecules and the odorant-guided social behavior of irradiated mice were not affected by the decrease in the number of new neurons. Only long-term olfactory memory was found to be sensitive to SVZ irradiation. Conclusion/Significance: These findings suggest that the continuous production of adult-generated neurons is involved in consolidating or restituting long-lasting olfactory traces.			Lazarini, F (corresponding author), Inst Pasteur, Lab Percept & Memory, Paris, France.	pmlledo@pasteur.fr	Olivo-Marin, Jean-Christophe/K-4428-2015; Abrous, Nora-Djoher/N-6977-2017	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; de Chaumont, Fabrice/0000-0001-7613-7204; abrous, nora/0000-0002-8589-305X; Mouthon, Marc-Andre/0000-0003-2633-9179; Boussin, francois/0000-0003-3778-4403; Lazarini, Francoise/0000-0001-5572-6982				Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; Aimone JB, 2009, NEURON, V61, P187, DOI 10.1016/j.neuron.2008.11.026; Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; ALTMAN J, 1965, NATURE, V207, P953, DOI 10.1038/207953a0; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Bath KG, 2008, J NEUROSCI, V28, P2383, DOI 10.1523/JNEUROSCI.4387-07.2008; Becker S, 2005, HIPPOCAMPUS, V15, P722, DOI 10.1002/hipo.20095; Bodyak N, 1999, CHEM SENSES, V24, P637, DOI 10.1093/chemse/24.6.637; Brennan PA, 2006, NATURE, V444, P308, DOI 10.1038/nature05404; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Chaillan FA, 1997, EUR J NEUROSCI, V9, P884, DOI 10.1111/j.1460-9568.1997.tb01439.x; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Dietrich J, 2008, ONCOLOGIST, V13, P1285, DOI 10.1634/theoncologist.2008-0130; Dranovsky A, 2006, BIOL PSYCHIAT, V59, P1136, DOI 10.1016/j.biopsych.2006.03.082; Drapeau E, 2008, AGING CELL, V7, P569, DOI 10.1111/j.1474-9726.2008.00369.x; Duan X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI 10.1016/j.conb.2008.04.001; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Farioli-Vecchioli S, 2008, PLOS BIOL, V6, P2188, DOI 10.1371/journal.pbio.0060246; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Granger R, 1991, Curr Opin Neurobiol, V1, P209, DOI 10.1016/0959-4388(91)90080-Q; Grubb MS, 2008, J NEUROSCI, V28, P2919, DOI 10.1523/JNEUROSCI.5550-07.2008; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Iwata Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002283; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kim WR, 2007, J NEUROSCI, V27, P14392, DOI 10.1523/JNEUROSCI.3903-07.2007; Linster C, 2002, J NEUROSCI, V22, P6842; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Magavi SSP, 2005, J NEUROSCI, V25, P10729, DOI 10.1523/JNEUROSCI.2250-05.2005; Mandairon N, 2006, EUR J NEUROSCI, V24, P3578, DOI 10.1111/j.1460-9568.2006.05235.x; Mizrahi A, 2007, NAT NEUROSCI, V10, P444, DOI 10.1038/nn1875; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Mouret A, 2008, J NEUROSCI, V28, P11511, DOI 10.1523/JNEUROSCI.2954-08.2008; NISSANT A, 2009, NAT NEUROSCI; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; Petreanu L, 2002, J NEUROSCI, V22, P6106; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rochefort C, 2005, EUR J NEUROSCI, V22, P2863, DOI 10.1111/j.1460-9568.2005.04486.x; Rochefort C, 2002, J NEUROSCI, V22, P2679, DOI 10.1523/JNEUROSCI.22-07-02679.2002; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Scotto-Lomassese S, 2003, J NEUROSCI, V23, P9289; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Steinbach S, 2009, J CLIN ONCOL, V27, P1899, DOI 10.1200/JCO.2008.19.2690; Tada E, 1999, EXP NEUROL, V160, P66, DOI 10.1006/exnr.1999.7172; Teuchert-Noodt G., 2000, Journal of Neural Transmission Supplement, V60, P315; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Yamaguchi M, 2005, P NATL ACAD SCI USA, V102, P9697, DOI 10.1073/pnas.0406082102; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	50	145	149	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7017	10.1371/journal.pone.0007017	http://dx.doi.org/10.1371/journal.pone.0007017			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753118	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796500008
J	Tidhar, A; Flashner, Y; Cohen, S; Levi, Y; Zauberman, A; Gur, D; Aftalion, M; Elhanany, E; Zvi, A; Shafferman, A; Mamroud, E				Tidhar, Avital; Flashner, Yehuda; Cohen, Sara; Levi, Yinon; Zauberman, Ayelet; Gur, David; Aftalion, Moshe; Elhanany, Eytan; Zvi, Anat; Shafferman, Avigdor; Mamroud, Emanuelle			The NlpD Lipoprotein Is a Novel Yersinia pestis Virulence Factor Essential for the Development of Plague	PLOS ONE			English	Article							STATIONARY-PHASE SURVIVAL; ESCHERICHIA-COLI CHROMOSOME; REPAIR METHYLTRANSFERASE; SIGMA(S) SUBUNIT; RNA-POLYMERASE; PROTECTS MICE; 59 MINUTES; RPOS; GENE; IDENTIFICATION	Yersinia pestis is the causative agent of plague. Previously we have isolated an attenuated Y. pestis transposon insertion mutant in which the pcm gene was disrupted. In the present study, we investigated the expression and the role of pcm locus genes in Y. pestis pathogenesis using a set of isogenic surE, pcm, nlpD and rpoS mutants of the fully virulent Kimberley53 strain. We show that in Y. pestis, nlpD expression is controlled from elements residing within the upstream genes surE and pcm. The NlpD lipoprotein is the only factor encoded from the pcm locus that is essential for Y. pestis virulence. A chromosomal deletion of the nlpD gene sequence resulted in a drastic reduction in virulence to an LD50 of at least 10(7) cfu for subcutaneous and airway routes of infection. The mutant was unable to colonize mouse organs following infection. The filamented morphology of the nlpD mutant indicates that NlpD is involved in cell separation; however, deletion of nlpD did not affect in vitro growth rate. Trans-complementation experiments with the Y. pestis nlpD gene restored virulence and all other phenotypic defects. Finally, we demonstrated that subcutaneous administration of the nlpD mutant could protect animals against bubonic and primary pneumonic plague. Taken together, these results demonstrate that Y. pestis NlpD is a novel virulence factor essential for the development of bubonic and pneumonic plague. Further, the nlpD mutant is superior to the EV76 prototype live vaccine strain in immunogenicity and in conferring effective protective immunity. Thus it could serve as a basis for a very potent live vaccine against bubonic and pneumonic plague.			Tidhar, A (corresponding author), Israel Inst Biol Res, Dept Biochem & Mol Genet, IL-70450 Ness Ziona, Israel.	emmym@iibr.gov.il						BADGER JL, 1995, J BACTERIOL, V177, P5370, DOI 10.1128/jb.177.18.5370-5373.1995; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Bearden SW, 1997, INFECT IMMUN, V65, P1659, DOI 10.1128/IAI.65.5.1659-1668.1997; BENGURION R, 1981, PLASMID, V5, P183, DOI 10.1016/0147-619X(81)90019-6; Ber R, 2003, APPL ENVIRON MICROB, V69, P5787, DOI 10.1128/AEM.69.10.5787-5792.2003; Bernhardt TG, 2004, MOL MICROBIOL, V52, P1255, DOI 10.1111/j.1365-2958.2004.04063.x; Bleves S, 2000, MICROBES INFECT, V2, P1451, DOI 10.1016/S1286-4579(00)01300-9; BRUBAKER R R, 1970, Infection and Immunity, V1, P446; Buist G, 2008, MOL MICROBIOL, V68, P838, DOI 10.1111/j.1365-2958.2008.06211.x; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; Cunning C, 1998, J BACTERIOL, V180, P4564, DOI 10.1128/JB.180.17.4564-4570.1998; Darling ACE, 2004, GENOME RES, V14, P1394, DOI 10.1101/gr.2289704; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; FANG FC, 1992, P NATL ACAD SCI USA, V89, P11978, DOI 10.1073/pnas.89.24.11978; Fetherston JD, 1999, MOL MICROBIOL, V32, P289, DOI 10.1046/j.1365-2958.1999.01348.x; Flashner Y, 2004, INFECT IMMUN, V72, P908, DOI 10.1128/IAI.72.2.908-915.2004; Forman S, 2008, INFECT IMMUN, V76, P578, DOI 10.1128/IAI.00219-07; FU JC, 1991, J BIOL CHEM, V266, P14562; Grosfeld H, 2003, ADV EXP MED BIOL, V529, P423; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; Hengge-Aronis R, 2002, J MOL MICROB BIOTECH, V4, P341; Hirsch M, 2005, J BACTERIOL, V187, P7204, DOI 10.1128/JB.187.21.7204-7213.2005; Hirsch M, 2005, J BACTERIOL, V187, P1568, DOI 10.1128/JB.187.5.1568-1580.2005; Hirsch M, 2002, J BACTERIOL, V184, P5077, DOI 10.1128/JB.184.18.5077-5087.2002; HOLZMAN T, 2006, MICROB CELL FACT, V5, P98; Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006; ICHIKAWA JK, 1994, J BACTERIOL, V176, P1630, DOI 10.1128/jb.176.6.1630-1638.1994; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; IRIARTE M, 1995, INFECT IMMUN, V63, P1840, DOI 10.1128/IAI.63.5.1840-1847.1995; Kajimura J, 2005, MOL MICROBIOL, V58, P1087, DOI 10.1111/j.1365-2958.2005.04881.x; Lai XH, 2006, FEMS MICROBIOL LETT, V258, P78, DOI 10.1111/j.1574-6968.2006.00197.x; LANGE R, 1995, J BACTERIOL, V177, P4676, DOI 10.1128/jb.177.16.4676-4680.1995; LANGE R, 1994, MOL MICROBIOL, V13, P733, DOI 10.1111/j.1365-2958.1994.tb00466.x; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; Lathem WW, 2005, P NATL ACAD SCI USA, V102, P17786, DOI 10.1073/pnas.0506840102; Lathem WW, 2007, SCIENCE, V315, P509, DOI 10.1126/science.1137195; LEARY SEC, 1995, INFECT IMMUN, V63, P2854, DOI 10.1128/IAI.63.8.2854-2858.1995; LI C, 1994, J BACTERIOL, V176, P6015, DOI 10.1128/jb.176.19.6015-6022.1994; Li C, 1997, MICROBIOL-UK, V143, P3513, DOI 10.1099/00221287-143-11-3513; Lloyd AL, 2005, J MICROBIOL METH, V60, P291, DOI 10.1016/j.mimet.2004.10.009; Marketon MM, 2005, SCIENCE, V309, P1739, DOI 10.1126/science.1114580; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Munier-Lehmann H, 2003, BIOCHEM J, V373, P515, DOI 10.1042/BJ20030284; Navarro-Llorens JM, 2002, ARCH MICROBIOL, V179, P33, DOI 10.1007/s00203-002-0493-4; Paesold G, 1999, J BACTERIOL, V181, P1264, DOI 10.1128/JB.181.4.1264-1268.1999; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Petit CM, 2001, FEMS MICROBIOL LETT, V200, P229, DOI 10.1111/j.1574-6968.2001.tb10720.x; Pilgrim S, 2003, INFECT IMMUN, V71, P3473, DOI 10.1128/IAI.71.6.3473-3484.2003; Pujol C, 2005, P NATL ACAD SCI USA, V102, P12909, DOI 10.1073/pnas.0502849102; Rawlings ND, 2008, NUCLEIC ACIDS RES, V36, pD320, DOI 10.1093/nar/gkm954; REED L. J., 1938, AMER JOUR HYG, V27, P493; Robichon C, 2005, J BIOL CHEM, V280, P974, DOI 10.1074/jbc.M411059200; Sander P, 2004, MOL MICROBIOL, V52, P1543, DOI 10.1111/j.1365-2958.2004.04041.x; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Sha J, 2008, INFECT IMMUN, V76, P1390, DOI 10.1128/IAI.01529-07; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; Viboud GI, 2005, ANNU REV MICROBIOL, V59, P69, DOI 10.1146/annurev.micro.59.030804.121320; Visick JE, 1998, FEMS MICROBIOL LETT, V167, P19, DOI 10.1111/j.1574-6968.1998.tb13202.x; Visick JE, 1998, J BACTERIOL, V180, P2623, DOI 10.1128/JB.180.10.2623-2629.1998; Weber H, 2005, J BACTERIOL, V187, P1591, DOI 10.1128/JB.187.5.1591-1603.2005; Welkos SL, 1997, MICROB PATHOGENESIS, V23, P211, DOI 10.1006/mpat.1997.0154; Zauberman A, 2006, INFECT IMMUN, V74, P3239, DOI 10.1128/IAI.00097-06; Zauberman A, 2007, ADV EXP MED BIOL, V603, P312; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X	66	66	72	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7023	10.1371/journal.pone.0007023	http://dx.doi.org/10.1371/journal.pone.0007023			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759820	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796300018
J	Davidson, CD; Ali, NF; Micsenyi, MC; Stephney, G; Renault, S; Dobrenis, K; Ory, DS; Vanier, MT; Walkley, SU				Davidson, Cristin D.; Ali, Nafeeza F.; Micsenyi, Matthew C.; Stephney, Gloria; Renault, Sophie; Dobrenis, Kostantin; Ory, Daniel S.; Vanier, Marie T.; Walkley, Steven U.			Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression	PLOS ONE			English	Article							PHARMACEUTICAL APPLICATIONS; LYSOSOMAL CHOLESTEROL; MOUSE MODELS; LIFE-SPAN; NPC1; ACCUMULATION; PROTEIN; BINDING; BRAIN; GANGLIOSIDES	Background: Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder caused most commonly by a defect in the NPC1 protein and characterized by widespread intracellular accumulation of unesterified cholesterol and glycosphingolipids (GSLs). While current treatment therapies are limited, a few drugs tested in Npc1(-/-) mice have shown partial benefit. During a combination treatment trial using two such compounds, N-butyldeoxynojirimycin (NB-DNJ) and allopregnanolone, we noted increased lifespan for Npc1(-/-) mice receiving only 2-hydroxypropyl-beta-cyclodextrin (CD), the vehicle for allopregnanolone. This finding suggested that administration of CD alone, but with greater frequency, might provide additional benefit. Methodology/Principal Findings: Administration of CD to Npc1(-/-) mice beginning at either P7 or P21 and continuing every other day delayed clinical onset, reduced intraneuronal cholesterol and GSL storage as well as free sphingosine accumulation, reduced markers of neurodegeneration, and led to longer survival than any previous treatment regime. We reasoned that other lysosomal diseases characterized by cholesterol and GSL accumulation, including NPC disease due to NPC2 deficiency, GM1 gangliosidosis and mucopolysaccharidosis (MPS) type IIIA, might likewise benefit from CD treatment. Treated Npc2(-/-) mice showed benefits similar to NPC1 disease, however, mice with GM1 gangliosidosis or MPS IIIA failed to show reduction in storage. Conclusions/Significance: Treatment with CD delayed clinical disease onset, reduced intraneuronal storage and secondary markers of neurodegeneration, and significantly increased lifespan of both Npc1(-/-) and Npc2(-/-) mice. In contrast, CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis and MPS IIIA disease. Understanding the mechanism(s) by which CD leads to reduced neuronal storage may provide important new opportunities for treatment of NPC and related neurodegenerative diseases characterized by cholesterol dyshomeostasis.			Davidson, CD (corresponding author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Rose F Kennedy Ctr Res Mental Retardat & Human De, Bronx, NY 10467 USA.	walkley@aecom.yu.edu	Davidson, Cristin/F-4889-2017; Davidson, Cristin/AAA-2733-2020	Davidson, Cristin/0000-0002-5508-8113; Davidson, Cristin/0000-0002-5508-8113	NICHD NIH HHS [HD045561, R01 HD045561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD045561] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; Benarroch EE, 2008, NEUROLOGY, V71, P1368, DOI 10.1212/01.wnl.0000333215.93440.36; Bhaumik M, 1999, GLYCOBIOLOGY, V9, P1389, DOI 10.1093/glycob/9.12.1389; Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Chevallier J, 2008, J BIOL CHEM, V283, P27871, DOI 10.1074/jbc.M801463200; Deng D, 2009, BBA-BIOMEMBRANES, V1788, P470, DOI 10.1016/j.bbamem.2008.11.018; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; Gondre-Lewis MC, 2003, CURR BIOL, V13, P1324, DOI 10.1016/S0960-9822(03)00531-1; Gould S, 2005, FOOD CHEM TOXICOL, V43, P1451, DOI 10.1016/j.fct.2005.03.007; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Hahn CN, 1997, HUM MOL GENET, V6, P205, DOI 10.1093/hmg/6.2.205; Infante RE, 2008, P NATL ACAD SCI USA, V105, P15287, DOI 10.1073/pnas.0807328105; Infante RE, 2008, J BIOL CHEM, V283, P1052, DOI 10.1074/jbc.M707943200; Irie T, 1997, J PHARM SCI-US, V86, P147, DOI 10.1021/js960213f; Jeulin H, 2009, ANTIVIR RES, V81, P261, DOI 10.1016/j.antiviral.2008.12.006; Jeyakumar M, 2003, BRAIN, V126, P974, DOI 10.1093/brain/awg089; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Lachmann RH, 2001, EXPERT OPIN INV DRUG, V10, P455, DOI 10.1517/13543784.10.3.455; Lange Y, 2002, J LIPID RES, V43, P198; Lau AA, 2008, BEHAV BRAIN RES, V191, P130, DOI 10.1016/j.bbr.2008.03.024; Liao GH, 2007, AM J PATHOL, V171, P962, DOI 10.2353/ajpath.2007.070052; Liu B, 2008, J LIPID RES, V49, P663, DOI 10.1194/jlr.M700525-JLR200; Liu B, 2009, P NATL ACAD SCI USA, V106, P2377, DOI 10.1073/pnas.0810895106; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Lloyd-Evans E, 2008, NAT MED, V14, P1247, DOI 10.1038/nm.1876; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; McGlynn R, 2004, J COMP NEUROL, V480, P415, DOI 10.1002/cne.20355; Micsenyi MC, 2009, J NEUROPATH EXP NEUR, V68, P125, DOI 10.1097/NEN.0b013e3181942cf0; Monnaert V, 2004, J PHARMACOL EXP THER, V310, P745, DOI 10.1124/jpet.104.067512; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Pacheco CD, 2007, HUM MOL GENET, V16, P1495, DOI 10.1093/hmg/ddm100; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Patterson MC, 2007, LANCET NEUROL, V6, P765, DOI 10.1016/S1474-4422(07)70194-1; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; Rajewski RA, 1996, J PHARM SCI, V85, P1142, DOI 10.1021/js960075u; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; Sarna JR, 2003, J COMP NEUROL, V456, P279, DOI 10.1002/cne.10522; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; Walkley SU, 2007, ACTA PAEDIATR, V96, P26, DOI 10.1111/j.1651-2227.2007.00202.x; Walkley SU, 2009, BBA-MOL CELL RES, V1793, P726, DOI 10.1016/j.bbamcr.2008.11.014; Walkley SU, 2004, BBA-MOL CELL BIOL L, V1685, P48, DOI 10.1016/j.bbalip.2004.08.011; Walkley SU, 2004, SEMIN CELL DEV BIOL, V15, P433, DOI 10.1016/j.semcdb.2004.03.002; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7; Zhang M, 2008, J NEUROSCI RES, V86, P2848, DOI 10.1002/jnr.21730; Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026	49	314	327	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6951	10.1371/journal.pone.0006951	http://dx.doi.org/10.1371/journal.pone.0006951			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750228	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696600006
J	Quack, T; Knobloch, J; Beckmann, S; Vicogne, J; Dissous, C; Grevelding, CG				Quack, Thomas; Knobloch, Juergen; Beckmann, Svenja; Vicogne, Jerome; Dissous, Colette; Grevelding, Christoph G.			The Formin-Homology Protein SmDia Interacts with the Src Kinase SmTK and the GTPase SmRho1 in the Gonads of Schistosoma mansoni	PLOS ONE			English	Article							DIAPHANOUS-RELATED FORMIN; MALE-FEMALE INTERACTION; TYROSINE KINASE; CELL MORPHOGENESIS; RHO-GTPASES; SH3 DOMAIN; FAMILY; DYNAMICS; PROLINE; SWI/SNF	Background: Schistosomiasis (bilharzia) is a parasitic disease of worldwide significance affecting human and animals. As schistosome eggs are responsible for pathogenesis, the understanding of processes controlling gonad development might open new perspectives for intervention. The Src-like tyrosine-kinase SmTK3 of Schistosoma mansoni is expressed in the gonads, and its pharmacological inhibition reduces mitogenic activity and egg production in paired females in vitro. Since Src kinases are important signal transduction proteins it is of interest to unravel the signaling cascades SmTK3 is involved in to understand its cellular role in the gonads. Methodology and Results: Towards this end we established and screened a yeast two-hybrid (Y2H) cDNA library of adult S. mansoni with a bait construct encoding the SH3 (src homology) domain and unique site of SmTK3. Among the binding partners found was a diaphanous homolog (SmDia), which was characterized further. SmDia is a single-copy gene transcribed throughout development with a bias towards male transcription. Its deduced amino acid sequence reveals all diaphanous-characteristic functional domains. Binding studies with truncated SmDia clones identified SmTK3 interaction sites demonstrating that maximal binding efficiency depends on the N-terminal part of the FH1 (formin homology) domain and the inter-domain region of SmDia located upstream of FH1 in combination with the unique site and the SH3 domain of SmTK3, respectively. SmDia also directly interacted with the GTPase SmRho1 of S. mansoni. In situ hybridization experiments finally demonstrated that SmDia, SmRho1, and SmTK3 are transcribed in the gonads of both genders. Conclusion: These data provide first evidence for the existence of two cooperating pathways involving Rho and Src that bridge at SmDia probably organizing cytoskeletal events in the reproductive organs of a parasite, and beyond that in gonads of eukaryotes. Furthermore, the FH1 and inter domain region of SmDia have been discovered as binding sites for the SH3 and unique site domains of SmTK3, respectively.			Quack, T (corresponding author), Univ Giessen, Inst Parasitol, Giessen, Germany.	Christoph.Grevelding@vetmed.uni-giessen.de		Vicogne, Jerome/0000-0001-8360-7497; Knobloch, Jurgen/0000-0001-6868-0055; Dissous, Colette/0000-0002-5003-8205				Aspenstrom P, 2005, FEBS LETT, V579, P5253, DOI 10.1016/j.febslet.2005.08.053; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Bahia D, 2006, MEM I OSWALDO CRUZ, V101, P137, DOI 10.1590/S0074-02762006000900022; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Botros S, 2005, INT J PARASITOL, V35, P787, DOI 10.1016/j.ijpara.2005.02.005; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chitsulo L, 2004, NAT REV MICROBIOL, V2, P12, DOI 10.1038/nrmicro801; Cimato TR, 2002, J NEUROSCI RES, V67, P435, DOI 10.1002/jnr.10123; Dissous C, 2007, BIOESSAYS, V29, P1281, DOI 10.1002/bies.20662; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; El-Sayed NMA, 2004, TRENDS PARASITOL, V20, P154, DOI 10.1016/j.pt.2004.02.002; Engen JR, 2008, CELL MOL LIFE SCI, V65, P3058, DOI 10.1007/s00018-008-8122-2; Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001; FINKEN M, 1994, MOL BIOCHEM PARASIT, V64, P135, DOI 10.1016/0166-6851(94)90141-4; FOSTER AC, 1985, J NEUROCHEM, V45, P199, DOI 10.1111/j.1471-4159.1985.tb05493.x; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Grevelding CG, 2004, CURR BIOL, V14, pR545, DOI 10.1016/j.cub.2004.07.006; GREVELDING CG, 1995, MOL BIOCHEM PARASIT, V71, P269, DOI 10.1016/0166-6851(94)00058-U; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Haas BJ, 2007, EXP PARASITOL, V117, P225, DOI 10.1016/j.exppara.2007.06.005; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hoffmann KF, 2004, PARASITOLOGY, V128, pS11, DOI 10.1017/S0031182004006213; JEFFREY R, 2004, PNAS, V101, P6237; Jia CYH, 2005, MOL CELL PROTEOMICS, V4, P1155, DOI 10.1074/mcp.M500108-MCP200; Kaneko T, 2008, FRONT BIOSCI-LANDMRK, V13, P4938, DOI 10.2741/3053; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Kapp K, 2004, MOL BIOCHEM PARASIT, V138, P171, DOI 10.1016/j.molbiopara.2004.07.010; Kapp K, 2001, PARASITOLOGY, V122, P317, DOI 10.1017/S0031182001007430; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Knobloch J, 2007, EXP PARASITOL, V117, P318, DOI 10.1016/j.exppara.2007.04.006; Knobloch J, 2006, INT J PARASITOL, V36, P1261, DOI 10.1016/j.ijpara.2006.06.004; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Krebs A, 2001, J CELL SCI, V114, P3663; Kunz W, 2001, TRENDS PARASITOL, V17, P227, DOI 10.1016/S1471-4922(01)01893-1; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; Liu R, 2010, BBA-MOL CELL RES, V1803, P207, DOI 10.1016/j.bbamcr.2008.09.016; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LoVerde PT, 2007, EXP PARASITOL, V117, P304, DOI 10.1016/j.exppara.2007.06.002; LoVerde PT, 2004, CAN J ZOOL, V82, P357, DOI 10.1139/Z03-217; Ludolf F, 2007, BIOCHEM BIOPH RES CO, V360, P163, DOI 10.1016/j.bbrc.2007.06.018; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005; Ou Y, 2004, INT REV CYTOL, V238, P119, DOI 10.1016/S0074-7696(04)38003-4; Quack T, 2006, BERL MUNCH TIERARZTL, V119, P365; Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Sandilands E, 2008, TRENDS CELL BIOL, V18, P322, DOI 10.1016/j.tcb.2008.05.004; Santos TM, 2002, MOL BIOCHEM PARASIT, V125, P103, DOI 10.1016/S0166-6851(02)00218-9; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; Takahashi A, 2009, EXP CELL RES, V315, P1117, DOI 10.1016/j.yexcr.2009.02.010; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Vermeire JJ, 2003, INT J PARASITOL, V33, P721, DOI 10.1016/S0020-7519(03)00046-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Weiler MC, 1996, J MOL NEUROSCI, V7, P203, DOI 10.1007/BF02736841; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Young KG, 2010, BBA-MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017	62	35	36	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6998	10.1371/journal.pone.0006998	http://dx.doi.org/10.1371/journal.pone.0006998			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746159	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696500009
J	Cooley, K; Szczurko, O; Perri, D; Mills, EJ; Bernhardt, B; Zhou, Q; Seely, D				Cooley, Kieran; Szczurko, Orest; Perri, Dan; Mills, Edward J.; Bernhardt, Bob; Zhou, Qi; Seely, Dugald			Naturopathic Care for Anxiety: A Randomized Controlled Trial ISRCTN78958974	PLOS ONE			English	Article							WHOLE SYSTEMS RESEARCH; WITHANIA-SOMNIFERA; ADAPTOGENIC ACTIVITY; DISORDERS; COMPLEMENTARY; EPIDEMIOLOGY; MEDICINE; HEALTH; PREVALENCE; VALIDATION	Background: Anxiety is a serious personal health condition and represents a substantial burden to overall quality of life. Additionally anxiety disorders represent a significant cost to the health care system as well as employers through benefits coverage and days missed due to incapacity. This study sought to explore the effectiveness of naturopathic care on anxiety symptoms using a randomized trial. Methods: Employees with moderate to severe anxiety of longer than 6 weeks duration were randomized based on age and gender to receive naturopathic care (NC) (n = 41) or standardized psychotherapy intervention (PT) (n = 40) over a period of 12 weeks. Blinding of investigators and participants during randomization and allocation was maintained. Participants in the NC group received dietary counseling, deep breathing relaxation techniques, a standard multi-vitamin, and the herbal medicine, ashwagandha (Withania somnifera) (300 mg b.i.d. standardized to 1.5% withanolides, prepared from root). The PT intervention received psychotherapy, and matched deep breathing relaxation techniques, and placebo. The primary outcome measure was the Beck Anxiety Inventory (BAI) and secondary outcome measures included the Short Form 36 (SF-36), Fatigue Symptom Inventory (FSI), and Measure Yourself Medical Outcomes Profile (MY-MOP) to measure anxiety, mental health, and quality of life respectively. Participants were blinded to the placebo-controlled intervention. Results: Seventy-five participants (93%) were followed for 8 or more weeks on the trial. Final BAI scores decreased by 56.5% (p < 0.0001) in the NC group and 30.5% (p < 0.0001) in the PT group. BAI group scores were significantly decreased in the NC group compared to PT group (p = 0.003). Significant differences between groups were also observed in mental health, concentration, fatigue, social functioning, vitality, and overall quality of life with the NC group exhibiting greater clinical benefit. No serious adverse reactions were observed in either group. Relevance: Many patients seek alternatives and/or complementary care to conventional anxiety treatments. To date, no study has evaluated the potential of a naturopathic treatment protocol to effectively treat anxiety. Knowledge of the efficacy, safety or risk of natural health products, and naturopathic treatments is important for physicians and the public in order to make informed decisions. Interpretation: Both NC and PT led to significant improvements in patients' anxiety. Group comparison demonstrated a significant decrease in anxiety levels in the NC group over the PT group. Significant improvements in secondary quality of life measures were also observed in the NC group as compared to PT. The whole system of naturopathic care for anxiety needs to be investigated further including a closer examination of the individual components within the context of their additive effect. Trial Registration: Controlled-Trials.com ISRCTN78958974			Cooley, K (corresponding author), Canadian Coll Naturopath Med, Dept Res & Clin Epidemiol, Toronto, ON, Canada.	kcooley@ccnm.edu	Cooley, Kieran/L-3080-2019; Zhou, Qi/GSM-9583-2022	Cooley, Kieran/0000-0001-7960-6504; 				Alonso J, 2007, J CLIN PSYCHIAT, V68, P3; [Anonymous], 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003383; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; Bhattacharya SK, 2003, PHARMACOL BIOCHEM BE, V75, P547, DOI 10.1016/S0091-3057(03)00110-2; Bhattacharya SK, 2000, PHYTOMEDICINE, V7, P463, DOI 10.1016/S0944-7113(00)80030-6; Borgerson K, 2005, PERSPECT BIOL MED, V48, P502, DOI 10.1353/pbm.2005.0084; Bower P, 2003, PSYCHOL MED, V33, P203, DOI 10.1017/S0033291702006979; Brawman-Mintzer O, 2004, CNS SPECTRUMS, V9, P19, DOI 10.1017/S1092852900002339; Brown R P, 2001, J Psychiatr Pract, V7, P75, DOI 10.1097/00131746-200103000-00002; *CAN H, 2009, NAT HLTH PROD REG; Dhuley JN, 1998, J ETHNOPHARMACOL, V60, P173, DOI 10.1016/S0378-8741(97)00151-7; Elder C, 2006, J ALTERN COMPLEM MED, V12, P843, DOI 10.1089/acm.2006.12.843; Erickson DH, 2007, PSYCHIAT SERV, V58, P1205, DOI 10.1176/appi.ps.58.9.1205; Faragher EB, 2005, OCCUP ENVIRON MED, V62, P105, DOI 10.1136/oem.2002.006734; Furukawa TA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004364.pub2; Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28; Grunze H, 2000, NEUROPSYCHOBIOLOGY, V42, P28, DOI 10.1159/000054849; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Herman PM, 2008, ALTERN THER HEALTH M, V14, P32; Hotopf M, 1999, BRIT J PSYCHIAT, V175, P217, DOI 10.1192/bjp.175.3.217; Howell HB, 2001, PSYCHIAT CLIN N AM, V24, P165, DOI 10.1016/S0193-953X(05)70212-4; JONAS WB, 2002, CLIN RES METHODS COM, P3; KICK SD, 1994, PSYCHOSOM MED, V56, P570, DOI 10.1097/00006842-199411000-00014; KIRSANAPRAKOMKI.T, 2006, COCHRANE DB SYST REV; LE CP, 2001, HLTH NUMBERS PROBLEM; Leahy, 2017, COGNITIVE THERAPY TE; Lepine JP, 2002, J CLIN PSYCHIAT, V63, P4; Marciniak M, 2004, DEPRESS ANXIETY, V19, P112, DOI 10.1002/da.10131; Mishra L C, 2000, Altern Med Rev, V5, P334; MONTEIRO MG, 1990, J CLIN PSYCHIAT, V51, P12; Nutt DJ, 2007, J CLIN PSYCHIAT, V68, P42; Osman A, 2004, PSYCHOL ASSESSMENT, V16, P120, DOI 10.1037/1040-3590.16.2.120; Paterson C, 2000, QUAL LIFE RES, V9, P521, DOI 10.1023/A:1008930521566; Paterson C, 1996, BRIT MED J, V312, P1016; Paterson C, 2000, J Health Serv Res Policy, V5, P27; Pilkington K, 2006, HOMEOPATHY, V95, P151, DOI 10.1016/j.homp.2006.05.005; Rafferty AP, 2002, AM J PUBLIC HEALTH, V92, P1598, DOI 10.2105/AJPH.92.10.1598; RAINEY JM, 1984, PSYCHOPHARMACOL BULL, V20, P45; Ritenbaugh C, 2003, ALTERN THER HEALTH M, V9, P32; ROSNER B, 2001, FUNDAMENTALS BIOSTAT; Roy-Byrne PP, 2005, PSYCHOSOMATICS, V46, P117, DOI 10.1176/appi.psy.46.2.117; Sarris J, 2007, PHYTOTHER RES, V21, P703, DOI 10.1002/ptr.2187; SEELY D, 2007, ECAM, V4, P75; Singh B, 2003, PHYTOTHER RES, V17, P531, DOI 10.1002/ptr.1189; Smith MJ, 2002, MED CLIN N AM, V86, P173, DOI 10.1016/S0025-7125(03)00079-8; Somer E, 2005, BEHAV RES THER, V43, P669, DOI 10.1016/j.brat.2004.05.006; STRAZNICKY NE, 1993, J HYPERTENS, V11, P427, DOI 10.1097/00004872-199304000-00014; SZCZURKO O, 2007, PUBLIC LIB IN PRESS; Timmermans S, 2003, GOLD STANDARD CHALLE; USTUN TB, 1995, MENTAL ILLNESS GEN H; Van der Windt DAWM, 2000, BRIT J GEN PRACT, V50, P371; Verhoef MJ, 2005, COMPLEMENT THER MED, V13, P206, DOI 10.1016/j.ctim.2005.05.001; Ware DL, 1996, QUALITY LIFE PHARMAC, P337; ALTERN MED REV, V9, P211	54	62	62	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6628	10.1371/journal.pone.0006628	http://dx.doi.org/10.1371/journal.pone.0006628			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489JH	19718255	Green Published, gold			2022-12-27	WOS:000269415900001
J	Ridgway, CL; Ong, KK; Tammelin, TH; Sharp, S; Ekelund, U; Jarvelin, MR				Ridgway, Charlotte L.; Ong, Ken K.; Tammelin, Tuija H.; Sharp, Stephen; Ekelund, Ulf; Jarvelin, Marjo-Riitta			Infant Motor Development Predicts Sports Participation at Age 14 Years: Northern Finland Birth Cohort of 1966	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; SKILL PROFICIENCY; MILLENNIUM COHORT; WEIGHT-GAIN; CHILDREN; PERFORMANCE; ADOLESCENTS; CHILDHOOD; FITNESS; YOUTH	Background: Motor proficiency is positively associated with physical activity levels. The aim of this study is to investigate associations between the timing of infant motor development and subsequent sports participation during adolescence. Methods: Prospective observational study. The study population consisted of 9,009 individuals from the Northern Finland Birth Cohort 1966. Motor development was assessed by parental report at age 1 year, using age at walking with support and age at standing unaided. At follow up aged 14 years, data were collected on the school grade awarded for physical education (PE). Self report was used to collect information on the frequency of sports participation and number of different sports reported. Principal Findings: Earlier infant motor development was associated with improved school PE grade, for age at walking supported (p < 0.001) and standing unaided (p = <0.001). Earlier infant motor development, in terms of age at walking supported, was positively associated with the number of different sports reported (p = 0.003) and with a greater frequency of sports participation (p = 0.043). These associations were independent of gestational age and birth weight, as well as father's social class and body mass index at age 14 years. Conclusions: Earlier infant motor development may predict higher levels of physical activity as indicated by higher school PE grade, participation in a greater number of different types of sports and increased frequency of sports participation. Identification of young children with slower motor development may allow early targeted interventions to improve motor skills and thereby increase physical activity in later life.			Ridgway, CL (corresponding author), MRC, Epidemiol Unit, Inst Metab Sci, Cambridge, England.	ulf.ekelund@mrc-epid.cam.ac.uk	Curtis, Charlotte/AAV-1156-2020; Ridgway, Charlotte/H-4378-2013	Curtis, Charlotte/0000-0002-1022-3887; Ridgway, Charlotte/0000-0002-1022-3887; Jarvelin, Marjo-Riitta/0000-0002-2149-0630	MRC [MC_U106179473, MC_U106179472] Funding Source: UKRI; Medical Research Council [MC_U106179472, MC_U106179473] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aarnio M, 2002, SCAND J MED SCI SPOR, V12, P179, DOI 10.1034/j.1600-0838.2002.00250.x; Barnett LM, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-40; Barnett LM, 2008, MED SCI SPORT EXER, V40, P2137, DOI 10.1249/MSS.0b013e31818160d3; Hediger ML, 2002, PAEDIATR PERINAT EP, V16, P33, DOI 10.1046/j.1365-3016.2002.00393.x; Brodersen NH, 2007, BRIT J SPORT MED, V41, P140, DOI 10.1136/bjsm.2006.031138; Kelly Y, 2006, DEV MED CHILD NEUROL, V48, P825, DOI 10.1017/S0012162206001770; Kuh D, 2006, J GERONTOL A-BIOL, V61, P702, DOI 10.1093/gerona/61.7.702; Kuh D, 2006, AM J EPIDEMIOL, V164, P110, DOI 10.1093/aje/kwj193; McPhillips M, 2007, J CHILD PSYCHOL PSYC, V48, P1214, DOI 10.1111/j.1469-7610.2007.01814.x; Musch J, 2001, DEV REV, V21, P147, DOI 10.1006/drev.2000.0516; Nader PR, 2008, JAMA-J AM MED ASSOC, V300, P295, DOI 10.1001/jama.300.3.295; Nelson MC, 2006, PEDIATRICS, V118, pE1627, DOI 10.1542/peds.2006-0926; Okely AD, 2004, RES Q EXERCISE SPORT, V75, P238, DOI 10.1080/02701367.2004.10609157; Osika W, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a699; Pfeiffer KA, 2006, J ADOLESCENT HEALTH, V39, P523, DOI 10.1016/j.jadohealth.2006.03.005; RANTAKALLIO P, 1979, SOC SCI MED-MED SOC, V13, P423, DOI 10.1016/0160-7979(79)90131-0; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; Ridgway CL, 2009, MED SCI SPORT EXER, V41, P1212, DOI 10.1249/MSS.0b013e31819794ab; Sacker A, 2006, PEDIATRICS, V118, pE682, DOI 10.1542/peds.2005-3141; Sallis JF, 2000, MED SCI SPORT EXER, V32, P963, DOI 10.1097/00005768-200009000-00012; Salmon J, 2008, INT J OBESITY, V32, P601, DOI 10.1038/sj.ijo.0803805; Steele RM, 2008, J APPL PHYSIOL, V105, P342, DOI 10.1152/japplphysiol.00072.2008; Strohle A, 2007, PSYCHOL MED, V37, P1657, DOI 10.1017/S003329170700089X; Tammelin T, 2003, AM J PREV MED, V24, P22, DOI 10.1016/S0749-3797(02)00575-5; U.S. Department of Health and Human Services, 2008, PHYS ACT GUID ADV CO; Vestergaard M, 1999, ACTA PAEDIATR, V88, P1327, DOI 10.1080/080352599750030022; *WHO MULT GROWTH R, ACTA PAEDIAT S, V450, P86; Wickel EE, 2007, MED SCI SPORT EXER, V39, P1493, DOI 10.1249/mss.0b013e318093f56a; Williams HG, 2008, OBESITY, V16, P1421, DOI 10.1038/oby.2008.214; Wrotniak BH, 2006, PEDIATRICS, V118, pE1758, DOI 10.1542/peds.2006-0742; ACTA PAEDIAT S, V450, P66	31	33	34	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6837	10.1371/journal.pone.0006837	http://dx.doi.org/10.1371/journal.pone.0006837			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489JH	19718258	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900010
J	Van Haastert, PJM; Bosgraaf, L				Van Haastert, Peter J. M.; Bosgraaf, Leonard			Food Searching Strategy of Amoeboid Cells by Starvation Induced Run Length Extension	PLOS ONE			English	Article							WIN-STAY; LOSE-SHIFT; CHEMOTAXIS; SUCCESS; ABSENCE; MOTION	Food searching strategies of animals are key to their success in heterogeneous environments. The optimal search strategy may include specialized random walks such as Levy walks with heavy power-law tail distributions, or persistent walks with preferred movement in a similar direction. We have investigated the movement of the soil amoebae Dictyostelium searching for food. Dictyostelium cells move by extending pseudopodia, either in the direction of the previous pseudopod (persistent step) or in a different direction (turn). The analysis of similar to 4000 pseudopodia reveals that step and turn pseudopodia are drawn from a probability distribution that is determined by cGMP/PLA2 signaling pathways. Starvation activates these pathways thereby suppressing turns and inducing steps. As a consequence, starved cells make very long nearly straight runs and disperse over similar to 30-fold larger areas, without extending more or larger pseudopodia than vegetative cells. This 'win-stay/lose-shift' strategy for food searching is called Starvation Induced Run-length Extension. The SIRE walk explains very well the observed differences in search behavior between fed and starving organisms such as bumble-bees, flower bug, hoverfly and zooplankton.			Van Haastert, PJM (corresponding author), Univ Groningen, Dept Cell Biochem, Haren, Netherlands.	P.J.M.van.haastert@rug.nl						Andrew N, 2007, NAT CELL BIOL, V9, P193, DOI 10.1038/ncb1536; Bartumeus F, 2008, J THEOR BIOL, V252, P43, DOI 10.1016/j.jtbi.2008.01.009; Bartumeus F, 2003, P NATL ACAD SCI USA, V100, P12771, DOI 10.1073/pnas.2137243100; Bartumeus F, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.097901; Benhamou S, 2006, ECOLOGY, V87, P518, DOI 10.1890/05-0495; Bicca-Marques JC, 2005, J COMP PSYCHOL, V119, P343, DOI 10.1037/0735-7036.119.3.343; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; BOSGRAAF L, 2009, QUIMP3 AUTOMATED PSE; Bosgraaf L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005253; Chen LF, 2007, DEV CELL, V12, P603, DOI 10.1016/j.devcel.2007.03.005; CODLING EA, 2008, J R SOC INTERFACE, V15, P15; Conradt L, 2003, AM NAT, V161, P905, DOI 10.1086/375298; Edwards AM, 2007, NATURE, V449, P1044, DOI 10.1038/nature06199; Henaut Y, 2002, J APPL ENTOMOL, V126, P501, DOI 10.1046/j.1439-0418.2002.00694.x; HOHL HR, 1963, J BACTERIOL, V85, P191, DOI 10.1128/JB.85.1.191-198.1963; Li L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002093; MACARTHUR RH, 1966, AM NAT, V100, P603, DOI 10.1086/282454; Mayer-Scholl A, 2004, CURR OPIN MICROBIOL, V7, P62, DOI 10.1016/j.mib.2003.12.004; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Posch M, 1999, J THEOR BIOL, V198, P183, DOI 10.1006/jtbi.1999.0909; POTEL MJ, 1979, J CELL SCI, V36, P281; ROTHERAY GE, 1984, ENTOMOL EXP APPL, V36, P17, DOI 10.1007/BF00345199; Shlesinger MF, 2006, NATURE, V443, P281, DOI 10.1038/443281a; Stephens D.W., 1986, pi; Takagi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002648; van Haastert PJM, 2007, J CELL BIOL, V177, P809, DOI 10.1083/jcb.200701134; Veltman DM, 2008, J CELL BIOL, V180, P747, DOI 10.1083/jcb.200709180; Viswanathan GM, 1999, NATURE, V401, P911, DOI 10.1038/44831	29	26	26	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6814	10.1371/journal.pone.0006814	http://dx.doi.org/10.1371/journal.pone.0006814			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714242	Green Submitted, gold, Green Published			2022-12-27	WOS:000269415800004
J	Thu, MS; Najbauer, J; Kendall, SE; Harutyunyan, I; Sangalang, N; Gutova, M; Metz, MZ; Garcia, E; Frank, RT; Kim, SU; Moats, RA; Aboody, KS				Thu, Mya S.; Najbauer, Joseph; Kendall, Stephen E.; Harutyunyan, Ira; Sangalang, Nicole; Gutova, Margarita; Metz, Marianne Z.; Garcia, Elizabeth; Frank, Richard T.; Kim, Seung U.; Moats, Rex A.; Aboody, Karen S.			Iron Labeling and Pre-Clinical MRI Visualization of Therapeutic Human Neural Stem Cells in a Murine Glioma Model	PLOS ONE			English	Article							PROGENITOR CELLS; TARGETED DELIVERY; BRAIN; MIGRATION; FERUMOXIDES; TROPISM; TRANSPLANTATION; NANOPARTICLES; RADIOTHERAPY; TRAFFICKING	Background: Treatment strategies for the highly invasive brain tumor, glioblastoma multiforme, require that cells which have invaded into the surrounding brain be specifically targeted. The inherent tumor-tropism of neural stem cells (NSCs) to primary and invasive tumor foci can be exploited to deliver therapeutics to invasive brain tumor cells in humans. Use of the strategy of converting prodrug to drug via therapeutic transgenes delivered by immortalized therapeutic NSC lines have shown efficacy in animal models. Thus therapeutic NSCs are being proposed for use in human brain tumor clinical trials. In the context of NSC-based therapies, MRI can be used both to non-invasively follow dynamic spatio-temporal patterns of the NSC tumor targeting allowing for the optimization of treatment strategies and to assess efficacy of the therapy. Iron-labeling of cells allows their presence to be visualized and tracked by MRI. Thus we aimed to iron-label therapeutic NSCs without affecting their cellular physiology using a method likely to gain United States Federal Drug Administration (FDA) approval. Methodology: For human use, the characteristics of therapeutic Neural Stem Cells must be clearly defined with any pertubation to the cell including iron labeling requiring reanalysis of cellular physiology. Here, we studied the effect of iron-loading of the therapeutic NSCs, with ferumoxide-protamine sulfate complex (FE-Pro) on viability, proliferation, migratory properties and transgene expression, when compared to non-labeled cells. FE-Pro labeled NSCs were imaged by MRI at tumor sites, after intracranial administration into the hemisphere contralateral to the tumor, in an orthotopic human glioma xenograft mouse model. Conclusion: FE-Pro labeled NSCs retain their proliferative status, tumor tropism, and maintain stem cell character, while allowing in vivo cellular MRI tracking at 7 Tesla, to monitor their real-time migration and distribution at brain tumor sites. Of significance, this work directly supports the use of FE-Pro-labeled NSCs for real-time tracking in the clinical trial under development: "A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically modified Neural Stem Cells Expressing Escherichia coli Cytosine Deaminase for Treatment of Recurrent High-Grade Gliomas''.			Thu, MS (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA.	mthu@coh.org; kaboody@coh.org	Moats, Rex A/F-5995-2015					Aboody KS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000023; Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Aboody KS, 2006, NEURO-ONCOLOGY, V8, P119, DOI 10.1215/15228517-2005-012; Anderson SA, 2005, BLOOD, V105, P420, DOI 10.1182/blood-2004-06-2222; Arbab AS, 2006, STEM CELLS, V24, P671, DOI 10.1634/stemcells.2005-0017; Arbab AS, 2003, RADIOLOGY, V229, P838, DOI 10.1148/radiol.2293021215; Arbab AS, 2005, NMR BIOMED, V18, P553, DOI 10.1002/nbm.991; Arbab AS, 2005, NMR BIOMED, V18, P383, DOI 10.1002/nbm.970; Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; Brekke C, 2007, NEUROIMAGE, V37, P769, DOI 10.1016/j.neuroimage.2007.06.006; Brown AB, 2003, HUM GENE THER, V14, P1777, DOI 10.1089/104303403322611782; Castro MG, 2003, PHARMACOL THERAPEUT, V98, P71, DOI 10.1016/S0163-7258(03)00014-7; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Corot C, 2006, ADV DRUG DELIVER REV, V58, P1471, DOI 10.1016/j.addr.2006.09.013; Daldrup-Link HE, 2003, RADIOLOGY, V228, P760, DOI 10.1148/radiol.2283020322; Danks MK, 2007, CANCER RES, V67, P22, DOI 10.1158/0008-5472.CAN-06-3607; Dickson PV, 2007, J PEDIATR SURG, V42, P48, DOI 10.1016/j.jpedsurg.2006.09.050; Dwain Irvin, 2006, Curr Stem Cell Res Ther, V1, P79, DOI 10.2174/157488806775269070; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Ehtesham M, 2002, CANCER RES, V62, P5657; Ehtesham Moneeb, 2005, Neurosurg Focus, V19, pE5; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Gutova M, 2008, STEM CELLS, V26, P1406, DOI 10.1634/stemcells.2008-0141; Guzman R, 2008, J NEUROSCI RES, V86, P873, DOI 10.1002/jnr.21542; Guzman R, 2007, P NATL ACAD SCI USA, V104, P10211, DOI 10.1073/pnas.0608519104; Heese O, 2005, NEURO-ONCOLOGY, V7, P476, DOI 10.1215/S1152851704000754; Heyn C, 2006, MAGNET RESON MED, V55, P23, DOI 10.1002/mrm.20747; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Kendall SE, 2008, STEM CELLS, V26, P1575, DOI 10.1634/stemcells.2007-0887; Kim DE, 2004, STROKE, V35, P952, DOI 10.1161/01.STR.0000120308.21946.5D; Kim DE, 2006, RADIOLOGY, V241, P822, DOI 10.1148/radiol.2413050466; Kim Seung U, 2002, Methods Mol Biol, V198, P55; Kim SK, 2006, CLIN CANCER RES, V12, P5550, DOI 10.1158/1078-0432.CCR-05-2508; Kostura L, 2004, NMR BIOMED, V17, P513, DOI 10.1002/nbm.925; Lepore AC, 2006, EXP NEUROL, V201, P49, DOI 10.1016/j.expneurol.2006.03.032; Lesniak MS, 2006, EXPERT REV ANTICANC, V6, pS1, DOI 10.1586/14737140.6.9s.S1; Lin D, 2007, NEUROIMAGE, V37, pS18, DOI 10.1016/j.neuroimage.2007.03.076; Modo M, 2002, NEUROIMAGE, V17, P803, DOI 10.1006/nimg.2002.1194; Modo M, 2004, NEUROIMAGE, V21, P311, DOI 10.1016/j.neuroimage.2003.08.030; Modo Mike, 2006, Curr Stem Cell Res Ther, V1, P55, DOI 10.2174/157488806775269106; Neri M, 2008, STEM CELLS, V26, P505, DOI 10.1634/stemcells.2007-0251; Noble M, 2000, P NATL ACAD SCI USA, V97, P12393, DOI 10.1073/pnas.97.23.12393; Pawelczyk E, 2008, STEM CELLS, V26, P1366, DOI 10.1634/stemcells.2007-0707; Pawelczyk E, 2006, NMR BIOMED, V19, P581, DOI 10.1002/nbm.1038; Price SJ, 2007, EUR RADIOL, V17, P1675, DOI 10.1007/s00330-006-0561-2; Schmidt NO, 2005, NEOPLASIA, V7, P623, DOI 10.1593/neo.04781; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Stupp R, 2005, ONKOLOGIE, V28, P315, DOI 10.1159/000085575; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; SYKOVA E, 2007, CELL DEATH DIFFER; Sykova E, 2006, NEURODEGENER DIS, V3, P62, DOI 10.1159/000092095; Toso C, 2008, AM J TRANSPLANT, V8, P701, DOI 10.1111/j.1600-6143.2007.02120.x; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Yip S, 2003, CANCER J, V9, P189, DOI 10.1097/00130404-200305000-00007; Zhang ZG, 2004, NEUROIMAGE, V23, P281, DOI 10.1016/j.neuroimage.2004.05.019	59	81	84	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7218	10.1371/journal.pone.0007218	http://dx.doi.org/10.1371/journal.pone.0007218			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787043	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100017
J	Seung, KJ; Omatayo, DB; Keshavjee, S; Furin, JJ; Farmer, PE; Satti, H				Seung, Kwonjune J.; Omatayo, David B.; Keshavjee, Salmaan; Furin, Jennifer J.; Farmer, Paul E.; Satti, Hind			Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa	PLOS ONE			English	Article								Background: Little is known about treatment of multidrug-resistant tuberculosis (MDR-TB) in high HIV-prevalence settings such as sub-Saharan Africa. Methodology/Principal Findings: We did a retrospective analysis of early outcomes of the first cohort of patients registered in the Lesotho national MDR-TB program between July 21, 2007 and April 21, 2008. Seventy-six patients were included for analysis. Patient follow-up ended when an outcome was recorded, or on October 21, 2008 for those still on treatment. Fifty-six patients (74%) were infected with HIV; the median CD4 cell count was 184 cells/mu l (range 5-824 cells/mu l). By the end of the follow-up period, study patients had been followed for a median of 252 days (range 12-451 days). Twenty-two patients (29%) had died, and 52 patients (68%) were alive and in treatment. In patients who did not die, culture conversion was documented in 52/54 patients (96%). One patient had defaulted, and one patient had transferred out. Death occurred after a median of 66 days in treatment (range 12-374 days). Conclusions/Significance: In a region where clinicians and program managers are increasingly confronted by drug-resistant tuberculosis, this report provides sobering evidence of the difficulty of MDR-TB treatment in high HIV-prevalence settings. In Lesotho, an innovative community-based treatment model that involved social and nutritional support, twice-daily directly observed treatment and early empiric use of second-line TB drugs was successful in reducing mortality of MDR-TB patients. Further research is urgently needed to improve MDR-TB treatment outcomes in high HIV-prevalence settings.			Seung, KJ (corresponding author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.	kjseung@pih.org		Keshavjee, Salmaan/0000-0002-6967-3305				Alvarez GG, 2004, INT J TUBERC LUNG D, V8, P1472; Basu S, 2007, LANCET, V370, P1500, DOI 10.1016/S0140-6736(07)61636-5; *BUR STAT MIN HLTH, 2004, DEM HLTH SURV; Cegielski JP, 2004, INT J TUBERC LUNG D, V8, P286; Furin JJ, 2001, INT J TUBERC LUNG D, V5, P648; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000; Holtz TH, 2006, INT J TUBERC LUNG D, V10, P649; Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640; Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1; Mangili A, 2006, CLIN INFECT DIS, V42, P836, DOI 10.1086/500398; Marks DJB, 2009, INT J STD AIDS, V20, P339, DOI 10.1258/ijsa.2008.008361; *MIN HLTH SOC WELF, 2007, TB HIV COINF; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2; Murphy RA, 2008, CLIN INFECT DIS, V46, P1729, DOI 10.1086/587903; Murray J, 1999, AM J RESP CRIT CARE, V159, P733, DOI 10.1164/ajrccm.159.3.9804147; Nathanson E, 2004, INT J TUBERC LUNG D, V8, P1382; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6; Rich ML, 2006, INT J TUBERC LUNG D, V10, P290; Saravia JC, 2005, INT J TUBERC LUNG D, V9, P421; Shean KP, 2008, INT J TUBERC LUNG D, V12, P1182; Shin S, 2004, SOC SCI MED, V59, P1529, DOI 10.1016/j.socscimed.2004.01.027; Shin SS, 2007, INT J TUBERC LUNG D, V11, P1314; Shin SS, 2006, INT J TUBERC LUNG D, V10, P402; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004; Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352; Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665; *WHO, WHO GLOB TB DAT; *WHO IUATLD, 2008, WHOHTMTB2008394 IUAT; World Health Organization, 2009, MAN MDR TB FIELD GUI; World Health Organization, 2008, WHOHTMTB2008402; Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC	36	101	104	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7186	10.1371/journal.pone.0007186	http://dx.doi.org/10.1371/journal.pone.0007186			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779624	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200018
J	Proverbio, AM; Mariani, S; Zani, A; Adorni, R				Proverbio, Alice Mado; Mariani, Serena; Zani, Alberto; Adorni, Roberta			How Are 'Barack Obama' and 'President Elect' Differentially Stored in the Brain? An ERP Investigation on the Processing of Proper and Common Noun Pairs	PLOS ONE			English	Article							MEDIAL TEMPORAL-LOBE; FIELD POTENTIALS; PEOPLES NAMES; ANOMIA; MEMORY; FACE; NETWORK; N400; PRESERVATION; IMPAIRMENT	Background: One of the most debated issues in the cognitive neuroscience of language is whether distinct semantic domains are differentially represented in the brain. Clinical studies described several anomic dissociations with no clear neuroanatomical correlate. Neuroimaging studies have shown that memory retrieval is more demanding for proper than common nouns in that the former are purely arbitrary referential expressions. In this study a semantic relatedness paradigm was devised to investigate neural processing of proper and common nouns. Methodology/Principal Findings: 780 words (arranged in pairs of Italian nouns/adjectives and the first/last names of well known persons) were presented. Half pairs were semantically related ("Woody Allen'' or "social security''), while the others were not ("Sigmund Parodi'' or "judicial cream''). All items were balanced for length, frequency, familiarity and semantic relatedness. Participants were to decide about the semantic relatedness of the two items in a pair. RTs and N400 data suggest that the task was more demanding for common nouns. The LORETA neural generators for the related-unrelated contrast (for proper names) included the left fusiform gyrus, right medial temporal gyrus, limbic and parahippocampal regions, inferior parietal and inferior frontal areas, which are thought to be involved in the conjoined processing a familiar face with the relevant episodic information. Person name was more emotional and sensory vivid than common noun semantic access. Conclusions/Significance: When memory retrieval is not required, proper name access (conspecifics knowledge) is not more demanding. The neural generators of N400 to unrelated items (unknown persons and things) did not differ as a function of lexical class, thus suggesting that proper and common nouns are not treated differently as belonging to different grammatical classes.			Proverbio, AM (corresponding author), Univ Milano Bicocca, Dept Psychol, Milan, Italy.	mado.proverbio@unimib.it	Zani, Alberto/ABG-8894-2020; Adorni, Roberta/GMW-9037-2022; Zani, Alberto/ABI-3498-2020	Adorni, Roberta/0000-0002-2851-8376; Zani, Alberto/0000-0002-3906-7988; Proverbio, Alice Mado/0000-0002-5138-1523; Lauwereyns, Jan/0000-0003-0551-2550				Barber H, 2005, J COGNITIVE NEUROSCI, V17, P137, DOI 10.1162/0898929052880101; BERTINETTO PM, 2006, CORPUS LESSICO FREQU; BRENNEN T, 1990, MEM COGNITION, V18, P339, DOI 10.3758/BF03197123; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; BURKE DM, 1991, J MEM LANG, V30, P542, DOI 10.1016/0749-596X(91)90026-G; BURTON AM, 1992, BRIT J PSYCHOL, V83, P45, DOI 10.1111/j.2044-8295.1992.tb02424.x; Campanella S, 2001, NEUROIMAGE, V14, P873, DOI 10.1006/nimg.2001.0877; Caramazza A, 2006, COGN NEUROPSYCHOL, V23, P13, DOI 10.1080/02643290542000021; CARNEY R, 1993, COGNITIVE NEUROPSYCH, V10, P185, DOI 10.1080/02643299308253460; Cipolotti L, 1993, Memory, V1, P289, DOI 10.1080/09658219308258240; COHEN G, 1990, BRIT J PSYCHOL, V81, P287, DOI 10.1111/j.2044-8295.1990.tb02362.x; COHEN G, 1986, BRIT J DEV PSYCHOL, V4, P187, DOI 10.1111/j.2044-835X.1986.tb01010.x; COHEN L, 1994, J NEUROL NEUROSUR PS, V57, P1283, DOI 10.1136/jnnp.57.10.1283; COULSON S, 2007, METHDOS COGNITIVE LI; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; DEHAENE S, 1995, NEUROREPORT, V6, P2153, DOI 10.1097/00001756-199511000-00014; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Douville K, 2005, NEUROPSYCHOLOGIA, V43, P693, DOI 10.1016/j.neuropsychologia.2004.09.005; Druzgal TJ, 2001, NEURON, V32, P947, DOI 10.1016/S0896-6273(01)00519-0; FERY P, 1995, CORTEX, V31, P191, DOI 10.1016/S0010-9452(13)80117-7; Hagoort P, 2008, PHILOS T R SOC B, V363, P1055, DOI 10.1098/rstb.2007.2159; HARRIS DM, 1995, CORTEX, V31, P575, DOI 10.1016/S0010-9452(13)80068-8; HITTMAIRDELAZER M, 1994, NEUROPSYCHOLOGIA, V32, P465, DOI 10.1016/0028-3932(94)90091-4; Johnson BW, 2000, CLIN NEUROPHYSIOL, V111, P532, DOI 10.1016/S1388-2457(99)00270-9; KAPUR N, 1995, CORTEX, V31, P99, DOI 10.1016/S0010-9452(13)80108-6; Kay J, 2002, COGN NEUROPSYCHOL, V19, P113, DOI 10.1080/02643290143000114; Kissler J, 2009, BIOL PSYCHOL, V80, P75, DOI 10.1016/j.biopsycho.2008.03.004; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Kutas M, 2000, TRENDS COGN SCI, V4, P463, DOI 10.1016/S1364-6613(00)01560-6; KUTAS M, 1984, NATURE, V307, P161, DOI 10.1038/307161a0; KUTAS M, 1994, PSYCHOLINGUISTICS EL, P83; Lau EF, 2008, NAT REV NEUROSCI, V9, P920, DOI 10.1038/nrn2532; LUCCHELLI F, 1992, CORTEX, V28, P221, DOI 10.1016/S0010-9452(13)80050-0; Lyons F, 2002, CORTEX, V38, P23, DOI 10.1016/S0010-9452(08)70636-1; Maess B, 2006, BRAIN RES, V1096, P163, DOI 10.1016/j.brainres.2006.04.037; Martins IP, 2007, NEUROPSYCHOLOGIA, V45, P1744, DOI 10.1016/j.neuropsychologia.2006.12.016; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; MCKENNA P, 1978, J NEUROL NEUROSUR PS, V41, P571, DOI 10.1136/jnnp.41.6.571; MCKENNA P, 1980, J NEUROL NEUROSUR PS, V43, P781, DOI 10.1136/jnnp.43.9.781; Miceli G, 2000, COGN NEUROPSYCHOL, V17, P489, DOI 10.1080/02643290050110629; NOBRE AC, 1995, J NEUROSCI, V15, P1090; Otsuka Y, 2005, CORTEX, V41, P39, DOI 10.1016/S0010-9452(08)70176-X; Palmero-Soler E, 2007, PHYS MED BIOL, V52, P1783, DOI 10.1088/0031-9155/52/7/002; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Proverbio AM, 2008, NEUROPSYCHOLOGIA, V46, P2292, DOI 10.1016/j.neuropsychologia.2008.03.024; Proverbio AM, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-27; Proverbio AM, 2004, NEUROPSYCHOLOGIA, V42, P1636, DOI 10.1016/j.neuropsychologia.2004.04.013; Proverbio AM, 2001, NEUROPSYCHOLOGIA, V39, P815, DOI 10.1016/S0028-3932(01)00003-3; Semenza C, 1993, Memory, V1, P265, DOI 10.1080/09658219308258238; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SEMENZA C, 1988, COGNITIVE NEUROPSYCH, V5, P711, DOI 10.1080/02643298808253279; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Silva-Pereyra J, 2003, CLIN NEUROPHYSIOL, V114, P2469, DOI 10.1016/S1388-2457(03)00248-7; Tempini MLG, 1998, BRAIN, V121, P2103, DOI 10.1093/brain/121.11.2103; Thompson SA, 2003, NEUROLOGY, V61, P1196, DOI 10.1212/01.WNL.0000091868.28557.B8; Tranel D, 2006, NEUROPSYCHOLOGY, V20, P1, DOI 10.1037/0894-4105.20.1.1; VALENTINE T, 1996, COGNITIVE PSYCHOL PR; Warrington E K, 1993, Memory, V1, P281, DOI 10.1080/09658219308258239	58	19	19	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7126	10.1371/journal.pone.0007126	http://dx.doi.org/10.1371/journal.pone.0007126			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	498RP	19774070	gold, Green Published, Green Submitted			2022-12-27	WOS:000270160900011
J	Zou, SM; Kamei, H; Modi, Z; Duan, CM				Zou, Shuming; Kamei, Hiroyasu; Modi, Zubin; Duan, Cunming			Zebrafish IGF Genes: Gene Duplication, Conservation and Divergence, and Novel Roles in Midline and Notochord Development	PLOS ONE			English	Article							GROWTH-FACTOR-I; MESSENGER-RNA EXPRESSION; TISSUE DISTRIBUTION; GENOME DUPLICATION; RED SEABREAM; FACTOR CDNA; INSULIN; TELEOST; FISH; INDUCTION	Insulin-like growth factors (IGFs) are key regulators of development, growth, and longevity. In most vertebrate species including humans, there is one IGF-1 gene and one IGF-2 gene. Here we report the identification and functional characterization of 4 distinct IGF genes (termed as igf-1a, -1b, -2a, and -2b) in zebrafish. These genes encode 4 structurally distinct and functional IGF peptides. IGF-1a and IGF-2a mRNAs were detected in multiple tissues in adult fish. IGF-1b mRNA was detected only in the gonad and IGF-2b mRNA only in the liver. Functional analysis showed that all 4 IGFs caused similar developmental defects but with different potencies. Many of these embryos had fully or partially duplicated notochords, suggesting that an excess of IGF signaling causes defects in the midline formation and an expansion of the notochord. IGF-2a, the most potent IGF, was analyzed in depth. IGF-2a expression caused defects in the midline formation and expansion of the notochord but it did not alter the anterior neural patterning. These results not only provide new insights into the functional conservation and divergence of the multiple igf genes but also reveal a novel role of IGF signaling in midline formation and notochord development in a vertebrate model.			Zou, SM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	cduan@umich.edu		KAMEI, HIROYASU/0000-0001-7123-040X				Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; ADAMO ML, 1993, ADV EXP MED BIOL, V343, P1; ADASHI EY, 1992, GROWTH REGULAT, V2, P10; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Brown Y. A. R., 2009, ENDOCRINOLOGY, V150, P4366, DOI [10.1210/en.2009-0356, DOI 10.1210/EN.2009-0356]; Brunet FG, 2006, MOL BIOL EVOL, V23, P1808, DOI 10.1093/molbev/msl049; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; Chen MHC, 2001, GENE, V268, P67, DOI 10.1016/S0378-1119(01)00433-4; CHEW SL, 1995, ENDOCRINOLOGY, V136, P1939, DOI 10.1210/en.136.5.1939; Chuang JC, 1999, MECH DEVELOP, V84, P195, DOI 10.1016/S0925-4773(99)00077-5; Du SJ, 2003, COMP BIOCHEM PHYS B, V134, P123, DOI 10.1016/S1096-4959(02)00194-X; DUAN C, 1993, J ENDOCRINOL, V139, P243, DOI 10.1677/joe.0.1390243; DUAN C, 1992, J ENDOCRINOL, V133, P211, DOI 10.1677/joe.0.1330211; Duan CM, 1997, AM ZOOL, V37, P491; DUAN CM, 1993, FISH PHYSIOL BIOCHEM, V11, P371, DOI 10.1007/BF00004587; DUAN CM, 1993, ZOOL SCI, V10, P473; DUGUAY SJ, 1995, FEBS LETT, V371, P69, DOI 10.1016/0014-5793(95)00879-E; DUGUAY SJ, 1992, MOL ENDOCRINOL, V6, P1202, DOI 10.1210/me.6.8.1202; Duguay SJ, 1996, J MOL ENDOCRINOL, V16, P123, DOI 10.1677/jme.0.0160123; Eivers E, 2004, INT J DEV BIOL, V48, P1131, DOI 10.1387/ijdb.041913ee; GUTIERREZ J, 1995, J ENDOCRINOL, V146, P35, DOI 10.1677/joe.0.1460035; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAGAWA H, 1994, GEN COMP ENDOCR, V95, P293, DOI 10.1006/gcen.1994.1126; KAGAWA H, 1995, GEN COMP ENDOCR, V99, P307, DOI 10.1006/gcen.1995.1114; Kamei H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003091; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Le Roith D, 2001, TRENDS ENDOCRIN MET, V12, P48; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; MORITA T, 1995, NEUROSCI LETT, V198, P131, DOI 10.1016/0304-3940(95)11988-9; NAGAMATSU S, 1991, J BIOL CHEM, V266, P2397; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; Papasani MR, 2006, PHYSIOL GENOMICS, V27, P79, DOI 10.1152/physiolgenomics.00012.2006; Pera EM, 2001, DEV CELL, V1, P655, DOI 10.1016/S1534-5807(01)00069-7; Postlethwait J, 2004, TRENDS GENET, V20, P481, DOI 10.1016/j.tig.2004.08.001; Richard-Parpaillon L, 2002, DEV BIOL, V244, P407, DOI 10.1006/dbio.2002.0605; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Russell SJ, 2007, NAT REV MOL CELL BIO, V8, P681, DOI 10.1038/nrm2234; Sang XP, 2008, ENDOCRINOLOGY, V149, P5035, DOI 10.1210/en.2008-0534; Schauerte HE, 1998, DEVELOPMENT, V125, P2983; Schlueter PJ, 2006, FASEB J, V20, P1230, DOI 10.1096/fj.05-3882fje; SCHLUETER PJ, 2007, CELL DEATH DIFFER, P1; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; Shamblott Michael J., 1993, Molecular Marine Biology and Biotechnology, V2, P351; SHAMBLOTT MJ, 1995, P NATL ACAD SCI USA, V92, P6943, DOI 10.1073/pnas.92.15.6943; Steinke D, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-20; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Toyoshima Y, 2008, ENDOCRINOLOGY, V149, P5996, DOI 10.1210/en.2008-0329; Wagner GP, 2005, J MOL EVOL, V60, P665, DOI 10.1007/s00239-004-0252-z; Wang DS, 2008, BIOCHEM BIOPH RES CO, V367, P336, DOI 10.1016/j.bbrc.2007.12.136; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Wood AW, 2005, INT REV CYTOL, V243, P215, DOI 10.1016/S0074-7696(05)43004-1; Wood AW, 2005, MOL ENDOCRINOL, V19, P1024, DOI 10.1210/me.2004-0392; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Zhou JF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003926	64	95	106	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7026	10.1371/journal.pone.0007026	http://dx.doi.org/10.1371/journal.pone.0007026			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759899	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970200002
J	Chen, YJ; Cairns, R; Papandreou, I; Koong, A; Denko, NC				Chen, Yijun; Cairns, Rob; Papandreou, Ioanna; Koong, Albert; Denko, Nicholas C.			Oxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect	PLOS ONE			English	Article								Background: The unique metabolism of tumors was described many years ago by Otto Warburg, who identified tumor cells with increased glycolysis and decreased mitochondrial activity. However, "aerobic glycolysis" generates fewer ATP per glucose molecule than mitochondrial oxidative phosphorylation, so in terms of energy production, it is unclear how increasing a less efficient process provides tumors with a growth advantage. Methods/Findings: We carried out a screen for loss of genetic elements in pancreatic tumor cells that accelerated their growth as tumors, and identified mitochondrial ribosomal protein L28 (MRPL28). Knockdown of MRPL28 in these cells decreased mitochondrial activity, and increased glycolysis, but paradoxically, decreased cellular growth in vitro. Following Warburg's observations, this mutation causes decreased mitochondrial function, compensatory increase in glycolysis and accelerated growth in vivo. Likewise, knockdown of either mitochondrial ribosomal protein L12 (MRPL12) or cytochrome oxidase had a similar effect. Conversely, expression of the mitochondrial uncoupling protein 1 (UCP1) increased oxygen consumption and decreased tumor growth. Finally, treatment of tumor bearing animals with dichloroacetate (DCA) increased pyruvate consumption in the mitochondria, increased total oxygen consumption, increased tumor hypoxia and slowed tumor growth. Conclusions: We interpret these findings to show that non-oncogenic genetic changes that alter mitochondrial metabolism can regulate tumor growth through modulation of the consumption of oxygen, which appears to be a rate limiting substrate for tumor proliferation.			Chen, YJ (corresponding author), Stanford Univ, Dept Radiat Oncol, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA.	ndenko@stanford.edu	Pinheiro, Maísa/E-7424-2012; Papandreou, Ioanna/G-1703-2014; Cairns, Rob A/A-3232-2009; denko, nicholas/F-8444-2010	Cairns, Rob A/0000-0001-9540-7927; Koong, Albert/0000-0001-9824-1643	NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA67166, P01 CA067166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104; Chen L, 2008, BIOCHEMISTRY-US, V47, P5368, DOI 10.1021/bi800228w; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Denko NC, 2008, NAT REV CANC; Evans SM, 2001, AM J CLIN ONCOL-CANC, V24, P467, DOI 10.1097/00000421-200110000-00011; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Krishnan KJ, 2007, NUCLEIC ACIDS RES, V35, P7399, DOI 10.1093/nar/gkm635; Liu VWS, 2001, CANCER RES, V61, P5998; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Mithani SK, 2007, CLIN CANCER RES, V13, P4331, DOI 10.1158/1078-0432.CCR-06-2613; MOORE JV, 1985, BRIT J CANCER, V51, P407, DOI 10.1038/bjc.1985.55; MUSCHEL RJ, 1995, CANCER RES, V55, P995; Nishikawa M, 2001, CANCER RES, V61, P1843; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Rosenfeld E, 2002, YEAST, V19, P1299, DOI 10.1002/yea.918; Santore MT, 2002, AM J PHYSIOL-LUNG C, V282, pL727, DOI 10.1152/ajplung.00281.2001; SECOMB TW, 1995, ACTA ONCOL, V34, P313, DOI 10.3109/02841869509093981; Secomb TW, 1998, ADV EXP MED BIOL, V454, P629; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Tuttle SW, 2007, J BIOL CHEM, V282, P36790, DOI 10.1074/jbc.M700327200; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; WARBURG O, 1956, Oncologia, V9, P75; WARBURG O, 1956, SCIENCE, V124, P269; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100; Zhou SY, 2007, P NATL ACAD SCI USA, V104, P7540, DOI 10.1073/pnas.0610818104	49	126	135	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7033	10.1371/journal.pone.0007033	http://dx.doi.org/10.1371/journal.pone.0007033			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753307	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796500017
J	Bradrick, SS; Gromeier, M				Bradrick, Shelton S.; Gromeier, Matthias			Identification of Gemin5 as a Novel 7-Methylguanosine Cap-Binding Protein	PLOS ONE			English	Article							MESSENGER-RNA; SMN COMPLEX; U-SNRNA; TRANSLATION INITIATION; STRUCTURAL BASIS; WD REPEAT; POLY(A)-SPECIFIC RIBONUCLEASE; SMALL NUCLEAR; RRM DOMAIN; IN-VITRO	Background: A unique attribute of RNA molecules synthesized by RNA polymerase II is the presence of a 7-methylguanosine (m(7)G) cap structure added co-transcriptionally to the 5' end. Through its association with trans-acting effector proteins, the m(7)G cap participates in multiple aspects of RNA metabolism including localization, translation and decay. However, at present relatively few eukaryotic proteins have been identified as factors capable of direct association with m(7)G. Methodology/Principal Findings: Employing an unbiased proteomic approach, we identified gemin5, a component of the survival of motor neuron (SMN) complex, as a factor capable of direct and specific interaction with the m(7)G cap. Gemin5 was readily purified by cap-affinity chromatography in contrast to other SMN complex proteins. Investigating the underlying basis for this observation, we found that purified gemin5 associates with m 7 G-linked sepharose in the absence of detectable eIF4E, and specifically crosslinks to radiolabeled cap structure after UV irradiation. Deletion analysis revealed that an intact set of WD repeat domains located in the N-terminal half of gemin5 are required for cap-binding. Moreover, using structural modeling and site-directed mutagenesis, we identified two proximal aromatic residues located within the WD repeat region that significantly impact m(7)G association. Conclusions/Significance: This study rigorously identifies gemin5 as a novel cap-binding protein and describes an unprecedented role for WD repeat domains in m(7)G recognition. The findings presented here will facilitate understanding of gemin5's role in the metabolism of non-coding snRNAs and perhaps other RNA pol II transcripts.			Bradrick, SS (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	shelton.bradrick@duke.edu			NATIONAL CANCER INSTITUTE [R01CA124756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067781, K01DK082613] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA124756, CA124756] Funding Source: Medline; NIDDK NIH HHS [F32 DK067781, DK067781, K01 DK082613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Battle DJ, 2006, COLD SPRING HARB SYM, V71, P313, DOI 10.1101/sqb.2006.71.001; Battle DJ, 2007, J BIOL CHEM, V282, P27953, DOI 10.1074/jbc.M702317200; Battle DJ, 2006, MOL CELL, V23, P273, DOI 10.1016/j.molcel.2006.05.036; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; Cioce M, 2005, ANNU REV CELL DEV BI, V21, P105, DOI 10.1146/annurev.cellbio.20.010403.103738; Eulalio A, 2008, NAT STRUCT MOL BIOL, V15, P346, DOI 10.1038/nsmb.1405; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Golembe TJ, 2005, MOL CELL BIOL, V25, P10989, DOI 10.1128/MCB.25.24.10989-11004.2005; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Guilligay D, 2008, NAT STRUCT MOL BIOL, V15, P500, DOI 10.1038/nsmb.1421; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; Hock J, 2007, EMBO REP, V8, P1052, DOI 10.1038/sj.embor.7401088; Hogue CWV, 1997, TRENDS BIOCHEM SCI, V22, P314, DOI 10.1016/S0968-0004(97)01093-1; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Kaiser C, 2008, RNA, V14, P2170, DOI 10.1261/rna.1171808; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kiriakidou M, 2007, CELL, V129, P1141, DOI 10.1016/j.cell.2007.05.016; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; Kroiss M, 2008, P NATL ACAD SCI USA, V105, P10045, DOI 10.1073/pnas.0802287105; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; Lau CK, 2009, NAT STRUCT MOL BIOL, V16, P486, DOI 10.1038/nsmb.1584; Lloyd RE, 2006, VIRUS RES, V119, P76, DOI 10.1016/j.virusres.2005.10.016; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matera AG, 2007, NAT REV MOL CELL BIO, V8, P209, DOI 10.1038/nrm2124; Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mazza C, 2002, EMBO J, V21, P5548, DOI 10.1093/emboj/cdf538; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mohri K, 2004, J BIOL CHEM, V279, P31697, DOI 10.1074/jbc.M403351200; Monecke T, 2008, J MOL BIOL, V382, P827, DOI 10.1016/j.jmb.2008.07.073; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nagata T, 2008, NUCLEIC ACIDS RES, V36, P4754, DOI 10.1093/nar/gkn458; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Otter S, 2007, J BIOL CHEM, V282, P5825, DOI 10.1074/jbc.M608528200; Pacheco A, 2009, NUCLEIC ACIDS RES, V37, P582, DOI 10.1093/nar/gkn979; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Penalva LOF, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-24; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Rosettani P, 2007, J MOL BIOL, V368, P691, DOI 10.1016/j.jmb.2007.02.019; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Simon E, 2006, TRENDS BIOCHEM SCI, V31, P241, DOI 10.1016/j.tibs.2006.03.001; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; Sonenberg N, 2008, BIOCHEM CELL BIOL, V86, P178, DOI 10.1139/O08-034; Thermann R, 2007, NATURE, V447, P875, DOI 10.1038/nature05878; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wu MS, 2009, STRUCTURE, V17, P276, DOI 10.1016/j.str.2008.11.012	64	36	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7030	10.1371/journal.pone.0007030	http://dx.doi.org/10.1371/journal.pone.0007030			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750007	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796300020
J	Wang, ZS; Li, V; Chan, GCK; Phan, T; Nudelman, AS; Xia, ZG; Storm, DR				Wang, Zhenshan; Li, Vicky; Chan, Guy C. K.; Phan, Trongha; Nudelman, Aaron S.; Xia, Zhengui; Storm, Daniel R.			Adult Type 3 Adenylyl Cyclase-Deficient Mice Are Obese	PLOS ONE			English	Article							BARDET-BIEDL-SYNDROME; BROWN ADIPOSE-TISSUE; BASAL BODY DYSFUNCTION; DIET-INDUCED OBESITY; TRANSGENIC MICE; OVEREXPRESSING LEPTIN; LOCOMOTOR-ACTIVITY; PHYSICAL-ACTIVITY; GENE-EXPRESSION; ENERGY-BALANCE	Background: A recent study of obesity in Swedish men found that polymorphisms in the type 3 adenylyl cyclase (AC3) are associated with obesity, suggesting the interesting possibility that AC3 may play a role in weight control. Therefore, we examined the weight of AC3 mice over an extended period of time. Methodology/Principal Findings: We discovered that AC3(-/-) mice become obese as they age. Adult male AC3(-/-) mice are about 40% heavier than wild type male mice while female AC3(-/-) are 70% heavier. The additional weight of AC3(-/-) mice is due to increased fat mass and larger adipocytes. Before the onset of obesity, young AC3(-/-) mice exhibit reduced physical activity, increased food consumption, and leptin insensitivity. Surprisingly, the obesity of AC3(-/-) mice is not due to a loss of AC3 from white adipose and a decrease in lipolysis. Conclusions/Significance: We conclude that mice lacking AC3 exhibit obesity that is apparently caused by low locomotor activity, hyperphagia, and leptin insensitivity. The presence of AC3 in primary cilia of neurons of the hypothalamus suggests that cAMP signals generated by AC3 in the hypothalamus may play a critical role in regulation of body weight.			Wang, ZS (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	dstorm@u.washington.edu			NIDCD NIH HHS [R01 DC004158, DC04158] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004158] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ainsworth C, 2007, NATURE, V448, P638, DOI 10.1038/448638a; Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Benoit SC, 2004, RECENT PROG HORM RES, V59, P267, DOI 10.1210/rp.59.1.267; Bingham NC, 2008, ENDOCRINOLOGY, V149, P2138, DOI 10.1210/en.2007-1200; Bishop GA, 2007, J COMP NEUROL, V505, P562, DOI 10.1002/cne.21510; Blacque OE, 2006, CELL MOL LIFE SCI, V63, P2145, DOI 10.1007/s00018-006-6180-x; Bray GA, 2006, J MED CHEM, V49, P4001, DOI 10.1021/jm0680124; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHALLET E, 1995, PHYSIOL BEHAV, V58, P257, DOI 10.1016/0031-9384(95)00001-Y; Charon C, 1995, BIOCHEM J, V312, P781, DOI 10.1042/bj3120781; Chaudhry A, 1997, AM J PHYSIOL-REG I, V273, pR762, DOI 10.1152/ajpregu.1997.273.2.R762; CORBIN JD, 1970, J BIOL CHEM, V245, P4849; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Davis RE, 2007, P NATL ACAD SCI USA, V104, P19422, DOI 10.1073/pnas.0708571104; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; Dhillon H, 2006, NEURON, V49, P191, DOI 10.1016/j.neuron.2005.12.021; Eckel-Mahan KL, 2008, NAT NEUROSCI, V11, P1074, DOI 10.1038/nn.2174; Fontaine K R, 2001, Obes Rev, V2, P173, DOI 10.1046/j.1467-789x.2001.00032.x; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; GRANNEMAN JG, 1995, ENDOCRINOLOGY, V136, P2007, DOI 10.1210/en.136.5.2007; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Havel PJ, 1996, J CLIN ENDOCR METAB, V81, P4406, DOI 10.1210/jc.81.12.4406; Hearn T, 2005, DIABETES, V54, P1581, DOI 10.2337/diabetes.54.5.1581; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Joosen AMCP, 2005, AM J CLIN NUTR, V82, P1253, DOI 10.1093/ajcn/82.6.1253; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; King BA, 2006, PHYSIOL BEHAV, V87, P221, DOI 10.1016/j.physbeh.2005.10.007; Kohno D, 2007, ENDOCRINOLOGY, V148, P2251, DOI 10.1210/en.2006-1240; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Majdic G, 2002, ENDOCRINOLOGY, V143, P607, DOI 10.1210/en.143.2.607; Nordman S, 2008, INT J OBESITY, V32, P407, DOI 10.1038/sj.ijo.0803742; Ogus S, 2003, ENDOCRINOLOGY, V144, P2865, DOI 10.1210/en.2002-0178; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pietilainen KH, 2008, OBESITY, V16, P409, DOI 10.1038/oby.2007.72; Qiu J, 2001, ENDOCRINOLOGY, V142, P348, DOI 10.1210/en.142.1.348; Rahmouni K, 2008, J CLIN INVEST, V118, P1458, DOI 10.1172/JCI32357; Rios M, 2001, MOL ENDOCRINOL, V15, P1748, DOI 10.1210/me.15.10.1748; RohnerJeanrenaud F, 1996, NEW ENGL J MED, V334, P324, DOI 10.1056/NEJM199602013340511; Scarpace P, 2005, DIABETOLOGIA, V48, P1075, DOI 10.1007/s00125-005-1763-x; Scarpace PJ, 2007, FRONT BIOSCI-LANDMRK, V12, P3531, DOI 10.2741/2332; Schulz S, 2000, J PHYSIOLOGY-PARIS, V94, P259, DOI 10.1016/S0928-4257(00)00212-6; Shapiro A, 2008, DIABETES, V57, P614, DOI 10.2337/db07-0863; Sheriff S, 2003, PEPTIDES, V24, P245, DOI 10.1016/S0196-9781(03)00037-8; Snell WJ, 2004, CELL, V117, P693, DOI 10.1016/j.cell.2004.05.019; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tou JCL, 2002, EXP BIOL MED, V227, P587, DOI 10.1177/153537020222700806; van Harmelen V, 2003, INT J OBESITY, V27, P889, DOI 10.1038/sj.ijo.0802314; Wang ZS, 2006, J NEUROSCI, V26, P7375, DOI 10.1523/JNEUROSCI.1967-06.2006; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; WOODS SC, 2001, INT J OBESITY, V5, pS35; Zhao AZ, 2005, CURR TOP DEV BIOL, V67, P207, DOI 10.1016/S0070-2153(05)67006-8; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	60	95	105	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6979	10.1371/journal.pone.0006979	http://dx.doi.org/10.1371/journal.pone.0006979			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750222	gold, Green Published, Green Submitted			2022-12-27	WOS:000269696600014
J	van der Most, RG; Currie, AJ; Cleaver, AL; Salmons, J; Nowak, AK; Mahendran, S; Larma, I; Prosser, A; Robinson, BWS; Smyth, MJ; Scalzo, AA; Degli-Esposti, MA; Lake, RA				van der Most, Robbert G.; Currie, Andrew J.; Cleaver, Amanda L.; Salmons, Joanne; Nowak, Anna K.; Mahendran, Sathish; Larma, Irma; Prosser, Amy; Robinson, Bruce W. S.; Smyth, Mark J.; Scalzo, Anthony A.; Degli-Esposti, Mariapia A.; Lake, Richard A.			Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth	PLOS ONE			English	Article								Background: Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory. Pre-clinical models clearly demonstrate that chemotherapy can synergize with immunotherapy, raising the question how the immune system can be mobilized to generate anti-tumor immune responses in the context of chemotherapy. Methods and Findings: We used a mouse model of malignant mesothelioma, AB1-HA, to investigate T cell-dependent tumor resolution after chemotherapy. Established AB1-HA tumors were cured by a single dose of cyclophosphamide in a CD8 T cell-and NK cell-dependent manner. This treatment was associated with an IFN-alpha/beta response and a profound negative impact on the anti-tumor and total CD8 T cell responses. Despite this negative effect, CD8 T cells were essential for curative responses. The important effector molecules used by the anti-tumor immune response included IFN-gamma and TRAIL. The importance of TRAIL was supported by experiments in nude mice where the lack of functional T cells could be compensated by agonistic anti-TRAIL-receptor (DR5) antibodies. Conclusion: The data support a model in which chemotherapy sensitizes tumor cells for T cell-, and possibly NK cell-, mediated apoptosis. A key role of tumor cell sensitization to immune attack is supported by the role of TRAIL in tumor resolution and explains the paradox of successful CD8 T cell-dependent anti-tumor responses in the absence of CD8 T cell expansion.			van der Most, RG (corresponding author), Univ Western Australia, Natl Res Ctr Asbestos Related Dis, Perth, WA 6009, Australia.	robbertvdm@gmail.com; rlake@cyllene.uwa.edu.au	Degli-Esposti, Mariapia/H-9073-2014; Flow, CMCA/C-4191-2013; Currie, Andrew/C-2778-2015; Nowak, Anna K/B-2487-2013; Smyth, Mark J/H-8709-2014; Robinson, Bruce/N-1900-2014; Degli-Esposti, Mariapia/E-9529-2013	Nowak, Anna K/0000-0002-9317-9526; Smyth, Mark J/0000-0001-7098-7240; Cleaver, Amanda/0000-0001-7545-5868; Currie, Andrew/0000-0002-5193-3404; Degli-Esposti, Mariapia/0000-0002-7808-5935; Prosser, Amy/0000-0003-3540-5203				Angulo I, 2000, BLOOD, V95, P212; AWWAD M, 1989, CANCER RES, V49, P1649; Belyanskaya LL, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-66; Brooks AD, 2005, CANCER IMMUNOL IMMUN, V54, P499, DOI 10.1007/s00262-004-0595-8; Broomfield SA, 2009, J IMMUNOL, V182, P5217, DOI 10.4049/jimmunol.0803826; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cretney E, 2007, INT J BIOCHEM CELL B, V39, P280, DOI 10.1016/j.biocel.2006.10.005; Currie AJ, 2008, J IMMUNOL, V180, P1535, DOI 10.4049/jimmunol.180.3.1535; DUMONT FJ, 1986, EUR J IMMUNOL, V16, P735, DOI 10.1002/eji.1830160704; Ercolini AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167; Fan ZS, 2006, BLOOD, V107, P1342, DOI 10.1182/blood-2005-08-3485; Frew AJ, 2008, P NATL ACAD SCI USA, V105, P11317, DOI 10.1073/pnas.0801868105; GERDES J, 1984, J IMMUNOL, V133, P1710; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; HAYNES NM, 2008, CURR OPIN IMMUNOL; Ibe S, 2001, J EXP MED, V194, P1549, DOI 10.1084/jem.194.11.1549; Janssen E, 2006, IMMUNITY, V24, P787, DOI 10.1016/j.immuni.2006.03.024; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jovasevic VM, 2001, J IMMUNOL, V167, P4895, DOI 10.4049/jimmunol.167.9.4895; Khodadoust MM, 1998, BLOOD, V92, P2399, DOI 10.1182/blood.V92.7.2399.2399_2399_2409; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Liu WH, 2001, AM J RESP CELL MOL, V25, P111, DOI 10.1165/ajrcmb.25.1.4472; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; MANNING LS, 1991, INT J CANCER, V47, P285, DOI 10.1002/ijc.2910470219; Marzo AL, 1999, J IMMUNOL, V162, P5838; Marzo AL, 1999, CANCER RES, V59, P1071; Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020; Mokyr MB, 2006, CANCER IMMUNOL IMMUN, V55, P459, DOI 10.1007/s00262-005-0029-2; NORTH RJ, 1990, IMMUNOLOGY, V71, P90; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; Nowak AK, 2003, CANCER RES, V63, P4490; Nowak AK, 2002, CANCER RES, V62, P2353; Park SY, 2004, EUR J BIOCHEM, V271, P4222, DOI 10.1111/j.1432-1033.2004.04362.x; Pelaez B, 2001, J IMMUNOL, V166, P6608, DOI 10.4049/jimmunol.166.11.6608; POZAROWSKI P, 2004, CURR PROTOC CELL BIO, pCH18, DOI DOI 10.1002/0471143030.CB1808S21; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rad AN, 2003, CANCER RES, V63, P5143; RIVIERE Y, 1977, P NATL ACAD SCI USA, V74, P2135, DOI 10.1073/pnas.74.5.2135; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Schiavoni G, 2000, BLOOD, V95, P2024, DOI 10.1182/blood.V95.6.2024; Shankar S, 2005, INT J MOL MED, V16, P1125; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Smyth MJ, 1999, J IMMUNOL, V162, P6658; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Stumbles PA, 2004, J IMMUNOL, V173, P5923, DOI 10.4049/jimmunol.173.10.5923; Suzuki E, 2007, CANCER BIOL THER, V6, P880, DOI 10.4161/cbt.6.6.4090; Taieb J, 2006, J IMMUNOL, V176, P2722, DOI 10.4049/jimmunol.176.5.2722; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2008, P NATL ACAD SCI USA, V105, P10895, DOI 10.1073/pnas.0802702105; TESNIERE A, 2008, CURR OPIN IMMUNOL; Thomas AM, 2004, J EXP MED, V200, P297, DOI 10.1084/jem.20031435; Uno T, 2006, NAT MED, V12, P693, DOI 10.1038/nm1405; van der Most RG, 2008, CELL DEATH DIFFER, V15, P13, DOI 10.1038/sj.cdd.4402255; van der Most RG, 2006, CANCER RES, V66, P601, DOI 10.1158/0008-5472.CAN-05-2967; van der Most RG, 2009, CANCER IMMUNOL IMMUN, V58, P1219, DOI 10.1007/s00262-008-0628-9; WEILAND T, 2008, J PHARM EXP THER; Zitvogel L, 2004, ADV IMMUNOL, V84, P131, DOI 10.1016/S0065-2776(04)84004-5	61	73	76	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6982	10.1371/journal.pone.0006982	http://dx.doi.org/10.1371/journal.pone.0006982			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746156	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696500003
J	Dodd, PJ; Ferguson, NM				Dodd, Peter J.; Ferguson, Neil M.			A Many-Body Field Theory Approach to Stochastic Models in Population Biology	PLOS ONE			English	Article								Background: Many models used in theoretical ecology, or mathematical epidemiology are stochastic, and may also be spatially-explicit. Techniques from quantum field theory have been used before in reaction-diffusion systems, principally to investigate their critical behavior. Here we argue that they make many calculations easier and are a possible starting point for new approximations. Methodology: We review the many-body field formalism for Markov processes and illustrate how to apply it to a 'Brownian bug' population model, and to an epidemic model. We show how the master equation and the moment hierarchy can both be written in particularly compact forms. The introduction of functional methods allows the systematic computation of the effective action, which gives the dynamics of mean quantities. We obtain the 1-loop approximation to the effective action for general (space-) translation invariant systems, and thus approximations to the non-equilibrium dynamics of the mean fields. Conclusions: The master equations for spatial stochastic systems normally take a neater form in the many-body field formalism. One can write down the dynamics for generating functional of physically-relevant moments, equivalent to the whole moment hierarchy. The 1-loop dynamics of the mean fields are the same as those of a particular moment-closure.			Dodd, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, London, England.	peter.dodd@imperial.ac.uk	Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Dodd, Pete/0000-0001-5825-9347	Medical Research Council [G0600719B] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council Funding Source: Medline; Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bailey NTJ, 1975, MATH THEORY INFECT D; Birch DA, 2006, THEOR POPUL BIOL, V70, P26, DOI 10.1016/j.tpb.2005.11.007; Bolker BM, 1999, B MATH BIOL, V61, P849, DOI 10.1006/bulm.1999.0115; Buchbinder I., 1992, EFFECTIVE ACTION QUA; CARDY JL, 1998, J STAT PHYS, V90; DOI M, 1976, J PHYS A-MATH GEN, V9, P1465, DOI 10.1088/0305-4470/9/9/008; Eyink GL, 1996, PHYS REV E, V54, P3419, DOI 10.1103/PhysRevE.54.3419; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; FEYNMAN RP, 1948, REV MOD PHYS, V20, P367, DOI 10.1103/RevModPhys.20.367; HASSELL MP, 1994, NATURE, V370, P290, DOI 10.1038/370290a0; HILLERY M, 1982, PHYS REV A, V26, P451, DOI 10.1103/PhysRevA.26.451; Kleinert H., 2004, PATH INTEGRALS QUANT; Negele J. W., 1998, QUANTUM MANY PARTICL; Ovaskainen O, 2006, P NATL ACAD SCI USA, V103, P12781, DOI 10.1073/pnas.0603994103; PELITI L, 1985, J PHYS-PARIS, V46, P1469, DOI 10.1051/jphys:019850046090146900; RIVERS R, 1990, PATH INTEGRAL METHOD; Sasai M, 2003, P NATL ACAD SCI USA, V100, P2374, DOI 10.1073/pnas.2627987100	17	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6855	10.1371/journal.pone.0006855	http://dx.doi.org/10.1371/journal.pone.0006855			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489XX	19730742	Green Submitted, Green Published, Green Accepted, gold			2022-12-27	WOS:000269461100001
J	de Luca, A; Vassallo, S; Benitez-Temino, B; Menichetti, G; Rossi, F; Buffo, A				de Luca, Annarita; Vassallo, Stefania; Benitez-Temino, Beatriz; Menichetti, Gianluca; Rossi, Ferdinando; Buffo, Annalisa			Distinct Modes of Neuritic Growth in Purkinje Neurons at Different Developmental Stages: Axonal Morphogenesis and Cellular Regulatory Mechanisms	PLOS ONE			English	Article							CEREBELLAR PURKINJE; POSTNATAL-DEVELOPMENT; CELLS; EXPRESSION; PROTEIN; REGENERATION; PARVALBUMIN; DEGRADATION; SURVIVAL; AXOTOMY	Background: During development, neurons modify their axon growth mode switching from an elongating phase, in which the main axon stem reaches the target territory through growth cone-driven extension, to an arborising phase, when the terminal arbour is formed to establish synaptic connections. To investigate the relative contribution of cell-autonomous factors and environmental signals in the control of these distinct axon growth patterns, we examined the neuritogenesis of Purkinje neurons in cerebellar cultures prepared at elongating ( embryonic day 17) or arborising ( postnatal day zero) stages of Purkinje axon maturation. Methodology/Principal Findings: When placed in vitro, Purkinje cells of both ages undergo an initial phase of neurite elongation followed by the development of terminal ramifications. Nevertheless, elongation of the main axon stem prevails in embryonic Purkinje axons, and many of these neurons are totally unable to form terminal branches. On the contrary, all postnatal neurites switch to arbour growth within a few days in culture and spread extensive terminal trees. Regardless of their elongating or arborising pattern, defined growth features ( e. g. growth rate and tree extension) of embryonic Purkinje axons remain distinct from those of postnatal neurites. Thus, Purkinje neurons of different ages are endowed with intrinsic stage-specific competence for neuritic growth. Such competence, however, can be modified by environmental cues. Indeed, while exposure to the postnatal environment stimulates the growth of embryonic axons without modifying their phenotype, contact-mediated signals derived from granule cells specifically induce arborising growth and modulate the dynamics of neuritic elongation. Conclusions/Significance: Cultured Purkinje cells recapitulate an intrinsically coded neuritogenic program, involving initial navigation of the axon towards the target field and subsequent expansion of the terminal arborisation. The execution of this program is regulated by environmental signals that modify the growth competence of Purkinje cells, so to adapt their endogenous properties to the different phases of neuritic morphogenesis.			de Luca, A (corresponding author), Univ Turin, Dept Neurosci, Turin, Italy.	annalisa.buffo@unito.it	Buffo, Annalisa/O-7207-2019; Benítez Temiño, Beatriz/F-8888-2015; Buffo, Annalisa/K-4560-2016	Buffo, Annalisa/0000-0001-7637-0006; Benítez Temiño, Beatriz/0000-0002-3852-1093; Buffo, Annalisa/0000-0001-7637-0006				Aloy EM, 2006, BRAIN CELL BIOL, V35, P137, DOI 10.1007/s11068-007-9014-3; Altman J, 1997, DEV CEREBELLAR SYSTE; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BEATTIE CE, 1993, J NEUROSCI, V13, P1784; Behringer KA, 1996, J NEUROCHEM, V66, P1347; Bhide PG, 1999, J COMP NEUROL, V411, P119; Buffo A, 1997, J NEUROSCI, V17, P8778; Buffo A, 2000, J NEUROSCI, V20, P2275; Canal I, 1998, J NEUROSCI, V18, P999; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; Chan-Palay V, 1977, CEREBELLAR DENTATE N; CHEDOTAL A, 1993, DEV BRAIN RES, V76, P207, DOI 10.1016/0165-3806(93)90209-S; Corvetti L, 2005, J NEUROSCI, V25, P7150, DOI 10.1523/JNEUROSCI.0683-05.2005; DAVIES AM, 1989, NATURE, V337, P553, DOI 10.1038/337553a0; DAVIES AM, 1994, CURR BIOL, V4, P1142, DOI 10.1016/S0960-9822(00)00258-X; Dusart I, 1999, J COMP NEUROL, V408, P399; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; Dusart I, 1997, J NEUROSCI, V17, P3710; EISENMAN LM, 1991, DEV BRAIN RES, V60, P261, DOI 10.1016/0165-3806(91)90055-N; ERZURUMLU RS, 1995, EXP NEUROL, V135, P1, DOI 10.1006/exnr.1995.1061; FAWCETT J, 2001, BRAIN DAMAGE BRAIN R; GARDETTE R, 1985, DEV BRAIN RES, V19, P47, DOI 10.1016/0165-3806(85)90230-5; Gianola S, 2003, J NEUROSCI, V23, P4613; Gianola S, 2002, EXP NEUROL, V176, P25, DOI 10.1006/exnr.2002.7924; Gianola S, 2009, NEUROSCIENCE, V158, P570, DOI 10.1016/j.neuroscience.2008.10.022; Gianola S, 2001, J COMP NEUROL, V430, P101, DOI 10.1002/1096-9861(20010129)430:1<101::AID-CNE1017>3.0.CO;2-Z; Goldberg JL, 2003, GENE DEV, V17, P941, DOI 10.1101/gad.1062303; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Goslin, 1998, CULTURING NERVE CELL, P419; Grusser-Cornehls U, 2001, PROG NEUROBIOL, V63, P489, DOI 10.1016/S0301-0082(00)00024-1; Hirai H, 2000, J NEUROSCI, V20, P5217, DOI 10.1523/JNEUROSCI.20-14-05217.2000; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; KAPFHAMMER JP, 1994, J COMP NEUROL, V340, P194, DOI 10.1002/cne.903400206; Maricich SM, 1999, J NEUROBIOL, V41, P281, DOI 10.1002/(SICI)1097-4695(19991105)41:2<281::AID-NEU10>3.0.CO;2-5; Morrison ME, 1998, J NEUROSCI, V18, P3563; Oldreive CE, 2008, NEUROSCI LETT, V438, P17, DOI 10.1016/j.neulet.2008.04.045; Ozdinler PH, 2002, J NEUROSCI, V22, P4540, DOI 10.1523/JNEUROSCI.22-11-04540.2002; Pfister BJ, 2004, J NEUROSCI, V24, P7978, DOI 10.1523/JNEUROSCI.1974-04.2004; Poulain FE, 2008, J NEUROSCI, V28, P7387, DOI 10.1523/JNEUROSCI.1942-08.2008; Rossi F, 2007, PROG NEUROBIOL, V81, P1, DOI 10.1016/j.pneurobio.2006.12.001; Rossi F, 2006, CEREBELLUM, V5, P174, DOI 10.1080/14734220600786444; SCHREYER DJ, 1991, J NEUROSCI, V11, P3738; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; Smith DS, 1997, J NEUROSCI, V17, P646; Sotelo C, 2004, PROG NEUROBIOL, V72, P295, DOI 10.1016/j.pneurobio.2004.03.004; SOTELO C, 2009, NEUROSCIENC IN PRESS; Ulupinar E, 1999, MOL CELL NEUROSCI, V13, P281, DOI 10.1006/mcne.1999.0747; Verma P, 2005, J NEUROSCI, V25, P331, DOI 10.1523/JNEUROSCI.3073-04.2005; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Weisheit G, 2006, EUR J NEUROSCI, V24, P466, DOI 10.1111/j.1460-9568.2006.04915.x; Yamada Keiko, 2002, Anatomical Science International, V77, P94, DOI 10.1046/j.0022-7722.2002.00021.x	51	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6848	10.1371/journal.pone.0006848	http://dx.doi.org/10.1371/journal.pone.0006848			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718257	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900020
J	Djikeng, A; Kuzmickas, R; Anderson, NG; Spiro, DJ				Djikeng, Appolinaire; Kuzmickas, Ryan; Anderson, Norman G.; Spiro, David J.			Metagenomic Analysis of RNA Viruses in a Fresh Water Lake	PLOS ONE			English	Article							OCEAN SAMPLING EXPEDITION; VIRAL COMMUNITY; MARINE; GENOMES	Freshwater lakes and ponds present an ecological interface between humans and a variety of host organisms. They are a habitat for the larval stage of many insects and may serve as a medium for intraspecies and interspecies transmission of viruses such as avian influenza A virus. Furthermore, freshwater bodies are already known repositories for disease-causing viruses such as Norwalk Virus, Coxsackievirus, Echovirus, and Adenovirus. While RNA virus populations have been studied in marine environments, to this date there has been very limited analysis of the viral community in freshwater. Here we present a survey of RNA viruses in Lake Needwood, a freshwater lake in Maryland, USA. Our results indicate that just as in studies of other aquatic environments, the majority of nucleic acid sequences recovered did not show any significant similarity to known sequences. The remaining sequences are mainly from viral types with significant similarity to approximately 30 viral families. We speculate that these novel viruses may infect a variety of hosts including plants, insects, fish, domestic animals and humans. Among these viruses we have discovered a previously unknown dsRNA virus closely related to Banna Virus which is responsible for a febrile illness and is endemic to Southeast Asia. Moreover we found multiple viral sequences distantly related to Israeli Acute Paralysis virus which has been implicated in honeybee colony collapse disorder. Our data suggests that due to their direct contact with humans, domestic and wild animals, freshwater ecosystems might serve as repositories of a wide range of viruses (both pathogenic and non-pathogenic) and possibly be involved in the spread of emerging and pandemic diseases.			Djikeng, A (corresponding author), JCVI, Infect Dis Grp, Rockville, MD USA.	adjikeng@jcvi.org; dspiro@jcvi.org		Djikeng, Appolinaire/0000-0001-9271-3419				Allan GM, 2000, J VET DIAGN INVEST, V12, P3, DOI 10.1177/104063870001200102; Andersson AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002836; Angly FE, 2006, PLOS BIOL, V4, P2121, DOI 10.1371/journal.pbio.0040368; Bench SR, 2007, APPL ENVIRON MICROB, V73, P7629, DOI 10.1128/AEM.00938-07; Biagini P, 2004, VET MICROBIOL, V98, P95, DOI 10.1016/j.vetmic.2003.10.004; Breitbart M, 2005, TRENDS MICROBIOL, V13, P278, DOI 10.1016/j.tim.2005.04.003; Breitbart M, 2004, FEMS MICROBIOL LETT, V236, P249, DOI 10.1016/j.femsle.2004.05.042; Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003; Chen BQ, 1996, CHINESE MED J-PEKING, V109, P13; Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498; Culley AI, 2003, NATURE, V424, P1054, DOI 10.1038/nature01886; Culley AI, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-69; Culley AI, 2006, SCIENCE, V312, P1795, DOI 10.1126/science.1127404; de Miranda JR, 2004, J GEN VIROL, V85, P2263, DOI 10.1099/vir.0.79990-0; Djikeng A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-5; Edwards RA, 2005, NAT REV MICROBIOL, V3, P504, DOI 10.1038/nrmicro1163; Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011; Goldberg SMD, 2006, P NATL ACAD SCI USA, V103, P11240, DOI 10.1073/pnas.0604351103; Huson DH, 2007, GENOME RES, V17, P377, DOI 10.1101/gr.5969107; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Martin HG, 2006, NAT BIOTECHNOL, V24, P1263, DOI 10.1038/nbt1247; Martin-Cuadrado AB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000914; Nabeshima T, 2008, EMERG INFECT DIS, V14, P1276, DOI 10.3201/eid1408.080100; Nakamura S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004219; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Schoenfeld T, 2008, APPL ENVIRON MICROB, V74, P4164, DOI 10.1128/AEM.02598-07; Seshadri R, 2007, PLOS BIOL, V5, P394, DOI 10.1371/journal.pbio.0050075; Short CM, 2005, APPL ENVIRON MICROB, V71, P480, DOI 10.1128/AEM.71.1.480-486.2005; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; VAN MM, 2002, J GEN VIROL, V83, P3131; WATANABE RA, 1988, APPL ENVIRON MICROB, V54, P1606, DOI 10.1128/AEM.54.6.1606-1609.1988; Williamson SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001456; Zhang T, 2006, PLOS BIOL, V4, P108, DOI 10.1371/journal.pbio.0040003	34	132	135	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7264	10.1371/journal.pone.0007264	http://dx.doi.org/10.1371/journal.pone.0007264			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787045	Green Submitted, gold, Green Published			2022-12-27	WOS:000270290100028
J	Hellemans, KH; Hannaert, JC; Denys, B; Steffensen, KR; Raemdonck, C; Martens, GA; Van Veldhoven, PP; Gustafsson, JA; Pipeleers, D				Hellemans, Karine H.; Hannaert, Jean-Claude; Denys, Bart; Steffensen, Knut R.; Raemdonck, Cindy; Martens, Geert A.; Van Veldhoven, Paul P.; Gustafsson, Jan-Ake; Pipeleers, Daniel			Susceptibility of Pancreatic Beta Cells to Fatty Acids Is Regulated by LXR/PPAR alpha-Dependent Stearoyl-Coenzyme A Desaturase	PLOS ONE			English	Article							ELEMENT-BINDING PROTEIN-1C; ENDOPLASMIC-RETICULUM STRESS; INSULIN-SECRETION; COA DESATURASE-1; RECEPTOR-ALPHA; ER STRESS; ADIPOSE-TISSUE; A DESATURASE; ISLET CELLS; GLUCOSE	Chronically elevated levels of fatty acids-FA can cause beta cell death in vitro. Beta cells vary in their individual susceptibility to FA-toxicity. Rat beta cells were previously shown to better resist FA-toxicity in conditions that increased triglyceride formation or mitochondrial and peroxisomal FA-oxidation, possibly reducing cytoplasmic levels of toxic FA-moieties. We now show that stearoyl-CoA desaturase-SCD is involved in this cytoprotective mechanism through its ability to transfer saturated FA into monounsaturated FA that are incorporated in lipids. In purified beta cells, SCD expression was induced by LXR- and PPAR alpha-agonists, which were found to protect rat, mouse and human beta cells against palmitate toxicity. When their SCD was inhibited or silenced, the agonist-induced protection was also suppressed. A correlation between beta cell-SCD expression and susceptibility to palmitate was also found in beta cell preparations isolated from different rodent models. In mice with LXR- deletion (LXR beta(-/-) and LXR alpha beta(-/-)), beta cells presented a reduced SCD-expression as well as an increased susceptibility to palmitate-toxicity, which could not be counteracted by LXR or PPAR alpha agonists. In Zucker fatty rats and in rats treated with the LXR- agonist TO1317, beta cells show an increased SCD-expression and lower palmitate-toxicity. In the normal rat beta cell population, the subpopulation with lower metabolic responsiveness to glucose exhibits a lower SCD1 expression and a higher susceptibility to palmitate toxicity. These data demonstrate that the beta cell susceptibility to saturated fatty acids can be reduced by stearoyl-coA desaturase, which upon stimulation by LXR and PPAR alpha agonists favors their desaturation and subsequent incorporation in neutral lipids.			Hellemans, KH (corresponding author), Brussels Free Univ VUB, Diabet Res Ctr, Brussels, Belgium.	karine.hellemans@vub.ac.be	Martens, Geert/ABA-6297-2020; Martens, Geert A./F-6920-2015; , Van Veldhoven Paul/U-6359-2019; Hellemans, Karine/B-7573-2013	Martens, Geert/0000-0003-1208-6289; Martens, Geert A./0000-0003-1208-6289; , Van Veldhoven Paul/0000-0002-4478-2564; Hellemans, Karine/0000-0001-9306-4369; Pipeleers, Daniel/0000-0002-6440-2485				AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Biddinger SB, 2006, DIABETES, V55, P2032, DOI 10.2337/db05-0742; Borg J, 2009, ENDOCRINOLOGY, V150, P3049, DOI 10.1210/en.2008-0913; Busch AK, 2005, DIABETES, V54, P2917, DOI 10.2337/diabetes.54.10.2917; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Choe SS, 2007, DIABETES, V56, P1534, DOI 10.2337/db06-1059; Chu K, 2006, MOL CELL BIOL, V26, P6786, DOI 10.1128/MCB.00077-06; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Cnop M, 2008, BIOCHEM SOC T, V36, P909, DOI 10.1042/BST0360909; Cnop M, 2008, BIOCHEM SOC T, V36, P348, DOI 10.1042/BST0360348; Diakogiannaki E, 2008, BIOCHEM SOC T, V36, P959, DOI 10.1042/BST0360959; Diraison F, 2004, BIOCHEM J, V378, P769, DOI 10.1042/BJ20031277; Diraison F, 2008, J LIPID RES, V49, P814, DOI 10.1194/jlr.M700533-JLR200; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; Efanov AM, 2004, DIABETES, V53, pS75, DOI 10.2337/diabetes.53.suppl_3.S75; Eitel K, 2002, BIOCHEM BIOPH RES CO, V299, P853, DOI 10.1016/S0006-291X(02)02752-3; Finegood DT, 2001, DIABETES, V50, P1021, DOI 10.2337/diabetes.50.5.1021; Flowers JB, 2007, DIABETES, V56, P1228, DOI 10.2337/db06-1142; Flowers MT, 2008, CURR OPIN LIPIDOL, V19, P248, DOI 10.1097/MOL.0b013e3282f9b54d; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Gerin I, 2005, J BIOL CHEM, V280, P23024, DOI 10.1074/jbc.M412564200; Green CD, 2009, ENDOCRINOLOGY, V150, P2637, DOI 10.1210/en.2008-1039; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; Hellemans K, 2007, FEBS J, V274, P6094, DOI 10.1111/j.1742-4658.2007.06131.x; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Hu TH, 2005, ENDOCRINOLOGY, V146, P5380, DOI 10.1210/en.2005-0591; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Kaiser N, 2009, FRONT BIOSCI-LANDMRK, V14, P1099, DOI 10.2741/3296; Kakuma T, 2002, BIOCHEM BIOPH RES CO, V297, P1259, DOI 10.1016/S0006-291X(02)02375-6; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Kato T, 2008, DIABETES, V57, P2382, DOI 10.2337/db06-1806; Kato T, 2006, CELL METAB, V4, P143, DOI 10.1016/j.cmet.2006.06.009; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; Kumadaki S, 2008, BIOCHEM BIOPH RES CO, V368, P261, DOI 10.1016/j.bbrc.2008.01.075; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lai E, 2008, AM J PHYSIOL-ENDOC M, V294, pE540, DOI 10.1152/ajpendo.00478.2007; Lalloyer F, 2006, DIABETES, V55, P1605, DOI 10.2337/db06-0016; Lazar MA, 2007, CELL METAB, V5, P159, DOI 10.1016/j.cmet.2007.02.001; Ling ZD, 2006, DIABETES, V55, P78, DOI 10.2337/diabetes.55.01.06.db05-0820; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Maedler K, 2003, DIABETES, V52, P726, DOI 10.2337/diabetes.52.3.726; Martens GA, 2005, J BIOL CHEM, V280, P20389, DOI 10.1074/jbc.M411869200; Martens GA, 2007, J BIOL CHEM, V282, P21134, DOI 10.1074/jbc.M700083200; Meng ZX, 2009, DIABETOLOGIA, V52, P125, DOI 10.1007/s00125-008-1174-x; Moffitt JH, 2005, DIABETOLOGIA, V48, P1819, DOI 10.1007/s00125-005-1861-9; Moloney F, 2004, AM J CLIN NUTR, V80, P887; Morgan NG, 2008, BIOCHEM SOC T, V36, P905, DOI 10.1042/BST0360905; Parton LE, 2006, AM J PHYSIOL-ENDOC M, V291, pE982, DOI 10.1152/ajpendo.00067.2006; Peter A, 2008, AM J PHYSIOL-ENDOC M, V295, pE339, DOI 10.1152/ajpendo.00022.2008; Pinnamaneni SK, 2006, DIABETOLOGIA, V49, P3027, DOI 10.1007/s00125-006-0427-9; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Poitout V, 2008, ENDOCR REV, V29, P351, DOI 10.1210/er.2007-0023; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; Qin Y, 2009, BBA-MOL CELL BIOL L, V1791, P140, DOI 10.1016/j.bbalip.2008.12.003; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Riserus U, 2007, DIABETES CARE, V30, P2928, DOI 10.2337/dc07-0360; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Shimano H, 2007, DIABETES OBES METAB, V9, P133, DOI 10.1111/j.1463-1326.2007.00779.x; Shimano H, 2009, FEBS J, V276, P616, DOI 10.1111/j.1742-4658.2008.06806.x; Sol ERM, 2008, BIOCHEM BIOPH RES CO, V375, P517, DOI 10.1016/j.bbrc.2008.08.013; Steffensen KR, 2003, BIOCHEM BIOPH RES CO, V310, P589, DOI 10.1016/j.bbrc.2003.08.139; Takahashi A, 2005, DIABETES, V54, P492, DOI 10.2337/diabetes.54.2.492; Tenenbaum H, 2007, ATHEROSCLEROSIS, V194, P265, DOI 10.1016/j.atherosclerosis.2006.08.005; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; WAHLE KWJ, 1994, COMP BIOCHEM PHYS A, V109, P235, DOI 10.1016/0300-9629(94)90126-0; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang MY, 2008, P NATL ACAD SCI USA, V105, P6139, DOI 10.1073/pnas.0801981105; Wente W, 2007, ENDOCRINOLOGY, V148, P1843, DOI 10.1210/en.2006-1247; ZHANG Y, 2009, J LIPID RES; Zitzer H, 2006, ENDOCRINOLOGY, V147, P3898, DOI 10.1210/en.2005-1483	76	38	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7266	10.1371/journal.pone.0007266	http://dx.doi.org/10.1371/journal.pone.0007266			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787047	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290100029
J	Yang, XY; Kathuria, SV; Vadrevu, R; Matthews, CR				Yang, Xiaoyan; Kathuria, Sagar V.; Vadrevu, Ramakrishna; Matthews, C. Robert			beta alpha-Hairpin Clamps Brace beta alpha beta Modules and Can Make Substantive Contributions to the Stability of TIM Barrel Proteins	PLOS ONE			English	Article								Non-local hydrogen bonding interactions between main chain amide hydrogen atoms and polar side chain acceptors that bracket consecutive beta alpha or alpha beta elements of secondary structure in alpha TS from E. coli, a TIM barrel protein, have previously been found to contribute 4-6 kcal mol(-1) to the stability of the native conformation. Experimental analysis of similar beta alpha-hairpin clamps in a homologous pair of TIM barrel proteins of low sequence identity, IGPS from S. solfataricus and E. coli, reveals that this dramatic enhancement of stability is not unique to alpha TS. A survey of 71 TIM barrel proteins demonstrates a 4-fold symmetry for the placement of beta alpha-hairpin clamps, bracing the fundamental beta alpha beta building block and defining its register in the (beta alpha)(8) motif. The preferred sequences and locations of beta alpha-hairpin clamps will enhance structure prediction algorithms and provide a strategy for engineering stability in TIM barrel proteins.			Yang, XY (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA.	C.Robert.Matthews@umassmed.edu	Kathuria, Sagar/A-7473-2008		NIGMS NIH HHS [R01 GM023303, GM 23303] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023303] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altamirano MM, 2000, NATURE, V403, P617, DOI 10.1038/35001001; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bilsel O, 1999, BIOCHEMISTRY-US, V38, P1018, DOI 10.1021/bi982365q; Branden C., 1999, INTRO PROTEIN STRUCT; Brylinski M, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000405; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; delPino MMS, 1997, BIOCHEMISTRY-US, V36, P5560, DOI 10.1021/bi963133z; FarzadFard F, 2008, J STRUCT BIOL, V161, P101, DOI 10.1016/j.jsb.2007.09.024; Forsyth WR, 2002, J MOL BIOL, V320, P1119, DOI 10.1016/S0022-2836(02)00557-0; Frenkel ZM, 2005, J BIOMOL STRUCT DYN, V22, P643, DOI 10.1080/07391102.2005.10507032; Gao JM, 2009, NAT STRUCT MOL BIOL, V16, P684, DOI 10.1038/nsmb.1610; Gerlt JA, 2003, CURR OPIN CHEM BIOL, V7, P252, DOI 10.1016/S1367-5931(03)00019-X; Gerlt JA, 2009, CURR OPIN CHEM BIOL, V13, P10, DOI 10.1016/j.cbpa.2009.01.014; Gerstein M, 1997, J MOL BIOL, V274, P562, DOI 10.1006/jmbi.1997.1412; Gromiha MM, 2004, PROTEINS, V55, P316, DOI 10.1002/prot.20052; Gu ZY, 2007, J MOL BIOL, V368, P582, DOI 10.1016/j.jmb.2007.02.027; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Ibarra-Molero B, 2004, J MOL BIOL, V336, P989, DOI 10.1016/j.jmb.2003.12.069; Jurgens C, 2000, P NATL ACAD SCI USA, V97, P9925, DOI 10.1073/pnas.160255397; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kunin V, 2001, J MOL BIOL, V307, P939, DOI 10.1006/jmbi.2001.4466; MATTHEWS CR, 1987, METHOD ENZYMOL, V154, P498; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Myers JK, 1996, BIOPHYS J, V71, P2033, DOI 10.1016/S0006-3495(96)79401-8; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; Rohl CA, 2004, PROTEINS, V55, P656, DOI 10.1002/prot.10629; Rothlisberger D, 2008, NATURE, V453, P190, DOI 10.1038/nature06879; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schneider B, 2005, BIOCHEMISTRY-US, V44, P16405, DOI 10.1021/bi051640n; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; Vadrevu R, 2008, J MOL BIOL, V377, P294, DOI 10.1016/j.jmb.2007.11.010; Wieczorek SJ, 1999, J AM CHEM SOC, V121, P4540, DOI 10.1021/ja990500w; Wierenga RK, 2001, FEBS LETT, V492, P193, DOI 10.1016/S0014-5793(01)02236-0; WILMANNS M, 1992, J MOL BIOL, V223, P477, DOI 10.1016/0022-2836(92)90665-7; Wu Y, 2007, J MOL BIOL, V366, P1624, DOI 10.1016/j.jmb.2006.12.005; Yang XY, 2007, PROTEIN SCI, V16, P1398, DOI 10.1110/ps.062704507; Yates F., 1934, JR STATIST SOC     S, V1, P217, DOI DOI 10.2307/2983604; Zitzewitz JA, 1999, PROTEIN SCI, V8, P1200, DOI 10.1110/ps.8.6.1200	47	13	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7179	10.1371/journal.pone.0007179	http://dx.doi.org/10.1371/journal.pone.0007179			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787060	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290100007
J	Goff, LA; Davila, J; Swerdel, MR; Moore, JC; Cohen, RI; Wu, H; Sun, YE; Hart, RP				Goff, Loyal A.; Davila, Jonathan; Swerdel, Mavis R.; Moore, Jennifer C.; Cohen, Rick I.; Wu, Hao; Sun, Yi E.; Hart, Ronald P.			Ago2 Immunoprecipitation Identifies Predicted MicroRNAs in Human Embryonic Stem Cells and Neural Precursors	PLOS ONE			English	Article							GENES; DIFFERENTIATION; EVOLUTION; DISCOVERY; EXPANSION; PATTERN; TARGETS; ROLES; LINES	Background: MicroRNAs are required for maintenance of pluripotency as well as differentiation, but since more microRNAs have been computationally predicted in genome than have been found, there are likely to be undiscovered microRNAs expressed early in stem cell differentiation. Methodology/Principal Findings: SOLiD ultra-deep sequencing identified > 10(7) unique small RNAs from human embryonic stem cells (hESC) and neural-restricted precursors that were fit to a model of microRNA biogenesis to computationally predict 818 new microRNA genes. These predicted genomic loci are associated with chromatin patterns of modified histones that are predictive of regulated gene expression. 146 of the predicted microRNAs were enriched in Ago2-containing complexes along with 609 known microRNAs, demonstrating association with a functional RISC complex. This Ago2 IP-selected subset was consistently expressed in four independent hESC lines and exhibited complex patterns of regulation over development similar to previously-known microRNAs, including pluripotency-specific expression in both hESC and iPS cells. More than 30% of the Ago2 IP-enriched predicted microRNAs are new members of existing families since they share seed sequences with known microRNAs. Conclusions/Significance: Extending the classic definition of microRNAs, this large number of new microRNA genes, the majority of which are less conserved than their canonical counterparts, likely represent evolutionarily recent regulators of early differentiation. The enrichment in Ago2 containing complexes, the presence of chromatin marks indicative of regulated gene expression, and differential expression over development all support the identification of 146 new microRNAs active during early hESC differentiation.			Goff, LA (corresponding author), Rutgers State Univ, Rutgers Stem Cell Res Ctr, Piscataway, NJ 08855 USA.	rhart@rci.rutgers.edu	Hart, Ronald P/G-6530-2019; Wu, Hao/G-4145-2013; Hart, Ronald P/D-5219-2009	Hart, Ronald P/0000-0003-4836-8712; Wu, Hao/0000-0002-1256-6891; Hart, Ronald P/0000-0003-4836-8712; Goff, Loyal/0000-0003-2875-451X; Wu, Hao/0000-0003-4395-6929	NIMH NIH HHS [R01 MH084095, 1R01MH084095-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH084095] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bar M, 2008, STEM CELLS, V26, P2496, DOI 10.1634/stemcells.2008-0356; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914; Berezikov E, 2006, GENOME RES, V16, P1289, DOI 10.1101/gr.5159906; Cao H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002820; Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Cloonan N, 2008, NAT METHODS, V5, P613, DOI 10.1038/nmeth.1223; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Friedlander MR, 2008, NAT BIOTECHNOL, V26, P407, DOI 10.1038/nbt1394; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Garber M, 2009, BIOINFORMATICS, V25, pI54, DOI 10.1093/bioinformatics/btp190; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188; Heimberg AM, 2008, P NATL ACAD SCI USA, V105, P2946, DOI 10.1073/pnas.0712259105; Hendrickson DG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002126; Hertel J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-25; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lakshmipathy U, 2007, STEM CELLS DEV, V16, P1003, DOI 10.1089/scd.2007.0026; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103; Liang H, 2009, MOL BIOL EVOL, V26, P1195, DOI 10.1093/molbev/msp053; Linsen SEV, 2009, NAT METHODS, V6, P474, DOI 10.1038/nmeth0709-474; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Ludwig TE, 2006, NAT METHODS, V3, P637, DOI 10.1038/NMETH902; Maniataki E, 2005, RNA, V11, P849, DOI 10.1261/rna.2210805; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nat R, 2007, GLIA, V55, P385, DOI 10.1002/glia.20463; Piriyapongsa J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000203; Prochnik SE, 2007, DEV GENES EVOL, V217, P73, DOI 10.1007/s00427-006-0116-1; Rudel S, 2008, RNA, V14, P1244, DOI 10.1261/rna.973808; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shin S, 2007, STEM CELLS, V25, P1298, DOI 10.1634/stemcells.2006-0660; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Valouev A, 2008, GENOME RES, V18, P1051, DOI 10.1101/gr.076463.108; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Ware CB, 2006, STEM CELLS, V24, P2677, DOI 10.1634/stemcells.2005-0452; Wu CI, 2009, GENOME RES, V19, P734, DOI 10.1101/gr.084640.108; Wu H, 2007, P NATL ACAD SCI USA, V104, P13821, DOI 10.1073/pnas.0706199104; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zhang R, 2007, GENOME RES, V17, P612, DOI 10.1101/gr.6146507	52	94	226	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7192	10.1371/journal.pone.0007192	http://dx.doi.org/10.1371/journal.pone.0007192			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784364	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290000009
J	Jain, A; Munn, LL				Jain, Abhishek; Munn, Lance L.			Determinants of Leukocyte Margination in Rectangular Microchannels	PLOS ONE			English	Article							TOTAL ANALYSIS SYSTEMS; RED-CELL AGGREGATION; BLOOD-FLOW; WHOLE-BLOOD; SHEAR RATE; ADHESION; ERYTHROCYTES; MICROFLUIDICS; EMIGRATION; CAPILLARY	Microfabrication of polydimethylsiloxane (PDMS) devices has provided a new set of tools for studying fluid dynamics of blood at the scale of real microvessels. However, we are only starting to understand the power and limitations of this technology. To determine the applicability of PDMS microchannels for blood flow analysis, we studied white blood cell (WBC) margination in channels of various geometries and blood compositions. We found that WBCs prefer to marginate downstream of sudden expansions, and that red blood cell (RBC) aggregation facilitates the process. In contrast to tubes, WBC margination was restricted to the sidewalls in our low aspect ratio, pseudo-2D rectangular channels and consequently, margination efficiencies of more than 95% were achieved in a variety of channel geometries. In these pseudo-2D channels blood rheology and cell integrity were preserved over a range of flow rates, with the upper range limited by the shear in the vertical direction. We conclude that, with certain limitations, rectangular PDMS microfluidic channels are useful tools for quantitative studies of blood rheology.			Jain, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Steele Lab Tumor Biol, Charlestown, MA USA.	lance@steele.mgh.harvard.edu	Munn, Lance L/L-3950-2016	Munn, Lance L/0000-0003-0698-7232; Jain, Abhishek/0000-0003-2235-5139	NATIONAL CANCER INSTITUTE [R21CA126761] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA126761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbitt KB, 2003, AM J PHYSIOL-HEART C, V285, pH229, DOI 10.1152/ajpheart.00408.2002; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Andersson H, 2003, SENSOR ACTUAT B-CHEM, V92, P315, DOI 10.1016/S0925-4005(03)00266-1; BAGGE U, 1983, INT J MICROCIRC, V2, P215; BAGGE U, 1980, MICROVASC RES, V20, P92, DOI 10.1016/0026-2862(80)90023-0; BARBEE JH, 1971, MICROVASC RES, V3, P17, DOI 10.1016/0026-2862(71)90003-3; BARBEE JH, 1971, MICROVASC RES, V3, P6, DOI 10.1016/0026-2862(71)90002-1; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BRENNER H, 1961, CHEM ENG SCI, V16, P242, DOI 10.1016/0009-2509(61)80035-3; Chen P, 2008, FRONT BIOSCI-LANDMRK, V13, P2464, DOI 10.2741/2859; Chen X, 2009, MICROSYST TECHNOL, V15, P667, DOI 10.1007/s00542-009-0783-8; COLDITZ IG, 1985, SURV SYN PATHOL RES, V4, P44; Davis JA, 2006, P NATL ACAD SCI USA, V103, P14779, DOI 10.1073/pnas.0605967103; DEITCHER SR, 2003, CANC THROMBOSIS MECH, P21; Dittrich PS, 2006, ANAL CHEM, V78, P3887, DOI 10.1021/ac0605602; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Faivre M, 2006, BIORHEOLOGY, V43, P147; FIRRELL JC, 1989, AM J PHYSIOL, V256, pH1667, DOI 10.1152/ajpheart.1989.256.6.H1667; Goldsmith H L, 1984, Kroc Found Ser, V16, P131; GOLDSMITH H L, 1971, Biorheology, V7, P235; GOLDSMITH HL, 1971, FED PROC, V30, P1578; GOLDSMITH HL, 1984, MICROVASC RES, V27, P204, DOI 10.1016/0026-2862(84)90054-2; Higgins JM, 2007, P NATL ACAD SCI USA, V104, P20496, DOI 10.1073/pnas.0707122105; Iigo Y, 1997, AM J PHYSIOL-HEART C, V273, pH138, DOI 10.1152/ajpheart.1997.273.1.H138; Jaggi RD, 2007, MICROFLUID NANOFLUID, V3, P47, DOI 10.1007/s10404-006-0104-9; JAIN A, 2009, LAB ON A CHIP TECHNO; Kim S, 2005, AM J PHYSIOL-HEART C, V288, pH584, DOI 10.1152/ajpheart.00690.2004; Kim S, 2007, AM J PHYSIOL-HEART C, V293, pH1947, DOI 10.1152/ajpheart.00764.2006; LAWRENCE MB, 1987, BLOOD, V70, P1284; LESS JR, 1991, CANCER RES, V51, P265; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Lima R, 2008, BIOMED MICRODEVICES, V10, P153, DOI 10.1007/s10544-007-9121-z; MUNN LL, 1994, BIOPHYS J, V67, P889, DOI 10.1016/S0006-3495(94)80550-8; Munn LL, 1996, BIOPHYS J, V71, P466, DOI 10.1016/S0006-3495(96)79248-2; Nash GB, 2008, CLIN HEMORHEOL MICRO, V39, P303, DOI 10.3233/CH-2008-1109; Neu B, 2008, BIOPHYS J, V95, P3059, DOI 10.1529/biophysj.108.130328; NOBIS U, 1985, MICROVASC RES, V29, P295, DOI 10.1016/0026-2862(85)90020-2; Pearson MJ, 2004, MICROCIRCULATION, V11, P295, DOI 10.1080/10739680490425994; Pearson MJ, 2000, AM J PHYSIOL-HEART C, V279, pH1460, DOI 10.1152/ajpheart.2000.279.4.H1460; PHIBBS RH, 1966, AM J PHYSIOL, V210, P919, DOI 10.1152/ajplegacy.1966.210.5.919; Rosenbluth MJ, 2008, LAB CHIP, V8, P1062, DOI 10.1039/b802931h; Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SCHMIDSCHONBEIN H, 1968, J CLIN INVEST, V47, P1447, DOI 10.1172/JCI105836; Secomb TW, 2003, P NATL ACAD SCI USA, V100, P7231, DOI 10.1073/pnas.1232173100; SEGRE G, 1962, J FLUID MECH, V14, P136, DOI 10.1017/S0022112062001111; Shah R. K., 1978, LAMINAR FLOW FORCED, P196; Shevkoplyas SS, 2006, LAB CHIP, V6, P914, DOI 10.1039/b601554a; Shevkoplyas SS, 2005, ANAL CHEM, V77, P933, DOI 10.1021/ac049037i; Shevkoplyas SS, 2003, MICROVASC RES, V65, P132, DOI 10.1016/S0026-2862(02)00034-1; Skalak R. C., 1987, HDB BIOENGINEERING; Sun CH, 2005, BIOPHYS J, V88, P1635, DOI 10.1529/biophysj.104.051151; Sun CH, 2003, BIOPHYS J, V85, P208, DOI 10.1016/S0006-3495(03)74467-1; SUN CH, 2006, INFLUENCE ERYTHROCYT, P191; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Toner M, 2005, ANNU REV BIOMED ENG, V7, P77, DOI 10.1146/annurev.bioeng.7.011205.135108; VanDelinder V, 2007, ANAL CHEM, V79, P2023, DOI 10.1021/ac061659b; VLODAVSKY I, 2007, HEPARANASE HEPARIN C, pS112; Wan JD, 2008, P NATL ACAD SCI USA, V105, P16432, DOI 10.1073/pnas.0805779105; Wang HB, 2007, NAT IMMUNOL, V8, P882, DOI 10.1038/ni1491; Weibel DB, 2006, CURR OPIN CHEM BIOL, V10, P584, DOI 10.1016/j.cbpa.2006.10.016; Weigl B, 2008, LAB CHIP, V8, P1999, DOI 10.1039/b811314a; West J, 2008, ANAL CHEM, V80, P4403, DOI 10.1021/ac800680j; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; WILLIAMSON J, 1961, AM J PATHOL, V39, P239	66	66	79	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7104	10.1371/journal.pone.0007104	http://dx.doi.org/10.1371/journal.pone.0007104			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768109	gold, Green Published, Green Submitted			2022-12-27	WOS:000270154000008
J	Vellaichamy, A; Sreekumar, A; Strahler, JR; Rajendiran, T; Yu, JD; Varambally, S; Li, Y; Omenn, GS; Chinnaiyan, AM; Nesvizhskii, AI				Vellaichamy, Adaikkalam; Sreekumar, Arun; Strahler, John R.; Rajendiran, Theckelnaycke; Yu, Jindan; Varambally, Sooryanarayana; Li, Yong; Omenn, Gilbert S.; Chinnaiyan, Arul M.; Nesvizhskii, Alexey I.			Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases	PLOS ONE			English	Article							GENE-EXPRESSION; STATISTICAL-MODEL; IDENTIFICATION; PEPTIDES; NETWORKS; PATHWAYS; PROTEINS; LNCAP	Prostate cancer remains the most common malignancy among men in United States, and there is no remedy currently available for the advanced stage hormone-refractory cancer. This is partly due to the incomplete understanding of androgen-regulated proteins and their encoded functions. Whole-cell proteomes of androgen-starved and androgen-treated LNCaP cells were analyzed by semi-quantitative MudPIT ESI-ion trap MS/MS and quantitative iTRAQ MALDI-TOF MS/MS platforms, with identification of more than 1300 high-confidence proteins. An enrichment-based pathway mapping of the androgen-regulated proteomic data sets revealed a significant dysregulation of aminoacyl tRNA synthetases, indicating an increase in protein biosynthesis-a hallmark during prostate cancer progression. This observation is supported by immunoblot and transcript data from LNCaP cells, and prostate cancer tissue. Thus, data derived from multiple proteomics platforms and transcript data coupled with informatics analysis provides a deeper insight into the functional consequences of androgen action in prostate cancer.			Vellaichamy, A (corresponding author), Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.	asreekumar@mcg.edu; nesvi@med.umich.edu	Nesvizhskii, Alexey/A-5410-2012; Vellaichamy, Adaikkalam/GWN-0713-2022	Nesvizhskii, Alexey/0000-0002-2806-7819; Vellaichamy, Adaikkalam/0000-0002-1740-1252; Omenn, Gilbert S./0000-0002-8976-6074; Varambally, Sooryanarayana/0000-0002-2277-1127	NATIONAL CANCER INSTITUTE [R01CA126239, K99CA129565, U01CA111275, R01CA133458, P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U54DA021519] Funding Source: NIH RePORTER; NCI NIH HHS [K99 CA129565-02S1, R01CA126239, K99 CA129565-01A1, K99 CA129565, R01CA133458, U01 CA111275, R01 CA126239, K99 CA129565-02, R01 CA133458, 1K99CA129565-01A1, P50 CA069568, P50 CA69568] Funding Source: Medline; NIDA NIH HHS [U54DA021519, U54 DA021519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bodnar WM, 2003, J AM SOC MASS SPECTR, V14, P971, DOI 10.1016/S1044-0305(03)00209-5; DEHM SM, 2007, ANDROGEN RECEPTOR ST, P2855; DePrimo SE, 2002, GENOME BIOL, V3; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gobinet J, 2002, MOL CELL ENDOCRINOL, V198, P15, DOI 10.1016/S0303-7207(02)00364-7; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Lin BY, 2005, CANCER RES, V65, P3081, DOI 10.1158/0008-5472.CAN-04-3218; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Mallick P, 2007, NAT BIOTECHNOL, V25, P125, DOI 10.1038/nbt1275; Martin DB, 2004, CANCER RES, V64, P347, DOI 10.1158/0008-5472.CAN-03-2062; Meehan KL, 2004, PROTEOMICS, V4, P1116, DOI 10.1002/pmic.200300649; Nelson PS, 2000, ELECTROPHORESIS, V21, P1823; Nesvizhskii AI, 2005, MOL CELL PROTEOMICS, V4, P1419, DOI 10.1074/mcp.R500012-MCP200; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nesvizhskii AI, 2007, NAT METHODS, V4, P787, DOI 10.1038/NMETH1088; Ott LW, 2007, J PROTEOME RES, V6, P2176, DOI 10.1021/pr060665l; Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; TU LC, 2007, PROTEOMICS ANAL INTE, P575; Waghray A, 2001, PROTEOMICS, V1, P1327, DOI 10.1002/1615-9861(200110)1:10<1327::AID-PROT1327>3.3.CO;2-2; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wright ME, 2004, GENOME BIOL, V5; Wu WW, 2006, J PROTEOME RES, V5, P651, DOI 10.1021/pr050405o; YOCUM AK, 2008, MOL CELL PROTEOMICS; YOUNG CYF, 1991, CANCER RES, V51, P3748; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; ZYBAILOV B, 2006, STAT ANAL MEMBRANE E, P2339	35	41	43	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7075	10.1371/journal.pone.0007075	http://dx.doi.org/10.1371/journal.pone.0007075			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763266	gold, Green Submitted, Green Published			2022-12-27	WOS:000269970400011
J	Arnesano, F; Scintilla, S; Calo, V; Bonfrate, E; Ingrosso, C; Losacco, M; Pellegrino, T; Rizzarelli, E; Natile, G				Arnesano, Fabio; Scintilla, Simone; Calo, Vincenza; Bonfrate, Elena; Ingrosso, Chiara; Losacco, Maurizio; Pellegrino, Teresa; Rizzarelli, Enrico; Natile, Giovanni			Copper-Triggered Aggregation of Ubiquitin	PLOS ONE			English	Article								Neurodegenerative disorders share common features comprising aggregation of misfolded proteins, failure of the ubiquitin-proteasome system, and increased levels of metal ions in the brain. Protein aggregates within affected cells often contain ubiquitin, however no report has focused on the aggregation propensity of this protein. Recently it was shown that copper, differently from zinc, nickel, aluminum, or cadmium, compromises ubiquitin stability and binds to the N-terminus with 0.1 micromolar affinity. This paper addresses the role of copper upon ubiquitin aggregation. In water, incubation with Cu(II) leads to formation of spherical particles that can progress from dimers to larger conglomerates. These spherical oligomers are SDS-resistant and are destroyed upon Cu(II) chelation or reduction to Cu( I). In water/trifluoroethanol (80:20, v/v), a mimic of the local decrease in dielectric constant experienced in proximity to a membrane surface, ubiquitin incubation with Cu(II) causes time-dependent changes in circular dichroism and Fourier-transform infrared spectra, indicative of increasing beta-sheet content. Analysis by atomic force and transmission electron microscopy reveals, in the given order, formation of spherical particles consistent with the size of early oligomers detected by gel electrophoresis, clustering of these particles in straight and curved chains, formation of ring structures, growth of trigonal branches from the rings, coalescence of the trigonal branched structures in a network. Notably, none of these ubiquitin aggregates was positive to tests for amyloid and Cu( II) chelation or reduction produced aggregate disassembly. The early formed Cu(II)-stabilized spherical oligomers, when reconstituted in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes and in POPC planar bilayers, form annular and pore-like structures, respectively, which are common to several neurodegenerative disorders including Parkinson's, Alzheimer's, amyotrophic lateral sclerosis, and prion diseases, and have been proposed to be the primary toxic species. Susceptibility to aggregation of ubiquitin, as it emerges from the present study, may represent a potential risk factor for disease onset or progression while cells attempt to tag and process toxic substrates.			Arnesano, F (corresponding author), Univ Bari A Moro, Dipartimento Farmacochim, Bari, Italy.	arnesano@farmchim.uniba.it	Arnesano, Fabio/C-3066-2016; Pellegrino, teresa/G-6417-2010	Arnesano, Fabio/0000-0002-8399-0964; RIZZARELLI, ENRICO/0000-0001-5367-0823; Scintilla, Simone/0000-0002-8872-0920; Pellegrino, Teresa/0000-0001-5518-1134; Natile, Giovanni/0000-0002-1790-6365				Amici M, 2002, J BIOL INORG CHEM, V7, P750, DOI 10.1007/s00775-002-0352-4; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Barnham KJ, 2008, CURR OPIN CHEM BIOL, V12, P222, DOI 10.1016/j.cbpa.2008.02.019; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Binolfi A, 2006, J AM CHEM SOC, V128, P9893, DOI 10.1021/ja0618649; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Chwiej J, 2008, J TRACE ELEM MED BIO, V22, P183, DOI 10.1016/j.jtemb.2008.03.006; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cole NB, 2005, J BIOL CHEM, V280, P9678, DOI 10.1074/jbc.M409946200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; Donnelly PS, 2007, CURR OPIN CHEM BIOL, V11, P128, DOI 10.1016/j.cbpa.2007.01.678; Gaggelli E, 2006, CHEM REV, V106, P1995, DOI 10.1021/cr040410w; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Hawe A, 2008, PHARM RES-DORDR, V25, P1487, DOI 10.1007/s11095-007-9516-9; Herrera FE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003394; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hess S, 2007, EMBO REP, V8, P1196, DOI 10.1038/sj.embor.7401096; Ide-Ektessabi A, 2005, ANAL SCI, V21, P885, DOI 10.2116/analsci.21.885; Jackson SE, 2006, ORG BIOMOL CHEM, V4, P1845, DOI 10.1039/b600829c; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Lashuel H. A., 2005, SCI AGING KNOWLEDGE, V2005, pe28; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee JC, 2008, J AM CHEM SOC, V130, P6898, DOI 10.1021/ja711415b; Liang XY, 2007, CHEM SOC REV, V36, P968, DOI 10.1039/b617040b; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Lowe J, 2005, METHOD ENZYMOL, V399, P86, DOI 10.1016/S0076-6879(05)99007-1; Lowe R, 2004, PROTEIN SCI, V13, P3245, DOI 10.1110/ps.04879704; Maryon EB, 2007, BIOMETALS, V20, P355, DOI 10.1007/s10534-006-9066-3; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Milardi D, 2007, ANGEW CHEM INT EDIT, V46, P7993, DOI 10.1002/anie.200701987; Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Moriya M, 2008, AM J PHYSIOL-CELL PH, V295, pC708, DOI 10.1152/ajpcell.00029.2008; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; Pellistri F, 2008, J BIOL CHEM, V283, P29950, DOI 10.1074/jbc.M803992200; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; Rees EM, 2007, J BIOL CHEM, V282, P21629, DOI 10.1074/jbc.M703397200; Ren PH, 2009, NAT CELL BIOL, V11, P219, DOI 10.1038/ncb1830; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Ryu KY, 2008, P NATL ACAD SCI USA, V105, P4016, DOI 10.1073/pnas.0800096105; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Sixt SU, 2008, BBA-MOL BASIS DIS, V1782, P817, DOI 10.1016/j.bbadis.2008.06.005; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Tan JMM, 2008, HUM MOL GENET, V17, P431, DOI 10.1093/hmg/ddm320; Trovato A, 2006, PLOS COMPUT BIOL, V2, P1608, DOI 10.1371/journal.pcbi.0020170; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wakabayashi K, 2007, NEUROPATHOLOGY, V27, P494, DOI 10.1111/j.1440-1789.2007.00803.x; Wand AJ, 1996, BIOCHEMISTRY-US, V35, P6116, DOI 10.1021/bi9530144; WANG AC, 1995, J BIOMOL NMR, V5, P376; Wright JA, 2008, J NEUROSCI RES, V86, P496, DOI 10.1002/jnr.21461; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Yamaguchi K, 2006, J MOL BIOL, V363, P279, DOI 10.1016/j.jmb.2006.08.030; Yang LC, 2005, P NATL ACAD SCI USA, V102, P11179, DOI 10.1073/pnas.0406547102; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904	70	38	40	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7052	10.1371/journal.pone.0007052	http://dx.doi.org/10.1371/journal.pone.0007052			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756145	Green Submitted, gold, Green Published			2022-12-27	WOS:000269970000018
J	Worth, CL; Kleinau, G; Krause, G				Worth, Catherine L.; Kleinau, Gunnar; Krause, Gerd			Comparative Sequence and Structural Analyses of G-Protein-Coupled Receptor Crystal Structures and Implications for Molecular Models	PLOS ONE			English	Article							3RD EXTRACELLULAR LOOP; CONFORMATIONAL-CHANGES; THYROTROPIN RECEPTOR; HORMONE RECEPTOR; LIGAND-BINDING; RHODOPSIN; MUTATIONS; GENE; IDENTIFICATION; ACTIVATION	Background: Up until recently the only available experimental (high resolution) structure of a G-protein-coupled receptor (GPCR) was that of bovine rhodopsin. In the past few years the determination of GPCR structures has accelerated with three new receptors, as well as squid rhodopsin, being successfully crystallized. All share a common molecular architecture of seven transmembrane helices and can therefore serve as templates for building molecular models of homologous GPCRs. However, despite the common general architecture of these structures key differences do exist between them. The choice of which experimental GPCR structure(s) to use for building a comparative model of a particular GPCR is unclear and without detailed structural and sequence analyses, could be arbitrary. The aim of this study is therefore to perform a systematic and detailed analysis of sequence-structure relationships of known GPCR structures. Methodology: We analyzed in detail conserved and unique sequence motifs and structural features in experimentally-determined GPCR structures. Deeper insight into specific and important structural features of GPCRs as well as valuable information for template selection has been gained. Using key features a workflow has been formulated for identifying the most appropriate template(s) for building homology models of GPCRs of unknown structure. This workflow was applied to a set of 14 human family A GPCRs suggesting for each the most appropriate template(s) for building a comparative molecular model. Conclusions: The available crystal structures represent only a subset of all possible structural variation in family A GPCRs. Some GPCRs have structural features that are distributed over different crystal structures or which are not present in the templates suggesting that homology models should be built using multiple templates. This study provides a systematic analysis of GPCR crystal structures and a consistent method for identifying suitable templates for GPCR homology modelling that will help to produce more reliable three-dimensional models.			Worth, CL (corresponding author), Leibniz Inst Mol Pharmakol FMP, Berlin, Germany.	gkrause@fmp-berlin.de	Niv, Masha Y/E-3148-2010; Kleinau, Gunnar/GPX-6330-2022	Worth, Catherine/0000-0002-1796-9606				Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Ahuja S, 2009, NAT STRUCT MOL BIOL, V16, P168, DOI 10.1038/nsmb.1549; ANGEL TE, 2009, P NATL ACAD SCI US; Attrill H, 2009, PROTEIN EXPRES PURIF, V64, P32, DOI 10.1016/j.pep.2008.10.001; Bairoch A, 2008, NUCLEIC ACIDS RES, V36, pD190, DOI 10.1093/nar/gkm895; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BELLOT G, 2009, J MOL BIOL; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhattacharya S, 2008, J MOL BIOL, V382, P539, DOI 10.1016/j.jmb.2008.06.084; Ceruso MA, 2002, J MOL BIOL, V318, P1237, DOI 10.1016/S0022-2836(02)00221-8; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Dean B, 2002, MOL PSYCHIATR, V7, P1083, DOI 10.1038/sj.mp.4001199; Deflorian F, 2008, PROTEINS, V71, P783, DOI 10.1002/prot.21763; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEVILLE J, 2009, J MOL EVOL; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Dror RO, 2009, P NATL ACAD SCI USA, V106, P4689, DOI 10.1073/pnas.0811065106; Fernandez-Fuentes N, 2006, NUCLEIC ACIDS RES, V34, P2085, DOI 10.1093/nar/gkl156; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; FUCHS S, 1994, HUM MOL GENET, V3, P1203, DOI 10.1093/hmg/3.7.1203; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Glatt SJ, 2006, AM J MED GENET B, V141B, P149, DOI 10.1002/ajmg.b.30273; Hanson MA, 2009, STRUCTURE, V17, P8, DOI 10.1016/j.str.2008.12.003; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; Hetherington SL, 2005, ARTERIOSCL THROM VAS, V25, P252, DOI 10.1161/01.ATV.0000148708.44691.27; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Horn F, 2003, NUCLEIC ACIDS RES, V31, P294, DOI 10.1093/nar/gkg103; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; Kleinau G, 2008, CELL MOL LIFE SCI, V65, P3664, DOI 10.1007/s00018-008-8450-2; Kleinau G, 2007, MOL ENDOCRINOL, V21, P574, DOI 10.1210/me.2006-0309; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; Kneissl B, 2009, J MED CHEM, V52, P3166, DOI 10.1021/jm8014487; Krause G, 2000, MOL PHARMACOL, V57, P232; Lattig J, 2009, J PEPT SCI, V15, P479, DOI 10.1002/psc.1146; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; Lubrano-Berthelier C, 2006, J CLIN ENDOCR METAB, V91, P1811, DOI 10.1210/jc.2005-1411; MCLACHLAN A, 2009, ACTA CRYSTALLOGR A, V38, P871; Mehler EL, 2002, J COMPUT AID MOL DES, V16, P841, DOI 10.1023/A:1023845015343; Meyer-Lindenberg A., 2008, MOL PSYCHIAT; Michalsky E, 2003, PROTEIN ENG, V16, P979, DOI 10.1093/protein/gzg119; MICHINO M, 2009, NAT REV DRUG DISCOV; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Murakami M, 2008, NATURE, V453, P363, DOI 10.1038/nature06925; NEUMANN S, 2009, P NATL ACAD SCI US; Nijenhuis WAJ, 2003, J BIOL CHEM, V278, P22939, DOI 10.1074/jbc.M211326200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Oliveira L, 2004, FEBS LETT, V564, P269, DOI 10.1016/S0014-5793(04)00320-5; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pardo L, 2007, CHEMBIOCHEM, V8, P19, DOI 10.1002/cbic.200600429; Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Ren H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004509; ROBINSON GC, 1993, AM J DIS CHILD, V147, P325, DOI 10.1001/archpedi.1993.02160270087028; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; RUSSO D, 1995, ONCOGENE, V11, P1907; Russo P, 2007, J CLIN ENDOCR METAB, V92, P2382, DOI 10.1210/jc.2006-2523; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; SCHEERER P, 2009, P NATL ACAD SCI US; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Shimamura T, 2008, J BIOL CHEM, V283, P17753, DOI 10.1074/jbc.C800040200; Smits G, 2003, NEW ENGL J MED, V349, P760, DOI 10.1056/NEJMoa030064; Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917; Standfuss J, 2007, J MOL BIOL, V372, P1179, DOI 10.1016/j.jmb.2007.03.007; Tarnow P, 2003, J BIOL CHEM, V278, P48666, DOI 10.1074/jbc.M309941200; Tarnow P, 2008, OBESITY FACTS, V1, P155, DOI 10.1159/000138251; Tunaru S, 2005, MOL PHARMACOL, V68, P1271, DOI 10.1124/mol.105.015750; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Van Durme J, 2006, MOL ENDOCRINOL, V20, P2247, DOI 10.1210/me.2006-0020; Vasseur C, 2003, NEW ENGL J MED, V349, P753, DOI 10.1056/NEJMoa030065; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954, DOI 10.1124/mol.58.5.954; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yohannan S, 2004, P NATL ACAD SCI USA, V101, P959, DOI 10.1073/pnas.0306077101	85	67	68	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7011	10.1371/journal.pone.0007011	http://dx.doi.org/10.1371/journal.pone.0007011			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756152	Green Published, gold, Green Accepted, Green Submitted			2022-12-27	WOS:000269970000009
J	Bohbot, JD; Dickens, JC				Bohbot, Jonathan D.; Dickens, Joseph C.			Characterization of an Enantioselective Odorant Receptor in the Yellow Fever Mosquito Aedes aegypti	PLOS ONE			English	Article								Enantiomers differ only in the left or right handedness (chirality) of their orientations and exhibit identical chemical and physical properties. In chemical communication systems, enantiomers can be differentially active at the physiological and behavioral levels. Only recently were enantioselective odorant receptors demonstrated in mammals while their existence in insects has remained hypothetical. Using the two-microelectrode voltage clamp of Xenopus oocytes, we show that the yellow fever mosquito, Aedes aegypti, odorant receptor 8 (AaOR8) acts as a chiral selective receptor for the (R)-(-)-enantiomer of 1-octen-3-ol, which in the presence of other kairomones is an attractant used by blood-sucking insects to locate their hosts. In addition to steric constraints, chain length and degree of unsaturation play important roles in this recognition process. This is the first characterization of an enantioselective odorant receptor in insects and the results demonstrate that an OR alone, without helper proteins, can account for chiral specificity exhibited by olfactory sensory neurons (OSNs).			Bohbot, JD (corresponding author), ARS, USDA,Invas Insect Biocontrol & Behav Lab, Henry A Wallace Beltsville Agr Res Ctr, Inst Plant Sci, Beltsville, MD USA.	joseph.dickens@ars.usda.gov	Dickens, Dick/AGY-7295-2022					Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; Benton R, 2009, CELL, V136, P149, DOI 10.1016/j.cell.2008.12.001; BIERL BA, 1970, SCIENCE, V170, P87, DOI 10.1126/science.170.3953.87; Blackwell A, 1996, PHYSIOL ENTOMOL, V21, P15, DOI 10.1111/j.1365-3032.1996.tb00830.x; Bohbot J, 2007, INSECT MOL BIOL, V16, P525, DOI 10.1111/j.1365-2583.2007.00748.x; Cork A, 1996, MED VET ENTOMOL, V10, P269, DOI 10.1111/j.1365-2915.1996.tb00742.x; DICKENS JC, 1990, CHEM SENSES, V15, P311, DOI 10.1093/chemse/15.3.311; DICKENS JC, 1978, ENTOMOL EXP APPL, V24, P336, DOI 10.1007/BF02385082; GILLIES MT, 1980, B ENTOMOL RES, V70, P525, DOI 10.1017/S0007485300007811; Gong Y, 2009, CHEM BIOL, V16, P162, DOI 10.1016/j.chembiol.2009.01.005; GRANT AJ, 1995, J COMP PHYSIOL A, V177, P389, DOI 10.1007/BF00187475; Greenwood DR, 2005, NATURE, V438, P1097, DOI 10.1038/4381097a; Grosse-Wilde E, 2007, EUR J NEUROSCI, V25, P2364, DOI 10.1111/j.1460-9568.2007.05512.x; HALL DR, 1984, INSECT SCI APPL, V5, P335, DOI 10.1017/S1742758400008626; Hallem EA, 2006, CELL, V125, P143, DOI 10.1016/j.cell.2006.01.050; Hallem EA, 2004, CELL, V117, P965, DOI 10.1016/j.cell.2004.05.012; Hallem EA, 2004, NATURE, V427, P212, DOI 10.1038/427212a; HANSEN K, 1984, PHYSIOL ENTOMOL, V9, P9, DOI 10.1111/j.1365-3032.1984.tb00676.x; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; IWAKI S, 1974, J AM CHEM SOC, V96, P7842, DOI 10.1021/ja00832a055; Jones WD, 2005, CURR BIOL, V15, pR119, DOI 10.1016/j.cub.2005.02.007; Kline DL, 2007, MED VET ENTOMOL, V21, P323, DOI 10.1111/j.1365-2915.2007.00697.x; KNUDSEN JT, 1993, PHYTOCHEMISTRY, V33, P253, DOI 10.1016/0031-9422(93)85502-I; Krieger J, 2004, P NATL ACAD SCI USA, V101, P11845, DOI 10.1073/pnas.0403052101; Krzywinski J, 2001, SYST BIOL, V50, P540, DOI 10.1080/106351501750435095; Lartigue A, 2003, J BIOL CHEM, V278, P30213, DOI 10.1074/jbc.M304688200; Laska M, 2007, NEUROSCIENCE, V144, P295, DOI 10.1016/j.neuroscience.2006.08.063; Laska M, 1999, AM J PHYSIOL-REG I, V277, pR1098, DOI 10.1152/ajpregu.1999.277.4.R1098; Laska M, 2001, BEHAV NEUROSCI, V115, P632, DOI 10.1037/0735-7044.115.3.632; Laughlin JD, 2008, CELL, V133, P1255, DOI 10.1016/j.cell.2008.04.046; Leal WS, 1996, P NATL ACAD SCI USA, V93, P12112, DOI 10.1073/pnas.93.22.12112; Liberles SD, 2006, NATURE, V442, P645, DOI 10.1038/nature05066; Lu T, 2007, CURR BIOL, V17, P1533, DOI 10.1016/j.cub.2007.07.062; Melo ACA, 2004, CHEM SENSES, V29, P403, DOI 10.1093/chemse/bjh041; Mori K, 1998, CHIRALITY, V10, P578, DOI 10.1002/(SICI)1520-636X(1998)10:7<578::AID-CHIR5>3.0.CO;2-Z; Nakagawa T, 2005, SCIENCE, V307, P1638, DOI 10.1126/science.1106267; Neuhaus EM, 2005, NAT NEUROSCI, V8, P15, DOI 10.1038/nn1371; PIERCE AM, 1989, ENVIRON ENTOMOL, V18, P747, DOI 10.1093/ee/18.5.747; Pitts RJ, 2004, P NATL ACAD SCI USA, V101, P5058, DOI 10.1073/pnas.0308146101; Plettner E, 2000, BIOCHEMISTRY-US, V39, P8953, DOI 10.1021/bi000461x; Pophof B, 2004, CHEM SENSES, V29, P117, DOI 10.1093/chemse/bjh012; Reisenman CE, 2004, J NEUROSCI, V24, P2602, DOI 10.1523/JNEUROSCI.5192-03.2004; Robertson HM, 2006, GENOME RES, V16, P1395, DOI 10.1101/gr.5057506; Saito H, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000016; Sato K, 2008, NATURE, V452, P1002, DOI 10.1038/nature06850; SUMIKAWA K, 1981, NATURE, V292, P862, DOI 10.1038/292862a0; Syed Z, 2007, CHEM SENSES, V32, P727, DOI 10.1093/chemse/bjm040; Syed Z, 2006, P NATL ACAD SCI USA, V103, P16538, DOI 10.1073/pnas.0607874103; Tanaka K, 2009, CURR BIOL, V19, P881, DOI 10.1016/j.cub.2009.04.035; TUMLINSON JH, 1977, SCIENCE, V197, P789, DOI 10.1126/science.197.4305.789; Turin L, 1996, CHEM SENSES, V21, P773, DOI 10.1093/chemse/21.6.773; VOGT RG, 1989, J NEUROSCI, V9, P3332; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Wanner KW, 2007, P NATL ACAD SCI USA, V104, P14383, DOI 10.1073/pnas.0705459104; Wicher D, 2008, NATURE, V452, P1007, DOI 10.1038/nature06861; Wojtasek H, 1998, BIOCHEM BIOPH RES CO, V250, P217, DOI 10.1006/bbrc.1998.9278; Xia YF, 2006, INSECT BIOCHEM MOLEC, V36, P169, DOI 10.1016/j.ibmb.2005.12.003; Zhang QH, 2004, J CHEM ECOL, V30, P1849, DOI 10.1023/B:JOEC.0000042406.76705.ab	58	73	74	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7032	10.1371/journal.pone.0007032	http://dx.doi.org/10.1371/journal.pone.0007032			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753115	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796500016
J	Collins, PW; Latta, BC; Roemer, GW				Collins, Paul W.; Latta, Brian C.; Roemer, Gary W.			Does the Order of Invasive Species Removal Matter? The Case of the Eagle and the Pig	PLOS ONE			English	Article							SANTA-CRUZ ISLAND; GOLDEN EAGLES; FERAL PIGS; AQUILA-CHRYSAETOS; ERADICATION; PREDATORS; PREY	Background: Invasive species are recognized as a primary driver of native species endangerment and their removal is often a key component of a conservation strategy. Removing invasive species is not always a straightforward task, however, especially when they interact with other species in complex ways to negatively influence native species. Because unintended consequences may arise if all invasive species cannot be removed simultaneously, the order of their removal is of paramount importance to ecological restoration. In the mid-1990s, three subspecies of the island fox Urocyon littoralis were driven to near extinction on the northern California Channel Islands owing to heightened predation by golden eagles Aquila chrysaetos. Eagles were lured to the islands by an abundant supply of feral pigs Sus scrofa and through the process of apparent competition pigs indirectly facilitated the decline in foxes. As a consequence, both pigs and eagles had to be removed to recover the critically endangered fox. Complete removal of pigs was problematic: removing pigs first could force eagles to concentrate on the remaining foxes, increasing their probability of extinction. Removing eagles first was difficult: eagles are not easily captured and lethal removal was politically distasteful. Methodology/Principal Findings: Using prey remains collected from eagle nests both before and after the eradication of pigs, we show that one pair of eagles that eluded capture did indeed focus more on foxes. These results support the premise that if the threat of eagle predation had not been mitigated prior to pig removal, fox extinction would have been a more likely outcome. Conslusions/Significance: If complete eradication of all interacting invasive species is not possible, the order in which they are removed requires careful consideration. If overlooked, unexpected consequences may result that could impede restoration.			Collins, PW (corresponding author), Santa Barbara Museum Nat Hist, Santa Barbara, CA USA.	groemer@nmsu.edu						Angulo E, 2007, CONSERV BIOL, V21, P1082, DOI 10.1111/j.1523-1739.2007.00721.x; [Anonymous], CALIFORNIA ISLANDS; [Anonymous], CHANNEL ISLANDS GOLD; Bergstrom DM, 2009, J APPL ECOL, V46, P73, DOI 10.1111/j.1365-2664.2008.01601.x; Clouet M, 1999, J RAPTOR RES, V33, P102; COLLINS PW, 2005, P 6 CAL ISL S I WILD, P103; COLLINS PW, P 7 CAL ISL IN PRESS; COONAN TJ, 2009, ISLAND FOX RECOVERY; COONAN TJ, 2008, ISLAND FOX RECOVERY, P2007; Courchamp F, 2003, SCIENCE, V302, P1532, DOI 10.1126/science.1089492; Cruz F, 2009, J WILDLIFE MANAGE, V73, P191, DOI 10.2193/2007-551; Dixon J. B., 1937, Condor Berkeley, V39, P49, DOI 10.2307/1363773; Dratch P, 2004, SCIENCE, V305, P777, DOI 10.1126/science.305.5685.777; HUEY LAURENCE M., 1962, AUK, V79, P485; Imber M, 2000, NEW ZEAL J ECOL, V24, P153; Marzluff JM, 1997, AUK, V114, P673, DOI 10.2307/4089287; McGrady MJ, 2002, J RAPTOR RES, V36, P62; Morrison SA, 2007, FRONT ECOL ENVIRON, V5, P271, DOI 10.1890/1540-9295(2007)5[271:FTDAEE]2.0.CO;2; Nogales M, 2004, CONSERV BIOL, V18, P310, DOI 10.1111/j.1523-1739.2004.00442.x; Ramsey DSL, 2009, CONSERV BIOL, V23, P449, DOI 10.1111/j.1523-1739.2008.01119.x; Rayner MJ, 2007, P NATL ACAD SCI USA, V104, P20862, DOI 10.1073/pnas.0707414105; Roemer GW, 2004, SCIENCE, V305, P778; Roemer GW, 2002, P NATL ACAD SCI USA, V99, P791, DOI 10.1073/pnas.012422499; Roemer GW, 2001, ANIM CONSERV, V4, P307, DOI 10.1017/S1367943001001366; STALMASTER M.V., 1987, BALD EAGLE; STEENHOF K, 1988, J ANIM ECOL, V57, P37, DOI 10.2307/4761; Swarts HM, 2009, ANIM CONSERV, V12, P120, DOI 10.1111/j.1469-1795.2008.00229.x; TAYLOR R H, 1979, New Zealand Journal of Ecology, V2, P42; VEITCH CR, 2002, P INT C ER ISL INV A; WANLESS RM, 2007, BIOL LETT, DOI DOI 10.1098/NBL.2007.0120; WATSON J, 1997, GOLDEN EAGLE; Zavaleta ES, 2001, TRENDS ECOL EVOL, V16, P454, DOI 10.1016/S0169-5347(01)02194-2	32	18	19	1	66	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7005	10.1371/journal.pone.0007005	http://dx.doi.org/10.1371/journal.pone.0007005			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759894	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796300015
J	Shenoy, A; Blelloch, R				Shenoy, Archana; Blelloch, Robert			Genomic Analysis Suggests that mRNA Destabilization by the Microprocessor Is Specialized for the Auto-Regulation of Dgcr8	PLOS ONE			English	Article							MICRORNA; EXPRESSION; DICER; DROSHA; COMPLEX; BIOGENESIS; SIRNAS; TRBP	Background: The Microprocessor, containing the RNA binding protein Dgcr8 and RNase III enzyme Drosha, is responsible for processing primary microRNAs to precursor microRNAs. The Microprocessor regulates its own levels by cleaving hairpins in the 5'UTR and coding region of the Dgcr8 mRNA, thereby destabilizing the mature transcript. Methodology/Principal Findings: To determine whether the Microprocessor has a broader role in directly regulating other coding mRNA levels, we integrated results from expression profiling and ultra high-throughput deep sequencing of small RNAs. Expression analysis of mRNAs in wild-type, Dgcr8 knockout, and Dicer knockout mouse embryonic stem (ES) cells uncovered mRNAs that were specifically upregulated in the Dgcr8 null background. A number of these transcripts had evolutionarily conserved predicted hairpin targets for the Microprocessor. However, analysis of deep sequencing data of 18 to 200nt small RNAs in mouse ES, HeLa, and HepG2 indicates that exonic sequence reads that map in a pattern consistent with Microprocessor activity are unique to Dgcr8. Conclusion/Significance: We conclude that the Microprocessor's role in directly destabilizing coding mRNAs is likely specifically targeted to Dgcr8 itself, suggesting a specialized cellular mechanism for gene auto-regulation.			Shenoy, A (corresponding author), Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Ctr Reprod Sci, San Francisco, CA 94143 USA.	BlellochR@stemcell.ucsf.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS048118, R01NS057221] Funding Source: NIH RePORTER; NINDS NIH HHS [K08 NS048118-02, R01 NS057221, K08 NS048118, K08 NS048118-04, R01 NS057221-03, R01 NS057221-01A1, K08 NS048118-03, K08 NS048118-05, R01 NS057221-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Fejes-Toth K, 2009, NATURE, V457, P1028, DOI 10.1038/nature07759; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Han J, 2009, CELL, V136, P75, DOI 10.1016/j.cell.2008.10.053; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; KADENER S, 2009, GENOME WIDE IDENTIFI; Karolchik D, 2008, NUCLEIC ACIDS RES, V36, pD773, DOI 10.1093/nar/gkm966; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Maselli V, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-457; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Pedersen JS, 2006, PLOS COMPUT BIOL, V2, P251, DOI 10.1371/journal.pcbi.0020033; Rebbapragada I, 2009, CURR OPIN CELL BIOL, V21, P394, DOI 10.1016/j.ceb.2009.02.007; Ruby JG, 2007, GENOME RES, V17, P1850, DOI 10.1101/gr.6597907; Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904; TRABUCCHI M, 2009, NATURE; Triboulet R, 2009, RNA, V15, P1005, DOI 10.1261/rna.1591709; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908	32	42	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6971	10.1371/journal.pone.0006971	http://dx.doi.org/10.1371/journal.pone.0006971			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759829	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696600011
J	Cannas, A; Kalunga, G; Green, C; Calvo, L; Katemangwe, P; Reither, K; Perkins, MD; Maboko, L; Hoelscher, M; Talbot, EA; Mwaba, P; Zumla, AI; Girardi, E; Huggett, JF				Cannas, Angela; Kalunga, Glendah; Green, Clare; Calvo, Ludovica; Katemangwe, Patrick; Reither, Klaus; Perkins, Mark D.; Maboko, Leonard; Hoelscher, Michael; Talbot, Elizabeth A.; Mwaba, Peter; Zumla, Alimuddin I.; Girardi, Enrico; Huggett, Jim F.		TB TrDNA Consortium	Implications of Storing Urinary DNA from Different Populations for Molecular Analyses	PLOS ONE			English	Article								Background: Molecular diagnosis using urine is established for many sexually transmitted diseases and is increasingly used to diagnose tumours and other infectious diseases. Storage of urine prior to analysis, whether due to home collection or bio-banking, is increasingly advocated yet no best practice has emerged. Here, we examined the stability of DNA in stored urine in two populations over 28 days. Methodology: Urine from 40 (20 male) healthy volunteers from two populations, Italy and Zambia, was stored at four different temperatures (RT, 4 degrees C, -20 degrees C & -80 degrees C) with and without EDTA preservative solution. Urines were extracted at days 0, 1, 3, 7 and 28 after storage. Human DNA content was measured using multi-copy (ALU J) and single copy (TLR2) targets by quantitative real-time PCR. Zambian and Italian samples contained comparable DNA quantity at time zero. Generally, two trends were observed during storage; no degradation, or rapid degradation from days 0 to 7 followed by little further degradation to 28 days. The biphasic degradation was always observed in Zambia regardless of storage conditions, but only twice in Italy. Conclusion: Site-specific differences in urine composition significantly affect the stability of DNA during storage. Assessing the quality of stored urine for molecular analysis, by using the type of strategy described here, is paramount before these samples are used for molecular prognostic monitoring, genetic analyses and disease diagnosis.			Cannas, A (corresponding author), IRCCS, Natl Inst Infect Dis L Spallanzani, Rome, Italy.	clare.green@ucl.ac.uk	Mwaba, Peter/V-6017-2019; Hoelscher, Michael/D-3436-2012; ZUMLA, Alimuddin/ABA-8208-2020; Huggett, Jim/N-9316-2013	ZUMLA, Alimuddin/0000-0002-5111-5735; Girardi, Enrico/0000-0001-8182-5896; Reither, Klaus/0000-0001-6195-8237; Huggett, Jim/0000-0002-0945-1911	Medical Research Council [G0601466] Funding Source: Medline; MRC [G0601466] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aceti A, 1999, THORAX, V54, P145, DOI 10.1136/thx.54.2.145; Bryzgunova OE, 2006, ANN NY ACAD SCI, V1075, P334, DOI 10.1196/annals.1368.045; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cairns P, 2004, ANN NY ACAD SCI, V1022, P40, DOI 10.1196/annals.1318.007; Cannas A, 2008, INT J TUBERC LUNG D, V12, P146; Chapin Kimberle C, 2006, Med Health R I, V89, P202; Elliott P, 2008, INT J EPIDEMIOL, V37, P234, DOI 10.1093/ije/dym276; Fisa R, 2008, AM J TROP MED HYG, V78, P741, DOI 10.4269/ajtmh.2008.78.741; GARRINGER LA, 2002, GEN M AM SOC MICR, V102, P129; GOPINATH K, 2008, INT J INFECT DIS; Green C, 2009, LANCET INFECT DIS, V9, P505, DOI 10.1016/S1473-3099(09)70149-5; Gu ZL, 2000, GENE, V259, P81, DOI 10.1016/S0378-1119(00)00434-0; Huggett J. F., 2008, BMC RES NOTES, V1; Ingersoll J, 2008, J CLIN MICROBIOL, V46, P1628, DOI 10.1128/JCM.02486-07; JOHNSON DJ, 2004, VARIATION NUCL DNA C, P110; Kafwabulula M, 2002, INT J TUBERC LUNG D, V6, P732; Kanavarioti A, 2001, ASTROBIOLOGY, V1, P271, DOI 10.1089/15311070152757465; MCMILLIAN RA, 2004, GEN M AM SOC MICR, V104, P173; Mehta TK, 2006, TRANSPL P, V38, P3420, DOI 10.1016/j.transproceed.2006.10.149; Mharakurwa S, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-103; Milde A, 1999, INT J LEGAL MED, V112, P209, DOI 10.1007/s004140050237; Morre SA, 1999, J CLIN MICROBIOL, V37, P976; Murdoch DR, 1996, CLIN INFECT DIS, V23, P475, DOI 10.1093/clinids/23.3.475; Nolan T, 2006, ANAL BIOCHEM, V351, P308, DOI 10.1016/j.ab.2006.01.051; Peakman TC, 2008, INT J EPIDEMIOL, V37, P2, DOI 10.1093/ije/dyn019; PRINZ M, 1993, INT J LEGAL MED, V106, P75, DOI 10.1007/BF01225044; Rebollo MJ, 2006, DIAGN MICR INFEC DIS, V56, P141, DOI 10.1016/j.diagmicrobio.2006.03.018; Sechi LA, 1997, MOL CELL PROBE, V11, P281, DOI 10.1006/mcpr.1997.0119; Swartz B., 2007, Abstracts of the General Meeting of the American Society for Microbiology, V107, P217; Torrea G, 2005, J MED MICROBIOL, V54, P39, DOI 10.1099/jmm.0.45688-0; van der Hel OL, 2002, ANAL BIOCHEM, V304, P206, DOI 10.1006/abio.2002.5634; Vu NT, 1999, FORENSIC SCI INT, V102, P23, DOI 10.1016/S0379-0738(99)00034-1	32	38	46	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6985	10.1371/journal.pone.0006985	http://dx.doi.org/10.1371/journal.pone.0006985			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746164	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696500005
J	Sorby, R; Austbo, L; Press, CM; Skretting, G; Landsverk, T; Espenes, A				Sorby, Randi; Austbo, Lars; Press, Charles McL.; Skretting, Grethe; Landsverk, Thor; Espenes, Arild			PrP Expression, PrPSc Accumulation and Innervation of Splenic Compartments in Sheep Experimentally Infected with Scrapie	PLOS ONE			English	Article								Background: In prion disease, the peripheral expression of PrPC is necessary for the transfer of infectivity to the central nervous system. The spleen is involved in neuroinvasion and neural dissemination in prion diseases but the nature of this involvement is not known. The present study undertook the investigation of the spatial relationship between sites of PrPSc accumulation, localisation of nerve fibres and PrPC expression in the tissue compartments of the spleen of scrapie-inoculated and control sheep. Methodology/Principal Findings: Laser microdissection and quantitative PCR were used to determine PrP mRNA levels and results were compared with immunohistochemical protocols to distinguish PrPC and PrPSc in tissue compartments of the spleen. In sheep experimentally infected with scrapie, the major sites of accumulation of PrPSc in the spleen, namely the lymphoid nodules and the marginal zone, expressed low levels of PrP mRNA. Double immunohistochemical labelling for PrPSc and the pan-nerve fibre marker, PGP, was used to evaluate the density of innervation of splenic tissue compartments and the intimacy of association between PrPSc and nerves. Some nerve fibres were observed to accompany blood vessels into the PrPSc-laden germinal centres. However, the close association between nerves and PrPSc was most apparent in the marginal zone. Other sites of close association were adjacent to the wall of the central artery of PALS and the outer rim of germinal centres. Conclusions/Significance: The findings suggest that the degree of PrPSc accumulation does not depend on the expression level of PrPC. Though several splenic compartments may contribute to neuroinvasion, the marginal zone may play a central role in being the compartment with most apparent association between nerves and PrPSc.			Sorby, R (corresponding author), Norwegian Sch Vet Sci, Dept Basic Sci & Aquat Med, Oslo, Norway.	randi.sorby@veths.no						Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Aucouturier P, 2001, J CLIN INVEST, V108, P703, DOI 10.1172/JCI200113155; Austbo L, 2007, J GEN VIROL, V88, P2083, DOI 10.1099/vir.0.82791-0; Austbo L, 2006, J GEN VIROL, V87, P3463, DOI 10.1099/vir.0.82008-0; Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; Bruce ME, 2000, IMMUNOL TODAY, V21, P442, DOI 10.1016/S0167-5699(00)01696-0; Crozet C, 2007, J INFECT DIS, V195, P997, DOI 10.1086/512085; Ersdal C, 2005, VET PATHOL, V42, P258, DOI 10.1354/vp.42-3-258; FELTEN D L, 1988, Brain Behavior and Immunity, V2, P293, DOI 10.1016/0889-1591(88)90031-1; FELTEN DL, 1987, J NEUROSCI RES, V18, P28, DOI 10.1002/jnr.490180107; FELTEN DL, 1985, J IMMUNOL, V135, pS755; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Follet J, 2002, J VIROL, V76, P2434, DOI 10.1128/JVI.76.5.2434-2439.2002; Glatzel M, 2000, J GEN VIROL, V81, P2813, DOI 10.1099/0022-1317-81-11-2813; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; Heggebo R, 2003, J COMP PATHOL, V128, P172, DOI 10.1053/jcpa.2002.0625; Heggebo R, 2002, J GEN VIROL, V83, P479, DOI 10.1099/0022-1317-83-2-479; KIMBERLIN RH, 1982, J ROY SOC MED, V75, P618; KIMBERLIN RH, 1989, VIRUS RES, V12, P213, DOI 10.1016/0168-1702(89)90040-3; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; Kubosaki A, 2000, BIOCHEM BIOPH RES CO, V273, P890, DOI 10.1006/bbrc.2000.3035; LORTON D, 1991, BRAIN BEHAV IMMUN, V5, P29, DOI 10.1016/0889-1591(91)90005-U; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; McGovern G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001304; McLennan NF, 2001, NEUROPATH APPL NEURO, V27, P373, DOI 10.1046/j.0305-1846.2001.00343.x; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Raymond CR, 2007, J NEUROIMMUNOL, V187, P114, DOI 10.1016/j.jneuroim.2007.05.006; REYNOLDS JD, 1985, ADV EXP MED BIOL, V186, P111	33	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6885	10.1371/journal.pone.0006885	http://dx.doi.org/10.1371/journal.pone.0006885			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727393	Green Submitted, Green Published, gold			2022-12-27	WOS:000269522900014
J	Nishide, K; Nakatani, Y; Kiyonari, H; Kondo, T				Nishide, Kenji; Nakatani, Yuka; Kiyonari, Hiroshi; Kondo, Toru			Glioblastoma Formation from Cell Population Depleted of Prominin1-Expressing Cells	PLOS ONE			English	Article							CANCER STEM-CELLS; DIPHTHERIA-TOXIN FRAGMENT; CD133 EXPRESSION; MARKER; CRE; IDENTIFICATION; MOLECULE; SHOW	Prominin1 (Prom1, also known as CD133 in human) has been widely used as a marker for cancer stem cells (CSCs), which self-renew and are tumorigenic, in malignant tumors including glioblastoma multiforme (GBM). However, there is other evidence showing that Prom1-negative cancer cells also form tumors in vivo. Thus it remains controversial whether Prom1 is a bona fide marker for CSCs. To verify if Prom1-expressing cells are essential for tumorigenesis, we established a mouse line, whose Prom1-expressing cells can be eliminated conditionally by a Cre-inducible DTA gene on the Prom1 locus together with a tamoxifen-inducible CreER (TM), and generated glioma-initiating cells (GICs-LD) by overexpressing both the SV40 Large T antigen and an oncogenic H-Ras(L61) in neural stem cells of the mouse line. We show here that the tamoxifen-treated GICs-LD (GICs-DTA) form tumor-spheres in culture and transplantable GBM in vivo. Thus, our studies demonstrate that Prom1-expressing cells are dispensable for gliomagenesis in this mouse model.			Nishide, K (corresponding author), RIKEN, Ctr Dev Biol, Lab Cell Lineage Modulat, Kobe, Hyogo, Japan.	tkondo@cdb.riken.jp	Kiyonari, Hiroshi/N-7936-2015; Kondo, Toru/F-9420-2012					Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Corbeil D, 2009, GLIA, V57, P860, DOI 10.1002/glia.20812; Coskun V, 2008, P NATL ACAD SCI USA, V105, P1026, DOI 10.1073/pnas.0710000105; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Florek M, 2005, CELL TISSUE RES, V319, P15, DOI 10.1007/s00441-004-1018-z; Griguer CE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003655; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Ivanova A, 2005, GENESIS, V43, P129, DOI 10.1002/gene.20162; Jeuken J, 2007, ACTA NEUROPATHOL, V114, P121, DOI 10.1007/s00401-007-0239-0; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; McLendon R., 2006, RUSSELL RUBINSTEINS, P103; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Murata T, 2004, GENE EXPR PATTERNS, V5, P171, DOI 10.1016/j.modgep.2004.08.007; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Srivastava VK, 2008, CYTOM PART A, V73A, P940, DOI 10.1002/cyto.a.20633; Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128; Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270; Takanaga H, 2009, STEM CELLS, V27, P165, DOI 10.1634/stemcells.2008-0580; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	33	49	49	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6869	10.1371/journal.pone.0006869	http://dx.doi.org/10.1371/journal.pone.0006869			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718438	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900030
J	Cisse, B; Cairns, M; Faye, E; NDiaye, O; Faye, B; Cames, C; Cheng, Y; NDiaye, M; Lo, AC; Simondon, K; Trape, JF; Faye, O; NDiaye, JL; Gaye, O; Greenwood, B; Milligan, P				Cisse, Badara; Cairns, Matthew; Faye, Ernest; NDiaye, Ousmane; Faye, Babacar; Cames, Cecile; Cheng, Yue; NDiaye, Maguette; Lo, Aminata Colle; Simondon, Kirsten; Trape, Jean-Francois; Faye, Oumar; NDiaye, Jean Louis; Gaye, Oumar; Greenwood, Brian; Milligan, Paul			Randomized Trial of Piperaquine with Sulfadoxine-Pyrimethamine or Dihydroartemisinin for Malaria Intermittent Preventive Treatment in Children	PLOS ONE			English	Article							FALCIPARUM DIHYDROFOLATE-REDUCTASE; PLASMODIUM-FALCIPARUM; SENEGALESE CHILDREN; RESISTANCE; SAFETY; MUTATIONS; EFFICACY; IPTC	Background: The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria studies of its use for prevention have been done in Africa. We did a cluster randomized trial to determine whether piperaquine in combination with either dihydroartemisin (DHA) or sulfadoxine-pyrimethamine (SP) is as effective, and better tolerated, than SP plus amodiaquine (AQ), when used for intermittent preventive treatment in children delivered by community health workers in a rural area of Senegal. Methods: Treatments were delivered to children 3-59 months of age in their homes once per month during the transmission season by community health workers. 33 health workers, each covering about 60 children, were randomized to deliver either SP+AQ, DHA+PQ or SP+PQ. Primary endpoints were the incidence of attacks of clinical malaria, and the incidence of adverse events. Results: 1893 children were enrolled. Coverage of monthly rounds and compliance with daily doses was similar in all groups; 90% of children received at least 2 monthly doses. Piperaquine combinations were better tolerated than SP+AQ with a significantly lower risk of common, mild adverse events. 103 episodes of clinical malaria were recorded during the course of the trial. 68 children had malaria with parasitaemia.3000/mL, 29/671 (4.3%) in the SP+AQ group, compared with 22/604 (3.6%) in the DHA+PQ group (risk difference 0.47%, 95% CI -2.3%,+3.3%), and 17/618 (2.8%) in the SP+PQ group (risk difference 1.2%, 95% CI -1.3%,+3.6%). Prevalences of parasitaemia and the proportion of children carrying Pfdhfr and Pfdhps mutations associated with resistance to SP were very low in all groups at the end of the transmission season. Conclusions: Seasonal IPT with SP+PQ in children is highly effective and well tolerated; the combination of two long-acting drugs is likely to impede the emergence of resistant parasites.			Cisse, B (corresponding author), Univ Cheikh Anta Diop, Dept Parasitol & Mycol, Dakar, Senegal.	paul.milligan@lshtm.ac.uk	Milligan, Paul/D-8985-2017	Milligan, Paul/0000-0003-3430-3395; Bork, Kirsten/0000-0002-5909-7332; Cames, Cecile/0000-0001-8374-7107; Ndiaye, Jean/0000-0003-0450-5551	MRC [G0700837] Funding Source: UKRI; Medical Research Council [G0700837] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmed T, 2008, J CLIN PHARMACOL, V48, P166, DOI 10.1177/0091270007310384; BENAZET F, 1965, PLASMODIUM BERGHEI; Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839; CHANGXIONG L, 1989, CHIN J PARASITOL PAR, V7, P163; CHEN L, 1982, CHINESE MED J-PEKING, V95, P281; Cheung YB, 2008, TROP MED INT HEALTH, V13, P247, DOI 10.1111/j.1365-3156.2007.01997.x; Cisse B, 2007, TROP MED INT HEALTH, V12, P46; Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0; *EUR MED AG, 2006, CPMPICH273899; European Medical Agency. Committee for Medicinal Products for Human Use (CHMP), 2005, GUID CHOIC NONINF MA; Greenwood B, 2008, TRENDS PARASITOL, V24, P485, DOI 10.1016/j.pt.2008.08.003; Hayes RJ, 2009, INTERD STAT, P3; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; LAFAIX C, 1967, B SOC MED AFR NOIRE, V22, P546; LV HY, 1988, ACAD J 1 MIL MED C S, V8, P460; Marbiah NT, 1998, AM J TROP MED HYG, V58, P1; Myint HY, 2007, T ROY SOC TROP MED H, V101, P858, DOI 10.1016/j.trstmh.2007.05.018; Pagnoni F, 2009, TRENDS PARASITOL, V25, P115, DOI 10.1016/j.pt.2008.12.003; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Qu F Y, 1981, Zhonghua Yi Xue Za Zhi, V61, P388; SENQI H, 1980, JAPAN J TROP MED HYG, V8, P159; SHENG N, 1981, TI ERH CHUN TA HSUEH, V1, P40; Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471; Tarning J, 2005, ANTIMICROB AGENTS CH, V49, P5127, DOI 10.1128/AAC.49.12.5127-5128.2005; Vidal L., 2005, PROFESSIONNELS SANTE; WANG P, 1995, MOL BIOCHEM PARASIT, V71, P115, DOI 10.1016/0166-6851(95)00041-X; WHO, 1998, US ART ITS DER ANT D; Who, 1967, WHO TECHN REP SER, V375; *WORK GROUP MAL PR, 1980, ACAD J 2 MIL MED COL, V1, P30; ZHAO HJ, 1981, ACAD J 2 MIL MED COL, V1, P47	32	58	58	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7164	10.1371/journal.pone.0007164	http://dx.doi.org/10.1371/journal.pone.0007164			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784374	Green Published, gold, Green Accepted, Green Submitted			2022-12-27	WOS:000270290000004
J	Gjesing, AP; Sparso, T; Borch-Johnsen, K; Jorgensen, T; Pedersen, O; Hansen, T; Olsen, NV				Gjesing, Anette P.; Sparso, Thomas; Borch-Johnsen, Knut; Jorgensen, Torben; Pedersen, Oluf; Hansen, Torben; Olsen, Niels V.			No Consistent Effect of ADRB2 Haplotypes on Obesity, Hypertension and Quantitative Traits of Body Fatness and Blood Pressure among 6,514 Adult Danes	PLOS ONE			English	Article								Background: Evidence regarding the association of variation within ADRB2, the gene encoding the beta-adrenergic receptor 2 (ADRB2) with obesity and hypertension is exceedingly ambiguous. Despite negative reports, functional impacts of individual genetic variants have been reported. Also, functional haplotypes as well as haplotype combinations affecting expression levels in vivo of ADRB2 mRNA and protein as well as receptor sensitivity have been reported. The aim of the present study was therefore to evaluate if variations within ADRB2 as haplotypes or as haplotype combinations confer an increased prevalence of obesity and hypertension among adults. Methodology/Principal Findings: We genotyped five variants required to capture common variation in a region including the ADRB2 locus in a population-based study of 6,514 unrelated, middle-aged Danes. Phases of the genotypes were estimated in silico. The variations were then investigated for their combined association with obesity, hypertension and related quantitative traits. The present study did not find consistent evidence for an association of ADRB2 variants with either obesity or hypertension when variations were analysed in a case-control study. The same lack of impact was also seen in the quantitative trait analyses, apart from nominal differences on waist-to-hip ratio and systolic blood pressure between specific haplotype combinations. Conclusions/Significance: In a population-based sample of 6,514 Danes we found no consistent associations between five common variants which tag the ADRB2 locus and prevalence of obesity or hypertension neither when analysed as individual haplotypes nor as haplotype pairs.			Gjesing, AP (corresponding author), Hagedorn Res Inst, Gentofte, Denmark.	apri@hagedorn.dk	Pedersen, Oluf/AAG-8015-2020; Jørgensen, Torben/Z-1335-2018; Pedersen, Oluf/Z-1731-2019; Gjesing, Anette/ACC-7521-2022	Pedersen, Oluf/0000-0002-3321-3972; Gjesing, Anette/0000-0003-4580-1576; Jorgensen, Torben/0000-0001-9453-2830				Bengtsson K, 2001, HYPERTENSION, V37, P1303, DOI 10.1161/01.HYP.37.5.1303; Binder A, 2006, J HYPERTENS, V24, P471, DOI 10.1097/01.hjh.0000209983.28735.33; Cerrone GE, 2007, MOL CELL PROBE, V21, P222, DOI 10.1016/j.mcp.2006.12.004; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Eriksson P, 2004, INT J OBESITY, V28, P185, DOI 10.1038/sj.ijo.0802521; Gjesing AP, 2007, DIABETIC MED, V24, P392, DOI 10.1111/j.1464-5491.2006.02031.x; Gjesing AP, 2007, DIABETOLOGIA, V50, P563, DOI 10.1007/s00125-006-0578-8; Jorgensen Torben, 2003, Eur J Cardiovasc Prev Rehabil, V10, P377; Pereira AC, 2003, HYPERTENSION, V42, P685, DOI 10.1161/01.HYP.0000085648.65419.17; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501	12	13	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7206	10.1371/journal.pone.0007206	http://dx.doi.org/10.1371/journal.pone.0007206			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779622	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200025
J	Gulliford, MC; Charlton, J; Ashworth, M; Rudd, AG; Toschke, AM				Gulliford, Martin C.; Charlton, Judith; Ashworth, Mark; Rudd, Anthony G.; Toschke, Andre Michael		eCRT Res Team	Selection of Medical Diagnostic Codes for Analysis of Electronic Patient Records. Application to Stroke in a Primary Care Database	PLOS ONE			English	Article								Background: Electronic patient records from primary care databases are increasingly used in public health and health services research but methods used to identify cases with disease are not well described. This study aimed to evaluate the relevance of different codes for the identification of acute stroke in a primary care database, and to evaluate trends in the use of different codes over time. Methods: Data were obtained from the General Practice Research Database from 1997 to 2006. All subjects had a minimum of 24 months of up-to-standard record before the first recorded stroke diagnosis. Initially, we identified stroke cases using a supplemented version of the set of codes for prevalent stroke used by the Office for National Statistics in Key health statistics from general practice 1998 (ONS codes). The ONS codes were then independently reviewed by four raters and a restricted set of 121 codes for 'acute stroke' was identified but the kappa statistic was low at 0.23. Results: Initial extraction of data using the ONS codes gave 48,239 cases of stroke from 1997 to 2006. Application of the restricted set of codes reduced this to 39,424 cases. There were 2,288 cases whose index medical codes were for 'stroke annual review' and 3,112 for 'stroke monitoring'. The frequency of stroke review and monitoring codes as index codes increased from 9 per year in 1997 to 1,612 in 2004, 1,530 in 2005 and 1,424 in 2006. The one year mortality of cases with the restricted set of codes was 29.1% but for 'stroke annual review,' 4.6% and for 'stroke monitoring codes', 5.7%. Conclusion: In the analysis of electronic patient records, different medical codes for a single condition may have varying clinical and prognostic significance; utilisation of different medical codes may change over time; researchers with differing clinical or epidemiological experience may have differing interpretations of the relevance of particular codes. There is a need for greater transparency in the selection of sets of codes for different conditions, for the reporting of sensitivity analyses using different sets of codes, as well as sharing of code sets among researchers.			Gulliford, MC (corresponding author), Kings Coll London, Div Hlth & Social Care Res, London WC2R 2LS, England.	martin.gulliford@kcl.ac.uk	Toschke, Andre M/A-8848-2010; Gulliford, Martin C/I-8606-2018; Greiver, Michelle/N-8764-2015	Gulliford, Martin C/0000-0003-1898-9075; Greiver, Michelle/0000-0001-8957-0285; Delaney, Brendan/0000-0002-3518-0131; Yardley, Lucy/0000-0002-3853-883X; Ashworth, Mark/0000-0001-6514-9904; van Staa, Tjeerd/0000-0001-9363-742X; Little, Paul/0000-0003-3664-1873	National Institute for Health Research [RP-PG-0407-10184] Funding Source: researchfish; Wellcome Trust Funding Source: Medline; Department of Health [RP-PG-0407-10184] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); Department of Health		Andersohn F, 2006, STROKE, V37, P1725, DOI 10.1161/01.STR.0000226642.55207.94; Becker C, 2007, HEADACHE, V47, P1374, DOI 10.1111/j.1526-4610.2007.00937.x; Cleary P, 2004, LANCET, V363, P1184, DOI 10.1016/S0140-6736(04)15946-1; Department of Health, 2009, NEW GMS CONTR QOF IM; Derby LE, 1999, BRIT J CLIN PHARMACO, V47, P565, DOI 10.1046/j.1365-2125.1999.00928.x; Douglas IJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1227; Gallagher AM, 2008, J THROMB HAEMOST, V6, P1500, DOI 10.1111/j.1538-7836.2008.03059.x; Hall GC, 2004, NEUROLOGY, V62, P563, DOI 10.1212/01.WNL.0000110312.36809.7F; Hansell A, 1999, THORAX, V54, P413, DOI 10.1136/thx.54.5.413; Hollowell J, 1997, Popul Trends, P36; Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445; Mulnier HE, 2006, DIABETOLOGIA, V49, P2859, DOI 10.1007/s00125-006-0493-z; *NAT STAT, 2000, SER MB6 NAT STAT, V2; Renoux C, 2008, MATURITAS, V61, P305, DOI 10.1016/j.maturitas.2008.09.020; Rietbrock S, 2008, AM HEART J, V156, P57, DOI 10.1016/j.ahj.2008.03.010; TOSCHKE AM, 2009, CEREBROVASC IN PRESS	16	54	54	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7168	10.1371/journal.pone.0007168	http://dx.doi.org/10.1371/journal.pone.0007168			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777060	Green Published, Green Accepted, gold, Green Submitted			2022-12-27	WOS:000270164600009
J	Arribas, A; Garrido, G; Viseras, C; Soria, JM; Pla, S; Solano, JG; Garces, M; Beamud, E; Carrion, JS				Arribas, Alfonso; Garrido, Guiomar; Viseras, Cesar; Soria, Jesus M.; Pla, Sila; Solano, Jose G.; Garces, Miguel; Beamud, Elisabet; Carrion, Jose S.			A Mammalian Lost World in Southwest Europe during the Late Pliocene	PLOS ONE			English	Article							LOWER PLEISTOCENE SITE; GUADIX-BAZA BASIN; FONELAS P-1; BETIC CORDILLERA; DISPERSAL; GRANADA; ASSEMBLAGE; EVOLUTION; CARNIVORA; TAPHONOMY	Background: Over the last decades, there has been an increasing interest on the chronology, distribution and mammal taxonomy (including hominins) related with the faunal turnovers that took place around the Pliocene-Pleistocene transition [ca. 1.8 mega-annum (Ma)] in Europe. However, these turnovers are not fully understood due to: the precarious nature of the period's fossil record; the "non-coexistence'' in this record of many of the species involved; and the enormous geographical area encompassed. This palaeontological information gap can now be in part bridged with data from the Fonelas P-1 site (Granada, Spain), whose faunal composition and late Upper Pliocene date shed light on some of the problems concerning the timing and geography of the dispersals. Methodology/Principal Findings: This rich fossil site yielded 32 species of mammals, among which autochthonous species of the European Upper Villafranchian coexist with canids (Canis), ovibovines (Praeovibos) and giraffids (Mitilanotherium) from Asia. Typical African species, such as the brown hyena (Hyaena brunnea) and the bush pig (Potamochoerus) are also present. Conclusions/Significance: This assemblage is taxonomically and palaeobiogeographically unique, and suggests that fewer dispersal events than was previously thought (possibly only one close to 2.0 Ma) are responsible for the changes seen around 1.9-1.7 Ma ago in the fauna of the two continents.			Arribas, A (corresponding author), Inst Geol & Minero Espana, Dept Invest Recursos, Madrid, Spain.	a.arribas@igme.es	Viseras, Cesar/AAV-2519-2021; Beamud, Elisabet/D-9750-2014; Carrion, Jose S/A-8983-2015; Arribas, Alfonso/Z-4722-2019; Garces, Miguel/D-4386-2014; Pla Pueyo, Sila/D-7773-2016; García, José A Solano/B-4742-2016; Garrido, Guiomar/GSD-7024-2022; garces, miguel/AAC-9358-2021	Beamud, Elisabet/0000-0003-3158-2966; Carrion, Jose S/0000-0002-6949-4382; Garces, Miguel/0000-0001-7666-6392; Pla Pueyo, Sila/0000-0003-4884-4096; García, José A Solano/0000-0001-6300-2351; Garrido, Guiomar/0000-0001-6742-2177; garces, miguel/0000-0001-7666-6392; Soria, Jesus Miguel/0000-0003-4848-3366; Arribas, Alfonso/0000-0003-4777-3062				Alberdi MT, 2001, PALAEOGEOGR PALAEOCL, V165, P1, DOI 10.1016/S0031-0182(00)00151-6; Arribas A., 2001, Boletin Geologico y Minero (Madrid), V112, P3; Arribas A., 2004, Boletin Geologico y Minero (Madrid), V115, P567; Arribas A, 1998, GEOBIOS-LYON, V31, P3, DOI 10.1016/S0016-6995(98)80056-9; Arribas A, 1999, J ARCHAEOL SCI, V26, P571, DOI 10.1006/jasc.1998.0346; Arribas A, 2007, CR PALEVOL, V6, P545, DOI 10.1016/j.crpv.2007.06.002; Arzarello M, 2007, NATURWISSENSCHAFTEN, V94, P107, DOI 10.1007/s00114-006-0173-3; Ascenzi A, 1996, J HUM EVOL, V31, P409, DOI 10.1006/jhev.1996.0069; AZZAROLI A, 1983, PALAEOGEOGR PALAEOCL, V44, P117, DOI 10.1016/0031-0182(83)90008-1; Azzaroli A, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P311; Bar-Yosef O, 2001, QUATERN INT, V75, P19, DOI 10.1016/S1040-6182(00)00074-4; Bermudez De Castro J. M., 1997, Science (Washington D C), V276, P1392, DOI 10.1126/science.276.5317.1392; Blanc PL, 2002, GEODIN ACTA, V15, P303, DOI 10.1016/S0985-3111(02)01095-1; Carbonell E, 2008, NATURE, V452, P465, DOI 10.1038/nature06815; Crusafont Pairo M., 1964, CR Acad Sci Paris, V258, P2869; DZAPARIDZE V, 1989, JB ROM GERM ZENTRALM, V36, P67; FERNANDEZ J, 1996, TERTIARY BASINS SPAI, P353; FERNANDEZ J, 1996, TERTIARY BASINS SPAI, P366; Gabunia L, 2000, J HUM EVOL, V38, P785, DOI 10.1006/jhev.1999.0383; GARRIDO G, 2006, THESIS COMPLUTENSE U; Garrido G, 2008, GEOBIOS-LYON, V41, P751, DOI 10.1016/j.geobios.2008.05.002; Geraads Denis, 2006, Transactions of the Royal Society of South Africa, V61, P97; Gue C., 1996, GRANDS MAMMIFE RES P, P1; Guerin C., 2004, GEOBIOS S1, V26, P349; Loget N, 2006, SEDIMENT GEOL, V188, P341, DOI 10.1016/j.sedgeo.2006.03.012; LOURENS L, 2004, GEOLOGIC TIME SCALE, P409, DOI DOI 10.1017/CBO9780511536045.022; MAZZA P, 1994, REND LINCEI-SCI FIS, V5, P17; MCFADDEN PL, 1990, GEOPHYS J INT, V103, P725, DOI 10.1111/j.1365-246X.1990.tb05683.x; Mithen S, 2002, J HUM EVOL, V43, P433, DOI 10.1006/jhev.2002.0584; O'Regan H, 2006, COUR FOR SEKENBG, V256, P305; O'Regan HJ, 2008, QUATERNARY SCI REV, V27, P2136, DOI 10.1016/j.quascirev.2008.08.007; Palmqvist P, 2003, PALEOBIOLOGY, V29, P205, DOI 10.1666/0094-8373(2003)029<0205:PROALP>2.0.CO;2; Palmqvist P, 2001, PALEOBIOLOGY, V27, P512, DOI 10.1666/0094-8373(2001)027<0512:TDOTPI>2.0.CO;2; PALOMBO M.R., 2003, GEOL ROMANA, V37, P145; Palombo MR, 2007, QUATERN INT, V160, P30, DOI 10.1016/j.quaint.2006.10.003; Raia P, 2009, PALAEOGEOGR PALAEOCL, V276, P15, DOI 10.1016/j.palaeo.2009.02.005; Sahnouni M, 1998, J ARCHAEOL SCI, V25, P1083, DOI 10.1006/jasc.1998.0278; Soria J.M., 2008, VERTEBRADOS PLIOCENO, V10, P3; Soria JM, 1998, GEOL MAG, V135, P565, DOI 10.1017/S0016756898001186; Torre D, 1992, COURIER FORSCH I SEN, V153, P51; Torre Danilo, 1996, Acta Zoologica Cracoviensia, V39, P559; Turq A., 1996, PAL O, V8, P161; Valli AMF, 2006, GEODIVERSITAS, V28, P297; VISERAS C, 1994, SEDIMENT GEOL, V88, P201, DOI 10.1016/0037-0738(94)90062-0; VISERAS C, 1992, J GEOL SOC LONDON, V149, P1021, DOI 10.1144/gsjgs.149.6.1021; Viseras C, 2006, PALAEOGEOGR PALAEOCL, V242, P139, DOI 10.1016/j.palaeo.2006.05.013	46	54	58	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7127	10.1371/journal.pone.0007127	http://dx.doi.org/10.1371/journal.pone.0007127			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	498RP	19774089	Green Published, gold			2022-12-27	WOS:000270160900012
J	Han, Y; Miller, A; Mangada, J; Liu, Y; Swistowski, A; Zhan, M; Rao, MS; Zeng, XM				Han, Yi; Miller, Aaron; Mangada, Julie; Liu, Ying; Swistowski, Andrzej; Zhan, Ming; Rao, Mahendra S.; Zeng, Xianmin			Identification by Automated Screening of a Small Molecule that Selectively Eliminates Neural Stem Cells Derived from hESCs but Not Dopamine Neurons	PLOS ONE			English	Article								Background: We have previously described fundamental differences in the biology of stem cells as compared to other dividing cell populations. We reasoned therefore that a differential screen using US Food and Drug Administration (FDA)-approved compounds may identify either selective survival factors or specific toxins and may be useful for the therapeutically-driven manufacturing of cells in vitro and possibly in vivo. Methodology/Principal Findings: In this study we report on optimized methods for feeder-free culture of hESCs and hESC-derived neural stem cells (NSCs) to facilitate automated screening. We show that we are able to measure ATP as an indicator of metabolic activity in an automated screening assay. With this optimized platform we screened a collection of FDA-approved drugs to identify compounds that have differential toxicity to hESCs and their neural derivatives. Nine compounds were identified to be specifically toxic for NSCs to a greater extent than for hESCs. Six of these initial hits were retested and verified by large-scale cell culture to determine dose-responsive NSC toxicity. One of the compounds retested, amiodarone HCL, was further tested for possible effects on postmitotic neurons, a likely target for transplant therapy. Amiodarone HCL was found to be selectively toxic to NSCs but not to differentiated neurons or glial cells. Treated and untreated NSCs and neurons were then interrogated with global gene expression analysis to explore the mechanisms of action of amiodarone HCl. The gene expression analysis suggests that activation of cell-type specific cationic channels may underlie the toxicity of the drug. Conclusions/Significance: In conclusion, we have developed a screening strategy that allows us to rapidly identify clinically approved drugs for use in a Chemistry, Manufacture and Control protocol that can be safely used to deplete unwanted contaminating precursor cells from a differentiated cell product. Our results also suggest that such a strategy is rich in the potential of identifying lineage specific reagents and provides additional evidence for the utility of stem cells in screening and discovery paradigms.			Han, Y (corresponding author), Buck Inst Aging Res, Novato, CA USA.	xzeng@buckinstitute.org			NATIONAL INSTITUTE ON AGING [ZICAG000619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS PW, 1982, INT J CANCER, V29, P523, DOI 10.1002/ijc.2910290507; Baumann S, 2003, ONCOGENE, V22, P1333, DOI 10.1038/sj.onc.1206126; CAI J, 2005, STEM CELLS; CALKINS H, 1992, J AM COLL CARDIOL, V19, P347, DOI 10.1016/0735-1097(92)90490-E; Cho YM, 2006, BIOCHEM BIOPH RES CO, V348, P1472, DOI 10.1016/j.bbrc.2006.08.020; Das B, 2003, PHARMACOL RES, V47, P447, DOI 10.1016/S1043-6618(02)00335-3; Deffois A, 1996, NEUROSCI LETT, V220, P117, DOI 10.1016/S0304-3940(96)13227-4; Dong H, 2006, J CELL BIOCHEM, V98, P1495, DOI 10.1002/jcb.20755; ELLERSTROM C, 2007, STEM CELLS; FLAKER GC, 1985, AM HEART J, V110, P371, DOI 10.1016/0002-8703(85)90158-9; Freed WJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001422; Fujii J, 2008, INFECT IMMUN, V76, P3679, DOI 10.1128/IAI.01581-07; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1996, J INFLAMM, V47, P8; Hirasawa Y, 2009, CIRC J, V73, P639, DOI 10.1253/circj.CJ-08-0794; Holmes DS, 2000, J CARDIOVASC ELECTR, V11, P1152, DOI 10.1111/j.1540-8167.2000.tb01762.x; Jin W, 2007, FEBS LETT, V581, P3826, DOI 10.1016/j.febslet.2007.07.008; Johansson S, 2008, STEM CELLS, V26, P2444, DOI 10.1634/stemcells.2008-0116; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Liu YX, 2006, BIOCHEM BIOPH RES CO, V346, P131, DOI 10.1016/j.bbrc.2006.05.086; Liu Y, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-20; Lu J, 2006, P NATL ACAD SCI USA, V103, P5688, DOI 10.1073/pnas.0601383103; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Papp, 1996, J Cardiovasc Pharmacol Ther, V1, P287; PATTERSON E, 1983, CIRCULATION, V68, P857, DOI 10.1161/01.CIR.68.4.857; SATO R, 1994, J PHARMACOL EXP THER, V269, P1213; Schulz TC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-478; SHELDON RS, 1989, CIRC RES, V65, P477, DOI 10.1161/01.RES.65.2.477; SWISTOWSKA AM, 2009, STEM CELLS IN PRESS; Swistowski A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006233; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wang SP, 2008, CLIN EXP PHARMACOL P, V35, P1077, DOI 10.1111/j.1440-1681.2008.04964.x; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; XI D, 1992, J BIOL CHEM, V267, P25025; Yano T, 2008, APOPTOSIS, V13, P543, DOI 10.1007/s10495-008-0186-9; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Yeih D F, 2000, Heart, V84, pE8, DOI 10.1136/heart.84.4.e8; Yin L, 2008, STEM CELLS DEV, V17, P53, DOI 10.1089/scd.2007.0063; Zeng XM, 2006, NEUROPSYCHOPHARMACOL, V31, P2708, DOI 10.1038/sj.npp.1301125; Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925; Zeng XM, 2003, STEM CELLS, V21, P647, DOI 10.1634/stemcells.21-6-647; Zhang XP, 2009, INT J CANCER, V124, P1980, DOI 10.1002/ijc.24139	44	36	38	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7155	10.1371/journal.pone.0007155	http://dx.doi.org/10.1371/journal.pone.0007155			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774075	gold, Green Published, Green Submitted			2022-12-27	WOS:000270160900020
J	Kim, IM; Wolf, MJ				Kim, Il-Man; Wolf, Matthew J.			Serial Examination of an Inducible and Reversible Dilated Cardiomyopathy in Individual Adult Drosophila	PLOS ONE			English	Article								Recent work has demonstrated that Drosophila can be used as a model of dilated cardiomyopathy, defined as an enlarged cardiac chamber at end-diastole when the heart is fully relaxed and having an impaired systolic function when the heart is fully contracted. Gene mutations that cause cardiac dysfunction in adult Drosophila can result from abnormalities in cardiac development or alterations in post-developmental heart function. To clarify the contribution of transgene expression to post-developmental cardiac abnormalities, we applied strategies to examine the temporal and spacial effects of transgene expression on cardiac function. We engineered transgenic Drosophila based on the well-characterized temperature-sensitive Gal80 protein in the context of the bipartite Gal4/UAS transgenic expression system in Drosophila employing the cardiac specific driver, tinC Delta 4-Gal4. Then, we developed a strategy using optical coherence tomography to serially measure cardiac function in the individual flies over time course of several days. As a proof of concept we examined the effects of the expression of a human mutant delta-sarcoglycan associated with familial heart failure and observed a reversible, post-developmental dilated cardiomyopathy in Drosophila. Our results show that the unique imaging strategy based on the non-destructive, non-invasive properties of optical coherence tomography can be applied to serially examine cardiac function in individual adult flies. Furthermore, the induction and reversal of cardiac transgene expression can be investigated in adult flies thereby providing insight into the post-developmental effects of transgene expression.			Wolf, MJ (corresponding author), Duke Univ, Dept Med, Durham, NC 27706 USA.	wolf0008@mc.duke.edu		Wolf, Matthew/0000-0001-8004-4852; Kim, Il-man/0000-0002-9268-8337	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL085072] Funding Source: NIH RePORTER; American Heart Association-American Stroke Association [0825499E] Funding Source: Medline; NHLBI NIH HHS [K08HL085072, K08 HL085072] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association-American Stroke Association(American Heart Association); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikian MJ, 2007, HUM MOL GENET, V16, P2933, DOI 10.1093/hmg/ddm254; Fink M, 2009, BIOTECHNIQUES, V46, P101, DOI 10.2144/000113078; Heydemann A, 2007, TRENDS CARDIOVAS MED, V17, P55, DOI 10.1016/j.tcm.2006.12.002; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; McGuire SE, 2004, TRENDS GENET, V20, P384, DOI 10.1016/j.tig.2004.06.012; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; Ocorr K, 2007, P NATL ACAD SCI USA, V104, P3943, DOI 10.1073/pnas.0609278104; Ocorr KA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000601; Paternostro G, 2001, CIRC RES, V88, P1053, DOI 10.1161/hh1001.090857; Taghli-Lamallem O, 2008, AGING CELL, V7, P237, DOI 10.1111/j.1474-9726.2008.00367.x; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Wessel RJ, 2004, BIOTECHNIQUES, V37, P58, DOI 10.2144/04371ST01; Wolf MJ, 2006, P NATL ACAD SCI USA, V103, P1394, DOI 10.1073/pnas.0507359103; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; Yin ZZ, 1998, DEV GENET, V22, P187	17	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7132	10.1371/journal.pone.0007132	http://dx.doi.org/10.1371/journal.pone.0007132			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771157	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400020
J	Wensman, H; Heldin, NE; Pejler, G; Hellmen, E				Wensman, Helena; Heldin, Nils-Erik; Pejler, Gunnar; Hellmen, Eva			Diverse Bone Morphogenetic Protein Expression Profiles and Smad Pathway Activation in Different Phenotypes of Experimental Canine Mammary Tumors	PLOS ONE			English	Article								Background: BMPs are currently receiving attention for their role in tumorigenesis and tumor progression. Currently, most BMP expression studies are performed on carcinomas, and not much is known about the situation in sarcomas. Methodology/Principal Findings: We have investigated the BMP expression profiles and Smad activation in clones from different spontaneous canine mammary tumors. Spindle cell tumor and osteosarcoma clones expressed high levels of BMPs, in particular BMP-2, -4 and -6. Clones from a scirrhous carcinoma expressed much lower BMP levels. The various clones formed different tumor types in nude mice but only clones that expressed high levels of BMP-6 gave bone formation. Phosphorylated Smad-1/5, located in the nucleus, was detected in tumors derived from clones expressing high levels of BMPs, indicating an active BMP signaling pathway and BMP-2 stimulation of mammary tumor cell clones in vitro resulted in activation of the Smad-1/5 pathway. In contrast BMP-2 stimulation did not induce phosphorylation of the non-Smad pathway p38 MAPK. Interestingly, an increased level of the BMP-antagonist chordin-like 1 was detected after BMP stimulation of non-bone forming clones. Conclusions/Significance: We conclude that the specific BMP expression repertoire differs substantially between different types of mammary tumors and that BMP-6 expression most probably has a biological role in bone formation of canine mammary tumors.			Wensman, H (corresponding author), Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden.	helena.wensman@afb.slu.se; eva.hellmen@afb.slu.se						Akiyoshi T, 2004, VET PATHOL, V41, P154, DOI 10.1354/vp.41-2-154; Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1; Andreev K, 2006, EXP EYE RES, V83, P1162, DOI 10.1016/j.exer.2006.06.003; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BAADE RT, 2004, ONCOGENE, V23, P3024; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Du J, 2008, J CELL BIOCHEM, V103, P1584, DOI 10.1002/jcb.21547; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719; HELDIN NE, 1991, ENDOCRINOLOGY, V129, P2187, DOI 10.1210/endo-129-4-2187; HELLMEN E, 1995, J COMP PATHOL, V113, P327, DOI 10.1016/S0021-9975(05)80119-7; Hellmen E, 2000, BREAST CANCER RES TR, V61, P197, DOI 10.1023/A:1006410020384; Helms MW, 2005, J PATHOL, V206, P366, DOI 10.1002/path.1785; Jane JA, 2002, MOL THER, V6, P464, DOI 10.1006/mthe.2002.0691; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kraunz KS, 2005, BRIT J CANCER, V93, P949, DOI 10.1038/sj.bjc.6602790; Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200; MISDORP W, 1999, ARMED FORCES I PATHO, V7; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pouliot F, 2003, CANCER RES, V63, P277; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; Tateyama S, 2001, VET PATHOL, V38, P703, DOI 10.1354/vp.38-6-703; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wensman H, 2008, VET PATHOL, V45, P803, DOI 10.1354/vp.45-6-803; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; Yoshikawa H, 2004, J ORTHOP SCI, V9, P334, DOI 10.1007/s00776-004-0764-9	33	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7133	10.1371/journal.pone.0007133	http://dx.doi.org/10.1371/journal.pone.0007133			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771160	gold, Green Submitted, Green Published			2022-12-27	WOS:000270154400021
J	Katsogiannou, M; El Boustany, C; Gackiere, F; Delcourt, P; Athias, A; Mariot, P; Dewailly, E; Jouy, N; Lamaze, C; Bidaux, G; Mauroy, B; Prevarskaya, N; Slomianny, C				Katsogiannou, Maria; El Boustany, Charbel; Gackiere, Florian; Delcourt, Philippe; Athias, Anne; Mariot, Pascal; Dewailly, Etienne; Jouy, Nathalie; Lamaze, Christophe; Bidaux, Gabriel; Mauroy, Brigitte; Prevarskaya, Natalia; Slomianny, Christian			Caveolae Contribute to the Apoptosis Resistance Induced by the alpha(1A)-Adrenoceptor in Androgen-Independent Prostate Cancer Cells	PLOS ONE			English	Article							SIGNAL-REGULATED-KINASE; PROTEIN-COUPLED RECEPTORS; LIPID RAFTS; POLY(ADP-RIBOSE) POLYMERASE; SURVIVAL/CLONAL GROWTH; CALCIUM-CHANNELS; EXPRESSION; ACTIVATION; DOMAINS; QUANTIFICATION	Background: During androgen ablation prostate cancer cells' growth and survival become independent of normal regulatory mechanisms. These androgen-independent cells acquire the remarkable ability to adapt to the surrounding microenvironment whose factors, such as neurotransmitters, influence their survival. Although findings are becoming evident about the expression of alpha(1A)-adrenoceptors in prostate cancer epithelial cells, their exact functional role in androgen-independent cells has yet to be established. Previous work has demonstrated that membrane lipid rafts associated with key signalling proteins mediate growth and survival signalling pathways in prostate cancer cells. Methodology/Principal Findings: In order to analyze the membrane topology of the alpha(1A)-adrenoceptor we explored its presence by a biochemical approach in purified detergent resistant membrane fractions of the androgen-independent prostate cancer cell line DU145. Electron microscopy observations demonstrated the colocalisation of the alpha(1A)-adrenoceptor with caveolin-1, the major protein component of caveolae. In addition, we showed that agonist stimulation of the alpha(1A)-adrenoceptor induced resistance to thapsigargin-induced apoptosis and that caveolin-1 was necessary for this process. Further, immunohistofluorescence revealed the relation between high levels of alpha(1A)-adrenoceptor and caveolin-1 expression with advanced stage prostate cancer. We also show by immunoblotting that the TG-induced apoptosis resistance described in DU145 cells is mediated by extracellular signal-regulated kinases (ERK). Conclusions/Significance: In conclusion, we propose that alpha(1A)-adrenoceptor stimulation in androgen-independent prostate cancer cells via caveolae constitutes one of the mechanisms contributing to their protection from TG-induced apoptosis.			Katsogiannou, M (corresponding author), Univ Lille 1 Sci & Technol, INSERM, U800, Villeneuve Dascq, France.	Christian.Slomianny@inserm.fr	Lamaze, Christophe/M-4912-2017; Slomianny, Christian/L-8285-2018; Bidaux, Gabriel/F-1294-2016	LAMAZE, Christophe/0000-0001-5430-2707; Bidaux, Gabriel/0000-0002-6162-3223; Mariot, Pascal/0000-0001-7226-9162; Prevarskaya, natacha/0000-0003-0316-197X				Abo K, 2000, CLIN BIOCHEM, V33, P541, DOI 10.1016/S0009-9120(00)00167-3; Andersson KE, 1997, PROSTATE, V30, P202; Anglin IE, 2002, PROSTATE CANCER P D, V5, P88, DOI 10.1038/sj.pcan.4500561; Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; BECART J, 1990, HRC-J HIGH RES CHROM, V13, P126; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bruchas MR, 2008, EUR J PHARMACOL, V578, P349, DOI 10.1016/j.ejphar.2007.09.029; CHAPPLE CR, 1994, BRIT J UROL, V74, P585, DOI 10.1111/j.1464-410X.1994.tb09188.x; Chiang CF, 2005, PROSTATE, V64, P408, DOI 10.1002/pros.20260; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; CLERK A, 1994, J BIOL CHEM, V269, P32848; Collins MD, 2008, P NATL ACAD SCI USA, V105, P124, DOI 10.1073/pnas.0702970105; DAAKA Y, 2004, SCI STKE, pRE2; de Almeida RFM, 2005, J MOL BIOL, V346, P1109, DOI 10.1016/j.jmb.2004.12.026; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dreja K, 2002, ARTERIOSCL THROM VAS, V22, P1267, DOI 10.1161/01.ATV.0000023438.32585.A1; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Fujita T, 2001, CARDIOVASC RES, V51, P709, DOI 10.1016/S0008-6363(01)00348-0; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; Gackiere F, 2008, J BIOL CHEM, V283, P10162, DOI 10.1074/jbc.M707159200; Gioeli D, 1999, CANCER RES, V59, P279; Goetz JG, 2008, CANC METASTASIS REV; Gohji K, 2001, J UROLOGY, V165, P1033, DOI 10.1016/S0022-5347(05)66597-4; HIGGINS JRA, 1989, PROSTATE, P5; Huang Y, 2007, CIRCULATION, V115, P763, DOI 10.1161/CIRCULATIONAHA.106.664862; Humez S, 2006, ENDOCR-RELAT CANCER, V13, P181, DOI 10.1677/erc.1.01079; Kajstura M, 2007, CYTOM PART A, V71A, P125, DOI 10.1002/cyto.a.20357; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kojima Y, 2006, PROSTATE, V66, P761, DOI 10.1002/pros.20399; Kusumi A, 2005, BBA-MOL CELL RES, V1746, P234, DOI 10.1016/j.bbamcr.2005.10.001; Kyprianou N, 2000, CANCER RES, V60, P4550; Kyprianou N, 2000, Curr Urol Rep, V1, P89, DOI 10.1007/s11934-000-0042-0; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEPOR H, 1995, J UROLOGY, V154, P2096, DOI 10.1016/S0022-5347(01)66704-1; Li LK, 2001, CANCER RES, V61, P4386; MARSHALL I, 1995, BRIT J PHARMACOL, V115, P781, DOI 10.1111/j.1476-5381.1995.tb15001.x; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Morris DP, 2008, J BIOL CHEM, V283, P2973, DOI 10.1074/jbc.M705795200; Morris JB, 2006, J MOL CELL CARDIOL, V41, P17, DOI 10.1016/j.yjmcc.2006.03.011; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Nasu K, 1996, BRIT J PHARMACOL, V119, P797, DOI 10.1111/j.1476-5381.1996.tb15742.x; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neidhold S, 2007, BRIT J PHARMACOL, V150, P261, DOI 10.1038/sj.bjp.0706980; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; RAGHAVAN D, 1988, SEMIN ONCOL, V15, P371; Raj GV, 2002, J UROLOGY, V167, P1458, DOI 10.1016/S0022-5347(05)65345-1; SCHRODER FH, 1992, PROSTATE, P129; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Taguchi K, 1998, N-S ARCH PHARMACOL, V357, P100, DOI 10.1007/PL00005143; Tahir SA, 2001, CANCER RES, V61, P3882; Takeda M, 1999, EUR UROL, V36, P31, DOI 10.1159/000052315; Taub JS, 2003, CANCER RES, V63, P2037; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; van Helmond ZK, 2007, NEUROPATH APPL NEURO, V33, P317, DOI 10.1111/j.1365-2990.2006.00815.x; Wang L, 2005, MOL BIOL CELL, V16, P2234, DOI 10.1091/mbc.E04-12-1044; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899; Yang G, 1998, CLIN CANCER RES, V4, P1873; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yuan CB, 2002, BIOPHYS J, V82, P2526, DOI 10.1016/S0006-3495(02)75596-3	75	10	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7068	10.1371/journal.pone.0007068	http://dx.doi.org/10.1371/journal.pone.0007068			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763272	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970400008
J	Sinnaeve, PR; Donahue, MP; Grass, P; Seo, D; Vonderscher, J; Chibout, SD; Kraus, WE; Sketch, M; Nelson, C; Ginsburg, GS; Goldschmidt-Clermont, PJ; Granger, CB				Sinnaeve, Peter R.; Donahue, Mark P.; Grass, Peter; Seo, David; Vonderscher, Jacky; Chibout, Salah-Dine; Kraus, William E.; Sketch, Michael, Jr.; Nelson, Charlotte; Ginsburg, Geoffrey S.; Goldschmidt-Clermont, Pascal J.; Granger, Christopher B.			Gene Expression Patterns in Peripheral Blood Correlate with the Extent of Coronary Artery Disease	PLOS ONE			English	Article							C-REACTIVE PROTEIN; ATHEROSCLEROTIC PLAQUES; DIFFERENTIATION; INFLAMMATION; MICROARRAY; MONOCYTES; RISK; HYPERTENSION; MACROPHAGES; LIPOPROTEIN	Systemic and local inflammation plays a prominent role in the pathogenesis of atherosclerotic coronary artery disease, but the relationship of whole blood gene expression changes with coronary disease remains unclear. We have investigated whether gene expression patterns in peripheral blood correlate with the severity of coronary disease and whether these patterns correlate with the extent of atherosclerosis in the vascular wall. Patients were selected according to their coronary artery disease index (CADi), a validated angiographical measure of the extent of coronary atherosclerosis that correlates with outcome. RNA was extracted from blood of 120 patients with at least a stenosis greater than 50% (CADi >= 23) and from 121 controls without evidence of coronary stenosis (CADi = 0). 160 individual genes were found to correlate with CADi (rho>0.2, P<0.003). Prominent differential expression was observed especially in genes involved in cell growth, apoptosis and inflammation. Using these 160 genes, a partial least squares multivariate regression model resulted in a highly predictive model (r(2) = 0.776, P<0.0001). The expression pattern of these 160 genes in aortic tissue also predicted the severity of atherosclerosis in human aortas, showing that peripheral blood gene expression associated with coronary atherosclerosis mirrors gene expression changes in atherosclerotic arteries. In conclusion, the simultaneous expression pattern of 160 genes in whole blood correlates with the severity of coronary artery disease and mirrors expression changes in the atherosclerotic vascular wall.			Sinnaeve, PR (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.	peter.sinnaeve@uzleuven.be	Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Sinnaeve, Peter/0000-0003-4716-5892; Kraus, William E/0000-0003-1930-9684				Abedin MJ, 2003, J LEUKOCYTE BIOL, V73, P650, DOI 10.1189/jlb.0402163; Alcorta D, 2002, EXP NEPHROL, V10, P139; Arroyo-Espliguero R, 2004, EUR HEART J, V25, P401, DOI 10.1016/j.ehj.2003.12.017; Arvanitis DA, 2005, J CELL MOL MED, V9, P153, DOI 10.1111/j.1582-4934.2005.tb00345.x; Aziz Hamza, 2007, Genomic Med, V1, P105, DOI 10.1007/s11568-008-9017-x; Baldini PM, 2003, J LEUKOCYTE BIOL, V73, P502, DOI 10.1189/jlb.0702377; Bomprezzi R, 2003, HUM MOL GENET, V12, P2191, DOI 10.1093/hmg/ddg221; Cagnin S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-13; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; Donahue MP, 2006, AM HEART J, V152, P478, DOI 10.1016/j.ahj.2006.03.007; Eriksson EE, 2001, FASEB J, V15, P1149, DOI 10.1096/fj.00-0537com; Felker GM, 2002, J AM COLL CARDIOL, V39, P210, DOI 10.1016/S0735-1097(01)01738-7; Fernandez-Fernandez JM, 2004, J CLIN INVEST, V113, P1032, DOI 10.1172/JCI200420347; Fritsche J, 2000, BIOCHEM BIOPH RES CO, V270, P17, DOI 10.1006/bbrc.2000.2371; Gibbons GH, 2004, CIRCULATION, V109, P47, DOI 10.1161/01.CIR.0000133440.86427.26; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; GRIMM RH, 1985, JAMA-J AM MED ASSOC, V254, P1932, DOI 10.1001/jama.254.14.1932; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Hiltunen MO, 2002, ATHEROSCLEROSIS, V165, P23, DOI 10.1016/S0021-9150(02)00187-9; Horwitz PA, 2004, CIRCULATION, V110, P3815, DOI 10.1161/01.CIR.0000150539.72783.BF; Hunt ME, 2001, AM HEART J, V141, P206, DOI 10.1067/mhj.2001.112488; Ijas P, 2007, ARTERIOSCL THROM VAS, V27, P154, DOI 10.1161/01.ATV.0000251991.64617.e7; Jarvis JN, 2004, ARTHRITIS RES THER, V6, pR15, DOI 10.1186/ar1018; Jison ML, 2004, BLOOD, V104, P270, DOI 10.1182/blood-2003-08-2760; King PH, 2000, GENE, V242, P125, DOI 10.1016/S0378-1119(99)00537-5; Kzhyshkowska J, 2004, J LEUKOCYTE BIOL, V76, P1151, DOI 10.1189/jlb.0504300; Lanzani C, 2005, J HYPERTENS, V23, P543, DOI 10.1097/01.hjh.0000160210.48479.78; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin CP, 2003, INT J CARDIOL, V89, P53, DOI 10.1016/S0167-5273(02)00428-X; Liu B, 2004, INT J BIOCHEM CELL B, V36, P766, DOI 10.1016/S1357-2725(03)00250-4; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Logan MR, 2003, J ALLERGY CLIN IMMUN, V111, P923, DOI 10.1067/mai.2003.1573; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; Mohler ER, 2008, ARTERIOSCL THROM VAS, V28, P850, DOI 10.1161/ATVBAHA.107.154534; Morikawa Shigeru, 2004, J Atheroscler Thromb, V11, P62; Nanni L, 2006, J MOL CELL CARDIOL, V41, P934, DOI 10.1016/j.yjmcc.2006.08.009; Pankow JS, 2005, AM J HYPERTENS, V18, P672, DOI 10.1016/j.amjhyper.2004.12.004; Paysant J, 1998, BRIT J HAEMATOL, V100, P45, DOI 10.1046/j.1365-2141.1998.00528.x; Pitzalis MV, 2003, J HYPERTENS, V21, P1491, DOI 10.1097/00004872-200308000-00012; Randi AM, 2003, J THROMB HAEMOST, V1, P829, DOI 10.1046/j.1538-7836.2003.00113.x; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rosamond WD, 2001, INT J EPIDEMIOL, V30, pS17, DOI 10.1093/ije/30.suppl_1.S17; Rosenson RS, 2003, AM J CARDIOL, V92, p10I, DOI 10.1016/S0002-9149(03)00504-6; Schirmer SH, 2009, J MOL CELL CARDIOL, V46, P177, DOI 10.1016/j.yjmcc.2008.10.029; SCHMIDT SB, 1985, AM J CARDIOL, V55, P1459, DOI 10.1016/0002-9149(85)90953-1; Schonbeck U, 2001, CIRC RES, V89, P1092, DOI 10.1161/hh2401.101272; Seo D, 2004, ARTERIOSCL THROM VAS, V24, P1922, DOI 10.1161/01.ATV.0000141358.65242.1f; Shepherd MC, 2004, BRIT J PHARMACOL, V142, P339, DOI 10.1038/sj.bjp.0705770; Sluimer JC, 2007, PHYSIOL GENOMICS, V30, P335, DOI 10.1152/physiolgenomics.00076.2007; Snyder SK, 2001, AM J REPROD IMMUNOL, V45, P205, DOI 10.1111/j.8755-8920.2001.450403.x; Tobin MD, 2004, EUR HEART J, V25, P459, DOI 10.1016/j.ehj.2003.11.014; Tribioli C, 1996, P NATL ACAD SCI USA, V93, P695, DOI 10.1073/pnas.93.2.695; Wang J, 2004, CLIN BIOCHEM, V37, P741, DOI 10.1016/j.clinbiochem.2004.03.013; Wingrove JA, 2008, CIRC-CARDIOVASC GENE, V1, P31, DOI 10.1161/CIRCGENETICS.108.782730; You SA, 2005, CLIN CHIM ACTA, V357, P1, DOI 10.1016/j.cccn.2005.02.001; You SA, 2003, PHYSIOL GENOMICS, V13, P25, DOI 10.1152/physiolgenomics.00124.2002; Yu G, 2003, J IMMUNOL, V171, P106, DOI 10.4049/jimmunol.171.1.106; Zebrack JS, 2002, J AM COLL CARDIOL, V39, P632, DOI 10.1016/S0735-1097(01)01804-6	60	109	114	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7037	10.1371/journal.pone.0007037	http://dx.doi.org/10.1371/journal.pone.0007037			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750006	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796300022
J	Mokarram, P; Kumar, K; Brim, H; Naghibalhossaini, F; Saberi-Firoozi, M; Nouraie, M; Green, R; Lee, E; Smoot, DT; Ashktorab, H				Mokarram, Pooneh; Kumar, Krishan; Brim, Hassan; Naghibalhossaini, Fakhraddin; Saberi-firoozi, Mehdi; Nouraie, Mehdi; Green, Robert; Lee, Ed; Smoot, Duane T.; Ashktorab, Hassan			Distinct High-Profile Methylated Genes in Colorectal Cancer	PLOS ONE			English	Article								Background: Mutations and promoters' methylation of a set of candidate cancer genes (CAN genes) are associated with progression of colorectal cancer (CRC). We hypothesized that these genes' promoters are inactivated through epigenetic silencing and may show a different profile in high-risk populations. We investigated the status of CAN gene methylation and CHD5 protein expression in African American CRC tissue microarrays (TMA) using immunohistochemical staining. Methodology/Principal Findings: The promoter methylation status of the CAN genes was studied by methylation-specific PCR (MSP) in 51 Iranians (a white population) and 51 African Americans (AA). Microsatellite instability (MSI) was analyzed as well. The differential frequency of methylation for each gene was tested by chi-square analysis between the two groups based on matched age and sex. CHD5 protein expression was evaluated in moderate to well differentiated and poorly differentiated carcinomas compared to matched normal tissue using TMA. In addition, the correlation between these epigenetic biomarkers and various clinicopathological factors, including, age, location, and stage of the disease were analyzed. Seventy-seven and 34% of tumors were distal in Iranian and African American patients, respectively. In both populations, the percentage of methylation was >65% for SYNE1, MMP2, APC2, GPNMB, EVL, PTPRD, and STARD8, whereas methylation was <50% for LGR6, RET, CD109, and RNF. The difference in methylation between the two populations was statistically significant for CHD5, ICAM5 and GPNMB. Thirty-one percent AA tumors showed MSI-H, compared to 28% in Iranians. Conclusions/Significance: A significantly higher methylation rate was found for GPNMB, ICAM5, and CHD5 genes in AA patients compared to Iranians. These genes might play a role in the high incidence and aggressiveness of CRC in the AA population. The hypermethylation of the CAN genes can be considered as a marker of colon carcinogenesis.			Mokarram, P (corresponding author), Iran Univ Med Sci, Dept Internal Med, Tehran, Iran.	hashktorab@howard.edu	Mokarram, Pooneh/E-1613-2012; Ashktorab, hassan/AAJ-2908-2020; Nouraie, Seyed Mehdi/O-4071-2018; Naghibalhossaini, Fakhraddin/I-1650-2018	Mokarram, Pooneh/0000-0002-9717-0473; Nouraie, Seyed Mehdi/0000-0001-7465-0581; Naghibalhossaini, Fakhraddin/0000-0003-4573-502X	NCI NIH HHS [R01 CA102681, CA102681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; Ashktorab H, 2007, DIGEST DIS SCI, V52, P1462, DOI 10.1007/s10620-006-9236-8; Ashktorab H, 2005, INT J CANCER, V116, P914, DOI 10.1002/ijc.21062; Ashktorab H, 2003, CLIN CANCER RES, V9, P1112; ASHKTORAB H, 2008, DIG DIS SCI IN PRESS; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bienz M, 2004, CURR OPIN CELL BIOL, V16, P528, DOI 10.1016/j.ceb.2004.08.001; Boland CR, 1998, CANCER RES, V58, P5248; Bournier O, 2006, BIOL CELL, V98, P279, DOI 10.1042/BC20050024; BRIM H, 2008, MOL CANC IN PRESS; Brim H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-68; Carethers J M, 1999, J Assoc Acad Minor Phys, V10, P59; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Fan J, 2004, J CELL SCI, V117, P619, DOI 10.1242/jcs.00892; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Goodman JE, 2004, CARCINOGENESIS, V25, P2467, DOI 10.1093/carcin/bgh260; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Hewitt SM, 2006, METHOD ENZYMOL, V410, P400, DOI 10.1016/S0076-6879(06)10020-8; Hosseini SV, 2004, ANZ J SURG, V74, P547, DOI 10.1111/j.1445-2197.2004.03064.x; Hsieh PC, 2007, ONCOGENE, V26, P4928, DOI 10.1038/sj.onc.1210304; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Iacopetta B, 2006, INT J CANCER, V119, P2272, DOI 10.1002/ijc.22237; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jurvansuu Jaana M, 2008, Recent Pat Biotechnol, V2, P47; Kawai K, 2007, BIOCHEM BIOPH RES CO, V364, P783, DOI 10.1016/j.bbrc.2007.10.052; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078-0432.CCR-05-2797; Lindsberg PJ, 2002, NEUROLOGY, V58, P446, DOI 10.1212/WNL.58.3.446; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Overall CM, 2006, CANCER METAST REV, V25, P69, DOI 10.1007/s10555-006-7890-0; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Satia JA, 2005, CANCER EPIDEM BIOMAR, V14, P429, DOI 10.1158/1055-9965.EPI-04-0486; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Slattery ML, 2007, INT J CANCER, V120, P656, DOI 10.1002/ijc.22342; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Sweeney C, 2006, CANCER EPIDEM BIOMAR, V15, P744, DOI 10.1158/1055-9965.EPI-05-0814; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Wood LD, 2007, SCIENCE; Yazdizadeh Bahareh, 2005, Asian Pac J Cancer Prev, V6, P130; Zhang QP, 2001, J CELL SCI, V114, P4485	52	104	112	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e7012	10.1371/journal.pone.0007012	http://dx.doi.org/10.1371/journal.pone.0007012			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750230	Green Submitted, Green Published, gold			2022-12-27	WOS:000269696600017
J	Kou, Z; Li, YD; Yin, ZH; Guo, S; Wang, ML; Gao, XB; Li, P; Tang, LJ; Jiang, P; Luo, Z; Xin, Z; Ding, C; He, YB; Ren, ZY; Cui, P; Zhao, HF; Zhang, Z; Tang, SA; Yan, BP; Lei, FM; Li, TX				Kou, Zheng; Li, Yongdong; Yin, Zuohua; Guo, Shan; Wang, Mingli; Gao, Xuebin; Li, Peng; Tang, Lijun; Jiang, Ping; Luo, Ze; Xin, Zhi; Ding, Changqing; He, Yubang; Ren, Zuyi; Cui, Peng; Zhao, Hongfeng; Zhang, Zhong; Tang, Shuang; Yan, Baoping; Lei, Fumin; Li, Tianxian			The Survey of H5N1 Flu Virus in Wild Birds in 14 Provinces of China from 2004 to 2007	PLOS ONE			English	Article								Background: The highly pathogenic H5N1 avian influenza emerged in the year 1996 in Asia, and has spread to Europe and Africa recently. At present, effective monitoring and data analysis of H5N1 are not sufficient in Chinese mainland. Methodology/Principal Findings: During the period from April of 2004 to August of 2007, we collected 14,472 wild bird samples covering 56 species of 10 orders in 14 provinces of China and monitored the prevalence of flu virus based on RTPCR specific for H5N1 subtype. The 149 positive samples involved six orders. Anseriformes had the highest prevalence while Passeriformes had the lowest prevalence (2.70% versus 0.36%). Among the 24 positive species, mallard (Anas platyrhynchos) had the highest prevalence (4.37%). A difference of prevalence was found among 14 provinces. Qinghai had a higher prevalence than the other 13 provinces combined (3.88% versus 0.43%). The prevalence in three species in Qinghai province (Pintail (Anas acuta), Mallard (Anas platyrhynchos) and Tufted Duck (Aythya fuligula)) were obviously higher than those in other 13 provinces. The results of sequence analysis indicated that the 17 strains isolated from wild birds were distributed in five clades (2.3.1, 2.2, 2.5, 6, and 7), which suggested that genetic diversity existed among H5N1 viruses isolated from wild birds. The five isolates from Qinghai came from one clade (2.2) and had a short evolutionary distance with the isolates obtained from Qinghai in the year 2005. Conclusions/Significance: We have measured the prevalence of H5N1 virus in 56 species of wild birds in 14 provinces of China. Continuous monitoring in the field should be carried out to know whether H5N1 virus can be maintained by wild birds.			Kou, Z (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.	leifm@ioz.ac.cn; litx@wh.iov.cn		KOU, Zheng/0000-0003-4758-2872				Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Chen H, 2006, P NATL ACAD SCI USA, V103, P2845, DOI 10.1073/pnas.0511120103; Chen HL, 2006, J VIROL, V80, P5976, DOI 10.1128/JVI.00110-06; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Fouchier RAM, 2005, J VIROL, V79, P2814, DOI 10.1128/JVI.79.5.2814-2822.2005; Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; Keawcharoen J, 2008, EMERG INFECT DIS, V14, P600, DOI 10.3201/eid1404.071016; Kilpatrick AM, 2006, P NATL ACAD SCI USA, V103, P19368, DOI 10.1073/pnas.0609227103; Kou Z, 2005, J VIROL, V79, P15460, DOI 10.1128/JVI.79.24.15460-15466.2005; Krauss S, 2004, VECTOR-BORNE ZOONOT, V4, P177, DOI 10.1089/vbz.2004.4.177; Kuiken T, 2006, SCIENCE, V312, P394, DOI 10.1126/science.1122818; Kuiken T, 2005, SCIENCE, V309, P1680, DOI 10.1126/science.1113310; Lei FM, 2007, AVIAN DIS, V51, P568, DOI 10.1637/0005-2086(2007)51[568:COHIVI]2.0.CO;2; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273; *MIN AGR PEOPL REP, 2009, REP H5N1 CONF CAS HU; Munster VJ, 2007, PLOS PATHOG, V3, P630, DOI 10.1371/journal.ppat.0030061; Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438; Parmley EJ, 2008, EMERG INFECT DIS, V14, P84, DOI 10.3201/eid1401.061562; Peterson AT, 2008, EMERG INFECT DIS, V14, P1644, DOI 10.3201/eid1410.080169; Saad MD, 2007, EMERG INFECT DIS, V13, P1120, DOI 10.3201/eid1307.061222; Shu YL, 2006, NEW ENGL J MED, V354, P1421, DOI 10.1056/NEJMc053524; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WHO, 2007, REC LAB PROC DET AV; *WHO, 2009, CONT PROGR UN NOM SY; Wu WL, 2008, J VIROL, V82, P1798, DOI 10.1128/JVI.02256-07; Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820; Zhu QY, 2006, NEW ENGL J MED, V354, P2731, DOI 10.1056/NEJMc066058	30	55	58	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6926	10.1371/journal.pone.0006926	http://dx.doi.org/10.1371/journal.pone.0006926			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742325	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622500009
J	Portillo, IJG; Gleiser, PM				Portillo, Ignacio J. Gomez; Gleiser, Pablo M.			An Adaptive Complex Network Model for Brain Functional Networks	PLOS ONE			English	Article							HIERARCHICAL ORGANIZATION; CONNECTIVITY; SYNCHRONIZATION; NEUROANATOMY; EVOLUTION	Brain functional networks are graph representations of activity in the brain, where the vertices represent anatomical regions and the edges their functional connectivity. These networks present a robust small world topological structure, characterized by highly integrated modules connected sparsely by long range links. Recent studies showed that other topological properties such as the degree distribution and the presence ( or absence) of a hierarchical structure are not robust, and show different intriguing behaviors. In order to understand the basic ingredients necessary for the emergence of these complex network structures we present an adaptive complex network model for human brain functional networks. The microscopic units of the model are dynamical nodes that represent active regions of the brain, whose interaction gives rise to complex network structures. The links between the nodes are chosen following an adaptive algorithm that establishes connections between dynamical elements with similar internal states. We show that the model is able to describe topological characteristics of human brain networks obtained from functional magnetic resonance imaging studies. In particular, when the dynamical rules of the model allow for integrated processing over the entire network scale-free non-hierarchical networks with well defined communities emerge. On the other hand, when the dynamical rules restrict the information to a local neighborhood, communities cluster together into larger ones, giving rise to a hierarchical structure, with a truncated power law degree distribution.			Gleiser, PM (corresponding author), Ctr Atom Bariloche, Stat & Interdisciplinary Phys Grp, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina.	gleiser@cab.cnea.gov.ar						Acebron JA, 2005, REV MOD PHYS, V77, P137, DOI 10.1103/RevModPhys.77.137; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Arenas A, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.114102; Arenas A, 2008, PHYS REP, V469, P93, DOI 10.1016/j.physrep.2008.09.002; Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182; Bassettt DS, 2006, P NATL ACAD SCI USA, V103, P19518, DOI 10.1073/pnas.0606005103; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Dorogovtsev SN, 2002, ADV PHYS, V51, P1079, DOI 10.1080/00018730110112519; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; FERRARINI L, 2008, HUM BRAIN MAPP  1001; Gleiser PM, 2006, EUR PHYS J B, V53, P233, DOI [10.1140/epjb/e2006-00362-y, 10.1140/opjh/e2006-00362-y]; Gong P, 2004, EUROPHYS LETT, V67, P328, DOI 10.1209/epl/i2003-10287-7; Gong PL, 2003, PHYSICA A, V321, P679, DOI 10.1016/S0378-4371(02)01735-1; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; MANRUBIA SC, 2004, EMERGENCE DYNAMICAL; Motter AE, 2006, PHYSICA D, V224, pVII, DOI 10.1016/j.physd.2006.09.012; Newman MEJ, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.036122; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Newman MEJ., 2006, STRUCTURE DYNAMICS N; Park CH, 2008, PHYSICA A, V387, P5958, DOI 10.1016/j.physa.2008.06.048; Pikovsky A, 2001, SYNCHRONIZATION UNIV; Ravasz E, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.026112; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Sporns O, 2000, CEREB CORTEX, V10, P127, DOI 10.1093/cercor/10.2.127; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O, 2004, PLOS BIOL, V2, P1910, DOI 10.1371/journal.pbio.0020369; Sporns O, 2000, NEURAL NETWORKS, V13, P909, DOI 10.1016/S0893-6080(00)00053-8; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Sporns O, 2006, P NATL ACAD SCI USA, V103, P19219, DOI 10.1073/pnas.0609523103; Stam Cornelis J, 2007, Nonlinear Biomed Phys, V1, P3, DOI 10.1186/1753-4631-1-3; Strogatz S.H., 2003, SYNC EMERGING SCI SP; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; van den Berg D, 2004, EUROPHYS LETT, V65, P459, DOI 10.1209/epl/i2003-10116-1; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Zamora-Lopez G, 2009, CHAOS, V19, DOI 10.1063/1.3089559; Zhou CS, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.238103	39	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6863	10.1371/journal.pone.0006863	http://dx.doi.org/10.1371/journal.pone.0006863			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738902	Green Submitted, Green Published, gold			2022-12-27	WOS:000269622300005
J	Dunn, LK; Mohammad, KS; Fournier, PGJ; McKenna, CR; Davis, HW; Niewolna, M; Peng, XH; Chirgwin, JM; Guise, TA				Dunn, Lauren K.; Mohammad, Khalid S.; Fournier, Pierrick G. J.; McKenna, C. Ryan; Davis, Holly W.; Niewolna, Maria; Peng, Xiang Hong; Chirgwin, John M.; Guise, Theresa A.			Hypoxia and TGF-beta Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment	PLOS ONE			English	Article								Background: Most patients with advanced breast cancer develop bone metastases, which cause pain, hypercalcemia, fractures, nerve compression and paralysis. Chemotherapy causes further bone loss, and bone-specific treatments are only palliative. Multiple tumor-secreted factors act on the bone microenvironment to drive a feed-forward cycle of tumor growth. Effective treatment requires inhibiting upstream regulators of groups of prometastatic factors. Two central regulators are hypoxia and transforming growth factor (TGF)-beta. We asked whether hypoxia (via HIF-1 alpha) and TGF-beta signaling promote bone metastases independently or synergistically, and we tested molecular versus pharmacological inhibition strategies in an animal model. Methodology/Principal Findings: We analyzed interactions between HIF-1 alpha and TGF-beta pathways in MDA-MB-231 breast cancer cells. Only vascular endothelial growth factor (VEGF) and the CXC chemokine receptor 4 (CXCR4), of 16 genes tested, were additively increased by both TGF-beta and hypoxia, with effects on the proximal promoters. We inhibited HIF-1 alpha and TGF-beta pathways in tumor cells by shRNA and dominant negative receptor approaches. Inhibition of either pathway decreased bone metastasis, with no further effect of double blockade. We tested pharmacologic inhibitors of the pathways, which target both the tumor and the bone microenvironment. Unlike molecular blockade, combined drug treatment decreased bone metastases more than either alone, with effects on bone to decrease osteoclastic bone resorption and increase osteoblast activity, in addition to actions on tumor cells. Conclusions/Significance: Hypoxia and TGF-beta signaling in parallel drive tumor bone metastases and regulate a common set of tumor genes. In contrast, small molecule inhibitors, by acting on both tumor cells and the bone microenvironment, additively decrease tumor burden, while improving skeletal quality. Our studies suggest that inhibitors of HIF-1 alpha and TGF-beta may improve treatment of bone metastases and increase survival.			Dunn, LK (corresponding author), Univ Virginia, Dept Med, Div Endocrinol, Charlottesville, VA 22903 USA.	tguise@iupui.edu	Mohammad, Khalid/AFE-4205-2022; Fournier, Pierrick/B-6560-2015; Mohammad, Khalid/AAE-9569-2022	Fournier, Pierrick/0000-0001-7633-8129; 	NATIONAL CANCER INSTITUTE [R01CA069158, T32CA009109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA69158, T32 CA009109, PC061185, T32-CA009109, PC040341, PC051194, BC073157, R01 CA069158] Funding Source: Medline; NIGMS NIH HHS [T32-GM007267, T32 GM007267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akagi Y, 1998, CANCER RES, V58, P4008; Albertella MR, 2008, CLIN CANCER RES, V14, P1096, DOI 10.1158/1078-0432.CCR-07-4020; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321; Bauerle T, 2008, NEOPLASIA, V10, P511, DOI 10.1593/neo.08220; Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Bartholin L, 2007, CANCER LETT, V246, P230, DOI 10.1016/j.canlet.2006.02.019; BAUERLE T, 2008, EUR J RADIOL; Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008-5472.CAN-05-2630; Bendre MS, 2002, CANCER RES, V62, P5571; Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; CABIOGLU N, 2009, ANN ONCOL; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Cicek M, 2007, CANCER RES, V67, P10106, DOI 10.1158/0008-5472.CAN-07-1362; Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; DIAMOND P, 2009, J BONE MINER RES; Duivenvoorden WCM, 1999, CLIN EXP METASTAS, V17, P27; Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078-0432.CCR-06-0162; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11-10-1121; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355; Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774-007-0765-9; Iida J, 2007, MELANOMA RES, V17, P205, DOI 10.1097/CMR.0b013e3282a660ad; Janssen HLK, 2002, INT J RADIAT ONCOL, V54, P1537, DOI 10.1016/S0360-3016(02)03935-4; Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008-5472.CAN-06-3950; Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319; KNOWLES HJ, 2009, J PATHOL; Komatsu DE, 2007, J BONE MINER RES, V22, P366, DOI 10.1359/JBMR.061207; LaVallee TM, 2008, MOL CANCER THER, V7, P1472, DOI 10.1158/1535-7163.MCT-08-0107; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Mooberry Susan L., 2003, Current Opinion in Oncology, V15, P425, DOI 10.1097/00001622-200311000-00004; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Raleigh JA, 1998, CANCER RES, V58, P3765; Richert MM, 2009, ONCOL REP, V21, P761, DOI 10.3892/or_00000282; Ricker JL, 2004, CLIN CANCER RES, V10, P8665, DOI 10.1158/1078-0432.CCR-04-1393; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sibonga JD, 2003, ENDOCRINOLOGY, V144, P785, DOI 10.1210/en.2002-220632; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Tevaarwerk AJ, 2009, CLIN CANCER RES, V15, P1460, DOI 10.1158/1078-0432.CCR-08-1599; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200; Zhong H, 1999, CANCER RES, V59, P5830; Zhou DC, 2008, NEUROL RES, V30, P268, DOI 10.1179/016164107X229920	72	164	170	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6896	10.1371/journal.pone.0006896	http://dx.doi.org/10.1371/journal.pone.0006896			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727403	gold, Green Submitted, Green Published			2022-12-27	WOS:000269522900023
J	Huang, SMA; Hancock, MK; Pitman, JL; Orth, AP; Gekakis, N				Huang, Shih-Min A.; Hancock, Michael K.; Pitman, Jeffrey L.; Orth, Anthony P.; Gekakis, Nicholas			Negative Regulators of Insulin Signaling Revealed in a Genome-Wide Functional Screen	PLOS ONE			English	Article								Background: Type 2 diabetes develops due to a combination of insulin resistance and beta-cell failure and current therapeutics aim at both of these underlying causes. Several negative regulators of insulin signaling are known and are the subject of drug discovery efforts. We sought to identify novel contributors to insulin resistance and hence potentially novel targets for therapeutic intervention. Methodology: An arrayed cDNA library encoding 18,441 human transcripts was screened for inhibitors of insulin signaling and revealed known inhibitors and numerous potential novel regulators. The novel hits included proteins of various functional classes such as kinases, phosphatases, transcription factors, and GTPase associated proteins. A series of secondary assays confirmed the relevance of the primary screen hits to insulin signaling and provided further insight into their modes of action. Conclusion/Significance: Among the novel hits was PALD (KIAA1274, paladin), a previously uncharacterized protein that when overexpressed led to inhibition of insulin's ability to down regulate a FOXO1A-driven reporter gene, reduced upstream insulin-stimulated AKT phosphorylation, and decreased insulin receptor (IR) abundance. Conversely, knockdown of PALD gene expression resulted in increased IR abundance, enhanced insulin-stimulated AKT phosphorylation, and an improvement in insulin's ability to suppress FOXO1A-driven reporter gene activity. The present data demonstrate that the application of arrayed genome-wide screening technologies to insulin signaling is fruitful and is likely to reveal novel drug targets for insulin resistance and the metabolic syndrome.			Huang, SMA (corresponding author), Novartis Inst Biomed Res Dev & Mol Pathways, Cambridge, MA USA.	gekakis@scripps.edu						Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Berglund L, 2008, MOL CELL PROTEOMICS, V7, P2019, DOI 10.1074/mcp.R800013-MCP200; Brachmann SM, 2005, MOL CELL BIOL, V25, P1596, DOI 10.1128/MCB.25.5.1596-1607.2005; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Cho YJ, 2007, MOL CELL BIOL, V27, P899, DOI 10.1128/MCB.00756-06; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; TAN EC, 1993, J BIOL CHEM, V268, P27291; Tu YZ, 2001, BIOCHEM J, V354, P315, DOI 10.1042/0264-6021:3540315; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; Xu H., 2005, J BIOL CHEM; Xu HY, 2003, J BIOL CHEM, V278, P30187, DOI 10.1074/jbc.M302010200; Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474	28	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6871	10.1371/journal.pone.0006871	http://dx.doi.org/10.1371/journal.pone.0006871			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727444	Green Published, gold, Green Submitted			2022-12-27	WOS:000269522900008
J	Lynch, VJ; Brayer, K; Gellersen, B; Wagner, GP				Lynch, Vincent J.; Brayer, Kathryn; Gellersen, Birgit; Wagner, Guenter P.			HoxA-11 and FOXO1A Cooperate to Regulate Decidual Prolactin Expression: Towards Inferring the Core Transcriptional Regulators of Decidual Genes	PLOS ONE			English	Article							BINDING-PROTEIN-BETA; HUMAN-ENDOMETRIUM; CYCLIC-AMP; PROMOTER; RECEPTOR; HOXA10; ACTIVATION; FKHR	Background: During the menstrual cycle, the ovarian steroid hormones estrogen and progesterone control a dramatic transcriptional reprogramming of endometrial stromal cells (ESCs) leading to a receptive state for blastocyst implantation and the establishment of pregnancy. A key marker gene of this decidualization process is the prolactin gene. Several transcriptional regulators have been identified that are essential for decidualization of ESCs, including the Hox genes HoxA-10 and HoxA-11, and the forkhead box gene FOXO1A. While previous studies have identified downstream target genes for HoxA-10 and FOXO1A, the role of HoxA-11 in decidualization has not been investigated. Here, we show that HoxA-11 is required for prolactin expression in decidualized ESC. While HoxA-11 alone is a repressor on the decidual prolactin promoter, it turns into an activator when combined with FOXO1A. Conversely, HoxA-10, which has been previously shown to associate with FOXO1A to upregulate decidual IGFBP-1 expression, is unable to upregulate PRL expression when co-expressed with FOXO1A. By co-immunoprecipitation and chromatin immunoprecipitation, we demonstrate physical association of HoxA-11 and FOXO1A, and binding of both factors to an enhancer region (2395 to 2148 relative to the PRL transcriptional start site) of the decidual prolactin promoter. Because FOXO1A is induced upon decidualization, it serves to assemble a decidual-specific transcriptional complex including HoxA-11. These data highlight cooperativity between numerous transcription factors to upregulate PRL in differentiating ESC, and suggest that this core set of transcription factors physically and functionally interact to drive the expression of a gene battery upregulated in differentiated ESC. In addition, the functional non-equivalence of HoxA-11 and HoxA-10 with respect to PRL regulation suggests that these transcription factors regulate distinct sets of target genes during decidualization.			Lynch, VJ (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.	vincent.j.lynch@yale.edu		Lynch, Vincent/0000-0001-5311-3824; Wagner, Gunter/0000-0002-3097-002X				Bao L, 2007, ENDOCRINOLOGY, V148, P2326, DOI 10.1210/en.2006-1643; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; Brar AK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290099; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; Buzzio OL, 2006, ENDOCRINOLOGY, V147, P3870, DOI 10.1210/en.2006-0167; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; Daftary GS, 2002, MOL ENDOCRINOL, V16, P571, DOI 10.1210/me.16.3.571; DALY DC, 1983, AM J OBSTET GYNECOL, V145, P672, DOI 10.1016/0002-9378(83)90572-0; Deb S, 1999, ENDOCRINOLOGY, V140, P4442, DOI 10.1210/en.140.10.4442; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; Featherstone M, 2003, AD DEV BIOL, V13, P1; Gellersen B, 2003, J ENDOCRINOL, V178, P357, DOI 10.1677/joe.0.1780357; Gellersen B, 2007, SEMIN REPROD MED, V25, P445, DOI 10.1055/s-2007-991042; Gendron RL, 1997, BIOL REPROD, V56, P1097, DOI 10.1095/biolreprod56.5.1097; Gerlo S, 2006, BIOESSAYS, V28, P1051, DOI 10.1002/bies.20468; Grinius L, 2006, J ENDOCRINOL, V189, P179, DOI 10.1677/joe.1.06451; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Jabbour HN, 2001, REPRODUCTION, V121, P197, DOI 10.1530/rep.0.1210197; Kessler CA, 2006, MOL HUM REPROD, V12, P71, DOI 10.1093/molehr/gal008; Kim JJ, 2007, MOL HUM REPROD, V13, P323, DOI 10.1093/molehr/gam005; Kim JJ, 2003, BIOL REPROD, V68, P24, DOI 10.1095/biolreprod.102.009316; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lynch VJ, 2008, P NATL ACAD SCI USA, V105, P14928, DOI 10.1073/pnas.0802355105; Ma L, 1999, SEMIN REPROD ENDOCR, V17, P205, DOI 10.1055/s-2007-1016228; Mantena SR, 2006, P NATL ACAD SCI USA, V103, P1870, DOI 10.1073/pnas.0507261103; MASLAR IA, 1979, AM J OBSTET GYNECOL, V135, P751, DOI 10.1016/0002-9378(79)90386-7; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Reem GH, 1999, J MOL ENDOCRINOL, V22, P285, DOI 10.1677/jme.0.0220285; Roth JJ, 2005, J EXP ZOOL PART B, V304B, P468, DOI 10.1002/jez.b.21061; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; Taylor HS, 2000, SEMIN REPROD MED, V18, P81, DOI 10.1055/s-2000-13478; Telgmann R, 1998, HUM REPROD UPDATE, V4, P472, DOI 10.1093/humupd/4.5.472; Troy PJ, 2003, MOL CELL BIOL, V23, P1, DOI 10.1128/MCB.23.1.1-13.2003; Watanabe K, 2001, MOL ENDOCRINOL, V15, P638, DOI 10.1210/me.15.4.638; WU WX, 1995, J MOL ENDOCRINOL, V14, P255, DOI 10.1677/jme.0.0140255; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833	38	64	66	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6845	10.1371/journal.pone.0006845	http://dx.doi.org/10.1371/journal.pone.0006845			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727442	Green Submitted, Green Published, gold			2022-12-27	WOS:000269522900004
J	Rasanen, K; Virtanen, I; Salmenpera, P; Grenman, R; Vaheri, A				Rasanen, Kati; Virtanen, Ismo; Salmenpera, Pertteli; Grenman, Reidar; Vaheri, Antti			Differences in the Nemosis Response of Normal and Cancer-Associated Fibroblasts from Patients with Oral Squamous Cell Carcinoma	PLOS ONE			English	Article							GROWTH-FACTOR; SKIN FIBROBLASTS; TUMOR; EXPRESSION; ACTIVATION; INDUCTION; RADIOSENSITIVITY; MYOFIBROBLAST; HETEROGENEITY; INVASION	Background: Tumor-stroma reaction is associated with activation of fibroblasts. Nemosis is a novel type of fibroblast activation. It leads to an increased production of growth factors and proinflammatory and proteolytic proteins, while at the same time cytoskeletal proteins are degraded. Here we used paired normal skin fibroblasts and cancer-associated fibroblasts (CAF) and primary and recurrent oral squamous cell carcinoma (SCC) cells to study the nemosis response. Principal Findings: Fibroblast nemosis was analyzed by protein and gene expression and the paracrine regulation with colony formation assay. One of the normal fibroblast strains, FB-43, upregulated COX-2 in nemosis, but FB-74 cells did not. In contrast, CAF-74 spheroids expressed COX-2 but CAF-43 cells did not. Alpha-SMA protein was expressed in both CAF strains and in FB-74 cells, but not in FB-43 fibroblasts. Its mRNA levels were downregulated in nemosis, but the CAFs started to regain the expression. FSP1 mRNA was downregulated in normal fibroblasts and CAF-74 cells, but not in CAF-43 fibroblasts. Serine protease FAP was upregulated in all fibroblasts, more so in nemotic CAFs. VEGF, HGF/SF and FGF7 mRNA levels were upregulated to variable degree in nemosis. CAFs increased the colony formation of primary tumor cell lines UT-SCC-43A and UT-SCC-74A, but normal fibroblasts inhibited the anchorage-independent growth of recurrent UT-SCC-43B and UT-SCC-74B cells. Conclusions: Nemosis response, as observed by COX-2 and growth factor induction, and expression of CAF markers alpha-SMA, FSP1 and FAP, varies between fibroblast populations. The expression of CAF markers differs between normal fibroblasts and CAFs in nemosis. These results emphasize the heterogeneity of fibroblasts and the evolving tumor-promoting properties of CAFs.			Rasanen, K (corresponding author), Univ Helsinki, Haartman Inst, Helsinki, Finland.	kati.rasanen@helsinki.fi	Vaheri, Antti/AAV-1523-2020; Räsänen, Kati/I-5769-2014					Ali MALS, 2008, CANCER SCI, V99, P1589, DOI 10.1111/j.1349-7006.2008.00861.x; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023; Barclay WW, 2005, ENDOCRINOLOGY, V146, P13, DOI 10.1210/en.2004-1123; Bizik J, 2004, CELL DEATH DIFFER, V11, P183, DOI 10.1038/sj.cdd.4401317; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Daly AJ, 2008, ORAL ONCOL, V44, P646, DOI 10.1016/j.oraloncology.2007.08.012; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Enzerink A, 2009, MOL IMMUNOL, V46, P1787, DOI 10.1016/j.molimm.2009.01.018; Francisco IFS, 2004, INT J CANCER, V112, P213, DOI 10.1002/ijc.20388; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gold KA, 2009, CANCER-AM CANCER SOC, V115, P922, DOI 10.1002/cncr.24123; Haikonen J, 2003, INT J CANCER, V103, P784, DOI 10.1002/ijc.10890; Hamakawa H, 2008, HEAD NECK-J SCI SPEC, V30, P800, DOI 10.1002/hed.20830; Hassan NMM, 2008, CANCER LETT, V270, P108, DOI 10.1016/j.canlet.2008.04.052; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Honkanen J, 1998, J CANCER RES CLIN, V124, P415, DOI 10.1007/s004320050193; Jin CL, 2004, CANCER RES, V64, P4555, DOI 10.1158/0008-5472.CAN-03-3752; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kankuri E, 2005, CANCER RES, V65, P9914, DOI 10.1158/0008-5472.CAN-05-1559; Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001; Kelly T, 2005, DRUG RESIST UPDATE, V8, P51, DOI 10.1016/j.drup.2005.03.002; Kramer RH, 2005, CANCER METAST REV, V24, P35, DOI 10.1007/s10555-005-5046-2; Micke P, 2005, EXPERT OPIN THER TAR, V9, P1217, DOI 10.1517/14728222.9.6.1217; Ohtani N, 2009, CANCER SCI, V100, P792, DOI 10.1111/j.1349-7006.2009.01123.x; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Rasanen K, 2008, MOL ONCOL, V2, P340, DOI 10.1016/j.molonc.2008.09.002; Ruutu M, 2005, ONCOL REP, V14, P1511; Salmenpera P, 2008, EXP CELL RES, V314, P3444, DOI 10.1016/j.yexcr.2008.09.004; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; Shannon DB, 2006, WOUND REPAIR REGEN, V14, P172, DOI 10.1111/j.1743-6109.2006.00107.x; Shaoul R, 2006, BIOCHEM BIOPH RES CO, V350, P825, DOI 10.1016/j.bbrc.2006.08.198; Sherbet GV, 2009, CANCER LETT, V280, P15, DOI 10.1016/j.canlet.2008.10.037; Siren V, 2006, ANN MED, V38, P212, DOI 10.1080/07853890500494999; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Sund M, 2009, CANCER METAST REV, V28, P177, DOI 10.1007/s10555-008-9175-2; Tsellou E, 2008, FUTURE ONCOL, V4, P427, DOI 10.2217/14796694.4.3.427; Vaheri A, 2009, EXP CELL RES, V315, P1633, DOI 10.1016/j.yexcr.2009.03.005; VIRTANEN I, 1985, ANN NY ACAD SCI, V455, P635, DOI 10.1111/j.1749-6632.1985.tb50441.x; ZHENG J, 1995, INT J CANCER, V61, P658, DOI 10.1002/ijc.2910610512	46	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6879	10.1371/journal.pone.0006879	http://dx.doi.org/10.1371/journal.pone.0006879			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489XX	19721715	Green Published, Green Submitted, gold			2022-12-27	WOS:000269461100008
J	Khiabanian, H; Farrell, GM; St George, K; Rabadan, R				Khiabanian, Hossein; Farrell, Gregory M.; St George, Kirsten; Rabadan, Raul			Differences in Patient Age Distribution between Influenza A Subtypes	PLOS ONE			English	Article								Since the spring of 1977, two subtypes of influenza A virus (H3N2 and H1N1) have been seasonally infecting the human population. In this work we study the distribution of patient ages within the populations that exhibit the symptomatic disease caused by each of the different subtypes of seasonal influenza viruses. When the publicly available extensive information is pooled across multiple geographical locations and seasons, striking differences emerge between these subtypes. We report that the symptomatic flu due to H1N1 is distributed mainly in a younger population relative to H3N2. (The median age of the H3N2 patients is 23 years while H1N1 patients are 9 years old.) These distinct characteristic spectra of age groups, possibly carried over from previous pandemics, are consistent with previous reports from various regional population studies and also findings on the evolutionary dynamics of each subtype. Moreover, they are relevant to age-related risk assessments, modeling of epidemiological networks for specific age groups, and age-specific vaccine design. Recently, a novel H1N1 virus has spread around the world. Preliminary reports suggest that this new strain causes symptomatic disease in the younger population in a similar fashion to the seasonal H1N1 strains.			Khiabanian, H (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biomed Informat, 630 W 168th St, New York, NY 10032 USA.	hossein@c2b2.columbia.edu	Khiabanian, Hossein/N-7207-2019; Rabadan, Raul/AAZ-7367-2020	Khiabanian, Hossein/0000-0003-1446-4394; Rabadan, Raul/0000-0001-7946-9255				Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07; BEVERIDGE WIB, 1978, NEW SCI, V77, P790; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; FOX JP, 1982, AM J EPIDEMIOL, V116, P228, DOI 10.1093/oxfordjournals.aje.a113408; Ghedin E, 2005, NATURE, V437, P1162, DOI 10.1038/nature04239; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kelly H, 2009, INFLUENZA OTHER RESP, V3, P183, DOI 10.1111/j.1750-2659.2009.00088.x; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254; KILBOURNE ED, 1976, NY TIMES        0413, V33; MONTO AS, 1985, AM J EPIDEMIOL, V121, P811, DOI 10.1093/oxfordjournals.aje.a114052; MONTO AS, 1995, AM J EPIDEMIOL, V141, P502, DOI 10.1093/oxfordjournals.aje.a117464; Olson DR, 2007, PLOS MED, V4, P1349, DOI 10.1371/journal.pmed.0040247; Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945; Simonsen L, 1998, J INFECT DIS, V178, P53, DOI 10.1086/515616; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Trifonov V, 2009, EUROSURVEILLANCE, V14, P6	17	37	44	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6832	10.1371/journal.pone.0006832	http://dx.doi.org/10.1371/journal.pone.0006832			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718262	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900005
J	Mori, S; Chang, JT; Andrechek, ER; Potti, A; Nevins, JR				Mori, Seiichi; Chang, Jeffrey T.; Andrechek, Eran R.; Potti, Anil; Nevins, Joseph R.			Utilization of Genomic Signatures to Identify Phenotype-Specific Drugs	PLOS ONE			English	Article							HUMAN BREAST-CANCER; EXPRESSION SIGNATURES; ESTROGEN-RECEPTOR; DISCOVERY; GROWTH; IDENTIFICATION; PREVENTION; ONCOGENES; PROFILES; THERAPY	Genetic and genomic studies highlight the substantial complexity and heterogeneity of human cancers and emphasize the general lack of therapeutics that can match this complexity. With the goal of expanding opportunities for drug discovery, we describe an approach that makes use of a phenotype-based screen combined with the use of multiple cancer cell lines. In particular, we have used the NCI-60 cancer cell line panel that includes drug sensitivity measures for over 40,000 compounds assayed on 59 independent cells lines. Targets are cancer-relevant phenotypes represented as gene expression signatures that are used to identify cells within the NCI-60 panel reflecting the signature phenotype and then connect to compounds that are selectively active against those cells. As a proof-of-concept, we show that this strategy effectively identifies compounds with selectivity to the RAS or PI3K pathways. We have then extended this strategy to identify compounds that have activity towards cells exhibiting the basal phenotype of breast cancer, a clinically-important breast cancer characterized as ER-, PR-, and Her2- that lacks viable therapeutic options. One of these compounds, Simvastatin, has previously been shown to inhibit breast cancer cell growth in vitro and importantly, has been associated with a reduction in ER-, PR-breast cancer in a clinical study. We suggest that this approach provides a novel strategy towards identification of therapeutic agents based on clinically relevant phenotypes that can augment the conventional strategies of target-based screens.			Mori, S (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Genom Oncol Programme, Singapore 117548, Singapore.	nevin001@mc.duke.edu		Andrechek, Eran/0000-0002-8680-3423	NATIONAL CANCER INSTITUTE [U54CA112952] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER; NCI NIH HHS [5U54CA-112952-05, U54 CA112952] Funding Source: Medline; NLM NIH HHS [R00 LM009837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Balis FM, 2002, J NATL CANCER I, V94, P78, DOI 10.1093/jnci/94.2.78; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Herbst RS, 2006, J CLIN ONCOL, V24, P190, DOI 10.1200/JCO.2005.04.8678; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hsu DS, 2007, J CLIN ONCOL, V25, P4350, DOI 10.1200/JCO.2007.11.0593; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; RAMASWAMY S, 2003, NAT GENET, V33, P59; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; TAKAHASHI K, 1979, J ANTIBIOT, V32, P36, DOI 10.7164/antibiotics.32.36; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Tanaka H, 1999, JPN J CANCER RES, V90, P1139, DOI 10.1111/j.1349-7006.1999.tb00688.x; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOBERT JA, 1987, CIRCULATION, V76, P534, DOI 10.1161/01.CIR.76.3.534; Trusheim MR, 2007, NAT REV DRUG DISCOV, V6, P287, DOI 10.1038/nrd2251; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; von Tresckow B, 2007, HAEMATOL-HEMATOL J, V92, P682, DOI 10.3324/haematol.11020; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972; Zanders E D, 2000, Pharmacogenomics, V1, P375, DOI 10.1517/14622416.1.4.375	48	19	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6772	10.1371/journal.pone.0006772	http://dx.doi.org/10.1371/journal.pone.0006772			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714244	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415800002
J	Krauss, V; Eisenhardt, C; Unger, T				Krauss, Veiko; Eisenhardt, Carina; Unger, Tina			The Genome of the Stick Insect Medauroidea extradentata Is Strongly Methylated within Genes and Repetitive DNA	PLOS ONE			English	Article							NON-CPG METHYLATION; CYTOSINE METHYLATION; RESOLUTION; CELLS; 5-METHYLCYTOSINE; TRANSCRIPTION; ARABIDOPSIS; CHROMOSOME; MARKERS; SYSTEM	Background: Cytosine DNA methylation has been detected in many eukaryotic organisms and has been shown to play an important role in development and disease of vertebrates including humans. Molecularly, DNA methylation appears to be involved in the suppression of initiation or of elongation of transcription. Resulting organismal functions are suggested to be the regulation of gene silencing, the suppression of transposon activity and the suppression of initiation of transcription within genes. However, some data concerning the distribution of methylcytosine in insect species appear to contradict such roles. Principal Findings: By comparison of MspI and HpaII restriction patterns in genomic DNA of several insects we show that stick insects (Phasmatodea) have highly methylated genomes. We isolated methylated DNA fragments from the Vietnamese Walking Stick Medauroidea extradentata (formerly known as Baculum extradentatum) and demonstrated that most of the corresponding sequences are repetitive. Bisulfite sequencing of one of these fragments and of parts of conserved protein-coding genes revealed a methylcytosine content of 12.6%, mostly found at CpG, but also at CpT and CpA dinucleotides. Corresponding depletions of CpG and enrichments of TpG and CpA dinucleotides in some highly conserved protein-coding genes of Medauroidea reach a similar degree as in vertebrates and show that CpG methylation has occurred in the germline of these insects. Conclusions: Using four different methods, we demonstrate that the genome of Medauroidea extradentata is strongly methylated. Both repetitive DNA and coding genes appear to contain high levels of methylcytosines. These results argue for similar functions of DNA methylation in stick insects as those already known for vertebrates.			Krauss, V (corresponding author), Univ Leipzig, Dept Bioinformat, Leipzig, Germany.	krauss@rz.uni-leipzig.de		Krauss, Veiko/0000-0002-2868-8367				Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bongiorni S, 2003, GENETICA, V117, P271, DOI 10.1023/A:1022964700446; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DEOBAGKAR DN, 1982, J BIOSCIENCE, V4, P513, DOI 10.1007/BF02704646; Field LM, 2000, BIOCHEM J, V349, P863, DOI 10.1042/bj3490863; Field LM, 2004, INSECT MOL BIOL, V13, P109, DOI 10.1111/j.0962-1075.2004.00470.x; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Grandjean V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001136; GREGORY TR, 2009, ANIMAL GENOME SIZE D; Grimaldi David, 2005, pi; Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352; Krauss V, 2008, MOL BIOL EVOL, V25, P821, DOI 10.1093/molbev/msn013; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Mandrioli M, 2003, GENETICA, V119, P187, DOI 10.1023/A:1026016021415; Mandrioli M, 2007, CHROMOSOME RES, V15, P1015, DOI 10.1007/s10577-007-1176-4; Mazin AL, 2009, AGEING RES REV, V8, P314, DOI 10.1016/j.arr.2009.04.005; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Mohan KN, 2005, MOL GENET GENOMICS, V274, P557, DOI 10.1007/s00438-005-0004-9; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; Phalke S, 2009, NAT GENET, V41, P696, DOI 10.1038/ng.360; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; REBASE, RESTR ENZ DAT; Regev A, 1998, MOL BIOL EVOL, V15, P880, DOI 10.1093/oxfordjournals.molbev.a025992; Rein T, 1998, NUCLEIC ACIDS RES, V26, P2255, DOI 10.1093/nar/26.10.2255; Simmen MW, 2008, GENOMICS, V92, P33, DOI 10.1016/j.ygeno.2008.03.009; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Suzuki MM, 2007, GENOME RES, V17, P625, DOI 10.1101/gr.6163007; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Wang Y, 2006, SCIENCE, V314, P645, DOI 10.1126/science.1135213; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Whiting MF, 2003, NATURE, V421, P264, DOI 10.1038/nature01313; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003; Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929	40	24	28	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7223	10.1371/journal.pone.0007223	http://dx.doi.org/10.1371/journal.pone.0007223			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787064	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290100020
J	Lim, S; Pnueli, L; Tan, JH; Naor, Z; Rajagopal, G; Melamed, P				Lim, Stefan; Pnueli, Lilach; Tan, Jing Hui; Naor, Zvi; Rajagopal, Gunaretnam; Melamed, Philippa			Negative Feedback Governs Gonadotrope Frequency-Decoding of Gonadotropin Releasing Hormone Pulse-Frequency	PLOS ONE			English	Article							N-TERMINAL KINASE; SIGNAL-REGULATED KINASE; SUBUNIT GENE-EXPRESSION; DIFFERENTIAL REGULATION; STIMULATED ACTIVITY; DEPENDENT ACTIVATION; PROTEIN-KINASE; MAPK CASCADES; RECEPTOR GENE; CROSS-TALK	The synthesis of the gonadotropin subunits is directed by pulsatile gonadotropin-releasing hormone (GnRH) from the hypothalamus, with the frequency of GnRH pulses governing the differential expression of the common alpha-subunit, luteinizing hormone beta-subunit (LH beta) and follicle-stimulating hormone beta-subunit (FSH beta). Three mitogen-activated protein kinases, (MAPKs), ERK1/2, JNK and p38, contribute uniquely and combinatorially to the expression of each of these subunit genes. In this study, using both experimental and computational methods, we found that dual specificity phosphatase regulation of the activity of the three MAPKs through negative feedback is required, and forms the basis for decoding the frequency of pulsatile GnRH. A fourth MAPK, ERK5, was shown also to be activated by GnRH. ERK5 was found to stimulate FSH beta promoter activity and to increase FSH beta mRNA levels, as well as enhancing its preference for low GnRH pulse frequencies. The latter is achieved through boosting the ultrasensitive behavior of FSH beta gene expression by increasing the number of MAPK dependencies, and through modulating the feedforward effects of JNK activation on the GnRH receptor (GnRH-R). Our findings contribute to understanding the role of changing GnRH pulse-frequency in controlling transcription of the pituitary gonadotropins, which comprises a crucial aspect in regulating reproduction. Pulsatile stimuli and oscillating signals are integral to many biological processes, and elucidation of the mechanisms through which the pulsatility is decoded explains how the same stimulant can lead to various outcomes in a single cell.			Melamed, P (corresponding author), Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel.	philippa@technion.ac.il		Rajagopal, Gunaretnam/0000-0003-0111-1936				Bedecarrats GY, 2003, ENDOCRINOLOGY, V144, P1802, DOI 10.1210/en.2002-221140; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Bonfil D, 2004, ENDOCRINOLOGY, V145, P2228, DOI 10.1210/en.2003-1418; Bornholdt S, 2005, SCIENCE, V310, P449, DOI 10.1126/science.1119959; Buchler NE, 2003, P NATL ACAD SCI USA, V100, P5136, DOI 10.1073/pnas.0930314100; DALKIN AC, 1989, ENDOCRINOLOGY, V125, P917, DOI 10.1210/endo-125-2-917; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; Ellsworth BS, 2003, ENDOCRINOLOGY, V144, P839, DOI 10.1210/en.2002-220784; Ferris HA, 2006, BIOL REPROD, V74, P993, DOI 10.1095/biolreprod.105.049049; Garmendia-Torres C, 2007, CURR BIOL, V17, P1044, DOI 10.1016/j.cub.2007.05.032; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; Goldbeter A, 2001, CHAOS, V11, P247, DOI 10.1063/1.1345727; Goldbeter A, 2007, DEV DYNAM, V236, P1495, DOI 10.1002/dvdy.21193; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRUMBACH MM, 2003, WILLIAMS TXB ENDOCRI, P115; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; HAISENLEDER DJ, 1990, ENDOCRINOLOGY, V127, P2869, DOI 10.1210/endo-127-6-2869; Harris D, 2002, ENDOCRINOLOGY, V143, P1018, DOI 10.1210/en.143.3.1018; Harris D, 2003, ENDOCRINOLOGY, V144, P612, DOI 10.1210/en.2002-220690; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Holtzendorff J, 2004, SCIENCE, V304, P983, DOI 10.1126/science.1095191; Ivakhno S, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-27; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kaiser UB, 1995, P NATL ACAD SCI USA, V92, P12280, DOI 10.1073/pnas.92.26.12280; Kaiser UB, 1997, ENDOCRINOLOGY, V138, P1224, DOI 10.1210/en.138.3.1224; Kanasaki H, 2005, ENDOCRINOLOGY, V146, P5503, DOI 10.1210/en.2004-1317; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; KATT JA, 1985, ENDOCRINOLOGY, V116, P2113, DOI 10.1210/endo-116-5-2113; Koschorreck M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-336; Krakauer DC, 2002, J THEOR BIOL, V218, P457, DOI 10.1006/jtbi.2002.3092; Lawson MA, 2007, MOL ENDOCRINOL, V21, P1175, DOI 10.1210/me.2006-0392; Lim S, 2007, MOL CELL BIOL, V27, P4105, DOI 10.1128/MCB.00248-07; Luo M, 2005, MOL CELL BIOL, V25, P7386, DOI 10.1128/MCB.25.16.7386-7398.2005; Melamed P, 2006, MOL CELL ENDOCRINOL, V252, P167, DOI 10.1016/j.mce.2006.03.024; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; PAPAVASILIOU SS, 1986, P NATL ACAD SCI USA, V83, P4026, DOI 10.1073/pnas.83.11.4026; Pawson AJ, 2008, ENDOCRINOLOGY, V149, P1415, DOI 10.1210/en.2007-1159; Ruf F, 2004, TRENDS ENDOCRIN MET, V15, P331, DOI 10.1016/j.tem.2004.07.008; Ruf F, 2003, FRONT NEUROENDOCRIN, V24, P181, DOI 10.1016/S0091-3022(03)00027-X; Sadie H, 2003, ENDOCRINOLOGY, V144, P1958, DOI 10.1210/en.2002-220874; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Washington Talitha M, 2004, Theor Biol Med Model, V1, P9, DOI 10.1186/1742-4682-1-9; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Zhang T, 2006, J MOL ENDOCRINOL, V36, P41, DOI 10.1677/jme.1.01881	46	40	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7244	10.1371/journal.pone.0007244	http://dx.doi.org/10.1371/journal.pone.0007244			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787048	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100022
J	GeurtsvanKessel, CH; Bergen, IM; Muskens, F; Boon, L; Hoogsteden, HC; Osterhaus, ADME; Rimmelzwaan, GF; Lambrecht, BN				GeurtsvanKessel, Corine H.; Bergen, Ingrid M.; Muskens, Femke; Boon, Louis; Hoogsteden, Henk C.; Osterhaus, Albert D. M. E.; Rimmelzwaan, Guus F.; Lambrecht, Bart N.			Both Conventional and Interferon Killer Dendritic Cells Have Antigen-Presenting Capacity during Influenza Virus Infection	PLOS ONE			English	Article								Natural killer cells are innate effector cells known for their potential to produce interferon-gamma and kill tumour and virus-infected cells. Recently, B220(+)CD11c(int)NK1.1(+) NK cells were found to also have antigen-presenting capacity like dendritic cells (DC), hence their name interferon-producing killer DC (IKDC). Shortly after discovery, it has already been questioned if IKDC really represent a separate subset of NK cells or merely represent a state of activation. Despite similarities with DCs, in vivo evidence that they behave as bona fide APCs is lacking. Here, using a model of influenza infection, we found recruitment of both conventional B220(-) NK cells and IKDCs to the lung. To study antigen-presenting capacity of NK cell subsets and compare it to cDCs, all cell subsets were sorted from lungs of infected mice and co-cultured ex vivo with antigen specific T cells. Both IKDCs and conventional NK cells as well as cDCs presented virus-encoded antigen to CD8 T cells, whereas only cDCs presented to CD4 T cells. The absence of CD4 responses was predominantly due to a deficiency in MHCII processing, as preprocessed peptide antigen was presented equally well by cDCs and IKDCs. In vivo, the depletion of NK1.1-positive NK cells and IKDCs reduced the expansion of viral nucleoprotein-specific CD8 T cells in the lung and spleen, but did finally not affect viral clearance from the lung. In conclusion, we found evidence for APC function of lung NK cells during influenza infection, but this is a feature not exclusive to the IKDC subset.			GeurtsvanKessel, CH (corresponding author), Erasmus Univ, Med Ctr, Dept Pulm Med, Rotterdam, Netherlands.	bart.lambrecht@ugent.be	Boon, Laurence/HCI-3629-2022; Lambrecht, Bart N/K-2484-2014	Lambrecht, Bart N/0000-0003-4376-6834; Boon, Louis/0000-0002-0937-9171; Osterhaus, Albert/0000-0002-6074-1172				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Biassoni R, 2001, IMMUNOL REV, V181, P203, DOI 10.1034/j.1600-065X.2001.1810117.x; Blasius AL, 2007, J EXP MED, V204, P2561, DOI 10.1084/jem.20070991; Bonmort M, 2008, CURR OPIN IMMUNOL, V20, P558, DOI 10.1016/j.coi.2008.04.006; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Caminschi I, 2007, J EXP MED, V204, P2579, DOI 10.1084/jem.20071351; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352; Cooper MA, 2004, TRENDS IMMUNOL, V25, P47, DOI 10.1016/j.it.2003.10.012; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; HENNET T, 1992, J GEN VIROL, V73, P39, DOI 10.1099/0022-1317-73-1-39; Ho LP, 2008, EUR J IMMUNOL, V38, P1913, DOI 10.1002/eji.200738017; Kambayashi T, 2000, J IMMUNOL, V165, P4964, DOI 10.4049/jimmunol.165.9.4964; Kessel CHG, 2008, MUCOSAL IMMUNOL, V1, P442, DOI 10.1038/mi.2008.39; Kim GG, 2007, J IMMUNOL METHODS, V325, P51, DOI 10.1016/j.jim.2007.05.013; Kos FJ, 1996, CELL IMMUNOL, V173, P1, DOI 10.1006/cimm.1996.0245; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Legge KL, 2005, IMMUNITY, V23, P649, DOI 10.1016/j.immuni.2005.11.006; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Mailliard RB, 2003, J IMMUNOL, V171, P2366, DOI 10.4049/jimmunol.171.5.2366; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Rimmelzwaan GF, 1998, J VIROL METHODS, V74, P57, DOI 10.1016/S0166-0934(98)00071-8; RONCAROLO MG, 1991, J IMMUNOL, V147, P781; Spits H, 2007, IMMUNITY, V26, P11, DOI 10.1016/j.immuni.2007.01.004; STEINSTREILEIN J, 1983, J IMMUNOL, V131, P2699; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Thomas PG, 2006, P NATL ACAD SCI USA, V103, P2764, DOI 10.1073/pnas.0511185103; Topham DJ, 2001, J IMMUNOL, V167, P6983, DOI 10.4049/jimmunol.167.12.6983; Ullrich E, 2008, J IMMUNOL, V180, P7887, DOI 10.4049/jimmunol.180.12.7887; Vitale M, 2005, BLOOD, V106, P566, DOI 10.1182/blood-2004-10-4035; Vosshenrich CAJ, 2007, J EXP MED, V204, P2569, DOI 10.1084/jem.20071451; Walzer T, 2005, BLOOD, V106, P2252, DOI 10.1182/blood-2005-03-1154; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711	45	35	35	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7187	10.1371/journal.pone.0007187	http://dx.doi.org/10.1371/journal.pone.0007187			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784375	Green Published, gold			2022-12-27	WOS:000270290000007
J	Zhang, CK; Truong, KK; Zhou, QY				Zhang, Chengkang; Truong, Kimberly K.; Zhou, Qun-Yong			Efferent Projections of Prokineticin 2 Expressing Neurons in the Mouse Suprachiasmatic Nucleus	PLOS ONE			English	Article							CIRCADIAN-RHYTHMS; ORGANIZATION; CLOCK; RAT; LOCALIZATION; OSCILLATIONS; FLUOROGOLD; TRANSPORT; PATTERNS; HAMSTER	The suprachiasmatic nucleus (SCN) in the hypothalamus is the predominant circadian clock in mammals. To function as a pacemaker, the intrinsic timing signal from the SCN must be transmitted to different brain regions. Prokineticin 2 (PK2) is one of the candidate output molecules from the SCN. In this study, we investigated the efferent projections of PK2-expressing neurons in the SCN through a transgenic reporter approach. Using a bacterial artificial chromosome (BAC) transgenic mouse line, in which the enhanced green fluorescence protein (EGFP) reporter gene expression was driven by the PK2 promoter, we were able to obtain an efferent projections map from the EGFP-expressing neurons in the SCN. Our data revealed that EGFP-expressing neurons in the SCN, hence representing some of the PK2-expressing neurons, projected to many known SCN target areas, including the ventral lateral septum, medial preoptic area, subparaventricular zone, paraventricular nucleus, dorsomedial hypothalamic nucleus, lateral hypothalamic area and paraventricular thalamic nucleus. The efferent projections of PK2-expressing neurons supported the role of PK2 as an output molecule of the SCN.			Zhang, CK (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA.	qzhou@uci.edu	ZHANG, CHENGKANG/A-8141-2008	Zhang, Chengkang/0000-0002-3746-2095	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067753] Funding Source: NIH RePORTER; NIMH NIH HHS [MH67753] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abrahamson EE, 2001, BRAIN RES, V916, P172, DOI 10.1016/S0006-8993(01)02890-6; Antle MC, 2005, TRENDS NEUROSCI, V28, P145, DOI 10.1016/j.tins.2005.01.003; Buijs RM, 1996, PROG BRAIN RES, V111, P229, DOI 10.1016/S0079-6123(08)60411-2; Burgoon PW, 2004, J COMP PHYSIOL A, V190, P167, DOI 10.1007/s00359-003-0486-z; CARD JP, 1981, J NEUROSCI, V1, P1289; Cheng MY, 2006, J COMP NEUROL, V498, P796, DOI 10.1002/cne.21087; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; CHENG MY, 2005, BMC NEUROSCI, V17, P2; CHIBA T, 1985, BRAIN RES BULL, V14, P261, DOI 10.1016/0361-9230(85)90091-7; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; DAAN S, 1978, J THEOR BIOL, V70, P297, DOI 10.1016/0022-5193(78)90378-8; Daan S, 2001, J BIOL RHYTHM, V16, P105, DOI 10.1177/074873001129001809; de la Iglesia HO, 2000, SCIENCE, V290, P799, DOI 10.1126/science.290.5492.799; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; Hamada T, 2004, EUR J NEUROSCI, V19, P1741, DOI 10.1111/j.1460-9568.2004.03275.x; Hu WP, 2007, SLEEP, V30, P247; Inagaki N, 2007, P NATL ACAD SCI USA, V104, P7664, DOI 10.1073/pnas.0607713104; Jagota A, 2000, NAT NEUROSCI, V3, P372, DOI 10.1038/73943; Jethwa PH, 2008, AM J PHYSIOL-REG I, V294, pR1968, DOI 10.1152/ajpregu.00778.2007; KALSBEEK A, 1993, J COMP NEUROL, V332, P293, DOI 10.1002/cne.903320304; Leak RK, 2001, J COMP NEUROL, V433, P312, DOI 10.1002/cne.1142; LEHMAN MN, 1987, J NEUROSCI, V7, P1626; Li JD, 2006, J NEUROSCI, V26, P11615, DOI 10.1523/JNEUROSCI.3679-06.2006; Masumoto K, 2006, EUR J NEUROSCI, V23, P2959, DOI 10.1111/j.1460-9568.2006.04834.x; Meyer-Bernstein EL, 1999, ENDOCRINOLOGY, V140, P207, DOI 10.1210/en.140.1.207; Morin LP, 2007, J BIOL RHYTHM, V22, P3, DOI 10.1177/0748730406296749; Morin LP, 2006, NEUROSCIENCE, V137, P1285, DOI 10.1016/j.neuroscience.2005.10.030; MORIN LP, 2006, BRAIN RES REV, V1, P60; Ohta H, 2005, NAT NEUROSCI, V8, P267, DOI 10.1038/nn1395; Paxinos G, 2001, MOUSE BRAIN STEREOTA, pxxv; Piggins HD, 2005, CURR BIOL, V15, pR455, DOI 10.1016/j.cub.2005.06.019; Prosser HM, 2007, P NATL ACAD SCI USA, V104, P648, DOI 10.1073/pnas.0606884104; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; Silver R, 2005, METHOD ENZYMOL, V393, P451, DOI 10.1016/S0076-6879(05)93022-X; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Thompson RH, 1998, BRAIN RES REV, V27, P89, DOI 10.1016/S0165-0173(98)00010-1; Ueyama T, 1999, NAT NEUROSCI, V2, P1051, DOI 10.1038/15973; van Esseveldt LKE, 2000, BRAIN RES REV, V33, P34, DOI 10.1016/S0165-0173(00)00025-4; WATTS AG, 1987, J COMP NEUROL, V258, P230, DOI 10.1002/cne.902580205; WATTS AG, 1987, J COMP NEUROL, V258, P204, DOI 10.1002/cne.902580204; Yan L, 2005, J NEUROSCI, V25, P9017, DOI 10.1523/JNEUROSCI.2538-05.2005; Zhang CK, 2007, J BIOL CHEM, V282, P6917, DOI 10.1074/jbc.C600290200; Zhou QY, 2005, FEBS J, V272, P5703, DOI 10.1111/j.1742-4658.2005.04984.x	44	54	56	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7151	10.1371/journal.pone.0007151	http://dx.doi.org/10.1371/journal.pone.0007151			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784373	Green Published, gold			2022-12-27	WOS:000270290000002
J	Dinis-Oliveira, RJ; de Pinho, PG; Santos, L; Teixeira, H; Magalhaes, T; Santos, A; Bastos, MD; Remiao, F; Duarte, JA; Carvalho, F				Dinis-Oliveira, Ricardo Jorge; de Pinho, Paula Guedes; Santos, Liliana; Teixeira, Helena; Magalhaes, Teresa; Santos, Agostinho; Bastos, Maria de Lourdes; Remiao, Fernando; Duarte, Jose Alberto; Carvalho, Felix			Postmortem Analyses Unveil the Poor Efficacy of Decontamination, Anti-Inflammatory and Immunosuppressive Therapies in Paraquat Human Intoxications	PLOS ONE			English	Article								Background: Fatalities resulting from paraquat (PQ) self-poisonings represent a major burden of this herbicide. Specific therapeutic approaches have been followed to interrupt its toxic pathway, namely decontamination measures to prevent PQ absorption and to increase its excretion from organism, as well as the administration of anti-inflammatory and immunosuppressive drugs. Until now, none of the postmortem studies resulting from human PQ poisonings have assessed the relationship of these therapeutic measures with PQ toxicokinetics and related histopathological lesions, these being the aims of the present study. Methodology/Principal Findings: For that purpose, during 2008, we collected human fluids and tissues from five forensic autopsies following fatal PQ poisonings. PQ levels were measured by gas chromatography-ion trap mass spectrometry. Structural inflammatory lesions were evaluated by histological and immunohistochemistry analysis. The samples of cardiac blood, urine, gastric and duodenal wall, liver, lung, kidney, heart and diaphragm, showed quantifiable levels of PQ even at 6 days post-intoxication. Structural analysis showed diffused necrotic areas, intense macrophage activation and leukocyte infiltration in all analyzed tissues. By immunohistochemistry it was possible to observe a strong nuclear factor kappa-B (NF-kappa B) activation and excessive collagen deposition. Conclusions/Significance: Considering the observed PQ levels in all analyzed tissues and the expressive inflammatory reaction that ultimately leads to fibrosis, we conclude that the therapeutic protocol usually performed needs to be reviewed, in order to increase the efficacy of PQ elimination from the body as well as to diminish the inflammatory process.			Dinis-Oliveira, RJ (corresponding author), Univ Porto, Fac Med, Rua Campo Alegre 823, P-4100 Oporto, Portugal.	ricardinis@sapo.pt; felixdc@ff.up.pt	Dinis-Oliveira, Ricardo Jorge/D-9186-2013; Magalhães, Teresa/J-7897-2013; de Lourdes Bastos, Maria/D-8588-2013; Duarte, Jose Alberto/F-1443-2013; Remião, Fernando/D-8646-2013; de Pinho, P. Guedes/D-4847-2013; Teixeira, Helena M./AHB-9671-2022; Carvalho, Félix/D-4914-2013	Dinis-Oliveira, Ricardo Jorge/0000-0001-7430-6297; de Lourdes Bastos, Maria/0000-0001-9895-503X; Duarte, Jose Alberto/0000-0003-4756-5917; Remião, Fernando/0000-0003-1382-5119; de Pinho, P. Guedes/0000-0002-7395-5700; Teixeira, Helena M./0000-0001-7570-5521; Carvalho, Félix/0000-0003-3858-3494; Santos, Agostinho/0000-0002-1396-4234; Magalhaes, Teresa/0000-0002-8098-8076				BASELT RC, 1989, DISPOSITION TOXIC DR, P637; BEEBEEJAUN AR, 1971, CLIN TOXICOL, V4, P397, DOI 10.3109/15563657108990492; BISMUTH C, 1988, J TOXICOL CLIN EXPER, V8, P211; BISMUTH C, 1987, HUM TOXICOL, V6, P63, DOI 10.1177/096032718700600110; BISMUTH C, 1982, J TOXICOL-CLIN TOXIC, V19, P461, DOI 10.3109/15563658208992501; BISMUTH C, 1995, PARAQUAT POISONING M; CARSON D J L, 1976, Forensic Science, V7, P151, DOI 10.1016/0300-9432(76)90031-5; Castro Rui, 2005, Acta Med Port, V18, P423; COOPER JD, 1985, J THORAC CARDIOV SUR, V89, P734; de Almeida RM, 2007, J CHROMATOGR B, V853, P260, DOI 10.1016/j.jchromb.2007.03.026; de la Grandmaison GL, 2001, FORENSIC SCI INT, V119, P149, DOI 10.1016/S0379-0738(00)00401-1; DEBROE ME, 1986, HUM TOXICOL, V5, P11, DOI 10.1177/096032718600500103; Dinis-Oliveira RJ, 2008, CRIT REV TOXICOL, V38, P13, DOI 10.1080/10408440701669959; Dinis-Oliveira RJ, 2006, FREE RADICAL BIO MED, V41, P1213, DOI 10.1016/j.freeradbiomed.2006.06.012; Dinis-Oliveira RJ, 2009, TOXICOLOGY, V255, P187, DOI 10.1016/j.tox.2008.10.015; Dinis-Oliveira RJ, 2006, PEDIATR EMERG CARE, V22, P537, DOI 10.1097/01.pec.0000223179.07633.8a; Fardel O., 2002, Annales Pharmaceutiques Francaises, V60, P380; Fardel O, 2001, TOXICOLOGY, V167, P37, DOI 10.1016/S0300-483X(01)00456-5; Gil HW, 2008, CLIN TOXICOL, V46, P515, DOI 10.1080/15563650701549403; Hong SY, 2003, TOXICOL IND HEALTH, V19, P17, DOI 10.1191/0748233703th171oa; HOUZE P, 1990, HUM EXP TOXICOL, V9, P5, DOI 10.1177/096032719000900103; HOUZE P, 1995, PARAQUAT POISONING M, P161; IM JG, 1991, AM J ROENTGENOL, V157, P697, DOI 10.2214/ajr.157.4.1892020; KOPPEL C, 1994, J TOXICOL-CLIN TOXIC, V32, P205, DOI 10.3109/15563659409000452; Leveridge YR, 1998, VET HUM TOXICOL, V40, P42; LEWIS CPL, 1995, PARAQUAT POISONING M, P107; Lewis J H, 1999, Clin Liver Dis, V3, P433, DOI 10.1016/S1089-3261(05)70079-9; Mullick F G, 1981, Liver, V1, P209; Noguchi N, 1990, Nihon Hoigaku Zasshi, V44, P6; OKONEK S, 1983, J TOXICOL-CLIN TOXIC, V19, P807, DOI 10.3109/15563658208992514; OKONEK S, 1979, KLIN WOCHENSCHR, V57, P957, DOI 10.1007/BF01478553; PARKINSON C, 1980, HISTOPATHOLOGY, V4, P171, DOI 10.1111/j.1365-2559.1980.tb02910.x; Pontes H, 2008, TOXICOLOGY, V252, P64, DOI 10.1016/j.tox.2008.07.064; Povoa R, 1992, Arq Bras Cardiol, V59, P95; *PRES REP, DIARIO REPUBLICA A, V1, P5362; REIF RM, 1983, J FORENSIC SCI, V28, P505; ROSE MS, 1976, BIOCHEM PHARMACOL, V25, P419, DOI 10.1016/0006-2952(76)90344-0; Ruiz-Bailen M, 2001, CHEST, V119, P1956, DOI 10.1378/chest.119.6.1956; RUSSELL LA, 1981, CLIN TOXICOL, V18, P915, DOI 10.3109/15563658108990319; Senarathna L, 2009, QJM-INT J MED, V102, P251, DOI 10.1093/qjmed/hcp006; SHARP CW, 1972, TOXICOL APPL PHARM, V22, P241, DOI 10.1016/0041-008X(72)90174-3; Tabata N, 1999, FORENSIC SCI INT, V100, P117, DOI 10.1016/S0379-0738(98)00190-X; TAKEGOSHI K, 1988, LIVER, V8, P330; Teixeira H, 2004, FORENSIC SCI INT, V143, P199, DOI 10.1016/j.forsciint.2004.02.037; Van GIESON I., 1889, NEW YORK MED J, V50, P57; VANDEVYVER FL, 1985, J TOXICOL-CLIN TOXIC, V23, P117, DOI 10.3109/15563658508990622; VANDIJK A, 1975, ARCH TOXICOL, V34, P129, DOI 10.1007/BF00353313; Weigert K., 1904, Z WISS MIKROSK, V21, P1; Wesseling C, 2001, Int J Occup Environ Health, V7, P90; Wilks MF, 2008, PLOS MED, V5, P250, DOI 10.1371/journal.pmed.0050049; ZIMMERMAN HJ, 1987, MED TOXICOL ADV DRUG, V2, P112, DOI 10.1007/BF03260010	52	44	60	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7149	10.1371/journal.pone.0007149	http://dx.doi.org/10.1371/journal.pone.0007149			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779613	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200006
J	Balgi, AD; Fonseca, BD; Donohue, E; Tsang, TCF; Lajoie, P; Proud, CG; Nabi, IR; Roberge, M				Balgi, Aruna D.; Fonseca, Bruno D.; Donohue, Elizabeth; Tsang, Trevor C. F.; Lajoie, Patrick; Proud, Christopher G.; Nabi, Ivan R.; Roberge, Michel			Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling	PLOS ONE			English	Article								Background: Mammalian target of rapamycin complex 1 (mTORC1) is a protein kinase that relays nutrient availability signals to control numerous cellular functions including autophagy, a process of cellular self-eating activated by nutrient depletion. Addressing the therapeutic potential of modulating mTORC1 signaling and autophagy in human disease requires active chemicals with pharmacologically desirable properties. Methodology/Principal Findings: Using an automated cell-based assay, we screened a collection of >3,500 chemicals and identified three approved drugs (perhexiline, niclosamide, amiodarone) and one pharmacological reagent (rottlerin) capable of rapidly increasing autophagosome content. Biochemical assays showed that the four compounds stimulate autophagy and inhibit mTORC1 signaling in cells maintained in nutrient-rich conditions. The compounds did not inhibit mTORC2, which also contains mTOR as a catalytic subunit, suggesting that they do not inhibit mTOR catalytic activity but rather inhibit signaling to mTORC1. mTORC1 inhibition and autophagosome accumulation induced by perhexiline, niclosamide or rottlerin were rapidly reversed upon drug withdrawal whereas amiodarone inhibited mTORC1 essentially irreversibly. TSC2, a negative regulator of mTORC1, was required for inhibition of mTORC1 signaling by rottlerin but not for mTORC1 inhibition by perhexiline, niclosamide and amiodarone. Transient exposure of immortalized mouse embryo fibroblasts to these drugs was not toxic in nutrient-rich conditions but led to rapid cell death by apoptosis in starvation conditions, by a mechanism determined in large part by the tuberous sclerosis complex protein TSC2, an upstream regulator of mTORC1. By contrast, transient exposure to the mTORC1 inhibitor rapamycin caused essentially irreversible mTORC1 inhibition, sustained inhibition of cell growth and no selective cell killing in starvation. Conclusion/Significance: The observation that drugs already approved for human use can reversibly inhibit mTORC1 and stimulate autophagy should greatly facilitate the preclinical and clinical testing of mTORC1 inhibition for indications such as tuberous sclerosis, diabetes, cardiovascular disease and cancer.			Balgi, AD (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada.	michelr@interchange.ubc.ca	Nabi, Ivan/GWZ-5144-2022	Nabi, Ivan/0000-0002-0670-0513; Proud, Christopher/0000-0003-0704-6442; Lajoie, Patrick/0000-0002-1614-176X				Abozguia K, 2006, NAT CLIN PRACT CARD, V3, P490, DOI 10.1038/ncpcardio0583; ANAND N, 1997, APPROACHES DESIGN SY, V25, P239; Ashrafian H, 2007, CARDIOVASC DRUG REV, V25, P76, DOI 10.1111/j.1527-3466.2007.00006.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chan EYW, 2009, MOL CELL BIOL, V29, P157, DOI 10.1128/MCB.01082-08; CHEN N, 2009, BIOCH BIOPHYS ACTA; Cheong H, 2008, MOL BIOL CELL, V19, P668, DOI 10.1091/mbc.E07-08-0826; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Curnock AP, 2001, BIOCHEM PHARMACOL, V61, P227, DOI 10.1016/S0006-2952(00)00552-9; Ding WX, 2009, METHOD ENZYMOL, V453, P397, DOI 10.1016/S0076-6879(08)04020-2; Fairweather I, 1999, VET J, V158, P81, DOI 10.1053/tvjl.1999.0377; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Galluzzi L, 2008, BIOCHEM SOC T, V36, P786, DOI 10.1042/BST0360786; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hosoi H, 1999, CANCER RES, V59, P886; HOSOKAWA N, 2009, MOL BIOL CELL; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Inglis Sally, 2006, Eur J Cardiovasc Nurs, V5, P175, DOI 10.1016/j.ejcnurse.2006.01.001; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678; Kodama I, 1999, AM J CARDIOL, V84, p20R; Kojima K, 2008, BIOCHEM BIOPH RES CO, V376, P434, DOI 10.1016/j.bbrc.2008.09.007; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Le Tourneau C, 2008, BRIT J CANCER, V99, P1197, DOI 10.1038/sj.bjc.6604636; Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900; Lee L, 2004, EUR HEART J, V25, P634, DOI 10.1016/j.ehj.2004.02.018; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Merschiohann K, 2008, EXP PARASITOL, V118, P637, DOI 10.1016/j.exppara.2007.12.001; *MOSB INC, MOSB 2004 DRUG GUID; Moschella PC, 2007, J MOL CELL CARDIOL, V43, P754, DOI 10.1016/j.yjmcc.2007.09.015; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; PAMPORI NA, 1984, J HELMINTHOL, V58, P39, DOI 10.1017/S0022149X00028042; PAMPORI NA, 1984, MOL BIOCHEM PARASIT, V11, P205, DOI 10.1016/0166-6851(84)90066-5; Patrick G. L., 1995, INTRO MED CHEM; PAX RA, 1989, J PARASITOL, V75, P169, DOI 10.2307/3282962; PILCHER J, 1985, THER DRUG MONIT, V7, P54, DOI 10.1097/00007691-198503000-00009; Prick T, 2006, BIOCHEM J, V394, P153, DOI 10.1042/BJ20051243; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Sarkar S, 2009, METHOD ENZYMOL, V453, P83, DOI 10.1016/S0076-6879(08)04005-6; SAZ HJ, 1981, ANNU REV PHYSIOL, V43, P323, DOI 10.1146/annurev.ph.43.030181.001543; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; SINGH BN, 1986, BRIT J CLIN PHARMACO, V21, pS109, DOI 10.1111/j.1365-2125.1986.tb02860.x; Singh BN, 2004, J CARDIOVASC PHARM T, V9, P219, DOI 10.1177/107424840400900401; Soltoff SP, 2007, TRENDS PHARMACOL SCI, V28, P453, DOI 10.1016/j.tips.2007.07.003; Song KS, 2008, AUTOPHAGY, V4, P650, DOI 10.4161/auto.6057; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wang LJ, 2003, BIOCHEM J, V373, P603, DOI 10.1042/BJ20030454; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wang XM, 2008, J BIOL CHEM, V283, P30482, DOI 10.1074/jbc.M803348200; Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006; World Health Organization, WHOVBCDS8863; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xie ZP, 2008, MOL BIOL CELL, V19, P3290, DOI 10.1091/mbc.E07-12-1292; Yang YP, 2005, ACTA PHARMACOL SIN, V26, P1421, DOI 10.1111/j.1745-7254.2005.00235.x; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Zhang DH, 2007, J PHARMACOL EXP THER, V322, P913, DOI 10.1124/jpet.107.124669; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104; Zhang YQ, 2007, J BIOL CHEM, V282, P37844, DOI 10.1074/jbc.M707593200	90	267	273	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7124	10.1371/journal.pone.0007124	http://dx.doi.org/10.1371/journal.pone.0007124			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771169	Green Published, gold, Green Submitted, Green Accepted			2022-12-27	WOS:000270154400017
J	Alcaide, M; Rico, C; Ruiz, S; Soriguer, R; Munoz, J; Figuerola, J				Alcaide, Miguel; Rico, Ciro; Ruiz, Santiago; Soriguer, Ramon; Munoz, Joaquin; Figuerola, Jordi			Disentangling Vector-Borne Transmission Networks: A Universal DNA Barcoding Method to Identify Vertebrate Hosts from Arthropod Bloodmeals	PLOS ONE			English	Article							MOLECULAR ANALYSIS; IDENTIFICATION; MEALS	Emerging infectious diseases represent a challenge for global economies and public health. About one fourth of the last pandemics have been originated by the spread of vector-borne pathogens. In this sense, the advent of modern molecular techniques has enhanced our capabilities to understand vector-host interactions and disease ecology. However, host identification protocols have poorly profited of international DNA barcoding initiatives and/or have focused exclusively on a limited array of vector species. Therefore, ascertaining the potential afforded by DNA barcoding tools in other vector-host systems of human and veterinary importance would represent a major advance in tracking pathogen life cycles and hosts. Here, we show the applicability of a novel and efficient molecular method for the identification of the vertebrate host's DNA contained in the midgut of blood-feeding arthropods. To this end, we designed a eukaryote-universal forward primer and a vertebrate-specific reverse primer to selectively amplify 758 base pairs (bp) of the vertebrate mitochondrial Cytochrome c Oxidase Subunit I (COI) gene. Our method was validated using both extensive sequence surveys from the public domain and Polymerase Chain Reaction (PCR) experiments carried out over specimens from different Classes of vertebrates (Mammalia, Aves, Reptilia and Amphibia) and invertebrate ectoparasites (Arachnida and Insecta). The analysis of mosquito, culicoid, phlebotomie, sucking bugs, and tick bloodmeals revealed up to 40 vertebrate hosts, including 23 avian, 16 mammalian and one reptilian species. Importantly, the inspection and analysis of direct sequencing electropherograms also assisted the resolving of mixed bloodmeals. We therefore provide a universal and high-throughput diagnostic tool for the study of the ecology of haematophagous invertebrates in relation to their vertebrate hosts. Such information is crucial to support the efficient management of initiatives aimed at reducing epidemiologic risks of arthropod vector-borne pathogens, a priority for public health.			Alcaide, M (corresponding author), CSIC, Estac Biol Donana, E-41080 Seville, Spain.	malcaide@ebd.csic.es	Soriguer, Ramon/J-1494-2014; Rico, Ciro/K-5725-2015; 赵, 鹏/B-8401-2009; Munoz, Joaquin/B-9938-2009; Figuerola, Jordi/B-7917-2008; Ruíz, Santiago/HGU-6016-2022; Alcaide, Miguel/A-1400-2012; Rico, Ciro/P-9750-2019	Soriguer, Ramon/0000-0002-9165-7766; Rico, Ciro/0000-0002-0822-336X; Munoz, Joaquin/0000-0003-3623-2439; Figuerola, Jordi/0000-0002-4664-9011; Rico, Ciro/0000-0002-0822-336X; Alcaide, Miguel/0000-0001-6945-0972				Ali Oshaghi M, 2006, EXP PARASITOL, V112, P232, DOI 10.1016/j.exppara.2005.11.008; FALCO RC, 1992, EXP APPL ACAROL, V14, P165, DOI 10.1007/BF01219108; Foley JE, 2008, VECTOR-BORNE ZOONOT, V8, P49, DOI 10.1089/vbz.2007.0175; Gratz NG, 1999, ANNU REV ENTOMOL, V44, P51, DOI 10.1146/annurev.ento.44.1.51; Hall TA., 1999, NUCL ACIDS S SERIES, V41, P95; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536; Kent RJ, 2009, MOL ECOL RESOUR, V9, P4, DOI 10.1111/j.1755-0998.2008.02469.x; Kent RJ, 2005, AM J TROP MED HYG, V73, P336, DOI 10.4269/ajtmh.2005.73.336; Kent RJ, 2004, AM J TROP MED HYG, V71, P514, DOI 10.4269/ajtmh.2004.71.514; King RA, 2008, MOL ECOL, V17, P947, DOI 10.1111/j.1365-294X.2007.03613.x; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; Meusnier I, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-214; Perez-Tris J, 2005, ECOL LETT, V8, P838, DOI 10.1111/j.1461-0248.2005.00788.x; Rasgon JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002198; Ratnasingham S, 2007, MOL ECOL NOTES, V7, P355, DOI 10.1111/j.1471-8286.2007.01678.x; Tavares ES, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-81; Thomsen R, 2006, PRIMATES, V47, P397, DOI 10.1007/s10329-006-0194-8; Townzen JS, 2008, MED VET ENTOMOL, V22, P386, DOI 10.1111/j.1365-2915.2008.00760.x; Traugott M, 2008, MOL ECOL, V17, P3928, DOI 10.1111/j.1365-294X.2008.03878.x; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Valentini A, 2009, TRENDS ECOL EVOL, V24, P110, DOI 10.1016/j.tree.2008.09.011; Waugh J, 2007, BIOESSAYS, V29, P188, DOI 10.1002/bies.20529; Wheeler SS, 2009, CONDOR, V111, P1, DOI 10.1525/cond.2009.080013; Wickramasekara Samanthi, 2008, Emerg Infect Dis, V14, P1273, DOI 10.3201/eid1408.080227; Woods ME, 2009, AM J TROP MED HYG, V80, P998, DOI 10.4269/ajtmh.2009.80.998	26	110	117	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7092	10.1371/journal.pone.0007092	http://dx.doi.org/10.1371/journal.pone.0007092			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768113	Green Published, gold			2022-12-27	WOS:000270154000005
J	Aanensen, DM; Huntley, DM; Feil, EJ; al-Own, F; Spratt, BG				Aanensen, David M.; Huntley, Derek M.; Feil, Edward J.; al-Own, Fada'a; Spratt, Brian G.			EpiCollect: Linking Smartphones to Web Applications for Epidemiology, Ecology and Community Data Collection	PLOS ONE			English	Article								Background: Epidemiologists and ecologists often collect data in the field and, on returning to their laboratory, enter their data into a database for further analysis. The recent introduction of mobile phones that utilise the open source Android operating system, and which include (among other features) both GPS and Google Maps, provide new opportunities for developing mobile phone applications, which in conjunction with web applications, allow two-way communication between field workers and their project databases. Methodology: Here we describe a generic framework, consisting of mobile phone software, EpiCollect, and a web application located within www.spatialepidemiology.net. Data collected by multiple field workers can be submitted by phone, together with GPS data, to a common web database and can be displayed and analysed, along with previously collected data, using Google Maps (or Google Earth). Similarly, data from the web database can be requested and displayed on the mobile phone, again using Google Maps. Data filtering options allow the display of data submitted by the individual field workers or, for example, those data within certain values of a measured variable or a time period. Conclusions: Data collection frameworks utilising mobile phones with data submission to and from central databases are widely applicable and can give a field worker similar display and analysis tools on their mobile phone that they would have if viewing the data in their laboratory via the web. We demonstrate their utility for epidemiological data collection and display, and briefly discuss their application in ecological and community data collection. Furthermore, such frameworks offer great potential for recruiting 'citizen scientists' to contribute data easily to central databases through their mobile phone.			Aanensen, DM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.	d.aanensen@imperial.ac.uk	Aanensen, David M/D-6849-2011		Wellcome Trust [089472] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, pW728, DOI 10.1093/nar/gki415; Butler D, 2006, NATURE, V439, P6, DOI 10.1038/439006a; Kwok R, 2009, NATURE, V458, P959, DOI 10.1038/458959a; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Morris K, 2009, LANCET INFECT DIS, V9, P274, DOI 10.1016/S1473-3099(09)70118-5	5	219	226	2	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e6968	10.1371/journal.pone.0006968	http://dx.doi.org/10.1371/journal.pone.0006968			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756138	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970000003
J	Johnson, RI; Cagan, RL				Johnson, Ruth I.; Cagan, Ross L.			A Quantitative Method to Analyze Drosophila Pupal Eye Patterning	PLOS ONE			English	Article								Background: The Drosophila pupal eye has become a popular paradigm for understanding morphogenesis and tissue patterning. Correct rearrangement of cells between ommatidia is required to organize the ommatidial array across the eye field. This requires cell movement, cell death, changes to cell-cell adhesion, signaling and fate specification. Methodology: We describe a method to quantitatively assess mis-patterning of the Drosophila pupal eye and objectively calculate a 'mis-patterning score' characteristic of a specific genotype. This entails step-by-step scoring of specific traits observed in pupal eyes dissected 40-42 hours after puparium formation and subsequent statistical analysis of this data. Significance: This method provides an unbiased quantitative score of mis-patterning severity that can be used to compare the impact of different genetic mutations on tissue patterning.			Johnson, RI (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY USA.	Ross.Cagan@mssm.edu	Cagan, Ross Leigh/AAV-9528-2021	Cagan, Ross/0000-0001-5297-450X	NEI NIH HHS [NIH R01 EY1149] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Brachmann CB, 2003, TRENDS GENET, V19, P91, DOI 10.1016/S0168-9525(02)00041-0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CAGAN RL, CURRENT TOP IN PRESS; Cordero J, 2004, MECH DEVELOP, V121, P1523, DOI 10.1016/j.mod.2004.07.004; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Johnson RI, 2008, J CELL BIOL, V180, P1191, DOI 10.1083/jcb.200706108; Kafer J, 2007, P NATL ACAD SCI USA, V104, P18549, DOI 10.1073/pnas.0704235104; LARSON DE, 2007, MECH DEV; Monserrate JP, 2007, CELL DEATH DIFFER, V14, P209, DOI 10.1038/sj.cdd.4401947; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5	11	16	16	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7008	10.1371/journal.pone.0007008	http://dx.doi.org/10.1371/journal.pone.0007008			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753121	Green Published, gold			2022-12-27	WOS:000269796500004
J	Yu, J; Huang, NF; Wilson, KD; Velotta, JB; Huang, M; Li, ZJ; Lee, A; Robbins, RC; Cooke, JP; Wu, JC				Yu, Jin; Huang, Ngan F.; Wilson, Kitchener D.; Velotta, Jeffrey B.; Huang, Mei; Li, Zongjin; Lee, Andrew; Robbins, Robert C.; Cooke, John P.; Wu, Joseph C.			nAChRs Mediate Human Embryonic Stem Cell-Derived Endothelial Cells: Proliferation, Apoptosis, and Angiogenesis	PLOS ONE			English	Article							SMOKE EXPOSURE; DIFFERENTIATION; TRANSPLANTATION; SURVIVAL; INHIBITION; GENERATION; PATHWAY	Background: Many patients with ischemic heart disease have cardiovascular risk factors such as cigarette smoking. We tested the effect of nicotine (a key component of cigarette smoking) on the therapeutic effects of human embryonic stem cell-derived endothelial cells (hESC-ECs). Methods and Results: To induce endothelial cell differentiation, undifferentiated hESCs (H9 line) underwent 4-day floating EB formation and 8-day outgrowth differentiation in EGM-2 media. After 12 days, CD31(+) cells (13.7 +/- 2.5%) were sorted by FACScan and maintained in EGM-2 media for further differentiation. After isolation, these hESC-ECs expressed endothelial specific markers such as vWF (96.3 +/- 1.4%), CD31 (97.2 +/- 2.5%), and VE-cadherin (93.7 +/- 2.8%), form vascular-like channels, and incorporated Dil-labeled acetylated low-density lipoprotein (Dil-Ac-LDL). Afterward, 5610 6 hESC-ECs treated for 24 hours with nicotine (10(-8) M) or PBS (as control) were injected into the hearts of mice undergoing LAD ligation followed by administration for two weeks of vehicle or nicotine (100 mu g/ml) in the drinking water. Surprisingly, bioluminescence imaging (BLI) showed significant improvement in the survival of transplanted hESC-ECs in the nicotine treated group at 6 weeks. Postmortem analysis confirmed increased presence of small capillaries in the infarcted zones. Finally, in vitro mechanistic analysis suggests activation of the MAPK and Akt pathways following activation of nicotinic acetylcholine receptors (nAChRs). Conclusions: This study shows for the first time that short-term systemic administrations of low dose nicotine can improve the survival of transplanted hESC-ECs, and enhance their angiogenic effects in vivo. Furthermore, activation of nAChRs has anti-apoptotic, angiogenic, and proliferative effects through MAPK and Akt signaling pathways.			Yu, J (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Cardiovasc Med, Xian 710032, Peoples R China.	joewu@stanford.edu	Li, Zongjin/A-1115-2014; Wilson, Kitchener/A-7146-2016; Li, Zongjin/G-3118-2010; Wu, Joseph/H-1067-2013	Li, Zongjin/0000-0002-4603-3743; Li, Zongjin/0000-0002-4603-3743; Wu, Joseph/0000-0002-6068-8041; Cooke, John/0000-0003-0033-9138; Huang, Ngan/0000-0003-2298-6790	NCI NIH HHS [R01 CA098303-04, R01 CA098303, NIH R01CA098303] Funding Source: Medline; NHLBI NIH HHS [1K12 HL087746, NIH HL091453, NIH R33 HL089027, R21 HL089027, R21 HL089027-03, K12 HL087746, K12 HL087746-04, R33 HL089027, R21 HL091453, R21 HL091453-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098303] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL087746, R33HL089027, R21HL091453, R21HL089027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURNS DM, 1991, CLIN CHEST MED, V12, P631; Cao F, 2006, CIRCULATION, V113, P1005, DOI 10.1161/CIRCULATIONAHA.105.588954; Chen CF, 2007, MAMM GENOME, V18, P316, DOI 10.1007/s00335-007-9032-6; Chen T, 2007, STEM CELLS, V25, P392, DOI 10.1634/stemcells.2006-0145; Cho SW, 2007, CIRCULATION, V116, P2409, DOI 10.1161/CIRCULATIONAHA.106.687038; Cooke JP, 2007, LIFE SCI, V80, P2347, DOI 10.1016/j.lfs.2007.01.061; Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103; Ferreira LS, 2007, CIRC RES, V101, P286, DOI 10.1161/CIRCRESAHA.107.150201; Finkelstein EI, 2001, AM J PHYSIOL-LUNG C, V281, pL732, DOI 10.1152/ajplung.2001.281.3.L732; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Heeschen C, 2003, J AM COLL CARDIOL, V41, P489, DOI 10.1016/S0735-1097(02)02818-8; Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676; Heeschen C, 2006, J AM COLL CARDIOL, V48, P2553, DOI 10.1016/j.jacc.2006.07.066; Heiss C, 2008, J AM COLL CARDIOL, V51, P1760, DOI 10.1016/j.jacc.2008.01.040; JIANG J, 2007, STEM CELLS, V17, P17; Klimanskaya I, 2008, NAT REV DRUG DISCOV, V7, P131, DOI 10.1038/nrd2403; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100; Levenberg S, 2007, BLOOD, V110, P806, DOI 10.1182/blood-2006-08-019190; Li ZJ, 2008, STEM CELLS, V26, P864, DOI 10.1634/stemcells.2007-0843; Li Z, 2007, CIRCULATION, V116, pI46, DOI 10.1161/CIRCULATIONAHA.106.680561; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu SJ, 2007, NAT METHODS, V4, P501, DOI 10.1038/nmeth1041; Michaud SE, 2003, FASEB J, V17, P1150, DOI 10.1096/fj.02-0172fje; Mills CM, 1997, ARCH DERMATOL, V133, P823, DOI 10.1001/archderm.133.7.823; Moon SY, 2006, MOL THER, V13, P5, DOI 10.1016/j.ymthe.2005.09.008; Rodriguez JW, 1999, IMMUNOPHARM IMMUNOT, V21, P379, DOI 10.3109/08923979909052769; Sadis C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000469; Schulz TC, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-27; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Sone M, 2007, ARTERIOSCL THROM VAS, V27, P2127, DOI 10.1161/ATVBAHA.107.143149; Sugimoto A, 2007, STEM CELLS DEV, V16, P649, DOI 10.1089/scd.2007.9991; Suzuki J, 2003, J AM COLL CARDIOL, V41, P482, DOI 10.1016/S0735-1097(02)02820-6; Swijnenburg RJ, 2008, P NATL ACAD SCI USA, V105, P12991, DOI 10.1073/pnas.0805802105; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Villablanca AC, 1998, J APPL PHYSIOL, V84, P2089, DOI 10.1152/jappl.1998.84.6.2089; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang ZZ, 2007, NAT BIOTECHNOL, V25, P317, DOI 10.1038/nbt1287; Xie XY, 2007, CLONING STEM CELLS, V9, P549, DOI 10.1089/clo.2007.0032; Yamahara K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001666; Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8	42	47	48	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7040	10.1371/journal.pone.0007040	http://dx.doi.org/10.1371/journal.pone.0007040			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753305	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796500020
J	Hesselson, SE; Matsson, P; Shima, JE; Fukushima, H; Yee, SW; Kobayashi, Y; Gow, JM; Ha, C; Ma, B; Poon, A; Johns, SJ; Stryke, D; Castro, RA; Tahara, H; Choi, JH; Chen, LG; Picard, N; Sjodin, E; Roelofs, MJE; Ferrin, TE; Myers, R; Kroetz, DL; Kwok, PY; Giacomini, KM				Hesselson, Stephanie E.; Matsson, Paer; Shima, James E.; Fukushima, Hisayo; Yee, Sook Wah; Kobayashi, Yuya; Gow, Jason M.; Ha, Connie; Ma, Benjamin; Poon, Annie; Johns, Susan J.; Stryke, Doug; Castro, Richard A.; Tahara, Harunobu; Choi, Ji Ha; Chen, Ligong; Picard, Nicolas; Sjodin, Elin; Roelofs, Maarke J. E.; Ferrin, Thomas E.; Myers, Richard; Kroetz, Deanna L.; Kwok, Pui-Yan; Giacomini, Kathleen M.			Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation	PLOS ONE			English	Article								Membrane transporters play crucial roles in the cellular uptake and efflux of an array of small molecules including nutrients, environmental toxins, and many clinically used drugs. We hypothesized that common genetic variation in the proximal promoter regions of transporter genes contribute to observed variation in drug response. A total of 579 polymorphisms were identified in the proximal promoters (-250 to +50 bp) and flanking 59 sequence of 107 transporters in the ATP Binding Cassette (ABC) and Solute Carrier (SLC) superfamilies in 272 DNA samples from ethnically diverse populations. Many transporter promoters contained multiple common polymorphisms. Using a sliding window analysis, we observed that, on average, nucleotide diversity (pi) was lowest at approximately 300 bp upstream of the transcription start site, suggesting that this region may harbor important functional elements. The proximal promoters of transporters that were highly expressed in the liver had greater nucleotide diversity than those that were highly expressed in the kidney consistent with greater negative selective pressure on the promoters of kidney transporters. Twenty-one promoters were evaluated for activity using reporter assays. Greater nucleotide diversity was observed in promoters with strong activity compared to promoters with weak activity, suggesting that weak promoters are under more negative selective pressure than promoters with high activity. Collectively, these results suggest that the proximal promoter region of membrane transporters is rich in variation and that variants in these regions may play a role in interindividual variation in drug disposition and response.			Hesselson, SE (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.	kathy.giacomini@ucsf.edu	Giacomini, Kathleen/AEF-2452-2022; Kwok, Pui-Yan/F-7725-2014; Chen, Ligong/F-7492-2016; Chen, Ligong/AAE-8536-2020; Picard, Nicolas/O-2410-2014	Kwok, Pui-Yan/0000-0002-5087-3059; Chen, Ligong/0000-0002-7893-7173; Picard, Nicolas/0000-0001-8460-903X; Matsson, Par/0000-0002-9094-2581; Yee, Sook Wah/0000-0001-8121-8746	NCRR NIH HHS [UL1 RR024131] Funding Source: Medline; NIGMS NIH HHS [U19 GM061390, U01 GM061390, GM61390] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U19GM061390, U01GM061390] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bleasby K, 2006, XENOBIOTICA, V36, P963, DOI 10.1080/00498250600861751; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Cooper SJ, 2006, GENOME RES, V16, P1, DOI 10.1101/gr.4222606; Fay JC, 2000, GENETICS, V155, P1405; Gao B, 2000, J PHARMACOL EXP THER, V294, P73; Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Haygood R, 2007, NAT GENET, V39, P1140, DOI 10.1038/ng2104; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; Hilgendorf C, 2007, DRUG METAB DISPOS, V35, P1333, DOI 10.1124/dmd.107.014902; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kimura M., 1983, NEUTRAL THEORY MOL E; Leabman MK, 2003, P NATL ACAD SCI USA, V100, P5896, DOI 10.1073/pnas.0730857100; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Mills RE, 2006, GENOME RES, V16, P1182, DOI 10.1101/gr.4565806; Mrazek DA, 2009, AM J MED GENET B, V150B, P341, DOI 10.1002/ajmg.b.30816; Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452; Ozawa N, 2004, PHARM RES-DORDR, V21, P2133, DOI 10.1023/B:PHAM.0000048207.11160.d0; Pasanen MK, 2006, PHARMACOGENET GENOM, V16, P873, DOI 10.1097/01.fpc.0000230416.82349.90; Poonkuzhali B, 2008, DRUG METAB DISPOS, V36, P780, DOI 10.1124/dmd.107.018366; Prades C, 2002, CYTOGENET GENOME RES, V98, P160, DOI 10.1159/000069852; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; ROWLAND M, 1995, CLIN PHARMACOKINET, P203; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; Sethupathy P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003137; Shu Y, 2008, CLIN PHARMACOL THER, V83, P273, DOI 10.1038/sj.clpt.6100275; Smith AD, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100114; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; TAHARA H, 2009, J PHARM EXP IN PRESS; TAJIMA F, 1989, GENETICS, V123, P585; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Wray GA, 2007, NAT REV GENET, V8, P206, DOI 10.1038/nrg2063; Yee SW, 2009, J PHARMACOL EXP THER, V328, P699, DOI 10.1124/jpet.108.147207	45	31	31	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6942	10.1371/journal.pone.0006942	http://dx.doi.org/10.1371/journal.pone.0006942			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742321	Green Published, gold			2022-12-27	WOS:000269622500015
J	Bencsik, A; Debeer, S; Petit, T; Baron, T				Bencsik, Anna; Debeer, Sabine; Petit, Thierry; Baron, Thierry			Possible Case of Maternal Transmission of Feline Spongiform Encephalopathy in a Captive Cheetah	PLOS ONE			English	Article								Feline spongiform encephalopathy (FSE) is considered to be related to bovine spongiform encephalopathy (BSE) and has been reported in domestic cats as well as in captive wild cats including cheetahs, first in the United Kingdom (UK) and then in other European countries. In France, several cases were described in cheetahs either imported from UK or born in France. Here we report details of two other FSE cases in captive cheetah including a 2(nd) case of FSE in a cheetah born in France, most likely due to maternal transmission. Complete prion protein immunohistochemical study on both brains and peripheral organs showed the close likeness between the two cases. In addition, transmission studies to the TgOvPrP4 mouse line were also performed, for comparison with the transmission of cattle BSE. The TgOvPrP4 mouse brains infected with cattle BSE and cheetah FSE revealed similar vacuolar lesion profiles, PrPd brain mapping with occurrence of typical florid plaques. Collectively, these data indicate that they harbor the same strain of agent as the cattle BSE agent. This new observation may have some impact on our knowledge of vertical transmission of BSE agent-linked TSEs such as in housecat FSE, or vCJD.			Bencsik, A (corresponding author), AFSSA, Unite ATNC, Lyon, France.	a.bencsik@afssa.fr	BENCSIK, Anna A/HGC-4260-2022	BENCSIK, Anna A/0000-0002-8671-6290				Baron T, 2004, J VIROL, V78, P6243, DOI 10.1128/JVI.78.12.6243-6251.2004; Baron T, 1997, VET REC, V141, P270, DOI 10.1136/vr.141.11.270; Baron T, 2007, EMERG INFECT DIS, V13, P1887, DOI 10.3201/eid1312.070635; Bellworthy SJ, 2005, VET REC, V157, P206, DOI 10.1136/vr.157.7.206; Bencsik A, 2005, J VIROL METHODS, V124, P197, DOI 10.1016/j.jviromet.2004.11.027; Bencsik A, 2007, HISTOCHEM CELL BIOL, V127, P531, DOI 10.1007/s00418-007-0276-8; Bencsik A, 2007, J INFECT DIS, V195, P989, DOI 10.1086/512087; Bencsik AA, 2006, J HISTOCHEM CYTOCHEM, V54, P849, DOI 10.1369/jhc.5C6895.2006; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1996, PRION DIS, P223; Cordier C, 2006, J GEN VIROL, V87, P3763, DOI 10.1099/vir.0.82062-0; Crozet C, 2001, EMBO REP, V2, P952, DOI 10.1093/embo-reports/kve204; Didier A, 2008, BIOCHEM BIOPH RES CO, V369, P841, DOI 10.1016/j.bbrc.2008.02.108; Donnelly CA, 1997, P ROY SOC B-BIOL SCI, V264, P1647, DOI 10.1098/rspb.1997.0229; Eloit M, 2005, VET REC, V156, P523, DOI 10.1136/vr.156.16.523-b; Foster JD, 2004, J GEN VIROL, V85, P3159, DOI 10.1099/vir.0.80099-0; FRASER H, 1994, VET REC, V134, P449, DOI 10.1136/vr.134.17.449; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; GREEN R, 2004, J COMP PATHOL, V40, P1; Hamir AN, 2002, J VET DIAGN INVEST, V14, P444, DOI 10.1177/104063870201400519; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Houston F, 2003, NATURE, V423, P498, DOI 10.1038/423498a; Ironside JW, 1997, LANCET, V350, P1475, DOI 10.1016/S0140-6736(05)64239-0; KIRKWOOD JK, 1994, VET REC, V135, P296, DOI 10.1136/vr.135.13.296; Kirkwood JK, 1995, J ZOO WILDLIFE MED, V26, P577; Konold T, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-14; Kratzel Christine, 2007, BMC Vet Res, V3, P22, DOI 10.1186/1746-6148-3-22; Lacroux C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000238; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Lezmi S, 2003, HISTOCHEM CELL BIOL, V119, P415, DOI 10.1007/s00418-003-0524-5; Ligios C, 2005, NAT MED, V11, P1137, DOI 10.1038/nm1105-1137; MURRAY K, 2009, J NEUROL NEUROSURG P; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Taylor DM, 1997, VET MICROBIOL, V58, P167, DOI 10.1016/S0378-1135(97)00165-X; Williams ES, 2003, REV SCI TECH OIE, V22, P145, DOI 10.20506/rst.22.1.1385; WILLOUGHBY K, 1992, VET REC, V131, P431, DOI 10.1136/vr.131.19.431; WYATT JM, 1991, VET REC, V129, P233, DOI 10.1136/vr.129.11.233; WYATT JM, 1990, VET REC	39	18	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6929	10.1371/journal.pone.0006929	http://dx.doi.org/10.1371/journal.pone.0006929			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738899	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300013
J	Wozniak, KL; Ravi, S; Macias, S; Young, ML; Olszewski, MA; Steele, C; Wormley, FL				Wozniak, Karen L.; Ravi, Sailatha; Macias, Sandra; Young, Mattie L.; Olszewski, Michal A.; Steele, Chad; Wormley, Floyd L., Jr.			Insights into the Mechanisms of Protective Immunity against Cryptococcus neoformans Infection Using a Mouse Model of Pulmonary Cryptococcosis	PLOS ONE			English	Article								Cryptococcus neoformans is an opportunistic fungal pathogen that causes life-threatening pneumonia and meningoencephalitis in immune compromised individuals. Previous studies have shown that immunization of BALB/c mice with an IFN gamma-producing C. neoformans strain, H99 gamma, results in complete protection against a second pulmonary challenge with an otherwise lethal cryptococcal strain. The current study evaluated local anamnestic cell-mediated immune responses against pulmonary cryptococcosis in mice immunized with C. neoformans strain H99 gamma compared to mice immunized with heat-killed C. neoformans (HKC.n.). Mice immunized with C. neoformans strain H99 gamma had significantly reduced pulmonary fungal burden post-secondary challenge compared to mice immunized with HKC.n. Protection against pulmonary cryptococcosis was associated with increased pulmonary granulomatous formation and leukocyte infiltration followed by a rapid resolution of pulmonary inflammation, which protected the lungs from severe allergic bronchopulmonary mycosis (ABPM)-pathology that developed in the lungs of mice immunized with HKC.n. Pulmonary challenge of interleukin (IL)-4 receptor, IL-12p40, IL-12p35, IFN-gamma, T cell and B cell deficient mice with C. neoformans strain H99 gamma demonstrated a requirement for Th1-type T cell-mediated immunity, but not B cell-mediated immunity, for the induction of H99 gamma-mediated protective immune responses against pulmonary C. neoformans infection. CD4(+) T cells, CD11c(+) cells, and Gr-1(+) cells were increased in both proportion and absolute number in protected mice. In addition, significantly increased production of Th1-type/pro-inflammatory cytokines and chemokines, and conversely, reduced Th2-type cytokine production was observed in the lungs of protected mice. Interestingly, protection was not associated with increased production of cytokines IFN-gamma or TNF-alpha in lungs of protected mice. In conclusion, immunization with C. neoformans strain H99 gamma results in the development of protective anti-cryptococcal immune responses that may be measured and subsequently used in the development of immune-based therapies to combat pulmonary cryptococcosis.			Wozniak, KL (corresponding author), Univ Texas San Antonio, Dept Biol, San Antonio, TX USA.	floyd.wormley@utsa.edu	RAVI, Sailatha/AAT-2514-2020	RAVI, Sailatha/0000-0002-5527-4805; OLSZEWSKI, MICHAL/0000-0001-7474-0843; Wozniak, Karen/0000-0003-1798-2146	NHLBI NIH HHS [R01 HL080317, HL080317] Funding Source: Medline; NIAID NIH HHS [R01 AI071752-03, R01 AI071752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allendoerfer R, 1998, J IMMUNOL, V160, P6072; Allendoerfer Ruth, 1998, Revista Iberoamericana de Micologia, V15, P256; Arora S, 2005, J IMMUNOL, V174, P6346, DOI 10.4049/jimmunol.174.10.6346; Bauman SK, 2003, INFECT IMMUN, V71, P68, DOI 10.1128/IAI.71.1.68-74.2003; Biondo C, 2002, INFECT IMMUN, V70, P2383, DOI 10.1128/IAI.70.5.2383-2391.2002; Blackstock R, 1999, INFECT IMMUN, V67, P3601, DOI 10.1128/IAI.67.7.3601-3609.1999; BLASI E, 1994, INFECT IMMUN, V62, P3189, DOI 10.1128/IAI.62.8.3189-3196.1994; Buchanan KL, 2000, INFECT IMMUN, V68, P456, DOI 10.1128/IAI.68.2.456-462.2000; Cain JA, 1998, INFECT IMMUN, V66, P1473, DOI 10.1128/IAI.66.4.1473-1481.1998; Casadevall A, 2005, CURR MOL MED, V5, P421, DOI 10.2174/1566524054022567; CASADEVALL A, 1995, INFECT IMMUN, V63, P4211, DOI 10.1128/IAI.63.11.4211-4218.1995; Casadevall A, 1998, TRENDS MICROBIOL, V6, P102, DOI 10.1016/S0966-842X(98)01208-6; Chen GH, 2008, INFECT IMMUN, V76, P2379, DOI 10.1128/IAI.01143-07; Chen GH, 2007, AM J PATHOL, V170, P1028, DOI 10.2353/ajpath.2007.060595; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; CLEMONS KV, 1994, ANTIMICROB AGENTS CH, V38, P460, DOI 10.1128/AAC.38.3.460; Cox GM, 2000, INFECT IMMUN, V68, P443, DOI 10.1128/IAI.68.2.443-448.2000; Cox GM, 2001, MOL MICROBIOL, V39, P166, DOI 10.1046/j.1365-2958.2001.02236.x; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Dalod M, 2003, J EXP MED, V197, P885, DOI 10.1084/jem.20021522; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Decken K, 1998, INFECT IMMUN, V66, P4994, DOI 10.1128/IAI.66.10.4994-5000.1998; Deepe GS, 2006, J INFECT DIS, V193, P322; DROMER F, 1987, INFECT IMMUN, V55, P749, DOI 10.1128/IAI.55.3.749-752.1987; Graybill JR, 1997, J MED VET MYCOL, V35, P243; Herring AC, 2002, INFECT IMMUN, V70, P2959, DOI 10.1128/IAI.70.6.2959-2964.2002; Herring AC, 2005, INFECT IMMUN, V73, P39, DOI 10.1128/IAI.73.1.39-49.2005; HILL JO, 1991, J EXP MED, V173, P755, DOI 10.1084/jem.173.3.755; Huang C, 2002, INFECT IMMUN, V70, P5485, DOI 10.1128/IAI.70.10.5485-5493.2002; Huffnagle GB, 1996, J IMMUNOL, V157, P4529; Huffnagle GB, 1998, RES IMMUNOL, V149, P387, DOI 10.1016/S0923-2494(98)80762-1; HUFFNAGLE GB, 1994, J LEUKOCYTE BIOL, V55, P35, DOI 10.1002/jlb.55.1.35; HUFFNAGLE GB, 1991, INFECT IMMUN, V59, P1423, DOI 10.1128/IAI.59.4.1423-1433.1991; HUFFNAGLE GB, 1991, J EXP MED, V173, P793, DOI 10.1084/jem.173.4.793; JOLY V, 1994, J INFECT DIS, V170, P1331, DOI 10.1093/infdis/170.5.1331; Kawakami K, 1996, CLIN EXP IMMUNOL, V106, P468, DOI 10.1046/j.1365-2249.1996.d01-870.x; Kawakami K, 1997, INFECT IMMUN, V65, P1307, DOI 10.1128/IAI.65.4.1307-1312.1997; Kawakami K, 1996, CLIN EXP IMMUNOL, V104, P208, DOI 10.1046/j.1365-2249.1996.14723.x; Kawakami K, 1996, FEMS IMMUNOL MED MIC, V13, P123, DOI 10.1016/0928-8244(95)00093-3; Kawakami K, 1997, J IMMUNOL, V159, P5528; Koguchi Yoshinobu, 2002, Int Rev Immunol, V21, P423, DOI 10.1080/08830180213274; Levitz SM, 2001, P NATL ACAD SCI USA, V98, P10422, DOI 10.1073/pnas.181331398; LEVITZ SM, 1991, REV INFECT DIS, V13, P1163; Luberto C, 2003, J CLIN INVEST, V112, P1080, DOI 10.1172/JCI200318309; Lutz JE, 2000, J ANTIMICROB CHEMOTH, V46, P437, DOI 10.1093/jac/46.3.437; Mandel MA, 2000, INFECT IMMUN, V68, P6196, DOI 10.1128/IAI.68.11.6196-6201.2000; Mednick AJ, 2003, EUR J IMMUNOL, V33, P1744, DOI 10.1002/eji.200323626; MITCHELL TG, 1995, CLIN MICROBIOL REV, V8, P515, DOI 10.1128/CMR.8.4.515; MODY CH, 1990, J IMMUNOL, V144, P1472; Mordue DG, 2003, J LEUKOCYTE BIOL, V74, P1015, DOI 10.1189/jlb.0403164; Muller U, 2007, J IMMUNOL, V179, P5367, DOI 10.4049/jimmunol.179.8.5367; MUKHERJEE J, 1993, P NATL ACAD SCI USA, V90, P3636, DOI 10.1073/pnas.90.8.3636; Murphy JW, 1998, INFECT IMMUN, V66, P2632, DOI 10.1128/IAI.66.6.2632-2639.1998; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Osterholzer JJ, 2008, J IMMUNOL, V181, P610, DOI 10.4049/jimmunol.181.1.610; Pappas PG, 2004, J INFECT DIS, V189, P2185, DOI 10.1086/420829; Santangelo R, 2004, INFECT IMMUN, V72, P2229, DOI 10.1128/IAI.72.4.2229-2239.2004; Shoham S, 2005, BRIT J HAEMATOL, V129, P569, DOI 10.1111/j.1365-2141.2005.05397.x; Singh N, 1997, CLIN TRANSPLANT, V11, P66; Singh N, 2008, CLIN INFECT DIS, V47, P1321, DOI 10.1086/592690; Voelz K, 2009, INFECT IMMUN; Wormley FL, 2007, INFECT IMMUN, V75, P1453, DOI 10.1128/IAI.00274-06; Wuthrich M, 2002, J IMMUNOL, V169, P6969, DOI 10.4049/jimmunol.169.12.6969; Yauch LE, 2006, PLOS PATHOG, V2, P1060, DOI 10.1371/journal.ppat.0020120; Young M, 2009, PROTEOMICS, V9, P2578, DOI 10.1002/pmic.200800713; Zhou P, 1998, J IMMUNOL, V160, P1359; Zhou Q, 2007, J IMMUNOL, V178, P5753, DOI 10.4049/jimmunol.178.9.5753	67	76	79	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6854	10.1371/journal.pone.0006854	http://dx.doi.org/10.1371/journal.pone.0006854			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727388	gold, Green Published, Green Submitted			2022-12-27	WOS:000269522900006
J	Not, F; del Campo, J; Balague, V; de Vargas, C; Massana, R				Not, Fabrice; del Campo, Javier; Balague, Vanessa; de Vargas, Colomban; Massana, Ramon			New Insights into the Diversity of Marine Picoeukaryotes	PLOS ONE			English	Article							16S RIBOSOMAL-RNA; DNA; PCR; SEQUENCES; LIBRARIES; OCEAN; GENE; AMPLIFICATION	Over the last decade, culture-independent surveys of marine picoeukaryotic diversity based on 18S ribosomal DNA clone libraries have unveiled numerous sequences of novel high-rank taxa. This newfound diversity has significantly altered our understanding of marine microbial food webs and the evolution of eukaryotes. However, the current picture of marine eukaryotic biodiversity may be significantly skewed by PCR amplification biases, occurrence of rDNA genes in multiple copies within a single cell, and the capacity of DNA to persist as extracellular material. In this study we performed an analysis of the metagenomic dataset from the Global Ocean Survey (GOS) expedition, seeking eukaryotic ribosomal signatures. This PCR-free approach revealed similar phylogenetic patterns to clone library surveys, suggesting that PCR steps do not impose major biases in the exploration of environmental DNA. The different cell size fractions within the GOS dataset, however, displayed a distinct picture. High protistan diversity in the <0.8 mu m size fraction, in particular sequences from radiolarians and ciliates (and their absence in the 0.8-3 mu m fraction), suggest that most of the DNA in this fraction comes from extracellular material from larger cells. In addition, we compared the phylogenetic patterns from rDNA and reverse transcribed rRNA 18S clone libraries from the same sample harvested in the Mediterranean Sea. The libraries revealed major differences, with taxa such as pelagophytes or picobiliphytes only detected in the 18S rRNA library. MAST (Marine Stramenopiles) appeared as potentially prominent grazers and we observed a significant decrease in the contribution of alveolate and radiolarian sequences, which overwhelmingly dominated rDNA libraries. The rRNA approach appears to be less affected by taxon-specific rDNA copy number and likely better depicts the biogeochemical significance of marine protists.			Not, F (corresponding author), CSIC, Inst Ciencies Mar, Barcelona, Spain.	not@sb-roscoff.fr	del Campo, Javier/B-5233-2008; Massana, Ramon/F-4205-2016	del Campo, Javier/0000-0002-5292-1421; de Vargas, Colomban/0000-0002-6476-6019; Massana, Ramon/0000-0001-9172-5418				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Buckley BA, 2004, MAR ECOL PROG SER, V282, P143, DOI 10.3354/meps282143; Chambouvet A, 2008, SCIENCE, V322, P1254, DOI 10.1126/science.1164387; Cottrell MT, 2005, ENVIRON MICROBIOL, V7, P1883, DOI 10.1111/j.1462-2920.2005.00762.x; COURTIES C, 1994, NATURE, V370, P255, DOI 10.1038/370255a0; Dell'Anno A, 2005, SCIENCE, V309, P2179, DOI 10.1126/science.1117475; ELWOOD HJ, 1985, MOL BIOL EVOL, V2, P399; Epstein S, 2008, BIODIVERS CONSERV, V17, P261, DOI 10.1007/s10531-007-9250-y; Fuller NJ, 2006, AQUAT MICROB ECOL, V43, P79, DOI 10.3354/ame043079; Gentile G, 2006, ENVIRON MICROBIOL, V8, P2150, DOI 10.1111/j.1462-2920.2006.01097.x; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P720, DOI 10.1128/jb.170.2.720-726.1988; GODHE A, 2008, APPL ENV MICROBIOLOG; Guillou L, 2008, ENVIRON MICROBIOL, V10, P3349, DOI 10.1111/j.1462-2920.2008.01731.x; JIANG SC, 1995, APPL ENVIRON MICROB, V61, P317, DOI 10.1128/AEM.61.1.317-325.1995; Jurgens K., 2008, MICROB ECOL OCEAN, P383, DOI [DOI 10.1002/9780470281840.CH11, 10.1002/9780470281840.ch11]; Kirchman DL, 2002, FEMS MICROBIOL ECOL, V39, P91, DOI 10.1111/j.1574-6941.2002.tb00910.x; Liles MR, 2003, APPL ENVIRON MICROB, V69, P2684, DOI 10.1128/AEM.69.5.2684-2691.2003; LIU H, 2009, P NATL ACAD IN PRESS; Lopez-Garcia P, 2001, NATURE, V409, P603, DOI 10.1038/35054537; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Massana R, 2004, APPL ENVIRON MICROB, V70, P3528, DOI 10.1128/AEM.70.6.3528-3534.2004; Massana R, 2008, CURR OPIN MICROBIOL, V11, P213, DOI 10.1016/j.mib.2008.04.004; Massana R, 2006, ENVIRON MICROBIOL, V8, P1515, DOI 10.1111/j.1462-2920.2006.01042.x; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Mills HJ, 2005, APPL ENVIRON MICROB, V71, P3235, DOI 10.1128/AEM.71.6.3235-3247.2005; Moeseneder MM, 2005, FEMS MICROBIOL ECOL, V51, P341, DOI 10.1016/j.femsec.2004.09.012; Not F, 2004, APPL ENVIRON MICROB, V70, P4064, DOI 10.1128/AEM.70.7.4064-4072.2004; Not F, 2008, DEEP-SEA RES PT I, V55, P1456, DOI 10.1016/j.dsr.2008.06.007; Not F, 2007, ENVIRON MICROBIOL, V9, P1233, DOI 10.1111/j.1462-2920.2007.01247.x; Not F, 2007, SCIENCE, V315, P253, DOI 10.1126/science.1136264; PAUL JH, 1990, APPL ENVIRON MICROB, V56, P1963, DOI 10.1128/AEM.56.6.1963-1966.1990; Piganeau G, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r5; POULSEN LK, 1993, APPL ENVIRON MICROB, V59, P1354, DOI 10.1128/AEM.59.5.1354-1360.1993; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Schloss PD, 2006, APPL ENVIRON MICROB, V72, P6773, DOI 10.1128/AEM.00474-06; Schloss PD, 2005, APPL ENVIRON MICROB, V71, P1501, DOI 10.1128/AEM.71.3.1501-1506.2005; Seshadri R, 2007, PLOS BIOL, V5, P394, DOI 10.1371/journal.pbio.0050075; SHI X, NOVEL PHOTOSYN UNPUB; Singleton DR, 2001, APPL ENVIRON MICROB, V67, P4374, DOI 10.1128/AEM.67.9.4374-4376.2001; Stoeck T, 2007, MICROB ECOL, V53, P328, DOI 10.1007/s00248-006-9166-1; Suzuki MT, 1996, APPL ENVIRON MICROB, V62, P625, DOI 10.1128/AEM.62.2.625-630.1996; Thornhill DJ, 2007, MOL ECOL, V16, P5326, DOI 10.1111/j.1365-294X.2007.03576.x; Vaulot D, 2002, TRENDS MICROBIOL, V10, P266, DOI 10.1016/S0966-842X(02)02366-1; Vlassov VV, 2007, BIOESSAYS, V29, P654, DOI 10.1002/bies.20604; von Wintzingerode F, 1997, FEMS MICROBIOL REV, V21, P213; Worden A Z, 2008, MICROECOL OCEANS, V2, P159, DOI [10.1002/9780470281840.ch6, DOI 10.1002/9780470281840.CH6]; Zhu F, 2005, FEMS MICROBIOL ECOL, V52, P79, DOI 10.1016/j.femsec.2004.10.006	47	168	170	1	66	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7143	10.1371/journal.pone.0007143	http://dx.doi.org/10.1371/journal.pone.0007143			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787059	gold, Green Published			2022-12-27	WOS:000270290100004
J	Dawson, W; Yamamoto, K				Dawson, Wayne; Yamamoto, Kenji			Home Educating in an Extended Family Culture and Aging Society May Fare Best during a Pandemic	PLOS ONE			English	Article							INFLUENZA; EPIDEMIC; TIME; STRATEGIES; FARMERS	Large cities can contain populations that move rapidly from one section to another in an efficient transportation network. An emerging air-borne or contact based pathogen could use these transportation routes to rapidly spread an infection throughout an entire population in a short time. Further, in many developed countries, the aging population is increasing. The family structure in these societies may also affect the course of a disease. To help understand the impact of an epidemic on family structure in a networked population, an individual based computer model that randomly generates networked cities with a specified range of population and disease characteristics and individual schedules, infectivity, transmission and hygiene factors was developed. Several salient issues emerged. First, a city of highly active individuals may in fact diminish the number of fatalities because the average duration of the interactions between agents is reduced. Second, home schooling can significantly improve survival because the institutional clustering of weak individuals is minimized. Third, the worst scenario for an aging population is the nuclear family where the aged population is confined to large housing facilities. Naturally, hygiene is the first barrier to infection. The results suggest that societies where extended families and small groups manage most of their own affairs may also be the most suitable for defense against a pandemic. This may prove applicable in city planning and policy making.			Dawson, W (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bioinformat Engn Lab,Bunkyo Ku, Tokyo, Japan.	dawson@bi.a.u-tokyo.ac.jp	Dawson, Wayne/AAY-5576-2020; YAMAMOTO, Kenji/I-1758-2013	Dawson, Wayne/0000-0001-7751-7778; 				Anderson GF, 2000, HEALTH AFFAIR, V19, P191, DOI 10.1377/hlthaff.19.3.191; ATTI MLC, 2008, PLOS ONE, V3, P1790; BARRETT CL, 2005, SMALLPOX STRIKES POR, P32; Bartlett H P, 1995, Korea J Popul Dev, V24, P181; Beggs CB, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-114; Bettencourt LMA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002185; Bolzoni L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000747; Caley P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000143; Chaix R, 2007, CURR BIOL, V17, P43, DOI 10.1016/j.cub.2006.10.058; Chowell G, 2003, J THEOR BIOL, V224, P1, DOI 10.1016/S0022-5193(03)00228-5; Curry A, 2008, SCIENCE, V319, P278, DOI 10.1126/science.319.5861.278; Diamond J, 2003, SCIENCE, V300, P597, DOI 10.1126/science.1078208; Fraser C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000758; Guan Y, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-132; Haak W, 2005, SCIENCE, V310, P1016, DOI 10.1126/science.1118725; Iwami S, 2008, J THEOR BIOL, V252, P732, DOI 10.1016/j.jtbi.2008.02.020; Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536; Kerneis S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001478; Lawler A, 2008, SCIENCE, V320, P1276, DOI 10.1126/science.320.5881.1276; Lawler A, 2008, SCIENCE, V320, P1281, DOI 10.1126/science.320.5881.1281; Le Souef PN, 2000, LANCET, V356, P242; LEVINE J, 2006, SCI AGING KNOWLEDGE, pPE16, DOI DOI 10.1126/SAGEKE.2006.10.PE16; Martin L G, 1989, Popul Bull, V44, P1; Moghadas SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001839; Neumann K, 2003, SCIENCE, V301, P180, DOI 10.1126/science.1086677; Patel MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002269; POIRIER FE, 1987, UNDERSTANDING HUMAN; Skeik N, 2008, INT J INFECT DIS, V12, P233, DOI 10.1016/j.ijid.2007.07.002; Ster IC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000502; Takeuchi F, 2006, J THEOR BIOL, V243, P39, DOI 10.1016/j.jtbi.2006.05.033; Taleb NN, 2005, FOOLED RANDOMNESS HI; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Ur JA, 2007, SCIENCE, V317, P1188, DOI 10.1126/science.1138728; Uys PW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000757; Yashiro N, 1997, J Asian Econ, V8, P245; YASUDA H, 2008, J URBAN HLTH B NEW Y; Zietz BP, 2004, INT J HYG ENVIR HEAL, V207, P165, DOI 10.1078/1438-4639-00259	37	1	1	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7221	10.1371/journal.pone.0007221	http://dx.doi.org/10.1371/journal.pone.0007221			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784366	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290000018
J	Li, HC; Sekine, M; Seng, S; Avraham, S; Avraham, HK				Li, Huchun; Sekine, Masayuki; Seng, Seyha; Avraham, Shalom; Avraham, Hava Karsenty			BRCA1 Interacts with Smad3 and Regulates Smad3-Mediated TGF-beta Signaling during Oxidative Stress Responses	PLOS ONE			English	Article								Background: BRCA1 is a key regulatory protein participating in cell cycle checkpoint and DNA damage repair networks. BRCA1 plays important roles in protecting numerous cellular processes in response to cell damaging signals. Transforming growth factor-beta (TGF-beta) is a potent regulator of growth, apoptosis and invasiveness of tumor cells. TFG-beta activates Smad signaling via its two cell surface receptors, the TbetaRII and ALK5/TbetaRI, leading to Smad-mediated transcriptional regulation. Methodology/Principal Findings: Here, we report an important role of BRCA1 in modulating TGF-beta signaling during oxidative stress responses. Wild-type (WT) BRCA1, but not mutated BRCA1 failed to activate TGF-beta mediated transactivation of the TGF-beta responsive reporter, p3TP-Lux. Further, WT-BRCA1, but not mutated BRCA1 increased the expression of Smad3 protein in a dose-dependent manner, while silencing of WT-BRCA1 by siRNA decreased Smad3 and Smad4 interaction induced by TGF-beta in MCF-7 breast cancer cells. BRCA1 interacted with Smad3 upon TGF-beta 1 stimulation in MCF-7 cells and this interaction was mediated via the domain of 298-436aa of BRCA1 and Smad3 domain of 207-426aa. In addition, H2O2 increased the colocalization and the interaction of Smad3 with WT-BRCA1. Interestingly, TGF-beta 1 induced Smad3 and Smad4 interaction was increased in the presence of H2O2 in cells expressing WT-BRCA1, while the TGF-beta 1 induced interaction between Smad3 and Smad4 was decreased upon H2O2 treatment in a dose-dependent manner in HCC1937 breast cancer cells, deficient for endogenous BRCA1. This interaction between Smad3 and Smad4 was increased in reconstituted HCC1937 cells expressing WT-BRCA1 (HCC1937/BRCA1). Further, loss of BRCA1 resulted in H2O2 induced nuclear export of phosphor-Smad3 protein to the cytoplasm, resulting decreased of Smad3 and Smad4 interaction induced by TGF-beta and in significant decrease in Smad3 and Smad4 transcriptional activities. Conclusions/Significance: These results strongly suggest that loss or reduction of BRCA1 alters TGF-beta growth inhibiting activity via Smad3 during oxidative stress responses.			Li, HC (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02215 USA.	havraham@bidmc.harvard.edu	Sekine, Masayuki/AAB-8321-2022	Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA135226, R21 CA135226, R01 CA096805, CA096805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA135226, R01CA096805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dubrovska A, 2005, ONCOGENE, V24, P2289, DOI 10.1038/sj.onc.1208443; Gilmore PM, 2004, CANCER RES, V64, P4148, DOI 10.1158/0008-5472.CAN-03-4080; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; Gupta V, 2004, CURR CANCER DRUG TAR, V4, P165, DOI 10.2174/1568009043481542; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kang HJ, 2006, J BIOL CHEM, V281, P13047, DOI 10.1074/jbc.M513033200; Kawabata M, 1999, ANN NY ACAD SCI, V886, P73, DOI 10.1111/j.1749-6632.1999.tb09402.x; Kim YK, 2006, CELL SIGNAL, V18, P236, DOI 10.1016/j.cellsig.2005.04.008; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurisaki A, 2006, MOL CELL BIOL, V26, P1318, DOI 10.1128/MCB.26.4.1318-1332.2006; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; Lin DB, 2005, J BIOL CHEM, V280, P13682, DOI 10.1074/jbc.M407762200; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371; Orian A, 2001, Sci STKE, V2001, ppe1; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Seong HA, 2007, J BIOL CHEM, V282, P12272, DOI 10.1074/jbc.M609279200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Starita LM, 2006, CANCER BIOL THER, V5, P137, DOI 10.4161/cbt.5.2.2479; Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xiao CY, 2007, CELL, V128, P977, DOI 10.1016/j.cell.2007.01.034; Xiao Z, 2003, J BIOL CHEM, V278, P34245, DOI 10.1074/jbc.M301596200; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2006, BBA-GENE STRUCT EXPR, V1759, P503, DOI 10.1016/j.bbaexp.2006.11.001; Yakmovych I, 2001, FASEB J, V15, P553; Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140	41	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7091	10.1371/journal.pone.0007091	http://dx.doi.org/10.1371/journal.pone.0007091			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768112	gold, Green Published, Green Submitted			2022-12-27	WOS:000270154000004
J	Orgel, JPRO; Eid, A; Antipova, O; Bella, J; Scott, JE				Orgel, Joseph P. R. O.; Eid, Aya; Antipova, Olga; Bella, Jordi; Scott, John E.			Decorin Core Protein (Decoron) Shape Complements Collagen Fibril Surface Structure and Mediates Its Binding	PLOS ONE			English	Article								Decorin is the archetypal small leucine rich repeat proteoglycan of the vertebrate extracellular matrix (ECM). With its glycosaminoglycuronan chain, it is responsible for stabilizing inter-fibrillar organization. Type I collagen is the predominant member of the fibrillar collagen family, fulfilling both organizational and structural roles in animal ECMs. In this study, interactions between decoron (the decorin core protein) and binding sites in the d and e(1) bands of the type I collagen fibril were investigated through molecular modeling of their respective X-ray diffraction structures. Previously, it was proposed that a model-based, highly curved concave decoron interacts with a single collagen molecule, which would form extensive van der Waals contacts and give rise to strong non-specific binding. However, the large well-ordered aggregate that is the collagen fibril places significant restraints on modes of ligand binding and necessitates multi-collagen molecular contacts. We present here a relatively high-resolution model of the decoron-fibril collagen complex. We find that the respective crystal structures complement each other well, although it is the monomeric form of decoron that shows the most appropriate shape complementarity with the fibril surface and favorable calculated energies of interaction. One molecule of decoron interacts with four to six collagen molecules, and the binding specificity relies on a large number of hydrogen bonds and electrostatic interactions, primarily with the collagen motifs KXGDRGE and AKGDRGE (d and e(1) bands). This work helps us to understand collagen-decorin interactions and the molecular architecture of the fibrillar ECM in health and disease.			Orgel, JPRO (corresponding author), IIT, Pritzker Inst Biomed Sci & Engn, BioCAT Ctr, Chicago, IL 60616 USA.	orgel@iit.edu	Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562	NCRR NIH HHS [RR08630, P41 RR008630] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bella J, 2008, CELL MOL LIFE SCI, V65, P2307, DOI 10.1007/s00018-008-8019-0; Camacho CJ, 2005, BIOINFORMATICS, V21, P2534, DOI 10.1093/bioinformatics/bti322; Christopher NA, 1996, COMPUT CHEM, V20, P339, DOI 10.1016/0097-8485(95)00075-5; Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064; Fischer E, 2002, J MOL STRUCT, V602, P303, DOI 10.1016/S0022-2860(01)00733-5; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; Haverkamp RG, 2005, BIOMACROMOLECULES, V6, P1816, DOI 10.1021/bm0500392; Hooft RWW, 1996, PROTEINS, V26, P363; HULMES DJS, 1981, P NATL ACAD SCI-BIOL, V78, P3567, DOI 10.1073/pnas.78.6.3567; HULMES DJS, 1995, BIOPHYS J, V68, P1661, DOI 10.1016/S0006-3495(95)80391-7; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kalamajski S, 2007, J BIOL CHEM, V282, P16062, DOI 10.1074/jbc.M700073200; Kimura S, 1995, J ELECTRON MICROSC, V44, P445; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; McEwan PA, 2006, J STRUCT BIOL, V155, P294, DOI 10.1016/j.jsb.2006.01.016; MEEK KM, 1985, J MICROSC-OXFORD, V139, P205, DOI 10.1111/j.1365-2818.1985.tb02637.x; Nareyeck G, 2004, EUR J BIOCHEM, V271, P3389, DOI 10.1111/j.1432-1033.2004.04273.x; Orgel JPRO, 2006, P NATL ACAD SCI USA, V103, P9001, DOI 10.1073/pnas.0502718103; Perumal S, 2008, P NATL ACAD SCI USA, V105, P2824, DOI 10.1073/pnas.0710588105; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCOTT JE, 1981, BIOCHEM J, V195, P573, DOI 10.1042/bj1950573; Scott JE, 1998, J ANAT, V192, P391, DOI 10.1046/j.1469-7580.1998.19230391.x; Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1984, BIOCHEM J, V218, P229, DOI 10.1042/bj2180229; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; Scott John E., 1993, Biochemical Society Transactions, V21, p123S; Scott JE, 2008, BIORHEOLOGY, V45, P209, DOI 10.3233/BIR-2008-0477; Scott JE, 2006, J PHYSIOL-LONDON, V574, P643, DOI 10.1113/jphysiol.2006.108100; Scott PG, 2006, J BIOL CHEM, V281, P13324, DOI 10.1074/jbc.M513470200; Scott PG, 2006, J BIOMECH, V39, P1159, DOI 10.1016/j.jbiomech.2006.01.011; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Sweeney SM, 2008, J BIOL CHEM, V283, P21187, DOI 10.1074/jbc.M709319200; TROTTER JA, 1989, CELL TISSUE RES, V258, P527; Twardowski T, 2007, CURR PHARM DESIGN, V13, P3608, DOI 10.2174/138161207782794176; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wiehe K, 2007, PROTEINS, V69, P719, DOI 10.1002/prot.21747; YU L, 1993, DERMATAN SULPHATE PR, P183	47	101	104	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7028	10.1371/journal.pone.0007028	http://dx.doi.org/10.1371/journal.pone.0007028			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753304	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796500013
J	Bax, M; van Vliet, SJ; Litjens, M; Garcia-Vallejo, JJ; van Kooyk, Y				Bax, Marieke; van Vliet, Sandra J.; Litjens, Manja; Garcia-Vallejo, Juan J.; van Kooyk, Yvette			Interaction of Polysialic Acid with CCL21 Regulates the Migratory Capacity of Human Dendritic Cells	PLOS ONE			English	Article							GLYCOSYLATION; MATURATION; CHEMOKINES; RECOGNITION; ACTIVATION; INHIBITOR; ANTIGENS; IMMATURE; MEMBER	Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs). Immature DCs (iDCs) are situated in the periphery where they capture pathogen. Subsequently, they migrate as mature DCs (mDCs) to draining lymph nodes to activate T cells. CCR7 and CCL21 contribute to the migratory capacity of the DC, but it is not completely understood what molecular requirements are involved. Here we demonstrate that monocyte-derived DCs dramatically change ST8Sia IV expression during maturation, leading to the generation of polysialic acid (polySia). PolySia expression is highly upregulated after 2 days Toll-like receptor-4 (TLR4) triggering. Surprisingly, only immunogenic and not tolerogenic mDCs upregulated polySia expression. Furthermore, we show that polySia expression on DCs is required for CCL21 directed migration, whereby polySia directly captures CCL21. Corresponding to polySia, the expression level of CCR7 is maximal two days after TLR4 triggering. In contrast, although TLR agonists other than LPS induce upregulation of CCR7, they achieve only a moderate polySia expression. In situ we could detect polySia expressing APCs in the T cell zone of the lymph node and in the deep dermis. Together our results indicate that prolonged TLR4 engagement is required for the generation of polySia-expressing DCs that facilitate CCL21 capture and subsequent CCL21-directed migration.			Bax, M (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.	y.vankooyk@vumc.nl	Garcia-Vallejo, Juan/H-4162-2012; Van Vliet, Sandra/AAO-9534-2020; Vallejo, Juan Garcia/AAA-3765-2020	Garcia-Vallejo, Juan/0000-0001-6238-7069; Van Kooyk, Yvette/0000-0001-5997-3665; van Vliet, Sandra/0000-0003-1811-2687				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bax M, 2007, J IMMUNOL, V179, P8216, DOI 10.4049/jimmunol.179.12.8216; Bros M, 2007, BLOOD, V109, P3820, DOI 10.1182/blood-2006-07-035576; Cebo C, 2002, BBA-GEN SUBJECTS, V1572, P422, DOI 10.1016/S0304-4165(02)00323-9; Curreli S, 2007, J BIOL CHEM, V282, P30346, DOI 10.1074/jbc.M702965200; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; FINNE J, 1982, J BIOL CHEM, V257, P1966; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HUANG J, 1992, ONCOL RES, V4, P507; Jenner J, 2006, EXP HEMATOL, V34, P1212, DOI 10.1016/j.exphem.2006.04.016; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Morgan R, 2004, J IMMUNOL, V173, P7200, DOI 10.4049/jimmunol.173.12.7200; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Rutishauser U, 2008, NAT REV NEUROSCI, V9, P26, DOI 10.1038/nrn2285; Scandella E, 2004, BLOOD, V103, P1595, DOI 10.1182/blood-2003-05-1643; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Veerman KM, 2007, NAT IMMUNOL, V8, P532, DOI 10.1038/ni1456; Vizzardelli C, 2006, EUR J IMMUNOL, V36, P1504, DOI 10.1002/eji.200535488; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; Yanagihara S, 1998, J IMMUNOL, V161, P3096; ZUBER C, 1992, J BIOL CHEM, V267, P9965	30	32	32	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6987	10.1371/journal.pone.0006987	http://dx.doi.org/10.1371/journal.pone.0006987			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750015	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796300010
J	Hou, YB; Lin, SJ				Hou, Yubo; Lin, Senjie			Distinct Gene Number-Genome Size Relationships for Eukaryotes and Non-Eukaryotes: Gene Content Estimation for Dinoflagellate Genomes	PLOS ONE			English	Article							DNA-CONTENT; BINDING-PROTEIN; SYMBIODINIUM; ORGANIZATION; SEQUENCE; EVOLUTION; SMALLEST; TRENDS; CYCLE	The ability to predict gene content is highly desirable for characterization of not-yet sequenced genomes like those of dinoflagellates. Using data from completely sequenced and annotated genomes from phylogenetically diverse lineages, we investigated the relationship between gene content and genome size using regression analyses. Distinct relationships between log(10)-transformed protein-coding gene number (Y') versus log(10)-transformed genome size (X', genome size in kbp) were found for eukaryotes and non-eukaryotes. Eukaryotes best fit a logarithmic model, Y' = ln(-46.200+22.678X', whereas non-eukaryotes a linear model, Y' = 0.045+0.977X', both with high significance (p<0.001, R-2>.0.91). Total gene number shows similar trends in both groups to their respective protein coding regressions. The distinct correlations reflect lower and decreasing gene-coding percentages as genome size increases in eukaryotes (82%-1%) compared to higher and relatively stable percentages in prokaryotes and viruses (97%-47%). The eukaryotic regression models project that the smallest dinoflagellate genome (3 x 10(6) kbp) contains 38,188 protein-coding (40,086 total) genes and the largest (245 x 10(6) kbp) 87,688 protein-coding (92,013 total) genes, corresponding to 1.8% and 0.05% gene-coding percentages. These estimates do not likely represent extraordinarily high functional diversity of the encoded proteome but rather highly redundant genomes as evidenced by high gene copy numbers documented for various dinoflagellate species.			Hou, YB (corresponding author), Univ Connecticut, Dept Marine Sci, Groton, CT 06340 USA.	senjie.lin@uconn.edu	zhang, yaqun/J-8478-2014; Lin, Senjie/A-7466-2011; Guo, chentao/G-7320-2016					ALLEN JR, 1975, CELL, V6, P161, DOI 10.1016/0092-8674(75)90006-9; Anderson Donald M., 1992, Molecular Marine Biology and Biotechnology, V1, P89; Archibald JM, 2007, BIOESSAYS, V29, P392, DOI 10.1002/bies.20551; Aury JM, 2006, NATURE, V444, P171, DOI 10.1038/nature05230; Bachvaroff TR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002929; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Bertomeu T, 2004, BIOCHEM BIOPH RES CO, V323, P1172, DOI 10.1016/j.bbrc.2004.09.008; Bhaud Y, 2000, J CELL SCI, V113, P1231; BLANK RJ, 1987, MAR BIOL, V94, P143, DOI 10.1007/BF00392906; Bouligand Y, 2001, BIOCHIMIE, V83, P187, DOI 10.1016/S0300-9084(00)01211-6; Chan YH, 2007, NUCLEIC ACIDS RES, V35, P2573, DOI 10.1093/nar/gkm165; Coats DW, 2002, J PHYCOL, V38, P417, DOI 10.1046/j.1529-8817.2002.03832.x; Gregory TR, 2007, NUCLEIC ACIDS RES, V35, pD332, DOI 10.1093/nar/gkl828; Gregory T. Ryan, 2005, P427; Gregory TR, 2005, NAT REV GENET, V6, P699, DOI 10.1038/nrg1674; Hackett JD, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-80; Hackett JD, 2004, AM J BOT, V91, P1523, DOI 10.3732/ajb.91.10.1523; HINNEBUSCH AG, 1980, BIOCHEMISTRY-US, V19, P1744, DOI 10.1021/bi00550a004; HOLMHANSEN O, 1969, SCIENCE, V163, P87, DOI 10.1126/science.163.3862.87; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Konstantinidis KT, 2004, P NATL ACAD SCI USA, V101, P3160, DOI 10.1073/pnas.0308653100; LaJeunesse TC, 2005, J PHYCOL, V41, P880, DOI 10.1111/j.0022-3646.2005.04231.x; Le QH, 1997, MOL GEN GENET, V255, P595, DOI 10.1007/s004380050533; LEE DH, 1993, J BIOL CHEM, V268, P8842; Lin S., 2008, RNA DNA EDITING MOL, P280, DOI DOI 10.1002/9780470262269.CH13; Lin SJ, 2006, J PHYCOL, V42, P746, DOI 10.1111/j.1529-8817.2006.00213.x; Liu LY, 2006, J PHYCOL, V42, P96, DOI 10.1111/j.1529-8817.2006.00165.x; Loeblich A.R., 1981, Journal of Plankton Research, V3, P67, DOI 10.1093/plankt/3.1.67; Lukes J, 2009, P NATL ACAD SCI USA, V106, P9963, DOI 10.1073/pnas.0901004106; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Lynch M., 2007, ORIGINS GENOME ARCHI, P193; McEwan M, 2008, J EUKARYOT MICROBIOL, V55, P530, DOI 10.1111/j.1550-7408.2008.00357.x; Moreau H, 1998, Int Microbiol, V1, P35; Patron NJ, 2006, J MOL BIOL, V357, P1373, DOI 10.1016/j.jmb.2006.01.084; Patron NJ, 2005, J MOL BIOL, V348, P1015, DOI 10.1016/j.jmb.2005.03.030; Pfiester L. A., 1987, BIOL DINOFLAGELLATES, P611; Ramsey J, 1998, ANNU REV ECOL SYST, V29, P467, DOI 10.1146/annurev.ecolsys.29.1.467; Reichman JR, 2003, MOL BIOL EVOL, V20, P2143, DOI 10.1093/molbev/msg233; Rizzo P.J., 1987, Botanical Monographs (Oxford), V21, P143; RIZZO PJ, 1973, J PROTOZOOL, V20, P666, DOI 10.1111/j.1550-7408.1973.tb03595.x; ROBERTS TM, 1974, NATURE, V248, P446, DOI 10.1038/248446a0; Salois P, 1997, J PHYCOL, V33, P1063, DOI 10.1111/j.0022-3646.1997.01063.x; Santos SR, 2003, BIOL BULL-US, V204, P10, DOI 10.2307/1543491; SIGEE DC, 1983, BIOSYSTEMS, V16, P203, DOI 10.1016/0303-2647(83)90004-7; Slamovits CH, 2008, CURR BIOL, V18, pR550, DOI 10.1016/j.cub.2008.04.054; Slamovits CH, 2008, MOL BIOL EVOL, V25, P1297, DOI 10.1093/molbev/msn075; Spector D.L., 1984, P107; STEEL RE, 1980, THESIS YALE U NEW HA; Van Dolah FM, 2009, HARMFUL ALGAE, V8, P562, DOI 10.1016/j.hal.2008.11.004; Veldhuis MJW, 1997, J PHYCOL, V33, P527, DOI 10.1111/j.0022-3646.1997.00527.x; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Xu L, 2006, MOL BIOL EVOL, V23, P1107, DOI 10.1093/molbev/msk019; Zhang H, 2006, J EUKARYOT MICROBIOL, V53, P142, DOI 10.1111/j.1550-7408.2005.00085.x; Zhang H, 2003, J PHYCOL, V39, P1160, DOI 10.1111/j.0022-3646.2003.03-055.x; Zhang H, 2009, MOL BIOL EVOL, V26, P1757, DOI 10.1093/molbev/msp083	55	136	139	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6978	10.1371/journal.pone.0006978	http://dx.doi.org/10.1371/journal.pone.0006978			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750009	Green Submitted, gold, Green Published			2022-12-27	WOS:000269796300008
J	Welch, M; Govindarajan, S; Ness, JE; Villalobos, A; Gurney, A; Minshull, J; Gustafsson, C				Welch, Mark; Govindarajan, Sridhar; Ness, Jon E.; Villalobos, Alan; Gurney, Austin; Minshull, Jeremy; Gustafsson, Claes			Design Parameters to Control Synthetic Gene Expression in Escherichia coli	PLOS ONE			English	Article							TRANSLATION INITIATION; CODON PAIRS; NGG CODONS; RNA; SEQUENCE; BIAS; OVEREXPRESSION; CONSTRUCTION; TERMINATION; PROTEINS	Background: Production of proteins as therapeutic agents, research reagents and molecular tools frequently depends on expression in heterologous hosts. Synthetic genes are increasingly used for protein production because sequence information is easier to obtain than the corresponding physical DNA. Protein-coding sequences are commonly re-designed to enhance expression, but there are no experimentally supported design principles. Principal Findings: To identify sequence features that affect protein expression we synthesized and expressed in E. coli two sets of 40 genes encoding two commercially valuable proteins, a DNA polymerase and a single chain antibody. Genes differing only in synonymous codon usage expressed protein at levels ranging from undetectable to 30% of cellular protein. Using partial least squares regression we tested the correlation of protein production levels with parameters that have been reported to affect expression. We found that the amount of protein produced in E. coli was strongly dependent on the codons used to encode a subset of amino acids. Favorable codons were predominantly those read by tRNAs that are most highly charged during amino acid starvation, not codons that are most abundant in highly expressed E. coli proteins. Finally we confirmed the validity of our models by designing, synthesizing and testing new genes using codon biases predicted to perform well. Conclusion: The systematic analysis of gene design parameters shown in this study has allowed us to identify codon usage within a gene as a critical determinant of achievable protein expression levels in E. coli. We propose a biochemical basis for this, as well as design algorithms to ensure high protein production from synthetic genes. Replication of this methodology should allow similar design algorithms to be empirically derived for any expression system.			Welch, M (corresponding author), DNA2 0, Menlo Pk, CA USA.	mwelch@DNA20.com	Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Gustafsson, Claes/0000-0003-2181-3126				Bjornsson A, 1996, NUCLEIC ACIDS RES, V24, P1753, DOI 10.1093/nar/24.9.1753; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; Bonomo J, 2005, BIOTECHNOL BIOENG, V90, P116, DOI 10.1002/bit.20436; Boycheva S, 2003, BIOINFORMATICS, V19, P987, DOI 10.1093/bioinformatics/btg082; Burgess-Brown NA, 2008, PROTEIN EXPRES PURIF, V59, P94, DOI 10.1016/j.pep.2008.01.008; CHEN GFT, 1994, GENE DEV, V8, P2641, DOI 10.1101/gad.8.21.2641; de Valdivia EIG, 2005, FEBS J, V272, P5306, DOI 10.1111/j.1742-4658.2005.04926.x; de Valdivia EIG, 2004, NUCLEIC ACIDS RES, V32, P5198, DOI 10.1093/nar/gkh857; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; Dittmar KA, 2005, EMBO REP, V6, P151, DOI 10.1038/sj.embor.7400341; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; DONG HJ, 1995, J BACTERIOL, V177, P1497, DOI 10.1128/jb.177.6.1497-1504.1995; Elf J, 2003, SCIENCE, V300, P1718, DOI 10.1126/science.1083811; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; EYREWALKER A, 1993, NUCLEIC ACIDS RES, V21, P4599, DOI 10.1093/nar/21.19.4599; Fuglsang A, 2003, PROTEIN EXPRES PURIF, V31, P247, DOI 10.1016/S1046-5928(03)00213-4; GRAF M, 2009, SYSTEMS BIOL SYNTHET, P411, DOI DOI 10.1002/9780470437988.CH12; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; GUTMAN GA, 1989, P NATL ACAD SCI USA, V86, P3699, DOI 10.1073/pnas.86.10.3699; Harcum SW, 2002, J BIOTECHNOL, V93, P189, DOI 10.1016/S0168-1656(01)00347-9; HENAUT A, 1996, ESCHERICHIA COLI SAL, V2, P2047; Holland JH, 1975, ADOPTION NATURAL ART, Vsecond; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; ITAKURA K, 1977, SCIENCE, V198, P1056, DOI 10.1126/science.412251; Kaberdin VR, 2006, FEMS MICROBIOL REV, V30, P967, DOI 10.1111/j.1574-6976.2006.00043.x; Kaberdin VR, 2003, NUCLEIC ACIDS RES, V31, P4710, DOI 10.1093/nar/gkg690; KANE JF, 1995, CURR OPIN BIOTECH, V6, P494, DOI 10.1016/0958-1669(95)80082-4; Kudla G, 2009, SCIENCE, V324, P255, DOI 10.1126/science.1170160; Liao J, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-16; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Newcomb J, 2007, GENOME SYNTHESIS DES; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROJIANI MV, 1990, P NATL ACAD SCI USA, V87, P1511, DOI 10.1073/pnas.87.4.1511; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shultzaberger RK, 2001, J MOL BIOL, V313, P215, DOI 10.1006/jmbi.2001.5040; Sohn YH, 2005, P NATL ACAD SCI USA, V102, P75, DOI 10.1073/pnas.0406581101; Sorensen MA, 2005, J MOL BIOL, V354, P16, DOI 10.1016/j.jmb.2005.08.076; Stenstrom CM, 2002, GENE, V288, P1, DOI 10.1016/S0378-1119(02)00501-2; Stenstrom CM, 2001, GENE, V263, P273, DOI 10.1016/S0378-1119(00)00550-3; Stenstrom CM, 2001, GENE, V273, P259, DOI 10.1016/S0378-1119(01)00584-4; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Villalobos A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-285; Welch M, 2009, J R SOC INTERFACE, V6, DOI 10.1098/rsif.2008.0520.focus; Wold S., 1994, PLS MULTIVARIATE LIN; Wu G, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100175; Wu G, 2007, NUCLEIC ACIDS RES, V35, pD76, DOI 10.1093/nar/gkl648	48	253	305	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7002	10.1371/journal.pone.0007002	http://dx.doi.org/10.1371/journal.pone.0007002			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759823	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796300014
J	Dorsey, ER; Thompson, JP; Carrasco, M; de Roulet, J; Vitticore, P; Nicholson, S; Johnston, SC; Holloway, RG; Moses, H				Dorsey, E. Ray; Thompson, Joel P.; Carrasco, Melisa; de Roulet, Jason; Vitticore, Philip; Nicholson, Sean; Johnston, S. Claiborne; Holloway, Robert G.; Moses, Hamilton, III			Financing of US Biomedical Research and New Drug Approvals across Therapeutic Areas	PLOS ONE			English	Article							ANATOMY; BURDEN	Background: We estimated U.S. biomedical research funding across therapeutic areas, determined the association with disease burden, and evaluated new drug approvals that resulted from this investment. Methodology/Principal Findings: We calculated funding from 1995 to 2005 and totaled Food and Drug Administration approvals in eight therapeutic areas (cardiovascular, endocrine, gastrointestinal, genitourinary, HIV/AIDS, infectious disease excluding HIV, oncology, and respiratory) primarily using public data. We then calculated correlations between funding, published estimates of disease burden, and drug approvals. Financial support for biomedical research from 1995 to 2005 increased across all therapeutic areas between 43% and 369%. Industry was the principal funder of all areas except HIV/AIDS, infectious disease, and oncology, which were chiefly sponsored by the National Institutes of Health (NIH). Total (r = 0.70; P =.03) and industry funding (r = 0.69; P = .04) were correlated with projected disease burden in high income countries while NIH support (r = 0.80; P = .01) was correlated with projected disease burden globally. From 1995 to 2005 the number of new approvals was flat or declined across therapeutic areas, and over an 8-year lag period, neither total nor industry funding was correlated with future approvals. Conclusions/Significance: Across therapeutic areas, biomedical research funding increased substantially, appears aligned with disease burden in high income countries, but is not linked to new drug approvals. The translational gap between funding and new therapies is affecting all of medicine, and remedies must include changes beyond additional financial investment.			Dorsey, ER (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.	ray.dorsey@ctcc.rochester.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024136] Funding Source: NIH RePORTER; NCRR NIH HHS [KL2 RR024136] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams CP, 2006, HEALTH AFFAIR, V25, P420, DOI 10.1377/hlthaff.25.2.420; *AM CAN SOC, 1998, AM CANC SOC ANN REP; *AM DIAB ASS, 1998, AM DIAB ASS ANN REP; *AM HEART ASS, AM HEART ASS ANN REP; *AM LUNG ASS, 1998, AM LUNG ASS ANN REP; Azoulay P, 2007, NEW ENGL J MED, V357, P2049, DOI 10.1056/NEJMsa067417; BLUM J, FDA APPROVES 19 NEW; Booth B, 2004, NAT REV DRUG DISCOV, V3, P451, DOI 10.1038/nrd1384; *BURR WELLC FUND, NEWS PUBL ANN REP; Butler D, 2008, NATURE, V453, P840, DOI 10.1038/453840a; Carande-Kulis Vilma G, 2007, J Public Health Manag Pract, V13, P227; Connelly E, 2006, INVESTMENT US HLTH R; Cutler DM, 2006, NEW ENGL J MED, V355, P920, DOI 10.1056/NEJMsa054744; *DAN FDN, DAN FDN ANN REP; Destler B, 2008, NATURE, V453, P853, DOI 10.1038/453853a; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; DiMasi JA, 2007, MANAG DECIS ECON, V28, P469, DOI 10.1002/mde.1360; Dorsey ER, 2006, ANN NEUROL, V60, P652, DOI 10.1002/ana.21047; Dorsey ER, 2009, MOVEMENT DISORD, V24, P731, DOI 10.1002/mds.22446; *FDN CTR, 2004, TOP 50 US FDN AW GRA; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; HALL P, 1998, INNOVATIVE MILIEU CI; JAMES S, MCDONNELL FDN ARCH G; Johnson MR, 2006, BIOL PSYCHIAT, V60, P11, DOI 10.1016/j.biopsych.2005.11.012; Johnston SC, 2007, ANN NEUROL, V62, pA6; *JUV DIAB RES FDN, 2002, JUV DIAB RES FDN ANN; *LEUK LYMPH SOC, 2002, LEUK LYMPH SOC ANN R; Martinez B., 2007, WALL STREET J, pA1; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; *MCKNIGHT BRAIN RE, 2001, MCKNIGHT BRAIN RES F; Moses H, 2005, JAMA-J AM MED ASSOC, V294, P1333, DOI 10.1001/jama.294.11.1333; Moses H, 2006, ANN NEUROL, V60, P647, DOI 10.1002/ana.21048; Murphy KM, 2003, MEASURING THE GAINS FROM MEDICAL RESEARCH, P41; Murray CJL, 1997, J HEALTH ECON, V16, P703, DOI 10.1016/S0167-6296(97)00004-0; *NAT HEART LUND BL, LEG INF NHLBI DIR PA; *NAT I DIAB DIG KI, BUDG LEG INF; *NIH, NIH NIH ALM APPR; *NIH, NIH PRIC IND; *OFF AIDS RES, OAR PUBL INF; *PHARM RES MAN AM, 2000, PHARM IND PROF 2000; *PHARM RES MAN AM, 1998, PHARM IND PROF 1998; Pharmaceutical Research and Manufacturers of America, 2002, PHARM IND PROF 2002; Pharmaceutical Research and Manufacturers of America, 2006, PHARM IND PROF 2006; Pisano G. P., 2006, SCI BUSINESS PROMISE, P1; *RES AM, WHAT DO YOU THINK IS; *RES AM, 2006, 2006 INV US HLTH RES; *THOMS CENTERWATCH, AB THOMS CENTERWATCH; *US BUR CENS, 1996, CURR IND REP PHARM P; *US FDA, CTR DRUG EV RES DRUG; *US SEC EXCH COMM, DIV CORP FIN STAND I; *US SEC EXCH COMM, SEC FIL FORMS EDGAR; *WHIT FDN, WHIT FDN ANN REP; Wood AJJ, 2006, NEW ENGL J MED, V355, P618, DOI 10.1056/NEJMsb055203; Zerhouni EA, 2005, JAMA-J AM MED ASSOC, V294, P1352, DOI 10.1001/jama.294.11.1352; Zerhouni EA, 2006, SCIENCE, V314, P1088, DOI 10.1126/science.1136931; 2009, PHARM IND PROFILE 20	56	40	40	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e7015	10.1371/journal.pone.0007015	http://dx.doi.org/10.1371/journal.pone.0007015			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750225	Green Published, gold			2022-12-27	WOS:000269696600018
J	Carlson, AE; Burnett, LA; del Camino, D; Quill, TA; Hille, B; Chong, JA; Moran, MM; Babcock, DF				Carlson, Anne E.; Burnett, Lindsey A.; del Camino, Donato; Quill, Timothy A.; Hille, Bertil; Chong, Jayhong A.; Moran, Magdalene M.; Babcock, Donner F.			Pharmacological Targeting of Native CatSper Channels Reveals a Required Role in Maintenance of Sperm Hyperactivation	PLOS ONE			English	Article								The four sperm-specific CatSper ion channel proteins are required for hyperactivated motility and male fertility, and for Ca(2+) entry evoked by alkaline depolarization. In the absence of external Ca(2+), Na(+) carries current through CatSper channels in voltage-clamped sperm. Here we show that CatSper channel activity can be monitored optically with the [Na(+)](i)-reporting probe SBFI in populations of intact sperm. Removal of external Ca(2+) increases SBFI signals in wild-type but not CatSper2-null sperm. The rate of the indicated rise of [Na(+)](i) is greater for sperm alkalinized with NH(4)Cl than for sperm acidified with propionic acid, reflecting the alkaline-promoted signature property of CatSper currents. In contrast, the [Na(+)](i) rise is slowed by candidate CatSper blocker HC-056456 (IC(50) similar to 3 mu M). HC-056456 similarly slows the rise of [Ca(2+)](i) that is evoked by alkaline depolarization and reported by fura-2. HC-056456 also selectively and reversibly decreased CatSper currents recorded from patch-clamped sperm. HC-056456 does not prevent activation of motility by HCO(3)(-) but does prevent the development of hyperactivated motility by capacitating incubations, thus producing a phenocopy of the CatSper-null sperm. When applied to hyperactivated sperm, HC-056456 causes a rapid, reversible loss of flagellar waveform asymmetry, similar to the loss that occurs when Ca(2+) entry through the CatSper channel is terminated by removal of external Ca(2+). Thus, open CatSper channels and entry of external Ca(2+) through them sustains hyperactivated motility. These results indicate that pharmacological targeting of the CatSper channel may impose a selective late-stage block to fertility, and that high-throughput screening with an optical reporter of CatSper channel activity may identify additional selective blockers with potential for male-directed contraception.			Carlson, AE (corresponding author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.	donner@u.washington.edu	Carlson, Anne/I-9495-2019	Carlson, Anne/0000-0003-2724-1325; Burnett, Lindsey/0000-0002-6430-4498; Babcock, Donner/0000-0002-4461-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD045028, R01HD036022, P50HD012629] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12629-27, R01 HD036022, R43 HD045028, HD-36022, U54 HD012629, R43 HD045028-01, P50 HD012629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABCOCK DF, 1983, J BIOL CHEM, V258, P6380; Carlson AE, 2005, J BIOL CHEM, V280, P32238, DOI 10.1074/jbc.M501430200; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Carlson AE, 2007, DEV BIOL, V312, P183, DOI 10.1016/j.ydbio.2007.09.017; COOPER TG, 1984, GAMETE RES, V9, P55, DOI 10.1002/mrd.1120090106; Dunlop J, 2008, NAT REV DRUG DISCOV, V7, P358, DOI 10.1038/nrd2552; Esposito G, 2004, P NATL ACAD SCI USA, V101, P2993, DOI 10.1073/pnas.0400050101; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; Hess KC, 2005, DEV CELL, V9, P249, DOI 10.1016/j.devcel.2005.06.007; Ho K, 2009, REPROD FERT DEVELOP, V21, P345, DOI 10.1071/RD08183; Jin JL, 2007, BIOL REPROD, V77, P37, DOI 10.1095/biolreprod.107.060186; Kirichok Y, 2006, NATURE, V439, P737, DOI 10.1038/nature04417; Liu J, 2007, J BIOL CHEM, V282, P18945, DOI 10.1074/jbc.M701083200; Marquez B, 2007, BIOL REPROD, V76, P660, DOI 10.1095/biolreprod.106.055038; Meier SD, 2006, J NEUROSCI METH, V155, P251, DOI 10.1016/j.jneumeth.2006.01.009; Morgan DJ, 2008, P NATL ACAD SCI USA, V105, P20740, DOI 10.1073/pnas.0810971105; Nass SJ, 2004, NAT REV DRUG DISCOV, V3, P885, DOI 10.1038/nrd1526; Navarro B, 2008, INT J DEV BIOL, V52, P607, DOI 10.1387/ijdb.072554bn; Navarro B, 2007, P NATL ACAD SCI USA, V104, P7688, DOI 10.1073/pnas.0702018104; Nolan MA, 2004, P NATL ACAD SCI USA, V101, P13483, DOI 10.1073/pnas.0405580101; Qi HY, 2007, P NATL ACAD SCI USA, V104, P1219, DOI 10.1073/pnas.0610286104; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Schuh SM, 2006, BIOL REPROD, V74, P492, DOI 10.1095/biolreprod.105.047837; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; Wennemuth G, 2003, DEVELOPMENT, V130, P1317, DOI 10.1242/dev.00353; Xie F, 2006, DEV BIOL, V296, P353, DOI 10.1016/j.ydbio.2006.05.038; YANAGIMACHI R, 1982, GAMETE RES, V5, P323, DOI 10.1002/mrd.1120050404	28	63	64	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6844	10.1371/journal.pone.0006844	http://dx.doi.org/10.1371/journal.pone.0006844			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718436	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415900017
J	Bauer, J; Liebisch, G; Hofmann, C; Huy, C; Schmitz, G; Obermeier, F; Bock, J				Bauer, Jessica; Liebisch, Gerhard; Hofmann, Claudia; Huy, Christian; Schmitz, Gerd; Obermeier, Florian; Bock, Juergen			Lipid Alterations in Experimental Murine Colitis: Role of Ceramide and Imipramine for Matrix Metalloproteinase-1 Expression	PLOS ONE			English	Article								Background: Dietary lipids or pharmacologic modulation of lipid metabolism are potential therapeutic strategies in inflammatory bowel disease (IBD). Therefore, we analysed alterations of bioactive lipids in experimental models of colitis and examined the functional consequence of the second messenger ceramide in inflammatory pathways leading to tissue destruction. Methodology/Principal Findings: Chronic colitis was induced by dextran-sulphate-sodium (DSS) or transfer of CD4(+)CD62L(+) cells into RAG1(-/-)-mice. Lipid content of isolated murine intestinal epithelial cells (IEC) was analysed by tandem mass spectrometry. Concentrations of MMP-1 in supernatants of Caco-2-IEC and human intestinal fibroblasts from patients with ulcerative colitis were determined by ELISA. Imipramine was used for pharmacologic inhibition of acid sphingomyelinase (ASM). Ceramide increased by 71% in chronic DSS-induced colitis and by 159% in the transfer model of colitis. Lysophosphatidylcholine (LPC) decreased by 22% in both models. No changes were detected for phosphatidylcholine. Generation of ceramide by exogenous SMase increased MMP-1-protein production of Caco-2-IEC up to 7-fold. Inhibition of ASM completely abolished the induction of MMP-1 by TNF or IL-1 beta in Caco-2-IEC and human intestinal fibroblasts. Conclusions/Significance: Mucosal inflammation leads to accumulation of ceramide and decrease of LPC in the intestinal epithelium. One aspect of ceramide generation is an increase of MMP-1. Induction of MMP-1 by TNF or IL-1 beta is completely blocked by inhibition of ASM with imipramine. Therefore, inhibition of ASM may offer a treatment strategy to reduce MMP-1 expression and tissue destruction in inflammatory conditions.			Bauer, J (corresponding author), Univ Med Ctr, Dept Internal Med 1, Regensburg, Germany.	juergen.bock@klinik.uni-regensburg.de	Bauer, Jessica/AAT-7399-2020; Liebisch, Gerhard/G-6130-2010	Bauer, Jessica/0000-0001-9022-9877; Liebisch, Gerhard/0000-0003-4886-0811				ALBOUZ S, 1981, BIOMED EXPRESS, V35, P218; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bauer J, 2009, FEBS LETT, V583, P915, DOI 10.1016/j.febslet.2009.02.008; Baugh MD, 1999, GASTROENTEROLOGY, V117, P814, DOI 10.1016/S0016-5085(99)70339-2; Bock J, 2003, BIOCHEM BIOPH RES CO, V305, P890, DOI 10.1016/S0006-291X(03)00763-0; Bock J, 2007, WORLD J GASTROENTERO, V13, P5217, DOI 10.3748/wjg.v13.i39.5217; Brenmoehl J, 2008, INT J COLORECTAL DIS, V23, P947, DOI 10.1007/s00384-008-0523-z; Bu Shizhong, 2006, FASEB J, V20, P184; Daig R, 2000, GUT, V46, P350, DOI 10.1136/gut.46.3.350; Duan RD, 2006, BBA-MOL CELL BIOL L, V1761, P281, DOI 10.1016/j.bbalip.2006.03.007; Ehehalt R, 2008, WORLD J GASTROENTERO, V14, P1528, DOI 10.3748/wjg.14.1528; Esmaeili A, 2008, GASTROENTEROLOGY, V134, pA100; FABIA R, 1992, DIGESTION, V53, P35, DOI 10.1159/000200969; FARR A, 1991, J HISTOCHEM CYTOCHEM, V39, P645, DOI 10.1177/39.5.2016514; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Heuschkel RB, 2000, GUT, V47, P57, DOI 10.1136/gut.47.1.57; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; LAFUMA C, 1994, J INVEST DERMATOL, V102, P945, DOI 10.1111/1523-1747.ep12384118; Lang F, 2007, ARCH BIOCHEM BIOPHYS, V462, P189, DOI 10.1016/j.abb.2006.12.028; Langmann T, 2004, GASTROENTEROLOGY, V127, P26, DOI 10.1053/j.gastro.2004.04.019; Leeb SN, 2002, GROWTH FACTORS, V20, P81, DOI 10.1080/08977190290031941; Liebisch G, 2005, BBA-MOL CELL BIOL L, V1734, P86, DOI 10.1016/j.bbalip.2005.01.002; Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003; Liu-Wu Y, 1998, ATHEROSCLEROSIS, V137, P351, DOI 10.1016/S0021-9150(97)00295-5; MACKAY AR, 1992, INVAS METAST, V12, P168; Maskrey BH, 2007, J BIOL CHEM, V282, P20151, DOI 10.1074/jbc.M611776200; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; Meijer MJW, 2007, WORLD J GASTROENTERO, V13, P2960, DOI 10.3748/wjg.v13.i21.2960; Mourelle M, 1996, GASTROENTEROLOGY, V110, P1093, DOI 10.1053/gast.1996.v110.pm8612998; Mudter J, 2002, PATHOBIOLOGY, V70, P170, DOI 10.1159/000068150; Naito Yuji, 2005, Molecular Aspects of Medicine, V26, P379; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; Obermeier F, 1999, CLIN EXP IMMUNOL, V116, P238; Olofsson KE, 2008, BIOCHEM BIOPH RES CO, V370, P348, DOI 10.1016/j.bbrc.2008.03.087; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Sakata A, 2007, IMMUNOLOGY, V122, P54, DOI 10.1111/j.1365-2567.2007.02612.x; Sakata A, 2007, CELL IMMUNOL, V245, P24, DOI 10.1016/j.cellimm.2007.03.005; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Sengupta N, 2007, PHYSIOLOGY, V22, P401, DOI 10.1152/physiol.00027.2007; Smith EL, 2008, FASEB J, V22, P3419, DOI 10.1096/fj.08-108043; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Stremmel W, 2005, GUT, V54, P966, DOI 10.1136/gut.2004.052316; Teichgraber V, 2008, NAT MED, V14, P382, DOI 10.1038/nm1748; Treede I, 2007, J BIOL CHEM, V282, P27155, DOI 10.1074/jbc.M704408200; Wang YD, 2007, WORLD J GASTROENTERO, V13, P5926, DOI 10.3748/wjg.v13.i44.5926; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wiesner P, 2009, J LIPID RES, V50, P574, DOI 10.1194/jlr.D800028-JLR200; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335	57	32	33	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7197	10.1371/journal.pone.0007197	http://dx.doi.org/10.1371/journal.pone.0007197			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787068	gold, Green Published, Green Submitted			2022-12-27	WOS:000270290100012
J	Horlitz, M; Lucas, A; Sprenger-Haussels, M				Horlitz, Martin; Lucas, Annabelle; Sprenger-Haussels, Markus			Optimized Quantification of Fragmented, Free Circulating DNA in Human Blood Plasma Using a Calibrated Duplex Real-Time PCR	PLOS ONE			English	Article							FETAL DNA	Background: Duplex real-time PCR assays have been widely used to determine amounts and concentrations of free circulating DNA in human blood plasma samples. Circulatory plasma DNA is highly fragmented and hence a PCR-based determination of DNA concentration may be affected by the limited availability of full-length targets in the DNA sample. This leads to inaccuracies when counting PCR target copy numbers as whole genome equivalents. Methodology/Principal Findings: A model system was designed allowing for assessment of bias in a duplex real-time PCR research assay. We collected blood plasma samples from male donors in pools of 6 to 8 individuals. Circulatory plasma DNA was extracted and separated by agarose gel electrophoresis. Separated DNA was recovered from the gel in discrete size fractions and analyzed with different duplex real-time PCR Taqman assays detecting a Y chromosome-specific target and an autosomal target. The real-time PCR research assays used differed significantly in their ability to determine the correct copy number ratio of 0.5 between Y chromosome and autosome targets in DNA of male origin. Longer PCR targets did not amplify quantitatively in circulatory DNA, due to limited presence of full-length target sequence in the sample. Conclusions: PCR targets of the same small size are preferred over longer targets when comparing fractional circulatory DNA concentrations by real-time PCR. As an example, a DYS14/18S duplex real-time PCR research assay is presented that correctly measures the fractional concentration of male DNA in a male/female mixture of circulatory, fragmented DNA.			Horlitz, M (corresponding author), QIAGEN GmbH, R&D Dept, Hilden, Germany.	martin.horlitz@qiagen.com						Antonov J, 2005, LAB INVEST, V85, P1040, DOI 10.1038/labinvest.3700303; Atamaniuk J, 2006, CLIN CHEM, V52, P523, DOI 10.1373/clinchem.2005.058883; Boom R, 2002, J CLIN MICROBIOL, V40, P4105, DOI 10.1128/JCM.40.11.4105-4113.2002; Chan KCA, 2004, CLIN CHEM, V50, P88, DOI 10.1373/clinchem.2003.024893; Hein AE, 2007, ANAL BIOCHEM, V360, P41, DOI 10.1016/j.ab.2006.10.016; Hiromadnikova I, 2006, DNA CELL BIOL, V25, P635, DOI 10.1089/dna.2006.25.635; Ishii T, 2007, ANAL BIOCHEM, V362, P201, DOI 10.1016/j.ab.2006.12.004; Koide K, 2005, PRENATAL DIAG, V25, P604, DOI 10.1002/pd.1213; Li Y, 2004, CLIN CHEM, V50, P1002, DOI 10.1373/clinchem.2003.029835; Lun FMF, 2008, CLIN CHEM, V54, P1664, DOI 10.1373/clinchem.2008.111385; Nicklas JA, 2006, J FORENSIC SCI, V51, P1005, DOI 10.1111/j.1556-4029.2006.00211.x; Swarup V, 2007, FEBS LETT, V581, P795, DOI 10.1016/j.febslet.2007.01.051; van der Vaart M, 2007, CLIN CHEM, V53, P2215, DOI 10.1373/clinchem.2007.092734; Yun JJ, 2006, NUCLEIC ACIDS RES, V34, P6718, DOI 10.1093/nar/gkl1020; Zhong XY, 2001, SWISS MED WKLY, V131, P70; Zimmermann B, 2005, CLIN CHEM, V51, P1598, DOI 10.1373/clinchem.2005.051235	16	16	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7207	10.1371/journal.pone.0007207	http://dx.doi.org/10.1371/journal.pone.0007207			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784371	gold, Green Submitted, Green Published			2022-12-27	WOS:000270290000013
J	Bhagat, M; Bhushan, C; Saha, G; Shimjo, S; Watanabe, K; Bhattacharya, J				Bhagat, Mayank; Bhushan, Chitresh; Saha, Goutam; Shimjo, Shinsuke; Watanabe, Katsumi; Bhattacharya, Joydeep			Investigating Neuromagnetic Brain Responses against Chromatic Flickering Stimuli by Wavelet Entropies	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; NONLINEAR-ANALYSIS; EEG; EPILEPSY; PHOTOSENSITIVITY; MEG; LOCALIZATION; SEIZURES; SYSTEM	Background: Photosensitive epilepsy is a type of reflexive epilepsy triggered by various visual stimuli including colourful ones. Despite the ubiquitous presence of colorful displays, brain responses against different colour combinations are not properly studied. Methodology/Principal Findings: Here, we studied the photosensitivity of the human brain against three types of chromatic flickering stimuli by recording neuromagnetic brain responses (magnetoencephalogram, MEG) from nine adult controls, an unmedicated patient, a medicated patient, and two controls age-matched with patients. Dynamical complexities of MEG signals were investigated by a family of wavelet entropies. Wavelet entropy is a newly proposed measure to characterize large scale brain responses, which quantifies the degree of order/disorder associated with a multifrequency signal response. In particular, we found that as compared to the unmedicated patient, controls showed significantly larger wavelet entropy values. We also found that Renyi entropy is the most powerful feature for the participant classification. Finally, we also demonstrated the effect of combinational chromatic sensitivity on the underlying order/disorder in MEG signals. Conclusions/Significance: Our results suggest that when perturbed by potentially epileptic-triggering stimulus, healthy human brain manages to maintain a non-deterministic, possibly nonlinear state, with high degree of disorder, but an epileptic brain represents a highly ordered state which making it prone to hyper-excitation. Further, certain colour combination was found to be more threatening than other combinations.			Bhagat, M (corresponding author), Indian Inst Technol, Dept Elect Engn, Kharagpur 721302, W Bengal, India.	j.bhattacharya@gold.ac.uk	Saha, Goutam/AAH-6281-2020; Bhushan, Chitresh/AAG-3305-2020	Saha, Goutam/0000-0001-6187-1684; Bhushan, Chitresh/0000-0002-2935-2515; Watanabe, Katsumi/0000-0003-1282-9994				Abasolo D, 2005, CLIN NEUROPHYSIOL, V116, P1826, DOI 10.1016/j.clinph.2005.04.001; Anninos PA, 2000, BRAIN TOPOGR, V13, P135, DOI 10.1023/A:1026611219551; Barkley GL, 2003, J CLIN NEUROPHYSIOL, V20, P163, DOI 10.1097/00004691-200305000-00002; Basar E, 2001, INT J PSYCHOPHYSIOL, V39, P91, DOI 10.1016/S0167-8760(00)00135-5; Baumgartner C, 2004, CLIN NEUROPHYSIOL, V115, P1010, DOI 10.1016/j.clinph.2003.12.010; BELAIR J, 1995, CHAOS, V5, P1, DOI 10.1063/1.166069; Ben-Jacob E, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.051903; Bhattacharya J, 2004, INT J BIFURCAT CHAOS, V14, P2701, DOI 10.1142/S0218127404010850; Bhattacharya J, 2002, NEUROREPORT, V13, P1727, DOI 10.1097/00001756-200210070-00007; Bhattacharya J, 2000, IEEE T BIO-MED ENG, V47, P738, DOI 10.1109/10.844222; Bracewell R, 1986, PENTAGRAM NOTATION C, V2nd, P192; COHEN D, 1983, ELECTROEN CLIN NEURO, V56, P38, DOI 10.1016/0013-4694(83)90005-6; da Silva FHL, 2003, IEEE T BIO-MED ENG, V50, P540, DOI 10.1109/TBME.2003.810703; DAUBECHIES I, 1990, IEEE T INFORM THEORY, V36, P961, DOI 10.1109/18.57199; Doron I, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.258101; Drew P, 2001, EXP BRAIN RES, V136, P256, DOI 10.1007/s002210000605; Fernandez A, 2006, CLIN NEUROPHYSIOL, V117, P306, DOI 10.1016/j.clinph.2005.10.017; Harding G., 1994, PHOTOSENSITIVE EPILE; Harding GFA, 1998, NAT MED, V4, P265, DOI 10.1038/nm0398-265; Herrmann CS, 2001, EXP BRAIN RES, V137, P346, DOI 10.1007/s002210100682; Inoue Y, 1999, EPILEPSIA, V40, P8, DOI 10.1111/j.1528-1157.1999.tb00900.x; Ishida S, 1998, EPILEPSIA, V39, P1340, DOI 10.1111/j.1528-1157.1998.tb01334.x; KAWABATA N, 1973, IEEE T BIO-MED ENG, VBM20, P444, DOI 10.1109/TBME.1973.324218; Mallat S., 1999, WAVELET TOUR SIGNAL, DOI 10.1016/B978-012466606-1/50008-8; Nagarajan L, 2003, PEDIATR NEUROL, V29, P222, DOI 10.1016/S0887-8994(03)00207-8; NEWMARK ME, 1979, PHOTOSENSITIVITY EPI; Nishifuji S, 2003, SICE 2003 ANNUAL CONFERENCE, VOLS 1-3, P2438; Parra J, 2003, BRAIN, V126, P1164, DOI 10.1093/brain/awg109; Porciatti V, 2000, NAT NEUROSCI, V3, P259, DOI 10.1038/72972; Quiroga RQ, 2001, BIOL CYBERN, V84, P291, DOI 10.1007/s004220000212; Rosso OA, 2006, J NEUROSCI METH, V153, P163, DOI 10.1016/j.jneumeth.2005.10.009; Rosso OA, 2001, J NEUROSCI METH, V105, P65, DOI 10.1016/S0165-0270(00)00356-3; Rosso OA, 2007, INT J PSYCHOPHYSIOL, V64, P75, DOI 10.1016/j.ijpsycho.2006.07.010; Rubboli G, 2004, EPILEPSIA, V45, P35, DOI 10.1111/j.0013-9580.2004.451002.x; Samar VJ, 1999, BRAIN LANG, V66, P7, DOI 10.1006/brln.1998.2024; Senhadji L, 2002, NEUROPHYSIOL CLIN, V32, P175, DOI 10.1016/S0987-7053(02)00304-0; Stam CJ, 1997, BIOL CYBERN, V77, P247, DOI 10.1007/s004220050385; TAKAHASHI T, 1976, ELECTROEN CLIN NEURO, V41, P124, DOI 10.1016/0013-4694(76)90040-7; TallonBaudry C, 1996, J NEUROSCI, V16, P4240; Tobimatsu S, 1999, ANN NEUROL, V45, P790, DOI 10.1002/1531-8249(199906)45:6<790::AID-ANA14>3.0.CO;2-7; TRENITE DGA, 1989, PHOTOSENSITIVITY EPI; Trenite DGAKN, 2001, EPILEPSIA, V42, P692, DOI 10.1046/j.1528-1157.2001.30600.x; TSALLIS C, 1988, J STAT PHYS, V52, P479, DOI 10.1007/BF01016429; Vandenhouten R, 2000, IEEE T BIO-MED ENG, V47, P729, DOI 10.1109/10.844220; Vermeulen J, 2008, CLIN NEUROPHYSIOL, V119, P842, DOI 10.1016/j.clinph.2007.11.177; Verrotti A, 2004, J CHILD NEUROL, V19, P571, DOI 10.1177/088307380401900802; Verrotti A, 2004, DEV MED CHILD NEUROL, V46, P347, DOI 10.1017/S0012162204000568; Walker AE, 1944, ARCH NEURO PSYCHIATR, V52, P117, DOI 10.1001/archneurpsyc.1944.02290320032004; Watanabe K, 2002, NEUROREPORT, V13, P2161, DOI 10.1097/00001756-200211150-00034; Wheless JW, 1999, EPILEPSIA, V40, P931, DOI 10.1111/j.1528-1157.1999.tb00800.x; Yasuda K, 2000, NEUROREPORT, V11, P203, DOI 10.1097/00001756-200001170-00040; Zifkin BG, 2000, EPILEPTIC DISORD, V2, P129	52	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7173	10.1371/journal.pone.0007173	http://dx.doi.org/10.1371/journal.pone.0007173			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779630	Green Submitted, Green Accepted, Green Published, gold			2022-12-27	WOS:000270176200014
J	Savage, CJ; Vickers, AJ				Savage, Caroline J.; Vickers, Andrew J.			Empirical Study of Data Sharing by Authors Publishing in PLoS Journals	PLOS ONE			English	Article								Background: Many journals now require authors share their data with other investigators, either by depositing the data in a public repository or making it freely available upon request. These policies are explicit, but remain largely untested. We sought to determine how well authors comply with such policies by requesting data from authors who had published in one of two journals with clear data sharing policies. Methods and Findings: We requested data from ten investigators who had published in either PLoS Medicine or PLoS Clinical Trials. All responses were carefully documented. In the event that we were refused data, we reminded authors of the journal's data sharing guidelines. If we did not receive a response to our initial request, a second request was made. Following the ten requests for raw data, three investigators did not respond, four authors responded and refused to share their data, two email addresses were no longer valid, and one author requested further details. A reminder of PLoS's explicit requirement that authors share data did not change the reply from the four authors who initially refused. Only one author sent an original data set. Conclusions: We received only one of ten raw data sets requested. This suggests that journal policies requiring data sharing do not lead to authors making their data sets available to independent investigators.			Savage, CJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.	vickersa@mskcc.org		Vickers, Andrew/0000-0003-1525-6503	NATIONAL CANCER INSTITUTE [P50CA092629] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA92629, P50 CA092629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], SCI MAGAZINE; [Anonymous], NATURE J; National Institute of Health, NIH DAT SHAR POL; *NIH, NIH DAT SHAR POL BRO; SudlowC GallacherJ, 2015, PLOS MED, V12; Vickers AJ, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-15; Wicherts JM, 2006, AM PSYCHOL, V61, P726, DOI 10.1037/0003-066X.61.7.726; 2001, ETHICAL STANDARDS RE, P387	8	216	219	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7078	10.1371/journal.pone.0007078	http://dx.doi.org/10.1371/journal.pone.0007078			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763261	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970400013
J	de Oca, RM; Shoemaker, CJ; Gucek, M; Cole, RN; Wilson, KL				de Oca, Rocio Montes; Shoemaker, Christopher J.; Gucek, Marjan; Cole, Robert N.; Wilson, Katherine L.			Barrier-to-Autointegration Factor Proteome Reveals Chromatin-Regulatory Partners	PLOS ONE			English	Article							TRANSCRIPTIONAL COACTIVATOR PC4; IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOTIDE EXCISION-REPAIR; LEM-DOMAIN PROTEINS; DNA-BINDING; HISTONE H3; FACTOR BAF; NUCLEAR-ENVELOPE; S-PHASE; POLY(ADP-RIBOSE) POLYMERASE-1	Nuclear lamin filaments and associated proteins form a nucleoskeletal ("lamina'') network required for transcription, replication, chromatin organization and epigenetic regulation in metazoans. Lamina defects cause human disease ("laminopathies'') and are linked to aging. Barrier-to-autointegration factor (BAF) is a mobile and essential component of the nuclear lamina that binds directly to histones, lamins and LEM-domain proteins, including the inner nuclear membrane protein emerin, and has roles in chromatin structure, mitosis and gene regulation. To understand BAF's mechanisms of action, BAF associated proteins were affinity-purified from HeLa cell nuclear lysates using BAF-conjugated beads, and identified by tandem mass spectrometry or independently identified and quantified using the iTRAQ method. We recovered A- and B-type lamins and core histones, all known to bind BAF directly, plus four human transcription factors ( Requiem, NonO, p15, LEDGF), disease-linked proteins (e.g., Huntingtin, Treacle) and several proteins and enzymes that regulate chromatin. Association with endogenous BAF was independently validated by co-immunoprecipitation from HeLa cells for seven candidates including Requiem, poly(ADP-ribose) polymerase 1 (PARP1), retinoblastoma binding protein 4 (RBBP4), damage-specific DNA binding protein 1 (DDB1) and DDB2. Interestingly, endogenous BAF and emerin each associated with DDB2 and CUL4A in a UV- and time-dependent manner, suggesting BAF and emerin have dynamic roles in genome integrity and might help couple DNA damage responses to the nuclear lamina network. We conclude this proteome is a rich source of candidate partners for BAF and potentially also A- and B-type lamins, which may reveal how chromatin regulation and genome integrity are linked to nuclear structure.			de Oca, RM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21218 USA.	klwilson@jhmi.edu	Wilson, Katherine/HII-8144-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048646] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48646, R01 GM048646] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee S, 2004, MOL CELL BIOL, V24, P2052, DOI 10.1128/MCB.24.5.2052-2062.2004; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Batta K, 2009, J MOL BIOL, V385, P788, DOI 10.1016/j.jmb.2008.11.008; Bengtsson L, 2006, MOL BIOL CELL, V17, P1154, DOI 10.1091/mbc.E05-04-0356; Bradley CM, 2005, NAT STRUCT MOL BIOL, V12, P935, DOI 10.1038/nsmb989; Bridger JM, 2007, FEBS J, V274, P1354, DOI 10.1111/j.1742-4658.2007.05694.x; Broers JLV, 2006, PHYSIOL REV, V86, P967, DOI 10.1152/physrev.00047.2005; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Capell BC, 2006, NAT REV GENET, V7, P940, DOI 10.1038/nrg1906; Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200; Collins RE, 2008, NAT STRUCT MOL BIOL, V15, P245, DOI 10.1038/nsmb.1384; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Amours D, 2001, J CELL SCI, V114, P3771; Dai QA, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-14; Das C, 2006, MOL CELL BIOL, V26, P8303, DOI 10.1128/MCB.00887-06; de Oca ROM, 2005, J BIOL CHEM, V280, P42252, DOI 10.1074/jbc.M509917200; Dechat T, 2004, J CELL SCI, V117, P6117, DOI 10.1242/jcs.01529; Dorner D, 2007, FEBS J, V274, P1362, DOI 10.1111/j.1742-4658.2007.05695.x; Engelman A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000046; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Furukawa K, 2003, J CELL SCI, V116, P3811, DOI 10.1242/jcs.00682; Furuyama T, 2006, P NATL ACAD SCI USA, V103, P6172, DOI 10.1073/pnas.0601686103; GABIG TG, 1994, J BIOL CHEM, V269, P29515; Gant TM, 1999, J CELL BIOL, V144, P1083, DOI 10.1083/jcb.144.6.1083; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goldberg M, 1999, P NATL ACAD SCI USA, V96, P2852, DOI 10.1073/pnas.96.6.2852; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947; Haraguchi T, 2001, J CELL SCI, V114, P4575; Haraguchi T, 2008, J CELL SCI, V121, P2540, DOI 10.1242/jcs.033597; Haraguchi T, 2007, J CELL SCI, V120, P1967, DOI 10.1242/jcs.03461; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; Holaska JM, 2007, BIOCHEMISTRY-US, V46, P8897, DOI 10.1021/bi602636m; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; Ito T, 2008, BIOCHEM J, V411, P201, DOI 10.1042/BJ20071075; Jacob KN, 2006, MOL GENET METAB, V87, P289, DOI 10.1016/j.ymgme.2005.10.018; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jacque JM, 2006, NATURE, V441, P641, DOI 10.1038/nature04682; Joselin AP, 2006, J BIOL CHEM, V281, P12475, DOI 10.1074/jbc.M509859200; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kishore AH, 2007, BIOCHEM J, V406, P437, DOI 10.1042/BJ20070390; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Li JY, 2006, CANCER RES, V66, P8590, DOI 10.1158/0008-5472.CAN-06-1115; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; Manju K, 2006, J CELL SCI, V119, P2704, DOI 10.1242/jcs.03009; Mansharamani M, 2003, J VIROL, V77, P13084, DOI 10.1128/JVI.77.24.13084-13092.2003; Margalit A, 2005, P NATL ACAD SCI USA, V102, P3290, DOI 10.1073/pnas.0408364102; Margalit A, 2007, J CELL BIOL, V178, P661, DOI 10.1083/jcb.200704049; Margalit A, 2007, TRENDS CELL BIOL, V17, P202, DOI 10.1016/j.tcb.2007.02.004; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Mortusewicz O, 2008, J CELL BIOL, V183, P769, DOI 10.1083/jcb.200808097; Moser J, 2005, DNA REPAIR, V4, P571, DOI 10.1016/j.dnarep.2005.01.001; Mulky A, 2008, J VIROL, V82, P5860, DOI 10.1128/JVI.00076-08; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Polo SE, 2006, CELL, V127, P481, DOI 10.1016/j.cell.2006.08.049; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Ramirez CL, 2007, CELL MOL LIFE SCI, V64, P155, DOI 10.1007/s00018-006-6349-3; Reinberg D, 2006, J BIOL CHEM, V281, P23297, DOI 10.1074/jbc.R600007200; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Ridgway P, 2000, J CELL SCI, V113, P2647; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Scaffidi P, 2006, SCIENCE, V312, P1059, DOI 10.1126/science.1127168; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Segura-Totten M, 2004, TRENDS CELL BIOL, V14, P261, DOI 10.1016/j.tcb.2004.03.004; Shaklai S, 2007, FEBS J, V274, P1383, DOI 10.1111/j.1742-4658.2007.05697.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Shumaker DK, 2008, J CELL BIOL, V181, P269, DOI 10.1083/jcb.200708155; Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Shun MC, 2007, J VIROL, V81, P166, DOI 10.1128/JVI.01953-06; Sridharan D, 2003, J CELL SCI, V116, P823, DOI 10.1242/jcs.00294; Sridharan DM, 2006, CELL BIOL INT, V30, P866, DOI 10.1016/j.cellbi.2006.06.005; Stiff T, 2008, HUM MOL GENET, V17, P3247, DOI 10.1093/hmg/ddn220; Sugimura K, 2008, J CELL BIOL, V183, P1203, DOI 10.1083/jcb.200806068; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Trinkle-Mulcahy L, 2008, J CELL BIOL, V183, P223, DOI 10.1083/jcb.200805092; Vidakovic M, 2004, J CELL BIOCHEM, V93, P1155, DOI 10.1002/jcb.20289; Wacker DA, 2007, MOL CELL BIOL, V27, P7475, DOI 10.1128/MCB.01314-07; Wagner N, 2007, INT REV CYTOL, V261, P1, DOI 10.1016/S0074-7696(07)61001-8; Wang HB, 2006, MOL CELL, V22, P383, DOI 10.1016/j.molcel.2006.03.035; Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200; Wiebe MS, 2007, CELL HOST MICROBE, V1, P187, DOI 10.1016/j.chom.2007.03.007; Wong DCF, 2006, BIOTECHNOL BIOENG, V95, P350, DOI 10.1002/bit.20871; Worman HJ, 2007, EXP CELL RES, V313, P2121, DOI 10.1016/j.yexcr.2007.03.028; Wu LM, 2008, P NATL ACAD SCI USA, V105, P11200, DOI 10.1073/pnas.0802885105; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang J, 1998, J PORPHYR PHTHALOCYA, V2, P93, DOI 10.1002/(SICI)1099-1409(199803/04)2:2<93::AID-JPP81>3.3.CO;2-O; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197	97	74	78	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7050	10.1371/journal.pone.0007050	http://dx.doi.org/10.1371/journal.pone.0007050			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19759913	gold, Green Published, Green Submitted			2022-12-27	WOS:000269970000017
J	Si, Y; Shi, H; Lee, K				Si, Yaguang; Shi, Hai; Lee, Kyongbum			Metabolic Flux Analysis of Mitochondrial Uncoupling in 3T3-L1 Adipocytes	PLOS ONE			English	Article								Background: Increasing energy expenditure at the cellular level offers an attractive option to limit adiposity and improve whole body energy balance. In vivo and in vitro observations have correlated mitochondrial uncoupling protein-1 (UCP1) expression with reduced white adipose tissue triglyceride (TG) content. The metabolic basis for this correlation remains unclear. Methodology/Principal Findings: This study tested the hypothesis that mitochondrial uncoupling requires the cell to compensate for the decreased oxidation phosphorylation efficiency by up-regulating lactate production, thus redirecting carbon flux away from TG synthesis. Metabolic flux analysis was used to characterize the effects of non-lethal, long-term mitochondrial uncoupling (up to 18 days) on the pathways of intermediary metabolism in differentiating 3T3-L1 adipocytes. Uncoupling was induced by forced expression of UCP1 and chemical (FCCP) treatment. Chemical uncoupling significantly decreased TG content by ca. 35%. A reduction in the ATP level suggested diminished oxidative phosphorylation efficiency in the uncoupled adipocytes. Flux analysis estimated significant up-regulation of glycolysis and down-regulation of fatty acid synthesis, with chemical uncoupling exerting quantitatively larger effects. Conclusions/Significance: The results of this study support our hypothesis regarding uncoupling-induced redirection of carbon flux into glycolysis and lactate production, and suggest mitochondrial proton translocation as a potential target for controlling adipocyte lipid metabolism.			Si, Y (corresponding author), Boston Univ, Sch Med, Obes Res Ctr, Boston, MA 02118 USA.	kyongbum.lee@tufts.edu	Shi, Hai/K-6254-2012	Lee, Kyongbum/0000-0002-0699-8057	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067228] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK67228-01, R21 DK067228] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baumruk F, 1999, FEBS LETT, V444, P206, DOI 10.1016/S0014-5793(99)00053-8; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; Christian M, 2005, MOL CELL BIOL, V25, P9383, DOI 10.1128/MCB.25.21.9383-9391.2005; COHEN SA, 1994, J CHROMATOGR A, V661, P25, DOI 10.1016/0021-9673(93)E0821-B; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; FABREGAT I, 1987, MOL CELL BIOCHEM, V74, P77; Gajewski CD, 2003, MOL BIOL CELL, V14, P3628, DOI 10.1091/mbc.E02-12-0796; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HAUNER H, 2001, ADIPOSE TISSUE PROTO, V13, P334; Hvizdos KM, 1999, DRUGS, V58, P743, DOI 10.2165/00003495-199958040-00015; KATZ J, 1966, J BIOL CHEM, V241, P3600; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; KLAUS S, 1995, J CELL SCI, V108, P3171; Kopecky J, 2004, PHYSIOL RES, V53, pS225; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; LOOMIS ME, 1961, J LAB CLIN MED, V57, P966; MITROU P, 2008, RATES GLUCOSE UPTAKE; NICHOLLS JG, 1984, RES MOTIVATION ED ST, V1, P64; NIEMINEN AL, 1994, AM J PHYSIOL, V267, pC67, DOI 10.1152/ajpcell.1994.267.1.C67; Nolan RP, 2006, METAB ENG, V8, P30, DOI 10.1016/j.ymben.2005.08.004; Orci L, 2004, P NATL ACAD SCI USA, V101, P2058, DOI 10.1073/pnas.0308258100; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Park J, 2007, DIABETES RES CLIN PR, V77, pS11, DOI 10.1016/j.diabres.2007.01.037; Powelka AM, 2006, J CLIN INVEST, V116, P125, DOI 10.1172/JCI26040; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Rossmeisl M, 2000, FASEB J, V14, P1793, DOI 10.1096/fj.99-0965com; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; Si YG, 2007, AM J PHYSIOL-ENDOC M, V292, pE1637, DOI 10.1152/ajpendo.00670.2006; Si YG, 2007, J LIPID RES, V48, P826, DOI 10.1194/jlr.M600343-JLR200; SNYDER JW, 1993, AM J PHYSIOL, V264, pC709, DOI 10.1152/ajpcell.1993.264.3.C709; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Sun XC, 2003, J NUTR BIOCHEM, V14, P219, DOI 10.1016/S0955-2863(03)00004-4; Tejerina S, 2009, J CELL SCI, V122, P145, DOI 10.1242/jcs.027508; TERADA H, 1981, BIOCHIM BIOPHYS ACTA, V639, P225, DOI 10.1016/0304-4173(81)90011-2; Tiraby C, 2003, J BIOL CHEM, V278, P33370, DOI 10.1074/jbc.M305235200; TRINDER P, 1969, J CLIN PATHOL, V22, P158, DOI 10.1136/jcp.22.2.158; Van Gaal LF, 1998, EXP CLIN ENDOCR DIAB, V106, P35, DOI 10.1055/s-0029-1212035; Wang T, 2003, OBES RES, V11, P880, DOI 10.1038/oby.2003.121; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	43	25	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e7000	10.1371/journal.pone.0007000	http://dx.doi.org/10.1371/journal.pone.0007000			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746157	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696500010
J	Tanaka, H; Yi, TM				Tanaka, Hiromasa; Yi, Tau-Mu			Synthetic Morphology Using Alternative Inputs	PLOS ONE			English	Article								Designing the shape and size of a cell is an interesting challenge for synthetic biology. Prolonged exposure to the mating pheromone alpha-factor induces an unusual morphology in yeast cells: multiple mating projections. The goal of this work was to reproduce the multiple projections phenotype in the absence of alpha-factor using a gain-of-function approach termed "Alternative Inputs (AIs)''. An alternative input is defined as any genetic manipulation that can activate the signaling pathway instead of the natural input. Interestingly, none of the alternative inputs were sufficient to produce multiple projections although some produced a single projection. Then, we extended our search by creating all combinations of alternative inputs and deletions that were summarized in an AIs-Deletions matrix. We found a genetic manipulation (AI-Ste5p ste2 Delta) that enhanced the formation of multiple projections. Following up this lead, we demonstrated that AI-Ste4p and AI-Ste5p were sufficient to produce multiple projections when combined. Further, we showed that overexpression of a membrane-targeted form of Ste5p alone could also induce multiple projections. Thus, we successfully re-engineered the multiple projections mating morphology using alternative inputs without alpha-factor.			Tanaka, H (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA.	tmy@uci.edu			NIGMS NIH HHS [R01GM75309, R01 GM075309, P50 GM076516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075309, P50GM076516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Ballon DR, 2006, CELL, V126, P1079, DOI 10.1016/j.cell.2006.07.030; Bharucha JP, 2008, EUKARYOT CELL, V7, P1246, DOI 10.1128/EC.00024-08; Bidlingmaier S, 2004, J CELL BIOL, V164, P207, DOI 10.1083/jcb.200307065; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; CHENEVERT J, 1994, GENETICS, V136, P1287; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Drubin DA, 2007, GENE DEV, V21, P242, DOI 10.1101/gad.1507207; Elion EA, 2001, J CELL SCI, V114, P3967; Giot L, 1997, MOL BIOL CELL, V8, P987, DOI 10.1091/mbc.8.6.987; Harris K, 2001, CURR BIOL, V11, P1815, DOI 10.1016/S0960-9822(01)00567-X; Hawkins KM, 2006, J BIOL CHEM, V281, P13485, DOI 10.1074/jbc.M512317200; Hilioti Z, 2008, CURR BIOL, V18, P1700, DOI 10.1016/j.cub.2008.09.027; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Kroll ES, 1996, GENETICS, V143, P95; KURJAN J, 1985, MOL CELL BIOL, V5, P787, DOI 10.1128/MCB.5.4.787; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Matheos D, 2004, J CELL BIOL, V165, P99, DOI 10.1083/jcb.200309089; MOORE SA, 1983, J BIOL CHEM, V258, P3849; Moore TI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003865; Moriya H, 2006, PLOS GENET, V2, P1034, DOI 10.1371/journal.pgen.0020111; Ohya Y, 2005, P NATL ACAD SCI USA, V102, P19015, DOI 10.1073/pnas.0509436102; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne D, 2000, J CELL SCI, V113, P571; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Schwartz MA, 2004, ANNU REV GENET, V38, P725, DOI 10.1146/annurev.genet.39.073003.112634; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Siekhaus DE, 2003, NAT CELL BIOL, V5, P231, DOI 10.1038/ncb941; Sopko R, 2006, MOL CELL, V21, P319, DOI 10.1016/j.molcel.2005.12.011; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; van Drogen F, 2000, CURR BIOL, V10, P630, DOI 10.1016/S0960-9822(00)00511-X; Wang YM, 2005, J BIOL CHEM, V280, P13084, DOI 10.1074/jbc.M410461200; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wedlich-Soldner R, 2004, J CELL BIOL, V166, P889, DOI 10.1083/jcb.200405061; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yeh BJ, 2007, NAT CHEM BIOL, V3, P521, DOI 10.1038/nchembio0907-521; Yi TM, 2003, P NATL ACAD SCI USA, V100, P10764, DOI 10.1073/pnas.1834247100	46	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6946	10.1371/journal.pone.0006946	http://dx.doi.org/10.1371/journal.pone.0006946			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746161	gold, Green Published			2022-12-27	WOS:000269696500002
J	Jaramillo, M; Bellemare, MJ; Martel, C; Shio, MT; Contreras, AP; Godbout, M; Roger, M; Gaudreault, E; Gosselin, J; Bohle, DS; Olivier, M				Jaramillo, Maritza; Bellemare, Marie-Josee; Martel, Caroline; Shio, Marina Tiemi; Contreras, Ana Paulina; Godbout, Marianne; Roger, Michel; Gaudreault, Eric; Gosselin, Jean; Bohle, D. Scott; Olivier, Martin			Synthetic Plasmodium-Like Hemozoin Activates the Immune Response: A Morphology - Function Study	PLOS ONE			English	Article								Increasing evidence points to an important role for hemozoin (HZ), the malaria pigment, in the immunopathology related to this infection. However, there is no consensus as to whether HZ exerts its immunostimulatory activity in absence of other parasite or host components. Contamination of native HZ preparations and the lack of a unified protocol to produce crystals that mimic those of Plasmodium HZ (PHZ) are major technical limitants when performing functional studies with HZ. In fact, the most commonly used methods generate a heterogeneous nanocrystalline material. Thus, it is likely that such aggregates do not resemble to PHZ and differ in their inflammatory properties. To address this issue, the present study was designed to establish whether synthetic HZ (sHZ) crystals produced by different methods vary in their morphology and in their ability to activate immune responses. We report a new method of HZ synthesis (the precise aqueous acid-catalyzed method) that yields homogeneous sHZ crystals (Plasmodium-like HZ) which are very similar to PHZ in their size and physicochemical properties. Importantly, these crystals are devoid of protein and DNA contamination. Of interest, structure-function studies revealed that the size and shape of the synthetic crystals influences their ability to activate inflammatory responses (e. g. nitric oxide, chemokine and cytokine mRNA) in vitro and in vivo. In summary, our data confirm that sHZ possesses immunostimulatory properties and underline the importance of verifying by electron microscopy both the morphology and homogeneity of the synthetic crystals to ensure that they closely resemble those of the parasite. Periodic quality control experiments and unification of the method of HZ synthesis are key steps to unravel the role of HZ in malaria immunopathology.			Jaramillo, M (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Dept Med,Ctr Study Host Res, Montreal, PQ, Canada.	martin.olivier@mcgill.ca	Jaramillo, Maritza/T-7467-2019; Shio, Marina Tiemi/E-6466-2019	Jaramillo, Maritza/0000-0002-1910-5684; Shio, Marina Tiemi/0000-0002-2494-6816				Amodu OK, 1998, T ROY SOC TROP MED H, V92, P54, DOI 10.1016/S0035-9203(98)90952-X; ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; Biswas S, 2001, FEMS MICROBIOL LETT, V194, P175, DOI 10.1111/j.1574-6968.2001.tb09465.x; Bohle D. S., 1994, INORGANIC ORGANOMETA, P497; Bohle DS, 1997, J BIOL CHEM, V272, P713, DOI 10.1074/jbc.272.2.713; Bohle DS, 2002, ACTA CRYSTALLOGR D, V58, P1752, DOI 10.1107/S0907444902014294; Bose M, 1995, IMMUNOL LETT, V48, P59, DOI 10.1016/0165-2478(95)02444-1; BURGMANN H, 1995, CLIN IMMUNOL IMMUNOP, V76, P32, DOI 10.1006/clin.1995.1084; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; EDINGTON GM, 1967, BMJ-BRIT MED J, V1, P715, DOI 10.1136/bmj.1.5542.715; Egan TJ, 2008, J INORG BIOCHEM, V102, P1288, DOI 10.1016/j.jinorgbio.2007.12.004; Egan TJ, 2008, MOL BIOCHEM PARASIT, V157, P127, DOI 10.1016/j.molbiopara.2007.11.005; FITCH CD, 1987, J BIOL CHEM, V262, P15552; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GOLDIE P, 1990, AM J TROP MED HYG, V43, P584, DOI 10.4269/ajtmh.1990.43.584; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Jaramillo M, 2005, J IMMUNOL, V174, P475, DOI 10.4049/jimmunol.174.1.475; Jaramillo M, 2004, J IMMUNOL, V172, P3101, DOI 10.4049/jimmunol.172.5.3101; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; Keller CC, 2004, INFECT IMMUN, V72, P4868, DOI 10.1128/IAI.72.8.4868-4873.2004; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Martiney JA, 2000, INFECT IMMUN, V68, P2259, DOI 10.1128/IAI.68.4.2259-2267.2000; Mordmuller B, 1998, EUR CYTOKINE NETW, V9, P239; Newton CRJC, 1998, AM J TROP MED HYG, V58, P673, DOI 10.4269/ajtmh.1998.58.673; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; Noland GS, 2003, MOL BIOCHEM PARASIT, V130, P91, DOI 10.1016/S0166-6851(03)00163-4; NUSSLER AK, 1994, J INFECT DIS, V169, P1418, DOI 10.1093/infdis/169.6.1418; Ochiel DO, 2005, INFECT IMMUN, V73, P4190, DOI 10.1128/IAI.73.7.4190-4197.2005; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Park PH, 2007, J BIOL CHEM, V282, P21695, DOI 10.1074/jbc.M701419200; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; PHU NH, 1995, T ROY SOC TROP MED H, V89, P200, DOI 10.1016/0035-9203(95)90496-4; PICHYANGKUL S, 1994, AM J TROP MED HYG, V51, P430, DOI 10.4269/ajtmh.1994.51.430; Pichyangkul S, 1997, AM J TROP MED HYG, V57, P383, DOI 10.4269/ajtmh.1997.57.383; PRADA J, 1995, EUR CYTOKINE NETW, V6, P109; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; ROCKETT KA, 1994, PARASITE IMMUNOL, V16, P243, DOI 10.1111/j.1365-3024.1994.tb00346.x; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403; Scorza T, 2005, INFECT IMMUN, V73, P2974, DOI 10.1128/IAI.73.5.2974-2985.2005; SHERRY BA, 1995, J INFLAMM, V45, P85; SHIO MT, 2009, PLOS PATHOG IN PRESS; Skorokhod OA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-73; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; Solomonov I, 2007, J AM CHEM SOC, V129, P2615, DOI 10.1021/ja0674183; Sullivan AD, 1996, PARASITOLOGY, V112, P285, DOI 10.1017/S003118200006580X; URQUHART AD, 1994, CLIN INFECT DIS, V19, P117, DOI 10.1093/clinids/19.1.117; WEINBERG JB, 1995, BLOOD, V86, P1184; Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150; YAMADA KA, 1979, EXP PARASITOL, V48, P61, DOI 10.1016/0014-4894(79)90055-9	50	60	64	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6957	10.1371/journal.pone.0006957	http://dx.doi.org/10.1371/journal.pone.0006957			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742308	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622500018
J	Lacraz, G; Giroix, MH; Kassis, N; Coulaud, J; Galinier, A; Noll, C; Cornut, M; Schmidlin, F; Paul, JL; Janel, N; Irminger, JC; Kergoat, M; Portha, B; Donath, MY; Ehses, JA; Homo-Delarche, F				Lacraz, Gregory; Giroix, Marie-Helene; Kassis, Nadim; Coulaud, Josiane; Galinier, Anne; Noll, Christophe; Cornut, Melanie; Schmidlin, Fabien; Paul, Jean-Louis; Janel, Nathalie; Irminger, Jean-Claude; Kergoat, Micheline; Portha, Bernard; Donath, Marc Y.; Ehses, Jan A.; Homo-Delarche, Francoise			Islet Endothelial Activation and Oxidative Stress Gene Expression Is Reduced by IL-1Ra Treatment in the Type 2 Diabetic GK Rat	PLOS ONE			English	Article							GOTO-KAKIZAKI RAT; INTERLEUKIN-1 RECEPTOR ANTAGONIST; NITRIC-OXIDE SYNTHASE; RENIN-ANGIOTENSIN SYSTEM; NECROSIS-FACTOR-ALPHA; BETA-CELL MASS; PANCREATIC-ISLETS; HEME OXYGENASE-1; CARDIOVASCULAR-DISEASE; NADPH OXIDASE	Background: Inflammation followed by fibrosis is a component of islet dysfunction in both rodent and human type 2 diabetes. Because islet inflammation may originate from endothelial cells, we assessed the expression of selected genes involved in endothelial cell activation in islets from a spontaneous model of type 2 diabetes, the Goto-Kakizaki (GK) rat. We also examined islet endotheliuml/oxidative stress (OS)/inflammation-related gene expression, islet vascularization and fibrosis after treatment with the interleukin-1 (IL-1) receptor antagonist (IL-1Ra). Methodology/Principal Findings: Gene expression was analyzed by quantitative RT-PCR on islets isolated from 10-week-old diabetic GK and control Wistar rats. Furthermore, GK rats were treated s.c twice daily with IL-1Ra (Kineret, Amgen, 100 mg/kg/day) or saline, from 4 weeks of age onwards (onset of diabetes). Four weeks later, islet gene analysis and pancreas immunochemistry were performed. Thirty-two genes were selected encoding molecules involved in endothelial cell activation, particularly fibrinolysis, vascular tone, OS, angiogenesis and also inflammation. All genes except those encoding angiotensinogen and epoxide hydrolase (that were decreased), and 12-lipoxygenase and vascular endothelial growth factor (that showed no change), were significantly up-regulated in GK islets. After IL-1Ra treatment of GK rats in vivo, most selected genes implied in endothelium/OS/immune cells/fibrosis were significantly down-regulated. IL-1Ra also improved islet vascularization, reduced fibrosis and ameliorated glycemia. Conclusions/Significance: GK rat islets have increased mRNA expression of markers of early islet endothelial cell activation, possibly triggered by several metabolic factors, and also some defense mechanisms. The beneficial effect of IL-1Ra on most islet endothelial/OS/immune cells/fibrosis parameters analyzed highlights a major endothelial-related role for IL-1 in GK islet alterations. Thus, metabolically-altered islet endothelium might affect the beta-cell microenvironment and contribute to progressive type 2 diabetic beta-cell dysfunction in GK rats. Counteracting islet endothelial cell inflammation might be one way to ameliorate/prevent beta-cell dysfunction in type 2 diabetes.			Lacraz, G (corresponding author), Univ Paris Diderot, CNRS, Lab Biol & Pathol Endocrine Pancreas, Funct & Adapt Biol Unit,EA 7059, Paris, France.	francoise.homo-delarche@paris7.jussieu.fr	paul, jean-louis/D-8071-2017; Portha, Bernard/AAW-3021-2021; Ehses, Jan/AAK-1635-2020	Galinier, Anne/0000-0003-2454-5681; Ehses, Jan/0000-0001-9066-7607; Janel, Nathalie/0000-0002-4746-8941				Adams B, 2007, TRENDS CARDIOVAS MED, V17, P246, DOI 10.1016/j.tcm.2007.08.005; Ahmed FN, 2006, ANN NY ACAD SCI, V1084, P481, DOI 10.1196/annals.1372.022; Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Andersson AK, 2005, MOL CELL ENDOCRINOL, V240, P50, DOI 10.1016/j.mce.2005.06.001; Apostolakis Stavros, 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P150, DOI 10.2174/187152508783955006; Argoud K, 2006, DIABETOLOGIA, V49, P2679, DOI 10.1007/s00125-006-0396-z; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Barlic J, 2007, J LEUKOCYTE BIOL, V82, P226, DOI 10.1189/jlb.1206761; Becker T, 2007, TRANSPLANTATION, V84, P1644, DOI 10.1097/01.tp.0000290233.81395.81; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Beltowski J, 2003, ATHEROSCLEROSIS, V170, P21, DOI 10.1016/S0021-9150(03)00236-3; Beltowski J, 2006, ATHEROSCLEROSIS, V189, P47, DOI 10.1016/j.atherosclerosis.2006.03.003; Bitar MS, 2005, EUR J PHARMACOL, V511, P53, DOI 10.1016/j.ejphar.2005.01.014; Borjesson A, 2007, J ENDOCRINOL, V192, P381, DOI 10.1677/joe.1.06676; Brigelius-Flohe R, 2004, ARCH BIOCHEM BIOPHYS, V423, P66, DOI 10.1016/j.abb.2003.12.008; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520; Calderari S, 2007, DIABETOLOGIA, V50, P1463, DOI 10.1007/s00125-007-0676-2; Calles-Escandon J, 2001, ENDOCR REV, V22, P36, DOI 10.1210/er.22.1.36; Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78; Chen P, 2007, AM J PHYSIOL-REG I, V293, pR1619, DOI 10.1152/ajpregu.00290.2007; Cheng ZJ, 2001, HYPERTENSION, V37, P433, DOI 10.1161/01.HYP.37.2.433; Clark A, 2004, DIABETOLOGIA, V47, P157, DOI 10.1007/s00125-003-1304-4; Creager MA, 2003, CIRCULATION, V108, P1527, DOI 10.1161/01.CIR.0000091257.27563.32; Dammanahalli KJ, 2008, CLIN EXP PHARMACOL P, V35, P2, DOI 10.1111/j.1440-1681.2007.04830.x; Daugherty A, 2004, CIRCULATION, V110, P3849, DOI 10.1161/01.CIR.0000150540.54220.C4; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; DEJANA E, 1987, BLOOD, V69, P695; Dinarello CA, 2004, CURR OPIN PHARMACOL, V4, P378, DOI 10.1016/j.coph.2004.03.010; Ding H, 2007, EUR J PHARMACOL, V561, P121, DOI 10.1016/j.ejphar.2006.12.034; Donath MY, 2008, DIABETES CARE, V31, pS161, DOI 10.2337/dc08-s243; Donath MY, 2008, ENDOCR REV, V29, P334, DOI 10.1210/er.2007-0033; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001; Ehses JA, 2009, P NATL ACAD SCI USA, V106, P13998, DOI 10.1073/pnas.0810087106; Ehses JA, 2007, DIABETES, V56, P2356, DOI 10.2337/db06-1650; Ehses Jan A., 2007, Current Immunology Reviews, V3, P216; Ellingsgaard H, 2008, P NATL ACAD SCI USA, V105, P13163, DOI 10.1073/pnas.0801059105; Fadini GP, 2008, DIABETOLOGIA, V51, P1091, DOI 10.1007/s00125-008-1021-0; FORTIN LJ, 1995, CLIN BIOCHEM, V28, P155, DOI 10.1016/0009-9120(94)00073-5; Fujita H, 2007, BIOCHEM BIOPH RES CO, V363, P37, DOI 10.1016/j.bbrc.2007.08.090; Galinier A, 2006, FEBS LETT, V580, P6391, DOI 10.1016/j.febslet.2006.10.052; GIROIX MH, 1993, ENDOCRINOLOGY, V132, P815, DOI 10.1210/en.132.2.815; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; GRANKVIST K, 1981, BIOCHEM J, V199, P393, DOI 10.1042/bj1990393; Haddad JJ, 2005, MOL IMMUNOL, V42, P987, DOI 10.1016/j.molimm.2004.09.029; Hamelet J, 2007, EUR J CLIN INVEST, V37, P933, DOI 10.1111/j.1365-2362.2007.01879.x; Harris AK, 2005, DIABETES, V54, P2638, DOI 10.2337/diabetes.54.9.2638; Hayashi T, 2007, BBA-MOL BASIS DIS, V1772, P364, DOI 10.1016/j.bbadis.2006.11.011; Hayden MR, 2007, ANTIOXID REDOX SIGN, V9, P891, DOI 10.1089/ars.2007.1610; HELSET E, 1993, MEDIAT INFLAMM, V2, P417, DOI 10.1155/S0962935193000596; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; Higuchi S, 2007, CLIN SCI, V112, P417, DOI 10.1042/CS20060342; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Hodroj W, 2007, ARTERIOSCL THROM VAS, V27, P525, DOI 10.1161/01.ATV.0000254814.63768.3b; Holven KB, 2008, J NUTR, V138, P2070, DOI 10.3945/jn.108.090704; Homo-Delarche F, 2008, DIABETOLOGIA, V51, pS308; Homo-Delarche F, 2006, DIABETES, V55, P1625, DOI 10.2337/db05-1526; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Iglarz M, 2007, J CARDIOVASC PHARM, V50, P621, DOI 10.1097/FJC.0b013e31813c6cc3; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Jia XX, 2007, MOL PHARM, V4, P199, DOI 10.1021/mp060091s; Jonas JC, 2003, DIABETOLOGIA, V46, P1234, DOI 10.1007/s00125-003-1174-9; Kamide K, 2004, J HYPERTENS, V22, P121, DOI 10.1097/00004872-200401000-00021; Kim F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851; Kim JW, 2008, FRONT BIOSCI-LANDMRK, V13, P6022, DOI 10.2741/3133; Kimura I, 1998, IMMUNOPHARMACOLOGY, V40, P105, DOI 10.1016/S0162-3109(98)00024-1; Ko SH, 2004, BIOCHEM BIOPH RES CO, V316, P114, DOI 10.1016/j.bbrc.2004.02.023; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lacraz G, 2007, DIABETOLOGIA, V50, pS177; Lacraz G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006500; Lai EY, 2007, AM J PHYSIOL-ENDOC M, V292, pE1616, DOI 10.1152/ajpendo.00640.2006; Lamkanfi M, 2007, J LEUKOCYTE BIOL, V82, P220, DOI 10.1189/jlb.1206756; Larsen BT, 2007, TRENDS PHARMACOL SCI, V28, P32, DOI 10.1016/j.tips.2006.11.002; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; Lentz SR, 2001, ARTERIOSCL THROM VAS, V21, P1385; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Leung PS, 2007, J PHYSIOL-LONDON, V580, P31, DOI 10.1113/jphysiol.2006.126193; Li XQ, 2006, DIABETES, V55, P2965, DOI 10.2337/db06-0733; Libby P, 2006, AM J CLIN NUTR, V83, p456S; Linton MF, 2004, CURR OPIN PHARMACOL, V4, P116, DOI 10.1016/j.coph.2003.12.003; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Marculescu R, 2002, DIABETES, V51, P3582, DOI 10.2337/diabetes.51.12.3582; Masuyama T, 2004, BIOCHEM BIOPH RES CO, V314, P870, DOI 10.1016/j.bbrc.2003.12.180; Meigs JB, 2007, DIABETES CARE, V30, P1219, DOI 10.2337/dc06-2484; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Michaelis UR, 2006, PHARMACOL THERAPEUT, V111, P584, DOI 10.1016/j.pharmthera.2005.11.003; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Morgan D, 2007, DIABETOLOGIA, V50, P359, DOI 10.1007/s00125-006-0462-6; Movassat J, 1997, DIABETOLOGIA, V40, P916, DOI 10.1007/s001250050768; Nakamura M, 1995, DIABETES RES CLIN PR, V30, P89, DOI 10.1016/0168-8227(95)01155-2; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Oak JH, 2007, DIABETES, V56, P118, DOI 10.2337/db06-0288; OLEARCZYK JJ, 2008, CLIN SCI LOND; Perrier S, 2006, FEBS LETT, V580, P6289, DOI 10.1016/j.febslet.2006.10.061; Portha B, 2009, MOL CELL ENDOCRINOL, V297, P73, DOI 10.1016/j.mce.2008.06.013; RISTIMAKI A, 1992, PROSTAG LEUKOTR ESS, V47, P93, DOI 10.1016/0952-3278(92)90143-7; Rojas A, 2006, ARCH MED RES, V37, P436, DOI 10.1016/j.arcmed.2005.11.012; Rozenberg O, 2008, FREE RADICAL BIO MED, V44, P1951, DOI 10.1016/j.freeradbiomed.2008.02.012; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Sacerdoti D, 2005, CELL MOL BIOL, V51, P363, DOI 10.1170/T639; Sachidanandam K, 2007, DIABETES, V56, P2753, DOI 10.2337/db07-0426; Salehi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002165; Sauter NS, 2008, ENDOCRINOLOGY, V149, P2208, DOI 10.1210/en.2007-1059; Schalkwijk CG, 2005, CLIN SCI, V109, P143, DOI 10.1042/CS20050025; Schulze PC, 2004, J BIOL CHEM, V279, P30369, DOI 10.1074/jbc.M400549200; Seldon MP, 2007, J IMMUNOL, V179, P7840, DOI 10.4049/jimmunol.179.11.7840; Sena CM, 2008, NUTR RES, V28, P113, DOI 10.1016/j.nutres.2007.12.005; Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256; Shao JQ, 2006, BIOCHEM BIOPH RES CO, V344, P1224, DOI 10.1016/j.bbrc.2006.04.011; Sharma M, 2007, EUR J PHARMACOL, V574, P49, DOI 10.1016/j.ejphar.2007.07.022; Shinohara M, 2004, EXP DIABESITY RES, V5, P253, DOI 10.1080/15438600490898609; Spector AA, 2007, AM J PHYSIOL-CELL PH, V292, pC996, DOI 10.1152/ajpcell.00402.2006; Staels B, 2005, CURR MED RES OPIN, V21, pS13, DOI 10.1185/030079905X36440; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Svensson AM, 2005, J ENDOCRINOL, V184, P319, DOI 10.1677/joe.1.05676; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; Tran POT, 2004, J BIOL CHEM, V279, P53988, DOI 10.1074/jbc.M404809200; Ulu A, 2008, J CARDIOVASC PHARM, V52, P314, DOI 10.1097/FJC.0b013e318185fa3c; VANMINKELEN R, 2008, ATHEROSCLEROSIS; Vink A, 2004, CURR OPIN LIPIDOL, V15, P515, DOI 10.1097/00041433-200410000-00004; Von Dobschuetz E, 2008, PANCREAS, V36, P377, DOI 10.1097/MPA.0b013e31815ceb0e; Wadt KAW, 1998, DIABETES, V47, P1602, DOI 10.2337/diabetes.47.10.1602; Wallis RH, 2004, DIABETOLOGIA, V47, P1096, DOI 10.1007/s00125-004-1416-5; Wang PH, 1998, P NATL ACAD SCI USA, V95, P4556, DOI 10.1073/pnas.95.8.4556; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9	135	53	59	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6963	10.1371/journal.pone.0006963	http://dx.doi.org/10.1371/journal.pone.0006963			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742300	gold, Green Submitted, Green Published			2022-12-27	WOS:000269622500023
J	Ferwerda, B; McCall, MBB; de Vries, MC; Hopman, J; Maiga, B; Dolo, A; Doumbo, O; Daou, M; de Jong, D; Joosten, LAB; Tissingh, RA; Reubsaet, FAG; Sauerwein, R; van der Meer, JWM; van der Ven, AJAM; Netea, MG				Ferwerda, Bart; McCall, Matthew B. B.; de Vries, Maaike C.; Hopman, Joost; Maiga, Boubacar; Dolo, Amagana; Doumbo, Ogobara; Daou, Modibo; de Jong, Dirk; Joosten, Leo A. B.; Tissingh, Rudi A.; Reubsaet, Frans A. G.; Sauerwein, Robert; van der Meer, Jos W. M.; van der Ven, Andre J. A. M.; Netea, Mihai G.			Caspase-12 and the Inflammatory Response to Yersinia pestis	PLOS ONE			English	Article								Background: Caspase-12 functions as an antiinflammatory enzyme inhibiting caspase-1 and the NOD2/RIP2 pathways. Due to increased susceptibility to sepsis in individuals with functional caspase-12, an early-stop mutation leading to the loss of caspase-12 has replaced the ancient genotype in Eurasia and a significant proportion of individuals from African populations. In African-Americans, it has been shown that caspase-12 inhibits the pro-inflammatory cytokine production. Methodology/Principal Findings: We assessed whether similar mechanisms are present in African individuals, and whether evolutionary pressures due to plague may have led to the present caspase-12 genotype population frequencies. No difference in cytokine induction through the caspase-1 and/or NOD2/RIP2 pathways was observed in two independent African populations, among individuals with either an intact or absent caspase-12. In addition, stimulations with Yersinia pestis and two other species of Yersinia were preformed to investigate whether caspase-12 modulates the inflammatory reaction induced by Yersinia. We found that caspase-12 did not modulate cytokine production induced by Yersinia spp. Conclusions: Our experiments demonstrate for the first time the involvement of the NOD2/RIP2 pathway for recognition of Yersinia. However, caspase-12 does not modulate innate host defense against Y. pestis and alternative explanations for the geographical distribution of caspase-12 should be sought.			Ferwerda, B (corresponding author), Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	E.ferwerda@aig.umcn.nl	van der Meer, Jos W.M./C-8521-2013; van der Ven, A.J.A.M./H-8102-2014; Joosten, Leo AB/H-3138-2015; Sauerwein, Robert/C-8519-2013; de Vries, M.C./L-4735-2015; Netea, Mihai/N-5155-2014	van der Meer, Jos W.M./0000-0001-5120-3690; van der Ven, A.J.A.M./0000-0003-1833-3391; Joosten, Leo AB/0000-0001-6166-9830; Ferwerda, Bart/0000-0002-7050-5931; McCall, Matthew/0000-0002-5738-1401				Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Dolo A, 2005, AM J TROP MED HYG, V72, P243, DOI 10.4269/ajtmh.2005.72.243; Eckhart L, 2008, MOL BIOL EVOL, V25, P831, DOI 10.1093/molbev/msn012; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Grebenchtchikov N, 2005, EUR CYTOKINE NETW, V16, P215; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Kachapati Kritika, 2006, Hum Mutat, V27, P975, DOI 10.1002/humu.9448; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; LeBlanc PM, 2008, CELL HOST MICROBE, V3, P146, DOI 10.1016/j.chom.2008.02.004; Levasseur A, 2007, BIOL REV, V82, P551, DOI 10.1111/j.1469-185X.2007.00024.x; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Montminy SW, 2006, NAT IMMUNOL, V7, P1066, DOI 10.1038/ni1386; Nadiri A, 2006, J IMMUNOL, V177, P4239, DOI 10.4049/jimmunol.177.7.4239; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Netea MG, 2005, NETH J MED, V63, P305; O'Brien TR, 2007, SCAND J GASTROENTERO, V42, P416, DOI 10.1080/00365520601076074; Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Schotte P, 2004, J BIOL CHEM, V279, P25134, DOI 10.1074/jbc.M401245200; Scott AM, 2007, CELL DEATH DIFFER, V14, P23, DOI 10.1038/sj.cdd.4402026; Sing A, 2003, INT J MED MICROBIOL, V293, P341, DOI 10.1078/1438-4221-00277; Wang XX, 2006, PLOS BIOL, V4, P366, DOI 10.1371/journal.pbio.0040052; Xue YL, 2006, AM J HUM GENET, V78, P659, DOI 10.1086/503116	30	21	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6870	10.1371/journal.pone.0006870	http://dx.doi.org/10.1371/journal.pone.0006870			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489XX	19721713	Green Submitted, gold, Green Published			2022-12-27	WOS:000269461100002
J	Samoshkin, A; Arnaoutov, A; Jansen, LET; Ouspenski, I; Dye, L; Karpova, T; McNally, J; Dasso, M; Cleveland, DW; Strunnikov, A				Samoshkin, Alexander; Arnaoutov, Alexei; Jansen, Lars E. T.; Ouspenski, Ilia; Dye, Louis; Karpova, Tatiana; McNally, James; Dasso, Mary; Cleveland, Don W.; Strunnikov, Alexander			Human Condensin Function Is Essential for Centromeric Chromatin Assembly and Proper Sister Kinetochore Orientation	PLOS ONE			English	Article							MITOTIC CHROMOSOME ARCHITECTURE; AURORA-B; HISTONE H3; MICROTUBULE ATTACHMENT; STRUCTURAL INTEGRITY; OUTER PLATE; COMPLEX; SEGREGATION; PROTEIN; PHOSPHORYLATION	Condensins I and II in vertebrates are essential ATP-dependent complexes necessary for chromosome condensation in mitosis. Condensins depletion is known to perturb structure and function of centromeres, however the mechanism of this functional link remains elusive. Depletion of condensin activity is now shown to result in a significant loss of loading of CENP-A, the histone H3 variant found at active centromeres and the proposed epigenetic mark of centromere identity. Absence of condensins and/or CENP-A insufficiency produced a specific kinetochore defect, such that a functional mitotic checkpoint cannot prevent chromosome missegregation resulting from improper attachment of sister kinetochores to spindle microtubules. Spindle microtubule-dependent deformation of both inner kinetochores and the HEC1/Ndc80 microtubule-capturing module, then results in kinetochore separation from the Aurora B pool and ensuing reduced kinase activity at centromeres. Moreover, recovery from mitosis-inhibition by monastrol revealed a high incidence of merotelic attachment that was nearly identical with condensin depletion, Aurora B inactivation, or both, indicating that the Aurora B dysfunction is the key defect leading to chromosome missegregation in condensin-depleted cells. Thus, beyond a requirement for global chromosome condensation, condensins play a pivotal role in centromere assembly, proper spatial positioning of microtubule-capturing modules and positioning complexes of the inner centromere versus kinetochore plates.			Samoshkin, A (corresponding author), NICHHD, Unit Chromosome Struct & Funct, NICHD, LGRD, Bethesda, MD 20892 USA.	strunnik@mail.nih.gov	Cleveland, Don/AAN-9783-2021	Dasso, Mary/0000-0002-5410-1371; Cleveland, Don/0000-0002-1934-3682; Karpova, Tatiana/0000-0001-6025-2128; Strunnikov, Alexander/0000-0002-9058-2256; Jansen, Lars/0000-0002-2158-0345; Arnaoutov, Alexei/0000-0001-7647-7217; Samoshkin, Alexander/0000-0001-6296-2254	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [R01 GM074150, GM074150] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Boyarchuk Y, 2007, J CELL BIOL, V176, P919, DOI 10.1083/jcb.200609044; Ciferri C, 2008, CELL, V133, P427, DOI 10.1016/j.cell.2008.03.020; Cimini D, 2004, CURR BIOL, V14, P2149, DOI 10.1016/j.cub.2004.11.029; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Dong YM, 2007, NAT CELL BIOL, V9, P516, DOI 10.1038/ncb1576; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Gassmann R, 2004, EXP CELL RES, V296, P35, DOI 10.1016/j.yexcr.2004.03.006; Gerlich D, 2006, CURR BIOL, V16, P333, DOI 10.1016/j.cub.2005.12.040; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Ham MF, 2007, CANCER SCI, V98, P1041, DOI 10.1111/j.1349-7006.2007.00500.x; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; Hirano T, 2004, CELL CYCLE, V3, P26; Hirota T, 2004, J CELL SCI, V117, P6435, DOI 10.1242/jcs.01604; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hudson DF, 2003, DEV CELL, V5, P323, DOI 10.1016/S1534-5807(03)00199-0; Jager H, 2005, CHROMOSOMA, V113, P350, DOI 10.1007/s00412-004-0322-4; Jansen LET, 2007, J CELL BIOL, V176, P795, DOI 10.1083/jcb.200701066; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lipp JJ, 2007, J CELL SCI, V120, P1245, DOI 10.1242/jcs.03425; Liu D, 2009, SCIENCE, V323, P1350, DOI 10.1126/science.1167000; Maddox PS, 2006, P NATL ACAD SCI USA, V103, P15097, DOI 10.1073/pnas.0606993103; Maresca TJ, 2009, J CELL BIOL, V184, P373, DOI 10.1083/jcb.200808130; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Moore LL, 2005, MOL CELL BIOL, V25, P2583, DOI 10.1128/MCB.25.7.2583-2592.2005; Nakazawa N, 2008, J CELL BIOL, V180, P1115, DOI 10.1083/jcb.200708170; Ohi R, 2003, DEV CELL, V5, P309, DOI 10.1016/S1534-5807(03)00229-6; Oliveira RA, 2005, MOL CELL BIOL, V25, P8971, DOI 10.1128/MCB.25.20.8971-8984.2005; Ono T, 2004, MOL BIOL CELL, V15, P3296, DOI 10.1091/mbc.E04-03-0242; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Ribeiro SA, 2009, MOL BIOL CELL, V20, P2371, DOI 10.1091/mbc.E08-11-1127; Salmon ED, 2005, PHILOS T R SOC B, V360, P553, DOI 10.1098/rstb.2004.1610; Stear JH, 2002, GENE DEV, V16, P1498, DOI 10.1101/gad.989102; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Takemoto A, 2007, NUCLEIC ACIDS RES, V35, P2403, DOI 10.1093/nar/gkm157; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Uchida KSK, 2009, J CELL BIOL, V184, P383, DOI 10.1083/jcb.200811028; Vader G, 2007, MOL BIOL CELL, V18, P4553, DOI 10.1091/mbc.E07-04-0328; Vagnarelli P, 2006, NAT CELL BIOL, V8, P1133, DOI 10.1038/ncb1475; Vas ACJ, 2007, MOL BIOL CELL, V18, P557, DOI 10.1091/mbc.E06-05-0454; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang BD, 2005, MOL CELL BIOL, V25, P7216, DOI 10.1128/MCB.25.16.7216-7225.2005; Wang BD, 2006, CELL CYCLE, V5, P2260, DOI 10.4161/cc.5.19.3292; Wei RR, 2007, NAT STRUCT MOL BIOL, V14, P54, DOI 10.1038/nsmb1186; Yeh E, 2008, CURR BIOL, V18, P81, DOI 10.1016/j.cub.2007.12.019; Yeong FM, 2003, CURR BIOL, V13, P2058, DOI 10.1016/j.cub.2003.10.032; Yoda K, 2004, METHOD ENZYMOL, V375, P270; Yong-Gonzalez V, 2007, GENES CELLS, V12, P1075, DOI 10.1111/j.1365-2443.2007.01109.x; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	61	62	62	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6831	10.1371/journal.pone.0006831	http://dx.doi.org/10.1371/journal.pone.0006831			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714251	Green Submitted, gold, Green Published			2022-12-27	WOS:000269415800015
J	Root, DH; Fabbricatore, AT; Barker, DJ; Ma, S; Pawlak, AP; West, MO				Root, David H.; Fabbricatore, Anthony T.; Barker, David J.; Ma, Sisi; Pawlak, Anthony P.; West, Mark O.			Evidence for Habitual and Goal-Directed Behavior Following Devaluation of Cocaine: A Multifaceted Interpretation of Relapse	PLOS ONE			English	Article							DRUG-SEEKING BEHAVIOR; DISCRIMINATIVE-STIMULUS TASK; BASOLATERAL AMYGDALA; INTRAVENOUS COCAINE; SMOKED COCAINE; ACCUMBENS CORE; ALTERNATIVE REINFORCEMENT; CONTINGENCY KNOWLEDGE; INDUCED REINSTATEMENT; ADDICTIVE BEHAVIOR	Background: Cocaine addiction is characterized as a chronically relapsing disorder. It is believed that cues present during self-administration become learned and increase the probability that relapse will occur when they are confronted during abstinence. However, the way in which relapse-inducing cues are interpreted by the user has remained elusive. Recent theories of addiction posit that relapse-inducing cues cause relapse habitually or automatically, bypassing processing information related to the consequences of relapse. Alternatively, other theories hypothesize that relapse-inducing cues produce an expectation of the drug's consequences, designated as goal-directed relapse. Discrete discriminative stimuli signaling the availability of cocaine produce robust cue-induced responding after thirty days of abstinence. However, it is not known whether cue-induced responding is a goal-directed action or habit. Methodology/Principal Findings: We tested whether cue-induced responding is a goal-directed action or habit by explicitly pairing or unpairing cocaine with LiCl-induced sickness (n = 7/group), thereby decreasing or not altering the value of cocaine, respectively. Following thirty days of abstinence, no difference in responding between groups was found when animals were reintroduced to the self-administration environment alone, indicating habitual behavior. However, upon discriminative stimulus presentations, cocaine-sickness paired animals exhibited decreased cue-induced responding relative to unpaired controls, indicating goal-directed behavior. In spite of the difference between groups revealed during abstinent testing, no differences were found between groups when animals were under the influence of cocaine. Conclusions/Significance: Unexpectedly, both habitual and goal-directed responding occurred during abstinent testing. Furthermore, habitual or goal-directed responding may have been induced by cues that differed in their correlation with the cocaine infusion. Non-discriminative stimulus cues were weak correlates of the infusion, which failed to evoke a representation of the value of cocaine and led to habitual behavior. However, the discriminative stimulus-nearly perfectly correlated with the infusion-likely evoked a representation of the value of the infusion and led to goal-directed behavior. These data indicate that abstinent cue-induced responding is multifaceted, dynamically engendering habitual or goal-directed behavior. Moreover, since goal-directed behavior terminated habitual behavior during testing, therapeutic approaches aimed at reducing the perceived value of cocaine in addicted individuals may reduce the capacity of cues to induce relapse.			Root, DH (corresponding author), Rutgers State Univ, Dept Psychol, New Brunswick, NJ 08903 USA.	markwest@rutgers.edu	Ma, Sisi/E-6367-2015; Barker, David JP/A-5671-2013		NATIONAL INSTITUTE ON DRUG ABUSE [F31DA026252, R01DA006886] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 026252, F31 DA026252-01, R01 DA006886, DA 06886, F31 DA026252] Funding Source: Medline; NIMH NIH HHS [MH0919957] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS CD, 1981, Q J EXP PSYCHOL-B, V33, P109, DOI 10.1080/14640748108400816; ADAMS CD, 1982, Q J EXP PSYCHOL-B, V34, P77, DOI 10.1080/14640748208400878; Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298; Anderson KG, 2000, BEHAV PHARMACOL, V11, P413, DOI 10.1097/00008877-200008000-00007; Balleine BW, 2009, BEHAV BRAIN RES, V199, P43, DOI 10.1016/j.bbr.2008.10.034; BALLEINE BW, 1995, J EXP PSYCHOL ANIM B, V21, P203, DOI 10.1037/0097-7403.21.3.203; Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019; Berglind WJ, 2006, NEUROSCIENCE, V137, P699, DOI 10.1016/j.neuroscience.2005.08.064; Bordnick PS, 2004, BEHAV INTERVENT, V19, P1, DOI 10.1002/bin.146; Callu D, 2007, NEUROBIOL DIS, V27, P228, DOI 10.1016/j.nbd.2007.04.007; Caprioli D, 2009, BIOL PSYCHIAT, V65, P893, DOI 10.1016/j.biopsych.2008.12.009; Carelli RM, 1997, J NEUROSCI, V17, P1804; CARROLL ME, 1985, DRUG ALCOHOL DEPEN, V16, P95, DOI 10.1016/0376-8716(85)90109-7; Childress AR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001506; Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; Ciccocioppo R, 2001, P NATL ACAD SCI USA, V98, P1976, DOI 10.1073/pnas.98.4.1976; Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004; DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010; Donny EC, 2004, PSYCHOPHARMACOLOGY, V172, P316, DOI 10.1007/s00213-003-1655-z; Donny EC, 2003, DRUG ALCOHOL DEPEN, V69, P289, DOI 10.1016/S0376-8716(02)00327-7; Donny EC, 2006, PSYCHOPHARMACOLOGY, V186, P544, DOI 10.1007/s00213-006-0312-8; EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266; Epstein DH, 2003, PSYCHOPHARMACOLOGY, V168, P31, DOI 10.1007/s00213-003-1470-6; Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089; FLEMENBAUM A, 1977, PHARMACOL BIOCHEM BE, V7, P83, DOI 10.1016/0091-3057(77)90015-6; Foltin FW, 1999, J EXP ANAL BEHAV, V72, P215, DOI 10.1901/jeab.1999.72-215; Foltin RW, 1997, EXP CLIN PSYCHOPHARM, V5, P404; Foltin RW, 2000, PSYCHOPHARMACOLOGY, V149, P24, DOI 10.1007/s002139900340; Fuchs RA, 2006, J NEUROSCI, V26, P3584, DOI 10.1523/JNEUROSCI.5146-05.2006; Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579; Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789; Gawin F H, 1996, NIDA Res Monogr, V163, P224; Ghitza UE, 2004, J NEUROPHYSIOL, V92, P1608, DOI 10.1152/jn.00268.2004; Ghitza UE, 2003, J NEUROSCI, V23, P7239; Haney M, 1999, PSYCHOPHARMACOLOGY, V143, P102, DOI 10.1007/s002130050925; Hart CL, 2007, BEHAV PHARMACOL, V18, P71, DOI 10.1097/FBP.0b013e328014139d; Hart CL, 2000, BEHAV PHARMACOL, V11, P87, DOI 10.1097/00008877-200002000-00010; Hayes RJ, 2003, PSYCHOPHARMACOLOGY, V168, P75, DOI 10.1007/s00213-002-1328-3; Hogarth L, 2006, PSYCHOPHARMACOLOGY, V184, P553, DOI 10.1007/s00213-005-0150-0; Hogarth L, 2006, PSYCHOPHARMACOLOGY, V185, P495, DOI 10.1007/s00213-005-0287-x; Hogarth L, 2005, PSYCHOPHARMACOLOGY, V177, P428, DOI 10.1007/s00213-004-1973-9; Hogarth L, 2008, PSYCHOPHARMACOLOGY, V201, P29, DOI 10.1007/s00213-008-1244-2; Hogarth L, 2007, J EXP PSYCHOL ANIM B, V33, P484, DOI 10.1037/0097-7403.33.4.484; Hogarth L, 2006, ADDICTION, V101, P1153, DOI 10.1111/j.1360-0443.2006.01459.x; Hogarth L, 2009, EXP CLIN PSYCHOPHARM, V17, P21, DOI 10.1037/a0014957; Hollander JA, 2005, NEUROPSYCHOPHARMACOL, V30, P1464, DOI 10.1038/sj.npp.1300748; Hollander JA, 2007, J NEUROSCI, V27, P3535, DOI 10.1523/JNEUROSCI.3667-06.2007; Jaffe J.H., 1990, PHARMACOL BASIS THER, P522; Kantak KM, 2002, J NEUROSCI, V22, P1126, DOI 10.1523/JNEUROSCI.22-03-01126.2002; Kruzich PJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-14-j0002.2001; Lau-Barraco C, 2008, AM J DRUG ALCOHOL AB, V34, P211, DOI 10.1080/00952990701877136; Lenoir M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000698; Lynch WJ, 2006, PSYCHOPHARMACOLOGY, V185, P306, DOI 10.1007/s00213-006-0323-5; Macey DJ, 2004, PSYCHOPHARMACOLOGY, V172, P384, DOI 10.1007/s00213-003-1676-7; MARLATT GA, 1985, RELAPSE PREVENTION, P00250; MCLELLAN A T, 1985, Journal of Substance Abuse Treatment, V2, P187, DOI 10.1016/0740-5472(85)90051-0; Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927; MUCHA RF, 1982, BRAIN RES, V243, P91, DOI 10.1016/0006-8993(82)91123-4; NADER MA, 1992, BEHAV PHARMACOL, V3, P635; Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006; Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005; Norman AB, 2006, BRAIN RES, V1116, P143, DOI 10.1016/j.brainres.2006.07.092; OBRIEN CP, 1975, PHARMACOL REV, V27, P533; Peoples LL, 1996, J NEUROSCI, V16, P3459; Peoples LL, 1997, BRAIN RES, V757, P280, DOI 10.1016/S0006-8993(97)00299-0; Peters J, 2008, PSYCHOPHARMACOLOGY, V197, P319, DOI 10.1007/s00213-007-1034-2; PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122; Porrino LJ, 2004, J NEUROSCI, V24, P3554, DOI 10.1523/JNEUROSCI.5578-03.2004; Redish AD, 2008, BEHAV BRAIN SCI, V31, P415, DOI 10.1017/S0140525X0800472X; Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216; See RE, 2005, EUR J PHARMACOL, V526, P140, DOI 10.1016/j.ejphar.2005.09.034; Smelson DA, 2001, AM J DRUG ALCOHOL AB, V27, P391, DOI 10.1081/ADA-100103716; Smith BJ, 2001, PSYCHOPHARMACOLOGY, V156, P435, DOI 10.1007/s002130100740; Stalnaker TA, 2007, NAT NEUROSCI, V10, P949, DOI 10.1038/nn1931; SUZUKI T, 1992, JPN J PHARMACOL, V58, P435, DOI 10.1254/jjp.58.435; Tang C, 2008, J PHARMACOL EXP THER, V324, P701, DOI 10.1124/jpet.107.129734; Tang CK, 2007, EUR J NEUROSCI, V25, P1212, DOI 10.1111/j.1460-9568.2007.05353.x; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; Wang GJ, 1999, LIFE SCI, V64, P775, DOI 10.1016/S0024-3205(98)00619-5; Ward AS, 1997, BEHAV PHARMACOL, V8, P736, DOI 10.1097/00008877-199712000-00009; Ward AS, 1997, PSYCHOPHARMACOLOGY, V132, P375, DOI 10.1007/s002130050358; WILSON CL, 1981, J EXP PSYCHOL ANIM B, V7, P165, DOI 10.1037/0097-7403.7.2.165; Woolverton WL, 1997, DRUG ALCOHOL DEPEN, V49, P71, DOI 10.1016/S0376-8716(97)00145-2; Woolverton WL, 2006, PSYCHOPHARMACOLOGY, V186, P99, DOI 10.1007/s00213-006-0355-x; Woolverton WL, 2004, EUR J PHARMACOL, V486, P251, DOI 10.1016/j.ejphar.2004.01.003; WOOLVERTON WL, 1979, COMMUN PSYCHOPHARMAC, V3, P309; Woolverton WL, 1998, PSYCHOPHARMACOLOGY, V138, P102, DOI 10.1007/s002130050651; Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x; Yun IA, 2003, NEUROSCIENCE, V121, P747, DOI 10.1016/S0306-4522(03)00531-1	90	23	23	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7170	10.1371/journal.pone.0007170	http://dx.doi.org/10.1371/journal.pone.0007170			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	498WL	19779607	Green Submitted, Green Published, gold			2022-12-27	WOS:000270176200012
J	Grigor'eva, EV; Shevchenko, AI; Mazurok, NA; Elisaphenko, EA; Zhelezova, AI; Shilov, AG; Dyban, PA; Dyban, AP; Noniashvili, EM; Slobodyanyuk, SY; Nesterova, TB; Brockdorff, N; Zakian, SM				Grigor'eva, Elena V.; Shevchenko, Alexander I.; Mazurok, Nina A.; Elisaphenko, Eugeny A.; Zhelezova, Antonina I.; Shilov, Alexander G.; Dyban, Pavel A.; Dyban, Andrey P.; Noniashvili, Ekaterina M.; Slobodyanyuk, Sergey Ya; Nesterova, Tatyana B.; Brockdorff, Neil; Zakian, Suren M.			FGF4 Independent Derivation of Trophoblast Stem Cells from the Common Vole	PLOS ONE			English	Article								The derivation of stable multipotent trophoblast stem (TS) cell lines from preimplantation, and early postimplantation mouse embryos has been reported previously. FGF4, and its receptor FGFR2, have been identified as embryonic signaling factors responsible for the maintenance of the undifferentiated state of multipotent TS cells. Here we report the derivation of stable TS-like cell lines from the vole M. rossiaemeridionalis, in the absence of FGF4 and heparin. Vole TS-like cells are similar to murine TS cells with respect to their morphology, transcription factor gene expression and differentiation in vitro into derivatives of the trophectoderm lineage, and with respect to their ability to invade and erode host tissues, forming haemorrhagic tumours after subcutaneous injection into nude mice. Moreover, vole TS-like cells carry an inactive paternal X chromosome, indicating that they have undergone imprinted X inactivation, which is characteristic of the trophoblast lineage. Our results indicate that an alternative signaling pathway may be responsible for the establishment and stable proliferation of vole TS-like cells.			Grigor'eva, EV (corresponding author), Russian Acad Sci, Inst Cytol & Genet, Siberian Dept, Novosibirsk 630090, Russia.	zakian@bionet.nsc.ru	Grigor'eva, Elena V/V-5416-2018; Shevchenko, Alexander I./T-3400-2018; Zakian, Suren/J-2196-2018; Elisaphenko, Eugeny/V-5115-2018; Elisafenko, Eugeny/AAD-5901-2020	Elisafenko, Eugeny/0000-0002-3204-8178; Brockdorff, Neil/0000-0003-4838-2653; Grigor'eva, Elena/0000-0002-9162-9108; Nesterova, Tatyana/0000-0001-7740-4386; Zakian, Suren/0000-0003-2448-6511	Wellcome Trust [103768, 081385] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; Cross JC, 2002, MOL CELL ENDOCRINOL, V187, P207, DOI 10.1016/S0303-7207(01)00703-1; CROSS JC, 1995, DEVELOPMENT, V121, P2513; Elisaphenko EA, 1998, CHROMOSOME RES, V6, P351, DOI 10.1023/A:1009284031287; Erlebacher A, 2004, DEV BIOL, V275, P158, DOI 10.1016/j.ydbio.2004.07.032; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GARDNER RL, 1973, J EMBRYOL EXP MORPH, V30, P561; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GRAVES KH, 1993, MOL REPROD DEV, V36, P424, DOI 10.1002/mrd.1080360404; Grummer R, 1999, PLACENTA, V20, P547, DOI 10.1053/plac.1999.0406; Guzman-Ayala M, 2004, P NATL ACAD SCI USA, V101, P15656, DOI 10.1073/pnas.0405429101; Haffner-Krausz R, 1999, MECH DEVELOP, V85, P167, DOI 10.1016/S0925-4773(99)00082-9; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Hughes M, 2004, DEV BIOL, V271, P26, DOI 10.1016/j.ydbio.2004.03.029; Iwatsuki K, 2000, BIOL REPROD, V62, P1352, DOI 10.1095/biolreprod62.5.1352; Kibschull M, 2004, DEV BIOL, V273, P63, DOI 10.1016/j.ydbio.2004.04.037; Kirchhof N, 2000, BIOL REPROD, V63, P1698, DOI 10.1095/biolreprod63.6.1698; Kunath T, 2005, DEVELOPMENT, V132, P1649, DOI 10.1242/dev.01715; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mazurok NA, 1995, HEREDITAS, V123, P47, DOI 10.1111/j.1601-5223.1995.t01-1-00047.x; MAZUROK NA, 2003, ONTOGENEZ, V34, P213; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nesterova TB, 1998, CHROMOSOME RES, V6, P41, DOI 10.1023/A:1009266324602; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; NISWANDER L, 1992, DEVELOPMENT, V114, P755; Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040; NOTARIANNI E, 1991, J REPROD FERTIL, P255; NOTARIANNI E, 1990, J REPROD FERTIL, P51; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Ralston A, 2005, CLIN GENET, V68, P106, DOI 10.1111/j.1399-0004.2005.00478.x; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Romejs B., 1953, MICROSCOPICAL TECHNI, P71; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Shevchenko AI, 2008, RUSS J GENET+, V44, P1280, DOI 10.1134/S1022795408110057; Simmons DG, 2005, DEV BIOL, V284, P12, DOI 10.1016/j.ydbio.2005.05.010; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Soares MJ, 1996, PLACENTA, V17, P277, DOI 10.1016/S0143-4004(96)90051-X; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vassilieva S, 2000, EXP CELL RES, V258, P361, DOI 10.1006/excr.2000.4940; Yan JL, 2001, DEV BIOL, V235, P422, DOI 10.1006/dbio.2001.0300; ZAKIAN SM, 1991, GENET RES, V58, P105, DOI 10.1017/S0016672300029748; ZAKIAN SM, 1987, GENET RES, V50, P23, DOI 10.1017/S0016672300023296	63	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7161	10.1371/journal.pone.0007161	http://dx.doi.org/10.1371/journal.pone.0007161			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777059	Green Published, gold, Green Submitted			2022-12-27	WOS:000270164600007
J	Arunajadai, SG				Arunajadai, Srikesh G.			RNA Unwinding by NS3 Helicase: A Statistical Approach	PLOS ONE			English	Article								The study of double-stranded RNA unwinding by helicases is a problem of basic scientific interest. One such example is provided by studies on the hepatitis C virus (HCV) NS3 helicase using single molecule mechanical experiments. HCV currently infects nearly 3% of the world population and NS3 is a protein essential for viral genome replication. The objective of this study is to model the RNA unwinding mechanism based on previously published data and study its characteristics and their dependence on force, ATP and NS3 protein concentration. In this work, RNA unwinding by NS3 helicase is hypothesized to occur in a series of discrete steps and the steps themselves occurring in accordance with an underlying point process. A point process driven change point model is employed to model the RNA unwinding mechanism. The results are in large agreement with findings in previous studies. A gamma distribution based renewal process was found to model well the point process that drives the unwinding mechanism. The analysis suggests that the periods of constant extension observed during NS3 activity can indeed be classified into pauses and subpauses and that each depend on the ATP concentration. The step size is independent of external factors and seems to have a median value of 11.37 base pairs. The steps themselves are composed of a number of substeps with an average of about 4 substeps per step and an average substep size of about 3.7 base pairs. An interesting finding pertains to the stepping velocity. Our analysis indicates that stepping velocity may be of two kinds- a low and a high velocity.			Arunajadai, SG (corresponding author), Columbia Univ, Dept Biostat & Anesthesiol, New York, NY 10027 USA.	sarunajadai@columbia.edu						Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Arunajadai SG, 2009, MATH BIOSCI, V220, P57, DOI 10.1016/j.mbs.2009.04.003; BOX GE, 2008, TIME SERIES ANAL FOR; BRILLINGER DR, 1978, COMP ASPECTS STUDY O, V1; Brodsky B. E., 1993, NONPARAMETRIC METHOD, V243; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Chen J., 2000, PARAMETRIC STAT CHAN, DOI 10.1007/978-1-4757-3131-6; Cox D., 1980, POINT PROCESSES; Cox DR, 1966, STAT ANAL SERIES EVE; Danilowicz C, 2003, P NATL ACAD SCI USA, V100, P1694, DOI 10.1073/pnas.262789199; Duda R.O., 2000, PATTERN CLASSIFICATI; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Myong S, 2007, SCIENCE, V317, P513, DOI 10.1126/science.1144130; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Weeks JD, 2005, BIOPHYS J, V88, P2752, DOI 10.1529/biophysj.104.047340	16	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e6937	10.1371/journal.pone.0006937	http://dx.doi.org/10.1371/journal.pone.0006937			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771177	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400001
J	Favier, J; Briere, JJ; Burnichon, N; Riviere, J; Vescovo, L; Benit, P; Giscos-Douriez, I; De Reynies, A; Bertherat, J; Badoual, C; Tissier, F; Amar, L; Libe, R; Plouin, PF; Jeunemaitre, X; Rustin, P; Gimenez-Roqueplo, AP				Favier, Judith; Briere, Jean-Jacques; Burnichon, Nelly; Riviere, Julie; Vescovo, Laure; Benit, Paule; Giscos-Douriez, Isabelle; De Reynies, Aurelien; Bertherat, Jerome; Badoual, Cecile; Tissier, Frederique; Amar, Laurence; Libe, Rosella; Plouin, Pierre-Francois; Jeunemaitre, Xavier; Rustin, Pierre; Gimenez-Roqueplo, Anne-Paule			The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas	PLOS ONE			English	Article								The Warburg effect describes how cancer cells down-regulate their aerobic respiration and preferentially use glycolysis to generate energy. To evaluate the link between hypoxia and Warburg effect, we studied mitochondrial electron transport, angiogenesis and glycolysis in pheochromocytomas induced by germ-line mutations in VHL, RET, NF1 and SDH genes. SDH and VHL gene mutations have been shown to lead to the activation of hypoxic response, even in normoxic conditions, a process now referred to as pseudohypoxia. We observed a decrease in electron transport protein expression and activity, associated with increased angiogenesis in SDH- and VHL-related, pseudohypoxic tumors, while stimulation of glycolysis was solely observed in VHL tumors. Moreover, microarray analyses revealed that expression of genes involved in these metabolic pathways is an efficient tool for classification of pheochromocytomas in accordance with the predisposition gene mutated. Our data suggest an unexpected association between pseudohypoxia and loss of p53, which leads to a distinct Warburg effect in VHL-related pheochromocytomas.			Favier, J (corresponding author), INSERM, U970, Paris, France.	judith.favier@inserm.fr	GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018; Favier, Judith/M-7601-2017; de Reyniès, Aurélien/Q-8640-2017; Amar, Laurence/P-5278-2017; JEUNEMAITRE, Xavier/AAQ-4853-2021; Burnichon, Nelly/AAF-6003-2020	GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X; Favier, Judith/0000-0001-8190-5853; de Reyniès, Aurélien/0000-0002-1328-5290; Amar, Laurence/0000-0003-3942-4276; JEUNEMAITRE, Xavier/0000-0001-5925-381X; libe, rossella/0000-0003-2881-6362; Badoual, Cecile/0000-0002-1143-3085; BERTHERAT, Jerome/0000-0003-2551-3008				Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Benit P, 2006, CLIN CHIM ACTA, V374, P81, DOI 10.1016/j.cca.2006.05.034; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Craven RA, 2006, PROTEOMICS, V6, P2853, DOI 10.1002/pmic.200500549; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P897, DOI 10.1677/erc.1.00838; Favier J, 2005, HORM RES, V63, P171, DOI 10.1159/000084685; Favier J, 1999, FEBS LETT, V462, P19, DOI 10.1016/S0014-5793(99)01476-3; Fredlund E, 2008, BIOCHEM BIOPH RES CO, V366, P1054, DOI 10.1016/j.bbrc.2007.12.074; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V20, P24, DOI 10.1002/(SICI)1098-2264(199709)20:1<24::AID-GCC4>3.3.CO;2-V; Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Nilsson H, 2005, EXP CELL RES, V303, P447, DOI 10.1016/j.yexcr.2004.10.003; Petri BJ, 2008, MODERN PATHOL, V21, P407, DOI 10.1038/modpathol.3801013; Pollard PJ, 2006, J CLIN ENDOCR METAB, V91, P4593, DOI 10.1210/jc.2006-0920; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; RUSTIN P, 2007, ERNST SHER RES FDN W, P62; Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; VANNEDERVEEN FH, 2009, LANCET ONCOL; WARBURG O, 1956, SCIENCE, V124, P269; Warburg O, 1930, UEBER STOFFWECHSEL T; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yoshimoto T, 1998, J ENDOCRINOL, V159, P247, DOI 10.1677/joe.0.1590247; Zelinka T, 2008, ENDOCR-RELAT CANCER, V15, P311, DOI 10.1677/ERC-07-0217; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	42	183	183	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7094	10.1371/journal.pone.0007094	http://dx.doi.org/10.1371/journal.pone.0007094			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763184	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970400018
J	Li, MD; Mangold, JE; Seneviratne, C; Chen, GB; Ma, JZ; Lou, XY; Payne, TJ				Li, Ming D.; Mangold, Jamie E.; Seneviratne, Chamindi; Chen, Guo-Bo; Ma, Jennie Z.; Lou, Xiang-Yang; Payne, Thomas J.			Association and Interaction Analyses of GABBR1 and GABBR2 with Nicotine Dependence in European- and African-American Populations	PLOS ONE			English	Article								Previous studies have demonstrated that the gamma-aminobutyric acid type B (GABA(B)) receptor plays an essential role in modulating neurotransmitter release and regulating the activity of ion channels and adenyl cyclase. However, whether the naturally occurring polymorphisms in the two GABA(B) receptor subunit genes interact with each other to alter susceptibility to nicotine dependence (ND) remains largely unknown. In this study, we genotyped 5 and 33 single nucleotide polymorphisms (SNPs) for GABA(B) receptor subunit 1 and 2 genes (GABBR1, GABBR2), respectively, in a sample of 2037 individuals from 602 nuclear families of African-American (AA) or European-American (EA) origin. We conducted association analyses to determine (1) the association of each subunit gene with ND at both the individual SNP and haplotype levels and (2) the collective effect(s) of SNPs in both GABA(B) subunits on the development of ND. Several individual SNPs and haplotypes in GABBR2 were significantly associated with ND in both ethnic samples. Two haplotypes in AAs and one haplotype in EAs showed a protective effect against ND, whilst two other haplotypes in AAs and three haplotypes in EAs showed a risk effect for developing ND. Interestingly, these significant haplotypes were confined to two regions of GABBR2 in the AA and EA samples. Additionally, we found two minor haplotypes in GABBR1 to be positively associated with Heaviness of Smoking Index (HSI) in the EA sample. Finally, we demonstrated the presence of epistasis between GABBR1 and GABBR2 for developing ND. The variants of GABBR1 and GABBR2 are significantly associated with ND, and the involvement of GABBR1 is most likely through its interaction with GABBR2, whereas GABBR2 polymorphisms directly alter susceptibility to ND. Future studies are needed with more dense SNP coverage of GABBR1 and GABBR2 to verify the epistatic effects of the two subunit genes.			Li, MD (corresponding author), Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22903 USA.	Ming_Li@virginia.edu	Payne, Thomas/R-4290-2019; Lou, Xiang-Yang/B-6291-2013; Chen, Guo-Bo/C-2435-2009	Payne, Thomas/0000-0002-9839-6255; Chen, Guo-Bo/0000-0001-5475-8237; seneviratne, Chamindi/0000-0002-3135-2979	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA025095, R01DA012844] Funding Source: NIH RePORTER; NIDA NIH HHS [R01DA012844, R01DA025095, R01 DA025095, R01 DA012844] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bergen AW, 1999, GENET EPIDEMIOL, V17, pS55; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Beuten J, 2005, AM J HUM GENET, V76, P859, DOI 10.1086/429839; Bierut LJ, 2004, AM J MED GENET A, V124A, P19, DOI 10.1002/ajmg.a.20329; Calver AR, 2001, J NEUROSCI, V21, P1203; Cousins M S, 2001, Nicotine Tob Res, V3, P123, DOI 10.1080/14622200110042624; Cousins MS, 2002, DRUG ALCOHOL DEPEN, V65, P209, DOI 10.1016/S0376-8716(01)00163-6; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gelernter J, 2007, BIOL PSYCHIAT, V61, P119, DOI 10.1016/j.biopsych.2006.08.023; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Lange C, 2003, HUM HERED, V56, P10, DOI 10.1159/000073728; Li MD, 2008, MOL PSYCHIATR, V13, P407, DOI 10.1038/sj.mp.4002038; Li MD, 2007, MOL PSYCHIATR, V12, P462, DOI 10.1038/sj.mp.4001933; Li MD, 2003, ADDICTION, V98, P23, DOI 10.1046/j.1360-0443.2003.00295.x; Li MD, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-S1-S103; Li MD, 2005, HUM MOL GENET, V14, P1211, DOI 10.1093/hmg/ddi132; Li MD, 2008, HUM GENET, V123, P119, DOI 10.1007/s00439-008-0473-0; Li MD, 2006, AM J HUM GENET, V79, P745, DOI 10.1086/508208; Lou XY, 2008, AM J HUM GENET, V83, P457, DOI 10.1016/j.ajhg.2008.09.001; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Schwarz DA, 2000, J BIOL CHEM, V275, P32174, DOI 10.1074/jbc.M005333200; Sullivan P F, 1999, Nicotine Tob Res, V1 Suppl 2, pS51; Sullivan P.F., 1999, NICOTINE TOB RES S2, V1, pS69; Sun DX, 2007, NEUROPSYCHOPHARMACOL, V32, P110, DOI 10.1038/sj.npp.1301134; U.S. Department of Health and Human Services, 2000, RED TOB US REP SURG; Uhl GR, 2002, TRENDS GENET, V18, P420, DOI 10.1016/S0168-9525(02)02719-1; Ulrich D, 2007, CURR OPIN NEUROBIOL, V17, P298, DOI 10.1016/j.conb.2007.04.001	30	34	36	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7055	10.1371/journal.pone.0007055	http://dx.doi.org/10.1371/journal.pone.0007055			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763258	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970400005
J	Mavrodiev, EV				Mavrodiev, Evgeny V.			Classical Morphology of Plants as an Elementary Instance of Classical Invariant Theory	PLOS ONE			English	Article								It has long been known that structural chemistry shows an intriguing correspondence with Classical Invariant Theory (CIT). Under this view, an algebraic binary form of the degree n corresponds to a chemical atom with valence n and each physical molecule or ion has an invariant-theoretic counterpart. This theory was developed using the Aronhold symbolical approach and the symbolical processes of convolution/transvection in CIT was characterized as a potential "accurate morphological method''. However, CIT has not been applied to the formal morphology of living organisms. Based on the morphological interpretation of binary form, as well as the process of convolution/transvection, the First and Second Fundamental Theorems of CIT and the Nullforms of CIT, we show how CIT can be applied to the structure of plants, especially when conceptualized as a series of plant metamers (phytomers). We also show that the weight of the covariant/invariant that describes a morphological structure is a criterion of simplicity and, therefore, we argue that this allows us to formulate a parsimonious method of formal morphology. We demonstrate that the "theory of axilar bud'' is the simplest treatment of the grass seedling/embryo. Our interpretations also represent Troll's bauplan of the angiosperms, the principle of variable proportions, morphological misfits, the basic types of stem segmentation, and Goethe's principle of metamorphosis in terms of CIT. Binary forms of different degrees might describe any repeated module of plant organisms. As bacteria, invertebrates, and higher vertebrates are all generally shared a metameric morphology, wider implications of the proposed symmetry between CIT and formal morphology of plants are apparent.			Mavrodiev, EV (corresponding author), Univ Florida, Dept Biol, Gainesville, FL 32610 USA.	evgeny@ufl.edu						ALEXEJEFF W, 1901, CHEMIE, V38, P741; Andrews JH, 1998, ANNU REV MICROBIOL, V52, P105, DOI 10.1146/annurev.micro.52.1.105; Arber A, 1954, MIND EYE STUDY BIOL; Arber A., 1950, NATURAL PHILOS PLANT; BARLOW P, 1989, BOT J LINN SOC, V100, P225; BARLOW PW, 1994, BIOL REV, V69, P475, DOI 10.1111/j.1469-185X.1994.tb01248.x; Barthelemy D, 2007, ANN BOT-LONDON, V99, P375, DOI 10.1093/aob/mcl260; Bateson W., 1894, MAT STUDY VARIATION; BEKLEMISHEV WN, 1964, PRINCIPLES COMP ANAT; Bell A., 1991, PLANT FORM ILLUSTRAT; Born M, 1932, ANGEW CHEM-GER EDIT, V45, P0006, DOI 10.1002/ange.19320450103; Bossinger G., 1992, Barley: genetics, biochemistry, molecular biology and biotechnology., P231; BROWN WALTER V., 1960, PHYTOMORPHOLOGY [DELHI], V10, P215; CELAKOVSKY LJ, 1901, BOT Z, V59, P79; CLIFFORD W, 1878, AM J MATH, V1, P126; DICKSON A, 1885, T P BOT SOC EDINBURG, V16, P130; ETTER ALFRED GORDON, 1951, ANN MISSOURI BOT GARD, V38, P293, DOI 10.2307/2394639; Forster BP, 2007, ANN BOT-LONDON, V100, P725, DOI 10.1093/aob/mcm183; GALINAT W. C., 1959, BOT MUS LEAFLETS HARVARD UNIV, V19, P1; Gaudichaud C., 1841, CR HEBD ACAD SCI, V12, P627; Goethe J.W., 1952, BOT WRITINGS; Gordan P, 1900, Z PHYS CHEM-STOCH VE, V35, P610; Grace John Hilton, 1903, ALGEBRA INVARIANTS; Griffith J. S., 1964, MATH GAZ, V48, P57; Halle F., 1978, TROPICAL TREES FORES, Vfirst; Ivanov P. P., 1944, ZH OBSHCH BIOL, V5, P61; JACQUESFELIX H, 1957, CR HEBD ACAD SCI, V245, P1260; Kaplan DR, 2001, AM J BOT, V88, P1711, DOI 10.2307/3558347; Kaplan DR, 2001, INT J PLANT SCI, V162, P465, DOI 10.1086/320135; Louarn G, 2007, ANN BOT-LONDON, V99, P425, DOI 10.1093/aob/mcl276; McCall MA, 1934, J AGRIC RES, V48, P0283; McSteen P, 2005, ANNU REV PLANT BIOL, V56, P353, DOI 10.1146/annurev.arplant.56.032604.144122; NAYAR BK, 1985, CURR SCI INDIA, V54, P1025; Olver P.J., 1999, CLASSICAL INVARIANT; OLVER PJ, 1989, ADV MATH, V75, P212, DOI 10.1016/0001-8708(89)90038-8; Percival J., 1921, WHEAT PLANT MONOGRAP; Priestley JH, 1935, ANN BOT-LONDON, V49, P161, DOI 10.1093/oxfordjournals.aob.a090494; RAY TS, 1987, AM J BOT, V74, P1373, DOI 10.2307/2444315; RICHENS RH, 1946, NATURE, V157, P127, DOI 10.1038/157127a0; Romer A.S., 1962, VERTEBRATE BODY; ROUVRAY DH, 1974, CHEM SOC REV, V3, P355, DOI 10.1039/cs9740300355; RUMER G, 1932, NACHR GES WIS GOT MP, P499; Rutishauser R, 2001, ANN BOT-LONDON, V88, P1173, DOI 10.1006/anbo.2001.1498; SCHUEPP O, 1969, AM J BOT, V56, P899; SMIRNOV P. A., 1953, BIULL MOSKOVSKOVO OBSHCHESTVA ISPYTATELEI PRIRODY OTDEL BIOL, V58, P71; SVETLOV P G, 1957, Arkh Anat Gistol Embriol, V34, P3; Sylvester J, 1878, AM J MATH, V1, P64, DOI [DOI 10.2307/2369436, 10.2307/2369436]; SYLVESTER JJ, 1996, KANT HILBERT SOURCE, V1, P511; TAKASO T, 1991, AM J BOT, V78, P417, DOI 10.2307/2444964; Thiele R, 2003, AM MATH MON, V110, P1, DOI 10.2307/3072340; Tillich HJ, 2007, ANN BOT-LONDON, V100, P1413, DOI 10.1093/aob/mcm238; TROLL W, 1950, GOETHES MORPHOLOGISC; TZVELEV NN, 1997, B MOSC SOC NAT BIOL, V102, P54; VELENOVSKY J, 1907, VERGLEICHENDE MORPHO, V2; Weyl H., 1949, PHILOS MATH NATURAL; WEYL H, 1949, PHILOSPOPHY MATH NAT, P266; Wormer PES, 2006, ADV QUANTUM CHEM, V51, P59, DOI 10.1016/S0065-3276(06)51002-0	57	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6969	10.1371/journal.pone.0006969	http://dx.doi.org/10.1371/journal.pone.0006969			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759908	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696600010
J	Bjorkholm, B; Bok, CM; Lundin, A; Rafter, J; Hibberd, ML; Pettersson, S				Bjorkholm, Britta; Bok, Chek Mei; Lundin, Annelie; Rafter, Joseph; Hibberd, Martin Lloyd; Pettersson, Sven			Intestinal Microbiota Regulate Xenobiotic Metabolism in the Liver	PLOS ONE			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X-RECEPTOR; GERM-FREE; NEUROTROPHIC FACTOR; MICROSOMAL METABOLISM; CONDITIONAL DELETION; NUCLEAR RECEPTORS; DRUG-METABOLISM; INNATE IMMUNITY; BILE-ACIDS	Background: The liver is the central organ for xenobiotic metabolism (XM) and is regulated by nuclear receptors such as CAR and PXR, which control the metabolism of drugs. Here we report that gut microbiota influences liver gene expression and alters xenobiotic metabolism in animals exposed to barbiturates. Principal findings: By comparing hepatic gene expression on microarrays from germfree (GF) and conventionally-raised mice (SPF), we identified a cluster of 112 differentially expressed target genes predominantly connected to xenobiotic metabolism and pathways inhibiting RXR function. These findings were functionally validated by exposing GF and SPF mice to pentobarbital which confirmed that xenobiotic metabolism in GF mice is significantly more efficient (shorter time of anesthesia) when compared to the SPF group. Conclusion: Our data demonstrate that gut microbiota modulates hepatic gene expression and function by altering its xenobiotic response to drugs without direct contact with the liver.			Bjorkholm, B (corresponding author), Smittskyddsinst, Swedish Inst Infect Dis Control, Solna, Sweden.	sven.pettersson@ki.se	Hibberd, Martin L/D-5050-2009; Pettersson, Sven/F-9511-2015	Hibberd, Martin/0000-0001-8587-1849				Amador-Noguez D, 2004, AGING CELL, V3, P423, DOI 10.1111/j.1474-9728.2004.00125.x; Amador-Noguez D, 2007, AGING CELL, V6, P453, DOI 10.1111/j.1474-9726.2007.00300.x; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; EINARSSO.K, 1974, P SOC EXP BIOL MED, V145, P48; EINARSSON K, 1977, P SOC EXP BIOL MED, V154, P319; EINARSSON K, 1973, J BIOL CHEM, V248, P3623; Gachon F, 2006, CELL METAB, V4, P25, DOI 10.1016/j.cmet.2006.04.015; Gachon F, 2007, ANN MED, V39, P562, DOI 10.1080/07853890701491034; Gems D, 2005, MECH AGEING DEV, V126, P381, DOI 10.1016/j.mad.2004.09.001; Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102; Gray J, 2007, INT J OBESITY, V31, P359, DOI 10.1038/sj.ijo.0803390; Gray J, 2006, DIABETES, V55, P3366, DOI 10.2337/db06-0550; GUSTAFSSON BE, 1977, J LIPID RES, V18, P717; GUSTAFSSON BE, 1975, J BIOL CHEM, V250, P8496; GUSTAFSSON BE, 1960, J EXP MED, V112, P975, DOI 10.1084/jem.112.6.975; Handschin C, 2005, ARCH BIOCHEM BIOPHYS, V433, P387, DOI 10.1016/j.abb.2004.08.030; Henderson CJ, 2003, J BIOL CHEM, V278, P13480, DOI 10.1074/jbc.M212087200; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Lundin A, 2008, CELL MICROBIOL, V10, P1093, DOI 10.1111/j.1462-5822.2007.01108.x; Meyer UA, 2007, DRUG METAB REV, V39, P639, DOI 10.1080/03602530701498737; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Qatanani M, 2005, CURR DRUG METAB, V6, P329, DOI 10.2174/1389200054633899; Rios M, 2001, MOL ENDOCRINOL, V15, P1748, DOI 10.1210/me.15.10.1748; Roth A, 2008, PHARMACOGENET GENOM, V18, P325, DOI 10.1097/FPC.0b013e3282f706e0; Roth A, 2008, MOL PHARMACOL, V73, P1282, DOI 10.1124/mol.107.041012; SNYDER DL, 1990, J GERONTOL, V45, pB52, DOI 10.1093/geronj/45.2.B52; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388; TAZUME S, 1991, EXP ANIM TOKYO, V40, P517, DOI 10.1538/expanim1978.40.4_517; Vitek L, 2005, J HEPATOL, V42, P238, DOI 10.1016/j.jhep.2004.10.012; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073	38	164	171	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6958	10.1371/journal.pone.0006958	http://dx.doi.org/10.1371/journal.pone.0006958			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742318	gold, Green Submitted, Green Accepted, Green Published			2022-12-27	WOS:000269622500019
J	Azdad, K; Chavez, M; Bischop, PD; Wetzelaer, P; Marescau, B; De Deyn, PP; Gall, D; Schiffmann, SN				Azdad, Karima; Chavez, Marcelo; Bischop, Patrick Don; Wetzelaer, Pim; Marescau, Bart; De Deyn, Peter Paul; Gall, David; Schiffmann, Serge N.			Homeostatic Plasticity of Striatal Neurons Intrinsic Excitability following Dopamine Depletion	PLOS ONE			English	Article								The striatum is the major input structure of basal ganglia and is involved in adaptive control of behaviour through the selection of relevant informations. Dopaminergic neurons that innervate striatum die in Parkinson disease, leading to inefficient adaptive behaviour. Neuronal activity of striatal medium spiny neurons (MSN) is modulated by dopamine receptors. Although dopamine signalling had received substantial attention, consequences of dopamine depletion on MSN intrinsic excitability remain unclear. Here we show, by performing perforated patch clamp recordings on brain slices, that dopamine depletion leads to an increase in MSN intrinsic excitability through the decrease of an inactivating A-type potassium current, I-A. Despite the large decrease in their excitatory synaptic inputs determined by the decreased dendritic spines density and the increase in minimal current to evoke the first EPSP, this increase in intrinsic excitability resulted in an enhanced responsiveness to their remaining synapses, allowing them to fire similarly or more efficiently following input stimulation than in control condition. Therefore, this increase in intrinsic excitability through the regulation of IA represents a form of homeostatic plasticity allowing neurons to compensate for perturbations in synaptic transmission and to promote stability in firing. The present observations show that this homeostatic ability to maintain firing rates within functional range also occurs in pathological conditions, allowing stabilizing neural computation within affected neuronal networks.	[Azdad, Karima; Chavez, Marcelo; Bischop, Patrick Don; Wetzelaer, Pim; Gall, David; Schiffmann, Serge N.] Univ Brussels ULB, Neurophysiol Lab, Brussels, Belgium; [Marescau, Bart; De Deyn, Peter Paul] Univ Antwerp, Inst Born Bunge, Dept Biomed Sci, Lab Neurochem & Behaviour, Antwerp, Belgium; [Azdad, Karima; Chavez, Marcelo; Bischop, Patrick Don; Wetzelaer, Pim; Gall, David; Schiffmann, Serge N.] European Grad Sch Neurosci EURON, Maastricht, Netherlands	Universite Libre de Bruxelles; University of Antwerp; Maastricht University	Azdad, K (corresponding author), Univ Brussels ULB, Neurophysiol Lab, Brussels, Belgium.	kazdad@ulb.ac.be; sschiffm@ulb.ac.be		Wetzelaer, Pim/0000-0002-7450-0046; Schiffmann, Serge/0000-0002-0118-9816	FMRE (Belgium); FNRS (Belgium); Van Buuren Foundation; FER from ULB; Action de Recherche Concertee; EC fellowship [QLG3-20001-01056]; FRS-FNRS Belgium [7.4.531.06 .F]; EC Marie Curie Early Training Site program fellowship [MEST-CT-2005-020589]	FMRE (Belgium); FNRS (Belgium)(Fonds de la Recherche Scientifique - FNRS); Van Buuren Foundation; FER from ULB; Action de Recherche Concertee; EC fellowship; FRS-FNRS Belgium(Fonds de la Recherche Scientifique - FNRS); EC Marie Curie Early Training Site program fellowship	This work was supported by FMRE (Belgium), FNRS (Belgium), Van Buuren Foundation, FER from ULB, Action de Recherche Concertee (2008-2013) from the CFWB. K.A. was supported by an EC fellowship (QLG3-20001-01056), M.C. by a grant Televie from the FRS-FNRS Belgium (7.4.531.06 .F) and P.W. by an EC Marie Curie Early Training Site program fellowship (MEST-CT-2005-020589). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AZDAD K, 2008, NEUROPSYCHOPHARMACOL; CALABRESI P, 1993, BRAIN, V116, P433; Calabresi P, 2000, TRENDS NEUROSCI, V23, pS57, DOI 10.1016/S1471-1931(00)00017-3; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; DANGELO E, 1995, J PHYSIOL-LONDON, V484, P397, DOI 10.1113/jphysiol.1995.sp020673; Day M, 2006, NAT NEUROSCI, V9, P251, DOI 10.1038/nn1632; DUCREUX C, 1995, J PHYSIOL-LONDON, V486, P439, DOI 10.1113/jphysiol.1995.sp020824; Fino E, 2007, NEUROSCI RES, V58, P305, DOI 10.1016/j.neures.2007.04.002; Gabel LA, 1998, J NEUROPHYSIOL, V79, P1989, DOI 10.1152/jn.1998.79.4.1989; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Hernandez-Echeagaray E, 2004, EUR J NEUROSCI, V19, P2455, DOI 10.1111/j.0953-816X.2004.03344.x; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hopf FW, 2003, J NEUROSCI, V23, P5079; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ingham CA, 1998, J NEUROSCI, V18, P4732; Kim JY, 2007, NEURON, V54, P933, DOI 10.1016/j.neuron.2007.05.026; KOMBIAN SB, 1994, NATURE, V368, P242, DOI 10.1038/368242a0; Kreitzer AC, 2007, NATURE, V445, P643, DOI 10.1038/nature05506; Mahon S, 2003, J PHYSIOL-LONDON, V550, P947, DOI 10.1113/jphysiol.2003.043125; Mahon S, 2000, LEARN MEMORY, V7, P357, DOI 10.1101/lm.34800; MOODY CA, 1992, PSYCHOPHARMACOLOGY, V107, P39, DOI 10.1007/BF02244963; Nakamura TY, 1997, AM J PHYSIOL-HEART C, V273, pH1775, DOI 10.1152/ajpheart.1997.273.4.H1775; Neely MD, 2007, NEUROSCIENCE, V149, P457, DOI 10.1016/j.neuroscience.2007.06.044; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Nisenbaum ES, 1998, SYNAPSE, V29, P213, DOI 10.1002/(SICI)1098-2396(199807)29:3<213::AID-SYN3>3.3.CO;2-3; NISENBAUM ES, 1995, J NEUROSCI, V15, P4449; PENNARTZ CMA, 1992, J NEUROPHYSIOL, V67, P1325, DOI 10.1152/jn.1992.67.5.1325; PENNARTZ CMA, 1992, NEUROSCI LETT, V136, P109, DOI 10.1016/0304-3940(92)90660-Y; Perez MF, 2006, J NEUROPHYSIOL, V96, P2217, DOI 10.1152/jn.00254.2006; Sacco T, 2002, J PHYSIOL-LONDON, V543, P505, DOI 10.1113/jphysiol.2002.022525; SCHIFFMANN SN, 1993, J NEUROSCI, V13, P1080; Shen WX, 2008, SCIENCE, V321, P848, DOI 10.1126/science.1160575; Surmeier DJ, 2007, TRENDS NEUROSCI, V30, P228, DOI 10.1016/j.tins.2007.03.008; Thompson SM, 2007, NEURON, V54, P850, DOI 10.1016/j.neuron.2007.06.008; Tkatch T, 2000, J NEUROSCI, V20, P579, DOI 10.1523/JNEUROSCI.20-02-00579.2000; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; TWERY MJ, 1993, SYNAPSE, V13, P322, DOI 10.1002/syn.890130405; Van Dam D, 2005, NEUROCHEM INT, V46, P409, DOI 10.1016/j.neuint.2004.11.005; Zhang W, 2003, NAT REV NEUROSCI, V4, P885, DOI 10.1038/nrn1248	40	55	55	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6908	10.1371/journal.pone.0006908	http://dx.doi.org/10.1371/journal.pone.0006908			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730738	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100013
J	Wei, HY; Wang, R; Yuan, ZQ; Chen, CY; Huang, D; Halliday, L; Zhong, WH; Zeng, GC; Shen, Y; Shen, L; Wang, YQ; Chen, ZW				Wei, Huiyong; Wang, Richard; Yuan, Zhuqing; Chen, Crystal Y.; Huang, Dan; Halliday, Lisa; Zhong, Weihua; Zeng, Gucheng; Shen, Yun; Shen, Ling; Wang, Yunqi; Chen, Zheng W.			DR*W201/P65 Tetramer Visualization of Epitope-Specific CD4 T-Cell during M. tuberculosis Infection and Its Resting Memory Pool after BCG Vaccination	PLOS ONE			English	Article								Background: In vivo kinetics and frequencies of epitope-specific CD4 T cells in lymphoid compartments during M. tuberculosis infection and their resting memory pool after BCG vaccination remain unknown. Methodology/Findings: Macaque DR*W201 tetramer loaded with Ag85B peptide 65 was developed to directly measure epitope-specific CD4 T cells in blood and tissues form macaques after M. tuberculosis infection or BCG vaccination via direct staining and tetramer-enriched approach. The tetramer-based enrichment approach showed that P65 epitope-specific CD4 T cells emerged at mean frequencies of similar to 500 and similar to 4500 per 10(7) PBL at days 28 and 42, respectively, and at day 63 increased further to similar to 22,000/10(7) PBL after M. tuberculosis infection. Direct tetramer staining showed that the tetramer-bound P65-specific T cells constituted about 0.2-0.3% of CD4 T cells in PBL, lymph nodes, spleens, and lungs at day 63 post-infection. 10-fold expansion of these tetramer-bound epitope-specific CD4 T cells was seen after the P65 peptide stimulation of PBL and tissue lymphocytes. The tetramer-based enrichment approach detected BCG-elicited resting memory P65-specific CD4 T cells at a mean frequency of 2,700 per 10(7) PBL. Significance: Our work represents the first elucidation of in vivo kinetics and frequencies for tetramer-bound epitope-specific CD4 T cells in the blood, lymphoid tissues and lungs over times after M. tuberculosis infection, and BCG immunization.			Wei, HY (corresponding author), Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.	zchen@uic.edu	Zeng, Gucheng/N-9397-2015; WANG, YUNQI/F-4668-2014		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013601] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064560] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR13601, R01 RR013601] Funding Source: Medline; NHLBI NIH HHS [R01 HL64560, R01 HL064560] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali Z, 2007, J IMMUNOL, V179, P8287, DOI 10.4049/jimmunol.179.12.8287; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bieganowska K, 1999, J IMMUNOL, V162, P1765; Bronke C, 2005, HUM IMMUNOL, V66, P950, DOI 10.1016/j.humimm.2005.06.011; Bruns H, 2009, J CLIN INVEST, V119, P1167, DOI 10.1172/JCI38482; Chen ZW, 2001, J IMMUNOL, V166, P4525, DOI 10.4049/jimmunol.166.7.4525; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003; de Groot N, 2004, J IMMUNOL, V172, P6152, DOI 10.4049/jimmunol.172.10.6152; Dzuris JL, 2001, J VIROL, V75, P10958, DOI 10.1128/JVI.75.22.10958-10968.2001; GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831; GONG G, 2008, BLOOD; Hammond AS, 2008, J INFECT DIS, V197, P295, DOI 10.1086/524685; Hohn H, 2007, SCAND J IMMUNOL, V65, P467, DOI 10.1111/j.1365-3083.2007.01924.x; Huang D, 2008, INFECT IMMUN, V76, P426, DOI 10.1128/IAI.01008-07; Kotzin BL, 2000, P NATL ACAD SCI USA, V97, P291, DOI 10.1073/pnas.97.1.291; Kuroda MJ, 2000, J VIROL, V74, P8751, DOI 10.1128/JVI.74.18.8751-8756.2000; Kwok WW, 2000, J IMMUNOL, V164, P4244, DOI 10.4049/jimmunol.164.8.4244; Lalvani A, 2008, AUTOIMMUN REV, V8, P147, DOI 10.1016/j.autrev.2008.07.011; Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051; Meyer AL, 2000, P NATL ACAD SCI USA, V97, P11433, DOI 10.1073/pnas.190335897; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Murali-Krishna K, 1998, ADV EXP MED BIOL, V452, P123; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Scriba TJ, 2005, J IMMUNOL, V175, P6334, DOI 10.4049/jimmunol.175.10.6334; Shen Y, 2004, J VIROL, V78, P14023, DOI 10.1128/JVI.78.24.14023-14032.2004; Tan LC, 1999, J IMMUNOL, V162, P1827; Tully G, 2005, J IMMUNOL, V174, P2174, DOI 10.4049/jimmunol.174.4.2174; Vollers SS, 2008, IMMUNOLOGY, V123, P305, DOI 10.1111/j.1365-2567.2007.02801.x; Wei HY, 2008, J IMMUNOL, V181, P4798, DOI 10.4049/jimmunol.181.7.4798; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	32	16	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6905	10.1371/journal.pone.0006905	http://dx.doi.org/10.1371/journal.pone.0006905			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730727	gold, Green Published, Green Submitted			2022-12-27	WOS:000269622100010
J	Adler, PB; Leiker, J; Levine, JM				Adler, Peter B.; Leiker, James; Levine, Jonathan M.			Direct and Indirect Effects of Climate Change on a Prairie Plant Community	PLOS ONE			English	Article							SPECIES INTERACTIONS; VARIABILITY; COMPETITION	Background: Climate change directly affects species by altering their physical environment and indirectly affects species by altering interspecific interactions such as predation and competition. Recent studies have shown that the indirect effects of climate change may amplify or counteract the direct effects. However, little is known about the the relative strength of direct and indirect effects or their potential to impact population persistence. Methodology/Principal Findings: We studied the effects of altered precipitation and interspecific interactions on the low-density tiller growth rates and biomass production of three perennial grass species in a Kansas, USA mixed prairie. We transplanted plugs of each species into local neighborhoods of heterospecific competitors and then exposed the plugs to a factorial manipulation of growing season precipitation and neighbor removal. Precipitation treatments had significant direct effects on two of the three species. Interspecific competition also had strong effects, reducing low-density tiller growth rates and aboveground biomass production for all three species. In fact, in the presence of competitors, ( log) tiller growth rates were close to or below zero for all three species. However, we found no convincing evidence that per capita competitive effects changed with precipitation, as shown by a lack of significant precipitation x competition interactions. Conclusions/Significance: We found little evidence that altered precipitation will influence per capita competitive effects. However, based on species' very low growth rates in the presence of competitors in some precipitation treatments, interspecific interactions appear strong enough to affect the balance between population persistence and local extinction. Therefore, ecological forecasting models should include the effect of interspecific interactions on population growth, even if such interaction coefficients are treated as constants.			Adler, PB (corresponding author), Utah State Univ, Dept Wildland Resources, Logan, UT 84322 USA.	peter.adler@usu.edu	Levine, Jonathan/A-7167-2014; Adler, Peter B./D-3781-2009	Levine, Jonathan/0000-0003-2857-7904				Adler PB, 2007, OIKOS, V116, P221, DOI [10.1111/j.2006.0030-1299.15327.x, 10.1111/j.0030-1299.2007.15327.x]; Adler PB, 2006, P NATL ACAD SCI USA, V103, P12793, DOI 10.1073/pnas.0600599103; Adler PB, 2008, ECOLOGY, V89, P3049, DOI 10.1890/07-1569.1; ALBERTSON F. W., 1965, ECOLOGY, V46, P714, DOI 10.2307/1935011; BERTNESS MD, 1994, TRENDS ECOL EVOL, V9, P191, DOI 10.1016/0169-5347(94)90088-4; CHESSON P, 1994, THEOR POPUL BIOL, V45, P227, DOI 10.1006/tpbi.1994.1013; Christensen JH, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P847; Davis AJ, 1998, NATURE, V391, P783, DOI 10.1038/35842; Franco M, 2004, ECOLOGY, V85, P531, DOI 10.1890/02-0651; IVES AR, 1995, ECOLOGY, V76, P926, DOI 10.2307/1939357; Klanderud K, 2005, J ECOL, V93, P127, DOI 10.1111/j.1365-2745.2004.00944.x; Knapp AK, 2002, SCIENCE, V298, P2202, DOI 10.1126/science.1076347; LEVINE JM, ECOLOGY IN PRESS; Liang XZ, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006685; Maestre FT, 2009, J ECOL, V97, P199, DOI 10.1111/j.1365-2745.2008.01476.x; R Core Team, 2018, R LANG ENV STAT COMP; Reece PE, 2007, RANGELAND ECOL MANAG, V60, P203, DOI 10.2111/05-147R1.1; Seabloom EW, 2003, P NATL ACAD SCI USA, V100, P13384, DOI 10.1073/pnas.1835728100; Sears ALW, 2007, ECOLOGY, V88, P2240, DOI 10.1890/06-0645.1; Suttle KB, 2007, SCIENCE, V315, P640, DOI 10.1126/science.1136401; Tylianakis JM, 2008, ECOL LETT, V11, P1351, DOI 10.1111/j.1461-0248.2008.01250.x; WOOTTON JT, 1994, ANNU REV ECOL SYST, V25, P443, DOI 10.1146/annurev.es.25.110194.002303; Yahdjian L, 2002, OECOLOGIA, V133, P95, DOI 10.1007/s00442-002-1024-3	23	47	52	4	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6887	10.1371/journal.pone.0006887	http://dx.doi.org/10.1371/journal.pone.0006887			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727390	Green Submitted, Green Published, gold			2022-12-27	WOS:000269522900016
J	Schulz, H; Kolde, R; Adler, P; Aksoy, I; Anastassiadis, K; Bader, M; Billon, N; Boeuf, H; Bourillot, PY; Buchholz, F; Dani, C; Doss, MX; Forrester, L; Gitton, M; Henrique, D; Hescheler, J; Himmelbauer, H; Hubner, N; Karantzali, E; Kretsovali, A; Lubitz, S; Pradier, L; Rai, M; Reimand, J; Rolletschek, A; Sachinidis, A; Savatier, P; Stewart, F; Storm, MP; Trouillas, M; Vilo, J; Welham, MJ; Winkler, J; Wobus, AM; Hatzopoulos, AK				Schulz, Herbert; Kolde, Raivo; Adler, Priit; Aksoy, Irene; Anastassiadis, Konstantinos; Bader, Michael; Billon, Nathalie; Boeuf, Helene; Bourillot, Pierre-Yves; Buchholz, Frank; Dani, Christian; Doss, Michael Xavier; Forrester, Lesley; Gitton, Murielle; Henrique, Domingos; Hescheler, Juergen; Himmelbauer, Heinz; Huebner, Norbert; Karantzali, Efthimia; Kretsovali, Androniki; Lubitz, Sandra; Pradier, Laurent; Rai, Meena; Reimand, Jueri; Rolletschek, Alexandra; Sachinidis, Agapios; Savatier, Pierre; Stewart, Francis; Storm, Mike P.; Trouillas, Marina; Vilo, Jaak; Welham, Melanie J.; Winkler, Johannes; Wobus, Anna M.; Hatzopoulos, Antonis K.		Functional Genomics Embryonic Stem	The FunGenES Database: A Genomics Resource for Mouse Embryonic Stem Cell Differentiation	PLOS ONE			English	Article							SELF-RENEWAL; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; REGULATORY NETWORKS; GENE-FUNCTION; EXPRESSION; PLURIPOTENCY; NANOG; EMBRYOGENESIS; ESTABLISHMENT	Embryonic stem (ES) cells have high self-renewal capacity and the potential to differentiate into a large variety of cell types. To investigate gene networks operating in pluripotent ES cells and their derivatives, the "Functional Genomics in Embryonic Stem Cells'' consortium (FunGenES) has analyzed the transcriptome of mouse ES cells in eleven diverse settings representing sixty-seven experimental conditions. To better illustrate gene expression profiles in mouse ES cells, we have organized the results in an interactive database with a number of features and tools. Specifically, we have generated clusters of transcripts that behave the same way under the entire spectrum of the sixty-seven experimental conditions; we have assembled genes in groups according to their time of expression during successive days of ES cell differentiation; we have included expression profiles of specific gene classes such as transcription regulatory factors and Expressed Sequence Tags; transcripts have been arranged in "Expression Waves'' and juxtaposed to genes with opposite or complementary expression patterns; we have designed search engines to display the expression profile of any transcript during ES cell differentiation; gene expression data have been organized in animated graphs of KEGG signaling and metabolic pathways; and finally, we have incorporated advanced functional annotations for individual genes or gene clusters of interest and links to microarray and genomic resources. The FunGenES database provides a comprehensive resource for studies into the biology of ES cells.	[Rai, Meena; Hatzopoulos, Antonis K.] Vanderbilt Univ, Dept Cell & Dev Biol, Dept Med, Div Cardiovasc Med, Nashville, TN USA; [Schulz, Herbert; Bader, Michael; Huebner, Norbert] Max Delbruck Ctr Mol Med Berlin Buch, Berlin, Germany; [Kolde, Raivo; Adler, Priit; Reimand, Jueri; Vilo, Jaak] Univ Tartu, Inst Comp Sci, Tartu, Estonia; [Aksoy, Irene; Bourillot, Pierre-Yves; Savatier, Pierre] INSERM U846, Stem Cell & Brain Res Inst, Bron, France; [Anastassiadis, Konstantinos; Lubitz, Sandra; Stewart, Francis] Tech Univ Dresden, BioInnovat Zent, Dresden, Germany; [Billon, Nathalie; Dani, Christian] CNRS, UMR 6543, Ctr Biochim, Nice, France; [Boeuf, Helene; Trouillas, Marina] Univ Bordeaux 2, CNRS, UMR 5164, F-33076 Bordeaux, France; [Buchholz, Frank] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany; [Doss, Michael Xavier; Hescheler, Juergen; Sachinidis, Agapios; Winkler, Johannes] Univ Cologne, Inst Neurophysiol, D-5000 Cologne, Germany; [Forrester, Lesley] Univ Edinburgh, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland; [Gitton, Murielle; Pradier, Laurent] Sanofi Aventis, Ctr Rech Paris, Paris, France; [Henrique, Domingos] Inst Med Mol, Fac Med Lisboa, Lisbon, Portugal; [Himmelbauer, Heinz] Max Planck Inst Mol Genet, Berlin, Germany; [Himmelbauer, Heinz] UPF, CRG, Barcelona, Spain; [Karantzali, Efthimia; Kretsovali, Androniki] Inst Mol Biol & Biotechnol, FORTH, Iraklion, Greece; [Rolletschek, Alexandra; Wobus, Anna M.] Leibniz Inst IPK, Gatersleben, Germany; [Storm, Mike P.; Welham, Melanie J.] Univ Bath, Ctr Regenerat Med, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; [Hatzopoulos, Antonis K.] Helmholtz Ctr Munich, German Res Ctr Environm Hlth, Inst Clin Mol Biol & Tumor Genet, Munich, Germany	Vanderbilt University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Tartu; Institut National de la Sante et de la Recherche Medicale (Inserm); Technische Universitat Dresden; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Max Planck Society; University of Cologne; University of Edinburgh; Sanofi-Aventis; Sanofi France; Universidade de Lisboa; Max Planck Society; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; University of Bath; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Hatzopoulos, AK (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, Dept Med, Div Cardiovasc Med, Nashville, TN USA.	antonis.hatzopoulos@vanderbilt.edu	Bader, Michael/K-2124-2013; Bourillot, Pierre-Yves/M-6956-2014; Rai, Meena/AAI-6381-2021; Sachinidis, Agapios/AAD-4178-2020; Winkler, Johannes/A-7615-2011; Anastassiadis, Konstantinos/A-8944-2010; Kolde, Raivo/AAB-8149-2022; Hatzopoulos, Antonis/D-2049-2010; Vilo, Jaak/A-7183-2008; Hatzopoulos, Antonis/X-2043-2019; Storm, Mike/AAC-8733-2020; Aksoy, Irene/O-2238-2013; Sachinidis, Agapios/AAM-7988-2020; SAVATIER, Pierre/J-4663-2014; Henrique, Domingos M/E-5460-2010; Buchholz, Frank/B-4700-2017; Reimand, Jüri/U-9264-2019; DANI, Christian/G-3639-2014; Stewart, A. Francis/E-7789-2010; Vilo, Jaak/AAK-2228-2020; Jesudoss, Michael Xavier Doss/D-1983-2015	Bourillot, Pierre-Yves/0000-0003-1657-8555; Anastassiadis, Konstantinos/0000-0002-9814-0559; Kolde, Raivo/0000-0003-2886-6298; Vilo, Jaak/0000-0001-5604-4107; Hatzopoulos, Antonis/0000-0001-5610-0017; Aksoy, Irene/0000-0003-4353-5876; Henrique, Domingos M/0000-0001-8869-1894; Buchholz, Frank/0000-0002-4577-3344; Reimand, Jüri/0000-0002-2299-2309; DANI, Christian/0000-0003-3228-0230; Vilo, Jaak/0000-0001-5604-4107; Bader, Michael/0000-0003-4780-4164; Himmelbauer, Heinz/0000-0001-8897-2928; Jesudoss, Michael Xavier Doss/0000-0001-6339-9782	NHLBI NIH HHS [R01 HL083958-01, R01 HL083958-03, R01 HL083958-02, R01 HL083958, R01 HL083958-04S1, R01 HL083958-04, HL08395] Funding Source: Medline; Medical Research Council [G0700711B, G9900991B] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083958] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler P, 2008, BIOINFORMATICS, V24, P588, DOI 10.1093/bioinformatics/btm581; *AFF, 1999, GEN EXPR AN TECHN MA; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Assou S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006-0352; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Barrow JR, 2007, DEV BIOL, V312, P312, DOI 10.1016/j.ydbio.2007.09.030; *BIOM TEAM, 2009, BIOMART PROJ; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Burt RK, 2008, JAMA-J AM MED ASSOC, V299, P925, DOI 10.1001/jama.299.8.925; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cinelli P, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-57; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Doss MX, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r56; Doss MX, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r184; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Gasch AP, 2002, GENOME BIOL, V3; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hatzopoulos AK, 1999, ANGIOGENESIS AND CARDIOVASCULAR DISEASE, P3; Hong Y, 2007, MUTAT RES-FUND MOL M, V614, P48, DOI 10.1016/j.mrfmmm.2006.06.006; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r65; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood-2004-07-2681; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Mariappan D, 2009, GENES CELLS, V14, P243, DOI 10.1111/j.1365-2443.2008.01268.x; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Muller FJ, 2008, NATURE, V455, P401, DOI 10.1038/nature07213; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Ogawa K, 2007, DEV BIOL, V306, P391, DOI 10.1016/j.ydbio.2007.03.575; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Porter Christopher J., 2007, V407, P137, DOI 10.1007/978-1-59745-536-7_11; Potta SP, 2009, HYPERTENSION, V53, P196, DOI 10.1161/HYPERTENSIONAHA.108.121863; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; ROLLETSCHEK A, 2009, INT J DEV B IN PRESS; Saretzki G, 2004, STEM CELLS, V22, P962, DOI 10.1634/stemcells.22-6-962; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Savatier P, 1996, ONCOGENE, V12, P309; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Sekkai D, 2005, STEM CELLS, V23, P1634, DOI 10.1634/stemcells.2005-0182; Singec I, 2007, ANNU REV MED, V58, P313, DOI 10.1146/annurev.med.58.070605.115252; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takaoka K, 2007, CURR OPIN GENET DEV, V17, P344, DOI 10.1016/j.gde.2007.06.001; Tam PPL, 2007, NAT REV GENET, V8, P368, DOI 10.1038/nrg2084; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Trouillas M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-73; Tu Y, 2002, P NATL ACAD SCI USA, V99, P14031, DOI 10.1073/pnas.222164199; Vastrik I, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r39; Walker E, 2007, CELL STEM CELL, V1, P71, DOI 10.1016/j.stem.2007.04.002; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang ZX, 2007, J BIOL CHEM, V282, P12822, DOI 10.1074/jbc.M611814200; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104	76	47	47	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6804	10.1371/journal.pone.0006804	http://dx.doi.org/10.1371/journal.pone.0006804			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727443	Green Published, Green Accepted, gold, Green Submitted			2022-12-27	WOS:000269522900003
J	Chen, XN; Sun, CE; Chen, Q; O'Neill, FA; Walsh, D; Fanous, AH; Chowdari, KV; Nimgaonkar, VL; Scott, A; Schwab, SG; Wildenauer, DB; Che, RL; Tang, W; Shi, YY; He, L; Luo, XJ; Su, B; Edwards, TL; Zhao, ZM; Kendler, KS				Chen, Xiangning; Sun, Cuie; Chen, Qi; O'Neill, F. Anthony; Walsh, Dermot; Fanous, Ayman H.; Chowdari, Kodavali V.; Nimgaonkar, Vishwajit L.; Scott, Adrian; Schwab, Sibylle G.; Wildenauer, Dieter B.; Che, Ronglin; Tang, Wei; Shi, Yongyong; He, Lin; Luo, Xiong-jian; Su, Bing; Edwards, Todd L.; Zhao, Zhongming; Kendler, Kenneth S.			Apoptotic Engulfment Pathway and Schizophrenia	PLOS ONE			English	Article							MULTIFACTOR-DIMENSIONALITY REDUCTION; CELL CORPSE ENGULFMENT; GENE-GENE INTERACTIONS; ALZHEIMERS-DISEASE; NUCLEAR FAMILIES; RECEPTOR CED-1; ASSOCIATION; ABCA1; LINKAGE; PHAGOCYTOSIS	Background: Apoptosis has been speculated to be involved in schizophrenia. In a previously study, we reported the association of the MEGF10 gene with the disease. In this study, we followed the apoptotic engulfment pathway involving the MEGF10, GULP1, ABCA1 and ABCA7 genes and tested their association with the disease. Methodology/Principal Findings: Ten, eleven and five SNPs were genotyped in the GULP1, ABCA1 and ABCA7 genes respectively for the ISHDSF and ICCSS samples. In all 3 genes, we observed nominally significant associations. Rs2004888 at GULP1 was significant in both ISHDSF and ICCSS samples (p = 0.0083 and 0.0437 respectively). We sought replication in independent samples for this marker and found highly significant association (p = 0.0003) in 3 Caucasian replication samples. But it was not significant in the 2 Chinese replication samples. In addition, we found a significant 2-marker (rs2242436 * rs3858075) interaction between the ABCA1 and ABCA7 genes in the ISHDSF sample (p = 0.0022) and a 3-marker interaction (rs246896 * rs4522565 * rs3858075) amongst the MEGF10, GULP1 and ABCA1 genes in the ICCSS sample (p = 0.0120). Rs3858075 in the ABCA1 gene was involved in both 2- and 3-marker interactions in the two samples. Conclusions/Significance: From these data, we concluded that the GULP1 gene and the apoptotic engulfment pathway are involved in schizophrenia in subjects of European ancestry and multiple genes in the pathway may interactively increase the risks to the disease.			Chen, XN (corresponding author), Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23284 USA.	xchen@vcu.edu	Shi, Yongyong/GSO-1627-2022; O'Neill, Francis A/C-5582-2008; Tang, Wei/H-7103-2013; Fanous, Ayman H/O-1263-2017; Edwards, Todd/B-9750-2012; Kendler, Kenneth/AAF-2876-2019	Shi, Yongyong/0000-0003-1710-1505; O'Neill, Francis A/0000-0002-7531-7657; Tang, Wei/0000-0002-7089-4391; 	NIMH NIH HHS [R01MH41953, R01 MH041953] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041953] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Awasaki T, 2006, NEURON, V50, P855, DOI 10.1016/j.neuron.2006.04.027; Banerjee H, 2003, PLASMID, V49, P30, DOI 10.1016/S0147-619X(02)00106-3; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Chen Q, 2008, MOL PSYCHIATR, V13, P930, DOI 10.1038/sj.mp.4002051; Chen Q, 2008, SCHIZOPHR RES, V106, P200, DOI 10.1016/j.schres.2008.08.006; Chen X, 2007, MOL PSYCHIATR, V12, P273, DOI 10.1038/sj.mp.4001932; Chen XN, 2008, AM J MED GENET B, V147B, P1231, DOI 10.1002/ajmg.b.30759; Chen X, 2008, BIOL PSYCHIAT, V63, P441, DOI 10.1016/j.biopsych.2007.11.003; Chen XN, 2006, HUM MOL GENET, V15, P3329, DOI 10.1093/hmg/ddl409; Chowdari KV, 2002, HUM MOL GENET, V11, P1373, DOI 10.1093/hmg/11.12.1373; Chu LW, 2007, AM J MED GENET B, V144B, P1007, DOI 10.1002/ajmg.b.30525; Conradt Barbara, 2005, WormBook, P1; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Hamon Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000120; Haskins KA, 2008, DEV CELL, V15, P87, DOI 10.1016/j.devcel.2008.05.006; Hayashi M, 2005, J LIPID RES, V46, P1703, DOI 10.1194/jlr.M500092-JLR200; Jehle AW, 2006, J CELL BIOL, V174, P547, DOI 10.1083/jcb.200601030; Jones AL, 2005, IMMUNOL CELL BIOL, V83, P9, DOI 10.1111/j.1440-1711.2005.01305.x; Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012; Kendler KS, 2000, AM J PSYCHIAT, V157, P402, DOI 10.1176/appi.ajp.157.3.402; Kinchen JM, 2007, J CELL SCI, V120, P2143, DOI 10.1242/jcs.03463; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; Lamitina T, 2008, DEV CELL, V15, P3, DOI 10.1016/j.devcel.2008.06.007; Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Mallat M, 2005, CURR OPIN NEUROBIOL, V15, P101, DOI 10.1016/j.conb.2005.01.006; Mangahas PM, 2005, SEMIN CELL DEV BIOL, V16, P295, DOI 10.1016/j.semcdb.2004.12.005; Martin ER, 2006, GENET EPIDEMIOL, V30, P111, DOI 10.1002/gepi.20128; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; Martin ER, 2003, GENET EPIDEMIOL, V25, P203, DOI 10.1002/gepi.10258; Martins-Silva C, 2006, BRAIN RES, V1119, P1, DOI 10.1016/j.brainres.2006.08.064; Moore JH, 2004, EXPERT REV MOL DIAGN, V4, P795, DOI 10.1586/14737159.4.6.795; MOSKVINA V, 2008, MOL PSYCHIAT; Moynault A, 1998, BIOCHEM SOC T, V26, P629, DOI 10.1042/bst0260629; NAPOLI I, 2008, NEUROSCIENCE; NUNES SO, 2006, SCHIZOPHR RES; O'Donovan MC, 2009, MOL PSYCHIATR, V14, P30, DOI 10.1038/mp.2008.108; O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201; Petryshen TL, 2005, MOL PSYCHIATR, V10, P1074, DOI 10.1038/sj.mp.4001739; Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218; Rodriguez-Rodriguez E, 2007, AM J MED GENET B, V144B, P964, DOI 10.1002/ajmg.b.30552; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schmitz C, 2007, P NATL ACAD SCI USA, V104, P834, DOI 10.1073/pnas.0510527104; Schmitz T, 2008, THESCIENTIFICWORLDJO, V8, P1119, DOI 10.1100/tsw.2008.140; Schwab SG, 1997, MOL PSYCHIATR, V2, P156, DOI 10.1038/sj.mp.4000263; Siegmund KD, 2000, AM J HUM GENET, V67, P244, DOI 10.1086/302973; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Straub RE, 1997, MOL PSYCHIATR, V2, P148, DOI 10.1038/sj.mp.4000258; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Sun SL, 2008, NEUROSCI LETT, V440, P35, DOI 10.1016/j.neulet.2008.05.029; Sundar PD, 2007, NEUROBIOL AGING, V28, P856, DOI 10.1016/j.neurobiolaging.2006.04.005; Suzuki E, 2007, EXP CELL RES, V313, P2451, DOI 10.1016/j.yexcr.2007.03.041; Suzuki E, 2007, EXP CELL RES, V313, P3729, DOI 10.1016/j.yexcr.2007.06.015; Takahashi Kei, 2005, Medical Molecular Morphology, V38, P2, DOI 10.1007/s00795-004-0278-8; van den Oord EJCG, 2003, BIOTECHNIQUES, V34, P610, DOI 10.2144/03343dd04; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Yu XM, 2008, PLOS BIOL, V6, P581, DOI 10.1371/journal.pbio.0060061; Yu XM, 2006, DEV CELL, V10, P743, DOI 10.1016/j.devcel.2006.04.007; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	68	28	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6875	10.1371/journal.pone.0006875	http://dx.doi.org/10.1371/journal.pone.0006875			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489XX	19721717	Green Published, Green Accepted, gold			2022-12-27	WOS:000269461100004
J	Boesgaard, TW; Gjesing, AP; Grarup, N; Rutanen, J; Jansson, PA; Hribal, ML; Sesti, G; Fritsche, A; Stefan, N; Staiger, H; Haring, H; Smith, U; Laakso, M; Pedersen, O; Hansen, T				Boesgaard, Trine Wellov; Gjesing, Anette Prior; Grarup, Niels; Rutanen, Jarno; Jansson, Per-Anders; Hribal, Marta Letizia; Sesti, Giorgio; Fritsche, Andreas; Stefan, Norbert; Staiger, Harald; Haering, Hans; Smith, Ulf; Laakso, Markku; Pedersen, Oluf; Hansen, Torben		EUGENE2 Consortium	Variant near ADAMTS9 Known to Associate with Type 2 Diabetes Is Related to Insulin Resistance in Offspring of Type 2 Diabetes Patients-EUGENE2 Study	PLOS ONE			English	Article								Backround: A meta-analysis combining results from three genome-wide association studies and followed by large-scale replication identified six novel type 2 diabetes loci. Subsequent studies of the effect of these variants on estimates of the beta-cell function and insulin sensitivity have been inconclusive. We examined these variants located in or near the JAZF1 (rs864745), THADA (rs7578597), TSPAN8 (rs7961581), ADAMTS9 (rs4607103), NOTCH2 (rs10923931) and the CDC123/CAMK1D (rs12779790) genes for associations with measures of pancreatic beta-cell function and insulin sensitivity. Methodology/Results: Oral and intravenous glucose stimulated insulin release (n=849) and insulin sensitivity (n=596) estimated from a hyperinsulinemic euglycemic clamp were measured in non-diabetic offspring of type 2 diabetic patients from five European populations. Assuming an additive genetic model the diabetes-associated major C-allele of rs4607103 near ADAMTS9 associated with reduced insulin-stimulated glucose uptake (p=0.002) during a hyperinsulinemic euglycemic clamp. However, following intravenous and oral administration of glucose serum insulin release was increased in individuals with the C-allele (p=0.003 and p=0.01, respectively). A meta-analyse combining clamp and IVGTT data from a total of 905 non-diabetic individuals showed that the C-risk allele associated with decreased insulin sensitivity (p=0.003) and increased insulin release (p=0.002). The major T-allele of the intronic JAZF1 rs864745 conferring increased diabetes risk was associated with increased 2(nd) phase serum insulin release during an IVGTT (p=0.03), and an increased fasting serum insulin level (p=0.001). The remaining variants did not show any associations with insulin response, insulin sensitivity or any other measured quantitative traits. Conclusion: The present studies suggest that the diabetogenic impact of the C-allele of rs4607103 near ADAMTS9 may in part be mediated through decreased insulin sensitivity of peripheral tissues.			Boesgaard, TW (corresponding author), Steno Diabet Ctr, Copenhagen, Denmark.	tweb@steno.dk	Sesti, Giorgio/B-1509-2012; Grarup, Niels/K-2807-2015; Gjesing, Anette/ACC-7521-2022; Pedersen, Oluf/Z-1731-2019; Pedersen, Oluf/AAG-8015-2020	Grarup, Niels/0000-0001-5526-1070; Gjesing, Anette/0000-0003-4580-1576; Pedersen, Oluf/0000-0002-3321-3972; Sesti, Giorgio/0000-0002-1618-7688; Stefan, Norbert/0000-0002-2186-9595; Staiger, Harald/0000-0002-9507-5333				Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Boesgaard TW, 2008, DIABETOLOGIA, V51, P816, DOI 10.1007/s00125-008-0955-6; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ek J, 2001, DIABETOLOGIA, V44, P1170, DOI 10.1007/s001250100629; Grarup N, 2008, DIABETES, V57, P2534, DOI 10.2337/db08-0436; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; Laakso M, 2008, DIABETOLOGIA, V51, P502, DOI 10.1007/s00125-007-0899-2; Nakajima T, 2004, NUCLEIC ACIDS RES, V32, P4194, DOI 10.1093/nar/gkh741; Oliva E, 2007, AM J SURG PATHOL, V31, P1277, DOI 10.1097/PAS.0b013e318031f012; Sanghera DK, 2009, J HUM GENET, V54, P162, DOI 10.1038/jhg.2009.7; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Staiger H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003019; Stancakova A, 2008, J CLIN ENDOCR METAB, V93, P1924, DOI 10.1210/jc.2007-2218; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Trikalinos TA, 2008, ADV GENET, V60, P311, DOI 10.1016/S0065-2660(07)00413-0; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	21	42	44	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7236	10.1371/journal.pone.0007236	http://dx.doi.org/10.1371/journal.pone.0007236			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789630	Green Published, Green Submitted, gold			2022-12-27	WOS:000270354100008
J	Pichard, V; Aubert, D; Ferry, N				Pichard, Virginie; Aubert, Dominique; Ferry, Nicolas			Direct In Vivo Cell Lineage Analysis in the Retrorsine and 2AAF Models of Liver Injury after Genetic Labeling in Adult and Newborn Rats	PLOS ONE			English	Article								Backgrounds and Aims: When hepatocyte proliferation is impaired, liver regeneration proceeds from the division of non parenchymal hepatocyte progenitors. Oval cells and Small Hepatocyte-like Progenitor Cells (SHPCs) represent the two most studied examples of such epithelial cells with putative stem cell capacity. In the present study we wished to compare the origin of SHPCs proliferating after retrorsine administration to the one of oval cells observed after 2-Acetyl-Amino fluorene (2-AAF) treatment. Methodology/Principal Findings: We used retroviral-mediated nlslacZ genetic labeling of dividing cells to study the fate of cells in the liver. Labeling was performed either in adult rats before treatment or in newborn animals. Labeled cells were identified and characterised by immunohistochemistry. In adult-labeled animals, labeling was restricted to mature hepatocytes. Retrorsine treatment did not modify the overall number of labeled cells in the liver whereas after 2-AAF administration unlabeled oval cells were recorded and the total number of labeled cells decreased significantly. When labeling was performed in newborn rats, results after retrorsine administration were identical to those obtained in adult-labeled rats. In contrast, in the 2-AAF regimen numerous labeled oval cells were present and were able to generate new labeled hepatocytes. Furthermore, we also observed labeled biliary tracts in 2-AAF treated rats. Conclusions: Our results srongly suggest that SHPCs are derived from hepatocytes and we confirm that SHPCs and oval cells do not share the same origin. We also show that hepatic progenitors are labeled in newborn rats suggesting future directions for in vivo lineage studies.			Pichard, V (corresponding author), CHU Hotel Dieu, INSERM, U948, Nantes, France.	nicolas.ferry@inserm.fr						Aubert D, 2002, MOL THER, V5, P388, DOI 10.1006/mthe.2002.0561; Avril A, 2004, J HEPATOL, V41, P737, DOI 10.1016/j.jhep.2004.07.029; Bellodi-Privato M, 2005, HEPATOLOGY, V42, P431, DOI 10.1002/hep.20794; Best DH, 2007, HEPATOLOGY, V46, P1611, DOI 10.1002/hep.21876; Best DH, 2007, J HEPATOL, V46, P1055, DOI 10.1016/j.jhep.2007.01.040; Bralet MP, 1996, LAB INVEST, V74, P871; Braun KM, 2000, AM J PATHOL, V157, P561, DOI 10.1016/S0002-9440(10)64566-X; Dezso K, 2007, AM J PATHOL, V171, P1529, DOI 10.2353/ajpath.2007.070273; EVARTS RP, 1989, CANCER RES, V49, P1541; EVARTS RP, 1987, CARCINOGENESIS, V8, P1737, DOI 10.1093/carcin/8.11.1737; FARBER E, 1956, CANCER RES, V16, P142; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Gordon GJ, 2000, AM J PATHOL, V157, P771, DOI 10.1016/S0002-9440(10)64591-9; Gordon GJ, 2000, AM J PATHOL, V156, P607, DOI 10.1016/S0002-9440(10)64765-7; Higgins GM, 1931, ARCH PATHOL, V12, P186; Kitten O, 1997, HUM GENE THER, V8, P1491, DOI 10.1089/hum.1997.8.12-1491; Kofman AV, 2005, HEPATOLOGY, V41, P1252, DOI 10.1002/hep.20696; Kuwahara R, 2008, HEPATOLOGY, V47, P1994, DOI 10.1002/hep.22218; Menthena A, 2004, STEM CELLS, V22, P1049, DOI 10.1634/stemcells.22-6-1049; Oertel M, 2007, HEPATOLOGY, V46, P1236, DOI 10.1002/hep.21775; Oh SH, 2007, GASTROENTEROLOGY, V132, P1077, DOI 10.1053/j.gastro.2007.01.001; Paku S, 2001, AM J PATHOL, V158, P1313, DOI 10.1016/S0002-9440(10)64082-5; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Petersen B, 2008, HEPATOLOGY, V47, P1810, DOI 10.1002/hep.22333; Pichard V, 2001, BIOCHEM BIOPH RES CO, V286, P929, DOI 10.1006/bbrc.2001.5495; Pichard V, 2008, J HEPATOL, V48, P368, DOI 10.1016/j.jhep.2007.11.001; Puppi J, 2004, J HEPATOL, V41, P222, DOI 10.1016/j.jhep.2004.04.015; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; TATEMATSU M, 1984, AM J PATHOL, V114, P418; Vig P, 2006, HEPATOLOGY, V43, P316, DOI 10.1002/hep.21018; Yovchev MI, 2008, HEPATOLOGY, V47, P636, DOI 10.1002/hep.22047; Yovchev MI, 2007, HEPATOLOGY, V45, P139, DOI 10.1002/hep.21448	32	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7267	10.1371/journal.pone.0007267	http://dx.doi.org/10.1371/journal.pone.0007267			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789635	gold, Green Published, Green Submitted			2022-12-27	WOS:000270354100020
J	Clark, JL; Lescano, AG; Konda, KA; Leon, SR; Jones, FR; Klausner, JD; Coates, TJ; Caceres, CF				Clark, Jesse L.; Lescano, Andres G.; Konda, Kelika A.; Leon, Segundo R.; Jones, Franca R.; Klausner, Jeffrey D.; Coates, Thomas J.; Caceres, Carlos F.		NIMH Int Collaborative HIV STD Pre	Syndromic Management and STI Control in Urban Peru	PLOS ONE			English	Article								Background: Syndromic management is an inexpensive and effective method for the treatment of symptomatic sexually transmitted infections (STIs), but its effectiveness as a method of STI control in at-risk populations is questionable. We sought to determine the potential utility of syndromic management as a public health strategy to control STI transmission in high-risk populations in urban Peru. Methodology: We surveyed 3,285 at-risk men and women from three Peruvian cities from 2003-05. Participants were asked about the presence of genital ulcers, discharge, or dysuria in the preceding six months. Participants reporting symptoms were asked about subsequent health-seeking and partner notification behavior. Urine and vaginal swab samples were tested for Neisseria gonorrhoeae and Chlamydia trachomatis by nucleic acid testing. Serum was tested for syphilis and Herpes Simplex Virus-Type 2 antibodies. Findings: Recent urogenital discharge or dysuria was reported by 42.1% of participants with gonorrhea or chlamydia versus 28.3% of participants without infection. Genital ulceration was reported by 6.2% of participants with, and 7.4% of participants without, recent syphilis. Many participants reporting symptoms continued sexual activity while symptomatic, and approximately half of all symptomatic participants sought treatment. The positive and negative predictive values of urogenital discharge or genital ulcer disease in detecting STIs that are common in the study population were 14.4% and 81.5% for chlamydia in women and 8.3% and 89.5% for syphilis among gay-identified men. Conclusions: In our study, STIs among high-risk men and women in urban Peru were frequently asymptomatic and symptomatic participants often remained sexually active without seeking treatment. Additional research is needed to assess the costs and benefits of targeted, laboratory-based STI screening as part of a comprehensive STI control program in developing countries.			Clark, JL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.	jlclark@mednet.ucla.edu	Lescano, Andres G./M-9849-2019; Lescano, Andres G/B-8479-2008; Leon, Segundo Ramos/J-3058-2019	Lescano, Andres G./0000-0001-9779-633X; Lescano, Andres G/0000-0001-9779-633X; Leon, Segundo Ramos/0000-0002-5630-5714; Caceres, Carlos F./0000-0002-8101-0790; Clark, Jesse/0000-0001-5862-6530	FIC NIH HHS [D43 TW007393-06, D43 TW007393] Funding Source: Medline; NIMH NIH HHS [T32 MH080634, U10 MH061536, K23 MH084611, U10 MH61536] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW007393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH080634, U10MH061536, K23MH084611] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams EJ, 2003, SEX TRANSM DIS, V30, P379, DOI 10.1097/00007435-200305000-00002; Caceres CF, 2008, AIDS BEHAV, V12, P544, DOI 10.1007/s10461-007-9348-y; Crosby RA, 2004, SEX TRANSM DIS, V31, P421, DOI [10.1097/01.OLQ.0000130534.12309.2C, 10.1097/01.olq.0000130534.12309.2C]; Garcia P, 2003, B WORLD HEALTH ORGAN, V81, P806; Garcia PJ, 2007, SEX TRANSM INFECT, V83, P142, DOI 10.1136/sti.2006.022657; Garcia PJ, 1998, SEX TRANSM INFECT, V74, pS153; Hook EW, 1997, SEX TRANSM DIS, V24, P443, DOI 10.1097/00007435-199709000-00001; Irwin DE, 1999, SEX TRANSM DIS, V26, P286, DOI 10.1097/00007435-199905000-00009; Konda KA, 2005, SEX TRANSM DIS, V32, P534, DOI 10.1097/01.olq.0000175413.89733.ae; Korenromp EL, 2002, INT J STD AIDS, V13, P91, DOI 10.1258/0956462021924712; Liu HJ, 2003, SEX TRANSM DIS, V30, P327, DOI 10.1097/00007435-200304000-00010; Liu HJ, 2002, SEX TRANSM DIS, V29, P335, DOI 10.1097/00007435-200206000-00005; *MIN SAL, 2004, GUIAS NAC AT INT SAL; RAY K, 2009, INT J INFECT DIS; Romoren M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-27; Sanchez J, 2002, SEX TRANSM DIS, V29, P559, DOI 10.1097/00007435-200210000-00001; STIGMA, 2019, GUID MAN SEX TRANSM; Tann CJ, 2006, SEX TRANSM INFECT, V82, P285, DOI 10.1136/sti.2005.014845; TSAI CH, 2008, SEX TRANSM INFECT; VIBERG N, 2009, SEX TRANSM IN PRESS; Wang QQ, 2002, INT J STD AIDS, V13, P469, DOI 10.1258/09564620260079626; Wilkinson D, 1999, B WORLD HEALTH ORGAN, V77, P22	22	24	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7201	10.1371/journal.pone.0007201	http://dx.doi.org/10.1371/journal.pone.0007201			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779620	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200022
J	Cremieux, AC; Dumitrescu, O; Lina, G; Vallee, C; Cote, JF; Muffat-Joly, M; Lilin, T; Etienne, J; Vandenesch, F; Saleh-Mghir, A				Cremieux, Anne-Claude; Dumitrescu, Oana; Lina, Gerard; Vallee, Christian; Cote, Jean-Francois; Muffat-Joly, Martine; Lilin, Thomas; Etienne, Jerome; Vandenesch, Francois; Saleh-Mghir, Azzam			Panton-Valentine Leukocidin Enhances the Severity of Community-Associated Methicillin-Resistant Staphylococcus aureus Rabbit Osteomyelitis	PLOS ONE			English	Article								Background: Extensive spread of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in the United States, and the concomitant increase in severe invasive staphylococcal infections, including osteomyelitis, in healthy children, has led to renewed interest in Panton-Valentine leukocidin (PVL). However, the pathogenetic role of PVL in staphylococcal infections remains controversial, possibly because it depends on the site of infection. Methodology/Principal Findings: We compared the course of experimental rabbit osteomyelitis due to the PVL-positive CA-MRSA strain USA 300 (LAC) and its PVL-negative isogenic derivative (LAC Delta pvl), using a low and a high inoculum (8610 5 and 4 x 10(8) CFU). With the low inoculum, bone infection was less frequent on day 7 (D7) and day 28 (D28) with LACDpvl than with LAC (respectively 12/19 and 18/19 animals, p = 0.042). With the high inoculum of both strains, all the animals were infected on D7 and the infection persisted on D28 in almost every case. However, tibial bacterial counts and the serum CRP concentration fell significantly between D7 and D28 with LACDpvl but not with LAC. Respectively 67% and 60% of LAC-infected rabbits had bone deformation and muscle/joint involvement on D7, compared to 0% and 7% of LAC Delta pvl-infected rabbits (p = 0.001 and p = 0.005 respectively). Between D0 and D28, the anti-PVL antibody titer increased significantly only with the high inoculum of LAC. Conclusions/Significance: PVL appears to play a role in the persistence and rapid local extension of rabbit osteomyelitis, in keeping with the greater severity of human bone infections due to PVL-positive S. aureus. The possible therapeutic implications of these findings are discussed.			Cremieux, AC (corresponding author), Hop Raymond Poincare, AP HP, Dept Med Aigue, Garches, France.	anne-claude.cremieux@rpc.aphp.fr; denesch@univ-lyon1.fr	Vandenesch, Francois/C-7209-2014; Lina, Gerard J/L-9352-2014; Dumitrescu, Oana/C-6222-2013; ETIENNE, Jerome/C-5471-2014	Vandenesch, Francois/0000-0001-9412-7106; Dumitrescu, Oana/0000-0001-8193-1437; ETIENNE, Jerome/0000-0002-3348-3315; Lina, Gerard/0000-0002-9236-7998				Badiou C, 2008, CLIN MICROBIOL INFEC, V14, P1180, DOI 10.1111/j.1469-0691.2008.02105.x; Bocchini CE, 2006, PEDIATRICS, V117, P433, DOI 10.1542/peds.2005-0566; Brown EL, 2009, CLIN MICROBIOL INFEC, V15, P156, DOI 10.1111/j.1469-0691.2008.02648.x; Brown EL, 2009, CLIN VACCINE IMMUNOL, V16, P139, DOI 10.1128/CVI.00360-08; Chambers HF, 2009, J INFECT DIS, V199, P291, DOI 10.1086/595983; Cremieux AC, 1997, CLIN INFECT DIS, V25, P1295, DOI 10.1086/516135; Croze M, 2009, CLIN MICROBIOL INFEC, V15, P144, DOI 10.1111/j.1469-0691.2008.02650.x; Diep BA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003198; Dohin B, 2007, PEDIATR INFECT DIS J, V26, P1042, DOI 10.1097/INF.0b013e318133a85e; Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684; Gerber JS, 2009, CLIN INFECT DIS, V49, P65, DOI 10.1086/599348; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Gillet Y, 2007, CLIN INFECT DIS, V45, P315, DOI 10.1086/519263; Gonzalez BE, 2005, PEDIATRICS, V115, P642, DOI 10.1542/peds.2004-2300; King MD, 2006, ANN INTERN MED, V144, P309, DOI 10.7326/0003-4819-144-5-200603070-00005; Labandeira-Rey M, 2007, SCIENCE, V315, P1130, DOI 10.1126/science.1137165; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Martinez-Aguilar G, 2004, PEDIATR INFECT DIS J, V23, P701, DOI 10.1097/01.inf.0000133044.79130.2a; NORDEN CW, 1970, J INFECT DIS, V122, P410, DOI 10.1093/infdis/122.5.410; Panton PN, 1932, LANCET, V1, P506; Scheman L, 1941, J AMER MED ASSOC, V117, P1525, DOI 10.1001/jama.1941.02820440033008; SZMIGIELSKI S, 1966, J PATHOL BACTERIOL, V91, P599, DOI 10.1002/path.1700910237; Tristan A, 2007, EMERG INFECT DIS, V13, P594, DOI 10.3201/eid1304.061316; Valentine FCO, 1939, LANCET, V1, P973; VOLK A, 1994, MAGN RESON IMAGING, V12, P1039, DOI 10.1016/0730-725X(94)91235-O; Voyich JM, 2006, J INFECT DIS, V194, P1761, DOI 10.1086/509506; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; Wardenburg JB, 2008, J INFECT DIS, V198, P1166, DOI 10.1086/592053; WHALEN JL, 1988, J BONE JOINT SURG AM, V70A, P1383, DOI 10.2106/00004623-198870090-00017; 2007, MMWR MORB MORTAL WKL, V56, P325; 2001, J AM VET MED ASS, V218, P669	31	93	95	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7204	10.1371/journal.pone.0007204	http://dx.doi.org/10.1371/journal.pone.0007204			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779608	Green Submitted, Green Published, gold			2022-12-27	WOS:000270176200024
J	Davis, DR; Zhang, YQ; Smith, RR; Cheng, K; Terrovitis, J; Malliaras, K; Li, TS; White, A; Makkar, R; Marban, E				Davis, Darryl R.; Zhang, Yiqiang; Smith, Rachel R.; Cheng, Ke; Terrovitis, John; Malliaras, Konstantinos; Li, Tao-Sheng; White, Anthony; Makkar, Raj; Marban, Eduardo			Validation of the Cardiosphere Method to Culture Cardiac Progenitor Cells from Myocardial Tissue	PLOS ONE			English	Article							STEM-CELLS; ADULT; RENEWAL	Background: At least four laboratories have shown that endogenous cardiac progenitor cells (CPCs) can be grown directly from adult heart tissue in primary culture, as cardiospheres or their progeny (cardiosphere-derived cells, CDCs). Indeed, CDCs are already being tested in a clinical trial for cardiac regeneration. Nevertheless, the validity of the cardiosphere strategy to generate CPCs has been called into question by reports based on variant methods. In those reports, cardiospheres are argued to be cardiomyogenic only because of retained cardiomyocytes, and stem cell activity has been proposed to reflect hematological contamination. We use a variety of approaches (including genetic lineage tracing) to show that neither artifact is applicable to cardiospheres and CDCs grown using established methods, and we further document the stem cell characteristics (namely, clonogenicity and multilineage potential) of CDCs. Methodology/Principal Findings: CPCs were expanded from human endomyocardial biopsies (n = 160), adult bi-transgenic MerCreMer-Z/EG mice (n = 6), adult C57BL/6 mice (n = 18), adult GFP(+) C57BL/6 transgenic mice (n = 3), Yucatan mini pigs (n = 67), adult SCID beige mice (n = 8), and adult Wistar-Kyoto rats (n = 80). Cellular yield was enhanced by collagenase digestion and process standardization; yield was reduced in altered media and in specific animal strains. Heparinization/retrograde organ perfusion did not alter the ability to generate outgrowth from myocardial sample. The initial outgrowth from myocardial samples was enriched for sub-populations of CPCs (c-Kit(+)), endothelial cells (CD31(+), CD34(+)), and mesenchymal cells (CD90(+)). Lineage tracing using MerCreMer-Z/EG transgenic mice revealed that the presence of cardiomyocytes in the cellular outgrowth is not required for the generation of CPCs. Rat CDCs are shown to be clonogenic, and cloned CDCs exhibit spontaneous multineage potential. Conclusions/Significance: This study demonstrates that direct culture and expansion of CPCs from myocardial tissue is simple, straightforward, and reproducible when appropriate techniques are used.			Davis, DR (corresponding author), Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA.	eduardo.marban@csmc.edu	White, Anthony J/I-1472-2013; Marban, Eduardo/GWC-8514-2022; Zhang, Yiqiang/D-9613-2012	White, Anthony J/0000-0002-5442-6985; Zhang, Yiqiang/0000-0003-0691-6645; Li, Tao-Sheng/0000-0002-7653-8873; Davis, Darryl/0000-0001-9642-3910	NHLBI NIH HHS [R01 HL083109] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083109] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Heart Association, 2009, HEART DIS STROK STAT; Andersen DC, 2009, STEM CELLS, V27, P1571, DOI 10.1002/stem.72; Bearzi C, 2007, P NATL ACAD SCI USA, V104, P14068, DOI 10.1073/pnas.0706760104; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Chimenti I, 2007, CIRC RES, V101, P1209; Davis DR, 2008, CIRC RES, V103, P1495; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; Gerecht S, 2007, P NATL ACAD SCI USA, V104, P11298, DOI 10.1073/pnas.0703723104; Hsieh PCH, 2007, NAT MED, V13, P970, DOI 10.1038/nm1618; Johnston P, 2007, CIRC RES, V101, P1209; Li ZJ, 2009, J AM COLL CARDIOL, V53, P1229, DOI 10.1016/j.jacc.2008.12.036; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Ott Harald C, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS27, DOI 10.1038/ncpcardio0771; Shenje LT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001929; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687; Tang YL, 2007, BIOCHEM BIOPH RES CO, V359, P877, DOI 10.1016/j.bbrc.2007.05.216	20	219	237	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7195	10.1371/journal.pone.0007195	http://dx.doi.org/10.1371/journal.pone.0007195			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779618	Green Published, gold, Green Submitted			2022-12-27	WOS:000270176200020
J	Graves, N; Barnett, AG; Halton, KA; Veerman, JL; Winkler, E; Owen, N; Reeves, MM; Marshall, A; Eakin, E				Graves, Nicholas; Barnett, Adrian G.; Halton, Kate A.; Veerman, Jacob L.; Winkler, Elisabeth; Owen, Neville; Reeves, Marina M.; Marshall, Alison; Eakin, Elizabeth			Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet	PLOS ONE			English	Article								Background: Given escalating rates of chronic disease, broad-reach and cost-effective interventions to increase physical activity and improve dietary intake are needed. The cost-effectiveness of a Telephone Counselling intervention to improve physical activity and diet, targeting adults with established chronic diseases in a low socio-economic area of a major Australian city was examined. Methodology/Principal Findings: A cost-effectiveness modelling study using data collected between February 2005 and November 2007 from a cluster-randomised trial that compared Telephone Counselling with a "Usual Care'' (brief intervention) alternative. Economic outcomes were assessed using a state-transition Markov model, which predicted the progress of participants through five health states relating to physical activity and dietary improvement, for ten years after recruitment. The costs and health benefits of Telephone Counselling, Usual Care and an existing practice (Real Control) group were compared. Telephone Counselling compared to Usual Care was not cost-effective ($78,489 per quality adjusted life year gained). However, the Usual Care group did not represent existing practice and is not a useful comparator for decision making. Comparing Telephone Counselling outcomes to existing practice (Real Control), the intervention was found to be cost-effective ($29,375 per quality adjusted life year gained). Usual Care (brief intervention) compared to existing practice (Real Control) was also cost-effective ($12,153 per quality adjusted life year gained). Conclusions/Significance: This modelling study shows that a decision to adopt a Telephone Counselling program over existing practice (Real Control) is likely to be cost-effective. Choosing the 'Usual Care' brief intervention over existing practice (Real Control) shows a lower cost per quality adjusted life year, but the lack of supporting evidence for efficacy or sustainability is an important consideration for decision makers. The economics of behavioural approaches to improving health must be made explicit if decision makers are to be convinced that allocating resources toward such programs is worthwhile.			Graves, N (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia.	n.graves@qut.edu.au	Veerman, Lennert/A-9973-2011; Marshall, Alison/A-6693-2011; Eakin, Elizabeth G/F-7918-2010; Barnett, Adrian/I-9850-2012; Reeves, Marina M/B-3813-2009; Owen, Neville/F-8329-2010; Graves, Nicholas/A-3052-2011; Halton, Kate/I-9964-2012; Winkler, Elisabeth/AAD-7153-2022; Owen, Neville/K-5986-2012	Veerman, Lennert/0000-0002-3206-8232; Eakin, Elizabeth G/0000-0002-8835-9995; Barnett, Adrian/0000-0001-6339-0374; Reeves, Marina M/0000-0003-3052-2013; Winkler, Elisabeth/0000-0003-1452-6102; Owen, Neville/0000-0003-2784-4820; Graves, Nicholas/0000-0002-5559-3267; Marshall, Alison/0000-0001-5707-9424; Halton, Kate/0000-0001-9785-1458					0	58	59	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7135	10.1371/journal.pone.0007135	http://dx.doi.org/10.1371/journal.pone.0007135			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779611	gold, Green Published			2022-12-27	WOS:000270176200001
J	Pai, NP; Estes, M; Moodie, EEM; Reingold, AL; Tulsky, JP				Pai, Nitika Pant; Estes, Milton; Moodie, Erica E. M.; Reingold, Arthur L.; Tulsky, Jacqueline P.			The Impact of Antiretroviral Therapy in a Cohort of HIV Infected Patients Going in and out of the San Francisco County Jail	PLOS ONE			English	Article								Background: Jails are an important venue of HIV care and a place for identification, treatment and referral for care. HIV infected inmates in the San Francisco County jail are offered antiretroviral treatment ( ART), which many take only while in jail. We evaluated the effect of ART administration in a cohort of jail inmates going in and out of jail over a nine year period. Methodology/Principal Findings: In this retrospective study, we examined inmates with HIV going in and out of jail. Inmates were categorized by patterns of ART use: continuous ART - ART both in and out of jail, intermittent ART - ART only in jail; never on ART - eligible by national guidelines, but refused ART. CD4 and HIV viral load (VL) were compared over time in these groups. Over a 9 year period, 512 inmates were studied: 388 (76%) on intermittent ART, 79 (15%) on continuous ART and 45(9%) never-on ART. In a linear mixed model analysis, inmates on intermittent ART were 1.43; 95%CI (1.03, 1.99) times and those never on ART were 2.89; 95%CI (1.71, 4.87) times more likely to have higher VL than inmates on continuous ART. Furthermore, Inmates on intermittent ART and never-on ART lost 1.60; 95%CI (1.06, 2.13) and 1.97; 95%CI (0.96, 3.00) more CD4 cells per month, respectively, compared to continuously treated inmates. The continuous ART inmates gained 0.67CD4 cells/month. Conclusions/Significance: Continuous ART therapy in jail inmate's benefits CD4 cell counts and control of VL especially compared to those who never took ART. Although jail inmates on intermittent ART were more likely to lose CD4 cells and experience higher VL over time than those on continuous ART, CD4 cell loss was slower in these inmates as compared to inmates never on ART. Further studies are needed to evaluate whether or not intermittent ART provides some benefit in outcome if continuous ART is not possible or likely.			Pai, NP (corresponding author), McGill Univ, Ctr Hlth, Div Infect Dis, Div Clin Epidemiol, Montreal, PQ, Canada.	jtulsky@php.ucsf.edu		Pant Pai, Nitika/0000-0002-4672-0500	FIC NIH HHS [I-D43-TW00008-16] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000008] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Blankenship KM, 2005, J HEALTH CARE POOR U, V16, P140, DOI 10.1353/hpu.2005.0110; Burman W, 2008, JAIDS-J ACQ IMM DEF, V49, P142, DOI 10.1097/QAI.0b013e318183a9ad; ELSADR WMG, 2008, ANN INTERN MED, V149, P30; Hammett TM, 2006, AM J PUBLIC HEALTH, V96, P974, DOI 10.2105/AJPH.2005.066993; Palepu A, 2004, ANTIVIR THER, V9, P713; Pontali E, 2005, HIV CLIN TRIALS, V6, P25; Rabe-Hesketh S.S.A., 2005, MULTILEVEL LONGITUDI; ROUX AVA, 2005, J INFECT DIS, V191; Spaulding A, 2002, CLIN INFECT DIS, V35, P305, DOI 10.1086/341418; Spaulding A C, 1998, Med Health R I, V81, P204; Springer SA, 2004, CLIN INFECT DIS, V38, P1754, DOI 10.1086/421392; Springer Sandra A, 2005, Curr HIV/AIDS Rep, V2, P165, DOI 10.1007/s11904-005-0011-9; Stephenson BL, 2005, PUBLIC HEALTH REP, V120, P84, DOI 10.1177/003335490512000114; White MC, 2001, INT J STD AIDS, V12, P380, DOI 10.1258/0956462011923327; Wohl David A, 2006, AIDS Read, V16, P247; 2004, HIV AIDS POLICY LAW, V9, P50; 2004, HIV AIDS POLICY LAW, V9, P52	17	28	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7115	10.1371/journal.pone.0007115	http://dx.doi.org/10.1371/journal.pone.0007115			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771176	Green Published, gold			2022-12-27	WOS:000270154400011
J	Goldstein, J; Morris, WE; Loidl, CF; Tironi-Farinatti, C; McClane, BA; Uzal, FA; Miyakawa, MEF				Goldstein, Jorge; Morris, Winston E.; Fabian Loidl, Cesar; Tironi-Farinatti, Carla; McClane, Bruce A.; Uzal, Francisco A.; Fernandez Miyakawa, Mariano E.			Clostridium perfringens Epsilon Toxin Increases the Small Intestinal Permeability in Mice and Rats	PLOS ONE			English	Article								Epsilon toxin is a potent neurotoxin produced by Clostridium perfringens types B and D, an anaerobic bacterium that causes enterotoxaemia in ruminants. In the affected animal, it causes oedema of the lungs and brain by damaging the endothelial cells, inducing physiological and morphological changes. Although it is believed to compromise the intestinal barrier, thus entering the gut vasculature, little is known about the mechanism underlying this process. This study characterizes the effects of epsilon toxin on fluid transport and bioelectrical parameters in the small intestine of mice and rats. The enteropooling and the intestinal loop tests, together with the single-pass perfusion assay and in vitro and ex vivo analysis in Ussing's chamber, were all used in combination with histological and ultrastructural analysis of mice and rat small intestine, challenged with or without C. perfringens epsilon toxin. Luminal epsilon toxin induced a time and concentration dependent intestinal fluid accumulation and fall of the transepithelial resistance. Although no evident histological changes were observed, opening of the mucosa tight junction in combination with apoptotic changes in the lamina propria were seen with transmission electron microscopy. These results indicate that C. perfringens epsilon toxin alters the intestinal permeability, predominantly by opening the mucosa tight junction, increasing its permeability to macromolecules, and inducing further degenerative changes in the lamina propria of the bowel.			Goldstein, J (corresponding author), Univ Buenos Aires, Fac Med, Dept Fisiol, Lab Fisiopatogenia, RA-1425 Buenos Aires, DF, Argentina.	mfernandez@cnia.inta.gov.ar		Fernandez Miyakawa, Mariano Enrique/0000-0001-5251-4685; Goldstein, Jorge/0000-0002-9488-0074				Adamson RH, 2005, INFECT IMMUN, V73, P4879, DOI 10.1128/IAI.73.8.4879-4887.2005; Athman R, 2002, AM J PHYSIOL-GASTR L, V282, pG634, DOI 10.1152/ajpgi.00327.2001; BALLARD ST, 1995, ANNU REV NUTR, V15, P35, DOI 10.1146/annurev.nu.15.070195.000343; BULLEN JJ, 1957, J PATHOL BACTERIOL, V73, P511, DOI 10.1002/path.1700730221; EWE K, 1988, PHARMACOLOGY, V36, P73, DOI 10.1159/000138424; Femandez-Miyakawa ME, 2008, VET MICROBIOL, V127, P379, DOI 10.1016/j.vetmic.2007.09.013; Fernandez-Miyakawa ME, 2007, INFECT IMMUN, V75, P4282, DOI 10.1128/IAI.00562-07; Finnie JW, 2003, AUST VET J, V81, P219, DOI 10.1111/j.1751-0813.2003.tb11474.x; FINNIE JW, 1984, J COMP PATHOL, V94, P363, DOI 10.1016/0021-9975(84)90024-0; FRIZZELL RA, 1972, J GEN PHYSIOL, V59, P318, DOI 10.1085/jgp.59.3.318; GARDNER DE, 1973, J COMP PATHOL, V83, P509, DOI 10.1016/0021-9975(73)90009-1; GRINER LA, 1961, AM J VET RES, V22, P429; Kucharzik T, 2000, ALIMENT PHARM THERAP, V14, P247; LANGE S, 1994, SCAND J GASTROENTERO, V29, P38, DOI 10.3109/00365529409090435; Losada-Eaton DM, 2008, TOXICON, V51, P1207, DOI 10.1016/j.toxicon.2008.02.008; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; McClane BA, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 4, THIRD EDITION, P698, DOI 10.1007/0-387-30744-3_22; Minami J, 1997, MICROBIOL IMMUNOL, V41, P527, DOI 10.1111/j.1348-0421.1997.tb01888.x; Miyakawa MEF, 2003, ANAEROBE, V9, P145, DOI 10.1016/S1075-9964(03)00069-6; Miyakawa MEF, 2003, VET RES COMMUN, V27, P231, DOI 10.1023/A:1023348708599; Miyamoto O, 2000, FEMS MICROBIOL LETT, V189, P109, DOI 10.1111/j.1574-6968.2000.tb09215.x; MORGAN KT, 1974, J COMP PATHOL, V84, P181, DOI 10.1016/0021-9975(74)90059-0; NAGAHAMA M, 1991, TOXICON, V29, P211, DOI 10.1016/0041-0101(91)90105-Z; NAGAHAMA M, 1993, TOXICON, V31, P427, DOI 10.1016/0041-0101(93)90178-L; OHISHI I, 1983, INFECT IMMUN, V40, P691, DOI 10.1128/IAI.40.2.691-695.1983; Priestley J.V., 1992, ELECT MICROSCOPIC IM, P89; RIVIERE PJM, 1991, J PHARMACOL EXP THER, V256, P547; ROBERT A, 1976, PROSTAG OTH LIPID M, V11, P809, DOI 10.1016/0090-6980(76)90189-1; SAKURAI J, 1989, FEMS MICROBIOL LETT, V58, P269, DOI 10.1016/0378-1097(89)90051-7; Sears CL, 1996, MICROBIOL REV, V60, P167, DOI 10.1128/MMBR.60.1.167-215.1996; Tamai E, 2003, INFECT IMMUN, V71, P5371, DOI 10.1128/IAI.71.9.5371-5375.2003; UZAL FA, 1994, VET REC, V135, P279, DOI 10.1136/vr.135.12.279; Uzal FA, 2004, J VET DIAGN INVEST, V16, P403, DOI 10.1177/104063870401600506; Uzal FA, 2004, ANAEROBE, V10, P135, DOI 10.1016/j.anaerobe.2003.08.005; Uzal FA, 1998, VET PATHOL, V35, P132, DOI 10.1177/030098589803500207	35	33	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7065	10.1371/journal.pone.0007065	http://dx.doi.org/10.1371/journal.pone.0007065			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763257	Green Published, Green Accepted, gold			2022-12-27	WOS:000269970400007
J	Johnson, F; Kaplitt, MG				Johnson, Felicity; Kaplitt, Michael G.			Novel Mitochondrial Substrates of Omi Indicate a New Regulatory Role in Neurodegenerative Disorders	PLOS ONE			English	Article								The mitochondrial protease OMI (also known as HtrA2) has been implicated in Parkinson's Disease (PD) and deletion or protease domain point mutations have shown profound neuropathologies in mice. A beneficial role by OMI, in preserving cell viability, is assumed to occur via the avoidance of dysfunctional protein turnover. However relatively few substrates for mitochondrial Omi are known. Here we report our identification of three novel mitochondrial substrates that impact metabolism and ATP production. Using a dual proteomic approach we have identified three interactors based upon ability to bind to OMI, and/or to persist in the proteome after OMI activity has been selectively inhibited. One candidate, the chaperone HSPA8, was common to each independent study. Two others (PDHB subunit and IDH3A subunit) did not appear to bind to OMI, however persisted in the mito-proteome when OMI was inhibited. Pyruvate dehydrogenase (PDH) and isocitrate dehydrogenase (IDH) are two key Kreb's cycle enzymes that catalyse oxidative decarboxylation control points in mitochondrial respiration. We verified both PDHB and IDH3A co-immunoprecipitate with HSPA8 and after elution, were degraded by recombinant HtrA2 in vitro. Additionally our gene expression studies, using rotenone (an inhibitor of Complex I) showed Omi expression was silenced when pdhb and idh3a were increased when a sub-lethal dose was applied. However higher dose treatment caused increased Omi expression and decreased levels of pdhb and idh3a transcripts. This implicates mitochondrial OMI in a novel mechanism relating to metabolism.			Johnson, F (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol Surg, New York, NY 10021 USA.	fej2001@med.cornell.edu						Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Cilenti L, 2003, J BIOL CHEM, V278, P11489, DOI 10.1074/jbc.M212819200; Exner N, 2007, J NEUROSCI, V27, P12413, DOI 10.1523/JNEUROSCI.0719-07.2007; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Huttunen HJ, 2007, J BIOL CHEM, V282, P28285, DOI 10.1074/jbc.M702951200; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; JONES JM, 1993, GENOMICS, V16, P669, DOI 10.1006/geno.1993.1246; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kampinga HH, 2009, CELL STRESS CHAPERON, V14, P105, DOI 10.1007/s12192-008-0068-7; Kawamoto Y, 2008, J NEUROPATH EXP NEUR, V67, P984, DOI 10.1097/NEN.0b013e31818809f4; Kiang JG, 2006, AM J PHYSIOL-GASTR L, V291, pG117, DOI 10.1152/ajpgi.00397.2005; Klupsch K, 2006, CELL DEATH DIFFER, V13, P2157, DOI 10.1038/sj.cdd.4401955; Leverenz JB, 2007, BRAIN PATHOL, V17, P139, DOI 10.1111/j.1750-3639.2007.00048.x; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; MOISOI N, 2008, CELL DEATH DIFFER; Nam MK, 2006, EXP MOL MED, V38, P36, DOI 10.1038/emm.2006.5; Park HJ, 2006, J BIOL CHEM, V281, P34277, DOI 10.1074/jbc.M603443200; Plun-Favreau H, 2008, ANN NY ACAD SCI, V1147, P30, DOI 10.1196/annals.1427.032; PLUNFAVREAU H, 2007, NAT CELL BIOL; Ross OA, 2008, PARKINSONISM RELAT D, V14, P539, DOI 10.1016/j.parkreldis.2008.08.003; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; SIMONSANCHEZ J, 2008, HUM MOL GENET; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TAIN LS, 2009, CELL DEATH DIFFER; Thomas B, 2007, HUM MOL GENET, V16, pR183, DOI 10.1093/hmg/ddm159; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Whitworth AJ, 2008, DIS MODEL MECH, V1, P168, DOI 10.1242/dmm.000109; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Yang L, 2007, J BIOL CHEM, V282, P10981, DOI 10.1074/jbc.M700445200; Yun J, 2008, J NEUROSCI, V28, P14500, DOI 10.1523/JNEUROSCI.5141-08.2008; Zhang XF, 2004, BIOCHEMISTRY-MOSCOW+, V69, P687, DOI 10.1023/B:BIRY.0000033743.09806.1a; Zhang YN, 2007, PROTEIN SCI, V16, P1738, DOI 10.1110/ps.072833207	41	18	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7100	10.1371/journal.pone.0007100	http://dx.doi.org/10.1371/journal.pone.0007100			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763263	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970400021
J	Barabote, RD; Xie, G; Brettin, TS; Hinrichs, SH; Fey, PD; Jay, JJ; Engle, JL; Godbole, SD; Noronha, JM; Scheuermann, RH; Zhou, LW; Lion, C; Dempsey, MP				Barabote, Ravi D.; Xie, Gary; Brettin, Thomas S.; Hinrichs, Steven H.; Fey, Paul D.; Jay, Justin J.; Engle, Jennifer L.; Godbole, Shubhada D.; Noronha, Jyothi M.; Scheuermann, Richard H.; Zhou, Liwei W.; Lion, Christine; Dempsey, Michael P.			Complete Genome Sequence of Francisella tularensis Subspecies holarctica FTNF002-00	PLOS ONE			English	Article								Francisella tularensis subspecies holarctica FTNF002-00 strain was originally obtained from the first known clinical case of bacteremic F. tularensis pneumonia in Southern Europe isolated from an immunocompetent individual. The FTNF002-00 complete genome contains the RD23 deletion and represents a type strain for a clonal population from the first epidemic tularemia outbreak in Spain between 1997-1998. Here, we present the complete sequence analysis of the FTNF002-00 genome. The complete genome sequence of FTNF002-00 revealed several large as well as small genomic differences with respect to two other published complete genome sequences of F. tularensis subsp. holarctica strains, LVS and OSU18. The FTNF002-00 genome shares >99.9% sequence similarity with LVS and OSU18, and is also similar to 5 MB smaller by comparison. The overall organization of the FTNF002-00 genome is remarkably identical to those of LVS and OSU18, except for a single 3.9 kb inversion in FTNF002-00. Twelve regions of difference ranging from 0.1-1.5 kb and forty-two small insertions and deletions were identified in a comparative analysis of FTNF002-00, LVS, and OSU18 genomes. Two small deletions appear to inactivate two genes in FTNF002-00 causing them to become pseudogenes; the intact genes encode a protein of unknown function and a drug:H+ antiporter. In addition, we identified ninety-nine proteins in FTNF002-00 containing amino acid mutations compared to LVS and OSU18. Several non-conserved amino acid replacements were identified, one of which occurs in the virulence-associated intracellular growth locus subunit D protein. Many of these changes in FTNF002-00 are likely the consequence of direct selection that increases the fitness of this subsp. holarctica clone within its endemic population. Our complete genome sequence analyses lay the foundation for experimental testing of these possibilities.			Barabote, RD (corresponding author), Los Alamos Natl Lab, Biosci Div, M888, Los Alamos, NM 87545 USA.	dempseym@afip.osd.mil	Dempsey, Michael/GSM-7774-2022; Barabote, Ravi/B-8727-2011; Barabote, Ravi/C-1299-2017	Scheuermann, Richard H./0000-0003-1355-892X; Barabote, Ravi/0000-0002-0403-246X; xie, gary/0000-0002-9176-924X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bellido-Casado J, 2000, EUR J CLIN MICROBIOL, V19, P218, DOI 10.1007/s100960050462; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Broekhuijsen M, 2003, J CLIN MICROBIOL, V41, P2924, DOI 10.1128/JCM.41.7.2924-2931.2003; Brosch R, 2001, TRENDS MICROBIOL, V9, P452, DOI 10.1016/S0966-842X(01)02131-X; Chain PSG, 2004, P NATL ACAD SCI USA, V101, P13826, DOI 10.1073/pnas.0404012101; de la Puente-Redondo VA, 2000, J CLIN MICROBIOL, V38, P1016, DOI 10.1128/JCM.38.3.1016-1022.2000; del Blanco NG, 2004, VET REC, V154, P55, DOI 10.1136/vr.154.2.55; Del Blanco NG, 2002, J CLIN MICROBIOL, V40, P2964, DOI 10.1128/JCM.40.8.2964-2972.2002; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Dempsey MP, 2007, APPL ENVIRON MICROB, V73, P7465, DOI 10.1128/AEM.00646-07; Dempsey MP, 2006, J BACTERIOL, V188, P5904, DOI 10.1128/JB.00437-06; Ellis J, 2002, CLIN MICROBIOL REV, V15, P631, DOI 10.1128/CMR.15.4.631-646.2002; EVANS ME, 1997, TXB MILITARY MED 1, P10; Farlow J, 2005, EMERG INFECT DIS, V11, P1835, DOI 10.3201/eid1112.050728; Garcia Pena F.J, 1998, MED VET, V15, P418; Griffiths-Jones S, 2005, NUCLEIC ACIDS RES, V33, pD121, DOI 10.1093/nar/gki081; Haft DH, 2001, NUCLEIC ACIDS RES, V29, P41, DOI 10.1093/nar/29.1.41; Haristoy X, 2003, J CLIN MICROBIOL, V41, P2774, DOI 10.1128/JCM.41.6.2774-2776.2003; HOPLA CE, 1994, TULAREMIA, P113; Johansson A, 2004, J BACTERIOL, V186, P5808, DOI 10.1128/JB.186.17.5808-5818.2004; Keim P, 2007, ANN NY ACAD SCI, V1105, P30, DOI 10.1196/annals.1409.011; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lopatin DE, 2000, INFECT IMMUN, V68, P1980, DOI 10.1128/IAI.68.4.1980-1987.2000; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Luque PB, 1998, REV CLIN ESP, V198, P789; McCoy G, 1912, J INFECT DIS, V10, P61, DOI 10.1093/infdis/10.1.61; Nano FE, 2004, J BACTERIOL, V186, P6430, DOI 10.1128/JB.186.19.6430-6436.2004; Perez-Castrillon JL, 2001, CLIN INFECT DIS, V33, P573, DOI 10.1086/322601; Petersen JM, 2005, VET RES, V36, P455, DOI 10.1051/vetres:2005006; Petrosino JF, 2006, J BACTERIOL, V188, P6977, DOI 10.1128/JB.00506-06; Puiu D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003427; Samrakandi MM, 2004, FEMS MICROBIOL LETT, V237, P9, DOI [10.1111/j.1574-6968.2004.tb09672.x, 10.1016/j.femsle.2004.06.008]; Slater GS, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-31; Staples JE, 2006, EMERG INFECT DIS, V12, P1113; Svensson K, 2005, J BACTERIOL, V187, P3903, DOI 10.1128/JB.187.11.3903-3908.2005; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; *TIGR, 2006, MAN HOM PAG; *USDHHS, 1999, BIOS MICR BIOM LAB B; Vogler AJ, 2009, J BACTERIOL, V191, P2474, DOI 10.1128/JB.01786-08; Weiss DS, 2007, P NATL ACAD SCI USA, V104, P6037, DOI 10.1073/pnas.0609675104; Wilson K, 1997, CURRENT PROTOCOLS MO, p2 4 1	43	32	290	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7041	10.1371/journal.pone.0007041	http://dx.doi.org/10.1371/journal.pone.0007041			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756146	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970000010
J	Ortigue, S; Thompson, JC; Parasuraman, R; Grafton, ST				Ortigue, Stephanie; Thompson, James C.; Parasuraman, Raja; Grafton, Scott T.			Spatio-Temporal Dynamics of Human Intention Understanding in Temporo-Parietal Cortex: A Combined EEG/fMRI Repetition Suppression Paradigm	PLOS ONE			English	Article								Inferring the intentions of other people from their actions recruits an inferior fronto-parietal action observation network as well as a putative social network that includes the posterior superior temporal sulcus (STS). However, the functional dynamics within and among these networks remains unclear. Here we used functional magnetic resonance imaging (fMRI) and high-density electroencephalogram (EEG), with a repetition suppression design, to assess the spatio-temporal dynamics of decoding intentions. Suppression of fMRI activity to the repetition of the same intention was observed in inferior frontal lobe, anterior intraparietal sulcus (aIPS), and right STS. EEG global field power was reduced with repeated intentions at an early (starting at 60 ms) and a later (similar to 330 ms) period after the onset of a hand-on-object encounter. Source localization during these two intervals involved right STS and aIPS regions highly consistent with RS effects observed with fMRI. These results reveal the dynamic involvement of temporal and parietal networks at multiple stages during the intention decoding and without a strict segregation of intention decoding between these networks.			Ortigue, S (corresponding author), UCSB Brain Imaging Ctr, Dept Psychol, Inst Collaborat Biotechnol, Santa Barbara, CA 93106 USA.	sortigue@syr.edu; grafton@psych.ucsb.edu	Thompson, James/E-7569-2010					Aglioti SM, 2008, NAT NEUROSCI, V11, P1109, DOI 10.1038/nn.2182; Allison T, 2000, TRENDS COGN SCI, V4, P267, DOI 10.1016/S1364-6613(00)01501-1; Binkofski F, 1998, NEUROLOGY, V50, P1253, DOI 10.1212/WNL.50.5.1253; Brass M, 2007, CURR BIOL, V17, P2117, DOI 10.1016/j.cub.2007.11.057; Bullier J, 2001, BRAIN RES REV, V36, P96, DOI 10.1016/S0165-0173(01)00085-6; CROSS E, 2008, SENSITIVITY ACTION O; Cross ES, 2006, NEUROIMAGE, V31, P1257, DOI 10.1016/j.neuroimage.2006.01.033; De Lange FP, 2008, CURR BIOL, V18, P454, DOI 10.1016/j.cub.2008.02.057; Dinstein I, 2007, J NEUROPHYSIOL, V98, P1415, DOI 10.1152/jn.00238.2007; Frey SH, 2005, COGNITIVE BRAIN RES, V23, P397, DOI 10.1016/j.cogbrainres.2004.11.010; Grafton ST, 2008, NAT NEUROSCI, V11, P248, DOI 10.1038/nn0308-248; Grafton ST, 2007, HUM MOVEMENT SCI, V26, P590, DOI 10.1016/j.humov.2007.05.009; Grafton ST, 2009, ANN NY ACAD SCI, V1156, P97, DOI 10.1111/j.1749-6632.2009.04425.x; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Grill-Spector K, 2006, TRENDS COGN SCI, V10, P14, DOI 10.1016/j.tics.2005.11.006; Grill-Spector K, 2001, ACTA PSYCHOL, V107, P293, DOI 10.1016/S0001-6918(01)00019-1; Grossman ED, 2005, VISION RES, V45, P2847, DOI 10.1016/j.visres.2005.05.027; Guo C, 2007, NEUROSCIENCE, V149, P747, DOI 10.1016/j.neuroscience.2007.07.060; Hamilton AF, 2007, ATTENTION PERFORM, P381, DOI DOI 10.1093/ACPR0F:0S0/9780199231447.003.0018; Hamilton AFD, 2006, J NEUROSCI, V26, P1133, DOI 10.1523/JNEUROSCI.4551-05.2006; Hamilton AFD, 2008, CEREB CORTEX, V18, P1160, DOI 10.1093/cercor/bhm150; HESSE MD, 2008, J COGN NEUROSCI; Iacoboni M, 2005, PLOS BIOL, V3, P529, DOI 10.1371/journal.pbio.0030079; Ishai A, 2006, BRAIN RES BULL, V70, P289, DOI 10.1016/j.brainresbull.2006.06.002; Jellema T, 2000, BRAIN COGNITION, V44, P280, DOI 10.1006/brcg.2000.1231; Keysers C, 2007, TRENDS COGN SCI, V11, P194, DOI 10.1016/j.tics.2007.02.002; Kilner JM, 2008, CURR BIOL, V18, pR32, DOI 10.1016/j.cub.2007.11.008; KRZANOWSKI WJ, 1988, BIOMETRICS, V44, P23, DOI 10.2307/2531893; Lehmann D., 1987, HDB ELECTROENCEPHALO, V1, P309; Materna S, 2008, NEUROPSYCHOLOGIA, V46, P2759, DOI 10.1016/j.neuropsychologia.2008.05.016; Menendez RGD, 2001, BRAIN TOPOGR, V14, P131, DOI 10.1023/A:1012944913650; Murray MM, 2008, BRAIN TOPOGR, V20, P249, DOI 10.1007/s10548-008-0054-5; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; Noppeney U, 2006, HUM BRAIN MAPP, V27, P411, DOI 10.1002/hbm.20242; Pelphrey KA, 2004, J COGNITIVE NEUROSCI, V16, P1706, DOI 10.1162/0898929042947900; Pickering EC, 2003, J EXP PSYCHOL LEARN, V29, P1298, DOI 10.1037/0278-7393.29.6.1298; Pobric G, 2006, CURR BIOL, V16, P524, DOI 10.1016/j.cub.2006.01.033; Rizzolatti Giacomo, 2008, MIRRORS BRAIN OUR MI; Saxe R, 2004, NEUROPSYCHOLOGIA, V42, P1435, DOI 10.1016/j.neuropsychologia.2004.04.015; Schutz-Bosbach S, 2007, TRENDS COGN SCI, V11, P349, DOI 10.1016/j.tics.2007.06.005; Shmuelof L, 2007, NEUROSCIENTIST, V13, P667, DOI 10.1177/1073858407302457; Sitnikova T, 2003, PSYCHOPHYSIOLOGY, V40, P160, DOI 10.1111/1469-8986.00016; Thompson JC, 2007, NEUROIMAGE, V37, P966, DOI 10.1016/j.neuroimage.2007.05.058; Thompson JC, 2005, J NEUROSCI, V25, P9059, DOI 10.1523/JNEUROSCI.2129-05.2005; VANDERCRUYSSEN L, 2008, SOCIAL NEUROSCIENCE, V4, P165; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X; Wong KF, 2008, FRONT NEUROSCI-SWITZ, V2, P245, DOI 10.3389/neuro.01.028.2008; Xu YD, 2007, J NEUROSCI, V27, P5981, DOI 10.1523/JNEUROSCI.5527-06.2007	48	50	52	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6962	10.1371/journal.pone.0006962	http://dx.doi.org/10.1371/journal.pone.0006962			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750227	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696600008
J	Song, SO; Varner, J				Song, Sang Ok; Varner, Jeffrey			Modeling and Analysis of the Molecular Basis of Pain in Sensory Neurons	PLOS ONE			English	Article							INOSITOL TRISPHOSPHATE RECEPTOR; METABOTROPIC P2Y RECEPTORS; ATP-GATED CHANNELS; SENSITIVITY-ANALYSIS; DORSAL-ROOT; ENDOPLASMIC-RETICULUM; PURINERGIC RECEPTORS; NEUROBLASTOMA-CELLS; NOCICEPTIVE NEURONS; SIGNALING PATHWAYS	Intracellular calcium dynamics are critical to cellular functions like pain transmission. Extracellular ATP plays an important role in modulating intracellular calcium levels by interacting with the P2 family of surface receptors. In this study, we developed a mechanistic mathematical model of ATP-induced P2 mediated calcium signaling in archetype sensory neurons. The model architecture, which described 90 species connected by 162 interactions, was formulated by aggregating disparate molecular modules from literature. Unlike previous models, only mass action kinetics were used to describe the rate of molecular interactions. Thus, the majority of the 252 unknown model parameters were either association, dissociation or catalytic rate constants. Model parameters were estimated from nine independent data sets taken from multiple laboratories. The training data consisted of both dynamic and steady-state measurements. However, because of the complexity of the calcium network, we were unable to estimate unique model parameters. Instead, we estimated a family or ensemble of probable parameter sets using a multi-objective thermal ensemble method. Each member of the ensemble met an error criterion and was located along or near the optimal trade-off surface between the individual training data sets. The model quantitatively reproduced experimental measurements from dorsal root ganglion neurons as a function of extracellular ATP forcing. Hypothesized architecture linking phosphoinositide regulation with P2X receptor activity explained the inhibition of P2X-mediated current flow by activated metabotropic P2Y receptors. Sensitivity analysis using individual and the whole system outputs suggested which molecular subsystems were most important following P2 activation. Taken together, modeling and analysis of ATP-induced P2 mediated calcium signaling generated qualitative insight into the critical interactions controlling ATP induced calcium dynamics. Understanding these critical interactions may prove useful for the design of the next generation of molecular pain management strategies.			Song, SO (corresponding author), Cornell Univ, Sch Chem & Biomol Engn, Ithaca, NY 14853 USA.	jdv27@cornell.edu						ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Battogtokh D, 2002, P NATL ACAD SCI USA, V99, P16904, DOI 10.1073/pnas.262658899; BEMIER LP, 2008, MOL PHARM, V74, P785; Bernier LP, 2008, J NEUROSCI, V28, P12938, DOI 10.1523/JNEUROSCI.3038-08.2008; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Blaustein MP, 2002, ANN NY ACAD SCI, V976, P356; Brown KS, 2004, PHYS BIOL, V1, P184, DOI 10.1088/1478-3967/1/3/006; Brown KS, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.021904; Burgoyne RD, 2007, NAT REV NEUROSCI, V8, P182, DOI 10.1038/nrn2093; Burnstock G, 2006, TRENDS PHARMACOL SCI, V27, P166, DOI 10.1016/j.tips.2006.01.005; Burnstock G, 2000, BRIT J ANAESTH, V84, P476, DOI 10.1093/oxfordjournals.bja.a013473; Burnstock G, 1996, CURR OPIN NEUROBIOL, V6, P526, DOI 10.1016/S0959-4388(96)80060-2; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Cesare P, 1997, CURR OPIN NEUROBIOL, V7, P493, DOI 10.1016/S0959-4388(97)80028-1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chen WW, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.74; Chen Y, 2008, P NATL ACAD SCI USA, V105, P16773, DOI 10.1073/pnas.0801793105; Chizh BA, 2001, PHARMACOL REV, V53, P553; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Cook SP, 1997, NEUROPHARMACOLOGY, V36, P1303, DOI 10.1016/S0028-3908(97)00132-9; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; DICKINSON RP, 1976, J COMPUT PHYS, V21, P123, DOI 10.1016/0021-9991(76)90007-3; Ding YN, 2000, J AUTONOM NERV SYST, V81, P289, DOI 10.1016/S0165-1838(00)00131-4; Doi T, 2005, J NEUROSCI, V25, P950, DOI 10.1523/JNEUROSCI.2727-04.2005; Fedirko N, 2004, NEUROPHYSIOLOGY+, V36, P169, DOI 10.1023/B:NEPH.0000048339.09774.09; FONSECA CM, 1993, P INT C GEN ALG, V5, P416; Fujiwara Y, 2006, J PHYSIOL-LONDON, V576, P135, DOI 10.1113/jphysiol.2006.115246; Gadkar KG, 2005, SYSTEMS BIOL, V2, P17, DOI 10.1049/sb:20045029; GEREVICH PI, 2005, EUR J PHARM, V521; Gerevich Z, 2007, BRIT J PHARMACOL, V151, P226, DOI 10.1038/sj.bjp.0707217; Gerevich Zoltan, 2004, Purinergic Signal, V1, P3, DOI 10.1007/s11302-004-4740-9; Gover TD, 2003, J NEUROSCI, V23, P4793; HAGENACKER T, 2007, CELL CALCIUM; Hamilton Sara G, 2002, Pain Pract, V2, P289, DOI 10.1046/j.1533-2500.2002.02041.x; He ML, 2003, AM J PHYSIOL-CELL PH, V285, pC467, DOI 10.1152/ajpcell.00042.2003; HEARNE JW, 1985, APPL MATH MODEL, V9, P106, DOI 10.1016/0307-904X(85)90121-0; Hilliges M, 2002, PAIN, V98, P59, DOI 10.1016/S0304-3959(01)00469-9; Inoue K, 2003, DRUG DEVELOP RES, V59, P56, DOI 10.1002/ddr.10201; Iwamoto T, 2004, J PHARMACOL SCI, V96, P27, DOI 10.1254/jphs.FMJ04002X6; Jennings EA, 2007, DRUG DEVELOP RES, V68, P321, DOI 10.1002/ddr.20195; Kennedy C, 2005, NEUROSCIENTIST, V11, P345, DOI 10.1177/1073858404274063; Koizumi S, 2004, BIOCHEM J, V380, P329, DOI 10.1042/BJ20031089; KOLEN HS, 2006, PURINERG SIGNAL, V2, P451; Kress M, 1999, J NEUROPHYSIOL, V81, P2612, DOI 10.1152/jn.1999.81.6.2612; Kurnellas MP, 2004, FASEB J, V18, P298, DOI 10.1096/fj.04-2549fje; Lakshmi S, 2005, CELL MOL NEUROBIOL, V25, P819, DOI 10.1007/s10571-005-4936-8; Lehotsky J, 2002, FRONT BIOSCI-LANDMRK, V7, pD53, DOI 10.2741/lehotsky; Lemon G, 2003, J THEOR BIOL, V223, P93, DOI 10.1016/S0022-5193(03)00079-1; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; Luan D, 2007, PLOS COMPUT BIOL, V3, P1347, DOI 10.1371/journal.pcbi.0030142; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Mahdavi A, 2007, PLOS COMPUT BIOL, V3, P1257, DOI 10.1371/journal.pcbi.0030130; Maurya MR, 2007, BIOPHYS J, V93, P709, DOI 10.1529/biophysj.106.097469; Mishra J, 2002, BIOPHYS J, V83, P1298, DOI 10.1016/S0006-3495(02)73901-5; Molliver DC, 2002, EUR J NEUROSCI, V16, P1850, DOI 10.1046/j.1460-9568.2002.02253.x; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Nakayama S, 2004, FASEB J, V18, P1562, DOI 10.1096/fj.04-1933fje; Nathanson NM, 2008, PHARMACOL THERAPEUT, V119, P33, DOI 10.1016/j.pharmthera.2008.04.006; Nayak S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002016; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; North RA, 2004, J PHYSIOL-LONDON, V554, P301, DOI 10.1113/jphysiol.2003.048587; Okuse K, 2007, INT J BIOCHEM CELL B, V39, P490, DOI 10.1016/j.biocel.2006.11.016; Paukert M, 2001, J BIOL CHEM, V276, P21077, DOI 10.1074/jbc.M101465200; Pelled D, 2003, J BIOL CHEM, V278, P29496, DOI 10.1074/jbc.M302964200; Prestwich GD, 2004, CHEM BIOL, V11, P619, DOI 10.1016/j.chembiol.2004.03.025; Purvis JE, 2008, BLOOD, V112, P4069, DOI 10.1182/blood-2008-05-157883; Purvis JE, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000298; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ruan HZ, 2005, J HISTOCHEM CYTOCHEM, V53, P1273, DOI 10.1369/jhc.4A6556.2005; Ruan HZ, 2003, HISTOCHEM CELL BIOL, V120, P415, DOI 10.1007/s00418-003-0579-3; Sanada M, 2002, NEUROSCIENCE, V111, P413, DOI 10.1016/S0306-4522(02)00005-2; Schuh K, 2004, J BIOL CHEM, V279, P28220, DOI 10.1074/jbc.M312599200; Sneyd J, 2004, PROG BIOPHYS MOL BIO, V85, P121, DOI 10.1016/j.pbiomolbio.2004.01.013; Sneyd J, 2002, P NATL ACAD SCI USA, V99, P2398, DOI 10.1073/pnas.032281999; Sokolova E, 2006, MOL PHARMACOL, V70, P373, DOI 10.1124/mol.106.023564; Stelling J, 2004, P NATL ACAD SCI USA, V101, P13210, DOI 10.1073/pnas.0401463101; Stucky CL, 2004, PAIN, V109, P36, DOI 10.1016/j.pain.2004.01.007; Suh BC, 2008, ANNU REV BIOPHYS, V37, P175, DOI 10.1146/annurev.biophys.37.032807.125859; Tang YH, 1996, BIOPHYS J, V70, P246, DOI 10.1016/S0006-3495(96)79567-X; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; Tsuda M, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0007.2000; Vial C, 2002, BRIT J PHARMACOL, V135, P363, DOI 10.1038/sj.bjp.0704486; WATRAS J, 1991, J NEUROSCI, V11, P3239; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Zhao Q, 2007, CHANNELS, V1, P46; Zhao Q, 2007, PFLUG ARCH EUR J PHY, V455, P181, DOI 10.1007/s00424-007-0271-x	97	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6758	10.1371/journal.pone.0006758	http://dx.doi.org/10.1371/journal.pone.0006758			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750220	Green Published, gold			2022-12-27	WOS:000269696600001
J	Baltzer, C; Tiefenbock, SK; Marti, M; Frei, C				Baltzer, Claudia; Tiefenboeck, Stefanie K.; Marti, Mark; Frei, Christian			Nutrition Controls Mitochondrial Biogenesis in the Drosophila Adipose Tissue through Delg and Cyclin D/Cdk4	PLOS ONE			English	Article								Mitochondria are cellular organelles that perform critical metabolic functions: they generate energy from nutrients but also provide metabolites for de novo synthesis of fatty acids and several amino acids. Thus mitochondrial mass and activity must be coordinated with nutrient availability, yet this remains poorly understood. Here, we demonstrate that Drosophila larvae grown in low yeast food have strong defects in mitochondrial abundance and respiration activity in the larval fat body. This correlates with reduced expression of genes encoding mitochondrial proteins, particularly genes involved in oxidative phosphorylation. Second, genes involved in glutamine metabolism are also expressed in a nutrient-dependent manner, suggesting a coordination of amino acid synthesis with mitochondrial abundance and activity. Moreover, we show that Delg (CG6338), the Drosophila homologue to the alpha subunit of mammalian transcription factor NRF-2/GABP, is required for proper expression of most genes encoding mitochondrial proteins. Our data demonstrate that Delg is critical to adjust mitochondrial abundance in respect to Cyclin D/Cdk4, a growth-promoting complex and glutamine metabolism according to nutrient availability. However, in contrast to nutrients, Delg is not involved in the regulation of mitochondrial activity in the fat body. These findings are the first genetic evidence that the regulation of mitochondrial mass can be uncoupled from mitochondrial activity.			Baltzer, C (corresponding author), ETH, Dept Biol, Zurich, Switzerland.	Christian.frei@cell.biol.ethz.ch						Arbeitman MN, 2002, SCIENCE, V297, P2270, DOI 10.1126/science.1072152; Baker KD, 2007, CELL METAB, V6, P257, DOI 10.1016/j.cmet.2007.09.002; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Blesa JR, 2007, GENE, V391, P198, DOI 10.1016/j.gene.2006.12.024; Blesa JR, 2006, BIOCHEM CELL BIOL, V84, P813, DOI 10.1139/O06-064; Blesa JR, 2004, MITOCHONDRION, V3, P251, DOI 10.1016/j.mito.2004.02.001; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Candy DJ, 1997, COMP BIOCHEM PHYS B, V117, P497, DOI 10.1016/S0305-0491(97)00212-5; CARTER RS, 1992, J BIOL CHEM, V267, P23418; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Datar SA, 2006, CELL CYCLE, V5, P647; de la Cova C, 2006, SEMIN CANCER BIOL, V16, P303, DOI 10.1016/j.semcancer.2006.07.010; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Emmerich J, 2004, GENETICS, V168, P867, DOI 10.1534/genetics.104.027417; Frei C, 2005, EMBO J, V24, P623, DOI 10.1038/sj.emboj.7600523; GAJEWSKI KM, 1995, ONCOGENE, V11, P1033; Gershman B, 2007, PHYSIOL GENOMICS, V29, P24, DOI 10.1152/physiolgenomics.00061.2006; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; GREWAL SS, 2008, INT J BIOCH CELL BIO; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Guo XF, 2005, NEURON, V47, P379, DOI 10.1016/j.neuron.2005.06.027; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Koushika SP, 1999, MOL CELL BIOL, V19, P3998; Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Martinez-Diez M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000107; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Ongwijitwat S, 2005, GENE, V360, P65, DOI 10.1016/j.gene.2005.06.015; Ongwijitwat S, 2004, GENE, V337, P163, DOI 10.1016/j.gene.2004.04.024; Ongwijitwat S, 2006, GENE, V374, P39, DOI 10.1016/j.gene.2006.01.009; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; Puig O, 2006, CELL CYCLE, V5, P503, DOI 10.4161/cc.5.5.2501; Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Schieke SM, 2008, CELL CYCLE, V7, P1782, DOI 10.4161/cc.7.12.6067; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; SCHULZ RA, 1993, ONCOGENE, V8, P3369; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Teleman AA, 2008, CELL METAB, V7, P21, DOI 10.1016/j.cmet.2007.11.010; THE SM, 1992, ONCOGENE, V7, P2471; Villena JA, 1998, BIOCHEM J, V331, P121, DOI 10.1042/bj3310121; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Yang ZF, 2007, NAT CELL BIOL, V9, P339, DOI 10.1038/ncb1548; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600	59	36	36	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6935	10.1371/journal.pone.0006935	http://dx.doi.org/10.1371/journal.pone.0006935			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742324	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622500013
J	Liu, YZ; Pei, YF; Liu, JF; Yang, F; Guo, Y; Zhang, L; Liu, XG; Yan, H; Wang, L; Zhang, YP; Levy, S; Recker, RR; Deng, HW				Liu, Yao-Zhong; Pei, Yu-Fang; Liu, Jian-Feng; Yang, Fang; Guo, Yan; Zhang, Lei; Liu, Xiao-Gang; Yan, Han; Wang, Liang; Zhang, Yin-Ping; Levy, Shawn; Recker, Robert R.; Deng, Hong-Wen			Powerful Bivariate Genome-Wide Association Analyses Suggest the SOX6 Gene Influencing Both Obesity and Osteoporosis Phenotypes in Males	PLOS ONE			English	Article								Background: Current genome-wide association studies (GWAS) are normally implemented in a univariate framework and analyze different phenotypes in isolation. This univariate approach ignores the potential genetic correlation between important disease traits. Hence this approach is difficult to detect pleiotropic genes, which may exist for obesity and osteoporosis, two common diseases of major public health importance that are closely correlated genetically. Principal Findings: To identify such pleiotropic genes and the key mechanistic links between the two diseases, we here performed the first bivariate GWAS of obesity and osteoporosis. We searched for genes underlying co-variation of the obesity phenotype, body mass index (BMI), with the osteoporosis risk phenotype, hip bone mineral density (BMD), scanning similar to 380,000 SNPs in 1,000 unrelated homogeneous Caucasians, including 499 males and 501 females. We identified in the male subjects two SNPs in intron 1 of the SOX6 (SRY-box 6) gene, rs297325 and rs4756846, which were bivariately associated with both BMI and hip BMD, achieving p values of 6.82x10(-7) and 1.47x10(-6), respectively. The two SNPs ranked at the top in significance for bivariate association with BMI and hip BMD in the male subjects among all the similar to 380,000 SNPs examined genome-wide. The two SNPs were replicated in a Framingham Heart Study (FHS) cohort containing 3,355 Caucasians (1,370 males and 1,985 females) from 975 families. In the FHS male subjects, the two SNPs achieved p values of 0.03 and 0.02, respectively, for bivariate association with BMI and femoral neck BMD. Interestingly, SOX6 was previously found to be essential to both cartilage formation/chondrogenesis and obesity-related insulin resistance, suggesting the gene's dual role in both bone and fat. Conclusions: Our findings, together with the prior biological evidence, suggest the SOX6 gene's importance in coregulation of obesity and osteoporosis.			Liu, YZ (corresponding author), Univ Missouri, Sch Med, Kansas City, MO 64108 USA.	dengh@umkc.edu	Liu, Yaozhong/ABD-5544-2020; Guo, Yan/G-8742-2014	Guo, Yan/0000-0002-7364-2392; Liu, Jian-Feng/0000-0002-5766-7864; Deng, Hong-Wen/0000-0002-0387-8818; Levy, Shawn/0000-0002-1369-5740	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050496, P50AR055081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG027110, R01AG026564] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR050496-01, P50 AR055081, R01 AR050496] Funding Source: Medline; NIA NIH HHS [R01 AG026564, R21 AG027110] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison DB, 2000, MED CLIN N AM, V84, P305, DOI 10.1016/S0025-7125(05)70223-6; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cohen-Barak G, 2001, GENE, V265, P157, DOI 10.1016/S0378-1119(01)00346-8; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Deng FY, 2006, OSTEOPOROSIS INT, V17, P119, DOI 10.1007/s00198-005-1930-4; Deng HW, 2002, AM J HUM GENET, V70, P1138, DOI 10.1086/339934; Di XJ, 2005, BIOINFORMATICS, V21, P1958, DOI 10.1093/bioinformatics/bti275; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Farber CR, 2007, MAMM GENOME, V18, P635, DOI 10.1007/s00335-007-9046-0; Fawcett GL, 2008, OBESITY, V16, P1861, DOI 10.1038/oby.2008.300; FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507; Fisher R.A., 1948, AM STAT, V2, P30, DOI DOI 10.2307/2681650; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Freimer N, 2004, NAT GENET, V36, P1045, DOI 10.1038/ng1433; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; Iguchi H, 2005, J BIOL CHEM, V280, P37669, DOI 10.1074/jbc.M505392200; Iguchi H, 2007, J BIOL CHEM, V282, P19052, DOI 10.1074/jbc.M700460200; Ioannidis JPA, 2007, J BONE MINER RES, V22, P173, DOI 10.1359/JBMR.060806; Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894; Khaodhiar L, 1999, Clin Cornerstone, V2, P17, DOI 10.1016/S1098-3597(99)90002-9; Korner A, 2007, INT J OBESITY, V31, P353, DOI 10.1038/sj.ijo.0803428; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983; Lewis CE, 2005, INT J OBESITY, V29, P639, DOI 10.1038/sj.ijo.0802916; Liu JF, 2009, GENET EPIDEMIOL, V33, P217, DOI 10.1002/gepi.20372; Ma LJ, 2005, DIABETES, V54, P1598, DOI 10.2337/diabetes.54.5.1598; MARCUS R, 1994, J BONE MINER RES, V9, P1467, DOI 10.1002/jbmr.5650090920; Melton LJ, 2003, J BONE MINER RES, V18, P1139, DOI 10.1359/jbmr.2003.18.6.1139; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Ober C, 2006, CURR ALLERGY ASTHM R, V6, P241, DOI 10.1007/s11882-006-0041-4; PEI YF, 2009, ANN HUM GENET; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2000, GENETICS, V155, P945; Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741; Ravn P, 1999, J BONE MINER RES, V14, P1622, DOI 10.1359/jbmr.1999.14.9.1622; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Schousboe K, 2003, TWIN RES, V6, P409, DOI 10.1375/twin.6.5.409; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tang ZH, 2007, J CLIN ENDOCR METAB, V92, P2751, DOI 10.1210/jc.2006-2607; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x; XIAO P, 2006, J BONE MINE IN PRESS; XIONG DH, 2006, J BONE MINE IN PRESS; Zhao LJ, 2007, J CLIN ENDOCR METAB, V92, P1640, DOI 10.1210/jc.2006-0572	49	80	90	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6827	10.1371/journal.pone.0006827	http://dx.doi.org/10.1371/journal.pone.0006827			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714249	Green Submitted, gold, Green Published			2022-12-27	WOS:000269415800011
J	Sivapalasingam, S; Wangechi, B; Marshed, F; Laverty, M; Essajee, S; Holzman, RS; Valentine, F				Sivapalasingam, Sumathi; Wangechi, Beatrice; Marshed, Fatuma; Laverty, Maura; Essajee, Shaffiq; Holzman, Robert S.; Valentine, Fred			Monitoring Virologic Responses to Antiretroviral Therapy in HIV-Infected Adults in Kenya: Evaluation of a Low-Cost Viral Load Assay	PLOS ONE			English	Article							RESOURCE-LIMITED SETTINGS; FIXED-DOSE COMBINATION; CD4 CELL COUNT; ADHERENCE; FAILURE; STRATEGIES; OUTCOMES; SUPPRESSION; PREDICTORS; RESISTANCE	Background: A key advantage of monitoring HIV viral load (VL) in persons receiving antiretroviral therapy (ART) is the ability to detect virologic failure before clinical deterioration or resistance occurs. Detection of virologic failure will help clarify the need for enhanced adherence counseling or a change to second-line therapy. Low-cost, locally performable alternates to expensive VL assays are needed where resources are limited. Methodology/Principal Findings: We monitored the response to 48-week ART in 100 treatment-naive Kenyan adults using a low-cost VL measurement, the Cavidi reverse transcriptase (RT) assay and gold-standard assays, Roche RNA PCR and Bayer Versant HIV-1 RNA (bDNA) assays. In Altman-Bland plots, the mean difference in viral loads between the three assays was small (< 0.5 log(10) copies/mL). However, the limits of agreement between the methods exceeded the biologically relevant change of 0.5 log copies/ml. Therefore, the RT assay cannot be used interchangeably with the other assays to monitor individual patients. The RT assay was 100% sensitive in detecting viral loads of >= 400 copies/ml compared to gold-standard assays. After 24 weeks of treatment, viral load measured by the RT assay was undetectable in 95% of 65 patients with undetectable RNA PCR VL (< 400 copies/ml), 90% of 67 patients with undetectable bDNA VL, and 96% of 57 patients with undetectable VL in both RNA PCR and bDNA assays. The negative predictive value of the RT assay was 100% compared to either assay; the positive predictive value was 86% compared to RNA PCR and 70% compared to bDNA. Conclusion: The RT assay compared well with gold standard assays. Our study highlights the importance of not interchanging viral load assays when monitoring an individual patient. Furthermore, the RT assay may be limited by low positive predictive values when used in populations with low prevalence of virologic failure.			Sivapalasingam, S (corresponding author), NYU, Sch Med, Dept Med, Div Infect Dis, New York, NY 10016 USA.	Sumathi.sivapalasingam@gmail.com		Valentine, Fred/0000-0002-6046-5913	NIAID NIH HHS [3 P30 AI27742-15S2, P30 AI027742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bendavid E, 2008, ARCH INTERN MED, V168, P1910, DOI 10.1001/archinternmed.2008.1; Bishai D, 2007, AIDS, V21, P1333, DOI 10.1097/QAD.0b013e328137709e; Bisson GP, 2006, AIDS, V20, P1613, DOI 10.1097/01.aids.0000238407.00874.dc; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979; Elbeik T, 2000, J CLIN MICROBIOL, V38, P1113, DOI 10.1128/JCM.38.3.1113-1120.2000; Erali M, 1999, J CLIN MICROBIOL, V37, P792, DOI 10.1128/JCM.37.3.792-795.1999; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Ferradini L, 2007, AIDS, V21, P2293, DOI 10.1097/QAD.0b013e32828cc8b7; Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417; Greengrass VL, 2005, CURR HIV RES, V3, P183, DOI 10.2174/1570162053506955; Holguin A, 1999, EUR J CLIN MICROBIOL, V18, P256, DOI 10.1007/s100960050273; Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e; Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005; Kamya MR, 2007, JAIDS-J ACQ IMM DEF, V46, P187, DOI 10.1097/QAI.0b013e31814278c0; Laurent C, 2004, LANCET, V364, P29, DOI 10.1016/S0140-6736(04)16586-0; Lawn SD, 2008, LANCET, V372, P287, DOI 10.1016/S0140-6736(08)61101-0; Mine M, 2009, J VIROL METHODS, V159, P93, DOI 10.1016/j.jviromet.2009.03.008; Moore DM, 2006, JAIDS-J ACQ IMM DEF, V43, P436, DOI 10.1097/01.qai.0000243105.80393.42; Nieuwkerk PT, 2005, JAIDS-J ACQ IMM DEF, V38, P445, DOI 10.1097/01.qai.0000147522.34369.12; Orrell C, 2007, ANTIVIR THER, V12, P83; Phillips AN, 2008, LANCET, V371, P1443, DOI 10.1016/S0140-6736(08)60624-8; Ramadhani HO, 2007, CLIN INFECT DIS, V45, P1492, DOI 10.1086/522991; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Shah B, 2007, CLIN INFECT DIS, V44, P1235, DOI 10.1086/513429; Sivapalasingam S, 2005, J CLIN MICROBIOL, V43, P3793, DOI 10.1128/JCM.43.8.3793-3796.2005; Spacek LA, 2006, CLIN INFECT DIS, V42, P252, DOI 10.1086/499044; Steegen K, 2007, J VIROL METHODS, V146, P178, DOI 10.1016/j.jviromet.2007.06.019; Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745; Vijayaraghavan A, 2007, JAIDS-J ACQ IMM DEF, V46, P91; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; Wilson D, 2009, T ROY SOC TROP MED H, V103, P601, DOI 10.1016/j.trstmh.2008.11.007; World Health Organization, 2008, UN ACC SCAL PRIOR HI; World Health Organization, 2006, ANT THER HIV INF AD	37	18	18	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6828	10.1371/journal.pone.0006828	http://dx.doi.org/10.1371/journal.pone.0006828			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714253	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415800012
J	Montesinos, A; Tonsor, SJ; Alonso-Blanco, C; Pico, FX				Montesinos, Alicia; Tonsor, Stephen J.; Alonso-Blanco, Carlos; Xavier Pico, F.			Demographic and Genetic Patterns of Variation among Populations of Arabidopsis thaliana from Contrasting Native Environments	PLOS ONE			English	Article							EVOLUTIONARY ECOLOGY; NATURAL-POPULATIONS; GERMINATION; PLANT; RESPONSES; SELECTION; TRAIT; CONSEQUENCES; BIOGEOGRAPHY; ADAPTATION	Background: Understanding the relationship between environment and genetics requires the integration of knowledge on the demographic behavior of natural populations. However, the demographic performance and genetic composition of Arabidopsis thaliana populations in the species' native environments remain largely uncharacterized. This information, in combination with the advances on the study of gene function, will improve our understanding on the genetic mechanisms underlying adaptive evolution in A. thaliana. Methodology/Principal Findings: We report the extent of environmental, demographic, and genetic variation among 10 A. thaliana populations from Mediterranean (coastal) and Pyrenean (montane) native environments in northeast Spain. Geographic, climatic, landscape, and soil data were compared. Demographic traits, including the dynamics of the soil seed bank and the attributes of aboveground individuals followed over a complete season, were also analyzed. Genetic data based on genome-wide SNP markers were used to describe genetic diversity, differentiation, and structure. Coastal and montane populations significantly differed in terms of environmental, demographic, and genetic characteristics. Montane populations, at higher altitude and farther from the sea, are exposed to colder winters and prolonged spring moisture compared to coastal populations. Montane populations showed stronger secondary seed dormancy, higher seedling/juvenile mortality in winter, and initiated flowering later than coastal populations. Montane and coastal regions were genetically differentiated, montane populations bearing lower genetic diversity than coastal ones. No significant isolation-by-distance pattern and no shared multilocus genotypes among populations were detected. Conclusions/Significance: Between-region variation in climatic patterns can account for differences in demographic traits, such as secondary seed dormancy, plant mortality, and recruitment, between coastal and montane A. thaliana populations. In addition, differences in plant mortality can partly account for differences in the genetic composition of coastal and montane populations. This study shows how the interplay between variation in environmental, demographic, and genetic parameters may operate in natural A. thaliana populations.	[Montesinos, Alicia; Xavier Pico, F.] CSIC, Estn Biol Donana EBD, Dept Ecol Integrat, E-41080 Seville, Spain; [Montesinos, Alicia; Tonsor, Stephen J.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Alonso-Blanco, Carlos] CSIC, Ctr Nacl Biol CNB, Dept Genet Mol Plantas, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Consejo Superior de Investigaciones Cientificas (CSIC)	Pico, FX (corresponding author), CSIC, Estn Biol Donana EBD, Dept Ecol Integrat, E-41080 Seville, Spain.	xpico@ebd.csic.es	Pico, Xavier/E-5697-2016; Navarro, Alicia Montesinos/K-6707-2012; Alonso-Blanco, Carlos/F-8864-2016	Pico, Xavier/0000-0003-2849-4922; Navarro, Alicia Montesinos/0000-0003-4656-0321; Alonso-Blanco, Carlos/0000-0002-4738-5556				Alonso-Blanco C, 2005, INT J DEV BIOL, V49, P717, DOI 10.1387/ijdb.051994ca; ARANY AM, 2005, PLANT BIOLOGY, V7, P1; Arany AM, 2009, PLANT ECOL, V201, P651, DOI 10.1007/s11258-008-9530-y; Archibold O.W., 1995, ECOLOGY WORLD VEGETA, VDordrecht; Ausin I, 2005, INT J DEV BIOL, V49, P689, DOI 10.1387/ijdb.052022ia; Bakker EG, 2006, MOL ECOL, V15, P1405, DOI 10.1111/j.1365-294X.2006.02884.x; Banta JA, 2007, EVOLUTION, V61, P2419, DOI 10.1111/j.1558-5646.2007.00189.x; BASKIN JM, 1983, BOT GAZ, V144, P540, DOI 10.1086/337408; BASKIN JM, 1972, CAN J BOTANY, V50, P353, DOI 10.1139/b72-049; Beck JB, 2008, MOL ECOL, V17, P902, DOI 10.1111/j.1365-294X.2007.03615.x; BERNATZKY R, 1986, THEOR APPL GENET, V72, P314, DOI 10.1007/BF00288567; CASTROVIEJO S, 1989, FLORA IBERICA PLANTA, V4; COHEN D, 1966, J THEOR BIOL, V12, P119, DOI 10.1016/0022-5193(66)90188-3; Corbesier L, 2005, PLANT CELL ENVIRON, V28, P54, DOI 10.1111/j.1365-3040.2005.01283.x; Donohue K, 2005, EVOLUTION, V59, P758, DOI 10.1111/j.0014-3820.2005.tb01751.x; Donohue K, 2005, EVOLUTION, V59, P771, DOI 10.1111/j.0014-3820.2005.tb01752.x; Donohue K, 2005, EVOLUTION, V59, P740, DOI 10.1111/j.0014-3820.2005.tb01752.x; Donohue K, 2002, ECOLOGY, V83, P1006, DOI 10.1890/0012-9658(2002)083[1006:GTINSO]2.0.CO;2; Ehrlen J, 2009, AM NAT, V173, P819, DOI 10.1086/598492; ELLSTRAND NC, 1993, ANNU REV ECOL SYST, V24, P217, DOI 10.1146/annurev.es.24.110193.001245; EXCOFFIER L, 1992, GENETICS, V131, P479; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Feder ME, 2003, NAT REV GENET, V4, P651, DOI 10.1038/nrg1128; Finch-Savage WE, 2006, NEW PHYTOL, V171, P501, DOI 10.1111/j.1469-8137.2006.01787.x; Francois O, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000075; Gomez JM, 2000, AM NAT, V155, P657, DOI 10.1086/303353; Goudet J, 1995, J HERED, V86, P485, DOI 10.1093/oxfordjournals.jhered.a111627; Griffith C, 2004, AM J BOT, V91, P837, DOI 10.3732/ajb.91.6.837; Herrera CM, 2000, ECOLOGY, V81, P3036, DOI 10.1890/0012-9658(2000)081[3036:IDIPVI]2.0.CO;2; Hoffmann MH, 2005, EVOLUTION, V59, P1425; Hoffmann MH, 2002, J BIOGEOGR, V29, P125, DOI 10.1046/j.1365-2699.2002.00647.x; Hutchings Michael J., 1997, P325; Jensen JL, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-13; Kalinowski ST, 2005, MOL ECOL NOTES, V5, P187, DOI 10.1111/j.1471-8286.2004.00845.x; KALISZ S, 1992, ECOLOGY, V73, P1082, DOI 10.2307/1940182; Karrenberg S, 2008, CURR OPIN PLANT BIOL, V11, P156, DOI 10.1016/j.pbi.2008.01.004; Lawton-Rauh A, 2008, CURR OPIN PLANT BIOL, V11, P103, DOI 10.1016/j.pbi.2008.02.009; Le Corre V, 2005, MOL ECOL, V14, P4181, DOI 10.1111/j.1365-294X.2005.02722.x; MANTEL N, 1967, CANCER RES, V27, P209; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Metcalf CJE, 2007, TRENDS ECOL EVOL, V22, P205, DOI 10.1016/j.tree.2006.12.001; Mitchell-Olds T, 2008, HEREDITY, V100, P101, DOI 10.1038/sj.hdy.6801015; Mitchell-Olds T, 2006, NATURE, V441, P947, DOI 10.1038/nature04878; Nordborg M, 2005, PLOS BIOL, V3, P1289, DOI 10.1371/journal.pbio.0030196; Ostrowski MF, 2006, MOL ECOL, V15, P1507, DOI 10.1111/j.1365-294X.2006.02865.x; Pico FX, 2008, PLANT BIOLOGY, V10, P374, DOI 10.1111/j.1438-8677.2008.00044.x; Pico FX, 2008, GENETICS, V180, P1009, DOI 10.1534/genetics.108.089581; Pigliucci M, 2003, AM NAT, V161, P68, DOI 10.1086/345460; Schmid K, 2006, THEOR APPL GENET, V112, P1104, DOI 10.1007/s00122-006-0212-7; Sharbel TF, 2000, MOL ECOL, V9, P2109, DOI 10.1046/j.1365-294X.2000.01122.x; SLATKIN M, 1995, GENETICS, V139, P457; Stenoien HK, 2005, MOL ECOL, V14, P137, DOI 10.1111/j.1365-294X.2004.02359.x; Stinchcombe JR, 2008, HEREDITY, V100, P158, DOI 10.1038/sj.hdy.6800937; Tonsor SJ, 2008, MOL ECOL, V17, P1614, DOI 10.1111/j.1365-294X.2008.03690.x; Tonsor SJ, 2005, PLANT CELL ENVIRON, V28, P2, DOI 10.1111/j.1365-3040.2004.01264.x; Tonsor SJ, 2007, AM NAT, V169, pE119, DOI 10.1086/513493; Venable DL, 2007, ECOLOGY, V88, P1086, DOI 10.1890/06-1495; Vergeer P, 2003, J ECOL, V91, P18, DOI 10.1046/j.1365-2745.2003.00736.x; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x; WESTERMAN JM, 1970, HEREDITY, V25, P609, DOI 10.1038/hdy.1970.66; Wilczek AM, 2009, SCIENCE, V323, P930, DOI 10.1126/science.1165826; Woodward F.I., 1987, CLIMATE PLANT DISTRI; Zhao KY, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030004	63	66	66	0	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7213	10.1371/journal.pone.0007213	http://dx.doi.org/10.1371/journal.pone.0007213			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787050	gold, Green Accepted, Green Published, Green Submitted			2022-12-27	WOS:000270290100015
J	Hauge, B; Oggero, C; Nguyen, N; Fu, CL; Dong, FG				Hauge, Brian; Oggero, Christopher; Nguyen, Nicole; Fu, Changlin; Dong, Fenggao			Single Tube, High Throughput Cloning of Inverted Repeat Constructs for Double-Stranded RNA Expression	PLOS ONE			English	Article							LIGATION-INDEPENDENT CLONING; TRANSCRIPTIONAL INTERFERENCE; PCR PRODUCTS; DNA; EFFICIENT; VECTORS; PRIMERS	Background: RNA interference (RNAi) has emerged as a powerful tool for the targeted knockout of genes for functional genomics, system biology studies and drug discovery applications. To meet the requirements for high throughput screening in plants we have developed a new method for the rapid assembly of inverted repeat-containing constructs for the in vivo production of dsRNAs. Methodology/Principal Findings: The procedure that we describe is based on tagging the sense and antisense fragments with unique single-stranded (ss) tails which are then assembled in a single tube Ligase Independent Cloning (LIC) reaction. Since the assembly reaction is based on the annealing of unique complementary single stranded tails which can only assemble in one orientation, greater than ninety percent of the resultant clones contain the desired insert. Conclusion/Significance: Our single-tube reaction provides a highly efficient method for the assembly of inverted repeat constructs for gene suppression applications. The single tube assembly is directional, highly efficient and readily adapted for high throughput applications.			Hauge, B (corresponding author), Biotechnol Monsanto Co, St Louis, MO USA.	Brian.hauge@monsanto.com						ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; AUSUBEL FM, 2007, CURRENT PROTOCOLS MO; Bao S, 2006, RNA, V12, P2020, DOI 10.1261/rna.258406; Callen BP, 2004, MOL CELL, V14, P647, DOI 10.1016/j.molcel.2004.05.010; Coljee VW, 2000, NAT BIOTECHNOL, V18, P789, DOI 10.1038/77363; Donahue WF, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf094; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gal J, 1999, MOL GEN GENET, V260, P569, DOI 10.1007/s004380050930; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; Helliwell CA, 2002, FUNCT PLANT BIOL, V29, P1217, DOI 10.1071/FP02033; HUNT HD, 1989, GENE, V77, P51; LEACH DRF, 1983, NATURE, V305, P448, DOI 10.1038/305448a0; LEE I, 1997, Patent No. 9708185; Li CA, 1997, NUCLEIC ACIDS RES, V25, P4165, DOI 10.1093/nar/25.20.4165; NEWTON CR, 1993, NUCLEIC ACIDS RES, V21, P1155, DOI 10.1093/nar/21.5.1155; Pawloski LC, 2005, PLANT CELL PHYSIOL, V46, P1872, DOI 10.1093/pcp/pci191; RASHTCHIAN A, 1992, ANAL BIOCHEM, V206, P91, DOI 10.1016/S0003-2697(05)80015-6; Seyhan AA, 2005, RNA, V11, P837, DOI 10.1261/rna.7285805; Shearwin KE, 2005, TRENDS GENET, V21, P339, DOI 10.1016/j.tig.2005.04.009; WALLACE RB, 1995, Patent No. 5426039; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880; Yan H, 2006, PLANT PHYSIOL, V141, P1508, DOI 10.1104/pp.106.082271	23	4	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7205	10.1371/journal.pone.0007205	http://dx.doi.org/10.1371/journal.pone.0007205			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784365	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290000012
J	Kapogiannis, D; Barbey, AK; Su, M; Krueger, F; Grafman, J				Kapogiannis, Dimitrios; Barbey, Aron K.; Su, Michael; Krueger, Frank; Grafman, Jordan			Neuroanatomical Variability of Religiosity	PLOS ONE			English	Article							VOXEL-BASED MORPHOMETRY; ANTISOCIAL-BEHAVIOR; MENTAL-HEALTH; NEURAL BASIS; CORTEX; MATTER; RELIGIOUSNESS; THICKNESS; MEMORY; BRAIN	We hypothesized that religiosity, a set of traits variably expressed in the population, is modulated by neuroanatomical variability. We tested this idea by determining whether aspects of religiosity were predicted by variability in regional cortical volume. We performed structural magnetic resonance imaging of the brain in 40 healthy adult participants who reported different degrees and patterns of religiosity on a survey. We identified four Principal Components of religiosity by Factor Analysis of the survey items and associated them with regional cortical volumes measured by voxel-based morphometry. Experiencing an intimate relationship with God and engaging in religious behavior was associated with increased volume of R middle temporal cortex, BA 21. Experiencing fear of God was associated with decreased volume of L precuneus and L orbitofrontal cortex BA 11. A cluster of traits related with pragmatism and doubting God's existence was associated with increased volume of the R precuneus. Variability in religiosity of upbringing was not associated with variability in cortical volume of any region. Therefore, key aspects of religiosity are associated with cortical volume differences. This conclusion complements our prior functional neuroimaging findings in elucidating the proximate causes of religion in the brain.			Kapogiannis, D (corresponding author), NIA, Clin Res Branch, NIH, Baltimore, MD 21224 USA.	grafmanj@ninds.nih.gov	Barbey, Aron/L-7312-2015; Kapogiannis, Dimitrios/AAW-4934-2020	Barbey, Aron/0000-0002-6092-0912; Kapogiannis, Dimitrios/0000-0003-2181-3118; Grafman, Jordan H./0000-0001-8645-4457; Lauwereyns, Jan/0000-0003-0551-2550	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000966] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA AG000966-03, Z99 AG999999] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Beauregard M, 2006, NEUROSCI LETT, V405, P186, DOI 10.1016/j.neulet.2006.06.060; Bouchard T J Jr, 1999, Twin Res, V2, P88, DOI 10.1375/twin.2.2.88; Boyer P, 2003, TRENDS COGN SCI, V7, P119, DOI 10.1016/S1364-6613(03)00031-7; Boyer P, 2008, ANNU REV ANTHROPOL, V37, P111, DOI 10.1146/annurev.anthro.37.081407.085201; Boyer P, 2008, NATURE, V455, P1038, DOI 10.1038/4551038a; Brannan S, 2001, P NATL ACAD SCI USA, V98, P2029, DOI 10.1073/pnas.98.4.2029; Bulbulia J, 2004, BIOL PHILOS, V19, P655, DOI 10.1007/s10539-005-5568-6; Bulbulia J., 2004, EVOLUTION COGNITION, V10, P19; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cunningham WA, 2004, J COGNITIVE NEUROSCI, V16, P1717, DOI 10.1162/0898929042947919; Dawkins R, 2006, SELFISH GENE; de Quervain DJF, 2006, P NATL ACAD SCI USA, V103, P4270, DOI 10.1073/pnas.0510212103; de Quervain DJF, 2003, NAT NEUROSCI, V6, P1141, DOI 10.1038/nn1146; de Quervain DJF, 2007, NAT NEUROSCI, V10, P1137, DOI 10.1038/nn1945; Dickerson BC, 2008, NEUROIMAGE, V39, P10, DOI 10.1016/j.neuroimage.2007.08.042; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Fuster J.M, 2003, CORTEX MIND UNIFYING; Gaser C, 2003, J NEUROSCI, V23, P9240; Glasser MF, 2008, CEREB CORTEX, V18, P2471, DOI 10.1093/cercor/bhn011; Goghari VM, 2007, CEREB CORTEX, V17, P415, DOI 10.1093/cercor/bhj158; Goghari VM, 2007, BRIT J PSYCHIAT, V191, P229, DOI 10.1192/bjp.bp.106.034595; Hariri AR, 2003, BIOL PSYCHIAT, V53, P494, DOI 10.1016/S0006-3223(02)01786-9; Hassabis D, 2007, J NEUROSCI, V27, P14365, DOI 10.1523/JNEUROSCI.4549-07.2007; Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041; Kapogiannis D, 2009, P NATL ACAD SCI USA, V106, P4876, DOI 10.1073/pnas.0811717106; Kennerknecht I, 2008, AM J MED GENET A, V146A, P2863, DOI 10.1002/ajmg.a.32552; Kleim JA, 1996, J NEUROSCI, V16, P4529; Koenig HG, 2009, CAN J PSYCHIAT, V54, P283, DOI 10.1177/070674370905400502; Koenig LB, 2007, J PERS, V75, P265, DOI 10.1111/j.1467-6494.2007.00439.x; Koenig LB, 2009, HEALTH PSYCHOL, V28, P117, DOI 10.1037/a0012984; Koenig LB, 2005, J PERS, V73, P471, DOI 10.1111/j.1467-6494.2005.00316.x; Koenig LB, 2003, BEHAV GENET, V33, P708; Krueger F, 2009, TRENDS COGN SCI, V13, P103, DOI 10.1016/j.tics.2008.12.005; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lissek S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002023; Lui S, 2009, AM J PSYCHIAT, V166, P196, DOI 10.1176/appi.ajp.2008.08020183; Lundstrom BN, 2005, NEUROIMAGE, V27, P824, DOI 10.1016/j.neuroimage.2005.05.008; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Maguire EA, 2006, HIPPOCAMPUS, V16, P1091, DOI 10.1002/hipo.20233; McCullough ME, 2009, PSYCHOL BULL, V135, P69, DOI 10.1037/a0014213; MCNAMARA P, 2001, RELIG MIND COGNITIVE, P236; Mischel W, 2004, ANNU REV PSYCHOL, V55, P1, DOI 10.1146/annurev.psych.55.042902.130709; Moreira-Almeida A, 2006, REV BRAS PSIQUIATR, V28, P242, DOI 10.1590/S1516-44462006000300018; Mueller PS, 2001, MAYO CLIN PROC, V76, P1225, DOI 10.4065/76.12.1225; Narayan VM, 2008, NEUROREPORT, V19, P1551, DOI 10.1097/WNR.0b013e3283112720; Newberg A, 2001, PSYCHIAT RES-NEUROIM, V106, P113, DOI 10.1016/S0925-4927(01)00074-9; Noriuchi M, 2008, BIOL PSYCHIAT, V63, P415, DOI 10.1016/j.biopsych.2007.05.018; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Papassotiropoulos A, 2006, SCIENCE, V314, P475, DOI 10.1126/science.1129837; PERSINGER MA, 1983, PERCEPT MOTOR SKILL, V57, P1255, DOI 10.2466/pms.1983.57.3f.1255; Pochon JB, 2002, P NATL ACAD SCI USA, V99, P5669, DOI 10.1073/pnas.082111099; Rilling JK, 2008, NAT NEUROSCI, V11, P426, DOI 10.1038/nn2072; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Schjodt U, 2008, NEUROSCI LETT, V443, P165, DOI 10.1016/j.neulet.2008.07.068; Schjoedt U, 2009, SOC COGN AFFECT NEUR, V4, P199, DOI 10.1093/scan/nsn050; Schlaug G, 2001, ANN NY ACAD SCI, V930, P281, DOI 10.1111/j.1749-6632.2001.tb05739.x; SHAMAYTSOORY SG, 2008, BRAIN; Simeon D, 2000, AM J PSYCHIAT, V157, P1782, DOI 10.1176/appi.ajp.157.11.1782; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Spencer MD, 2007, NEUROIMAGE, V35, P1181, DOI 10.1016/j.neuroimage.2007.01.008; Tinbergen N, 2005, ANIM BIOL, V55, P297, DOI 10.1163/157075605774840941; Van den Stock J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003195; Vanderwal T, 2008, NEUROIMAGE, V41, P1437, DOI 10.1016/j.neuroimage.2008.03.058; Wade Nicholas, 2006, DAWN RECOVERING LOST; Walhovd KB, 2005, NEUROBIOL AGING, V26, P1261, DOI 10.1016/j.neurobiolaging.2005.05.020; Walhovd KB, 2004, NEUROLOGY, V63, P1193, DOI 10.1212/01.WNL.0000140489.33249.95; WALHOVD KB, 2008, NEUROBIOL AGING; Walhovd KB, 2009, NEUROBIOL AGING; Walhovd KB, 2006, NEUROIMAGE, V31, P1343, DOI 10.1016/j.neuroimage.2006.01.011; Wang AT, 2007, ARCH GEN PSYCHIAT, V64, P698, DOI 10.1001/archpsyc.64.6.698; Wright CI, 2006, CEREB CORTEX, V16, P1809, DOI 10.1093/cercor/bhj118; Zahn R, 2009, CEREB CORTEX, V19, P276, DOI 10.1093/cercor/bhn080	74	39	40	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7180	10.1371/journal.pone.0007180	http://dx.doi.org/10.1371/journal.pone.0007180			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	500HQ	19784372	Green Published, gold			2022-12-27	WOS:000270290000005
J	Sarkar, A; Mitra, S; Mehta, S; Raices, R; Wewers, MD				Sarkar, Anasuya; Mitra, Srabani; Mehta, Sonya; Raices, Raquel; Wewers, Mark D.			Monocyte Derived Microvesicles Deliver a Cell Death Message via Encapsulated Caspase-1	PLOS ONE			English	Article								Apoptosis depends upon the activation of intracellular caspases which are classically induced by either an intrinsic (mitochondrial based) or extrinsic (cytokine) pathway. However, in the process of explaining how endotoxin activated monocytes are able to induce apoptosis of vascular smooth muscle cells when co-cultured, we uncovered a transcellular apoptosis inducing pathway that utilizes caspase-1 containing microvesicles. Endotoxin stimulated monocytes induce the cell death of VSMCs but this activity is found in 100,000 g pellets of cell free supernatants of these monocytes. This activity is not a direct effect of endotoxin, and is inhibited by the caspase-1 inhibitor YVADcmk but not by inhibitors of Fas-L, IL-1 beta and IL-18. Importantly, the apoptosis inducing activity co-purifies with 100 nm sized microvesicles as determined by TEM of the pellets. These microvesicles contain caspase-1 and caspase-1 encapsulation is required since disruption of microvesicular integrity destroys the apoptotic activity but not the caspase-1 enzymatic activity. Thus, monocytes are capable of delivering a cell death message which depends upon the release of microvesicles containing functional caspase-1. This transcellular apoptosis induction pathway describes a novel pathway for inflammation induced programmed cell death.			Sarkar, A (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.	wewers.2@osu.edu	Wewers, Mark/AAB-6202-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040871, R01HL076278, R01HL040871] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40871, R01 HL040871, R01 HL076278, HL076278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boyle J. J., 2005, Current Vascular Pharmacology, V3, P63, DOI 10.2174/1570161052773861; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3; Distler JHW, 2006, AUTOIMMUNITY, V39, P683, DOI 10.1080/08916930601061538; Elkon KB, 1999, J EXP MED, V190, P1725, DOI 10.1084/jem.190.12.1725; Elliott JM, 2009, J BIOL CHEM, V284, P6546, DOI 10.1074/jbc.M806121200; Fahy RJ, 1999, J IMMUNOL, V163, P1755; Fahy RJ, 2008, AM J RESP CRIT CARE, V177, P983, DOI 10.1164/rccm.200703-418OC; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GAVRILIN MA, 2009, J IMMUNOL IN PRESS; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Huber LC, 2007, APOPTOSIS, V12, P363, DOI 10.1007/s10495-006-0622-7; Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004; Imanishi T, 2002, ATHEROSCLEROSIS, V161, P143, DOI 10.1016/S0021-9150(01)00631-1; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kahlenberg JM, 2004, J LEUKOCYTE BIOL, V76, P676, DOI 10.1189/jlb.0404221; Kim HJ, 2004, J IMMUNOL, V172, P4948, DOI 10.4049/jimmunol.172.8.4948; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Ludewig B, 2004, P NATL ACAD SCI USA, V101, P11529, DOI 10.1073/pnas.0404612101; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McKechnie NM, 2006, EXP EYE RES, V83, P304, DOI 10.1016/j.exer.2005.11.028; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sarkar A, 2006, AM J RESP CRIT CARE, V174, P1003, DOI 10.1164/rccm.200604-546OC; Sarkar A, 2006, J IMMUNOL, V176, P4979, DOI 10.4049/jimmunol.176.8.4979; Seshiah PN, 2002, CIRCULATION, V105, P174, DOI 10.1161/hc0202.102248; Shaw MH, 2008, CURR OPIN IMMUNOL, V20, P377, DOI 10.1016/j.coi.2008.06.001; STELLER H, 1995, ICE LIKE PROTEASES A, P198; Taniguchi S, 2007, SEMIN IMMUNOPATHOL, V29, P231, DOI 10.1007/s00281-007-0082-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; van der Velden AWM, 2003, J IMMUNOL, V171, P6742, DOI 10.4049/jimmunol.171.12.6742; Wang J, 2000, J CELL SCI, V113, P753; Watanabe JJ, 2003, J BIOL CHEM, V278, P33161, DOI 10.1074/jbc.M305321200; Wewers MD, 1997, J IMMUNOL, V159, P5964; Wewers MD, 2004, P NATL ACAD SCI USA, V101, P10241, DOI 10.1073/pnas.0403971101; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	50	125	131	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7140	10.1371/journal.pone.0007140	http://dx.doi.org/10.1371/journal.pone.0007140			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779610	Green Submitted, Green Published, gold			2022-12-27	WOS:000270176200002
J	Ramakrishnan, MA; Tu, ZJ; Singh, S; Chockalingam, AK; Gramer, MR; Wang, P; Goyal, SM; Yang, M; Halvorson, DA; Sreevatsan, S				Ramakrishnan, Muthannan A.; Tu, Zheng Jin; Singh, Sushmita; Chockalingam, Ashok K.; Gramer, Marie R.; Wang, Ping; Goyal, Sagar M.; Yang, My; Halvorson, David A.; Sreevatsan, Srinand			The Feasibility of Using High Resolution Genome Sequencing of Influenza A Viruses to Detect Mixed Infections and Quasispecies	PLOS ONE			English	Article								Background: The rapidly expanding availability of de novo sequencing technologies can greatly facilitate efforts to monitor the relatively high mutation rates of influenza A viruses and the detection of quasispecies. Both the mutation rates and the lineages of influenza A viruses are likely to play an important role in the natural history of these viruses and the emergence of phenotypically and antigenically distinct strains. Methodology and Principal Findings: We evaluated quasispecies and mixed infections by de novo sequencing the whole genomes of 10 virus isolates, including eight avian influenza viruses grown in embryonated chicken eggs (six waterfowl isolates - five H3N2 and one H4N6; an H7N3 turkey isolate; and a bald eagle isolate with H1N1/H2N1 mixed infection), and two tissue cultured H3N2 swine influenza viruses. Two waterfowl cloacal swabs were included in the analysis. Full-length sequences of all segments were obtained with 20 to 787-X coverage for the ten viruses and one cloacal swab. The second cloacal swab yielded 15 influenza reads of similar to 230 bases, sufficient for bioinformatic inference of mixed infections or quasispecies. Genomic subpopulations or quasispecies of viruses were identified in four egg grown avian influenza isolates and one cell cultured swine virus. A bald eagle isolate and the second cloacal swab showed evidence of mixed infections with two (H1 and H2) and three (H1, H3, and H4) HA subtypes, respectively. Multiple sequence differences were identified between cloacal swab and the virus recovered using embryonated chicken eggs. Conclusions: We describe a new approach to comprehensively identify mixed infections and quasispecies in low passage influenza A isolates and cloacal swabs and add to the understanding of the ecology of influenza A virus populations.			Ramakrishnan, MA (corresponding author), Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA.	sreev001@umn.edu	Sreevatsan, Srinand/V-6808-2019; Ramakrishnan, Muthannan Andavar/Y-3338-2019; Culhane, Marie/H-3143-2019	Sreevatsan, Srinand/0000-0002-5162-2403; Ramakrishnan, Muthannan Andavar/0000-0001-7789-328X	PHS HHS [HHSN266200700007C] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bright RA, 2006, JAMA-J AM MED ASSOC, V295, P891, DOI 10.1001/jama.295.8.joc60020; Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027; Cohen NJ, 2008, INFECTION, V36, P458, DOI 10.1007/s15010-008-7295-9; Delwart EL, 2007, REV MED VIROL, V17, P115, DOI 10.1002/rmv.532; Deyde VM, 2007, J INFECT DIS, V196, P249, DOI 10.1086/518936; Deyde VM, 2009, ANTIMICROB AGENTS CH, V53, P1039, DOI 10.1128/AAC.01446-08; Deyde VM, 2009, ANTIVIR RES, V81, P16, DOI 10.1016/j.antiviral.2008.08.008; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Domingo E, 1998, EMERG INFECT DIS, V4, P521, DOI 10.3201/eid0404.980402; DOMINGO E, 1985, GENE, V40, P1, DOI 10.1016/0378-1119(85)90017-4; Dugan VG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000076; Ghedin E, 2005, NATURE, V437, P1162, DOI 10.1038/nature04239; Higgins RR, 2009, J CLIN VIROL, V44, P91, DOI 10.1016/j.jcv.2008.10.001; Hoper D, 2009, J CLIN MICROBIOL, V47, P674, DOI 10.1128/JCM.01028-08; Katz JM, 2009, POULTRY SCI, V88, P872, DOI 10.3382/ps.2008-00465; Lackenby A, 2008, ANTIVIR THER, V13, P809; LAPLANTE JM, 2009, J CLIN MICROBIOL; Lee CW, 2009, COMP IMMUNOL MICROB, V32, P301, DOI 10.1016/j.cimid.2008.01.007; Nakamura S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004219; Pourmand N, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000095; Rothberg JM, 2008, NAT BIOTECHNOL, V26, P1117, DOI 10.1038/nbt1485; Sampath R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000489; Stech J, 1999, J VIROL, V73, P1878, DOI 10.1128/JVI.73.3.1878-1884.1999; Wang RX, 2008, VIROLOGY, V375, P182, DOI 10.1016/j.virol.2008.01.041; Waybright N, 2008, J VIROL METHODS, V154, P200, DOI 10.1016/j.jviromet.2008.09.013	26	54	55	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7105	10.1371/journal.pone.0007105	http://dx.doi.org/10.1371/journal.pone.0007105			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771155	Green Submitted, gold, Green Published			2022-12-27	WOS:000270154400005
J	Orelio, C; Verkuijlen, P; Geissler, J; van den Berg, TK; Kuijpers, TW				Orelio, Claudia; Verkuijlen, Paul; Geissler, Judy; van den Berg, Timo K.; Kuijpers, Taco W.			SBDS Expression and Localization at the Mitotic Spindle in Human Myeloid Progenitors	PLOS ONE			English	Article								Background: Shwachman-Diamond Syndrome (SDS) is a hereditary disease caused by mutations in the SBDS gene. SDS is clinically characterized by pancreatic insufficiency, skeletal abnormalities and bone marrow dysfunction. The hematologic abnormalities include neutropenia, neutrophil chemotaxis defects, and an increased risk of developing Acute Myeloid Leukemia (AML). Although several studies have suggested that SBDS as a protein plays a role in ribosome processing/maturation, its impact on human neutrophil development and function remains to be clarified. Methodology/Principal Findings: We observed that SBDS RNA and protein are expressed in the human myeloid leukemia PLB-985 cell line and in human hematopoietic progenitor cells by quantitative RT-PCR and Western blot analysis. SBDS expression is downregulated during neutrophil differentiation. Additionally, we observed that the differentiation and proliferation capacity of SDS-patient bone marrow hematopoietic progenitor cells in a liquid differentiation system was reduced as compared to control cultures. Immunofluorescence analysis showed that SBDS co-localizes with the mitotic spindle and in vitro binding studies reveal a direct interaction of SBDS with microtubules. In interphase cells a perinuclear enrichment of SBDS protein which co-localized with the microtubule organizing center ( MTOC) was observed. Also, we observed that transiently expressed SDS patient-derived SBDS-K62 or SBDS-C84 mutant proteins could co-localize with the MTOC and mitotic spindle. Conclusions/Significance: SBDS co-localizes with the mitotic spindle, suggesting a role for SBDS in the cell division process, which corresponds to the decreased proliferation capacity of SDS-patient bone marrow CD34(+) hematopoietic progenitor cells in our culture system and also to the neutropenia in SDS patients. A role in chromosome missegregation has not been clarified, since similar spatial and time-dependent localization is observed when patient-derived SBDS mutant proteins are studied. Thus, the increased risk of myeloid malignancy in SDS remains unexplained.			Orelio, C (corresponding author), Dept Blood Cell Res, Sanquin Res & Landsteiner Lab, Amsterdam, Netherlands.	orelio.c@hsleiden.nl	van den Berg, Timo K/AAC-2479-2022					Austin KM, 2008, J CLIN INVEST, V118, P1511, DOI 10.1172/JCI33764; Austin KM, 2005, BLOOD, V106, P1253, DOI 10.1182/blood-2005-02-0807; Badano JL, 2005, NAT REV GENET, V6, P194, DOI 10.1038/nrg1557; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; BODIAN M, 1964, ACTA PAEDIATR, V53, P282, DOI 10.1111/j.1651-2227.1964.tb07237.x; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; Buitenhuis M, 2005, BLOOD, V105, P4272, DOI 10.1182/blood-2004-12-4883; Donadieu J, 2005, HAEMATOLOGICA, V90, P45; Dror Y, 1999, BLOOD, V94, P3048, DOI 10.1182/blood.V94.9.3048.421k24_3048_3054; Elghetany MT, 2002, BLOOD CELL MOL DIS, V28, P260, DOI 10.1006/bcmd.2002.0513; Ganapathi KA, 2007, BLOOD, V110, P1458, DOI 10.1182/blood-2007-02-075184; Ginzberg H, 1999, J PEDIATR-US, V135, P81, DOI 10.1016/S0022-3476(99)70332-X; Goobie S, 2001, AM J HUM GENET, V68, P1048, DOI 10.1086/319505; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Kawakami T, 2005, TOHOKU J EXP MED, V206, P253, DOI 10.1620/tjem.206.253; Kuijpers TW, 2005, BLOOD, V106, P356, DOI 10.1182/blood-2004-11-4371; LIU JM, 2006, BLOOD; Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994; Nicolis Elena, 2005, Hum Mutat, V25, P410, DOI 10.1002/humu.9324; Orelio C, 2007, INFLAMM RES, V56, P98, DOI 10.1007/s00011-006-6058-2; Rawls AS, 2007, BLOOD, V110, P2414, DOI 10.1182/blood-2006-03-007112; Savchenko A, 2005, J BIOL CHEM, V280, P19213, DOI 10.1074/jbc.M414421200; Shammas C, 2005, J BIOL CHEM, V280, P19221, DOI 10.1074/jbc.M414656200; Shimamura A, 2006, SEMIN HEMATOL, V43, P178, DOI 10.1053/j.seminhematol.2006.04.006; SHWACHMAN H, 1964, J PEDIATR, V65, P645; van Mirre E, 2006, BLOOD, V108, P584, DOI 10.1182/blood-2005-12-4997; Wiese C, 2006, J CELL SCI, V119, P4143, DOI 10.1242/jcs.03226; Willig TN, 2000, CURR OPIN HEMATOL, V7, P85, DOI 10.1097/00062752-200003000-00003; Woloszynek JR, 2004, BLOOD, V104, P3588, DOI 10.1182/blood-2004-04-1516; Yamaguchi M, 2007, EXP HEMATOL, V35, P579, DOI 10.1016/j.exphem.2006.12.010; Zhang SY, 2006, MOL CELL BIOL, V26, P6656, DOI 10.1128/MCB.00091-06	31	29	31	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7084	10.1371/journal.pone.0007084	http://dx.doi.org/10.1371/journal.pone.0007084			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759903	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970200013
J	Zumsteg, A; Baeriswyl, V; Imaizumi, N; Schwendener, R; Ruegg, C; Christofori, G				Zumsteg, Adrian; Baeriswyl, Vanessa; Imaizumi, Natsuko; Schwendener, Reto; Rueegg, Curzio; Christofori, Gerhard			Myeloid Cells Contribute to Tumor Lymphangiogenesis	PLOS ONE			English	Article								The formation of new blood vessels (angiogenesis) and lymphatic vessels (lymphangiogenesis) promotes tumor outgrowth and metastasis. Previously, it has been demonstrated that bone marrow-derived cells (BMDC) can contribute to tumor angiogenesis. However, the role of BMDC in lymphangiogenesis has largely remained elusive. Here, we demonstrate by bone marrow transplantation/reconstitution and genetic lineage-tracing experiments that BMDC integrate into tumor-associated lymphatic vessels in the Rip1Tag2 mouse model of insulinoma and in the TRAMP-C1 prostate cancer transplantation model, and that the integrated BMDC originate from the myelomonocytic lineage. Conversely, pharmacological depletion of tumor-associated macrophages reduces lymphangiogenesis. No cell fusion events are detected by genetic tracing experiments. Rather, the phenotypical conversion of myeloid cells into lymphatic endothelial cells and their integration into lymphatic structures is recapitulated in two in vitro tube formation assays and is dependent on fibroblast growth factor-mediated signaling. Together, the results reveal that myeloid cells can contribute to tumor-associated lymphatic vessels, thus extending the findings on the previously reported role of hematopoietic cells in lymphatic vessel formation.			Zumsteg, A (corresponding author), Univ Basel, Inst Biochem & Genet, Dept Biomed, Basel, Switzerland.	Gerhard.christofori@unibas.ch	Schwendener, Reto A/F-6373-2011	Schwendener, Reto/0000-0002-8114-6321				Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Ando T., 2005, Lymphatic Research and Biology, V3, P105, DOI 10.1089/lrb.2005.3.105; Bailey AS, 2006, P NATL ACAD SCI USA, V103, P13156, DOI 10.1073/pnas.0604203103; Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Benard A, 2006, EUR J IMMUNOL, V36, P2324, DOI 10.1002/eji.200636434; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Cho CH, 2007, CIRC RES, V100, pE47, DOI 10.1161/01.RES.0000259564.92792.93; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eilken HM, 2009, NATURE, V457, P896, DOI 10.1038/nature07760; Ferron M, 2005, GENESIS, V41, P138, DOI 10.1002/gene.20108; Foster BA, 1997, CANCER RES, V57, P3325; Gannon G, 2002, CANCER RES, V62, P603; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gingrich JR, 1996, CANCER RES, V56, P4096; Gregory C. A., 2005, SCI STKE, ppe37; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hamrah P, 2003, AM J PATHOL, V163, P57, DOI 10.1016/S0002-9440(10)63630-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; He YL, 2004, CANCER RES, V64, P3737, DOI 10.1158/0008-5472.CAN-04-0088; Ichise H, 2009, DEVELOPMENT, V136, P191, DOI 10.1242/dev.025353; Jiang SG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003812; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Lancrin C, 2009, NATURE, V457, P892, DOI 10.1038/nature07679; Loomans CJM, 2006, ARTERIOSCL THROM VAS, V26, P1760, DOI 10.1161/01.ATV.0000229243.49320.c9; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; McDonnell CO, 2003, BRIT J SURG, V90, P1373, DOI 10.1002/bjs.4338; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ozerdem U, 2006, PROSTATE, V66, P294, DOI 10.1002/pros.20346; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105; Religa P, 2005, BLOOD, V106, P4184, DOI 10.1182/blood-2005-01-0226; Schledzewski K, 2006, J PATHOL, V209, P67, DOI 10.1002/path.1942; Sebzda E, 2006, DEV CELL, V11, P349, DOI 10.1016/j.devcel.2006.07.007; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240	50	92	93	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7067	10.1371/journal.pone.0007067	http://dx.doi.org/10.1371/journal.pone.0007067			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759906	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970200005
J	Bosnakovski, D; Daughters, RS; Xu, ZHH; Slack, JMW; Kyba, M				Bosnakovski, Darko; Daughters, Randy S.; Xu, Zhaohui; Slack, Jonathan M. W.; Kyba, Michael			Biphasic Myopathic Phenotype of Mouse DUX, an ORF within Conserved FSHD-Related Repeats	PLOS ONE			English	Article								Facioscapulohumeral muscular dystrophy ( FSHD) is caused by contractions of D4Z4 repeats at 4q35.2 thought to induce misregulation of nearby genes, one of which, DUX4, is actually localized within each repeat. A conserved ORF (mDUX), embedded within D4Z4-like repeats, encoding a double-homeodomain protein, was recently identified on mouse chromosome 10. We show here that high level mDUX expression induces myoblast death, while low non-toxic levels block myogenic differentiation by down-regulating MyoD and Myf5. Toxicity and MyoD/Myf5 expression changes were competitively reversed by overexpression of Pax3 or Pax7, implying mechanistic similarities with the anti-myogenic activity of human DUX4. We tested the effect of mDUX expression on Xenopus development, and found that global overexpression led to abnormalities in gastrulation. When targeted unilaterally into blastomeres fated to become tail muscle in 16-cell embryos, mDUX caused markedly reduced tail myogenesis on the injected side. These novel cell and animal models highlight the myopathic nature of sequences within the FSHD-related repeat array.			Bosnakovski, D (corresponding author), Univ Minnesota, Lillehei Heart Inst, Minneapolis, MN 55455 USA.	kyba@umn.edu	Bosnakovski, Darko/T-8292-2019	Slack, Jonathan/0000-0002-7154-6778; Xu, Zhaohui/0000-0003-0645-1737; Bosnakovski, Darko/0000-0002-7198-2019; Kyba, Michael/0000-0002-5579-7534	NHLBI NIH HHS [U01 HL100407] Funding Source: Medline; NIAMS NIH HHS [NIH T32 AR050938, T32 AR050938] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR050938] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Barro M, 2008, J CELL MOL MED; BOSNAKOVSKI D, 2008, EXP NEUROL; Bosnakovski D, 2008, EMBO J, V27, P2766, DOI 10.1038/emboj.2008.201; Buckingham M, 2007, CR BIOL, V330, P530, DOI 10.1016/j.crvi.2007.03.015; Celegato B, 2006, PROTEOMICS, V6, P5303, DOI 10.1002/pmic.200600056; Cheng L, 2006, BIOCHEM BIOPH RES CO, V344, P1290, DOI 10.1016/j.bbrc.2006.03.234; Clapp J, 2007, AM J HUM GENET, V81, P264, DOI 10.1086/519311; DALE L, 1987, DEVELOPMENT, V100, P279; Dixit M, 2007, P NATL ACAD SCI USA, V104, P18157, DOI 10.1073/pnas.0708659104; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Gabriels J, 1999, GENE, V236, P25, DOI 10.1016/S0378-1119(99)00267-X; IACOVINO M, 2008, STEM CELLS DEV; Jiang GC, 2003, HUM MOL GENET, V12, P2909, DOI 10.1093/hmg/ddg323; Kowaljow V, 2007, NEUROMUSCULAR DISORD, V17, P611, DOI 10.1016/j.nmd.2007.04.002; Laoudj-Chenivesse D, 2005, J MOL MED, V83, P216, DOI 10.1007/s00109-004-0583-7; Macaione V, 2007, ACTA NEUROL SCAND, V115, P115, DOI 10.1111/j.1600-0404.2006.00724.x; Maves L, 2007, DEVELOPMENT, V134, P3371, DOI 10.1242/dev.003905; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; Morosetti R, 2007, STEM CELLS, V25, P3173, DOI 10.1634/stemcells.2007-0465; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Ottaviani A, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000394; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SLACK JMW, 1980, J EMBRYOL EXP MORPH, V56, P283; SNIDER L, 2009, HUM MOL GENET; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; van Geel M, 1999, GENOMICS, V61, P55, DOI 10.1006/geno.1999.5942; van Overveld PGM, 2003, NAT GENET, V35, P315, DOI 10.1038/ng1262; vanDeutekom JCT, 1996, HUM MOL GENET, V5, P581, DOI 10.1093/hmg/5.5.581; WIJMENGA C, 1992, NAT GENET, V2, P26, DOI 10.1038/ng0992-26; Winokur ST, 2003, NEUROMUSCULAR DISORD, V13, P322, DOI 10.1016/S0960-8966(02)00284-5; Winokur ST, 2003, HUM MOL GENET, V12, P2895, DOI 10.1093/hmg/ddg327; WRIGHT TJ, 1993, HUM MOL GENET, V2, P1673, DOI 10.1093/hmg/2.10.1673; Yip DJ, 2003, FEBS LETT, V537, P133, DOI 10.1016/S0014-5793(03)00110-8	35	47	49	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7003	10.1371/journal.pone.0007003	http://dx.doi.org/10.1371/journal.pone.0007003			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756142	Green Published, gold, Green Accepted, Green Submitted			2022-12-27	WOS:000269970000007
J	Chatterjee, S; Mookerjee, A; Basu, JM; Chakraborty, P; Ganguly, A; Adhikary, A; Mukhopadhyay, D; Ganguli, S; Banerjee, R; Ashraf, M; Biswas, J; Das, PK; Sa, G; Chatterjee, M; Das, T; Choudhuri, SK				Chatterjee, Shilpak; Mookerjee, Ananda; Basu, Jayati Mookerjee; Chakraborty, Paramita; Ganguly, Avishek; Adhikary, Arghya; Mukhopadhyay, Debanjan; Ganguli, Sudipta; Banerjee, Rajdeep; Ashraf, Mohammad; Biswas, Jaydip; Das, Pradeep K.; Sa, Gourisankar; Chatterjee, Mitali; Das, Tanya; Choudhuri, Soumitra Kumar			A Novel Copper Chelate Modulates Tumor Associated Macrophages to Promote Anti-Tumor Response of T Cells	PLOS ONE			English	Article							IN-VITRO; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; INTERFERON-GAMMA; ACTIVATION; ANGIOGENESIS; APOPTOSIS; CD4(+); CANCER; TH1	Background: At the early stages of carcinogenesis, the induction of tumor specific T cell mediated immunity seems to block the tumor growth and give protective anti-tumor immune response. However, tumor associated macrophages (TAMs) might play an immunosuppressive role and subvert this anti tumor immunity leading to tumor progression and metastasis. Methodology/Principal Findings: The Cu (II) complex, (chelate), copper N-(2-hydroxy acetophenone) glycinate (CuNG), synthesized by us, has previously been shown to have a potential usefulness in immunotherapy of multiple drug resistant cancers. The current study demonstrates that CuNG treatment of TAMs modulates their status from immunosuppressive to proimmunogenic nature. Interestingly, these activated TAMs produced high levels of IL-12 along with low levels of IL-10 that not only allowed strong Th1 response marked by generation of high levels of IFN-gamma but also reduced activation induced T cell death. Similarly, CuNG treatment of peripheral blood monocytes from chemotherapy and/or radiotherapy refractory cancer patients also modulated their cytokine status. Most intriguingly, CuNG treated TAMs could influence reprogramming of TGF-beta producing CD4(+)CD25(+) T cells toward IFN-gamma producing T cells. Conclusion/Significance: Our results show the potential usefulness of CuNG in immunotherapy of drug-resistant cancers through reprogramming of TAMs that in turn reprogram the T cells and reeducate the T helper function to elicit proper anti-tumorogenic Th1 response leading to effective reduction in tumor growth.			Chatterjee, S (corresponding author), Chittaranjan Natl Canc Inst, Dept Vitro Carcinogenesis & Cellular Chemotherapy, Kolkata, India.	soumitra01@yahoo.com	Ganguly, Avishek/R-6138-2019; Chatterjee, Mitali/AAV-2129-2021; Ganguly, Sudipto/S-9152-2019; Mukhopadhyay, Debanjan/S-3347-2019; Chakraborty, Paramita/AAL-9606-2020	Ganguly, Sudipto/0000-0002-2662-8897; Mukhopadhyay, Debanjan/0000-0002-8921-4106; Chakraborty, Paramita/0000-0002-0320-8697				Basu JM, 2008, ANTIMICROB AGENTS CH, V52, P1080, DOI 10.1128/AAC.01196-07; Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1788-1797.2006, 10.1128/AAC.50.5.1768-1797.2006]; Bharhani MS, 2006, AM J PHYSIOL-GASTR L, V291, pG820, DOI 10.1152/ajpgi.00438.2005; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; Bronte V, 2001, J IMMUNOTHER, V24, P431, DOI 10.1097/00002371-200111000-00001; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Choudhuri SK, 1998, ANTI-CANCER DRUG, V9, P825, DOI 10.1097/00001813-199810000-00013; DULUC D, 2009, INT J CANC      0227; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hagenbaugh A, 1997, J EXP MED, V185, P2101, DOI 10.1084/jem.185.12.2101; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; KIM J, 1995, J IMMUNOL, V155, P2240; Kusaba H, 2005, J BIOL CHEM, V280, P1037, DOI 10.1074/jbc.M405204200; Leary SC, 2007, EMBO REP, V8, P224, DOI 10.1038/sj.embor.7400915; Leek RD, 1996, CANCER RES, V56, P4625; Lin Elaine Y, 2004, Novartis Found Symp, V256, P158; Lu BF, 2004, P NATL ACAD SCI USA, V101, P3023, DOI 10.1073/pnas.0307743100; Lu BF, 2006, IMMUNOL RES, V36, P275, DOI 10.1385/IR:36:1:275; Majumder S, 2003, EUR J MED CHEM, V38, P893, DOI 10.1016/j.ejmech.2003.08.002; Majumder S, 2009, BIOMETALS, V22, P377, DOI 10.1007/s10534-008-9174-3; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Mookerjee A, 2006, CLIN CANCER RES, V12, P4339, DOI 10.1158/1078-0432.CCR-06-0001; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Murata Y, 2002, INT IMMUNOL, V14, P201, DOI 10.1093/intimm/14.2.201; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Percival SS, 1998, AM J CLIN NUTR, V67, p1064S, DOI 10.1093/ajcn/67.5.1064S; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Strauss L, 2007, CLIN CANCER RES, V13, P4345, DOI 10.1158/1078-0432.CCR-07-0472; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wall L, 2003, CLIN CANCER RES, V9, P2487; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; Whiteside TL, 2005, CANCER METAST REV, V24, P95, DOI 10.1007/s10555-005-5050-6; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	46	34	36	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7048	10.1371/journal.pone.0007048	http://dx.doi.org/10.1371/journal.pone.0007048			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756150	Green Published, gold			2022-12-27	WOS:000269970000015
J	Ho, CK; Lam, AF; Symington, LS				Ho, Chu Kwen; Lam, Alicia F.; Symington, Lorraine S.			Identification of Nucleases and Phosphatases by Direct Biochemical Screen of the Saccharomyces cerevisiae Proteome	PLOS ONE			English	Article								The availability of yeast strain collections expressing individually tagged proteins to facilitate one-step purification provides a powerful approach to identify proteins with particular biochemical activities. To identify novel exo- and endo-nucleases that might function in DNA repair, we undertook a proteomic screen making use of the movable ORF (MORF) library of yeast expression plasmids. This library consists of 5,854 yeast strains each expressing a unique yeast ORF fused to a tripartite tag consisting of His(6), an HA epitope, a protease 3C cleavage site, and the IgG-binding domain (ZZ) from protein A, under the control of the GAL1 promoter for inducible expression. Pools of proteins were partially purified on IgG sepharose and tested for nuclease activity using three different radiolabeled DNA substrates. Several known nucleases and phosphatases were identified, as well as two new members of the histidine phosphatase superfamily, which includes phosphoglycerate mutases and phosphatases. Subsequent characterization revealed YDR051c/Det1 to be an acid phosphatase with broad substrate specificity, whereas YOR283w has a broad pH range and hydrolyzes hydrophilic phosphorylated substrates. Although no new nuclease activities were identified from this screen, we did find phosphatase activity associated with a protein of unknown function, YOR283w, and with the recently characterized protein Det1. This knowledge should guide further genetic and biochemical characterization of these proteins.			Ho, CK (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	lss5@columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041784] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041784-22, R01 GM041784, GM041784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; Davies L, 2007, PROTEINS, V67, P720, DOI 10.1002/prot.21357; de los Santos T, 2003, GENETICS, V164, P81; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; Fairn GD, 2007, P NATL ACAD SCI USA, V104, P15352, DOI 10.1073/pnas.0705571104; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Ip SCY, 2008, NATURE, V456, P357, DOI 10.1038/nature07470; Jackman JE, 2003, RNA, V9, P574, DOI 10.1261/rna.5070303; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Liao SR, 2008, NUCLEIC ACIDS RES, V36, P6091, DOI 10.1093/nar/gkn616; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDQVIST Y, 1993, J BIOL CHEM, V268, P20744; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200; Rigden DJ, 2008, BIOCHEM J, V409, P333, DOI 10.1042/BJ20071097; Rigden DJ, 2003, J MOL BIOL, V325, P411, DOI 10.1016/S0022-2836(02)01229-9; Sullivan DP, 2009, EUKARYOT CELL, V8, P161, DOI 10.1128/EC.00135-08; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; Toh E.A., 1976, BIOCHIM BIOPHYS ACTA, V428, P182; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Xue Y, 2000, MOL CELL BIOL, V20, P4006, DOI 10.1128/MCB.20.11.4006-4015.2000; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	39	5	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e6993	10.1371/journal.pone.0006993	http://dx.doi.org/10.1371/journal.pone.0006993			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753119	gold, Green Published, Green Submitted			2022-12-27	WOS:000269796500002
J	Karami, S; Brennan, P; Rosenberg, PS; Navratilova, M; Mates, D; Zaridze, D; Janout, V; Kollarova, H; Bencko, V; Matveev, V; Szeszenia-Dabrowska, N; Holcatova, I; Yeager, M; Chanock, S; Menashe, I; Rothman, N; Chow, WH; Boffetta, P; Moore, LE				Karami, Sara; Brennan, Paul; Rosenberg, Philip S.; Navratilova, Marie; Mates, Dana; Zaridze, David; Janout, Vladimir; Kollarova, Helena; Bencko, Vladimir; Matveev, Vsevolod; Szeszenia-Dabrowska, Neonila; Holcatova, Ivana; Yeager, Meredith; Chanock, Stephen; Menashe, Idan; Rothman, Nathaniel; Chow, Wong-Ho; Boffetta, Paolo; Moore, Lee E.			Analysis of SNPs and Haplotypes in Vitamin D Pathway Genes and Renal Cancer Risk	PLOS ONE			English	Article							D-RECEPTOR POLYMORPHISMS; CELL CARCINOMA; PROSTATE-CANCER; ASSOCIATION; EXPRESSION; VDR; CALCITRIOL; PROMOTER; EASTERN; BINDING	In the kidney vitamin D is converted to its active form. Since vitamin D exerts its activity through binding to the nuclear vitamin D receptor (VDR), most genetic studies have primarily focused on variation within this gene. Therefore, analysis of genetic variation in VDR and other vitamin D pathway genes may provide insight into the role of vitamin D in renal cell carcinoma (RCC) etiology. RCC cases (N = 777) and controls (N = 1,035) were genotyped to investigate the relationship between RCC risk and variation in eight target genes. Minimum-p-value permutation (Min-P) tests were used to identify genes associated with risk. A three single nucleotide polymorphism (SNP) sliding window was used to identify chromosomal regions with a False Discovery Rate of < 10%, where subsequently, haplotype relative risks were computed in Haplostats. Min-P values showed that VDR (p-value = 0.02) and retinoid-X-receptor-alpha (RXRA) (p-value = 0.10) were associated with RCC risk. Within VDR, three haplotypes across two chromosomal regions of interest were identified. The first region, located within intron 2, contained two haplotypes that increased RCC risk by approximately 25%. The second region included a haplotype (rs2239179, rs12717991) across intron 4 that increased risk among participants with the TC (OR = 1.31, 95% CI = 1.09-1.57) haplotype compared to participants with the common haplotype, TT. Across RXRA, one haplotype located 39 of the coding sequence (rs748964, rs3118523), increased RCC risk 35% among individuals with the variant haplotype compared to those with the most common haplotype. This study comprehensively evaluated genetic variation across eight vitamin D pathway genes in relation to RCC risk. We found increased risk associated with VDR and RXRA. Replication studies are warranted to confirm these findings.			Karami, S (corresponding author), NCI, Div Canc Epidemiol, NIH, DHHS, Bethesda, MD 20892 USA.	karamis@mail.nih.gov	Bencko, Vladimir/H-8598-2017; Zaridze, David/K-5605-2013; Szeszenia-Dabrowska, Neonila/F-7190-2010; Menashe, Idan/AAC-8670-2020; Menashe, Idan/W-6214-2019; Janout, Vladimir/M-5133-2014; Holcatova, Ivana/C-8327-2017; Matveev, Vsevolod B/O-7476-2017; Yeager, Meredith/AAA-5322-2020; Boffetta, Paolo/AAI-7767-2021	Bencko, Vladimir/0000-0003-1935-2228; Menashe, Idan/0000-0003-1961-1461; Holcatova, Ivana/0000-0002-1366-0337; Matveev, Vsevolod B/0000-0001-7748-9527; Boffetta, Paolo/0000-0002-3811-2791; Kollarova, Helena/0000-0001-6951-6716; mates, dana/0000-0002-6219-9807; Rosenberg, Philip/0000-0001-6349-9126	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIACP010120] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Beer TM, 2003, J CLIN ONCOL, V21, P123, DOI 10.1200/jco.2003.05.117; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brennan P, 2007, HUM MOL GENET, V16, P1794, DOI 10.1093/hmg/ddm127; Buentig N, 2004, CANCER BIOTHER RADIO, V19, P331, DOI 10.1089/1084978041425007; Capon F, 2004, HUM MOL GENET, V13, P2361, DOI 10.1093/hmg/ddh273; Chen BSE, 2006, GENET EPIDEMIOL, V30, P495, DOI 10.1002/gepi.20162; Dalhoff K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fujioka T, 2000, WORLD J SURG, V24, P1205, DOI 10.1007/s002680010206; Fukazawa T, 1999, J NEUROL SCI, V166, P47, DOI 10.1016/S0022-510X(99)00112-4; Handoko H, 2006, AM J HUM BIOL, V18, P415, DOI 10.1002/ajhb.20504; Holick CN, 2007, CANCER EPIDEM BIOMAR, V16, P1990, DOI 10.1158/1055-9965.EPI-07-0487; Holick MF, 2006, PROG BIOPHYS MOL BIO, V92, P49, DOI 10.1016/j.pbiomolbio.2006.02.014; Hsu CC, 2007, AM J EPIDEMIOL, V166, P62, DOI 10.1093/aje/kwm043; Hung RJ, 2008, CANCER EPIDEM BIOMAR, V17, P3081, DOI 10.1158/1055-9965.EPI-08-0411; Hunt JD, 2005, INT J CANCER, V114, P101, DOI 10.1002/ijc.20618; Ikuyama T, 2002, ENDOCR J, V49, P433, DOI 10.1507/endocrj.49.433; *INT AG RES CANC, GLOBACAN; Karami S, 2008, J TOXICOL ENV HEAL A, V71, P367, DOI 10.1080/15287390701798685; Kong G, 2005, CANCER RES, V65, P3462, DOI 10.1158/0008-5472.CAN-03-2912; Lawrence JA, 1998, CANCER EPIDEM BIOMAR, V7, P29; Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Ma J, 1998, CANCER EPIDEM BIOMAR, V7, P385; Maalej A, 2005, GENES IMMUN, V6, P707, DOI 10.1038/sj.gene.6364260; Madej A, 2003, NEPHRON EXP NEPHROL, V93, P150, DOI 10.1159/000070239; Martinet N, 2000, CANCER RES, V60, P2869; Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262; Nejentsev S, 2004, HUM MOL GENET, V13, P1633, DOI 10.1093/hmg/ddh169; Norman AW, 1998, AM J CLIN NUTR, V67, P1108, DOI 10.1093/ajcn/67.6.1108; Obara W, 2007, INT J UROL, V14, P483, DOI 10.1111/j.1442-2042.2007.01771.x; Ordonez-Moran P, 2005, FRONT BIOSCI-LANDMRK, V10, P2723, DOI 10.2741/1731; Packer BR, 2006, NUCLEIC ACIDS RES, V34, pD617, DOI 10.1093/nar/gkj151; Prufer K, 2002, MOL ENDOCRINOL, V16, P961, DOI 10.1210/me.16.5.961; Puzianowska-Kuznicka M, 2000, CANCER LETT, V155, P145, DOI 10.1016/S0304-3835(00)00416-X; Sauna ZE, 2007, CANCER RES, V67, P9609, DOI 10.1158/0008-5472.CAN-07-2377; Sawada N, 2004, BIOCHEMISTRY-US, V43, P4530, DOI 10.1021/bi030207f; Slattery ML, 2007, NUTR REV, V65, pS102, DOI 10.1111/j.1753-4887.2007.tb00332.x; Tokar E, 2005, CLIN EXP METASTAS, V22, P275, DOI 10.1007/s10585-005-8393-z; Trump DL, 2004, J STEROID BIOCHEM, V89-90, P519, DOI 10.1016/j.jsbmb.2004.03.068; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; Valdivielso JM, 2006, CLIN CHIM ACTA, V371, P1, DOI 10.1016/j.cca.2006.02.016; Verboven C, 2002, NAT STRUCT BIOL, V9, P131, DOI 10.1038/nsb754; Vidal M, 2002, MOL CELL BIOL, V22, P2777, DOI 10.1128/MCB.22.8.2777-2787.2002; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P885; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P513; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719	48	28	29	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7013	10.1371/journal.pone.0007013	http://dx.doi.org/10.1371/journal.pone.0007013			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753122	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796500006
J	Kelly, TL; Wilson, KE; Heymsfield, SB				Kelly, Thomas L.; Wilson, Kevin E.; Heymsfield, Steven B.			Dual Energy X-Ray Absorptiometry Body Composition Reference Values from NHANES	PLOS ONE			English	Article								In 2008 the National Center for Health Statistics released a dual energy x-ray absorptiometry (DXA) whole body dataset from the NHANES population-based sample acquired with modern fan beam scanners in 15 counties across the United States from 1999 through 2004. The NHANES dataset was partitioned by gender and ethnicity and DXA whole body measures of %fat, fat mass/height(2), lean mass/height(2), appendicular lean mass/height(2), %fat trunk/%fat legs ratio, trunk/limb fat mass ratio of fat, bone mineral content (BMC) and bone mineral density (BMD) were analyzed to provide reference values for subjects 8 to 85 years old. DXA reference values for adults were normalized to age; reference values for children included total and sub-total whole body results and were normalized to age, height, or lean mass. We developed an obesity classification scheme by using estabbody mass index (BMI) classification thresholds and prevalences in young adults to generate matching classification thresholds for Fat Mass Index (FMI; fat mass/height(2)). These reference values should be helpful in the evaluation of a variety of adult and childhood abnormalities involving fat, lean, and bone, for establishing entry criteria into clinical trials, and for other medical, research, and epidemiological uses.			Kelly, TL (corresponding author), Hologic Inc, Bedford, MA USA.	tkelly@hologic.com	Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425				[Anonymous], WHO TECH REP SER, V854, P1; Baim S, 2008, J CLIN DENSITOM, V11, P6, DOI 10.1016/j.jocd.2007.12.002; Bishop N, 2008, J CLIN DENSITOM, V11, P29, DOI 10.1016/j.jocd.2007.12.004; Bonnet E, 2005, J CLIN DENSITOM, V8, P287, DOI 10.1385/JCD:8:3:287; Cavalcanti RB, 2005, J CLIN DENSITOM, V8, P293, DOI 10.1385/JCD:8:3:293; Chumlea WC, 2002, INT J OBESITY, V26, P1596, DOI 10.1038/sj.ijo.0802167; Flegal KM, 2009, AM J CLIN NUTR, V89, P500, DOI 10.3945/ajcn.2008.26847; Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694; Gordon CM, 2008, J CLIN DENSITOM, V11, P43, DOI 10.1016/j.jocd.2007.12.005; Heymsfield SB, 2007, AM J CLIN NUTR, V86, P82, DOI 10.1093/ajcn/86.1.82; Hsu FC, 2005, OBES RES, V13, P312, DOI 10.1038/oby.2005.42; Iannuzzi-Sucich M, 2002, J GERONTOL A-BIOL, V57, pM772, DOI 10.1093/gerona/57.12.M772; Kyle UG, 2003, NUTRITION, V19, P597, DOI 10.1016/S0899-9007(03)00061-3; Law M, 2006, ANTIVIR THER, V11, P179; Leonard CM, 2009, PEDIATR RADIOL, V39, P148, DOI 10.1007/s00247-008-1067-7; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; LOOKER AC, 2008, AGE GENDER RACE ETHN; Pan H, 2004, STAT MED, V23, P1749, DOI 10.1002/sim.1692; Schoeller DA, 2005, AM J CLIN NUTR, V81, P1018; Schoenau E, 2002, CALCIFIED TISSUE INT, V70, P405, DOI 10.1007/s00223-001-0048-8; VANITALLIE TB, 1990, AM J CLIN NUTR, V52, P953, DOI 10.1093/ajcn/52.6.953; WHO TECH REP SER, V894, pR1; WHO TECH REP SER, V894, P1	23	638	655	4	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7038	10.1371/journal.pone.0007038	http://dx.doi.org/10.1371/journal.pone.0007038			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753111	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796500019
J	Medendorp, K; van Groningen, JJM; Vreede, L; Hetterschijt, L; van den Hurk, WH; de Bruijn, DRH; Brugmans, L; van Kessel, AG				Medendorp, Klaas; van Groningen, Jan J. M.; Vreede, Lilian; Hetterschijt, Lisette; van den Hurk, Wilhelmina H.; de Bruijn, Diederik R. H.; Brugmans, Linda; van Kessel, Ad Geurts			The Mitotic Arrest Deficient Protein MAD2B Interacts with the Small GTPase RAN throughout the Cell Cycle	PLOS ONE			English	Article								Background: Previously, we identified the mitotic arrest deficient protein MAD2B (MAD2L2) as a bona fide interactor of the renal cell carcinoma (RCC)-associated protein PRCC. In addition, we found that fusion of PRCC with the transcription factor TFE3 in t(X;1)(p11;q21)-positive RCCs results in an impairment of this interaction and, concomitantly, an abrogation of cell cycle progression. Although MAD2B is thought to inhibit the anaphase promoting complex (APC) by binding to CDC20 and/or CDH1(FZR1), its exact role in cell cycle control still remains to be established. Methodology/Principal Findings: Using a yeast two-hybrid interaction trap we identified the small GTPase RAN, a well-known cell cycle regulator, as a novel MAD2B binding protein. Endogenous interaction was established in mammalian cells via co-localization and co-immunoprecipitation of the respective proteins. The interaction domain of RAN could be assigned to a C-terminal moiety of 60 amino acids, whereas MAD2B had to be present in its full-length conformation. The MAD2B-RAN interaction was found to persist throughout the cell cycle. During mitosis, co-localization at the spindle was observed. Conclusions/Significance: The small GTPase RAN is a novel MAD2B binding protein. This novel protein-protein interaction may play a role in (i) the control over the spindle checkpoint during mitosis and (ii) the regulation of nucleocytoplasmic trafficking during interphase.			Medendorp, K (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.	a.geurtsvankessel@antrg.umcn.nl	Vreede, Lilian/E-2557-2018; van Kessel, Ad Geurts/A-2810-2010; de Bruijn, D.R.H./L-4233-2015					Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01257-2; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; BRONS PPT, 1990, CYTOMETRY, V11, P837, DOI 10.1002/cyto.990110710; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Chan SH, 2001, EUR J BIOCHEM, V268, P2107, DOI 10.1046/j.1432-1327.2001.02091.x; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; de Bruijn DRH, 2008, ONCOGENE, V27, P653, DOI 10.1038/sj.onc.1210688; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Hardwick KG, 2005, CURR BIOL, V15, pR122, DOI 10.1016/j.cub.2005.02.008; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Hong CF, 2009, J BIOL CHEM, V284, P19613, DOI 10.1074/jbc.M109.005017; Hoyt MA, 2000, CELL, V102, P267, DOI 10.1016/S0092-8674(00)00031-3; Iwai H, 2007, CELL, V130, P611, DOI 10.1016/j.cell.2007.06.043; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Kalab P, 2006, NATURE, V440, P697, DOI 10.1038/nature04589; Kantardzhieva A, 2005, INVEST OPHTH VIS SCI, V46, P2192, DOI 10.1167/iovs.04-1417; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lenart P, 2006, CURR BIOL, V16, pR412, DOI 10.1016/j.cub.2006.05.008; Li L, 2007, MOL CELL BIOCHEM, V304, P297, DOI 10.1007/s11010-007-9512-8; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Medendorp K, 2009, EXP CELL RES, V315, P2399, DOI 10.1016/j.yexcr.2009.04.022; Murakumo Y, 2002, MUTAT RES-FUND MOL M, V510, P37, DOI 10.1016/S0027-5107(02)00250-6; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Sanderson HS, 2006, CURR BIOL, V16, pR466, DOI 10.1016/j.cub.2006.05.032; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Thornton BR, 2006, GENE DEV, V20, P449, DOI 10.1101/gad.1396906; van den Hurk WH, 2004, CYTOGENET GENOME RES, V106, P68, DOI 10.1159/000078562; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zhang L, 2007, MOL CELL BIOL, V27, P2861, DOI 10.1128/MCB.02276-06; Zheng YX, 2004, ANNU REV CELL DEV BI, V20, P867, DOI 10.1146/annurev.cellbio.20.012103.094648	39	23	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7020	10.1371/journal.pone.0007020	http://dx.doi.org/10.1371/journal.pone.0007020			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753112	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796500010
J	McKinnon, LR; Mao, XJ; Kimani, J; Wachihi, C; Semeniuk, C; Mendoza, M; Liang, BH; Luo, M; Fowke, KR; Plummer, FA; Ball, TB				McKinnon, Lyle R.; Mao, Xiaojuan; Kimani, Joshua; Wachihi, Charles; Semeniuk, Christina; Mendoza, Mark; Liang, Binhua; Luo, Ma; Fowke, Keith R.; Plummer, Francis A.; Ball, T. Blake			Epitope Mapping of HIV-Specific CD8+T cells in a Cohort Dominated by Clade A1 Infection	PLOS ONE			English	Article								Background: CD8+ T cell responses are often detected at large magnitudes in HIV-infected subjects, and eliciting these responses is the central aim of many HIV-1 vaccine strategies. Population differences in CD8+ T cell epitope specificity will need to be understood if vaccines are to be effective in multiple geographic regions. Methodology/Principal Findings: In a large Kenyan cohort, we compared responsive CD8+ T cell HIV-1 Env overlapping peptides (OLPs) to Best Defined Epitopes (BDEs), many of which have been defined in clade B infection. While the majority of BDEs (69%) were recognized in this population, nearly half of responsive OLPs (47%) did not contain described epitopes. Recognition frequencies of BDEs were inversely correlated to epitopic sequence differences between clade A1 and BDE (P = 0.019), and positively selected residues were more frequent in "new'' OLPs ( without BDEs). We assessed the impact of HLA and TAP binding on epitope recognition frequencies, focusing on predicted and actual epitopes in the HLA B7 supertype. Conclusions/Significance: Although many previously described CD8 epitopes were recognized, several novel CD8 epitopes were defined in this population, implying that epitope mapping efforts have not been completely exhausted. Expansion of these studies will be critical to understand population differences in CD8 epitope recognition.			McKinnon, LR (corresponding author), Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.	sijuisijali@gmail.com	Liang, Binhua/ABN-9806-2022	liang, binhua/0000-0002-1108-6407; McKinnon, Lyle/0000-0002-7157-0700; Fowke, Keith/0000-0001-8227-6649	NIAID NIH HHS [R01 AI56980 A1, R01 AI056980] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003; Bansal A, 2006, AIDS, V20, P353, DOI 10.1097/01.aids.0000206501.16783.67; Barugahare B, 2005, J VIROL, V79, P4132, DOI 10.1128/JVI.79.7.4132-4139.2005; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Bhasin M, 2004, PROTEIN SCI, V13, P596, DOI 10.1110/ps.03373104; Bihl F, 2006, J IMMUNOL, V176, P4094, DOI 10.4049/jimmunol.176.7.4094; Chen Z, 2001, STUD FUZZ SOFT COMP, V62, P1; Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450; Currier JR, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-8; Frahm N, 2006, NAT IMMUNOL, V7, P173, DOI 10.1038/ni1281; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; FRAHM N, 2005, HIV MOL IMMUNOLOGY, P3; Frahm N, 2007, J IMMUNOL, V179, P6638, DOI 10.4049/jimmunol.179.10.6638; Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365; Geels MJ, 2005, J VIROL, V79, P11247, DOI 10.1128/JVI.79.17.11247-11258.2005; Geldmacher C, 2007, AIDS, V21, P135, DOI 10.1097/01.aids.0000247589.77061.f7; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Liang BH, 2008, CURR HIV RES, V6, P370, DOI 10.2174/157016208785132554; Luo M, 2002, TISSUE ANTIGENS, V59, P370, DOI 10.1034/j.1399-0039.2002.590503.x; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; McKinnon LR, 2005, JAIDS-J ACQ IMM DEF, V40, P245, DOI 10.1097/01.qai.0000184858.16447.04; MCKINNON LR, 2008, J ACQUIR IMMUNE DEFI; McKinnon LR, 2007, J IMMUNOL, V178, P3750, DOI 10.4049/jimmunol.178.6.3750; Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; Peters HO, 2008, J VIROL, V82, P1980, DOI 10.1128/JVI.02742-06; Rutebemberwa A, 2005, AIDS, V19, P1165, DOI 10.1097/01.aids.0000176216.02743.98; Saavedra-Lozano J, 2006, PEDIATR INFECT DIS J, V25, P1142, DOI 10.1097/01.inf.0000246976.40494.af; Sabado RL, 2005, J IMMUNOL METHODS, V296, P1, DOI 10.1016/j.jim.2004.09.017; Schaubert KL, 2007, J IMMUNOL, V178, P7756, DOI 10.4049/jimmunol.178.12.7756; Scheliens IMM, 2008, AIDS, V22, P33, DOI 10.1097/QAD.0b013e3282f15622; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737; Thakar MR, 2005, J INFECT DIS, V192, P749, DOI 10.1086/432547; Tsegaye A, 2007, JAIDS-J ACQ IMM DEF, V45, P389, DOI 10.1097/QAI.0b013e318059beaa; Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005; Yu XG, 2005, AIDS, V19, P1449, DOI 10.1097/01.aids.0000183126.32077.c8; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	40	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6965	10.1371/journal.pone.0006965	http://dx.doi.org/10.1371/journal.pone.0006965			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750221	gold, Green Published, Green Submitted			2022-12-27	WOS:000269696600009
J	Costa, MA; Matheson, C; Iachetta, L; Llagostera, A; Appenzeller, O				Antonietta Costa, Maria; Matheson, Carney; Iachetta, Lucia; Llagostera, Agustin; Appenzeller, Otto			Ancient Leishmaniasis in a Highland Desert of Northern Chile	PLOS ONE			English	Article								Background: Leishmaniasis is an infectious disease endemic today in many areas of South America. Methodology: We discovered morphologic and molecular evidence of ancient infections in 4 female skulls in the archaeological cemetery of Coyo Oriente, in the desert of San Pedro de Atacama, Northern Chile. The boney facial lesions visible in the skulls could have been caused by a number of chronic infections including chronic Leishmaniasis. This diagnosis was confirmed using PCR-sequenced analyses of bone fragments from the skulls of the affected individuals. Leishmaniasis is not normally found in the high-altitude desert of Northern Chile; where the harsh climate does not allow the parasite to complete its life cycle. The presence of Leishmaniasis in ancient skulls from the region implies infection by the protozoan in an endemic area-likely, in our subjects, to have been the lowlands of North-Eastern Argentina or in Southern Bolivia. Conclusions: We propose that the presence of the disease in ancient times in the high altitude desert of San Pedro de Atacama is the result of an exogamic system of patrilocal marriages, where women from different cultures followed their husbands to their ancestral homes, allowing immigrant women, infected early in life, to be incorporated in the Atacama desert society before they became disfigured by the disease. The present globalization of goods and services and the extraordinary facile movement of people across borders and continents have lead to a resurgence of infectious diseases and re-emergence of infections such as Leishmaniasis. We show here that such factors were already present millennia ago, shaping demographic trends and the epidemiology of infections just as they do today.			Costa, MA (corresponding author), Univ Catolica Norte, Inst Invest Arqueol & Museo, San Pedro De Atacama, Chile.	oarun@unm.edu	Matheson, Carney/ABE-5699-2020	Matheson, Carney/0000-0002-3890-1838				ALISON MJ, 1984, PALEOPATHOLOGY ORIGI, P515; ALTAMIRANO AJ, 2000, THESIS FUNDACAO OSWA; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bass W. M., 2005, HUMAN OSTEOLOGY LAB, V5th; Berenguer Jose, 1986, CHUGARA, V5, P17; COCKBURN TA, 1998, MUMMIES DIS ANCIENT, P135; FAUCI AS, 2009, HARRISONS PRINCIPLES, pCH205; HRDLICKA A, 1914, SMITHSONIAN MISCELLA, V61, P57; Le Paige G., 1972, ACTAS 6 CONGRESO ARQ; LLAGOSTERA A, 2006, HIST ANDINA, V32, P303; Llagostera A., 2004, ANTIGUOS HABITANTES; Llagostera A, 1995, B MUSEO CHILENO ARTE, P9; Llagostera Agustin, 1996, INTEGACION ANDINA 5, P17; MEINDL RS, 1985, AM J PHYS ANTHROPOL, V68, P57, DOI 10.1002/ajpa.1330680106; Rathor H. R., 1996, Eastern Mediterranean Health Journal, V2, P61; SUMMER JW, 1987, THESIS U CALIFORNIA; SUMMER JW, 1992, DIS DEMOGRAPHY AM, P15; TELLO JC, 1908, THESIS UNMSM LIMA; TORRES CM, 1991, CURR ANTHROPOL, V32, P640, DOI 10.1086/204014; UBELAKER DH, 1989, MANUAL ARCHAEOLOGY, V2; WEISS P, 1984, B LIMA, V33, P17; WEISS PH, 1970, PATHOLOGY; WEISS PH, 1943, LIMA MEDI MAGAZINECA, V2, P209; *WHO, 2007, DIS ITS EP; *WHO, 1984, TECHN REP SER WHO, V701; Zink AR, 2006, EMERG INFECT DIS, V12, P1616, DOI 10.3201/eid1210.060169	26	29	31	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6983	10.1371/journal.pone.0006983	http://dx.doi.org/10.1371/journal.pone.0006983			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746163	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696500004
J	Arumugam, PI; Urbinati, F; Velu, CS; Higashimoto, T; Grimes, HL; Malik, P				Arumugam, Paritha I.; Urbinati, Fabrizia; Velu, Chinavenmeni S.; Higashimoto, Tomoyasu; Grimes, H. Leighton; Malik, Punam			The 3 ' Region of the Chicken Hypersensitive Site-4 Insulator Has Properties Similar to Its Core and Is Required for Full Insulator Activity	PLOS ONE			English	Article							HUMAN BETA-GLOBIN; RETROVIRAL VECTOR DESIGN; LOCUS-CONTROL REGION; CHROMATIN INSULATOR; CHS4 INSULATOR; GENE-THERAPY; HISTONE MODIFICATION; REGULATORY ELEMENTS; ENHANCER BLOCKING; CTCF-BINDING	Chromatin insulators separate active transcriptional domains and block the spread of heterochromatin in the genome. Studies on the chicken hypersensitive site-4 (cHS4) element, a prototypic insulator, have identified CTCF and USF-1/2 motifs in the proximal 250 bp of cHS4, termed the "core'', which provide enhancer blocking activity and reduce position effects. However, the core alone does not insulate viral vectors effectively. The full-length cHS4 has excellent insulating properties, but its large size severely compromises vector titers. We performed a structure-function analysis of cHS4 flanking lentivirus-vectors and analyzed transgene expression in the clonal progeny of hematopoietic stem cells and epigenetic changes in cHS4 and the transgene promoter. We found that the core only reduced the clonal variegation in expression. Unique insulator activity resided in the distal 400 bp cHS4 sequences, which when combined with the core, restored full insulator activity and open chromatin marks over the transgene promoter and the insulator. These data consolidate the known insulating activity of the canonical 59 core with a novel 39 400 bp element with properties similar to the core. Together, they have excellent insulating properties and viral titers. Our data have important implications in understanding the molecular basis of insulator function and design of gene therapy vectors.			Arumugam, PI (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.	Punam.Malik@cchmc.org		Higashimoto, Tomoyasu/0000-0003-0435-065X; Grimes, H. Leighton/0000-0001-8162-6758	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070135, Z01HL006008, P01HL073104, R01HL079574, U54HL070595] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HL006008] Funding Source: Medline; NHLBI NIH HHS [U54 HL070595, R01 HL079574, R01-HL70135-01, U54-HL06-008, P01 HL073104, HL079574, R01 HL070135, U54-HL070595, P01-HL073104] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aker M, 2007, HUM GENE THER, V18, P333, DOI 10.1089/hum.2007.021; Arumugam PI, 2007, MOL THER, V15, P1863, DOI 10.1038/sj.mt.6300259; Bell A, 1998, COLD SPRING HARB SYM, V63, P509, DOI 10.1101/sqb.1998.63.509; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Carr JM, 2001, ARCH VIROL, V146, P2191, DOI 10.1007/s007050170029; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; Crusselle-Davis VJ, 2006, MOL CELL BIOL, V26, P6832, DOI 10.1128/MCB.01770-05; Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108; Elnitski L, 1997, J BIOL CHEM, V272, P369; Emery DW, 2002, BLOOD, V100, P2012, DOI 10.1182/blood-2002-01-0219; Evans-Galea MV, 2007, MOL THER, V15, P801, DOI 10.1038/sj.mt.6300103; Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Huang S, 2007, MOL CELL BIOL, V27, P7991, DOI 10.1128/MCB.01326-07; Imren S, 2002, P NATL ACAD SCI USA, V99, P14380, DOI 10.1073/pnas.212507099; JUNKER U, 1995, GENE THER, V2, P639; Kalberer CP, 2000, P NATL ACAD SCI USA, V97, P5411, DOI 10.1073/pnas.100082597; Kim A, 2007, MOL CELL BIOL, V27, P1271, DOI 10.1128/MCB.01684-06; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Kraunus J, 2004, GENE THER, V11, P1568, DOI 10.1038/sj.gt.3302309; Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103; Li CL, 2008, GENE THER, V15, P49, DOI 10.1038/sj.gt.3303009; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Modlich U, 2006, BLOOD, V108, P2545, DOI 10.1182/blood-2005-08-024976; Mohamedali A, 2004, MOL THER, V10, P249, DOI 10.1016/j.ymthe.2004.05.002; Moreau-Gaudry F, 2001, BLOOD, V98, P2664, DOI 10.1182/blood.V98.9.2664; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Neff T, 1997, STEM CELLS, V15, P265; Osborne CS, 1999, J VIROL, V73, P5490, DOI 10.1128/JVI.73.7.5490-5496.1999; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; Pant V, 2004, MOL CELL BIOL, V24, P3497, DOI 10.1128/MCB.24.8.3497-3504.2004; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PERUMBETI A, 2009, BLOOD; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Puthenveetil G, 2004, BLOOD, V104, P3445, DOI 10.1182/blood-2004-04-1427; Recillas-Targa F, 2002, P NATL ACAD SCI USA, V99, P6883, DOI 10.1073/pnas.102179399; Rivella S, 2000, J VIROL, V74, P4679, DOI 10.1128/JVI.74.10.4679-4687.2000; Ryu BY, 2008, BLOOD, V111, P1866, DOI 10.1182/blood-2007-04-085506; Ryu BY, 2007, BLOOD CELL MOL DIS, V39, P221, DOI 10.1016/j.bcmd.2007.05.003; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith ST, 2009, DEV BIOL, V328, P518, DOI 10.1016/j.ydbio.2008.12.039; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; STUMPH WE, 1984, P NATL ACAD SCI-BIOL, V81, P6667, DOI 10.1073/pnas.81.21.6667; URBINATI F, 2009, MOL THER; Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; West AG, 2004, MOL CELL, V16, P453, DOI 10.1016/j.molcel.2004.10.005; Williams A, 2008, J EXP MED, V205, P747, DOI 10.1084/jem.20080066; Xie XH, 2007, P NATL ACAD SCI USA, V104, P7145, DOI 10.1073/pnas.0701811104; Yannaki E, 2002, MOL THER, V5, P589, DOI 10.1006/mthe.2002.0582; Yao SY, 2003, NUCLEIC ACIDS RES, V31, P5317, DOI 10.1093/nar/gkg742; Yusufzai TM, 2004, P NATL ACAD SCI USA, V101, P8620, DOI 10.1073/pnas.0402938101; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zychlinski D, 2008, MOL THER, V16, P718, DOI 10.1038/mt.2008.5	66	52	55	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6995	10.1371/journal.pone.0006995	http://dx.doi.org/10.1371/journal.pone.0006995			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746166	Green Submitted, Green Published, gold			2022-12-27	WOS:000269696500008
J	Dickhaut, K; Hoepner, S; Eckhard, J; Wiesmueller, KH; Schindler, L; Jung, G; Falk, K; Roetzschke, O				Dickhaut, Katharina; Hoepner, Sabine; Eckhard, Jamina; Wiesmueller, Karl-Heinz; Schindler, Luise; Jung, Guenther; Falk, Kirsten; Roetzschke, Olaf			Enhancement of Tumour-Specific Immune Responses In Vivo by 'MHC Loading-Enhancer' (MLE)	PLOS ONE			English	Article							T-CELL CLONES; PEPTIDE-RECEPTIVE STATE; PARTICLE VACCINE; LIGAND-EXCHANGE; DENDRITIC CELLS; YOUNG-WOMEN; NY-ESO-1; ANTIGEN; IDENTIFICATION; LYMPHOCYTES	Background: Class II MHC molecules (MHC II) are cell surface receptors displaying short protein fragments for the surveillance by CD4+ T cells. Antigens therefore have to be loaded onto this receptor in order to induce productive immune responses. On the cell surface, most MHC II molecules are either occupied by ligands or their binding cleft has been blocked by the acquisition of a non-receptive state. Direct loading with antigens, as required during peptide vaccinations, is therefore hindered. Principal Findings: Here we show, that the in vivo response of CD4+ T cells can be improved, when the antigens are administered together with 'MHC-loading enhancer' (MLE). MLE are small catalytic compounds able to open up the MHC binding site by triggering ligand-release and stabilizing the receptive state. Their enhancing effect on the immune response was demonstrated here with an antigen from the influenza virus and tumour associated antigens (TAA) derived from the NYESO-1 protein. The application of these antigens in combination with adamantane ethanol (AdEtOH), an MLE compound active on human HLA-DR molecules, significantly increased the frequency of antigen-specific CD4+ T cells in mice transgenic for the human MHC II molecule. Notably, the effect was evident only with the MLE-susceptible HLA-DR molecule and not with murine MHC II molecules non-susceptible for the catalytic effect of the MLE. Conclusion: MLE can specifically increase the potency of a vaccine by facilitating the efficient transfer of the antigen onto the MHC molecule. They may therefore open a new way to improve vaccination efficacy and tumour-immunotherapy.			Dickhaut, K (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.	falk@mdc-berlin.de						Bouneaud C, 2000, IMMUNITY, V13, P829, DOI 10.1016/S1074-7613(00)00080-7; Call MJ, 2009, J IMMUNOL, V182, P6342, DOI 10.4049/jimmunol.0803464; Chen QY, 2004, P NATL ACAD SCI USA, V101, P9363, DOI 10.1073/pnas.0403271101; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; Falk K, 2002, J BIOL CHEM, V277, P2709, DOI 10.1074/jbc.M109098200; FFRENCH RA, 1989, J VIROL, V63, P3087, DOI 10.1128/JVI.63.7.3087-3094.1989; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Gnjatic S, 2006, ADV CANCER RES, V95, P1, DOI 10.1016/S0065-230X(06)95001-5; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Gupta S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001814; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Hopner S, 2006, J BIOL CHEM, V281, P38535, DOI 10.1074/jbc.M606437200; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jager E, 2000, J EXP MED, V191, P625, DOI 10.1084/jem.191.4.625; JANEWAY C, 1989, COLD SPRING HARB S Q; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Marin-Esteban V, 2004, J BIOL CHEM, V279, P50684, DOI 10.1074/jbc.M407598200; Marin-Esteban V, 2003, J AUTOIMMUN, V20, P63, DOI 10.1016/S0896-8411(02)00107-5; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Nicholson MJ, 2006, J IMMUNOL, V176, P4208, DOI 10.4049/jimmunol.176.7.4208; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Rosloniec EF, 1997, J EXP MED, V185, P1113, DOI 10.1084/jem.185.6.1113; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7; WIESMULLER KH, 1989, VACCINE, V7, P29, DOI 10.1016/0264-410X(89)90007-8; Zarour HM, 2002, CANCER RES, V62, P213; Zarour HM, 2000, CANCER RES, V60, P4946; Zeng G, 2000, J IMMUNOL, V165, P1153, DOI 10.4049/jimmunol.165.2.1153	41	11	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6811	10.1371/journal.pone.0006811	http://dx.doi.org/10.1371/journal.pone.0006811			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738910	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300003
J	Gutierrez, J				Gutierrez, Jayson			A Developmental Systems Perspective on Epistasis: Computational Exploration of Mutational Interactions in Model Developmental Regulatory Networks	PLOS ONE			English	Article							GAP GENE SYSTEM; DELETERIOUS MUTATIONS; POSITIONAL INFORMATION; DROSOPHILA-MELANOGASTER; STATISTICAL EPISTASIS; EVOLUTION; ROBUSTNESS; ARCHITECTURE; COMPLEXITY; EXPRESSION	The way in which the information contained in genotypes is translated into complex phenotypic traits (i.e. embryonic expression patterns) depends on its decoding by a multilayered hierarchy of biomolecular systems (regulatory networks). Each layer of this hierarchy displays its own regulatory schemes (i.e. operational rules such as +/- feedback) and associated control parameters, resulting in characteristic variational constraints. This process can be conceptualized as a mapping issue, and in the context of highly-dimensional genotype-phenotype mappings (GPMs) epistatic events have been shown to be ubiquitous, manifested in non-linear correspondences between changes in the genotype and their phenotypic effects. In this study I concentrate on epistatic phenomena pervading levels of biological organization above the genetic material, more specifically the realm of molecular networks. At this level, systems approaches to studying GPMs are specially suitable to shed light on the mechanistic basis of epistatic phenomena. To this aim, I constructed and analyzed ensembles of highly-modular (fully interconnected) networks with distinctive topologies, each displaying dynamic behaviors that were categorized as either arbitrary or functional according to early patterning processes in the Drosophila embryo. Spatio-temporal expression trajectories in virtual syncytial embryos were simulated via reaction-diffusion models. My in silico mutational experiments show that: 1) the average fitness decay tendency to successively accumulated mutations in ensembles of functional networks indicates the prevalence of positive epistasis, whereas in ensembles of arbitrary networks negative epistasis is the dominant tendency; and 2) the evaluation of epistatic coefficients of diverse interaction orders indicates that, both positive and negative epistasis are more prevalent in functional networks than in arbitrary ones. Overall, I conclude that the phenotypic and fitness effects of multiple perturbations are strongly conditioned by both the regulatory architecture (i.e. pattern of coupled feedback structures) and the dynamic nature of the spatio-temporal expression trajectories displayed by the simulated networks.	Univ Antioquia, Inst Fis, Grp Fis & Astrofis Computac, Medellin, Colombia	Universidad de Antioquia	Gutierrez, J (corresponding author), Univ Antioquia, Inst Fis, Grp Fis & Astrofis Computac, Medellin, Colombia.	jayson.gutierrez@siu.udea.edu.co						Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; Azevedo L, 2006, TRENDS GENET, V22, P581, DOI 10.1016/j.tig.2006.08.001; Azevedo RBR, 2006, NATURE, V440, P87, DOI 10.1038/nature04488; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bergman A, 2003, NATURE, V424, P549, DOI 10.1038/nature01765; Boone C, 2007, NAT REV GENET, V8, P437, DOI 10.1038/nrg2085; Carter AJR, 2005, THEOR POPUL BIOL, V68, P179, DOI 10.1016/j.tpb.2005.05.002; Carter GW, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100137; Ciliberti S, 2007, PLOS COMPUT BIOL, V3, P164, DOI 10.1371/journal.pcbi.0030015; Davis GK, 2002, ANNU REV ENTOMOL, V47, P669, DOI 10.1146/annurev.ento.47.091201.145251; Dayarian A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000256; Dichtel-Danjoy ML, 2004, TRENDS GENET, V20, P268, DOI 10.1016/j.tig.2004.03.010; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Elena SF, 1999, J MOL EVOL, V49, P703, DOI 10.1007/PL00000082; Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52; Giaever G, 2009, NAT BIOTECHNOL, V27, P149, DOI 10.1038/nbt0209-149; Gibson G, 1996, THEOR POPUL BIOL, V49, P58, DOI 10.1006/tpbi.1996.0003; Gjuvsland AB, 2007, GENETICS, V175, P411, DOI 10.1534/genetics.106.058859; Gjuvsland AB, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-57; Gould SJ, 1997, P NATL ACAD SCI USA, V94, P10750, DOI 10.1073/pnas.94.20.10750; Han JDJ, 2008, CELL RES, V18, P224, DOI 10.1038/cr.2008.16; Hansen TF, 2006, EVOLUTION, V60, P1523; Hansen TF, 2006, ANNU REV ECOL EVOL S, V37, P123, DOI 10.1146/annurev.ecolsys.37.091305.110224; Holland JB, 2007, CURR OPIN PLANT BIOL, V10, P156, DOI 10.1016/j.pbi.2007.01.003; Jaeger J, 2004, GENETICS, V167, P1721, DOI 10.1534/genetics.104.027334; Jaeger J, 2004, NATURE, V430, P368, DOI 10.1038/nature02678; Jaeger J, 2006, BIOESSAYS, V28, P1102, DOI 10.1002/bies.20494; Kwon YK, 2008, BIOINFORMATICS, V24, P987, DOI 10.1093/bioinformatics/btn060; Lenski RE, 1999, NATURE, V400, P661, DOI 10.1038/23245; Liu PZ, 2005, EVOL DEV, V7, P629, DOI 10.1111/j.1525-142X.2005.05066.x; Loewe L, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-27; Loewe L, 2008, LECT N BIOINFORMAT, V5307, P156, DOI 10.1007/978-3-540-88562-7_14; Maisnier-Patin S, 2005, NAT GENET, V37, P1376, DOI 10.1038/ng1676; Mani R, 2008, P NATL ACAD SCI USA, V105, P3461, DOI 10.1073/pnas.0712255105; Martin G, 2007, NAT GENET, V39, P555, DOI 10.1038/ng1998; Moore JH, 2005, BIOESSAYS, V27, P637, DOI 10.1002/bies.20236; Munteanu A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000226; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Perkins TJ, 2006, PLOS COMPUT BIOL, V2, P417, DOI 10.1371/journal.pcbi.0020051; Phillips PC, 2008, NAT REV GENET, V9, P855, DOI 10.1038/nrg2452; Prill RJ, 2005, PLOS BIOL, V3, P1881, DOI 10.1371/journal.pbio.0030343; Reinitz J, 1998, DEV GENET, V23, P11, DOI 10.1002/(SICI)1520-6408(1998)23:1<11::AID-DVG2>3.3.CO;2-Q; REINITZ J, 1995, J EXP ZOOL, V271, P47, DOI 10.1002/jez.1402710106; Rifkin SA, 2005, NATURE, V438, P220, DOI 10.1038/nature04114; Rivero A, 2003, EVOLUTION, V57, P1698, DOI 10.1111/j.0014-3820.2003.tb00375.x; Roix J, 2002, HISTOCHEM CELL BIOL, V118, P105, DOI 10.1007/s00418-002-0446-7; ROTH FP, 2009, EPISTASIS J BIOL, V8, P35; Sanjuan R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002663; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Sharp DH, 1998, BIOSYSTEMS, V47, P79, DOI 10.1016/S0303-2647(98)00014-8; Slonim N, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100047; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Tyler AL, 2009, BIOESSAYS, V31, P220, DOI 10.1002/bies.200800022; Van Driessche N, 2005, NAT GENET, V37, P471, DOI 10.1038/ng1545; Veitia RA, 2006, BIOESSAYS, V28, P282, DOI 10.1002/bies.20377; Wang XW, 2008, CURR OPIN BIOTECH, V19, P482, DOI 10.1016/j.copbio.2008.07.011; Weinreich DM, 2005, EVOLUTION, V59, P1165; Wilke CO, 2001, P ROY SOC B-BIOL SCI, V268, P1469, DOI 10.1098/rspb.2001.1690; Zhu MJ, 2009, INT J BIOL SCI, V5, P161, DOI 10.7150/ijbs.5.161	59	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6823	10.1371/journal.pone.0006823	http://dx.doi.org/10.1371/journal.pone.0006823			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738908	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300004
J	Poon, AFY; Brouwer, KC; Strathdee, SA; Firestone-Cruz, M; Lozada, RM; Pond, SLK; Heckathorn, DD; Frost, SDW				Poon, Art F. Y.; Brouwer, Kimberly C.; Strathdee, Steffanie A.; Firestone-Cruz, Michelle; Lozada, Remedios M.; Pond, Sergei L. Kosakovsky; Heckathorn, Douglas D.; Frost, Simon D. W.			Parsing Social Network Survey Data from Hidden Populations Using Stochastic Context-Free Grammars	PLOS ONE			English	Article							INJECTION-DRUG USERS; RESPONDENT-DRIVEN; CITIES; HIV; TRAFFICKING; CONSUMPTION; PREVENTION; TRENDS; SPREAD; MEXICO	Background: Human populations are structured by social networks, in which individuals tend to form relationships based on shared attributes. Certain attributes that are ambiguous, stigmatized or illegal can create a OhiddenO population, so-called because its members are difficult to identify. Many hidden populations are also at an elevated risk of exposure to infectious diseases. Consequently, public health agencies are presently adopting modern survey techniques that traverse social networks in hidden populations by soliciting individuals to recruit their peers, e. g., respondent-driven sampling (RDS). The concomitant accumulation of network-based epidemiological data, however, is rapidly outpacing the development of computational methods for analysis. Moreover, current analytical models rely on unrealistic assumptions, e. g., that the traversal of social networks can be modeled by a Markov chain rather than a branching process. Methodology/Principal Findings: Here, we develop a new methodology based on stochastic context-free grammars (SCFGs), which are well-suited to modeling tree-like structure of the RDS recruitment process. We apply this methodology to an RDS case study of injection drug users (IDUs) in Tijuana, Mexico, a hidden population at high risk of blood-borne and sexually-transmitted infections (i.e., HIV, hepatitis C virus, syphilis). Survey data were encoded as text strings that were parsed using our custom implementation of the inside-outside algorithm in a publicly-available software package (HyPhy), which uses either expectation maximization or direct optimization methods and permits constraints on model parameters for hypothesis testing. We identified significant latent variability in the recruitment process that violates assumptions of Markov chain-based methods for RDS analysis: firstly, IDUs tended to emulate the recruitment behavior of their own recruiter; and secondly, the recruitment of like peers (homophily) was dependent on the number of recruits. Conclusions: SCFGs provide a rich probabilistic language that can articulate complex latent structure in survey data derived from the traversal of social networks. Such structure that has no representation in Markov chain-based models can interfere with the estimation of the composition of hidden populations if left unaccounted for, raising critical implications for the prevention and control of infectious disease epidemics.			Poon, AFY (corresponding author), Univ Calif San Diego, Div Comparat Pathol & Med, La Jolla, CA 92093 USA.	afpoon@ucsd.edu	Strathdee, Steffanie A/B-9042-2009; Poon, Art/W-9811-2019; Frost, Simon/F-3648-2010; Pond, Sergei LK/G-9830-2012	Poon, Art/0000-0003-3779-154X; Frost, Simon/0000-0002-5207-9879; Pond, Sergei LK/0000-0003-4817-4029; Strathdee, Steffanie/0000-0002-7724-691X	NIAID NIH HHS [AI57167, R01 AI047745, R56 AI047745, R21 AI080397, AI47745, AI36214-06, R01 AI057167, R01 AI47745, AI080397, R21 AI047745, P30 AI036214] Funding Source: Medline; NIDA NIH HHS [DA17934, K01DA020364, R01 DA019829, R37 DA019829, R01 DA009225, K01 DA020364, DA09225-S11, DA24998, R03 DA024998] Funding Source: Medline; NINR NIH HHS [R21 NR010961, NR10961] Funding Source: Medline; PHS HHS [U01 43638] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R56AI047745, R21AI080397, R21AI047745, R01AI047745, R01AI057167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R21NR010961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA020364, R01DA019829, R37DA019829, R03DA024998, R01DA009225] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abdul-Quader AS, 2006, J URBAN HEALTH, V83, pI1, DOI 10.1007/s11524-006-9108-8; Autebert J.-M., 1997, HDB FORMAL LANGUAGES, P111, DOI [DOI 10.1007/978-3-642-59136-5_3, 10.1007/978-3-642-59136-53, DOI 10.1007/978-3-642-59136-53]; Beyrer C, 2000, AIDS, V14, P75, DOI 10.1097/00002030-200001070-00009; Boily MC, 2000, SEX TRANSM DIS, V27, P558, DOI 10.1097/00007435-200011000-00004; Broadhead RS, 1999, PUBLIC HEALTH, V113, P42; Brouwer KC, 2006, SUBST USE MISUSE, V41, P707, DOI 10.1080/10826080500411478; Bucardo J, 2005, DRUG ALCOHOL DEPEN, V79, P281, DOI 10.1016/j.drugalcdep.2005.02.003; Burnham K. P., 2002, MODEL SELECTION MULT, V2nd; Cayley A., 1857, PHILOS MAG, V13, P172, DOI [10.1080/14786445708642275, DOI 10.1080/14786445708642275]; Chomsky Noam, 1975, LOGICAL STRUCTURE LI; Frost SDW, 2006, J URBAN HEALTH, V83, pI83, DOI 10.1007/s11524-006-9104-z; Fu K.S., 1974, MATH SCI ENG; Gelman A, 2007, STAT SCI, V22, P153, DOI 10.1214/088342306000000691; GOODMAN LA, 1961, ANN MATH STAT, V32, P148, DOI 10.1214/aoms/1177705148; Harris T. E., 1963, THEORY BRANCHING PRO; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; Heckathorn DD, 2001, POETICS, V28, P307, DOI 10.1016/S0304-422X(01)80006-1; Heckathorn DD, 2002, AIDS BEHAV, V6, P55; Johnston LG, 2006, J URBAN HEALTH, V83, pI16, DOI 10.1007/s11524-006-9099-5; KASAMI T, 1965, AFCRL65758 AIR FORC; McKnight C, 2006, J URBAN HEALTH, V83, pI54, DOI 10.1007/s11524-006-9102-1; MCMAHON JM, 2003, BMC MED RES METHODOL, V3; Pisani E, 2003, JAIDS-J ACQ IMM DEF, V34, P403, DOI 10.1097/00126334-200312010-00007; Platt L, 2006, J URBAN HEALTH, V83, pI39, DOI 10.1007/s11524-006-9101-2; Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079; Ramirez-Valles J, 2005, AIDS BEHAV, V9, P387, DOI 10.1007/s10461-005-9012-3; Robinson WT, 2006, J URBAN HEALTH, V83, pI29, DOI 10.1007/s11524-006-9100-3; Rzhetsky A, 2005, MOL BIOL EVOL, V22, P905, DOI 10.1093/molbev/msi074; Salganik MJ, 2004, SOCIOL METHODOL, V34, P193, DOI 10.1111/j.0081-1750.2004.00152.x; Simic M, 2006, J URBAN HEALTH, V83, pI6, DOI 10.1007/s11524-006-9098-6; SIPSER M, 1997, PWS SERIES COMPUTER; STERN M, 2005, TECHNICAL REPORT SOC; Stormer A, 2006, J URBAN HEALTH, V83, pI73, DOI 10.1007/s11524-006-9105-y; Thompson S.K., 1996, ADAPTIVE SAMPLING; Wang JC, 2005, DRUG ALCOHOL DEPEN, V78, P147, DOI 10.1016/j.drugalcdep.2004.10.011; WATTERS JK, 1989, SOC PROBL, V36, P416, DOI 10.1525/sp.1989.36.4.03a00070; Yeka W, 2006, J URBAN HEALTH, V83, pI60, DOI 10.1007/s11524-006-9103-0; YOUNGER DH, 1967, INFORM CONTROL, V10, P189, DOI 10.1016/S0019-9958(67)80007-X; Zheng T, 2006, J AM STAT ASSOC, V101, P409, DOI 10.1198/016214505000001168	40	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6777	10.1371/journal.pone.0006777	http://dx.doi.org/10.1371/journal.pone.0006777			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	491ZH	19738904	gold, Green Published, Green Submitted			2022-12-27	WOS:000269622300002
J	Vickers, DM; Zhang, Q; Osgood, ND				Vickers, David M.; Zhang, Qian; Osgood, Nathaniel D.			Immunobiological Outcomes of Repeated Chlamydial Infection from Two Models of Within-Host Population Dynamics	PLOS ONE			English	Article							SEXUALLY-TRANSMITTED INFECTIONS; GENITAL-TRACT INFECTION; TRACHOMATIS INFECTION; PROTECTIVE IMMUNITY; T-CELLS; RESPONSES; ANTIBODY; SUSCEPTIBILITY; EPIDEMIOLOGY; REINFECTION	Background: Chlamydia trachomatis is a common human pathogen that mediates disease processes capable of inflicting serious complications on reproduction. Aggressive inflammatory immune responses are thought to not only direct a person's level of immunity but also the potential for immunopathology. With human immunobiology being debated as a cause of prevailing epidemiological trends, we examined some fundamental issues regarding susceptibility to multiple chlamydial infections that could have implications for infection spread. We argue that, compared to less-frequent exposure, frequent exposure to chlamydia may well produce unique immunobiological characteristics that likely to have important clinical and epidemiological implications. Methods and Results: As a novel tool for studying chlamydia, we applied principles of modeling within-host pathogen dynamics to enable an understanding of some fundamental characteristics of an individual's immunobiology during multiple chlamydial infections. While the models were able to reproduce shorter-term infection kinetics of primary and secondary infections previously observed in animal models, it was also observed that longer periods between initial and second infection may increase an individual's chlamydial load and lengthen their duration of infectiousness. The cessation of short-term repeated exposure did not allow for the formation of long-lasting immunity. However, frequent re-exposure non-intuitively linked the formation of protective immunity, persistent infection, and the potential for immunopathology. Conclusions: Overall, these results provide interesting insights that should be verified with continued study. Nevertheless, these results appear to raise challenges for current evidence of the development of long-lasting immunity against chlamydia, and suggest the existence of a previously unidentified mechanism for the formation of persistent infection. The obvious next goal is to investigate the qualitative impact of these results on the spread of chlamydia.			Vickers, DM (corresponding author), Univ Saskatchewan, Dept Interdisciplinary Studies, Saskatoon, SK, Canada.	david.vickers@usask.ca	Osgood, Nathaniel/L-1805-2016; Zhang, Qian/M-5476-2017	Zhang, Qian/0000-0002-6157-9912				ANDERSON R M, 1991; Antia R, 1998, P NATL ACAD SCI USA, V95, P14926, DOI 10.1073/pnas.95.25.14926; Bavoil PM, 2000, MICROBIOL-UK, V146, P2723, DOI 10.1099/00221287-146-11-2723; Brady LJ, 2005, INFECT IMMUN, V73, P671, DOI 10.1128/IAI.73.2.671-678.2005; Brunham RC, 2005, J INFECT DIS, V192, P1836, DOI 10.1086/497341; Brunham RC, 2005, NAT REV IMMUNOL, V5, P149, DOI 10.1038/nri1551; BRUNHAM RC, 1994, SEX TRANSM DIS, V21, P353, DOI 10.1097/00007435-199411000-00010; BRUNHAM RC, 1999, CHLAMYDIA INTRACELLU; Brunham RC, 2008, SEX TRANSM DIS, V35, P53, DOI 10.1097/OLQ.0b013e31815e41a3; Callard R, 2007, IMMUNOL REV, V216, P119; Casadevall A, 2004, INFECT IMMUN, V72, P6191, DOI 10.1128/IAI.72.11.6191-6196.2004; Debattista J, 2003, FERTIL STERIL, V79, P1273, DOI 10.1016/S0015-0282(03)00396-0; GANTMACHER F. R., 1959, THEORY MATRICES; Garnett GP, 1996, J INFECT DIS, V174, pS150, DOI 10.1093/infdis/174.Supplement_2.S150; Heffernan JM, 2008, THEOR POPUL BIOL, V73, P134, DOI 10.1016/j.tpb.2007.10.003; IGIETSEME JU, 1991, INFECT IMMUN, V59, P1346, DOI 10.1128/IAI.59.4.1346-1351.1991; JAWETZ E, 1965, J AMER MED ASSOC, V194, P620; Johansson M, 1997, INFECT IMMUN, V65, P1032, DOI 10.1128/IAI.65.3.1032-1044.1997; Kaur A, 2008, J VIROL, V82, P1084, DOI 10.1128/JVI.02197-07; Kim PS, 2007, J THEOR BIOL, V246, P33, DOI 10.1016/j.jtbi.2006.12.012; Lena S, 2005, J INFECT DIS, V191, pS78, DOI 10.1086/425289; Leonhardt RM, 2007, INFECT IMMUN, V75, P5105, DOI 10.1128/IAI.00668-07; Low N, 2008, SEX TRANSM INFECT, V84, P80, DOI 10.1136/sti.2008.030338; Miller WC, 2008, SEX TRANSM INFECT, V84, P82, DOI 10.1136/sti.2007.028662; Mims C, 2002, MIMS PATHOGENESIS IN; Molano M, 2005, J INFECT DIS, V191, P907, DOI 10.1086/428287; Morre SA, 2002, INT J STD AIDS, V13, P12, DOI 10.1258/095646202762226092; Morrison RP, 2002, INFECT IMMUN, V70, P2741, DOI 10.1128/IAI.70.6.2741-2751.2002; MORRISON RP, 1995, INFECT IMMUN, V63, P4661, DOI 10.1128/IAI.63.12.4661-4668.1995; Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536; Ndoye I, 1998, SEX TRANSM INFECT, V74, pS112; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; Parks KS, 1997, SEX TRANSM DIS, V24, P229, DOI 10.1097/00007435-199704000-00008; Ramjee G, 1998, SEX TRANSM DIS, V25, P346, DOI 10.1097/00007435-199808000-00004; RANK RG, 1988, INFECT IMMUN, V56, P2243, DOI 10.1128/IAI.56.9.2243-2249.1988; Rekart ML, 2008, SEX TRANSM INFECT, V84, P87, DOI 10.1136/sti.2007.027938; Ribeiro RM, 2002, P NATL ACAD SCI USA, V99, P15572, DOI 10.1073/pnas.242358099; Sterman JD, 2006, AM J PUBLIC HEALTH, V96, P505, DOI 10.2105/AJPH.2005.066043; Su H, 1999, J INFECT DIS, V180, P1252, DOI 10.1086/315046; Su H, 1997, INFECT IMMUN, V65, P1993, DOI 10.1128/IAI.65.6.1993-1999.1997; Vickers DM, 2007, THEOR BIOL MED MODEL, V4, DOI 10.1186/1742-4682-4-49; Wodarz D, 2004, P ROY SOC B-BIOL SCI, V271, P1101, DOI 10.1098/rspb.2003.2664; Wodarz D, 2000, INT IMMUNOL, V12, P467, DOI 10.1093/intimm/12.4.467; Yao W, 2006, P R SOC B, V273, P2193, DOI 10.1098/rspb.2006.3563	46	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6886	10.1371/journal.pone.0006886	http://dx.doi.org/10.1371/journal.pone.0006886			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727394	gold, Green Published, Green Submitted			2022-12-27	WOS:000269522900015
J	Song, GS; Wang, L				Song, Guisheng; Wang, Li			Nuclear Receptor SHP Activates miR-206 Expression via a Cascade Dual Inhibitory Mechanism	PLOS ONE			English	Article								MicroRNAs play a critical role in many essential cellular functions in the mammalian species. However, limited information is available regarding the regulation of miRNAs gene transcription. Microarray profiling and real-time PCR analysis revealed a marked down-regulation of miR-206 in nuclear receptor SHP-/- mice. To understand the regulatory function of SHP with regard to miR-206 gene expression, we determined the putative transcriptional initiation site of miR-206 and also its full length primary transcript using a database mining approach and RACE. We identified the transcription factor AP1 binding sites on the miR-206 promoter and further showed that AP1 (c-Jun and c-Fos) induced miR-206 promoter transactivity and expression which was repressed by YY1. ChIP analysis confirmed the physical association of AP1 (c-Jun) and YY1 with the endogenous miR-206 promoter. In addition, we also identified nuclear receptor ERR gamma (NR3B3) binding site on the YY1 promoter and showed that YY1 promoter was transactivated by ERR gamma, which was inhibited by SHP (NROB2). ChIP analysis confirmed the ERR gamma binding to the YY1 promoter. Forced expression of SHP and AP1 induced miR-206 expression while overexpression of ERR gamma and YY1 reduced its expression. The effects of AP1, ERR gamma, and YY1 on miR-206 expression were reversed by siRNA knockdown of each gene, respectively. Thus, we propose a novel cascade "dual inhibitory'' mechanism governing miR-206 gene transcription by SHP: SHP inhibition of ERR gamma led to decreased YY1 expression and the derepression of YY1 on AP1 activity, ultimately leading to the activation of miR-206. This is the first report to elucidate a cascade regulatory mechanism governing miRNAs gene transcription.			Song, GS (corresponding author), Univ Utah, Sch Med, Dept Med, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	l.wang@hsc.utah.edu	song, guisheng/E-4913-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080440] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Anderson C, 2006, NUCLEIC ACIDS RES, V34, P5863, DOI 10.1093/nar/gkl743; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bavner A, 2005, TRENDS ENDOCRIN MET, V16, P478, DOI 10.1016/j.tem.2005.10.005; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fujimori S, 2003, FEBS LETT, V554, P17, DOI 10.1016/S0014-5793(03)01041-X; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hansen T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000873; He N, 2008, GASTROENTEROLOGY, V134, P793, DOI 10.1053/j.gastro.2008.01.006; Huang JS, 2007, HEPATOLOGY, V46, P147, DOI 10.1002/hep.21632; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Leibovitch BA, 2002, MOL CELL BIOL, V22, P6148, DOI 10.1128/MCB.22.17.6148-6157.2002; McCarthy JJ, 2008, BBA-GENE REGUL MECH, V1779, P682, DOI 10.1016/j.bbagrm.2008.03.001; Molina C, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-25; Morgante M, 2002, NAT GENET, V30, P194, DOI 10.1038/ng822; Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867; Park SM, 2008, CYTOKINE GROWTH F R, V19, P303, DOI 10.1016/j.cytogfr.2008.04.011; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Roccaro AM, 2009, BLOOD, V113, P4391, DOI 10.1182/blood-2008-09-178228; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Song GS, 2008, NUCLEIC ACIDS RES, V36, P5727, DOI 10.1093/nar/gkn567; Song GS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003574; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Walden TB, 2009, J CELL PHYSIOL, V218, P444, DOI 10.1002/jcp.21621; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wang L, 2005, CELL METAB, V2, P227, DOI 10.1016/j.cmet.2005.08.010; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Zhang YX, 2008, HEPATOLOGY, V48, P289, DOI 10.1002/hep.22342; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	34	39	40	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6880	10.1371/journal.pone.0006880	http://dx.doi.org/10.1371/journal.pone.0006880			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489XX	19721712	Green Submitted, Green Published, gold			2022-12-27	WOS:000269461100009
J	Lapan, P; Zhang, J; Hill, A; Zhang, Y; Martinez, R; Haney, S				Lapan, Peter; Zhang, Jing; Hill, Andrew; Zhang, Ying; Martinez, Robert; Haney, Steven			Image-Based Assessment of Growth and Signaling Changes in Cancer Cells Mediated by Direct Cell-Cell Contact	PLOS ONE			English	Article								Background: Many important biological processes are controlled through cell-cell interactions, including the colonization of metastatic tumor cells and the control of differentiation of stem cells within their niche. Despite the crucial importance of the cellular environment in regulating cellular signaling, in vitro methods for the study of such interactions are difficult and/or indirect. Methodology/Principal Findings: We report on the development of an image-based method for distinguishing two cell types grown in coculture. Furthermore, cells of one type that are in direct contact with cells of a second type (adjacent cells) can be analyzed separately from cells that are not within a single well. Changes are evaluated using population statistics, which are useful in detecting subtle changes across two populations. We have used this system to characterize changes in the LNCaP prostate carcinoma cell line when grown in contact with human vascular endothelial cells (HUVECs). We find that the expression and phosphorylation of WWOX is reduced in LNCaP cells when grown in direct contact with HUVECs. Reduced WWOX signaling has been associated with reduced activation or expression of JNK and p73. We find that p73 levels are also reduced in LNCaP cells grown in contact with HUVECs, but we did not observe such a change in JNK levels. Conclusions/Significance: We find that the method described is statistically robust and can be adapted to a wide variety of studies where cell function or signaling are affected by heterotypic cell-cell contact. Ironically, a potential challenge to the method is its high level of sensitivity is capable of classifying events as statistically significant (due to the high number cells evaluated individually), when the biological effect may be less clear. The methodology would be best used in conjunction with additional methods to evaluate the biological role of potentially subtle differences between populations. However, many important events, such as the establishment of a metastatic tumor, occur through rare but important changes, and methods such as we describe here can be used to identify and characterize the contribution of the environment to these changes.			Lapan, P (corresponding author), Wyeth Res, Dept Biol Technol, Cambridge, MA USA.	Steven.Haney@pfizer.com	Hill, Andrew F./GZL-4124-2022	Hill, Andrew F./0000-0001-5581-2354				Ahmad SA, 2002, SEMIN CANCER BIOL, V12, P105, DOI 10.1006/scbi.2001.0418; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Bander NH, 2006, NAT CLIN PRACT UROL, V3, P216, DOI 10.1038/ncpuro0452; Bednarek AK, 2001, CANCER RES, V61, P8068; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; CHAKRAVARTY A, 2008, HIGH CONTENT SCREENI, P269; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; COMLEY J, 2005, DRUG DISC WORLD, V6, P31; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Elpek Gulsum Ozlem, 2002, Pathology & Oncology Research, V8, P175; Fromigue O, 2003, ONCOGENE, V22, P8487, DOI 10.1038/sj.onc.1206918; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; Gaudio E, 2006, CANCER RES, V66, P11585, DOI 10.1158/0008-5472.CAN-06-3376; Giuliano KA, 1997, J BIOMOL SCREEN, V2, P249, DOI 10.1177/108705719700200410; Gottfried E, 2006, CELL CYCLE, V5, P691, DOI 10.4161/cc.5.7.2624; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haney S.A., 2008, HIGH CONTENT SCREENI; Haney SA, 2006, DRUG DISCOV TODAY, V11, P889, DOI 10.1016/j.drudis.2006.08.015; Huard C, 2007, GENOMICS, V89, P270, DOI 10.1016/j.ygeno.2006.10.006; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; Kerr DJ, 2004, NAT CLIN PRACT ONCOL, V1, P39, DOI 10.1038/ncponc0026; Khodarev NN, 2003, J CELL SCI, V116, P1013, DOI 10.1242/jcs.00281; Kim JB, 2005, SEMIN CANCER BIOL, V15, P365, DOI 10.1016/j.semcancer.2005.05.002; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Loo LH, 2007, NAT METHODS, V4, P445, DOI 10.1038/NMETH1032; MENDELSOHN J, 2001, MOL BASIS CANC; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Perlman ZE, 2004, SCIENCE, V306, P1194, DOI 10.1126/science.1100709; Qin HR, 2007, MOL CANCER RES, V5, P957, DOI 10.1158/1541-7786.MCR-07-0211; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Scholz D, 1996, CELL TISSUE RES, V284, P415, DOI 10.1007/s004410050602; Shen L, 2004, WORLD J GASTROENTERO, V10, P1682, DOI 10.3748/wjg.v10.i11.1682; Taylor D Lansing, 2005, Drug Discov Today Technol, V2, P149, DOI 10.1016/j.ddtec.2005.05.023; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Wang J, 2006, INT J MOL MED, V17, P849; Watanabe A, 2003, CANCER RES, V63, P8629	40	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6822	10.1371/journal.pone.0006822	http://dx.doi.org/10.1371/journal.pone.0006822			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19774227	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415900003
J	Rastegar, M; Hotta, A; Pasceri, P; Makarem, M; Cheung, AYL; Elliott, S; Park, KJ; Adachi, M; Jones, FS; Clarke, ID; Dirks, P; Ellis, J				Rastegar, Mojgan; Hotta, Akitsu; Pasceri, Peter; Makarem, Maisam; Cheung, Aaron Y. L.; Elliott, Shauna; Park, Katya J.; Adachi, Megumi; Jones, Frederick S.; Clarke, Ian D.; Dirks, Peter; Ellis, James			MECP2 Isoform-Specific Vectors with Regulated Expression for Rett Syndrome Gene Therapy	PLOS ONE			English	Article							CPG-BINDING PROTEIN; PLURIPOTENT STEM-CELLS; HISTONE DEACETYLASE; BDNF TRANSCRIPTION; MOUSE MODEL; NEURONS; DNA; DEFICIENCY; DISEASE; PHOSPHORYLATION	Background: Rett Syndrome (RTT) is an Autism Spectrum Disorder and the leading cause of mental retardation in females. RTT is caused by mutations in the Methyl CpG-Binding Protein-2 (MECP2) gene and has no treatment. Our objective is to develop viral vectors for MECP2 gene transfer into Neural Stem Cells (NSC) and neurons suitable for gene therapy of Rett Syndrome. Methodology/Principal Findings: We generated self-inactivating (SIN) retroviral vectors with the ubiquitous EF1 alpha promoter avoiding known silencer elements to escape stem-cell-specific viral silencing. High efficiency NSC infection resulted in long-term EGFP expression in transduced NSC and after differentiation into neurons. Infection with Myc-tagged MECP2-isoformspecific (E1 and E2) vectors directed MeCP2 to heterochromatin of transduced NSC and neurons. In contrast, vectors with an internal mouse Mecp2 promoter (MeP) directed restricted expression only in neurons and glia and not NSC, recapitulating the endogenous expression pattern required to avoid detrimental consequences of MECP2 ectopic expression. In differentiated NSC from adult heterozygous Mecp2(tm1.1Bird)+/- female mice, 48% of neurons expressed endogenous MeCP2 due to random inactivation of the X-linked Mecp2 gene. Retroviral MECP2 transduction with EF1a and MeP vectors rescued expression in 95-100% of neurons resulting in increased dendrite branching function in vitro. Insulated MECP2 isoformspecific lentiviral vectors show long-term expression in NSC and their differentiated neuronal progeny, and directly infect dissociated murine cortical neurons with high efficiency. Conclusions/Significance: MeP vectors recapitulate the endogenous expression pattern of MeCP2 in neurons and glia. They have utility to study MeCP2 isoform-specific functions in vitro, and are effective gene therapy vectors for rescuing dendritic maturation of neurons in an ex vivo model of RTT.			Rastegar, M (corresponding author), Univ Manitoba, Regenerat Med Program, Winnipeg, MB, Canada.	jellis@sickkids.ca	Rastegar, Mojgan/T-9394-2019; Ellis, James/F-4789-2011; Adachi, Megumi/M-7746-2017	Rastegar, Mojgan/0000-0003-3619-6116; Ellis, James/0000-0002-4400-0091; Adachi, Megumi/0000-0003-3404-6640; Hotta, Akitsu/0000-0002-2619-7441				Abuhatzira L, 2007, EPIGENETICS-US, V2, P214, DOI 10.4161/epi.2.4.5212; Adachi M, 2005, HUM MOL GENET, V14, P3709, DOI 10.1093/hmg/ddi402; Agarwal N, 2007, NUCLEIC ACIDS RES, V35, P5402, DOI 10.1093/nar/gkm599; Ballas N, 2009, NAT NEUROSCI, V12, P311, DOI 10.1038/nn.2275; Ben-Shachar S, 2009, HUM MOL GENET, V18, P2431, DOI 10.1093/hmg/ddp181; Buzina A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000051; Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252; Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; Collins AL, 2004, HUM MOL GENET, V13, P2679, DOI 10.1093/hmg/ddh282; Dalle B, 2005, MOL THER, V11, P591, DOI 10.1016/j.ymthe.2004.11.012; Diamandis P, 2007, NAT CHEM BIOL, V3, P268, DOI 10.1038/nchembio873; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Dragich JM, 2007, J COMP NEUROL, V501, P526, DOI 10.1002/cne.21264; Ellis J, 2007, CELL, V131, P13, DOI 10.1016/j.cell.2007.09.029; Fernandes KJL, 2006, EXP NEUROL, V201, P32, DOI 10.1016/j.expneurol.2006.03.018; Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515; Fyffe SL, 2008, NEURON, V59, P947, DOI 10.1016/j.neuron.2008.07.030; Ghosh RP, 2008, J BIOL CHEM, V283, P20523, DOI 10.1074/jbc.M803021200; Giacometti E, 2007, P NATL ACAD SCI USA, V104, P1931, DOI 10.1073/pnas.0610593104; Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Hotta A, 2009, NAT METHODS, V6, P370, DOI [10.1038/NMETH.1325, 10.1038/nmeth.1325]; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kishi N, 2004, MOL CELL NEUROSCI, V27, P306, DOI 10.1016/j.mcn.2004.07.006; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; Lorincz MC, 2001, MOL CELL BIOL, V21, P7913, DOI 10.1128/MCB.21.23.7913-7922.2001; Luikenhuis S, 2004, P NATL ACAD SCI USA, V101, P6033, DOI 10.1073/pnas.0401626101; Mnatzakanian GN, 2004, NAT GENET, V36, P339, DOI 10.1038/ng1327; Mullaney BC, 2004, NEUROSCIENCE, V123, P939, DOI 10.1016/j.neuroscience.2003.11.025; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nikitina T, 2007, J BIOL CHEM, V282, P28237, DOI 10.1074/jbc.M704304200; Osborne CS, 1999, J VIROL, V73, P5490, DOI 10.1128/JVI.73.7.5490-5496.1999; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129; Schmid RS, 2008, NEUROREPORT, V19, P393, DOI 10.1097/WNR.0b013e3282f5661c; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Smrt RD, 2007, NEUROBIOL DIS, V27, P77, DOI 10.1016/j.nbd.2007.04.005; Sun YE, 2006, NEURON, V49, P321, DOI 10.1016/j.neuron.2006.01.014; Swindle CS, 2004, J BIOL CHEM, V279, P34, DOI 10.1074/jbc.M309128200; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Wolf D, 2007, CELL, V131, P46, DOI 10.1016/j.cell.2007.07.026; Yao SY, 2004, MOL THER, V10, P27, DOI 10.1016/j.ymthe.2004.04.007; Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104; Young JI, 2005, P NATL ACAD SCI USA, V102, P17551, DOI 10.1073/pnas.0507856102; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhou ZL, 2006, NEURON, V52, P255, DOI 10.1016/j.neuron.2006.09.037	53	52	59	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6810	10.1371/journal.pone.0006810	http://dx.doi.org/10.1371/journal.pone.0006810			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710912	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415600021
J	King, FW; Fong, S; Griffin, C; Shoemaker, M; Staub, R; Zhang, YL; Cohen, I; Shtivelman, E				King, Frank W.; Fong, Sylvia; Griffin, Chandi; Shoemaker, Mark; Staub, Rick; Zhang, Yan-Ling; Cohen, Isaac; Shtivelman, Emma			Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through Inhibition of mTOR and Induction of ER Stress	PLOS ONE			English	Article								The aqueous extract of Anemarrhena asphodeloides (BN108) induces apoptosis in various cancer cell lines but is significantly less cytotoxic in non-transformed cells. Chemical fractionation of BN108 showed that its cytotoxicity is associated with timosaponins, steroidal saponins of coprostane type. Timosaponin BII (TBII) is a major saponin in BN108, but it shows little cytotoxicity. A much less abundant TAIII induces cell death in tumor cells but not in normal cells, reproducing the selectivity of the total extract BN108. Glycosidase treatment, by removing the extra sugar moiety in TBII, converts it to TAIII and confers cytotoxic activity. Analysis of the mechanisms of death induced by TAIII revealed activation of two distinct pro-apoptotic pathways: first, inhibition of mTORC1 manifested in much reduced phosphorylation of mTORC1 targets; second, induction of endoplasmic reticulum stress culminating in phosphorylation of eIF2 alpha and activation of caspase 4. These pro-apoptotic pathways are activated by TAIII selectively in tumor cells but not in normal cells. Both pathways play a causative role in TAIII cytotoxicity, as restoration of either mTOR activity or relief of ER stress alone offer only partial protection from TAIII. Inhibition of mTORC1 and induction of ER stress apparently contribute to the induction of the previously reported autophagic response in TAIII-treated cells. TAIII induced autophagy plays a protective role in TAIII induced death signaling, and failure to mount autophagic response is associated with heightened sensitivity to TAIII induced apoptosis. The multiple death-promoting and apparently tumor-selective responses to TAIII, its ability to inhibit mTORC1, and the possibility of further enhancing its cytotoxicity by pharmacological inhibition of autophagy, make TAIII an attractive candidate for development as a cancer therapeutic agent.	[King, Frank W.; Fong, Sylvia; Griffin, Chandi; Shoemaker, Mark; Staub, Rick; Zhang, Yan-Ling; Cohen, Isaac; Shtivelman, Emma] BioNovo Inc, Emeryville, CA USA		King, FW (corresponding author), BioNovo Inc, Emeryville, CA USA.	emmas@bionovo.com		Fong, Sylvia/0000-0002-3818-4146				Audas TE, 2008, MOL CELL BIOL, V28, P3952, DOI 10.1128/MCB.01439-07; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Carra S, 2009, J BIOL CHEM, V284, P5523, DOI 10.1074/jbc.M807440200; Colgan SM, 2007, INT J BIOCHEM CELL B, V39, P1843, DOI 10.1016/j.biocel.2007.05.002; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Diaz-Troya S, 2008, AUTOPHAGY, V4, P851, DOI 10.4161/auto.6555; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Harding HP, 2005, CELL METAB, V2, P361, DOI 10.1016/j.cmet.2005.11.005; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; KAWASAKI T, 1963, Chem Pharm Bull (Tokyo), V11, P1221; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; KOVACS WJ, 2008, J BIOL CHEM; Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227; Radhakrishnan A, 2008, CELL METAB, V8, P512, DOI 10.1016/j.cmet.2008.10.008; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; SAITO S, 1994, CHEM PHARM BULL, V42, P2342, DOI 10.1248/cpb.42.2342; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shoemaker M, 2005, PHYTOTHER RES, V19, P649, DOI 10.1002/ptr.1702; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653; Zhang JY, 1999, CLIN CHIM ACTA, V289, P79, DOI 10.1016/S0009-8981(99)00160-6	43	63	70	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7283	10.1371/journal.pone.0007283	http://dx.doi.org/10.1371/journal.pone.0007283			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789631	gold, Green Submitted, Green Published			2022-12-27	WOS:000270354100029
J	Schmitt-Ulms, G; Ehsani, S; Watts, JC; Westaway, D; Wille, H				Schmitt-Ulms, Gerold; Ehsani, Sepehr; Watts, Joel C.; Westaway, David; Wille, Holger			Evolutionary Descent of Prion Genes from the ZIP Family of Metal Ion Transporters	PLOS ONE			English	Article							SEQUENCE ALIGNMENTS; MASS-SPECTROMETRY; PROTEIN FUNCTION; TRANSGENIC MICE; COPPER-BINDING; CELL-ADHESION; ZINC; IDENTIFICATION; EXPRESSION; DOPPEL	In the more than twenty years since its discovery, both the phylogenetic origin and cellular function of the prion protein (PrP) have remained enigmatic. Insights into a possible function of PrP may be obtained through the characterization of its molecular neighborhood in cells. Quantitative interactome data demonstrated the spatial proximity of two metal ion transporters of the ZIP family, ZIP6 and ZIP10, to mammalian prion proteins in vivo. A subsequent bioinformatic analysis revealed the unexpected presence of a PrP-like amino acid sequence within the N-terminal, extracellular domain of a distinct sub-branch of the ZIP protein family that includes ZIP5, ZIP6 and ZIP10. Additional structural threading and orthologous sequence alignment analyses argued that the prion gene family is phylogenetically derived from a ZIP-like ancestral molecule. The level of sequence homology and the presence of prion protein genes in most chordate species place the split from the ZIP-like ancestor gene at the base of the chordate lineage. This relationship explains structural and functional features found within mammalian prion proteins as elements of an ancient involvement in the transmembrane transport of divalent cations. The phylogenetic and spatial connection to ZIP proteins is expected to open new avenues of research to elucidate the biology of the prion protein in health and disease.			Schmitt-Ulms, G (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada.	g.schmittulms@utoronto.ca	Ehsani, Sepehr/E-9257-2010; Wille, Holger/C-2280-2008	Ehsani, Sepehr/0000-0002-9613-6898; Wille, Holger/0000-0001-5102-8706; Watts, Joel/0000-0002-2604-2925	NATIONAL INSTITUTE ON AGING [P01AG002132, P01AG010770] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132, AG10770, P01 AG010770, P01 AG002132] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguzzi A, 2008, ANNU REV NEUROSCI, V31, P439, DOI 10.1146/annurev.neuro.31.060407.125620; Angst BD, 2001, J CELL SCI, V114, P629; Bai Y, 2008, MOL CELL PROTEOMICS, V7, P15, DOI 10.1074/mcp.M700077-MCP200; Baldwin MA, 2005, METHOD ENZYMOL, V405, P172, DOI 10.1016/S0076-6879(05)05008-1; BELL LM, 1994, J BIOL CHEM, V269, P22758; Brown DR, 2009, DALTON T, P4069, DOI 10.1039/b822135a; Calzolai L, 2005, P NATL ACAD SCI USA, V102, P651, DOI 10.1073/pnas.0408939102; Camponeschi F, 2009, DALTON T, P4643, DOI 10.1039/b907626n; Caughey B, 2006, NATURE, V443, P803, DOI 10.1038/nature05294; Chalkley RJ, 2005, MOL CELL PROTEOMICS, V4, P1194, DOI 10.1074/mcp.D500002-MCP200; Cotto E, 2005, FEBS J, V272, P500, DOI 10.1111/j.1742-4658.2004.04492.x; Date Shailesh V., 2007, V408, P109, DOI 10.1007/978-1-59745-547-3_7; Davies P, 2008, BIOCHEM J, V410, P237, DOI 10.1042/BJ20071477; Dunn CW, 2008, NATURE, V452, P745, DOI 10.1038/nature06614; Einhauer A, 2001, J BIOCHEM BIOPH METH, V49, P455, DOI 10.1016/S0165-022X(01)00213-5; Gingras AC, 2007, NAT REV MOL CELL BIO, V8, P645, DOI 10.1038/nrm2208; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; KAMBE T, 2008, MOL CELL BIOL; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kenward AG, 2007, BIOCHEMISTRY-US, V46, P4261, DOI 10.1021/bi602473r; Kornegay JR, 1996, J MOL EVOL, V42, P676, DOI 10.1007/BF02338801; KRAUT J, 1971, COLD SPRING HARB SYM, V36, P117, DOI 10.1101/SQB.1972.036.01.017; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lee IY, 1998, GENOME RES, V8, P1022, DOI 10.1101/gr.8.10.1022; Li GQ, 2004, BRIEF BIOINFORM, V5, P378, DOI 10.1093/bib/5.4.378; LICHTEN LA, 2009, ANN REV NUTR; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Malaga-Trillo E, 2009, PLOS BIOL, V7, P576, DOI 10.1371/journal.pbio.1000055; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; Naghibalhossaini F, 2004, J CELL SCI, V117, P761, DOI 10.1242/jcs.00903; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Premzl M, 2004, MOL BIOL EVOL, V21, P2210, DOI 10.1093/molbev/msh245; Prusiner SB, 1998, P NATL ACAD SCI USA, V117, P421; Qin KF, 2009, J BIOL CHEM, V284, P4582, DOI 10.1074/jbc.M808410200; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Rachidi W, 2009, J TRACE ELEM MED BIO, V23, P214, DOI 10.1016/j.jtemb.2009.02.007; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rivera-Milla E, 2003, TRENDS GENET, V19, P72, DOI 10.1016/S0168-9525(02)00032-X; Rivera-Milla E, 2006, FASEB J, V20, P317, DOI 10.1096/fj.05-4279fje; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Sadreyev RI, 2008, NUCLEIC ACIDS RES, V36, P2240, DOI 10.1093/nar/gkn065; Schmitt-Ulms G, 2004, NAT BIOTECHNOL, V22, P724, DOI 10.1038/nbt969; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Sprenger J, 2008, NUCLEIC ACIDS RES, V36, pD230, DOI 10.1093/nar/gkm950; Szyrwiel L, 2008, DALTON T, P6117, DOI 10.1039/b811224j; Taylor KM, 2007, MOL MED, V13, P396, DOI 10.2119/2007-00040.Taylor; Telling GC, 1997, PROTEIN SCI, V6, P825; Walter ED, 2007, J AM CHEM SOC, V129, P15440, DOI 10.1021/ja077146j; Watt NT, 2003, TRENDS BIOCHEM SCI, V28, P406, DOI 10.1016/S0968-0004(03)00166-X; Watts JC, 2007, EMBO J, V26, P4038, DOI 10.1038/sj.emboj.7601830; Watts JC, 2007, BBA-MOL BASIS DIS, V1772, P654, DOI 10.1016/j.bbadis.2007.05.001; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Zieske LR, 2006, J EXP BOT, V57, P1501, DOI 10.1093/jxb/erj168	65	97	99	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7208	10.1371/journal.pone.0007208	http://dx.doi.org/10.1371/journal.pone.0007208			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784368	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290000014
J	Kim, JH; Jee, MK; Lee, SY; Han, TH; Kim, BS; Kang, KS; Kang, SK				Kim, Jung Hwan; Jee, Min Ki; Lee, So Young; Han, Tae Hee; Kim, Bong Sun; Kang, Kyung Sun; Kang, Soo Kyung			Regulation of Adipose Tissue Stromal Cells Behaviors by Endogenic Oct4 Expression Control	PLOS ONE			English	Article							PLURIPOTENT STEM-CELLS; SELF-RENEWAL; DIFFERENTIATION; IDENTIFICATION; IMPROVEMENT; INDUCTION; ENHANCER; OCT-3/4; GENES; SOX2	Background: To clarify the role of the POU domain transcription factor Oct4 in Adipose Tissue Stromal Cells (ATSCs), we investigated the regulation of Oct4 expression and other embryonic genes in fully differentiated cells, in addition to identifying expression at the gene and protein levels. The ATSCs and several immature cells were routinely expressing Oct4 protein before and after differentiating into specific lineages. Methodology/Principal Findings and Conclusions: Here, we demonstrated the role of Oct4 in ATSCs on cell proliferation and differentiation. Exogenous Oct4 improves adult ATSCs cell proliferation and differentiation potencies through epigenetic reprogramming of stemness genes such as Oct4, Nanog, Sox2, and Rex1. Oct4 directly or indirectly induces ATSCs reprogramming along with the activation of JAK/STAT3 and ERK1/2. Exogenic Oct4 introduced a transdifferentiation priority into the neural lineage than mesodermal lineage. Global gene expression analysis results showed that Oct4 regulated target genes which could be characterized as differentially regulated genes such as pluripotency markers NANOG, SOX2, and KLF4 and markers of undifferentiated stem cells FOXD1, CDC2, and EPHB1. The negatively regulated genes included FAS, TNFR, COL6A1, JAM2, FOXQ1, FOXO1, NESTIN, SMAD3, SLIT3, DKK1, WNT5A, BMP1, and GLIS3 which are implicated in differentiation processes as well as a number of novel genes. Finally we have demonstrated the therapeutic utility of Oct4/ATSCs were introduced into the mouse traumatic brain, engrafted cells was more effectively induces regeneration activity with high therapeutic modality than that of control ATSCs. Engrafted Oct4/ATSCs efficiently migrated and transdifferentiated into action potential carrying, functionally neurons in the hippocampus and promoting the amelioration of lesion cavities.			Kim, JH (corresponding author), Seoul Natl Univ, Dept Vet Biotechnol, Seoul, South Korea.	sookang@snu.ac.kr	Kang, Kyung-Sun/G-6205-2013	Kim, Jung Hwan/0000-0002-2975-4899				Adjaye J, 2005, STEM CELLS, V23, P1514, DOI 10.1634/stemcells.2005-0113; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baal N, 2004, THROMB HAEMOSTASIS, V92, P767, DOI 10.1160/TH04-02-0079; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; CHRISTOPHER J, 2008, CELL CYCLE, V7, P725; Du ZW, 2001, BIOCHEM BIOPH RES CO, V282, P701, DOI 10.1006/bbrc.2001.4636; Freberg CT, 2007, MOL BIOL CELL, V18, P1543, DOI 10.1091/mbc.E07-01-0029; Goodell MA, 2003, CURR OPIN HEMATOL, V10, P208, DOI 10.1097/00062752-200305000-00003; Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014-4886(03)00089-X; Kim JH, 2008, STEM CELLS, V26, P2724, DOI 10.1634/stemcells.2008-0184; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lennmyr F, 2002, ACTA NEUROL SCAND, V106, P333, DOI 10.1034/j.1600-0404.2002.01313.x; LINGYI C, 2008, HUM MOL GENET, V17, pR23; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Matin MM, 2004, STEM CELLS, V22, P659, DOI 10.1634/stemcells.22-5-659; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; STEFANO Z, 2007, STEM CELLS, V25, P1675; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	29	42	42	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7166	10.1371/journal.pone.0007166	http://dx.doi.org/10.1371/journal.pone.0007166			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777066	Green Submitted, Green Published, gold			2022-12-27	WOS:000270164600008
J	Snyder, CM; Shroff, EH; Liu, J; Chandel, NS				Snyder, Colleen M.; Shroff, Emelyn H.; Liu, Jing; Chandel, Navdeep S.			Nitric Oxide Induces Cell Death by Regulating Anti-Apoptotic BCL-2 Family Members	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASES; MITOCHONDRIAL RESPIRATORY-CHAIN; CYTOCHROME-C; MCL-1; JNK; BAX; INHIBITION; PHOSPHORYLATION; MEMBRANE; OXYGEN	Nitric oxide (NO) activates the intrinsic apoptotic pathway to induce cell death. However, the mechanism by which this pathway is activated in cells exposed to NO is not known. Here we report that BAX and BAK are activated by NO and that cytochrome c is released from the mitochondria. Cells deficient in Bax and Bak or Caspase-9 are completely protected from NO-induced cell death. The individual loss of the BH3-only proteins, Bim, Bid, Puma, Bad or Noxa, or Bid knockdown in Bim(-/-)/Puma(-/-) MEFs, does not prevent NO-induced cell death. Our data show that the anti-apoptotic protein MCL-1 undergoes ASK1-JNK1 mediated degradation upon exposure to NO, and that cells deficient in either Ask1 or Jnk1 are protected against NO-induced cell death. NO can inhibit the mitochondrial electron transport chain resulting in an increase in superoxide generation and peroxynitrite formation. However, scavengers of ROS or peroxynitrite do not prevent NO-induced cell death. Collectively, these data indicate that NO degrades MCL-1 through the ASK1-JNK1 axis to induce BAX/BAK-dependent cell death.			Snyder, CM (corresponding author), Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA.	nav@northwestern.edu			NCI NIH HHS [CA123067-03, R01 CA123067] Funding Source: Medline; NHLBI NIH HHS [P01 HL071643, 2T32HL076139-06, 1P01HL071643, T32 HL076139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA123067] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL076139, P01HL071643] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brunelle JK, 2007, MOL CELL BIOL, V27, P1222, DOI 10.1128/MCB.01535-06; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ing DJ, 1999, CIRC RES, V84, P21; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lee VY, 2002, J BIOL CHEM, V277, P16067, DOI 10.1074/jbc.M111177200; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okada S, 1998, J IMMUNOL, V160, P2590; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Pervin S, 2001, CANCER RES, V61, P4701; Pfeilschifter J, 1996, FEBS LETT, V396, P67, DOI 10.1016/0014-5793(96)01070-8; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sarker KP, 2003, J NEUROCHEM, V87, P1345, DOI 10.1046/j.1471-4159.2003.02096.x; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Shacka JJ, 2006, CELL DEATH DIFFER, V13, P1506, DOI 10.1038/sj.cdd.4401831; Song L, 2002, CHINESE MED J-PEKING, V115, P1241; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	51	81	82	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7059	10.1371/journal.pone.0007059	http://dx.doi.org/10.1371/journal.pone.0007059			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768117	Green Submitted, Green Published, gold			2022-12-27	WOS:000270154000002
J	Goyal, P; Behring, A; Kumar, A; Siess, W				Goyal, Pankaj; Behring, Antje; Kumar, Abhishek; Siess, Wolfgang			Identifying and Characterizing a Novel Protein Kinase STK35L1 and Deciphering Its Orthologs and Close-Homologs in Vertebrates	PLOS ONE			English	Article							GENOMIC ANALYSIS; STRESS FIBERS; GENE; SEQUENCE; IDENTIFICATION; TRANSLATION; EXPRESSION; EVOLUTION; CLUSTAL; POINT	Background: The human kinome containing 478 eukaryotic protein kinases has over 100 uncharacterized kinases with unknown substrates and biological functions. The Ser/Thr kinase 35 (STK35, Clik1) is a member of the NKF 4 (New Kinase Family 4) in the kinome with unknown substrates and biological functions. Various high throughput studies indicate that STK35 could be involved in various human diseases such as colorectal cancer and malaria. Methodology/Principal Findings: In this study, we found that the previously published coding sequence of the STK35 gene is incomplete. The newly identified sequence of the STK35 gene codes for a protein of 534 amino acids with a N-terminal elongation of 133 amino acids. It has been designated as STK35L (STK35 long). Since it is the first of further homologous kinases we termed it as STK35L1. The STK35L1 protein (58 kDa on SDS-PAGE), but not STK35 ( 44 kDa), was found to be expressed in all human cells studied ( endothelial cells, HeLa, and HEK cells) and was down-regulated after silencing with specific siRNA. EGFP-STK35L1 was localized in the nucleus and the nucleolus. By combining syntenic and gene structure pattern data and homology searches, two further STK35L1 homologs, STK35L2 (previously known as PDIK1L) and STK35L3, were found. All these protein kinase homologs were conserved throughout the vertebrates. The STK35L3 gene was specifically lost during placental mammalian evolution. Using comparative genomics, we have identified orthologous sets of these three protein kinases genes and their possible ancestor gene in two sea squirt genomes. Conclusions/Significance: We found the full-length coding sequence of the STK35 gene and termed it as STK35L1. We identified a new third STK35-like gene, STK35L3, in vertebrates and a possible ancestor gene in sea squirt genome. This study will provide a comprehensive platform to explore the role of STK35L kinases in cell functions and human diseases.			Goyal, P (corresponding author), Univ Munich, Inst Prevent Cardiovasc Dis, Munich, Germany.	pankaj.goyal@med.uni-muenchen.de	Siess, Wolfgang/A-6430-2009; Goyal, Pankaj/C-3567-2012; Kumar, Abhishek/A-8727-2012	Siess, Wolfgang/0000-0003-0698-6416; Kumar, Abhishek/0000-0003-4172-4059				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bauer K, 2000, BLOOD, V96, P4236; BERKS M, 1995, GENOME RES, V5, P99, DOI 10.1101/gr.5.2.99; Birney E, 2004, GENOME RES, V14, P988, DOI 10.1101/gr.1865504; Bradham CA, 2006, DEV BIOL, V300, P180, DOI 10.1016/j.ydbio.2006.08.074; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Guo LC, 2003, J GENET, V82, P27, DOI 10.1007/BF02715878; Hanks SK, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-111; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hourani Mou'ath, 2008, V453, P379, DOI 10.1007/978-1-60327-429-6_20; Hubbard TJP, 2007, NUCLEIC ACIDS RES, V35, pD610, DOI 10.1093/nar/gkl996; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Karolchik Donna, 2007, V395, P17; Kawaji H, 2006, NUCLEIC ACIDS RES, V34, pD632, DOI 10.1093/nar/gkj034; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kostich M, 2002, GENOME BIOL, V3; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krupa A, 2002, GENOME BIOL, V3; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martin DMA, 2009, NUCLEIC ACIDS RES, V37, pD244, DOI 10.1093/nar/gkn834; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14; Ponting CP, 2008, NAT REV GENET, V9, P689, DOI 10.1038/nrg2413; Prudencio M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000201; Putnam NH, 2008, NATURE, V453, P1064, DOI 10.1038/nature06967; Putnam NH, 2007, SCIENCE, V317, P86, DOI 10.1126/science.1139158; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; Sodergren E, 2006, SCIENCE, V314, P941, DOI 10.1126/science.1133609; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vallenius T, 2002, J CELL SCI, V115, P2067; Woodburne MO, 2003, MOL PHYLOGENET EVOL, V28, P360, DOI 10.1016/S1055-7903(03)00113-1	42	9	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e6981	10.1371/journal.pone.0006981	http://dx.doi.org/10.1371/journal.pone.0006981			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756140	Green Submitted, gold, Green Published			2022-12-27	WOS:000269970000005
J	Matthijsen, RA; Derikx, JPM; Kuipers, D; van Dam, RM; Dejong, CHC; Buurman, WA				Matthijsen, Robert A.; Derikx, Joep P. M.; Kuipers, Dian; van Dam, Ronald M.; Dejong, Cornelis H. C.; Buurman, Wim A.			Enterocyte Shedding and Epithelial Lining Repair Following Ischemia of the Human Small Intestine Attenuate Inflammation	PLOS ONE			English	Article								Background: Recently, we observed that small-intestinal ischemia and reperfusion was found to entail a rapid loss of apoptotic and necrotic cells. This study was conducted to investigate whether the observed shedding of ischemically damaged epithelial cells affects IR induced inflammation in the human small gut. Methods and Findings: Using a newly developed IR model of the human small intestine, the inflammatory response was studied on cellular, protein and mRNA level. Thirty patients were consecutively included. Part of the jejunum was subjected to 30 minutes of ischemia and variable reperfusion periods (mean reperfusion time 120 (+/- 11) minutes). Ethical approval and informed consent were obtained. Increased plasma intestinal fatty acid binding protein (I-FABP) levels indicated loss in epithelial cell integrity in response to ischemia and reperfusion (p < 0.001 vs healthy). HIF-1 alpha gene expression doubled (p = 0.02) and C3 gene expression increased 4-fold (p = 0.01) over the course of IR. Gut barrier failure, assessed as LPS concentration in small bowel venous effluent blood, was not observed (p = 0.18). Additionally, mRNA expression of HO-1, IL-6, IL-8 did not alter. No increased expression of endothelial adhesion molecules, TNF alpha release, increased numbers of inflammatory cells (p = 0.71) or complement activation, assessed as activated C3 (p = 0.14), were detected in the reperfused tissue. Conclusions: In the human small intestine, thirty minutes of ischemia followed by up to 4 hours of reperfusion, does not seem to lead to an explicit inflammatory response. This may be explained by a unique mechanism of shedding of damaged enterocytes, reported for the first time by our group.			Matthijsen, RA (corresponding author), Spaarne Hosp, Hoofddorp, Netherlands.	w.buurman@ah.unimaas.nl		derikx, joep/0000-0003-0694-7679				Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.0.CO;2-8; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Cuzzocrea S, 1999, J LEUKOCYTE BIOL, V66, P471, DOI 10.1002/jlb.66.3.471; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Daemen MARC, 1999, TRANSPLANTATION, V67, P792, DOI 10.1097/00007890-199903270-00003; de Groot H, 2007, TRANSPL P, V39, P481, DOI 10.1016/j.transproceed.2006.12.012; de Vries B, 2003, J IMMUNOL, V170, P3883, DOI 10.4049/jimmunol.170.7.3883; De Vries B, 2003, TRANSPLANTATION, V75, P375, DOI 10.1097/01.TP.0000044455.05584.2A; Derikx JPM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003428; Donath S, 2006, CIRCULATION, V113, P1203, DOI 10.1161/CIRCULATIONAHA.105.576785; ENGELBERTS I, 1991, LANCET, V338, P515, DOI 10.1016/0140-6736(91)90591-C; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Kanda T, 1996, GASTROENTEROLOGY, V110, P339, DOI 10.1053/gast.1996.v110.pm8566578; Laufer J, 2000, CLIN EXP IMMUNOL, V120, P30, DOI 10.1046/j.1365-2249.2000.01168.x; LIBBY P, 1973, J CLIN INVEST, V52, P599, DOI 10.1172/JCI107221; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; LUCCHESI BR, 1990, ANNU REV PHYSIOL, V52, P561, DOI 10.1146/annurev.ph.52.030190.003021; MA XL, 1991, J CLIN INVEST, V88, P1237, DOI 10.1172/JCI115427; MATTHIJSEN RA, 2009, MOL IMMUNOL; Matthijsen RA, 2007, AM J PATHOL, V171, P1743, DOI 10.2353/ajpath.2007.070184; Murohara T, 1996, J IMMUNOL, V156, P3550; Patel A, 2004, TRANSPLANTATION, V78, P1479, DOI 10.1097/01.TP.0000144182.27897.1E; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; SCHOENBERG MH, 1991, GUT, V32, P905, DOI 10.1136/gut.32.8.905; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Taylor CT, 2007, J MOL MED, V85, P1295, DOI 10.1007/s00109-007-0277-z; Tsuruma T, 1998, TRANSPLANT P, V30, P2644, DOI 10.1016/S0041-1345(98)00765-9; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; Wada K, 2001, GASTROENTEROLOGY, V120, P126, DOI 10.1053/gast.2001.20873; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	42	43	44	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7045	10.1371/journal.pone.0007045	http://dx.doi.org/10.1371/journal.pone.0007045			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753114	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796500021
J	Kenchington, EL; Hamilton, L; Cogswell, A; Zouros, E				Kenchington, Ellen L.; Hamilton, Lorraine; Cogswell, Andrew; Zouros, Eleftherios			Paternal mtDNA and Maleness Are Co-Inherited but Not Causally Linked in Mytilid Mussels	PLOS ONE			English	Article							DOUBLY UNIPARENTAL INHERITANCE; DEPENDENT SEX-RATIO; MITOCHONDRIAL-DNA; SPERM MITOCHONDRIA; CONTROL REGION; BLUE MUSSELS; EDULIS; GALLOPROVINCIALIS; GENOMES; SEGREGATION	Background: In marine mussels of the genus Mytilus there are two mitochondrial genomes. One is transmitted through the female parent, which is the normal transmission route in animals, and the other is transmitted through the male parent which is an unusual phenomenon. In males the germ cell line is dominated by the paternal mitochondrial genome and the somatic cell line by the maternal. Research to date has not allowed a clear answer to the question of whether inheritance of the paternal genome is causally related to maleness. Methodology/Principal Findings: Here we present results from hybrid crosses, from triploid mussels and from observations of sperm mitochondria in fertilized eggs which clearly show that maleness and presence of the paternal mitochondrial genome can be decoupled. These same results show that the female mussel has exclusive control of whether her progeny will inherit the mitochondrial genome of the male parent. Conclusions/Significance: These findings are important in our efforts to understand the mechanistic basis of this unusual mode of mitochondrial DNA inheritance that is common among bivalves.			Kenchington, EL (corresponding author), Bedford Inst Oceanog, Dept Fisheries & Oceans, Dartmouth, NS, Canada.	Kenchingtone@mar.dfo-mpo.gc.ca						AHMED M, 1970, BIOL BULL-US, V138, P1, DOI 10.2307/1540286; BEAUMONT AR, 1989, J EXP MAR BIOL ECOL, V132, P69, DOI 10.1016/0022-0981(89)90177-9; Burt A, 2006, GENES CONFLICT BIOL; Burzynski A, 2003, MOL BIOL EVOL, V20, P388, DOI 10.1093/molbev/msg058; Burzynski A, 2006, GENETICS, V174, P1081, DOI 10.1534/genetics.106.063180; Cao LQ, 2009, GENETICS, V181, P1045, DOI 10.1534/genetics.108.093229; Cao LQ, 2004, GENETICS, V166, P883, DOI 10.1534/genetics.166.2.883; Cao LQ, 2004, GENETICS, V167, P835, DOI 10.1534/genetics.103.026187; Cogswell AT, 2006, GENOME, V49, P799, DOI 10.1139/G06-036; COGSWELL AT, 2005, 2572 FISH AQ SCI; FISHER C, 1990, P ROY SOC B-BIOL SCI, V242, P149, DOI 10.1098/rspb.1990.0118; Garrido O, 1996, INVERTEBR REPROD DEV, V29, P95, DOI 10.1080/07924259.1996.9672501; Garrido-Ramos MA, 1998, GENOME, V41, P818, DOI 10.1139/gen-41-6-818; Heath DD, 1995, AQUACULTURE, V137, P51, DOI 10.1016/0044-8486(96)83524-1; HOWARD DW, 1983, NMFSFNEC25 NOAA, P1; HURST LD, 1994, NATURE, V368, P811, DOI 10.1038/368811a0; JACKSON DL, 2003, 2460 FISH AQ SCI; Kenchington E, 2002, GENETICS, V161, P1579; Kiyomoto M, 1996, ZOOL SCI, V13, P393, DOI 10.2108/zsj.13.393; Ladoukakis ED, 2002, MOL ECOL, V11, P755, DOI 10.1046/j.1365-294X.2002.01473.x; Mizi A, 2005, MOL BIOL EVOL, V22, P952, DOI 10.1093/molbev/msi079; Obata M, 2005, DEV GROWTH DIFFER, V47, P255; Obata Mayu, 2003, Zoological Science (Tokyo), V20, P1556; Quesada H, 1998, GENETICS, V149, P1511; Rawson PD, 1996, HEREDITY, V77, P599, DOI 10.1038/hdy.1996.187; Rawson PD, 1996, GENETICS, V144, P241; Saavedra C, 1996, GENETICS, V143, P1359; Saavedra C, 1997, GENETICS, V145, P1073; SHAW BARBARA L., 1957, CANADIAN JOUR ZOOL, V35, P325, DOI 10.1139/z57-026; SKIBINSKI DOF, 1994, NATURE, V368, P817, DOI 10.1038/368817b0; SKIBINSKI DOF, 1994, GENETICS, V138, P801; Sutovsky P, 2000, BIOL REPROD, V63, P582, DOI 10.1095/biolreprod63.2.582; Theologidis I, 2008, EVOLUTION, V62, P959, DOI 10.1111/j.1558-5646.2008.00329.x; Theologidis L, 2007, GENETICS, V176, P1367, DOI 10.1534/genetics.106.069930; Venetis C, 2007, GENE, V406, P79, DOI 10.1016/j.gene.2007.06.001; Venetis C, 2006, P R SOC B, V273, P2483, DOI 10.1098/rspb.2006.3607; Verdonk N.H., 1983, P91; Wood AR, 2003, HEREDITY, V91, P354, DOI 10.1038/sj.hdy.6800345; ZOUROS E, 1994, P NATL ACAD SCI USA, V91, P7463, DOI 10.1073/pnas.91.16.7463; ZOUROS E, 1994, NATURE, V368, P818, DOI 10.1038/368818a0; Zouros E, 2000, GENES GENET SYST, V75, P313, DOI 10.1266/ggs.75.313	41	38	38	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6976	10.1371/journal.pone.0006976	http://dx.doi.org/10.1371/journal.pone.0006976			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759895	Green Submitted, Green Published, gold			2022-12-27	WOS:000269696600013
J	Duan, ZF; Choy, E; Harmon, D; Yang, C; Ryu, K; Schwab, J; Mankin, H; Hornicek, FJ				Duan, Zhenfeng; Choy, Edwin; Harmon, David; Yang, Cao; Ryu, Keinosuke; Schwab, Joseph; Mankin, Henry; Hornicek, Francis J.			ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis (R)) and PM00104 (Zalypsis (R)) in Human Cancer Cell Lines	PLOS ONE			English	Article								Background: ET-743 (trabectedin, Yondelis (R)) and PM00104 (Zalypsis (R)) are marine derived compounds that have antitumor activity. ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood. Methodology/Principal Findings: Human chondrosarcoma cell lines resistant to ET-743 (CS-1/ER) or PM00104 (CS-1/PR) were established in this study. The CS-1/ER and CS-1/PR exhibited cross resistance to cisplatin and methotrexate but not to doxorubicin. Human Affymetrix Gene Chip arrays were used to examine relative gene expression in these cell lines. We found that a large number of genes have altered expression levels in CS-1/ER and CS-1/PR when compared to the parental cell line. 595 CS-1/ER and 498 CS-1/PR genes were identified as overexpressing; 856 CS-1/ER and 874 CS-1/PR transcripts were identified as underexpressing. Three zinc finger protein (ZNF) genes were on the top 10 overexpressed genes list. These genes have not been previously associated with drug resistance in tumor cells. Differential expressions of ZNF93 and ZNF43 genes were confirmed in both CS-1/ER and CS-1/PR resistant cell lines by real-time RT-PCR. ZNF93 was overexpressed in two ET-743 resistant Ewing sarcoma cell lines as well as in a cisplatin resistant ovarian cancer cell line, but was not overexpressed in paclitaxel resistant cell lines. ZNF93 knockdown by siRNA in CS-1/ER and CS-1/PR caused increased sensitivity for ET-743, PM00104, and cisplatin. Furthermore, ZNF93 transfected CS-1 cells are relatively resistant to ET-743, PM00104 and cisplatin. Conclusions/Significance: This study suggests that zinc finger proteins, and ZNF93 in particular, are involved in resistance to ET-743 and PM00104.			Duan, ZF (corresponding author), Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.	zduan@partners.org		Choy, Edwin/0000-0001-9896-8084	NCI NIH HHS [R01-CA119617, R01 CA119617] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA119617] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amador ML, 2003, ANN ONCOL, V14, P1607, DOI 10.1093/annonc/mdg443; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cuevas C, 2009, NAT PROD REP, V26, P322, DOI 10.1039/b808331m; Damia G, 2001, INT J CANCER, V92, P583, DOI 10.1002/ijc.1221; DUAN Z, 2008, CAN CHEMOTHER PHARM; Duan ZF, 1999, CLIN CANCER RES, V5, P3445; Duan ZF, 2005, CANCER CHEMOTH PHARM, V55, P277, DOI 10.1007/s00280-004-0878-y; Duan ZF, 1999, GENE, V229, P75, DOI 10.1016/S0378-1119(99)00042-6; Erba E, 2000, BRIT J CANCER, V82, P1732; Faircloth G, 2006, PROG MOLEC, V43, P363, DOI 10.1007/978-3-540-30880-5_16; Herrero AB, 2006, CANCER RES, V66, P8155, DOI 10.1158/0008-5472.CAN-06-0179; Ishiguchi H, 2004, INT J CANCER, V111, P900, DOI 10.1002/ijc.20358; Kanzaki A, 2002, MOL CANCER THER, V1, P1327; Lin XJ, 2006, MOL CANCER THER, V5, P1239, DOI 10.1158/1535-7163.MCT-05-0491; Manara MC, 2005, INT J ONCOL, V27, P1605; Marchini S, 2005, EUR J CANCER, V41, P323, DOI 10.1016/j.ejca.2004.10.021; Morioka H, 2003, CLIN CANCER RES, V9, P1211; Orth P, 2008, MOL BIOTECHNOL, V38, P137, DOI 10.1007/s12033-007-0071-8; RIEDEL RF, 2009, CURR TREAT OPTIONS O; Rinehart KL, 2000, MED RES REV, V20, P1; Shao L, 2003, BIOCHEM PHARMACOL, V66, P2381, DOI 10.1016/j.bcp.2003.08.033; Soares DG, 2007, P NATL ACAD SCI USA, V104, P13062, DOI 10.1073/pnas.0609877104; Susa M, 2009, ANTICANCER RES, V29, P1879; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Valoti G, 1998, CLIN CANCER RES, V4, P1977; Wakasugi T, 2007, ONCOGENE, V26, P5194, DOI 10.1038/sj.onc.1210326; Yin JM, 2005, RAPID COMMUN MASS SP, V19, P689, DOI 10.1002/rcm.1848	27	16	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6967	10.1371/journal.pone.0006967	http://dx.doi.org/10.1371/journal.pone.0006967			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742314	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622500025
J	Temime-Smaali, N; Guittat, L; Sidibe, A; Shin-Ya, K; Trentesaux, C; Riou, JF				Temime-Smaali, Nassima; Guittat, Lionel; Sidibe, Assitan; Shin-ya, Kazuo; Trentesaux, Chantal; Riou, Jean-Francois			The G-Quadruplex Ligand Telomestatin Impairs Binding of Topoisomerase III alpha to G-Quadruplex-Forming Oligonucleotides and Uncaps Telomeres in ALT Cells	PLOS ONE			English	Article								In Alternative Lengthening of Telomeres (ALT) cell lines, specific nuclear bodies called APBs ( ALT-associated PML bodies) concentrate telomeric DNA, shelterin components and recombination factors associated with telomere recombination. Topoisomerase III alpha (Topo III) is an essential telomeric-associated factor in ALT cells. We show here that the binding of Topo III to telomeric G-overhang is modulated by G-quadruplex formation. Topo III binding to G-quadruplex-forming oligonucleotides was strongly inhibited by telomestatin, a potent and specific G-quadruplex ligand. In ALT cells, telomestatin treatment resulted in the depletion of the Topo III/BLM/TRF2 complex and the disruption of APBs and led to the segregation of PML, shelterin components and Topo III. Interestingly, a DNA damage response was observed at telomeres in telomestatin-treated cells. These data indicate the importance of G-quadruplex stabilization during telomere maintenance in ALT cells. The function of TRF2/TopoIII/BLM in the resolution of replication intermediates at telomeres is discussed.			Temime-Smaali, N (corresponding author), Univ Reims, UFR Pharm, Lab Oncopharmacol, JE 2428, Reims, France.	riou@mnhn.fr		riou, jean-francois/0000-0002-0055-6506; Guittat, Lionel/0000-0002-9971-7161				Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348; Amiard S, 2007, NAT STRUCT MOL BIOL, V14, P147, DOI 10.1038/nsmb1192; Amor-Gueret M, 2006, CANCER LETT, V236, P1, DOI 10.1016/j.canlet.2005.04.023; Brassart B, 2007, MOL PHARMACOL, V72, P631, DOI 10.1124/mol.107.036574; Cesare AJ, 2008, MECH AGEING DEV, V129, P99, DOI 10.1016/j.mad.2007.11.006; Changela A, 2007, J MOL BIOL, V368, P105, DOI 10.1016/j.jmb.2007.01.065; Chen CF, 2007, J BIOL CHEM, V282, P28971, DOI 10.1074/jbc.M705427200; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; De Cian A, 2008, BIOCHIMIE, V90, P131, DOI 10.1016/j.biochi.2007.07.011; De Cian A, 2007, P NATL ACAD SCI USA, V104, P17347, DOI 10.1073/pnas.0707365104; Douarre C, 2005, NUCLEIC ACIDS RES, V33, P2192, DOI 10.1093/nar/gki514; DRASKOVIC I, 2009, P NATL ACAD IN PRESS; Fouche N, 2006, J BIOL CHEM, V281, P37486, DOI 10.1074/jbc.M608778200; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2006, J BIOL CHEM, V281, P38721, DOI 10.1074/jbc.M605828200; Gomez D, 2006, CANCER RES, V66, P6908, DOI 10.1158/0008-5472.CAN-06-1581; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Grobelny JV, 2000, J CELL SCI, V113, P4577; Huppert JL, 2008, BIOCHIMIE, V90, P1140, DOI 10.1016/j.biochi.2008.01.014; JIANG WQ, 2007, ONCOGENE; Kelland L, 2007, CLIN CANCER RES, V13, P4960, DOI 10.1158/1078-0432.CCR-07-0422; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Lavelle F, 2000, CRIT REV ONCOL HEMAT, V34, P111, DOI 10.1016/S1040-8428(00)00057-3; Lemarteleur T, 2004, BIOCHEM BIOPH RES CO, V323, P802, DOI 10.1016/j.bbrc.2004.08.150; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; Liu Y, 2008, GENE DEV, V22, P2737, DOI 10.1101/gad.1732808; Mankouri HW, 2007, TRENDS BIOCHEM SCI, V32, P538, DOI 10.1016/j.tibs.2007.09.009; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Monchaud D, 2008, ORG BIOMOL CHEM, V6, P627, DOI 10.1039/b714772b; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pennarun G, 2005, ONCOGENE, V24, P2917, DOI 10.1038/sj.onc.1208468; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200; Riou Jean-Francois, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P439, DOI 10.2174/1568011043352740; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; RODRIGUEZ R, 2008, J AM CHEM SOC; Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Singh TR, 2008, GENE DEV, V22, P2856, DOI 10.1101/gad.1725108; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; Tahara H, 2006, ONCOGENE, V25, P1955, DOI 10.1038/sj.onc.1209217; Temime-Smaali N, 2008, EMBO J, V27, P1513, DOI 10.1038/emboj.2008.74; Tsai HJ, 2006, J BIOL CHEM, V281, P13717, DOI 10.1074/jbc.M600649200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wu YL, 2008, MOL CELL BIOL, V28, P4116, DOI 10.1128/MCB.02210-07; Xu DY, 2008, GENE DEV, V22, P2843, DOI 10.1101/gad.1708608; Yeager TR, 1999, CANCER RES, V59, P4175; Zhong ZH, 2007, J BIOL CHEM, V282, P29314, DOI 10.1074/jbc.M701413200	57	54	56	4	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6919	10.1371/journal.pone.0006919	http://dx.doi.org/10.1371/journal.pone.0006919			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742304	Green Submitted, Green Published, gold			2022-12-27	WOS:000269622500005
J	Sloan, CD; Andrew, AD; Duell, EJ; Williams, SM; Karagas, MR; Moore, JH				Sloan, Chantel D.; Andrew, Angeline D.; Duell, Eric J.; Williams, Scott M.; Karagas, Margaret R.; Moore, Jason H.			Genetic Population Structure Analysis in New Hampshire Reveals Eastern European Ancestry	PLOS ONE			English	Article							INFERENCE; EXAMPLE	Genetic structure due to ancestry has been well documented among many divergent human populations. However, the ability to associate ancestry with genetic substructure without using supervised clustering has not been explored in more presumably homogeneous and admixed US populations. The goal of this study was to determine if genetic structure could be detected in a United States population from a single state where the individuals have mixed European ancestry. Using Bayesian clustering with a set of 960 single nucleotide polymorphisms (SNPs) we found evidence of population stratification in 864 individuals from New Hampshire that can be used to differentiate the population into six distinct genetic subgroups. We then correlated self-reported ancestry of the individuals with the Bayesian clustering results. Finnish and Russian/Polish/Lithuanian ancestries were most notably found to be associated with genetic substructure. The ancestral results were further explained and substantiated using New Hampshire census data from 1870 to 1930 when the largest waves of European immigrants came to the area. We also discerned distinct patterns of linkage disequilibrium (LD) between the genetic groups in the growth hormone receptor gene (GHR). To our knowledge, this is the first time such an investigation has uncovered a strong link between genetic structure and ancestry in what would otherwise be considered a homogenous US population.			Sloan, CD (corresponding author), Dartmouth Med Sch, Dept Genet, Computat Genet Lab, Lebanon, NH USA.	jason.h.moore@dartmouth.edu	Williams, Scott/Q-4812-2019; Sloan-Aagard, Chantel/GWC-7572-2022; Williams, Scott/B-9491-2012; Moore, Jason H./AAV-9645-2021	Williams, Scott/0000-0002-4835-9544; Moore, Jason H./0000-0002-5015-1099; Duell, Eric J/0000-0001-5256-0163	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047447] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007373] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM009012] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057494, CA57494] Funding Source: Medline; NICHD NIH HHS [R01 HD047447, HD047447] Funding Source: Medline; NIEHS NIH HHS [P42 ES007373, ES007373] Funding Source: Medline; NLM NIH HHS [R01 LM009012, LM009012] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Andrew AS, 2008, HUM HERED, V65, P105, DOI 10.1159/000108942; Andrew AS, 2009, HUM GENET, V125, P527, DOI 10.1007/s00439-009-0645-6; Arnaiz-Villena A, 2002, TISSUE ANTIGENS, V60, P111, DOI 10.1034/j.1399-0039.2002.600201.x; ArnaizVillena A, 1997, IMMUNOGENETICS, V47, P37, DOI 10.1007/s002510050324; Bosch E, 2000, EUR J HUM GENET, V8, P360, DOI 10.1038/sj.ejhg.5200464; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Clegg LX, 2002, ARCH INTERN MED, V162, P1985, DOI 10.1001/archinte.162.17.1985; Crawford MH, 2007, AM J HUM BIOL, V19, P203, DOI 10.1002/ajhb.20631; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; Falush D, 2003, GENETICS, V164, P1567; FALUSH D, 2007, MOL ECOL NOTES; Helgason A, 2005, NAT GENET, V37, P90, DOI 10.1038/ng1492; Lappalainen T, 2006, GENE, V376, P207, DOI 10.1016/j.gene.2006.03.004; Lefevre-Witier P, 2006, AM J HUM BIOL, V18, P492, DOI 10.1002/ajhb.20511; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282; Liu XQ, 2006, ANN HUM GENET, V70, P496, DOI 10.1111/j.1469-1809.2005.00255.x; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Pritchard JK, 2000, GENETICS, V155, P945; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Seldin MF, 2006, PLOS GENET, V2, P1339, DOI 10.1371/journal.pgen.0020143; Sinnwell JP, 2009, HAPLO STATS STAT ANA; Sokal RR, 2000, P NATL ACAD SCI USA, V97, P6067, DOI 10.1073/pnas.97.11.6067; Sokal RR, 1997, P NATL ACAD SCI USA, V94, P12728, DOI 10.1073/pnas.94.23.12728; Sokal RR, 2004, AM J HUM BIOL, V16, P1, DOI 10.1002/ajhb.10231; Steffens M, 2006, HUM HERED, V62, P20, DOI 10.1159/000095850; Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; *U VIRG GEOSP STAT, 2009, HIST CENS BROWS; WRIGHT S, 1950, NATURE, V166, P247, DOI 10.1038/166247a0	31	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6928	10.1371/journal.pone.0006928	http://dx.doi.org/10.1371/journal.pone.0006928			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738909	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622300012
J	Chahine, G; Krekelberg, B				Chahine, George; Krekelberg, Bart			Cortical Contributions to Saccadic Suppression	PLOS ONE			English	Article								The stability of visual perception is partly maintained by saccadic suppression: the selective reduction of visual sensitivity that accompanies rapid eye movements. The neural mechanisms responsible for this reduced perisaccadic visibility remain unknown, but the Lateral Geniculate Nucleus (LGN) has been proposed as a likely site. Our data show, however, that the saccadic suppression of a target flashed in the right visual hemifield increased with an increase in background luminance in the left visual hemifield. Because each LGN only receives retinal input from a single hemifield, this hemifield interaction cannot be explained solely on the basis of neural mechanisms operating in the LGN. Instead, this suggests that saccadic suppression must involve processing in higher level cortical areas that have access to a considerable part of the ipsilateral hemifield.			Chahine, G (corresponding author), Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA.	bart@rutgers.edu	Krekelberg, Bart/N-7938-2019	Krekelberg, Bart/0000-0003-1083-6103	NATIONAL EYE INSTITUTE [R01EY017605] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY17605, R01 EY017605-01A1, R01 EY017605] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BURR DC, 1994, NATURE, V371, P511, DOI 10.1038/371511a0; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; Diamond MR, 2000, J NEUROSCI, V20, P3449, DOI 10.1523/JNEUROSCI.20-09-03449.2000; Ibbotson MR, 2008, J NEUROSCI, V28, P10952, DOI 10.1523/JNEUROSCI.3950-08.2008; KAMMER T, 2005, EXP BRAIN RES, V160; Kleiser R, 2004, CURR BIOL, V14, P386, DOI 10.1016/j.cub.2004.02.036; Krekelberg B, 2003, NEURON, V37, P537, DOI 10.1016/S0896-6273(03)00003-5; MALPELI JG, 1975, J COMP NEUROL, V161; Reppas JB, 2002, NEURON, V35, P961, DOI 10.1016/S0896-6273(02)00823-1; Rossi AF, 1999, J NEUROSCI, V19, P6145, DOI 10.1523/JNEUROSCI.19-14-06145.1999; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; Sylvester R, 2005, CURR BIOL, V15, P37, DOI 10.1016/j.cub.2004.12.061; Sylvester R, 2006, NEUROIMAGE, V30, P214, DOI 10.1016/j.neuroimage.2005.09.014; Thiele A, 2002, SCIENCE, V295, P2460, DOI 10.1126/science.1068788; Thilo KV, 2004, NAT NEUROSCI, V7, P13, DOI 10.1038/nn1171; Vallines I, 2006, J NEUROSCI, V26, P5965, DOI 10.1523/JNEUROSCI.0817-06.2006; Watson TL, 2009, CURR BIOL, V19, P1040, DOI 10.1016/j.cub.2009.04.052; Wichmann FA, 2001, PERCEPT PSYCHOPHYS, V63, P1293, DOI 10.3758/BF03194544; Wurtz RH, 2008, VISION RES, V48, P2070, DOI 10.1016/j.visres.2008.03.021	19	8	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6900	10.1371/journal.pone.0006900	http://dx.doi.org/10.1371/journal.pone.0006900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730739	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100005
J	Outeiro, TF; Klucken, J; Bercury, K; Tetzlaff, J; Putcha, P; Oliveira, LMA; Quintas, A; McLean, PJ; Hyman, BT				Outeiro, Tiago F.; Klucken, Jochen; Bercury, Kathryn; Tetzlaff, Julie; Putcha, Preeti; Oliveira, Luis M. A.; Quintas, Alexandre; McLean, Pamela J.; Hyman, Bradley T.			Dopamine-Induced Conformational Changes in Alpha-Synuclein	PLOS ONE			English	Article							PROTEIN SECONDARY STRUCTURE; PARKINSONS-DISEASE; OLIGOMERIZATION; STABILIZATION; AGGREGATION; DICHROWEB; TOXICITY; BINDING; SITE	Background: Oligomerization and aggregation of alpha-synuclein molecules play a major role in neuronal dysfunction and loss in Parkinson's disease [1]. However, alpha-synuclein oligomerization and aggregation have mostly been detected indirectly in cells using detergent extraction methods [2,3,4]. A number of in vitro studies showed that dopamine can modulate the aggregation of alpha-synuclein by inhibiting the formation of or by disaggregating amyloid fibrils [5,6,7]. Methodology/Principal Findings: Here, we show that alpha-synuclein adopts a variety of conformations in primary neuronal cultures using fluorescence lifetime imaging microscopy (FLIM). Importantly, we found that dopamine, but not dopamine agonists, induced conformational changes in alpha-synuclein which could be prevented by blocking dopamine transport into the cell. Dopamine also induced conformational changes in alpha-synuclein expressed in neuronal cell lines, and these changes were also associated with alterations in oligomeric/aggregated species. Conclusion/Significance: Our results show, for the first time, a direct effect of dopamine on the conformation of alpha-synuclein in neurons, which may help explain the increased vulnerability of dopaminergic neurons in Parkinson's disease.			Outeiro, TF (corresponding author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimer Res Unit, Charlestown, MA USA.	touteiro@fm.ul.pt; bhyman@partners.org	Tetzlaff, Julie/ABA-3395-2021; Outeiro, Tiago/M-8106-2019; Outeiro, Tiago F/C-1067-2008; Quintas, Alexandre/J-6436-2012; Outeiro, Tiago/L-7351-2019; Oliveira, Luis M. A./I-7994-2014	Outeiro, Tiago F/0000-0003-1679-1727; Quintas, Alexandre/0000-0002-5188-0453; Outeiro, Tiago/0000-0003-1679-1727; Oliveira, Luis M. A./0000-0002-2958-181X; Klucken, Jochen/0000-0001-6645-9437; McLean, Pamela/0000-0003-4870-5715	NINDS NIH HHS [P50 NS038372, R01 NS063963, 5P50-NS38372A-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS063963, P50NS038372] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Berezovska O, 2003, J NEUROSCI, V23, P4560; BEREZOVSKA O, 2003, SCI AGING KNOWLEDGE, pPE14; Cappai R, 2005, FASEB J, V19, P1377, DOI 10.1096/fj.04-3437fje; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; CRAWFORD GD, 1992, J NEUROSCI, V12, P3392; Fortin DL, 2005, J NEUROSCI, V25, P10913, DOI 10.1523/JNEUROSCI.2922-05.2005; Galvin JE, 2006, ACTA NEUROPATHOL, V112, P115, DOI 10.1007/s00401-006-0096-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kessler JC, 2003, BIOCHEMISTRY-US, V42, P672, DOI 10.1021/bi020429y; KLUCKEN J, 2004, J BIOL CHEM; Klucken J, 2006, FASEB J, V20, P2050, DOI 10.1096/fj.05-5422com; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806; Mazzulli JR, 2007, J BIOL CHEM, V282, P31621, DOI 10.1074/jbc.M704737200; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; Norris EH, 2005, ANTIOXID REDOX SIGN, V7, P673; Outeiro TF, 2006, BIOCHEM BIOPH RES CO, V351, P631, DOI 10.1016/j.bbrc.2006.10.085; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Soto C, 2008, ARCH NEUROL-CHICAGO, V65, P184, DOI 10.1001/archneurol.2007.56; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Winklhofer KF, 2008, EMBO J, V27, P336, DOI 10.1038/sj.emboj.7601930; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200	36	51	51	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6906	10.1371/journal.pone.0006906	http://dx.doi.org/10.1371/journal.pone.0006906			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730729	Green Submitted, Green Published, gold			2022-12-27	WOS:000269622100011
J	Wei, H; Cheng, RH; Berriman, J; Rice, WJ; Stokes, DL; Katz, A; Morgan, DG; Gottlieb, P				Wei, Hui; Cheng, R. Holland; Berriman, John; Rice, William J.; Stokes, David L.; Katz, A.; Morgan, David Gene; Gottlieb, Paul			Three-Dimensional Structure of the Enveloped Bacteriophage Phi 12: An Incomplete T=13 Lattice Is Superposed on an Enclosed T=1 Shell	PLOS ONE			English	Article								Background: Bacteriophage phi 12 is a member of the Cystoviridae, a unique group of lipid containing membrane enveloped bacteriophages that infect the bacterial plant pathogen Pseudomonas syringae pv. phaseolicola. The genomes of the virus species contain three double-stranded (dsRNA) segments, and the virus capsid itself is organized in multiple protein shells. The segmented dsRNA genome, the multi-layered arrangement of the capsid and the overall viral replication scheme make the Cystoviridae similar to the Reoviridae. Methodology/Principal Findings: We present structural studies of cystovirus phi 12 obtained using cryo-electron microscopy and image processing techniques. We have collected images of isolated phi 12 virions and generated reconstructions of both the entire particles and the polymerase complex (PC). We find that in the nucleocapsid (NC), the phi 12 P8 protein is organized on an incomplete T = 13 icosahedral lattice where the symmetry axes of the T = 13 layer and the enclosed T = 1 layer of the PC superpose. This is the same general protein-component organization found in phi 6 NC's but the detailed structure of the entire phi 12 P8 layer is distinct from that found in the best classified cystovirus species phi 6. In the reconstruction of the NC, the P8 layer includes protein density surrounding the hexamers of P4 that sit at the 5-fold vertices of the icosahedral lattice. We believe these novel features correspond to dimers of protein P7. Conclusions/Significance: In conclusion, we have determined that the phi 12 NC surface is composed of an incomplete T = 13 P8 layer forming a net-like configuration. The significance of this finding in regard to cystovirus assembly is that vacancies in the lattice could have the potential to accommodate additional viral proteins that are required for RNA packaging and synthesis.			Wei, H (corresponding author), CUNY City Coll, Dept Microbiol & Immunol, Sophie Davis Sch Biomed Educ, New York, NY 10031 USA.	pgottl@med.cuny.edu	Morgan, David Gene/W-3429-2019; Cheng, Holland/A-8973-2008	Rice, William/0000-0002-5187-255X	NCRR NIH HHS [G12 RR003060, G12RR-03060] Funding Source: Medline; NIGMS NIH HHS [R01 GM071044] Funding Source: Medline; Div Of Molecular and Cellular Bioscience [0741914] Funding Source: National Science Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071044] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alimova A, 2005, PHOTOCHEM PHOTOBIOL, V81, P879, DOI 10.1562/2005-01-14-RA-416R1.1; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DAY LA, 1980, VIROLOGY, V103, P376, DOI 10.1016/0042-6822(80)90196-8; de Haas F, 1999, J MOL BIOL, V294, P357, DOI 10.1006/jmbi.1999.3260; Eryilmaz E, 2008, J MOL BIOL, V382, P402, DOI 10.1016/j.jmb.2008.07.006; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; GOTTLIEB P, 1988, J VIROL, V62, P181, DOI 10.1128/JVI.62.1.181-187.1988; Gottlieb P, 2002, VIROLOGY, V295, P266, DOI 10.1006/viro.2002.1436; Gottlieb P, 2002, VIROLOGY, V293, P118, DOI 10.1006/viro.2001.1288; GOTTLIEB P, 1990, J BACTERIOL, V172, P5774, DOI 10.1128/jb.172.10.5774-5782.1990; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Hu GB, 2008, VIROLOGY, V372, P1, DOI 10.1016/j.virol.2007.10.013; Huiskonen JT, 2006, STRUCTURE, V14, P1039, DOI 10.1016/j.str.2006.03.018; Jaalinoja HT, 2007, STRUCTURE, V15, P157, DOI 10.1016/j.str.2006.12.004; Jayaram H, 2004, VIRUS RES, V101, P67, DOI 10.1016/j.virusres.2003.12.007; JOHNSON MD, 1994, J BACTERIOL, V176, P4124, DOI 10.1128/JB.176.13.4124-4132.1994; Juuti JT, 1997, J MOL BIOL, V266, P891, DOI 10.1006/jmbi.1996.0817; Li TC, 2003, VIROLOGY, V311, P115, DOI 10.1016/S0042-6822(03)00141-7; Lisal J, 2004, J BIOL CHEM, V279, P1343, DOI 10.1074/jbc.M309587200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mancini EJ, 2004, CELL, V118, P743, DOI 10.1016/j.cell.2004.09.007; Mancini EJ, 2004, ACTA CRYSTALLOGR D, V60, P588, DOI 10.1107/S0907444904001052; Mindich L, 1999, J BACTERIOL, V181, P4505, DOI 10.1128/JB.181.15.4505-4508.1999; MINDICH L, 1988, ADV VIRUS RES, V35, P137; Mindich L, 2004, VIRUS RES, V101, P83, DOI 10.1016/j.virusres.2003.12.008; Patton JT, 1996, J VIROL, V70, P7940, DOI 10.1128/JVI.70.11.7940-7947.1996; Qiao J, 2003, J BACTERIOL, V185, P4572, DOI 10.1128/JB.185.15.4572-4577.2003; Qiao XY, 2008, P NATL ACAD SCI USA, V105, P15956, DOI 10.1073/pnas.0807489105; Sen A, 2008, J BIOL CHEM, V283, P12227, DOI 10.1074/jbc.M710508200; SINCLAIR JF, 1975, J VIROL, V16, P685, DOI 10.1128/JVI.16.3.685-695.1975; STITT BL, 1983, VIROLOGY, V127, P459, DOI 10.1016/0042-6822(83)90158-7; VANETTEN J, 1976, J VIROL, V18, P652, DOI 10.1128/JVI.18.2.652-658.1976; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; Yang HY, 2003, VIROLOGY, V314, P706, DOI 10.1016/S0042-6822(03)00460-4; Zeng CQY, 1998, J VIROL, V72, P201, DOI 10.1128/JVI.72.1.201-208.1998; Zhang X, 2003, NAT STRUCT BIOL, V10, P1011, DOI 10.1038/nsb1009	38	20	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6850	10.1371/journal.pone.0006850	http://dx.doi.org/10.1371/journal.pone.0006850			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727406	Green Published, gold			2022-12-27	WOS:000269522900005
J	Tabib, A; Krispin, A; Trahtemberg, U; Verbovetski, I; Lebendiker, M; Danieli, T; Mevorach, D				Tabib, Adi; Krispin, Alon; Trahtemberg, Uriel; Verbovetski, Inna; Lebendiker, Mario; Danieli, Tsafi; Mevorach, Dror			Thrombospondin-1-N-Terminal Domain Induces a Phagocytic State and Thrombospondin-1-C-Terminal Domain Induces a Tolerizing Phenotype in Dendritic Cells	PLOS ONE			English	Article								In our previous study, we have found that thrombospondin-1 (TSP-1) is synthesized de novo upon monocyte and neutrophil apoptosis, leading to a phagocytic and tolerizing phenotype of dendritic cells ( DC), even prior to DC-apoptotic cell interaction. Interestingly, we were able to show that heparin binding domain (HBD), the N-terminal portion of TSP-1, was cleaved and secreted simultaneously in a caspase-and serine protease-dependent manner. In the current study we were interested to examine the role of HBD in the clearance of apoptotic cells, and whether the phagocytic and tolerizing state of DCs is mediated by the HBD itself, or whether the entire TSP-1 is needed. Therefore, we have cloned the human HBD, and compared its interactions with DC to those with TSP-1. Here we show that rHBD by itself is not directly responsible for immune paralysis and tolerizing phenotype of DCs, at least in the monomeric form, but has a significant role in rendering DCs phagocytic. Binding of TSP-1-C-terminal domain on the other hand induces a tolerizing phenotype in dendritic cells.			Tabib, A (corresponding author), Hebrew Univ Jerusalem, Rheumatol Res Unit, Lab Cellular & Mol Immunol, Jerusalem, Israel.	mevorachd@hadassah.org.il	Trahtemberg, Uriel/B-3127-2008	Trahtemberg, Uriel/0000-0001-9103-2494				Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; Adams JC, 2003, J MOL BIOL, V328, P479, DOI 10.1016/S0022-2836(03)00248-1; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Bornstein P, 2004, INT J BIOCHEM CELL B, V36, P1115, DOI 10.1016/j.biocel.2004.01.012; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Demeure CE, 2000, J IMMUNOL, V164, P2193, DOI 10.4049/jimmunol.164.4.2193; Doyen V, 2003, J EXP MED, V198, P1277, DOI 10.1084/jem.20030705; Elzie CA, 2004, INT J BIOCHEM CELL B, V36, P1090, DOI 10.1016/j.biocel.2003.12.012; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Krispin A, 2006, BLOOD, V108, P3580, DOI 10.1182/blood-2006-03-013334; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Orr AW, 2004, J BIOL CHEM, V279, P48983, DOI 10.1074/jbc.M404881200; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Silverstein RL, 2002, J CELL BIOL, V159, P203, DOI 10.1083/jcb.200209138; Tan K, 2006, STRUCTURE, V14, P33, DOI 10.1016/j.str.2005.09.017; Verbovetski I, 2002, J EXP MED, V196, P1553, DOI 10.1084/jem.20020263; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109	20	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6840	10.1371/journal.pone.0006840	http://dx.doi.org/10.1371/journal.pone.0006840			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19721725	gold, Green Published			2022-12-27	WOS:000269415900013
J	Ursing, J; Kofoed, PE; Rodrigues, A; Rombo, L				Ursing, Johan; Kofoed, Poul-Erik; Rodrigues, Amabelia; Rombo, Lars			No Seasonal Accumulation of Resistant P-falciparum when High-Dose Chloroquine Is Used	PLOS ONE			English	Article								Background: Potentially chloroquine resistant P. falciparum, identified by the 76T haplotype in the chloroquine resistance transporter (pfcrt 76T), are highly prevalent throughout Africa. In Guinea-Bissau, normal and double dose chloroquine have respective efficacies of 34% and 78% against P. falciparum with pfcrt 76T and approximately three times the normal dose of chloroquine is routinely taken. Proportions of pfcrt 76T generally increase during high transmission seasons, as P. falciparum with pfcrt 76T commonly survive treatment with normal dose chloroquine. In Guinea-Bissau, there should be no seasonal increase of pfcrt 76T if the high doses of CQ commonly used are effective. Methods and Findings: P. falciparum parasite density, age, sex, the proportion of chloroquine resistance associated haplotypes pfcrt 76T and P. falciparum multidrug resistance gene 1 86Y were assessed in 988 samples collected from children between 2002 and 2007. There was no seasonal accumulation of any allele. During the high and low transmission periods the pfcrt 76T proportions were 24% (95% CI, 21-27%) and 26% (95% CI, 20-33%). There was no significant change of pfcrt 76T (OR 1.05, 95% CI; 0.94-1.16 p = 0.39) or pfmdr1 86Y (OR 0.92, 95% CI; 0.83-1.01 p = 0.08) proportions between 2003 and 2007. Lower median parasite density (P. falciparum/mu l) was associated with pfcrt 76T (15254 [95% CI, 12737-17772]; n = 164) compared to pfcrt 76K (18664 [95% CI, 16676-20653]; p = 0.003; n = 591). Similarly, pfmdr1 86Y was associated with a lower median parasite density (16320 [95% CI, 13696-18944]; n = 224) compared to pfmdr1 86N, (18880 [95% CI, 16701-21059]; P = 0.018; n = 445). Conclusions: In contrast to the rest of Africa, P. falciparum parasites resistant to normal dose chloroquine do not have a selective advantage great enough to become the dominant P. falciparum type in Guinea-Bissau. This is most likely due to the efficacy of high-dose chloroquine as used in Guinea-Bissau, combined with a loss of fitness associated with pfcrt 76T.			Ursing, J (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Infect Dis, S-10401 Stockholm, Sweden.	johan.ursing@ki.se		Ursing, Johan/0000-0002-5508-9327				Abdel-Muhsin AMA, 2004, J INFECT DIS, V189, P1239, DOI 10.1086/382509; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Ginsburg H, 2005, ACTA TROP, V96, P16, DOI 10.1016/j.actatropica.2005.06.021; Hastings IM, 2005, ACTA TROP, V94, P218, DOI 10.1016/j.actatropica.2005.04.003; Hayward R, 2005, MOL MICROBIOL, V55, P1285, DOI 10.1111/j.1365-2958.2004.04470.x; HELLGREN U, 1991, T ROY SOC TROP MED H, V85, P36, DOI 10.1016/0035-9203(91)90144-N; Kofoed PE, 2007, T ROY SOC TROP MED H, V101, P231, DOI 10.1016/j.trstmh.2006.05.008; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032; Ord R, 2007, J INFECT DIS, V196, P1613, DOI 10.1086/522154; Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x; Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7; Ursing J, 2007, INFECT GENET EVOL, V7, P555, DOI 10.1016/j.meegid.2007.03.006; Ursing J, 2007, AM J TROP MED HYG, V76, P844, DOI 10.4269/ajtmh.2007.76.844; Ursing J, 2009, ANTIMICROB AGENTS CH, V53, P180, DOI 10.1128/AAC.01111-08; Veiga MI, 2006, MOL CELL PROBE, V20, P100, DOI 10.1016/j.mcp.2005.10.003; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	18	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6866	10.1371/journal.pone.0006866	http://dx.doi.org/10.1371/journal.pone.0006866			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718439	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900027
J	Verginelli, F; Bishehsari, F; Napolitano, F; Mahdavinia, M; Cama, A; Malekzadeh, R; Miele, G; Raiconi, G; Tagliaferri, R; Mariani-Costantini, R				Verginelli, Fabio; Bishehsari, Faraz; Napolitano, Francesco; Mahdavinia, Mahboobeh; Cama, Alessandro; Malekzadeh, Reza; Miele, Gennaro; Raiconi, Giancarlo; Tagliaferri, Roberto; Mariani-Costantini, Renato			Transitions at CpG Dinucleotides, Geographic Clustering of TP53 Mutations and Food Availability Patterns in Colorectal Cancer	PLOS ONE			English	Article							TUMOR-SUPPRESSOR GENE; NITRIC-OXIDE SYNTHASE; INFLAMMATORY-BOWEL-DISEASE; ONE-CARBON METABOLISM; N-NITROSO COMPOUNDS; P53 MUTATIONS; COLON-CANCER; ENERGY-INTAKE; RED MEAT; NUTRITION TRANSITION	Background: Colorectal cancer is mainly attributed to diet, but the role exerted by foods remains unclear because involved factors are extremely complex. Geography substantially impacts on foods. Correlations between international variation in colorectal cancer-associated mutation patterns and food availabilities could highlight the influence of foods on colorectal mutagenesis. Methodology: To test such hypothesis, we applied techniques based on hierarchical clustering, feature extraction and selection, and statistical pattern recognition to the analysis of 2,572 colorectal cancer-associated TP53 mutations from 12 countries/geographic areas. For food availabilities, we relied on data extracted from the Food Balance Sheets of the Food and Agriculture Organization of the United Nations. Dendrograms for mutation sites, mutation types and food patterns were constructed through Ward's hierarchical clustering algorithm and their stability was assessed evaluating silhouette values. Feature selection used entropy-based measures for similarity between clusterings, combined with principal component analysis by exhaustive and heuristic approaches. Conclusion/Significance: Mutations clustered in two major geographic groups, one including only Western countries, the other Asia and parts of Europe. This was determined by variation in the frequency of transitions at CpGs, the most common mutation type. Higher frequencies of transitions at CpGs in the cluster that included only Western countries mainly reflected higher frequencies of mutations at CpG codons 175, 248 and 273, the three major TP53 hotspots. Pearson's correlation scores, computed between the principal components of the datamatrices for mutation types, food availability and mutation sites, demonstrated statistically significant correlations between transitions at CpGs and both mutation sites and availabilities of meat, milk, sweeteners and animal fats, the energy-dense foods at the basis of "Western'' diets. This is best explainable by differential exposure to nitrosative DNA damage due to foods that promote metabolic stress and chronic inflammation.			Verginelli, F (corresponding author), Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy.	rmc@unich.it	Mariani-Costantini, Renato/B-6637-2012; Malekzadeh, Reza/U-1382-2017; Tagliaferri, Roberto/AAZ-6113-2020; Miele, Gennaro/F-3628-2010; Miele, Gennaro/AAG-6782-2020; CAMA, Alessandro/J-3964-2018; Napolitano, Francesco/Q-1669-2016	Mariani-Costantini, Renato/0000-0002-4440-1848; Malekzadeh, Reza/0000-0002-9820-6335; Miele, Gennaro/0000-0002-2028-0578; Miele, Gennaro/0000-0002-2028-0578; CAMA, Alessandro/0000-0003-3647-1368; Napolitano, Francesco/0000-0002-7782-8506; Raiconi, Giancarlo/0000-0001-5307-7173; Malekzadeh, Reza/0000-0003-1043-3814; Tagliaferri, Roberto/0000-0001-8134-9025; VERGINELLI, Fabio/0000-0002-8636-2517; Mahdavinia, mahboobeh/0000-0003-4004-203X; Bishehsari, Faraz/0000-0001-5644-2586				*AM I CANC RES, 1997, FOOD NUTR PREV CANC; Ambs S, 1999, J NATL CANCER I, V91, P86, DOI 10.1093/jnci/91.1.86; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Ambs S, 1998, CANCER RES, V58, P334; Arasaradnam RP, 2008, EPIGENETICS-US, V3, P193, DOI 10.4161/epi.3.4.6508; Arulampalam V, 2008, J INTERN MED, V263, P607, DOI 10.1111/j.1365-2796.2008.01964.x; Asbeck I, 2002, PUBLIC HEALTH NUTR, V5, P683, DOI 10.1079/PHN2002337; BAKER SJ, 1990, CANCER RES, V50, P7717; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bingham S, 2004, NAT REV CANCER, V4, P206, DOI 10.1038/nrc1298; Bingham SA, 1996, CARCINOGENESIS, V17, P515, DOI 10.1093/carcin/17.3.515; Bock C, 2008, BIOINFORMATICS, V24, P1, DOI 10.1093/bioinformatics/btm546; Broughton KS, 2002, J NUTR, V132, P88, DOI 10.1093/jn/132.1.88; CASTILLO L, 1993, P NATL ACAD SCI USA, V90, P193, DOI 10.1073/pnas.90.1.193; Collins AR, 2003, CARCINOGENESIS, V24, P511, DOI 10.1093/carcin/24.3.511; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Cross AJ, 2004, ENVIRON MOL MUTAGEN, V44, P44, DOI 10.1002/em.20030; Cross AJ, 2003, CANCER RES, V63, P2358; Cross RK, 2003, INFLAMM BOWEL DIS, V9, P179, DOI 10.1097/00054725-200305000-00006; Curtin K, 2007, CARCINOGENESIS, V28, P1672, DOI 10.1093/carcin/bgm089; Day NE, 2001, INT J EPIDEMIOL, V30, P309, DOI 10.1093/ije/30.2.309; Devaraj S, 2008, METABOLISM, V57, P867, DOI 10.1016/j.metabol.2008.02.016; Drewnowski A, 1997, NUTR REV, V55, P31, DOI 10.1111/j.1753-4887.1997.tb01593.x; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; Ferrari P, 2002, PUBLIC HEALTH NUTR, V5, P1329, DOI 10.1079/PHN2002409; Food and Agriculture Organization of the United Nations, 2001, FOOD BAL SHEETS HDB; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Friso S, 2005, CURR DRUG METAB, V6, P37, DOI 10.2174/1389200052997339; Gal A, 1996, P NATL ACAD SCI USA, V93, P15102, DOI 10.1073/pnas.93.26.15102; Gerner EW, 2007, BIOCHEM SOC T, V35, P322, DOI 10.1042/BST0350322; Ghassemi H, 2002, PUBLIC HEALTH NUTR, V5, P149, DOI 10.1079/PHN2001287; Giugliano D, 2006, J AM COLL CARDIOL, V48, P677, DOI 10.1016/j.jacc.2006.03.052; Goldman R, 2003, J NUTR, V133, p965S, DOI 10.1093/jn/133.3.965S; Goodman JE, 2004, ENVIRON MOL MUTAGEN, V44, P3, DOI 10.1002/em.20024; Grisham MB, 2002, J INVEST MED, V50, P272, DOI 10.2310/6650.2002.33281; Gunter MJ, 2006, J NUTR BIOCHEM, V17, P145, DOI 10.1016/j.jnutbio.2005.06.011; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2002, NAT MED, V8, P21, DOI 10.1038/nm0102-21; Hao XP, 2002, GUT, V50, P834, DOI 10.1136/gut.50.6.834; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Hughes MN, 2008, METHOD ENZYMOL, V436, P3, DOI 10.1016/S0076-6879(08)36001-7; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; Huycke MM, 2004, EXP BIOL MED, V229, P586, DOI 10.1177/153537020422900702; Iacopetta B, 2006, ANN ONCOL, V17, P842, DOI 10.1093/annonc/mdl035; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Innis SM, 2007, NUTR REV, V65, pS188, DOI 10.1301/nr.2007.dec.S188-S193; Ishibe N, 2001, CANCER INVEST, V19, P524, DOI 10.1081/CNV-100103850; Jagerstad M, 2005, MUTAT RES-FUND MOL M, V574, P156, DOI 10.1016/j.mrfmmm.2005.01.030; Johansson G, 2001, PUBLIC HEALTH NUTR, V4, P919, DOI 10.1079/PHN2001124; Johnson .T, 2007, ALIMENT PHARM THER, V26, P161, DOI 10.1111/j.1365-2036.2007.03371.x; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kallio P, 2008, AM J CLIN NUTR, V87, P1497, DOI 10.1093/ajcn/87.5.1497; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; Kim YI, 2005, J NUTR, V135, P2703, DOI 10.1093/jn/135.11.2703; Kolonel LN, 2004, NAT REV CANCER, V4, P519, DOI 10.1038/nrc1389; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lewin MH, 2006, CANCER RES, V66, P1859, DOI 10.1158/0008-5472.CAN-05-2237; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029; MacFarlane AJ, 2007, NUTR REV, V65, pS157, DOI [10.1111/j.1753-4887.2007.tb00355.x, 10.1301/nr.2007.dec.S157-S166]; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Mahdavinia M, 2008, J CELL PHYSIOL, V216, P543, DOI 10.1002/jcp.21428; MANTEL N, 1970, BIOMETRICS, V26, P547, DOI 10.2307/2529108; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Oates PS, 2006, WORLD J GASTROENTERO, V12, P4281, DOI 10.3748/wjg.v12.i27.4281; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier Magali, 2004, IARC Sci Publ, P247; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; Pfeifer GP, 2006, CURR TOP MICROBIOL, V301, P259; Pfeifer GP, 1998, ENVIRON MOL MUTAGEN, V31, P197, DOI 10.1002/(SICI)1098-2280(1998)31:3<197::AID-EM1>3.0.CO;2-I; Pinto D, 2005, EXP CELL RES, V306, P357, DOI 10.1016/j.yexcr.2005.02.022; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Quinlivan EP, 2005, J NUTR, V135, P389, DOI 10.1093/jn/135.3.389; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Schernhammer ES, 2008, GASTROENTEROLOGY, V135, P770, DOI 10.1053/j.gastro.2008.06.033; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Serra-Majem L, 2003, J EPIDEMIOL COMMUN H, V57, P74, DOI 10.1136/jech.57.1.74; Slattery ML, 2008, AM J CLIN NUTR, V88, P14, DOI 10.1093/ajcn/88.1.14; Slattery ML, 2002, CANCER EPIDEM BIOMAR, V11, P541; Souici AC, 2000, CARCINOGENESIS, V21, P281, DOI 10.1093/carcin/21.2.281; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tricker AR, 1997, EUR J CANCER PREV, V6, P226, DOI 10.1097/00008469-199706000-00003; Ulrich CM, 2005, J NUTR, V135, P2462, DOI 10.1093/jn/135.10.2462; US Department of Agriculture, USDA NUTR DAT STAND; Vaninetti NM, 2008, MOL CARCINOGEN, V47, P275, DOI 10.1002/mc.20382; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WARREN W, 1995, CARCINOGENESIS, V16, P1181, DOI 10.1093/carcin/16.5.1181; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; World Cancer Research Fund/American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; Wright BE, 2002, CANCER RES, V62, P5641; Yerushalmi HF, 2006, MOL CARCINOGEN, V45, P93, DOI 10.1002/mc.20168; You YH, 1998, MUTAT RES-GEN TOX EN, V420, P55, DOI 10.1016/S1383-5718(98)00147-8; Zell JA, 2007, INT J CANCER, V120, P459, DOI 10.1002/ijc.22311	114	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6824	10.1371/journal.pone.0006824	http://dx.doi.org/10.1371/journal.pone.0006824			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718455	Green Submitted, gold, Green Published			2022-12-27	WOS:000269415900004
J	Diaz, Z; Xavier, KB; Miller, ST				Diaz, Zamia; Xavier, Karina B.; Miller, Stephen T.			The Crystal Structure of the Escherichia coli Autoinducer-2 Processing Protein LsrF	PLOS ONE			English	Article								Many bacteria produce and respond to the quorum sensing signal autoinducer-2 (AI-2). Escherichia coli and Salmonella typhimurium are among the species with the lsr operon, an operon containing AI-2 transport and processing genes that are up regulated in response to AI-2. One of the Lsr proteins, LsrF, has been implicated in processing the phosphorylated form of AI-2. Here, we present the structure of LsrF, unliganded and in complex with two phospho-AI-2 analogues, ribose-5-phosphate and ribulose-5-phosphate. The crystal structure shows that LsrF is a decamer of (alpha beta)(8)-barrels that exhibit a previously unseen N-terminal domain swap and have high structural homology with aldolases that process phosphorylated sugars. Ligand binding sites and key catalytic residues are structurally conserved, strongly implicating LsrF as a class I aldolase.			Diaz, Z (corresponding author), Swarthmore Coll, Dept Chem & Biochem, Swarthmore, PA 19081 USA.	smiller1@swarthmore.edu	Xavier, Karina/B-9425-2008	Xavier, Karina/0000-0001-5210-1434				Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; [Anonymous], ACTA CRYSTALLOGR D, V50, P760; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Federle MJ, 2003, J CLIN INVEST, V112, P1291, DOI 10.1172/JCI200320195; Gefflaut T, 1995, PROG BIOPHYS MOL BIO, V63, P301, DOI 10.1016/0079-6107(95)00008-9; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hammer BK, 2003, MOL MICROBIOL, V50, P101, DOI 10.1046/j.1365-2958.2003.03688.x; Hammer BK, 2007, P NATL ACAD SCI USA, V104, P11145, DOI 10.1073/pnas.0703860104; Hardie KR, 2008, NAT REV MICROBIOL, V6, P635, DOI 10.1038/nrmicro1916; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; Huang K, 1999, STRUCT FOLD DES, V7, P539, DOI 10.1016/S0969-2126(99)80070-7; HUANG Z, 2008, J MOL MICROBIOL BIOT; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Laasik E, 2006, FEMS MICROBIOL LETT, V258, P227, DOI 10.1111/j.1574-6968.2006.00222.x; Lenz DH, 2005, MOL MICROBIOL, V58, P1186, DOI 10.1111/j.1365-2958.2005.04902.x; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Li M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-4; Lombardia E, 2006, J BACTERIOL, V188, P4442, DOI 10.1128/JB.00165-06; Lorentzen E, 2005, BIOCHEMISTRY-US, V44, P4222, DOI 10.1021/bi048192o; Lorentzen E, 2003, J BIOL CHEM, V278, P47253, DOI 10.1074/jbc.M305922200; Lupyan D, 2005, BIOINFORMATICS, V21, P3255, DOI 10.1093/bioinformatics/bti527; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; Mok KC, 2003, EMBO J, V22, P870, DOI 10.1093/emboj/cdg085; Morar M, 2007, BIOCHEMISTRY-US, V46, P10562, DOI 10.1021/bi700934v; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Neiditch MB, 2006, CELL, V126, P1095, DOI 10.1016/j.cell.2006.07.032; Neiditch MB, 2005, MOL CELL, V18, P507, DOI 10.1016/j.molcel.2005.04.020; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pereira CS, 2008, MOL MICROBIOL, V70, P1223, DOI 10.1111/j.1365-2958.2008.06477.x; Rader BA, 2007, J BACTERIOL, V189, P6109, DOI 10.1128/JB.00246-07; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Steiner RA, 2003, ACTA CRYSTALLOGR D, V59, P2114, DOI 10.1107/S0907444903018675; Sztajer H, 2008, J BACTERIOL, V190, P401, DOI 10.1128/JB.01086-07; Taga ME, 2003, MOL MICROBIOL, V50, P1411, DOI 10.1046/j.1365-2958.2003.03781.x; Taga ME, 2001, MOL MICROBIOL, V42, P777, DOI 10.1046/j.1365-2958.2001.02669.x; Thorell S, 2002, J MOL BIOL, V319, P161, DOI 10.1016/S0022-2836(02)00258-9; Tropea Joseph E, 2007, Methods Mol Biol, V363, P1, DOI 10.1007/978-1-59745-209-0_1; Waters CM, 2006, GENE DEV, V20, P2754, DOI 10.1101/gad.1466506; Xavier KB, 2007, ACS CHEM BIOL, V2, P128, DOI 10.1021/cb600444h; Xavier KB, 2005, NATURE, V437, P750, DOI 10.1038/nature03960; Xavier KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI 10.1016/S1369-5274(03)00028-6; Xavier KB, 2005, J BACTERIOL, V187, P238, DOI 10.1128/JB.187.1.238-248.2005	48	11	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6820	10.1371/journal.pone.0006820	http://dx.doi.org/10.1371/journal.pone.0006820			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714241	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415800009
J	Scaglia, N; Chisholm, JW; Igal, RA				Scaglia, Natalia; Chisholm, Jeffrey W.; Igal, R. Ariel			Inhibition of StearoylCoA Desaturase-1 Inactivates Acetyl-CoA Carboxylase and Impairs Proliferation in Cancer Cells: Role of AMPK	PLOS ONE			English	Article								Cancer cells activate the biosynthesis of saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) in order to sustain an increasing demand for phospholipids with appropriate acyl composition during cell replication. We have previously shown that a stable knockdown of stearoyl-CoA desaturase 1 (SCD1), the main Delta 9-desaturase that converts SFA into MUFA, in cancer cells decreases the rate of lipogenesis, reduces proliferation and in vitro invasiveness, and dramatically impairs tumor formation and growth. Here we report that pharmacological inhibition of SCD1 with a novel small molecule in cancer cells promoted the activation of AMP-activated kinase (AMPK) and the subsequent reduction of acetylCoA carboxylase activity, with a concomitant inhibition of glucose-mediated lipogenesis. The pharmacological inhibition of AMPK further decreased proliferation of SCD1-depleted cells, whereas AMPK activation restored proliferation to control levels. Addition of supraphysiological concentrations of glucose or pyruvate, the end product of glycolysis, did not reverse the low proliferation rate of SCD1-ablated cancer cells. Our data suggest that cancer cells require active SCD1 to control the rate of glucose-mediated lipogenesis, and that when SCD1 activity is impaired cells downregulate SFA synthesis via AMPK-mediated inactivation of acetyl-CoA carboxylase, thus preventing the harmful effects of SFA accumulation.			Scaglia, N (corresponding author), Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08903 USA.	igal@aesop.rutgers.edu						ASHCRAFT BA, 1980, J BIOL CHEM, V255, P33; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUGNOUX P, 1992, BREAST CANCER RES TR, V20, P185; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Chajes V, 2006, CANCER RES, V66, P5287, DOI 10.1158/0008-5472.CAN-05-1489; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; CLARKE SD, 1985, FED PROC, V44, P2458; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; deVries JE, 1997, J LIPID RES, V38, P1384; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; HA J, 1994, J BIOL CHEM, V269, P22162; Hardy S, 2000, CANCER RES, V60, P6353; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim JE, 2008, BONE, V43, P394, DOI 10.1016/j.bone.2008.03.021; Kim JE, 2008, J PHARMACOL SCI, V106, P394, DOI 10.1254/jphs.FP0071857; Koltun DO, 2009, BIOORG MED CHEM LETT, V19, P3050, DOI 10.1016/j.bmcl.2009.04.004; Koltun DO, 2009, BIOORG MED CHEM LETT, V19, P2048, DOI 10.1016/j.bmcl.2009.02.019; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kumar-Sinha C, 2003, CANCER RES, V63, P132; LEPAGE G, 1984, J LIPID RES, V25, P1391; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Lu JX, 1997, MOL CARCINOGEN, V20, P204, DOI 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M; Maedler K, 2001, DIABETES, V50, P69, DOI 10.2337/diabetes.50.1.69; Menna PL, 2003, CANCER RES, V63, P2284; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Munday MR, 1999, ADV ENZYME REGUL, V39, P205, DOI 10.1016/S0065-2571(98)00016-8; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NAKANISHI S, 1970, EUR J BIOCHEM, V16, P161, DOI 10.1111/j.1432-1033.1970.tb01068.x; NIKAWA J, 1979, FEBS LETT, V102, P223, DOI 10.1016/0014-5793(79)80005-8; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Pizer ES, 1996, CANCER RES, V56, P2745; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; RUGGIERI S, 1979, J LIPID RES, V20, P772; Scaglia N, 2005, J BIOL CHEM, V280, P25339, DOI 10.1074/jbc.M501159200; Scaglia N, 2005, BBA-MOL CELL BIOL L, V1687, P141, DOI 10.1016/j.bbalip.2004.11.015; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Taylor EB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1055, DOI 10.1152/ajpendo.00516.2004; Thai SF, 2001, CARCINOGENESIS, V22, P1317, DOI 10.1093/carcin/22.8.1317; UNDERWOOD AH, 1965, BIOCHEM J, V95, P868, DOI 10.1042/bj0950868; URADE R, 1992, J BIOCH, V91, P1639; Wang HQ, 2005, ONCOGENE, V24, P3574, DOI 10.1038/sj.onc.1208463; Wang X, 2007, BIOCHEM BIOPH RES CO, V352, P463, DOI 10.1016/j.bbrc.2006.11.032; Wilson R, 2001, J CHROMATOGR A, V905, P251, DOI 10.1016/S0021-9673(00)01006-2; Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200; Yahagi N, 2005, EUR J CANCER, V41, P1316, DOI 10.1016/j.ejca.2004.12.037	66	142	155	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6812	10.1371/journal.pone.0006812	http://dx.doi.org/10.1371/journal.pone.0006812			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710915	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415600022
J	Vicens, Q; Gooding, AR; Duarte, LF; Batey, RT				Vicens, Quentin; Gooding, Anne R.; Duarte, Luis F.; Batey, Robert T.			Preparation of Group I Introns for Biochemical Studies and Crystallization Assays by Native Affinity Purification	PLOS ONE			English	Article								The study of functional RNAs of various sizes and structures requires efficient methods for their synthesis and purification. Here, 23 group I intron variants ranging in length from 246 to 341 nucleotides-some containing exons-were subjected to a native purification technique previously applied only to shorter RNAs (< 160 nucleotides). For the RNAs containing both exons, we adjusted the original purification protocol to allow for purification of radiolabeled molecules. The resulting RNAs were used in folding assays on native gel electrophoresis and in self-splicing assays. The intron-only RNAs were subjected to the regular native purification scheme, assayed for folding and employed in crystallization screens. All RNAs that contained a 39 overhang of one nucleotide were efficiently cleaved off from the support and were at least 90% pure after the non-denaturing purification. A representative subset of these RNAs was shown to be folded and self-splicing after purification. Additionally, crystals were grown for a 286 nucleotide long variant of the Clostridium botulinum intron. These results demonstrate the suitability of the native affinity purification method for the preparation of group I introns. We hope these findings will stimulate a broader application of this strategy to the preparation of other large RNA molecules.			Vicens, Q (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	quentin.vicens@colorado.edu	Vicens, Quentin/N-6139-2019; Vicens, Quentin/A-8319-2009; Batey, Robert/A-8265-2009	Vicens, Quentin/0000-0003-3751-530X; Vicens, Quentin/0000-0003-3751-530X; Batey, Robert/0000-0002-1384-6625	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073850] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM073850] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PL, 2004, RNA, V10, P1867, DOI 10.1261/rna.7140504; Batey RT, 2007, RNA, V13, P1384, DOI 10.1261/rna.528007; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Batey RT, 2004, NATURE, V432, P411, DOI 10.1038/nature03037; BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Chase E, 2005, ACTA CRYSTALLOGR F, V61, P71, DOI 10.1107/S1744309104028337; Chen X, 2000, J MOL BIOL, V301, P265, DOI 10.1006/jmbi.2000.3963; CHU FK, 1986, CELL, V45, P157, DOI 10.1016/0092-8674(86)90379-X; DANN CE, 2007, RNA CELL, V130, P878; DOUDNA JA, 1993, P NATL ACAD SCI USA, V90, P7829, DOI 10.1073/pnas.90.16.7829; Edwards Andrea L., 2009, V535, P135, DOI 10.1007/978-1-59745-557-2_9; EHRENMAN K, 1989, NUCLEIC ACIDS RES, V17, P9147, DOI 10.1093/nar/17.22.9147; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Gesteland R., 2006, RNA WORLD, V3rd edn. Cold Spring Harbor; Golden BL, 2003, J STRUCT BIOL, V142, P98, DOI 10.1016/S1047-8477(03)00042-X; Hansen CL, 2002, P NATL ACAD SCI USA, V99, P16531, DOI 10.1073/pnas.262485199; Hanson BL, 2003, J STRUCT BIOL, V142, P77, DOI 10.1016/S1047-8477(03)00040-6; Heilman-Miller SL, 2003, J MOL BIOL, V328, P385, DOI 10.1016/S0022-2836(03)00304-8; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Juneau K, 2001, STRUCTURE, V9, P221, DOI 10.1016/S0969-2126(01)00579-2; Kieft JS, 2004, RNA, V10, P988, DOI 10.1261/rna.7040604; Kriminski S, 2002, ACTA CRYSTALLOGR D, V58, P459, DOI 10.1107/S0907444902000112; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; Leontis NB, 2001, RNA, V7, P499, DOI 10.1017/S1355838201002515; Machouart-Dubach M, 2002, FEMS MICROBIOL LETT, V208, P187, DOI 10.1111/j.1574-6968.2002.tb11080.x; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Pichler A, 2002, J BIOL CHEM, V277, P17987, DOI 10.1074/jbc.M111798200; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5357, DOI 10.1093/nar/20.20.5357; Rosenstein SP, 1996, BIOCHEMISTRY-US, V35, P11403, DOI 10.1021/bi9609984; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; Vicens Q, 2008, RNA, V14, P2013, DOI 10.1261/rna.1027208; Waldsich C, 2002, GENE DEV, V16, P2300, DOI 10.1101/gad.231302; Williams KP, 2002, NUCLEIC ACIDS RES, V30, P179, DOI 10.1093/nar/30.1.179; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; ZAUG AJ, 1993, BIOCHEMISTRY-US, V32, P7946, DOI 10.1021/bi00082a016	40	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6740	10.1371/journal.pone.0006740	http://dx.doi.org/10.1371/journal.pone.0006740			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710925	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415600001
J	Plevneshi, A; Svoboda, T; Armstrong, I; Tyrrell, GJ; Miranda, A; Green, K; Low, D; McGeer, A				Plevneshi, Agron; Svoboda, Tomislav; Armstrong, Irene; Tyrrell, Gregory J.; Miranda, Anna; Green, Karen; Low, Donald; McGeer, Allison		Toronto Invasive Bacterial Dis Net	Population-Based Surveillance for Invasive Pneumococcal Disease in Homeless Adults in Toronto	PLOS ONE			English	Article							SELF-REPORTED COMORBIDITIES; USUAL CARE; PNEUMONIA; VACCINATION; RECOMMENDATIONS; INFECTIONS; BACTEREMIA; VACCINES; OUTBREAK; IMPACT	Background: Identification of high-risk populations for serious infection due to S. pneumoniae will permit appropriately targeted prevention programs. Methods: We conducted prospective, population-based surveillance for invasive pneumococcal disease and laboratory confirmed pneumococcal pneumonia in homeless adults in Toronto, a Canadian city with a total population of 2.5 M, from January 1, 2002 to December 31, 2006. Results: We identified 69 cases of invasive pneumococcal disease and 27 cases of laboratory confirmed pneumococcal pneumonia in an estimated population of 5050 homeless adults. The incidence of invasive pneumococcal disease in homeless adults was 273 infections per 100,000 persons per year, compared to 9 per 100,000 persons per year in the general adult population. Homeless persons with invasive pneumococcal disease were younger than other adults (median age 46 years vs 67 years, P < .001), and more likely than other adults to be smokers (95% vs. 31%, P < .001), to abuse alcohol (62% vs 15%, P < .001), and to use intravenous drugs (42% vs 4%, P < .001). Relative to age matched controls, they were more likely to have underlying lung disease (12/69, 17% vs 17/272, 6%, P = .006), but not more likely to be HIV infected (17/69, 25% vs 58/282, 21%, P = .73). The proportion of patients with recurrent disease was five fold higher for homeless than other adults (7/58, 12% vs. 24/943, 2.5%, P < .001). In homeless adults, 28 (32%) of pneumococcal isolates were of serotypes included in the 7-valent conjugate vaccine, 42 (48%) of serotypes included in the 13-valent conjugate vaccine, and 72 (83%) of serotypes included in the 23-valent polysaccharide vaccine. Although no outbreaks of disease were identified in shelters, there was evidence of clustering of serotypes suggestive of transmission of pathogenic strains within the homeless population. Conclusions: Homeless persons are at high risk of serious pneumococcal infection. Vaccination, physical structure changes or other program to reduce transmission in shelters, harm reduction programs to reduce rates of smoking, alcohol abuse and infection with bloodborne pathogens, and improved treatment programs for HIV infection may all be effective in reducing the risk.			Plevneshi, A (corresponding author), Toronto Invas Bacterial Dis Network, Toronto, ON, Canada.	amcgeer@mtsinai.on.ca	McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014; Tyrrell, Gregory/ABA-7203-2021	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137; Walmsley, Sharon/0000-0002-3959-5692; Powis, Jeff/0000-0003-2053-6083				Al-Sukhni W, 2008, VACCINE, V26, P1432, DOI 10.1016/j.vaccine.2008.01.001; Birtles A, 2005, J CLIN MICROBIOL, V43, P2004, DOI 10.1128/JCM.43.4.2004-2008.2005; BURMAN LA, 1985, REV INFECT DIS, V7, P133; Christenson B, 2004, EUR RESPIR J, V23, P363, DOI 10.1183/09031936.04.00063504; *CIT TOR PUBL HLTH, 2003, HOML REP CARD STREET; Clinical and Laboratory Standards Institute (CLSI), 2006, M7A5 CLSI; Daneman N, 2006, CLIN INFECT DIS, V43, P432, DOI 10.1086/505871; de Roux A, 2006, CHEST, V129, P1219, DOI 10.1378/chest.129.5.1219; DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446; Einarsdottir HM, 2005, CLIN MICROBIOL INFEC, V11, P744, DOI 10.1111/j.1469-0691.2005.01221.x; Flannery B, 2006, ANN INTERN MED, V144, P1, DOI 10.7326/0003-4819-144-1-200601030-00004; Frankish CJ, 2005, CAN J PUBLIC HEALTH, V96, pS23, DOI 10.1007/BF03403700; Garibaldi B, 2005, J GEN INTERN MED, V20, P726, DOI 10.1111/j.1525-1497.2005.0142.x; Greene CM, 2006, CLIN INFECT DIS, V43, P141, DOI 10.1086/505117; Hwang SW, 2001, CAN MED ASSOC J, V164, P229; King MD, 2003, CLIN INFECT DIS, V37, P1029, DOI 10.1086/377736; Kumar D, 2008, BONE MARROW TRANSPL, V41, P743, DOI 10.1038/sj.bmt.1705964; Kumar D, 2007, AM J TRANSPLANT, V7, P1209, DOI 10.1111/j.1600-6143.2006.01705.x; Kyaw MH, 2005, J INFECT DIS, V192, P377, DOI 10.1086/431521; Marra CA, 2000, CAN J PUBLIC HEALTH, V91, P334, DOI 10.1007/BF03404802; McEllistrem MC, 2002, J INFECT DIS, V185, P1364, DOI 10.1086/339882; McKenzie H, 2000, J MED MICROBIOL, V49, P361, DOI 10.1099/0022-1317-49-4-361; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505; Musher DM, 2000, MEDICINE, V79, P210, DOI 10.1097/00005792-200007000-00002; *NAT ADV COMM IMM, 2006, ACT IMM AG 4; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; O'Brien KL, 2007, LANCET INFECT DIS, V7, P597, DOI 10.1016/S1473-3099(07)70210-4; O'Toole TP, 2002, J URBAN HEALTH, V79, P200, DOI 10.1093/jurban/79.2.200; Ortqvist A, 2005, SEMIN RESP CRIT CARE, V26, P563, DOI 10.1055/s-2005-925523; Pastor P, 1998, CLIN INFECT DIS, V26, P590, DOI 10.1086/514589; Pritchard John W., 2004, Reviews on Environmental Health, V19, P363; RodriguezCreixems M, 1996, ARCH INTERN MED, V156, P1429, DOI 10.1001/archinte.156.13.1429; Shariatzadeh MR, 2005, MEDICINE, V84, P147, DOI 10.1097/01.md.0000164302.03972.d7; Sisk JE, 2003, ANN INTERN MED, V138, P960, DOI 10.7326/0003-4819-138-12-200306170-00007; Targonski PV, 2007, CLEV CLIN J MED, V74, P401, DOI 10.3949/ccjm.74.6.401; Turett GS, 2001, ARCH INTERN MED, V161, P2141, DOI 10.1001/archinte.161.17.2141; Turnbull J, 2007, CAN MED ASSOC J, V177, P1065, DOI 10.1503/cmaj.071294	38	34	34	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7255	10.1371/journal.pone.0007255	http://dx.doi.org/10.1371/journal.pone.0007255			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787070	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100025
J	O'Valle, F; Del Moral, RGM; Benitez, MD; Martin-Oliva, D; Gomez-Morales, M; Aguilar, D; Aneiros-Fernandez, J; Hernandez-Cortes, P; Osuna, A; Moreso, F; Seron, D; Oliver, FJ; Del Moral, RG				O'Valle, Francisco; Del Moral, Raimundo G. M.; del Carmen Benitez, Maria; Martin-Oliva, David; Gomez-Morales, Mercedes; Aguilar, David; Aneiros-Fernandez, Jose; Hernandez-Cortes, Pedro; Osuna, Antonio; Moreso, Francesc; Seron, Daniel; Oliver, Francisco J.; Del Moral, Raimundo G.			Poly[ADP-Ribose] Polymerase-1 Expression Is Related To Cold Ischemia, Acute Tubular Necrosis, and Delayed Renal Function In Kidney Transplantation	PLOS ONE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; REPERFUSION INJURY; GRAFT FUNCTION; SYNTHETASE; INHIBITION; DONOR; CELLS; MICE	Cold ischemia time especially impacts on outcomes of expanded-criteria donor (ECD) transplantation. Ischemia-reperfusion (IR) injury produces excessive poly[ADP-Ribose] Polymerase-1 (PARP-1) activation. The present study explored the hypothesis that increased tubular expression of PARP-1 contributes to delayed renal function in suboptimal ECD kidney allografts and in non-ECD allografts that develop posttransplant acute tubular necrosis (ATN). Materials and Methods: Nuclear PARP-1 immunohistochemical expression was studied in 326 paraffin-embedded renal allograft biopsies (193 with different degrees of ATN and 133 controls) and in murine Parp-1 knockout model of IR injury. Results: PARP-1 expression showed a significant relationship with cold ischemia time (r coefficient = 0.603), time to effective diuresis (r = 0.770), serum creatinine levels at biopsy (r = 0.649), and degree of ATN (r = 0.810) (p = 0.001, Pearson test). In the murine IR model, western blot showed an increase in PARP-1 that was blocked by Parp-1 inhibitor. Immunohistochemical study of PARP-1 in kidney allograft biopsies would allow early detection of possible delayed renal function, and the administration of PARP-1 inhibitors may offer a therapeutic option to reduce damage from IR in donor kidneys by preventing or minimizing ATN. In summary, these results suggest a pivotal role for PARP-1 in the ATN of renal transplantation. We propose the immunohistochemical assessment of PARP-1 in kidney allograft biopsies for early detection of a possible delayed renal function.	[O'Valle, Francisco; Del Moral, Raimundo G. M.; del Carmen Benitez, Maria; Gomez-Morales, Mercedes; Aguilar, David; Aneiros-Fernandez, Jose; Del Moral, Raimundo G.] Univ Granada, Dept Pathol, Sch Med, Granada, Spain; [O'Valle, Francisco; Del Moral, Raimundo G. M.; del Carmen Benitez, Maria; Gomez-Morales, Mercedes; Aguilar, David; Aneiros-Fernandez, Jose; Del Moral, Raimundo G.] Univ Granada, Sch Med, Inst Biopathol & Regenerat Med IBIMER, Granada, Spain; [Martin-Oliva, David] Univ Granada, Dept Cell Biol, Granada, Spain; [Hernandez-Cortes, Pedro] San Cecilio Univ Hosp, Dept Traumatol & Orthopaed Surg, Granada, Spain; [Osuna, Antonio] Virgen de las Nieves Univ Hosp, Dept Nephrol, Granada, Spain; [Moreso, Francesc; Seron, Daniel] Bellvitge Univ Hosp, Dept Nephrol, Barcelona, Spain; [Oliver, Francisco J.] CSIC, Inst Parasitol & Biomed, Granada, Spain	University of Granada; University of Granada; University of Granada; Hospital Universitario San Cecilio; Hospital Universitario Virgen de las Nieves; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	O'Valle, F (corresponding author), Univ Granada, Dept Pathol, Sch Med, Granada, Spain.	fovalle@ugr.es	Osuna, Antonio/H-1896-2015; Mateos, Francesc Moreso/O-6451-2016; Aneiros-Fernandez, Jose/AAB-2470-2019; Hernández-Cortés, Pedro/AAS-7691-2020; Martín-Oliva, David/L-8472-2014; Oliver, Javier/S-1725-2018; OValle, Francisco/AAA-9151-2019	Martín-Oliva, David/0000-0002-8095-5442; Oliver, Javier/0000-0001-8468-1998; Moreso, Francesc/0000-0002-7267-3963				Chatterjee PK, 2000, FASEB J, V14, P641, DOI 10.1096/fasebj.14.5.641; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Gueler F, 2004, KIDNEY INT, V66, P523, DOI 10.1111/j.1523-1755.2004.761_11.x; Johnston TD, 2004, CLIN TRANSPLANT, V18, P28, DOI 10.1111/j.1399-0012.2004.00214.x; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Mangino MJ, 2004, AM J PHYSIOL-RENAL, V286, pF838, DOI 10.1152/ajprenal.00230.2003; Martin DR, 2000, AM J PHYSIOL-REG I, V279, pR1834, DOI 10.1152/ajpregu.2000.279.5.R1834; O'Valle F, 2005, TRANSPL P, V37, P1421, DOI 10.1016/j.transproceed.2005.02.040; O'Valle F, 2004, TRANSPL P, V36, P733, DOI 10.1016/j.transproceed.2004.03.029; Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011; PALLER MS, 1994, J INVEST MED, V42, P632; Perico N, 2004, LANCET, V364, P1814, DOI 10.1016/S0140-6736(04)17406-0; Remuzzi G, 2006, NEW ENGL J MED, V354, P343, DOI 10.1056/NEJMoa052891; Salahudeen AK, 2004, J INVEST MED, V52, P296, DOI 10.1136/jim-52-05-28; Salahudeen AK, 2004, KIDNEY INT, V65, P713, DOI 10.1111/j.1523-1755.2004.00416.x; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Weight SC, 1996, BRIT J SURG, V83, P162, DOI 10.1002/bjs.1800830206; WIECEK A, 1996, ANN TRANSPL, V9, P1; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang PL, 2008, KIDNEY INT, V73, P608, DOI 10.1038/sj.ki.5002697; Zheng JF, 2005, AM J PHYSIOL-RENAL, V288, pF387, DOI 10.1152/ajprenal.00436.2003	28	12	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7138	10.1371/journal.pone.0007138	http://dx.doi.org/10.1371/journal.pone.0007138			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784367	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290000001
J	Hu, J; Winqvist, O; Flores-Morales, A; Wikstrom, AC; Norstedt, G				Hu, Jin; Winqvist, Ola; Flores-Morales, Amilcar; Wikstroem, Ann-Charlotte; Norstedt, Gunnar			SOCS2 Influences LPS Induced Human Monocyte-Derived Dendritic Cell Maturation	PLOS ONE			English	Article								Dendritic cells (DCs) are highly specific antigen presenting cells, which link innate and adaptive immune responses and participate in protecting hosts from invading pathogens. DCs can be generated in vitro by culturing human monocytes with GM-CSF and IL-4 followed by LPS induced DC maturation. We set out to study the suppressor of cytokine signaling (SOCS) proteins during maturation and activation of human monocyte-derived DCs from peripheral blood in vitro. We found that the expression of SOCS2 mRNA and protein is dramatically up-regulated during DC maturation. Silencing of SOCS2 using siRNA, inhibited DC maturation as evidenced by a decreased expression of maturation markers such as CD83, co-stimulatory molecules CD40, CD86 and HLA-DR. Furthermore, silencing of SOCS2 decreased LPS induced activation of MAP kinases (SAKP/JNK, p38, ERK), IRF3, decreased the translocation of the NF-kappa B transcription factor and reduced downstream gene mRNA expression. These results suggest a role for SOCS2 in the MyD88-dependent and -independent TLR4 signaling pathways. In conclusion, our results demonstrate that SOCS2 is required for appropriate TLR4 signaling in maturating human DCs via both the MyD88-dependent and -independent signaling pathway.			Hu, J (corresponding author), Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.	Gunnar.Norstedt@ki.se		winqvist, Ola/0000-0003-0842-4441; Norstedt, Gunnar/0000-0002-7759-3241				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2000, J ENDOTOXIN RES, V6, P383, DOI 10.1177/09680519000060050901; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; An HZ, 2008, NAT IMMUNOL, V9, P542, DOI 10.1038/ni.1604; An HZ, 2006, IMMUNITY, V25, P919, DOI 10.1016/j.immuni.2006.10.014; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bottcher I, 2008, IMMUNOLOGY, V123, P139, DOI 10.1111/j.1365-2567.2007.02754.x; Bullock AN, 2006, P NATL ACAD SCI USA, V103, P7637, DOI 10.1073/pnas.0601638103; Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31; Dauer M, 2003, J IMMUNOL, V170, P4069, DOI 10.4049/jimmunol.170.8.4069; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Flores-Morales A, 2006, MOL ENDOCRINOL, V20, P241, DOI 10.1210/me.2005-0170; Frobose H, 2006, MOL ENDOCRINOL, V20, P1587, DOI 10.1210/me.2005-0301; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Jackson SH, 2004, J IMMUNOL, V172, P2307, DOI 10.4049/jimmunol.172.4.2307; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lang T, 2007, IMMUNOL CELL BIOL, V85, P425, DOI 10.1038/sj.icb.7100094; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Machado FS, 2008, J EXP MED, V205, P1077, DOI 10.1084/jem.20072416; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Naka T, 2005, ADV IMMUNOL, V87, P61, DOI 10.1016/S0065-2776(05)87003-8; Nakahara T, 2006, J DERMATOL SCI, V42, P1, DOI 10.1016/j.jdermsci.2005.11.004; O'Neill LAJ, 2008, IMMUNITY, V29, P12, DOI 10.1016/j.immuni.2008.06.004; Orr SJ, 2007, J BIOL CHEM, V282, P3418, DOI 10.1074/jbc.C600216200; Piemonti L, 1995, EUR CYTOKINE NETW, V6, P245; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Rico-Bautista E, 2006, CYTOKINE GROWTH F R, V17, P431, DOI 10.1016/j.cytogfr.2006.09.008; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Strengell M, 2006, J LEUKOCYTE BIOL, V79, P1279, DOI 10.1189/jlb.0905503; Tannahill GM, 2005, MOL CELL BIOL, V25, P9115, DOI 10.1128/MCB.25.20.9115-9126.2005; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	51	33	35	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7178	10.1371/journal.pone.0007178	http://dx.doi.org/10.1371/journal.pone.0007178			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779605	Green Published, gold, Green Submitted			2022-12-27	WOS:000270176200015
J	Tromas, A; Braun, N; Muller, P; Khodus, T; Paponov, IA; Palme, K; Ljung, K; Lee, JY; Benfey, P; Murray, JAH; Scheres, B; Perrot-Rechenmann, C				Tromas, Alexandre; Braun, Nils; Muller, Philippe; Khodus, Tatyana; Paponov, Ivan A.; Palme, Klaus; Ljung, Karin; Lee, Ji-Young; Benfey, Philip; Murray, James A. H.; Scheres, Ben; Perrot-Rechenmann, Catherine			The AUXIN BINDING PROTEIN 1 Is Required for Differential Auxin Responses Mediating Root Growth	PLOS ONE			English	Article							ARABIDOPSIS ROOT; CELL-DIVISION; TRANSCRIPTION FACTOR; MODULATING AUXIN; TIR1; EXPRESSION; MECHANISM; MAINTENANCE; RECEPTORS; TRANSPORT	Background: In plants, the phytohormone auxin is a crucial regulator sustaining growth and development. At the cellular level, auxin is interpreted differentially in a tissue-and dose-dependent manner. Mechanisms of auxin signalling are partially unknown and the contribution of the AUXIN BINDING PROTEIN 1 (ABP1) as an auxin receptor is still a matter of debate. Methodology/Principal Findings: Here we took advantage of the present knowledge of the root biological system to demonstrate that ABP1 is required for auxin response. The use of conditional ABP1 defective plants reveals that the protein is essential for maintenance of the root meristem and acts at least on the D-type CYCLIN/RETINOBLASTOMA pathway to control entry into the cell cycle. ABP1 affects PLETHORA gradients and confers auxin sensitivity to root cells thus defining the competence of the cells to be maintained within the meristem or to elongate. ABP1 is also implicated in the regulation of gene expression in response to auxin. Conclusions/Significance: Our data support that ABP1 is a key regulator for root growth and is required for auxin-mediated responses. Differential effects of ABP1 on various auxin responses support a model in which ABP1 is the major regulator for auxin action on the cell cycle and regulates auxin-mediated gene expression and cell elongation in addition to the already well known TIR1-mediated ubiquitination pathway.			Tromas, A (corresponding author), Univ Paris Sud, CNRS, UPR2355, Inst Sci Vegetal, Gif Sur Yvette, France.	catherine.rechenmann@isv.cnrs-gif.fr	Paponov, Ivan A./H-9680-2016; Lee, Ji-Young/E-2196-2012; Ljung, Karin/AAE-8691-2019; Lee, Ji-Young/F-7455-2013; TROMAS, Alexandre/L-5767-2015; Murray, James AH/D-3399-2009; Palme, Klaus/A-9524-2013	Paponov, Ivan A./0000-0002-2138-0722; Ljung, Karin/0000-0003-2901-189X; TROMAS, Alexandre/0000-0002-9084-3874; Murray, James AH/0000-0002-2282-3839; Palme, Klaus/0000-0002-2728-3835; Scheres, Ben/0000-0001-5400-9578; Lee, Ji-Young/0000-0002-7631-5127	BBSRC [BB/E024858/2, BB/E024858/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E024858/1, BB/E024858/2] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018; Badescu GO, 2006, TRENDS PLANT SCI, V11, P217, DOI 10.1016/j.tplants.2006.03.001; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Braun N, 2008, PLANT CELL, V20, P2746, DOI 10.1105/tpc.108.059048; Chen JG, 2001, GENE DEV, V15, P902, DOI 10.1101/gad.866201; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; David KM, 2007, PLANT J, V50, P197, DOI 10.1111/j.1365-313X.2007.03038.x; del Pozo JC, 2002, PLANT CELL, V14, P3057, DOI 10.1105/tpc.006791; del Pozo JC, 2006, PLANT CELL, V18, P2224, DOI 10.1105/tpc.105.039651; Dello Ioio R, 2008, SCIENCE, V322, P1380, DOI 10.1126/science.1164147; Dello Ioio R, 2007, CURR BIOL, V17, P678, DOI 10.1016/j.cub.2007.02.047; Dewitte W, 2003, PLANT CELL, V15, P79, DOI 10.1105/tpc.004838; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; EDLUND A, 1995, PLANT PHYSIOL, V108, P1043, DOI 10.1104/pp.108.3.1043; Fukaki H, 1998, PLANT J, V14, P425, DOI 10.1046/j.1365-313X.1998.00137.x; Galinha C, 2007, NATURE, V449, P1053, DOI 10.1038/nature06206; Grieneisen VA, 2007, NATURE, V449, P1008, DOI 10.1038/nature06215; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Leblanc N, 1999, J BIOL CHEM, V274, P28314, DOI 10.1074/jbc.274.40.28314; Lee JY, 2006, P NATL ACAD SCI USA, V103, P6055, DOI 10.1073/pnas.0510607103; Leyser O, 2005, CELL, V121, P819, DOI 10.1016/j.cell.2005.06.005; Ljung K, 2005, PLANT CELL, V17, P1090, DOI 10.1105/tpc.104.029272; Magyar Z, 2005, PLANT CELL, V17, P2527, DOI 10.1105/tpc.105.033761; Malamy JE, 1997, DEVELOPMENT, V124, P33; Menges M, 2006, PLANT CELL, V18, P893, DOI 10.1105/tpc.105.039636; Mockaitis K, 2000, PLANT J, V24, P785, DOI 10.1046/j.1365-313x.2000.00921.x; Mockaitis K, 2008, ANNU REV CELL DEV BI, V24, P55, DOI 10.1146/annurev.cellbio.23.090506.123214; Monroe-Augustus M, 2003, PLANT CELL, V15, P2979, DOI 10.1105/tpc.017046; Nakajima K, 2002, PLANT CELL, V14, pS265, DOI 10.1105/tpc.010471; Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Overvoorde PJ, 2005, PLANT CELL, V17, P3282, DOI 10.1105/tpc.105.036723; Perez-Torres CA, 2008, PLANT CELL, V20, P3258, DOI 10.1105/tpc.108.058719; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Sabatini S, 2003, GENE DEV, V17, P354, DOI 10.1101/gad.252503; Scherer GFE, 2002, PLANT MOL BIOL, V49, P357, DOI 10.1023/A:1015290510483; Scherer GFE, 2007, FEBS LETT, V581, P4205, DOI 10.1016/j.febslet.2007.07.059; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Shin R, 2007, PLANT CELL, V19, P2440, DOI 10.1105/tpc.107.050963; Strader LC, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-41; Tan X, 2007, NATURE, V446, P640, DOI 10.1038/nature05731; Tanaka H, 2006, CELL MOL LIFE SCI, V63, P2738, DOI 10.1007/s00018-006-6116-5; Tao LZ, 2005, PLANT CELL, V17, P2369, DOI 10.1105/tpc.105.032987; Tao LZ, 2002, PLANT CELL, V14, P2745, DOI 10.1105/tpc.006320; Ueda M, 2004, DEVELOPMENT, V131, P2101, DOI 10.1242/dev.01096; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Vanneste S, 2009, CELL, V136, P1005, DOI 10.1016/j.cell.2009.03.001; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; Winter D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000718	52	108	118	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e6648	10.1371/journal.pone.0006648	http://dx.doi.org/10.1371/journal.pone.0006648			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777056	Green Submitted, Green Published, gold, Green Accepted			2022-12-27	WOS:000270164600001
J	Dace, DS; Khan, AA; Stark, JL; Kelly, J; Cross, AH; Apte, RS				Dace, Dru S.; Khan, Aslam A.; Stark, Jennifer L.; Kelly, Jennifer; Cross, Anne H.; Apte, Rajendra S.			Interleukin-10 Overexpression Promotes Fas-Ligand-Dependent Chronic Macrophage-Mediated Demyelinating Polyneuropathy	PLOS ONE			English	Article								Background: Demyelinating polyneuropathy is a debilitating, poorly understood disease that can exist in acute (Guillain-Barre syndrome) or chronic forms. Interleukin-10 (IL-10), although traditionally considered an anti-inflammatory cytokine, has also been implicated in promoting abnormal angiogenesis in the eye and in the pathobiology of autoimmune diseases such as lupus and encephalomyelitis. Principal Findings: Overexpression of IL-10 in a transgenic mouse model leads to macrophage-mediated demyelinating polyneuropathy. IL-10 upregulates ICAM-1 within neural tissues, promoting massive macrophage influx, inflammation-induced demyelination, and subsequent loss of neural tissue resulting in muscle weakness and paralysis. The primary insult is to perineural myelin followed by secondary axonal loss. Infiltrating macrophages within the peripheral nerves demonstrate a highly pro-inflammatory signature. Macrophages are central players in the pathophysiology, as in vivo depletion of macrophages using clodronate liposomes reverses the phenotype, including progressive nerve loss and paralysis. Macrophage-mediate demyelination is dependent on Fas-ligand (FasL)-mediated Schwann cell death. Significance: These findings mimic the human disease chronic idiopathic demyelinating polyneuropathy (CIDP) and may also promote further understanding of the pathobiology of related conditions such as acute idiopathic demyelinating polyneuropathy (AIDP) or Guillain-Barre syndrome.			Dace, DS (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.	apte@vision.wustl.edu		Cross, Anne/0000-0003-0829-7569	NATIONAL EYE INSTITUTE [P30EY002687, K08EY016139] Funding Source: NIH RePORTER; NEI NIH HHS [K08 EY016139, P30 EY002687, P30 EY 02687, K08EY016139] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adorini L, 2003, CLIN EXP IMMUNOL, V132, P185, DOI 10.1046/j.1365-2249.2003.02144.x; Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310; Cannella B, 1996, J NEUROSCI RES, V45, P735, DOI 10.1002/(SICI)1097-4547(19960915)45:6<735::AID-JNR10>3.0.CO;2-V; Croxford JL, 1998, J IMMUNOL, V160, P5181; Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Ferguson Thomas A, 2002, Int Rev Immunol, V21, P153; FRASER CC, 1995, BLOOD, V86, P183, DOI 10.1182/blood.V86.1.183.bloodjournal861183; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hai M, 2002, J NEUROSCI RES, V69, P497, DOI 10.1002/jnr.10327; Horste GMZ, 2007, NAT CLIN PRACT NEURO, V3, P198, DOI 10.1038/ncpneuro0452; Jadus MR, 1998, J IMMUNOL, V160, P361; Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430; Kramer F, 2004, CYTOGENET GENOME RES, V105, P107, DOI 10.1159/000078016; Lee MS, 1997, AUTOIMMUNITY, V26, P215, DOI 10.3109/08916939709008027; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Nagelkerken L, 1997, INT IMMUNOL, V9, P1243, DOI 10.1093/intimm/9.9.1243; Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; Persson S, 1996, SCAND J IMMUNOL, V44, P607, DOI 10.1046/j.1365-3083.1996.d01-355.x; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; Stark JL, 2006, INT IMMUNOL, V18, P347, DOI 10.1093/intimm/dxh373; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; WOGENSEN L, 1993, J EXP MED, V178, P175, DOI 10.1084/jem.178.1.175	28	29	32	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7121	10.1371/journal.pone.0007121	http://dx.doi.org/10.1371/journal.pone.0007121			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771172	Green Submitted, Green Published, gold			2022-12-27	WOS:000270154400014
J	Guo, YL; Liu, DQ; Bian, Z; Zhang, CY; Zen, K				Guo, Ya-Lan; Liu, Dan-Qing; Bian, Zhen; Zhang, Chen-Yu; Zen, Ke			Down-Regulation of Platelet Surface CD47 Expression in Escherichia coli O157:H7 Infection-Induced Thrombocytopenia	PLOS ONE			English	Article								Background: Platelet depletion is a key feature of hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) infection. The mechanism underlying STEC-induced platelet depletion, however, is not completely understood. Methodology/Principal Findings: Here we demonstrated for the first time that platelet surface expression of CD47 was significantly decreased in C57BL6 mice treated with concentrated culture filtrates (CCF) from STEC O157:H7. STEC O157:H7 CCF treatment also led to a sharp drop of platelet counts. The reduction of cell surface CD47 was specific for platelets but not for neutrophil, monocytes and red blood cells. Down-regulation of platelet surface CD47 was also observed in isolated human platelets treated with O157:H7 CCF. Platelet surface CD47 reduction by O157:H7 CCF could be blocked by anti-TLR4 antibody but not anti-CD62 antibody. Down-regulation of platelet surface CD47 was positively correlated with platelet activation and phagocytosis by human monocyte-derived macrophages. Furthermore, the enhanced phagocytosis process of O157:H7 CCF-treated platelets was abolished by addition of soluble CD47 recombinants. Conclusions/Significance: Our results suggest that platelet CD47 down-regulation may be a novel mechanism underneath STEC-induced platelet depletion, and that the interactions between CD47 and its receptor, signal regulatory protein a (SIRPa), play an essential role in modulating platelet homeostasis.			Guo, YL (corresponding author), Nanjing Univ, Sch Life Sci, Inst Virol, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China.	cyzhang@nju.edu.cn; kzen@nju.edu.cn						APPIANI AC, 1982, CLIN NEPHROL, V17, P195; Aslam R, 2006, BLOOD, V107, P637, DOI 10.1182/blood-2005-06-2202; COHEN A, 1987, J BIOL CHEM, V262, P17088; Cooling LLW, 1998, INFECT IMMUN, V66, P4355; Fernandez GC, 2000, CLIN IMMUNOL, V95, P227, DOI 10.1006/clim.2000.4862; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gu L, 2008, BIOCHEM BIOPH RES CO, V369, P1061, DOI 10.1016/j.bbrc.2008.02.160; Ide K, 2007, P NATL ACAD SCI USA, V104, P5062, DOI 10.1073/pnas.0609661104; Ikeda M, 2004, PEDIATR NEPHROL, V19, P485, DOI 10.1007/s00467-003-1395-7; Janssen WJ, 2008, AM J RESP CRIT CARE, V178, P158, DOI 10.1164/rccm.200711-1661OC; Jung SM, 2000, TRENDS CARDIOVAS MED, V10, P285, DOI 10.1016/S1050-1738(01)00064-0; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; Karpman D, 1997, J INFECT DIS, V175, P611, DOI 10.1093/infdis/175.3.611; Karpman D, 2001, BLOOD, V97, P3100, DOI 10.1182/blood.V97.10.3100; KATAYAMA M, 1993, BRIT J HAEMATOL, V84, P702, DOI 10.1111/j.1365-2141.1993.tb03149.x; Khandelwal S, 2007, TRANSFUSION, V47, P1725, DOI 10.1111/j.1537-2995.2007.01348.x; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Nolasco LH, 2005, BLOOD, V106, P4199, DOI 10.1182/blood-2005-05-2111; OBRIG TG, 1988, INFECT IMMUN, V56, P2373, DOI 10.1128/IAI.56.9.2373-2378.1988; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Olsson M, 2005, BLOOD, V105, P3577, DOI 10.1182/blood-2004-08-2980; Poole JA, 2008, J ALLERGY CLIN IMMUN, V122, P375, DOI 10.1016/j.jaci.2008.05.023; ROSE PE, 1985, J CLIN PATHOL, V38, P438, DOI 10.1136/jcp.38.4.438; Sauter KAD, 2008, INFECT IMMUN, V76, P4469, DOI 10.1128/IAI.00592-08; Stahl AL, 2006, BLOOD, V108, P167, DOI 10.1182/blood-2005-08-3219; Taylor FB, 1999, AM J PATHOL, V154, P1285, DOI 10.1016/S0002-9440(10)65380-1; te Loo DMWM, 2000, BLOOD, V95, P3396, DOI 10.1182/blood.V95.11.3396.011k19_3396_3402; TESH VL, 1991, J INFECT DIS, V164, P344, DOI 10.1093/infdis/164.2.344; Tsai RK, 2008, J CELL BIOL, V180, P989, DOI 10.1083/jcb.200708043; Uchida H, 1999, PEDIATR RES, V45, P133, DOI 10.1203/00006450-199901000-00022; Viisoreanu D, 2000, THROMB RES, V98, P403, DOI 10.1016/S0049-3848(00)00191-2; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P2438, DOI 10.1128/IAI.58.8.2438-2445.1990; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Yamazaki M, 2001, THROMB RES, V104, P197, DOI 10.1016/S0049-3848(01)00350-4; Zhang GY, 2009, J IMMUNOL, V182, P7997, DOI 10.4049/jimmunol.0802884; Zhang WL, 2002, J CLIN MICROBIOL, V40, P1441, DOI 10.1128/JCM.40.4.1441-1446.2002	38	14	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7131	10.1371/journal.pone.0007131	http://dx.doi.org/10.1371/journal.pone.0007131			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771158	Green Submitted, Green Published, gold			2022-12-27	WOS:000270154400019
J	Schule, S; Kloke, BP; Kaiser, JK; Heidmeier, S; Panitz, S; Wolfrum, N; Cichutek, K; Schweizer, M				Schuele, Silke; Kloke, Bjoern-Philipp; Kaiser, Julia K.; Heidmeier, Sabine; Panitz, Sylvia; Wolfrum, Nina; Cichutek, Klaus; Schweizer, Matthias			Restriction of HIV-1 Replication in Monocytes Is Abolished by Vpx of SIVsmmPBj	PLOS ONE			English	Article							VIRUS TYPE-2 VPX; VIRAL PREINTEGRATION COMPLEX; CELL-CYCLE ARREST; DENDRITIC CELLS; NUCLEAR-LOCALIZATION; REVERSE TRANSCRIPTION; STABLE TRANSDUCTION; EARLY STEPS; OLD-WORLD; INFECTION	Background: Human primary monocytes are refractory to infection with the human immunodeficiency virus 1 (HIV-1) or transduction with HIV-1-derived vectors. In contrast, efficient single round transduction of monocytes is mediated by vectors derived from simian immunodeficiency virus of sooty mangabeys (SIVsmmPBj), depending on the presence of the viral accessory protein Vpx. Methods and Findings: Here we analyzed whether Vpx of SIVsmmPBj is sufficient for transduction of primary monocytes by HIV-1-derived vectors. To enable incorporation of PBj Vpx into HIV-1 vector particles, a HA-Vpr/Vpx fusion protein was generated. Supplementation of HIV-1 vector particles with this fusion protein was not sufficient to facilitate transduction of human monocytes. However, monocyte transduction with HIV-1-derived vectors was significantly enhanced after delivery of Vpx proteins by virus-like particles (VLPs) derived from SIVsmmPBj. Moreover, pre-incubation with Vpx-containing VLPs restored replication capacity of infectious HIV-1 in human monocytes. In monocytes of non-human primates, single-round transduction with HIV-1 vectors was enabled. Conclusion: Vpx enhances transduction of primary human and even non-human monocytes with HIV-1-derived vectors, only if delivered in the background of SIVsmmPBj-derived virus-like particles. Thus, for accurate Vpx function the presence of SIVsmmPBj capsid proteins might be required. Vpx is essential to overcome a block of early infection steps in primary monocytes.			Schule, S (corresponding author), Paul Ehrlich Inst, Div Med Biotechnol, D-6070 Langen, Germany.	schmt@pei.de	Wolfrum, Nina/AAR-5772-2021	Wolfrum, Nina/0000-0001-6583-2658				Arfi V, 2008, J VIROL, V82, P6557, DOI 10.1128/JVI.02321-07; Belshan M, 2006, VIROLOGY, V346, P118, DOI 10.1016/j.virol.2005.10.036; Berger G, 2009, GENE THER, V16, P159, DOI 10.1038/gt.2008.128; Brennan G, 2007, J VIROL, V81, P12210, DOI 10.1128/JVI.02499-06; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Dong CS, 2009, J VIROL, V83, P3518, DOI 10.1128/JVI.02665-08; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Goujon C, 2006, GENE THER, V13, P991, DOI 10.1038/sj.gt.3302753; Goujon C, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-2; Goujon C, 2008, J VIROL, V82, P12335, DOI 10.1128/JVI.01181-08; Gruber A, 2000, BLOOD, V96, P1327, DOI 10.1182/blood.V96.4.1327.h8001327_1327_1333; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; Iwatani Y, 2007, NUCLEIC ACIDS RES, V35, P7096, DOI 10.1093/nar/gkm750; Jarrosson-Wuilleme L, 2006, J VIROL, V80, P1152, DOI 10.1128/JVI.80.3.1152-1159.2006; KAPPES JC, 1991, VIROLOGY, V184, P197, DOI 10.1016/0042-6822(91)90836-Z; Kino T, 2004, DNA CELL BIOL, V23, P193, DOI 10.1089/104454904773819789; LaBonte JA, 2002, J EXP MED, V196, P431, DOI 10.1084/jem.20020468; Lee K, 2004, P NATL ACAD SCI USA, V101, P10496, DOI 10.1073/pnas.0404066101; Liou LY, 2002, J VIROL, V76, P10579, DOI 10.1128/JVI.76.21.10579-10587.2002; Mahalingam S, 2001, J VIROL, V75, P362, DOI 10.1128/JVI.75.1.362-374.2001; Mahnke LA, 2006, VIROLOGY, V348, P165, DOI 10.1016/j.virol.2005.12.023; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Muhlebach MD, 2005, MOL THER, V12, P1206, DOI 10.1016/j.ymthe.2005.06.483; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neil S, 2001, J VIROL, V75, P5448, DOI 10.1128/JVI.75.12.5448-5456.2001; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pancio HA, 2000, J VIROL, V74, P6162, DOI 10.1128/JVI.74.13.6162-6167.2000; Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512; PENG G, 2007, BLOOD; Pion M, 2006, J EXP MED, V203, P2887, DOI 10.1084/jem.20061519; POOLE JA, 2009, AM J PHYSL LUNG CELL; Sakuma R, 2007, GENE THER, V14, P185, DOI 10.1038/sj.gt.3302852; Sakuma R, 2007, NAT MED, V13, P631, DOI 10.1038/nm1562; Sakuma R, 2007, J VIROL, V81, P10201, DOI 10.1128/JVI.00419-07; SCHUITEMAKER H, 1992, J CLIN INVEST, V89, P1154, DOI 10.1172/JCI115697; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Sharova N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000057; Shi J, 2006, VIROLOGY, V350, P493, DOI 10.1016/j.virol.2006.03.013; Singhal PK, 2006, J VIROL, V80, P526, DOI 10.1128/JVI.80.1.526-536.2006; SINGHAL PK, 2006, J VIROL; Sleigh R, 1998, VIROLOGY, V245, P338, DOI 10.1006/viro.1998.9159; Sokolskaja E, 2006, J VIROL, V80, P2855, DOI 10.1128/JVI.80.6.2855-2862.2006; Song B, 2005, J VIROL, V79, P3930, DOI 10.1128/JVI.79.7.3930-3937.2005; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Sonza S, 2001, AIDS, V15, P17, DOI 10.1097/00002030-200101050-00005; STRAPPE PM, 2005, RETROVIROLOGY, V55, P1; Stremlau M, 2005, J VIROL, V79, P3139, DOI 10.1128/JVI.79.5.3139-3145.2005; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Tan PH, 2005, BLOOD, V105, P3824, DOI 10.1182/blood-2004-10-3880; Triques K, 2004, J VIROL, V78, P5523, DOI 10.1128/JVI.78.10.5523-5527.2004; Wolfrum N, 2007, VIROLOGY, V364, P330, DOI 10.1016/j.virol.2007.03.008	53	22	22	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7098	10.1371/journal.pone.0007098	http://dx.doi.org/10.1371/journal.pone.0007098			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768115	gold, Green Published, Green Submitted			2022-12-27	WOS:000270154000006
J	Frisa, PS; Jacobberger, JW				Frisa, Phyllis S.; Jacobberger, James W.			Cell Cycle-Related Cyclin B1 Quantification	PLOS ONE			English	Article								Background: To obtain non-relative measures of cell proteins, purified preparations of the same proteins are used as standards in Western blots. We have previously quantified SV40 large T antigen expressed over a several fold range in different cell lines and correlated the average number of molecules to average fluorescence obtained by cytometry and determined cell cycle phase related expression by calculation from multi-parametric cytometry data. Using a modified approach, we report quantification of endogenous cyclin B1 and generation of the cell cycle time related expression profile. Methodology: Recombinant cyclin B1 was purified from a baculovirus lysate using an antibody affinity column and concentrated. We created fixed cell preparations from nocodazole-treated (high cyclin B1) and serum starved (low cyclin B1) PC3 cells that were either lyophilized (for preservation) or solubilized. The lysates and purified cyclin B1 were subjected to Western blotting; the cell preparations were subjected to cytometry, and fluorescence was correlated to molecules. Three untreated cell lines (K562, HeLa, and RKO) were prepared for cytometry without lyophilization and also prepared for Western blotting. These were quantified by Western blotting and by cytometry using the standard cell preparations. Results: The standard cell preparations had 1.5x10(5) to 2.5X10(6) molecules of cyclin B1 per cell on average (i.e., 16-fold range). The average coefficient of variation was 24%. Fluorescence varied 12-fold. The relationship between molecules/cell (Western blot) and immunofluorescence (cytometry) was linear (r(2) = 0.87). Average cyclin B1 levels for the three untreated cell lines determined by Western blotting and cytometry agreed within a factor of 2. The non-linear rise in cyclin B1 in S phase was quantified from correlated plots of cyclin B1 and DNA content. The peak levels achieved in G2 were similar despite differences in lineage, growth conditions, and rates of increase through the cell cycle (range: 1.6-2.2X10(6) molecules per cell). Conclusions: Net cyclin B1 expression begins in G1 in human somatic cells lines; increases non-linearly with variation in rates of accumulation, but peaks at similar peak values in different cell lines growing under different conditions. This suggests tight quantitative end point control.			Frisa, PS (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.	jwj@case.edu	Jacobberger, James/P-9183-2014	Jacobberger, James/0000-0002-3092-5157	NCI NIH HHS [P30CA43703, R01 CA073413, P30 CA043703, R01CA73413] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA073413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Bagwell CB, 2005, CYTOM PART A, V64A, P34, DOI 10.1002/cyto.a.20114; Bantscheff M, 2007, ANAL BIOANAL CHEM, V389, P1017, DOI 10.1007/s00216-007-1486-6; Chang P, 1999, MICROSC RES TECHNIQ, V44, P415, DOI 10.1002/(SICI)1097-0029(19990315)44:6<415::AID-JEMT3>3.0.CO;2-4; Cross FR, 2002, MOL BIOL CELL, V13, P52, DOI 10.1091/mbc.01-05-0265; Darzynkiewicz Zbigniew, 2003, Prog Cell Cycle Res, V5, P533; Frisa PS, 2000, CYTOMETRY, V39, P79, DOI 10.1002/(SICI)1097-0320(20000101)39:1<79::AID-CYTO11>3.0.CO;2-3; Frisa PS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-10; FRISA PS, 1994, J NEUROSCI RES, V39, P47, DOI 10.1002/jnr.490390107; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; Hood Leroy, 2008, Briefings in Functional Genomics & Proteomics, V7, P239, DOI 10.1093/bfgp/eln027; Jacobberger JW, 1999, CYTOMETRY, V35, P284, DOI 10.1002/(SICI)1097-0320(19990301)35:3<284::AID-CYTO12>3.0.CO;2-K; Jorgensen P, 2007, MOL BIOL CELL, V18, P3523, DOI 10.1091/mbc.E06-10-0973; Kanatsu-Shinohara M, 2000, BIOL REPROD, V63, P1610, DOI 10.1095/biolreprod63.6.1610; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SLADEK TL, 1994, CELL PROLIFERAT, V27, P711, DOI 10.1111/j.1365-2184.1994.tb01386.x; Soni DV, 2008, CELL CYCLE, V7, P1285, DOI 10.4161/cc.7.9.5711; van Riel NAW, 2006, BRIEF BIOINFORM, V7, P364, DOI 10.1093/bib/bbl040; Viallard JF, 1999, EXP CELL RES, V247, P208, DOI 10.1006/excr.1998.4352; Viallard JF, 2000, CYTOMETRY, V39, P117, DOI 10.1002/(SICI)1097-0320(20000201)39:2<117::AID-CYTO4>3.3.CO;2-R; Xu NH, 2007, CELL CYCLE, V6, P1639, DOI 10.4161/cc.6.13.4385; Yu AM, 2009, DRUG METAB DISPOS, V37, P170, DOI 10.1124/dmd.108.024166	24	30	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7064	10.1371/journal.pone.0007064	http://dx.doi.org/10.1371/journal.pone.0007064			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763267	gold, Green Published, Green Submitted			2022-12-27	WOS:000269970400006
J	Jayaraman, S; Mabweijano, JR; Lipnick, MS; Caldwell, N; Miyamoto, J; Wangoda, R; Mijumbi, C; Hsia, R; Dicker, R; Ozgediz, D				Jayaraman, Sudha; Mabweijano, Jacqueline R.; Lipnick, Michael S.; Caldwell, Nolan; Miyamoto, Justin; Wangoda, Robert; Mijumbi, Cephas; Hsia, Renee; Dicker, Rochelle; Ozgediz, Doruk			First Things First: Effectiveness and Scalability of a Basic Prehospital Trauma Care Program for Lay First-Responders in Kampala, Uganda	PLOS ONE			English	Article							LOW-INCOME COUNTRIES; COST-EFFECTIVENESS; MEDICAL-SERVICES; NORTH IRAQ; EXPERIENCE; MORTALITY; INJURIES; CAMBODIA; SYSTEMS; HEALTH	Background: We previously showed that in the absence of a formal emergency system, lay people face a heavy burden of injuries in Kampala, Uganda, and we demonstrated the feasibility of a basic prehospital trauma course for lay people. This study tests the effectiveness of this course and estimates the costs and cost-effectiveness of scaling up this training. Methods and Findings: For six months, we prospectively followed 307 trainees (police, taxi drivers, and community leaders) who completed a one-day basic prehospital trauma care program in 2008. Cross-sectional surveys and fund of knowledge tests were used to measure their frequency of skill and supply use, reasons for not providing aid, perceived utility of the course and kit, confidence in using skills, and knowledge of first-aid. We then estimated the cost-effectiveness of scaling up the program. At six months, 188 (62%) of the trainees were followed up. Their knowledge retention remained high or increased. The mean correct score on a basic fund of knowledge test was 92%, up from 86% after initial training (n = 146 pairs, p = 0.0016). 97% of participants had used at least one skill from the course: most commonly haemorrhage control, recovery position and lifting/moving and 96% had used at least one first-aid item. Lack of knowledge was less of a barrier and trainees were significantly more confident in providing first-aid. Based on cost estimates from the World Health Organization, local injury data, and modelling from previous studies, the projected cost of scaling up this program was $0.12 per capita or $25-75 per life year saved. Key limitations of the study include small sample size, possible reporter bias, preliminary local validation of study instruments, and an indirect estimate of mortality reduction. Conclusions: Lay first-responders effectively retained knowledge on prehospital trauma care and confidently used their first-aid skills and supplies for at least six months. The costs of scaling up this intervention to cover Kampala are very modest. This may be a cost-effective first step toward developing formal emergency services in Uganda other resource-constrained settings. Further research is needed in this critical area of trauma care in low-income countries.			Jayaraman, S (corresponding author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.	dozgediz@hotmail.com	Jayaraman, Sudha/AAH-3059-2019	Jayaraman, Sudha/0000-0003-1094-5836				Aboutanos MB, 2007, J TRAUMA, V62, P714, DOI 10.1097/TA.0b013e318031b56d; [Anonymous], 2000, STRAT PLAN 2000; AYYAZ M, 2008, AM COLL SURG 94 ANN; Backman G, 2008, LANCET, V372, P2047, DOI 10.1016/S0140-6736(08)61781-X; Baker R, 1999, JAMA-J AM MED ASSOC, V281, P859, DOI 10.1001/jama.281.9.859; Bishai D, 2008, INJURY PREV, V14, P223, DOI 10.1136/ip.2008.018341; Bishai D, 2007, AIDS, V21, P1333, DOI 10.1097/QAD.0b013e328137709e; GAUTHAM S, 2008, AM COLL SURG 94 ANN; Husum H, 2003, MIL MED, V168, P934, DOI 10.1093/milmed/168.11.934; Husum H, 2003, J TRAUMA, V54, P1188, DOI 10.1097/01.TA.0000073609.12530.19; Husum H, 2003, MED TEACH, V25, P142, DOI 10.1080/0142159031000092526; JAYARAMAN S, 2009, WORLD J SUR IN PRESS; Kobusingye OC, 2000, J TRAUMA, V48, P498, DOI 10.1097/00005373-200003000-00022; Kobusingye OC, 2002, INJ PREV, V8, P133, DOI 10.1136/ip.8.2.133; Kobusingye OC, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1261; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mock C, 2004, LANCET, V363, P2172, DOI 10.1016/S0140-6736(04)16510-0; Mock C., 2004, GUIDELINES ESSENTIAL; Mock C, 2006, WORLD J SURG, V30, P946, DOI 10.1007/s00268-005-0768-4; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011; Mock CN, 1997, J TRAUMA, V42, P504, DOI 10.1097/00005373-199703000-00019; Mock CN, 2002, J TRAUMA, V53, P90, DOI 10.1097/00005373-200207000-00018; Nantulya Vinand M, 2003, Inj Control Saf Promot, V10, P13, DOI 10.1076/icsp.10.1.13.14116; Peden M., 2004, WORLD REPORT ROAD TR; POGGETTI R, 2008, AM COLL SURG 94 ANN; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Roberts I, 2005, BRIT MED J, V331, P1094, DOI 10.1136/bmj.331.7525.1094; Sachs J., 2001, INVESTING HLTH REPOR; Tiska MA, 2004, EMERG MED J, V21, P237, DOI 10.1136/emj.2002.002097; *WHO, 2005, PREH TRAUM CAR SYST; WHO, 2008, WORLD HLTH STAT	31	98	98	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6955	10.1371/journal.pone.0006955	http://dx.doi.org/10.1371/journal.pone.0006955			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759831	Green Published, gold, Green Submitted			2022-12-27	WOS:000269696600007
J	Maier, N; Morris, G; Johenning, FW; Schmitz, D				Maier, Nikolaus; Morris, Genela; Johenning, Friedrich W.; Schmitz, Dietmar			An Approach for Reliably Investigating Hippocampal Sharp Wave-Ripples In Vitro	PLOS ONE			English	Article								Background: Among the various hippocampal network patterns, sharp wave-ripples (SPW-R) are currently the mechanistically least understood. Although accurate information on synaptic interactions between the participating neurons is essential for comprehensive understanding of the network function during complex activities like SPW-R, such knowledge is currently notably scarce. Methodology/Principal Findings: We demonstrate an in vitro approach to SPW-R that offers a simple experimental tool allowing detailed analysis of mechanisms governing the sharp wave-state of the hippocampus. We combine interface storage of slices with modifications of a conventional submerged recording system and established in vitro SPW-R comparable to their in vivo counterpart. We show that slice storage in the interface chamber close to physiological temperature is the required condition to preserve network integrity that is necessary for the generation of SPW-R. Moreover, we demonstrate the utility of our method for studying synaptic and network properties of SPW-R, using electrophysiological and imaging methods that can only be applied in the submerged system. Conclusions/Significance: The approach presented here demonstrates a reliable and experimentally simple strategy for studying hippocampal sharp wave-ripples. Given its utility and easy application we expect our model to foster the generation of new insight into the network physiology underlying SPW-R.			Maier, N (corresponding author), Charite, Neurosci Res Ctr, D-13353 Berlin, Germany.	dietmar.schmitz@charite.de	Maier, Nikolaus/CAF-2990-2022; Maier, Nikolaus/CAH-9008-2022	Maier, Nikolaus/0000-0001-5203-0736; Morris, Genela/0000-0002-5417-8977; Schmitz, Dietmar/0000-0003-2741-5241				Behrens CJ, 2005, NAT NEUROSCI, V8, P1560, DOI 10.1038/nn1571; Both M, 2008, HIPPOCAMPUS, V18, P899, DOI 10.1002/hipo.20446; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Colgin LL, 2005, NEUROSCI LETT, V385, P46, DOI 10.1016/j.neulet.2005.05.005; Csicsvari J, 2000, NEURON, V28, P585, DOI 10.1016/S0896-6273(00)00135-5; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Foffani G, 2007, NEURON, V55, P930, DOI 10.1016/j.neuron.2007.07.040; HAAS HL, 1979, J NEUROSCI METH, V1, P323, DOI 10.1016/0165-0270(79)90021-9; Hajos N, 2009, EUR J NEUROSCI, V29, P319, DOI 10.1111/j.1460-9568.2008.06577.x; Ikegaya Y, 2005, NEUROSCI RES, V52, P132, DOI 10.1016/j.neures.2005.02.004; Johenning FW, 2007, CELL CALCIUM, V41, P271, DOI 10.1016/j.ceca.2006.07.005; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Klausberger T, 2005, J NEUROSCI, V25, P9782, DOI 10.1523/JNEUROSCI.3269-05.2005; Klausberger T, 2004, NAT NEUROSCI, V7, P41, DOI 10.1038/nn1159; Klausberger T, 2008, SCIENCE, V321, P53, DOI 10.1126/science.1149381; Kubota D, 2003, J NEUROPHYSIOL, V89, P81, DOI 10.1152/jn.00542.2002; Kudrimoti HS, 1999, J NEUROSCI, V19, P4090; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; Maier N, 2003, J PHYSIOL-LONDON, V550, P873, DOI 10.1113/jphysiol.2003.044602; Maier N, 2002, J PHYSIOL-LONDON, V541, P521, DOI 10.1113/jphysiol.2002.017624; Meyer AH, 2002, J NEUROSCI, V22, P7055; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Papatheodoropoulos C, 2002, BRAIN RES BULL, V57, P187, DOI 10.1016/S0361-9230(01)00738-9; Papatheodoropoulos C, 2002, NEUROSCI LETT, V319, P17, DOI 10.1016/S0304-3940(01)02505-8; Schuchmann S, 2002, J NEUROPHYSIOL, V87, P2929, DOI 10.1152/jn.2002.87.6.2929; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUZUKI SS, 1988, ELECTROEN CLIN NEURO, V69, P532, DOI 10.1016/0013-4694(88)90165-4; Wong T, 2005, NEUROSCIENCE, V134, P107, DOI 10.1016/j.neuroscience.2005.04.019; Wu CP, 2006, J PHYSIOL-LONDON, V576, P457, DOI 10.1113/jphysiol.2006.114918; Wu CP, 2009, HIPPOCAMPUS, V19, P205, DOI 10.1002/hipo.20497; Wu CP, 2005, J NEUROPHYSIOL, V94, P741, DOI 10.1152/jn.00086.2005; Wu CP, 2005, J NEUROPHYSIOL, V93, P2302, DOI 10.1152/jn.00806.2004; Wu CP, 2002, J PHYSIOL-LONDON, V540, P509, DOI 10.1113/jphysiol.2001.013441; YLINEN A, 1995, J NEUROSCI, V15, P30; Zhang L, 2008, HIPPOCAMPUS, V18, P294, DOI 10.1002/hipo.20389	39	48	48	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6925	10.1371/journal.pone.0006925	http://dx.doi.org/10.1371/journal.pone.0006925			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738897	gold, Green Accepted, Green Published, Green Submitted			2022-12-27	WOS:000269622300010
J	Muller, S; Gotz, M; Beier, D				Mueller, Stefanie; Goetz, Monika; Beier, Dagmar			Histidine Residue 94 Is Involved in pH Sensing by Histidine Kinase ArsS of Helicobacte pylori	PLOS ONE			English	Article								Background: The ArsRS two-component system is the master regulator of acid adaptation in the human gastric pathogen Helicobacter pylori. Low pH is supposed to trigger the autophosphorylation of the histidine kinase ArsS and the subsequent transfer of the phosphoryl group to its cognate response regulator ArsR which then acts as an activator or repressor of pH-responsive genes. Orthologs of the ArsRS two-component system are also present in H. pylori's close relatives H. hepaticus, Campylobacter jejuni and Wolinella succinogenes which are non-gastric colonizers. Methodology/Principal Findings: In order to investigate the mechanism of acid perception by ArsS, derivatives of H. pylori 26695 expressing ArsS proteins with substitutions of the histidine residues present in its periplasmic input domain were constructed. Analysis of pH-responsive transcription of selected ArsRS target genes in these mutants revealed that H94 is relevant for pH sensing, however, our data indicate that protonatable amino acids other than histidine contribute substantially to acid perception by ArsS. By the construction and analysis of H. pylori mutants carrying arsS allels from the related epsilon-proteobacteria we demonstrate that WS1818 of W. succinogenes efficiently responds to acidic pH. Conclusions/Significance: We show that H94 in the input domain of ArsS is crucial for acid perception in H. pylori 26695. In addition our data suggest that ArsS is able to adopt different conformations depending on the degree of protonation of acidic amino acids in the input domain. This might result in different activation states of the histidine kinase allowing a gradual transcriptional response to low pH conditions. Although retaining considerable similarity to ArsS the orthologous proteins of H. hepaticus and C. jejuni may have evolved to sensors of a different environmental stimulus in accordance with the non gastric habitat of these bacteria.			Muller, S (corresponding author), Tech Univ Munich, Lehrstuhl Mikrobiol Okol, D-8050 Freising Weihenstephan, Germany.	d.beier@biozentrum.uni-wuerzburg.de						Baar C, 2003, P NATL ACAD SCI USA, V100, P11690, DOI 10.1073/pnas.1932838100; Baltrus DA, 2009, J BACTERIOL, V191, P447, DOI 10.1128/JB.01416-08; Beier D, 2000, J BACTERIOL, V182, P2068, DOI 10.1128/JB.182.8.2068-2076.2000; Beier D, 1997, J BACTERIOL, V179, P4676, DOI 10.1128/jb.179.15.4676-4683.1997; Belzer C, 2005, MICROBIOL-SGM, V151, P3989, DOI 10.1099/mic.0.28188-0; Bijlsma JJE, 1998, FEMS MICROBIOL LETT, V167, P309, DOI 10.1111/j.1574-6968.1998.tb13244.x; Bijlsma JJE, 2000, J INFECT DIS, V182, P1566, DOI 10.1086/315855; Bury-Mone S, 2004, MOL MICROBIOL, V53, P623, DOI 10.1111/j.1365-2958.2004.04137.x; Contreras M, 2003, MOL MICROBIOL, V49, P947, DOI 10.1046/j.1365-2958.2003.03621.x; Dietz P, 2002, J BACTERIOL, V184, P350, DOI 10.1128/JB.184.2.350-362.2002; EATON KA, 1994, INFECT IMMUN, V62, P3604, DOI 10.1128/IAI.62.9.3604-3607.1994; Eppinger M, 2004, NAT REV MICROBIOL, V2, P872, DOI 10.1038/nrmicro1024; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; Gancz H, 2006, INFECT IMMUN, V74, P602, DOI 10.1128/IAI.74.1.602-614.2006; Ge ZM, 2008, MICROB PATHOGENESIS, V45, P18, DOI 10.1016/j.micpath.2008.02.003; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Loh JT, 2006, INFECT IMMUN, V74, P3052, DOI 10.1128/IAI.74.5.3052-3059.2006; Marcus EA, 2005, J BACTERIOL, V187, P729, DOI 10.1128/JB.187.2.729-738.2005; Merrell DS, 2003, INFECT IMMUN, V71, P3529, DOI 10.1128/IAI.71.6.3529-3539.2003; Mollenhauer-Rektorschek M, 2002, RES MICROBIOL, V153, P659, DOI 10.1016/S0923-2508(02)01380-3; Muller S, 2007, MICROBIOL RES, V162, P1, DOI 10.1016/j.micres.2006.01.003; Niehus E, 2004, MOL MICROBIOL, V52, P947, DOI 10.1111/j.1365-2958.2004.04006.x; Panthel K, 2003, INFECT IMMUN, V71, P5381, DOI 10.1128/IAI.71.9.5381-5385.2003; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Perez JC, 2007, MOL MICROBIOL, V63, P283, DOI 10.1111/j.1365-2958.2006.05512.x; Pflock M, 2005, INFECT IMMUN, V73, P6437, DOI 10.1128/IAI.73.10.6437-6445.2005; Pflock M, 2004, FEMS MICROBIOL LETT, V234, P51, DOI 10.1016/j.femsle.2004.03.023; Pflock M, 2007, CURR MICROBIOL, V54, P320, DOI 10.1007/s00284-006-0520-9; Pflock M, 2006, J BACTERIOL, V188, P3449, DOI 10.1128/JB.188.10.3449-3462.2006; Prost LR, 2008, CELL MICROBIOL, V10, P576, DOI 10.1111/j.1462-5822.2007.01111.x; Prost LR, 2007, MOL CELL, V26, P165, DOI 10.1016/j.molcel.2007.03.008; Sachs G, 2005, PHYSIOLOGY, V20, P429, DOI 10.1152/physiol.00032.2005; Scott DR, 2000, INFECT IMMUN, V68, P470, DOI 10.1128/IAI.68.2.470-477.2000; Skouloubris S, 1998, INFECT IMMUN, V66, P4517; Suerbaum S, 2003, P NATL ACAD SCI USA, V100, P7901, DOI 10.1073/pnas.1332093100; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Waidner B, 2005, J BACTERIOL, V187, P4683, DOI 10.1128/JB.187.13.4683-4688.2005; WANG Y, 1990, GENE, V94, P23, DOI 10.1016/0378-1119(90)90463-2; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Weeks DL, 2001, MOL MICROBIOL, V40, P1249, DOI 10.1046/j.1365-2958.2001.02466.x; Wen Y, 2006, J BACTERIOL, V188, P1750, DOI 10.1128/JB.188.5.1750-1761.2006; Wen Y, 2003, INFECT IMMUN, V71, P5921, DOI 10.1128/IAI.71.10.5921-5939.2003; Wen Y, 2007, J BACTERIOL, V189, P2426, DOI 10.1128/JB.01492-06; Wen Y, 2009, J BACTERIOL, V191, P449, DOI 10.1128/JB.01219-08; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	46	34	34	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6930	10.1371/journal.pone.0006930	http://dx.doi.org/10.1371/journal.pone.0006930			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19759826	Green Submitted, Green Published, gold			2022-12-27	WOS:000269622300014
J	Carnoy, C; Roten, CA				Carnoy, Christophe; Roten, Claude-Alain			The dif/Xer Recombination Systems in Proteobacteria	PLOS ONE			English	Article							SITE-SPECIFIC RECOMBINATION; CHROMOSOME DIMER RESOLUTION; ESCHERICHIA-COLI; FILAMENTOUS PHAGE; TERMINUS REGION; DIF SITE; DNA; GENOME; XERC; INTEGRATION	In E. coli, 10 to 15% of growing bacteria produce dimeric chromosomes during DNA replication. These dimers are resolved by XerC and XerD, two tyrosine recombinases that target the 28-nucleotide motif (dif) associated with the chromosome's replication terminus. In streptococci and lactococci, an alternative system is composed of a unique, Xer-like recombinase (XerS) genetically linked to a dif-like motif (dif(SL)) located at the replication terminus. Preliminary observations have suggested that the dif/Xer system is commonly found in bacteria with circular chromosomes but that assumption has not been confirmed in an exhaustive analysis. The aim of the present study was to extensively characterize the dif/Xer system in the proteobacteria, since this taxon accounts for the majority of genomes sequenced to date. To that end, we analyzed 234 chromosomes from 156 proteobacterial species and showed that most species (87.8%) harbor XerC and XerD-like recombinases and a dif-related sequence which (i) is located in non-coding sequences, (ii) is close to the replication terminus (as defined by the cumulative GC skew) (iii) has a palindromic structure, (iv) is encoded by a low G+C content and (v) contains a highly conserved XerD binding site. However, not all proteobacteria display this dif/XerCD system. Indeed, a sub-group of pathogenic epsilon-proteobacteria (including Helicobacter sp and Campylobacter sp) harbors a different recombination system, composed of a single recombinase (XerH) which is phylogenetically distinct from the other Xer recombinases and a motif (dif(H)) sharing homologies with dif(SL). Furthermore, no homologs to dif or Xer recombinases could be detected in small endosymbiont genomes or in certain bacteria with larger chromosomes like the Legionellales. This raises the question of the presence of other chromosomal deconcatenation systems in these species. Our study highlights the complexity of dif/Xer recombinase systems in proteobacteria and paves the way for systematic detection of these components in prokaryotes.			Carnoy, C (corresponding author), INSERM, U801, F-59045 Lille, France.	christophe.carnoy@univ-lille2.fr		CARNOY, Christophe/0000-0003-2047-5153				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersson SGE, 2006, SCIENCE, V314, P259, DOI 10.1126/science.1133739; Aussel L, 2002, CELL, V108, P195, DOI 10.1016/S0092-8674(02)00624-4; Bigot S, 2007, MOL MICROBIOL, V64, P1434, DOI 10.1111/j.1365-2958.2007.05755.x; Blakely G, 1996, GENE DEV, V10, P762, DOI 10.1101/gad.10.6.762; BLAKELY G, 1991, NEW BIOL, V3, P789; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; Bloor AE, 2006, APPL ENVIRON MICROB, V72, P2520, DOI 10.1128/AEM.72.4.2520-2525.2006; BRENNER DJ, 1984, BERGEYS MANUAL SYSTE, V1, P279; Campbell BJ, 2006, NAT REV MICROBIOL, V4, P458, DOI 10.1038/nrmicro1414; Campos J, 2003, J BACTERIOL, V185, P5685, DOI 10.1128/JB.185.19.5685-5696.2003; Carnoy C, 2002, J BACTERIOL, V184, P4489, DOI 10.1128/JB.184.16.4489-4499.2002; Chalker AF, 2000, J MOL MICROB BIOTECH, V2, P225; CLERGET M, 1991, NEW BIOL, V3, P780; Cooke GD, 2003, J BIOTECHNOL, V101, P229, DOI 10.1016/S0168-1656(02)00339-5; Cornet F, 1996, GENE DEV, V10, P1152, DOI 10.1101/gad.10.9.1152; Cui TL, 2007, EMBO REP, V8, P181, DOI 10.1038/sj.embor.7400880; DAI H, 1988, VIROLOGY, V167, P613, DOI 10.1016/0042-6822(88)90124-9; Derbise A, 2007, MOL MICROBIOL, V63, P1145, DOI 10.1111/j.1365-2958.2006.05570.x; Giovannoni SJ, 2005, SCIENCE, V309, P1242, DOI 10.1126/science.1114057; Gonzalez MD, 2002, J BACTERIOL, V184, P6050, DOI 10.1128/JB.184.21.6050-6055.2002; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Hamilton HL, 2005, MOL MICROBIOL, V55, P1704, DOI 10.1111/j.1365-2958.2005.04521.x; Hayes F, 1997, J MOL BIOL, V266, P525, DOI 10.1006/jmbi.1996.0828; Hayes F, 1997, GENE, V198, P105, DOI 10.1016/S0378-1119(97)00299-0; Hendrickson H, 2007, MOL MICROBIOL, V64, P42, DOI 10.1111/j.1365-2958.2007.05596.x; Huber KE, 2002, NATURE, V417, P656, DOI 10.1038/nature00782; Iida T, 2002, J BACTERIOL, V184, P4933, DOI 10.1128/JB.184.17.4933-4935.2002; Jensen RB, 2006, J BACTERIOL, V188, P6016, DOI 10.1128/JB.00330-06; KERSULYTE D, 2009, PLOS ONE IN PRESS; Krause A, 2006, NAT BIOTECHNOL, V24, P1385, DOI 10.1038/nbt1243; Kuempel P, 1996, GENE DEV, V10, P1162, DOI 10.1101/gad.10.9.1162; KUEMPEL PL, 1991, NEW BIOL, V3, P799; Le Bourgeois P, 2007, PLOS GENET, V3, P1190, DOI 10.1371/journal.pgen.0030117; LESLIE NR, 1995, EMBO J, V14, P1561, DOI 10.1002/j.1460-2075.1995.tb07142.x; Lin NT, 2001, MOL GENET GENOMICS, V266, P425, DOI 10.1007/s004380100532; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; McLeod SM, 2004, MOL MICROBIOL, V54, P935, DOI 10.1111/j.1365-2958.2004.04309.x; Neilson L, 1999, MOL MICROBIOL, V31, P915, DOI 10.1046/j.1365-2958.1999.01231.x; Noe L, 2005, NUCLEIC ACIDS RES, V33, pW540, DOI 10.1093/nar/gki478; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Perals K, 2000, MOL MICROBIOL, V36, P33, DOI 10.1046/j.1365-2958.2000.01847.x; Recchia GD, 1999, MOL MICROBIOL, V34, P1146, DOI 10.1046/j.1365-2958.1999.01668.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sciochetti SA, 2001, J BACTERIOL, V183, P1058, DOI 10.1128/JB.183.3.1058-1068.2001; SIROIS S, 1995, J BACTERIOL, V177, P4183, DOI 10.1128/jb.177.14.4183-4186.1995; Slater SC, 2009, J BACTERIOL, V191, P2501, DOI 10.1128/JB.01779-08; Snyder LAS, 2005, MICROBIOL-SGM, V151, P4005, DOI 10.1099/mic.0.27925-0; Steiner W, 1999, MOL MICROBIOL, V31, P579, DOI 10.1046/j.1365-2958.1999.01198.x; Steiner WW, 1998, J BACTERIOL, V180, P6269; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; STIRLING CJ, 1988, EMBO J, V7, P4389, DOI 10.1002/j.1460-2075.1988.tb03338.x; STIRLING CJ, 1988, MOL GEN GENET, V214, P80, DOI 10.1007/BF00340183; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; SUMMERS DK, 1988, EMBO J, V7, P851, DOI 10.1002/j.1460-2075.1988.tb02884.x; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Val ME, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000201; Val ME, 2005, MOL CELL, V19, P559, DOI 10.1016/j.molcel.2005.07.002; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Yen MR, 2002, APPL ENVIRON MICROB, V68, P2924, DOI 10.1128/AEM.68.6.2924-2933.2002	61	76	79	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6531	10.1371/journal.pone.0006531	http://dx.doi.org/10.1371/journal.pone.0006531			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727445	Green Published, Green Submitted, gold			2022-12-27	WOS:000269522900001
J	Cesselin, F; Bourgoin, S; Mauborgne, A; Hamon, M; Le Bars, D				Cesselin, Francois; Bourgoin, Sylvie; Mauborgne, Annie; Hamon, Michel; Le Bars, Daniel			Freezing of Enkephalinergic Functions by Multiple Noxious Foci: A Source of Pain Sensitization?	PLOS ONE			English	Article								Background: The functional significance of proenkephalin systems in processing pain remains an open question and indeed is puzzling. For example, a noxious mechanical stimulus does not alter the release of Met-enkephalin-like material (MELM) from segments of the spinal cord related to the stimulated area of the body, but does increase its release from other segments. Methodology/Principal Findings: Here we show that, in the rat, a noxious mechanical stimulus applied to either the right or the left hind paw elicits a marked increase of MELM release during perifusion of either the whole spinal cord or the cervico-trigeminal area. However, these stimulatory effects were not additive and indeed, disappeared completely when the right and left paws were stimulated simultaneously. Conclusion/Significance: We have concluded that in addition to the concept of a diffuse control of the transmission of nociceptive signals through the dorsal horn, there is a diffuse control of the modulation of this transmission. The "freezing'' of Met-enkephalinergic functions represents a potential source of central sensitization in the spinal cord, notably in clinical situations involving multiple painful foci, e. g. cancer with metastases, poly-traumatism or rheumatoid arthritis.			Cesselin, F (corresponding author), CNRS, INSERM, UMRS 975, Team Pain,UMR 7225, Paris, France.	francois.cesselin@upmc.fr						BASBAUM AI, 1979, J COMP NEUROL, V187, P513, DOI 10.1002/cne.901870304; BERNARD JF, 1995, J COMP NEUROL, V353, P480, DOI 10.1002/cne.903530403; BING Z, 1990, NEUROSCIENCE, V37, P809, DOI 10.1016/0306-4522(90)90110-P; BING Z, 1991, NEUROSCIENCE, V44, P693, DOI 10.1016/0306-4522(91)90088-6; BING Z, 1991, PAIN, V47, P71, DOI 10.1016/0304-3959(91)90013-N; BOUHASSIRA D, 1992, BRAIN RES, V595, P353, DOI 10.1016/0006-8993(92)91071-L; BOURGOIN S, 1986, J PHARMACOL EXP THER, V238, P360; BOURGOIN S, 1988, PAIN, V32, P107, DOI 10.1016/0304-3959(88)90029-2; BRENNAN TJ, 1989, J NEUROPHYSIOL, V61, P573, DOI 10.1152/jn.1989.61.3.573; CADDEN SW, 1993, BRAIN RES, V628, P65, DOI 10.1016/0006-8993(93)90938-J; CADDEN SW, 1991, BRAIN RES, V558, P63, DOI 10.1016/0006-8993(91)90714-7; CESSELIN F, 1980, BRAIN RES, V191, P289, DOI 10.1016/0006-8993(80)90335-2; CESSELIN F, 1985, BRAIN RES, V339, P305, DOI 10.1016/0006-8993(85)90096-4; CESSELIN F, 1982, BRAIN RES, V237, P325, DOI 10.1016/0006-8993(82)90445-0; CESSELIN F, 1999, OPIOIDS PAIN CONTROL, P70; COLLIN E, 1992, SYNAPSE, V11, P76, DOI 10.1002/syn.890110110; Fields HL, 2006, WALL MELZACKS TXB PA, P125; FLEISCHMANN A, 1989, PHYSIOL BEHAV, V46, P151, DOI 10.1016/0031-9384(89)90248-5; FREMINET A, 1972, PFLUG ARCH EUR J PHY, V334, P293, DOI 10.1007/BF00592164; GERHART KD, 1981, J NEUROPHYSIOL, V46, P1309, DOI 10.1152/jn.1981.46.6.1309; Heinricher M.M., 2008, SENSES COMPREHENSIVE, V5, P593; HYLDEN JLK, 1989, NEUROSCIENCE, V28, P27, DOI 10.1016/0306-4522(89)90229-7; LEBARS D, 1987, BRAIN RES, V412, P190, DOI 10.1016/0006-8993(87)91460-0; LEBARS D, 1981, BRAIN RES, V204, P387, DOI 10.1016/0006-8993(81)90597-7; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; McGaraughty S, 1997, BRAIN RES BULL, V43, P263, DOI 10.1016/S0361-9230(97)00002-6; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; MORGAN MM, 1994, J NEUROPHYSIOL, V72, P1152, DOI 10.1152/jn.1994.72.3.1152; MORTON CR, 1988, PAIN, V34, P75, DOI 10.1016/0304-3959(88)90184-4; MORTON CR, 1987, BRAIN RES, V410, P347, DOI 10.1016/0006-8993(87)90336-2; NESS TJ, 1991, J NEUROPHYSIOL, V66, P29, DOI 10.1152/jn.1991.66.1.29; NESS TJ, 1991, J NEUROPHYSIOL, V66, P20, DOI 10.1152/jn.1991.66.1.20; Neugebauer V, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-8; SATO A, 2002, INT C SERIES, V1238; SCHOUENBORG J, 1985, BRAIN RES, V328, P23, DOI 10.1016/0006-8993(85)91318-6; TOMLINSON RWW, 1983, BRAIN RES, V279, P291, DOI 10.1016/0006-8993(83)90195-6; VILLANUEVA L, 1986, J NEUROPHYSIOL, V56, P1185, DOI 10.1152/jn.1986.56.4.1185; VILLANUEVA L, 1994, J PHYSIOL-LONDON, V475, P255, DOI 10.1113/jphysiol.1994.sp020066; Villanueva L, 1996, PAIN, V67, P231, DOI 10.1016/0304-3959(96)03121-1; WEILFUGAZZA J, 1984, BRAIN RES, V297, P247, DOI 10.1016/0006-8993(84)90566-3; Whitehouse MW, 2007, INFLAMM RES, V56, P133, DOI 10.1007/s00011-006-6117-8; WILLER JC, 1990, EUR J PHARMACOL, V182, P347, DOI 10.1016/0014-2999(90)90293-F; YAKSH TL, 1980, BRAIN RES, V192, P133, DOI 10.1016/0006-8993(80)91014-8	43	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6874	10.1371/journal.pone.0006874	http://dx.doi.org/10.1371/journal.pone.0006874			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727441	gold, Green Submitted, Green Published			2022-12-27	WOS:000269522900010
J	Sabot, OJ; Mwita, A; Cohen, JM; Ipuge, Y; Gordon, M; Bishop, D; Odhiambo, M; Ward, L; Goodman, C				Sabot, Oliver J.; Mwita, Alex; Cohen, Justin M.; Ipuge, Yahya; Gordon, Megumi; Bishop, David; Odhiambo, Moses; Ward, Lorrayne; Goodman, Catherine			Piloting the Global Subsidy: The Impact of Subsidized Artemisinin-Based Combination Therapies Distributed through Private Drug Shops in Rural Tanzania	PLOS ONE			English	Article								Background: WHO estimates that only 3% of fever patients use recommended artemisinin-based combination therapies (ACTs), partly reflecting their high prices in the retail sector from where many patients seek treatment. To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania. Methods/Principal Findings: Three districts were assigned to serve either as a control or to receive the subsidy plus a package of supporting interventions. From October 2007, ACTs were sold at a 90% subsidy through the normal private supply chain to intervention district drug shops. Data were collected at baseline and during intervention using interviews with drug shop customers, retail audits, mystery shoppers, and audits of public and NGO facilities. The proportion of consumers in the intervention districts purchasing ACTs rose from 1% at baseline to 44.2% one year later (p<0.001), and was significantly higher among consumers purchasing for children under 5 than for adults (p=0.005). No change in ACT usage was observed in the control district. Consumers paid a mean price of $0.58 for ACTs, which did not differ significantly from the price paid for sulphadoxine-pyrimethamine, the most common alternative. Drug shops in population centers were significantly more likely to stock ACTs than those in more remote areas (p<0.001). Conclusions: A subsidy introduced at the top of the private sector supply chain can significantly increase usage of ACTs and reduce their retail price to the level of common monotherapies. Additional interventions may be needed to ensure access to ACTs in remote areas and for poorer individuals who appear to seek treatment at drug shops less frequently.			Sabot, OJ (corresponding author), Clinton Fdn HIV AIDS Initiat, Malaria Control Team, Boston, MA USA.	osabot@clintonfoundation.org		Cohen, Justin/0000-0003-4481-6784; Goodman, Catherine/0000-0002-2241-3485	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 2008, WORLD MAL REP 2008; *AUSTR GOV, 2006, ARR OP COMM SERV OBL; CHEN A, 2008, REV PRIVATE SECTOR A; Cohen JM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-200; Goodman C, 2004, TROP MED INT HEALTH, V9, P655, DOI 10.1111/j.1365-3156.2004.01245.x; Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs, 2004, SAVING LIVES BUYING; Kachur SP, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-25; Laxminarayan R, 2006, HEALTH AFFAIR, V25, P325, DOI 10.1377/hlthaff.25.2.325; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; *MED MAL VENT, 2008, UND ANT MARK UG 2007; Oxfam, 2009, BLIND OPT CHALL MYTH; Rehwagen Christiane, 2006, BMJ, V332, P1176, DOI 10.1136/bmj.332.7551.1176-b; ROBINSON JC, 1987, JAMA-J AM MED ASSOC, V257, P3241, DOI 10.1001/jama.257.23.3241; *ROLL BACK MAL PAR, 2007, TECHN DIG AFF MED FA; *TACAIDS, 2006, TANZ HIV AIDS IND SU; *TANZ FOOD DRUG AU, 2007, REG DUK DAW BAR TANZ; *TANZ NAT BUR STAT, 2004, 2002 POP HOUS CENS G; Tanzania Ministry of Health and Social Welfare, 2006, NAT GUID MAL DIAGN T; *UNICEF ROLL BACK, 2007, MAL CHILDR PROGR INT; WHO, 2006, GUID TREATM MAL; Wolf K., 2005, COSTING ARTEMISININ; Worrall E, 2005, TROP MED INT HEALTH, V10, P1047, DOI 10.1111/j.1365-3156.2005.01476.x	22	68	68	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6857	10.1371/journal.pone.0006857	http://dx.doi.org/10.1371/journal.pone.0006857			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RW	19724644	Green Published, Green Accepted, gold			2022-12-27	WOS:000269522800004
J	Zhang, H; Yang, JH; Zheng, YS; Zhang, P; Chen, X; Wu, J; Xu, L; Luo, XQ; Ke, ZY; Zhou, H; Qu, LH; Chen, YQ				Zhang, Hua; Yang, Jian-Hua; Zheng, Yu-Sheng; Zhang, Peng; Chen, Xiao; Wu, Jun; Xu, Ling; Luo, Xue-Qun; Ke, Zhi-Yong; Zhou, Hui; Qu, Liang-Hu; Chen, Yue-Qin			Genome-Wide Analysis of Small RNA and Novel MicroRNA Discovery in Human Acute Lymphoblastic Leukemia Based on Extensive Sequencing Approach	PLOS ONE			English	Article							EXPRESSION PROFILES; MIRNA EXPRESSION; GENES; INTENSIFICATION; CANDIDATES; PREDICTION; MANAGEMENT; ONCOGENES; CHILDREN; IMPROVES	Background: MicroRNAs ( miRNAs) have been proved to play an important role in various cellular processes and function as tumor suppressors or oncogenes in cancers including leukemia. The identification of a large number of novel miRNAs and other small regulatory RNAs will provide valuable insights into the roles they play in tumorgenesis. Methodology/Principal Findings: To gain further understanding of the role of miRNAs relevant to acute lymphoblastic leukemia ( ALL), we employed the sequencing-by-synthesis (SBS) strategy to sequence small RNA libraries prepared from ALL patients and normal donors. In total we identified 159 novel miRNAs and 116 novel miRNA*s from both libraries. Among the 159 novel miRNAs, 42 were identified with high stringency in our data set. Furthermore, we demonstrated the different expression patterns of 20 newly identified and several known miRNAs between ALL patients and normal donors, suggesting these miRNAs may be associated with ALL and could constitute an ALL-specific miRNA signature. Interestingly, GO "biological process'' classifications revealed that a set of significantly abnormally expressed miRNAs are associated with disease relapse, which implies that these dysregulated miRNAs might promote the progression of ALL by regulating genes involved in the pathway of the disease development. Conclusion/Significance: The study presents a comprehensive picture of the expression of small RNAs in human acute lymphoblastic leukemia and highlights novel and known miRNAs differentially expressed between ALL patients and normal donors. To our knowledge, this is the first study to look at genome-wide known and novel miRNA expression patterns in in human acute lymphoblastic leukemia. Our data revealed that these deregulated miRNAs may be associated with ALL or the onset of relapse.			Zhang, H (corresponding author), Sun Yat Sen Univ, State Key Lab Biocontrol, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Guangdong, Peoples R China.	lsscyq@mail.sysu.edu.cn	Yang, JianHua/A-5330-2011; Zhang, Hua/AAF-3999-2020; Zhang, Hua/AAA-2164-2022	Zhang, Hua/0000-0001-9731-2737; Qu, Liang-Hu/0000-0003-3657-2863; Zhou, Hui/0000-0001-9157-3792; Yang, Jian-Hua/0000-0003-3863-2786				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2006, GENOME RES, V16, P1289, DOI 10.1101/gr.5159906; Bergsland M, 2006, GENE DEV, V20, P3475, DOI 10.1101/gad.403406; Bonnet E, 2004, BIOINFORMATICS, V20, P2911, DOI 10.1093/bioinformatics/bth374; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Castillo-Davis CI, 2003, BIOINFORMATICS, V19, P891, DOI 10.1093/bioinformatics/btg114; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Clote P, 2005, RNA, V11, P578, DOI 10.1261/rna.7220505; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Faderl S, 2003, CANCER-AM CANCER SOC, V98, P1337, DOI 10.1002/cncr.11664; Friedlander MR, 2008, NAT BIOTECHNOL, V26, P407, DOI 10.1038/nbt1394; Glazov EA, 2008, GENOME RES, V18, P957, DOI 10.1101/gr.074740.107; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Hutchinson RJ, 2003, J CLIN ONCOL, V21, P1790, DOI 10.1200/JCO.2003.03.009; Kuchenbauer F, 2008, GENOME RES, V18, P1787, DOI 10.1101/gr.077578.108; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Marton S, 2008, LEUKEMIA, V22, P330, DOI 10.1038/sj.leu.2405022; Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Narayan S, 2007, HEMATOLOGY, V12, P39, DOI 10.1080/10245330600938125; O'Toole AS, 2006, NUCLEIC ACIDS RES, V34, P3338, DOI 10.1093/nar/gkl428; Okamura K, 2008, NAT STRUCT MOL BIOL, V15, P354, DOI 10.1038/nsmb.1409; Pui CH, 2003, J CLIN ONCOL, V21, P179, DOI 10.1200/JCO.2003.10.032; Pui CH, 2008, LANCET ONCOL, V9, P257, DOI 10.1016/S1470-2045(08)70070-6; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Ro S, 2007, NUCLEIC ACIDS RES, V35, P5944, DOI 10.1093/nar/gkm641; Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schotte D, 2009, LEUKEMIA, V23, P313, DOI 10.1038/leu.2008.286; Seitz H, 2008, CURR BIOL, V18, P147, DOI 10.1016/j.cub.2007.12.049; Steffen P, 2006, BIOINFORMATICS, V22, P500, DOI 10.1093/bioinformatics/btk010; Takada S, 2008, LEUKEMIA, V22, P1274, DOI 10.1038/sj.leu.2405031; Wang X, 2008, BRIT J HAEMATOL, V143, P248, DOI 10.1111/j.1365-2141.2008.07329.x; Washietl S, 2005, P NATL ACAD SCI USA, V102, P2454, DOI 10.1073/pnas.0409169102; Wojcik I, 2005, NEOPLASMA, V52, P318; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	54	33	36	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6849	10.1371/journal.pone.0006849	http://dx.doi.org/10.1371/journal.pone.0006849			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RW	19724645	gold, Green Submitted, Green Published			2022-12-27	WOS:000269522800002
J	Ni, M; Zhou, H; Wey, SA; Baumeister, P; Lee, AS				Ni, Min; Zhou, Hui; Wey, Shiuan; Baumeister, Peter; Lee, Amy S.			Regulation of PERK Signaling and Leukemic Cell Survival by a Novel Cytosolic Isoform of the UPR Regulator GRP78/BiP	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; PRE-MESSENGER-RNA; VIRUS PRECORE PROTEIN; ER CHAPERONE; ATPASE ACTIVITY; BINDING-SITE; CANCER CELLS; IN-VITRO; BIP	The unfolded protein response (UPR) is an evolutionarily conserved mechanism to allow cells to adapt to stress targeting the endoplasmic reticulum (ER). Induction of ER chaperone GRP78/BiP increases protein folding capacity; as such it represents a major survival arm of UPR. Considering the central importance of the UPR in regulating cell survival and death, evidence is emerging that cells evolve feedback regulatory pathways to modulate the key UPR executors, however, the precise mechanisms remain to be elucidated. Here, we report the fortuitous discovery of GRP78va, a novel isoform of GRP78 generated by alternative splicing (retention of intron 1) and alternative translation initiation. Bioinformatic and biochemical analyses revealed that expression of GRP78va is enhanced by ER stress and is notably elevated in human leukemic cells and leukemia patients. In contrast to the canonical GRP78 which is primarily an ER lumenal protein, GRP78va is devoid of the ER signaling peptide and is cytosolic. Through specific knockdown of endogenous GRP78va by siRNA without affecting canonical GRP78, we showed that GRP78va promotes cell survival under ER stress. We further demonstrated that GRP78va has the ability to regulate PERK signaling and that GRP78va is able to interact with and antagonize PERK inhibitor P58 IPK. Our study describes the discovery of GRP78va, a novel cytosolic isoform of GRP78/BiP, and the first characterization of the modulation of UPR signaling via alternative splicing of nuclear pre-mRNA. Our study further reveals a novel survival mechanism in leukemic cells and other cell types where GRP78va is expressed.			Ni, M (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.	amylee@ccnt.usc.edu		Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R01CA111700, R01CA027607] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA027607, R01 CA111700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afshar N, 2005, MOL CELL BIOL, V25, P8844, DOI 10.1128/MCB.25.20.8844-8853.2005; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Ast G, 2004, NAT REV GENET, V5, P773, DOI 10.1038/nrg1451; BAUMEISTER P, 2009, MOL CANC TH IN PRESS; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Duriez M, 2008, J BIOL CHEM, V283, P32352, DOI 10.1074/jbc.M807178200; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; Gardner LB, 2008, MOL CELL BIOL, V28, P3729, DOI 10.1128/MCB.02284-07; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Goodman AG, 2007, J VIROL, V81, P2221, DOI 10.1128/JVI.02151-06; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Kurisu J, 2003, GENES CELLS, V8, P189, DOI 10.1046/j.1365-2443.2003.00625.x; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; Levine CG, 2005, MOL BIOL CELL, V16, P279, DOI 10.1091/mbc.E04-06-0508; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Liu C, 2003, AM J PATHOL, V163, P1859, DOI 10.1016/S0002-9440(10)63545-6; Liu Y, 2007, MOL PHARMACEUT, V4, P435, DOI 10.1021/mp060122j; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Okuda-Shimizu Y, 2007, MOL CELL, V28, P544, DOI 10.1016/j.molcel.2007.09.012; Ota J, 2003, ONCOGENE, V22, P5720, DOI 10.1038/sj.onc.1206855; Oyadomari S, 2006, CELL, V126, P727, DOI 10.1016/j.cell.2006.06.051; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Pattacini L, 2004, LEUKEMIA RES, V28, P191, DOI 10.1016/S0145-2126(03)00218-2; Petrova K, 2008, EMBO J, V27, P2862, DOI 10.1038/emboj.2008.199; Philippova M, 2008, MOL CELL BIOL, V28, P4004, DOI 10.1128/MCB.00157-08; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rauschert N, 2008, LAB INVEST, V88, P375, DOI 10.1038/labinvest.2008.2; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2007, MOL BIOL CELL, V18, P3681, DOI 10.1091/mbc.e07-03-0272; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sakabe NJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-59; Salesse S, 2004, LEUKEMIA, V18, P727, DOI 10.1038/sj.leu.2403310; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Theoleyre O, 2004, ONCOGENE, V23, P920, DOI 10.1038/sj.onc.1207206; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; Ushioda R, 2008, SCIENCE, V321, P569, DOI 10.1126/science.1159293; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060; WANG M, 2009, ANTIOXID RE IN PRESS; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yu DH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003951; Zhang YC, 2006, MOL PHARMACOL, V70, P1424, DOI 10.1124/mol.106.024323; Zhou JH, 2006, P NATL ACAD SCI USA, V103, P14343, DOI 10.1073/pnas.0606480103	70	114	116	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6868	10.1371/journal.pone.0006868	http://dx.doi.org/10.1371/journal.pone.0006868			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718440	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900029
J	Ocbina, PJR; Tuson, M; Anderson, KV				Ocbina, Polloneal Jymmiel R.; Tuson, Miquel; Anderson, Kathryn V.			Primary Cilia Are Not Required for Normal Canonical Wnt Signaling in the Mouse Embryo	PLOS ONE			English	Article								Background: Sonic hedgehog (Shh) signaling in the mouse requires the microtubule-based organelle, the primary cilium. The primary cilium is assembled and maintained through the process of intraflagellar transport (IFT) and the response to Shh is blocked in mouse mutants that lack proteins required for IFT. Although the phenotypes of mouse IFT mutants do not overlap with phenotypes of known Wnt pathway mutants, recent studies report data suggesting that the primary cilium modulates responses to Wnt signals. Methodology/Principal Findings: We therefore carried out a systematic analysis of canonical Wnt signaling in mutant embryos and cells that lack primary cilia because of loss of the anterograde IFT kinesin-II motor (Kif3a) or IFT complex B proteins (Ift172 or Ift88). We also analyzed mutant embryos with abnormal primary cilia due to defects in retrograde IFT (Dync2h1). The mouse IFT mutants express the canonical Wnt target Axin2 and activate a transgenic canonical Wnt reporter, BAT-gal, in the normal spatial pattern and to the same quantitative level as wild type littermates. Similarly, mouse embryonic fibroblasts (MEFs) derived from IFT mutants respond normally to added Wnt3a. The switch from canonical to non-canonical Wnt also appears normal in IFT mutant MEFs, as both wild-type and mutant cells do not activate the canonical Wnt reporter in the presence of both Wnt3a and Wnt5a. Conclusions: We conclude that loss of primary cilia or defects in retrograde IFT do not affect the response of the midgestation embryo or embryo-derived fibroblasts to Wnt ligands.			Ocbina, PJR (corresponding author), Sloan Kettering Inst, Dev Biol Program, New York, NY USA.	k-anderson@sloankettering.edu		Tuson, Miquel/0000-0003-2239-0532; Anderson, Kathryn/0000-0003-1657-2161	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK074038] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK074038] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AANSTAD P, 2009, CURR BIOL; Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Chazaud C, 2006, DEVELOPMENT, V133, P3379, DOI 10.1242/dev.02523; Cho A, 2008, DEV BIOL, V321, P27, DOI 10.1016/j.ydbio.2008.05.558; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Dunty WC, 2008, DEVELOPMENT, V135, P85, DOI 10.1242/dev.009266; Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249; Eggenschwiler JT, 2000, DEV BIOL, V227, P648, DOI 10.1006/dbio.2000.9918; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Fischer E, 2006, NAT GENET, V38, P21, DOI 10.1038/ng1701; Gerdes JM, 2007, NAT GENET, V39, P1350, DOI 10.1038/ng.2007.12; Gerdes JM, 2008, CURR TOP DEV BIOL, V85, P175, DOI 10.1016/S0070-2153(08)00807-7; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gorivodsky M, 2009, DEV BIOL, V325, P24, DOI 10.1016/j.ydbio.2008.09.019; Greene NDE, 1998, MECH DEVELOP, V73, P59, DOI 10.1016/S0925-4773(98)00029-X; Haraguchi K, 2006, J BIOL CHEM, V281, P4094, DOI 10.1074/jbc.M507028200; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; He X, 2008, NAT CELL BIOL, V10, P11, DOI 10.1038/ncb0108-11; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jones C, 2008, NAT GENET, V40, P69, DOI 10.1038/ng.2007.54; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kishimoto N, 2008, DEV CELL, V14, P954, DOI 10.1016/j.devcel.2008.03.010; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nurnberger J, 2002, MOL BIOL CELL, V13, P3096, DOI 10.1091/mbc.E02-04-0195; Ocbina PJR, 2008, DEV DYNAM, V237, P2030, DOI 10.1002/dvdy.21551; Oishi I, 2006, NAT GENET, V38, P1316, DOI 10.1038/ng1892; PERRY WL, 1995, GENETICS, V141, P321; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Scholey JM, 2006, CELL, V125, P439, DOI 10.1016/j.cell.2006.04.013; Serluca FC, 2009, DEVELOPMENT, V136, P1621, DOI 10.1242/dev.020735; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Tobin JL, 2008, P NATL ACAD SCI USA, V105, P6714, DOI 10.1073/pnas.0707057105; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wong SY, 2008, CURR TOP DEV BIOL, V85, P225, DOI 10.1016/S0070-2153(08)00809-0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	58	101	103	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6839	10.1371/journal.pone.0006839	http://dx.doi.org/10.1371/journal.pone.0006839			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718259	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900012
J	Honig, G; Jongsma, ME; van der Hart, MCG; Tecott, LH				Honig, Gerard; Jongsma, Minke E.; van der Hart, Marieke C. G.; Tecott, Laurence H.			Chronic Citalopram Administration Causes a Sustained Suppression of Serotonin Synthesis in the Mouse Forebrain	PLOS ONE			English	Article							ACUTE TRYPTOPHAN DEPLETION; OF-FUNCTION MUTATION; SELECTIVE SEROTONIN; REUPTAKE INHIBITOR; ANTIDEPRESSANT ACTION; RAT-BRAIN; EXTRACELLULAR SEROTONIN; IN-VIVO; FLUOXETINE TREATMENT; MONOAMINE SYNTHESIS	Background: Serotonin (5-HT) is a neurotransmitter with important roles in the regulation of neurobehavioral processes, particularly those regulating affect in humans. Drugs that potentiate serotonergic neurotransmission by selectively inhibiting the reuptake of serotonin (SSRIs) are widely used for the treatment of psychiatric disorders. Although the regulation of serotonin synthesis may be an factor in SSRI efficacy, the effect of chronic SSRI administration on 5-HT synthesis is not well understood. Here, we describe effects of chronic administration of the SSRI citalopram (CIT) on 5-HT synthesis and content in the mouse forebrain. Methodology/Principal Findings: Citalopram was administered continuously to adult male C57BL/6J mice via osmotic minipump for 2 days, 14 days or 28 days. Plasma citalopram levels were found to be within the clinical range. 5-HT synthesis was assessed using the decarboxylase inhibition method. Citalopram administration caused a suppression of 5-HT synthesis at all time points. CIT treatment also caused a reduction in forebrain 5-HIAA content. Following chronic CIT treatment, forebrain 5-HT stores were more sensitive to the depleting effects of acute decarboxylase inhibition. Conclusions/Significance: Taken together, these results demonstrate that chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. Furthermore, our results indicate that chronic 5-HT reuptake inhibition renders 5-HT brain stores more sensitive to alterations in serotonin synthesis. These results suggest that the regulation of 5-HT synthesis warrants consideration in efforts to develop novel antidepressant strategies.			Honig, G (corresponding author), Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA.	ghonig@gmail.com	Honig, Gerard/ABB-5333-2020	Honig, Gerard/0000-0001-9147-7450	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Agazzi A, 2003, DIGEST LIVER DIS, V35, P590, DOI 10.1016/S1590-8658(03)00277-9; Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678; Anthony JP, 2000, J NEUROSCI RES, V61, P82, DOI 10.1002/1097-4547(20000701)61:1<82::AID-JNR10>3.0.CO;2-E; Arborelius L, 1996, N-S ARCH PHARMACOL, V353, P630, DOI 10.1007/BF00167182; Artigas F, 2006, CURR DRUG TARGETS, V7, P139, DOI 10.2174/138945006775515446; Artigas F, 2001, TRENDS PHARMACOL SCI, V22, P224, DOI 10.1016/S0165-6147(00)01682-5; AZMITIA EC, 1969, SCIENCE, V166, P1274, DOI 10.1126/science.166.3910.1274; BADAWY AAB, 1991, BRIT J PHARMACOL, V102, P429, DOI 10.1111/j.1476-5381.1991.tb12190.x; BADAWY AAB, 1981, BIOCHEM PHARMACOL, V30, P1211, DOI 10.1016/0006-2952(81)90299-9; BADAWY AAB, 1982, BRIT J PHARMACOL, V77, P59, DOI 10.1111/j.1476-5381.1982.tb09269.x; Bano S, 1999, Pak J Pharm Sci, V12, P11; Barton CL, 1999, SYNAPSE, V31, P13, DOI 10.1002/(SICI)1098-2396(199901)31:1<13::AID-SYN3>3.0.CO;2-Y; Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649; BENKELFAT C, 1994, ARCH GEN PSYCHIAT, V51, P687; Benkelfat C, 1999, NEUROPSYCHOPHARMACOL, V21, P153; Berton O, 2006, NAT REV NEUROSCI, V7, P137, DOI 10.1038/nrn1846; Blakely RD, 2005, NEURON, V48, P701, DOI 10.1016/j.neuron.2005.11.029; BLIER P, 1988, N-S ARCH PHARMACOL, V337, P246, DOI 10.1007/BF00168834; BOADLEBIBER MC, 1978, BIOCHEM PHARMACOL, V27, P1069, DOI 10.1016/0006-2952(78)90160-0; BOHMAKER K, 1992, NEUROPHARMACOLOGY, V31, P451, DOI 10.1016/0028-3908(92)90083-2; Booij L, 2002, NEUROPSYCHOPHARMACOL, V27, P852, DOI 10.1016/S0893-133X(02)00361-5; BOSKER FJ, 1995, NEUROPHARMACOLOGY, V34, P501, DOI 10.1016/0028-3908(95)00023-Y; BOSKER FJ, 2009, J NEUROCHEM; Brosen K, 2001, EUR NEUROPSYCHOPHARM, V11, P275, DOI 10.1016/S0924-977X(01)00101-8; CACCIA S, 1993, BRIT J PHARMACOL, V110, P355, DOI 10.1111/j.1476-5381.1993.tb13817.x; CACCIA S, 1992, NEUROPHARMACOLOGY, V31, P343, DOI 10.1016/0028-3908(92)90066-X; CACCIA S, 1992, J PHARM PHARMACOL, V44, P250, DOI 10.1111/j.2042-7158.1992.tb03592.x; Calcagno E, 2007, J NEUROCHEM, V103, P1111, DOI 10.1111/j.1471-4159.2007.04806.x; CARLSSON A, 1972, J NEURAL TRANSM, V33, P23, DOI 10.1007/BF01244726; CARLSSON A, 1970, J PHARM PHARMACOL, V22, P726, DOI 10.1111/j.2042-7158.1970.tb12769.x; CARLSSON A, 1976, J NEURAL TRANSM, V39, P1, DOI 10.1007/BF01248762; CARLSSON A, 1973, J NEURAL TRANSM, V34, P79, DOI 10.1007/BF01244661; Carlsson A, 1972, Biochem Soc Symp, P17; CARLSSON A, 1978, J NEURAL TRANSM, V43, P73, DOI 10.1007/BF01579067; CARLSSON A, 1978, N-S ARCH PHARMACOL, V303, P157, DOI 10.1007/BF00508062; Castren E, 2005, NAT REV NEUROSCI, V6, P241, DOI 10.1038/nrn1629; Cervo L, 2005, J NEUROSCI, V25, P8165, DOI 10.1523/JNEUROSCI.1816-05.2005; CHAPUT Y, 1986, N-S ARCH PHARMACOL, V333, P342, DOI 10.1007/BF00500007; Costa E, 1972, Adv Biochem Psychopharmacol, V4, P171; CREMERS T, 2008, J NEUROSCI METHODS; Cremers TIFH, 2000, EUR J PHARMACOL, V397, P63, DOI 10.1016/S0014-2999(00)00247-8; Daugherty WP, 2001, BRAIN RES, V923, P103, DOI 10.1016/S0006-8993(01)03198-5; Dawson LA, 2000, BRIT J PHARMACOL, V130, P797, DOI 10.1038/sj.bjp.0703378; DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411; DELGADO PL, 1994, ARCH GEN PSYCHIAT, V51, P865; DELGADO PL, 1991, PSYCHOPHARMACOL BULL, V27, P321; DELIA G, 1978, ACTA PSYCHIAT SCAND, V57, P239, DOI 10.1111/j.1600-0447.1978.tb06890.x; DEMONTIGNY C, 1990, J CLIN PSYCHIAT, V51, P4; DUFOUR H, 1987, INT CLIN PSYCHOPHARM, V2, P225, DOI 10.1097/00004850-198707000-00005; Dygalo NN, 2006, PHARMACOL BIOCHEM BE, V85, P220, DOI 10.1016/j.pbb.2006.08.004; Esteban S, 1999, N-S ARCH PHARMACOL, V360, P135, DOI 10.1007/s002109900045; Evans AK, 2009, NEUROSCI LETT, V455, P36, DOI 10.1016/j.neulet.2009.03.025; Felton TM, 2003, N-S ARCH PHARMACOL, V367, P297, DOI 10.1007/s00210-002-0688-x; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; Fox M, 2008, PSYCHOPHARMACOLOGY, V201, P203, DOI 10.1007/s00213-008-1268-7; Gardier AM, 2003, J NEUROCHEM, V86, P13, DOI 10.1046/j.1471-4159.2003.01827.x; Glatt C.E., 2005, NEURON, V45, P11; Glatt CE, 2005, NEURON, V48, P704, DOI 10.1016/j.neuron.2005.11.019; Hervas I, 2001, NEUROPSYCHOPHARMACOL, V24, P11, DOI 10.1016/S0893-133X(00)00175-5; Heurteaux C, 2006, NAT NEUROSCI, V9, P1134, DOI 10.1038/nn1749; HJORTH S, 1994, NEUROPHARMACOLOGY, V33, P331, DOI 10.1016/0028-3908(94)90062-0; Holt A, 1996, N-S ARCH PHARMACOL, V354, P17; Homberg JR, 2007, NEUROSCIENCE, V146, P1662, DOI 10.1016/j.neuroscience.2007.03.030; HWANG EC, 1980, RES COMMUN CHEM PATH, V29, P79; INVERNIZZI R, 1992, BRAIN RES, V584, P322, DOI 10.1016/0006-8993(92)90914-U; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; Jans LAW, 2007, MOL PSYCHIATR, V12, P522, DOI 10.1038/sj.mp.4001920; Johnson DA, 2007, BIOL PSYCHIAT, V62, P1228, DOI 10.1016/j.biopsych.2007.05.003; Jongsma ME, 2005, PROG NEURO-PSYCHOPH, V29, P738, DOI 10.1016/j.pnpbp.2005.04.026; JONGSMA ME, 2006, SEROTONERGIC AUGMENT; KABUTO H, 1994, ACTA MED OKAYAMA, V48, P311; KABUTO H, 1994, NEUROCHEM RES, V19, P463, DOI 10.1007/BF00967325; Kam K, 2007, J NEUROSCI, V27, P9192, DOI 10.1523/JNEUROSCI.1198-07.2007; Kanemaru K, 2009, NEUROCHEM INT, V54, P363, DOI 10.1016/j.neuint.2009.01.005; KATZUNG BG, 2004, BASIC CLIN PHARM, pR14; Kawahara Y, 2007, PSYCHOPHARMACOLOGY, V194, P73, DOI 10.1007/s00213-007-0826-8; Kim DK, 2005, NEUROPHARMACOLOGY, V49, P798, DOI 10.1016/j.neuropharm.2005.08.010; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; KRAGHSORENSEN P, 1981, ACTA PHARMACOL TOX, V48, P53; KRAMER PD, 1997, LISTENING PROZAC, pR19; Lakhan SE, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-2; LASSEN J B, 1978, European Journal of Pharmacology, V47, P351; Leyton M, 2000, J PSYCHOPHARMACOL, V14, P284, DOI 10.1177/026988110001400317; Leyton M, 1997, NEUROPSYCHOPHARMACOL, V16, P294, DOI 10.1016/S0893-133X(96)00262-X; Lira A, 2003, BIOL PSYCHIAT, V54, P960, DOI 10.1016/S0006-3223(03)00696-6; Maciag D, 2006, EUR J PHARMACOL, V532, P265, DOI 10.1016/j.ejphar.2005.12.081; Marsteller DA, 2007, SYNAPSE, V61, P877, DOI 10.1002/syn.20428; Mathews TA, 2004, J NEUROSCI METH, V140, P169, DOI 10.1016/j.jneumeth.2004.05.017; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; Moller S E, 1990, Eur Neuropsychopharmacol, V1, P41, DOI 10.1016/0924-977X(90)90009-Y; Moore P, 1998, ARCH GEN PSYCHIAT, V55, P534, DOI 10.1001/archpsyc.55.6.534; MORET C, 1992, NEUROPHARMACOLOGY, V31, P679, DOI 10.1016/0028-3908(92)90146-G; Moret C, 1997, J NEURAL TRANSM, V104, P147, DOI 10.1007/BF01273177; MUCKSELER D, 1995, NEUROPSYCHOPHARMACOL, V12, P251; MuckSeler D, 1996, J NEUROCHEM, V67, P2434; NURIA B, 1996, J NEUROCHEM, V67, P669; O'Leary OF, 2007, PSYCHOPHARMACOLOGY, V192, P357, DOI 10.1007/s00213-007-0728-9; Olivier JDA, 2008, PSYCHOPHARMACOLOGY, V200, P243, DOI 10.1007/s00213-008-1201-0; Olivier JDA, 2008, NEUROSCIENCE, V152, P573, DOI 10.1016/j.neuroscience.2007.12.032; OSIPOVA DV, 2008, J NEUROSCI RES; OVERO KF, 1982, PROG NEURO-PSYCHOPH, V6, P311, DOI 10.1016/S0278-5846(82)80181-4; Parker G, 2009, BRIT J PSYCHIAT, V194, P1, DOI 10.1192/bjp.bp.108.054767; PEDERSEN OL, 1982, PSYCHOPHARMACOLOGY, V77, P199, DOI 10.1007/BF00464566; PERRY KW, 1992, LIFE SCI, V50, P1683, DOI 10.1016/0024-3205(92)90423-M; Peters EJ, 2009, PHARMACOGENET GENOM, V19, P1, DOI 10.1097/FPC.0b013e3283163ecd; Graziano P, 2006, PSYCHOPHARMACOLOGY, V186, P362, DOI 10.1007/s00213-005-0213-2; Pothos EN, 2000, J NEUROSCI, V20, P7297; Rasmussen BB, 2000, THER DRUG MONIT, V22, P143, DOI 10.1097/00007691-200004000-00001; RUTTER JJ, 1993, J PHARMACOL EXP THER, V265, P1319; Shoaf SE, 1998, NEUROPSYCHOPHARMACOL, V19, P345, DOI 10.1016/S0893-133X(98)00032-3; Shoaf SE, 2000, J CEREBR BLOOD F MET, V20, P244, DOI 10.1097/00004647-200002000-00004; SHOPSIN B, 1975, PSYCHOPHARMACOL COMM, V1, P239; Smith KA, 1999, BRIT J PSYCHIAT, V174, P525, DOI 10.1192/bjp.174.6.525; Stenfors C, 2002, LIFE SCI, V71, P2867, DOI 10.1016/S0024-3205(02)02138-0; Stenfors C, 2001, N-S ARCH PHARMACOL, V363, P222, DOI 10.1007/s002100000347; Tao R, 2000, J PHARMACOL EXP THER, V294, P571; Taylor TN, 2009, J NEUROSCI, V29, P8103, DOI 10.1523/JNEUROSCI.1495-09.2009; Tenner K, 2008, NEUROSCI LETT, V431, P21, DOI 10.1016/j.neulet.2007.11.012; Thase Michael E, 2008, Curr Psychiatry Rep, V10, P487; TROUVIN JH, 1993, LIFE SCI, V52, pPL187, DOI 10.1016/0024-3205(93)90116-K; TROUVIN JH, 1992, APPETITE, V19, P222, DOI 10.1016/0195-6663(92)90150-5; Van den Bogaert A, 2005, NEURON, V48, P704, DOI 10.1016/j.neuron.2005.11.017; WALINDER J, 1981, ACTA PSYCHIAT SCAND, V63, P179, DOI 10.1111/j.1600-0447.1981.tb00719.x; WALINDER J, 1975, LANCET, V1, P984; WALINDER J, 1976, ARCH GEN PSYCHIAT, V33, P1384; *WHO, 2008, MENT HLTH DIS DEPR; Yamane F, 2001, BIOCHEM PHARMACOL, V62, P1481, DOI 10.1016/S0006-2952(01)00798-5; Zhang XD, 2004, SCIENCE, V305, P217, DOI 10.1126/science.1097540; Zhang XD, 2005, NEURON, V45, P11, DOI 10.1016/j.neuron.2004.12.014; Zhou Z., 2005, NEURON, V48, P702; Zhou ZF, 2005, NEURON, V48, P702, DOI 10.1016/j.neuron.2005.11.018	132	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6797	10.1371/journal.pone.0006797	http://dx.doi.org/10.1371/journal.pone.0006797			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710918	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415600011
J	Fimbel, E; Lauzon, S; Rainville, C				Fimbel, Eric; Lauzon, Stephane; Rainville, Constant			Performance of Humans vs. Exploration Algorithms on the Tower of London Test	PLOS ONE			English	Article							OF-LONDON; INDIVIDUAL-DIFFERENCES; PLANNING ABILITIES; SKILL ACQUISITION; TASK; INFORMATION; DETERMINANTS; WORKING; SEARCH; MEMORY	The Tower of London Test (TOL) used to assess executive functions was inspired in Artificial Intelligence tasks used to test problem-solving algorithms. In this study, we compare the performance of humans and of exploration algorithms. Instead of absolute execution times, we focus on how the execution time varies with the tasks and/or the number of moves. This approach used in Algorithmic Complexity provides a fair comparison between humans and computers, although humans are several orders of magnitude slower. On easy tasks (1 to 5 moves), healthy elderly persons performed like exploration algorithms using bounded memory resources, i.e., the execution time grew exponentially with the number of moves. This result was replicated with a group of healthy young participants. However, for difficult tasks (5 to 8 moves) the execution time of young participants did not increase significantly, whereas for exploration algorithms, the execution time keeps on increasing exponentially. A pre-and post-test control task showed a 25% improvement of visuo-motor skills but this was insufficient to explain this result. The findings suggest that naive participants used systematic exploration to solve the problem but under the effect of practice, they developed markedly more efficient strategies using the information acquired during the test.			Fimbel, E (corresponding author), Fatronik Fdn, Biorobot Dept, San Sebastian, Spain.	efimbel@fatronik.com						ACKERMAN PL, 1988, J EXP PSYCHOL GEN, V117, P288, DOI 10.1037/0096-3445.117.3.288; Ackerman PL, 2000, J EXP PSYCHOL-APPL, V6, P259, DOI 10.1037//1076-898X.6.4.259; ANZAI Y, 1979, PSYCHOL REV, V86, P124, DOI 10.1037/0033-295X.86.2.124; Beauchamp MH, 2003, NEUROIMAGE, V20, P1649, DOI 10.1016/j.neuroimage.2003.07.003; Berg WK, 2002, J CLIN EXP NEUROPSYC, V24, P586, DOI 10.1076/jcen.24.5.586.1006; BRASSARD G, 1996, FUNDAMENTALS ALGORIT, P524; Card S. K., 1983, PSYCHOL HUMAN COMPUT; Carder HP, 2004, Q J EXP PSYCHOL-A, V57, P1459, DOI 10.1080/02724980343000864; Churchland P S, 1992, COMPUTATIONAL BRAIN, P544; Cormen TH, 2001, INTRO ALGORITHMS, P1180; Dijkstra E.W, 1959, NUMER MATH, V1, P269, DOI DOI 10.1007/BF01386390; FIMBEL EJ, 2009, PROBLEM SPACE TOWER; Garson G. D., 2008, TOPICS MULTIVARIATE; HAYES-ROTH B, 1979, Cognitive Science, V3, P275, DOI 10.1016/S0364-0213(79)80010-5; Hodgson TL, 2000, J COGNITIVE NEUROSCI, V12, P894, DOI 10.1162/089892900562499; Hogg T, 1996, ARTIF INTELL, V81, P1, DOI 10.1016/0004-3702(95)00044-5; Kaller CP, 2004, COGNITIVE BRAIN RES, V20, P462, DOI 10.1016/j.cogbrainres.2004.04.002; KOTOVSKY K, 1985, COGNITIVE PSYCHOL, V17, P248, DOI 10.1016/0010-0285(85)90009-X; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Marr D., 1982, VISION; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Morris R.G., 1987, COGNITIVE NEUROCHEMI, P21; Newell A., 1972, HUMAN PROBLEM SOLVIN, DOI [10.2307/2063712, DOI 10.2307/2063712]; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Phillips LH, 2002, EMOTION, V2, P263, DOI 10.1037/1528-3542.2.3.263; Rainville C, 2002, ARCH CLIN NEUROPSYCH, V17, P513, DOI 10.1016/S0887-6177(01)00132-9; Saling LL, 2007, BRAIN RES BULL, V73, P1, DOI 10.1016/j.brainresbull.2007.02.009; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Sussman G., 1975, COMPUTATIONAL MODEL; Unterrainer JM, 2004, J CLIN EXP NEUROPSYC, V26, P846, DOI 10.1080/13803390490509574; Unterrainer JM, 2003, COGNITIVE BRAIN RES, V17, P675, DOI 10.1016/S0926-6410(03)00191-5	34	5	5	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7263	10.1371/journal.pone.0007263	http://dx.doi.org/10.1371/journal.pone.0007263			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	500HR	19787066	Green Submitted, gold, Green Published			2022-12-27	WOS:000270290100027
J	Vercoulen, Y; Wehrens, EJ; van Teijlingen, NH; de Jager, W; Beekman, JM; Prakken, BJ				Vercoulen, Yvonne; Wehrens, Ellen J.; van Teijlingen, Nienke H.; de Jager, Wilco; Beekman, Jeffrey M.; Prakken, Berent J.			Human Regulatory T Cell Suppressive Function Is Independent of Apoptosis Induction in Activated Effector T Cells	PLOS ONE			English	Article							TGF-BETA; INTERLEUKIN (IL)-2; FOXP3 EXPRESSION; IL-2; EXPANSION; ARTHRITIS; ANTIBODY; MICE; TH17	Background: CD4(+)CD25(+)FOXP3(+) Regulatory T cells (Treg) play a central role in the immune balance to prevent autoimmune disease. One outstanding question is how Tregs suppress effector immune responses in human. Experiments in mice demonstrated that Treg restrict effector T cell (Teff) responses by deprivation of the growth factor IL-2 through Treg consumption, resulting in apoptosis of Teff. Principal Findings: In this study we investigated the relevance of Teff apoptosis induction to human Treg function. To this end, we studied naturally occurring Treg (nTreg) from peripheral blood of healthy donors, and, to investigate Treg function in inflammation in vivo, Treg from synovial fluid of Juvenile Idiopathic Arthritis (JIA) patients (SF-Treg). Both nTreg and SF-Treg suppress Teff proliferation and cytokine production efficiently as predicted. However, in contrast with murine Treg, neither nTreg nor SF-Treg induce apoptosis in Teff. Furthermore, exogenously supplied IL-2 and IL-7 reverse suppression, but do not influence apoptosis of Teff. Significance: Our functional data here support that Treg are excellent clinical targets to counteract autoimmune diseases. For optimal functional outcome in human clinical trials, future work should focus on the ability of Treg to suppress proliferation and cytokine production of Teff, rather than induction of Teff apoptosis.			Vercoulen, Y (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Mol & Cellular Intervent, Dept Pediat Immunol, Utrecht, Netherlands.	y.vercoulen@umcutrecht.nl	Beekman, Jeffrey M/I-7781-2014	Beekman, Jeffrey M/0000-0003-4886-3756; de Jager, Wilco/0000-0002-0014-0682; Vercoulen, Yvonne/0000-0002-5060-2603				Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Bardel E, 2008, J IMMUNOL, V181, P6898, DOI 10.4049/jimmunol.181.10.6898; Brandenburg S, 2008, EUR J IMMUNOL, V38, P1643, DOI 10.1002/eji.200737791; Chauhan SK, 2009, J IMMUNOL, V182, P1247, DOI 10.4049/jimmunol.182.3.1247; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; D'Cruz LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/ni1264; de Jager W, 2007, ANN RHEUM DIS, V66, P589, DOI 10.1136/ard.2006.061853; de Kleer IM, 2004, J IMMUNOL, V172, P6435, DOI 10.4049/jimmunol.172.10.6435; de la Rosa M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274; Earle KE, 2005, CLIN IMMUNOL, V115, P3, DOI 10.1016/j.clim.2005.02.017; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Hoffmann P, 2004, BLOOD, V104, P895, DOI 10.1182/blood-2004-01-0086; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Koenen HJPM, 2003, J IMMUNOL, V171, P6431, DOI 10.4049/jimmunol.171.12.6431; Le Bras S, 2006, J CLIN INVEST, V116, P1473, DOI 10.1172/JCI28880; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Maloy KJ, 2005, NAT IMMUNOL, V6, P1071, DOI 10.1038/ni1105-1071; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Oberle N, 2007, J IMMUNOL, V179, P3578, DOI 10.4049/jimmunol.179.6.3578; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Qiao M, 2007, IMMUNOLOGY, V120, P447, DOI 10.1111/j.1365-2567.2007.02544.x; RAGHAVAN S, 2008, ANN RHEUM DIS; Rodriguez-Palmero M, 2006, J RHEUMATOL, V33, P110; Roncarolo MG, 2008, EUR J IMMUNOL, V38, P925, DOI 10.1002/eji.200838168; Scheffold A, 2005, EUR J IMMUNOL, V35, P1336, DOI 10.1002/eji.200425887; Scheffold A, 2007, NAT IMMUNOL, V8, P1285, DOI 10.1038/ni1207-1285; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Stummvoll GH, 2008, J IMMUNOL, V181, P1908, DOI 10.4049/jimmunol.181.3.1908; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656; van Amelsfort JMR, 2007, ARTHRITIS RHEUM, V56, P732, DOI 10.1002/art.22414; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; You S, 2007, P NATL ACAD SCI USA, V104, P6335, DOI 10.1073/pnas.0701171104; Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	40	26	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7183	10.1371/journal.pone.0007183	http://dx.doi.org/10.1371/journal.pone.0007183			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779623	Green Submitted, Green Published, gold			2022-12-27	WOS:000270176200016
J	Lui, G; Manches, O; Angel, J; Molens, JP; Chaperot, L; Plumas, J				Lui, Gabrielle; Manches, Olivier; Angel, Juliette; Molens, Jean-Paul; Chaperot, Laurence; Plumas, Joel			Plasmacytoid Dendritic Cells Capture and Cross-Present Viral Antigens from Influenza-Virus Exposed Cells	PLOS ONE			English	Article								Among the different subsets of dendritic cells (DC), plasmacytoid dendritic cells (PDC) play a unique role in secreting large amounts of type I interferons upon viral stimulation, but their efficiency as antigen-presenting cells has not been completely characterized. We show here, by flow cytometry, with human primary blood PDC and with a PDC cell line, that PDC display poor endocytic capacity for soluble or cellular antigens when compared to monocyte-derived myeloid DC. However, immature PDC efficiently take up cellular material from live influenza-exposed cells, subsequently mature and cross-present viral antigens very efficiently to specific CD8+ T cells. Therefore, during viral infection PDC not only secrete immunomodulatory cytokines, but also recognize infected cells and function as antigen cross-presenting cells to trigger the anti-viral immune response.			Lui, G (corresponding author), Univ Grenoble 1, Grenoble, France.	laurence.chaperot@efs.sante.fr	MANCHES, OLIVIER/F-5448-2019; Plumas, Joel/N-2516-2013; chaperot, laurence/N-2927-2013	MANCHES, OLIVIER/0000-0003-4509-2941; chaperot, laurence/0000-0002-1479-9410				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Barron MA, 2003, J INFECT DIS, V187, P26, DOI 10.1086/345957; Bave U, 2003, J IMMUNOL, V171, P3296, DOI 10.4049/jimmunol.171.6.3296; Bendriss-Vermare N, 2005, J LEUKOCYTE BIOL, V78, P954, DOI 10.1189/jlb.0704383; Benitez-Ribas D, 2006, J EXP MED, V203, P1629, DOI 10.1084/jem.20052364; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Blom B, 2000, J EXP MED, V192, P1785, DOI 10.1084/jem.192.12.1785; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chaperot L, 2001, BLOOD, V97, P3210, DOI 10.1182/blood.V97.10.3210; Chaperot L, 2006, J IMMUNOL, V176, P248, DOI 10.4049/jimmunol.176.1.248; Chaperot L, 2004, EUR J IMMUNOL, V34, P418, DOI 10.1002/eji.200324531; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; DALGAARD J, 2005, J LEUKOC BIOL; Di Pucchio T, 2008, NAT IMMUNOL, V9, P551, DOI 10.1038/ni.1602; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; FONTENEAU JF, 2003, BLOOD, V2, P2; Frleta D, 2009, J IMMUNOL, V182, P2766, DOI 10.4049/jimmunol.0801720; Fuchs A, 2005, BLOOD, V106, P2076, DOI 10.1182/blood-2004-12-4802; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401; Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717; Harshyne LA, 2003, J IMMUNOL, V170, P2302, DOI 10.4049/jimmunol.170.5.2302; Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x; Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hoeffel G, 2007, IMMUNITY, V27, P481, DOI 10.1016/j.immuni.2007.07.021; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jacob MC, 2003, HAEMATOLOGICA, V88, P941; Jarrossay D, 2001, EUR J IMMUNOL, V31, P3388, DOI 10.1002/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO;2-Q; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kawamura K, 2006, BLOOD, V107, P1031, DOI 10.1182/blood-2005-04-1737; Kotelkin A, 2003, J VIROL, V77, P9156, DOI 10.1128/JVI.77.17.9156-9172.2003; Krug A, 2003, J EXP MED, V197, P899, DOI 10.1084/jem.20021091; LATZ E, 2004, NAT IMMUNOL; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lui G, 2004, CYTOTHERAPY, V6, P235, DOI 10.1080/14653240410006059; Manches O, 2008, CYTOTHERAPY, V10, P642, DOI 10.1080/14653240802317647; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Moutaftsi M, 2002, BLOOD, V99, P2913, DOI 10.1182/blood.V99.8.2913; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Phipps-Yonas H, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000193; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Robinson SP, 1999, EUR J IMMUNOL, V29, P2769, DOI 10.1002/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2; Salio M, 2004, J EXP MED, V199, P567, DOI 10.1084/jem.20031059; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Schlecht G, 2004, BLOOD, V104, P1808, DOI 10.1182/blood-2004-02-0426; Schnurr M, 2005, BLOOD, V105, P2465, DOI 10.1182/blood-2004-08-3105; Servet-Delprat C, 2000, J IMMUNOL, V164, P1753, DOI 10.4049/jimmunol.164.4.1753; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Villadangos JA, 2008, IMMUNITY, V29, P352, DOI 10.1016/j.immuni.2008.09.002	58	73	73	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7111	10.1371/journal.pone.0007111	http://dx.doi.org/10.1371/journal.pone.0007111			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771163	Green Published, Green Submitted, gold			2022-12-27	WOS:000270154400009
J	Remes, K; Ortega, F; Fierro, I; Joger, U; Kosma, R; Ferrer, JMM; Ide, OA; Maga, A				Remes, Kristian; Ortega, Francisco; Fierro, Ignacio; Joger, Ulrich; Kosma, Ralf; Marin Ferrer, Jose Manuel; Ide, Oumarou Amadou; Maga, Abdoulaye		Project PALDES; Niger Project SNHM	A New Basal Sauropod Dinosaur from the Middle Jurassic of Niger and the Early Evolution of Sauropoda	PLOS ONE			English	Article							SUUWASSEA-EMILIEAE SAUROPODA; MORRISON FORMATION; PHYLOGENETIC-RELATIONSHIPS; MONTANA; ANATOMY; USA; FLAGELLICAUDATA; CETIOSAURUS; SAURISCHIA; OSTEOLOGY	Background: The early evolution of sauropod dinosaurs is poorly understood because of a highly incomplete fossil record. New discoveries of Early and Middle Jurassic sauropods have a great potential to lead to a better understanding of early sauropod evolution and to reevaluate the patterns of sauropod diversification. Principal Findings: A new sauropod from the Middle Jurassic of Niger, Spinophorosaurus nigerensis n. gen. et sp., is the most complete basal sauropod currently known. The taxon shares many anatomical characters with Middle Jurassic East Asian sauropods, while it is strongly dissimilar to Lower and Middle Jurassic South American and Indian forms. A possible explanation for this pattern is a separation of Laurasian and South Gondwanan Middle Jurassic sauropod faunas by geographic barriers. Integration of phylogenetic analyses and paleogeographic data reveals congruence between early sauropod evolution and hypotheses about Jurassic paleoclimate and phytogeography. Conclusions: Spinophorosaurus demonstrates that many putatively derived characters of Middle Jurassic East Asian sauropods are plesiomorphic for eusauropods, while South Gondwanan eusauropods may represent a specialized line. The anatomy of Spinophorosaurus indicates that key innovations in Jurassic sauropod evolution might have taken place in North Africa, an area close to the equator with summer-wet climate at that time. Jurassic climatic zones and phytogeography possibly controlled early sauropod diversification.			Remes, K (corresponding author), Univ Bonn, Steinmann Inst Geol Mineral & Paleontol, D-5300 Bonn, Germany.	kristian.remes@uni-bonn.de	Tent-Manclus, Jose Enrique/I-1090-2015; Sanz, Jose Luis/O-1421-2019; Ortega, Francisco/K-3255-2015; Ortega, Francisco/B-5760-2009	Tent-Manclus, Jose Enrique/0000-0002-3393-741X; Ortega, Francisco/0000-0002-7431-354X; Ortega, Francisco/0000-0002-7431-354X; Chiappe, Luis/0000-0001-9661-0601; Sanz, Jose Luis/0000-0002-5214-5725; Maga, Abdoulaye/0000-0002-4684-217X				Allain R, 2008, GEODIVERSITAS, V30, P345; Barrett PM, 2005, SAUROPODS: EVOLUTION AND PALEOBIOLOGY, P125; Behrensmeyer A.K., 1992, TERRESTRIAL ECOSYSTE, P588; Berman D. S., 1978, B CARNEGIE MUS NAT H, V8, P1; BLAKEY RC, 2004, DETAILED GLOBAL PALE; BONAPARTE J F, 1986, Annales de Paleontologie, V72, P247; CABRERA A, 1947, PALEONTOLOGIA, V12, P1; Casanovas Maria Lourdes, 2001, Paleontologia i Evolucio, V32-33, P99; Chatterjee S, 2002, ZOOL J LINN SOC-LOND, V136, P145, DOI 10.1046/j.1096-3642.2002.00037.x; COOPER M R, 1984, Palaeontologia Africana, V25, P203; DONG ZM, 1984, VERTEBRAT PALASIATIC, V22, P69; Galton PM, 2006, GEOL MAG, V143, P905, DOI 10.1017/S0016756806002561; Gilmore C. W., 1936, Memoirs of the Carnegie Museum, V11, P175; HALLAM A, 1994, PALAEOCLIMATES THEIR, P79; Harris JD, 2006, J VERTEBR PALEONTOL, V26, P88, DOI 10.1671/0272-4634(2006)26[88:COOSES]2.0.CO;2; Harris JD, 2004, ACTA PALAEONTOL POL, V49, P197; Harris JD, 2007, GEOBIOS-LYON, V40, P501, DOI 10.1016/j.geobios.2006.02.002; Harris JD, 2006, PALAEONTOLOGY, V49, P1091, DOI 10.1111/j.1475-4983.2006.00577.x; Harris JD, 2006, J SYST PALAEONTOL, V4, P185, DOI 10.1017/S1477201906001805; Hatcher JB., 1903, MEM CARNEGIE MUS, V2, P1; Hatcher JB., 1901, MEM CARNEGIE MUS, V1, P1, DOI [10.5962/p.234818, DOI 10.5962/P.234818]; HE XL, 1988, MIDDLE JURASSIC DINO, V2, P143; Hennig E., 1924, PALAEONTOGRAPHICA S, V7; Jain S. L., 1996, J PAL SOC INDIA, V41, P1; Janensch W., 1935, PALAEONTOGRAPHICA S7, V7, P147; Janensch W., 1950, PALAEONTOGRAPHICA, V3, P27; Janensch WJ., 1961, PALAEONTOGRAPHICA S, P177; Larson A., 1994, P371; MADDISON DR, 2003, MACCLADE 4 06; Marsh OC., 1878, AM J SCI, V16, P411, DOI [DOI 10.2475/AJS.S3-16.95.411, 10.2475/ajs.s3-16.95.411]; Ouyang H, 1989, ZIGONG DINOSAUR MUSE, V2, P10; Ouyang H, 2002, 1 MAMENCHISAURIAN SK, P111; Owen R., 1842, REPORT BRIT ASS ADV, V9, P60; RAATH M A, 1972, Arnoldia (Rhodesia), V5, P1; Rauhut Oliver W.M., 2003, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V6, P173; Rauhut OWM, 2009, PALAEOGEOGR PALAEOCL, V271, P259, DOI 10.1016/j.palaeo.2008.10.019; Rauhut OWM, 2005, NATURE, V435, P670, DOI 10.1038/nature03623; Rauhut OWM, 2003, AMEGHINIANA, V40, P425; Rees PM, 2004, J GEOL, V112, P643, DOI 10.1086/424577; Rees PM, 2000, WARM CLIMATES EARTH, P297, DOI [DOI 10.1017/CB09780511564512.011, 10.1017/CBO9780511564512.011]; REMES K, 2008, EVOLUTION PECTORAL G, P355; Remes K, 2006, J VERTEBR PALEONTOL, V26, P651, DOI 10.1671/0272-4634(2006)26[651:ROTTSD]2.0.CO;2; Remes K, 2008, J VERTEBR PALEONTOL, V28, p131A; Rich Thomas H., 1999, National Science Museum Monographs, V15, P61; Russell Dale E., 1995, Historical Biology, V10, P3; Salgado Leonardo, 1992, Ameghiniana, V29, P337; Sander PM, 2008, SCIENCE, V322, P200, DOI 10.1126/science.1160904; Seeley H.G., 1887, P R SOC LONDON, V43, P165, DOI [10.1098/rspl.1887.0117, DOI 10.1098/RSPL.1887.0117]; Sellwood BW, 2008, P GEOLOGIST ASSOC, V119, P5, DOI 10.1016/S0016-7878(59)80068-7; Sereno PC, 1999, SCIENCE, V286, P1342, DOI 10.1126/science.286.5443.1342; Sereno PC, 2004, P ROY SOC B-BIOL SCI, V271, P1325, DOI 10.1098/rspb.2004.2692; SERENO PC, 1994, SCIENCE, V266, P267, DOI 10.1126/science.266.5183.267; SERENO PC, 1999, P 2 GONDW DIN S, P249; Swofford DL, 2002, PAUP PHYLOGENETIC AN; Taquet P., 1976, GEOLOGIE PALEONTOLOG, P191; TEMPLETON AR, 1983, EVOLUTION, V37, P221, DOI 10.1111/j.1558-5646.1983.tb05533.x; Upchurch P, 1999, J VERTEBR PALEONTOL, V19, P106, DOI 10.1080/02724634.1999.10011127; Upchurch P, 2003, J VERTEBR PALEONTOL, V23, P208, DOI 10.1671/0272-4634(2003)23[208:TAATOC]2.0.CO;2; Upchurch P, 2002, P ROY SOC B-BIOL SCI, V269, P613, DOI 10.1098/rspb.2001.1921; Upchurch P, 2002, PALAEONTOLOGY, V45, P1049, DOI 10.1111/1475-4983.00275; Upchurch P, 1998, ZOOL J LINN SOC-LOND, V124, P43, DOI 10.1111/j.1096-3642.1998.tb00569.x; UPCHURCH P, 1995, PHILOS T R SOC B, V349, P365, DOI 10.1098/rstb.1995.0125; Upchurch P, 2008, TRENDS ECOL EVOL, V23, P229, DOI 10.1016/j.tree.2007.11.006; Upchurch P, 2007, SPEC PAP PALAEONTOL, P57; Upchurch P, 2005, SAUROPODS: EVOLUTION AND PALEOBIOLOGY, P104; Upchurch P, 2008, J VERTEBR PALEONTOL, V28, p155A; Upchurch P, 2004, DINOSAURIA, 2ND EDITION, P259; Vickaryous MK, 2004, DINOSAURIA, 2ND EDITION, P363; VONHUENE F, 1926, ABHANDLUNGEN GEOLOGI, V15, P1; Wilson JA, 2002, ZOOL J LINN SOC-LOND, V136, P217; Yadagiri P., 1988, Records of the Geological Survey of India, V116, P102; Yadagiri P, 2001, J VERTEBR PALEONTOL, V21, P242, DOI 10.1671/0272-4634(2001)021[0242:TOOKYA]2.0.CO;2; Yates AM, 2007, SPEC PAP PALAEONTOL, P9; Zhang Y, 1988, MIDDLE JURASSIC DINO, V1, P89; Zheng Zhong, 1991, Vertebrata Palasiatica, V29, P108	75	80	83	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e6924	10.1371/journal.pone.0006924	http://dx.doi.org/10.1371/journal.pone.0006924			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756139	gold, Green Published			2022-12-27	WOS:000269970000001
J	Manganelli, M; Malfatti, F; Samo, TJ; Mitchell, BG; Wang, H; Azam, F				Manganelli, Maura; Malfatti, Francesca; Samo, Ty J.; Mitchell, B. Greg; Wang, Haili; Azam, Farooq			Major Role of Microbes in Carbon Fluxes during Austral Winter in the Southern Drake Passage	PLOS ONE			English	Article							GRADIENT GEL-ELECTROPHORESIS; BACTERIAL COMMUNITY COMPOSITION; NATURAL IRON FERTILIZATION; DISSOLVED ORGANIC-CARBON; PHYLOGENETIC COMPOSITION; GROWTH EFFICIENCY; BACTERIOPLANKTON BIOMASS; ARCHAEAL ASSEMBLAGES; PHYTOPLANKTON BLOOM; DEEP-SEA	Carbon cycling in Southern Ocean is a major issue in climate change, hence the need to understand the role of biota in the regulation of carbon fixation and cycling. Southern Ocean is a heterogeneous system, characterized by a strong seasonality, due to long dark winter. Yet, currently little is known about biogeochemical dynamics during this season, particularly in the deeper part of the ocean. We studied bacterial communities and processes in summer and winter cruises in the southern Drake Passage. Here we show that in winter, when the primary production is greatly reduced, Bacteria and Archaea become the major producers of biogenic particles, at the expense of dissolved organic carbon drawdown. Heterotrophic production and chemoautotrophic CO2 fixation rates were substantial, also in deep water, and bacterial populations were controlled by protists and viruses. A dynamic food web is also consistent with the observed temporal and spatial variations in archaeal and bacterial communities that might exploit various niches. Thus, Southern Ocean microbial loop may substantially maintain a wintertime food web and system respiration at the expense of summer produced DOC as well as regenerate nutrients and iron. Our findings have important implications for Southern Ocean ecosystem functioning and carbon cycle and its manipulation by iron enrichment to achieve net sequestration of atmospheric CO2.			Manganelli, M (corresponding author), ISPESL DIPIA, Monte Porzio Catone, RM, Italy.	maura.manganelli@ispesl.it; fmalfatt@ucsd.edu	Azam, Farooq/A-2306-2012; Manganelli, Maura/M-7103-2017	Manganelli, Maura/0000-0002-5650-8191; Samo, Ty/0000-0002-0548-4599; Mitchell, B. Greg/0000-0002-8550-4333				Abell GCJ, 2005, FEMS MICROBIOL ECOL, V51, P265, DOI 10.1016/j.femsec.2004.09.001; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AZAM F, 1991, POLAR RES, V10, P239, DOI 10.1111/j.1751-8369.1991.tb00649.x; Bano N, 2004, APPL ENVIRON MICROB, V70, P781, DOI 10.1128/AEM.70.2.781-789.2004; Bano N, 2002, APPL ENVIRON MICROB, V68, P505, DOI 10.1128/AEM.68.2.505-518.2002; Behrenfeld MJ, 1997, LIMNOL OCEANOGR, V42, P1, DOI 10.4319/lo.1997.42.1.0001; Bernhard AE, 2005, FEMS MICROBIOL ECOL, V52, P115, DOI 10.1016/j.femsec.2004.10.016; Bidle KD, 2003, LIMNOL OCEANOGR, V48, P1855, DOI 10.4319/lo.2003.48.5.1855; Bird DF, 1999, AQUAT MICROB ECOL, V19, P13, DOI 10.3354/ame019013; BJORNSEN PK, 1991, MAR ECOL PROG SER, V71, P185, DOI 10.3354/meps071185; Blain S, 2007, NATURE, V446, P1070, DOI 10.1038/nature05700; Bonilla-Findji O, 2008, DEEP-SEA RES PT II, V55, P790, DOI 10.1016/j.dsr2.2007.12.004; Bostrom KH, 2004, LIMNOL OCEANOGR-METH, V2, P365, DOI 10.4319/lom.2004.2.365; Boyd PW, 2007, SCIENCE, V315, P612, DOI 10.1126/science.1131669; BUESSELER KO, 2008, MAR ECOL PROGR SER, V43, P1; Carlson CA, 1999, AQUAT MICROB ECOL, V19, P229, DOI 10.3354/ame019229; CARLSON CA, 1994, NATURE, V371, P405, DOI 10.1038/371405a0; CHO BC, 1990, MAR ECOL PROG SER, V63, P253, DOI 10.3354/meps063253; Christaki U, 2008, DEEP-SEA RES PT II, V55, P706, DOI 10.1016/j.dsr2.2007.12.009; Church MJ, 2003, LIMNOL OCEANOGR, V48, P1893, DOI 10.4319/lo.2003.48.5.1893; COTA GF, 1990, DEEP-SEA RES, V37, P1145, DOI 10.1016/0198-0149(90)90056-2; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Doval MD, 2002, DEEP-SEA RES PT II, V49, P663, DOI 10.1016/S0967-0645(01)00117-5; Doval MD, 2001, MAR ECOL PROG SER, V223, P27, DOI 10.3354/meps223027; Duarte CM, 2005, LIMNOL OCEANOGR, V50, P1844, DOI 10.4319/lo.2005.50.6.1844; Ducklow HW, 1999, FEMS MICROBIOL ECOL, V30, P1, DOI 10.1111/j.1574-6941.1999.tb00630.x; Fandino LB, 2001, AQUAT MICROB ECOL, V23, P119, DOI 10.3354/ame023119; FERNANDEZ E, 1993, PCR METH APPL, V3, P122; Fuhrman JA, 1997, MAR ECOL PROG SER, V150, P275, DOI 10.3354/meps150275; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; Galand PE, 2006, AQUAT MICROB ECOL, V44, P115, DOI 10.3354/ame044115; Galand PE, 2009, ENVIRON MICROBIOL, V11, P971, DOI 10.1111/j.1462-2920.2008.01822.x; Grzymski JJ, 2006, APPL ENVIRON MICROB, V72, P1532, DOI 10.1128/AEM.72.2.1532-1541.2006; HANSON RB, 1983, APPL ENVIRON MICROB, V45, P1622, DOI 10.1128/AEM.45.5.1622-1632.1983; Herndl GJ, 2005, APPL ENVIRON MICROB, V71, P2303, DOI 10.1128/AEM.71.5.2303-2309.2005; Hopkinson BM, 2007, LIMNOL OCEANOGR, V52, P2540, DOI 10.4319/lo.2007.52.6.2540; HORRIGAN SG, 1981, LIMNOL OCEANOGR, V26, P378, DOI 10.4319/lo.1981.26.2.0378; Huber JA, 2006, ENVIRON MICROBIOL, V8, P88, DOI 10.1111/j.1462-2920.2005.00872.x; Huber JA, 2003, FEMS MICROBIOL ECOL, V43, P393, DOI 10.1111/j.1574-6941.2003.tb01080.x; KOTTMEIER ST, 1987, MAR ECOL PROG SER, V36, P287, DOI 10.3354/meps036287; LEE S, 1987, APPL ENVIRON MICROB, V53, P1298, DOI 10.1128/AEM.53.6.1298-1303.1987; Lochte K, 1997, DEEP-SEA RES PT II, V44, P321, DOI 10.1016/S0967-0645(96)00081-1; Lopez-Garcia P, 2001, ENVIRON MICROBIOL, V3, P72, DOI 10.1046/j.1462-2920.2001.00162.x; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; Malmstrom RR, 2007, AQUAT MICROB ECOL, V47, P45, DOI 10.3354/ame047045; Massana R, 2001, LIMNOL OCEANOGR, V46, P1181, DOI 10.4319/lo.2001.46.5.1181; Mehta MP, 2005, ENVIRON MICROBIOL, V7, P1525, DOI 10.1111/j.1462-2920.2005.00836.x; Moran XAG, 2001, MAR ECOL PROG SER, V222, P25, DOI 10.3354/meps222025; MORDY CW, 1995, MAR ECOL PROG SER, V122, P9, DOI 10.3354/meps122009; Moreira D, 2006, MICROBIOL-SGM, V152, P505, DOI 10.1099/mic.0.28254-0; Moriarty DJW, 1997, DEEP-SEA RES PT II, V44, P1005, DOI 10.1016/S0967-0645(96)00110-5; Murray AE, 1998, APPL ENVIRON MICROB, V64, P2585; Murray AE, 2007, PHILOS T R SOC B, V362, P2259, DOI 10.1098/rstb.2006.1944; MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993; Obernosterer I, 2008, DEEP-SEA RES PT II, V55, P777, DOI 10.1016/j.dsr2.2007.12.005; Patel A, 2007, NAT PROTOC, V2, P269, DOI 10.1038/nprot.2007.6; Pomeroy LR, 2001, AQUAT MICROB ECOL, V23, P187, DOI 10.3354/ame023187; Pommier T, 2007, MOL ECOL, V16, P867, DOI 10.1111/j.1365-294X.2006.03189.x; Prabagaran SR, 2007, FEMS MICROBIOL ECOL, V59, P342, DOI 10.1111/j.1574-6941.2006.00213.x; Rappe MS, 1997, LIMNOL OCEANOGR, V42, P811, DOI 10.4319/lo.1997.42.5.0811; Riemann L, 2000, APPL ENVIRON MICROB, V66, P578, DOI 10.1128/AEM.66.2.578-587.2000; Riemann L, 1999, DEEP-SEA RES PT II, V46, P1791, DOI 10.1016/S0967-0645(99)00044-2; Rivkin RB, 2001, SCIENCE, V291, P2398, DOI 10.1126/science.291.5512.2398; Shaw AK, 2008, ENVIRON MICROBIOL, V10, P2200, DOI 10.1111/j.1462-2920.2008.01626.x; Sherr BF, 2003, DEEP-SEA RES PT I, V50, P529, DOI 10.1016/S0967-0637(03)00030-X; SIMON M, 1989, MAR ECOL PROG SER, V51, P201, DOI 10.3354/meps051201; Smith David C., 1992, Marine Microbial Food Webs, V6, P107; Smith DC, 1992, ANTARCT J US, V27, P125; Smith MC, 2000, ANTARCT SCI, V12, P177, DOI 10.1017/S0954102000000237; Smith P, 2007, AR4 CLIMATE CHANGE 2007: MITIGATION OF CLIMATE CHANGE, P497; Van Heukelem L, 2001, J CHROMATOGR A, V910, P31, DOI 10.1016/S0378-4347(00)00603-4; Vaque D, 2002, DEEP-SEA RES PT II, V49, P847, DOI 10.1016/S0967-0645(01)00127-8; Vaque D, 2008, LIMNOL OCEANOGR, V53, P2427, DOI 10.4319/lo.2008.53.6.2427; Weinbauer MG, 2007, ENVIRON MICROBIOL, V9, P777, DOI 10.1111/j.1462-2920.2006.01200.x; West NJ, 2008, ENVIRON MICROBIOL, V10, P738, DOI 10.1111/j.1462-2920.2007.01497.x; Wiebinga CJ, 1998, MAR CHEM, V61, P185, DOI 10.1016/S0304-4203(98)00014-0	78	49	50	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6941	10.1371/journal.pone.0006941	http://dx.doi.org/10.1371/journal.pone.0006941			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759822	Green Submitted, Green Published			2022-12-27	WOS:000269796300001
J	Hirao, A; Tahara, Y; Kimura, I; Shibata, S				Hirao, Akiko; Tahara, Yu; Kimura, Ichiro; Shibata, Shigenobu			A Balanced Diet Is Necessary for Proper Entrainment Signals of the Mouse Liver Clock	PLOS ONE			English	Article							CIRCADIAN-RHYTHMS; GENE-EXPRESSION; GLYCEMIC INDEX; MESSENGER-RNA; PHASE; FOOD; PACEMAKER; GLUCOSE; TISSUES; PER1	Background: The peripheral circadian clock in mice is entrained not only by light-dark cycles but also by daily restricted feeding schedules. Behavioral and cell culture experiments suggest an increase in glucose level as a factor in such feeding-induced entrainment. For application of feeding-induced entrainment in humans, nutrient content and dietary variations should be considered. Principal Finding: To elucidate the food composition necessary for dietary entrainment, we examined whether complete or partial substitution of dietary nutrients affected phase shifts in liver clocks of mice. Compared with fasting mice or ad libitum fed mice, the liver bioluminescence rhythm advanced by 3-4 h on the middle day in Per2::luciferase knock-in mice that were administered a standard mouse diet, i.e. AIN-93M formula [0.6-0.85 g/10 g mouse BW] (composition: 14% casein, 47% cornstarch, 15% gelatinized cornstarch, 10% sugar, 4% soybean oil, and 10% other [fiber, vitamins, minerals, etc.]), for 2 days. When each nutrient was tested alone (100% nutrient), an insignificant weak phase advance was found to be induced by cornstarch and soybean oil, but almost no phase advance was induced by gelatinized cornstarch, high-amylose cornstarch, glucose, sucrose, or casein. A combination of glucose and casein without oil, vitamin, or fiber caused a significant phase advance. When cornstarch in AIN-93M was substituted with glucose, sucrose, fructose, polydextrose, high-amylose cornstarch, or gelatinized cornstarch, the amplitude of phase advance paralleled the increase in blood glucose concentration. Conclusions: Our results strongly suggest the following: (1) balanced diets containing carbohydrates/sugars and proteins are good for restricted feeding-induced entrainment of the peripheral circadian clock and (2) a balanced diet that increases blood glucose, but not by sugar alone, is suitable for entrainment. These findings may assist in the development of dietary recommendations for on-board meals served to air travelers and shift workers to reduce jet lag-like symptoms.			Shibata, S (corresponding author), Waseda Univ, Sch Adv Sci & Engn, Lab Physiol & Pharmacol, Shinjuku Ku, Tokyo, Japan.	shibatas@waseda.jp	Tahara, Yu/Q-4324-2018	Tahara, Yu/0000-0002-3015-8883				Abe M, 2002, J NEUROSCI, V22, P350, DOI 10.1523/JNEUROSCI.22-01-00350.2002; Arora S, 2006, NEUROPEPTIDES, V40, P375, DOI 10.1016/j.npep.2006.07.001; Bechtold D, 2008, J GENET, V87, P447, DOI 10.1007/s12041-008-0067-6; BOULOS Z, 1980, NEUROSCI BIOBEHAV R, V4, P119, DOI 10.1016/0149-7634(80)90010-X; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davidson AJ, 2003, GENES BRAIN BEHAV, V2, P32, DOI 10.1034/j.1601-183X.2003.00005.x; DOCKRAY GJ, 2009, REGUL PEPT IN PRESS; ENGLYST HN, 1987, AM J CLIN NUTR, V46, P873, DOI 10.1093/ajcn/46.6.873; Feillet CA, 2006, CURR BIOL, V16, P2016, DOI 10.1016/j.cub.2006.08.053; Frost G, 2000, DIABETIC MED, V17, P336, DOI 10.1046/j.1464-5491.2000.00266.x; GREEN GM, 1989, AM J PHYSIOL, V256, pG1016, DOI 10.1152/ajpgi.1989.256.6.G1016; Hara R, 2001, GENES CELLS, V6, P269, DOI 10.1046/j.1365-2443.2001.00419.x; Hayasaka N, 2007, ENDOCRINOLOGY, V148, P3316, DOI 10.1210/en.2007-0010; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; KATO H, 1984, LIFE SCI, V34, P331, DOI 10.1016/0024-3205(84)90620-9; Kawamoto T, 2006, J BIOCHEM, V140, P401, DOI 10.1093/jb/mvj165; KING DP, 2000, ANN REV NEU IN PRESS, V3, P713; Kobayashi H, 2004, GENES CELLS, V9, P857, DOI 10.1111/j.1365-2443.2004.00769.x; KRIEGER DT, 1972, SCIENCE, V178, P1205, DOI 10.1126/science.178.4066.1205; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; LIU X, 2009, J NUTR BIOCH; Lundberg K, 2007, NEUROPEPTIDES, V41, P59, DOI 10.1016/j.npep.2006.09.049; Meerlo P, 1997, J BIOL RHYTHM, V12, P80, DOI 10.1177/074873049701200109; MILLER JB, 1992, AM J CLIN NUTR, V56, P1034, DOI 10.1093/ajcn/56.6.1034; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; MORIYA T, 2009, EUR J NEURO IN PRESS; Ohta H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002601; SAITO M, 1981, EXPERIENTIA, V37, P754, DOI 10.1007/BF01967962; Shimazoe T, 2008, FASEB J, V22, P1479, DOI 10.1096/fj.07-9372com; Stephan FK, 2002, J BIOL RHYTHM, V17, P284, DOI 10.1177/074873002129002591; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; Stephan FK, 1998, PHYSIOL BEHAV, V65, P277, DOI 10.1016/S0031-9384(98)00166-8; Stephan FK, 1997, PHYSIOL BEHAV, V62, P995, DOI 10.1016/S0031-9384(97)00204-7; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Wakamatsu H, 2001, EUR J NEUROSCI, V13, P1190, DOI 10.1046/j.0953-816x.2001.01483.x; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Yoshikawa T, 2005, J BIOL RHYTHM, V20, P500, DOI 10.1177/0748730405280775; Young ME, 2002, J MOL CELL CARDIOL, V34, P223, DOI 10.1006/jmcc.2001.1504	39	61	63	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6909	10.1371/journal.pone.0006909	http://dx.doi.org/10.1371/journal.pone.0006909			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738906	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622300006
J	Song, C; Yao, HS				Song, Chen; Yao, Haishan			Duality in Binocular Rivalry: Distinct Sensitivity of Percept Sequence and Percept Duration to Imbalance between Monocular Stimuli	PLOS ONE			English	Article							CONTINUOUS FLASH SUPPRESSION; VISUAL AWARENESS; FUSION; CONSCIOUSNESS; COMPETITION; DOMINANCE; VISION; MODEL	Background: Visual perception is usually stable and accurate. However, when the two eyes are simultaneously presented with conflicting stimuli, perception falls into a sequence of spontaneous alternations, switching between one stimulus and the other every few seconds. Known as binocular rivalry, this visual illusion decouples subjective experience from physical stimulation and provides a unique opportunity to study the neural correlates of consciousness. The temporal properties of this alternating perception have been intensively investigated for decades, yet the relationship between two fundamental properties-the sequence of percepts and the duration of each percept-remains largely unexplored. Methodology/Principal Findings: Here we examine the relationship between the percept sequence and the percept duration by quantifying their sensitivity to the strength imbalance between two monocular stimuli. We found that the percept sequence is far more susceptible to the stimulus imbalance than does the percept duration. The percept sequence always begins with the stronger stimulus, even when the stimulus imbalance is too weak to cause a significant bias in the percept duration. Therefore, introducing a small stimulus imbalance affects the percept sequence, whereas increasing the imbalance affects the percept duration, but not vice versa. To investigate why the percept sequence is so vulnerable to the stimulus imbalance, we further measured the interval between the stimulus onset and the first percept, during which subjects experienced the fusion of two monocular stimuli. We found that this interval is dramatically shortened with increased stimulus imbalance. Conclusions/Significance: Our study shows that in binocular rivalry, the strength imblanace between monocular stimuli has a much greater impact on the percept sequence than on the percept duration, and increasing this imbalance can accelerate the process responsible for the percept sequence.			Song, C (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, State Key Lab Neurosci, Shanghai, Peoples R China.	chen.song@ieee.org	Song, Chen/B-3269-2008; Song, Chen/ABC-2033-2021	Song, Chen/0000-0002-5418-5747; Yao, Haishan/0000-0003-4974-9197				Andrews TJ, 2004, CURR BIOL, V14, P418, DOI 10.1016/j.cub.2004.02.030; Arnold DH, 2008, VISION RES, V48, P994, DOI 10.1016/j.visres.2008.01.020; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKE R, 1990, PERCEPT PSYCHOPHYS, V48, P593, DOI 10.3758/BF03211605; Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701; BLAKE R, 1991, INVEST OPHTH VIS SCI, V32, P2821; Blake R, 2003, NEURON, V39, P869, DOI 10.1016/S0896-6273(03)00495-1; BLAKE R, 1985, PERCEPT PSYCHOPHYS, V37, P114, DOI 10.3758/BF03202845; Blake R., 2001, BRAIN MIND, V2, P5, DOI [https://doi.org/10.1023/A:1017925416289, DOI 10.1023/A:1017925416289, 10.1023/A:1017925416289]; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Carter O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000343; Chen XC, 2004, CURR BIOL, V14, P1013, DOI 10.1016/j.cub.2004.05.042; Chong SC, 2006, VISION RES, V46, P1794, DOI 10.1016/j.visres.2005.10.031; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Ehrenstein WH, 2005, GRAEF ARCH CLIN EXP, V243, P926, DOI 10.1007/s00417-005-1128-7; Freeman AW, 2005, J NEUROPHYSIOL, V94, P4412, DOI 10.1152/jn.00557.2005; Hohwy J, 2008, COGNITION, V108, P687, DOI 10.1016/j.cognition.2008.05.010; Kim CY, 2005, TRENDS COGN SCI, V9, P381, DOI 10.1016/j.tics.2005.06.012; LEAT SJ, 1984, PERCEPTION, V13, P351, DOI 10.1068/p130351; Leopold DA, 2002, NAT NEUROSCI, V5, P605, DOI 10.1038/nn0602-851; LEVELT WJM, 1966, BRIT J PSYCHOL, V57, P225, DOI 10.1111/j.2044-8295.1966.tb01023.x; LIU L, 1992, VISION RES, V32, P1471, DOI 10.1016/0042-6989(92)90203-U; Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0; Maloney LT, 2005, P NATL ACAD SCI USA, V102, P3164, DOI 10.1073/pnas.0407157102; MUELLER TJ, 1990, VISUAL NEUROSCI, V4, P63, DOI 10.1017/S0952523800002777; Ning QA, 1997, NEURON, V18, P359, DOI 10.1016/S0896-6273(00)81238-6; Noest AJ, 2007, J VISION, V7, DOI 10.1167/7.8.10; Pearson J, 2004, J VISION, V4, P196, DOI 10.1167/4.3.6; Pearson J, 2008, TRENDS COGN SCI, V12, P334, DOI 10.1016/j.tics.2008.05.006; Rees G, 2002, NAT REV NEUROSCI, V3, P261, DOI 10.1038/nrn783; Tong F, 2003, NAT REV NEUROSCI, V4, P219, DOI 10.1038/nrn1055; Tong F, 2006, TRENDS COGN SCI, V10, P502, DOI 10.1016/j.tics.2006.09.003; Tononi G, 2008, ANN NY ACAD SCI, V1124, P239, DOI 10.1196/annals.1440.004; Tsuchiya N, 2005, NAT NEUROSCI, V8, P1096, DOI 10.1038/nn1500; Tsuchiya N, 2006, J VISION, V6, P1068, DOI 10.1167/6.10.6; Wheatstone C., 1838, PHILOS T ROY SOC LON, P371, DOI DOI 10.1098/RSTL.1838.0019; Wilson HR, 2003, P NATL ACAD SCI USA, V100, P14499, DOI 10.1073/pnas.2333622100; WOLFE JM, 1983, PERCEPTION, V12, P447, DOI 10.1068/p120447	38	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6912	10.1371/journal.pone.0006912	http://dx.doi.org/10.1371/journal.pone.0006912			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	491ZH	19738903	Green Published, Green Submitted, Green Accepted, gold			2022-12-27	WOS:000269622300008
J	Ruderfer, DM; Roberts, DC; Schreiber, SL; Perlstein, EO; Kruglyak, L				Ruderfer, Douglas M.; Roberts, David C.; Schreiber, Stuart L.; Perlstein, Ethan O.; Kruglyak, Leonid			Using Expression and Genotype to Predict Drug Response in Yeast	PLOS ONE			English	Article							ANTICANCER DRUGS; PROTEIN EXPRESSION; CANCER; PHARMACOGENOMICS; CHEMOSENSITIVITY; SENSITIVITY; RESISTANCE; PROFILES; TRAITS	Personalized, or genomic, medicine entails tailoring pharmacological therapies according to individual genetic variation at genomic loci encoding proteins in drug-response pathways. It has been previously shown that steady-state mRNA expression can be used to predict the drug response (i.e., sensitivity or resistance) of non-genotyped mammalian cancer cell lines to chemotherapeutic agents. In a real-world setting, clinicians would have access to both steady-state expression levels of patient tissue(s) and a patient's genotypic profile, and yet the predictive power of transcripts versus markers is not well understood. We have previously shown that a collection of genotyped and expression-profiled yeast strains can provide a model for personalized medicine. Here we compare the predictive power of 6,229 steady-state mRNA transcript levels and 2,894 genotyped markers using a pattern recognition algorithm. We were able to predict with over 70% accuracy the drug sensitivity of 104 individual genotyped yeast strains derived from a cross between a laboratory strain and a wild isolate. We observe that, independently of drug mechanism of action, both transcripts and markers can accurately predict drug response. Marker-based prediction is usually more accurate than transcript-based prediction, likely reflecting the genetic determination of gene expression in this cross.			Ruderfer, DM (corresponding author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.	eperlste@princeton.edu; leonid@genomics.princeton.edu	Ruderfer, Douglas M/M-5795-2016	Ruderfer, Douglas M/0000-0002-2365-386X; Perlstein, Ethan/0000-0002-4734-4391	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [P50 GM071508, 50GM071508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baudhuin LM, 2007, CLIN PHARMACOL THER, V82, P373, DOI 10.1038/sj.clpt.6100350; BENZ R, 1983, BIOPHYS J, V41, P381, DOI 10.1016/S0006-3495(83)84449-X; Brem RB, 2005, P NATL ACAD SCI USA, V102, P1572, DOI 10.1073/pnas.0408709102; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Chinn LW, 2007, CLIN PHARMACOL THER, V81, P265, DOI 10.1038/sj.clpt.6100052; Christians Uwe, 2005, Expert Opin Drug Metab Toxicol, V1, P641, DOI 10.1517/17425255.1.4.641; Court MH, 2007, J CLIN PHARMACOL, V47, P1087, DOI 10.1177/0091270007303768; Dan S, 2002, CANCER RES, V62, P1139; Fujita K, 2007, CURR DRUG METAB, V8, P554; Grant SFA, 2007, EXPERT REV MOL DIAGN, V7, P371, DOI 10.1586/14737159.7.4.371; Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797; HARFORD CM, 2007, PHARMACOGENOMICS, V8, P1159; Hastie T, 1998, CLASSIFICATION PAIRW; Huang RS, 2007, P NATL ACAD SCI USA, V104, P9758, DOI 10.1073/pnas.0703736104; Huang Y, 2007, CANCER METAST REV, V26, P183, DOI 10.1007/s10555-007-9050-6; Ifergan I, 2003, CANCER-AM CANCER SOC, V98, P1958, DOI 10.1002/cncr.11741; Kang HC, 2007, CANCER LETT, V247, P40, DOI 10.1016/j.canlet.2006.03.017; Keerthi SS, 2001, NEURAL COMPUT, V13, P637, DOI 10.1162/089976601300014493; Kim HS, 2007, P NATL ACAD SCI USA, V104, P19387, DOI 10.1073/pnas.0708194104; Lo HW, 2007, CURR OPIN PHARMACOL, V7, P367, DOI 10.1016/j.coph.2007.06.009; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lynch T, 2007, AM FAM PHYSICIAN, V76, P391; Ma Y, 2006, CLIN CANCER RES, V12, P4583, DOI 10.1158/1078-0432.CCR-06-0290; Marrer E, 2007, CHEM BIOL DRUG DES, V69, P381, DOI 10.1111/j.1747-0285.2007.00522.x; O'Shaughnessy KM, 2006, BRIT J CLIN PHARMACO, V61, P783, DOI 10.1111/j.1365-2125.2006.02683.x; Ooyama A, 2007, CANCER SCI, V98, P577, DOI 10.1111/j.1349-7006.2007.00424.x; Perlstein EO, 2006, CHEM BIOL, V13, P319, DOI 10.1016/j.chembiol.2006.01.010; Perlstein EO, 2007, NAT GENET, V39, P496, DOI 10.1038/ng1991; Platt  J., 1998, FAST TRAINING SUPPOR; Quintieri L, 2007, ADV EXP MED BIOL, V593, P95; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Swen JJ, 2007, PLOS MED, V4, P1317, DOI 10.1371/journal.pmed.0040209; Weber WA, 2005, J NUCL MED, V46, P983; Witten I. H., 2005, DATA MINING PRACTICA	35	14	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6907	10.1371/journal.pone.0006907	http://dx.doi.org/10.1371/journal.pone.0006907			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730698	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100012
J	Sainz, N; Rodriguez, A; Catalan, V; Becerril, S; Ramirez, B; Gomez-Ambrosi, J; Fruhbeck, G				Sainz, Neira; Rodriguez, Amaia; Catalan, Victoria; Becerril, Sara; Ramirez, Beatriz; Gomez-Ambrosi, Javier; Fruhbeck, Gema			Leptin Administration Favors Muscle Mass Accretion by Decreasing FoxO3a and Increasing PGC-1 alpha in ob/ob Mice	PLOS ONE			English	Article							GENETICALLY-OBESE MICE; FATTY-ACID OXIDATION; SKELETAL-MUSCLE; UBIQUITIN LIGASES; ADIPOSE-TISSUE; MITOCHONDRIAL BIOGENESIS; TRANSCRIPTION FACTORS; PROTEIN-DEGRADATION; CALORIC RESTRICTION; CELL-PROLIFERATION	Absence of leptin has been associated with reduced skeletal muscle mass in leptin-deficient ob/ob mice. The aim of our study was to examine the effect of leptin on the catabolic and anabolic pathways regulating muscle mass. Gastrocnemius, extensor digitorum longus and soleus muscle mass as well as fiber size were significantly lower in ob/ob mice compared to wild type littermates, being significantly increased by leptin administration (P<0.001). This effect was associated with an inactivation of the muscle atrophy-related transcription factor forkhead box class O3 (FoxO3a) (P<0.05), and with a decrease in the protein expression levels of the E3 ubiquitin-ligases muscle atrophy F-box (MAFbx) (P<0.05) and muscle RING finger 1 (MuRF1) (P<0.05). Moreover, leptin increased (P<0.01) protein expression levels of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), a regulator of muscle fiber type, and decreased (P<0.05) myostatin protein, a negative regulator of muscle growth. Leptin administration also activated (P<0.01) the regulators of cell cycle progression proliferating cell nuclear antigen (PCNA) and cyclin D1, and increased (P<0.01) myofibrillar protein troponin T. The present study provides evidence that leptin treatment may increase muscle mass of ob/ob mice by inhibiting myofibrillar protein degradation as well as enhancing muscle cell proliferation.			Sainz, N (corresponding author), Univ Navarra, Metab Res Lab, E-31080 Pamplona, Spain.	gfruhbeck@unav.es	Catalan, Victoria/H-3566-2017; Gómez-Ambrosi, Javier/D-2984-2017; Ramírez, Beatriz/I-1922-2017; Sáinz, Neira/AAA-4624-2019; Rodriguez, Amaia/D-3044-2019	Catalan, Victoria/0000-0002-7513-7509; Gómez-Ambrosi, Javier/0000-0001-5601-1604; Ramírez, Beatriz/0000-0003-3381-7220; Sainz, Neira/0000-0003-0298-3031; Becerril, Sara/0000-0002-3441-1970; Rodriguez, Amaia/0000-0002-2180-461X				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adams GR, 2006, APPL PHYSIOL NUTR ME, V31, P782, DOI 10.1139/h06-053; Allen DL, 2008, AM J PHYSIOL-ENDOC M, V294, pE918, DOI 10.1152/ajpendo.00798.2007; Allen DL, 2007, AM J PHYSIOL-CELL PH, V292, pC188, DOI 10.1152/ajpcell.00542.2005; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amirouche A, 2009, ENDOCRINOLOGY, V150, P286, DOI 10.1210/en.2008-0959; Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018; Barazzoni R, 2005, ENDOCRINOLOGY, V146, P2098, DOI 10.1210/en.2004-1396; BERGEN WG, 1975, AM J CLIN NUTR, V28, P157, DOI 10.1093/ajcn/28.2.157; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; Borriello A, 2007, CELL CYCLE, V6, P1053, DOI 10.4161/cc.6.9.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruusgaard JC, 2003, J PHYSIOL-LONDON, V551, P467, DOI 10.1113/jphysiol.2003.045328; Carbo N, 2000, J NUTR BIOCHEM, V11, P431, DOI 10.1016/S0955-2863(00)00101-7; Catalan V, 2007, HORM METAB RES, V39, P495, DOI 10.1055/s-2007-982502; Ceddia RB, 2001, FRONT BIOSCI-LANDMRK, V6, pD90, DOI 10.2741/ceddia; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Della-Fera MA, 2005, OBES RES, V13, P1540, DOI 10.1038/oby.2005.189; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dube JJ, 2007, AM J PHYSIOL-REG I, V293, pR642, DOI 10.1152/ajpregu.00133.2007; Durieux AC, 2007, ENDOCRINOLOGY, V148, P3140, DOI 10.1210/en.2006-1500; Eley HL, 2007, J BIOL CHEM, V282, P7087, DOI 10.1074/jbc.M610378200; Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103; Fruhbeck G, 1998, NATURE, V391, P843, DOI 10.1038/35993; Fruhbeck G, 2001, P NUTR SOC, V60, P301, DOI 10.1079/PNS200196; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Guerra B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003466; Harris RBS, 1999, ENDOCRINOLOGY, V140, P138, DOI 10.1210/en.140.1.138; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hittel DS, 2009, DIABETES, V58, P30, DOI 10.2337/db08-0943; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Ji M, 2008, CELL SIGNAL, V20, P1452, DOI 10.1016/j.cellsig.2008.03.013; JOHNSON SE, 1993, J CELL PHYSIOL, V154, P39, DOI 10.1002/jcp.1041540106; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Koncarevic A, 2007, FASEB J, V21, P427, DOI 10.1096/fj.06-6665com; Krawiec BJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE1555, DOI 10.1152/ajpendo.00622.2006; Lambert AJ, 2004, EXP GERONTOL, V39, P289, DOI 10.1016/j.exger.2003.12.009; Lang T, 2004, BIOCHEM BIOPH RES CO, V323, P1091, DOI 10.1016/j.bbrc.2004.08.192; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lee WJ, 2006, BIOCHEM BIOPH RES CO, V340, P291, DOI 10.1016/j.bbrc.2005.12.011; Li MY, 2008, J CELL PHYSIOL, V217, P377, DOI 10.1002/jcp.21507; Liu CM, 2007, CANCER GENE THER, V14, P945, DOI 10.1038/sj.cgt.7701091; Madiehe AM, 2002, ENDOCRINOLOGY, V143, P3875, DOI 10.1210/en.2002-220362; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Margetic S, 2002, INT J OBESITY, V26, P1407, DOI 10.1038/sj.ijo.0802142; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Moylan JS, 2008, AM J PHYSIOL-CELL PH, V295, pC986, DOI 10.1152/ajpcell.00041.2008; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; Nakashima K, 2007, BIOSCI BIOTECH BIOCH, V71, P1650, DOI 10.1271/bbb.70057; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; O'Connor RS, 2007, J APPL PHYSIOL, V103, P1099, DOI 10.1152/japplphysiol.00101.2007; Oda Akihiko, 2001, Kobe Journal of Medical Sciences, V47, P141; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Ramsay TG, 2003, J ANIM SCI, V81, P3046; Rathbone CR, 2008, MUSCLE NERVE, V37, P84, DOI 10.1002/mus.20897; Reilly ME, 2000, J MUSCLE RES CELL M, V21, P763, DOI 10.1023/A:1010336624154; Reisz-Porszasz S, 2003, AM J PHYSIOL-ENDOC M, V285, pE876, DOI 10.1152/ajpendo.00107.2003; Rodriguez A, 2007, ENDOCRINOLOGY, V148, P324, DOI 10.1210/en.2006-0940; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Sahu A, 2004, ENDOCRINOLOGY, V145, P2613, DOI 10.1210/en.2004-0032; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Southgate RJ, 2007, J BIOL CHEM, V282, P21176, DOI 10.1074/jbc.M702039200; Sriwijitkamol A, 2006, AM J PHYSIOL-ENDOC M, V290, pE925, DOI 10.1152/ajpendo.00429.2005; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tajmir P, 2004, ENDOCRINOLOGY, V145, P1550, DOI 10.1210/en.2003-1128; Tajmir P, 2003, J CELL PHYSIOL, V197, P122, DOI 10.1002/jcp.10351; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; TROSTLER N, 1982, INT J OBESITY, V6, P557; TROSTLER N, 1979, METABOLISM, V28, P928, DOI 10.1016/0026-0495(79)90093-3; Waddell DS, 2008, AM J PHYSIOL-ENDOC M, V295, pE785, DOI 10.1152/ajpendo.00646.2007; Warmington SA, 2000, INT J OBESITY, V24, P1040, DOI 10.1038/sj.ijo.0801357; WIELAND O, 1957, BIOCHEM Z, V329, P313; Wu AL, 2008, ENDOCRINOLOGY, V149, P1407, DOI 10.1210/en.2007-1470; Yang W, 2007, J BIOL CHEM, V282, P3799, DOI 10.1074/jbc.M610185200; Yu TY, 2008, BIOSCI BIOTECH BIOCH, V72, P13, DOI 10.1271/bbb.70244; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	92	107	110	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6808	10.1371/journal.pone.0006808	http://dx.doi.org/10.1371/journal.pone.0006808			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730740	Green Published, gold			2022-12-27	WOS:000269622100001
J	Wadlow, RC; Wittner, BS; Finley, SA; Bergquist, H; Upadhyay, R; Finn, S; Loda, M; Mahmood, U; Ramaswamy, S				Wadlow, Raymond C.; Wittner, Ben S.; Finley, S. Aidan; Bergquist, Henry; Upadhyay, Rabi; Finn, Stephen; Loda, Massimo; Mahmood, Umar; Ramaswamy, Sridhar			Systems-Level Modeling of Cancer-Fibroblast Interaction	PLOS ONE			English	Article								Cancer cells interact with surrounding stromal fibroblasts during tumorigenesis, but the complex molecular rules that govern these interactions remain poorly understood thus hindering the development of therapeutic strategies to target cancer stroma. We have taken a mathematical approach to begin defining these rules by performing the first large-scale quantitative analysis of fibroblast effects on cancer cell proliferation across more than four hundred heterotypic cell line pairings. Systems-level modeling of this complex dataset using singular value decomposition revealed that normal tissue fibroblasts variably express at least two functionally distinct activities, one which reflects transcriptional programs associated with activated mesenchymal cells, that act either coordinately or at cross-purposes to modulate cancer cell proliferation. These findings suggest that quantitative approaches may prove useful for identifying organizational principles that govern complex heterotypic cell-cell interactions in cancer and other contexts.			Wadlow, RC (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.	sridhar@mgh.harvard.edu	Finn, Stephen/V-3236-2019	Finn, Stephen/0000-0002-8628-5814; Wadlow, Raymond/0000-0003-1959-5406; Mahmood, Umar/0000-0001-7414-6123; Upadhyay, Rabi/0000-0002-2154-0132	NCI NIH HHS [K08 CA100339-06, K08 CA100339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA100339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affara Nesrine I., 2009, V539, P1, DOI 10.1007/978-1-60327-003-8_1; Beppu H, 2008, ONCOGENE, V27, P1063, DOI 10.1038/sj.onc.1210720; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Clark CJ, 2008, J CELL BIOCHEM, V104, P721, DOI 10.1002/jcb.21688; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; De Wever O, 2004, J CELL SCI, V117, P4691, DOI 10.1242/jcs.01322; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Efron Bradley, 1993, INTRO BOOTSTRAP, V57; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Friedman J., 2001, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-21606-5; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; LITTLE RJA, 2002, STAT ANAL WITH MISSI; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Louwerse DJ, 1999, J CHEMOMETR, V13, P491, DOI 10.1002/(SICI)1099-128X(199909/10)13:5<491::AID-CEM537>3.0.CO;2-2; MADSEN MW, 1990, EUR J CANCER, V26, P793, DOI 10.1016/0277-5379(90)90154-L; MANTONI TS, 2008, CANC BIOL THER, V7; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; Murase Kenya, 2004, Magn Reson Med Sci, V3, P165, DOI 10.2463/mrms.3.165; Nilsson J, 1997, J CHEMOMETR, V11, P511; Olumi AF, 1999, CANCER RES, V59, P5002; Orend G, 2005, INT J BIOCHEM CELL B, V37, P1066, DOI 10.1016/j.biocel.2004.12.002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Preffer FI, 2002, STEM CELLS, V20, P417, DOI 10.1634/stemcells.20-5-417; Rowe RG, 2009, J CELL BIOL, V184, P399, DOI 10.1083/jcb.200810113; Sakaie KE, 2007, NEUROIMAGE, V34, P169, DOI 10.1016/j.neuroimage.2006.08.034; Sasser AK, 2007, CANCER LETT, V254, P255, DOI 10.1016/j.canlet.2007.03.012; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Venables WN., 2002, MODERN APPL STAT S 4; WOLD S, 1978, TECHNOMETRICS, V20, P397, DOI 10.2307/1267639; Yashiro M, 2005, BREAST CANCER RES TR, V90, P307, DOI 10.1007/s10549-004-5364-z	37	20	21	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6888	10.1371/journal.pone.0006888	http://dx.doi.org/10.1371/journal.pone.0006888			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727395	Green Submitted, gold, Green Published			2022-12-27	WOS:000269522900017
J	Salas, A; Lovo-Gomez, J; Alvarez-Iglesias, V; Cerezo, M; Lareu, MV; Macaulay, V; Richards, MB; Carracedo, A				Salas, Antonio; Lovo-Gomez, Jose; Alvarez-Iglesias, Vanesa; Cerezo, Maria; Victoria Lareu, Maria; Macaulay, Vincent; Richards, Martin B.; Carracedo, Angel			Mitochondrial Echoes of First Settlement and Genetic Continuity in El Salvador	PLOS ONE			English	Article							MTDNA HAPLOGROUP X; DNA DIVERSITY; ANCIENT DNA; POPULATION; LINEAGES; AFFINITIES; AMERINDS; SEQUENCES; DIFFERENTIATION; EVOLUTIONARY	Background: From Paleo-Indian times to recent historical episodes, the Mesoamerican isthmus played an important role in the distribution and patterns of variability all around the double American continent. However, the amount of genetic information currently available on Central American continental populations is very scarce. In order to shed light on the role of Mesoamerica in the peopling of the New World, the present study focuses on the analysis of the mtDNA variation in a population sample from El Salvador. Methodology/Principal Findings: We have carried out DNA sequencing of the entire control region of the mitochondrial DNA (mtDNA) genome in 90 individuals from El Salvador. We have also compiled more than 3,985 control region profiles from the public domain and the literature in order to carry out inter-population comparisons. The results reveal a predominant Native American component in this region: by far, the most prevalent mtDNA haplogroup in this country (at similar to 90%) is A2, in contrast with other North, Meso- and South American populations. Haplogroup A2 shows a star-like phylogeny and is very diverse with a substantial proportion of mtDNAs (45%; sequence range 16090-16365) still unobserved in other American populations. Two different Bayesian approaches used to estimate admixture proportions in El Salvador shows that the majority of the mtDNAs observed come from North America. A preliminary founder analysis indicates that the settlement of El Salvador occurred about 13,400 +/- 65,200 Y.B.P.. The founder age of A2 in El Salvador is close to the overall age of A2 in America, which suggests that the colonization of this region occurred within a few thousand years of the initial expansion into the Americas. Conclusions/Significance: As a whole, the results are compatible with the hypothesis that today's A2 variability in El Salvador represents to a large extent the indigenous component of the region. Concordant with this hypothesis is also the observation of a very limited contribution from European and African women (similar to 5%). This implies that the Atlantic slave trade had a very small demographic impact in El Salvador in contrast to its transformation of the gene pool in neighbouring populations from the Caribbean facade.			Salas, A (corresponding author), Univ Santiago de Compostela, Fac Med, Unidade Xenet, Dept Anat Patol & Ciencias Forenses, Galicia, Spain.	antonio.salas@usc.es	Lareu, Maviky/E-4909-2013; Salas, Antonio/E-3977-2012; Carracedo, Angel/D-4257-2012; Salas, Antonio/U-2029-2019	Lareu, Maviky/0000-0002-6165-9795; Salas, Antonio/0000-0002-2336-702X; Carracedo, Angel/0000-0003-1085-8986; Salas, Antonio/0000-0002-2336-702X; RICHARDS, MARTIN/0000-0003-3118-0967; Cerezo Fernandez, Maria/0000-0003-3073-1130				Achilli A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001764; Alvarez-Iglesias V, 2007, FORENSIC SCI INT-GEN, V1, P44, DOI 10.1016/j.fsigen.2006.09.001; Alvarez-Iglesias V, 2006, INT C SERIES, V11, P4; Alves-Silva J, 2000, AM J HUM GENET, V67, P444, DOI 10.1086/303004; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bandelt HJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-113; BANDELT HJ, 1995, GENETICS, V141, P743; Bandelt HJ, 2004, SCIENCE, V305, P1402; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Bandelt HJ, 2002, AM J HUM GENET, V71, P1150, DOI 10.1086/344397; BATISTA O, 1995, HUM MOL GENET, V4, P921, DOI 10.1093/hmg/4.5.921; Beleza S, 2005, HUM GENET, V117, P366, DOI 10.1007/s00439-005-1290-3; Bert F, 2004, ANN HUM BIOL, V31, P9, DOI 10.1080/03014460310001616464; BOLES TC, 1995, J FORENSIC SCI, V40, P349; Bolnick DA, 2003, AM J PHYS ANTHROPOL, V122, P336, DOI 10.1002/ajpa.10284; Bonilla C, 2004, AM J HUM BIOL, V16, P289, DOI 10.1002/ajhb.20025; Brehm A, 2003, HUM GENET, V114, P77, DOI 10.1007/s00439-003-1024-3; Brown MD, 1998, AM J HUM GENET, V63, P1852, DOI 10.1086/302155; Budowle B, 2002, INT J LEGAL MED, V116, P212, DOI 10.1007/s00414-001-0283-6; Burckhardt F, 1999, NUCLEIC ACIDS RES, V27, P138, DOI 10.1093/nar/27.1.138; *CONCULTURA, 2000, BIBL HIST SALV EL SA; Dipierri JE, 1998, HUM BIOL, V70, P1001; Dornelles CL, 2005, AM J PHYS ANTHROPOL, V127, P439, DOI 10.1002/ajpa.20103; Dornelles CL, 2004, AM J HUM BIOL, V16, P479, DOI 10.1002/ajhb.20038; Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003; Forster P, 1996, AM J HUM GENET, V59, P935; Garcia-Bour J, 2004, AM J PHYS ANTHROPOL, V123, P361, DOI 10.1002/ajpa.10337; GINTHER C, 1993, EXS, V67, P211; Gonzalez AM, 2003, AM J PHYS ANTHROPOL, V120, P391, DOI 10.1002/ajpa.10168; Green LD, 2000, AM J HUM GENET, V66, P989, DOI 10.1086/302801; HORAI S, 1993, MOL BIOL EVOL, V10, P23; Kittles RA, 1999, AM J PHYS ANTHROPOL, V108, P381, DOI 10.1002/(SICI)1096-8644(199904)108:4<381::AID-AJPA1>3.0.CO;2-5; KOLMAN CJ, 1995, GENETICS, V140, P275; Kolman CJ, 1997, GENETICS, V147, P1289; Lalueza-Fox C, 2003, AM J PHYS ANTHROPOL, V121, P97, DOI 10.1002/ajpa.10236; Lalueza-Fox C, 2001, ANN HUM GENET, V65, P137, DOI 10.1017/S0003480001008533; LARIN JLY, 2000, EL SALVADOR DESCUBRI; LORENZ JC, 1994, SPE FORMATION EVAL, V9, P66, DOI 10.2118/21877-PA; Lovo-Gomez J, 2007, FORENSIC SCI INT, V171, P198, DOI 10.1016/j.forsciint.2006.07.005; Malhi RS, 2001, HUM BIOL, V73, P17, DOI 10.1353/hub.2001.0008; Malyarchuk BA, 2002, ANN HUM GENET, V66, P261, DOI 10.1017/S0003480002001161; Mendizabal I, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-213; MERRIWETHER DA, 2002, GENE FLOW GENETIC VA, P89; MERRIWETHER DA, 2000, AM PAST AM PRESENT G, P89; *MIN ED ES, 1994, HIST EL SALV; Monsalve MV, 2002, AM J PHYS ANTHROPOL, V119, P288, DOI 10.1002/ajpa.10116; Monson K.L., 2002, FORENSIC SCI COMMUN, V4, P2; Moraga M, 2005, AM J PHYS ANTHROPOL, V127, P170, DOI 10.1002/ajpa.10438; Moraga ML, 2000, AM J PHYS ANTHROPOL, V113, P19, DOI 10.1002/1096-8644(200009)113:1<19::AID-AJPA3>3.0.CO;2-X; Nei N, 1987, MOL EVOLUTIONARY GEN; Pagano S, 2005, J FORENSIC SCI, V50, P1239; Perego UA, 2009, CURR BIOL, V19, P1, DOI 10.1016/j.cub.2008.11.058; Pereira L, 2000, ANN HUM GENET, V64, P491, DOI 10.1046/j.1469-1809.2000.6460491.x; RIBEIRODOSSANTO.AK, 2006, FORENSIC SCI INT; RibeirodosSantos AKC, 1996, AM J PHYS ANTHROPOL, V101, P29, DOI 10.1002/(SICI)1096-8644(199609)101:1<29::AID-AJPA3>3.0.CO;2-8; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Rickards O, 1999, AM J HUM GENET, V65, P519, DOI 10.1086/302513; Rubicz R, 2003, HUM BIOL, V75, P809, DOI 10.1353/hub.2004.0009; Saillard J, 2000, AM J HUM GENET, V67, P718, DOI 10.1086/303038; Salas A, 2008, J HUM GENET, V53, P662, DOI 10.1007/s10038-008-0297-8; Salas A, 2007, FORENSIC SCI INT, V168, P1, DOI 10.1016/j.forsciint.2006.05.037; Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296; Salas A, 2005, AM J HUM GENET, V77, P676, DOI 10.1086/491675; Salas A, 2005, AM J PHYS ANTHROPOL, V128, P855, DOI 10.1002/ajpa.20117; Salas A, 2004, AM J HUM GENET, V74, P454, DOI 10.1086/382194; Salas A, 2002, AM J HUM GENET, V71, P1082, DOI 10.1086/344348; Salas A, 2005, BIOCHEM BIOPH RES CO, V335, P891, DOI 10.1016/j.bbrc.2005.07.161; SANTOS M, 1994, HUM BIOL, V66, P963; Santos SEB, 1996, ANN HUM GENET, V60, P305, DOI 10.1111/j.1469-1809.1996.tb01194.x; SHIELDS GF, 1993, AM J HUM GENET, V53, P549; Smith DG, 1999, AM J PHYS ANTHROPOL, V110, P271, DOI 10.1002/(SICI)1096-8644(199911)110:3<271::AID-AJPA2>3.0.CO;2-C; SOARES P, 2009, AM J HUM GE IN PRESS; Starikovskaya YB, 1998, AM J HUM GENET, V63, P1473, DOI 10.1086/302087; STONE AC, 1993, AM J PHYS ANTHROPOL, V92, P463, DOI 10.1002/ajpa.1330920405; Tamm E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000829; Torres MM, 2006, AM J HUM BIOL, V18, P59, DOI 10.1002/ajhb.20461; TORRONI A, 1993, AM J HUM GENET, V53, P591; TORRONI A, 1993, AM J HUM GENET, V53, P563; Trovoada MJ, 2004, ANN HUM GENET, V68, P40, DOI 10.1046/j.1529-8817.2003.00070.x; Vernesi C, 2002, HUM BIOL, V74, P725, DOI 10.1353/hub.2002.0060; Vona G, 2005, AM J PHYS ANTHROPOL, V127, P361, DOI 10.1002/ajpa.20070; Ward RH, 1996, AM J HUM BIOL, V8, P317, DOI 10.1002/(SICI)1520-6300(1996)8:3<317::AID-AJHB2>3.0.CO;2-X; WARD RH, 1993, P NATL ACAD SCI USA, V90, P10663, DOI 10.1073/pnas.90.22.10663; WARD RH, 1991, P NATL ACAD SCI USA, V88, P8720, DOI 10.1073/pnas.88.19.8720; Williams SR, 2002, AM J PHYS ANTHROPOL, V117, P246, DOI 10.1002/ajpa.10035; Yao YG, 2006, HUM GENET, V119, P505, DOI 10.1007/s00439-006-0154-9	86	20	20	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6882	10.1371/journal.pone.0006882	http://dx.doi.org/10.1371/journal.pone.0006882			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	490RW	19724647	Green Published, gold, Green Accepted, Green Submitted			2022-12-27	WOS:000269522800007
J	Stralberg, D; Jongsomjit, D; Howell, CA; Snyder, MA; Alexander, JD; Wiens, JA; Root, TL				Stralberg, Diana; Jongsomjit, Dennis; Howell, Christine A.; Snyder, Mark A.; Alexander, John D.; Wiens, John A.; Root, Terry L.			Re-Shuffling of Species with Climate Disruption: A No-Analog Future for California Birds?	PLOS ONE			English	Article							POLLEN SPECTRA; DISTRIBUTIONS; MODELS; VEGETATION; SELECTION; CONSEQUENCES; PALEOECOLOGY; CONSERVATION; COMMUNITIES; PREDICTION	By facilitating independent shifts in species' distributions, climate disruption may result in the rapid development of novel species assemblages that challenge the capacity of species to co-exist and adapt. We used a multivariate approach borrowed from paleoecology to quantify the potential change in California terrestrial breeding bird communities based on current and future species-distribution models for 60 focal species. Projections of future no-analog communities based on two climate models and two species-distribution-model algorithms indicate that by 2070 over half of California could be occupied by novel assemblages of bird species, implying the potential for dramatic community reshuffling and altered patterns of species interactions. The expected percentage of no-analog bird communities was dependent on the community scale examined, but consistent geographic patterns indicated several locations that are particularly likely to host novel bird communities in the future. These no-analog areas did not always coincide with areas of greatest projected species turnover. Efforts to conserve and manage biodiversity could be substantially improved by considering not just future changes in the distribution of individual species, but including the potential for unprecedented changes in community composition and unanticipated consequences of novel species assemblages.			Stralberg, D (corresponding author), PRBO Conservat Sci, Petaluma, CA USA.	dstralberg@prbo.org	Snyder, Mark/B-6835-2008; Alexander, John/GVS-7271-2022; Stralberg, Diana/W-9267-2019	Snyder, Mark/0000-0001-8242-7697; Stralberg, Diana/0000-0003-4900-024X				Araujo MB, 2004, GLOBAL CHANGE BIOL, V10, P1618, DOI 10.1111/j.1365-2486.2004.00828.x; Bakkenes M, 2002, GLOBAL CHANGE BIOL, V8, P390, DOI 10.1046/j.1354-1013.2001.00467.x; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brown JH, 2000, AM NAT, V156, P314, DOI 10.1086/303385; Brown JH, 1997, P NATL ACAD SCI USA, V94, P9729, DOI 10.1073/pnas.94.18.9729; Cayan DR, 2008, CLIMATIC CHANGE, V87, pS21, DOI 10.1007/s10584-007-9377-6; CHASE M, 2005, BIRD CONSERVATION IM, P130; Cramer W, 2001, GLOBAL CHANGE BIOL, V7, P357, DOI 10.1046/j.1365-2486.2001.00383.x; Dale VH, 2001, BIOSCIENCE, V51, P723, DOI 10.1641/0006-3568(2001)051[0723:CCAFD]2.0.CO;2; DALY C, 1994, J APPL METEOROL, V33, P140, DOI 10.1175/1520-0450(1994)033&lt;0140:ASTMFM&gt;2.0.CO;2; Davis F., 1998, CALIFORNIA GAP ANAL; deGroot RS, 1995, J BIOGEOGR, V22, P935, DOI 10.2307/2845994; Diffenbaugh NS, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035075; Ellis EC, 2008, FRONT ECOL ENVIRON, V6, P439, DOI 10.1890/070062; Everitt B., 1974, CLUSTER ANAL; Fielding AH, 1997, ENVIRON CONSERV, V24, P38, DOI 10.1017/S0376892997000088; Flower RJ, 1997, HYDROBIOLOGIA, V344, P27, DOI 10.1023/A:1002941908602; Gavin DG, 2003, QUATERNARY RES, V60, P356, DOI 10.1016/S0033-5894(03)00088-7; Gleason H.A., 1926, B TORREY BOT CLUB, V53, P7, DOI DOI 10.2307/2479933; Graham RW, 1996, SCIENCE, V272, P1601; Hastie T., 1986, STAT SCI, V1, P297; Heikkinen RK, 2007, GLOBAL ECOL BIOGEOGR, V16, P754, DOI 10.1111/j.1466-8238.2007.00345.x; Heikkinen RK, 2006, PROG PHYS GEOG, V30, P751, DOI 10.1177/0309133306071957; Hughes L, 2000, TRENDS ECOL EVOL, V15, P56, DOI 10.1016/S0169-5347(99)01764-4; HUNTLEY B, 1991, ANN BOT-LONDON, V67, P15, DOI 10.1093/oxfordjournals.aob.a088205; HUNTLEY B, 1990, QUATERNARY RES, V33, P360, DOI 10.1016/0033-5894(90)90062-P; Huntley B, 2004, ECOL LETT, V7, P417, DOI 10.1111/j.1461-0248.2004.00598.x; Huntley B., 2007, CLIMATIC ATLAS EUROP; Huntley B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001439; Jackson ST, 2004, ANNU REV EARTH PL SC, V32, P495, DOI 10.1146/annurev.earth.32.101802.120435; JACKSON ST, 1991, ECOLOGY, V72, P641, DOI 10.2307/2937204; Lawler JJ, 2009, ECOLOGY, V90, P588, DOI 10.1890/08-0823.1; Lenihan JM, 2008, CLIMATIC CHANGE, V87, pS215, DOI 10.1007/s10584-007-9362-0; Loarie SR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002502; Maurer EP, 2008, HYDROL EARTH SYST SC, V12, P551; MAYER KE, 1988, GUIDE WILDLIFE HABIT, P166; Moritz C, 2008, SCIENCE, V322, P261, DOI 10.1126/science.1163428; Nix H. A., 1986, ATLAS ELAPID SNAKES, V7, P4; OVERPECK JT, 1985, QUATERNARY RES, V23, P87, DOI 10.1016/0033-5894(85)90074-2; OVERPECK JT, 1992, GEOLOGY, V20, P1071, DOI 10.1130/0091-7613(1992)020<1071:MENAVC>2.3.CO;2; Pal JS, 2007, B AM METEOROL SOC, V88, P1395, DOI 10.1175/BAMS-88-9-1395; Pearson RG, 2004, ECOGRAPHY, V27, P285, DOI 10.1111/j.0906-7590.2004.03740.x; Pearson RG, 2003, GLOBAL ECOL BIOGEOGR, V12, P361, DOI 10.1046/j.1466-822X.2003.00042.x; Peterson AT, 2002, NATURE, V416, P626, DOI 10.1038/416626a; Phillips SJ, 2008, ECOGRAPHY, V31, P161, DOI 10.1111/j.0906-7590.2008.5203.x; Phillips SJ, 2009, ECOL APPL, V19, P181, DOI 10.1890/07-2153.1; R Development Core Team, 2007, R LANG ENV STAT COMP; Ralph C.J., 1993, GEN TECHNICAL REPORT; Ricklefs RE, 2008, AM NAT, V172, P741, DOI 10.1086/593002; ROOT TL, 1993, CONSERV BIOL, V7, P256, DOI 10.1046/j.1523-1739.1993.07020256.x; ROTENBERRY JT, 1985, OECOLOGIA, V67, P213, DOI 10.1007/BF00384286; Sauer J. R., 2005, N AM BREEDING BIRD S; Schweiger O, 2008, ECOLOGY, V89, P3472, DOI 10.1890/07-1748.1; Seastedt TR, 2008, FRONT ECOL ENVIRON, V6, P547, DOI 10.1890/070046; Seoane J, 2004, ECOL MODEL, V171, P209, DOI 10.1016/j.ecolmodel.2003.08.006; SHUFORD WD, 2008, STUDIES W BIRDS W FI, V1; Simpson GL, 2007, J STAT SOFTW, V22, P1; Snyder MA, 2005, EARTH INTERACT, V9; Solomon S., 2007, 4 IPCC; TEMPLE S A, 1989, American Birds, V43, P260; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Thuiller W, 2005, P NATL ACAD SCI USA, V102, P8245, DOI 10.1073/pnas.0409902102; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; WHITTAKER ROBERT H., 1960, ECOL MONOGR, V30, P279, DOI 10.2307/1943563; WIENS JA, P NATL ACAD SCI US; Williams JW, 2007, P NATL ACAD SCI USA, V104, P5738, DOI 10.1073/pnas.0606292104	66	132	135	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6825	10.1371/journal.pone.0006825	http://dx.doi.org/10.1371/journal.pone.0006825			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RW	19724641	Green Published, gold, Green Submitted			2022-12-27	WOS:000269522800001
J	Ichiyama, R; Potuzak, M; Balak, M; Kalderon, N; Edgerton, VR				Ichiyama, Ronaldo; Potuzak, Melissa; Balak, Marissa; Kalderon, Nurit; Edgerton, V. Reggie			Enhanced Motor Function by Training in Spinal Cord Contused Rats Following Radiation Therapy	PLOS ONE			English	Article								Weight-bearing stepping, without supraspinal re-connectivity, can be attained by treadmill training in an animal whose spinal cord has been completely transected at the lower thoracic level. Repair of damaged tissue and of supraspinal connectivity/circuitry following spinal cord injury in rat can be achieved by specific cell elimination with radiation therapy of the lesion site delivered within a critical time window, 2-3 weeks postinjury. Here we examined the effects of training in the repaired spinal cord following clinical radiation therapy. Studies were performed in a severe rat spinal cord contusion injury model, one similar to fracture/crush injuries in humans; the injury was at the lower thoracic level and the training was a combined hindlimb standing and stepping protocol. Radiotherapy, in a similar manner to that reported previously, resulted in a significant level of tissue repair/preservation at the lesion site. Training in the irradiated group, as determined by limb kinematics tests, resulted in functional improvements that were significant for standing and stepping capacity, and yielded a significant direct correlation between standing and stepping performance. In contrast, the training in the unirradiated group resulted in no apparent beneficial effects, and yielded an inverse correlation between standing and stepping performance, e. g., subject with good standing showed poor stepping capacity. Further, without any training, a differential functional change was observed in the irradiated group; standing capacity was significantly inhibited while stepping showed a slight trend of improvement compared with the unirradiated group. These data suggest that following repair by radiation therapy the spinal circuitries which control posture and locomotor were modified, and that the beneficial functional modulation of these circuitries is use dependent. Further, for restoring beneficial motor function following radiotherapy, training seems to be crucial.			Ichiyama, R (corresponding author), Univ Leeds, Fac Biol Sci, Inst Membrane & Syst Biol, Leeds, W Yorkshire, England.	kalderon@spinalcordcure.org; vre@ucla.edu	Ichiyama, Ronaldo/B-7856-2009; 慧, 胡/C-5968-2009	Ichiyama, Ronaldo/0000-0002-7640-8032	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039375, P01NS016333] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS016333, NS16333, R01 NS039375, NS39375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Belanger M, 1996, J NEUROPHYSIOL, V76, P471, DOI 10.1152/jn.1996.76.1.471; CAJAL SRY, 1928, DEGENERATION REGENER, V2, P482; Conta AC, 2004, J COMP NEUROL, V479, P347, DOI 10.1002/cne.20319; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; de Leon RD, 2002, PROG BRAIN RES, V137, P141; de Leon RD, 1999, J NEUROPHYSIOL, V81, P85, DOI 10.1152/jn.1999.81.1.85; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; de Leon RD, 1999, PROG BRAIN RES, V123, P341, DOI 10.1016/S0079-6123(08)62869-1; Edgerton V R, 1997, Adv Neurol, V72, P233; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Heng C, 2009, EXP NEUROL, V216, P139, DOI 10.1016/j.expneurol.2008.11.023; HODGSON JA, 1994, MED SCI SPORT EXER, V26, P1491; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; KAKULAS BA, 1987, PARAPLEGIA, V25, P212, DOI 10.1038/sc.1987.37; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11185, DOI 10.1073/pnas.93.20.11185; Kalderon N, 2005, CURR PHARM DESIGN, V11, P1237, DOI 10.2174/1381612053507477; Kalderon N, 2001, BRAIN RES, V904, P199, DOI 10.1016/S0006-8993(01)02402-7; KALDERON N, 1996, P NATL ACAD SCI USA, V93, P10079; Kalderon N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000565; LOVELY RG, 1990, BRAIN RES, V514, P206, DOI 10.1016/0006-8993(90)91417-F; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; PRATT CA, 1994, J NEUROPHYSIOL, V71, P1981, DOI 10.1152/jn.1994.71.5.1981; Qi HX, 2004, SOMATOSENS MOT RES, V21, P229, DOI 10.1080/08990220400012588; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Timoszyk WK, 2002, J NEUROPHYSIOL, V88, P3108, DOI 10.1152/jn.01050.2001; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Wu CWH, 2000, NEURON, V28, P967, DOI 10.1016/S0896-6273(00)00167-7	33	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6862	10.1371/journal.pone.0006862	http://dx.doi.org/10.1371/journal.pone.0006862			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718437	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900025
J	Nardinocchi, L; Puca, R; Sacchi, A; Rechavi, G; Givol, D; D'Orazi, G				Nardinocchi, Lavinia; Puca, Rosa; Sacchi, Ada; Rechavi, Gideon; Givol, David; D'Orazi, Gabriella			Targeting Hypoxia in Cancer Cells by Restoring Homeodomain Interacting Protein-Kinase 2 and p53 Activity and Suppressing HIF-1 alpha	PLOS ONE			English	Article								Background: The tumor suppressor homeodomain-interacting protein kinase-2 (HIPK2) by phosphorylating serine 46 (Ser46) is a crucial regulator of p53 apoptotic function. HIPK2 is also a transcriptional co-repressor of hypoxia-inducible factor-1 alpha (HIF-1 alpha) restraining tumor angiogenesis and chemoresistance. HIPK2 can be deregulated in tumors by several mechanisms including hypoxia. Here, we sought to target hypoxia by restoring HIPK2 function and suppressing HIF-1 alpha, in order to provide evidence for the involvement of both HIPK2 and p53 in counteracting hypoxia-induced chemoresistance. Methodology/Principal Findings: Upon exposure of colon and lung cancer cells to hypoxia, by either low oxygen or cobalt, HIPK2 function was impaired allowing for increased HIF-1 alpha expression and inhibiting the p53-apoptotic response to drug. Cobalt suppressed HIPK2 recruitment onto HIF-1 alpha promoter. Hypoxia induced expression of the p53 target MDM2 that downregulates HIPK2, thus MDM2 inhibition by siRNA restored the HIPK2/p53Ser46 response to drug. Zinc supplementation to hypoxia-treated cells increased HIPK2 protein stability and nuclear accumulation, leading to restoration of HIPK2 binding to HIF-1 alpha promoter, repression of MDR1, Bcl2, and VEGF genes, and activation of the p53 apoptotic response to drug. Combination of zinc and ADR strongly suppressed tumor growth in vivo by inhibiting HIF-1 pathway and upregulating p53 apoptotic target genes. Conclusions/Significance: We show here for the first time that hypoxia-induced HIPK2 deregulation was counteracted by zinc that restored HIPK2 suppression of HIF-1 pathway and reactivated p53 apoptotic response to drug, underscoring the potential use of zinc supplementation in combination with chemotherapy to address hypoxia and improve tumor treatment.			Nardinocchi, L (corresponding author), Natl Canc Inst Regina Elena, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy.	gdorazi@unich.it	D'Orazi, Gabriella/T-2792-2019	D'Orazi, Gabriella/0000-0001-6876-9105	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2006, CLIN CANCER RES, V12, P735, DOI 10.1158/1078-0432.CCR-05-1557; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Eby GA, 2005, MED HYPOTHESES, V64, P1124, DOI 10.1016/j.mehy.2004.12.019; Gresko E, 2005, BIOCHEM BIOPH RES CO, V329, P1293, DOI 10.1016/j.bbrc.2005.02.113; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ho E, 2004, J NUTR BIOCHEM, V15, P572, DOI 10.1016/j.jnutbio.2004.07.005; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JOENGER AC, 2007, ONCOGENE, V26, P2226; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004758; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Li XQ, 2008, MOL CANCER THER, V7, P1207, DOI 10.1158/1535-7163.MCT-07-2187; Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1; Nardinocchi L, 2009, BBA-MOL CELL RES, V1793, P368, DOI 10.1016/j.bbamcr.2008.10.013; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2002, BIOCHEM BIOPH RES CO, V290, P942, DOI 10.1006/bbrc.2001.6310; Pistritto G, 2007, CELL DEATH DIFFER, V14, P1837, DOI 10.1038/sj.cdd.4402186; Puca R, 2008, GYNECOL ONCOL, V109, P403, DOI 10.1016/j.ygyno.2008.02.018; Puca R, 2008, CANCER RES, V68, P3707, DOI 10.1158/0008-5472.CAN-07-6776; Puca R, 2009, EXP CELL RES, V315, P67, DOI 10.1016/j.yexcr.2008.10.018; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shah MR, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-84; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211	49	42	44	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6819	10.1371/journal.pone.0006819	http://dx.doi.org/10.1371/journal.pone.0006819			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714248	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415800008
J	Teixeira, VH; Olaso, R; Martin-Magniette, ML; Lasbleiz, S; Jacq, L; Oliveira, CR; Hilliquin, P; Gut, I; Cornelis, F; Petit-Teixeira, E				Teixeira, Vitor Hugo; Olaso, Robert; Martin-Magniette, Marie-Laure; Lasbleiz, Sandra; Jacq, Laurent; Oliveira, Catarina Resende; Hilliquin, Pascal; Gut, Ivo; Cornelis, Francois; Petit-Teixeira, Elisabeth			Transcriptome Analysis Describing New Immunity and Defense Genes in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis Patients	PLOS ONE			English	Article							MYELOID-RELATED PROTEINS; INFLAMMATORY FACTOR-I; ACUTE-PHASE PROTEIN; ALPHA(1)-ACID GLYCOPROTEIN; ALPHA-1-ACID GLYCOPROTEIN; ANTIMICROBIAL PEPTIDES; SYNOVIAL FIBROBLASTS; PSORIATIC-ARTHRITIS; AUTOIMMUNE-DISEASE; S100 PROTEINS	Background: Large-scale gene expression profiling of peripheral blood mononuclear cells from Rheumatoid Arthritis (RA) patients could provide a molecular description that reflects the contribution of diverse cellular responses associated with this disease. The aim of our study was to identify peripheral blood gene expression profiles for RA patients, using Illumina technology, to gain insights into RA molecular mechanisms. Methodology/Principal Findings: The Illumina Human-6v2 Expression BeadChips were used for a complete genome-wide transcript profiling of peripheral blood mononuclear cells (PBMCs) from 18 RA patients and 15 controls. Differential analysis per gene was performed with one-way analysis of variance (ANOVA) and P values were adjusted to control the False Discovery Rate (FDR < 5%). Genes differentially expressed at significant level between patients and controls were analyzed using Gene Ontology (GO) in the PANTHER database to identify biological processes. A differentially expression of 339 Reference Sequence genes (238 down-regulated and 101 up-regulated) between the two groups was observed. We identified a remarkably elevated expression of a spectrum of genes involved in Immunity and Defense in PBMCs of RA patients compared to controls. This result is confirmed by GO analysis, suggesting that these genes could be activated systemically in RA. No significant down-regulated ontology groups were found. Microarray data were validated by real time PCR in a set of nine genes showing a high degree of correlation. Conclusions/Significance: Our study highlighted several new genes that could contribute in the identification of innovative clinical biomarkers for diagnostic procedures and therapeutic interventions.			Teixeira, VH (corresponding author), Evry Univ Paris 7 Univ, Sch Med, GenHotel EA3886, Evry, France.	vitor@polyarthrite.net	Gut, Ivo/ABF-3188-2020; Olaso, Robert/AAC-4162-2019	Gut, Ivo/0000-0001-7219-632X; Oliveira, Catarina/0000-0001-6942-4328; Elisabeth, PETIT-TEIXEIRA/0000-0001-9724-3575				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Awomoyi AA, 2007, FEMS IMMUNOL MED MIC, V49, P324, DOI 10.1111/j.1574-695X.2007.00231.x; Baechler EC, 2006, IMMUNOL REV, V210, P120, DOI 10.1111/j.0105-2896.2006.00367.x; Barnes M, 2005, NUCLEIC ACIDS RES, V33, P5914, DOI 10.1093/nar/gki890; BARNHART MI, 1967, ANN RHEUM DIS, V26, P206, DOI 10.1136/ard.26.3.206; Batliwalla FM, 2005, GENES IMMUN, V6, P388, DOI 10.1038/sj.gene.6364209; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; Boneca IG, 2009, CELL HOST MICROBE, V5, P109, DOI 10.1016/j.chom.2009.01.007; Bovin LF, 2004, IMMUNOL LETT, V93, P217, DOI 10.1016/j.imlet.2004.03.018; Brentano F, 2005, CELL IMMUNOL, V233, P90, DOI 10.1016/j.cellimm.2005.04.018; Brutsche MH, 2001, CLIN EXP IMMUNOL, V123, P181, DOI 10.1046/j.1365-2249.2001.01441.x; Busso N, 2002, ARTHRITIS RHEUM, V46, P2268, DOI 10.1002/art.10498; Ceciliani F, 2007, CURR PROTEIN PEPT SC, V8, P91, DOI 10.2174/138920307779941497; Chen YS, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2645; Cho RJ, 2000, TRENDS GENET, V16, P409, DOI 10.1016/S0168-9525(00)02065-5; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Dahlback B, 2005, FEBS LETT, V579, P3310, DOI 10.1016/j.febslet.2005.03.001; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Filippin LI, 2008, CLIN EXP IMMUNOL, V152, P415, DOI 10.1111/j.1365-2249.2008.03634.x; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Foell D, 2004, ARTHRITIS RHEUM-US, V50, P3762, DOI 10.1002/art.20631; Foell D, 2003, RHEUMATOLOGY, V42, P1383, DOI 10.1093/rheumatology/keg385; Frosch M, 2000, ARTHRITIS RHEUM-US, V43, P628, DOI 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; GENTLEMAN R, 2002, RNEWS, V2, P1116; Gilliet M, 2008, CURR OPIN IMMUNOL, V20, P401, DOI 10.1016/j.coi.2008.06.008; Gladkevich A, 2005, MEDIAT INFLAMM, P317, DOI 10.1155/MI.2005.317; Harney SMJ, 2008, RHEUMATOLOGY, V47, P1761, DOI 10.1093/rheumatology/ken376; Haston JL, 2003, BIOMED CHROMATOGR, V17, P361, DOI 10.1002/bmc.251; Henriksen PA, 2002, CARDIOVASC RES, V54, P16, DOI 10.1016/S0008-6363(01)00516-8; Hochepied T, 2003, CYTOKINE GROWTH F R, V14, P25, DOI 10.1016/S1359-6101(02)00054-0; Hueber W, 2005, ARTHRITIS RHEUM-US, V52, P2645, DOI 10.1002/art.21269; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kane D, 2003, ARTHRITIS RHEUM, V48, P1676, DOI 10.1002/art.10988; Kim SH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-64; Kimura M, 2007, J IMMUNOL, V178, P3316, DOI 10.4049/jimmunol.178.5.3316; Kraan TCTMV, 2007, ANN RHEUM DIS, V66, P1008, DOI 10.1136/ard.2006.063412; LEBRE M, 2009, HUM IMMUNOL IN PRESS; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Mandel M, 2006, LUPUS, V15, P451, DOI 10.1191/0961203306lu2332oa; Maouche S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-302; Masuda K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar427; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; MIOSSEC P, 1986, ARTHRITIS RHEUM, V29, P461, DOI 10.1002/art.1780290402; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; O'Neill LA, 2008, NAT CLIN PRACT RHEUM, V4, P319, DOI 10.1038/ncprheum0802; Ospelt C, 2008, ARTHRITIS RHEUM-US, V58, P3684, DOI 10.1002/art.24140; Pekkari K, 2001, BLOOD, V97, P3184, DOI 10.1182/blood.V97.10.3184; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Rouleau P, 2003, CLIN IMMUNOL, V107, P46, DOI 10.1016/S1521-6616(02)00043-8; Saha S, 2009, CELL HOST MICROBE, V5, P137, DOI 10.1016/j.chom.2008.12.010; Seldin MF, 1999, ARTHRITIS RHEUM, V42, P1071, DOI 10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Smith KD, 2002, BIOMED CHROMATOGR, V16, P261, DOI 10.1002/bmc.158; Telfer JF, 2002, ANN RHEUM DIS, V61, P741, DOI 10.1136/ard.61.8.741; Toonen EJM, 2008, ANN RHEUM DIS, V67, P1663, DOI 10.1136/ard.2007.076588; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; WEINBERG JB, 1991, ARTHRITIS RHEUM, V34, P996, DOI 10.1002/art.1780340809; Yamagata T, 2006, IMMUNOL REV, V210, P52, DOI 10.1111/j.0105-2896.2006.00371.x; Yoshida S, 1999, J IMMUNOL, V163, P351; Youssef P, 1999, J RHEUMATOL, V26, P2523; Yuasa I, 1997, HUM GENET, V99, P393, DOI 10.1007/s004390050378; Zendman AJW, 2006, RHEUMATOLOGY, V45, P20, DOI 10.1093/rheumatology/kei111	73	65	67	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6803	10.1371/journal.pone.0006803	http://dx.doi.org/10.1371/journal.pone.0006803			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710928	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415600016
J	Simonetti, T; Lee, H; Bourke, M; Leamey, CA; Sawatari, A				Simonetti, Teresa; Lee, Hyunchul; Bourke, Michael; Leamey, Catherine A.; Sawatari, Atomu			Enrichment from Birth Accelerates the Functional and Cellular Development of a Motor Control Area in the Mouse	PLOS ONE			English	Article								Background: There is strong evidence that sensory experience in early life has a profound influence on the development of sensory circuits. Very little is known, however, about the role of experience in the early development of striatal networks which regulate both motor and cognitive function. To address this, we have investigated the influence of early environmental enrichment on motor development. Methodology/Principal Findings: Mice were raised in standard or enriched housing from birth. For animals assessed as adults, half of the mice had their rearing condition reversed at weaning to enable the examination of the effects of preversus post-weaning enrichment. We found that exclusively pre-weaning enrichment significantly improved performance on the Morris water maze compared to non-enriched mice. The effects of early enrichment on the emergence of motor programs were assessed by performing behavioural tests at postnatal day 10. Enriched mice traversed a significantly larger region of the test arena in an open-field test and had improved swimming ability compared to non-enriched cohorts. A potential cellular correlate of these changes was investigated using Wisteria-floribunda agglutinin (WFA) staining to mark chondroitin-sulfate proteoglycans (CSPGs). We found that the previously reported transition of CSPG staining from striosome-associated clouds to matrix-associated perineuronal nets (PNNs) is accelerated in enriched mice. Conclusions/Significance: This is the first demonstration that the early emergence of exploratory as well as coordinated movement is sensitive to experience. These behavioural changes are correlated with an acceleration of the emergence of striatal PNNs suggesting that they may consolidate the neural circuits underlying these behaviours. Finally, we confirm that pre-weaning experience can lead to life long changes in the learning ability of mice.			Simonetti, T (corresponding author), Univ Sydney, Sch Med Sci, Discipline Physiol, Sydney, NSW 2006, Australia.	atomu@medsci.usyd.edu.au		Bourke, Michael/0000-0001-8752-2941; Lee, Hyunchul/0000-0002-1427-6521; Leamey, Catherine/0000-0002-3390-4933				Allen JP, 2003, EUR J NEUROSCI, V17, P1881, DOI 10.1046/j.1460-9568.2003.02629.x; ALTMAN J, 1975, ANIM BEHAV, V23, P896, DOI 10.1016/0003-3472(75)90114-1; Arai JA, 2009, J NEUROSCI, V29, P1496, DOI 10.1523/JNEUROSCI.5057-08.2009; Ariano MA, 1997, BRAIN RES, V752, P26, DOI 10.1016/S0006-8993(96)01422-9; Bartoletti A, 2004, NAT NEUROSCI, V7, P215, DOI 10.1038/nn1201; BENNETT BD, 1994, NEUROSCIENCE, V62, P707, DOI 10.1016/0306-4522(94)90471-5; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; Bezard E, 2003, J NEUROSCI, V23, P10999; Bolivar VJ, 1996, DEV PSYCHOBIOL, V29, P123, DOI 10.1002/(SICI)1098-2302(199603)29:2<123::AID-DEV3>3.0.CO;2-U; Bracci E, 2002, J NEUROPHYSIOL, V87, P2190, DOI 10.1152/jn.00754.2001; Brenes JC, 2008, PHARMACOL BIOCHEM BE, V89, P85, DOI 10.1016/j.pbb.2007.11.004; Brenes JC, 2009, BEHAV BRAIN RES, V197, P125, DOI 10.1016/j.bbr.2008.08.014; Bruckner G, 2000, J COMP NEUROL, V428, P616, DOI 10.1002/1096-9861(20001225)428:4<616::AID-CNE3>3.0.CO;2-K; Cancedda L, 2004, J NEUROSCI, V24, P4840, DOI 10.1523/JNEUROSCI.0845-04.2004; Centonze D, 2003, J NEUROSCI, V23, P6245; CHESSELET MF, 1983, LIFE SCI, V33, P37, DOI 10.1016/0024-3205(83)90438-1; Ciucci F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000475; CUMMINS RA, 1982, DEV PSYCHOBIOL, V15, P187, DOI 10.1002/dev.420150302; Devan BD, 1996, NEUROBIOL LEARN MEM, V66, P305, DOI 10.1006/nlme.1996.0072; Devan BD, 1999, BEHAV BRAIN RES, V100, P5, DOI 10.1016/S0166-4328(98)00107-7; Dulawa SC, 1999, J NEUROSCI, V19, P9550; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9; FOX K, 1992, J NEUROSCI, V12, P1826; FOX WM, 1965, ANIM BEHAV, V13, P234, DOI 10.1016/0003-3472(65)90041-2; FRANCIS DD, 1995, PHYSIOL BEHAV, V58, P57, DOI 10.1016/0031-9384(95)00009-8; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; GLOBUS A, 1973, J COMP PHYSIOL PSYCH, V82, P175, DOI 10.1037/h0033910; Gordon JA, 1996, J NEUROSCI, V16, P3274; GRAYBIEL AM, 1984, P NATL ACAD SCI-BIOL, V81, P7980, DOI 10.1073/pnas.81.24.7980; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Harburger LL, 2007, BEHAV BRAIN RES, V185, P43, DOI 10.1016/j.bbr.2007.07.009; HARTIG W, 1992, NEUROREPORT, V3, P869; Hebb D.O., 1947, AM PSYCHOL, V2, P306; HOLLOWAY RALPH L., 1966, BRAIN RES, V2, P393, DOI 10.1016/0006-8993(66)90009-6; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Ibarra GR, 1996, NEUROREPORT, V7, P2491, DOI 10.1097/00001756-199611040-00018; Ibarra GR, 1995, BRAIN RES, V705, P39, DOI 10.1016/0006-8993(95)01076-9; Iso H, 2007, BEHAV BRAIN RES, V179, P90, DOI 10.1016/j.bbr.2007.01.025; Iwata E, 2007, PHYSIOL BEHAV, V91, P318, DOI 10.1016/j.physbeh.2007.03.013; Jamon M, 2002, BEHAV NEUROSCI, V116, P1014, DOI 10.1037//0735-7044.116.6.1014; Jamon M, 1998, BEHAV NEUROSCI, V112, P1218, DOI 10.1037/0735-7044.112.5.1218; Kikusui T, 2009, J NEUROENDOCRINOL, V21, P427, DOI 10.1111/j.1365-2826.2009.01837.x; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; KRECH D, 1962, J COMP PHYSIOL PSYCH, V55, P801, DOI 10.1037/h0044220; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; LEAMEY CA, 2009, CURR OPIN NEUROBIOL; Lee H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003020; Li SM, 2006, CURR BIOL, V16, P2303, DOI 10.1016/j.cub.2006.10.028; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nisenbaum LK, 1998, DEV NEUROSCI-BASEL, V20, P113, DOI 10.1159/000017307; Pietropaolo S, 2006, BEHAV NEUROSCI, V120, P787, DOI 10.1037/0735-7044.120.4.787; Pistell PJ, 2009, BEHAV BRAIN RES, V197, P138, DOI 10.1016/j.bbr.2008.08.015; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Prusky GT, 2000, BEHAV BRAIN RES, V114, P11, DOI 10.1016/S0166-4328(00)00186-8; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; Rossi HL, 2008, BEHAV BRAIN RES, V187, P478, DOI 10.1016/j.bbr.2007.09.021; Rubinstein M, 1997, CELL, V90, P991, DOI 10.1016/S0092-8674(00)80365-7; Sale A, 2004, NEUROPHARMACOLOGY, V47, P649, DOI 10.1016/j.neuropharm.2004.07.008; SCHAPIRO S, 1970, SCIENCE, V167, P292, DOI 10.1126/science.167.3916.292; SCHAPIRO S, 1970, SCIENCE, V168, P147, DOI 10.1126/science.168.3927.147; Smith SL, 2007, NAT NEUROSCI, V10, P370, DOI 10.1038/nn1844; Soiza-Reilly M, 2004, BRAIN RES, V1004, P217, DOI 10.1016/j.brainres.2004.01.050; STEHOUWER DJ, 1994, DEV BRAIN RES, V82, P143, DOI 10.1016/0165-3806(94)90157-0; STOMER VEV, 1987, NEUROPHARMACOLOGY, V26, P1351; STOMER VEV, 1990, NEUROTOXICOL TERATOL, V12, P85, DOI 10.1016/0892-0362(90)90117-U; Sugiyama S, 2008, CELL, V134, P508, DOI 10.1016/j.cell.2008.05.054; SWANSON HH, 1983, BEHAV PROCESS, V8, P1, DOI 10.1016/0376-6357(83)90039-6; UYLINGS HBM, 1978, EXP NEUROL, V62, P658, DOI 10.1016/0014-4886(78)90276-5; van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WAINWRIGHT PE, 1993, NEUROTOXICOL TERATOL, V15, P11, DOI 10.1016/0892-0362(93)90040-U; WESTERGA J, 1990, DEV BRAIN RES, V57, P163, DOI 10.1016/0165-3806(90)90042-W; Whitaker J, 2007, LAB ANIMAL, V36, P32, DOI 10.1038/laban1107-32; WIDMAN DR, 1990, PHYSIOL BEHAV, V47, P57, DOI 10.1016/0031-9384(90)90042-3; WIDMAN DR, 1992, PHYSIOL BEHAV, V51, P309, DOI 10.1016/0031-9384(92)90146-S; Williams BM, 2001, PHYSIOL BEHAV, V73, P649, DOI 10.1016/S0031-9384(01)00543-1; Zaharia MD, 1996, PSYCHOPHARMACOLOGY, V128, P227, DOI 10.1007/s002130050130; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024	82	29	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2009	4	8							e6780	10.1371/journal.pone.0006780	http://dx.doi.org/10.1371/journal.pone.0006780			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	488FQ	19756157	gold, Green Submitted, Green Published			2022-12-27	WOS:000269335000023
J	Cederroth, CR; Nef, S				Cederroth, Christopher R.; Nef, Serge			Fetal Programming of Adult Glucose Homeostasis in Mice	PLOS ONE			English	Article								Background: Emerging evidence suggests that dietary soy and phytoestrogens can have beneficial effects on lipid and glucose metabolism. We have previously shown that male mice fed from conception to adulthood with a high soycontaining diet had reduced body weight, adiposity and a decrease in glucose intolerance, an early marker of insulin resistance and diabetes. Objectives: The purpose of this study was to identify the precise periods of exposure during which phytoestrogens and dietary soy improve lipid and glucose metabolism. Since intrauterine position (IUP) has been shown to alter sensitivity to endocrine disruptors, we also investigated whether the combination of IUP and fetal exposure to dietary phytoestrogens could potentially affect adult metabolic parameters. Methods: Male outbred mice (CD-1) were allowed ad libitum access to either a high soy-containing diet or a soy-free diet either during gestation, lactation or after weaning. Adiposity and bone mass density was assessed by dual x-ray absorptiometry. Glucose tolerance was assessed by a glucose tolerance test. Blood pressure was examined by the tail-cuff system. Results: Here we show that metabolic improvements are dependent on precise windows of exposure during life. The beneficial effects of dietary soy and phytoestrogens on adiposity were apparent only in animals fed post-natally, while the improvements in glucose tolerance are restricted to animals with fetal exposure to soy. Interestingly, we observed that IUP influenced adult glucose tolerance, but not adiposity. Similar IUP trends were observed for other estrogen-related metabolic parameters such as blood pressure and bone mass density. Conclusion: Our results suggest that IUP and fetal exposure to estrogenic environmental disrupting compounds, such as dietary phytoestrogens, could alter metabolic and cardiovascular parameters in adult individuals independently of adipose gain.			Cederroth, CR (corresponding author), Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.	Serge.Nef@unige.ch	Nef, Serge/AAV-6445-2020; Cederroth, Christopher/B-9932-2011; Cederroth, Christopher R./AAO-9501-2020	Nef, Serge/0000-0001-5462-0676; Cederroth, Christopher/0000-0001-7267-5136				Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; BOKLAGE CE, 1985, AM J HUM GENET, V37, P591; Callewaert F, 2009, FASEB J, V23, P232, DOI 10.1096/fj.08-113456; Cederroth CR, 2008, DIABETES, V57, P1176, DOI 10.2337/db07-0630; Cederroth CR, 2008, CHIMIA, V62, P401, DOI 10.2533/chimia.2008.401; Cederroth CR, 2007, ENVIRON HEALTH PERSP, V115, P1467, DOI 10.1289/ehp.10413; Cederroth CR, 2009, MOL CELL ENDOCRINOL, V304, P30, DOI 10.1016/j.mce.2009.02.027; Cooper C, 1997, ANN RHEUM DIS, V56, P17, DOI 10.1136/ard.56.1.17; Cooper C, 2002, CALCIFIED TISSUE INT, V70, P391, DOI 10.1007/s00223-001-0044-z; COOPER C, 1995, J BONE MINER RES, V10, P940; Dempsey PJ, 1999, AM J HUM BIOL, V11, P577, DOI 10.1002/(SICI)1520-6300(199909/10)11:5<577::AID-AJHB1>3.0.CO;2-Y; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Grun F, 2007, REV ENDOCR METAB DIS, V8, P161, DOI 10.1007/s11154-007-9049-x; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1321, DOI 10.1093/oxfordjournals.aje.a116444; Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; Kaati G, 2006, PATIENT EDUC COUNS, V62, P95, DOI 10.1016/j.pec.2005.06.012; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lesage J, 2004, J ENDOCRINOL, V181, P291, DOI 10.1677/joe.0.1810291; Li SF, 1997, CANCER RES, V57, P4356; Lin HY, 2008, HEPATOLOGY, V47, P1924, DOI 10.1002/hep.22252; Lin HY, 2005, DIABETES, V54, P1717, DOI 10.2337/diabetes.54.6.1717; Lummaa V, 2007, P NATL ACAD SCI USA, V104, P10915, DOI 10.1073/pnas.0605875104; MCFADDEN D, 1993, P NATL ACAD SCI USA, V90, P11900, DOI 10.1073/pnas.90.24.11900; McFadden D, 1996, HEARING RES, V97, P102, DOI 10.1016/0378-5955(96)00065-2; MILLER EM, 1995, OPTOMETRY VISION SCI, V72, P34, DOI 10.1097/00006324-199501000-00007; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; MONTANO MM, 1991, PHYSIOL BEHAV, V50, P323, DOI 10.1016/0031-9384(91)90073-W; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Newbold RR, 2007, MOL NUTR FOOD RES, V51, P912, DOI 10.1002/mnfr.200600259; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506; RESNICK SM, 1993, BEHAV GENET, V23, P323, DOI 10.1007/BF01067432; Ryan BC, 2002, NEUROSCI BIOBEHAV R, V26, P665, DOI 10.1016/S0149-7634(02)00038-6; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; SAAL FSV, 1992, PHYSIOL BEHAV, V52, P163, DOI 10.1016/0031-9384(92)90447-A; Saegusa H, 1999, METABOLISM, V48, P1584, DOI 10.1016/S0026-0495(99)90249-4; Seckl JR, 2001, MOL CELL ENDOCRINOL, V185, P61, DOI 10.1016/S0303-7207(01)00633-5; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; van Anders SM, 2006, HORM BEHAV, V49, P315, DOI 10.1016/j.yhbeh.2005.08.003; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; VOMSAAL FS, 1983, PHYSIOL BEHAV, V30, P675, DOI 10.1016/0031-9384(83)90162-2; VOMSAAL FS, 1978, BIOL REPROD, V19, P842, DOI 10.1095/biolreprod19.4.842; VOMSAAL FS, 1990, BIOL REPROD, V43, P751, DOI 10.1095/biolreprod43.5.751; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weber KS, 2001, J ENDOCRINOL, V170, P591, DOI 10.1677/joe.0.1700591	56	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7281	10.1371/journal.pone.0007281	http://dx.doi.org/10.1371/journal.pone.0007281			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789640	Green Published, Green Submitted, gold			2022-12-27	WOS:000270354100027
J	Matter, AM; Hoot, SB; Anderson, PD; Neves, SS; Cheng, YQ				Matter, Andrea M.; Hoot, Sara B.; Anderson, Patrick D.; Neves, Susana S.; Cheng, Yi-Qiang			Valinomycin Biosynthetic Gene Cluster in Streptomyces: Conservation, Ecology and Evolution	PLOS ONE			English	Article								Many Streptomyces strains are known to produce valinomycin (VLM) antibiotic and the VLM biosynthetic gene cluster (vlm) has been characterized in two independent isolates. Here we report the phylogenetic relationships of these strains using both parsimony and likelihood methods, and discuss whether the vlm gene cluster shows evidence of horizontal transmission common in natural product biosynthetic genes. Eight Streptomyces strains from around the world were obtained and sequenced for three regions of the two large nonribosomal peptide synthetase genes (vlm1 and vlm2) involved in VLM biosynthesis. The DNA sequences representing the vlm gene cluster are highly conserved among all eight environmental strains. The geographic distribution pattern of these strains and the strict congruence between the trees of the two vlm genes and the housekeeping genes, 16S rDNA and trpB, suggest vertical transmission of the vlm gene cluster in Streptomyces with no evidence of horizontal gene transfer. We also explored the relationship of the sequence of vlm genes to that of the cereulide biosynthetic genes (ces) found in Bacillus cereus and found them highly divergent from each other at DNA level (genetic distance values >= 95.6%). It is possible that the vlm gene cluster and the ces gene cluster may share a relatively distant common ancestor but these two gene clusters have since evolved independently.			Matter, AM (corresponding author), Univ Wisconsin, Dept Biol Sci, POB 413, Milwaukee, WI 53201 USA.	ycheng@uwm.edu	Neves, Susana/B-8724-2008	Neves, Susana/0000-0001-8943-2624; Cheng, Eric/0000-0001-9336-2593				AGATA N, 1994, FEMS MICROBIOL LETT, V121, P31, DOI 10.1016/0378-1097(94)90141-4; Anderson AS, 2001, INT J SYST EVOL MICR, V51, P797, DOI 10.1099/00207713-51-3-797; Andersson MA, 1998, APPL ENVIRON MICROB, V64, P4767; Apetroaie C, 2005, ARCH MICROBIOL, V184, P141, DOI 10.1007/s00203-005-0032-1; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Brakhage AA, 2005, PHYTOCHEMISTRY, V66, P1200, DOI 10.1016/j.phytochem.2005.02.030; BROCKMANN H, 1955, CHEM BER-RECL, V88, P57, DOI 10.1002/cber.19550880111; Brown EW, 2001, ENVIRON MOL MUTAGEN, V38, P248, DOI 10.1002/em.1079; Cheng YQ, 2006, CHEMBIOCHEM, V7, P471, DOI 10.1002/cbic.200500425; Cole JR, 2005, NUCLEIC ACIDS RES, V33, pD294, DOI 10.1093/nar/gki038; Darlu P, 2002, MOL BIOL EVOL, V19, P432, DOI 10.1093/oxfordjournals.molbev.a004098; Dixon N, 2007, NAT PROD REP, V24, P1288, DOI 10.1039/b616808f; Ehling-Schulz M, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-20; FARRIS JS, 1994, CLADISTICS, V10, P315, DOI 10.1111/j.1096-0031.1996.tb00196.x; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Fischbach MA, 2008, P NATL ACAD SCI USA, V105, P4601, DOI 10.1073/pnas.0709132105; Gaschen B, 2001, BIOINFORMATICS, V17, P415, DOI 10.1093/bioinformatics/17.5.415; Haruo N, 1968, Google Patents, Patent No. [3365363, US3365363A]; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; Huddleston AS, 1997, APPL ENVIRON MICROB, V63, P1288, DOI 10.1128/AEM.63.4.1288-1297.1997; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kitching I. J., 1998, CLADISTICS THEORY PR; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Lawrence J, 1999, CURR OPIN GENET DEV, V9, P642, DOI 10.1016/S0959-437X(99)00025-8; Li W. H, 1997, MOL EVOLUTION; Liras P, 1998, Int Microbiol, V1, P271; Maddison DR, 1997, SYST BIOL, V46, P590, DOI 10.2307/2413497; MADDISON DR, 2001, MACCLADE 4 V 4 01; Magarvey NA, 2006, J AM CHEM SOC, V128, P10698, DOI 10.1021/ja0640187; Martiny JBH, 2006, NAT REV MICROBIOL, V4, P102, DOI 10.1038/nrmicro1341; McInerney JO, 1998, BIOINFORMATICS, V14, P372, DOI 10.1093/bioinformatics/14.4.372; Metsa-Ketela M, 2002, APPL ENVIRON MICROB, V68, P4472, DOI 10.1128/AEM.68.9.4472-4479.2002; Michel K.H., 1985, US Pat., Patent No. [4492650, 4,492,650]; Nylander JAA., 2004, BIOINFORMATICS; PAGE RDM, 1998, MOL EVOLUTION; PERKINS JB, 1990, J BACTERIOL, V172, P3108, DOI 10.1128/jb.172.6.3108-3116.1990; Pettit GR, 1999, BIOORGAN MED CHEM, V7, P895, DOI 10.1016/S0968-0896(99)00024-3; Rantala A, 2004, P NATL ACAD SCI USA, V101, P568, DOI 10.1073/pnas.0304489101; Rasko DA, 2007, J BACTERIOL, V189, P52, DOI 10.1128/JB.01313-06; Ridley CP, 2008, P NATL ACAD SCI USA, V105, P4595, DOI 10.1073/pnas.0710107105; Rounge TB, 2007, APPL ENVIRON MICROB, V73, P7322, DOI 10.1128/AEM.01475-07; Ryoo IJ, 2006, BIOL PHARM BULL, V29, P817, DOI 10.1248/bpb.29.817; SWOFFORD DL, 2003, PAUP PHYLOGENETIC AN; TABER WA, 1957, CAN J MICROBIOL, V3, P953, DOI 10.1139/m57-106; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wiener P, 1998, MOL ECOL, V7, P1205, DOI 10.1046/j.1365-294x.1998.00450.x; Zwickl DJ., 2006, THESIS	48	37	37	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7194	10.1371/journal.pone.0007194	http://dx.doi.org/10.1371/journal.pone.0007194			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787052	gold, Green Published, Green Submitted			2022-12-27	WOS:000270290100010
J	Song, W; Ruder, AM; Hu, LY; Li, YF; Ni, R; Shao, WS; Kaslow, RA; Butler, M; Tang, JM				Song, Wei; Ruder, Avima M.; Hu, Liangyuan; Li, Yufeng; Ni, Rong; Shao, Wenshuo; Kaslow, Richard A.; Butler, MaryAnn; Tang, Jianming			Genetic Epidemiology of Glioblastoma Multiforme: Confirmatory and New Findings from Analyses of Human Leukocyte Antigen Alleles and Motifs	PLOS ONE			English	Article								Background: Human leukocyte antigen (HLA) class I genes mediate cytotoxic T-lymphocyte responses and natural killer cell function. In a previous study, several HLA-B and HLA-C alleles and haplotypes were positively or negatively associated with the occurrence and prognosis of glioblastoma multiforme (GBM). Methodology/Principal Findings: As an extension of the Upper Midwest Health Study, we have performed HLA genotyping for 149 GBM patients and 149 healthy control subjects from a non-metropolitan population consisting almost exclusively of European Americans. Conditional logistic regression models did not reproduce the association of HLA-B*07 or the B*07-Cw*07 haplotype with GBM. Nonetheless, HLA-A*32, which has previously been shown to predispose GBM patients to a favorable prognosis, was negatively associated with occurrence of GBM (odds ratio = 0.41, p = 0.04 by univariate analysis). Other alleles (A*29, A*30, A*31 and A*33) within the A19 serology group to which A*32 belongs showed inconsistent trends. Sequencing-based HLA-A genotyping established that A*3201 was the single A*32 allele underlying the observed association. Additional evaluation of HLA-A promoter and exon 1 sequences did not detect any unexpected single nucleotide polymorphisms that could suggest differential allelic expression. Further analyses restricted to female GBM cases and controls revealed a second association with a specific HLA-B sequence motif corresponding to Bw4-80Ile (odds ratio = 2.71, p = 0.02). Conclusions/Significance: HLA-A allelic product encoded by A*3201 is likely to be functionally important to GBM. The novel, sex-specific association will require further confirmation in other representative study populations.			Song, W (corresponding author), Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.	jtang@uab.edu	Tang, Jianming "James"/O-4980-2019; Ruder, Avima/I-4155-2012	Tang, Jianming "James"/0000-0003-0137-7486; Ruder, Avima/0000-0003-0419-6664	NCI NIH HHS [CA097257, R03 CA128059, P50 CA097257, CA128059, CA097247, P50 CA097247] Funding Source: Medline; NIAID NIH HHS [K02 AI076123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA128059, P50CA097257, P50CA097247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI076123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aldape KD, 2003, CANCER J, V9, P99, DOI 10.1097/00130404-200303000-00005; APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157; BASHIROVA AA, 2006, ANN REV GENOMICS HUM; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Brenner AV, 2007, CARCINOGENESIS, V28, P2543, DOI 10.1093/carcin/bgm210; Burt RD, 1996, CANCER EPIDEM BIOMAR, V5, P879; Cao K, 2001, HUM IMMUNOL, V62, P1009, DOI 10.1016/S0198-8859(01)00298-1; *CBTRUS, 2000, CBTRUS STAND STAT RE; Chen PC, 2001, CANCER RES, V61, P3949; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Davis F G, 1999, Neuro Oncol, V1, P205, DOI 10.1093/neuonc/1.3.205; Debinski W, 2001, MOL MED, V7, P598, DOI 10.1007/BF03401866; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Frigerio S, 1999, CANCER GENET CYTOGEN, V109, P172, DOI 10.1016/S0165-4608(98)00161-7; Girdlestone J, 2000, BLOOD, V95, P3804; Goldsmith DB, 2002, CLIN OTOLARYNGOL, V27, P61, DOI 10.1046/j.0307-7772.2001.00529.x; Goymer P, 2008, NATURE, V454, P1047, DOI 10.1038/4541046a; Guerini FR, 2006, J NEURO-ONCOL, V77, P213, DOI 10.1007/s11060-005-9032-x; Hildesheim A, 2002, J NATL CANCER I, V94, P1780, DOI 10.1093/jnci/94.23.1780; Hildesheim A, 2002, VIRUS RES, V89, P229, DOI 10.1016/S0168-1702(02)00191-0; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Hughes AL, 2002, IMMUNOL REV, V190, P161, DOI 10.1034/j.1600-065X.2002.19012.x; Jiang XB, 2007, ACTA BIOCH BIOPH SIN, V39, P641, DOI 10.1111/j.1745-7270.2007.00331.x; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; KULKARNI S, 2008, SEMIN IMMUNOL; LAMPSON LA, 1986, J IMMUNOL, V136, P4054; Lefebvre S, 1999, PLACENTA, V20, P293, DOI 10.1053/plac.1998.0380; LHaridon M, 1996, NUCLEIC ACIDS RES, V24, P1928, DOI 10.1093/nar/24.10.1928; Machulla HKG, 2001, J NEURO-ONCOL, V52, P253, DOI 10.1023/A:1010612327647; Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005; Matsumoto K, 2003, INT J CANCER, V106, P919, DOI 10.1002/ijc.11332; McKenzie LM, 1999, GENES IMMUN, V1, P120, DOI 10.1038/sj.gene.6363648; Middleton D, 2000, HUM IMMUNOL, V61, P1048, DOI 10.1016/S0198-8859(00)00178-6; Mittelbronn M, 2007, J NEUROIMMUNOL, V189, P50, DOI 10.1016/j.jneuroim.2007.07.002; NITTA T, 1994, NEUROSURG REV, V17, P211, DOI 10.1007/BF00418435; Norman PJ, 2007, NAT GENET, V39, P1092, DOI 10.1038/ng2111; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Okano F, 2002, CLIN CANCER RES, V8, P2851; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; Ruder AM, 2006, J AGRIC SAF HEALTH, V12, P255, DOI 10.13031/2013.22013; Ruder AM, 2004, ARCH ENVIRON HEALTH, V59, P650, DOI 10.1080/00039890409602949; Schreuder GMT, 2005, HUM IMMUNOL, V66, P170, DOI 10.1016/j.humimm.2004.09.017; Shao W, 2004, TISSUE ANTIGENS, V64, P286, DOI 10.1111/j.0001-2815.2004.00295.x; Shete S, 2009, NAT GENET, V41, P899, DOI 10.1038/ng.407; Shimato S, 2008, J NEUROSURG, V109, P117, DOI 10.3171/JNS/2008/109/7/0117; Surawicz T S, 1999, Neuro Oncol, V1, P14, DOI 10.1093/neuonc/1.1.14; Tang J, 2005, CLIN CANCER RES, V11, P5292, DOI 10.1158/1078-0432.CCR-05-0545; Tang JM, 2008, J IMMUNOL, V181, P2626, DOI 10.4049/jimmunol.181.4.2626; Tang JM, 2005, CANCER EPIDEM BIOMAR, V14, P2040, DOI 10.1158/1055-9965.EPI-05-0136; Ueda R, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-68; van der Burg SH, 2001, INT J CANCER, V91, P612, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1119>3.0.CO;2-C; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wiendl H, 2003, SEMIN CANCER BIOL, V13, P343, DOI 10.1016/S1044-579X(03)00025-7; Wischhusen J, 2005, J NEUROPATH EXP NEUR, V64, P523, DOI 10.1093/jnen/64.6.523; Wrensch M, 2002, NEURO-ONCOLOGY, V4, P278, DOI 10.1093/neuonc/4.4.278; Wrensch M, 2009, NAT GENET, V41, P905, DOI 10.1038/ng.408; Wykosky J, 2008, CLIN CANCER RES, V14, P199, DOI 10.1158/1078-0432.CCR-07-1990; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zehbe I, 2003, HUM IMMUNOL, V64, P538, DOI 10.1016/S0198-8859(03)00033-8; Zehbe I, 2001, INT J CANCER, V94, P711, DOI 10.1002/ijc.1520	61	23	23	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7157	10.1371/journal.pone.0007157	http://dx.doi.org/10.1371/journal.pone.0007157			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774073	Green Submitted, Green Published, gold			2022-12-27	WOS:000270160900022
J	Marchetto, MCN; Yeo, GW; Kainohana, O; Marsala, M; Gage, FH; Muotri, AR				Marchetto, Maria C. N.; Yeo, Gene W.; Kainohana, Osamu; Marsala, Martin; Gage, Fred H.; Muotri, Alysson R.			Transcriptional Signature and Memory Retention of Human-Induced Pluripotent Stem Cells	PLOS ONE			English	Article							EPISOMAL VECTORS; MOUSE; GENERATION; EXPRESSION; IDENTIFICATION; INDUCTION; SOX2; MYC	Genetic reprogramming of somatic cells to a pluripotent state (induced pluripotent stem cells or iPSCs) by over-expression of specific genes has been accomplished using mouse and human cells. However, it is still unclear how similar human iPSCs are to human Embryonic Stem Cells (hESCs). Here, we describe the transcriptional profile of human iPSCs generated without viral vectors or genomic insertions, revealing that these cells are in general similar to hESCs but with significant differences. For the generation of human iPSCs without viral vectors or genomic insertions, pluripotent factors Oct4 and Nanog were cloned in episomal vectors and transfected into human fetal neural progenitor cells. The transient expression of these two factors, or from Oct4 alone, resulted in efficient generation of human iPSCs. The reprogramming strategy described here revealed a potential transcriptional signature for human iPSCs yet retaining the gene expression of donor cells in human reprogrammed cells free of viral and transgene interference. Moreover, the episomal reprogramming strategy represents a safe way to generate human iPSCs for clinical purposes and basic research.			Marchetto, MCN (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	muotri@ucsd.edu	Yeo, Gene/AAE-7676-2019	Yeo, Gene/0000-0002-0799-6037				AASEN T, 2008, NAT BIOTECHNOL; Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; Best SM, 2008, ANNU REV MICROBIOL, V62, P171, DOI 10.1146/annurev.micro.62.081307.163009; Brambrink T, 2008, CELL STEM CELL, V2, P151, DOI 10.1016/j.stem.2008.01.004; Breier JM, 2008, TOXICOL SCI, V105, P119, DOI 10.1093/toxsci/kfn115; Cezar GG, 2007, STEM CELLS DEV, V16, P869, DOI 10.1089/scd.2007.0022; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Donato R, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-36; Eminli S, 2008, STEM CELLS, V26, P2467, DOI 10.1634/stemcells.2008-0317; Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028; KAJI K, 2009, NATURE; Kameda T, 2006, BIOCHEM BIOPH RES CO, V349, P1269, DOI 10.1016/j.bbrc.2006.08.175; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Leight ER, 2000, REV MED VIROL, V10, P83, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;83::AID-RMV262&gt;3.0.CO;2-T; Leight ER, 2001, MOL CELL BIOL, V21, P4149, DOI 10.1128/MCB.21.13.4149-4161.2001; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; MARGOLSKEE RF, 1992, CURR TOP MICROBIOL, V158, P67; Masui S, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-45; Muotri AR, 2005, P NATL ACAD SCI USA, V102, P18644, DOI 10.1073/pnas.0509315102; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Park IH, 2008, NAT PROTOC, V3, P1180, DOI 10.1038/nprot.2008.92; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Van Craenenbroeck K, 2000, EUR J BIOCHEM, V267, P5665, DOI 10.1046/j.1432-1327.2000.01645.x; Van Craenenbroeck K, 2000, GENE, V253, P293, DOI 10.1016/S0378-1119(00)00242-0; Varas F, 2008, STEM CELLS; Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001; WOLTJEN K, 2009, NATURE; Yeo GW, 2007, PLOS COMPUT BIOL, V3, P1951, DOI 10.1371/journal.pcbi.0030196; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102; YU J, 2009, SCIENCE; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788	43	231	247	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7076	10.1371/journal.pone.0007076	http://dx.doi.org/10.1371/journal.pone.0007076			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763270	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970400012
J	Andreasen, C; Powell, DA; Carbonetti, NH				Andreasen, Charlotte; Powell, Daniel A.; Carbonetti, Nicholas H.			Pertussis Toxin Stimulates IL-17 Production in Response to Bordetella pertussis Infection in Mice	PLOS ONE			English	Article							ADENYLATE-CYCLASE TOXIN; CELL-MEDIATED-IMMUNITY; RESPIRATORY-TRACT COLONIZATION; DENDRITIC CELLS; NEUTROPHIL RECRUITMENT; INFLAMMATORY CYTOKINE; INTERLEUKIN-17; TH1; LIPOPOLYSACCHARIDE; IDENTIFICATION	In a mouse model of respiratory tract infection by Bordetella pertussis, bacteria multiply in the airways over the first week and are then cleared over the next 3-4 weeks by the host immune response. Pertussis toxin ( PT), a virulence factor secreted exclusively by B. pertussis, promotes bacterial growth in the airways by suppression and modulation of host immune responses. By comparison of wild type and PT-deficient strains, we examined the role of PT in modulating airway cytokine and chemokine responses affecting neutrophil recruitment during B. pertussis infection in mice. We found that, despite early inhibition of neutrophil recruitment by PT, high numbers of neutrophils were recruited to the airways by 4 days post-infection with the wild type strain, but not with the PT-deficient strain, and that this correlated with upregulation of neutrophil-attracting chemokine gene expression. In addition, there was similar upregulation of genes expressing the cytokines IL-17A (IL-17), TNF-alpha and IFN-gamma, indicating a mixed Th1/Th17 response. Expression of IL-6, a cytokine involved in Th17 induction, was upregulated earlier than the IL-17 response. We showed that PT, rather than bacterial numbers, was important for induction of these responses. Flow cytometric analysis revealed that the IL-17-producing cells were macrophages and neutrophils as well as T cells, and were present predominantly in the airways rather than the lung tissue. Antibody neutralization of IL-17 significantly reduced chemokine gene expression and neutrophil recruitment to the airways, but only modestly increased peak bacterial loads. These data indicate that PT stimulates inflammatory responses by induction of Th1- and Th17-associated cytokines, including IL-17, during B. pertussis infection in mice, but a role for IL-17 in protection against the infection remains to be established.			Andreasen, C (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA.	ncarbone@umaryland.edu		Powell, Daniel/0000-0003-0503-3330	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063080] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI063080] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreasen C, 2008, INFECT IMMUN, V76, P5139, DOI 10.1128/IAI.00895-08; Andreasen C, 2009, INFECT IMMUN, V77, P1182, DOI 10.1128/IAI.01150-08; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Aujla SJ, 2007, EXP LUNG RES, V33, P507, DOI 10.1080/01902140701756604; Ausiello CM, 1997, DEV BIOL STAND, V89, P315; Bagley KC, 2002, J LEUKOCYTE BIOL, V72, P962; Banus S, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-21; Barnard A, 1996, IMMUNOLOGY, V87, P372, DOI 10.1046/j.1365-2567.1996.497560.x; Carbonetti NH, 2005, INFECT IMMUN, V73, P2698, DOI 10.1128/IAI.73.5.2698-2703.2005; Carbonetti NH, 2004, INFECT IMMUN, V72, P3350, DOI 10.1128/IAI.72.6.3350-3358.2004; Carbonetti NH, 2003, INFECT IMMUN, V71, P6358, DOI 10.1128/IAI.71.11.6358-6366.2003; Carbonetti NH, 2007, CURR OPIN PHARMACOL, V7, P272, DOI 10.1016/j.coph.2006.12.004; Carbonetti NH, 2007, INFECT IMMUN, V75, P1713, DOI 10.1128/IAI.01578-06; Castro MG, 2001, CELL MICROBIOL, V3, P45, DOI 10.1046/j.1462-5822.2001.00092.x; Chen X, 2007, J IMMUNOL, V178, P6123, DOI 10.4049/jimmunol.178.10.6123; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Fedele G, 2005, INFECT IMMUN, V73, P1590, DOI 10.1128/IAI.73.3.1590-1597.2005; Fedele G, 2008, J IMMUNOL, V181, P208, DOI 10.4049/jimmunol.181.1.208; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; Iwamoto S, 2007, J IMMUNOL, V179, P1449, DOI 10.4049/jimmunol.179.3.1449; Kramer JM, 2007, J PERIODONTOL, V78, P1083, DOI 10.1902/jop.2007.060392; Lentschat A, 2005, J IMMUNOL, V174, P4252, DOI 10.4049/jimmunol.174.7.4252; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Linden A, 2000, EUR RESPIR J, V15, P973, DOI 10.1034/j.1399-3003.2000.15e28.x; Mascart F, 2003, J IMMUNOL, V170, P1504, DOI 10.4049/jimmunol.170.3.1504; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; MILLS KHG, 1993, INFECT IMMUN, V61, P399, DOI 10.1128/IAI.61.2.399-410.1993; Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1189/jlb.1006610; Perkins DJ, 2007, MOL MICROBIOL, V66, P1003, DOI 10.1111/j.1365-2958.2007.05972.x; PITTMAN M, 1980, J INFECT DIS, V142, P56, DOI 10.1093/infdis/142.1.56; Ross PJ, 2004, INFECT IMMUN, V72, P1568, DOI 10.1128/IAI.72.3.1568-1579.2004; Siciliano NA, 2006, J IMMUNOL, V177, P7131, DOI 10.4049/jimmunol.177.10.7131; Skinner JA, 2004, J IMMUNOL, V173, P1934, DOI 10.4049/jimmunol.173.3.1934; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yu JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P170, DOI 10.2741/2667; Zepp F, 1997, DEV BIOLOGICALS, V89, P307; ZHANG XK, 1993, J IMMUNOL, V150, P1011	42	84	87	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7079	10.1371/journal.pone.0007079	http://dx.doi.org/10.1371/journal.pone.0007079			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759900	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970200009
J	Elbers, CC; de Kovel, CGF; van der Schouw, YT; Meijboom, JR; Bauer, F; Grobbee, DE; Trynka, G; van Vliet-Ostaptchouk, JV; Wijmenga, C; Onland-Moret, NC				Elbers, Clara C.; de Kovel, Carolien G. F.; van der Schouw, Yvonne T.; Meijboom, Juliaan R.; Bauer, Florianne; Grobbee, Diederick E.; Trynka, Gosia; van Vliet-Ostaptchouk, Jana V.; Wijmenga, Cisca; Onland-Moret, N. Charlotte			Variants in Neuropeptide Y Receptor 1 and 5 Are Associated with Nutrient-Specific Food Intake and Are Under Recent Selection in Europeans	PLOS ONE			English	Article								There is a large variation in caloric intake and macronutrient preference between individuals and between ethnic groups, and these food intake patterns show a strong heritability. The transition to new food sources during the agriculture revolution around 11,000 years ago probably created selective pressure and shaped the genome of modern humans. One major player in energy homeostasis is the appetite-stimulating hormone neuropeptide Y, in which the stimulatory capacity may be mediated by the neuropeptide Y receptors 1, 2 and 5 (NPY1R, NPY2R and NPY5R). We assess association between variants in the NPY1R, NPY2R and NPY5R genes and nutrient intake in a cross-sectional, single-center study of 400 men aged 40 to 80 years, and we examine whether genomic regions containing these genes show signatures of recent selection in 270 HapMap individuals (90 Africans, 90 Asians, and 90 Caucasians) and in 846 Dutch bloodbank controls. Our results show that derived alleles in NPY1R and NPY5R are associated with lower carbohydrate intake, mainly because of a lower consumption of mono- and disaccharides. We also show that carriers of these derived alleles, on average, consume meals with a lower glycemic index and glycemic load and have higher alcohol consumption. One of these variants shows the hallmark of recent selection in Europe. Our data suggest that lower carbohydrate intake, consuming meals with a low glycemic index and glycemic load, and/or higher alcohol consumption, gave a survival advantage in Europeans since the agricultural revolution. This advantage could lie in overall health benefits, because lower carbohydrate intake, consuming meals with a low GI and GL, and/or higher alcohol consumption, are known to be associated with a lower risk of chronic diseases.			Elbers, CC (corresponding author), Univ Med Ctr Utrecht, Dept Biomed Genet, Complex Genet Sect, Utrecht, Netherlands.	Y.T.vanderSchouw@UMCUtrecht.nl	Wijmenga, Cisca/D-2173-2009; van der Schouw, Yvonne T./F-8327-2014; Grobbee, Diederick/C-7651-2014; de Kovel, Carolien/AAI-3531-2021; Onland-Moret, N. Charlotte/G-9185-2011; Wijmenga, Cisca/AAE-7719-2019	van der Schouw, Yvonne T./0000-0002-4605-435X; Grobbee, Diederick/0000-0003-4472-4468; de Kovel, Carolien/0000-0002-7818-1396; Onland-Moret, N. Charlotte/0000-0002-2360-913X; Wijmenga, Cisca/0000-0002-5635-1614; Trynka, Gosia/0000-0002-6955-9529; van Vliet-Ostaptchouk, Jana/0000-0002-7943-3153				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627; Bell CG, 2005, NAT REV GENET, V6, P221, DOI 10.1038/nrg1556; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beulens JWJ, 2005, DIABETES CARE, V28, P2933, DOI 10.2337/diacare.28.12.2933; Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987; Davies MJ, 2002, JAMA-J AM MED ASSOC, V287, P2559, DOI 10.1001/jama.287.19.2559; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; de Kleijn MJJ, 2001, J NUTR, V131, P1826; Diamond J, 2002, NATURE, V418, P700, DOI 10.1038/nature01019; DOWSE GK, 1991, AM J EPIDEMIOL, V133, P1093, DOI 10.1093/oxfordjournals.aje.a115822; Elbers CC, 2007, TRENDS ENDOCRIN MET, V18, P19, DOI 10.1016/j.tem.2006.11.003; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; JOBLING M, 2004, HUMAN EVOLUTIONARY G, V20; Kagawa Y, 2002, BIOCHEM BIOPH RES CO, V295, P207, DOI 10.1016/S0006-291X(02)00680-0; KALRA SP, 2004, TRENDS PHARMACOL SCI, V20, P43; Kenneth F, 2000, CAMBRIDGE WORLD HIST; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Loos RJF, 2005, AM J CLIN NUTR, V82, P1097, DOI 10.1093/ajcn/82.5.1097; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; MCDONALD RB, 1994, P SOC EXP BIOL MED, V207, P102, DOI 10.3181/00379727-207-43798; Muller M, 2003, EUR J ENDOCRINOL, V149, P583, DOI 10.1530/eje.0.1490583; NEEL JV, 1962, AM J HUM GENET, V14, P353; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Ocke MC, 1997, INT J EPIDEMIOL, V26, pS37, DOI 10.1093/ije/26.suppl_1.S37; Ocke MC, 1997, INT J EPIDEMIOL, V26, pS49, DOI 10.1093/ije/26.suppl_1.S49; Rankinen T, 2006, ANNU REV NUTR, V26, P413, DOI 10.1146/annurev.nutr.26.061505.111218; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Sierksma A, 2002, EUR J CLIN NUTR, V56, P1130, DOI 10.1038/sj.ejcn.1601459; STANLEY BG, 1985, PEPTIDES, V6, P1205, DOI 10.1016/0196-9781(85)90452-8; STEPHEN AM, 1995, AM J CLIN NUTR, V62, p851S, DOI 10.1093/ajcn/62.4.851S; Thiele TE, 2003, PHYSIOL BEHAV, V79, P95, DOI 10.1016/S0031-9384(03)00109-4; Tishkoff SA, 2007, NAT GENET, V39, P31, DOI 10.1038/ng1946; van Heel DA, 2007, NAT GENET, V39, P827, DOI 10.1038/ng2058; van Vliet-Ostaptchouk JV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001405; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366	40	10	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7070	10.1371/journal.pone.0007070	http://dx.doi.org/10.1371/journal.pone.0007070			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759915	Green Published, gold, Green Submitted			2022-12-27	WOS:000269970200006
J	Metzgar, D; Skochko, G; Gibbins, C; Hudson, N; Lott, L; Jones, MS				Metzgar, David; Skochko, Greg; Gibbins, Carl; Hudson, Nolan; Lott, Lisa; Jones, Morris S.			Evaluation and Validation of a Real-Time PCR Assay for Detection and Quantitation of Human Adenovirus 14 from Clinical Samples	PLOS ONE			English	Article							IDENTIFICATION	In 2007, the Centers for Disease Control and Prevention (CDC) reported that Human adenovirus type 14 (HAdV-14) infected 106 military personnel and was responsible for the death of one U. S. soldier at Lackland Air Force Base in Texas. Identification of the responsible adenovirus, which had not previously been seen in North America and for which rapid diagnostic tools were unavailable, required retrospective analysis at reference laboratories. Initial quarantine measures were also reliant on relatively slow traditional PCR analysis at other locations. To address this problem, we developed a real-time PCR assay that detects a 225 base pair sequence in the HAdV-14a hexon gene. Fifty-one oropharyngeal swab specimens from the Naval Health Research Center, San Diego, CA and Advanced Diagnostic Laboratory, Lackland AFB, TX were used to validate the new assay. The described assay detected eight of eight and 19 of 19 confirmed HAdV-14a clinical isolates in two separate cohorts from respiratory disease outbreaks. The real-time PCR assay had a wide dynamic range, detecting from 10 2 to 10 7 copies of genomic DNA per reaction. The assay did not cross-react with other adenoviruses, influenza, respiratory syncytial virus, or common respiratory tract bacteria. The described assay is easy to use, sensitive and specific for HAdV-14a in clinical throat swab specimens, and very rapid since turnaround time is less than four hours to obtain an answer.			Metzgar, D (corresponding author), Naval Hlth Res Ctr, Dept Resp Dis Res, San Diego, CA USA.	drmorrisj@yahoo.com						Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P1181; Benko M., 2005, VIRUS TAXONOMY 8 REP, P213; Chmielewicz B, 2005, J MED VIROL, V77, P232, DOI 10.1002/jmv.20441; DINGLE JH, 1968, AM REV RESPIR DIS, V97, P1; Ebner K, 2006, J CLIN MICROBIOL, V44, P2808, DOI 10.1128/JCM.00048-06; Ginsberg HS, 1955, AM J PUBLIC HEALTH N, V45, P915, DOI 10.2105/AJPH.45.7.915; Gu Z, 2003, J CLIN MICROBIOL, V41, P4636, DOI 10.1128/JCM.41.10.4636-4641.2003; HILLEMAN MR, 1954, P SOC EXP BIOL MED, V85, P183, DOI 10.3181/00379727-85-20825; Huang ML, 2008, DIAGN MICR INFEC DIS, V62, P263, DOI 10.1016/j.diagmicrobio.2008.06.009; Jones MS, 2007, J VIROL, V81, P5978, DOI 10.1128/JVI.02650-06; Kim HS, 2008, J CLIN MICROBIOL, V46, P2992, DOI 10.1128/JCM.00027-08; Louie JK, 2008, CLIN INFECT DIS, V46, P421, DOI 10.1086/525261; Madisch I, 2006, J MED VIROL, V78, P1210, DOI 10.1002/jmv.20683; Metzgar D, 2005, J CLIN MICROBIOL, V43, P5743, DOI 10.1128/JCM.43.11.5743-5752.2005; Metzgar D, 2007, J INFECT DIS, V196, P1465, DOI 10.1086/522970; Pang XL, 2004, J CLIN MICROBIOL, V42, P4679, DOI 10.1128/JCM.42.10.4679-4685.2004; ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714; TATE JE, 2009, J INFECT DIS    0406; WALSH MP, 2009, PLOS ONE IN PRESS; Wong S, 2008, J MED VIROL, V80, P856, DOI 10.1002/jmv.21136; Xu WH, 2001, J MED VIROL, V64, P537, DOI 10.1002/jmv.1083; Zhu Z, 2009, J CLIN MICROBIOL, V47, P697, DOI 10.1128/JCM.01769-08	22	16	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7081	10.1371/journal.pone.0007081	http://dx.doi.org/10.1371/journal.pone.0007081			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759905	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970200011
J	Nishizawa, D; Nagashima, M; Katoh, R; Satoh, Y; Tagami, M; Kasai, S; Ogai, Y; Han, WH; Hasegawa, J; Shimoyama, N; Sora, I; Hayashida, M; Ikeda, K				Nishizawa, Daisuke; Nagashima, Makoto; Katoh, Ryoji; Satoh, Yasuo; Tagami, Megumi; Kasai, Shinya; Ogai, Yasukazu; Han, Wenhua; Hasegawa, Junko; Shimoyama, Naohito; Sora, Ichiro; Hayashida, Masakazu; Ikeda, Kazutaka			Association between KCNJ6 (GIRK2) Gene Polymorphisms and Postoperative Analgesic Requirements after Major Abdominal Surgery	PLOS ONE			English	Article							WHOLE-GENOME ASSOCIATION; POTASSIUM CHANNELS; MORPHINE; SUBUNIT; LOCALIZATION; CONTRIBUTE; MUTATIONS; OPIOIDS; ETHANOL; POWER	Opioids are commonly used as effective analgesics for the treatment of acute and chronic pain. However, considerable individual differences have been widely observed in sensitivity to opioid analgesics. We focused on a G-protein-activated inwardly rectifying potassium (GIRK) channel subunit, GIRK2, that is an important molecule in opioid transmission. In our initial polymorphism search, a total of nine single-nucleotide polymorphisms (SNPs) were identified in the whole exon, 5'-flanking, and exon-intron boundary regions of the KCNJ6 gene encoding GIRK2. Among them, G-1250A and A1032G were selected as representative SNPs for further association studies. In an association study of 129 subjects who underwent major open abdominal surgery, the A/A genotype in the A1032G SNP and -1250G/1032A haplotype were significantly associated with increased postoperative analgesic requirements compared with other genotypes and haplotypes. The total dose (mean +/- SEM) of rescue analgesics converted to equivalent oral morphine doses was 20.45 +/- 9.27 mg, 10.84 +/- 2.24 mg, and 13.07 +/- 2.39 mg for the A/A, A/G, and G/G genotypes in the A1032G SNP, respectively. Additionally, KCNJ6 gene expression levels in the 1032A/A subjects were significantly decreased compared with the 1032A/G and 1032G/G subjects in a real-time quantitative PCR analysis using human brain tissues, suggesting that the 1032A/A subjects required more analgesics because of lower KCNJ6 gene expression levels and consequently insufficient analgesic effects. The results indicate that the A1032G SNP and G-1250A/A1032G haplotype could serve as markers that predict increased analgesic requirements. Our findings will provide valuable information for achieving satisfactory pain control and open new avenues for personalized pain treatment.			Nishizawa, D (corresponding author), Tokyo Inst Psychiat, Div Psychobiol, Tokyo, Japan.	Ikedak@prit.go.jp	Nishizawa, Daisuke/G-6933-2013; Ikeda, Kazutaka/I-4694-2013	Ikeda, Kazutaka/0000-0001-8342-0278				BAHAR M, 1985, ANAESTHESIA, V40, P529; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Basar H, 2003, J ENDOUROL, V17, P3, DOI 10.1089/089277903321196706; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blednow YA, 2003, P NATL ACAD SCI USA, V100, P277, DOI 10.1073/pnas.012682399; BUCHANAN WW, 1986, AM J MED, V80, P145, DOI 10.1016/0002-9343(86)90134-8; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Cohen J.E., 1988, STAT POWER ANAL BEHA; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; HOSKIN PJ, 1991, DRUGS, V41, P326, DOI 10.2165/00003495-199141030-00002; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Ikeda K, 2002, NEUROSCI RES, V44, P121, DOI 10.1016/S0168-0102(02)00094-9; Jelacic TM, 2000, J BIOL CHEM, V275, P36211, DOI 10.1074/jbc.M007087200; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; KLINCK JR, 1982, ANAESTHESIA, V37, P907, DOI 10.1111/j.1365-2044.1982.tb01852.x; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; Kobayashi T, 1999, NAT NEUROSCI, V2, P1091, DOI 10.1038/16019; Kobayashi T, 2006, CURR PHARM DESIGN, V12, P4513, DOI 10.2174/138161206779010468; Marker CL, 2005, J NEUROSCI, V25, P3551, DOI 10.1523/JNEUROSCI.4899-04.2005; Marker CL, 2004, J NEUROSCI, V24, P2806, DOI 10.1523/JNEUROSCI.5251-03.2004; Marker CL, 2002, NEUROREPORT, V13, P2509, DOI 10.1097/00001756-200212200-00026; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Ozcan S, 2002, SCAND J UROL NEPHROL, V36, P281, DOI 10.1080/003655902320248254; PATHAK KS, 1983, ANESTH ANALG, V62, P841; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; RAKIC P, 1973, P NATL ACAD SCI USA, V70, P240, DOI 10.1073/pnas.70.1.240; SAKURA H, 1995, FEBS LETT, V367, P193, DOI 10.1016/0014-5793(95)00498-X; Smith SB, 2008, PHARMACOGENET GENOM, V18, P231, DOI 10.1097/FPC.0b013e3282f55ab2; STOFFEL M, 1994, GENOMICS, V21, P254, DOI 10.1006/geno.1994.1253; SUNSHINE S, 1994, TXB PAIN, P923; Tong YH, 1996, FEBS LETT, V390, P63, DOI 10.1016/0014-5793(96)00632-1; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; YASUDA K, 1995, BIOCHEM BIOPH RES CO, V211, P1036, DOI 10.1006/bbrc.1995.1915; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	46	49	54	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7060	10.1371/journal.pone.0007060	http://dx.doi.org/10.1371/journal.pone.0007060			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756153	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970000022
J	Wu, CY; Steffen, J; Eide, DJ				Wu, Chang-Yi; Steffen, Janet; Eide, David J.			Cytosolic Superoxide Dismutase (SOD1) Is Critical for Tolerating the Oxidative Stress of Zinc Deficiency in Yeast	PLOS ONE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; COPPER CHAPERONE; NITRIC-OXIDE; DIETARY ZINC; CELL-DEATH; CU; AGGREGATION; ACTIVATION; RESISTANCE	Zinc deficiency causes oxidative stress in many organisms including the yeast Saccharomyces cerevisiae. Previous studies of this yeast indicated that the Tsa1 peroxiredoxin is required for optimal growth in low zinc because of its role in degrading H2O2. In this report, we assessed the importance of other antioxidant genes to zinc-limited growth. Our results indicated that the cytosolic superoxide dismutase Sod1 is also critical for growth under zinc-limiting conditions. We also found that Ccs1, the copper-delivering chaperone required for Sod1 activity is essential for optimal zinc-limited growth. To our knowledge, this is the first demonstration of the important roles these proteins play under this condition. It has been proposed previously that a loss of Sod1 activity due to inefficient metallation is one source of reactive oxygen species (ROS) under zinc-limiting conditions. Consistent with this hypothesis, we found that both the level and activity of Sod1 is diminished in zinc-deficient cells. However, under conditions in which Sod1 was overexpressed in zinc-limited cells and activity was restored, we observed no decrease in ROS levels. Thus, these data indicate that while Sod1 activity is critical for low zinc growth, diminished Sod1 activity is not a major source of the elevated ROS observed under these conditions.			Wu, CY (corresponding author), Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA.	deide@wisc.edu			NIGMS NIH HHS [R01-GM56285, R01 GM056285] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; Banci L, 2007, P NATL ACAD SCI USA, V104, P11263, DOI 10.1073/pnas.0704307104; Beckman JS, 2001, TRENDS NEUROSCI, V24, pS15, DOI 10.1016/S0166-2236(00)01981-0; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE JP, 1985, P SOC EXP BIOL MED, V179, P187; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; CHANG EC, 1989, J BIOL CHEM, V264, P12172; Crow JP, 1997, J NEUROCHEM, V69, P1936; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Eide DJ, 2009, J BIOL CHEM, V284, P18565, DOI 10.1074/jbc.R900014200; Ermilova IP, 2005, NEUROSCI LETT, V379, P42, DOI 10.1016/j.neulet.2004.12.045; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103; Furukawa Y, 2008, J BIOL CHEM, V283, P24167, DOI 10.1074/jbc.M802083200; Garay-Arroyo A, 2003, FEBS LETT, V539, P68, DOI 10.1016/S0014-5793(03)00199-6; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; Hart PJ, 2006, CURR OPIN CHEM BIOL, V10, P131, DOI 10.1016/j.cbpa.2006.02.034; Ho E, 2004, J NUTR BIOCHEM, V15, P572, DOI 10.1016/j.jnutbio.2004.07.005; Ho E, 2003, J NUTR, V133, P2543, DOI 10.1093/jn/133.8.2543; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; International Zinc Consultative Group, 2004, FOOD NUTR BULL, V25, pS99, DOI DOI 10.1177/15648265040251S205; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Luk E, 2005, J BIOL CHEM, V280, P22715, DOI 10.1074/jbc.M504257200; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Maret W, 2007, MOL MED, V13, P371, DOI 10.2119/2007-00036.Maret; OTEIZA PI, 1995, J NUTR, V125, P823; Park JI, 1998, J BIOL CHEM, V273, P22921, DOI 10.1074/jbc.273.36.22921; Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Sun JY, 2005, BIOL TRACE ELEM RES, V107, P153, DOI 10.1385/BTER:107:2:153; Tan SX, 2009, MOL BIOL CELL, V20, P1493, DOI 10.1091/mbc.E08-07-0697; Taysi S, 2008, BIOL TRACE ELEM RES, V123, P161, DOI 10.1007/s12011-008-8095-x; TRUMBULL KA, 2009, ANTIOXID RE IN PRESS; Wei JPJ, 2001, J BIOL CHEM, V276, P44798, DOI 10.1074/jbc.M104708200; Wu CY, 2007, J BIOL CHEM, V282, P2184, DOI 10.1074/jbc.M606639200; Wu CY, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-370	49	34	35	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7061	10.1371/journal.pone.0007061	http://dx.doi.org/10.1371/journal.pone.0007061			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756144	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970000023
J	Spangler, R; Goddard, NL; Thaler, DS				Spangler, Rudolph; Goddard, Noel L.; Thaler, David S.			Optimizing Taq Polymerase Concentration for Improved Signal-to-Noise in the Broad Range Detection of Low Abundance Bacteria	PLOS ONE			English	Article							CHAIN-REACTION REAGENTS; REAL-TIME PCR; CONTAMINATING DNA; ONE-CELL; ELIMINATION; DECONTAMINATION; IDENTIFICATION; ASSAY	Background: PCR in principle can detect a single target molecule in a reaction mixture. Contaminating bacterial DNA in reagents creates a practical limit on the use of PCR to detect dilute bacterial DNA in environmental or public health samples. The most pernicious source of contamination is microbial DNA in DNA polymerase preparations. Importantly, all commercial Taq polymerase preparations inevitably contain contaminating microbial DNA. Removal of DNA from an enzyme preparation is problematical. Methodology/Principal Findings: This report demonstrates that the background of contaminating DNA detected by quantitative PCR with broad host range primers can be decreased greater than 10-fold through the simple expedient of Taq enzyme dilution, without altering detection of target microbes in samples. The general method is: For any thermostable polymerase used for high-sensitivity detection, do a dilution series of the polymerase crossed with a dilution series of DNA or bacteria that work well with the test primers. For further work use the concentration of polymerase that gave the least signal in its negative control (H2O) while also not changing the threshold cycle for dilutions of spiked DNA or bacteria compared to higher concentrations of Taq polymerase. Conclusions/Significance: It is clear from the studies shown in this report that a straightforward procedure of optimizing the Taq polymerase concentration achieved "treatment-free" attenuation of interference by contaminating bacterial DNA in Taq polymerase preparations. This procedure should facilitate detection and quantification with broad host range primers of a small number of bona fide bacteria (as few as one) in a sample.			Spangler, R (corresponding author), Rockefeller Univ, Sackler Lab Mol Genet & Informat, 1230 York Ave, New York, NY 10021 USA.	rspangle@hunter.cuny.edu						BOTTGER EC, 1990, CLIN CHEM, V36, P1258; Carroll NM, 1999, J CLIN MICROBIOL, V37, P3402, DOI 10.1128/JCM.37.10.3402-3404.1999; Corless CE, 2000, J CLIN MICROBIOL, V38, P1747, DOI 10.1128/JCM.38.5.1747-1752.2000; FURRER B, 1990, NATURE, V346, P324, DOI 10.1038/346324b0; GOLDENBERGER D, 1995, J MICROBIOL METH, V21, P27, DOI 10.1016/0167-7012(94)00024-2; Harris KA, 2003, J MED MICROBIOL, V52, P685, DOI 10.1099/jmm.0.05213-0; Heininger A, 2003, J CLIN MICROBIOL, V41, P1763, DOI 10.1128/JCM.41.4.1763-1765.2003; Hilali F, 1997, MOL BIOTECHNOL, V7, P207, DOI 10.1007/BF02740812; HUGHES MS, 1994, J CLIN MICROBIOL, V32, P2007, DOI 10.1128/JCM.32.8.2007-2008.1994; Ishoey T, 2008, CURR OPIN MICROBIOL, V11, P198, DOI 10.1016/j.mib.2008.05.006; Iversen Bjorn G, 2007, Ann Clin Microbiol Antimicrob, V6, P3, DOI 10.1186/1476-0711-6-3; JINNO Y, 1990, NUCLEIC ACIDS RES, V18, P6739, DOI 10.1093/nar/18.22.6739; Klaschik S, 2002, MOL BIOTECHNOL, V22, P231, DOI 10.1385/MB:22:3:231; Lyons SR, 2000, J CLIN MICROBIOL, V38, P2362; MEIER A, 1993, J CLIN MICROBIOL, V31, P646, DOI 10.1128/JCM.31.3.646-652.1993; Mohammadi T, 2003, J CLIN MICROBIOL, V41, P4796, DOI 10.1128/JCM.41.10.4796-4798.2003; OU CY, 1991, BIOTECHNIQUES, V10, P442; RAND KH, 1990, MOL CELL PROBE, V4, P445, DOI 10.1016/0890-8508(90)90003-I; ROCHELLE PA, 1992, BIOTECHNIQUES, V13, P520; Sambrook J., 2001, MOL CLONING LAB MANU; SCHMIDT TM, 1991, BIOTECHNIQUES, V11, P176; SHARMA JK, 1992, NUCLEIC ACIDS RES, V20, P6117, DOI 10.1093/nar/20.22.6117; Silkie SS, 2008, J MICROBIOL METH, V72, P275, DOI 10.1016/j.mimet.2007.12.011; Spangler R, 2009, J MOL BIOL, V392, P283, DOI 10.1016/j.jmb.2009.07.012; Stepanauskas R, 2007, P NATL ACAD SCI USA, V104, P9052, DOI 10.1073/pnas.0700496104; Woyke T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005299; Yang S, 2002, J CLIN MICROBIOL, V40, P3449, DOI 10.1128/JCM.40.9.3449-3454.2002	27	34	36	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7010	10.1371/journal.pone.0007010	http://dx.doi.org/10.1371/journal.pone.0007010			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753123	gold, Green Published			2022-12-27	WOS:000269796500005
J	Estrada-Gelonch, A; Aramburu, J; Lopez-Rodriguez, C				Estrada-Gelonch, Anais; Aramburu, Jose; Lopez-Rodriguez, Cristina			Exclusion of NFAT5 from Mitotic Chromatin Resets Its Nucleo-Cytoplasmic Distribution in Interphase	PLOS ONE			English	Article								Background: The transcription factor NFAT5 is a major inducer of osmoprotective genes and is required to maintain the proliferative capacity of cells exposed to hypertonic stress. In response to hypertonicity, NFAT5 translocates to the nucleus, binds to regulatory regions of osmoprotective genes and activates their transcription. Besides stimulus-specific regulatory mechanisms, the activity of transcription factors in cycling cells is also regulated by the passage through mitosis, when most transcriptional processes are downregulated. It was not known whether mitosis could be a point of control for NFAT5. Methodology/Principal Findings: Using confocal microscopy we observed that NFAT5 was excluded from chromatin during mitosis in both isotonic and hypertonic conditions. Analysis of NFAT5 deletions showed that exclusion was mediated by the carboxy-terminal domain (CTD). NFAT5 mutants lacking this domain showed constitutive binding to mitotic chromatin independent of tonicity, which caused them to localize in the nucleus and remain bound to chromatin in the subsequent interphase without hypertonic stimulation. We analyzed the contribution of the CTD, DNA binding, and nuclear import and export signals to the subcellular localization of this factor. Our results indicated that cytoplasmic localization of NFAT5 in isotonic conditions required both the exclusion from mitotic DNA and active nuclear export in interphase. Finally, we identified several regions within the CTD of NFAT5, some of them overlapping with transactivation domains, which were separately capable of causing its exclusion from mitotic chromatin. Conclusions/Significance: Our results reveal a multipart mechanism regulating the subcellular localization of NFAT5. The transactivating module of NFAT5 switches its function from an stimulus-specific activator of transcription in interphase to an stimulus-independent repressor of binding to DNA in mitosis. This mechanism, together with export signals acting in interphase, resets the cytoplasmic localization of NFAT5 and prevents its nuclear accumulation and association with DNA in the absence of hypertonic stress.			Estrada-Gelonch, A (corresponding author), UPF, Dept Expt & Hlth Sci DCEXS, Immunol Unit, Parc Recerca Biomed Barcelona PRBB, Barcelona, Spain.	jose.aramburu@upf.edu; cristina.lopez-rodriguez@upf.edu	Lopez-Rodriguez, C/G-4482-2014; Aramburu, J/G-8991-2014	Lopez-Rodriguez, C/0000-0002-2311-2406; Aramburu, J/0000-0001-9279-9523				Aramburu J, 2006, BIOCHEM PHARMACOL, V72, P1597, DOI 10.1016/j.bcp.2006.07.002; Batonnet-Pichon S, 2006, EXP CELL RES, V312, P3999, DOI 10.1016/j.yexcr.2006.09.001; Burg MB, 2008, J BIOL CHEM, V283, P7309, DOI 10.1074/jbc.R700042200; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; Drews-Elger K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005245; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang Xuan, 2006, Methods Mol Biol, V314, P73; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jeon US, 2006, ACTA PHYSIOL, V187, P241, DOI 10.1111/j.1748-1716.2006.01551.x; Jiang ZR, 2000, INVEST OPHTH VIS SCI, V41, P1467; Kwon MS, 2008, J BIOL CHEM, V283, P22400, DOI 10.1074/jbc.M710550200; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Lopez-Rodriguez C, 1999, COLD SPRING HARB SYM, V64, P517, DOI 10.1101/sqb.1999.64.517; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; Miyakawa H, 1999, BBA-GENE STRUCT EXPR, V1446, P359, DOI 10.1016/S0167-4781(99)00122-0; Morancho B, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-13; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; Ranjbar S, 2006, PLOS PATHOG, V2, P1176, DOI 10.1371/journal.ppat.0020130; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rodriguez A, 1999, ANAL BIOCHEM, V272, P171, DOI 10.1006/abio.1999.4156; Sarge KD, 2005, TRENDS BIOCHEM SCI, V30, P605, DOI 10.1016/j.tibs.2005.09.004; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Tong EHY, 2006, J BIOL CHEM, V281, P23870, DOI 10.1074/jbc.M602556200; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Vikramadithyan RK, 2005, J CLIN INVEST, V115, P2434, DOI 10.1172/JCI24819; Xu SX, 2008, J BIOL CHEM, V283, P17624, DOI 10.1074/jbc.M800281200	42	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7036	10.1371/journal.pone.0007036	http://dx.doi.org/10.1371/journal.pone.0007036			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750013	Green Published, gold			2022-12-27	WOS:000269796300021
J	Heath, L; Fox, A; McClure, J; Diem, K; Van ' t, AB; Zhao, H; Park, DR; Schouten, JT; Twigg, HL; Corey, L; Mullins, JI; Mittler, JE				Heath, Laura; Fox, Alan; McClure, Jan; Diem, Kurt; Van ' t Wout, Angelique B.; Zhao, Hong; Park, David R.; Schouten, Jeffrey T.; Twigg, Homer L., III; Corey, Lawrence; Mullins, James I.; Mittler, John E.			Evidence for Limited Genetic Compartmentalization of HIV-1 between Lung and Blood	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; ALVEOLAR MACROPHAGES; INFECTED INDIVIDUALS; PERIPHERAL-BLOOD; T-LYMPHOCYTES; PROVIRAL DNA; COPY NUMBER; V3 LOOP; CELLS	Background: HIV-1 is frequently detected in the lungs of infected individuals and is likely important in the development of pulmonary opportunistic infections. The unique environment of the lung, rich in alveolar macrophages and with specialized local immune responses, may contribute to differential evolution or selection of HIV-1. Methodology and Findings: We characterized HIV-1 in the lung in relation to contemporaneous viral populations in the blood. The C2-V5 region of HIV-1 env was sequenced from paired lung (induced sputum or bronchoalveolar lavage) and blood (plasma RNA and proviral DNA from sorted or unsorted PBMC) from 18 subjects. Compartmentalization between tissue pairs was assessed using 5 established tree or distance-based methods, including permutation tests to determine statistical significance. We found statistical evidence of compartmentalization between lung and blood in 10/18 subjects, although lung and blood sequences were intermingled on phylogenetic trees in all subjects. The subject showing the greatest compartmentalization contained many nearly identical sequences in BAL sample, suggesting clonal expansion may contribute to reduced viral diversity in the lung in some cases. However, HIV-1 sequences in lung were not more homogeneous overall, nor were we able to find a lung-specific genotype associated with macrophage tropism in V3. In all four subjects in whom predicted X4 genotypes were found in blood, predicted X4 genotypes were also found in lung. Conclusions: Our results support a picture of continuous migration of HIV-1 between circulating blood and lung tissue, with perhaps a very limited degree of localized evolution or clonal replication.			Mittler, JE (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	jmittler@u.washington.edu	Fox, Alan/GPS-5041-2022; Corey, Lawrence/AAE-1796-2020	Fox, Alan/0000-0002-9047-1986; Corey, Lawrence/0000-0002-2179-2436	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI057005, P30AI027757] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL072631] Funding Source: Medline; NIAID NIH HHS [P30 AI027757, P01 AI057005, P30-AI027757, P01-AI057005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini C, 1996, IMMUNOL TODAY, V17, P359, DOI 10.1016/0167-5699(96)30022-4; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P49, DOI 10.1038/mi.2007.5; Clark JG, 2004, AM J RESP CELL MOL, V30, P220, DOI 10.1165/rcmb.2003-0208OC; CLARKE JR, 1995, THORAX, V50, P567, DOI 10.1136/thx.50.5.567; CLARKE JR, 1994, CLIN EXP IMMUNOL, V96, P182; Collins KR, 2000, J ACQ IMMUN DEF SYND, V24, P408, DOI 10.1097/00126334-200008150-00002; Collins KR, 2002, J VIROL, V76, P1697, DOI 10.1128/JVI.76.4.1697-1706.2002; Critchlow DE, 2000, MATH COMPUT MODEL, V32, P69, DOI 10.1016/S0895-7177(00)00120-5; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Deng W, 2007, BIOINFORMATICS, V23, P2334, DOI 10.1093/bioinformatics/btm331; Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137; Diem K, 2008, AIDS RES HUM RETROV, V24, P561, DOI 10.1089/aid.2007.0115; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; Gilbert PB, 2005, BIOMETRICS, V61, P106, DOI 10.1111/j.0006-341X.2005.020719.x; Grabar S, 2008, HIV MED, V9, P246, DOI 10.1111/j.1468-1293.2008.00554.x; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Hudson RR, 2000, GENETICS, V155, P2011; Hung CS, 1999, J VIROL, V73, P8216, DOI 10.1128/JVI.73.10.8216-8226.1999; ITESCU S, 1994, P NATL ACAD SCI USA, V91, P11378, DOI 10.1073/pnas.91.24.11378; JEFFREY AA, 1991, CLIN EXP IMMUNOL, V84, P488; Jensen MA, 2003, J VIROL, V77, P13376, DOI 10.1128/JVI.77.24.13376-13388.2003; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; Pond SLK, 2006, MOL BIOL EVOL, V23, P1891, DOI 10.1093/molbev/msl051; Kruger K, 2008, BRAIN BEHAV IMMUN, V22, P324, DOI 10.1016/j.bbi.2007.08.008; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; MADDISON WP, 1991, EVOLUTION, V45, P1184, DOI [10.1111/j.1558-5646.1991.tb04385.x, 10.2307/2409726]; MADDISON WP, 2001, MACCLADE ANAL PHYLOG, P503; McClure J, 2007, JAIDS-J ACQ IMM DEF, V44, P254, DOI 10.1097/QAI.0b013e318030f5c5; MITCHELL DM, 1995, THORAX, V50, P294, DOI 10.1136/thx.50.3.294; Moreno P, 1996, AIDS, V10, P682, DOI 10.1097/00002030-199606000-00019; Nakata K, 1997, AM J RESP CRIT CARE, V155, P996, DOI 10.1164/ajrccm.155.3.9117038; NAKATA K, 1995, MOL MED, V1, P744, DOI 10.1007/BF03401889; Ohagen A, 2003, J VIROL, V77, P12336, DOI 10.1128/JVI.77.22.12336-12345.2003; Park DR, 1996, J IMMUNOL, V157, P2528; Pillai SK, 2006, BRAIN, V129, P1872, DOI 10.1093/brain/awl136; Pillai SK, 2005, J VIROL, V79, P1734, DOI 10.1128/JVI.79.3.1734-1742.2005; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; RODRIGO AG, 1998, QUALITY ENDPOINT DIL; Rogan MP, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-29; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SEMENSATO G, 1995, BLOOD, V85, P2308, DOI 10.1182/blood.V85.9.2308.bloodjournal8592308; Singh A, 1999, J VIROL, V73, P6680, DOI 10.1128/JVI.73.8.6680-6690.1999; Swofford D. L., 1999, PAUP 4 0 PHYLOGENETI; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; Twigg HL, 2008, J INFECT DIS, V197, P109, DOI 10.1086/523766; vantWout AB, 1998, J VIROL, V72, P488; WAGNER TA, 2009, AIDS; Wang TH, 2001, J VIROL, V75, P11686, DOI 10.1128/JVI.75.23.11686-11699.2001; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Zarate S, 2007, J VIROL, V81, P6643, DOI 10.1128/JVI.02268-06; Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106	58	28	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6949	10.1371/journal.pone.0006949	http://dx.doi.org/10.1371/journal.pone.0006949			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759830	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796300006
J	Lindstrom, S; Eriksson, M; Vazin, T; Sandberg, J; Lundeberg, J; Frisen, J; Andersson-Svahn, H				Lindstrom, Sara; Eriksson, Malin; Vazin, Tandis; Sandberg, Julia; Lundeberg, Joakim; Frisen, Jonas; Andersson-Svahn, Helene			High-Density Microwell Chip for Culture and Analysis of Stem Cells	PLOS ONE			English	Article								With recent findings on the role of reprogramming factors on stem cells, in vitro screening assays for studying (de)differentiation is of great interest. We developed a miniaturized stem cell screening chip that is easily accessible and provides means of rapidly studying thousands of individual stem/progenitor cell samples, using low reagent volumes. For example, screening of 700,000 substances would take less than two days, using this platform combined with a conventional bio-imaging system. The microwell chip has standard slide format and consists of 672 wells in total. Each well holds 500 nl, a volume small enough to drastically decrease reagent costs but large enough to allow utilization of standard laboratory equipment. Results presented here include weeklong culturing and differentiation assays of mouse embryonic stem cells, mouse adult neural stem cells, and human embryonic stem cells. The possibility to either maintain the cells as stem/progenitor cells or to study cell differentiation of stem/progenitor cells over time is demonstrated. Clonality is critical for stem cell research, and was accomplished in the microwell chips by isolation and clonal analysis of single mouse embryonic stem cells using flow cytometric cell-sorting. Protocols for practical handling of the microwell chips are presented, describing a rapid and user-friendly method for the simultaneous study of thousands of stem cell cultures in small microwells. This microwell chip has high potential for a wide range of applications, for example directed differentiation assays and screening of reprogramming factors, opening up considerable opportunities in the stem cell field.			Lindstrom, S (corresponding author), Royal Inst Technol, AlbaNova Univ Ctr, Div Nanobiotechnol, Stockholm, Sweden.	helene.andersson-svahn@biotech.kth.se	Rockberg, Julia/HGB-6917-2022		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ashton RS, 2007, STEM CELLS, V25, P2928, DOI 10.1634/stemcells.2007-0468; Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103; Chin VI, 2004, BIOTECHNOL BIOENG, V88, P399, DOI 10.1002/bit.20254; Chu VT, 2001, P NATL ACAD SCI USA, V98, P7652, DOI 10.1073/pnas.141244198; Chung BG, 2005, LAB CHIP, V5, P401, DOI 10.1039/b417651k; Cimetta E, 2009, METHODS, V47, P81, DOI 10.1016/j.ymeth.2008.10.015; COLE R, 1964, EXP CELL RES, V37, P501; Coles-Takabe BLK, 2008, STEM CELLS, V26, P2938, DOI 10.1634/stemcells.2008-0558; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; Cordey M, 2008, STEM CELLS, V26, P2586, DOI 10.1634/stemcells.2008-0498; Dittrich PS, 2006, NAT REV DRUG DISCOV, V5, P210, DOI 10.1038/nrd1985; Falconnet D, 2006, BIOMATERIALS, V27, P3044, DOI 10.1016/j.biomaterials.2005.12.024; Figallo E, 2007, LAB CHIP, V7, P710, DOI 10.1039/b700063d; Flaim CJ, 2008, STEM CELLS DEV, V17, P29, DOI 10.1089/scd.2007.0085; Flaim CJ, 2005, NAT METHODS, V2, P119, DOI 10.1038/NMETH736; Gottwald E, 2007, LAB CHIP, V7, P777, DOI 10.1039/b618488j; Jessberger S, 2007, STEM CELLS, V25, P871, DOI 10.1634/stemcells.2006-0620; Jin A., 2009, NAT MED; Kamei KI, 2009, LAB CHIP, V9, P555, DOI 10.1039/b809105f; Kane RS, 1999, BIOMATERIALS, V20, P2363, DOI 10.1016/S0142-9612(99)00165-9; Khademhosseini A, 2006, P NATL ACAD SCI USA, V103, P2480, DOI 10.1073/pnas.0507681102; Khademhosseini A, 2006, BIOMATERIALS, V27, P5968, DOI 10.1016/j.biomaterials.2006.06.035; Kim MS, 2007, LAB CHIP, V7, P513, DOI 10.1039/b617760n; Lii J, 2008, ANAL CHEM, V80, P3640, DOI 10.1021/ac8000034; Lindstrom S, 2008, ELECTROPHORESIS, V29, P1219, DOI 10.1002/elps.200700536; Love JC, 2006, NAT BIOTECHNOL, V24, P703, DOI 10.1038/nbt1210; Moeller HC, 2008, BIOMATERIALS, V29, P752, DOI 10.1016/j.biomaterials.2007.10.030; Mohr JC, 2006, BIOMATERIALS, V27, P6032, DOI 10.1016/j.biomaterials.2006.07.012; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Ochsner M, 2007, LAB CHIP, V7, P1074, DOI 10.1039/b704449f; Orfao A, 1996, CLIN BIOCHEM, V29, P5, DOI 10.1016/0009-9120(95)02017-9; Rettig JR, 2005, ANAL CHEM, V77, P5628, DOI 10.1021/ac0505977; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rosenthal A, 2007, BIOMATERIALS, V28, P3208, DOI 10.1016/j.biomaterials.2007.03.023; Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004; Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011; Sim WY, 2007, LAB CHIP, V7, P1775, DOI 10.1039/b712361m; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Underhill GH, 2007, CURR OPIN CHEM BIOL, V11, P357, DOI 10.1016/j.cbpa.2007.05.036; Vazin T, 2008, RESTOR NEUROL NEUROS, V26, P447; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yaworsky PJ, 1999, DEV BIOL, V205, P309, DOI 10.1006/dbio.1998.9035	46	48	54	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6997	10.1371/journal.pone.0006997	http://dx.doi.org/10.1371/journal.pone.0006997			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750008	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796300013
J	Rao, L; Zhao, XB; Pan, F; Li, Y; Xue, YF; Ma, YH; Lu, JR				Rao, Lang; Zhao, Xiubo; Pan, Fang; Li, Yin; Xue, Yanfen; Ma, Yanhe; Lu, Jian R.			Solution Behavior and Activity of a Halophilic Esterase under High Salt Concentration	PLOS ONE			English	Article								Background: Halophiles are extremophiles that thrive in environments with very high concentrations of salt. Although the salt reliance and physiology of these extremophiles have been widely investigated, the molecular working mechanisms of their enzymes under salty conditions have been little explored. Methodology/Principal Findings: A halophilic esterolytic enzyme LipC derived from archeaon Haloarcula marismortui was overexpressed from Escherichia coli BL21. The purified enzyme showed a range of hydrolytic activity towards the substrates of p-nitrophenyl esters with different alkyl chains (n = 2 - 16), with the highest activity being observed for p-nitrophenyl acetate, consistent with the basic character of an esterase. The optimal esterase activities were found to be at pH 9.5 and [NaCl] = 3.4 M or [KCl] = 3.0 M and at around 45 degrees C. Interestingly, the hydrolysis activity showed a clear reversibility against changes in salt concentration. At the ambient temperature of 22 degrees C, enzyme systems working under the optimal salt concentrations were very stable against time. Increase in temperature increased the activity but reduced its stability. Circular dichroism (CD), dynamic light scattering (DLS) and small angle neutron scattering (SANS) were deployed to determine the physical states of LipC in solution. As the salt concentration increased, DLS revealed substantial increase in aggregate sizes, but CD measurements revealed the maximal retention of the alpha-helical structure at the salt concentration matching the optimal activity. These observations were supported by SANS analysis that revealed the highest proportion of unimers and dimers around the optimal salt concentration, although the coexistent larger aggregates showed a trend of increasing size with salt concentration, consistent with the DLS data. Conclusions/Significance: The solution alpha-helical structure and activity relation also matched the highest proportion of enzyme unimers and dimers. Given that all the solutions studied were structurally inhomogeneous, it is important for future work to understand how the LipC's solution aggregation affected its activity.			Rao, L (corresponding author), Chinese Acad Sci, Inst Microbiol, Beijing, Peoples R China.	mayanhe@im.ac.cn; j.lu@manchester.ac.uk	MA, YAN/HHN-2912-2022; Zhao, Xiubo/A-1690-2011; Li, Yin/C-6644-2009; Lu, Jian/GRY-4556-2022; Zhao, Xiubo/AAZ-9058-2021	Zhao, Xiubo/0000-0002-4620-2893; Li, Yin/0000-0003-0995-3070; Zhao, Xiubo/0000-0002-4620-2893; Yu, Hai/0000-0002-6386-9761				Amoozegar MA, 2008, J BASIC MICROB, V48, P160, DOI 10.1002/jobm.200700361; Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Baliga NS, 2004, GENOME RES, V14, P2221, DOI 10.1101/gr.2700304; Bhatnagar T, 2005, FEMS MICROBIOL LETT, V248, P133, DOI 10.1016/j.femsle.2005.05.044; Boutaiba S, 2006, J MOL CATAL B-ENZYM, V41, P21, DOI 10.1016/j.molcatb.2006.03.010; BREUIL C, 1975, CAN J MICROBIOL, V21, P423, DOI 10.1139/m75-061; Cho AR, 2000, FEMS MICROBIOL LETT, V186, P235, DOI 10.1016/S0378-1097(00)00150-6; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; Follmer C, 2004, BIOPHYS CHEM, V111, P79, DOI 10.1016/j.bpc.2004.03.009; GONZALEZ C, 1970, Canadian Journal of Microbiology, V16, P1165; Hasan F, 2006, ENZYME MICROB TECH, V39, P235, DOI 10.1016/j.enzmictec.2005.10.016; HERBERT RA, 1992, TRENDS BIOTECHNOL, V10, P395, DOI 10.1016/0167-7799(92)90282-Z; Imamura S, 2000, J BIOCHEM-TOKYO, V127, P419, DOI 10.1093/oxfordjournals.jbchem.a022623; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jaeger KE, 2002, CURR OPIN BIOTECH, V13, P390, DOI 10.1016/S0958-1669(02)00341-5; Jinwal UK, 2003, BIOORGAN MED CHEM, V11, P1041, DOI 10.1016/S0968-0896(02)00516-3; Kim J, 1997, BIOTECHNOL BIOENG, V55, P471, DOI 10.1002/(SICI)1097-0290(19970805)55:3<471::AID-BIT2>3.3.CO;2-D; King S.M., 1999, MODERN TECHNIQUES PO, P171; KOJIMA Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1564, DOI 10.1271/bbb.58.1564; Li HB, 2005, PROTEIN EXPRES PURIF, V42, P153, DOI 10.1016/j.pep.2005.03.011; Lu JR, 2005, LANGMUIR, V21, P3354, DOI 10.1021/la047162j; Luo Y, 2006, APPL MICROBIOL BIOT, V73, P349, DOI 10.1007/s00253-006-0478-3; Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142; MONSTADT GM, 1991, BIOCHEM J, V273, P739, DOI 10.1042/bj2730739; MULLERSANTOS M, 2009, BIOCHIM BIOPHYS ACTA, DOI DOI 10.1016/J.BBALIP.2009.1003.1006; NORBERG P, 1969, J GEN MICROBIOL, V55, P251, DOI 10.1099/00221287-55-2-251; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OREN A, 1990, INT J SYST BACTERIOL, V40, P209, DOI 10.1099/00207713-40-2-209; Panda T, 2005, APPL MICROBIOL BIOT, V67, P160, DOI 10.1007/s00253-004-1840-y; Pratuangdejkul J, 2000, MICROBIOL RES, V155, P95, DOI 10.1016/S0944-5013(00)80043-9; Reis P, 2009, ADV COLLOID INTERFAC, V147-48, P237, DOI 10.1016/j.cis.2008.06.001; Sana B, 2007, PROCESS BIOCHEM, V42, P1571, DOI 10.1016/j.procbio.2007.05.026; SchmidtDannert C, 1996, BBA-LIPID LIPID MET, V1301, P105, DOI 10.1016/0005-2760(96)00027-6; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; TONIOLO C, 1979, MACROMOLECULES, V12, P620, DOI 10.1021/ma60070a014; van den Burg B, 2003, CURR OPIN MICROBIOL, V6, P213, DOI 10.1016/S1369-5274(03)00060-2	37	43	46	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6980	10.1371/journal.pone.0006980	http://dx.doi.org/10.1371/journal.pone.0006980			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759821	Green Published, gold, Green Submitted, Green Accepted			2022-12-27	WOS:000269796300009
J	Marquez, L; Suarez, J; Iglesias, M; Bermudez-Silva, FJ; de Fonseca, FR; Andreu, M				Marquez, Lucia; Suarez, Juan; Iglesias, Mar; Javier Bermudez-Silva, Francisco; Rodriguez de Fonseca, Fernando; Andreu, Montserrat			Ulcerative Colitis Induces Changes on the Expression of the Endocannabinoid System in the Human Colonic Tissue	PLOS ONE			English	Article								Background: Recent studies suggest potential roles of the endocannabinoid system in gastrointestinal inflammation. Although cannabinoid CB(2) receptor expression is increased in inflammatory disorders, the presence and function of the remaining proteins of the endocannabinoid system in the colonic tissue is not well characterized. Methodology: Cannabinoid CB(1) and CB(2) receptors, the enzymes for endocannabinoid biosynthesis DAGL alpha, DAGL beta and NAPE-PLD, and the endocannabinoid-degradating enzymes FAAH and MAGL were analysed in both acute untreated active ulcerative pancolitis and treated quiescent patients in comparison with healthy human colonic tissue by immunocytochemistry. Analyses were carried out according to clinical criteria, taking into account the severity at onset and treatment received. Principal Findings: Western blot and immunocytochemistry indicated that the endocannabinoid system is present in the colonic tissue, but it shows a differential distribution in epithelium, lamina propria, smooth muscle and enteric plexi. Quantification of epithelial immunoreactivity showed an increase of CB(2) receptor, DAGL alpha and MAGL expression, mainly in mild and moderate pancolitis patients. In contrast, NAPE-PLD expression decreased in moderate and severe pancolitis patients. During quiescent pancolitis, CB(1), CB(2) and DAGL alpha expression dropped, while NAPE-PLD expression rose, mainly in patients treated with 5-ASA or 5-ASA+corticosteroids. The number of immune cells containing MAGL and FAAH in the lamina propria increased in acute pancolitis patients, but dropped after treatment. Conclusions: Endocannabinoids signaling pathway, through CB(2) receptor, may reduce colitis-associated inflammation suggesting a potential drugable target for the treatment of inflammatory bowel diseases.			Marquez, L (corresponding author), Univ Autonoma Barcelona, Hosp Mar, Dept Gastroenterol, E-08193 Barcelona, Spain.	fernando.rodriguez@fundacionimabis.org	Bermudez-Silva, Francisco-Javier/Q-6920-2016; Andreu, Montserrat/D-9911-2015; DE FONSECA, FERNANDO RODRIGUEZ/E-9767-2012; Suarez, Juan/I-5188-2015; Marquez, Lucia/AAI-8215-2021	Bermudez-Silva, Francisco-Javier/0000-0003-3133-9691; Andreu, Montserrat/0000-0003-4286-1098; Suarez, Juan/0000-0001-5254-9802; MARQUEZ MOSQUERA, LUCIA/0000-0002-3182-9570				Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Bermudez-Silva FJ, 2008, DIABETOLOGIA, V51, P476, DOI 10.1007/s00125-007-0890-y; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Calignano A, 2000, Prog Brain Res, V129, P471; Capasso R, 2005, GASTROENTEROLOGY, V129, P941, DOI 10.1053/j.gastro.2005.06.018; Casu MA, 2003, EUR J PHARMACOL, V459, P97, DOI 10.1016/S0014-2999(02)02830-3; D'Argenio G, 2006, FASEB J, V20, P568, DOI 10.1096/fj.05-4943fje; De Hertogh G, 2008, WORLD J GASTROENTERO, V14, P845, DOI 10.3748/wjg.14.845; Di Marzo V, 2006, GUT, V55, P1373, DOI 10.1136/gut.2005.090472; DICARLO G, 2003, EXPERT OPIN INV DRUG, V3, P771; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Duncan M, 2005, ALIMENT PHARM THER, V22, P667, DOI 10.1111/j.1365-2036.2005.02648.x; Duncan M, 2008, AM J PHYSIOL-GASTR L, V295, pG1255, DOI 10.1152/ajpgi.90500.2008; Fowler CJ, 2005, PHARMACOL BIOCHEM BE, V81, P248, DOI 10.1016/j.pbb.2005.01.023; Geboes K, 1998, NEUROGASTROENT MOTIL, V10, P189, DOI 10.1046/j.1365-2982.1998.00102.x; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Griffin G, 1997, EUR J PHARMACOL, V339, P53, DOI 10.1016/S0014-2999(97)01336-8; Ihenetu K, 2003, EUR J PHARMACOL, V464, P207, DOI 10.1016/S0014-2999(03)01379-7; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Izzo Angelo A., 2001, Current Opinion in Pharmacology, V1, P597, DOI 10.1016/S1471-4892(01)00102-3; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; Massa F, 2005, J MOL MED, V83, P944, DOI 10.1007/s00109-005-0698-5; Mathison R, 2004, BRIT J PHARMACOL, V142, P1247, DOI 10.1038/sj.bjp.0705889; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Okamoto Y, 2007, CHEM BIODIVERS, V4, P1842, DOI 10.1002/cbdv.200790155; Pertwee RG, 2001, GUT, V48, P859, DOI 10.1136/gut.48.6.859; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; Pinto L, 2002, PROSTAG LEUKOTR ESS, V66, P333, DOI 10.1054/plef.2001.0345; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Simon GM, 2006, J BIOL CHEM, V281, P26465, DOI 10.1074/jbc.M604660200; Storr M, 2002, CAN J PHYSIOL PHARM, V80, P67, DOI 10.1139/Y02-005; Storr MA, 2008, J MOL MED, V86, P925, DOI 10.1007/s00109-008-0359-6; Suarez J, 2008, J COMP NEUROL, V509, P400, DOI 10.1002/cne.21774; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026; Wright KL, 2008, BRIT J PHARMACOL, V153, P263, DOI 10.1038/sj.bjp.0707486	44	83	83	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6893	10.1371/journal.pone.0006893	http://dx.doi.org/10.1371/journal.pone.0006893			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730730	gold, Green Published, Green Submitted			2022-12-27	WOS:000269622100002
J	Rodrigue, S; Malmstrom, RR; Berlin, AM; Birren, BW; Henn, MR; Chisholm, SW				Rodrigue, Sebastien; Malmstrom, Rex R.; Berlin, Aaron M.; Birren, Bruce W.; Henn, Matthew R.; Chisholm, Sallie W.			Whole Genome Amplification and De novo Assembly of Single Bacterial Cells	PLOS ONE			English	Article							MULTIPLE DISPLACEMENT AMPLIFICATION; PROCHLOROCOCCUS; POLYMERASE; EVOLUTION	Background: Single-cell genome sequencing has the potential to allow the in-depth exploration of the vast genetic diversity found in uncultured microbes. We used the marine cyanobacterium Prochlorococcus as a model system for addressing important challenges facing high-throughput whole genome amplification (WGA) and complete genome sequencing of individual cells. Methodology/Principal Findings: We describe a pipeline that enables single-cell WGA on hundreds of cells at a time while virtually eliminating non-target DNA from the reactions. We further developed a post-amplification normalization procedure that mitigates extreme variations in sequencing coverage associated with multiple displacement amplification (MDA), and demonstrated that the procedure increased sequencing efficiency and facilitated genome assembly. We report genome recovery as high as 99.6% with reference-guided assembly, and 95% with de novo assembly starting from a single cell. We also analyzed the impact of chimera formation during MDA on de novo assembly, and discuss strategies to minimize the presence of incorrectly joined regions in contigs. Conclusions/Significance: The methods describe in this paper will be useful for sequencing genomes of individual cells from a variety of samples.			Rodrigue, S (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	chisholm@mit.edu	Malmstrom, Rex/K-7339-2012; Berlin, Aaron M/AFY-6549-2022	Berlin, Aaron M/0000-0002-0714-2808; Malmstrom, Rex/0000-0002-4758-7369; Chisholm, Sallie/0000-0003-1480-2445	NIAID NIH HHS [HHSN266200400001C] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Binga EK, 2008, ISME J, V2, P233, DOI 10.1038/ismej.2008.10; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Hosono S, 2003, GENOME RES, V13, P954, DOI 10.1101/gr.816903; Ibrahim SF, 2003, CURR OPIN BIOTECH, V14, P5, DOI 10.1016/S0958-1669(02)00009-5; Ibrahim SF, 2007, ADV BIOCHEM ENG BIOT, V106, P19, DOI 10.1007/10_2007_073; KARL DM, 2002, BIOGEOCHEMISTRY MARI, P315; Kettler GC, 2007, PLOS GENET, V3, P2515, DOI 10.1371/journal.pgen.0030231; Kvist T, 2007, APPL MICROBIOL BIOT, V74, P926, DOI 10.1007/s00253-006-0725-7; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; MacLean D, 2009, NAT REV MICROBIOL, V7, P287, DOI [10.1038/nrmicro2088, 10.1038/nrmicro2122]; Marcy Y, 2007, PLOS GENET, V3, P1702, DOI 10.1371/journal.pgen.0030155; Marcy Y, 2007, P NATL ACAD SCI USA, V104, P11889, DOI 10.1073/pnas.0704662104; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; McCutcheon JP, 2007, P NATL ACAD SCI USA, V104, P19392, DOI 10.1073/pnas.0708855104; Pan XH, 2008, P NATL ACAD SCI USA, V105, P15499, DOI 10.1073/pnas.0808028105; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Pinard R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-216; Raghunathan A, 2005, APPL ENVIRON MICROB, V71, P3342, DOI 10.1128/AEM.71.6.3342-3347.2005; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; Reinhardt JA, 2009, GENOME RES, V19, P294, DOI 10.1101/gr.083311.108; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Stepanauskas R, 2007, P NATL ACAD SCI USA, V104, P9052, DOI 10.1073/pnas.0700496104; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Woyke T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005299; Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107; Zhang K, 2006, NAT BIOTECHNOL, V24, P680, DOI 10.1038/nbt1214; Zhulidov PA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh031	32	182	224	0	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6864	10.1371/journal.pone.0006864	http://dx.doi.org/10.1371/journal.pone.0006864			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RW	19724646	Green Submitted, Green Published, gold			2022-12-27	WOS:000269522800006
J	Schippers, MB; Gazzola, V; Goebel, R; Keysers, C				Schippers, Marleen B.; Gazzola, Valeria; Goebel, Rainer; Keysers, Christian			Playing Charades in the fMRI: Are Mirror and/or Mentalizing Areas Involved in Gestural Communication?	PLOS ONE			English	Article							TEMPORO-PARIETAL JUNCTION; GRASP REPRESENTATIONS; ACTION RECOGNITION; SOCIAL-INTERACTION; NEURON SYSTEM; BROCAS AREA; MIND; BRAIN; PREMOTOR; MECHANISMS	Communication is an important aspect of human life, allowing us to powerfully coordinate our behaviour with that of others. Boiled down to its mere essentials, communication entails transferring a mental content from one brain to another. Spoken language obviously plays an important role in communication between human individuals. Manual gestures however often aid the semantic interpretation of the spoken message, and gestures may have played a central role in the earlier evolution of communication. Here we used the social game of charades to investigate the neural basis of gestural communication by having participants produce and interpret meaningful gestures while their brain activity was measured using functional magnetic resonance imaging. While participants decoded observed gestures, the putative mirror neuron system (pMNS: premotor, parietal and posterior mid-temporal cortex), associated with motor simulation, and the temporoparietal junction (TPJ), associated with mentalizing and agency attribution, were significantly recruited. Of these areas only the pMNS was recruited during the production of gestures. This suggests that gestural communication relies on a combination of simulation and, during decoding, mentalizing/agency attribution brain areas. Comparing the decoding of gestures with a condition in which participants viewed the same gestures with an instruction not to interpret the gestures showed that although parts of the pMNS responded more strongly during active decoding, most of the pMNS and the TPJ did not show such significant task effects. This suggests that the mere observation of gestures recruits most of the system involved in voluntary interpretation.			Schippers, MB (corresponding author), Univ Groningen, BCN Neuroimaging Ctr, Groningen, Netherlands.	m.b.schippers@med.umcg.nl	Keysers, Christian/H-6251-2013	Keysers, Christian/0000-0002-2845-5467; Gazzola, Valeria/0000-0003-0324-0619; Goebel, Rainer/0000-0003-1780-2467				Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Arbib MA, 2008, J PHYSIOL-PARIS, V102, P4, DOI 10.1016/j.jphysparis.2008.03.001; BLAKEMORE SJ, 2001, NATURE REV NEUROSCIE; Brass M, 2000, BRAIN COGNITION, V44, P124, DOI 10.1006/brcg.2000.1225; Brett M, 2002, NEUROIMAGE; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Buccino G, 2004, J COGNITIVE NEUROSCI, V16, P114, DOI 10.1162/089892904322755601; Buccino G, 2001, EUR J NEUROSCI, V13, P400, DOI 10.1046/j.1460-9568.2001.01385.x; Buxbaum LJ, 2005, COGNITIVE BRAIN RES, V25, P226, DOI 10.1016/j.cogbrainres.2005.05.014; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; Choi SH, 2001, EXP BRAIN RES, V139, P311, DOI 10.1007/s002210100777; Chong TTJ, 2008, CURR BIOL, V18, P1576, DOI 10.1016/j.cub.2008.08.068; Ciaramidaro A, 2007, NEUROPSYCHOLOGIA, V45, P3105, DOI 10.1016/j.neuropsychologia.2007.05.011; Cubelli R, 2006, NEUROSCI LETT, V407, P118, DOI 10.1016/j.neulet.2006.08.019; De Lange FP, 2008, CURR BIOL, V18, P454, DOI 10.1016/j.cub.2008.02.057; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; Decety J, 2007, NEUROSCIENTIST, V13, P580, DOI 10.1177/1073858407304654; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Ferrari PF, 2003, EUR J NEUROSCI, V17, P1703, DOI 10.1046/j.1460-9568.2003.02601.x; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Fogassi L, 2005, SCIENCE, V308, P662, DOI 10.1126/science.1106138; Fridman EA, 2006, NEUROIMAGE, V29, P417, DOI 10.1016/j.neuroimage.2005.07.026; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Fujii N, 2008, SOC NEUROSCI-UK, V3, P250, DOI 10.1080/17470910701434610; Gallagher HL, 2004, NEUROPSYCHOLOGIA, V42, P1725, DOI 10.1016/j.neuropsychologia.2004.05.006; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gallagher HL, 2002, NEUROIMAGE, V16, P814, DOI 10.1006/nimg.2002.1117; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Gazzola V, 2007, NEUROIMAGE, V35, P1674, DOI 10.1016/j.neuroimage.2007.02.003; GAZZOLA V, 2008, CEREB CORTEX; Gazzola V, 2007, CURR BIOL, V17, P1235, DOI 10.1016/j.cub.2007.06.045; Gazzola V, 2006, CURR BIOL, V16, P1824, DOI 10.1016/j.cub.2006.07.072; Gentilucci M, 2006, NEUROSCI BIOBEHAV R, V30, P949, DOI 10.1016/j.neubiorev.2006.02.004; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Hampton AN, 2008, P NATL ACAD SCI USA, V105, P6741, DOI 10.1073/pnas.0711099105; Hamzei F, 2003, NEUROIMAGE, V19, P637, DOI 10.1016/S1053-8119(03)00087-9; Heiser M, 2003, EUR J NEUROSCI, V17, P1123, DOI 10.1046/j.1460-9568.2003.02530.x; Hermsdorfer J, 2001, NEUROIMAGE, V14, P149, DOI 10.1006/nimg.2001.0796; Hickok G, 2009, J COGNITIVE NEUROSCI, V21, P1229, DOI 10.1162/jocn.2009.21189; Higuchi S, 2007, CORTEX, V43, P350, DOI 10.1016/S0010-9452(08)70460-X; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Iacoboni M, 2005, PLOS BIOL, V3, P529, DOI 10.1371/journal.pbio.0030079; Iacoboni M, 2004, NEUROIMAGE, V21, P1167, DOI 10.1016/j.neuroimage.2003.11.013; Iverson JM, 1998, NATURE, V396, P228, DOI 10.1038/24300; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; Kampe KKW, 2003, J NEUROSCI, V23, P5258; Kendon A., 1994, RES LANG SOC INTERAC, V27, P175, DOI [10.1207/s15327973rlsi2703_2, DOI 10.1207/S15327973RLSI2703_2]; Keysers C, 2003, EXP BRAIN RES, V153, P628, DOI 10.1007/s00221-003-1603-5; Keysers C, 2006, PROG BRAIN RES, V156, P379, DOI 10.1016/S0079-6123(06)56021-2; Keysers C, 2007, TRENDS COGN SCI, V11, P194, DOI 10.1016/j.tics.2007.02.002; KILNER J, 2007, SOCIAL NEUROSCIENCE, P158; KILNER JM, 2007, COGNITIVE PROCESSES; Kohler E, 2002, SCIENCE, V297, P846, DOI 10.1126/science.1070311; Lotze M, 2006, NEUROPSYCHOLOGIA, V44, P1787, DOI 10.1016/j.neuropsychologia.2006.03.016; McCabe K, 2001, P NATL ACAD SCI USA, V98, P11832, DOI 10.1073/pnas.211415698; McNeill D., 1992, HAND MIND WHAT GESTU; MELINGER A, 2004, GESTURE COMMUNICATIV; Mitchell JP, 2008, CEREB CORTEX, V18, P262, DOI 10.1093/cercor/bhm051; Moll J, 2000, NEUROLOGY, V54, P1331, DOI 10.1212/WNL.54.6.1331; Montgomery KJ, 2007, SOC COGN AFFECT NEUR, V2, P114, DOI 10.1093/scan/nsm004; Mozaz M, 2002, J INT NEUROPSYCH SOC, V8, P958, DOI 10.1017/S1355617702870114; Nair DG, 2003, COGNITIVE BRAIN RES, V15, P250, DOI 10.1016/S0926-6410(02)00197-0; Nelissen K, 2005, SCIENCE, V310, P332, DOI 10.1126/science.1115593; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; OCHIPA C, 1989, ANN NEUROL, V25, P190, DOI 10.1002/ana.410250214; Ohgami Y, 2004, NEUROREPORT, V15, P1903, DOI 10.1097/00001756-200408260-00014; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pazzaglia M, 2008, CURR BIOL, V18, P1766, DOI 10.1016/j.cub.2008.09.061; Pelphrey KA, 2004, J COGNITIVE NEUROSCI, V16, P1706, DOI 10.1162/0898929042947900; Petrides M, 2005, NATURE, V435, P1235, DOI 10.1038/nature03628; Poldrack RA, 2006, TRENDS COGN SCI, V10, P59, DOI 10.1016/j.tics.2005.12.004; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; Rizzolatti G, 1996, EXP BRAIN RES, V111, P246; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; ROTHI LJG, 1985, J NEUROL NEUROSUR PS, V48, P207, DOI 10.1136/jnnp.48.3.207; Saxe R, 2004, NEUROPSYCHOLOGIA, V42, P1435, DOI 10.1016/j.neuropsychologia.2004.04.015; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Saxe R, 2005, NEUROPSYCHOLOGIA, V43, P1391, DOI 10.1016/j.neuropsychologia.2005.02.013; Scholz J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004869; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Sommer M, 2007, NEUROIMAGE, V35, P1378, DOI 10.1016/j.neuroimage.2007.01.042; Thioux M, 2008, CURR BIOL, V18, pR431, DOI 10.1016/j.cub.2008.03.018; Thompson JC, 2007, NEUROIMAGE, V37, P966, DOI 10.1016/j.neuroimage.2007.05.058; Umilta MA, 2001, NEURON, V31, P155, DOI 10.1016/S0896-6273(01)00337-3; van der Gaag C, 2007, SOC NEUROSCI-UK, V2, P179, DOI 10.1080/17470910701376878; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Vogeley K, 2003, TRENDS COGN SCI, V7, P38, DOI 10.1016/S1364-6613(02)00003-7; Walter H, 2004, J COGNITIVE NEUROSCI, V16, P1854, DOI 10.1162/0898929042947838; Wheaton KJ, 2004, NEUROIMAGE, V22, P277, DOI 10.1016/j.neuroimage.2003.12.043; Willems RM, 2007, CEREB CORTEX, V17, P2322, DOI 10.1093/cercor/bhl141	95	53	53	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6801	10.1371/journal.pone.0006801	http://dx.doi.org/10.1371/journal.pone.0006801			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710923	Green Published, gold			2022-12-27	WOS:000269415600015
J	Skilton, A; Ho, JCY; Mercer, B; Outwin, E; Watts, FZ				Skilton, Andrew; Ho, Jenny C. Y.; Mercer, Brenda; Outwin, Emily; Watts, Felicity Z.			SUMO Chain Formation Is Required for Response to Replication Arrest in S. pombe	PLOS ONE			English	Article								SUMO is a ubiquitin-like protein that is post-translationally attached to one or more lysine residues on target proteins. Despite having only 18% sequence identity with ubiquitin, SUMO contains the conserved beta beta alpha beta beta alpha beta fold present in ubiquitin. However, SUMO differs from ubiquitin in having an extended N-terminus. In S. pombe the N-terminus of SUMO/Pmt3 is significantly longer than those of SUMO in S. cerevisiae, human and Drosophila. Here we investigate the role of this N-terminal region. We have used two dimensional gel electrophoresis to demonstrate that S. pombe SUMO/Pmt3 is phosphorylated, and that this occurs on serine residues at the extreme N-terminus of the protein. Mutation of these residues (in pmt3-1) results in a dramatic reduction in both the levels of high Mr SUMO-containing species and of total SUMO/Pmt3, indicating that phosphorylation of SUMO/Pmt3 is required for its stability. Despite the significant reduction in high Mr SUMO-containing species, pmt3-1 cells do not display an aberrant cell morphology or sensitivity to genotoxins or stress. Additionally, we demonstrate that two lysine residues in the N-terminus of S. pombe SUMO/Pmt3 (K14 and K30) can act as acceptor sites for SUMO chain formation in vitro. Inability to form SUMO chains results in aberrant cell and nuclear morphologies, including stretched and fragmented chromatin. SUMO chain mutants are sensitive to the DNA synthesis inhibitor, hydroxyurea (HU), but not to other genotoxins, such as UV, MMS or CPT. This implies a role for SUMO chains in the response to replication arrest in S. pombe.			Skilton, A (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England.	f.z.watts@sussex.ac.uk	Skilton, Andi/AAS-5885-2021	Skilton, Andi/0000-0002-9573-372X	Biotechnology and Biological Sciences Research Council [85/C15586, BD/D526861/1, G/07462] Funding Source: Medline; Medical Research Council [G122/18, G0500308] Funding Source: Medline; Medical Research Council [G0300662B] Funding Source: researchfish; MRC [G0500308] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Andrews EA, 2005, MOL CELL BIOL, V25, P185, DOI 10.1128/MCB.25.1.185-196.2005; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Ho JCY, 2003, BIOCHEM J, V372, P97, DOI 10.1042/BJ20021645; Ho JCY, 2001, NUCLEIC ACIDS RES, V29, P4179, DOI 10.1093/nar/29.20.4179; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Klein HL, 2006, CELL, V127, P455, DOI 10.1016/j.cell.2006.10.019; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Matic I, 2008, J PROTEOME RES, V7, P4050, DOI 10.1021/pr800368m; Mullen JR, 2008, J BIOL CHEM, V283, P19912, DOI 10.1074/jbc.M802690200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; Takahashi Y, 2003, J BIOCHEM, V133, P415, DOI 10.1093/jb/mvg054; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Ulrich HD, 2008, MOL CELL, V32, P301, DOI 10.1016/j.molcel.2008.10.010; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Watts FZ, 2007, CHROMOSOMA, V116, P15, DOI 10.1007/s00412-006-0079-z; Xhemalce B, 2004, EMBO J, V23, P3844, DOI 10.1038/sj.emboj.7600394	36	22	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2009	4	8							e6750	10.1371/journal.pone.0006750	http://dx.doi.org/10.1371/journal.pone.0006750			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	487MJ	19707600	Green Published, gold, Green Submitted, Green Accepted			2022-12-27	WOS:000269278400015
J	Rodriguez, A; Luukkaala, T; Fleming, RE; Britton, RS; Bacon, BR; Parkkila, S				Rodriguez, Alejandra; Luukkaala, Tiina; Fleming, Robert E.; Britton, Robert S.; Bacon, Bruce R.; Parkkila, Seppo			Global Transcriptional Response to Hfe Deficiency and Dietary Iron Overload in Mouse Liver and Duodenum	PLOS ONE			English	Article							MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; HEPCIDIN EXPRESSION; PEPTIDE HEPCIDIN; TRANSPORTER; HEMOCHROMATOSIS; IDENTIFICATION; LIPOCALIN; PROTEINS	Iron is an essential trace element whose absorption is usually tightly regulated in the duodenum. HFE-related hereditary hemochromatosis (HH) is characterized by abnormally low expression of the iron-regulatory hormone, hepcidin, which results in increased iron absorption. The liver is crucial for iron homeostasis as it is the main production site of hepcidin. The aim of this study was to explore and compare the genome-wide transcriptome response to Hfe deficiency and dietary iron overload in murine liver and duodenum. Illumina (TM) arrays containing over 47,000 probes were used to study global transcriptional changes. Quantitative RT-PCR (Q-RT-PCR) was used to validate the microarray results. In the liver, the expression of 151 genes was altered in Hfe(-/-) mice while dietary iron overload changed the expression of 218 genes. There were 173 and 108 differentially expressed genes in the duodenum of Hfe(-/-) mice and mice with dietary iron overload, respectively. There was 93.5% concordance between the results obtained by microarray analysis and Q-RT-PCR. Overexpression of genes for acute phase reactants in the liver and a strong induction of digestive enzyme genes in the duodenum were characteristic of the Hfe-deficient genotype. In contrast, dietary iron overload caused a more pronounced change of gene expression responsive to oxidative stress. In conclusion, Hfe deficiency caused a previously unrecognized increase in gene expression of hepatic acute phase proteins and duodenal digestive enzymes.			Rodriguez, A (corresponding author), Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland.	alejandra.rodriguez.martinez@uta.fi		Parkkila, Seppo/0000-0001-7323-8536; Luukkaala, Tiina/0000-0003-4636-9586	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041816] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66225, R01 HL066225] Funding Source: Medline; NIDDK NIH HHS [R01 DK041816, DK41816] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Abgueguen E, 2006, MAMM GENOME, V17, P430, DOI 10.1007/s00335-005-0122-z; Ahmad KA, 2002, BLOOD CELL MOL DIS, V29, P361, DOI 10.1006/bcmd.2002.0575; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Britton RS, 1996, SEMIN LIVER DIS, V16, P3, DOI 10.1055/s-2007-1007214; Brown KE, 2007, TOXICOL APPL PHARM, V223, P180, DOI 10.1016/j.taap.2007.05.011; Coppin H, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r221; Damdinsuren B, 2005, INT J ONCOL, V26, P319; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Dupic F, 2002, GUT, V51, P648, DOI 10.1136/gut.51.5.648; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2005, SEMIN LIVER DIS, V25, P411, DOI 10.1055/s-2005-923313; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Fleming RE, 2002, ANNU REV PHYSIOL, V64, P663, DOI 10.1146/annurev.physiol.64.081501.155838; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Ilyin G, 2003, FEBS LETT, V542, P22, DOI 10.1016/S0014-5793(03)00329-6; Kautz L, 2008, BLOOD, V112, P1503, DOI 10.1182/blood-2008-03-143354; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Morey JS, 2006, BIOL PROCED ONLINE, V8, P175, DOI 10.1251/bpo126; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Norton JD, 2000, J CELL SCI, V113, P3897; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Parkkila S, 2001, GASTROENTEROLOGY, V121, P1489, DOI 10.1053/gast.2001.29617; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Qiu AD, 2006, CELL, V127, P917, DOI 10.1016/j.cell.2006.09.041; Ramm GA, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P494; Rodriguez A, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-379; Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025; Trinder D, 2002, P NATL ACAD SCI USA, V99, P5622, DOI 10.1073/pnas.082112299; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Yan QW, 2007, DIABETES, V56, P2533, DOI 10.2337/db07-0007; Yang J, 2003, AM J PHYSIOL-RENAL, V285, pF9, DOI 10.1152/ajprenal.00008.2003; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492; Zoller H, 1999, LANCET, V353, P2120, DOI 10.1016/S0140-6736(98)11179-0; DAVID BIOINFORMATIC	44	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7212	10.1371/journal.pone.0007212	http://dx.doi.org/10.1371/journal.pone.0007212			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787063	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100014
J	Capparelli, R; Romanelli, A; Iannaccone, M; Nocerino, N; Ripa, R; Pensato, S; Pedone, C; Iannelli, D				Capparelli, Rosanna; Romanelli, Alessandra; Iannaccone, Marco; Nocerino, Nunzia; Ripa, Raffaella; Pensato, Soccorsa; Pedone, Carlo; Iannelli, Domenico			Synergistic Antibacterial and Anti-Inflammatory Activity of Temporin A and Modified Temporin B In Vivo	PLOS ONE			English	Article								Temporins are antimicrobial peptides secreted by the granular glands of the European red frog (Rana temporaria). They are 10-14 amino acid long polypeptides active prevalently against gram positive bacteria. This study shows that a synthetic temporin B analogue (TB-YK), acquires the capacity to act in synergism with temporin A and to exert antimicrobial and anti-inflammatory activity in vivo against gram positive and gram negative bacteria. Administration of 3.4 mg/Kg of temporin A (TA)+1.6 mg/Kg TB-YK, given to individual mice concurrently with a lethal dose of bacteria (gram positive or negative), rescued 100% of the animals. More importantly, the same doses of temporins, administered one week after experimental infection with a sub lethal dose of bacteria, sterilized 100% of the animals within 3-6 days. Also, it is described an animal model based on the use of sub lethal doses of bacteria, which closely mimics bacterial infection in humans. The model offers the possibility to test in a preclinical setting the true potential of TA and TB-YK in combination as antimicrobial and anti-inflammatory agents.			Capparelli, R (corresponding author), Univ Naples Federico 2, Sch Biotechnol Sci, Dept Soil Plant Environm & Anim Prod Sci, Naples, Italy.	capparel@unina.it	Iannaccone, Marco/K-7559-2016; Capparelli, Rosanna/Q-3144-2017	Iannaccone, Marco/0000-0002-2283-6613; Capparelli, Rosanna/0000-0001-8614-6251; ROMANELLI, Alessandra/0000-0002-7609-4061				Ananias M, 2008, BRAZ J MED BIOL RES, V41, P877, DOI 10.1590/S0100-879X2008001000008; Becker K, 1998, J CLIN MICROBIOL, V36, P2548, DOI 10.1128/JCM.36.9.2548-2553.1998; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; Bubert A, 1999, APPL ENVIRON MICROB, V65, P4688; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Carotenuto A, 2008, J MED CHEM, V51, P2354, DOI 10.1021/jm701604t; Cirioni O, 2005, J INFECT DIS, V192, P1613, DOI 10.1086/496888; Conlon JM, 2007, METHODS, V42, P349, DOI 10.1016/j.ymeth.2007.01.004; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; EDMAN P, 1950, ACTA CHEM SCAND, V283, P293; Feezor RJ, 2003, INFECT IMMUN, V71, P5803, DOI 10.1128/IAI.71.10.5803-5813.2003; Giacometti A, 2006, ANTIMICROB AGENTS CH, V50, P2478, DOI 10.1128/AAC.01553-05; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hong Y, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-178; Hujakka H, 2001, BIOORGAN MED CHEM, V9, P1601, DOI 10.1016/S0968-0896(01)00047-5; Lee J, 2009, BIOCHEM BIOPH RES CO, V379, P676, DOI 10.1016/j.bbrc.2008.12.030; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Lu Y, 2006, PEPTIDES, V27, P3085, DOI 10.1016/j.peptides.2006.08.017; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; Oh H, 2000, ANTIMICROB AGENTS CH, V44, P68, DOI 10.1128/AAC.44.1.68-72.2000; Papagianni M, 2003, BIOTECHNOL ADV, V21, P465, DOI 10.1016/S0734-9750(03)00077-6; Rathinakumar R, 2009, J AM CHEM SOC, V131, P7609, DOI 10.1021/ja8093247; Rinaldi AC, 2002, BIOCHEM J, V368, P91, DOI 10.1042/BJ20020806; Rosenfeld Y, 2006, J BIOL CHEM, V281, P28565, DOI 10.1074/jbc.M606031200; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Terblanche M, 2006, LANCET INFECT DIS, V6, P242, DOI 10.1016/S1473-3099(06)70439-X; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhao HX, 2002, BIOCHEMISTRY-US, V41, P4425, DOI 10.1021/bi011929e	32	33	34	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7191	10.1371/journal.pone.0007191	http://dx.doi.org/10.1371/journal.pone.0007191			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784377	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290000008
J	Jen, MH; Bottle, A; Majeed, A; Bell, D; Aylin, P				Jen, Min Hua; Bottle, Alex; Majeed, Azeem; Bell, Derek; Aylin, Paul			Early In-Hospital Mortality following Trainee Doctors' First Day at Work	PLOS ONE			English	Article								Background: There is a commonly held assumption that early August is an unsafe period to be admitted to hospital in England, as newly qualified doctors start work in NHS hospitals on the first Wednesday of August. We investigate whether in-hospital mortality is higher in the week following the first Wednesday in August than in the previous week. Methodology: A retrospective study in England using administrative hospital admissions data. Two retrospective cohorts of all emergency patients admitted on the last Wednesday in July and the first Wednesday in August for 2000 to 2008, each followed up for one week. Principal Findings: The odds of death for patients admitted on the first Wednesday in August was 6% higher (OR 1.06, 95% CI 1.00 to 1.15, p = 0.05) after controlling for year, gender, age, socio-economic deprivation and co-morbidity. When subdivided into medical, surgical and neoplasm admissions, medical admissions admitted on the first Wednesday in August had an 8% (OR 1.08, 95% CI 1.01 to 1.16, p = 0.03) higher odds of death. In 2007 and 2008, when the system for junior doctors' job applications changed, patients admitted on Wednesday August 1(st) had 8% higher adjusted odds of death than those admitted the previous Wednesday, but this was not statistically significant (OR 1.08, 95% CI 0.95 to 1.23, p = 0.24). Conclusions: We found evidence that patients admitted on the first Wednesday in August have a higher early death rate in English hospitals compared with patients admitted on the previous Wednesday. This was higher for patients admitted with a medical primary diagnosis.			Jen, MH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, Dr Foster Unit, London, England.	m.h.jen@imperial.ac.uk	Jen, Min-Hua/AAP-4200-2021; Aylin, Paul/A-1073-2014	Bell, Derek/0000-0002-9944-1097; Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011; Majeed, Azeem/0000-0002-2357-9858				AYLIN P, 1994, BRIT MED J, V309, P1690, DOI 10.1136/bmj.309.6970.1690; AYLIN P, 2009, QUAL SAF HL IN PRESS; Aylin P, 2007, BMJ-BRIT MED J, V334, P1044, DOI 10.1136/bmj.39168.496366.55; Barry WA, 2003, J GEN INTERN MED, V18, P639, DOI 10.1046/j.1525-1497.2003.20605.x; BUCHWALD D, 1989, ARCH INTERN MED, V149, P765, DOI 10.1001/archinte.149.4.765; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; *CONN HLTH, 2008, SEC US SERV SUS ONL; Finkielman JD, 2004, CRIT CARE MED, V32, P1161, DOI 10.1097/01.CCM.0000126151.56590.99; Goldstein H, 2002, STAT MED, V21, P3291, DOI 10.1002/sim.1264; GOULD M, 2004, GUARDIAN        0512; Handler JA, 2000, ACAD EMERG MED, V7, P1183, DOI 10.1111/j.1553-2712.2000.tb00462.x; Healthcare Cost and Use Project (HCUP), CLIN CLASS SOFTW ICD; Huckman RS., 2005, NATL BUREAU EC RES W, DOI [10.3386/w11182, DOI 10.3386/W11182]; *INF CTR, HOSP EP STAT ONL; Lu TC, 2006, EMERG MED J, V23, P452, DOI 10.1136/emj.2004.022319; MERCURIO J, 1994, WORLD PRODUCTIONS BB; Nafsi T, 2007, EMERG MED J, V24, P691, DOI 10.1136/emj.2006.044867; PAXMAN J, 2007, BBC ONLINE      0731; Pickersgill T, 2001, BRIT MED J, V323, P1266, DOI 10.1136/bmj.323.7324.1266; Rasbash J., 2008, USERS GUIDE MLWIN VE; RICH E C, 1990, Journal of the American Medical Association, V263, P953, DOI 10.1001/jama.263.7.953; Shuhaiber JH, 2008, ANN THORAC SURG, V86, P123, DOI 10.1016/j.athoracsur.2008.03.041; Shulkin D J, 1995, Am J Med Qual, V10, P14, DOI 10.1177/0885713X9501000104; 2007, ONE HOSP STAYING AFL; 2007, WARNINGS JUNIOR DOCT	26	108	108	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7103	10.1371/journal.pone.0007103	http://dx.doi.org/10.1371/journal.pone.0007103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774078	Green Published, Green Submitted, gold			2022-12-27	WOS:000270160900007
J	Bull, M; Learn, G; Genowati, I; McKernan, J; Hitti, J; Lockhart, D; Tapia, K; Holte, S; Dragavon, J; Coombs, R; Mullins, J; Frenkel, L				Bull, Marta; Learn, Gerald; Genowati, Indira; McKernan, Jennifer; Hitti, Jane; Lockhart, David; Tapia, Kenneth; Holte, Sarah; Dragavon, Joan; Coombs, Robert; Mullins, James; Frenkel, Lisa			Compartmentalization of HIV-1 within the Female Genital Tract Is Due to Monotypic and Low-Diversity Variants Not Distinct Viral Populations	PLOS ONE			English	Article								Background: Compartmentalization of HIV-1 between the genital tract and blood was noted in half of 57 women included in 12 studies primarily using cell-free virus. To further understand differences between genital tract and blood viruses of women with chronic HIV-1 infection cell-free and cell-associated virus populations were sequenced from these tissues, reasoning that integrated viral DNA includes variants archived from earlier in infection, and provides a greater array of genotypes for comparisons. Methodology/Principal Findings: Multiple sequences from single-genome-amplification of HIV-1 RNA and DNA from the genital tract and blood of each woman were compared in a cross-sectional study. Maximum likelihood phylogenies were evaluated for evidence of compartmentalization using four statistical tests. Genital tract and blood HIV-1 appears compartmentalized in 7/13 women by >= 2 statistical analyses. These subjects' phylograms were characterized by low diversity genital-specific viral clades interspersed between clades containing both genital and blood sequences. Many of the genital-specific clades contained monotypic HIV-1 sequences. In 2/7 women, HIV-1 populations were significantly compartmentalized across all four statistical tests; both had low diversity genital tract-only clades. Collapsing monotypic variants into a single sequence diminished the prevalence and extent of compartmentalization. Viral sequences did not demonstrate tissue-specific signature amino acid residues, differential immune selection, or co-receptor usage. Conclusions/Significance: In women with chronic HIV-1 infection multiple identical sequences suggest proliferation of HIV-1-infected cells, and low diversity tissue-specific phylogenetic clades are consistent with bursts of viral replication. These monotypic and tissue-specific viruses provide statistical support for compartmentalization of HIV-1 between the female genital tract and blood. However, the intermingling of these clades with clades comprised of both genital and blood sequences and the absence of tissue-specific genetic features suggests compartmentalization between blood and genital tract may be due to viral replication and proliferation of infected cells, and questions whether HIV-1 in the female genital tract is distinct from blood.			Bull, M (corresponding author), Seattle Childrens Hosp, Res Inst, Seattle, WA USA.	lfrenkel@u.washington.edu	Learn, Gerald H/B-6934-2011; Learn, Jerry/E-3356-2012	Learn, Gerald H/0000-0003-0434-7733; 	NIAID NIH HHS [AI07140, P30 AI27757, T32 AI007140, P30 AI027757] Funding Source: Medline; NICHD NIH HHS [P01 HD040540, 1 P01 HD40540] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD040540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007140, P30AI027757] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adal M, 2005, AIDS RES HUM RETROV, V21, P649, DOI 10.1089/aid.2005.21.649; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Andreoletti L, 2007, J CLIN MICROBIOL, V45, P1838, DOI 10.1128/JCM.00113-07; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; BEERLI P, 2001, COMPUTATIONAL EVOLUT, P217; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BULL ME, 2009, J VIROL; Chomont N, 2007, AIDS, V21, P153, DOI 10.1097/QAD.0b013e328011f94b; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Critchlow DE, 2000, MATH COMPUT MODEL, V32, P69, DOI 10.1016/S0895-7177(00)00120-5; De Pasquale MP, 2003, JAIDS-J ACQ IMM DEF, V34, P37, DOI 10.1097/00126334-200309010-00005; DELASSUS S, 1992, J VIROL, V66, P5642, DOI 10.1128/JVI.66.9.5642-5645.1992; Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998; Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997; Diem K, 2008, AIDS RES HUM RETROV, V24, P561, DOI 10.1089/aid.2007.0115; Ellerbrock TV, 2001, J INFECT DIS, V184, P28, DOI 10.1086/321000; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Frenkel LM, 2006, AIDS RES HUM RETROV, V22, P870, DOI 10.1089/aid.2006.22.870; Ghosn J, 2004, AIDS, V18, P447, DOI 10.1097/00002030-200402200-00011; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Gupta P, 2000, J INFECT DIS, V182, P79, DOI 10.1086/315644; Hart CE, 1999, J INFECT DIS, V179, P871, DOI 10.1086/314656; Hermankova M, 2003, J VIROL, V77, P7383, DOI 10.1128/JVI.77.13.7383-7392.2003; Hudson RR, 2000, GENETICS, V155, P2011; Iversen AKN, 1998, J INFECT DIS, V177, P1214, DOI 10.1086/515266; JENSEN MA, 2003, BIOINFORMATIC PREDIC; Kemal KS, 2007, J INFECT DIS, V195, P535, DOI 10.1086/510855; Kemal KS, 2003, P NATL ACAD SCI USA, V100, P12972, DOI 10.1073/pnas.2134064100; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; Kovacs A, 2001, LANCET, V358, P1593, DOI 10.1016/S0140-6736(01)06653-3; Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005; Min SS, 2004, JAIDS-J ACQ IMM DEF, V37, P1577, DOI 10.1097/00126334-200412150-00008; Mitchell CM, 2008, AIDS RES HUM RETROV, V24, P667, DOI [10.1089/aid.2007.0268, 10.1089/aid.2008.0268]; Nickle DC, 2003, J VIROL, V77, P5540, DOI 10.1128/JVI.77.9.5540-5546.2003; Philpott S, 2005, J VIROL, V79, P353, DOI 10.1128/JVI.79.1.353-363.2005; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Poss M, 1998, J VIROL, V72, P8240, DOI 10.1128/JVI.72.10.8240-8251.1998; Reichelderfer PS, 2000, AIDS, V14, P2101, DOI 10.1097/00002030-200009290-00005; Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Si-Mohamed A, 2000, J INFECT DIS, V182, P112, DOI 10.1086/315679; SLATKIN M, 1989, GENETICS, V123, P603; Sullivan ST, 2005, J VIROL, V79, P9799, DOI 10.1128/JVI.79.15.9799-9809.2005; Tirado G, 2005, VIROLOGY, V334, P299, DOI 10.1016/j.virol.2005.01.030; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; Wright TC, 2001, AM J OBSTET GYNECOL, V184, P279, DOI 10.1067/mob.2001.108999; Yang ZH, 2005, MOL BIOL EVOL, V22, P1107, DOI 10.1093/molbev/msi097; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; ZARATE S, 2007, J VIROL; Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106; Zuckerman RA, 2007, J INFECT DIS, V196, P1500, DOI 10.1086/522523	54	52	52	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7122	10.1371/journal.pone.0007122	http://dx.doi.org/10.1371/journal.pone.0007122			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771165	gold, Green Submitted, Green Published			2022-12-27	WOS:000270154400015
J	James, AW; Theologis, AA; Brugmann, SA; Xu, Y; Carre, AL; Leucht, P; Hamilton, K; Korach, KS; Longaker, MT				James, Aaron W.; Theologis, Alexander A.; Brugmann, Samantha A.; Xu, Yue; Carre, Antoine L.; Leucht, Philipp; Hamilton, Katherine; Korach, Kenneth S.; Longaker, Michael T.			Estrogen/Estrogen Receptor Alpha Signaling in Mouse Posterofrontal Cranial Suture Fusion	PLOS ONE			English	Article								Background: While premature suture fusion, or craniosynostosis, is a relatively common condition, the cause is often unknown. Estrogens are associated with growth plate fusion of endochondral bones. In the following study, we explore the previously unknown significance of estrogen/estrogen receptor signaling in cranial suture biology. Methodology/Principal Findings: Firstly, estrogen receptor (ER) expression was examined in physiologically fusing (posterofrontal) and patent (sagittal) mouse cranial sutures by quantitative RT-PCR. Next, the cranial suture phenotype of ER alpha and ER beta knockout (alpha ERKO, beta ERKO) mice was studied. Subsequently, mouse suture-derived mesenchymal cells (SMCs) were isolated; the effects of 17-beta estradiol or the estrogen antagonist Fulvestrant on gene expression, osteogenic and chondrogenic differentiation were examined in vitro. Finally, in vivo experiments were performed in which Fulvestrant was administered subcutaneously to the mouse calvaria. Results showed that increased ER alpha but not ER beta transcript abundance temporally coincided with posterofrontal suture fusion. The alpha ERKO but not beta ERKO mouse exhibited delayed posterofrontal suture fusion. In vitro, addition of 17-beta estradiol enhanced both osteogenic and chondrogenic differentiation in suture-derived mesenchymal cells, effects reversible by Fulvestrant. Finally, in vivo application of Fulvestrant significantly diminished calvarial osteogenesis, inhibiting suture fusion. Conclusions/Significance: Estrogen signaling through ER alpha but not ER beta is associated with and necessary for normal mouse posterofrontal suture fusion. In vitro studies suggest that estrogens may play a role in osteoblast and/or chondrocyte differentiation within the cranial suture complex.			James, AW (corresponding author), Stanford Univ, Sch Med, Div Plast & Reconstruct Surg, Hagey Pediat Regenerat Res Lab,Dept Surg, Stanford, CA 94305 USA.	Longaker@stanford.edu	Leucht, Philipp/H-7238-2019	Leucht, Philipp/0000-0002-8409-8513; Korach, Kenneth/0000-0002-7765-418X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013194, R01DE014526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES070065] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDCR NIH HHS [R01 DE013194, R01 DE-13194, R01 DE014526, R01 DE-14526] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albrecht U, 1997, MOL CELLULAR METHODS, P23; Bradley JP, 1997, PLAST RECONSTR SURG, V100, P1091, DOI 10.1097/00006534-199710000-00001; Bradley JP, 1999, PLAST RECONSTR SURG, V104, P129, DOI 10.1097/00006534-199907000-00019; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; Chagin AS, 2007, ACTA PAEDIATR, V96, P1275, DOI 10.1111/j.1651-2227.2007.00415.x; Chagin AS, 2006, J ENDOCRINOL, V188, P193, DOI 10.1677/joe.1.06364; Chagin AS, 2004, J BONE MINER RES, V19, P72, DOI 10.1359/JBMR.0301203; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; CHOW JWM, 1992, ENDOCRINOLOGY, V130, P3025, DOI 10.1210/en.130.5.3025; D'Angelo M, 2001, J BONE MINER RES, V16, P2339, DOI 10.1359/jbmr.2001.16.12.2339; Egerbacher M, 2002, HORM RES, V58, P99, DOI 10.1159/000064661; Emmen JMA, 2005, ENDOCRINOLOGY, V146, P2817, DOI 10.1210/en.2004-1108; Farkas LG, 1999, J CRANIOFAC SURG, V10, P18, DOI 10.1097/00001665-199901000-00005; Foo C, 2007, GYNECOL ENDOCRINOL, V23, P535, DOI 10.1080/09513590701556483; Gaissmaier C, 2008, INJURY, V39, pS88, DOI 10.1016/j.injury.2008.01.035; GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787; Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007-0036; Greenwald JA, 2001, AM J PATHOL, V158, P441, DOI 10.1016/S0002-9440(10)63987-9; Greenwald JA, 2000, J BONE MINER RES, V15, P2413, DOI 10.1359/jbmr.2000.15.12.2413; Grumbach MM, 2000, J PEDIATR ENDOCR MET, V13, P1439; Grumbach MM, 2004, ANN NY ACAD SCI, V1038, P7, DOI 10.1196/annals.1315.008; Hernandez JL, 2008, ARTHRITIS RHEUM, V58, P1696, DOI 10.1002/art.23500; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Hirukawa K, 2005, ARCH ORAL BIOL, V50, P367, DOI 10.1016/j.archoralbio.2004.07.003; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367; Hong L, 2006, TISSUE ENG, V12, P2747, DOI 10.1089/ten.2006.12.2747; IGNARTROWBRIDGE DM, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432505; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JACQUES B, 1999, GENE DEV, V13, P2072; James AW, 2008, PLAST RECONSTR SURG, V122, P53, DOI 10.1097/PRS.0b013e31817747b5; James AW, 2009, PLAST RECONSTR SURG, V123, P31, DOI 10.1097/PRS.0b013e3181904c19; Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756-3282(03)00092-9; Kharode Yogendra P., 2008, V455, P111, DOI 10.1007/978-1-59745-104-8_8; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Koga K, 2008, ANTICANCER RES, V28, P731; KOKICH V G, 1986, P81; Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550-06; Lea CK, 1999, J ENDOCRINOL, V160, P111, DOI 10.1677/joe.0.1600111; Lenton KA, 2005, CURR TOP DEV BIOL, V66, P287, DOI 10.1016/S0070-2153(05)66009-7; Lin IC, 2004, J CRANIOFAC SURG, V15, P922, DOI 10.1097/00001665-200411000-00006; Lin IC, 2007, PLAST RECONSTR SURG, V120, P1137, DOI 10.1097/01.prs.0000279527.99734.bf; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; Maneix L, 2008, RHEUMATOLOGY, V47, P281, DOI 10.1093/rheumatology/kem323; MANZANARES MC, 1988, J ANAT, V161, P203; McCauley LK, 2003, CONNECT TISSUE RES, V44, P250, DOI 10.1080/03008200390181744; McCauley LK, 2002, CRIT REV EUKAR GENE, V12, P89, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i2.10; Mehrara BJ, 2002, PLAST RECONSTR SURG, V110, P506, DOI 10.1097/00006534-200208000-00022; Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791; Nilsson O, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730407; Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349; Ong DB, 2004, J BONE MINER RES, V19, P447, DOI 10.1359/JBMR.0301249; Opperman LA, 1997, J BONE MINER RES, V12, P301, DOI 10.1359/jbmr.1997.12.3.301; Panchal J, 2003, PLAST RECONSTR SURG, V111, P2032, DOI 10.1097/01.PRS.0000056839.94034.47; Parikka V, 2005, EUR J ENDOCRINOL, V152, P301, DOI 10.1530/eje.1.01832; Plant A, 2001, J CELL BIOCHEM, V82, P683, DOI 10.1002/jcb.1201; Plant A, 2002, J CELL BIOCHEM, V84, P285, DOI 10.1002/jcb.10021; Qu Q, 1999, J CELL BIOCHEM, V73, P500, DOI 10.1002/(SICI)1097-4644(19990615)73:4<500::AID-JCB8>3.0.CO;2-E; Rao L G, 2001, Drug Metabol Drug Interact, V18, P149; Roth DA, 1997, PLAST RECONSTR SURG, V99, P300, DOI 10.1097/00006534-199702000-00002; Roth DA, 1997, PLAST RECONSTR SURG, V99, P310; Sahar DE, 2005, DEV BIOL, V280, P344, DOI 10.1016/j.ydbio.2005.01.022; Sibonga JD, 1998, ENDOCRINOLOGY, V139, P3736, DOI 10.1210/en.139.9.3736; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Smith EP, 2008, J CLIN ENDOCR METAB, V93, P3088, DOI 10.1210/jc.2007-2397; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Talwar RM, 2006, J ORAL MAXIL SURG, V64, P600, DOI 10.1016/j.joms.2005.12.006; Tang X, 2008, J PERIODONTAL RES, V43, P311, DOI 10.1111/j.1600-0765.2007.01031.x; Tanko LB, 2008, CLIMACTERIC, V11, P4, DOI 10.1080/13697130701857639; van der Eerden BCJ, 2004, J ENDOCRINOL, V180, P457, DOI 10.1677/joe.0.1800457; Van Der Eerden BCJ, 2002, BONE, V30, P478, DOI 10.1016/S8756-3282(01)00703-7; van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004; Vanderschueren D, 2006, J CLIN ENDOCR METAB, V91, P378, DOI 10.1210/jc.2005-1766; Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474; Vidal O, 1999, BIOCHEM BIOPH RES CO, V265, P569, DOI 10.1006/bbrc.1999.1711; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; WESTERLIND KC, 1995, STEROIDS, V60, P484, DOI 10.1016/0039-128X(95)00056-V; Xu Y, 2007, PLAST RECONSTR SURG, V119, P819, DOI 10.1097/01.prs.0000255540.91987.a0; Xu Y, 2008, PLAST RECONSTR SURG, V122, P1649, DOI 10.1097/PRS.0b013e31818cbf44; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Yao XF, 2006, MED MOL MORPHOL, V39, P193, DOI 10.1007/s00795-006-0336-5; Yuasa T, 2002, J CELL PHYSIOL, V193, P225, DOI 10.1002/jcp.10166; ZHANG B, 2005, COMPUTER ENG APPL, V6, P7; Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002-0210; Zofkova I, 2003, PHYSIOL RES, V52, P657	84	47	47	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7120	10.1371/journal.pone.0007120	http://dx.doi.org/10.1371/journal.pone.0007120			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771170	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400013
J	Moniaux, N; Nemos, C; Deb, S; Zhu, B; Dornreiter, I; Hollingsworth, MA; Batra, SK				Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali; Zhu, Bing; Dornreiter, Irena; Hollingsworth, Michael A.; Batra, Surinder K.			The Human RNA Polymerase II-Associated Factor 1 (hPaf1): A New Regulator of Cell-Cycle Progression	PLOS ONE			English	Article								Background: The human PAF (hPAF) complex is part of the RNA polymerase II transcription apparatus and regulates multiple steps in gene expression. Further, the yeast homolog of hPaf1 has a role in regulating the expression of a subset of genes involved in the cell-cycle. We therefore investigated the role of hPaf1 during progression of the cell-cycle. Methodology/Findings: Herein, we report that the expression of hPaf1, a subunit of the hPAF complex, increases with cell-cycle progression and is regulated in a cell-cycle dependant manner. hPaf1 specifically regulates a subclass of genes directly implicated in cell-cycle progression during G1/S, S/G2, and G2/M. In prophase, hPaf1 aligns in filament-like structures, whereas in metaphase it is present within the pole forming a crown-like structure, surrounding the centrosomes. Moreover, hPaf1 is degraded during the metaphase to anaphase transition. In the nucleus, hPaf1 regulates the expression of cyclins A1, A2, D1, E1, B1, and Cdk1. In addition, expression of hPaf1 delays DNA replication but favors the G2/M transition, in part through microtubule assembly and mitotic spindle formation. Conclusion/Significance: Our results identify hPaf1 and the hPAF complex as key regulators of cell-cycle progression. Mutation or loss of stoichiometry of at least one of the members may potentially lead to cancer development.			Moniaux, N (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386	NATIONAL CANCER INSTITUTE [P50CA072712] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA72712, P50 CA072712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arora C, 2004, MOL CELL, V13, P549, DOI 10.1016/S1097-2765(04)00063-2; Betz JL, 2002, MOL GENET GENOMICS, V268, P272, DOI 10.1007/s00438-002-0752-8; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Dehde S, 2001, MOL CELL BIOL, V21, P2581, DOI 10.1128/MCB.21.7.2581-2593.2001; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; He YH, 2004, GENE DEV, V18, P2774, DOI 10.1101/gad.1244504; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Parusel CT, 2006, DEVELOPMENT, V133, P621, DOI 10.1242/dev.02235; Porter SE, 2002, EUKARYOT CELL, V1, P830, DOI 10.1128/EC.1.5.830-842.2002; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Sherr C J, 2000, Harvey Lect, V96, P73; Shi XM, 1996, MOL CELL BIOL, V16, P669; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; SZABO J, 1995, AM J HUM GENET, V56, P944; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105; ZHU FG, 1987, HISTOPATHOLOGY, V11, P631, DOI 10.1111/j.1365-2559.1987.tb02673.x; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	37	25	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7077	10.1371/journal.pone.0007077	http://dx.doi.org/10.1371/journal.pone.0007077			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771162	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154400003
J	Carlson, PE; Carr, KA; Janes, BK; Anderson, EC; Hanna, PC				Carlson, Paul E., Jr.; Carr, Katherine A.; Janes, Brian K.; Anderson, Erica C.; Hanna, Philip C.			Transcriptional Profiling of Bacillus anthracis Sterne (34F(2)) during Iron Starvation	PLOS ONE			English	Article							GENE-EXPRESSION; IN-VITRO; IDENTIFICATION; INFECTION; VIRULENCE; PROTEINS; FAMILY; GROWTH; MODEL	Lack of available iron is one of many environmental challenges that a bacterium encounters during infection and adaptation to iron starvation is important for the pathogen to efficiently replicate within the host. Here we define the transcriptional response of B. anthracis Sterne (34F(2)) to iron depleted conditions. Genome-wide transcript analysis showed that B. anthracis undergoes considerable changes in gene expression during growth in iron-depleted media, including the regulation of known and candidate virulence factors. Two genes encoding putative internalin proteins were chosen for further study. Deletion of either gene (GBAA0552 or GBAA1340) resulted in attenuation in a murine model of infection. This attenuation was amplified in a double mutant strain. These data define the transcriptional changes induced during growth in low iron conditions and illustrate the potential of this dataset in the identification of putative virulence determinants for future study.			Carlson, PE (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.	pchanna@umich.edu			NIAID NIH HHS [T32 AI007528, T32-AI-07528, 1-U54-AI-057053, N266200400059C-N01-AI-40059, N01AI40059] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacon J, 2007, MICROBIOL-SGM, V153, P1435, DOI 10.1099/mic.0.2006/004317-0; Bergman NH, 2007, INFECT IMMUN, V75, P3434, DOI 10.1128/IAI.01345-06; Bergman NH, 2006, J BACTERIOL, V188, P6092, DOI 10.1128/JB.00723-06; Bierne H, 2007, MICROBES INFECT, V9, P1156, DOI 10.1016/j.micinf.2007.05.003; Boyle EC, 2003, CURR OPIN CELL BIOL, V15, P633, DOI 10.1016/S0955-0674(03)00099-1; Cendrowski S, 2004, MOL MICROBIOL, V51, P407, DOI 10.1046/j.1365-2958.2003.03861.x; Deng K, 2006, INFECT IMMUN, V74, P4224, DOI 10.1128/IAI.01975-05; Desvaux M, 2006, FEMS MICROBIOL LETT, V256, P1, DOI 10.1111/j.1574-6968.2006.00122.x; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Fedhila S, 2006, MOL MICROBIOL, V62, P339, DOI 10.1111/j.1365-2958.2006.05362.x; Gat O, 2008, MOL MICROBIOL, V70, P983, DOI 10.1111/j.1365-2958.2008.06460.x; Gorke B, 2008, NAT REV MICROBIOL, V6, P613, DOI 10.1038/nrmicro1932; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heffernan BJ, 2007, FEMS MICROBIOL LETT, V271, P98, DOI 10.1111/j.1574-6968.2007.00713.x; Hoffmaster AR, 1997, INFECT IMMUN, V65, P3091, DOI 10.1128/IAI.65.8.3091-3099.1997; Janes BK, 2006, INFECT IMMUN, V74, P1949, DOI 10.1128/IAI.74.3.1949-1953.2006; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; Kim CC, 2003, INFECT IMMUN, V71, P3196, DOI 10.1128/IAI.71.6.3196-3205.2003; KIM HU, 1974, J APPL BACTERIOL, V37, P265, DOI 10.1111/j.1365-2672.1974.tb00438.x; KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/jb.176.3.586-595.1994; Lee JY, 2007, J BACTERIOL, V189, P1698, DOI 10.1128/JB.01526-06; Maresso AW, 2006, J BACTERIOL, V188, P8145, DOI 10.1128/JB.01011-06; Maresso AW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000132; Nanduri B, 2008, PROTEOMICS, V8, P2104, DOI 10.1002/pmic.200701048; Nguyen CC, 1995, FEBS LETT, V377, P98, DOI 10.1016/0014-5793(95)01344-X; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Passalacqua KD, 2007, J BACTERIOL, V189, P3996, DOI 10.1128/JB.00185-07; Passalacqua KD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004904; Patel Satish, 2004, Appl Bioinformatics, V3, P49; Pfleger BF, 2008, P NATL ACAD SCI USA, V105, P17133, DOI 10.1073/pnas.0808118105; Rozen S, 2000, Methods Mol Biol, V132, P365; Ruthel G, 2004, J INFECT DIS, V189, P1313, DOI 10.1086/382656; Sancho J, 2006, CELL MOL LIFE SCI, V63, P855, DOI 10.1007/s00018-005-5514-4; Seveau S, 2007, MICROBES INFECT, V9, P1167, DOI 10.1016/j.micinf.2007.05.004; Tong SX, 1996, J BACTERIOL, V178, P3260, DOI 10.1128/jb.178.11.3260-3269.1996; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Yu GX, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S1-S3; ZAWADZKA A, 2009, BIOCHEMISTRY	39	36	37	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e6988	10.1371/journal.pone.0006988	http://dx.doi.org/10.1371/journal.pone.0006988			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768119	Green Published, gold, Green Submitted			2022-12-27	WOS:000270154000001
J	Kilroy, G; Burk, DH; Floyd, ZE				Kilroy, Gail; Burk, David H.; Floyd, Z. Elizabeth			High Efficiency Lipid-Based siRNA Transfection of Adipocytes in Suspension	PLOS ONE			English	Article							PPAR-GAMMA	Background: Fully differentiated adipocytes are considered to be refractory to introduction of siRNA via lipid-based transfection. However, large scale siRNA-based loss-of-function screening of adipocytes using either electroporation or virally-mediated transfection approaches can be prohibitively complex and expensive. Methodology/Principal Findings: We present a method for introducing small interfering RNA ( siRNA) into differentiated 3T3-L1 adipocytes and primary human adipocytes using an approach based on forming the siRNA/cell complex with the adipocytes in suspension rather than as an adherent monolayer, a variation of "reverse transfection''. Conclusions/Significance: Transfection of adipocytes with siRNA by this method is economical, highly efficient, has a simple workflow, and allows standardization of the ratio of siRNA/cell number, making this approach well-suited for high-throughput screening of fully differentiated adipocytes.			Kilroy, G (corresponding author), Pennington Biomed Res Ctr, Ubiquitin Biol Lab, Baton Rouge, LA USA.	Elizabeth.Floyd@pbrc.edu	Floyd, Elizabeth/W-2758-2019; Burk, David/D-2056-2009; Floyd, Elizabeth/N-1962-2017	Floyd, Elizabeth/0000-0002-3002-6186; Floyd, Elizabeth/0000-0002-3002-6186	NCRR NIH HHS [P20-RR021945, P20 RR02195, P20 RR021945] Funding Source: Medline; NIDDK NIH HHS [P30 DK072476, 1 P30-DK072476] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amarzguioui M, 2004, BIOTECHNIQUES, V36, P766, DOI 10.2144/04365BM03; Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215; Echeverri CJ, 2006, NAT REV GENET, V7, P373, DOI 10.1038/nrg1836; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kilroy GE, 2009, OBESITY, V17, P665, DOI 10.1038/oby.2008.616; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Orlicky DJ, 2001, J LIPID RES, V42, P460; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 2008, MOL CELL, V29, P755, DOI 10.1016/j.molcel.2008.01.020; Puri V, 2007, J LIPID RES, V48, P465, DOI 10.1194/jlr.D600033-JLR200; Tang XQ, 2006, P NATL ACAD SCI USA, V103, P2087, DOI 10.1073/pnas.0507660103; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829	14	49	50	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6940	10.1371/journal.pone.0006940	http://dx.doi.org/10.1371/journal.pone.0006940			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759827	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696600003
J	Melekhin, VV; Shepherd, BE; Stinnette, SE; Rebeiro, PF; Barkanic, G; Raffanti, SP; Sterling, TR				Melekhin, Vlada V.; Shepherd, Bryan E.; Stinnette, Samuel E.; Rebeiro, Peter F.; Barkanic, Gema; Raffanti, Stephen P.; Sterling, Timothy R.			Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response	PLOS ONE			English	Article								Background: Pregnancy has been associated with a decreased risk of HIV disease progression in the highly active antiretroviral therapy (HAART) era. The effect of timing of HAART initiation relative to pregnancy on maternal virologic, immunologic and clinical outcomes has not been assessed. Methods: We conducted a retrospective cohort study from 1997-2005 among 112 pregnant HIV-infected women who started HAART before (N=12), during (N=70) or after pregnancy (N=30). Results: Women initiating HAART before pregnancy had lower CD4+ nadir and higher baseline HIV-1 RNA. Women initiating HAART after pregnancy were more likely to receive triple-nucleoside reverse transcriptase inhibitors. Multivariable analyses adjusted for baseline CD4+ lymphocytes, baseline HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, history of ADE, prior use of non-HAART ART, type of HAART regimen, prior pregnancies, and date of HAART start. In these models, women initiating HAART during pregnancy had better 6-month HIV-1 RNA and CD4+ changes than those initiating HAART after pregnancy (-0.35 vs. 0.10 log(10) copies/mL, P=0.03 and 183.8 vs. -70.8 cells/mm(3), P=0.03, respectively) but similar to those initiating HAART before pregnancy (-0.32 log(10) copies/mL, P=0.96 and 155.8 cells/mm(3), P=0.81, respectively). There were 3 (25%) AIDS-defining events or deaths in women initiating HAART before pregnancy, 3 (4%) in those initiating HAART during pregnancy, and 5 (17%) in those initiating after pregnancy (P=0.01). There were no statistical differences in rates of HIV disease progression between groups. Conclusions: HAART initiation during pregnancy was associated with better immunologic and virologic responses than initiation after pregnancy.			Melekhin, VV (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA.	vlada.melekhin@vanderbilt.edu		Rebeiro, Peter/0000-0003-1951-9104	NIAID NIH HHS [P30 AI054999, P30 AI54999, T32 AI07474-10, T32 AI007474] Funding Source: Medline; PHS HHS [K24 A1065298] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007474, P30AI054999] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alliegro MB, 1997, ARCH INTERN MED, V157, P2585, DOI 10.1001/archinte.157.22.2585; Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Arrive E, 2007, INT J EPIDEMIOL, V36, P1009, DOI 10.1093/ije/dym104; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bardeguez AD, 2003, JAIDS-J ACQ IMM DEF, V32, P170, DOI 10.1097/00126334-200302010-00009; Bardeguez AD, 2008, JAIDS-J ACQ IMM DEF, V48, P408, DOI 10.1097/QAI.0b013e31817bbe80; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Bessinger R, 1998, AM J EPIDEMIOL, V147, P434, DOI 10.1093/oxfordjournals.aje.a009468; BIGGAR RJ, 1989, AM J OBSTET GYNECOL, V161, P1239, DOI 10.1016/0002-9378(89)90674-1; Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Chaix ML, 2006, J INFECT DIS, V193, P482, DOI 10.1086/499966; Cheng DM, 2007, ALCOHOL CLIN EXP RES, V31, P829, DOI 10.1111/j.1530-0277.2007.00381.x; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; DESCHAMPS MM, 1993, J ACQ IMMUN DEF SYND, V6, P446; Dietz PM, 2007, PAEDIATR PERINAT EP, V21, P62, DOI 10.1111/j.1365-3016.2007.00862.x; Dronda F, 2004, AIDS, V18, P2210, DOI 10.1097/00002030-200411050-00018; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Ebrahim SH, 2000, JAMA-J AM MED ASSOC, V283, P361, DOI 10.1001/jama.283.3.361; Effros RB, 2003, CURR HIV RES, V1, P153, DOI 10.2174/1570162033485348; Ekpini RA, 2002, AIDS, V16, P625, DOI 10.1097/00002030-200203080-00015; FINGERHUT LA, 1990, AM J PUBLIC HEALTH, V80, P541, DOI 10.2105/AJPH.80.5.541; Giuliano M, 2003, AIDS, V17, P1570, DOI 10.1097/00002030-200307040-00022; Golub ET, 2008, CLIN INFECT DIS, V46, P305, DOI 10.1086/524752; HOCKE C, 1995, OBSTET GYNECOL, V86, P886, DOI 10.1016/0029-7844(95)00257-R; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Kakehasi FM, 2007, AIDS RES HUM RETROV, V23, P1515, DOI 10.1089/aid.2007.0025; Kaufmann GR, 2000, AIDS, V14, P959, DOI 10.1097/00002030-200005260-00007; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Kully C, 1999, J INFECT DIS, V179, P705, DOI 10.1086/314615; KUMAR RM, 1995, INT J GYNECOL OBSTET, V49, P137, DOI 10.1016/0020-7292(95)02356-H; Kuritzkes DR, 2007, J INFECT DIS, V195, P1169, DOI 10.1086/512619; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lucas GM, 2002, AIDS, V16, P767, DOI 10.1097/00002030-200203290-00012; Mellins CA, 2008, AIDS CARE, V20, P958, DOI 10.1080/09540120701767208; MINKOFF H, 1987, OBSTET GYNECOL, V69, P285; Modjarrad K, 2008, AIDS, V22, P2179, DOI 10.1097/QAD.0b013e328312c756; Mofenson L., 2006, Morbidity and Mortality Weekly Report, V55, P592; *PAN ANT GUID ADU, 2008, GUID US ANT AG HIV 1; *PER HIV GUID GROU, 2008, PUBL HLTH SERV TASK; Perez-Elias MJ, 2005, HIV CLIN TRIALS, V6, P312, DOI 10.1310/B3NK-V5XQ-6VX9-5DEK; Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227; Vaz MJR, 2007, INT J STD AIDS, V18, P28, DOI 10.1258/095646207779949808; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Saada M, 2000, AIDS, V14, P2355, DOI 10.1097/00002030-200010200-00017; Sanchez-Ramon S, 2005, IMMUNOL LETT, V96, P195, DOI 10.1016/j.imlet.2004.09.004; Savitz DA, 2002, AM J OBSTET GYNECOL, V187, P1660, DOI 10.1067/mob.2002.127601; SCOTT GB, 1985, JAMA-J AM MED ASSOC, V253, P363, DOI 10.1001/jama.253.3.363; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Tai JH, 2007, J INFECT DIS, V196, P1044, DOI 10.1086/520814; Thea DM, 1997, AIDS, V11, P437, DOI 10.1097/00002030-199704000-00006; *UN JOINT PROGR HI, 2008, 2007 AIDS EP UPD; Waller DK, 2000, PAEDIATR PERINAT EP, V14, P263, DOI 10.1046/j.1365-3016.2000.00275.x; Weisser M, 1998, J ACQ IMMUN DEF SYND, V17, P404, DOI 10.1097/00042560-199804150-00004; Welles SL, 2000, AIDS, V14, P263, DOI 10.1097/00002030-200002180-00008	56	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6961	10.1371/journal.pone.0006961	http://dx.doi.org/10.1371/journal.pone.0006961			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742315	gold, Green Published, Green Submitted			2022-12-27	WOS:000269622500022
J	Metzgar, D; Baynes, D; Hansen, CJ; McDonough, EA; Cabrera, DR; Ellorin, MM; Blair, PJ; Russell, KL; Faix, DJ				Metzgar, David; Baynes, Darcie; Hansen, Christian J.; McDonough, Erin A.; Cabrera, Daisy R.; Ellorin, Melody M.; Blair, Patrick J.; Russell, Kevin L.; Faix, Dennis J.			Inference of Antibiotic Resistance and Virulence among Diverse Group A Streptococcus Strains Using emm Sequencing and Multilocus Genotyping Methods	PLOS ONE			English	Article								Background: Group A Streptococcus pyogenes ( GAS) exhibits a high degree of clinically relevant phenotypic diversity. Strains vary widely in terms of antibiotic resistance (AbR), clinical severity, and transmission rate. Currently, strain identification is achieved by emm typing ( direct sequencing of the genomic segment coding for the antigenic portion of the M protein) or by multilocus genotyping methods. Phenotype analysis, including critical AbR typing, is generally achieved by much slower and more laborious direct culture-based methods. Methodology/Principal Findings: We compare genotype identification ( by emm typing and PCR/ESI-MS) with directly measured phenotypes ( AbR and outbreak associations) for 802 clinical isolates of GAS collected from symptomatic patients over a period of 6 years at 10 military facilities in the United States. All independent strain characterization methods are highly correlated. This shows that recombination, horizontal transfer, and other forms of reassortment are rare in GAS insofar as housekeeping genes, primary virulence and antibiotic resistance determinants, and the emm gene are concerned. Therefore, genotyping methods offer an efficient way to predict emm type and the associated AbR and virulence phenotypes. Conclusions/Significance: The data presented here, combined with much historical data, suggest that emm typing assays and faster molecular methods that infer emm type from genomic signatures could be used to efficiently infer critical phenotypic characteristics based on robust genotype: phenotype correlations. This, in turn, would enable faster and better-targeted responses during identified outbreaks of constitutively resistant or particularly virulent emm types.			Metzgar, D (corresponding author), Naval Hlth Res Ctr, Dept Resp Dis Res, San Diego, CA USA.	david.metzgar@med.navy.mil						BLACK CM, 1993, MOL CELL PROBE, V7, P255, DOI 10.1006/mcpr.1993.1038; Bronze MS, 1996, AM J MED SCI, V311, P41, DOI 10.1097/00000441-199601000-00008; Brundage JF, 1996, PEDIATRICS, V97, P964; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; Crum NF, 2005, CLIN INFECT DIS, V40, P511, DOI 10.1086/427502; Descheemaeker P, 2000, J ANTIMICROB CHEMOTH, V45, P167, DOI 10.1093/jac/45.2.167; Ecker DJ, 2005, P NATL ACAD SCI USA, V102, P8012, DOI 10.1073/pnas.0409920102; Enright MC, 2001, INFECT IMMUN, V69, P2416, DOI 10.1128/IAI.69.4.2416-2427.2001; Facklam R, 1999, EMERG INFECT DIS, V5, P247, DOI 10.3201/eid0502.990209; Grivea IN, 2006, ANTIMICROB AGENTS CH, V50, P256, DOI 10.1128/AAC.50.1.256-261.2006; GUNZENHAUSER JD, 1995, J INFECT DIS, V172, P124, DOI 10.1093/infdis/172.1.124; Horn DL, 1998, CLIN INFECT DIS, V26, P1341, DOI 10.1086/516375; Kaplan EL, 1999, PEDIATR INFECT DIS J, V18, P1069, DOI 10.1097/00006454-199912000-00008; KAPLAN EL, 1994, J INFECT DIS, V170, P1346, DOI 10.1093/infdis/170.5.1346; Lamagni TL, 2008, EMERG INFECT DIS, V14, P202, DOI 10.3201/eid1402.070888; Macris MH, 1998, PEDIATR INFECT DIS J, V17, P377, DOI 10.1097/00006454-199805000-00006; Martin JM, 2002, NEW ENGL J MED, V346, P1200, DOI 10.1056/NEJMoa013169; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; Perez-Trallero E, 1999, EMERG INFECT DIS, V5, P235, DOI 10.3201/eid0502.990207; RUSSELL KL, 2006, TXB MILITARY MED REC, P227; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WANNAMAKER LW, 1953, NEW ENGL J MED, V249, P1, DOI 10.1056/NEJM195307022490101	23	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6897	10.1371/journal.pone.0006897	http://dx.doi.org/10.1371/journal.pone.0006897			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730733	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100003
J	Birjmohun, RS; Vergeer, M; Stroes, ESG; Sandhu, MS; Ricketts, SL; Tanck, MW; Wareham, NJ; Jukema, JW; Kastelein, JJP; Khaw, KT; Boekholdt, SM				Birjmohun, Rakesh S.; Vergeer, Menno; Stroes, Erik S. G.; Sandhu, Manjinder S.; Ricketts, Sally L.; Tanck, Michael W.; Wareham, Nicholas J.; Jukema, J. Wouter; Kastelein, John J. P.; Khaw, Kay-Tee; Boekholdt, S. Matthijs			Both Paraoxonase-1 Genotype and Activity Do Not Predict the Risk of Future Coronary Artery Disease; the EPIC-Norfolk Prospective Population Study	PLOS ONE			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEART-DISEASE; GENE POLYMORPHISMS; MYOCARDIAL-INFARCTION; VITAMIN-E; ASSOCIATION ANALYSIS; SERUM PARAOXONASE; PON1; OXIDATION; THICKNESS	Paraoxonase-1 (PON1) is an antioxidant enzyme, that resides on high-density lipoprotein (HDL). PON1-activity, is heavily influenced by the PON1-Q192R polymorphism. PON1 is considered to protect against atherosclerosis, but it is unclear whether this relation is independent of its carrier, HDL. In order to evaluate the atheroprotective potential of PON1, we assessed the relationships among PON1-genotype, PON1-activity and risk of future coronary artery disease (CAD), in a large prospective case-control study. Methodology/Principal Findings: Cases (n = 1138) were apparently healthy men and women aged 45-79 years who developed fatal or nonfatal CAD during a mean follow-up of 6 years. Controls (n = 2237) were matched by age, sex and enrollment time. PON1-activity was similar in cases and controls (60.7 +/- 645.3 versus 62.6 +/- 645.8 U/L, p = 0.3) and correlated with HDL-cholesterol levels (r = 0.16, p < 0.0001). The PON1-Q192R polymorphism had a profound impact on PON1-activity, but did not predict CAD risk (Odds Ratio [OR] per R allele 0.98[0.84-1.15], p = 0.8). Using conditional logistic regression, quartiles of PON1-activity showed a modest inverse relation with CAD risk (OR for the highest versus the lowest quartile 0.77[0.63-0.95], p = 0.01; p-trend = 0.06). PON1-activity adjusted for Q192R polymorphism correlated better with HDL-cholesterol (r = 0.26, p < 0.0001) and more linearly predicted CAD risk (0.79[0.64-0.98], p = 0.03; p-trend = 0.008). However, these relationships were abolished after adjustment for HDL (particles-cholesterol-size) and apolipoprotein A-l (0.94[0.74-1.18], p-trend = 0.3). Conclusions/Significance: This study, shows that PON1-activity inversely relates to CAD risk, but not independent of HDL, due to its close association with the HDL-particle. These data strongly suggest that a low PON1-activity is not a causal factor in atherogenesis.			Birjmohun, RS (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	r.s.birjmohun@amc.uva.nl	Jukema, J. Wouter/ABD-6503-2021; Boekholdt, Matthijs S.M./G-7562-2014; Kastelein, John/AAF-7950-2020; Khaw, Kay-Tee/AAZ-3209-2021	Jukema, J. Wouter/0000-0002-3246-8359; Tanck, Michael/0000-0001-9828-4459; Ricketts, Sally/0000-0002-5644-7958; Boekholdt, Matthijs/0000-0002-0861-0765	British Heart Foundation [PG/08/094/26019] Funding Source: Medline; Cancer Research UK Funding Source: Medline; Medical Research Council [G0801566, G0401527] Funding Source: Medline; Wellcome Trust Funding Source: Medline; Department of Health Funding Source: Medline; MRC [G0801566] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERS JJ, 1992, CLIN CHEM, V38, P658; Ascherio A, 1999, ANN INTERN MED, V130, P963, DOI 10.7326/0003-4819-130-12-199906150-00003; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Barter P, 2004, ATHEROSCLEROSIS SUPP, V5, P25, DOI 10.1016/j.atherosclerosissup.2004.03.003; Bhattacharyya T, 2008, JAMA-J AM MED ASSOC, V299, P1265, DOI 10.1001/jama.299.11.1265; Boekholdt MS, 2004, AM J MED, V117, P390, DOI 10.1016/j.amjmed.2004.04.010; Bruins P, 1997, CIRCULATION, V96, P3542; Cascorbi I, 1999, PHARMACOGENETICS, V9, P755, DOI 10.1097/00008571-199912000-00010; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Fortunato G, 2003, ATHEROSCLEROSIS, V167, P141, DOI 10.1016/S0021-9150(02)00423-9; Frei B, 1996, VITAM HORM, V52, P1, DOI 10.1016/S0083-6729(08)60405-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gardemann A, 2000, ATHEROSCLEROSIS, V152, P421, DOI 10.1016/S0021-9150(99)00489-X; GARIN MCB, 1994, BIOCHEM J, V304, P549, DOI 10.1042/bj3040549; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRANE RM, 2006, J AM COLL CARDIOL, V20, P2429; Herrmann SM, 1996, ATHEROSCLEROSIS, V126, P299, DOI 10.1016/0021-9150(96)05917-5; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Jarvik GP, 2002, ARTERIOSCL THROM VAS, V22, P1329, DOI 10.1161/01.ATV.0000027101.40323.3A; Leus FR, 2000, ATHEROSCLEROSIS, V149, P371, DOI 10.1016/S0021-9150(99)00324-X; Li D, 1996, J LIPID RES, V37, P1978; Lonn E, 2006, NEW ENGL J MED, V355, P209; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338; Mackness B, 1998, ATHEROSCLEROSIS, V139, P341, DOI 10.1016/S0021-9150(98)00095-1; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Odawara M, 1997, J CLIN ENDOCR METAB, V82, P2257, DOI 10.1210/jc.82.7.2257; Oliveira SA, 2004, INT J CARDIOL, V94, P73, DOI 10.1016/j.ijcard.2003.05.011; Ombres D, 1998, ARTERIOSCL THROM VAS, V18, P1611, DOI 10.1161/01.ATV.18.10.1611; Rosenzweig A, 2007, NEW ENGL J MED, V357, P497, DOI 10.1056/NEJMe078121; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Smith GD, 2008, INT J EPIDEMIOL, V37, P416, DOI 10.1093/ije/dym187; Thomson MJ, 2007, CARDIOVASC DRUG THER, V21, P195, DOI 10.1007/s10557-007-6027-1; Thyagarajan B, 2008, CLIN CHEM, V54, P738, DOI 10.1373/clinchem.2007.099044; Troughton JA, 2008, ATHEROSCLEROSIS, V197, P556, DOI 10.1016/j.atherosclerosis.2007.08.019; Tsimikas S, 2005, NEW ENGL J MED, V353, P46, DOI 10.1056/NEJMoa043175; van Himbergen TM, 2008, ATHEROSCLEROSIS, V199, P408, DOI 10.1016/j.atherosclerosis.2007.11.018; Wang XL, 2003, ARTERIOSCL THROM VAS, V23, P328, DOI 10.1161/01.ATV.0000051702.38086.C1; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watzinger N, 2002, CARDIOLOGY, V98, P116, DOI 10.1159/000066321; Wheeler JG, 2004, LANCET, V363, P689, DOI 10.1016/S0140-6736(04)15642-0; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	45	40	41	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6809	10.1371/journal.pone.0006809	http://dx.doi.org/10.1371/journal.pone.0006809			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710913	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415600020
J	Boks, MP; Derks, EM; Weisenberger, DJ; Strengman, E; Janson, E; Sommer, IE; Kahn, RS; Ophoff, RA				Boks, Marco P.; Derks, Eske M.; Weisenberger, Daniel J.; Strengman, Erik; Janson, Esther; Sommer, Iris E.; Kahn, Rene S.; Ophoff, Roel A.			The Relationship of DNA Methylation with Age, Gender and Genotype in Twins and Healthy Controls	PLOS ONE			English	Article								Cytosine-5 methylation within CpG dinucleotides is a potentially important mechanism of epigenetic influence on human traits and disease. In addition to influences of age and gender, genetic control of DNA methylation levels has recently been described. We used whole blood genomic DNA in a twin set (23 MZ twin-pairs and 23 DZ twin-pairs, N = 92) as well as healthy controls (N = 96) to investigate heritability and relationship with age and gender of selected DNA methylation profiles using readily commercially available GoldenGate bead array technology. Despite the inability to detect meaningful methylation differences in the majority of CpG loci due to tissue type and locus selection issues, we found replicable significant associations of DNA methylation with age and gender. We identified associations of genetically heritable single nucleotide polymorphisms with large differences in DNA methylation levels near the polymorphism (cis effects) as well as associations with much smaller differences in DNA methylation levels elsewhere in the human genome (trans effects). Our results demonstrate the feasibility of array-based approaches in studies of DNA methylation and highlight the vast differences between individual loci. The identification of CpG loci of which DNA methylation levels are under genetic control or are related to age or gender will facilitate further studies into the role of DNA methylation and disease.			Boks, MP (corresponding author), Univ Med Ctr Utrecht, Dept Psychiat, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands.	Ophoff@ucla.edu	sommer, iris E/D-1190-2014; Weisenberger, Daniel/AAA-8314-2020; Derks, Eske M/A-1652-2017	sommer, iris E/0000-0002-2682-5313; Weisenberger, Daniel/0000-0001-8303-2603; Derks, Eske M/0000-0002-6292-6883; Sommer, Iris/0000-0001-5597-3262; Boks, Marco/0000-0001-6163-7484	NIMH NIH HHS [R01 MH078075] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH078075] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alberts R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000622; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P998, DOI 10.1038/nsmb0908-998b; Benjamini Y, 2005, GENETICS, V171, P783, DOI 10.1534/genetics.104.036699; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Chu MW, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-50; Connor CM, 2008, EPIGENETICS-US, V3, P55, DOI 10.4161/epi.3.2.5938; Cropley JE, 2006, P NATL ACAD SCI USA, V103, P17308, DOI 10.1073/pnas.0607090103; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Falconer D. S., 1996, INTRO QUANTITATIVE G; Feng YQ, 2006, PLOS GENET, V2, P461, DOI 10.1371/journal.pgen.0020065; Flanagan JM, 2006, AM J HUM GENET, V79, P67, DOI 10.1086/504729; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fuke C, 2004, ANN HUM GENET, V68, P196, DOI 10.1046/j.1529-8817.2004.00081.x; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Gopisetty G, 2006, MOL IMMUNOL, V43, P1729, DOI 10.1016/j.molimm.2005.11.010; Haque FN, 2009, AM J MED GENET C, V151C, P136, DOI 10.1002/ajmg.c.30206; Heijmans BT, 2007, HUM MOL GENET, V16, P547, DOI 10.1093/hmg/ddm010; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Kaminsky ZA, 2009, NAT GENET, V41, P240, DOI 10.1038/ng.286; Kitamura E, 2007, GENOMICS, V89, P326, DOI 10.1016/j.ygeno.2006.11.006; Martin GM, 2005, P NATL ACAD SCI USA, V102, P10413, DOI 10.1073/pnas.0504743102; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Mill J, 2006, AM J MED GENET B, V141B, P421, DOI 10.1002/ajmg.b.30316; Murphy BC, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-115; Murrell A, 2004, HUM MOL GENET, V13, P247, DOI 10.1093/hmg/ddh013; Nagase H, 2008, FEBS J, V275, P1617, DOI 10.1111/j.1742-4658.2008.06330.x; NEALE MC, 2003, MX STAT MODELING; Oates NA, 2006, AM J HUM GENET, V79, P155, DOI 10.1086/505031; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Petronis A, 2003, SCHIZOPHRENIA BULL, V29, P169, DOI 10.1093/oxfordjournals.schbul.a006988; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; R Development Core Team, 2005, R LANG ENV STAT COMP; Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shen Y, 2008, P NATL ACAD SCI USA, V105, P4709, DOI 10.1073/pnas.0712018105; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102; Weaver ICG, 2006, P NATL ACAD SCI USA, V103, P3480, DOI 10.1073/pnas.0507526103; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Zhang AP, 2007, SCHIZOPHR RES, V90, P97, DOI 10.1016/j.schres.2006.11.007	50	260	267	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2009	4	8							e6767	10.1371/journal.pone.0006767	http://dx.doi.org/10.1371/journal.pone.0006767			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	488FQ	19774229	Green Published, Green Submitted, gold			2022-12-27	WOS:000269335000013
J	Dykxhoorn, DM; Wu, YC; Xie, HM; Yu, FY; Lal, A; Petrocca, F; Martinvalet, D; Song, E; Lim, B; Lieberman, J				Dykxhoorn, Derek M.; Wu, Yichao; Xie, Huangming; Yu, Fengyan; Lal, Ashish; Petrocca, Fabio; Martinvalet, Denis; Song, Erwei; Lim, Bing; Lieberman, Judy			miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases	PLOS ONE			English	Article								Background: The development of metastases involves the dissociation of cells from the primary tumor to penetrate the basement membrane, invade and then exit the vasculature to seed, and colonize distant tissues. The last step, establishment of macroscopic tumors at distant sites, is the least well understood. Four isogenic mouse breast cancer cell lines (67NR, 168FARN, 4TO7, and 4T1) that differ in their ability to metastasize when implanted into the mammary fat pad are used to model the steps of metastasis. Only 4T1 forms macroscopic lung and liver metastases. Because some miRNAs are dysregulated in cancer and affect cellular transformation, tumor formation, and metastasis, we examined whether changes in miRNA expression might explain the differences in metastasis of these cells. Methodology/Principal Findings: miRNA expression was analyzed by miRNA microarray and quantitative RT-PCR in isogenic mouse breast cancer cells with distinct metastatic capabilities. 4T1 cells that form macroscopic metastases had elevated expression of miR-200 family miRNAs compared to related cells that invade distant tissues, but are unable to colonize. Moreover, over-expressing miR-200 in 4TO7 cells enabled them to metastasize to lung and liver. These findings are surprising since the miR-200 family was previously shown to promote epithelial characteristics by inhibiting the transcriptional repressor Zeb2 and thereby enhancing E-cadherin expression. We confirmed these findings in these cells. The most metastatic 4T1 cells acquired epithelial properties (high expression of E-cadherin and cytokeratin-18) compared to the less metastatic cells. Conclusions/Significance: Expression of miR-200, which promotes a mesenchymal to epithelial cell transition (MET) by inhibiting Zeb2 expression, unexpectedly enhances macroscopic metastases in mouse breast cancer cell lines. These results suggest that for some tumors, tumor colonization at metastatic sites might be enhanced by MET. Therefore the epithelial nature of a tumor does not predict metastatic outcome.			Dykxhoorn, DM (corresponding author), Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.	ddykxhoorn@med.miami.edu; lieberman@idi.harvard.edu	Dykxhoorn, Derek M/D-1357-2015; Lieberman, Judy/A-2717-2015; Xie, Huangming/B-2260-2012					Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; BRACKEN CP, 2009, CELL MOL LIFE SCI; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang K, 2006, NAT METHODS, V3, P707, DOI 10.1038/NMETH923; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dykxhoorn DM, 2008, ADV EXP MED BIOL, V615, P299, DOI 10.1007/978-1-4020-6554-5_14; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; GEBESHUBER CA, 2009, EMBO REP; Gonzalez MA, 1999, J PATHOL, V187, P523, DOI 10.1002/(SICI)1096-9896(199904)187:5<523::AID-PATH296>3.0.CO;2-3; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hashizume R, 1996, HISTOPATHOLOGY, V29, P139, DOI 10.1046/j.1365-2559.1996.d01-499.x; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kartenbeck J, 2005, EUR J CELL BIOL, V84, P417, DOI 10.1016/j.ejcb.2005.01.005; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; LIPPONEN P, 1994, J PATHOL, V174, P101, DOI 10.1002/path.1711740206; Liu G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003592; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Parker C, 2001, BRIT J CANCER, V85, P1958, DOI 10.1054/bjoc.2001.2178; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; PETER ME, 2009, CELL CYCLE, V8; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; SHI SR, 1993, J HISTOCHEM CYTOCHEM, V41, P1599, DOI 10.1177/41.11.7691930; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537; WICKRAMASINGHE NS, 2009, NUCL ACIDS RES; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	60	247	259	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7181	10.1371/journal.pone.0007181	http://dx.doi.org/10.1371/journal.pone.0007181			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787069	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290100008
J	Snyder, RL; Frederick-Hudson, KH; Schul, J				Snyder, Robert L.; Frederick-Hudson, Katy H.; Schul, Johannes			Molecular Phylogenetics of the Genus Neoconocephalus (Orthoptera, Tettigoniidae) and the Evolution of Temperate Life Histories	PLOS ONE			English	Article								Background: The katydid genus Neoconocephalus (25+ species) has a prominent acoustic communication system and occurs in large parts of the Neotropics and Nearctic. This group has been subject of numerous behavioral, physiological, and evolutionary studies of its acoustic communication system. Two distinct life histories occur in this group: The tropical life history incorporates multiple generations/year and direct egg development without environmental triggers. Temperate life history is characterized by overwintering in the egg stage, cold trigger of egg development, and one generation/year. This study reconstructs the phylogenetic relationships within the genus to (1) determine the evolutionary history of the temperate life history, and (2) to support comparative studies of evolutionary and physiological problems in this genus. Methodology/Principal Findings: We used Amplified Fragment Length Polymorphisms (AFLP), and sequences of two nuclear loci and one mitochondrial locus to reconstruct phylogenetic relationships. The analysis included 17 ingroup and two outgroup species. AFLP and mitochondrial data provided resolution at the species level while the two nuclear loci revealed only deeper nodes. The data sets were combined in a super-matrix to estimate a total evidence tree. Seven of the temperate species form a monophyletic group; however, three more temperate species were placed as siblings of tropical species. Conclusions/Significance: Our analyses support the reliability of the current taxonomic treatment of the Neoconocephalus fauna of Caribbean, Central, and North America. Ancestral state reconstruction of life history traits was not conclusive, however at least four transitions between life histories occurred among our sample of species. The proposed phylogeny will strengthen conclusions from comparative work in this group.			Snyder, RL (corresponding author), SUNY Coll Potsdam, Dept Biol, Potsdam, NY 13676 USA.	schulj@missouri.edu		Frederick, Katy/0000-0001-9651-3502; Schul, Johannes/0000-0003-4059-7123				Alexander R.D., 1956, THESIS OHIO STATE U, V2; BAILEY WJ, 1978, J NAT HIST, V12, P259, DOI 10.1080/00222937800770151; Ballard JWO, 2004, MOL ECOL, V13, P729, DOI 10.1046/j.1365-294X.2003.02063.x; Beckers OM, 2008, P ROY SOC B-BIOL SCI, V275, P1243, DOI 10.1098/rspb.2007.1765; BRUSH JS, 1985, PHYSIOL ENTOMOL, V10, P23, DOI 10.1111/j.1365-3032.1985.tb00015.x; Bush SL, 2009, J EXP BIOL, V212, P648, DOI 10.1242/jeb.024786; Colgan DJ, 1998, AUST J ZOOL, V46, P419, DOI 10.1071/ZO98048; Deily JA, 2006, J EXP BIOL, V209, P1757, DOI 10.1242/jeb.02189; Deily JA, 2004, J EXP BIOL, V207, P3523, DOI 10.1242/jeb.01179; Deily JA, 2009, J COMP PHYSIOL A, V195, P31, DOI 10.1007/s00359-008-0379-2; Dobzhansky T., 1937; Eades D. C., 2008, ORTHOPTERA SPECIES F; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Greenfield MD, 1997, P ROY SOC B-BIOL SCI, V264, P1355, DOI 10.1098/rspb.1997.0188; GREENFIELD MD, 1983, ANIM BEHAV, V31, P102, DOI 10.1016/S0003-3472(83)80178-X; GREENFIELD MD, 1993, NATURE, V364, P618, DOI 10.1038/364618a0; GREENFIELD MD, 1990, TETTIGONIIDAE BIOL S, P171; HEATH JE, 1970, BIOL BULL-US, V138, P272, DOI 10.2307/1540212; Huelsenbeck JP, 1996, TRENDS ECOL EVOL, V11, P152, DOI 10.1016/0169-5347(96)10006-9; Ji YJ, 2003, MOL ECOL NOTES, V3, P581, DOI 10.1046/j.1471-8286.2003.00519.x; JOSEPHSON RK, 1985, J EXP BIOL, V117, P357; JOSEPHSON RK, 1984, J EXP BIOL, V108, P77; Koopman WJM, 2008, AM J BOT, V95, P353, DOI 10.3732/ajb.95.3.353; Lin CP, 2002, ANN ENTOMOL SOC AM, V95, P162, DOI 10.1603/0013-8746(2002)095[0162:MPOTNA]2.0.CO;2; MADDISON D, 2005, MACCLADE 4; Meade A., 2007, BAYESTRAITS; MEIXNER AJ, 1979, ANN ENTOMOL SOC AM, V72, P602, DOI 10.1093/aesa/72.5.602; MEIXNER AJ, 1986, ANN ENTOMOL SOC AM, V79, P554, DOI 10.1093/aesa/79.4.554; Mendelson TC, 2005, NATURE, V433, P375, DOI 10.1038/433375a; NASRECKI P, 2000, KATYDIDS COSTA RICA, V1; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Nylander JAA, 2004, MRMODELTEST V2 0; REDTENBACHER J, 1891, VERH ZOOL BOT GES WI, V41, P315; Rehn J. A. G., 1915, Transactions of the American Entomological Society Philadelphia, V40; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schul J, 2003, J EXP BIOL, V206, P141, DOI 10.1242/jeb.00070; SWOFFORD DL, 2003, PAUP PHYLOGENETIC AN; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Walker T.J., 1983, Transactions of the American Entomological Society (Philadelphia), V109, P357; WALKER T J, 1973, Ohio Journal of Science, V73, P321; WALKER TJ, 1975, J INSECT PHYSIOL, V21, P595, DOI 10.1016/0022-1910(75)90163-8; WALKER TJ, 1978, ENTOMOL NEWS, V89, P27; WALKER TJ, 1978, FLA ENTOMOL, V61, P1, DOI 10.2307/3494421; WALKER TJ, 2008, SINGING INSECTS N AM; WHITESELL JJ, 1978, NATURE, V274, P887, DOI 10.1038/274887a0; WHITESELL JJ, 1969, THESIS U FLORIDA; Whitesell JJ, 1974, THESIS U FLORIDA FLO	47	17	19	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7203	10.1371/journal.pone.0007203	http://dx.doi.org/10.1371/journal.pone.0007203			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779617	gold, Green Submitted, Green Published			2022-12-27	WOS:000270176200023
J	Cohen, DJ; Morfino, RC; Maharbiz, MM				Cohen, Daniel J.; Morfino, Roberto C.; Maharbiz, Michel M.			A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression	PLOS ONE			English	Article							GRADIENTS; CHEMOTAXIS; HYDROGELS; PATTERN; CELLS	This paper presents a low-cost inkjet dosing system capable of continuous, two-dimensional spatiotemporal regulation of gene expression via delivery of diffusible regulators to a custom-mounted gel culture of E. coli. A consumer-grade, inkjet printer was adapted for chemical printing; E. coli cultures were grown on 750 mm thick agar embedded in micro-wells machined into commercial compact discs. Spatio-temporal regulation of the lac operon was demonstrated via the printing of patterns of lactose and glucose directly into the cultures; X-Gal blue patterns were used for visual feedback. We demonstrate how the bistable nature of the lac operon's feedback, when perturbed by patterning lactose (inducer) and glucose (inhibitor), can lead to coordination of cell expression patterns across a field in ways that mimic motifs seen in developmental biology. Examples of this include sharp boundaries and the generation of traveling waves of mRNA expression. To our knowledge, this is the first demonstration of reaction-diffusion effects in the well-studied lac operon. A finite element reaction-diffusion model of the lac operon is also presented which predicts pattern formation with good fidelity.			Cohen, DJ (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.	dancohen@berkeley.edu						AHMADZADEH A, 2005, ANAL LACTOSE METABOL, P879; Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; BANSAL T, 2009, IEEE BIOMEDICAL MICR, V11; Basu S, 2005, NATURE, V434, P1130, DOI 10.1038/nature03461; Boland T, 2007, MAT SCI ENG C-BIO S, V27, P372, DOI 10.1016/j.msec.2006.05.047; Boland Thomas, 2006, Biotechnology Journal, V1, P910, DOI 10.1002/biot.200600081; Bonner JT., 2000, 1 SIGNALS EVOLUTION; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BROWN T, 2007, IET SYNTHETIC BIOL, V1, P21; Campbell PG, 2005, BIOMATERIALS, V26, P6762, DOI 10.1016/j.biomaterials.2005.04.032; Chambers JJ, 2006, J NEUROPHYSIOL, V96, P2792, DOI 10.1152/jn.00318.2006; Chen D, 2008, P NATL ACAD SCI USA, V105, P16843, DOI 10.1073/pnas.0807916105; Cohen DL, 2006, TISSUE ENG, V12, P1325, DOI 10.1089/ten.2006.12.1325; Ducree J, 2007, J MICROMECH MICROENG, V17, pS103, DOI 10.1088/0960-1317/17/7/S07; Dunlop M. J., 2008, NATURE GENETICS, V40; Ellis-Davies GCR, 2007, NAT METHODS, V4, P619, DOI 10.1038/NMETH1072; Engelmann TW, 1881, PFLUGERS ARCH GESAMM, P285, DOI [10.1007/BF01661982, DOI 10.1007/BF01661982]; Fujikawa H, 2005, APPL ENVIRON MICROB, V71, P7920, DOI 10.1128/AEM.71.12.7920-7926.2005; Gu W, 2004, P NATL ACAD SCI USA, V101, P15861, DOI 10.1073/pnas.0404353101; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Ilkhanizadeh S, 2007, BIOMATERIALS, V28, P3936, DOI 10.1016/j.biomaterials.2007.05.018; Ismagilov RF, 2007, CURR OPIN CHEM BIOL, V11, P604, DOI 10.1016/j.cbpa.2007.10.003; Jeon NL, 2002, NAT BIOTECHNOL, V20, P826, DOI 10.1038/nbt712; Keenan TM, 2008, LAB CHIP, V8, P34, DOI 10.1039/b711887b; Lausted C, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r58; LEHNINGER A, 2004, PRINCIPLES BIOCH; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Madou M, 2006, ANNU REV BIOMED ENG, V8, P601, DOI 10.1146/annurev.bioeng.8.061505.095758; Mayer G, 2006, ANGEW CHEM INT EDIT, V45, P4900, DOI 10.1002/anie.200600387; Merrin J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000663; MURRAY JD, 1993, MATH BIOL, V2; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Park J, 2006, LAB CHIP, V6, P611, DOI 10.1039/b516483d; Peterman MC, 2004, P NATL ACAD SCI USA, V101, P9951, DOI 10.1073/pnas.0402089101; Rosoff WJ, 2005, BIOTECHNOL BIOENG, V91, P754, DOI 10.1002/bit.20564; Roth EA, 2004, BIOMATERIALS, V25, P3707, DOI 10.1016/j.biomaterials.2003.10.052; Saadi W, 2007, BIOMED MICRODEVICES, V9, P627, DOI 10.1007/s10544-007-9051-9; Saunders RE, 2008, BIOMATERIALS, V29, P193, DOI 10.1016/j.biomaterials.2007.09.032; Shestopalov IA, 2008, CHEM SOC REV, V37, P1294, DOI 10.1039/b703023c; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WONG P, MATH MODEL LAC OPERO, P132; Yildirim N, 2003, BIOPHYS J, V84, P2841, DOI 10.1016/S0006-3495(03)70013-7; ZICHA D, 1991, J CELL SCI, V99, P769	43	22	23	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7086	10.1371/journal.pone.0007086	http://dx.doi.org/10.1371/journal.pone.0007086			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763256	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970400014
J	Karpievitch, YV; Hill, EG; Leclerc, AP; Dabney, AR; Almeida, JS				Karpievitch, Yuliya V.; Hill, Elizabeth G.; Leclerc, Anthony P.; Dabney, Alan R.; Almeida, Jonas S.			An Introspective Comparison of Random Forest-Based Classifiers for the Analysis of Cluster-Correlated Data by Way of RF plus	PLOS ONE			English	Article							VARIABLE IMPORTANCE; MASS-SPECTROMETRY; CANCER; SERUM; CLASSIFICATION; ALGORITHM; DIAGNOSIS; PROTEINS; REVEALS; URINE	Many mass spectrometry-based studies, as well as other biological experiments produce cluster-correlated data. Failure to account for correlation among observations may result in a classification algorithm overfitting the training data and producing overoptimistic estimated error rates and may make subsequent classifications unreliable. Current common practice for dealing with replicated data is to average each subject replicate sample set, reducing the dataset size and incurring loss of information. In this manuscript we compare three approaches to dealing with cluster-correlated data: unmodified Breiman's Random Forest (URF), forest grown using subject-level averages (SLA),and RF++ with subject-level bootstrapping (SLB). RF++, a novel Random Forest-based algorithm implemented in C++, handles cluster-correlated data through a modification of the original resampling algorithm and accommodates subject-level classification. Subject-level bootstrapping is an alternative sampling method that obviates the need to average or otherwise reduce each set of replicates to a single independent sample. Our experiments show nearly identical median classification and variable selection accuracy for SLB forests and URF forests when applied to both simulated and real datasets. However, the run-time estimated error rate was severely underestimated for URF forests. Predictably, SLA forests were found to be more severely affected by the reduction in sample size which led to poorer classification and variable selection accuracy. Perhaps most importantly our results suggest that it is reasonable to utilize URF for the analysis of cluster-correlated data. Two caveats should be noted: first, correct classification error rates must be obtained using a separate test dataset, and second, an additional post-processing step is required to obtain subject-level classifications. RF++ is shown to be an effective alternative for classifying both clustered and non-clustered data. Source code and stand-alone compiled versions of command-line and easy-to-use graphical user interface (GUI) versions of RF++ for Windows and Linux as well as a user manual (Supplementary File S2) are available for download at: http://sourceforge.org/projects/rfpp/under the GNU public license.			Karpievitch, YV (corresponding author), Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA.	yuliya@stat.tamu.edu	Dabney, Alan/C-1171-2011; Almeida, Jonas/C-9093-2009	Almeida, Jonas/0000-0002-7883-7922	NATIONAL CANCER INSTITUTE [R25CA090301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K25DE016863] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007438] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adam BL, 2002, CANCER RES, V62, P3609; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Agranoff D, 2006, LANCET, V368, P1012, DOI 10.1016/S0140-6736(06)69342-2; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L, 1996, MACH LEARN, V24, P41, DOI 10.1023/A:1018094028462; Breiman L., 2017, CLASSIFICATION REGRE; Chen YD, 2004, CLIN CANCER RES, V10, P8380, DOI 10.1158/1078-0432.CCR-1162-03; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Conrads TP, 2004, ENDOCR-RELAT CANCER, V11, P163, DOI 10.1677/erc.0.0110163; Dabney AR, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-401; Efron B, 1994, INTRO BOOTSTRAP; Finehout EJ, 2007, ANN NEUROL, V61, P120, DOI 10.1002/ana.21038; Fung ET, 2005, INT J CANCER, V115, P783, DOI 10.1002/ijc.20928; Garden RW, 2000, ANAL CHEM, V72, P30, DOI 10.1021/ac9908997; Hilario M, 2006, MASS SPECTROM REV, V25, P409, DOI 10.1002/mas.20072; Izmirlian G, 2004, ANN NY ACAD SCI, V1020, P154, DOI 10.1196/annals.1310.015; Karpievitch YV, 2007, BIOINFORMATICS, V23, P264, DOI 10.1093/bioinformatics/btl583; KARPIEVITCH YV, 2009, NORMALIZATION PEAK I; Koomen JM, 2005, CLIN CANCER RES, V11, P1110; Lee SK, 2005, DATA MIN KNOWL DISC, V11, P273, DOI 10.1007/s10618-005-0004-8; Li LH, 2004, ARTIF INTELL MED, V32, P71, DOI 10.1016/j.artmed.2004.03.006; Morris JS, 2005, BIOINFORMATICS, V21, P1764, DOI 10.1093/bioinformatics/bti254; Palmer DS, 2007, J CHEM INF MODEL, V47, P150, DOI 10.1021/ci060164k; Pawlik TM, 2005, BREAST CANCER RES TR, V89, P149, DOI 10.1007/s10549-004-1710-4; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Quinlan JR, 1996, BAGGING BOOSTING C4; Rosner B., 2005, FUNDAMENTALS BIOSTAT; Schaub S, 2004, KIDNEY INT, V65, P323, DOI 10.1111/j.1523-1755.2004.00352.x; SEGAL MR, 1992, J AM STAT ASSOC, V87, P407, DOI 10.2307/2290271; Strobl C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-25; Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307; SVETNIK V, JUN 2004 P CAGL IT, P334; Vlahou A, 2004, CLIN CHEM, V50, P1438, DOI 10.1373/clinchem.2003.028035; Wu BL, 2003, BIOINFORMATICS, V19, P1636, DOI 10.1093/bioinformatics/btg210; Yasui Y, 2003, BIOSTATISTICS, V4, P449, DOI 10.1093/biostatistics/4.3.449; Zhang HP, 1998, J AM STAT ASSOC, V93, P180, DOI 10.2307/2669615	37	48	49	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7087	10.1371/journal.pone.0007087	http://dx.doi.org/10.1371/journal.pone.0007087			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763254	gold, Green Published, Green Submitted			2022-12-27	WOS:000269970400015
J	Lewis, DJM; Huo, ZM; Barnett, S; Kromann, I; Giemza, R; Galiza, E; Woodrow, M; Thierry-Carstensen, B; Andersen, P; Novicki, D; Del Giudice, G; Rappuoli, R				Lewis, David J. M.; Huo, Zhiming; Barnett, Susan; Kromann, Ingrid; Giemza, Rafaela; Galiza, Eva; Woodrow, Maria; Thierry-Carstensen, Birgit; Andersen, Peter; Novicki, Deborah; Del Giudice, Giuseppe; Rappuoli, Rino			Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin	PLOS ONE			English	Article								Background: An association was previously established between facial nerve paralysis (Bell's palsy) and intranasal administration of an inactivated influenza virosome vaccine containing an enzymatically active Escherichia coli Heat Labile Toxin (LT) adjuvant. The individual component(s) responsible for paralysis were not identified, and the vaccine was withdrawn. Methodology/Principal Findings: Subjects participating in two contemporaneous non-randomized Phase 1 clinical trials of nasal subunit vaccines against Human Immunodeficiency Virus and tuberculosis, both of which employed an enzymatically inactive non-toxic mutant LT adjuvant (LTK63), underwent active follow-up for adverse events using diary-cards and clinical examination. Two healthy subjects experienced transient peripheral facial nerve palsies 44 and 60 days after passive nasal instillation of LTK63, possibly a result of retrograde axonal transport after neuronal ganglioside binding or an inflammatory immune response, but without exaggerated immune responses to LTK63. Conclusions/Significance: While the unique anatomical predisposition of the facial nerve to compression suggests nasal delivery of neuronal-binding LT-derived adjuvants is inadvisable, their continued investigation as topical or mucosal adjuvants and antigens appears warranted on the basis of longstanding safety via oral, percutaneous, and other mucosal routes.			Lewis, DJM (corresponding author), St Georges Univ London, St Georges Vaccine Inst, London, England.	d.lewis@sgul.ac.uk		Lewis, David JM/0000-0003-3105-9075; Andersen, Peter/0000-0002-5869-2551	NIAID NIH HHS [N01AI05396, N0-1-AI-05396] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005396] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOUR KK, 1978, LARYNGOSCOPE, V88, P787; Badell E, 2009, VACCINE, V27, P28, DOI 10.1016/j.vaccine.2008.10.034; Barnetta SW, 2008, AIDS, V22, P339, DOI 10.1097/QAD.0b013e3282f3ca57; Couch RB, 2004, NEW ENGL J MED, V350, P860, DOI 10.1056/NEJMp048006; Dietrich J, 2006, J IMMUNOL, V177, P6353, DOI 10.4049/jimmunol.177.9.6353; Frech SA, 2008, LANCET, V371, P2019, DOI 10.1016/S0140-6736(08)60839-9; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; LEWIS DJM, 1991, EUR J IMMUNOL, V21, P2087, DOI 10.1002/eji.1830210917; Michetti P, 1999, GASTROENTEROLOGY, V116, P804, DOI 10.1016/S0016-5085(99)70063-6; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694; Peppoloni Samuele, 2003, Expert Rev Vaccines, V2, P285, DOI 10.1586/14760584.2.2.285; Piercy J, 2005, BRIT MED J, V330, P1374, DOI 10.1136/bmj.330.7504.1374; Rath B, 2007, VACCINE, V26, P1, DOI 10.1016/j.vaccine.2007.10.043; Sanchez J, 2008, CELL MOL LIFE SCI, V65, P1347, DOI 10.1007/s00018-008-7496-5; Schultze V, 2008, VACCINE, V26, P3209, DOI 10.1016/j.vaccine.2008.03.093; SCHWAB ME, 1979, J CELL BIOL, V82, P798, DOI 10.1083/jcb.82.3.798; Slutter B, 2008, J DRUG TARGET, V16, P1, DOI [10.1080/10611860701637966, 10.1080/10611860701637966 ]; Stephenson I, 2006, J VIROL, V80, P4962, DOI 10.1128/JVI.80.10.4962-4970.2006; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Vanopdenbosch LJ, 2005, J NEUROL NEUROSUR PS, V76, P1017, DOI 10.1136/jnnp.2004.043059; Waeber C, 2005, NEUROLOGY, V64, pS9, DOI 10.1212/WNL.64.10_suppl_2.S9; Zurbriggen Rinaldo, 2003, Expert Rev Vaccines, V2, P295, DOI 10.1586/14760584.2.2.295	23	216	221	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e6999	10.1371/journal.pone.0006999	http://dx.doi.org/10.1371/journal.pone.0006999			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756141	Green Published, Green Submitted, Green Accepted, gold			2022-12-27	WOS:000269970000006
J	Dawson, R; Condos, R; Tse, D; Huie, ML; Ress, S; Tseng, CH; Brauns, C; Weiden, M; Hoshino, Y; Bateman, E; Rom, WN				Dawson, Rod; Condos, Rany; Tse, Doris; Huie, Maryann L.; Ress, Stanley; Tseng, Chi-Hong; Brauns, Clint; Weiden, Michael; Hoshino, Yoshihiko; Bateman, Eric; Rom, William N.			Immunomodulation with Recombinant Interferon-gamma 1b in Pulmonary Tuberculosis	PLOS ONE			English	Article								Background: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-gamma 1b (rIFN-gamma b) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. Methodology/Principal Findings: We performed a randomized, controlled clinical trial of directly observed therapy (DOTS) versus DOTS supplemented with nebulized or subcutaneously administered rIFN-gamma 1b over 4 months to 89 patients with cavitary pulmonary tuberculosis. Bronchoalveolar lavage (BAL) and blood were sampled at 0 and 4 months. There was a significant decline in levels of inflammatory cytokines IL-1 beta, IL-6, IL-8, and IL-10 in 24-hour BAL supernatants only in the nebulized rIFN-gamma 1b group from baseline to week 16. Both rIFN-gamma 1b groups showed significant 3-fold increases in CD4+ lymphocyte response to PPD at 4 weeks. There was a significant (p = 0.03) difference in the rate of clearance of Mtb from the sputum smear at 4 weeks for the nebulized rIFN-gamma 1b adjuvant group compared to DOTS or DOTS with subcutaneous rIFN-gamma 1b. In addition, there was significant reduction in the prevalence of fever, wheeze, and night sweats at 4 weeks among patients receiving rFN-gamma 1b versus DOTS alone. Conclusion: Recombinant interferon-gamma 1b adjuvant therapy plus DOTS in cavitary pulmonary tuberculosis can reduce inflammatory cytokines at the site of disease, improve clearance of Mtb from the sputum, and improve constitutional symptoms.			Dawson, R (corresponding author), Univ Cape Town, Dept Med, Fac Hlth Sci, Div Pulmonol, ZA-7925 Cape Town, South Africa.	William.Rom@nyumc.edu	Hoshino, Yoshihiko/B-5159-2019	Hoshino, Yoshihiko/0000-0002-3132-0715; Rom, William/0000-0002-8793-7028	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832, R01HL057879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007267] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000096, MO1 RR00096] Funding Source: Medline; NHLBI NIH HHS [R01 HL057879, R01 HL059832-10, HL59832, HL57879, R01 HL059832] Funding Source: Medline; NIEHS NIH HHS [T32 ES007267] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bai XY, 2004, TUBERCULOSIS, V84, P375, DOI 10.1016/j.tube.2004.05.001; Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8; Bonecini-Almeida MG, 2004, INFECT IMMUN, V72, P2628, DOI 10.1128/IAI.72.5.2628-2634.2004; Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X; Condos R, 2003, INFECT IMMUN, V71, P2058, DOI 10.1128/IAI.71.4.2058-2064.2003; Dheda K, 2007, TUBERCULOSIS, V87, P237, DOI 10.1016/j.tube.2006.11.001; Dorman SE, 2004, LANCET, V364, P2113, DOI 10.1016/S0140-6736(04)17552-1; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156, DOI 10.1164/ajrccm.158.4.9803065; Gold JA, 2004, INFECT IMMUN, V72, P645, DOI 10.1128/IAI.72.2.645-650.2004; Grassi M, 2006, CLIN IMMUNOL, V121, P100, DOI 10.1016/j.clim.2006.06.008; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114; Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC; JAFFE HA, 1991, J CLIN INVEST, V88, P297, DOI 10.1172/JCI115291; Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6; Maartens G, 2007, LANCET, V370, P2030, DOI 10.1016/S0140-6736(07)61262-8; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; Marchant A, 2001, AM J RESP CELL MOL, V24, P187, DOI 10.1165/ajrcmb.24.2.4274; Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; Seneviratne SL, 2007, THORAX, V62, P97, DOI 10.1136/thx.2005.051649; Suarez-Mendez R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-44; Toossi Zahra, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P513; TRAMONTANA JM, 1995, MOL MED, V1, P384, DOI 10.1007/BF03401576; van der Wel N, 2007, CELL, V129, P1287, DOI 10.1016/j.cell.2007.05.059; Young DB, 2008, J CLIN INVEST, V118, P1255, DOI 10.1172/JCI34614; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	30	75	77	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e6984	10.1371/journal.pone.0006984	http://dx.doi.org/10.1371/journal.pone.0006984			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753300	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796500001
J	Nudds, RL; Codd, JR; Sellers, WI				Nudds, Robert L.; Codd, Jonathan R.; Sellers, William I.			Evidence for a Mass Dependent Step-Change in the Scaling of Efficiency in Terrestrial Locomotion	PLOS ONE			English	Article								A reanalysis of existing data suggests that the established tenet of increasing efficiency of transport with body size in terrestrial locomotion requires re-evaluation. Here, the statistical model that described the data best indicated a dichotomy between the data for small (<1 kg) and large animals (>1 kg). Within and between these two size groups there was no detectable difference in the scaling exponents (slopes) relating metabolic (E(met)) and mechanical costs (E(mech, CM)) of locomotion to body mass (M(b)). Therefore, no scaling of efficiency (E(mech, CM)/E(met)) with M(b) was evident within each size group. Small animals, however, appeared to be generally less efficient than larger animals (7% and 26% respectively). Consequently, it is possible that the relationship between efficiency and M(b) is not continuous, but, rather, involves a step-change. This step-change in the efficiency of locomotion mirrors previous findings suggesting a postural cause for an apparent size dichotomy in the relationship between E(met) and M(b). Currently data for E(mech, CM) is lacking, but the relationship between efficiency in terrestrial locomotion and M(b) is likely to be determined by posture and kinematics rather than body size alone. Hence, scaling of efficiency is likely to be more complex than a simple linear relationship across body sizes. A homogenous study of the mechanical cost of terrestrial locomotion across a broad range of species, body sizes, and importantly locomotor postures is a priority for future research.			Nudds, RL (corresponding author), Univ Manchester, Fac Life Sci, Manchester, Lancs, England.	Robert.Nudds@manchester.ac.uk	Sellers, William Irvin/Q-3843-2019	Sellers, William Irvin/0000-0002-2913-5406; Codd, Jonathan/0000-0003-0211-1786				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Alexander RM, 2005, J EXP BIOL, V208, P1645, DOI 10.1242/jeb.01484; Arampatzis A, 2000, J BIOMECH, V33, P457, DOI 10.1016/S0021-9290(99)00187-6; Burnham KP, 2001, WILDLIFE RES, V28, P111, DOI 10.1071/WR99107; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; DAWSON TJ, 1973, NATURE, V246, P313, DOI 10.1038/246313a0; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Full R.J., 1989, ENERGY TRANSFORMATIO, P175; HEGLUND NC, 1982, J EXP BIOL, V97, P41; HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239a0; Kramer PA, 2008, GAIT POSTURE, V27, P209, DOI 10.1016/j.gaitpost.2007.03.009; Minetti AE, 1999, J EXP BIOL, V202, P2329; Pfau T, 2006, J EXP BIOL, V209, P3742, DOI 10.1242/jeb.02439; RAYNER JMV, 1995, ISRAEL J ZOOL, V41, P321; Reilly SM, 2007, ZOOLOGY, V110, P271, DOI 10.1016/j.zool.2007.01.003; Reilly SM, 2006, P ROY SOC B-BIOL SCI, V273, P1563, DOI 10.1098/rspb.2006.3489; Saini M, 1998, J BIOMECH ENG-T ASME, V120, P133, DOI 10.1115/1.2834293; TAYLOR CR, 1982, J EXP BIOL, V97, P1; Thirunarayan M.A., 1996, GAIT POSTURE, P306, DOI 10.1016/0966-6362(95)01058-0	20	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6927	10.1371/journal.pone.0006927	http://dx.doi.org/10.1371/journal.pone.0006927			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738898	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622300011
J	Herbeck, JT; Gottlieb, GS; Wong, K; Detels, R; Phair, JP; Rinaldo, CR; Jacobson, LP; Margolick, JB; Mullins, JI				Herbeck, Joshua T.; Gottlieb, Geoffrey S.; Wong, Kim; Detels, Roger; Phair, John P.; Rinaldo, Charles R.; Jacobson, Lisa P.; Margolick, Joseph B.; Mullins, James I.			Fidelity of SNP Array Genotyping Using Epstein Barr Virus-Transformed B-Lymphocyte Cell Lines: Implications for Genome-Wide Association Studies	PLOS ONE			English	Article								Background: As availability of primary cells can be limited for genetic studies of human disease, lymphoblastoid cell lines (LCL) are common sources of genomic DNA. LCL are created in a transformation process that entails in vitro infection of human B-lymphocytes with the Epstein-Barr Virus (EBV). Methodology/Principal Findings: To test for genotypic errors potentially induced by the Epstein-Barr Virus transformation process, we compared single nucleotide polymorphism (SNP) genotype calls in peripheral blood mononuclear cells (PBMC) and LCL from the same individuals. The average mismatch rate across 19 comparisons was 0.12% for SNPs with a population call rate of at least 95%, and 0.03% at SNPs with a call rate of at least 99%. Mismatch rates were not correlated across genotype subarrays run on all sample pairs. Conclusions/Significance: Genotypic discrepancies found in PBMC and LCL pairs were not significantly different than control pairs, and were not correlated across subarrays. These results suggest that mismatch rates are minimal with stringent quality control, and that most genotypic discrepancies are due to technical artifacts rather than the EBV transformation process. Thus, LCL likely constitute a reliable DNA source for host genotype analysis.			Herbeck, JT (corresponding author), Univ Washington, Sch Med, Seattle, WA 98195 USA.	herbeck@u.washington.edu		Gottlieb, Geoffrey/0000-0002-5749-481X; Jacobson, Lisa P./0000-0003-1722-6826	NCRR NIH HHS [5MO1 RR00722, M01 RR000722] Funding Source: Medline; NIAID NIH HHS [T32 AI007140, U01 AI035041, U01 AI035039, U01 AI037613, R37 AI047734, U01 AI035040, R37 AI47734, P30AI27757, T32 AI07140, UO1 AI35042, UO1 AI37984, U01 AI035043, P30 AI027757, UO1 AI37613, UO1 AI35043, U01 AI035042, UO1 AI35040, U01 AI037984, UO1 AI35041, UO1 AI35039] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, U01AI035040, P30AI027757, R37AI047734, U01AI035043, U01AI037613, U01AI035039, U01AI035042, U01AI037984, T32AI007140] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AFF, 2007, BRLMM IMPR GEN CALL; CAPUTO JL, 1991, J TISSUE CULTURE MET, V13, P39; Choy E, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000287; Gimelbrant A, 2007, SCIENCE, V318, P1136, DOI 10.1126/science.1148910; Jeon JP, 2007, CANCER GENET CYTOGEN, V173, P122, DOI 10.1016/j.cancergencyto.2006.10.010; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LOUIE LG, 1991, AM J HUM GENET, V48, P637; McElroy JP, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-15; PELLOQUIN F, 1986, IN VITRO CELL DEV B, V22, P689; Plagnol V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002966; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Simon-Sanchez J, 2007, HUM MOL GENET, V16, P1, DOI 10.1093/hmg/ddl436	13	28	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6915	10.1371/journal.pone.0006915	http://dx.doi.org/10.1371/journal.pone.0006915			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730697	Green Published, Green Submitted, Green Accepted, gold			2022-12-27	WOS:000269622100015
J	Wallach, AD; Ritchie, EG; Read, J; O'Neill, AJ				Wallach, Arian D.; Ritchie, Euan G.; Read, John; O'Neill, Adam J.			More than Mere Numbers: The Impact of Lethal Control on the Social Stability of a Top-Order Predator	PLOS ONE			English	Article							NORTH-WESTERN AUSTRALIA; BIALOWIEZA PRIMEVAL FOREST; FECAL MARKING BEHAVIOR; SCENT-MARKING; CANIS-LUPUS; WOLF; WOLVES; DINGOES; ECOLOGY; MITOCHONDRIAL	Population control of socially complex species may have profound ecological implications that remain largely invisible if only their abundance is considered. Here we discuss the effects of control on a socially complex top-order predator, the dingo ( Canis lupus dingo). Since European occupation of Australia, dingoes have been controlled over much of the continent. Our aim was to investigate the effects of control on their abundance and social stability. We hypothesized that dingo abundance and social stability are not linearly related, and proposed a theoretical model in which dingo populations may fluctuate between three main states: ( A) below carrying capacity and socially fractured, ( B) above carrying capacity and socially fractured, or ( C) at carrying capacity and socially stable. We predicted that lethal control would drive dingoes into the unstable states A or B, and that relaxation of control would allow recovery towards C. We tested our predictions by surveying relative abundance ( track density) and indicators of social stability (scent-marking and howling) at seven sites in the arid zone subject to differing degrees of control. We also monitored changes in dingo abundance and social stability following relaxation and intensification of control. Sites where dingoes had been controlled within the previous two years were characterized by low scent-marking activity, but abundance was similar at sites with and without control. Signs of social stability steadily increased the longer an area was allowed to recover from control, but change in abundance did not follow a consistent path. Comparison of abundance and stability among all sites and years demonstrated that control severely fractures social groups, but that the effect of control on abundance was neither consistent nor predictable. Management decisions involving large social predators must therefore consider social stability to ensure their conservation and ecological functioning.			Wallach, AD (corresponding author), Univ Adelaide, Sch Earth & Environm Sci, Adelaide, SA, Australia.	arian.wallach@adelaide.edu.au	Wallach, Arian D./ABC-9215-2020; Ritchie, Euan/N-1088-2014	Wallach, Arian D./0000-0002-6640-3887; Ritchie, Euan/0000-0003-4410-8868; Read, John/0000-0003-0605-5259; Wallach, Arian/0000-0001-9689-0092				ALLEN L, 1998, AUSTR VERTEBRATE PES, V11, P421; Allen L., 2000, PACK SIZE PREY BEHAV; Allen LR, 2001, J APPL ECOL, V38, P76, DOI 10.1046/j.1365-2664.2001.00569.x; Andersone Z, 2002, MAMM BIOL, V67, P79, DOI 10.1078/1616-5047-00012; ANDERSSON M, 1984, ANNU REV ECOL SYST, V15, P165, DOI 10.1146/annurev.es.15.110184.001121; Barja I, 2005, FOLIA ZOOL, V54, P21; Barja I, 2004, NATURWISSENSCHAFTEN, V91, P489, DOI 10.1007/s00114-004-0557-1; Barja I, 2009, ANIM BEHAV, V77, P489, DOI 10.1016/j.anbehav.2008.11.004; Berger KM, 2006, CONSERV BIOL, V20, P751, DOI 10.1111/j.1523-1739.2006.00336.x; Brainerd SM, 2008, J WILDLIFE MANAGE, V72, P89, DOI 10.2193/2006-305; Burnham K. P., 2002, MODEL SELECTION MULT, V2nd; CATLING PC, 1992, WILDLIFE RES, V19, P195, DOI 10.1071/WR9920195; Chapron G, 2008, SCIENCE, V320, P47, DOI 10.1126/science.320.5872.47a; Conner MM, 1998, J WILDLIFE MANAGE, V62, P690, DOI 10.2307/3802345; Corbett L. K., 1995, DINGO AUSTR ASIA; Creel S, 2008, TRENDS ECOL EVOL, V23, P194, DOI 10.1016/j.tree.2007.12.004; Gehring TM, 2003, CAN FIELD NAT, V117, P419, DOI 10.22621/cfn.v117i3.744; Gese EM, 1998, CAN J ZOOL, V76, P1037, DOI 10.1139/cjz-76-6-1037; Glen AS, 2007, AUSTRAL ECOL, V32, P492, DOI 10.1111/j.1442-9993.2007.01721.x; Haber GC, 1996, CONSERV BIOL, V10, P1068, DOI 10.1046/j.1523-1739.1996.10041068.x; HARRINGTON FH, 1986, ANIM BEHAV, V34, P1575, DOI 10.1016/S0003-3472(86)80231-7; HARRINGTON FH, 1987, ANIM BEHAV, V35, P7, DOI 10.1016/S0003-3472(87)80204-X; Johnson C, 2006, AUSTR MAMMAL EXTINCT; Johnson CN, 2007, P R SOC B, V274, P341, DOI 10.1098/rspb.2006.3711; Knowlton FF, 1999, J RANGE MANAGE, V52, P398, DOI 10.2307/4003765; LEHMAN N, 1992, BEHAV ECOL SOCIOBIOL, V30, P83; Link WA, 2006, ECOLOGY, V87, P2626, DOI 10.1890/0012-9658(2006)87[2626:MWATFO]2.0.CO;2; MACDONALD DW, 1983, NATURE, V301, P379, DOI 10.1038/301379a0; MCILROY JC, 1991, WILDLIFE RES, V18, P315, DOI 10.1071/WR9910315; Nowak S, 2007, J ETHOL, V25, P231, DOI 10.1007/s10164-006-0015-y; O'Neill A., 2002, LIVING DINGO; Post E, 1999, NATURE, V401, P905, DOI 10.1038/44814; Quinn GP, 2003, EXPT DESIGN DATA ANA; Reddiex B, 2006, WILDLIFE RES, V33, P691, DOI 10.1071/WR05102; Ritchie EG, 2009, ECOL LETT, V12, P982, DOI 10.1111/j.1461-0248.2009.01347.x; ROTHMAN RJ, 1979, ANIM BEHAV, V27, P750, DOI 10.1016/0003-3472(79)90010-1; Sand H, 2006, ANIM BEHAV, V72, P781, DOI 10.1016/j.anbehav.2005.11.030; Sapolsky RM, 2006, SOC FORCES, V85, P217, DOI 10.1353/sof.2006.0142; Savolainen P, 2004, P NATL ACAD SCI USA, V101, P12387, DOI 10.1073/pnas.0401814101; Sillero-Zubiri C, 1998, J ZOOL, V245, P351, DOI 10.1111/j.1469-7998.1998.tb00110.x; Sinclair ARE, 2003, NATURE, V425, P288, DOI 10.1038/nature01934; Stahler DR, 2002, CAN J ZOOL, V80, P360, DOI 10.1139/Z01-223; THOMSON PC, 1992, WILDLIFE RES, V19, P531, DOI 10.1071/WR9920531; THOMSON PC, 1992, WILDLIFE RES, V19, P543, DOI 10.1071/WR9920543; THOMSON PC, 1992, WILDLIFE RES, V19, P519, DOI 10.1071/WR9920519; Van Meter PE, 2009, HORM BEHAV, V55, P329, DOI 10.1016/j.yhbeh.2008.11.001; VANDYCK S, 2008, MAMMALS AUSTR, P750; Vucetich JA, 2004, ANIM BEHAV, V67, P1117, DOI 10.1016/j.anbehav.2003.06.018; Vucetich JA, 1997, CONSERV BIOL, V11, P957, DOI 10.1046/j.1523-1739.1997.95366.x; Wallach AD, 2009, BIOL CONSERV, V142, P1253, DOI 10.1016/j.biocon.2009.01.011; Wallach AD, 2009, BIOL CONSERV, V142, P43, DOI 10.1016/j.biocon.2008.09.021; Zub K, 2003, BEHAVIOUR, V140, P635, DOI 10.1163/156853903322149478	52	72	82	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6861	10.1371/journal.pone.0006861	http://dx.doi.org/10.1371/journal.pone.0006861			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RW	19724642	Green Published, gold, Green Accepted, Green Submitted			2022-12-27	WOS:000269522800005
J	Bon, JM; Leader, JK; Weissfeld, JL; Coxson, HO; Zheng, B; Branch, RA; Kondragunta, V; Lee, JS; Zhang, YZ; Choi, AMK; Lokshin, AE; Kaminski, N; Gur, D; Sciurba, FC				Bon, Jessica M.; Leader, Joseph K.; Weissfeld, Joel L.; Coxson, Harvey O.; Zheng, Bin; Branch, Robert A.; Kondragunta, Venkateswarlu; Lee, Janet S.; Zhang, Yingze; Choi, Augustine M. K.; Lokshin, Anna E.; Kaminski, Naftali; Gur, David; Sciurba, Frank C.			The Influence of Radiographic Phenotype and Smoking Status on Peripheral Blood Biomarker Patterns in Chronic Obstructive Pulmonary Disease	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; QUANTITATIVE ASSESSMENT; INFLAMMATORY MARKERS; AIRWAY-OBSTRUCTION; CIGARETTE-SMOKE; EMPHYSEMA; SERUM; COPD; ASSOCIATIONS; DIMENSIONS	Background: Chronic obstructive pulmonary disease (COPD) is characterized by both airway remodeling and parenchymal destruction. The identification of unique biomarker patterns associated with airway dominant versus parenchymal dominant patterns would support the existence of unique phenotypes representing independent biologic processes. A cross-sectional study was performed to examine the association of serum biomarkers with radiographic airway and parenchymal phenotypes of COPD. Methodology/Principal Findings: Serum from 234 subjects enrolled in a CT screening cohort was analyzed for 33 cytokines and growth factors using a multiplex protein array. The association of serum markers with forced expiratory volume in one second percent predicted (FEV1%) and quantitative CT measurements of airway thickening and emphysema was assessed with and without stratification for current smoking status. Significant associations were found with several serum inflammatory proteins and measurements of FEV1%, airway thickening, and parenchymal emphysema independent of smoking status. The association of select analytes with airway thickening and emphysema was independent of FEV1%. Furthermore, the relationship between other inflammatory markers and measurements of physiologic obstruction or airway thickening was dependent on current smoking status. Conclusions/Significance: Airway and parenchymal phenotypes of COPD are associated with unique systemic serum biomarker profiles. Serum biomarker patterns may provide a more precise classification of the COPD syndrome, provide insights into disease pathogenesis and identify targets for novel patient-specific biological therapies.			Bon, JM (corresponding author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA.	bonjm@upmc.edu	Coxson, Harvey O/A-9861-2017; Sciurba, Frank/AAZ-9339-2021; Bon, Jessica/AAK-6714-2021; Zheng, Bin/HGU-5316-2022	Coxson, Harvey O/0000-0001-5750-9711; Kaminski, Naftali/0000-0001-5917-4601; sciurba, frank/0000-0001-7468-2225; Lee, Janet/0000-0002-6812-6043; Zheng, Bin/0000-0002-7682-6648	NATIONAL CANCER INSTITUTE [P50CA090440] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL084948] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA090440] Funding Source: Medline; NHLBI NIH HHS [P50 HL084948] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agusti AGN, 2003, EUR RESPIR J, V21, P347, DOI 10.1183/09031936.03.00405703; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Barnes PJ, 2004, PHARMACOL REV, V56, P515, DOI 10.1124/pr.56.4.2; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Drannik AG, 2004, AM J RESP CRIT CARE, V170, P1164, DOI 10.1164/rccm.200311-1521OC; Eid AA, 2001, AM J RESP CRIT CARE, V164, P1414, DOI 10.1164/ajrccm.164.8.2008109; Feghali-Bostwick CA, 2008, AM J RESP CRIT CARE, V177, P156, DOI 10.1164/rccm.200701-014OC; GELB AF, 1993, AM REV RESPIR DIS, V147, P1157, DOI 10.1164/ajrccm/147.5.1157; Gorelik E, 2005, CANCER EPIDEM BIOMAR, V14, P981, DOI 10.1158/1055-9965.EPI-04-0404; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; He JQ, 2006, HUM GENET, V119, P365, DOI 10.1007/s00439-006-0143-z; HERSH CP, 2006, AM J RESP CRIT CARE; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hoshino T, 2007, AM J RESP CRIT CARE, V176, P49, DOI 10.1164/rccm.200603-316OC; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kraan TCTMV, 2002, GENES IMMUN, V3, P436, DOI 10.1038/sj.gene.6363896; LEADER J, 2007, P SPIE, V6511; Leader JK, 2003, ACAD RADIOL, V10, P1224, DOI 10.1016/S1076-6332(03)00380-5; Lee JS, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-64; Lemos-Gonzalez Y, 2007, BRIT J CANCER, V96, P1569, DOI 10.1038/sj.bjc.6603770; MacNee William, 2005, Proc Am Thorac Soc, V2, P258, DOI 10.1513/pats.200504-045SR; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; Mouawad R, 2006, MELANOMA RES, V16, P335; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Muller V, 2006, ANTICANCER RES, V26, P1479; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120; Nakano Y, 2005, AM J RESP CRIT CARE, V171, P142, DOI 10.1164/rccm.200407-874OC; Nakano Y, 2002, CHEST, V122, p271S, DOI 10.1378/chest.122.6_suppl.271S-a; PATEL BD, 2008, AM J RESP CRIT CARE; Pinto-Plata V, 2007, THORAX, V62, P595, DOI 10.1136/thx.2006.064428; Sadeghnejad A, 2007, AM J RESP CRIT CARE, V176, P748, DOI 10.1164/rccm.200704-543OC; Schols AMWJ, 1996, THORAX, V51, P819, DOI 10.1136/thx.51.8.819; Sethi S, 2008, AM J RESP CRIT CARE, V177, P491, DOI 10.1164/rccm.200708-1234OC; Shapiro SD, 2001, AM J RESP CRIT CARE, V164, P339, DOI 10.1164/ajrccm.164.3.2105072c; Thakore AH, 2007, AM J CARDIOL, V99, P1598, DOI 10.1016/j.amjcard.2007.01.036; Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707; Wannamethee SG, 2005, EUR HEART J, V26, P1765, DOI 10.1093/eurheartj/ehi183; Zhang J, 2002, EXP BIOL MED, V227, P823, DOI 10.1177/153537020222700916; Zheng B, 2007, MED PHYS, V34, P2844, DOI 10.1118/1.2742777; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	42	34	39	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6865	10.1371/journal.pone.0006865	http://dx.doi.org/10.1371/journal.pone.0006865			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718453	Green Published, gold, Green Accepted			2022-12-27	WOS:000269415900026
J	Shahrestani, P; Leung, HT; Le, PK; Pak, WL; Tse, S; Ocorr, K; Huang, TS				Shahrestani, Parvin; Leung, Hung-Tat; Le, Phung Khanh; Pak, William L.; Tse, Stephanie; Ocorr, Karen; Huang, Taosheng			Heterozygous Mutation of Drosophila Opa1 Causes the Development of Multiple Organ Abnormalities in an Age-Dependent and Organ-Specific Manner	PLOS ONE			English	Article								Optic Atrophy 1 (OPA1) is a ubiquitously expressed dynamin-like GTPase in the inner mitochondrial membrane. It plays important roles in mitochondrial fusion, apoptosis, reactive oxygen species (ROS) and ATP production. Mutations of OPA1 result in autosomal dominant optic atrophy (DOA). The molecular mechanisms by which link OPA1 mutations and DOA are not fully understood. Recently, we created a Drosophila model to study the pathogenesis of optic atrophy. Heterozygous mutation of Drosophila OPA1 (dOpa1) by P-element insertion results in no obvious morphological abnormalities, whereas homozygous mutation is embryonic lethal. In eye-specific somatic clones, homozygous mutation of dOpa1 causes rough (mispatterning) and glossy (decreased lens deposition) eye phenotypes in adult Drosophila. In humans, heterozygous mutations in OPA1 have been associated with mitochondrial dysfunction, which is predicted to affect multiple organs. In this study, we demonstrated that heterozygous dOpa1 mutation perturbs the visual function and an ERG profile of the Drosophila compound eye. We independently showed that antioxidants delayed the onset of mutant phenotypes in ERG and improved larval vision function in phototaxis assay. Furthermore, heterozygous dOpa1 mutation also caused decreased heart rate, increased heart arrhythmia, and poor tolerance to stress induced by electrical pacing. However, antioxidants had no effects on the dysfunctional heart of heterozygous dOpa1 mutants. Under stress, heterozygous dOpa1 mutations caused reduced escape response, suggesting abnormal function of the skeletal muscles. Our results suggest that heterozygous mutation of dOpa1 shows organ-specific pathogenesis and is associated with multiple organ abnormalities in an age-dependent and organ-specific manner.			Shahrestani, P (corresponding author), Univ Calif Irvine, Irvine, CA 92717 USA.	huangts@uci.edu		Huang, Taosheng/0000-0001-6601-6687	NATIONAL EYE INSTITUTE [R01EY000033, R01EY018876, R37EY000033, R56EY000033] Funding Source: NIH RePORTER; NEI NIH HHS [R56 EY000033, 1R01EY018876-01, R01 EY000033, R37 EY000033, EY00033, R01 EY018876] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681; Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2; Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; Bette S, 2005, ACTA NEUROPATHOL, V109, P393, DOI 10.1007/s00401-004-0970-8; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; Cammarato A, 2008, MOL BIOL CELL, V19, P553, DOI 10.1091/mbc.E07-09-0890; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003; Chen SQ, 2007, AM J OPHTHALMOL, V143, P186, DOI 10.1016/j.ajo.2006.06.049; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delettre C, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-8; Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200; Eiberg H, 2006, J MED GENET, V43, P435, DOI 10.1136/jmg.2005.034892; EIBERG H, 1994, HUM MOL GENET, V3, P977, DOI 10.1093/hmg/3.6.977; GORGONE G, 1986, OPHTHALMOLOGICA, V192, P28, DOI 10.1159/000309608; Ke Tie, 2006, Zhonghua Yixue Yichuanxue Zazhi, V23, P481; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LILLY M, 1990, GENETICS, V124, P293; Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278; Misaka T, 2002, J BIOL CHEM, V277, P15834, DOI 10.1074/jbc.M109260200; Ocorr K, 2007, P NATL ACAD SCI USA, V104, P3943, DOI 10.1073/pnas.0609278104; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Tang S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004492; Tong JJY, 2007, NAT GENET, V39, P476, DOI 10.1038/ng2004; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Votruba M, 1998, J MED GENET, V35, P793, DOI 10.1136/jmg.35.10.793; Votruba M, 2003, J INHERIT METAB DIS, V26, P209, DOI 10.1023/A:1024441302074; Yarosh W, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040006; AM J HUM GENET, V65, P1428	34	28	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6867	10.1371/journal.pone.0006867	http://dx.doi.org/10.1371/journal.pone.0006867			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718456	Green Published, gold			2022-12-27	WOS:000269415900028
J	Armengol, L; Villatoro, S; Gonzalez, JR; Pantano, L; Garcia-Aragones, M; Rabionet, R; Caceres, M; Estivill, X				Armengol, Lluis; Villatoro, Sergi; Gonzalez, Juan R.; Pantano, Lorena; Garcia-Aragones, Manel; Rabionet, Raquel; Caceres, Mario; Estivill, Xavier			Identification of Copy Number Variants Defining Genomic Differences among Major Human Groups	PLOS ONE			English	Article							DEPENDENT PROBE AMPLIFICATION; HAPTOGLOBIN-RELATED PROTEIN; TRYPANOSOME LYTIC FACTOR; EVALUATION SEE PROJECT; SICKLE-CELL MUTATION; FACTOR-V-LEIDEN; S-GLOBIN GENE; MACULAR DEGENERATION; STRUCTURAL VARIATION; HIGH-RESOLUTION	Background: Understanding the genetic contribution to phenotype variation of human groups is necessary to elucidate differences in disease predisposition and response to pharmaceutical treatments in different human populations. Methodology/Principal Findings: We have investigated the genome-wide profile of structural variation on pooled samples from the three populations studied in the HapMap project by comparative genome hybridization (CGH) in different array platforms. We have identified and experimentally validated 33 genomic loci that show significant copy number differences from one population to the other. Interestingly, we found an enrichment of genes related to environment adaptation (immune response, lipid metabolism and extracellular space) within these regions and the study of expression data revealed that more than half of the copy number variants (CNVs) translate into gene-expression differences among populations, suggesting that they could have functional consequences. In addition, the identification of single nucleotide polymorphisms (SNPs) that are in linkage disequilibrium with the copy number alleles allowed us to detect evidences of population differentiation and recent selection at the nucleotide variation level. Conclusions: Overall, our results provide a comprehensive view of relevant copy number changes that might play a role in phenotypic differences among major human populations, and generate a list of interesting candidates for future studies.			Armengol, L (corresponding author), UPF, CRG, Genes & Dis Program, Genet Causes Dis Grp, Barcelona, Catalonia, Spain.	xavier.estivill@crg.es	Estivill, Xavier/A-3125-2013; rabionet, raquel/A-7407-2009; Rabionet, Raquel/C-8379-2009; Gonzalez, Juan R/B-7860-2018; Cáceres, Mario/A-6379-2009; Estivill, Xavier/E-2957-2012	Estivill, Xavier/0000-0002-0723-2256; rabionet, raquel/0000-0001-5006-8140; Rabionet, Raquel/0000-0001-5006-8140; Gonzalez, Juan R/0000-0003-3267-2146; Cáceres, Mario/0000-0002-7736-3251; Villatoro, Sergio/0000-0001-6940-2866				ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853; Armengol L, 2008, CYTOGENET GENOME RES, V123, P108, DOI 10.1159/000184698; Armour JAL, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1089; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; Barreiro LB, 2008, NAT GENET, V40, P340, DOI 10.1038/ng.78; Beckmann JS, 2007, NAT REV GENET, V8, P639, DOI 10.1038/nrg2149; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Brazier L, 1999, ATHEROSCLEROSIS, V144, P323, DOI 10.1016/S0021-9150(98)00333-5; Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CELIK T, 2008, NUTR METAB CARDIOVAS; Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Cooper GM, 2008, NAT GENET, V40, P1199, DOI 10.1038/ng.236; Cooper GM, 2007, NAT GENET, V39, pS22, DOI 10.1038/ng2054; Daar AS, 2005, NAT REV GENET, V6, P241, DOI 10.1038/nrg1559; de Stahl TD, 2008, HUM MUTAT, V29, P398, DOI 10.1002/humu.20659; Drain J, 2001, J BIOL CHEM, V276, P30254, DOI 10.1074/jbc.M010198200; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Estivill X, 1997, HUM MUTAT, V10, P135, DOI 10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.3.CO;2-P; EXCOFFIER L, 1992, GENETICS, V131, P479; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; GAETA G, 2007, NUTR METAB CARDIOVAS; Gasparini P, 2000, EUR J HUM GENET, V8, P19, DOI 10.1038/sj.ejhg.5200406; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gimelli G, 2003, HUM MOL GENET, V12, P849, DOI 10.1093/hmg/ddg101; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gonzalez JR, 2007, BIOINFORMATICS, V23, P644, DOI 10.1093/bioinformatics/btm025; Gonzalez JR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-261; Good P, 2000, PERMUTATION TESTS PR; Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030; Hahmann HW, 1999, ATHEROSCLEROSIS, V144, P221, DOI 10.1016/S0021-9150(99)00057-X; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HAPMAP CI, 2005, NATURE, V437, P1299; Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hurles ME, 2008, TRENDS GENET, V24, P238, DOI 10.1016/j.tig.2008.03.001; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742; Ke XY, 2004, HUM MOL GENET, V13, P577, DOI 10.1093/hmg/ddh060; Khaitovich P, 2005, SCIENCE, V309, P1850, DOI 10.1126/science.1108296; Kidd JM, 2008, NATURE, V453, P56, DOI 10.1038/nature06862; Kidd JM, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030063; Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504; Krafsur ES, 2003, TRENDS PARASITOL, V19, P162, DOI 10.1016/S1471-4922(03)00034-5; KULOZIK AE, 1986, AM J HUM GENET, V39, P239; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LAPOUMEROULIE C, 1992, HUM GENET, V89, P333; Locke DP, 2006, AM J HUM GENET, V79, P275, DOI 10.1086/505653; LOZANO J, UNPUB; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238; NAGEL RL, 1985, NEW ENGL J MED, V312, P880, DOI 10.1056/NEJM198504043121403; Nguyen DQ, 2006, PLOS GENET, V2, P198, DOI 10.1371/journal.pgen.0020020; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; Ogorelkova M, 1999, HUM MOL GENET, V8, P2087, DOI 10.1093/hmg/8.11.2087; Ogorelkova M, 2001, HUM MOL GENET, V10, P815, DOI 10.1093/hmg/10.8.815; Osborne LR, 2001, NAT GENET, V29, P321, DOI 10.1038/ng753; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; PAGNIER J, 1984, P NATL ACAD SCI-BIOL, V81, P1771, DOI 10.1073/pnas.81.6.1771; Pantano L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-573; Pays E, 2006, NAT REV MICROBIOL, V4, P477, DOI 10.1038/nrmicro1428; Perry GH, 2008, AM J HUM GENET, V82, P685, DOI 10.1016/j.ajhg.2007.12.010; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Ramachandran S, 2005, P NATL ACAD SCI USA, V102, P15942, DOI 10.1073/pnas.0507611102; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Sharp AJ, 2006, ANNU REV GENOM HUM G, V7, P407, DOI 10.1146/annurev.genom.7.080505.115618; Shen MC, 1997, THROMB RES, V87, P377, DOI 10.1016/S0049-3848(97)00141-2; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369; Spielman RS, 2007, NAT GENET, V39, P226, DOI 10.1038/ng1955; Stankiewicz P, 2003, AM J HUM GENET, V72, P1101, DOI 10.1086/374385; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Vanhollebeke B, 2008, SCIENCE, V320, P677, DOI 10.1126/science.1156296; Vanhollebeke B, 2007, P NATL ACAD SCI USA, V104, P4118, DOI 10.1073/pnas.0609902104; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; Watkins WS, 2003, GENOME RES, V13, P1607, DOI 10.1101/gr.894603; Weir BS, 2005, GENOME RES, V15, P1468, DOI 10.1101/gr.4398405; Weir BS, 2002, ANNU REV GENET, V36, P721, DOI 10.1146/annurev.genet.36.050802.093940; White SJ, 2007, CYTOGENET GENOME RES, V118, P19, DOI 10.1159/000106437; Yamazaki K, 2002, J HUM GENET, V47, P469, DOI 10.1007/s100380200067; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16; Zhang XZ, 2007, HUM GENET, V120, P681, DOI 10.1007/s00439-006-0253-7; 1994, HUM MUTAT, V4, P167	103	27	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7230	10.1371/journal.pone.0007230	http://dx.doi.org/10.1371/journal.pone.0007230			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789632	gold, Green Published			2022-12-27	WOS:000270354100004
J	Debeb, BG; Galat, V; Epple-Farmer, J; Iannaccone, S; Woodward, WA; Bader, M; Iannaccone, P; Binas, B				Debeb, Bisrat G.; Galat, Vasiliy; Epple-Farmer, Jessica; Iannaccone, Steve; Woodward, Wendy A.; Bader, Michael; Iannaccone, Philip; Binas, Bert			Isolation of Oct4-Expressing Extraembryonic Endoderm Precursor Cell Lines	PLOS ONE			English	Article								Background: The extraembryonic endoderm (ExEn) defines the yolk sac, a set of membranes that provide essential support for mammalian embryos. Recent findings suggest that the committed ExEn precursor is present already in the embryonic Inner Cell Mass (ICM) as a group of cells that intermingles with the closely related epiblast precursor. All ICM cells contain Oct4, a key transcription factor that is first expressed at the morula stage. In vitro, the epiblast precursor is most closely represented by the well-characterized embryonic stem (ES) cell lines that maintain the expression of Oct4, but analogous ExEn precursor cell lines are not known and it is unclear if they would express Oct4. Methodology/Principal Findings: Here we report the isolation and characterization of permanently proliferating Oct4-expressing rat cell lines ("XEN-P cell lines''), which closely resemble the ExEn precursor. We isolated the XEN-P cell lines from blastocysts and characterized them by plating and gene expression assays as well as by injection into embryos. Like ES cells, the XEN-P cells express Oct4 and SSEA1 at high levels and their growth is stimulated by leukemia inhibitory factor, but instead of the epiblast determinant Nanog, they express the ExEn determinants Gata6 and Gata4. Further, they lack markers characteristic of the more differentiated primitive/visceral and parietal ExEn stages, but exclusively differentiate into these stages in vitro and contribute to them in vivo. Conclusions/Significance: Our findings (i) suggest strongly that the ExEn precursor is a self-renewable entity, (ii) indicate that active Oct4 gene expression (transcription plus translation) is part of its molecular identity, and (iii) provide an in vitro model of early ExEn differentiation.			Debeb, BG (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA.	bbinas@hanyang.ac.kr	Bader, Michael/K-2124-2013; Woodward, Wendy/AAX-6593-2020	Bader, Michael/0000-0003-4780-4164; Woodward, Wendy/0000-0002-7935-739X; Galat, Vasiliy/0000-0003-3612-098X				Baron MH, 2003, EXP HEMATOL, V31, P1160, DOI 10.1016/j.exphem.2003.08.019; Batlle-Morera L, 2008, GENESIS, V46, P758, DOI 10.1002/dvg.20442; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Buehr M, 2003, BIOL REPROD, V68, P222, DOI 10.1095/biolreprod.102.006197; Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; Burton GJ, 2001, PLACENTA, V22, pS70, DOI 10.1053/plac.2001.0639; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; CHAZAUD C, 2006, DEV CELL, V615, P24; Ciruna BG, 1999, MECH DEVELOP, V81, P199, DOI 10.1016/S0925-4773(98)00243-3; DEBEB BG, 2007, MOL BIOL CELL S, V18, pA212; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Eakin GS, 2005, DEV BIOL, V288, P150, DOI 10.1016/j.ydbio.2005.09.028; EPPLEFARMER J, 2009, CELL TRANSPLANT 0429; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fandrich F, 2002, NAT MED, V8, P171, DOI 10.1038/nm0202-171; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; GALAT V, 2009, STEM CELLS DEV  0529; GARDNER RL, 1983, INT REV EXP PATHOL, V63, P133; GARDNER RL, 1985, PHILOS T R SOC LON B, V163, P78; Gerbe F, 2008, DEV BIOL, V313, P594, DOI 10.1016/j.ydbio.2007.10.048; Iannaccone PM, 2002, TRANSGENIC ANIMAL TE, P235; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kunath T, 2005, DEVELOPMENT, V132, P1649, DOI 10.1242/dev.01715; Kurimoto K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl050; Li CL, 2009, CELL RES, V19, P173, DOI 10.1038/cr.2008.301; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; Li WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nagy A., 2002, MANIPULATING MOUSE E; Nath AK, 2004, DEVELOPMENT, V131, P2485, DOI 10.1242/dev.01131; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nichols J, 1998, REPROD FERT DEVELOP, V10, P517, DOI 10.1071/RD98075; NICHOLS J, 2009, DEVELOPMENT 200 0826; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Notarianni E, 2001, PLACENTA, V22, P111, DOI 10.1053/plac.2000.0592; OVITT CE, 1998, MOL HUM REPROD, V1021, P31; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Plusa B, 2008, DEVELOPMENT, V135, P3081, DOI 10.1242/dev.021519; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Rossant J, 2008, CELL, V132, P527, DOI 10.1016/j.cell.2008.01.039; Sambrook J., 2001, MOL CLONING LAB MANU; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; Shimosato D, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-80; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; STEWART MH, 2006, NAT METHODS, V807, P15; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Tam PPL, 2007, NAT REV GENET, V8, P368, DOI 10.1038/nrg2084; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Yeom YI, 1996, DEVELOPMENT, V122, P881; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013	58	39	40	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7216	10.1371/journal.pone.0007216	http://dx.doi.org/10.1371/journal.pone.0007216			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784378	Green Published, gold			2022-12-27	WOS:000270290000016
J	Hernandez, H; Makarova, OV; Makarov, EM; Morgner, N; Muto, Y; Krummel, DP; Robinson, CV				Hernandez, Helena; Makarova, Olga V.; Makarov, Evgeny M.; Morgner, Nina; Muto, Yutaka; Krummel, Daniel Pomeranz; Robinson, Carol V.			Isoforms of U1-70k Control Subunit Dynamics in the Human Spliceosomal U1 snRNP	PLOS ONE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; SM PROTEINS D1; MASS-SPECTROMETRY; ARGININE RESIDUES; DOMAIN; PHOSPHORYLATION; COMPLEXES; 70K; RECONSTITUTION	Most human protein-encoding genes contain multiple exons that are spliced together, frequently in alternative arrangements, by the spliceosome. It is established that U1 snRNP is an essential component of the spliceosome, in human consisting of RNA and ten proteins, several of which are post-translationally modified and exist as multiple isoforms. Unresolved and challenging to investigate are the effects of these post translational modifications on the dynamics, interactions and stability of the particle. Using mass spectrometry we investigate the composition and dynamics of the native human U1 snRNP and compare native and recombinant complexes to isolate the effects of various subunits and isoforms on the overall stability. Our data reveal differential incorporation of four protein isoforms and dynamic interactions of subunits U1-A, U1-C and Sm-B/B'. Results also show that unstructured post-translationally modified C-terminal tails are responsible for the dynamics of Sm-B/B' and U1-C and that their interactions with the Sm core are controlled by binding to different U1-70k isoforms and their phosphorylation status in vivo. These results therefore provide the important functional link between proteomics and structure as well as insight into the dynamic quaternary structure of the native U1 snRNP important for its function.			Hernandez, H (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Morgner, Nina/O-7021-2018; Morgner, Nina/I-7975-2012	Morgner, Nina/0000-0002-1872-490X; robinson, carol/0000-0001-7829-5505; Makarov, Evgeny/0000-0003-2543-9637	MRC [MC_U105184330] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C004272/1] Funding Source: Medline; Medical Research Council [MC_U105184330] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Battle DJ, 2006, COLD SPRING HARB SYM, V71, P313, DOI 10.1101/sqb.2006.71.001; Beausoleil SA, 2006, NAT BIOTECHNOL, V24, P1285, DOI 10.1038/nbt1240; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; BRANLANT C, 1980, NUCLEIC ACIDS RES, V8, P4143, DOI 10.1093/nar/8.18.4143; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019; CHU JL, 1991, GENE, V97, P311; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Dieker J, 2008, CELL DEATH DIFFER, V15, P793, DOI 10.1038/sj.cdd.4402312; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donmez G, 2007, MOL CELL, V25, P399, DOI 10.1016/j.molcel.2006.12.019; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hanson CL, 2003, J BIOL CHEM, V278, P1259, DOI 10.1074/jbc.M208966200; Hernandez H, 2007, NAT PROTOC, V2, P715, DOI 10.1038/nprot.2007.73; Hernandez H, 2006, EMBO REP, V7, P605, DOI 10.1038/sj.embor.7400702; Hochleitner EO, 2005, J BIOL CHEM, V280, P2536, DOI 10.1074/jbc.M409587200; Hof D, 2005, AUTOIMMUN REV, V4, P380, DOI 10.1016/j.autrev.2005.02.003; Jurchen JC, 2003, J AM CHEM SOC, V125, P2817, DOI 10.1021/ja0211508; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kaltashov IA, 2008, J AM SOC MASS SPECTR, V19, P1239, DOI 10.1016/j.jasms.2008.05.018; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Krummel DAP, 2009, NATURE, V458, P475, DOI 10.1038/nature07851; Levy ED, 2008, NATURE, V453, P1262, DOI 10.1038/nature06942; Liu QS, 2006, CELL, V127, P1223, DOI 10.1016/j.cell.2006.10.037; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; McConnell TS, 2003, RNA, V9, P193, DOI 10.1261/rna.2136103; Mckay AR, 2006, J AM CHEM SOC, V128, P11433, DOI 10.1021/ja061468q; Miranda TB, 2004, BIOCHEM BIOPH RES CO, V323, P382, DOI 10.1016/j.bbrc.2004.08.107; Mouaikel J, 2003, EMBO REP, V4, P616, DOI 10.1038/sj.embor.embor863; Muto Y, 2004, J MOL BIOL, V341, P185, DOI 10.1016/j.jmb.2004.04.078; Muto Y, 2001, Nucleic Acids Res Suppl, P275; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Patel SB, 2008, NUCLEIC ACIDS RES, V36, P6482, DOI 10.1093/nar/gkn658; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; SCHMAUSS C, 1992, J BIOL CHEM, V267, P8521; Sharon M, 2006, PLOS BIOL, V4, P1314, DOI 10.1371/journal.pbio.0040267; Sharon M, 2009, STRUCTURE, V17, P31, DOI 10.1016/j.str.2008.10.012; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; Stark H, 2006, ANNU REV BIOPH BIOM, V35, P435, DOI 10.1146/annurev.biophys.35.040405.101953; Taverner T, 2008, ACCOUNTS CHEM RES, V41, P617, DOI 10.1021/ar700218q; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Uetrecht C, 2008, P NATL ACAD SCI USA, V105, P9216, DOI 10.1073/pnas.0800406105; VANDAM A, 1989, EMBO J, V8, P3853, DOI 10.1002/j.1460-2075.1989.tb08563.x; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Will CL, 1996, NUCLEIC ACIDS RES, V24, P4614, DOI 10.1093/nar/24.23.4614; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yu LR, 2007, J PROTEOME RES, V6, P4150, DOI 10.1021/pr070152u; Zhou M, 2008, P NATL ACAD SCI USA, V105, P18139, DOI 10.1073/pnas.0801313105; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	58	38	39	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7202	10.1371/journal.pone.0007202	http://dx.doi.org/10.1371/journal.pone.0007202			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784376	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290000011
J	Hammond, R; Blaess, S; Abeliovich, A				Hammond, Rachel; Blaess, Sandra; Abeliovich, Asa			Sonic Hedgehog Is a Chemoattractant for Midbrain Dopaminergic Axons	PLOS ONE			English	Article								Midbrain dopaminergic axons project from the substantia nigra (SN) and the ventral tegmental area (VTA) to rostral target tissues, including the striatum, pallidum, and hypothalamus. The axons from the medially located VTA project primarily to more medial target tissues in the forebrain, whereas the more lateral SN axons project to lateral targets including the dorsolateral striatum. This structural diversity underlies the distinct functions of these pathways. Although a number of guidance cues have been implicated in the formation of the distinct axonal projections of the SN and VTA, the molecular basis of their diversity remains unclear. Here we investigate the molecular basis of structural diversity in mDN axonal projections. We find that Sonic Hedgehog (Shh) is expressed at a choice point in the course of the rostral dopaminergic projections. Furthermore, in midbrain explants, dopaminergic projections are attracted to a Shh source. Finally, in mice in which Shh signaling is inactivated during late neuronal development, the most medial dopaminergic projections are deficient. In addition to the role of Shh in the induction of mDN precursors, Shh plays an important role in dopaminergic axon pathfinding to rostral target tissues. Furthermore, Shh signaling is involved in determining the structural diversity of these dopaminergic projections.			Hammond, R (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, Ctr Neurobiol, New York, NY 10027 USA.	aa900@columbia.edu	Blaess, Sandra/K-8503-2015	Blaess, Sandra/0000-0002-1898-4891	NINDS NIH HHS [R01 NS064433, R01 NS060832] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064433] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagri A, 2002, NEURON, V33, P233, DOI 10.1016/S0896-6273(02)00561-5; Barresi MJF, 2005, DEVELOPMENT, V132, P3643, DOI 10.1242/dev.01929; Blaess S, 2006, DEVELOPMENT, V133, P1799, DOI 10.1242/dev.02339; Bourikas D, 2005, NAT NEUROSCI, V8, P297, DOI 10.1038/nn1396; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Lin L, 2005, MOL CELL NEUROSCI, V28, P547, DOI 10.1016/j.mcn.2004.11.009; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Okada A, 2006, NATURE, V444, P369, DOI 10.1038/nature05246; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Sieber BA, 2004, MOL CELL NEUROSCI, V26, P418, DOI 10.1016/j.mcn.2004.03.009; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; Yam PT, 2009, NEURON, V62, P349, DOI 10.1016/j.neuron.2009.03.022; Yamauchi K, 2009, J NEUROSCI, V29, P4044, DOI 10.1523/JNEUROSCI.4794-08.2009; Zervas M, 2004, NEURON, V43, P345, DOI 10.1016/j.neuron.2004.07.010	19	34	34	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7007	10.1371/journal.pone.0007007	http://dx.doi.org/10.1371/journal.pone.0007007			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774071	Green Submitted, Green Published, gold			2022-12-27	WOS:000270160900002
J	Morales-Corraliza, J; Mazzella, MJ; Berger, JD; Diaz, NS; Choi, JHK; Levy, E; Matsuoka, Y; Planel, E; Mathews, PM				Morales-Corraliza, Jose; Mazzella, Matthew J.; Berger, Jason D.; Diaz, Nicole S.; Choi, Jennifer H. K.; Levy, Efrat; Matsuoka, Yasuji; Planel, Emmanuel; Mathews, Paul M.			In Vivo Turnover of Tau and APP Metabolites in the Brains of Wild-Type and Tg2576 Mice: Greater Stability of sAPP in the beta-Amyloid Depositing Mice	PLOS ONE			English	Article							PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; A-BETA; SECRETED FORMS; HYPERPHOSPHORYLATION; INHIBITION; NEURONS; SUPPRESSION; ACTIVATION; CLEARANCE	The metabolism of the amyloid precursor protein (APP) and tau are central to the pathobiology of Alzheimer's disease (AD). We have examined the in vivo turnover of APP, secreted APP (sAPP), Ab and tau in the wild-type and Tg2576 mouse brain using cycloheximide to block protein synthesis. In spite of overexpression of APP in the Tg2576 mouse, APP is rapidly degraded, similar to the rapid turnover of the endogenous protein in the wild-type mouse. sAPP is cleared from the brain more slowly, particularly in the Tg2576 model where the half-life of both the endogenous murine and transgene-derived human sAPP is nearly doubled compared to wild-type mice. The important Ab degrading enzymes neprilysin and IDE were found to be highly stable in the brain, and soluble A beta 40 and A beta 42 levels in both wild-type and Tg2576 mice rapidly declined following the depletion of APP. The cytoskeletal-associated protein tau was found to be highly stable in both wild-type and Tg2576 mice. Our findings unexpectedly show that of these various AD-relevant protein metabolites, sAPP turnover in the brain is the most different when comparing a wild-type mouse and a beta-amyloid depositing, APP overexpressing transgenic model. Given the neurotrophic roles attributed to sAPP, the enhanced stability of sAPP in the beta-amyloid depositing Tg2576 mice may represent a neuroprotective response.			Morales-Corraliza, J (corresponding author), Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA.	jmorales-corraliza@nki.rfmh.org; mathews@nki.rfmh.org	Tudor, Jennifer/L-2104-2013; Tudor, Jennifer/Q-2151-2019	Tudor, Jennifer/0000-0002-3826-3012; Tudor, Jennifer/0000-0002-3826-3012; Mathews, Paul/0000-0003-1742-7687; Morales-Corraliza, Jose/0000-0003-3287-9382; Planel, Emmanuel/0000-0001-5128-0565	NIA NIH HHS [AG017617, P01 AG017617, F31 AG029787, AG022455, K01 AG022455] Funding Source: Medline; NINDS NIH HHS [NS045205, R01 NS045205] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017617, F31AG029787, K01AG022455] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BARNEY CC, 1979, BRAIN RES BULL, V4, P355, DOI 10.1016/S0361-9230(79)80013-1; BASS NH, 1973, BRAIN RES, V52, P323, DOI 10.1016/0006-8993(73)90668-9; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Cirrito JR, 2003, J NEUROSCI, V23, P8844; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1992, ANN NY ACAD SCI, V674, P103; De Strooper B, 2000, J CELL SCI, V113, P1857; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GARNER JA, 1988, BRAIN RES, V458, P309, DOI 10.1016/0006-8993(88)90473-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLD PE, 1978, SCIENCE, V201, P367, DOI 10.1126/science.208153; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Gralle M, 2007, PROG NEUROBIOL, V82, P11, DOI 10.1016/j.pneurobio.2007.02.001; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Lyckman AW, 1998, J BIOL CHEM, V273, P11100, DOI 10.1074/jbc.273.18.11100; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mercken M, 1995, J NEUROSCI, V15, P8259; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Nishitomi K, 2006, J NEUROCHEM, V99, P1555, DOI 10.1111/j.1471-4159.2006.04178.x; Otth C, 2002, J ALZHEIMERS DIS, V4, P417, DOI 10.3233/JAD-2002-4508; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rozmahel R, 2002, NEUROBIOL AGING, V23, P187, DOI 10.1016/S0197-4580(01)00267-6; RUDICK RA, 1982, J NEUROSCI METH, V6, P253, DOI 10.1016/0165-0270(82)90088-7; Savage MJ, 2002, J NEUROSCI, V22, P3376; Savage MJ, 1998, J NEUROSCI, V18, P1743; Schmidt Stephen D., 2004, V299, P279; Schmidt Stephen D., 2004, V299, P267; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Tomidokoro Y, 2005, J BIOL CHEM, V280, P36883, DOI 10.1074/jbc.M504038200	52	46	46	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7134	10.1371/journal.pone.0007134	http://dx.doi.org/10.1371/journal.pone.0007134			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771166	Green Submitted, Green Published, gold			2022-12-27	WOS:000270154400022
J	Toujani, S; Dessen, P; Ithzar, N; Danglot, G; Richon, C; Vassetzky, Y; Robert, T; Lazar, V; Bosq, J; Da Costa, L; Perot, C; Ribrag, V; Patte, C; Wiels, J; Bernheim, A				Toujani, Saloua; Dessen, Philippe; Ithzar, Nathalie; Danglot, Gisele; Richon, Catherine; Vassetzky, Yegor; Robert, Thomas; Lazar, Vladimir; Bosq, Jacques; Da Costa, Lydie; Perot, Christine; Ribrag, Vincent; Patte, Catherine; Wiels, Joeelle; Bernheim, Alain			High Resolution Genome-Wide Analysis of Chromosomal Alterations in Burkitt's Lymphoma	PLOS ONE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; COPY NUMBER VARIATION; CELL-LINES; CANCER; EXPRESSION; HYBRIDIZATION; GENE; AMPLIFICATION; ABNORMALITIES	Additional chromosomal abnormalities are currently detected in Burkitt's lymphoma. They play major roles in the progression of BL and in prognosis. The genes involved remain elusive. A whole-genome oligonucleotide array CGH analysis correlated with karyotype and FISH was performed in a set of 27 Burkitt's lymphoma-derived cell lines and primary tumors. More than half of the 145 CNAs<2 Mb were mapped to Mendelian CNVs, including GSTT1, glutathione s-transferase and BIRC6, an anti-apoptotic protein, possibly predisposing to some cancers. Somatic cell line-specific CNVs localized to the IG locus were consistently observed with the 244 K aCGH platform. Among 136 CNAs>2 Mb, gains were found in 1q (12/27), 13q (7/27), 7q (6/27), 8q(4/27), 2p (3/27), 11q (2/27) and 15q (2/27). Losses were found in 3p (5/27), 4p (4/27), 4q (4/27), 9p (4/27), 13q (4/27), 6p (3/27), 17p (3/27), 6q (2/27), 11pterp13 (2/27) and 14q12q21.3 (2/27). Twenty one minimal critical regions (MCR), (range 0.04-71.36 Mb), were delineated in tumors and cell lines. Three MCRs were localized to 1q. The proximal one was mapped to 1q21.1q25.2 with a 6.3 Mb amplicon (1q21.1q21.3) harboring BCA2 and PIAS3. In the other 2 MCRs, 1q32.1 and 1q44, MDM4 and AKT3 appeared as possible drivers of these gains respectively. The 13q31.3q32.1 < 89.58-96.81 > MCR contained an amplicon and ABCC4 might be the driver of this amplicon. The 40 Kb 2p16.1 < 60.96-61 > MCR was the smallest gained MCR and specifically encompassed the REL oncogene which is already implicated in B cell lymphomas. The most frequently deleted MCR was 3p14.1 < 60.43-60.53 > that removed the fifth exon of FHIT. Further investigations which combined gene expression and functional studies are essential to understand the lymphomagenesis mechanism and for the development of more effective, targeted therapeutic strategies.			Toujani, S (corresponding author), Inst Gustave Roussy, CNRS, FRE2939, Villejuif, France.	bernheim@igr.fr	AMSELLEM, Sophie/B-3645-2012; Vassetzky, Yegor/M-3383-2019; Wiels, Joëlle/AGL-2319-2022; Lazar, Vladimir/AAV-2087-2020; Vassetzky, Yegor S/C-6447-2008; Lazar, Vladimir/AAQ-2086-2020	Vassetzky, Yegor/0000-0003-3101-7043; Wiels, Joëlle/0000-0002-3313-2937; Vassetzky, Yegor S/0000-0003-3101-7043; RICHON, Catherine/0000-0002-3556-3941				Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Aoufouchi S, 2008, J EXP MED, V205, P1357, DOI 10.1084/jem.20070950; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Berger R, 1985, IARC Sci Publ, P65; Bernheim A, 2008, LAB INVEST, V88, P464, DOI 10.1038/labinvest.2008.18; Bernheim A, 2007, CANCER GENET CYTOGEN, V176, P89, DOI 10.1016/j.cancergencyto.2007.03.008; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Burger AM, 2005, CANCER RES, V65, P10401, DOI 10.1158/0008-5472.CAN-05-2103; Chin L, 2008, NATURE, V452, P553, DOI 10.1038/nature06914; Clapper M L, 2000, Curr Oncol Rep, V2, P251, DOI 10.1007/s11912-000-0075-z; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Davidsson J, 2007, HUM MOL GENET, V16, P2215, DOI 10.1093/hmg/ddm173; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Greshock J, 2007, CANCER RES, V67, P3594, DOI 10.1158/0008-5472.CAN-06-3674; Harris NL, 2006, NEW ENGL J MED, V354, P2495, DOI 10.1056/NEJMe068075; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heerema Nyla A, 2005, Pediatr Blood Cancer, V45, P616, DOI 10.1002/pbc.20552; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Huppi K, 2008, MOL CANCER RES, V6, P212, DOI 10.1158/1541-7786.MCR-07-0105; Inghirami G, 2005, CELL CYCLE, V4, P1131, DOI 10.4161/cc.4.9.1985; Kallioniemi A, 2008, CURR OPIN BIOTECH, V19, P36, DOI 10.1016/j.copbio.2007.11.004; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Karpova MB, 2006, INT J ONCOL, V28, P605; Kawamata N, 2002, ONCOGENE, V21, P4983, DOI 10.1038/sj.onc.1205628; Kim TM, 2008, INT J CANCER, V123, P2808, DOI 10.1002/ijc.23901; Koseoglu S, 2007, CANCER BIOL THER, V6, P755, DOI 10.4161/cbt.6.5.3995; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; Lones MA, 2004, J PEDIAT HEMATOL ONC, V26, P169, DOI 10.1097/00043426-200403000-00006; Lucito R, 2007, CANCER BIOL THER, V6, P1592, DOI 10.4161/cbt.6.10.4725; Martin-Subero JI, 2009, BLOOD, V113, P2488, DOI 10.1182/blood-2008-04-152900; Mefford HC, 2008, NEW ENGL J MED, V359, P1685, DOI 10.1056/NEJMoa0805384; Morari EC, 2002, CANCER EPIDEM BIOMAR, V11, P1485; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; Nielaender I, 2006, LEUKEMIA, V20, P904, DOI 10.1038/sj.leu.2404173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102; Salaverria I, 2008, HAEMATOL-HEMATOL J, V93, P1327, DOI 10.3324/haematol.13071; Sebat J, 2007, NAT GENET, V39, pS3, DOI 10.1038/ng2095; Shaffer LG., 2005, INT SYSTEM HUMAN CYT; Sobol H, 2002, GENE CHROMOSOME CANC, V33, P217, DOI 10.1002/gcc.10022; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; Tagawa H, 2007, CANCER SCI, V98, P1482, DOI 10.1111/j.1349-7006.2007.00531.x; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Tresnasari K, 2007, CANCER SCI, V98, P978, DOI 10.1111/j.1349-7006.2007.00482.x; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Weniger MA, 2007, GENE CHROMOSOME CANC, V46, P406, DOI 10.1002/gcc.20420; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; WIMAN KG, 1991, ONCOGENE, V6, P1633; Yasui K, 2004, CANCER RES, V64, P1403, DOI 10.1158/0008-5472.CAN-3263-2; Zhao C, 2008, ONCOGENE, V27, P63, DOI 10.1038/sj.onc.1210637	55	45	47	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7089	10.1371/journal.pone.0007089	http://dx.doi.org/10.1371/journal.pone.0007089			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759907	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970200015
J	Raso, G; Li, YS; Zhao, ZY; Balen, J; Williams, GM; McManus, DP				Raso, Giovanna; Li, Yuesheng; Zhao, Zhengyuan; Balen, Julie; Williams, Gail M.; McManus, Donald P.			Spatial Distribution of Human Schistosoma japonicum Infections in the Dongting Lake Region, China	PLOS ONE			English	Article								Background: The aim of this study was to spatially model the effect of demographic, reservoir hosts and environmental factors on human Schistosoma japonicum infection prevalence in the Dongting Lake area of Hunan Province, China and to determine the potential of each indicator in targeting schistosomiasis control. Methodology/Principal Findings: Cross-sectional serological, coprological and demographic data were obtained from the 2004 nationwide periodic epidemiologic survey for Hunan Province. Environmental data were downloaded from the USGS EROS data centre. Bayesian geostatistical models were employed for spatial analysis of the infection prevalence among study participants. A total of 47,139 participants from 47 administrative villages were selected. Age, sex and occupation of residents and the presence of infected buffaloes and environmental factors, i.e. NDVI, distance to the lake and endemic type of setting, were significantly associated with S. japonicum infection prevalence. After taking into account spatial correlation, however, only demographic factors (age, sex and occupation) and the presence of infected buffaloes remained significant indicators. Conclusions/Significance: Long established demographic factors, as well presence of host reservoirs rather than environmental factors are driving human transmission. Findings of this work can be used for epidemiologic surveillance and for the future planning of interventions in the Dongting Lake area of Hunan Province.	[Raso, Giovanna] Ctr Suisse Rech Sci, Dept Environm & Sante, Abidjan, Cote Ivoire; [Balen, Julie] Nanyang Technol Univ, Ctr Non Trad Security Stud, S Rajaratnam Sch Int Relat, Singapore, Singapore; [Raso, Giovanna; Li, Yuesheng; Balen, Julie] Queensland Inst Med Res, Mol Parasitol Lab, Brisbane, Qld, Australia; [Balen, Julie; Williams, Gail M.; McManus, Donald P.] Univ Queensland, Sch Popul Hlth, Brisbane, Qld, Australia; [Zhao, Zhengyuan] WHO Collab Ctr Res & Control Schistosomiasis, Hunan Inst Parasit Dis, Yueyang, Hunan, Peoples R China; [Zhao, Zhengyuan] Cent S Univ, Sch Publ Hlth, Changsha, Peoples R China	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; QIMR Berghofer Medical Research Institute; University of Queensland; Central South University	Raso, G (corresponding author), Ctr Suisse Rech Sci, Dept Environm & Sante, Abidjan, Cote Ivoire.	Giovanna.Raso@gmail.com	LI, Yue/GRS-8071-2022; McManus, Donald P./G-2678-2013; McManus, Don/AAC-5394-2020; Williams, Gail/S-8833-2019	McManus, Don/0000-0001-6443-1449; Williams, Gail/0000-0002-4822-5263; Balen, Julie/0000-0002-4736-8465	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Balen J, 2007, B WORLD HEALTH ORGAN, V85, P519, DOI 10.2471/BLT.06.034033; BIAN Y, 2004, INT J HLTH PLANN S1, V19, P79; Booth M, 2004, PARASITE IMMUNOL, V26, P499, DOI 10.1111/j.0141-9838.2004.00735.x; Booth M, 2003, PARASITOLOGY, V127, P525, DOI 10.1017/S0031182003004128; Brooker S, 2007, GEOSPATIAL HEALTH, V1, P141, DOI 10.4081/gh.2007.262; Diggle PJ, 1998, J R STAT SOC C-APPL, V47, P299, DOI 10.1111/1467-9876.00113; Doenhoff MJ, 2004, TRENDS PARASITOL, V20, P35, DOI 10.1016/j.pt.2003.10.019; Engels D, 1996, AM J TROP MED HYG, V54, P319, DOI 10.4269/ajtmh.1996.54.319; GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776; Gray DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004058; Guo JG, 2006, AM J TROP MED HYG, V74, P335, DOI 10.4269/ajtmh.2006.74.335; Hay SI, 2000, ADV PARASIT, V47, P1, DOI 10.1016/S0065-308X(00)47005-3; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Li SZ, 2009, GEOSPATIAL HEALTH, V3, P221, DOI 10.4081/gh.2009.222; Li YS, 2007, EMERG INFECT DIS, V13, P973, DOI 10.3201/eid1307.060848; MALONE JB, 1994, AM J TROP MED HYG, V50, P714, DOI 10.4269/ajtmh.1994.50.714; McManus DP, 2009, EXPERT REV ANTI-INFE, V7, P473, DOI [10.1586/eri.09.17, 10.1586/ERI.09.17]; *MIN PUB HLTH PEOP, 2000, AN TREATM SCH HDB SC, P230; Paolino L, 2005, Parassitologia, V47, P171; Rinaldi L, 2006, GEOSPATIAL HEALTH, V1, P33, DOI 10.4081/gh.2006.279; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Spear RC, 2004, AM J TROP MED HYG, V70, P48, DOI 10.4269/ajtmh.2004.70.48; Steinmann P, 2007, GEOSPATIAL HEALTH, V2, P59, DOI 10.4081/gh.2007.255; Steinmann P, 2007, ACTA TROP, V104, P38, DOI 10.1016/j.actatropica.2007.07.003; Utzinger J, 2005, ACTA TROP, V96, P69, DOI 10.1016/j.actatropica.2005.08.004; Wang LD, 2008, LANCET, V372, P1793, DOI 10.1016/S0140-6736(08)61358-6; Wang XH, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000250; WU ZW, 1993, ACTA TROP, V54, P83, DOI 10.1016/0001-706X(93)90053-E; Yang GJ, 2005, INT J PARASITOL, V35, P155, DOI 10.1016/j.ijpara.2004.11.002; Yang J, 2009, INT J INFECT DIS; YU DB, 1992, CHIN J SCHISTO CONTR, V4, P260; ZHENG QS, 1996, CHIN J SCHISTO CONTR, V8, P344; Zhou XN, 2007, EMERG INFECT DIS, V13, P1470, DOI 10.3201/eid1310.061423; Zhu YC, 2005, ACTA TROP, V96, P130, DOI 10.1016/j.actatropica.2005.07.007	35	20	23	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6947	10.1371/journal.pone.0006947	http://dx.doi.org/10.1371/journal.pone.0006947			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19759819	Green Published, gold, Green Accepted, Green Submitted			2022-12-27	WOS:000269796300004
J	Shu, RZ; Zhang, F; Liu, XS; Li, CL; Wang, L; Tai, YL; Wu, XL; Yang, X; Liao, XD; Jin, Y; Gu, MM; Huang, L; Pang, XF; Wang, ZG				Shu, Run-Zhe; Zhang, Feng; Liu, Xue-Song; Li, Chun-Liang; Wang, Long; Tai, Yi-Lin; Wu, Xiao-Lin; Yang, Xue; Liao, Xiao-Dong; Jin, Ying; Gu, Ming-Min; Huang, Lei; Pang, Xiao-Fen; Wang, Zhu-Gang			Target Deletion of the Cytoskeleton-Associated Protein Palladin Does Not Impair Neurite Outgrowth in Mice	PLOS ONE			English	Article								Palladin is an actin cytoskeleton-associated protein which is crucial for cell morphogenesis and motility. Previous studies have shown that palladin is localized to the axonal growth cone in neurons and may play an important role in axonal extension. Previously, we have generated palladin knockout mice which display cranial neural tube closure defect and embryonic lethality before embryonic day 15.5 (E15.5). To further study the role of palladin in the developing nervous system, we examined the innervation of palladin-deficient mouse embryos since the 200 kd, 140 kd, 90-92 kd and 50 kd palladin isoforms were undetectable in the mutant mouse embryo brain. Contrary to the results of previous studies, we found no inhibition of the axonal extension in palladin-deficient mouse embryos. The cortical neurons derived from palladin-deficient mice also showed no significant difference in neurite outgrowth as compared with those from wild-type mice. Moreover, no difference was found in neurite outgrowth of neural stem cell derived-neurons between palladin-deficient mice and wild-type mice. In conclusion, these results suggest that palladin is dispensable for normal neurite outgrowth in mice.			Shu, RZ (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China.	xiaofenpang@126.com; zhugangw@shsmu.edu.cn	Yang, xue/G-3626-2016; Liu, Xue-Song/ADF-2183-2022; Li, Chunliang/P-4373-2018	Liu, Xue-Song/0000-0002-7736-0077; Huang, Lei/0000-0002-4851-4807; Li, Chunliang/0000-0002-5938-5510				Bentley CA, 2000, J NEUROSCI, V20, P7706; Boukhelifa M, 2006, FEBS J, V273, P26, DOI 10.1111/j.1742-4658.2005.05036.x; Boukhelifa M, 2004, CELL MOTIL CYTOSKEL, V58, P17, DOI 10.1002/cm.10173; Boukhelifa M, 2001, MOL BIOL CELL, V12, P2721, DOI 10.1091/mbc.12.9.2721; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dixon RDS, 2008, J BIOL CHEM, V283, P6222, DOI 10.1074/jbc.M707694200; Goicoechea SM, 2008, EUR J CELL BIOL, V87, P517, DOI 10.1016/j.ejcb.2008.01.010; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; HOGAN B, 1994, MANIPULATING MOUSE E, P340; Liu XS, 2007, BLOOD, V110, P870, DOI 10.1182/blood-2007-01-068528; Liu XS, 2007, J CELL BIOCHEM, V100, P1288, DOI 10.1002/jcb.21126; Luo HJ, 2005, MOL CELL NEUROSCI, V29, P507, DOI 10.1016/j.mcn.2004.12.002; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Mykkanen OM, 2001, MOL BIOL CELL, V12, P3060, DOI 10.1091/mbc.12.10.3060; Otey CA, 2005, INT REV CYTOL, V246, P31, DOI 10.1016/S0074-7696(05)46002-7; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Rachlin AS, 2006, J CELL SCI, V119, P995, DOI 10.1242/jcs.02825; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Wang HV, 2008, DEV DYNAM, V237, P3342, DOI 10.1002/dvdy.21755; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9	20	5	6	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6916	10.1371/journal.pone.0006916	http://dx.doi.org/10.1371/journal.pone.0006916			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730728	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100016
J	Lai, WYY; Lane, T; Jones, A				Lai, William Y. Y.; Lane, Trevor; Jones, Alison			Sources and Coverage of Medical News on Front Pages of US Newspapers	PLOS ONE			English	Article							SCIENCE; POWER	Background: Medical news that appears on newspaper front pages is intended to reach a wide audience, but how this type of medical news is prepared and distributed has not been systematically researched. We thus quantified the level of visibility achieved by front-page medical stories in the United States and analyzed their news sources. Methodology: Using the online resource Newseum, we investigated front-page newspaper coverage of four prominent medical stories, and a high-profile non-medical news story as a control, reported in the US in 2007. Two characteristics were quantified by two raters: which newspaper titles carried each target front-page story (interrater agreement, >96%; kappa, >0.92) and the news sources of each target story (interrater agreement, >94%; kappa, >0.91). National rankings of the top 200 US newspapers by audited circulation were used to quantify the extent of coverage as the proportion of the total circulation of ranked newspapers in Newseum. Findings: In total, 1630 front pages were searched. Each medical story appeared on the front pages of 85 to 117 (67.5%-78.7%) ranked newspaper titles that had a cumulative daily circulation of 23.1 to 33.4 million, or 61.8% to 88.4% of all newspapers. In contrast, the non-medical story achieved front-page coverage in 152 (99.3%) newspaper titles with a total circulation of 41.0 million, or 99.8% of all newspapers. Front-page medical stories varied in their sources, but the Washington Post, Los Angeles Times, New York Times and the Associated Press together supplied 61.7% of the total coverage of target front-page medical stories. Conclusion: Front-page coverage of medical news from different sources is more accurately revealed by analysis of circulation counts rather than of newspaper titles. Journals wishing to widen knowledge of research news and organizations with important health announcements should target at least the four dominant media organizations identified in this study.			Lai, WYY (corresponding author), Univ Hong Kong, Journalism & Media Studies Ctr, Pokfulam, Hong Kong, Peoples R China.	wyylai@yahoo.com	Lane, Trevor/B-2153-2009; Lane, Trevor/AAF-4871-2020	Lane, Trevor/0000-0001-8599-2173; 				Adelman RC, 2000, J HEALTH SOC BEHAV, V41, P347, DOI 10.2307/2676325; ANGELL M, 1994, NEW ENGL J MED, V331, P189, DOI 10.1056/NEJM199407213310309; *AUD BUR CIRC, 2007, ABC TOP 200 NEWSP LA; Campion EW, 2004, NEW ENGL J MED, V351, P2436, DOI 10.1056/NEJMe048289; *CHPA, 2007, MAK OTC COUGH COLD M; Danovaro-Holliday MC, 2002, JAMA-J AM MED ASSOC, V287, P1455, DOI 10.1001/jama.287.11.1455; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Kennedy GE, 1999, TOB CONTROL, V8, P254, DOI 10.1136/tc.8.3.254; Kiernan V, 2003, JOURNALISM MASS COMM, V80, P903, DOI 10.1177/107769900308000410; Kiernan V, 2003, SCI COMMUN, V25, P3, DOI 10.1177/1075547003255297; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Lai WYY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006103; LEESTJOHN J, 2007, TIME; Marshall E, 1998, SCIENCE, V280, P996, DOI 10.1126/science.280.5366.996; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Moynihan R, 2003, LANCET, V361, P2097, DOI 10.1016/S0140-6736(03)13729-4; Nelkin D, 1996, LANCET, V347, P1600, DOI 10.1016/S0140-6736(96)91081-8; NELKIN D, 1995, SELLING SCI PRESS CO, P62; *PEJ, 2008, STAT NEWS MED 2008; PHILLIPS DP, 1991, NEW ENGL J MED, V325, P1180, DOI 10.1056/NEJM199110173251620; Radford T, 1996, LANCET, V347, P1533, DOI 10.1016/S0140-6736(96)90677-7; Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653; Schwartz LM, 2002, JAMA-J AM MED ASSOC, V287, P3136, DOI 10.1001/jama.287.23.3136; Schwitzer G, 2008, PLOS MED, V5, P700, DOI 10.1371/journal.pmed.0050095; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Wilkes MS, 1997, J HEALTH COMMUN, V2, P3, DOI 10.1080/108107397127888; Woloshin S, 2006, MED J AUSTRALIA, V184, P576, DOI 10.5694/j.1326-5377.2006.tb00384.x; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	28	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2009	4	9							e6856	10.1371/journal.pone.0006856	http://dx.doi.org/10.1371/journal.pone.0006856			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	490RW	19724643	Green Published, gold, Green Submitted			2022-12-27	WOS:000269522800003
J	Chauhan, SC; Madhubala, R				Chauhan, Swati C.; Madhubala, Rentala			Glyoxalase I Gene Deletion Mutants of Leishmania donovani Exhibit Reduced Methylglyoxal Detoxification	PLOS ONE			English	Article								Background: Glyoxalase I is a metalloenzyme of the glyoxalase pathway that plays a central role in eliminating the toxic metabolite methyglyoxal. The protozoan parasite Leishmania donovani possesses a unique trypanothione dependent glyoxalase system. Principal Findings: Analysis of the L. donovani GLOI sequence predicted a mitochondrial targeting sequence, suggesting that the enzyme is likely to be targeted to the mitochondria. In order to determine definitively the intracellular localization of GLOI in L. donovani, a full-length GLOI gene was fused to green fluorescent protein (GFP) gene to generate a chimeric construct. Confocal microscopy of L. donovani promastigotes carrying this chimeric construct and immunofluorescence microscopy using anti-GLOI antibodies demonstrated that GLOI is localized in the kinetoplast of the parasite apart from the cytosol. To study the physiological role of GLOI in Leishmania, we first created promastigote mutants heterozygous for GLOI by targeted gene replacement using either hygromycin or neomycin phosphotransferases as selectable markers. Heterozygous mutants of L. donovani display a slower growth rate, have lower glyoxalase I activity and have reduced ability to detoxify methylglyoxal in comparison to the wild-type parasites. Complementation of the heterozygous mutant with an episomal GLOI construct showed the restoration of heterozygous mutant phenotype nearly fully to that of the wild-type. Null mutants were obtained only after GLOI was expressed from an episome in heterozygous mutants. Conclusions: We for the first time report localization of GLOI in L. donovani in the kinetoplast. To study the physiological role of GLOI in Leishmania, we have generated GLOI attenuated strains by targeted gene replacement and report that GLOI is likely to be an important gene since GLOI mutants in L. donovani showed altered phenotype. The present data supports that the GLOI plays an essential role in the survival of this pathogenic organism and that inhibition of the enzyme potentiates the toxicity of methylglyoxal.			Chauhan, SC (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India.	madhubala@mail.jnu.ac.in	madhubala, Rentala/C-3445-2015	madhubala, rentala/0000-0002-0034-399X				ALEXANDER NM, 1971, CANCER RES, V31, P1875; Amicarelli F, 2003, FREE RADICAL BIO MED, V35, P856, DOI 10.1016/S0891-5849(03)00438-6; ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; AYOUB FM, 1993, LEUKEMIA RES, V17, P397, DOI 10.1016/0145-2126(93)90094-2; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; CARRINGTON SJ, 1986, IRCS MED SCI-BIOCHEM, V14, P763; Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001; CLAPPER ML, 1991, BIOCHIM BIOPHYS ACTA, V1096, P209, DOI 10.1016/0925-4439(91)90007-V; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Clugston SL, 1998, BIOCHEMISTRY-US, V37, P8754, DOI 10.1021/bi972791w; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; D'Silva C, 2000, J MED CHEM, V43, P2072, DOI 10.1021/jm990259w; Dakin HD, 1913, J BIOL CHEM, V14, P155; DUDANI AK, 1984, BIOCHEM BIOPH RES CO, V119, P962, DOI 10.1016/0006-291X(84)90867-2; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; EGYUD LG, 1968, SCIENCE, V160, P1140, DOI 10.1126/science.160.3832.1140; EGYUD LG, 1966, P NATL ACAD SCI USA, V56, P203, DOI 10.1073/pnas.56.1.203; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; GILLESPIE E, 1981, BIOCHEM BIOPH RES CO, V98, P463, DOI 10.1016/0006-291X(81)90862-7; Goswami S, 2006, J BIOL CHEM, V281, P18914, DOI 10.1074/jbc.C600089200; Greig N, 2006, BIOCHEM J, V400, P217, DOI 10.1042/BJ20060882; He MM, 2000, BIOCHEMISTRY-US, V39, P8719, DOI 10.1021/bi000856g; Irsch T, 2004, J BIOL CHEM, V279, P22209, DOI 10.1074/jbc.M401240200; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; MacLean MJ, 1998, MOL MICROBIOL, V27, P563, DOI 10.1046/j.1365-2958.1998.00701.x; MARINARI UM, 1984, CELL BIOCHEM FUNCT, V2, P243, DOI 10.1002/cbf.290020411; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Neuberg C, 1913, BIOCHEM Z, V49, P502; NYANDIEKA HS, 1978, CLIN BIOCHEM, V11, P150, DOI 10.1016/S0009-9120(78)90349-1; Padmanabhan PK, 2006, BIOCHEM J, V393, P227, DOI 10.1042/BJ20050948; Padmanabhan PK, 2005, BIOCHEM BIOPH RES CO, V337, P1237, DOI 10.1016/j.bbrc.2005.09.179; Papadopoulou B, 1996, BIOCHEM BIOPH RES CO, V224, P772, DOI 10.1006/bbrc.1996.1098; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; RACKER E, 1951, J BIOL CHEM, V190, P685; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; THORNALLEY PJ, 1994, BIOCHEM PHARMACOL, V47, P418, DOI 10.1016/0006-2952(94)90035-3; VANDERJAGT DL, 1972, BIOCHEMISTRY-US, V11, P3735, DOI 10.1021/bi00770a011; VANDERJAGT DL, 1975, BIOCHEMISTRY-US, V14, P3669, DOI 10.1021/bi00687a024; Verma NK, 2004, ANTIMICROB AGENTS CH, V48, P3010, DOI 10.1128/AAC.48.8.3010-3015.2004; Vickers TJ, 2004, P NATL ACAD SCI USA, V101, P13186, DOI 10.1073/pnas.0402918101	43	28	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6805	10.1371/journal.pone.0006805	http://dx.doi.org/10.1371/journal.pone.0006805			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710909	gold, Green Published, Green Submitted			2022-12-27	WOS:000269415600017
J	Destoumieux-Garzon, D; Brehelin, M; Bulet, P; Boublik, Y; Girard, PA; Baghdiguian, S; Zumbihl, R; Escoubas, JM				Destoumieux-Garzon, Delphine; Brehelin, Michel; Bulet, Philippe; Boublik, Yvan; Girard, Pierre-Alain; Baghdiguian, Stephen; Zumbihl, Robert; Escoubas, Jean-Michel			Spodoptera frugiperda X-Tox Protein, an Immune Related Defensin Rosary, Has Lost the Function Ancestral Defensins	PLOS ONE			English	Article								Background: X-tox proteins are a family of immune-related proteins only found in Lepidoptera and characterized by imperfectly conserved tandem repeats of several defensin-like motifs. Previous phylogenetic analysis of X-tox genes supported the hypothesis that X-tox have evolved from defensins in a lineage-specific gene evolution restricted to Lepidoptera. In this paper, we performed a protein study in which we asked whether X-tox proteins have conserved the antimicrobial functions of their ancestral defensins and have evolved as defensin reservoirs. Methodology/Principal Findings: We followed the outcome of Spod-11-tox, an X-tox protein characterized in Spodoptera frugiperda, in bacteria-challenged larvae using both immunochemistry and antimicrobial assays. Three hours post infection, the Spod-11-tox protein was expressed in 80% of the two main classes of circulating hemocytes (granulocytes and plasmatocytes). Located in secretory granules of hemocytes, Spod-11-tox was never observed in contact with microorganisms entrapped within phagolyzosomes showing that Spod-11-tox is not involved in intracellular pathogen killing. In fact, the Spod-11-tox protein was found to be secreted into the hemolymph of experimentally challenged larvae. In order to determine antimicrobial properties of the Spod-11-tox protein, it was consequently fractionated according to a protocol frequently used for antimicrobial peptide purification. Over the course of purification, the anti-Spod-11-tox immunoreactivity was found to be dissociated from the antimicrobial activity. This indicates that Spod-11-tox is not processed into bioactive defensins in response to a microbial challenge. Conclusions/Significance: Altogether, our results show that X-tox proteins have not evolved as defensin reservoirs and have lost the antimicrobial properties of the ancestral insect defensins. The lepidopteran X-tox protein family will provide a valuable and tractable model to improve our knowledge on the molecular evolution of defensins, a class of innate immune effectors largely distributed over the three eukaryotic kingdoms.	[Destoumieux-Garzon, Delphine] CNRS, UMR5119, Lab Ecosyst Lagunaires, CC80, Montpellier, France; [Destoumieux-Garzon, Delphine] IFREMER, UMR 5119, Lab Ecosyst Lagunaires, CC80, Montpellier, France; [Destoumieux-Garzon, Delphine] Univ Montpellier 2, UMR5119, Lab Ecosyst Lagunaires, CC80, Montpellier, France; [Brehelin, Michel; Girard, Pierre-Alain; Zumbihl, Robert; Escoubas, Jean-Michel] INRA, UMR 1133, Lab Ecol Microbienne Insect & Interact Hote Pathog, CC54, Montpellier, France; [Brehelin, Michel; Girard, Pierre-Alain; Zumbihl, Robert; Escoubas, Jean-Michel] Univ Montpellier 2, UMR1133, Lab EMIP, CC54, Montpellier, France; [Bulet, Philippe] Univ Grenoble 1, CNRS, UMR5525, TIMC IMAG, Archamps, France; [Boublik, Yvan] CNRS, Plateforme Prot Recombinantes UMR5237, Montpellier, France; [Baghdiguian, Stephen] Univ Montpellier 2, CNRS, Inst Sci Evolut, UMR5554,CC63, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Universite de Montpellier; INRAE; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Escoubas, JM (corresponding author), INRA, UMR 1133, Lab Ecol Microbienne Insect & Interact Hote Pathog, CC54, Montpellier, France.	Jean-Michel.Escoubas@univ-montp2.fr	BUELT, PHILIPPE/C-8451-2014; Destoumieux-Garzón, Delphine/O-3328-2014; BULET, Philippe/C-8557-2014; ESCOUBAS, Jean-Michel/G-4027-2010	Destoumieux-Garzón, Delphine/0000-0002-8793-9138; BULET, Philippe/0000-0001-9016-265X; ESCOUBAS, Jean-Michel/0000-0002-6138-1148; Baghdiguian, Stephen/0000-0002-2992-9708				BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; Brehelin M., 1986, P36; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Cytrynska M, 2007, PEPTIDES, V28, P533, DOI 10.1016/j.peptides.2006.11.010; Destoumieux D, 2000, J CELL SCI, V113, P461; Eleftherianos I, 2007, CELL MICROBIOL, V9, P1137, DOI 10.1111/j.1462-5822.2006.00855.x; Evans JD, 2006, INSECT MOL BIOL, V15, P645, DOI 10.1111/j.1365-2583.2006.00682.x; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Girard PA, 2008, DEV COMP IMMUNOL, V32, P575, DOI 10.1016/j.dci.2007.09.004; Hetru C, 1997, Methods Mol Biol, V78, P35; Hoffmann J., 2007, ANN REV IMMUNOL; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lamberty M, 2001, J BIOL CHEM, V276, P4085, DOI 10.1074/jbc.M002998200; Lee YS, 2004, INSECT MOL BIOL, V13, P65, DOI 10.1111/j.1365-2583.2004.00462.x; Mitta G, 1999, J CELL SCI, V112, P4233; Nardi JB, 2003, DEV GENES EVOL, V213, P477, DOI 10.1007/s00427-003-0352-6; Ribeiro C, 2003, J BIOL CHEM, V278, P3030, DOI 10.1074/jbc.M210353200; Ribeiro C, 2006, J INSECT PHYSIOL, V52, P417, DOI 10.1016/j.jinsphys.2006.01.005; Seitz V, 2003, DEV COMP IMMUNOL, V27, P207, DOI 10.1016/S0145-305X(02)00097-6; Shelby KS, 2009, J INVERTEBR PATHOL, V101, P86, DOI 10.1016/j.jip.2009.05.002; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; Sicard M, 2004, APPL ENVIRON MICROB, V70, P6473, DOI 10.1128/AEM.70.11.6473-6480.2004; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TANAKA H, 2008, INSECT BIOCH MOL BIO; Taniai K, 2006, INSECT MOL BIOL, V15, P269, DOI 10.1111/j.1365-2583.2006.00639.x; Volkoff AN, 2003, GENE, V319, P43, DOI 10.1016/S0378-1119(03)00789-3; Yu XQ, 2002, EUR J BIOCHEM, V269, P1827, DOI 10.1046/j.1432-1033.2002.02830.x; Zou Z, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r177	31	14	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6795	10.1371/journal.pone.0006795	http://dx.doi.org/10.1371/journal.pone.0006795			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710910	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415600009
J	Dominguez, JF; Guo, LX; Molnar, MAC; Escobedo, AB; Dunphy, T; Lund, TD; Turman, JE				Dominguez, Jesus F.; Guo, Lixin; Carrasco Molnar, Marco A.; Ballester Escobedo, Antonio; Dunphy, Taylor; Lund, Trent D.; Turman, Jack E., Jr.			Novel Indirect Calorimetry Technology to Analyze Metabolism in Individual Neonatal Rodent Pups	PLOS ONE			English	Article								Background: The ability to characterize the development of metabolic function in neonatal rodents has been limited due to technological constraints. Low respiratory volumes and flows at rest pose unique problems, making it difficult to reliably measure O-2 consumption, CO2 production, respiratory quotient (RQ), and energy expenditure (EE). Our aim was to develop and validate a commercial-grade indirect calorimetry system capable of characterizing the metabolic phenotype of individual neonatal rodents. Methodology/Principal Findings: To address this research need, we developed a novel, highly sensitive open-circuit indirect calorimetry system capable of analyzing respiratory gas exchange in a single neonatal rodent pup. Additionally, we derived an equation from known metabolic relationships to estimate inlet flow rates, improving the efficiency of data collection. To validate the neonatal rodent indirect calorimetry system and evaluate the applicability of the derived equation for predicting appropriate flow rates, we conducted a series of experiments evaluating the impact of sex, litter size, time of day (during the light phase), and ambient temperature on neonatal rat metabolic parameters. Data revealed that the only metabolic parameter influenced by litter size is a neonatal rat's RQ, with rat pups reared in a small litter (5 pups) having lower RQ's than rat pups reared in either medium (8 pups) or large (11 pups) litters. Furthermore, data showed that ambient temperature affected all metabolic parameters measured, with colder temperatures being associated with higher CO2 production, higher O-2 consumption, and higher energy expenditure. Conclusion/Significance: The results of this study demonstrate that the modified Panlab Oxylet system reliably assesses early postnatal metabolism in individual neonatal rodents. This system will be of paramount importance to further our understanding of processes associated with the developmental origins of adult metabolic disease.			Dominguez, JF (corresponding author), Univ So Calif, Keck Sch Med, Ctr Premature Infant Hlth & Dev, Los Angeles, CA 90033 USA.	jdomingu@usc.edu	Linong, Ji/AAB-6543-2020					ALBERTS JR, 1978, J COMP PHYSIOL PSYCH, V92, P231, DOI 10.1037/h0077459; De Boo HA, 2006, AUST NZ J OBSTET GYN, V46, P4, DOI 10.1111/j.1479-828X.2006.00506.x; EVEN PC, 1994, NEUROSCI BIOBEHAV R, V18, P435, DOI 10.1016/0149-7634(94)90056-6; FIOROTTO ML, 1991, AM J PHYSIOL, V260, pR1104, DOI 10.1152/ajpregu.1991.260.6.R1104; Garrett-Cox RG, 2003, J PEDIATR SURG, V38, P37, DOI 10.1053/jpsu.2003.50006; KEEN CL, 1981, J NUTR, V111, P226, DOI 10.1093/jn/111.2.226; Kuhn CM, 1998, INT J DEV NEUROSCI, V16, P261, DOI 10.1016/S0736-5748(98)00034-3; Luketich JD, 1998, NUTRITION, V14, P672, DOI 10.1016/S0899-9007(98)00066-5; Lusk G, 1924, J BIOL CHEM, V59, P41; Plagemann A, 2006, HORM RES, V65, P83, DOI 10.1159/000091511; PLANCHE E, 1983, AM J PHYSIOL, V245, pE107, DOI 10.1152/ajpendo.1983.245.2.E107; Saiki C, 1996, J PHYSIOL-LONDON, V491, P261, DOI 10.1113/jphysiol.1996.sp021213; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363	13	9	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6790	10.1371/journal.pone.0006790	http://dx.doi.org/10.1371/journal.pone.0006790			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710924	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415600005
J	Sears, DD; Miles, PD; Chapman, J; Ofrecio, JM; Almazan, F; Thapar, D; Miller, YI				Sears, Dorothy D.; Miles, Philip D.; Chapman, Justin; Ofrecio, Jachelle M.; Almazan, Felicidad; Thapar, Divya; Miller, Yury I.			12/15-Lipoxygenase Is Required for the Early Onset of High Fat Diet-Induced Adipose Tissue Inflammation and Insulin Resistance in Mice	PLOS ONE			English	Article								Background: Recent understanding that insulin resistance is an inflammatory condition necessitates searching for genes that regulate inflammation in insulin sensitive tissues. 12/15-lipoxygenase (12/15LO) regulates the expression of proinflammatory cytokines and chemokines and is implicated in the early development of diet-induced atherosclerosis. Thus, we tested the hypothesis that 12/15LO is involved in the onset of high fat diet (HFD)-induced insulin resistance. Methodology/Principal Findings: Cells over-expressing 12/15LO secreted two potent chemokines, MCP-1 and osteopontin, implicated in the development of insulin resistance. We assessed adipose tissue inflammation and whole body insulin resistance in wild type (WT) and 12/15LO knockout (KO) mice after 2-4 weeks on HFD. In adipose tissue from WT mice, HFD resulted in recruitment of CD11b(+), F4/80(+) macrophages and elevated protein levels of the inflammatory markers IL-1 beta, IL-6, IL-10, IL-12, IFNc, Cxcl1 and TNF alpha. Remarkably, adipose tissue from HFD-fed 12/15LO KO mice was not infiltrated by macrophages and did not display any increase in the inflammatory markers compared to adipose tissue from normal chow-fed mice. WT mice developed severe whole body (hepatic and skeletal muscle) insulin resistance after HFD, as measured by hyperinsulinemic euglycemic clamp. In contrast, 12/15LO KO mice exhibited no HFD-induced change in insulin-stimulated glucose disposal rate or hepatic glucose output during clamp studies. Insulin-stimulated Akt phosphorylation in muscle tissue from HFD-fed mice was significantly greater in 12/15LO KO mice than in WT mice. Conclusions: These results demonstrate that 12/15LO mediates early stages of adipose tissue inflammation and whole body insulin resistance induced by high fat feeding.			Sears, DD (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.	dsears@ucsd.edu	Sears, Dorothy D/AHE-5524-2022	Sears, Dorothy D/0000-0002-9260-3540	NHLBI NIH HHS [R01 HL081862, R01HL081862] Funding Source: Medline; NIDDK NIH HHS [K01-DK62025, K01 DK062025] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062025] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; Bolick DT, 2006, ARTERIOSCL THROM VAS, V26, P1260, DOI 10.1161/01.ATV.0000217909.09198.d6; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P2301, DOI 10.1161/01.ATV.0000186181.19909.a6; Browse J, 2005, VITAM HORM, V72, P431, DOI 10.1016/S0083-6729(05)72012-4; CHAKRABARTI SK, 2009, 12 15 LIPOXYGENASE P; Chen M, 2005, DIABETOLOGIA, V48, P486, DOI 10.1007/s00125-005-1673-y; Cyrus T, 2001, CIRCULATION, V103, P2277; de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057; Delker C, 2006, PLANT BIOLOGY, V8, P297, DOI 10.1055/s-2006-923935; Dwarakanath RS, 2008, J VASC RES, V45, P132, DOI 10.1159/000109966; Dwarakanath RS, 2004, J MOL CELL CARDIOL, V36, P585, DOI 10.1016/j.yjmcc.2004.02.007; EZAKI M, 1995, J LIPID RES, V36, P1996; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Huo YQ, 2004, CIRCULATION, V110, P2024, DOI 10.1161/01.CIR.0000143628.37680.F6; Kamei N, 2006, J BIOL CHEM, V281, P26602, DOI 10.1074/jbc.M601284200; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Li SL, 2006, DIABETES, V55, P2611, DOI 10.2337/db06-0164; Li SL, 2005, J LIPID RES, V46, P220, DOI 10.1194/jlr.M400328-JLR200; Matsuzawa Y, 2006, FEBS LETT, V580, P2917, DOI 10.1016/j.febslet.2006.04.028; McDuffie M, 2008, DIABETES, V57, P199, DOI 10.2337/db07-0830; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Miller YI, 2005, ARTERIOSCL THROM VAS, V25, P1213, DOI 10.1161/01.ATV.0000159891.73193.31; Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200; Natarajan R, 1997, HYPERTENSION, V30, P873, DOI 10.1161/01.HYP.30.4.873; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Natarajan R, 2004, ARTERIOSCL THROM VAS, V24, P1542, DOI 10.1161/01.ATV.0000133606.69732.4c; Natarajan R, 2001, ARTERIOSCL THROM VAS, V21, P1408, DOI 10.1161/hq0901.095278; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Nomiyama T, 2007, J CLIN INVEST, V117, P2877, DOI 10.1172/JCI31986; Nunemaker CS, 2008, AM J PHYSIOL-ENDOC M, V295, pE1065, DOI 10.1152/ajpendo.90371.2008; Park SY, 2005, DIABETES, V54, P3530, DOI 10.2337/diabetes.54.12.3530; Patricia MK, 2001, CIRC RES, V88, P659, DOI 10.1161/hh0701.088838; Persaud SJ, 2007, DIABETES, V56, P197, DOI 10.2337/db06-0490; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Reilly KB, 2004, J BIOL CHEM, V279, P9440, DOI 10.1074/jbc.M303857200; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Trayhurn P, 2005, BIOCHEM SOC T, V33, P1078, DOI [10.1042/BST0331078, 10.1042/BST20051078]; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wen YH, 2008, AM J PHYSIOL-HEART C, V294, pH1933, DOI 10.1152/ajpheart.00260.2007; Wen YS, 2007, ENDOCRINOLOGY, V148, P1313, DOI 10.1210/en.2006-0665; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; Zhao L, 2004, TRENDS CARDIOVAS MED, V14, P191, DOI 10.1016/j.tcm.2004.04.003	47	104	107	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7250	10.1371/journal.pone.0007250	http://dx.doi.org/10.1371/journal.pone.0007250			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787041	gold, Green Published, Green Submitted			2022-12-27	WOS:000270290100023
J	Hanlon, K; Rudin, CE; Harries, LW				Hanlon, Katy; Rudin, Claudius E.; Harries, Lorna W.			Investigating the Targets of MIR-15a and MIR-16-1 in Patients with Chronic Lymphocytic Leukemia (CLL)	PLOS ONE			English	Article							TUMOR-SUPPRESSOR; CHROMOSOME 13Q14; MICRORNAS; GENES; CLONING; REGION; RAS; EXPRESSION; SEQUENCE; DELETION	Background: MicroRNAs (miRNAs) are short, noncoding RNAs that regulate the expression of multiple target genes. Deregulation of miRNAs is common in human tumorigenesis. The miRNAs, MIR-15a/16-1, at chromosome band 13q14 are down-regulated in the majority of patients with chronic lymphocytic leukaemia (CLL). Methodology/Principal Findings: We have measured the expression of MIR-15a/16-1, and 92 computationally-predicted MIR-15a/16-1 target genes in CLL patients and in normal controls. We identified 35 genes that are deregulated in CLL patients, 5 of which appear to be specific targets of the MIR-15a/16-1 cluster. These targets included 2 genes (BAZ2A and RNF41) that were significantly up-regulated (p < 0.05) and 3 genes (RASSF5, MKK3 and LRIG1) that were significantly downregulated (p < 0.05) in CLL patients with down-regulated MIR-15a/16-1 expression. Significance: The genes identified here as being subject to MIR-15a/16-1 regulation could represent direct or indirect targets of these miRNAs. Many of these are good biological candidates for involvement in tumorigenesis and as such, may be important in the aetiology of CLL.			Hanlon, K (corresponding author), Royal Devon & Exeter NHS Fdn Trust, Dept Haematol, Exeter, Devon, England.	L.W.Harries@exeter.ac.uk	Harries, Lorna/D-2241-2014; Lunnon, Katie/C-4638-2012	Harries, Lorna/0000-0001-7791-8061; Lunnon, Katie/0000-0001-7570-6065				Abdullah JM, 2001, BLOOD CELL MOL DIS, V27, P320, DOI 10.1006/bcmd.2001.0390; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; *APPL BIOS, 1997, US B APPL BIOS, V2, P11; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040; Bullrich F, 2001, CANCER RES, V61, P6640; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Calin GA, 2007, METHOD ENZYMOL, V427, P193, DOI 10.1016/S0076-6879(07)27011-9; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2008, LEUKEMIA, V22, P1095, DOI 10.1038/leu.2008.30; Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009; Facon T, 2001, BLOOD, V97, P1566, DOI 10.1182/blood.V97.6.1566; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Geli J, 2007, ENDOCR-RELAT CANCER, V14, P125, DOI 10.1677/ERC-06-0031; Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Jing X, 2008, EXP HEMATOL, V36, P1110, DOI 10.1016/j.exphem.2008.04.001; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; La Starza R, 1998, BLOOD, V91, P231, DOI 10.1182/blood.V91.1.231.231_231_237; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu Y, 1997, ONCOGENE, V15, P2463, DOI 10.1038/sj.onc.1201643; Mabuchi H, 2001, CANCER RES, V61, P2870; MATUTES E, 1994, LEUKEMIA, V8, P1640; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; Molica S, 2003, EUR J HAEMATOL, V70, P373, DOI 10.1034/j.1600-0609.2003.00064.x; MULLERHERMELINK HK, 2001, WHO CLASSIFICATION T, P127; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; Panagopoulos I, 2006, BRIT J HAEMATOL, V133, P270, DOI 10.1111/j.1365-2141.2006.06020.x; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Ringshausen I, 2004, LEUKEMIA, V18, P1964, DOI 10.1038/sj.leu.2403544; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Schlade-Bartusiak Kamilla, 2005, Journal of Applied Genetics, V46, P407; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Zojer N, 2000, BLOOD, V95, P1925, DOI 10.1182/blood.V95.6.1925	46	50	53	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7169	10.1371/journal.pone.0007169	http://dx.doi.org/10.1371/journal.pone.0007169			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779621	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200011
J	Pyka, M; Beckmann, CF; Schoning, S; Hauke, S; Heider, D; Kugel, H; Arolt, V; Konrad, C				Pyka, Martin; Beckmann, Christian F.; Schoening, Sonja; Hauke, Sascha; Heider, Dominik; Kugel, Harald; Arolt, Volker; Konrad, Carsten			Impact of Working Memory Load on fMRI Resting State Pattern in Subsequent Resting Phases	PLOS ONE			English	Article							INDEPENDENT COMPONENT ANALYSIS; TASK-INDUCED DEACTIVATION; STREAM-OF-CONSCIOUSNESS; DEFAULT-MODE NETWORK; FUNCTIONAL CONNECTIVITY; PREFRONTAL CORTEX; ALZHEIMERS-DISEASE; BRAIN ACTIVITY; AGE; FLUCTUATIONS	Background: The default-mode network (DMN) is a functional network with increasing relevance for psychiatric research, characterized by increased activation at rest and decreased activation during task performance. The degree of DMN deactivation during a cognitively demanding task depends on its difficulty. However, the relation of hemodynamic responses in the resting phase after a preceding cognitive challenge remains relatively unexplored. We test the hypothesis that the degree of activation of the DMN following cognitive challenge is influenced by the cognitive load of a preceding working-memory task. Methodology/Principal Findings: Twenty-five healthy subjects were investigated with functional MRI at 3 Tesla while performing a working-memory task with embedded short resting phases. Data were decomposed into statistically independent spatio-temporal components using Tensor Independent Component Analysis (TICA). The DMN was selected using a template-matching procedure. The spatial map contained rest-related activations in the medial frontal cortex, ventral anterior and posterior cingulate cortex. The time course of the DMN revealed increased activation at rest after 1-back and 2-back blocks compared to the activation after a 0-back block. Conclusion/Significance: We present evidence that a cognitively challenging working-memory task is followed by greater activation of the DMN than a simple letter-matching task. This might be interpreted as a functional correlate of self-evaluation and reflection of the preceding task or as relocation of cerebral resources representing recovery from high cognitive demands. This finding is highly relevant for neuroimaging studies which include resting phases in cognitive tasks as stable baseline conditions. Further studies investigating the DMN should take possible interactions of tasks and subsequent resting phases into account.			Pyka, M (corresponding author), Univ Munster, Dept Psychiat, Munster, Germany.	carsten.konrad@med.uni-marburg.de	Heider, Dominik/F-8545-2010; Beckmann, Christian F./E-6374-2012; Kugel, Harald/A-4963-2013	Heider, Dominik/0000-0002-3108-8311; Beckmann, Christian F./0000-0002-3373-3193; Kugel, Harald/0000-0002-4349-1984; Lauwereyns, Jan/0000-0003-0551-2550				ANTROBUS JS, 1966, PERCEPT MOTOR SKILL, V23, P399, DOI 10.2466/pms.1966.23.2.399; Bailey A, 2007, MULT SCLER J, V13, P73, DOI 10.1177/1352458506071162; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; CALHOUN VD, 2003, P INT WORKSH IND COM, P281; Chee MWL, 2004, J NEUROSCI, V24, P4560, DOI 10.1523/JNEUROSCI.0007-04.2004; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; GIAMBRA LM, 1995, CONSCIOUS COGN, V4, P1, DOI 10.1006/ccog.1995.1001; Gould RL, 2006, NEUROIMAGE, V31, P818, DOI 10.1016/j.neuroimage.2005.12.045; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; Harshman R. A., 1970, FDN PARAFAC PROCEDUR, P1; Hyvarinen A, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P71; Jansma JM, 2007, HUM BRAIN MAPP, V28, P431, DOI 10.1002/hbm.20297; KIM DI, 2009, HUM BRAIN M IN PRESS; Kineses ZT, 2008, NEUROIMAGE, V39, P1950, DOI 10.1016/j.neuroimage.2007.09.070; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Lustig C, 2003, P NATL ACAD SCI USA, V100, P14504, DOI 10.1073/pnas.2235925100; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Mazoyer B, 2001, BRAIN RES BULL, V54, P287, DOI 10.1016/S0361-9230(00)00437-8; McGuire PK, 1996, NEUROREPORT, V7, P2095; McKiernan KA, 2006, NEUROIMAGE, V29, P1185, DOI 10.1016/j.neuroimage.2005.09.030; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Nir Y, 2006, NEUROIMAGE, V30, P1313, DOI 10.1016/j.neuroimage.2005.11.018; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; Persson J, 2007, J COGNITIVE NEUROSCI, V19, P1021, DOI 10.1162/jocn.2007.19.6.1021; Pomarol-Clotet E, 2008, PSYCHOL MED, V38, P1185, DOI 10.1017/S0033291708003565; POPE KS, 1976, CONSCIOUSNESS SELF R, P101; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rombouts SARB, 2005, HUM BRAIN MAPP, V26, P231, DOI 10.1002/hbm.20160; SAMBATARO F, 2008, NEUROBIOLOG IN PRESS; SCHONING S, 2009, HUMAN BRAIN IN PRESS; SHEHZAD Z, 2009, CEREB CORTE IN PRESS; Sheline YI, 2009, P NATL ACAD SCI USA, V106, P1942, DOI 10.1073/pnas.0812686106; Shulman GL, 1997, CEREB CORTEX, V7, P193, DOI 10.1093/cercor/7.3.193; Smith APR, 2004, NEUROIMAGE, V22, P868, DOI 10.1016/j.neuroimage.2004.01.049; TEASDALE JD, 1995, MEM COGNITION, V23, P551, DOI 10.3758/BF03197257; Thomason ME, 2008, NEUROIMAGE, V41, P1493, DOI 10.1016/j.neuroimage.2008.03.029; van de Ven VG, 2004, HUM BRAIN MAPP, V22, P165, DOI 10.1002/hbm.20022; VANDENHEUVEL MP, 2009, HUMAN BRAIN IN PRESS; Waites AB, 2005, HUM BRAIN MAPP, V24, P59, DOI 10.1002/hbm.20069; Wig GS, 2008, P NATL ACAD SCI USA, V105, P18555, DOI 10.1073/pnas.0804546105; Wittchen H.-U., 1997, SKID 1 STRUKTURIERTE; YAN H, 2009, NEUROIMAGE IN PRESS	59	85	88	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7198	10.1371/journal.pone.0007198	http://dx.doi.org/10.1371/journal.pone.0007198			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779619	gold, Green Published, Green Submitted			2022-12-27	WOS:000270176200021
J	Quan, FS; Kim, YC; Yoo, DG; Compans, RW; Prausnitz, MR; Kang, SM				Quan, Fu-Shi; Kim, Yeu-Chun; Yoo, Dae-Goon; Compans, Richard W.; Prausnitz, Mark R.; Kang, Sang-Moo			Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin	PLOS ONE			English	Article								Background: Simple and effective vaccine administration is particularly important for annually recommended influenza vaccination. We hypothesized that vaccine delivery to the skin using a patch containing vaccine-coated microneedles could be an attractive approach to improve influenza vaccination compliance and efficacy. Methodology/Principal Findings: Solid microneedle arrays coated with inactivated influenza vaccine were prepared for simple vaccine delivery to the skin. However, the stability of the influenza vaccine, as measured by hemagglutination activity, was found to be significantly damaged during microneedle coating. The addition of trehalose to the microneedle coating formulation retained hemagglutination activity, indicating stabilization of the coated influenza vaccine. For both intramuscular and microneedle skin immunization, delivery of un-stabilized vaccine yielded weaker protective immune responses including viral neutralizing antibodies, protective efficacies, and recall immune responses to influenza virus. Immunization using un-stabilized vaccine also shifted the pattern of antibody isotypes compared to the stabilized vaccine. Importantly, a single microneedle-based vaccination using stabilized influenza vaccine was found to be superior to intramuscular immunization in controlling virus replication as well as in inducing rapid recall immune responses post challenge. Conclusions/Significance: The functional integrity of hemagglutinin is associated with inducing improved protective immunity against influenza. Simple microneedle influenza vaccination in the skin produced superior protection compared to conventional intramuscular immunization. This approach is likely to be applicable to other vaccines too.			Quan, FS (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.	Compans@microbio.emory.edu; prausnitz@gatech.edu; skang2@emory.edu	Kim, Yeu Chun/B-3389-2012; Quan, Fu-Shi/V-1826-2019; Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X; Prausnitz, Mark/0000-0002-9076-8448	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI074579, R01AI068003, U54AI057157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006369] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI074579-04, U01 AI074579-01, R01 AI068003-03, R01 AI068003-01, R01 AI068003-04, AI057157, R01 AI068003-02, R01 AI068003-05, U01 AI074579-03, U01 AI074579, R01 AI068003, U01 AI074579-02, AI0680003, U54 AI057157] Funding Source: Medline; NIBIB NIH HHS [R01 EB006369-01A1, R01 EB006369, R01 EB006369-02S1, EB006369] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alarcon JB, 2007, CLIN VACCINE IMMUNOL, V14, P375, DOI 10.1128/CVI.00387-06; Amorij JP, 2007, VACCINE, V25, P6447, DOI 10.1016/j.vaccine.2007.06.054; Auewarakul P, 2007, VACCINE, V25, P659, DOI 10.1016/j.vaccine.2006.08.026; Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555; Belshe RB, 2007, VACCINE, V25, P6755, DOI 10.1016/j.vaccine.2007.06.066; Belyakov IM, 2004, J CLIN INVEST, V113, P998, DOI 10.1172/JCI200420261; Beran J, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-13; Bright RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001501; Bright RA, 2007, VACCINE, V25, P3871, DOI 10.1016/j.vaccine.2007.01.106; Chen DX, 2000, NAT MED, V6, P1187, DOI 10.1038/80538; Chiu SS, 2007, PEDIATRICS, V119, P1076, DOI 10.1542/peds.2006-3176; COMPANS RW, 1970, VIROLOGY, V42, P880, DOI 10.1016/0042-6822(70)90337-5; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; DEBECKER G, 1994, EUR J IMMUNOL, V24, P1523, DOI 10.1002/eji.1830240710; Deng YP, 1997, J IMMUNOL, V158, P1507; FAZEKAS G, 1994, EUR J IMMUNOL, V24, P3063, DOI 10.1002/eji.1830241222; Flacher V, 2006, J IMMUNOL, V177, P7959, DOI 10.4049/jimmunol.177.11.7959; Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138; Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Gill HS, 2007, PHARM RES, V24, P1369, DOI 10.1007/s11095-007-9286-4; Gill HS, 2007, J CONTROL RELEASE, V117, P227, DOI 10.1016/j.jconrel.2006.10.017; Glenn G M, 1999, Expert Opin Investig Drugs, V8, P797, DOI 10.1517/13543784.8.6.797; Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225; Guebre-Xabier M, 2003, J VIROL, V77, P5218, DOI 10.1128/JVI.77.9.5218-5225.2003; HEUSSER CH, 1977, J EXP MED, V145, P1316, DOI 10.1084/jem.145.5.1316; Holland D, 2008, J INFECT DIS, V198, P650, DOI 10.1086/590434; Hon H, 2004, IMMUNOL RES, V29, P69, DOI 10.1385/IR:29:1-3:069; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Jayasekera JP, 2007, J VIROL, V81, P3487, DOI 10.1128/JVI.02128-06; Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540; Khanlou H, 2006, ARCH INTERN MED, V166, P1417, DOI 10.1001/archinte.166.13.1417; Koutsonanos DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004773; La Montagne JR, 2004, NEW ENGL J MED, V351, P2330, DOI 10.1056/NEJMe048314; Markine-Goriaynoff D, 2000, INT IMMUNOL, V12, P223, DOI 10.1093/intimm/12.2.223; Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040; Mitsui H, 2004, J INVEST DERMATOL, V122, P95, DOI 10.1046/j.0022-202X.2003.22116.x; Mozdzanowska K, 2006, VIROLOGY, V352, P418, DOI 10.1016/j.virol.2006.05.008; NEUBERGER MS, 1981, EUR J IMMUNOL, V11, P1012, DOI 10.1002/eji.1830111212; Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201; NOVAK M, 1993, VACCINE, V11, P55, DOI 10.1016/0264-410X(93)90339-Y; Oran AE, 2003, J IMMUNOL, V171, P1999, DOI 10.4049/jimmunol.171.4.1999; Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x; Quan FS, 2009, J VIROL, V83, P4489, DOI 10.1128/JVI.02035-08; Quan FS, 2008, J VIROL, V82, P1350, DOI 10.1128/JVI.01615-07; Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06; Rappuoli R, 2007, NAT BIOTECHNOL, V25, P1361, DOI 10.1038/nbt1207-1361; SCHULZE IT, 1970, VIROLOGY, V42, P890, DOI 10.1016/0042-6822(70)90338-7; Sha Z, 2000, J VIROL, V74, P4999, DOI 10.1128/JVI.74.11.4999-5005.2000; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Sugimura T, 2008, VACCINE, V26, P2700, DOI 10.1016/j.vaccine.2008.03.016; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Tumpey TM, 2005, J VIROL, V79, P14933, DOI 10.1128/JVI.79.23.14933-14944.2005; Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001; Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077; Van Reeth K, 2002, VIRAL IMMUNOL, V15, P583, DOI 10.1089/088282402320914520; Zhu QY, 2009, P NATL ACAD SCI USA, V106, P7968, DOI 10.1073/pnas.0812652106	57	84	90	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7152	10.1371/journal.pone.0007152	http://dx.doi.org/10.1371/journal.pone.0007152			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779615	Green Submitted, Green Published, gold			2022-12-27	WOS:000270176200007
J	Ladroue, C; Guo, SX; Kendrick, K; Feng, JF				Ladroue, Christophe; Guo, Shuixia; Kendrick, Keith; Feng, Jianfeng			Beyond Element-Wise Interactions: Identifying Complex Interactions in Biological Processes	PLOS ONE			English	Article							LINEAR-DEPENDENCE; CAUSALITY; FEEDBACK; DATABASE; TOOLS	Background: Biological processes typically involve the interactions of a number of elements (genes, cells) acting on each others. Such processes are often modelled as networks whose nodes are the elements in question and edges pairwise relations between them (transcription, inhibition). But more often than not, elements actually work cooperatively or competitively to achieve a task. Or an element can act on the interaction between two others, as in the case of an enzyme controlling a reaction rate. We call "complex'' these types of interaction and propose ways to identify them from time-series observations. Methodology: We use Granger Causality, a measure of the interaction between two signals, to characterize the influence of an enzyme on a reaction rate. We extend its traditional formulation to the case of multi-dimensional signals in order to capture group interactions, and not only element interactions. Our method is extensively tested on simulated data and applied to three biological datasets: microarray data of the Saccharomyces cerevisiae yeast, local field potential recordings of two brain areas and a metabolic reaction. Conclusions: Our results demonstrate that complex Granger causality can reveal new types of relation between signals and is particularly suited to biological data. Our approach raises some fundamental issues of the systems biology approach since finding all complex causalities (interactions) is an NP hard problem.			Ladroue, C (corresponding author), Univ Warwick, Dept Math & Comp Sci, Coventry CV4 7AL, W Midlands, England.	Jianfeng.Feng@warwick.ac.uk		feng, jianfeng/0000-0002-9328-5732; Kendrick, Keith/0000-0002-0371-5904	EPSRC [EP/E002331/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/E002331/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Aebersold R, 2000, NAT BIOTECHNOL, V18, P359, DOI 10.1038/74325; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Chen YH, 2006, J NEUROSCI METH, V150, P228, DOI 10.1016/j.jneumeth.2005.06.011; David O, 2008, PLOS BIOL, V6, P2683, DOI 10.1371/journal.pbio.0060315; Ding M, 2006, HDB TIME SERIES ANAL, DOI [DOI 10.1002/9783527609970, 10.1002/9783527609970]; Fletcher M, 2008, NEURAL NETWORKS, V21, P1076, DOI 10.1016/j.neunet.2008.06.009; Friston K., 2009, PLOS BIOL, V7; GEWEKE J, 1982, J AM STAT ASSOC, V77, P304, DOI 10.2307/2287238; GEWEKE JF, 1984, J AM STAT ASSOC, V79, P907, DOI 10.2307/2288723; Gourevitch B, 2006, BIOL CYBERN, V95, P349, DOI 10.1007/s00422-006-0098-0; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; GRANGER CWJ, 1980, J ECON DYN CONTROL, V2, P329, DOI 10.1016/0165-1889(80)90069-X; Guo SX, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000087; Horn R.A., 2013, MATRIX ANAL, P321; Kahvejian A, 2008, NAT BIOTECHNOL, V26, P1125, DOI 10.1038/nbt1494; Klamt S, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000385; KOSSLYN SM, 1998, FUNDAMENTAL NEUROSCI, P1521; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Mukherjee S, 2008, P NATL ACAD SCI USA, V105, P14313, DOI 10.1073/pnas.0802272105; NEEDHAM CJ, 2007, PLOS COMPUTATIONAL B, V3; PARKINSON H, 2008, NUCLEIC ACIDS RES; Peirce JW, 2000, NEUROPSYCHOLOGIA, V38, P475, DOI 10.1016/S0028-3932(99)00088-3; Royer L, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000108; Sachs K, 2005, SCIENCE, V308, P523, DOI 10.1126/science.1105809; Shendure J, 2008, NAT METHODS, V5, P585, DOI 10.1038/nmeth0708-585; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tate AJ, 2006, PHILOS T R SOC B, V361, P2155, DOI 10.1098/rstb.2006.1937; TEIXEIRA MC, 2006, NUCL ACIDS RES, V34; Timmer, 2006, HDB TIME SERIES ANAL, P335, DOI [10.1002/9783527609970.ch14, DOI 10.1002/9783527609970.CH14]; Wang RS, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-391; Wiener N, 1956, MODERN MATH ENG; Wu JH, 2008, J NEUROSCI METH, V167, P367, DOI 10.1016/j.jneumeth.2007.08.022; Yu J, 2004, BIOINFORMATICS, V20, P3594, DOI 10.1093/bioinformatics/bth448; ZOU CL, 2009, BMC BIOINFORMATICS, V10	35	31	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e6899	10.1371/journal.pone.0006899	http://dx.doi.org/10.1371/journal.pone.0006899			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774090	Green Submitted, Green Published, gold			2022-12-27	WOS:000270160900001
J	Wodarczyk, C; Rowe, I; Chiaravalli, M; Pema, M; Qian, F; Boletta, A				Wodarczyk, Claas; Rowe, Isaline; Chiaravalli, Marco; Pema, Monika; Qian, Feng; Boletta, Alessandra			A Novel Mouse Model Reveals that Polycystin-1 Deficiency in Ependyma and Choroid Plexus Results in Dysfunctional Cilia and Hydrocephalus	PLOS ONE			English	Article							KIDNEY-DISEASE; CYST FORMATION; PKD1; GENE; EXPRESSION; DEFECTS; RECEPTOR; CLEAVAGE; MICE; MECHANOSENSATION	Polycystin-1 (PC-1), the product of the PKD1 gene, mutated in the majority of cases of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is a very large (similar to 520 kDa) plasma membrane receptor localized in several subcellular compartments including cell-cell/matrix junctions as well as cilia. While heterologous over-expression systems have allowed identification of several of the potential biological roles of this receptor, its precise function remains largely elusive. Studying PC-1 in vivo has been a challenging task due to its complexity and low expression levels. To overcome these limitations and facilitate the study of endogenous PC-1, we have inserted HA-or Myc-tag sequences into the Pkd1 locus by homologous recombination. Here, we show that our approach was successful in generating a fully functional and easily detectable endogenous PC-1. Characterization of PC-1 distribution in vivo showed that it is expressed ubiquitously and is developmentally-regulated in most tissues. Furthermore, our novel tool allowed us to investigate the role of PC-1 in brain, where the protein is abundantly expressed. Subcellular localization of PC-1 revealed strong and specific staining in ciliated ependymal and choroid plexus cells. Consistent with this distribution, we observed hydrocephalus formation both in the ubiquitous knock-out embryos and in newborn mice with conditional inactivation of the Pkd1 gene in the brain. Both choroid plexus and ependymal cilia were morphologically normal in these mice, suggesting a role for PC-1 in ciliary function or signalling in this compartment, rather than in ciliogenesis. We propose that the role of PC-1 in the brain cilia might be to prevent hydrocephalus, a previously unrecognized role for this receptor and one that might have important implications for other genetic or sporadic diseases.			Wodarczyk, C (corresponding author), Ist Sci San Raffaele, Dulbecco Telethon Inst DTI Dibit, I-20132 Milan, Italy.	boletta.alessandra@hsr.it	rowe, isaline/AAN-1985-2020	rowe, isaline/0000-0002-5398-1776; chiaravalli, marco/0000-0003-0369-1989	NIDDK NIH HHS [R01 DK062199, DK062199] Funding Source: Medline; Telethon [GTF07004, TCR07005] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062199] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen E, 2006, HUM MOL GENET, V15, P11, DOI 10.1093/hmg/ddi421; Banizs B, 2005, DEVELOPMENT, V132, P5329, DOI 10.1242/dev.02153; Banizs B, 2007, AM J PHYSIOL-CELL PH, V292, pC1409, DOI 10.1152/ajpcell.00408.2006; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boca M, 2007, MOL BIOL CELL, V18, P4050, DOI 10.1091/mbc.E07-02-0142; Boca M, 2006, J AM SOC NEPHROL, V17, P637, DOI 10.1681/ASN.2005050534; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753; Distefano G, 2009, MOL CELL BIOL, V29, P2359, DOI 10.1128/MCB.01259-08; Driscoll JA, 2008, CHEST, V133, P1181, DOI 10.1378/chest.07-2147; Fliegauf M, 2007, NAT REV MOL CELL BIO, V8, P880, DOI 10.1038/nrm2278; Forni PE, 2006, J NEUROSCI, V26, P9593, DOI 10.1523/JNEUROSCI.2815-06.2006; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Huang K, 2007, J CELL BIOL, V179, P501, DOI 10.1083/jcb.200704069; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibanez-Tallon I, 2004, HUM MOL GENET, V13, P2133, DOI 10.1093/hmg/ddh219; Jiang ST, 2006, AM J PATHOL, V168, P205, DOI 10.2353/ajpath.2006.050342; Joly D, 2006, J BIOL CHEM, V281, P26329, DOI 10.1074/jbc.M601373200; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Lantinga-van Leeuwen IS, 2007, HUM MOL GENET, V16, P3188, DOI 10.1093/hmg/ddm299; Lechtreck KF, 2008, J CELL BIOL, V180, P633, DOI 10.1083/jcb.200710162; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Li XG, 2005, NAT CELL BIOL, V7, P1202, DOI 10.1038/ncb1326; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Low SH, 2006, DEV CELL, V10, P57, DOI 10.1016/j.devcel.2005.12.005; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385; Michaud EJ, 2006, CANCER RES, V66, P6463, DOI 10.1158/0008-5472.CAN-06-0462; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nauli SM, 2006, J AM SOC NEPHROL, V17, P1015, DOI 10.1681/ASN.2005080830; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Roitbak T, 2004, MOL BIOL CELL, V15, P1334, DOI 10.1091/mbc.E03-05-0296; Schaft J, 2001, GENESIS, V31, P6, DOI 10.1002/gene.1076; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; Spassky N, 2005, J NEUROSCI, V25, P10, DOI 10.1523/JNEUROSCI.1108-04.2005; STURROCK RR, 1979, J ANAT, V129, P777; Thivierge C, 2006, MOL CELL BIOL, V26, P1538, DOI 10.1128/MCB.26.4.1538-1548.2006; Torres VE, 2007, LANCET, V369, P1287, DOI 10.1016/S0140-6736(07)60601-1; Town T, 2008, P NATL ACAD SCI USA, V105, P2853, DOI 10.1073/pnas.0712385105; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Yu SQ, 2007, P NATL ACAD SCI USA, V104, P18688, DOI 10.1073/pnas.0708217104	48	66	67	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7137	10.1371/journal.pone.0007137	http://dx.doi.org/10.1371/journal.pone.0007137			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774080	gold, Green Published			2022-12-27	WOS:000270160900015
J	Cho, JS; Kim, YC; Morrison, SL				Cho, John S.; Kim, Yun C.; Morrison, Sherie L.			Inhibitors of MyD88-Dependent Proinflammatory Cytokine Production Identified Utilizing a Novel RNA Interference Screening Approach	PLOS ONE			English	Article								Background: The events required to initiate host defenses against invading pathogens involve complex signaling cascades comprised of numerous adaptor molecules, kinases, and transcriptional elements, ultimately leading to the production of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha). How these signaling cascades are regulated, and the proteins and regulatory elements participating are still poorly understood. Results: We report here the development a completely random short-hairpin RNA (shRNA) library coupled with a novel forward genetic screening strategy to identify inhibitors of Toll-like receptor (TLR) dependent proinflammatory responses. We developed a murine macrophage reporter cell line stably transfected with a construct expressing diphtheria toxin-A (DT-A) under the control of the TNF-alpha-promoter. Stimulation of the reporter cell line with the TLR ligand lipopolysaccharide (LPS) resulted in DT-A induced cell death, which could be prevented by the addition of an shRNA targeting the TLR adaptor molecule MyD88. Utilizing this cell line, we screened a completely random lentiviral short hairpin RNA (shRNA) library for sequences that inhibited TLR-mediated TNF-alpha production. Recovery of shRNA sequences from surviving cells led to the identification of unique shRNA sequences that significantly inhibited TLR4-dependent TNF-alpha gene expression. Furthermore, these shRNA sequences specifically blocked TLR2 but not TLR3-dependent TNF-alpha production. Conclusions: Thus, we describe the generation of novel tools to facilitate large-scale forward genetic screens in mammalian cells and the identification of potent shRNA inhibitors of TLR2 and TLR4-dependent proinflammatory responses.			Cho, JS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	johncho@ucla.edu			NCI NIH HHS [T32 CA009120, 5 T32 CA009120: 32] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi H, 2005, MOL BIOSYST, V1, P382, DOI 10.1039/b510159j; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Amarzguioui M, 2003, NUCLEIC ACIDS RES, V31, P589, DOI 10.1093/nar/gkg147; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Diederichs S, 2008, P NATL ACAD SCI USA, V105, P9284, DOI 10.1073/pnas.0800803105; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Du C, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-28; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Li Y, 2002, CANCER RES, V62, P2576; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Luo B, 2004, P NATL ACAD SCI USA, V101, P5494, DOI 10.1073/pnas.0400551101; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	44	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7029	10.1371/journal.pone.0007029	http://dx.doi.org/10.1371/journal.pone.0007029			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753301	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796500014
J	Das, A; Bellofatto, V				Das, Anish; Bellofatto, Vivian			The Non-Canonical CTD of RNAP-II Is Essential for Productive RNA Synthesis in Trypanosoma brucei	PLOS ONE			English	Article								The carboxy-terminal domain (CTD) of the largest subunit (RPB1) of RNA polymerase II (RNAP-II) is essential for gene expression in metazoa and yeast. The canonical CTD is characterized by heptapeptide repeats. Differential phosphorylation of canonical CTD orchestrates transcriptional and co-transcriptional maturation of mRNA and snRNA. Many organisms, including trypanosomes, lack a canonical CTD. In these organisms, the CTD is called a non-canonical CTD or pseudo-CTD (Psi CTD. In the African trypanosome, Trypanosoma brucei, the Psi CTD is similar to 285 amino acids long, rich in serines and prolines, and phosphorylated. We report that T. brucei RNAP-II lacking the entire Psi CTD or containing only a 95-amino-acid-long Psi CTD failed to support cell viability. In contrast, RNAP-II with a 186-amino-acid-long Psi CTD maintained cellular growth. RNAP-II with Psi CTD truncations resulted in abortive initiation of transcription. These data establish that non-canonical CTDs play an important role in gene expression.			Das, A (corresponding author), Univ Med & Dent New Jersey, Sch Dent, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.	A.Das-dasak@umdnj.edu; bellofat@umdnj.edu			NIAID NIH HHS [R01 AI029478, AI535835, AI29478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BANGS JD, 1992, J BIOL CHEM, V267, P9805; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; Chapman RD, 2005, MOL CELL BIOL, V25, P7665, DOI 10.1128/MCB.25.17.7665-7674.2005; Chapman RD, 2004, NUCLEIC ACIDS RES, V32, P35, DOI 10.1093/nar/gkh172; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; Cramer P, 2008, ANNU REV BIOPHYS, V37, P337, DOI 10.1146/annurev.biophys.37.032807.130008; Dacks JB, 2002, MOL BIOL EVOL, V19, P830, DOI 10.1093/oxfordjournals.molbev.a004140; Das A, 2005, MOL CELL BIOL, V25, P7314, DOI 10.1128/MCB.25.16.7314-7322.2005; Das A, 2006, MOL BIOCHEM PARASIT, V150, P201, DOI 10.1016/j.molbiopara.2006.08.002; Devaux S, 2006, MOL BIOCHEM PARASIT, V148, P60, DOI 10.1016/j.molbiopara.2006.02.020; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; Gilinger G, 2001, NUCLEIC ACIDS RES, V29, P1556, DOI 10.1093/nar/29.7.1556; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; Guo ZH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-69; Lustig Y, 2007, EMBO REP, V8, P408, DOI 10.1038/sj.embor.7400930; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Patrick KL, 2008, MOL MICROBIOL, V67, P435, DOI 10.1111/j.1365-2958.2007.06057.x; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Sambrook J., 2001, MOL CLONING; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schumacher MA, 2003, CELL, V115, P413, DOI 10.1016/S0092-8674(03)00887-0; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Smith ER, 2008, P NATL ACAD SCI USA, V105, P8575, DOI 10.1073/pnas.0804379105; SMITH JL, 1989, CELL, V56, P815, DOI 10.1016/0092-8674(89)90686-7; Stiller JW, 1998, P NATL ACAD SCI USA, V95, P11769, DOI 10.1073/pnas.95.20.11769; Thomas S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-152; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yurchenko VY, 2006, PARASITOLOGY, V133, P537, DOI 10.1017/S0031182006000746	35	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6959	10.1371/journal.pone.0006959	http://dx.doi.org/10.1371/journal.pone.0006959			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742309	Green Submitted, gold, Green Published			2022-12-27	WOS:000269622500020
J	Gravlee, CC; Non, AL; Mulligan, CJ				Gravlee, Clarence C.; Non, Amy L.; Mulligan, Connie J.			Genetic Ancestry, Social Classification, and Racial Inequalities in Blood Pressure in Southeastern Puerto Rico	PLOS ONE			English	Article							SKIN COLOR; POPULATION-STRUCTURE; AFRICAN-AMERICANS; RACE; HEALTH; ADMIXTURE; ETHNICITY; DISPARITIES; HYPERTENSION; ENVIRONMENT	Background: The role of race in human genetics and biomedical research is among the most contested issues in science. Much debate centers on the relative importance of genetic versus sociocultural factors in explaining racial inequalities in health. However, few studies integrate genetic and sociocultural data to test competing explanations directly. Methodology/Principal Findings: We draw on ethnographic, epidemiologic, and genetic data collected in southeastern Puerto Rico to isolate two distinct variables for which race is often used as a proxy: genetic ancestry versus social classification. We show that color, an aspect of social classification based on the culturally defined meaning of race in Puerto Rico, better predicts blood pressure than does a genetic-based estimate of continental ancestry. We also find that incorporating sociocultural variables reveals a new and significant association between a candidate gene polymorphism for hypertension (alpha(2C) adrenergic receptor deletion) and blood pressure. Conclusions/Significance: This study addresses the recognized need to measure both genetic and sociocultural factors in research on racial inequalities in health. Our preliminary results provide the most direct evidence to date that previously reported associations between genetic ancestry and health may be attributable to sociocultural factors related to race and racism, rather than to functional genetic differences between racially defined groups. Our results also imply that including sociocultural variables in future research may improve our ability to detect significant allele-phenotype associations. Thus, measuring sociocultural factors related to race may both empower future genetic association studies and help to clarify the biological consequences of social inequalities.			Gravlee, CC (corresponding author), Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA.	cgravlee@ufl.edu	Non, Amy/AAW-7116-2021; Gravlee, Clarence C/A-2249-2009	Gravlee, Clarence C/0000-0002-0913-2320				*AM J PUBL HLTH, 2005, AM J PUBLIC HLTH, V95; *AM PSYCH, 2005, AM PSYCHOL, V60; Anwar, 1998, Blood Press Monit, V3, P261; Boks MPM, 2007, INT J EPIDEMIOL, V36, P1363, DOI 10.1093/ije/dym215; Bonilla C, 2004, HUM GENET, V115, P57, DOI 10.1007/s00439-004-1125-7; BOYLE E, 1970, J AMER MED ASSOC, V213, P1637, DOI 10.1001/jama.213.10.1637; Braun L, 2006, INT J HEALTH SERV, V36, P557, DOI 10.2190/8JAF-D8ED-8WPD-J9WH; Braveman P, 2001, PUBLIC HEALTH REP, V116, P449, DOI 10.1093/phr/116.5.449; Brondolo E, 2003, ANN BEHAV MED, V25, P55, DOI 10.1207/S15324796ABM2501_08; Brondolo E, 2008, PSYCHOSOM MED, V70, P49, DOI 10.1097/PSY.0b013e31815ff3bd; Burchard EG, 2005, AM J PUBLIC HEALTH, V95, P2161, DOI 10.2105/AJPH.2005.068668; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Caulfield T, 2009, GENOME MED, V1, DOI 10.1186/gm8; CHAKRABORTY R, 1992, AM J HUM GENET, V50, P145; Choudhry S, 2006, AM J RESP CRIT CARE, V174, P1086, DOI [10.1164/RCCM.200605-596OC, 10.1164/rccm.200605-596OC]; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Cooper RS, 2003, ANN INTERN MED, V139, P437, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00011; COSTAS R, 1981, AM J PUBLIC HEALTH, V71, P614, DOI 10.2105/AJPH.71.6.614; Deo RC, 2007, PLOS GENET, V3, P2200, DOI 10.1371/journal.pgen.0030196; DRESSLER W W, 1991, Ethnicity and Disease, V1, P60; Dressler WW, 2005, ANNU REV ANTHROPOL, V34, P231, DOI 10.1146/annurev.anthro.34.081804.120505; Farmer MM, 2005, SOC SCI MED, V60, P191, DOI 10.1016/j.socscimed.2004.04.026; Fernandez JR, 2003, OBES RES, V11, P904, DOI 10.1038/oby.2003.124; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Frisancho AR, 1999, AM J HUM BIOL, V11, P489, DOI 10.1002/(SICI)1520-6300(1999)11:4<489::AID-AJHB8>3.0.CO;2-S; Fyr CLW, 2007, HUM GENET, V121, P615, DOI 10.1007/s00439-007-0353-z; GLEIBERMAN L, 1999, NATIVITY RACE RESPON, V34, pE7; Glover M. J., 2005, Morbidity and Mortality Weekly Report, V54, P7; Godreau IP, 2008, CENTRO J, V20; Goodman E, 2005, J ADOLESCENT HEALTH, V37, P484, DOI 10.1016/j.jadohealth.2004.11.126; Gower BA, 2003, DIABETES, V52, P1047, DOI 10.2337/diabetes.52.4.1047; Gravlee CC, 2005, AM J PUBLIC HEALTH, V95, P2191, DOI 10.2105/AJPH.2005.065615; Gravlee CC, 2005, AM J HUM BIOL, V17, P195, DOI 10.1002/ajhb.20111; Gravlee CC, 2005, SOC FORCES, V83, P949, DOI 10.1353/sof.2005.0033; Gravlee CC, 2008, MED ANTHROPOL Q, V22, P27, DOI 10.1111/j.1548-1387.2008.00002.x; Gravlee CC, 2009, AM J PHYS ANTHROPOL, V139, P47, DOI 10.1002/ajpa.20983; Halberstein RA, 1999, HUM BIOL, V71, P659; HARBURG E, 1978, AM J PUBLIC HEALTH, V68, P1177, DOI 10.2105/AJPH.68.12.1177; Harrell JP, 2003, AM J PUBLIC HEALTH, V93, P243, DOI 10.2105/AJPH.93.2.243; HERRING C, 2004, SKIN DEEP RACE COMPL, P248; JAMES S A, 1991, Ethnicity and Disease, V1, P91; Jones CP, 2008, ETHNIC DIS, V18, P496; Kaufman JS, 2008, ANN EPIDEMIOL, V18, P119, DOI 10.1016/j.annepidem.2007.09.002; Kaufman JS, 2001, AM J EPIDEMIOL, V154, P291, DOI 10.1093/aje/154.4.291; Krieger N, 2005, AM J PUBLIC HEALTH, V95, P2155, DOI 10.2105/AJPH.2005.067108; Krieger N, 2003, AM J PUBLIC HEALTH, V93, P194, DOI 10.2105/AJPH.93.2.194; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Li JL, 2006, HYPERTENSION, V47, P1140, DOI 10.1161/01.HYP.0000217972.80731.ef; McKeigue PM, 2000, ANN HUM GENET, V64, P171, DOI 10.1017/S0003480000008022; MINTZ SW, 1974, CARIBBEAN TRANSFORMA, P355; *NAT GEN, 2004, NAT GENET, V36; O'Brien E, 2001, BMJ-BRIT MED J, V322, P531, DOI 10.1136/bmj.322.7285.531; Pan American Health Organization, 2007, HLTH AM; Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100; Penner AM, 2008, P NATL ACAD SCI USA, V105, P19628, DOI 10.1073/pnas.0805762105; Peralta CA, 2006, J AM SOC NEPHROL, V17, P3491, DOI 10.1681/ASN.2006050493; Pfaff CL, 2001, AM J HUM GENET, V68, P198, DOI 10.1086/316935; Pfaff CL, 2004, GENET EPIDEMIOL, V26, P305, DOI 10.1002/gepi.10319; Pritchard JK, 2000, GENETICS, V155, P945; RACE E, 2005, AM J HUM GENET, V77, P519; Rebbeck TR, 2005, CANCER EPIDEM BIOMAR, V14, P2467, DOI 10.1158/1055-9965.EPI-05-0649; Reiner AP, 2007, HUM GENET, V121, P565, DOI 10.1007/s00439-007-0350-2; Risch N., 2002, GENOME BIOL, V3; ROMNEY AK, 1986, AM ANTHROPOL, V88, P313, DOI 10.1525/aa.1986.88.2.02a00020; Sankar P, 2004, JAMA-J AM MED ASSOC, V291, P2985, DOI 10.1001/jama.291.24.2985; Sankar P, 2002, SCIENCE, V298, P1337, DOI 10.1126/science.1074447; Sankar P, 2007, AM J MED GENET A, V143A, P961, DOI 10.1002/ajmg.a.31575; SCARANO FA, 1984, SUGAR SLAVERY PUERTO, P1800; Sweet E, 2007, AM J PUBLIC HEALTH, V97, P2253, DOI 10.2105/AJPH.2006.088799; Tang H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888; Tang H, 2006, HUM GENET, V119, P624, DOI 10.1007/s00439-006-0175-4; TYROLER HA, 1978, AM J PUBLIC HEALTH, V68, P1170, DOI 10.2105/AJPH.68.12.1170; *US BUR CENS, 2001, PROF GEN DEM CHAR CE, P320; VAZQUEZ MM, 1999, DISCRIMEN RAZON RAZA; Williams DR, 2009, J BEHAV MED, V32, P20, DOI 10.1007/s10865-008-9185-0; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3; Williams DR, 2005, HEALTH AFFAIR, V24, P325, DOI 10.1377/hlthaff.24.2.325; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	79	61	61	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6821	10.1371/journal.pone.0006821	http://dx.doi.org/10.1371/journal.pone.0006821			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	491ZI	19742303	Green Published, gold			2022-12-27	WOS:000269622500001
J	Kuroda, A; Rauch, TA; Todorov, I; Ku, HT; Al-Abdullah, IH; Kandeel, F; Mullen, Y; Pfeifer, GP; Ferreri, K				Kuroda, Akio; Rauch, Tibor A.; Todorov, Ivan; Ku, Hsun Teresa; Al-Abdullah, Ismail H.; Kandeel, Fouad; Mullen, Yoko; Pfeifer, Gerd P.; Ferreri, Kevin			Insulin Gene Expression Is Regulated by DNA Methylation	PLOS ONE			English	Article							PROINSULIN BIOSYNTHESIS; BETA-CELLS; BINDING PROTEIN; INS2 LOCUS; CHROMATIN; TRANSCRIPTION; ACTIVATION; PROMOTER; GLUCOSE; 5-METHYLCYTOSINE	Background: Insulin is a critical component of metabolic control, and as such, insulin gene expression has been the focus of extensive study. DNA sequences that regulate transcription of the insulin gene and the majority of regulatory factors have already been identified. However, only recently have other components of insulin gene expression been investigated, and in this study we examine the role of DNA methylation in the regulation of mouse and human insulin gene expression. Methodology/Principal Findings: Genomic DNA samples from several tissues were bisulfite-treated and sequenced which revealed that cytosine-guanosine dinucleotide (CpG) sites in both the mouse Ins2 and human INS promoters are uniquely demethylated in insulin-producing pancreatic beta cells. Methylation of these CpG sites suppressed insulin promoter-driven reporter gene activity by almost 90% and specific methylation of the CpG site in the cAMP responsive element (CRE) in the promoter alone suppressed insulin promoter activity by 50%. Methylation did not directly inhibit factor binding to the CRE in vitro, but inhibited ATF2 and CREB binding in vivo and conversely increased the binding of methyl CpG binding protein 2 (MeCP2). Examination of the Ins2 gene in mouse embryonic stem cell cultures revealed that it is fully methylated and becomes demethylated as the cells differentiate into insulin-expressing cells in vitro. Conclusions/Significance: Our findings suggest that insulin promoter CpG demethylation may play a crucial role in beta cell maturation and tissue-specific insulin gene expression.			Kuroda, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka, Japan.	kferreri@coh.org		Ku, Hsun/0000-0001-5662-9893; Ferreri, Kevin/0000-0003-0379-0389	NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR016607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081587, R01DK056952] Funding Source: NIH RePORTER; NCRR NIH HHS [U42 RR16607, U42 RR016607] Funding Source: Medline; NIDDK NIH HHS [R01 DK081587, R01 DK056952, DK056952, 5R01DK081587-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu M, 2003, J BIOL CHEM, V278, P8739, DOI 10.1074/jbc.M211084200; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259; Dell G, 2001, Methods Mol Biol, V181, P251; DELTOUR L, 1995, DEV BIOL, V168, P686, DOI 10.1006/dbio.1995.1114; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Duvillie B, 1998, GENOMICS, V47, P52, DOI 10.1006/geno.1997.5070; Evans-Molina C, 2007, DIABETES, V56, P827, DOI 10.2337/db06-1440; Faideau B, 2005, DIABETES, V54, pS87, DOI 10.2337/diabetes.54.suppl_2.S87; FEIL R, 1994, DEVELOPMENT, V120, P2933; Francis J, 2005, J BIOL CHEM, V280, P36244, DOI 10.1074/jbc.M505741200; Francis J, 2006, MOL ENDOCRINOL, V20, P3133, DOI 10.1210/me.2006-0126; Gasa R, 2004, P NATL ACAD SCI USA, V101, P13245, DOI 10.1073/pnas.0405301101; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; Gu GQ, 2002, DEVELOPMENT, V129, P2447; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; Hay CW, 2007, BBA-GENE STRUCT EXPR, V1769, P79, DOI 10.1016/j.bbaexp.2007.01.005; Hay CW, 2006, DIABETES, V55, P3201, DOI 10.2337/db06-0788; Iannello RC, 2000, J BIOL CHEM, V275, P19603, DOI 10.1074/jbc.M001867200; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Ku HT, 2007, DIABETES, V56, P921, DOI 10.2337/db06-0468; Lamotte L, 2004, TRANSGENIC RES, V13, P463, DOI 10.1007/s11248-004-9587-x; Lee CS, 2002, GENE DEV, V16, P1488, DOI 10.1101/gad.985002; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lorenzo M, 2008, J Anim Sci, V86, pE94; Lukowiak B, 2001, J HISTOCHEM CYTOCHEM, V49, P519, DOI 10.1177/002215540104900412; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Moore GE, 2001, DIABETES, V50, P199, DOI 10.2337/diabetes.50.1.199; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; Palumbo MO, 2006, DIABETES, V55, P2595, DOI 10.2337/db05-1651; Poitout V, 2006, J NUTR, V136, P873, DOI 10.1093/jn/136.4.873; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Sharma RP, 2005, J PSYCHIATR NEUROSCI, V30, P257; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Todorov I, 2006, PANCREAS, V32, P130, DOI 10.1097/01.mpa.0000202945.78331.93; Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631; Uchizono Y, 2007, DIABETES OBES METAB, V9, P56, DOI 10.1111/j.1463-1326.2007.00774.x; Vu TH, 2000, GENOMICS, V64, P132, DOI 10.1006/geno.1999.6094; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; WU C, 1981, P NATL ACAD SCI-BIOL, V78, P1577, DOI 10.1073/pnas.78.3.1577; Youngren JF, 2007, CELL MOL LIFE SCI, V64, P873, DOI 10.1007/s00018-007-6359-9; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	51	212	234	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6953	10.1371/journal.pone.0006953	http://dx.doi.org/10.1371/journal.pone.0006953			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742322	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622500016
J	Fujita, K; Seike, T; Yutsudo, N; Ohno, M; Yamada, H; Yamaguchi, H; Sakumi, K; Yamakawa, Y; Kido, MA; Takaki, A; Katafuchi, T; Tanaka, Y; Nakabeppu, Y; Noda, M				Fujita, Kyota; Seike, Toshihiro; Yutsudo, Noriko; Ohno, Mizuki; Yamada, Hidetaka; Yamaguchi, Hiroo; Sakumi, Kunihiko; Yamakawa, Yukiko; Kido, Mizuho A.; Takaki, Atsushi; Katafuchi, Toshihiko; Tanaka, Yoshinori; Nakabeppu, Yusaku; Noda, Mami			Hydrogen in Drinking Water Reduces Dopaminergic Neuronal Loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Parkinson's Disease	PLOS ONE			English	Article								It has been shown that molecular hydrogen (H(2)) acts as a therapeutic antioxidant and suppresses brain injury by buffering the effects of oxidative stress. Chronic oxidative stress causes neurodegenerative diseases such as Parkinson's disease (PD). Here, we show that drinking H(2)-containing water significantly reduced the loss of dopaminergic neurons in PD model mice using both acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The concentration-dependency of H(2) showed that H(2) as low as 0.08 ppm had almost the same effect as saturated H(2) water (1.5 ppm). MPTP-induced accumulation of cellular 8-oxoguanine (8-oxoG), a marker of DNA damage, and 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation were significantly decreased in the nigro-striatal dopaminergic pathway in mice drinking H(2)-containing water, whereas production of superoxide (O(2)center dot(-)) detected by intravascular injection of dihydroethidium (DHE) was not reduced significantly. Our results indicated that low concentration of H(2) in drinking water can reduce oxidative stress in the brain. Thus, drinking H(2)-containing water may be useful in daily life to prevent or minimize the risk of life style-related oxidative stress and neurodegeneration.			Fujita, K (corresponding author), Kyushu Univ, Lab Pathophysiol, Grad Sch Pharmaceut Sci, Fukuoka 812, Japan.	noda@phar.kyushu-u.ac.jp	Noda, Mami/AAC-3949-2020; TANAKA, YOSHINORI/GNO-9581-2022; Nakabeppu, Yusaku/A-8902-2011; Sakumi, Kunihiko/G-4808-2011	TANAKA, YOSHINORI/0000-0003-1123-127X; Nakabeppu, Yusaku/0000-0002-6739-242X; 				Awasthi YC, 2008, FREE RADICAL BIO MED, V45, P111, DOI 10.1016/j.freeradbiomed.2008.04.007; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Betarbet R, 1997, J NEUROSCI, V17, P6761; Cai JM, 2008, NEUROSCI LETT, V441, P167, DOI 10.1016/j.neulet.2008.05.077; Chiba Y, 2005, J GERONTOL A-BIOL, V60, P1087, DOI 10.1093/gerona/60.9.1087; CRABBE JC, 1982, BEHAV BRAIN RES, V4, P289, DOI 10.1016/0166-4328(82)90006-7; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Drukarch B, 2001, EXPERT OPIN INV DRUG, V10, P1855, DOI 10.1517/13543784.10.10.1855; DU XY, 1995, BRAIN RES, V680, P229, DOI 10.1016/0006-8993(95)00215-C; Fornai F, 2005, P NATL ACAD SCI USA, V102, P3413, DOI 10.1073/pnas.0409713102; Franklin K. B. J., 2001, MOUSE BRAIN STEREOTA; Fukuda KI, 2007, BIOCHEM BIOPH RES CO, V361, P670, DOI 10.1016/j.bbrc.2007.07.088; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; GUTTERIDGE JMC, 1992, ANN NEUROL, V32, pS16, DOI 10.1002/ana.410320705; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Iida T, 2001, NEURO-ONCOLOGY, V3, P73, DOI 10.1093/neuonc/3.2.73; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Kajitani K, 2009, CELL DEATH DIFFER, V16, P417, DOI 10.1038/cdd.2008.162; KATAFUCHI T, 1985, BRAIN RES, V359, P1, DOI 10.1016/0006-8993(85)91406-4; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Kikuchi H, 2002, ACTA NEUROPATHOL, V103, P408, DOI 10.1007/s00401-001-0480-x; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Langston J.W., 2002, PARKINSONS DIS DIAGN; Liang LP, 2007, J NEUROSCI, V27, P4326, DOI 10.1523/JNEUROSCI.0019-07.2007; Liberatore GT, 1999, NAT MED, V5, P1403; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; Mallajosyula JK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001616; Meredith GE, 1999, EUR J NEUROSCI, V11, P3585, DOI 10.1046/j.1460-9568.1999.00774.x; Mitsumoto Y, 1998, BIOCHEM BIOPH RES CO, V248, P660, DOI 10.1006/bbrc.1998.8986; Mount MP, 2007, J NEUROSCI, V27, P3328, DOI 10.1523/JNEUROSCI.5321-06.2007; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; NICKLAS WJ, 1987, LIFE SCI, V40, P721, DOI 10.1016/0024-3205(87)90299-2; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Ohashi S, 2006, NEUROSCI LETT, V401, P183, DOI 10.1016/j.neulet.2006.03.017; Ohno M, 2009, METHODS MOL BIOL, V554, P199, DOI 10.1007/978-1-59745-521-3_13; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Oka S, 2008, EMBO J, V27, P421, DOI 10.1038/sj.emboj.7601975; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; OOBOSHI H, 1993, EUR J PHARMACOL, V233, P165, DOI 10.1016/0014-2999(93)90363-M; Petroske E, 2001, NEUROSCIENCE, V106, P589, DOI 10.1016/S0306-4522(01)00295-0; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Rommelfanger KS, 2007, P NATL ACAD SCI USA, V104, P13804, DOI 10.1073/pnas.0702753104; Sakamoto K, 2007, CANCER RES, V67, P6599, DOI 10.1158/0008-5472.CAN-06-4802; Sakumi K, 2003, CANCER RES, V63, P902; Sato Y, 2008, BIOCHEM BIOPH RES CO, V375, P346, DOI 10.1016/j.bbrc.2008.08.020; Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7; Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shimura-Miura H, 1999, ANN NEUROL, V46, P920, DOI 10.1002/1531-8249(199912)46:6<920::AID-ANA17>3.0.CO;2-R; Song DD, 2000, J NEUROSCI, V20, P5102; Stadler K, 2008, FREE RADICAL BIO MED, V45, P866, DOI 10.1016/j.freeradbiomed.2008.06.023; Thomas B, 2007, HUM MOL GENET, V16, pR183, DOI 10.1093/hmg/ddm159; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Yamaguchi H, 2006, CELL DEATH DIFFER, V13, P551, DOI 10.1038/sj.cdd.4401788; Yanagihara T, 2005, BIOSCI BIOTECH BIOCH, V69, P1985, DOI 10.1271/bbb.69.1985; Zhang W, 2004, FASEB J, V18, P589, DOI 10.1096/fj.03-0983fje; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	69	144	161	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7247	10.1371/journal.pone.0007247	http://dx.doi.org/10.1371/journal.pone.0007247			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789628	Green Published, gold			2022-12-27	WOS:000270354100012
J	Colombo, L; Zevin, J				Colombo, Lucia; Zevin, Jason			Stress Priming in Reading and the Selective Modulation of Lexical and Sub-Lexical Pathways	PLOS ONE			English	Article							VISUAL WORD RECOGNITION; STRATEGIC CONTROL; NAMING TASK; DUAL-ROUTE; ALOUD; CONSISTENCY; ASSIGNMENT; REGULARITY; FREQUENCY; MODELS	Four experiments employed a priming methodology to investigate different mechanisms of stress assignment and how they are modulated by lexical and sub-lexical mechanisms in reading aloud in Italian. Lexical stress is unpredictable in Italian, and requires lexical look-up. The most frequent stress pattern (Dominant) is on the penultimate syllable [laVOro (work)], while stress on the antepenultimate syllable [MAcchina (car)] is relatively less frequent (non-Dominant). Word and pseudoword naming responses primed by words with non-dominant stress - which require whole-word knowledge to be read correctly - were compared to those primed by nonwords. Percentage of errors to words and percentage of dominant stress responses to nonwords were measured. In Experiments 1 and 2 stress errors increased for non-dominant stress words primed by nonwords, as compared to when they were primed by words. The results could be attributed to greater activation of sub-lexical codes, and an associated tendency to assign the dominant stress pattern by default in the nonword prime condition. Alternatively, they may have been the consequence of prosodic priming, inducing more errors on trials in which the stress pattern of primes and targets was not congruent. The two interpretations were investigated in Experiments 3 and 4. The results overall suggested a limited role of the default metrical pattern in word pronunciation, and showed clear effect of prosodic priming, but only when the sub-lexical mechanism prevailed.			Colombo, L (corresponding author), Univ Padua, Dipartimento Psicol Gen, Padua, Italy.	lucia.colombo@unipd.it; jdz2001@med.cornell.edu	Colombo, Lucia/B-7605-2008; Zevin, Jason/AAG-3266-2021	Zevin, Jason/0000-0001-8929-5914; COLOMBO, LUCIA/0000-0002-2564-7578				Burani C, 2004, BRAIN LANG, V90, P318, DOI 10.1016/S0093-934X(03)00444-9; BUTTERWORTH B, 1992, COGNITION, V42, P261, DOI 10.1016/0010-0277(92)90045-J; Colombo L, 2000, CORTEX, V36, P703, DOI 10.1016/S0010-9452(08)70547-1; Colombo L, 2004, NEUROPSYCHOLOGIA, V42, P1192, DOI 10.1016/j.neuropsychologia.2004.02.004; COLOMBO L, 1992, J EXP PSYCHOL HUMAN, V18, P987, DOI 10.1037/0096-1523.18.4.987; Coltheart M, 2001, PSYCHOL REV, V108, P204, DOI 10.1037//0033-295X.108.1.204; COLTHEART M, 1993, PSYCHOL REV, V100, P589, DOI 10.1037/0033-295X.100.4.589; Cortese MJ, 2000, MEM COGNITION, V28, P1269, DOI 10.3758/BF03211827; DELL GS, 1986, PSYCHOL REV, V93, P283, DOI 10.1037/0033-295X.93.3.283; Desain P, 2003, PERCEPTION, V32, P341, DOI 10.1068/p3370; Gonnerman LM, 2007, J EXP PSYCHOL GEN, V136, P323, DOI 10.1037/0096-3445.136.2.323; Harm MW, 2004, PSYCHOL REV, V111, P662, DOI 10.1037/0033-295X.111.3.662; Kello CT, 2000, J EXP PSYCHOL LEARN, V26, P719, DOI 10.1037/0278-7393.26.3.719; LEVELT W, 1995, COGNITION COGNITION, P301; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Lupker SJ, 1997, J EXP PSYCHOL LEARN, V23, P570, DOI 10.1037/0278-7393.23.3.570; MICELI G, 1993, COGNITIVE NEUROPSYCH, V10, P273, DOI 10.1080/02643299308253465; MONAGHAN P, 2008, P 30 ANN C COGN SCI; MONSELL S, 1989, J EXP PSYCHOL GEN, V118, P43, DOI 10.1037/0096-3445.118.1.43; Plaut DC, 1999, CARN S COGN, P381; Plaut DC, 1996, PSYCHOL REV, V103, P56, DOI 10.1037/0033-295X.103.1.56; Protopapas A, 2006, J RES READ, V29, P418, DOI 10.1111/j.1467-9817.2006.00316.x; Rastle K, 2000, J MEM LANG, V42, P342, DOI 10.1006/jmla.1999.2687; Rastle K, 2002, J EXP PSYCHOL HUMAN, V28, P307, DOI 10.1037//0096-1523.28.2.307; Roelofs A, 1998, J EXP PSYCHOL LEARN, V24, P922, DOI 10.1037/0278-7393.24.4.922; Schiller NO, 2004, BRAIN LANG, V90, P231, DOI 10.1016/S0093-934X(03)00436-X; SEIDENBERG MS, 1989, PSYCHOL REV, V96, P523, DOI 10.1037/0033-295X.96.4.523; Tabossi P., 1992, ORTHOGRAPHY PHONOLOG, P319; TILLMANN B, 2002, ADV CONSCIOUSNESS RE, P231; TREIMAN R, 1995, J EXP PSYCHOL GEN, V124, P107, DOI 10.1037/0096-3445.124.2.107; YANG J, 2006, P 28 ANN C COGN SCI; YANG JF, P 13 ANN C IN PRESS; Zevin JD, 2000, J EXP PSYCHOL LEARN, V26, P121, DOI 10.1037/0278-7393.26.1.121; Zevin JD, 2006, J MEM LANG, V54, P145, DOI 10.1016/j.jml.2005.08.002	34	30	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7219	10.1371/journal.pone.0007219	http://dx.doi.org/10.1371/journal.pone.0007219			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	500HR	19787062	gold, Green Published, Green Submitted			2022-12-27	WOS:000270290100018
J	Inoue, J; Misawa, A; Tanaka, Y; Ichinose, S; Sugino, Y; Hosoi, H; Sugimoto, T; Imoto, I; Inazawa, J				Inoue, Jun; Misawa, Akiko; Tanaka, Yukichi; Ichinose, Shizuko; Sugino, Yuriko; Hosoi, Hajime; Sugimoto, Tohru; Imoto, Issei; Inazawa, Johji			Lysosomal-Associated Protein Multispanning Transmembrane 5 Gene (LAPTM5) Is Associated with Spontaneous Regression of Neuroblastomas	PLOS ONE			English	Article								Background: Neuroblastoma (NB) is the most frequently occurring solid tumor in children, and shows heterogeneous clinical behavior. Favorable tumors, which are usually detected by mass screening based on increased levels of catecholamines in urine, regress spontaneously via programmed cell death (PCD) or mature through differentiation into benign ganglioneuroma (GN). In contrast, advanced-type NB tumors often grow aggressively, despite intensive chemotherapy. Understanding the molecular mechanisms of PCD during spontaneous regression in favorable NB tumors, as well as identifying genes with a pro-death role, is a matter of urgency for developing novel approaches to the treatment of advanced-type NB tumors. Principal Findings: We found that the expression of lysosomal associated protein multispanning transmembrane 5 (LAPTM5) was usually down-regulated due to DNA methylation in an NB cell-specific manner, but up-regulated in degenerating NB cells within locally regressing areas of favorable tumors detected by mass-screening. Experiments in vitro showed that not only a restoration of its expression but also the accumulation of LAPTM5 protein, was required to induce non-apoptotic cell death with autophagic vacuoles and lysosomal destabilization with lysosomal-membrane permeabilization (LMP) in a caspase-independent manner. While autophagy is a membrane-trafficking pathway to degrade the proteins in lysosomes, the LAPTM5-mediated lysosomal destabilization with LMP leads to an interruption of autophagic flux, resulting in the accumulation of immature autophagic vacuoles, p62/SQSTM1, and ubiqitinated proteins as substrates of autophagic degradation. In addition, ubiquitin-positive inclusion bodies appeared in degenerating NB cells. Conclusions: We propose a novel molecular mechanism for PCD with the accumulation of autophagic vacuoles due to LAPTM5-mediated lysosomal destabilization. LAPTM5-induced cell death is lysosomal cell death with impaired autophagy, not cell death by autophagy, so-called autophagic cell death. Thus LAPTM5-mediated PCD is closely associated with the spontaneous regression of NBs and opens new avenues for exploring innovative clinical interventions for this tumor.			Inoue, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012					Adra CN, 1996, GENOMICS, V35, P328, DOI 10.1006/geno.1996.0364; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brundin P, 2008, NAT REV NEUROSCI, V9, P741, DOI 10.1038/nrn2477; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Cortese R, 2008, INT J BIOCHEM CELL B, V40, P1494, DOI 10.1016/j.biocel.2007.11.018; Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463; Fritsch P, 2004, PEDIATR BLOOD CANCER, V43, P679, DOI 10.1002/pbc.20126; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Gonzalgo ML, 2007, NAT PROTOC, V2, P1931, DOI 10.1038/nprot.2007.271; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hero B, 2008, J CLIN ONCOL, V26, P1504, DOI 10.1200/JCO.2007.12.3349; Hoehner JC, 1997, BRIT J CANCER, V75, P1185, DOI 10.1038/bjc.1997.203; Ichimiya S, 2001, MED PEDIATR ONCOL, V36, P42, DOI 10.1002/1096-911X(20010101)36:1<42::AID-MPO1011>3.0.CO;2-K; IKEDA H, 1995, J PEDIATR SURG, V30, P805, DOI 10.1016/0022-3468(95)90752-1; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kodet R, 1998, Cesk Patol, V34, P123; Koizumi H, 2006, AM J SURG PATHOL, V30, P249, DOI 10.1097/01.pas.0000184805.60908.37; KOIZUMI H, 1995, VIRCHOWS ARCH, V427, P167; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Munirajan AK, 2008, J BIOL CHEM, V283, P24426, DOI 10.1074/jbc.M802316200; Ouchida R, 2008, IMMUNITY, V29, P33, DOI 10.1016/j.immuni.2008.04.024; Oue T, 2005, J PEDIATR SURG, V40, P359, DOI 10.1016/j.jpedsurg.2004.10.062; Oue T, 1996, J PEDIATR SURG, V31, P251, DOI 10.1016/S0022-3468(96)90009-3; Pak Y, 2006, J CELL BIOL, V175, P631, DOI 10.1083/jcb.200603001; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Reynolds CP, 2002, J NATL CANCER I, V94, P319; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Sugino Y, 2007, ONCOGENE, V26, P7401, DOI 10.1038/sj.onc.1210550; Tanaka K, 2007, ONCOGENE, V26, P6456, DOI 10.1038/sj.onc.1210459; Tardy C, 2006, BBA-REV CANCER, V1765, P101, DOI 10.1016/j.bbcan.2005.11.003; Tonini GP, 1997, J NEURO-ONCOL, V31, P209; Toyota M, 1999, CANCER RES, V59, P2307; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599	47	30	31	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7099	10.1371/journal.pone.0007099	http://dx.doi.org/10.1371/journal.pone.0007099			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787053	Green Published, Green Submitted, gold			2022-12-27	WOS:000270290100003
J	Spaulding, M; O'Leary, MA; Gatesy, J				Spaulding, Michelle; O'Leary, Maureen A.; Gatesy, John			Relationships of Cetacea (Artiodactyla) Among Mammals: Increased Taxon Sampling Alters Interpretations of Key Fossils and Character Evolution	PLOS ONE			English	Article							PHYLOGENETIC ANALYSIS; NORTHWEST PAKISTAN; BRANCH SUPPORT; WHALES; EOCENE; HIPPOPOTAMUS; POSITION; INCLUSION; DENTITION; ORIGINS	Background: Integration of diverse data (molecules, fossils) provides the most robust test of the phylogeny of cetaceans. Positioning key fossils is critical for reconstructing the character change from life on land to life in the water. Methodology/Principal Findings: We reexamine relationships of critical extinct taxa that impact our understanding of the origin of Cetacea. We do this in the context of the largest total evidence analysis of morphological and molecular information for Artiodactyla (661 phenotypic characters and 46,587 molecular characters, coded for 33 extant and 48 extinct taxa). We score morphological data for Carnivoramorpha, dagger Creodonta, Lipotyphla, and the dagger raoellid artiodactylan dagger Indohyus and concentrate on determining which fossils are positioned along stem lineages to major artiodactylan crown clades. Shortest trees place Cetacea within Artiodactyla and close to dagger Indohyus, with dagger Mesonychia outside of Artiodactyla. The relationships of dagger Mesonychia and dagger Indohyus are highly unstable, however - in trees only two steps longer than minimum length, dagger Mesonychia falls inside Artiodactyla and displaces dagger Indohyus from a position close to Cetacea. Trees based only on data that fossilize continue to show the classic arrangement of relationships within Artiodactyla with Cetacea grouping outside the clade, a signal incongruent with the molecular data that dominate the total evidence result. Conclusions/Significance: Integration of new fossil material of Indohyus impacts placement of another extinct clade Mesonychia, pushing it much farther down the tree. The phylogenetic position of Indohyus suggests that the cetacean stem lineage included herbivorous and carnivorous aquatic species. We also conclude that extinct members of Cetancodonta (whales + hippopotamids) shared a derived ability to hear underwater sounds, even though several cetancodontans lack a pachyostotic auditory bulla. We revise the taxonomy of living and extinct artiodactylans and propose explicit node and stem-based definitions for the ingroup.			Spaulding, M (corresponding author), Columbia Univ, Dept Earth & Environm Sci, New York, NY 10027 USA.	mspaulding@amnh.org		O'Leary, Maureen A./0000-0001-7837-5708				Arnason U, 2000, J MOL EVOL, V50, P569, DOI 10.1007/s002390010060; Asher Robert J., 2003, Journal of Mammalian Evolution, V10, P131, DOI 10.1023/A:1025504124129; AX P, 1985, Cladistics, V1, P279, DOI 10.1111/j.1096-0031.1985.tb00428.x; Ayoub NA, 2009, MOL PHYLOGENET EVOL, V52, P550, DOI 10.1016/j.ympev.2009.03.008; Barklow WE, 2004, ANIM BEHAV, V68, P1125, DOI 10.1016/j.anbehav.2003.10.034; BORENSTEIN S, 2007, WHALES MAY BE RELATE; BREMER K, 1994, CLADISTICS, V10, P295, DOI 10.1006/clad.1994.1019; BROCHU C, SYSTEMATIC IN PRESS; Bryant HN, 1996, SYST BIOL, V45, P174, DOI 10.2307/2413614; BRYANT HN, 1992, PHILOS T ROY SOC B, V337, P405, DOI 10.1098/rstb.1992.0117; Cole R, 1996, PROCEEDINGS OF THE SEVENTH ANNUAL ACM-SIAM SYMPOSIUM ON DISCRETE ALGORITHMS, P323; COOMBS MC, 1977, J MAMMAL, V58, P291, DOI 10.2307/1379328; Cope E. D., 1875, P ACADEMY NATURAL SC, V27, P444; De Queiroz K, 2007, SYST BIOL, V56, P956, DOI 10.1080/10635150701656378; Delgado S, 2005, J MOL EVOL, V60, P12, DOI 10.1007/s00239-003-0070-8; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; DEQUEIROZ K, 1992, ANNU REV ECOL SYST, V23, P449, DOI 10.1146/annurev.ecolsys.23.1.449; DEQUEIROZ K, COMPANION VOLU UNPUB; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Flynn JJ, 2005, RISE PLACENTAL MAMMA; Gatesy J, 2000, SYST BIOL, V49, P800, DOI 10.1080/106351500750049842; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gatesy J, 2001, TRENDS ECOL EVOL, V16, P562, DOI 10.1016/S0169-5347(01)02236-4; Geisler JH, 2003, J VERTEBR PALEONTOL, V23, P991, DOI 10.1671/32; Geisler JH, 1998, ADV VERT PALEOBIOL, P163; Geisler Jonathan H., 2005, Journal of Mammalian Evolution, V12, P145, DOI 10.1007/s10914-005-4963-8; Geisler Jonathan H., 2001, American Museum Novitates, V3344, P1, DOI 10.1206/0003-0082(2001)344<0001:NMEFTP>2.0.CO;2; Geisler Jonathan H., 2007, P19; Geisler JH, 2009, NATURE, V458, pE1, DOI 10.1038/nature07776; GILBERT D, 1992, SEQAPP VERSION 1 9A; Gingerich PD, 2001, SCIENCE, V293, P2239, DOI 10.1126/science.1063902; Goloboff PA, 2008, CLADISTICS, V24, P774, DOI 10.1111/j.1096-0031.2008.00217.x; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; GUNNELL GF, 1998, EVOLUTION TERTIARY M, V1, P91; Hiiemae K.M., 1985, P262; Irwin David M., 1994, Journal of Mammalian Evolution, V2, P37, DOI 10.1007/BF01464349; Kleineidam RG, 1999, J MOL EVOL, V48, P360, DOI 10.1007/PL00006480; Luo Z., 1999, U MICHIGAN PAPERS PA, V31, P1; McKenna MC, 1997, CLASSIFICATION MAMMA; Montgelard C, 1997, MOL BIOL EVOL, V14, P550, DOI 10.1093/oxfordjournals.molbev.a025792; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Nixon KC, 1999, CLADISTICS, V15, P407, DOI 10.1111/j.1096-0031.1999.tb00277.x; Novacek M, 2008, J VERTEBR PALEONTOL, V28, p121A; NOVACEK MJ, 1985, NATURE, V315, P140, DOI 10.1038/315140a0; O'Leary M.A., 2007, MORPHOBANK 2 5 WEB A; O'Leary MA, 2004, ASSEMBLING THE TREE OF LIFE, P490; O'Leary MA, 1999, SYST BIOL, V48, P455, DOI 10.1080/106351599260102; O'Leary MA, 1998, ADV VERT PALEOBIOL, P133; O'Leary MA, 2001, AM ZOOL, V41, P487, DOI 10.1668/0003-1569(2001)041[0487:TPPOCF]2.0.CO;2; O'Leary MA, 1999, PALEOBIOLOGY, V25, P534, DOI 10.1017/S0094837300020376; O'Leary MA, 2008, CLADISTICS, V24, P397, DOI 10.1111/j.1096-0031.2007.00187.x; OLeary MA, 2009, J MAMM EVOL, V16, P65, DOI DOI 10.1007/S10914-008-9088-4; Osborn H. F., 1924, American Museum Novitates, Vno. 146, P1; Polly PD, 1996, J VERTEBR PALEONTOL, V16, P303, DOI 10.1080/02724634.1996.10011318; RADINSKY LB, 1987, EVOLUTION VERTEBRATE; RUSSELL DE, 1983, P K NED AKAD B PHYS, V86, P285; SIMPSON GG, 1945, B AM MUS NAT HIST, V85, P1; Stucky Richard K., 1998, P358; Swofford DL, 2002, PAUP PHYLOGENETIC AN; Theodor Jessica M., 2005, Journal of Mammalian Evolution, V12, P161, DOI 10.1007/s10914-005-5706-6; Thewissen JGM, 2007, NATURE, V450, P1190, DOI 10.1038/nature06343; Thewissen JGM, 2009, NATURE, V458, pE5, DOI 10.1038/nature07775; THEWISSEN JGM, 1983, P K NED AKAD B PHYS, V86, P153; Thewissen JGM, 2001, NATURE, V413, P277, DOI 10.1038/35095005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VAN VALEN LEIGH, 1966, BULL AMER MUS NATUR HIST, V132, P1; Waddell PJ, 1999, SYST BIOL, V48, P1, DOI 10.1093/sysbio/48.1.1; Wesley-Hunt GD, 2005, J SYST PALAEONTOL, V3, P1; WITMER LM, 1995, FUNCTIONAL MORPHOLOGY IN VERTEBRATE PALEONTOLOGY, P19; WYSS AR, 1993, MAMMAL PHYLOGENY : PLACENTALS, P32	71	145	152	4	111	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7062	10.1371/journal.pone.0007062	http://dx.doi.org/10.1371/journal.pone.0007062			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774069	Green Published, gold, Green Submitted			2022-12-27	WOS:000270160900005
J	Dard, N; Le, T; Maro, B; Louvet-Vallee, S				Dard, Nicolas; Le, Tran; Maro, Bernard; Louvet-Vallee, Sophie			Inactivation of aPKC lambda Reveals a Context Dependent Allocation of Cell Lineages in Preimplantation Mouse Embryos	PLOS ONE			English	Article								Background: During mammalian preimplantation development, lineage divergence seems to be controlled by the interplay between asymmetric cell division (once cells are polarized) and positional information. In the mouse embryo, two distinct cell populations are first observed at the 16-cell stage and can be distinguished by both their position (outside or inside) and their phenotype (polarized or non-polarized). Many efforts have been made during the last decade to characterize the molecular mechanisms driving lineage divergence. Methodology/Principal Findings: In order to evaluate the importance of cell polarity in the determination of cell fate we have disturbed the activity of the apical complex aPKC/PAR6 using siRNA to down-regulate aPKC lambda expression. Here we show that depletion of aPKCl results in an absence of tight junctions and in severe polarity defects at the 16-cell stage. Importantly, we found that, in absence of aPKC lambda, cell fate depends on the cellular context: depletion of aPKC lambda in all cells results in a strong reduction of inner cells at the 16-cell stage, while inhibition of aPKC lambda in only half of the embryo biases the progeny of aPKC lambda defective blastomeres towards the inner cell mass. Finally, our study points to a role of cell shape in controlling cell position and thus lineage allocation. Conclusion: Our data show that aPKC lambda is dispensable for the establishment of polarity at the 8-cell stage but is essential for the stabilization of cell polarity at the 16-cell stage and for cell positioning. Moreover, this study reveals that in addition to positional information and asymmetric cell divisions, cell shape plays an important role for the control of lineage divergence during mouse preimplantation development. Cell shape is able to influence both the type of division (symmetric or asymmetric) and the position of the blastomeres within the embryo.			Dard, N (corresponding author), CNRS, Lab Biol Cellulaire Dev, UMR7622, 9 Quai St Bernard,Batiment C, Paris, France.	nicolas.dard@upmc.fr	Maro, Bernard/AAL-2220-2020	DARD, Nicolas/0000-0001-7036-2275				ALLEGRI L, 1986, AM J PATHOL, V125, P1; Balklava Z, 2007, NAT CELL BIOL, V9, P1066, DOI 10.1038/ncb1627; Carreno S, 2008, J CELL BIOL, V180, P739, DOI 10.1083/jcb.200709161; Chalmers AD, 2005, DEVELOPMENT, V132, P977, DOI 10.1242/dev.01645; Cui S, 2007, MOL CELL NEUROSCI, V34, P431, DOI 10.1016/j.mcn.2006.11.016; Dard N, 2004, DEV BIOL, V271, P87, DOI 10.1016/j.ydbio.2004.03.024; Dard N, 2001, DEV BIOL, V233, P161, DOI 10.1006/dbio.2001.0192; Dard N, 2008, MOL CELL ENDOCRINOL, V282, P70, DOI 10.1016/j.mce.2007.11.004; Dietrich JE, 2007, DEVELOPMENT, V134, P4219, DOI 10.1242/dev.003798; Eckert JJ, 2008, BBA-BIOMEMBRANES, V1778, P717, DOI 10.1016/j.bbamem.2007.09.031; FLEMING TP, 1987, DEV BIOL, V119, P520, DOI 10.1016/0012-1606(87)90055-8; FLEMING TP, 1993, DEVELOPMENT, V117, P1135; GOODALL H, 1986, J CELL BIOL, V102, P568, DOI 10.1083/jcb.102.2.568; Harris KP, 2008, J CELL BIOL, V183, P1129, DOI 10.1083/jcb.200807020; Hipfner DR, 2004, GENE DEV, V18, P2243, DOI 10.1101/gad.303304; HOULISTON E, 1989, DEV BIOL, V134, P342, DOI 10.1016/0012-1606(89)90106-1; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; Imai F, 2006, DEVELOPMENT, V133, P1735, DOI 10.1242/dev.02330; Jedrusik A, 2008, GENE DEV, V22, P2692, DOI 10.1101/gad.486108; Johnson M.H., 1986, EXPT APPROACHES MAMM, P35; JOHNSON MH, 1981, CELL, V24, P71, DOI 10.1016/0092-8674(81)90502-X; Johnson MH, 2004, SEMIN CELL DEV BIOL, V15, P583, DOI 10.1016/j.semcdb.2004.04.002; JOHNSON MH, 1985, CELL CONTACT ADHESIO, P27; Krieg M, 2008, NAT CELL BIOL, V10, P429, DOI 10.1038/ncb1705; Kunda P, 2008, CURR BIOL, V18, P91, DOI 10.1016/j.cub.2007.12.051; Lecuit T, 2007, NAT REV MOL CELL BIO, V8, P633, DOI 10.1038/nrm2222; Louvet S, 1996, DEV BIOL, V177, P568, DOI 10.1006/dbio.1996.0186; MARO B, 1991, CELL POLARITY MICROT, P17; MINTZ B, 1965, PREIMPLANTATION STAG, P194; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ninomiya H, 2008, NAT CELL BIOL, V10, P61, DOI 10.1038/ncb1669; PAPAIOANNOU VE, 1995, DEV DYNAM, V203, P393, DOI 10.1002/aja.1002030402; PICKERING SJ, 1988, DEVELOPMENT, V103, P353; Plusa B, 2005, J CELL SCI, V118, P505, DOI 10.1242/jcs.01666; Ralston A, 2008, DEV BIOL, V313, P614, DOI 10.1016/j.ydbio.2007.10.054; Sheth B, 1997, DEVELOPMENT, V124, P2027; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Suzuki A, 2002, J CELL SCI, V115, P3565, DOI 10.1242/jcs.00032; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; TARKOWSKI AK, 1967, J EMBRYOL EXP MORPH, V18, P155; Thomas FC, 2004, J CELL SCI, V117, P5599, DOI 10.1242/jcs.01424; Vinot S, 2005, DEV BIOL, V282, P307, DOI 10.1016/j.ydbio.2005.03.001; Yamanaka Y, 2006, DEV DYNAM, V235, P2301, DOI 10.1002/dvdy.20844	45	34	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7117	10.1371/journal.pone.0007117	http://dx.doi.org/10.1371/journal.pone.0007117			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768116	Green Published, Green Submitted, gold			2022-12-27	WOS:000270154000010
J	DeWard, AD; Leali, K; West, RA; Prendergast, GC; Alberts, AS				DeWard, Aaron D.; Leali, Kellie; West, Richard A.; Prendergast, George C.; Alberts, Arthur S.			Loss of RhoB Expression Enhances the Myelodysplastic Phenotype of Mammalian Diaphanous-Related Formin mDia1 Knockout Mice	PLOS ONE			English	Article								Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis and hyperplastic bone marrow. Complete loss or interstitial deletions of the long arm of chromosome 5 occur frequently in MDS. One candidate tumor suppressor on 5q is the mammalian Diaphanous (mDia)-related formin mDia1, encoded by DIAPH1 (5q31.3). mDia-family formins act as effectors for Rho-family small GTP-binding proteins including RhoB, which has also been shown to possess tumor suppressor activity. Mice lacking the Drf1 gene that encodes mDia1 develop age-dependent myelodysplastic features. We crossed mDia1 and RhoB knockout mice to test whether the additional loss of RhoB expression would compound the myelodysplastic phenotype. Drf1(-/-)RhoB(-/-) mice are fertile and develop normally. Relative to age-matched Drf1(-/-)RhoB(+/-) mice, the age of myelodysplasia onset was earlier in Drf1(-/-)RhoB(-/-) animals-including abnormally shaped erythrocytes, splenomegaly, and extramedullary hematopoiesis. In addition, we observed a statistically significant increase in the number of activated monocytes/macrophages in both the spleen and bone marrow of Drf1(-/-)RhoB(+/-) mice relative to Drf1(-/-)RhoB(+/-) mice. These data suggest a role for RhoB-regulated mDia1 in the regulation of hematopoietic progenitor cells.			DeWard, AD (corresponding author), Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI USA.	Art.Alberts@vai.org		West, Richard/0000-0003-1459-0825	NATIONAL CANCER INSTITUTE [R01CA100123] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100123] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Couderc B, 2008, CANCER GENE THER, V15, P456, DOI 10.1038/cgt.2008.12; Eisenmann KM, 2007, J BIOL CHEM, V282, P25152, DOI 10.1074/jbc.M703243200; EISENMANN KM, 2009, 5Q MYELODYS IN PRESS, V5, P5; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Ji P, 2008, NAT CELL BIOL, V10, P314, DOI 10.1038/ncb1693; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kamasani U, 2005, CANCER BIOL THER, V4, P282, DOI 10.4161/cbt.4.3.1498; KENT DG, 2009, BLOOD; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Morgan MA, 2003, LEUKEMIA, V17, P1482, DOI 10.1038/sj.leu.2403024; Nimer Stephen D, 2008, Hematology Am Soc Hematol Educ Program, P43, DOI 10.1182/asheducation-2008.1.43; Nolte F, 2008, ANN HEMATOL, V87, P777, DOI 10.1007/s00277-008-0502-z; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Peng J, 2007, CANCER RES, V67, P7565, DOI 10.1158/0008-5472.CAN-07-1467; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Sato N, 2007, INT J CANCER, V120, P543, DOI 10.1002/ijc.22328; Shi YQ, 2009, J IMMUNOL, V182, P3837, DOI 10.4049/jimmunol.0803838; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wallar BJ, 2007, EXP CELL RES, V313, P560, DOI 10.1016/j.yexcr.2006.10.033	22	12	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7102	10.1371/journal.pone.0007102	http://dx.doi.org/10.1371/journal.pone.0007102			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768111	Green Published, Green Submitted, gold			2022-12-27	WOS:000270154000007
J	Dinnage, R				Dinnage, Russell			Disturbance Alters the Phylogenetic Composition and Structure of Plant Communities in an Old Field System	PLOS ONE			English	Article							TAXONOMIC DISTINCTNESS; SPECIES-DIVERSITY; EVOLUTION; COMPETITION; SPACE; BIODIVERSITY; ORGANIZATION; DIVERGENCE; SUCCESSION; PREDATION	The changes in phylogenetic composition and structure of communities during succession following disturbance can give us insights into the forces that are shaping communities over time. In abandoned agricultural fields, community composition changes rapidly when a field is plowed, and is thought to reflect a relaxation of competition due to the elimination of dominant species which take time to re-establish. Competition can drive phylogenetic overdispersion, due to phylogenetic conservation of 'niche' traits that allow species to partition resources. Therefore, undisturbed old field communities should exhibit higher phylogenetic dispersion than recently disturbed systems, which should be relatively 'clustered' with respect to phylogenetic relationships. Several measures of phylogenetic structure between plant communities were measured in recently plowed areas and nearby 'undisturbed' sites. There was no difference in the absolute values of these measures between disturbed and 'undisturbed' sites. However, there was a difference in the 'expected' phylogenetic structure between habitats, leading to significantly lower than expected phylogenetic diversity in disturbed plots, and no difference from random expectation in 'undisturbed' plots. This suggests that plant species characteristic of each habitat are fairly evenly distributed on the shared species pool phylogeny, but that once the initial sorting of species into the two habitat types has occurred, the processes operating on them affect each habitat differently. These results were consistent with an analysis of correlation between phylogenetic distance and co-occurrence indices of species pairs in the two habitat types. This study supports the notion that disturbed plots are more clustered than expected, rather than 'undisturbed' plots being more overdispersed, suggesting that disturbed plant communities are being more strongly influenced by environmental filtering of conserved niche traits.			Dinnage, R (corresponding author), Univ Toronto, Dept Ecol & Evolutionary Biol, Toronto, ON, Canada.	russell.dinnage@utoronto.ca	Dinnage, Russell/L-9892-2013; Dinnage, Russell/H-9023-2019	Dinnage, Russell/0000-0003-0846-2819; Dinnage, Russell/0000-0003-0846-2819				Abellan P, 2006, FRESHWATER BIOL, V51, P1744, DOI 10.1111/j.1365-2427.2006.01613.x; ABRAMS P, 1983, ANNU REV ECOL SYST, V14, P359, DOI 10.1146/annurev.es.14.110183.002043; BENSON DA, 2005, NUCLEIC ACIDS RES, P33; BILLINGS W. D., 1938, ECOL MONOGR, V8, P437, DOI 10.2307/1943541; Cadotte MW, 2008, P NATL ACAD SCI USA, V105, P17012, DOI 10.1073/pnas.0805962105; Cahill JF, 2008, PERSPECT PLANT ECOL, V10, P41, DOI 10.1016/j.ppees.2007.10.001; CARSON WP, 1990, ECOLOGY, V71, P226, DOI 10.2307/1940262; Cavender-Bares J, 2004, AM NAT, V163, P823, DOI 10.1086/386375; Cavender-Bares J, 2009, ECOL LETT, V12, P693, DOI 10.1111/j.1461-0248.2009.01314.x; Chase J.M., 2009, ECOLOGICAL NICHES LI; Chase JM, 2007, P NATL ACAD SCI USA, V104, P17430, DOI 10.1073/pnas.0704350104; Chesson P, 2008, NATURE, V456, P235, DOI 10.1038/nature07248; CONNELL JH, 1977, AM NAT, V111, P1119, DOI 10.1086/283241; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; DAYTON PK, 1971, ECOL MONOGR, V41, P351, DOI 10.2307/1948498; Emerson BC, 2008, TRENDS ECOL EVOL, V23, P619, DOI 10.1016/j.tree.2008.07.005; FAITH DP, 1987, VEGETATIO, V69, P57, DOI 10.1007/BF00038687; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; GOLDBERG DE, 1987, B TORREY BOT CLUB, V114, P139, DOI 10.2307/2996123; Graham CH, 2008, ECOL LETT, V11, P1265, DOI 10.1111/j.1461-0248.2008.01256.x; GRIME JP, 1973, NATURE, V242, P344, DOI 10.1038/242344a0; Hardy OJ, 2008, J ECOL, V96, P914, DOI 10.1111/j.1365-2745.2008.01421.x; Hardy OJ, 2007, J ECOL, V95, P493, DOI 10.1111/j.1365-2745.2007.01222.x; Helmus MR, 2007, AM NAT, V169, pE68, DOI 10.1086/511334; Helmus MR, 2007, ECOL LETT, V10, P917, DOI 10.1111/j.1461-0248.2007.01083.x; HOLT RD, 1977, THEOR POPUL BIOL, V12, P197, DOI 10.1016/0040-5809(77)90042-9; HUSTON M, 1987, AM NAT, V130, P168, DOI 10.1086/284704; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198; KEMBEL SW, 2009, PICANTE R TOOLS INTE; Kim KJ, 2005, MOL BIOL EVOL, V22, P1783, DOI 10.1093/molbev/msi174; Knapp S, 2008, ECOL LETT, V11, P1054, DOI 10.1111/j.1461-0248.2008.01217.x; Kraft NJB, 2007, AM NAT, V170, P271, DOI 10.1086/519400; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P1, DOI 10.1007/BF02289565; MACARTHUR R, 1967, AM NAT, V101, P377, DOI 10.1086/282505; Maherali H, 2007, SCIENCE, V316, P1746, DOI 10.1126/science.1143082; Oksanen J., 2008, VEGAN COMMUNITY ECOL; Oosting H. J., 1942, American Midland Naturalist, V28, P1, DOI 10.2307/2420696; PETRAITIS PS, 1989, Q REV BIOL, V64, P393, DOI 10.1086/416457; R Core Team, 2018, R LANG ENV STAT COMP; Sanderson MJ, 2003, BIOINFORMATICS, V19, P301, DOI 10.1093/bioinformatics/19.2.301; SCHOENER TW, 1970, ECOLOGY, V51, P408, DOI 10.2307/1935376; Schweiger O, 2008, OECOLOGIA, V157, P485, DOI 10.1007/s00442-008-1082-2; Silvertown J, 2006, P ROY SOC B-BIOL SCI, V273, P39, DOI 10.1098/rspb.2005.3288; Terlizzi A, 2005, MAR BIOL, V148, P293, DOI 10.1007/s00227-005-0080-8; Vamosi SM, 2009, MOL ECOL, V18, P572, DOI 10.1111/j.1365-294X.2008.04001.x; Verdu M, 2007, J ECOL, V95, P1316, DOI 10.1111/j.1365-2745.2007.01300.x; Warwick RM, 1998, J APPL ECOL, V35, P532, DOI 10.1046/j.1365-2664.1998.3540532.x; Webb CO, 2002, ANNU REV ECOL SYST, V33, P475, DOI 10.1146/annurev.ecolsys.33.010802.150448; Webb CO, 2007, PHYLOCOM SOFTWARE AN; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782	52	71	74	3	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7071	10.1371/journal.pone.0007071	http://dx.doi.org/10.1371/journal.pone.0007071			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763265	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970400009
J	McCormick, MI				McCormick, Mark I.			Behaviourally Mediated Phenotypic Selection in a Disturbed Coral Reef Environment	PLOS ONE			English	Article							CLIMATE-CHANGE; EVOLUTIONARY CONSEQUENCES; HABITAT LOSS; FISH LARVAE; MARINE FISH; PREDATION; SURVIVAL; LIFE; SIZE; POMACENTRIDAE	Natural and anthropogenic disturbances are leading to changes in the nature of many habitats globally, and the magnitude and frequency of these perturbations are predicted to increase under climate change. Globally coral reefs are one of the most vulnerable ecosystems to climate change. Fishes often show relatively rapid declines in abundance when corals become stressed and die, but the processes responsible are largely unknown. This study explored the mechanism by which coral bleaching may influence the levels and selective nature of mortality on a juvenile damselfish, Pomacentrus amboinensis, which associates with hard coral. Recently settled fish had a low propensity to migrate small distances (40 cm) between habitat patches, even when densities were elevated to their natural maximum. Intraspecific interactions and space use differ among three habitats: live hard coral, bleached coral and dead algal-covered coral. Large fish pushed smaller fish further from the shelter of bleached and dead coral thereby exposing smaller fish to higher mortality than experienced on healthy coral. Small recruits suffered higher mortality than large recruits on bleached and dead coral. Mortality was not size selective on live coral. Survival was 3 times as high on live coral as on either bleached or dead coral. Subtle behavioural interactions between fish and their habitats influence the fundamental link between life history stages, the distribution of phenotypic traits in the local population and potentially the evolution of life history strategies.			McCormick, MI (corresponding author), James Cook Univ, ARC Ctr Excellence Coral Reef Studies, Townsville, Qld 4811, Australia.	mark.mccormick@jcu.edu.au	McCormick, Mark I/J-8301-2014	McCormick, Mark I/0000-0001-9289-1645				Almany GR, 2006, CORAL REEFS, V25, P19, DOI 10.1007/s00338-005-0044-y; Arvedlund M, 1999, MAR ECOL PROG SER, V188, P207, DOI 10.3354/meps188207; BERKELMANS R, 2009, BLEACHING MORTALITY, P103; Beukers JS, 1997, OECOLOGIA, V111, P50, DOI DOI 10.1007/S004420050419); Booth DJ, 2002, MAR ECOL PROG SER, V245, P205, DOI 10.3354/meps245205; Brooks TM, 2002, CONSERV BIOL, V16, P909, DOI 10.1046/j.1523-1739.2002.00530.x; Brown DR, 2008, BEHAV ECOL, V19, P1314, DOI 10.1093/beheco/arn073; Clark R, 2009, B MAR SCI, V84, P167; COATES D, 1980, J ANIM ECOL, V49, P335, DOI 10.2307/4292; Dixson DL, 2008, P ROY SOC B-BIOL SCI, V275, P2831, DOI 10.1098/rspb.2008.0876; Donner SD, 2005, GLOBAL CHANGE BIOL, V11, P2251, DOI 10.1111/j.1365-2486.2005.01073.x; Evans KL, 2009, OIKOS, V118, P251, DOI 10.1111/j.1600-0706.2008.17092.x; FEARY DA, 2009, J EXP MAR B IN PRESS; Feary DA, 2007, OECOLOGIA, V153, P727, DOI 10.1007/s00442-007-0773-4; Gagliano M, 2007, OIKOS, V116, P111, DOI 10.1111/j.2006.0030-1299.15418.x; Gardner TA, 2003, SCIENCE, V301, P958, DOI 10.1126/science.1086050; Gende SM, 2004, OIKOS, V104, P518, DOI 10.1111/j.0030-1299.2004.12762.x; Gerlach G, 2007, P NATL ACAD SCI USA, V104, P858, DOI 10.1073/pnas.0606777104; Hamilton SL, 2008, P NATL ACAD SCI USA, V105, P1561, DOI 10.1073/pnas.0707676105; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hoey A.S., 2006, PROC 10 INT CORAL RE, V2006, P420; Hoey AS, 2004, OECOLOGIA, V139, P23, DOI 10.1007/s00442-004-1489-3; Holmes TH, 2006, MAR ECOL PROG SER, V317, P203, DOI 10.3354/meps317203; Holmes TH, 2009, OECOLOGIA, V159, P401, DOI 10.1007/s00442-008-1220-x; Hughes TP, 2007, CURR BIOL, V17, P360, DOI 10.1016/j.cub.2006.12.049; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Jones GP, 2004, P NATL ACAD SCI USA, V101, P8251, DOI 10.1073/pnas.0401277101; JONES GP, 1987, ECOLOGY, V68, P1534, DOI 10.2307/1939237; Kokko H, 2001, EVOL ECOL RES, V3, P537; Lee JSF, 2009, ENVIRON BIOL FISH, V84, P411, DOI 10.1007/s10641-009-9450-2; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Long RA, 2008, J WILDLIFE MANAGE, V72, P1133, DOI 10.2193/2007-337; LYTHGOE JN, 1988, SENSORY BIOL AQUATIC, P75; Marshall NJ, 2003, COPEIA, P467, DOI 10.1643/01-056; Marshall NJ, 2000, PHILOS T ROY SOC B, V355, P1243, DOI 10.1098/rstb.2000.0676; Marshall PA, 2000, CORAL REEFS, V19, P155, DOI 10.1007/s003380000086; McClure MM, 2008, EVOL APPL, V1, P300, DOI 10.1111/j.1752-4571.2008.00030.x; McCormick MI, 2007, ECOLOGY, V88, P1562, DOI 10.1890/06-0830; McCormick MI, 1997, MAR ECOL PROG SER, V153, P247, DOI 10.3354/meps153247; McCormick MI, 2004, OIKOS, V106, P225, DOI 10.1111/j.0030-1299.2004.13131.x; McCormick MI, 2002, MAR BIOL, V141, P841, DOI 10.1007/s00227-002-0883-9; MCCORMICK MI, P 11 INT CO IN PRESS; McKinney ML, 2006, BIOL CONSERV, V127, P247, DOI 10.1016/j.biocon.2005.09.005; MEEKAN MG, ANIM BEHAV IN PRESS; MOORE JAY, 2007, INFLUENCE CORAL BLEA; Munday P. L., 2007, CLIMATE CHANGE GREAT, P357; Munday PL, 2008, FISH FISH, V9, P261, DOI 10.1111/j.1467-2979.2008.00281.x; Ohman MC, 1998, J EXP MAR BIOL ECOL, V225, P219, DOI 10.1016/S0022-0981(97)00224-4; Packer C, 2001, SCIENCE, V293, P690, DOI 10.1126/science.1062320; Pechenik JA, 1998, BIOSCIENCE, V48, P901, DOI 10.2307/1313294; Podolsky RD, 2006, INTEGR COMP BIOL, V46, P577, DOI 10.1093/icb/icl026; Pratchett M. S., 2009, V205, P139; Rasner CA, 2004, MOL ECOL, V13, P671, DOI 10.1046/j.1365-294X.2004.02104.x; Rincon PA, 2001, J FISH BIOL, V59, P968, DOI 10.1006/jfbi.2001.1711; Saccheri I, 2006, TRENDS ECOL EVOL, V21, P341, DOI 10.1016/j.tree.2006.03.018; Sale P.F., 1978, P313; SORENSEN PW, 1986, ENVIRON BIOL FISH, V17, P185, DOI 10.1007/BF00698197; Sponaugle S, 2006, INTEGR COMP BIOL, V46, P623, DOI 10.1093/icb/icl014; Strychar KB, 2009, J EXP MAR BIOL ECOL, V369, P31, DOI 10.1016/j.jembe.2008.10.021; Svanback R, 2009, AM NAT, V173, P507, DOI 10.1086/597223; SWEATMAN H, 1988, J EXP MAR BIOL ECOL, V124, P163, DOI 10.1016/0022-0981(88)90170-0; Valeix M, 2009, ECOLOGY, V90, P23, DOI 10.1890/08-0606.1; Vonesh JR, 2005, OECOLOGIA, V143, P280, DOI 10.1007/s00442-004-1806-x; Walker SPW, 2007, J FISH BIOL, V71, P1347, DOI 10.1111/j.1095-8649.2007.01595.x; WALLACE B, 1975, EVOLUTION, V29, P465, DOI [10.2307/2407259, 10.1111/j.1558-5646.1975.tb00836.x]; Webster MS, 2004, ECOLOGY, V85, P986, DOI 10.1890/02-0576; Wilson SK, 2006, GLOBAL CHANGE BIOL, V12, P2220, DOI 10.1111/j.1365-2486.2006.01252.x; Wittig RM, 2003, INT J PRIMATOL, V24, P847, DOI 10.1023/A:1024632923180; Wright KJ, 2005, MAR BIOL, V147, P1425, DOI 10.1007/s00227-005-0028-z	69	58	58	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e7096	10.1371/journal.pone.0007096	http://dx.doi.org/10.1371/journal.pone.0007096			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763262	Green Published, Green Accepted, gold			2022-12-27	WOS:000269970400020
J	De Roo, M; Klauser, P; Briner, A; Nikonenko, I; Mendez, P; Dayer, A; Kiss, JZ; Muller, D; Vutskits, L				De Roo, Mathias; Klauser, Paul; Briner, Adrian; Nikonenko, Irina; Mendez, Pablo; Dayer, Alexandre; Kiss, Jozsef Z.; Muller, Dominique; Vutskits, Laszlo			Anesthetics Rapidly Promote Synaptogenesis during a Critical Period of Brain Development	PLOS ONE			English	Article								Experience-driven activity plays an essential role in the development of brain circuitry during critical periods of early postnatal life, a process that depends upon a dynamic balance between excitatory and inhibitory signals. Since general anesthetics are powerful pharmacological modulators of neuronal activity, an important question is whether and how these drugs can affect the development of synaptic networks. To address this issue, we examined here the impact of anesthetics on synapse growth and dynamics. We show that exposure of young rodents to anesthetics that either enhance GABAergic inhibition or block NMDA receptors rapidly induce a significant increase in dendritic spine density in the somatosensory cortex and hippocampus. This effect is developmentally regulated; it is transient but lasts for several days and is also reproduced by selective antagonists of excitatory receptors. Analyses of spine dynamics in hippocampal slice cultures reveals that this effect is mediated through an increased rate of protrusions formation, a better stabilization of newly formed spines, and leads to the formation of functional synapses. Altogether, these findings point to anesthesia as an important modulator of spine dynamics in the developing brain and suggest the existence of a homeostatic process regulating spine formation as a function of neural activity. Importantly, they also raise concern about the potential impact of these drugs on human practice, when applied during critical periods of development in infants.			De Roo, M (corresponding author), Univ Geneva, Fac Med, Dept Neurosci, Geneva, Switzerland.	laszlo.vutskits@unige.ch	Mendez, Pablo/J-7552-2017	Mendez, Pablo/0000-0001-9862-6818; Klauser, Paul/0000-0003-0284-4947; De Roo, Mathias/0000-0001-9912-6954; Dayer, Alexandre/0000-0002-4490-9780				Adesnik H, 2008, P NATL ACAD SCI USA, V105, P5597, DOI 10.1073/pnas.0800946105; Akerman CJ, 2007, TRENDS NEUROSCI, V30, P382, DOI 10.1016/j.tins.2007.06.002; Chacko J, 1999, PEDIATR SURG INT, V15, P496, DOI 10.1007/s003830050648; Dani VS, 2005, P NATL ACAD SCI USA, V102, P12560, DOI 10.1073/pnas.0506071102; De Roo M, 2008, CEREB CORTEX, V18, P151, DOI 10.1093/cercor/bhm041; DeFelipe J, 1997, CEREB CORTEX, V7, P619, DOI 10.1093/cercor/7.7.619; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Hofer SB, 2009, NATURE, V457, P313, DOI 10.1038/nature07487; Holtmaat AJGD, 2005, NEURON, V45, P279, DOI 10.1016/j.neuron.2005.01.003; Holtmaat A, 2006, NATURE, V441, P979, DOI 10.1038/nature04783; Kabra NS, 2007, J PEDIATR-US, V150, P229, DOI 10.1016/j.jpeds.2006.11.039; Katagiri H, 2007, NEURON, V53, P805, DOI 10.1016/j.neuron.2007.02.026; Kleschevnikov AM, 2004, J NEUROSCI, V24, P8153, DOI 10.1523/JNEUROSCI.1766-04.2004; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Ludman L, 2001, J PEDIATR SURG, V36, P858, DOI 10.1053/jpsu.2001.23954; Lujan R, 2005, NEUROSCIENCE, V130, P567, DOI 10.1016/j.neuroscience.2004.09.042; Luthi A, 2001, NAT NEUROSCI, V4, P1102, DOI 10.1038/nn744; Maffei A, 2006, NATURE, V443, P81, DOI 10.1038/nature05079; Mateos JM, 2007, J PHYSIOL-LONDON, V581, P129, DOI 10.1113/jphysiol.2006.120550; Micheva KD, 1996, J COMP NEUROL, V373, P340, DOI 10.1002/(SICI)1096-9861(19960923)373:3<340::AID-CNE3>3.0.CO;2-2; MULLER M, 1993, P NATL ACAD SCI USA, V90, P257, DOI 10.1073/pnas.90.1.257; PETIT TL, 1988, DEV BRAIN RES, V41, P209, DOI 10.1016/0165-3806(88)90183-6; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Ultanir SK, 2007, P NATL ACAD SCI USA, V104, P19553, DOI 10.1073/pnas.0704031104; Varoqueaux F, 2006, NEURON, V51, P741, DOI 10.1016/j.neuron.2006.09.003; Wang DD, 2008, J NEUROSCI, V28, P5547, DOI 10.1523/JNEUROSCI.5599-07.2008; Xu HT, 2007, NAT NEUROSCI, V10, P549, DOI 10.1038/nn1883; Zha XM, 2005, MOL CELL NEUROSCI, V29, P494, DOI 10.1016/j.mcn.2005.04.007; Zuo Y, 2005, NEURON, V46, P181, DOI 10.1016/j.neuron.2005.04.001	38	117	117	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7043	10.1371/journal.pone.0007043	http://dx.doi.org/10.1371/journal.pone.0007043			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19756154	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970000012
J	Bednarski, BK; Baldwin, AS; Kim, HJ				Bednarski, Brian K.; Baldwin, Albert S., Jr.; Kim, Hong Jin			Addressing Reported Pro-Apoptotic Functions of NF-kappa B: Targeted Inhibition of Canonical NF-kappa B Enhances the Apoptotic Effects of Doxorubicin	PLOS ONE			English	Article							GENE-EXPRESSION; ACTIVATION; BETA; IKK; ALPHA; CHEMORESISTANCE; TRANSCRIPTION; MANAGEMENT; CPT-11; CELLS	The ability of the transcription factor NF-kappa B to upregulate anti-apoptotic proteins has been linked to the chemoresistance of solid tumors to standard chemotherapy. In contrast, recent studies have proposed that, in response to doxorubicin, NF-kappa B can be pro-apoptotic through repression of anti-apoptotic target genes. However, there is little evidence analyzing the outcome of NF-kappa B inhibition on the cytotoxicity of doxorubicin in studies describing pro-apoptotic NF-kappa B activity. In this study, we further characterize the activation of NF-kappa B in response to doxorubicin and evaluate its role in chemotherapy-induced cell death in sarcoma cells where NF-kappa B is reported to be pro-apoptotic. Doxorubicin treatment in U2OS cells induced canonical NF-kappa B activity as evidenced by increased nuclear accumulation of phosphorylated p65 at serine 536 and increased DNA-binding activity. Co-treatment with a small molecule IKK beta inhibitor, Compound A, abrogated this response. RT-PCR evaluation of anti-apoptotic gene expression revealed that doxorubicin-induced transcription of cIAP2 was inhibited by Compound A, while doxorubicin-induced repression of other anti-apoptotic genes was unaffected by Compound A or siRNA to p65. Furthermore, the combination of doxorubicin and canonical NF-kappa B inhibition with Compound A or siRNA to p65 resulted in decreased cell viability measured by trypan blue staining and MTS assay and increased apoptosis measured by cleaved poly (ADP-ribose) polymerase and cleaved caspase 3 when compared to doxorubicin alone. Our results demonstrate that doxorubicin-induced canonical NF-kappa B activity associated with phosphorylated p65 is anti-apoptotic in its function and that doxorubicin-induced repression of anti-apoptotic genes occurs independent of p65. Therefore, combination therapies incorporating NF-kappa B inhibitors together with standard chemotherapies remains a viable method to improve the clinical outcomes in patients with advanced stage malignancies.			Bednarski, BK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	hongjin_kim@med.unc.edu			NCI NIH HHS [K08 CA098240, T32 CA 009688, GI SPORE P50 CA10699, R01 CA 73756, K08 CA 098240, R01 CA073756, T32 CA009688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA098240, T32CA009688, R01CA073756] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashikawa K, 2004, BIOCHEM PHARMACOL, V67, P353, DOI 10.1016/j.bcp.2003.08.039; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bednarski BK, 2008, MOL CANCER THER, V7, P1827, DOI 10.1158/1535-7163.MCT-08-0321; Campbell KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-101; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen WS, 2008, J CELL BIOCHEM, V105, P554, DOI 10.1002/jcb.21856; Cusack JC, 2001, CANCER RES, V61, P3535; Cusack JC, 2000, CANCER RES, V60, P2323; GANGADHARAN C, 2009, J CELL BIOCH; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hueman MT, 2008, SURG CLIN N AM, V88, P583, DOI 10.1016/j.suc.2008.03.002; Hueman MT, 2008, SURG CLIN N AM, V88, pXIII, DOI 10.1016/j.suc.2008.04.009; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nadiminty N, 2008, PROSTATE, V68, P1725, DOI 10.1002/pros.20839; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Shen HM, 2009, APOPTOSIS, V14, P348, DOI 10.1007/s10495-009-0315-0; THORNTON K, 2008, SURG CLIN N AM, V88, pR8; Thornton K, 2008, SURG CLIN N AM, V88, P647, DOI 10.1016/j.suc.2008.03.004; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	24	35	35	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6992	10.1371/journal.pone.0006992	http://dx.doi.org/10.1371/journal.pone.0006992			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746155	Green Submitted, Green Published, gold			2022-12-27	WOS:000269696500006
J	Carpenter, J; Hutter, S; Baines, JF; Roller, J; Saminadin-Peter, SS; Parsch, J; Jiggins, FM				Carpenter, Jennifer; Hutter, Stephan; Baines, John F.; Roller, Julia; Saminadin-Peter, Sarah S.; Parsch, John; Jiggins, Francis M.			The Transcriptional Response of Drosophila melanogaster to Infection with the Sigma Virus (Rhabdoviridae)	PLOS ONE			English	Article							HOST-PARASITE INTERACTIONS; IMMUNE-RESPONSE; RNA VIRUSES; ANTIVIRAL RESPONSE; VIRAL-INFECTION; IN-VIVO; TOLL; GENES; TRANSMISSION; TRANSLATION	Background: Bacterial and fungal infections induce a potent immune response in Drosophila melanogaster, but it is unclear whether viral infections induce an antiviral immune response. Using microarrays, we examined the changes in gene expression in Drosophila that occur in response to infection with the sigma virus, a negative-stranded RNA virus (Rhabdoviridae) that occurs in wild populations of D. melanogaster. Principal Findings: We detected many changes in gene expression in infected flies, but found no evidence for the activation of the Toll, IMD or Jak-STAT pathways, which control immune responses against bacteria and fungi. We identified a number of functional categories of genes, including serine proteases, ribosomal proteins and chorion proteins that were overrepresented among the differentially expressed genes. We also found that the sigma virus alters the expression of many more genes in males than in females. Conclusions: These data suggest that either Drosophila do not mount an immune response against the sigma virus, or that the immune response is not controlled by known immune pathways. If the latter is true, the genes that we identified as differentially expressed after infection are promising candidates for controlling the host's response to the sigma virus.			Carpenter, J (corresponding author), Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.	jenny@jennycarpenter.com	Hutter, Stephan/K-3677-2014; Baines, John F/B-3580-2010	Baines, John F/0000-0002-8132-4909; Jiggins, Francis Michael/0000-0001-7470-8157; Hutter, Stephan/0000-0003-2432-8898	Wellcome Trust [WT081279] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ammar ED, 2009, ANNU REV ENTOMOL, V54, P447, DOI 10.1146/annurev.ento.54.110807.090454; Avila A, 2002, MOL CELL BIOL, V22, P8787, DOI 10.1128/MCB.22.24.8787-8795.2002; Baker DA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-454; Bangham J, 2008, MOL ECOL, V17, P3800, DOI 10.1111/j.1365-294X.2008.03873.x; Bangham J, 2008, GENETICS, V178, P2191, DOI 10.1534/genetics.107.085449; Bischoff V, 2006, PLOS PATHOG, V2, P139, DOI 10.1371/journal.ppat.0020014; Bourtzis K, 2000, INSECT MOL BIOL, V9, P635, DOI 10.1046/j.1365-2583.2000.00224.x; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Brun G, 1980, GENET BIOL DROSOPHIL, P625; Carpenter JA, 2007, MOL ECOL, V16, P3947, DOI 10.1111/j.1365-294X.2007.03460.x; Cherry S, 2005, GENE DEV, V19, P445, DOI 10.1101/gad.1267905; Cherry S, 2004, NAT IMMUNOL, V5, P81, DOI 10.1038/ni1019; CONTAMINE D, 1989, GENETICS, V123, P525; Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; FLEURIET A, 1988, EVOL BIOL, V23, P1; Flicek P, 2008, NUCLEIC ACIDS RES, V36, pD707, DOI 10.1093/nar/gkm988; Galiana-Arnoux D, 2006, NAT IMMUNOL, V7, P590, DOI 10.1038/ni1335; Gnad F, 2006, BIOINFORMATICS, V22, P2577, DOI 10.1093/bioinformatics/btl422; Hurst GDD, 2003, INSECT MOL BIOL, V12, P93, DOI 10.1046/j.1365-2583.2003.00380.x; Hutter S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r12; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Lewis E.B., 1960, DROS INFORM SERV, V34, P117, DOI DOI 10.1101/PDB.REC081414; McKean KA, 2005, EVOLUTION, V59, P1510; Obbard DJ, 2009, PHILOS T R SOC B, V364, P99, DOI 10.1098/rstb.2008.0168; Rainer J, 2006, NUCLEIC ACIDS RES, V34, pW498, DOI 10.1093/nar/gkl038; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Roxstrom-Lindquist K, 2004, EMBO REP, V5, P207, DOI 10.1038/sj.embor.7400073; Sanchez-Martinez JG, 2007, AQUAC RES, V38, P1339, DOI 10.1111/j.1365-2109.2007.01827.x; SPRADLING AC, 1980, P NATL ACAD SCI-BIOL, V77, P1096, DOI 10.1073/pnas.77.2.1096; Townsend JP, 2002, GENOME BIOL, V3; Townsend JP, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-54; Tsai CW, 2008, APPL ENVIRON MICROB, V74, P3251, DOI 10.1128/AEM.02248-07; Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694; Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006; Whitlow ZW, 2006, J VIROL, V80, P11733, DOI 10.1128/JVI.00971-06; WYERS F, 1995, J VIROL, V69, P4463, DOI 10.1128/JVI.69.7.4463-4470.1995; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102	42	56	58	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6838	10.1371/journal.pone.0006838	http://dx.doi.org/10.1371/journal.pone.0006838			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718442	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900011
J	Kanerva, K; Lappalainen, J; Makitie, LT; Virolainen, S; Kovanen, PT; Andersson, LC				Kanerva, Kristiina; Lappalainen, Jani; Makitie, Laura T.; Virolainen, Susanna; Kovanen, Petri T.; Andersson, Leif C.			Expression of Antizyme Inhibitor 2 in Mast Cells and Role of Polyamines as Selective Regulators of Serotonin Secretion	PLOS ONE			English	Article								Background: Upon IgE-mediated activation, mast cells (MC) exocytose their cytoplasmic secretory granules and release a variety of bioactive substances that trigger inflammatory responses. Polyamines mediate numerous cellular and physiological functions. We report here that MCs express antizyme inhibitor 2 (AZIN2), an activator of polyamine biosynthesis, previously reported to be exclusively expressed in the brain and testis. We have investigated the intracellular localization of AZIN2 both in resting and activated MCs. In addition, we have examined the functional role of polyamines, downstream effectors of AZIN2, as potential regulators of MC activity. Methodology/Principal Findings: Immunostainings show that AZIN2 is expressed in primary and neoplastic human and rodent MCs. We demonstrate that AZIN2 localizes in the Vamp-8 positive, serotonin-containing subset of MC granules, but not in tryptase-containing granules, as revealed by double immunofluorescence stainings. Furthermore, activation of MCs induces rapid upregulation of AZIN2 expression and its redistribution, suggesting a role for AZIN2 in secretory granule exocytosis. We also demonstrate that release of serotonin from activated MCs is polyamine-dependent whereas release of histamine and beta-hexosaminidase is not, indicating a granule subtype-specific function for polyamines. Conclusions/Significance: The study reports for the first time the expression of AZIN2 outside the brain and testis, and demonstrates the intracellular localization of endogenous AZIN2 in MCs. The granule subtype-specific expression and its induction after MC activation suggest a role for AZIN2 as a local, in situ regulator of polyamine biosynthesis in association with serotonin-containing granules of MCs. Furthermore, our data indicates a novel function for polyamines as selective regulators of serotonin release from MCs.			Kanerva, K (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland.	leif.andersson@helsinki.fi		Kanerva, Kristiina/0000-0003-1680-9448				Bercovich Z, 2004, J BIOL CHEM, V279, P54097, DOI 10.1074/jbc.M410234200; BUEB JL, 1992, BIOCHEM J, V282, P545, DOI 10.1042/bj2820545; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Ivanov IP, 1998, GENOMICS, V52, P119, DOI 10.1006/geno.1998.5434; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kanerva K, 2008, BIOCHEM J, V409, P187, DOI 10.1042/BJ20071004; Keren-Paz A, 2006, ONCOGENE, V25, P5163, DOI 10.1038/sj.onc.1209521; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KOENIG H, 1983, NATURE, V305, P530, DOI 10.1038/305530a0; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; Lappalainen J, 2007, CLIN EXP ALLERGY, V37, P1404, DOI 10.1111/j.1365-2222.2007.02778.x; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Lopez-Contreras AJ, 2008, J BIOL CHEM, V283, P20761, DOI 10.1074/jbc.M801024200; Makitie LT, 2009, EXP CELL RES, V315, P1008, DOI 10.1016/j.yexcr.2009.01.029; Mangold U, 2008, ONCOGENE, V27, P604, DOI 10.1038/sj.onc.1210685; MCCORMACK JG, 1989, BIOCHEM J, V264, P167, DOI 10.1042/bj2640167; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Pitkanen LT, 2001, BIOCHEM BIOPH RES CO, V287, P1051, DOI 10.1006/bbrc.2001.5703; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Puri N, 2008, P NATL ACAD SCI USA, V105, P2580, DOI 10.1073/pnas.0707854105; Schipper RG, 2004, J HISTOCHEM CYTOCHEM, V52, P1259, DOI 10.1369/jhc.4C6389.2004; Shantz LM, 2007, AMINO ACIDS, V33, P213, DOI 10.1007/s00726-007-0531-2; Shin M, 2008, HISTOCHEM CELL BIOL, V129, P659, DOI 10.1007/s00418-008-0400-4; Snapir Z, 2008, BIOCHEM J, V410, P613, DOI 10.1042/BJ20071423; TAUB D, 1995, J IMMUNOL, V154, P2393; THEOHARIDES TC, 1982, NATURE, V297, P229, DOI 10.1038/297229a0; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289	39	38	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6858	10.1371/journal.pone.0006858	http://dx.doi.org/10.1371/journal.pone.0006858			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718454	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415900023
J	Bronner, IF; Bochdanovits, Z; Rizzu, P; Kamphorst, W; Ravid, R; van Swieten, JC; Heutink, P				Bronner, Iraad F.; Bochdanovits, Zoltan; Rizzu, Patrizia; Kamphorst, Wouter; Ravid, Rivka; van Swieten, John C.; Heutink, Peter			Comprehensive mRNA Expression Profiling Distinguishes Tauopathies and Identifies Shared Molecular Pathways	PLOS ONE			English	Article								Background: Understanding the aetiologies of neurodegenerative diseases such as Alzheimer's disease (AD), Pick's disease (PiD), Progressive Supranuclear Palsy (PSP) and Frontotemporal dementia (FTD) is often hampered by the considerable clinical and molecular overlap between these diseases and normal ageing. The development of high throughput genomic technologies such as microarrays provide a new molecular tool to gain insight in the complexity and relationships between diseases, as they provide data on the simultaneous activity of multiple genes, gene networks and cellular pathways. Methodology/Principal Findings: We have constructed genome wide expression profiles from snap frozen post-mortem tissue from the medial temporal lobe of patients with four neurodegenerative disorders (5 AD, 5 PSP, 5 PiD and 5 FTD patients) and 5 control subjects. All patients were matched for age, gender, ApoE-e and MAPT (tau) haplotype. From all groups a total of 790 probes were shown to be differently expressed when compared to control individuals. The results from these experiments were then used to investigate the correlations between clinical, pathological and molecular findings. From the 790 identified probes we extracted a gene set of 166 probes whose expression could discriminate between these disorders and normal ageing. Conclusions/Significance: From genome wide expression profiles we extracted a gene set of 166 probes whose expression could discriminate between neurological disorders and normal ageing. This gene set can be further developed into an accurate microarray-based classification test. Furthermore, from this dataset we extracted a disease specific set of genes and identified two aging related transcription factors (FOXO1A and FOXO3A) as possible drug targets related to neurodegenerative disease.			Bronner, IF (corresponding author), Vrije Univ Amsterdam Med Ctr, Sect Med Genom, Dept Clin Genet, Amsterdam, Netherlands.	p.heutink@vumc.nl		Heutink, Peter/0000-0001-5218-1737; van Swieten, John/0000-0001-6278-6844				Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Bochdanovits Z, 2003, EVOLUTION, V57, P1829; Bochdanovits Z, 2003, MOL BIOL EVOL, V20, P1760, DOI 10.1093/molbev/msg179; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRONNER IF, 2005, BRAIN; Bronner IF, 2007, EUR J HUM GENET, V15, P369, DOI 10.1038/sj.ejhg.5201772; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Chiang AP, 2006, P NATL ACAD SCI USA, V103, P6287, DOI 10.1073/pnas.0600158103; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; CONSTANTINIDIS J, 1985, PICK DEMENTIA ANATOM, P72; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Fitzpatrick R, 2002, BBA-GENE STRUCT EXPR, V1574, P10, DOI 10.1016/S0167-4781(01)00322-0; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Harrison PJ, 1995, NEUROSCI LETT, V200, P151, DOI 10.1016/0304-3940(95)12102-A; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Huang TT, 2006, NAT CELL BIOL, V8, P1043, DOI 10.1038/ncb1006-1043; Hynd MR, 2003, J NEUROCHEM, V85, P543, DOI 10.1046/j.1471-4159.2003.01747.x; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Mandel S, 2005, ANN NY ACAD SCI, V1053, P356, DOI 10.1196/annals.1344.031; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Neary D, 2005, LANCET NEUROL, V4, P771, DOI 10.1016/S1474-4422(05)70223-4; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Park JW, 2006, J MED GENET, V43, P598, DOI 10.1136/jmg.2005.040162; Preece P, 2003, MOL BRAIN RES, V116, P7, DOI 10.1016/S0169-328X(03)00208-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rizzu P, 2006, AM J MED GENET B, V141B, P944, DOI 10.1002/ajmg.b.30410; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scaravilli T, 2005, MOVEMENT DISORD, V20, pS21, DOI 10.1002/mds.20536; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shelton JG, 2004, CELL CYCLE, V3, P372; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Stuart CA, 1999, METABOLISM, V48, P876, DOI 10.1016/S0026-0495(99)90222-6; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Yasojima K, 2001, BRAIN RES PROTOC, V8, P212, DOI 10.1016/S1385-299X(01)00119-2	49	32	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6826	10.1371/journal.pone.0006826	http://dx.doi.org/10.1371/journal.pone.0006826			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714246	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415800010
J	Nandy, A				Nandy, Ashesh			Empirical Relationship between Intra-Purine and Intra-Pyrimidine Differences in Conserved Gene Sequences	PLOS ONE			English	Article							GRAPHICAL REPRESENTATION; DNA-SEQUENCES; TOPOLOGICAL INDEXES; NUCLEOTIDE; EVOLUTION	DNA sequences seen in the normal character-based representation appear to have a formidable mixing of the four nucleotides without any apparent order. Nucleotide frequencies and distributions in the sequences have been studied extensively, since the simple rule given by Chargaff almost a century ago that equates the total number of purines to the pyrimidines in a duplex DNA sequence. While it is difficult to trace any relationship between the bases from studies in the character representation of a DNA sequence, graphical representations may provide a clue. These novel representations of DNA sequences have been useful in providing an overview of base distribution and composition of the sequences and providing insights into many hidden structures. We report here our observation based on a graphical representation that the intra-purine and intra-pyrimidine differences in sequences of conserved genes generally follow a quadratic distribution relationship and show that this may have arisen from mutations in the sequences over evolutionary time scales. From this hitherto undescribed relationship for the gene sequences considered in this report we hypothesize that such relationships may be characteristic of these sequences and therefore could become a barrier to large scale sequence alterations that override such characteristics, perhaps through some monitoring process inbuilt in the DNA sequences. Such relationship also raises the possibility of intron sequences playing an important role in maintaining the characteristics and could be indicative of possible intron-late phenomena.			Nandy, A (corresponding author), Jadavpur Univ, Sch Environm Studies, Kolkata, W Bengal, India.	anandy43@yahoo.com						Aguero-Chapin G, 2009, J PROTEOME RES, V8, P2122, DOI 10.1021/pr800867y; ARNOLD J, 1988, NUCLEIC ACIDS RES, V16, P7145, DOI 10.1093/nar/16.14.7145; Cruz-Monteagudo M, 2008, CHEM RES TOXICOL, V21, P619, DOI 10.1021/tx700296t; Estrada E, 2001, CURR MED CHEM, V8, P1573, DOI 10.2174/0929867013371923; Freeman JM., 1998, SCIENCE, V279, P1827, DOI [10.1126/science.279.5358.1827a, DOI 10.1126/science.279.5358.1827a, DOI 10.1126/SCIENCE.279.5358.1827A]; Garcia JA, 2005, REV MEX FIS, V51, P122; GATES MA, 1986, J THEOR BIOL, V119, P319, DOI 10.1016/S0022-5193(86)80144-8; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; Gonzalez-Diaz H, 2008, PROTEOMICS, V8, P750, DOI 10.1002/pmic.200700638; Gonzalez-Diaz H, 2007, CURR TOP MED CHEM, V7, P1015, DOI 10.2174/156802607780906771; Gonzalez-Diaz H, 2008, CURR TOP MED CHEM, V8, P1676, DOI 10.2174/156802608786786543; Greco C, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S4-S15; HAMORI E, 1983, J BIOL CHEM, V258, P1318; JEFFREY HJ, 1990, NUCLEIC ACIDS RES, V18, P2163, DOI 10.1093/nar/18.8.2163; Larionov S, 2008, CHAOS, V18, DOI 10.1063/1.2826631; LEONG PM, 1995, COMPUT APPL BIOSCI, V11, P503; LEWIN B, GENES, V9, P18; Liao B, 2006, CHEM PHYS LETT, V421, P313, DOI 10.1016/j.cplett.2006.01.030; Liebovitch LS, 1996, BIOPHYS J, V71, P1539, DOI 10.1016/S0006-3495(96)79356-6; Lo NW, 2007, J INF SCI ENG, V23, P1723; Lolle SJ, 2005, NATURE, V434, P505, DOI 10.1038/nature03380; NANDY A, 1995, CURR SCI INDIA, V68, P75; NANDY A, 1994, CURR SCI INDIA, V66, P309; Nandy A, 2006, ARKIVOC, P211, DOI 10.3998/ark.5550190.0007.907; Nandy Ashesh, 2009, In Silico Biology, V9, P77, DOI 10.3233/ISB-2009-0389; PENG CK, 1992, NATURE, V356, P168, DOI 10.1038/356168a0; Prusak B, 2004, ACTA BIOCHIM POL, V51, P897; QIDAI, 2007, J COMPUT CHEM, V28, P1434; Randic M, 2000, J CHEM INF COMP SCI, V40, P1235, DOI 10.1021/ci000034q; Raychaudhury C, 1999, J CHEM INF COMP SCI, V39, P243, DOI 10.1021/ci980077v; Roy A, 1998, J BIOSCIENCES, V23, P55, DOI 10.1007/BF02728525; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SUEOKA N, 1962, P NATL ACAD SCI USA, V48, P483; Wang WP, 2006, INT J QUANTUM CHEM, V106, P1998, DOI 10.1002/qua.21001	34	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6829	10.1371/journal.pone.0006829	http://dx.doi.org/10.1371/journal.pone.0006829			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714250	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415800013
J	Oakley, MS; Majam, V; Mahajan, B; Gerald, N; Anantharaman, V; Ward, JM; Faucette, LJ; McCutchan, TF; Zheng, H; Terabe, M; Berzofsky, JA; Aravind, L; Kumar, S				Oakley, Miranda S.; Majam, Victoria; Mahajan, Babita; Gerald, Noel; Anantharaman, Vivek; Ward, Jerrold M.; Faucette, Lawrence J.; McCutchan, Thomas F.; Zheng, Hong; Terabe, Masaki; Berzofsky, Jay A.; Aravind, L.; Kumar, Sanjai			Pathogenic Roles of CD14, Galectin-3, and OX40 during Experimental Cerebral Malaria in Mice	PLOS ONE			English	Article								An in-depth knowledge of the host molecules and biological pathways that contribute towards the pathogenesis of cerebral malaria would help guide the development of novel prognostics and therapeutics. Genome-wide transcriptional profiling of the brain tissue during experimental cerebral malaria (ECM) caused by Plasmodium berghei ANKA parasites in mice, a well established surrogate of human cerebral malaria, has been useful in predicting the functional classes of genes involved and pathways altered during the course of disease. To further understand the contribution of individual genes to the pathogenesis of ECM, we examined the biological relevance of three molecules -CD14, galectin-3, and OX40 that were previously shown to be overexpressed during ECM. We find that CD14 plays a predominant role in the induction of ECM and regulation of parasite density; deletion of the CD14 gene not only prevented the onset of disease in a majority of susceptible mice (only 21% of CD14-deficient compared to 80% of wildtype mice developed ECM, p < 0.0004) but also had an ameliorating effect on parasitemia (a 2 fold reduction during the cerebral phase). Furthermore, deletion of the galectin-3 gene in susceptible C57BL/6 mice resulted in partial protection from ECM (47% of galectin-3-deficient versus 93% of wildtype mice developed ECM, p < 0.0073). Subsequent adherence assays suggest that galectin-3 induced pathogenesis of ECM is not mediated by the recognition and binding of galectin-3 to P. berghei ANKA parasites. A previous study of ECM has demonstrated that brain infiltrating T cells are strongly activated and are CD44(+) CD62L(-) differentiated memory T cells [1]. We find that OX40, a marker of both T cell activation and memory, is selectively upregulated in the brain during ECM and its distribution among CD4(+) and CD8(+) T cells accumulated in the brain vasculature is approximately equal.			Oakley, MS (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Bacterial Parasit & Allergen Prod, Bethesda, MD 20014 USA.	sanjai.kumar@fda.hhs.gov	Anantharaman, Vivek/ABB-9991-2021	Anantharaman, Vivek/0000-0001-8395-0009; Aravind, L/0000-0003-0771-253X	NATIONAL CANCER INSTITUTE [ZIASC004020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000208, ZIGAI001047, Z01AI001047, ZIAAI000208] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [ZIALM594244] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akashi-Takamura S, 2008, CURR OPIN IMMUNOL, V20, P420, DOI 10.1016/j.coi.2008.07.001; Almkvist J, 2002, GLYCOCONJUGATE J, V19, P575, DOI 10.1023/B:GLYC.0000014088.21242.e0; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0; Bernardes ES, 2006, AM J PATHOL, V168, P1910, DOI 10.2353/ajpath.2006.050636; Carboni S, 2003, J NEUROIMMUNOL, V145, P1, DOI 10.1016/j.jneuroim.2003.07.001; CELADA A, 1984, INT ARCH ALLER A IMM, V73, P363, DOI 10.1159/000233499; CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2; Coban C, 2007, INT IMMUNOL, V19, P67, DOI 10.1093/intimm/dxl123; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; FINLEY RW, 1982, J IMMUNOL, V129, P2213; Giacomelli R, 2001, CLIN EXP RHEUMATOL, V19, P317; GRAU GE, 1986, J IMMUNOL, V137, P2348; Griffith JW, 2007, J INFECT DIS, V196, P1553, DOI 10.1086/522865; HAZIOT A, 1995, J IMMUNOL, V154, P6529; Haziot A, 2001, J IMMUNOL, V166, P1075, DOI 10.4049/jimmunol.166.2.1075; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Higgins LM, 1999, J IMMUNOL, V162, P486; Hori T, 2006, INT J HEMATOL, V83, P17, DOI 10.1532/IJH97.05151; HSU DK, 1992, J BIOL CHEM, V267, P14167; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Hughes RC, 2001, BIOCHIMIE, V83, P667; KHARAZMI A, 1984, SCAND J IMMUNOL, V20, P93, DOI 10.1111/j.1365-3083.1984.tb00981.x; Kleshchenko YY, 2004, INFECT IMMUN, V72, P6717, DOI 10.1128/IAI.72.11.6717-6721.2004; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; KUMAR S, 1989, J IMMUNOL, V143, P2017; Lepenies B, 2008, MED MICROBIOL IMMUN, V197, P39, DOI 10.1007/s00430-007-0057-y; Liu FT, 2005, INT ARCH ALLERGY IMM, V136, P385, DOI 10.1159/000084545; MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650; Maegraith B, 1972, Adv Parasitol, V10, P49, DOI 10.1016/S0065-308X(08)60172-4; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Miu J, 2008, J IMMUNOL, V180, P1217, DOI 10.4049/jimmunol.180.2.1217; Miyake K, 2006, J ENDOTOXIN RES, V12, P195, DOI 10.1179/096805106X118807; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nangia-Makker P, 2007, J BIOENERG BIOMEMBR, V39, P79, DOI 10.1007/s10863-006-9063-9; Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221; Oakley MS, 2008, INFECT IMMUN, V76, P4518, DOI 10.1128/IAI.00525-08; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; Potter S, 2006, INT J PARASITOL, V36, P485, DOI 10.1016/j.ijpara.2005.12.005; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Salek-Ardakani S, 2006, VACCINE, V24, P872, DOI 10.1016/j.vaccine.2005.07.108; Sato S, 2002, GLYCOCONJUGATE J, V19, P583, DOI 10.1023/B:GLYC.0000014089.17121.cc; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Takasawa N, 2001, JPN J CANCER RES, V92, P377, DOI 10.1111/j.1349-7006.2001.tb01105.x; TAYLOR TE, 2009, T R SOC TROP MED HYG; Togbe D, 2007, AM J PATHOL, V170, P1640, DOI 10.2353/ajpath.2007.060889; TRUBOWITZ S, 1968, SCIENCE, V162, P273, DOI 10.1126/science.162.3850.273; van den Berg TK, 2004, J IMMUNOL, V173, P1902, DOI 10.4049/jimmunol.173.3.1902; Wang ET, 2006, P NATL ACAD SCI USA, V103, P135, DOI 10.1073/pnas.0509691102; Weinberg AD, 1999, J IMMUNOL, V162, P1818; Weinberg AD, 2004, J LEUKOCYTE BIOL, V75, P962, DOI 10.1189/jlb.1103586; Wenisch C, 1996, CLIN EXP IMMUNOL, V105, P74, DOI 10.1046/j.1365-2249.1996.d01-723.x; Wiese L, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-3; Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yanez DM, 1996, J IMMUNOL, V157, P1620; Yoshioka T, 2000, EUR J IMMUNOL, V30, P2815, DOI 10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-#	62	30	30	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6793	10.1371/journal.pone.0006793	http://dx.doi.org/10.1371/journal.pone.0006793			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710907	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415600007
J	Deng, MQ; Li, R				Deng, Manqi; Li, Rong			Sperm Chromatin-Induced Ectopic Polar Body Extrusion in Mouse Eggs after ICSI and Delayed Egg Activation	PLOS ONE			English	Article								Meiotic chromosomes in an oocyte are not only a maternal genome carrier but also provide a positional signal to induce cortical polarization and define asymmetric meiotic division of the oocyte, resulting in polar body extrusion and haploidization of the maternal genome. The meiotic chromosomes play dual function in determination of meiosis: 1) organizing a bipolar spindle formation and 2) inducing cortical polarization and assembly of a distinct cortical cytoskeleton structure in the overlying cortex for polar body extrusion. At fertilization, a sperm brings exogenous paternal chromatin into the egg, which induces ectopic cortical polarization at the sperm entry site and leads to a cone formation, known as fertilization cone. Here we show that the sperm chromatin-induced fertilization cone formation is an abortive polar body extrusion due to lack of spindle induction by the sperm chromatin during fertilization. If experimentally manipulating the fertilization process to allow sperm chromatin to induce both cortical polarization and spindle formation, the fertilization cone can be converted into polar body extrusion. This suggests that sperm chromatin is also able to induce polar body extrusion, like its maternal counterpart. The usually observed cone formation instead of ectopic polar body extrusion induced by sperm chromatin during fertilization is due to special sperm chromatin compaction which restrains it from rapid spindle induction and therefore provides a protective mechanism to prevent a possible paternal genome loss during ectopic polar body extrusion.			Deng, MQ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet & Gynecol & Reprod Biol, Boston, MA 02115 USA.	Mdeng3@BICS.BWH.Harvard.edu; RLI@stowers-institute.org						Arney KL, 2001, INT J DEV BIOL, V45, P533; BALHORN R, 1982, J CELL BIOL, V93, P298, DOI 10.1083/jcb.93.2.298; Braun RE, 2001, NAT GENET, V28, P10, DOI 10.1038/88194; Bringmann H, 2005, NATURE, V436, P731, DOI 10.1038/nature03823; Bringmann H, 2005, CELL CYCLE, V4, P1709, DOI 10.4161/cc.4.12.2215; Calvin H. I, 1971, Journal Reprod Fertil, VNo. 13, P65; Cao LG, 1996, MOL BIOL CELL, V7, P225, DOI 10.1091/mbc.7.2.225; Caron C, 2005, PROG MOLEC, V38, P65; Cho C, 2003, BIOL REPROD, V69, P211, DOI 10.1095/biolreprod.102.015115; CHOURROUT D, 1982, REPROD NUTR DEV, V22, P713, DOI 10.1051/rnd:19820601; Churikov D, 2004, CYTOGENET GENOME RES, V105, P203, DOI 10.1159/000078190; CLARKE HJ, 1986, J CELL BIOL, V102, P1039, DOI 10.1083/jcb.102.3.1039; CROZET N, 1988, GAMETE RES, V19, P291, DOI 10.1002/mrd.1120190308; Dadoune JP, 2003, MICROSC RES TECHNIQ, V61, P56, DOI 10.1002/jemt.10317; Deng MQ, 2007, DEV CELL, V12, P301, DOI 10.1016/j.devcel.2006.11.008; Deng MQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005249; Deng MQ, 2005, DEV BIOL, V278, P358, DOI 10.1016/j.ydbio.2004.11.013; Deng MQ, 2003, DEV BIOL, V257, P166, DOI 10.1016/S0012-1606(03)00045-9; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Duncan FE, 2005, DEV BIOL, V280, P38, DOI 10.1016/j.ydbio.2004.12.034; Govin J, 2007, J CELL BIOL, V176, P283, DOI 10.1083/jcb.200604141; Hales KG, 1999, CURR OPIN CELL BIOL, V11, P717, DOI 10.1016/S0955-0674(99)00042-3; HARROUK W, 1993, CHROMOSOMA, V102, P279, DOI 10.1007/BF00352402; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hogan B., 1986, Manipulating the mouse embryo. A laboratory manual.; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Jones KT, 2005, REPRODUCTION, V130, P813, DOI 10.1530/rep.1.00710; Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; Kishigami S, 2006, NAT PROTOC, V1, P125, DOI 10.1038/nprot.2006.21; Laberge RM, 2005, ARCH ANDROLOGY, V51, P125, DOI 10.1080/014850190518134; Lawrence Y, 1997, DEVELOPMENT, V124, P233; LONGO FJ, 1978, DEV BIOL, V67, P249, DOI 10.1016/0012-1606(78)90197-5; LONGO FJ, 1988, INT REV CYTOL, V113, P233; LONGO FJ, 1985, DEV BIOL, V107, P382, DOI 10.1016/0012-1606(85)90320-3; MARO B, 1986, J EMBRYOL EXP MORPH, V92, P11; MARO B, 1984, J EMBRYOL EXP MORPH, V81, P211; Matson S, 2006, BIOL REPROD, V74, P169, DOI 10.1095/biolreprod.105.046409; Morris ID, 2002, HUM REPROD, V17, P990, DOI 10.1093/humrep/17.4.990; Ogura A, 1998, P NATL ACAD SCI USA, V95, P5611, DOI 10.1073/pnas.95.10.5611; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Rousseaux S, 2005, GENE, V345, P139, DOI 10.1016/j.gene.2004.12.004; Sasagawa I, 1998, BIOL REPROD, V58, P248, DOI 10.1095/biolreprod58.1.248; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; Tarozzi N, 2007, REPROD BIOMED ONLINE, V14, P746, DOI 10.1016/S1472-6483(10)60678-5; Terada Y, 2000, MOL REPROD DEV, V56, P89, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;89::AID-MRD11&gt;3.0.CO;2-I; Tesarik J, 1996, HUM REPROD, V11, P780; TILNEY LG, 1980, J CELL BIOL, V87, P771, DOI 10.1083/jcb.87.3.771; Tomashov-Matar R, 2005, REPRODUCTION, V130, P467, DOI 10.1530/rep.1.00746; VANBLERKOM J, 1986, J EMBRYOL EXP MORPH, V93, P213; Vinot S, 2004, CURR BIOL, V14, P520, DOI 10.1016/j.cub.2004.02.061; Vitale AM, 2007, MOL REPROD DEV, V74, P608, DOI 10.1002/mrd.20648; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Ward WS, 1999, BIOL REPROD, V60, P702, DOI 10.1095/biolreprod60.3.702; Ward WS, 2000, ZYGOTE, V8, P51, DOI 10.1017/S0967199400000824; WARD WS, 1991, BIOL REPROD, V44, P569, DOI 10.1095/biolreprod44.4.569; WARD WS, 1994, J CELL BIOCHEM, V55, P77, DOI 10.1002/jcb.240550109; Webster KE, 2005, P NATL ACAD SCI USA, V102, P4068, DOI 10.1073/pnas.0500702102; YOSHIDA N, 2006, DEV BIOL; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683; Zhao M, 2004, GENESIS, V38, P200, DOI 10.1002/gene.20019; 2008, FERTIL STERIL, V90, pS199	67	19	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2009	4	9							e7171	10.1371/journal.pone.0007171	http://dx.doi.org/10.1371/journal.pone.0007171			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HR	19787051	Green Submitted, Green Published, gold			2022-12-27	WOS:000270290100006
J	Bremer, J; Heikenwalder, M; Haybaeck, J; Tiberi, C; Krautler, NJ; Kurrer, MO; Aguzzi, A				Bremer, Juliane; Heikenwalder, Mathias; Haybaeck, Johannes; Tiberi, Cinzia; Krautler, Nike Julia; Kurrer, Michael O.; Aguzzi, Adriano			Repetitive Immunization Enhances the Susceptibility of Mice to Peripherally Administered Prions	PLOS ONE			English	Article							FOLLICULAR DENDRITIC CELLS; CREUTZFELDT-JAKOB-DISEASE; SCRAPIE AGENT; SPONGIFORM ENCEPHALOPATHIES; VARIANT; PROTEIN; NEUROINVASION; IMMUNE; SPLEEN; BSE	The susceptibility of humans and animals to prion infections is determined by the virulence of the infectious agent, by genetic modifiers, and by hitherto unknown host and environmental risk factors. While little is known about the latter two, the activation state of the immune system was surmised to influence prion susceptibility. Here we administered prions to mice that were repeatedly immunized by two initial injections of CpG oligodeoxynucleotides followed by repeated injections of bovine serum albumin/alum. Immunization greatly reduced the required dosage of peripherally administered prion inoculum necessary to induce scrapie in 50% of mice. No difference in susceptibility was observed following intracerebral prion challenge. Due to its profound impact onto scrapie susceptibility, the host immune status may determine disease penetrance after low-dose prion exposure, including those that may give rise to iatrogenic and variant Creutzfeldt-Jakob disease.			Bremer, J (corresponding author), Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano.aguzzi@usz.ch	Bremer, Juliane/AAH-9487-2020; Heikenwalder, Mathias/AAA-2269-2020; Bremer, Juliane/E-2298-2012; Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2004, NAT REV IMMUNOL, V4, P725, DOI 10.1038/nri1437; Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Aguzzi A, 1996, NATURE, V381, P734, DOI 10.1038/381734a0; Aguzzi A, 1996, NATURE, V383, P666, DOI 10.1038/383666a0; Aguzzi A, 2008, ANNU REV NEUROSCI, V31, P439, DOI 10.1146/annurev.neuro.31.060407.125620; Aguzzi A, 2008, ANNU REV PATHOL-MECH, V3, P11, DOI 10.1146/annurev.pathmechdis.3.121806.154326; Aguzzi A, 2003, ADV IMMUNOL, V81, P123, DOI 10.1016/S0065-2776(03)81004-0; Aucouturier P, 2001, J CLIN INVEST, V108, P703, DOI 10.1172/JCI200113155; Beringue V, 2000, J PATHOL, V190, P495, DOI 10.1002/(SICI)1096-9896(200003)190:4&lt;495::AID-PATH535&gt;3.0.CO;2-T; Boelle PY, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-26; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 2005, J NEUROL NEUROSUR PS, V76, P906, DOI 10.1136/jnnp.2004.048660; Collinge J, 1996, LANCET, V347, P916, DOI 10.1016/S0140-6736(96)91407-5; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Collinge J, 2006, LANCET, V367, P2068, DOI 10.1016/S0140-6736(06)68930-7; Cordier-Dirikoc S, 2008, J VIROL, V82, P8933, DOI 10.1128/JVI.02440-07; Cunningham C, 2009, BIOL PSYCHIAT, V65, P304, DOI 10.1016/j.biopsych.2008.07.024; Dore G, 2008, J NEUROIMMUNOL, V197, P74, DOI 10.1016/j.jneuroim.2008.03.016; Ferguson NM, 1997, PHILOS T R SOC B, V352, P803, DOI 10.1098/rstb.1997.0063; Friedman-Levi Y, 2007, J VIROL, V81, P9942, DOI 10.1128/JVI.00780-07; Frigg R, 1999, J VIROL, V73, P9584, DOI 10.1128/JVI.73.11.9584-9588.1999; Gilch S, 2007, FEBS J, V274, P5834, DOI 10.1111/j.1742-4658.2007.06105.x; Glatzel M, 2000, J GEN VIROL, V81, P2813, DOI 10.1099/0022-1317-81-11-2813; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; Heikenwalder M, 2005, SCIENCE, V307, P1107, DOI 10.1126/science.1106460; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Heikenwalder M, 2007, J NEUROIMMUNOL, V192, P113, DOI 10.1016/j.jneuroim.2007.09.022; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Ierna M, 2006, J VIROL, V80, P474, DOI 10.1128/JVI.80.1.474-482.2006; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kovacs GG, 2008, AM J PATHOL, V172, P555, DOI 10.2353/ajpath.2008.070442; Kranich J, 2008, J EXP MED, V205, P1293, DOI 10.1084/jem.20071019; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Levavasseur E, 2007, J GEN VIROL, V88, P2353, DOI 10.1099/vir.0.82816-0; Ligios C, 2005, NAT MED, V11, P1137, DOI 10.1038/nm1105-1137; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; Mabbott NA, 2003, J VIROL, V77, P6845, DOI 10.1128/JVI.77.12.6845-6854.2003; Mabbott NA, 2000, J VIROL, V74, P3338, DOI 10.1128/JVI.74.7.3338-3344.2000; Matthews L, 2001, ARCH VIROL, V146, P1173, DOI 10.1007/s007050170113; Mohan J, 2005, J VIROL, V79, P1888, DOI 10.1128/JVI.79.3.1888-1897.2005; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oehen S, 2002, J IMMUNOL, V169, P1453, DOI 10.4049/jimmunol.169.3.1453; OUTRAM GW, 1973, NATURE, V241, P536, DOI 10.1038/241536a0; OUTRAM GW, 1974, NATURE, V249, P855, DOI 10.1038/249855a0; Polymenidou M, 2005, LANCET NEUROL, V4, P805, DOI 10.1016/S1474-4422(05)70225-8; Polymenidou M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003872; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Prinz M, 2002, P NATL ACAD SCI USA, V99, P919, DOI 10.1073/pnas.022626399; Raeber A J, 2001, Dev Immunol, V8, P291, DOI 10.1155/2001/95404; Raeber AJ, 1999, P NATL ACAD SCI USA, V96, P3987, DOI 10.1073/pnas.96.7.3987; Raeber AJ, 1999, EMBO J, V18, P2702, DOI 10.1093/emboj/18.10.2702; Raymond CR, 2007, J IMMUNOL, V179, P7758, DOI 10.4049/jimmunol.179.11.7758; Raymond CR, 2007, J NEUROIMMUNOL, V187, P114, DOI 10.1016/j.jneuroim.2007.05.006; Seeger H, 2005, SCIENCE, V310, P324, DOI 10.1126/science.1118829; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Shibuya S, 1998, ANN NEUROL, V43, P826, DOI 10.1002/ana.410430618; Tal Y, 2003, J NEUROSCI RES, V71, P286, DOI 10.1002/jnr.10474; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Yang H, 1998, NEUROIMMUNOMODULAT, V5, P53, DOI 10.1159/000026326; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2	66	14	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7160	10.1371/journal.pone.0007160	http://dx.doi.org/10.1371/journal.pone.0007160			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779609	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200008
J	Kippert, F; Gerloff, DL				Kippert, Fred; Gerloff, Dietlind L.			Highly Sensitive Detection of Individual HEAT and ARM Repeats with HHpred and COACH	PLOS ONE			English	Article							PROTEIN REPEATS; DATABASE; ALIGNMENT; SERVER; FOLD	Background: HEAT and ARM repeats occur in a large number of eukaryotic proteins. As these repeats are often highly diverged, the prediction of HEAT or ARM domains can be challenging. Except for the most clear-cut cases, identification at the individual repeat level is indispensable, in particular for determining domain boundaries. However, methods using single sequence queries do not have the sensitivity required to deal with more divergent repeats and, when applied to proteins with known structures, in some cases failed to detect a single repeat. Methodology and Principal Findings: Testing algorithms which use multiple sequence alignments as queries, we found two of them, HHpred and COACH, to detect HEAT and ARM repeats with greatly enhanced sensitivity. Calibration against experimentally determined structures suggests the use of three score classes with increasing confidence in the prediction, and prediction thresholds for each method. When we applied a new protocol using both HHpred and COACH to these structures, it detected 82% of HEAT repeats and 90% of ARM repeats, with the minimum for a given protein of 57% for HEAT repeats and 60% for ARM repeats. Application to bona fide HEAT and ARM proteins or domains indicated that similar numbers can be expected for the full complement of HEAT/ARM proteins. A systematic screen of the Protein Data Bank for false positive hits revealed their number to be low, in particular for ARM repeats. Double false positive hits for a given protein were rare for HEAT and not at all observed for ARM repeats. In combination with fold prediction and consistency checking (multiple sequence alignments, secondary structure prediction, and position analysis), repeat prediction with the new HHpred/COACH protocol dramatically improves prediction in the twilight zone of fold prediction methods, as well as the delineation of HEAT/ARM domain boundaries. Significance: A protocol is presented for the identification of individual HEAT or ARM repeats which is straightforward to implement. It provides high sensitivity at a low false positive rate and will therefore greatly enhance the accuracy of predictions of HEAT and ARM domains.				f.kippert@trisc.net; gerloff@soe.ucsc.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrade MA, 2000, J MOL BIOL, V298, P521, DOI 10.1006/jmbi.2000.3684; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; Aravind L, 2006, CURR OPIN STRUC BIOL, V16, P409, DOI 10.1016/j.sbi.2006.04.006; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Biegert A, 2006, NUCLEIC ACIDS RES, V34, pW335, DOI 10.1093/nar/gkl217; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; Dunbrack RL, 2006, CURR OPIN STRUC BIOL, V16, P374, DOI 10.1016/j.sbi.2006.05.006; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edgar RC, 2004, BIOINFORMATICS, V20, P1309, DOI 10.1093/bioinformatics/bth091; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; Karplus K, 2003, PROTEINS, V53, P491, DOI 10.1002/prot.10540; Kippert F, 2004, CURR BIOL, V14, pR650, DOI 10.1016/j.cub.2004.08.008; Kippert F, 2002, CURR BIOL, V12, pR47, DOI 10.1016/S0960-9822(01)00670-4; Kobe B, 2000, TRENDS BIOCHEM SCI, V25, P509, DOI 10.1016/S0968-0004(00)01667-4; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; Marz P, 2004, J BIOL CHEM, V279, P35542, DOI 10.1074/jbc.M405865200; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Rook F, 2006, PLANT J, V46, P1045, DOI 10.1111/j.1365-313X.2006.02765.x; Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Striegl H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004656; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	35	26	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7148	10.1371/journal.pone.0007148	http://dx.doi.org/10.1371/journal.pone.0007148			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777061	Green Published, Green Submitted, gold			2022-12-27	WOS:000270164600003
J	Lea, WA; Xi, J; Jadhav, A; Lu, L; Austin, CP; Simeonov, A; Eckenhoff, RG				Lea, Wendy A.; Xi, Jin; Jadhav, Ajit; Lu, Louis; Austin, Christopher P.; Simeonov, Anton; Eckenhoff, Roderic G.			A High-Throughput Approach for Identification of Novel General Anesthetics	PLOS ONE			English	Article								Anesthetic development has been a largely empirical process. Recently, we described a GABAergic mimetic model system for anesthetic binding, based on apoferritin and an environment-sensitive fluorescent probe. Here, a competition assay based on 1-aminoanthracene and apoferritin has been taken to a high throughput screening level, and validated using the LOPAC(1280) library of drug-like compounds. A raw hit rate of similar to 15% was reduced through the use of computational filters to yield an overall hit rate of similar to 1%. These hits were validated using isothermal titration calorimetry. The success of this initial screen and computational triage provides feasibility to undergo a large scale campaign to discover novel general anesthetics.			Lea, WA (corresponding author), NHGRI, NIH Chem Genom Ctr, Bethesda, MD 20892 USA.	asimeono@mail.nih.gov; roderic.eckenhoff@uphs.upenn.edu		Eckenhoff, Roderic/0000-0002-5581-746X; Jadhav, Ajit/0000-0001-7955-1451	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIBHG200319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM055876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH084836] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIH P-01 GM55876, P01 GM055876] Funding Source: Medline; NIMH NIH HHS [R-03 MH84836, R03 MH084836] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baranov D, 2009, ANESTH ANALG, V108, P1627, DOI 10.1213/ane.0b013e318199dc72; Butts CA, 2009, P NATL ACAD SCI USA, V106, P6501, DOI 10.1073/pnas.0810590106; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Eckenhoff RG, 1999, MOL PHARMACOL, V56, P414, DOI 10.1124/mol.56.2.414; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; Li GD, 2006, J NEUROSCI, V26, P11599, DOI 10.1523/JNEUROSCI.3467-06.2006; Liu RY, 2005, FASEB J, V19, P567, DOI 10.1096/fj.04-3171com; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; VEDULA LS, 2009, J BIOL CHEM; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	12	13	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7150	10.1371/journal.pone.0007150	http://dx.doi.org/10.1371/journal.pone.0007150			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777064	Green Submitted, Green Published, gold			2022-12-27	WOS:000270164600004
J	Mauris, J; Evans, TC				Mauris, Jerome; Evans, Thomas C., Jr.			Adenosine Triphosphate Stimulates Aquifex aeolicus MutL Endonuclease Activity	PLOS ONE			English	Article								Background: Human PMS2 (hPMS2) homologues act to nick 59 and 39 to misincorporated nucleotides during mismatch repair in organisms that lack MutH. Mn(++) was previously found to stimulate the endonuclease activity of these homologues. ATP was required for the nicking activity of hPMS2 and yPMS1, but was reported to inhibit bacterial MutL proteins from Thermus thermophilus and Aquifex aeolicus that displayed homology to hPMS2. Mutational analysis has identified the DQHA(X)(2)E(X)(4)E motif present in the C-terminus of PMS2 homologues as important for endonuclease activity. Methodologies/Principal Findings: We examined the effect ATP had on the Mn(++) induced nicking of supercoiled pBR322 by full-length and mutant A. aeolicus MutL (Aae MutL) proteins. Assays were single time point, enzyme titration experiments or reaction time courses. The maximum velocity for MutL nicking was determined to be 1.6+/-0.08x10(-5) s(-1) and 4.2(+/-)0.3x10(-5) s(-1) in the absence and presence of ATP, respectively. AMPPNP stimulated the nicking activity to a similar extent as ATP. A truncated Aae MutL protein composed of only the C-terminal 123 amino acid residues was found to nick supercoiled DNA. Furthermore, mutations in the conserved C-terminal DQHA(X)(2)E(X)(4)E and CPHGRP motifs were shown to abolish Aae MutL endonuclease activity. Conclusions: ATP stimulated the Mn(++) induced endonuclease activity of Aae MutL. Experiments utilizing AMPPNP implied that the stimulation did not require ATP hydrolysis. A mutation in the DQHA(X)(2)E(X)(4)E motif of Aae MutL further supported the role of this region in endonclease activity. For the first time, to our knowledge, we demonstrate that changing the histidine residue in the conserved CPHGRP motif abolishes endonucleolytic activity of a hPMS2 homologue. Finally, the C-terminal 123 amino acid residues of Aae MutL were sufficient to display Mn(++) induced nicking activity.			Mauris, J (corresponding author), New England Biolabs Inc, Ipswich, MA USA.	evans@neb.com						Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ahrends R, 2006, NUCLEIC ACIDS RES, V34, P3169, DOI 10.1093/nar/gkl407; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Duppatla V., 2009, BIOCH J; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Fukui K, 2008, J BIOL CHEM, V283, P12136, DOI 10.1074/jbc.M800110200; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; Jiricny J, 2006, CELL, V126, P239, DOI 10.1016/j.cell.2006.07.003; Joseph N, 2004, DNA REPAIR, V3, P1561, DOI 10.1016/j.dnarep.2004.06.014; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kadyrov FA, 2007, J BIOL CHEM, V282, P37181, DOI 10.1074/jbc.M707617200; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; Kim TG, 2009, J BIOCHEM, V145, P199, DOI 10.1093/jb/mvn157; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kosinski J, 2005, J MOL BIOL, V351, P895, DOI 10.1016/j.jmb.2005.06.044; Kosinski J, 2008, J MOL BIOL, V382, P610, DOI 10.1016/j.jmb.2008.06.056; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Matson SW, 2006, NUCLEIC ACIDS RES, V34, P4089, DOI 10.1093/nar/gkl450; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Plotz G, 2006, BIOCHEM BIOPH RES CO, V340, P852, DOI 10.1016/j.bbrc.2005.12.096; Robertson AB, 2006, J BIOL CHEM, V281, P19949, DOI 10.1074/jbc.M601604200; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; Yang W, 2007, DNA REPAIR, V6, P135, DOI 10.1016/j.dnarep.2006.10.021	36	34	34	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7175	10.1371/journal.pone.0007175	http://dx.doi.org/10.1371/journal.pone.0007175			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777055	Green Published, gold, Green Submitted			2022-12-27	WOS:000270164600011
J	Milo, M; Cacciabue-Rivolta, D; Kneebone, A; Van Doorninck, H; Johnson, C; Lawoko-Kerali, G; Niranjan, M; Rivolta, M; Holley, M				Milo, Marta; Cacciabue-Rivolta, Daniela; Kneebone, Adam; Van Doorninck, Hikke; Johnson, Claire; Lawoko-Kerali, Grace; Niranjan, Mahesan; Rivolta, Marcelo; Holley, Matthew			Genomic Analysis of the Function of the Transcription Factor gata3 during Development of the Mammalian Inner Ear	PLOS ONE			English	Article								We have studied the function of the zinc finger transcription factor gata3 in auditory system development by analysing temporal profiles of gene expression during differentiation of conditionally immortal cell lines derived to model specific auditory cell types and developmental stages. We tested and applied a novel probabilistic method called the gamma Model for Oligonucleotide Signals to analyse hybridization signals from Affymetrix oligonucleotide arrays. Expression levels estimated by this method correlated closely (p<0.0001) across a 10-fold range with those measured by quantitative RT-PCR for a sample of 61 different genes. In an unbiased list of 26 genes whose temporal profiles clustered most closely with that of gata3 in all cell lines, 10 were linked to Insulin-like Growth Factor signalling, including the serine/threonine kinase Akt/PKB. Knock-down of gata3 in vitro was associated with a decrease in expression of genes linked to IGF-signalling, including IGF1, IGF2 and several IGF-binding proteins. It also led to a small decrease in protein levels of the serine-threonine kinase Akt2/PKB beta, a dramatic increase in Akt1/PKB alpha protein and relocation of Akt1/PKB alpha from the nucleus to the cytoplasm. The cyclin-dependent kinase inhibitor p27(kip1), a known target of PKB/Akt, simultaneously decreased. In heterozygous gata3 null mice the expression of gata3 correlated with high levels of activated Akt/PKB. This functional relationship could explain the diverse function of gata3 during development, the hearing loss associated with gata3 heterozygous null mice and the broader symptoms of human patients with Hearing-Deafness-Renal anomaly syndrome.			Milo, M (corresponding author), Univ Sheffield, Dept Biomed Sci, Addison Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	m.c.holley@sheffield.ac.uk		Holley, Matthew/0000-0001-9547-1953; Johnson, Claire/0000-0003-4428-3594; Niranjan, Mahesan/0000-0001-7021-140X	Wellcome Trust [042065/Z96/D, 074556/Z/04/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abe S, 2003, AM J HUM GENET, V72, P73, DOI 10.1086/345398; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aoki N, 2000, J INVEST DERMATOL, V115, P402, DOI 10.1046/j.1523-1747.2000.00070.x; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Camarero G, 2003, DEV BIOL, V262, P242, DOI 10.1016/S0012-1606(03)00387-7; Camarero G, 2001, J NEUROSCI, V21, P7630, DOI 10.1523/JNEUROSCI.21-19-07630.2001; Chen J, 2003, GENE, V302, P103, DOI 10.1016/S0378-1119(02)01095-8; Chen P, 1999, DEVELOPMENT, V126, P1581; CHILOECHES A, 2008, MOL ENDOCRINOL; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Davies D, 2002, J COMP NEUROL, V445, P122, DOI 10.1002/cne.10161; Diaz RC, 2007, JARO-J ASSOC RES OTO, V8, P422, DOI 10.1007/s10162-007-0089-4; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endo T, 2002, NEUROSCI LETT, V334, P173, DOI 10.1016/S0304-3940(02)01115-1; Fekete DM, 1999, TRENDS NEUROSCI, V22, P263, DOI 10.1016/S0166-2236(98)01366-6; Fekete DM, 2002, CURR OPIN NEUROBIOL, V12, P35, DOI 10.1016/S0959-4388(02)00287-8; Findlay GM, 2007, BIOCHEM J, V403, P13, DOI 10.1042/BJ20061881; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fritzsch B, 2006, BIOESSAYS, V28, P1181, DOI 10.1002/bies.20502; Fromigue O, 2003, INT J CANCER, V106, P355, DOI 10.1002/ijc.11232; Fujimoto S, 2004, NEUROSCI RES, V50, P179, DOI 10.1016/j.neures.2004.06.013; Helyer R, 2007, EUR J NEUROSCI, V25, P957, DOI 10.1111/j.1460-9568.2007.05338.x; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; HURVICH CM, 1989, BIOMETRIKA, V76, P297, DOI 10.2307/2336663; Ikeda K, 2003, J NEUROSCI, V23, P4667; Isenovic ER, 2004, INT J MOL MED, V13, P915; Janzen V, 2006, NATURE, V441, P418, DOI 10.1038/441418b; Karis A, 2001, J COMP NEUROL, V429, P615, DOI 10.1002/1096-9861(20010122)429:4<615::AID-CNE8>3.0.CO;2-F; Kelley MW, 2006, NAT REV NEUROSCI, V7, P837, DOI 10.1038/nrn1987; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; KORNHAUSER JM, 1994, MOL BRAIN RES, V23, P100, DOI 10.1016/0169-328X(94)90216-X; Kurek D, 2007, DEVELOPMENT, V134, P261, DOI 10.1242/dev.02721; Lawoko-Kerali G, 2004, DEV DYNAM, V231, P801, DOI 10.1002/dvdy.20187; Lawoko-Kerali G, 2004, MECH DEVELOP, V121, P287, DOI 10.1016/j.mod.2003.12.006; Lawoko-Kerali G, 2002, J COMP NEUROL, V442, P378, DOI 10.1002/cne.10088; Levine M, 2005, P NATL ACAD SCI USA, V102, P4936, DOI 10.1073/pnas.0408031102; Lillevali K, 2004, DEV DYNAM, V231, P775, DOI 10.1002/dvdy.20185; Lillevali K, 2006, MECH DEVELOP, V123, P415, DOI 10.1016/j.mod.2006.04.007; Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu XJ, 2005, BIOINFORMATICS, V21, P3637, DOI 10.1093/bioinformatics/bti583; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; MACKAY DJC, 1998, ERICE, P175; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Marelli MM, 2006, INT J ONCOL, V28, P723; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Milo M, 2003, BIOCHEM SOC T, V31, P1510; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; Nicholl AJ, 2005, EUR J NEUROSCI, V22, P343, DOI 10.1111/j.1460-9568.2005.04213.x; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Ohuchi H, 2005, DEV DYNAM, V233, P177, DOI 10.1002/dvdy.20319; Oshima A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.034397; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Pearson RD, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-211; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Rattray M, 2006, BRIEF BIOINFORM, V7, P37, DOI 10.1093/bib/bbk003; Rivolta MN, 2002, GENOME RES, V12, P1091, DOI 10.1101/gr.225602; Rivolta MN, 1998, P ROY SOC B-BIOL SCI, V265, P1595, DOI 10.1098/rspb.1998.0477; Rivolta MN, 1998, J NEUROCYTOL, V27, P637, DOI 10.1023/A:1006951813063; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Seong HA, 2007, J BIOL CHEM, V282, P12272, DOI 10.1074/jbc.M609279200; Shen XL, 2006, EXP CELL RES, V312, P3822, DOI 10.1016/j.yexcr.2006.08.011; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; van der Wees J, 2004, NEUROBIOL DIS, V16, P169, DOI 10.1016/j.nbd.2004.02.004; Van Esch H, 2001, CELL MOL LIFE SCI, V58, P1296, DOI 10.1007/PL00000940; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; Varela-Nieto I, 2004, HEARING RES, V196, P19, DOI 10.1016/j.heares.2003.12.022; Verri A, 2004, ANN GENET-PARIS, V47, P281, DOI 10.1016/j.anngen.2004.03.001; Wang XQ, 2005, J NEUROCHEM, V93, P1515, DOI 10.1111/j.1471-4159.2005.03147.x; Williams CKI, 2005, NEURAL COMPUT, V17, P1, DOI 10.1162/0899766052530884; Wirtz KWA, 2006, ADV ENZYME REGUL, V46, P301, DOI 10.1016/j.advenzreg.2006.01.020; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Xiao AY, 2002, J NEUROSCI, V22, P1350, DOI 10.1523/JNEUROSCI.22-04-01350.2002; Yang SL, 2007, AM J PHYSIOL-HEART C, V293, pH142, DOI 10.1152/ajpheart.00783.2006; Yu SP, 2003, PROG NEUROBIOL, V70, P363, DOI 10.1016/S0301-0082(03)00090-X; Zhou XM, 2001, BIOCHEM BIOPH RES CO, V285, P46, DOI 10.1006/bbrc.2001.5126	87	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7144	10.1371/journal.pone.0007144	http://dx.doi.org/10.1371/journal.pone.0007144			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774072	Green Submitted, Green Accepted, Green Published, gold			2022-12-27	WOS:000270160900018
J	Nishizawa, H; Suzuki, T; Shioya, T; Nakazato, Y; Daida, H; Kurebayashi, N				Nishizawa, Hiroto; Suzuki, Takeshi; Shioya, Takao; Nakazato, Yuji; Daida, Hiroyuki; Kurebayashi, Nagomi			Causes of Abnormal Ca2+ Transients in Guinea Pig Pathophysiological Ventricular Muscle Revealed by Ca2+ and Action Potential Imaging at Cellular Level	PLOS ONE			English	Article								Background: Abnormal Ca2+ transients are often observed in heart muscles under a variety of pathophysiological conditions including ventricular tachycardia. To clarify whether these abnormal Ca2+ transients can be attributed to abnormal action potential generation or abnormal Ca2+ handling/excitation-contraction (EC) coupling, we developed a procedure to determine Ca2+ and action potential signals at the cellular level in isolated heart tissues. Methodology/Principal Findings: After loading ventricular papillary muscle with rhod-2 and di-4-ANEPPS, mono-wavelength fluorescence images from rhod-2 and ratiometric images of two wavelengths of emission from di-4-ANEPPS were sequentially obtained. To mimic the ventricular tachycardia, the ventricular muscles were field-stimulated in nonflowing Krebs solution which elicited abnormal Ca2+ transients. For the failed and alternating Ca2+ transient generation, there were two types of causes, i.e., failed or abnormal action potential generation and abnormal EC coupling. In cells showing delayed initiation of Ca2+ transients with field stimulation, action potential onset was delayed and the rate of rise was slower than in healthy cells. Similar delayed onset was also observed in the presence of heptanol, an inhibitor of gap junction channels but having a non-specific channel blocking effect. A Na+ channel blocker, on the other hand, reduced the rate of rise of the action potentials but did not result in desynchronization of the action potentials. The delayed onset of action potentials can be explained primarily by impaired gap junctions and partly by Na+ channel inactivation. Conclusions/Significance: Our results indicate that there are multiple patterns for the causes of abnormal Ca2+ signals and that our methods are useful for investigating the physiology and pathophysiology of heart muscle.			Nishizawa, H (corresponding author), Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 113, Japan.	nagomik@juntendo.ac.jp						Aistrup GL, 2006, CIRC RES, V99, pE65, DOI 10.1161/01.RES.0000244087.36230.bf; Baker LC, 2000, CIRC RES, V86, P396, DOI 10.1161/01.RES.86.4.396; Bers DM, 2001, EXCITATION CONTRACTI; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; Choi BR, 2000, J PHYSIOL-LONDON, V529, P171, DOI 10.1111/j.1469-7793.2000.00171.x; Clusin WT, 2008, AM J PHYSIOL-HEART C, V294, pH1, DOI 10.1152/ajpheart.00802.2007; Clusin WT, 2003, CRIT REV CL LAB SCI, V40, P337, DOI 10.1080/713609356; Eisner DA, 2000, CIRC RES, V87, P1087, DOI 10.1161/01.RES.87.12.1087; Fujiwara K, 2008, CIRC RES, V103, P509, DOI 10.1161/CIRCRESAHA.108.176677; HATTORI Y, 1986, J CARDIOVASC PHARM, V8, P998, DOI 10.1097/00005344-198609000-00017; Horishita T, 2008, J PHARMACOL EXP THER, V326, P270, DOI 10.1124/jpet.108.138370; Kapur S, 2009, AM J PHYSIOL-HEART C, V296, pH1491, DOI 10.1152/ajpheart.00539.2008; Knisley SB, 2000, AM J PHYSIOL-HEART C, V279, pH1421, DOI 10.1152/ajpheart.2000.279.3.H1421; Kurebayashi N, 2004, AM J PHYSIOL-CELL PH, V287, pC1646, DOI 10.1152/ajpcell.00200.2004; Kurebayashi N, 2008, AM J PHYSIOL-CELL PH, V294, pC1419, DOI 10.1152/ajpcell.00413.2007; Lakireddy V, 2005, AM J PHYSIOL-HEART C, V288, pH400, DOI 10.1152/ajpheart.00502.2004; Laurita KR, 2001, AM J PHYSIOL-HEART C, V280, pH2053, DOI 10.1152/ajpheart.2001.280.5.H2053; LEE HC, 1988, CIRCULATION, V78, P1047, DOI 10.1161/01.CIR.78.4.1047; MONTANA V, 1989, BIOCHEMISTRY-US, V28, P4536, DOI 10.1021/bi00437a003; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ohara M, 1983, Nihon Seirigaku Zasshi, V45, P629; Pastore JM, 1999, CIRCULATION, V99, P1385, DOI 10.1161/01.CIR.99.10.1385; Pruvot EJ, 2004, CIRC RES, V94, P1083, DOI 10.1161/01.RES.0000125629.72053.95; Sato D, 2007, BIOPHYS J, V92, pL33, DOI 10.1529/biophysj.106.100982; Sato D, 2006, CIRC RES, V99, P520, DOI 10.1161/01.RES.0000240542.03986.e7; Shioya T, 2007, J PHYSIOL SCI, V57, P327, DOI 10.2170/physiolsci.RP010107; Sipido KR, 2004, CIRC RES, V94, P570, DOI 10.1161/01.RES.0000124606.14903.6F; Song LS, 2006, P NATL ACAD SCI USA, V103, P4305, DOI 10.1073/pnas.0509324103; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; Tomaselli GF, 2004, CIRC RES, V95, P754, DOI 10.1161/01.RES.0000145047.14691.db; Yamashita T, 1998, JPN HEART J, V39, P389	31	7	8	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2009	4	9							e7069	10.1371/journal.pone.0007069	http://dx.doi.org/10.1371/journal.pone.0007069			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PJ	19768114	Green Published, Green Submitted, gold			2022-12-27	WOS:000270154000003
J	Fragoso, CM; Burkard, GS; Oberle, M; Renggli, CK; Hilzinger, K; Roditi, I				Fragoso, Cristina M.; Burkard, Gabriela Schumann; Oberle, Michael; Renggli, Christina Kunz; Hilzinger, Karen; Roditi, Isabel			PSSA-2, a Membrane-Spanning Phosphoprotein of Trypanosoma brucei, Is Required for Efficient Maturation of Infection	PLOS ONE			English	Article								The coat of Trypanosoma brucei consists mainly of glycosylphosphatidylinositol-anchored proteins that are present in several million copies and are characteristic of defined stages of the life cycle. While these major components of the coats of bloodstream forms and procyclic (insect midgut) forms are well characterised, very little is known about less abundant stage-regulated surface proteins and their roles in infection and transmission. By creating epitope-tagged versions of procyclic-specific surface antigen 2 (PSSA-2) we demonstrated that it is a membrane-spanning protein that is expressed by several different life cycle stages in tsetse flies, but not by parasites in the mammalian bloodstream. In common with other membrane-spanning proteins in T. brucei, PSSA-2 requires its cytoplasmic domain in order to exit the endoplasmic reticulum. Correct localisation of PSSA-2 requires phosphorylation of a cytoplasmic threonine residue (T-305), a modification that depends on the presence of TbMAPK4. Mutation of T-305 to alanine (T(305)A) has no effect on the localisation of the protein in cells that express wild type PSSA-2. In contrast, this protein is largely intracellular when expressed in a null mutant background. A variant with a T305D mutation gives strong surface expression in both the wild type and null mutant, but slows growth of the cells, suggesting that it may function as a dominant negative mutant. The PSSA-2 null mutant exhibits no perceptible phenotype in culture and is fully competent at establishing midgut infections in tsetse, but is defective in colonising the salivary glands and the production of infectious metacyclic forms. Given the protein's structure and the effects of mutation of T-305 on proliferation and localisation, we postulate that PSSA-2 might sense and transmit signals that contribute to the parasite's decision to divide, differentiate or migrate.			Fragoso, CM (corresponding author), Ist Cantonale Microbiol, Bellinzona, Switzerland.	isabel.roditi@izb.unibe.ch		Roditi, Isabel/0000-0003-2812-6513	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BAYNE RAL, 1993, MOL BIOCHEM PARASIT, V61, P295, DOI 10.1016/0166-6851(93)90075-9; BEECROFT RP, 1993, MOL BIOCHEM PARASIT, V61, P285, DOI 10.1016/0166-6851(93)90074-8; BRUN R, 1979, ACTA TROP, V36, P289; BRUN R, 1981, Z PARASITENKD, V66, P17, DOI 10.1007/BF00941941; Burkard G, 2007, MOL BIOCHEM PARASIT, V153, P220, DOI 10.1016/j.molbiopara.2007.02.008; Butikofer P, 1999, J CELL SCI, V112, P1785; Butikofer P, 2002, MOL BIOCHEM PARASIT, V119, P7, DOI 10.1016/S0166-6851(01)00382-6; Chung WL, 2004, J BIOL CHEM, V279, P54887, DOI 10.1074/jbc.M409311200; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; DELAUW MF, 1985, EMBO J, V4, P989, DOI 10.1002/j.1460-2075.1985.tb03728.x; ENGSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1, DOI 10.1016/0166-6851(93)90153-O; FAIRBAIRN H, 1946, ANN TROP MED PARASIT, V40, P270, DOI 10.1080/00034983.1946.11685286; Grandgenett PM, 2007, PLOS PATHOG, V3, P1432, DOI 10.1371/journal.ppat.0030150; Guther MLS, 2006, MOL BIOL CELL, V17, P5265, DOI 10.1091/mbc.E06-08-0702; Guttinger A, 2007, MOL BIOCHEM PARASIT, V153, P203, DOI 10.1016/j.molbiopara.2007.02.001; Haenni S, 2006, MOL BIOCHEM PARASIT, V150, P144, DOI 10.1016/j.molbiopara.2006.07.005; HAJDUK SL, 1984, J PROTOZOOL, V31, P41, DOI 10.1111/j.1550-7408.1984.tb04287.x; JACKSON DG, 1993, J BIOL CHEM, V268, P1894; KOENIGMARTIN E, 1992, MOL BIOCHEM PARASIT, V55, P135, DOI 10.1016/0166-6851(92)90134-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERAY D, 1977, ANN SOC BELG MED TR, V57, P369; Liniger M, 2001, MOL MICROBIOL, V40, P869, DOI 10.1046/j.1365-2958.2001.02426.x; Pfister DD, 2006, EUKARYOT CELL, V5, P1126, DOI 10.1128/EC.00094-06; Qiao XG, 2006, EUKARYOT CELL, V5, P1229, DOI 10.1128/EC.00064-06; RICHARDSON JP, 1986, J IMMUNOL, V136, P2259; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Sakurai T, 2008, MOL BIOCHEM PARASIT, V161, P1, DOI 10.1016/j.molbiopara.2008.05.003; Schlaeppi AC, 2003, J BIOL CHEM, V278, P49980, DOI 10.1074/jbc.M309548200; Thuita JK, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000238; Urwyler S, 2007, MOL MICROBIOL, V63, P218, DOI 10.1111/j.1365-2958.2006.05492.x; Urwyler S, 2005, PLOS PATHOG, V1, P225, DOI 10.1371/journal.ppat.0010022; Utz S, 2006, EUKARYOT CELL, V5, P1430, DOI 10.1128/EC.00067-06; Vassella E, 2000, GENE DEV, V14, P615; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Vassella E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004493; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	40	24	24	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7074	10.1371/journal.pone.0007074	http://dx.doi.org/10.1371/journal.pone.0007074			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759911	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970200008
J	Bromberg-White, JL; Boguslawski, E; Duesbery, NS				Bromberg-White, Jennifer L.; Boguslawski, Elissa; Duesbery, Nicholas S.			Perturbation of Mouse Retinal Vascular Morphogenesis by Anthrax Lethal Toxin	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-TYROSINE PHOSPHORYLATION; KINASE-KINASE; PROTEOLYTIC INHIBITOR; FACTOR CLEAVES; TUMOR-GROWTH; ANGIOGENESIS; INACTIVATION; ACTIVATION; CELLS	Lethal factor, the enzymatic moiety of anthrax lethal toxin (LeTx) is a protease that inactivates mitogen activated protein kinase kinases (MEK or MKK). In vitro and in vivo studies demonstrate LeTx targets endothelial cells. However, the effects of LeTx on endothelial cells are incompletely characterized. To gain insight into this process we used a developmental model of vascularization in the murine retina. We hypothesized that application of LeTx would disrupt normal retinal vascularization, specifically during the angiogenic phase of vascular development. By immunoblotting and immunofluorescence microscopy we observed that MAPK activation occurs in a spatially and temporally regulated manner during retinal vascular development. Intravitreal administration of LeTx caused an early delay (4 d post injection) in retinal vascular development that was marked by reduced penetration of vessels into distal regions of the retina as well as failure of sprouting vessels to form the deep and intermediate plexuses within the inner retina. In contrast, later stages (8 d post injection) were characterized by the formation of abnormal vascular tufts that co-stained with phosphorylated MAPK in the outer retinal region. We also observed a significant increase in the levels of secreted VEGF in the vitreous 4 d and 8 d after LeTx injection. In contrast, the levels of over 50 cytokines other cytokines, including bFGF, EGF, MCP-1, and MMP-9, remained unchanged. Finally, co-injection of VEGF-neutralizing antibodies significantly decreased LeTx-induced neovascular growth. Our studies not only reveal that MAPK signaling plays a key role in retinal angiogenesis but also that perturbation of MAPK signaling by LeTx can profoundly alter vascular morphogenesis.			Bromberg-White, JL (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA.	duesbery@vai.org		DUESBERY, NICK/0000-0002-4258-5655; Duesbery, Nicholas/0000-0002-5708-4984	NCI NIH HHS [R01 CA109308, CA109308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Alfano RW, 2009, MOL CANCER RES, V7, P452, DOI 10.1158/1541-7786.MCR-08-0451; ARORA N, 1993, J BIOL CHEM, V268, P3334; ARORA N, 1992, J BIOL CHEM, V267, P15542; Bardwell AJ, 2004, BIOCHEM J, V378, P569, DOI 10.1042/BJ20031382; Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458; Bolcome RE, 2008, P NATL ACAD SCI USA, V105, P2439, DOI 10.1073/pnas.0712195105; Bromberg-White JL, 2008, METHOD ENZYMOL, V438, P355, DOI 10.1016/S0076-6879(07)38025-7; Bullard LE, 2003, INVEST OPHTH VIS SCI, V44, P1722, DOI 10.1167/iovs.01-1193; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Depeille P, 2007, CLIN CANCER RES, V13, P5926, DOI 10.1158/1078-0432.CCR-07-0732; Ding Y, 2008, MOL CANCER THER, V7, P648, DOI 10.1158/1535-7163.MCT-07-2229; Dorrell M.I., 2007, RETINAL VASCULAR DIS, P24; Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500; Dorrell MI, 2006, PROG RETIN EYE RES, V25, P277, DOI 10.1016/j.preteyeres.2006.01.001; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873; Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482; Guarner J, 2003, AM J PATHOL, V163, P701, DOI 10.1016/S0002-9440(10)63697-8; GUMA M, 2009, P NATL ACAD SCI US; Hayashi A, 1996, INVEST OPHTH VIS SCI, V37, P2146; Hayashi A, 1997, INVEST OPHTH VIS SCI, V38, P372; Kirby JE, 2004, INFECT IMMUN, V72, P430, DOI 10.1128/IAI.72.1.430-439.2004; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Kuo SR, 2008, MICROB PATHOGENESIS, V44, P467, DOI 10.1016/j.micpath.2007.12.001; Liu S, 2008, J BIOL CHEM, V283, P529, DOI 10.1074/jbc.M707419200; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Pang JJ, 2006, MOL VIS, V12, P756; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Qiao H, 2007, J LEUKOCYTE BIOL, V81, P1012, DOI 10.1189/jlb.0506342; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms; Sherer K, 2007, AM J RESP CRIT CARE, V175, P211, DOI 10.1164/rccm.200608-1239CP; SINGH Y, 1989, J BIOL CHEM, V264, P11099; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Su XJ, 2003, MOL VIS, V9, P171; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Warfel JM, 2005, AM J PATHOL, V166, P1871, DOI 10.1016/S0002-9440(10)62496-0; Yafai Y, 2007, GLIA, V55, P642, DOI 10.1002/glia.20495; Young JAT, 2007, ANNU REV BIOCHEM, V76, P243, DOI 10.1146/annurev.biochem.75.103004.142728	52	12	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e6956	10.1371/journal.pone.0006956	http://dx.doi.org/10.1371/journal.pone.0006956			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750016	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796300007
J	Senechal, P; Arseneault, G; Leroux, A; Lindquist, S; Rokeach, LA				Senechal, Patrick; Arseneault, Genevieve; Leroux, Alexandre; Lindquist, Susan; Rokeach, Luis A.			The Schizosaccharomyces pombe Hsp104 Disaggregase Is Unable to Propagate the [PSI+] Prion	PLOS ONE			English	Article								The molecular chaperone Hsp104 is a crucial factor in the acquisition of thermotolerance in yeast. Under stress conditions, the disaggregase activity of Hsp104 facilitates the reactivation of misfolded proteins. Hsp104 is also involved in the propagation of fungal prions. For instance, the well-characterized [PSI+] prion of Saccharomyces cerevisiae does not propagate in Delta hsp104 cells or in cells overexpressing Hsp104. In this study, we characterized the functional homolog of Hsp104 from Schizosaccharomyces pombe (Sp_Hsp104). As its S. cerevisiae counterpart, Sp_hsp104(+) is heat-inducible and required for thermotolerance in S. pombe. Sp_Hsp104 displays low disaggregase activity and cannot propagate the [PSI+] prion in S. cerevisiae. When overexpressed in S. cerevisiae, Sp_Hsp104 confers thermotolerance to Delta hsp104 cells and reactivates heat-aggregated proteins. However, overexpression of Sp_Hsp104 does not propagate nor eliminate [PSI+]. Strikingly, [PSI+] was cured by overexpression of a chimeric chaperone bearing the C- terminal domain (CTD) of the S. cerevisiae Hsp104 protein. Our study demonstrates that the ability to untangle aggregated proteins is conserved between the S. pombe and S. cerevisiae Hsp104 homologs, and points to a role of the CTD in the propagation of the S. cerevisiae [PSI+] prion.			Senechal, P (corresponding author), Univ Montreal, Dept Pathol & Cellular Biol, Montreal, PQ, Canada.	luis.rokeach@umontreal.ca						Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Alberti S, 2009, CELL, V137, P146, DOI 10.1016/j.cell.2009.02.044; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BEAUREGARD PB, 2009, J CELL SCI; Bosl B, 2006, J STRUCT BIOL, V156, P139, DOI 10.1016/j.jsb.2006.02.004; Bosl B, 2005, J BIOL CHEM, V280, P38170, DOI 10.1074/jbc.M506149200; Byrne LJ, 2007, P NATL ACAD SCI USA, V104, P11688, DOI 10.1073/pnas.0701392104; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Collin P, 2004, J CELL SCI, V117, P907, DOI 10.1242/jcs.00943; DEVIRGILIO C, 1990, FEBS LETT, V273, P107, DOI 10.1016/0014-5793(90)81062-S; Doyle SM, 2007, NAT STRUCT MOL BIOL, V14, P114, DOI 10.1038/nsmb1198; Elagoz A, 1999, J CELL SCI, V112, P4449; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Elliott B, 1996, GENETICS, V144, P923; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grably MR, 2002, MOL MICROBIOL, V44, P21, DOI 10.1046/j.1365-2958.2002.02860.x; Harrison PM, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-r40; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hung GC, 2006, GENETICS, V173, P611, DOI 10.1534/genetics.106.056820; Iwahashi H, 1998, APPL ENVIRON MICROB, V64, P4614; Jones GW, 2005, BIOESSAYS, V27, P823, DOI 10.1002/bies.20267; Kim KI, 1998, BIOCHEM J, V333, P671, DOI 10.1042/bj3330671; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Krawchuk MD, 1999, YEAST, V15, P1419, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1419::AID-YEA466>3.0.CO;2-Q; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Kurahashi H, 2007, MOL MICROBIOL, V63, P1669, DOI 10.1111/j.1365-2958.2007.05629.x; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Ling MF, 1995, NUCLEIC ACIDS RES, V23, P4924, DOI 10.1093/nar/23.23.4924; Liou ST, 2007, CELL STRESS CHAPERON, V12, P59, DOI 10.1379/CSC-220R.1; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Marechal A, 2004, BIOCHEM J, V380, P441, DOI 10.1042/BJ20031546; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Mata J, 2006, P NATL ACAD SCI USA, V103, P15517, DOI 10.1073/pnas.0603403103; Matsuyama A, 2006, NAT BIOTECHNOL, V24, P841, DOI 10.1038/nbt1222; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Peng G, 2000, MOL CELL BIOL, V20, P5140, DOI 10.1128/MCB.20.14.5140-5148.2000; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; Ribeiro MJS, 1997, MOL MICROBIOL, V25, P571, DOI 10.1046/j.1365-2958.1997.4961856.x; Ronicke V, 1997, METHOD ENZYMOL, V283, P313; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; Sambrook J., 1989, MOL CLONING LAB MANU, p3 v; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Satpute-Krishnan P, 2007, PLOS BIOL, V5, P251, DOI 10.1371/journal.pbio.0050024; Schaupp A, 2007, J MOL BIOL, V370, P674, DOI 10.1016/j.jmb.2007.04.070; Seppa L, 2004, MOL MICROBIOL, V52, P217, DOI 10.1111/j.1365-2958.2003.03959.x; Sherman F., 1981, METHODS YEAST GENETI; Shorter J, 2008, EMBO J, V27, P2712, DOI 10.1038/emboj.2008.194; Shorter J, 2006, MOL CELL, V23, P425, DOI 10.1016/j.molcel.2006.05.042; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Strub C, 2003, FEBS LETT, V553, P125, DOI 10.1016/S0014-5793(03)00985-2; Taneja V, 2007, MOL CELL, V27, P67, DOI 10.1016/j.molcel.2007.05.027; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tipton KA, 2008, MOL CELL, V32, P584, DOI 10.1016/j.molcel.2008.11.003; Tkach JM, 2004, J BIOL CHEM, V279, P35692, DOI 10.1074/jbc.M400782200; True HL, 2006, TRENDS GENET, V22, P110, DOI 10.1016/j.tig.2005.12.004; Wendler P, 2007, CELL, V131, P1366, DOI 10.1016/j.cell.2007.10.047; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yoshida J, 2005, CELL STRUCT FUNCT, V29, P125, DOI 10.1247/csf.29.125; Zenthon JF, 2006, EUKARYOT CELL, V5, P217, DOI 10.1128/EC.5.2.217-225.2006; Zolkiewski M, 2006, MOL MICROBIOL, V61, P1094, DOI 10.1111/j.1365-2958.2006.05309.x	71	16	17	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6939	10.1371/journal.pone.0006939	http://dx.doi.org/10.1371/journal.pone.0006939			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759825	gold, Green Submitted, Green Published			2022-12-27	WOS:000269696600002
J	Mury, FB; da Silva, JR; Ferreira, LS; Ferreira, BD; de Souza, GA; de Souza-Neto, JA; Ribolla, PEM; Silva, CP; do Nascimento, VV; Machado, OLT; Berbert-Molina, MA; Dansa-Petretski, M				Mury, Flavia Borges; da Silva, Jose Roberto; Ferreira, Ligia Souza; Ferreira, Beatriz dos Santos; de Souza-Filho, Goncalo Apolinario; de Souza-Neto, Jayme Augusto; Martins Ribolla, Paulo Eduardo; Silva, Carlos Peres; do Nascimento, Viviane Veiga; Tavares Machado, Olga Lima; Berbert-Molina, Marilia Amorim; Dansa-Petretski, Marilvia			Alpha-Glucosidase Promotes Hemozoin Formation in a Blood-Sucking Bug: An Evolutionary History	PLOS ONE			English	Article							DYSDERCUS-PERUVIANUS HEMIPTERA; PERIMICROVILLAR MEMBRANES; PLASMODIUM HEMOZOIN; HEME DETOXIFICATION; MALARIA PARASITE; MIDGUT; BINDING; PURIFICATION; HAEMOZOIN; POLYMERIZATION	Background: Hematophagous insects digest large amounts of host hemoglobin and release heme inside their guts. In Rhodnius prolixus, hemoglobin-derived heme is detoxified by biomineralization, forming hemozoin (Hz). Recently, the involvement of the R. prolixus perimicrovillar membranes in Hz formation was demonstrated. Methodology/Principal Findings: Hz formation activity of an alpha-glucosidase was investigated. Hz formation was inhibited by specific alpha-glucosidase inhibitors. Moreover, Hz formation was sensitive to inhibition by Diethypyrocarbonate, suggesting a critical role of histidine residues in enzyme activity. Additionally, a polyclonal antibody raised against a phytophagous insect alpha-glucosidase was able to inhibit Hz formation. The alpha-glucosidase inhibitors have had no effects when used 10 h after the start of reaction, suggesting that alpha-glucosidase should act in the nucleation step of Hz formation. Hz formation was seen to be dependent on the substrate-binding site of enzyme, in a way that maltose, an enzyme substrate, blocks such activity. dsRNA, constructed using the sequence of alpha-glucosidase gene, was injected into R. prolixus females' hemocoel. Gene silencing was accomplished by reduction of both alpha-glucosidase and Hz formation activities. Insects were fed on plasma or hemin-enriched plasma and gene expression and activity of alpha-glucosidase were higher in the plasma plus hemin-fed insects. The deduced amino acid sequence of alpha-glucosidase shows a high similarity to the insect alpha-glucosidases, with critical histidine and aspartic residues conserved among the enzymes. Conclusions/Significance: Herein the Hz formation is shown to be associated to an alpha-glucosidase, the biochemical marker from Hemipteran perimicrovillar membranes. Usually, these enzymes catalyze the hydrolysis of glycosidic bond. The results strongly suggest that alpha-glucosidase is responsible for Hz nucleation in the R. prolixus midgut, indicating that the plasticity of this enzyme may play an important role in conferring fitness to hemipteran hematophagy, for instance.			Mury, FB (corresponding author), Univ Estadual Norte Fluminense, Lab Quim & Funcao Prot & Peptideos, Campos Goytacazes, Rio De Janeiro, Brazil.	marilvia@uenf.br	Silva, Carlos P/N-8746-2014; Machado, Olga/P-1944-2019; Silva, José Roberto/F-2931-2017; Ribolla, Paulo/AAH-3354-2020; Souza-Neto, Jayme A/E-7841-2010; Ribolla, Paulo EM/B-9122-2012; Machado, Olga LT/G-7461-2012; de Souza Filho, Goncalo/S-7251-2017	Souza-Neto, Jayme A/0000-0001-9281-894X; Ribolla, Paulo EM/0000-0001-8735-6090; de Souza Filho, Goncalo/0000-0003-1028-4425; Silva, Carlos/0000-0001-5112-7050; Machado, Olga/0000-0003-0647-1762				BILLINGSLEY PF, 1983, CAN J ZOOL, V61, P2574, DOI 10.1139/z83-339; Brandt SM, 2008, GENETICS, V180, P1671, DOI 10.1534/genetics.108.089748; Bravo-Torres JC, 2004, INT J PARASITOL, V34, P455, DOI 10.1016/j.ijpara.2003.11.015; Chen MM, 2001, MOL BIOCHEM PARASIT, V113, P1, DOI 10.1016/S0166-6851(00)00365-0; Choi CYH, 1999, BIOCHEMISTRY-US, V38, P16916, DOI 10.1021/bi991665k; DESOUZAGARCIA E, 1975, AN ACAD BRAS CIENC, V47, P537; Dhanawansa R, 2002, GLYCOBIOLOGY, V12, P229, DOI 10.1093/glycob/12.3.229; Dillon RJ, 1997, COMP BIOCHEM PHYS B, V116, P35, DOI 10.1016/S0305-0491(96)00195-2; Dixon M., 1979, ENZYMES, Vthird; Egan TJ, 2008, J INORG BIOCHEM, V102, P1288, DOI 10.1016/j.jinorgbio.2007.12.004; Egan TJ, 2006, FEBS LETT, V580, P5105, DOI 10.1016/j.febslet.2006.08.043; Ferrer M, 2005, BIOCHEM J, V391, P269, DOI 10.1042/BJ20050346; Fitch CD, 1999, BBA-MOL BASIS DIS, V1454, P31, DOI 10.1016/S0925-4439(99)00017-4; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Graca-Souza AV, 2006, INSECT BIOCHEM MOLEC, V36, P322, DOI 10.1016/j.ibmb.2006.01.009; Jackson KE, 2004, MOL MICROBIOL, V54, P109, DOI 10.1111/j.1365-2958.2004.04284.x; Jacobson RL, 2001, ACTA TROP, V78, P41, DOI 10.1016/S0001-706X(00)00164-9; Jani D, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000053; Lara FA, 2003, J EXP BIOL, V206, P1707, DOI 10.1242/jeb.00334; Lehane MJ., 2005, BIOL BLOODS INS 2 ED, DOI 10.1017/CBO9780511610493; Lynn A, 1999, FEBS LETT, V459, P267, DOI 10.1016/S0014-5793(99)01260-0; MORGAN MRJ, 1975, J INSECT PHYSIOL, V21, P1045, DOI 10.1016/0022-1910(75)90114-6; Okuyama M, 2001, EUR J BIOCHEM, V268, P2270, DOI 10.1046/j.1432-1327.2001.02104.x; Oliveira MF, 2000, FEBS LETT, V477, P95, DOI 10.1016/S0014-5793(00)01786-5; Oliveira MF, 2005, FEBS LETT, V579, P6010, DOI 10.1016/j.febslet.2005.09.035; Oliveira MF, 1999, NATURE, V400, P517, DOI 10.1038/22910; Oliveira MF, 2000, MOL BIOCHEM PARASIT, V111, P217, DOI 10.1016/S0166-6851(00)00299-1; Oliveira PL, 2002, FEBS LETT, V525, P3, DOI 10.1016/S0014-5793(02)03026-0; Pandey AV, 2003, BIOCHEM BIOPH RES CO, V308, P736, DOI 10.1016/S0006-291X(03)01465-7; Pascoa V, 2002, INSECT BIOCHEM MOLEC, V32, P517, DOI 10.1016/S0965-1748(01)00130-8; Pisciotta JM, 2005, INT J PARASITOL, V35, P1037, DOI 10.1016/j.ijpara.2005.03.020; Pisciotta JM, 2008, PARASITOL INT, V57, P89, DOI 10.1016/j.parint.2007.09.009; Pisciotta JM, 2007, BIOCHEM J, V402, P197, DOI 10.1042/BJ20060986; Ribeiro JMC, 2004, INSECT BIOCHEM MOLEC, V34, P61, DOI 10.1016/j.ibmb.2003.09.004; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Romaniouk A, 1997, GLYCOBIOLOGY, V7, P399, DOI 10.1093/glycob/7.3.399; Schneider EL, 2005, BIOCHEMISTRY-US, V44, P979, DOI 10.1021/bi048570p; Shirai T, 2008, PROTEINS, V73, P126, DOI 10.1002/prot.22044; Silva CP, 2004, ARTHROPOD STRUCT DEV, V33, P139, DOI 10.1016/j.asd.2003.12.002; SILVA CP, 1994, INSECT BIOCHEM MOLEC, V24, P493, DOI 10.1016/0965-1748(94)90044-2; SILVA CP, 1995, J INSECT PHYSIOL, V41, P1093, DOI 10.1016/0022-1910(95)00066-4; Silva JR, 2007, INSECT BIOCHEM MOLEC, V37, P523, DOI 10.1016/j.ibmb.2007.01.001; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sullivan DJ, 2002, INT J PARASITOL, V32, P1645, DOI 10.1016/S0020-7519(02)00193-5; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; TERRA WR, 1979, BIOCHIM BIOPHYS ACTA, V571, P79, DOI 10.1016/0005-2744(79)90227-4; TERRA WR, 1988, BRAZ J MED BIOL RES, V21, P675; Whitby K, 2005, J VIROL, V79, P8698, DOI 10.1128/JVI.79.14.8698-8706.2005; Zeng YC, 1998, ARCH BIOCHEM BIOPHYS, V355, P26, DOI 10.1006/abbi.1998.0717	52	37	37	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6966	10.1371/journal.pone.0006966	http://dx.doi.org/10.1371/journal.pone.0006966			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742319	Green Published, Green Submitted, gold			2022-12-27	WOS:000269622500024
J	Patwardhan, GA; Zhang, QJ; Yin, DM; Gupta, V; Bao, JX; Senkal, CE; Ogretmen, B; Cabot, MC; Shah, GV; Sylvester, PW; Jazwinski, SM; Liu, YY				Patwardhan, Gauri A.; Zhang, Qian-Jin; Yin, Dongmei; Gupta, Vineet; Bao, Jianxiong; Senkal, Can E.; Ogretmen, Besim; Cabot, Myles C.; Shah, Girish V.; Sylvester, Paul W.; Jazwinski, S. Michal; Liu, Yong-Yu			A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis	PLOS ONE			English	Article							PROTEIN-KINASE-A; LONGEVITY ASSURANCE GENE-1; INDUCED CELL-DEATH; CERAMIDE GLYCOSYLATION; P-GLYCOPROTEIN; CANCER-CELLS; TELOMERASE ACTIVITY; HUMAN HEAD; IN-VITRO; EXPRESSION	Enhanced ceramide glycosylation catalyzed by glucosylceramide synthase (GCS) limits therapeutic efficiencies of antineoplastic agents including doxorubicin in drug-resistant cancer cells. Aimed to determine the role of GCS in tumor response to chemotherapy, a new mixed-backbone oligonucleotide (MBO-asGCS) with higher stability and efficiency has been generated to silence human GCS gene. MBO-asGCS was taken up efficiently in both drug-sensitive and drug-resistant cells, but it selectively suppressed GCS overexpression, and sensitized drug-resistant cells. MBO-asGCS increased doxorubicin sensitivity by 83-fold in human NCI/ADR-RES, and 43-fold in murine EMT6/AR1 breast cancer cells, respectively. In tumor-bearing mice, MBO-asGCS treatment dramatically inhibited the growth of multidrug-resistant NCI/ADR-RE tumors, decreasing tumor volume to 37%, as compared with scrambled control. Furthermore, MBO-asGCS sensitized multidrug-resistant tumors to chemotherapy, increasing doxorubicin efficiency greater than 2-fold. The sensitization effects of MBO-asGCS relied on the decreases of gene expression and enzyme activity of GCS, and on the increases of C-18-ceramide and of caspase-executed apoptosis. MBO-asGCS was accumulation in tumor xenografts was greater in other tissues, excepting liver and kidneys; but MBO-asGCS did not exert significant toxic effects on liver and kidneys. This study, for the first time in vivo, has demonstrated that GCS is a promising therapeutic target for cancer drug resistance, and MBO-asGCS has the potential to be developed as an antineoplastic agent.			Patwardhan, GA (corresponding author), Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, Monroe, LA USA.	yliu@ulm.edu	Liu, Yong-Yu/H-8593-2014	Liu, Yong-Yu/0000-0002-7968-0162	NCI NIH HHS [R01 CA096534, P01 CA097132, CA097132, R01 CA088932, CA088932] Funding Source: Medline; NCRR NIH HHS [P20 RR016456, P20 RR16456] Funding Source: Medline; NIDCR NIH HHS [DE016572, R01 DE016572] Funding Source: Medline; NIGMS NIH HHS [GM77391, R01 GM077391] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096534, P01CA097132, R01CA088932] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Bogin L, 2002, CANCER RES, V62, P1948; De Larco JE, 2001, CANCER RES, V61, P2857; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Diaz-Montero CM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-39; Dijkhuis AJ, 2006, MOL CANCER THER, V5, P593, DOI 10.1158/1535-7163.MCT-05-0457; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Goel S, 2003, CLIN CANCER RES, V9, P4069; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gouaze V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329; Gouaze V, 2004, MOL CANCER THER, V3, P633; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Itoh M, 2003, CLIN CANCER RES, V9, P415; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick R, 2007, CANCER CELL, V11, P473, DOI 10.1016/j.ccr.2007.05.003; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kraveka JM, 2003, ARCH BIOCHEM BIOPHYS, V419, P110, DOI 10.1016/j.abb.2003.08.034; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Liu YY, 2008, FASEB J, V22, P2541, DOI 10.1096/fj.07-092981; Liu Yong-Yu, 2004, Methods Mol Biol, V249, P177; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 2004, J LIPID RES, V45, P933, DOI 10.1194/jlr.M300486-JLR200; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Lucci A, 1998, ANTICANCER RES, V18, P475; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; McEachern KA, 2007, MOL GENET METAB, V91, P259, DOI 10.1016/j.ymgme.2007.04.001; Mehta K, 2002, J NATL CANCER I, V94, P1652; Mistry P, 2001, CANCER RES, V61, P749; Morjani H, 2001, INT J CANCER, V94, P157, DOI 10.1002/ijc.1449; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Olshefski RS, 2001, INT J CANCER, V93, P131, DOI 10.1002/ijc.1301; Primeau AJ, 2005, CLIN CANCER RES, V11, P8782, DOI 10.1158/1078-0432.CCR-05-1664; Rath G, 2009, INT J BIOCHEM CELL B, V41, P1165, DOI 10.1016/j.biocel.2008.10.021; Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034; Ruckhaberle E, 2009, J CANCER RES CLIN, V135, P81, DOI 10.1007/s00432-008-0436-9; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Sun YL, 2006, NEOPLASMA, V53, P1; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tepel J, 2004, PANCREAS, V28, P1, DOI 10.1097/00006676-200401000-00001; Tortora G, 2000, CLIN CANCER RES, V6, P2506; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Weiss M, 2003, CANCER RES, V63, P3654; Wu KJ, 1999, BIOCHEM J, V341, P395, DOI 10.1042/0264-6021:3410395; Xie P, 2008, LEUKEMIA RES, V32, P475, DOI 10.1016/j.leukres.2007.07.006; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100	55	42	44	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6938	10.1371/journal.pone.0006938	http://dx.doi.org/10.1371/journal.pone.0006938			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742320	gold, Green Published, Green Submitted			2022-12-27	WOS:000269622500014
J	Sakuma, T; Sakurai, A; Yasuda, J				Sakuma, Toshie; Sakurai, Akira; Yasuda, Jiro			Dimerization of Tetherin Is Not Essential for Its Antiviral Activity against Lassa and Marburg Viruses	PLOS ONE			English	Article								Tetherin (also known as BST2, CD317 or HM1.24) has recently been reported to inhibit a wide range of viruses. However, the antiviral mechanism of action of tetherin has not been determined. Both ends of the tetherin molecule are associated with the plasma membrane and it forms a homodimer. Therefore, a model in which progeny virions are retained on the cell surface by dimer formation between tetherin molecules on the viral envelope and plasma membrane has been proposed as the antiviral mechanism of action of this molecule. To investigate this possibility, we examined the correlation between dimerization and antiviral activity of tetherin in Lassa and Marburg virus-like particle production systems using tetherin mutants deficient in dimer formation. However, the tetherin mutant with complete loss of dimerization activity still showed apparent antiviral activity, indicating that dimerization of tetherin is not essential for its antiviral activity. This suggests that tetherin retains progeny virions on the cell surface by a mechanism other than dimerization.			Sakuma, T (corresponding author), Natl Res Inst Police Sci, Dept Forens Sci 1, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan.	yasuda@nrips.go.jp		Yasuda, Jiro/0000-0001-9928-5621				Blasius AL, 2006, J IMMUNOL, V177, P3260, DOI 10.4049/jimmunol.177.5.3260; Gottlinger HG, 2008, NATURE, V451, P406, DOI 10.1038/nature06364; ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H; Jouvenet N, 2009, J VIROL, V83, P1837, DOI 10.1128/JVI.02211-08; Kaletsky RL, 2009, P NATL ACAD SCI USA, V106, P2886, DOI 10.1073/pnas.0811014106; Kupzig S, 2003, TRAFFIC, V4, P694, DOI 10.1034/j.1600-0854.2003.00129.x; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Ohtomo T, 1999, BIOCHEM BIOPH RES CO, V258, P583, DOI 10.1006/bbrc.1999.0683; Sakuma T, 2009, J VIROL, V83, P2382, DOI 10.1128/JVI.01607-08; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Urata S, 2006, J VIROL, V80, P4191, DOI 10.1128/JVI.80.8.4191-4195.2006; Urata S, 2007, J VIROL, V81, P4895, DOI 10.1128/JVI.02829-06; Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001; Yasuda J, 2003, J VIROL, V77, P9987, DOI 10.1128/JVI.77.18.9987-9992.2003; Yasuda J, 2002, EMBO REP, V3, P636, DOI 10.1093/embo-reports/kvf132	15	41	42	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6934	10.1371/journal.pone.0006934	http://dx.doi.org/10.1371/journal.pone.0006934			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742323	Green Submitted, gold, Green Published			2022-12-27	WOS:000269622500012
J	Cao, Y; Zhang, DM; Pan, WQ				Cao, Yi; Zhang, Dongmei; Pan, Weiqing			Construction of Transgenic Plasmodium berghei as a Model for Evaluation of Blood-Stage Vaccine Candidate of Plasmodium falciparum Chimeric Protein 2.9	PLOS ONE			English	Article							MEROZOITE SURFACE PROTEIN-1; APICAL MEMBRANE ANTIGEN-1; RODENT MALARIA PARASITE; GROWTH IN-VITRO; FLUORESCENT PROTEIN; TERMINAL FRAGMENT; AOTUS MONKEYS; IMMUNOGENICITY; ANTIBODIES; YOELII	Background: The function of the 19 kDa C-terminal region of the merozoite surface protein 1 (MSP1-19) expressed by Plasmodium has been demonstrated to be conserved across distantly related Plasmodium species. The green fluorescent protein (GFP) is a reporter protein that has been widely used because it can be easily detected in living organisms by fluorescence microscopy and flow cytometry. Methodology and Results: In this study, we used gene targeting to generate transgenic P. berghei (Pb) parasites (designated as PfMSP1-19Pb) that express the MSP1-19 of P. falciparum (Pf) and the GFP reporter protein simultaneously. The replacement of the PbMSP1-19 locus by PfMSP1-19 was verified by PCR and Southern analysis. The expression of the chimeric PbfMSP-1 and the GFP was verified by Western blot and fluorescence microscopy, respectively. Moreover, GFP-expressing transgenic parasites in blood stages can be readily differentiated from other blood cells using flow cytometry. A comparion of growth rates between wild-type and the PfMSP1-19Pb transgenic parasite indicated that the replacement of the MSP1-19 region and the expression of the GFP protein were not deleterious to the transgenic parasites. We used this transgenic mouse parasite as a murine model to evaluate the protective efficacy in vivo of specific IgG elicited by a PfCP-2.9 malaria vaccine that contains the PfMSP1-19. The BALB/c mice passively transferred with purified rabbit IgG to the PfCP-2.9 survived a lethal challenge of the PfMSP1-19Pb transgenic murine parasites, but not the wild-type P. berghei whereas the control mice passively transferred with purified IgG obtained from adjuvant only-immunized rabbits were vulnerable to both transgenic and wild-type infections. Conclusions: We generated a transgenic P. berghei line that expresses PfMSP1-19 and the GFP reporter gene simultaneously. The availability of this parasite line provides a murine model to evaluate the protective efficacy in vivo of anti-MSP1-19 antibodies, including, potentially, those elicited by the PfCP-2.9 malaria vaccine in human volunteers.			Cao, Y (corresponding author), Second Mil Med Univ, Dept Pathogen Biol, Shanghai, Peoples R China.	wqpan0912@yahoo.com.cn						BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; Cao Yi, 2008, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V26, P327; Corran PH, 2004, INFECT IMMUN, V72, P6185, DOI 10.1128/IAI.72.10.6185-6189.2004; de Koning-Ward TF, 2003, J EXP MED, V198, P869, DOI 10.1084/jem.20030085; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Girard MP, 2007, VACCINE, V25, P1567, DOI 10.1016/j.vaccine.2006.09.074; Good MF, 2001, NAT REV IMMUNOL, V1, P117, DOI 10.1038/35100540; Herrera S, 2002, INT J PARASITOL, V32, P1625, DOI 10.1016/S0020-7519(02)00191-1; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; HOLDER AA, 1984, PHILOS T ROY SOC B, V307, P171, DOI 10.1098/rstb.1984.0117; Hu JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001952; Hu J, 2006, AM J TROP MED HYG, V75, P317; Janse CJ, 2006, NAT PROTOC, V1, P614, DOI 10.1038/nprot.2006.88; Kumar S, 2000, INFECT IMMUN, V68, P2215, DOI 10.1128/IAI.68.4.2215-2223.2000; Langermans JAM, 2006, HUM VACCINES, V2, P222, DOI 10.4161/hv.2.5.3276; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Mambo G, 2008, INFECT IMMUN, V76, P2018, DOI 10.1128/IAI.01409-07; Menard R, 1997, METHODS, V13, P148, DOI 10.1006/meth.1997.0507; Mota MM, 2001, MOL BIOCHEM PARASIT, V113, P271, DOI 10.1016/S0166-6851(01)00228-6; Nair M, 2002, J MOL BIOL, V322, P741, DOI 10.1016/S0022-2836(02)00806-9; Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Pan WQ, 2004, J IMMUNOL, V172, P6167, DOI 10.4049/jimmunol.172.10.6167; Ramjanee S, 2007, VACCINE, V25, P886, DOI 10.1016/j.vaccine.2006.09.035; Remarque EJ, 2008, TRENDS PARASITOL, V24, P74, DOI 10.1016/j.pt.2007.12.002; Sachdeva S, 2006, VACCINE, V24, P2007, DOI 10.1016/j.vaccine.2005.11.041; Sambrook J., 2001, MOL CLONING LAB MANU; Saul A, 2001, J EXP MED, V193, pF51, DOI 10.1084/jem.193.12.F51; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Stowers AW, 2002, INFECT IMMUN, V70, P6961, DOI 10.1128/IAI.70.12.6961-6967.2002; Sultan AA, 1999, INFECT IMMUN, V67, P2602, DOI 10.1128/IAI.67.5.2602-2606.1999; vanderWel AM, 1997, J EXP MED, V185, P1499, DOI 10.1084/jem.185.8.1499; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; 2004, MALVAC M 2004 EV MAL	37	20	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6894	10.1371/journal.pone.0006894	http://dx.doi.org/10.1371/journal.pone.0006894			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727400	gold, Green Submitted, Green Published			2022-12-27	WOS:000269522900022
J	Hu, JC; Cui, GF; Li, CM; Liu, C; Shang, EC; Lai, LH; Jin, CW; Wang, JW; Xia, B				Hu, Jicheng; Cui, Gaofeng; Li, Congmin; Liu, Cong; Shang, Erchang; Lai, Luhua; Jin, Changwen; Wang, Jiwu; Xia, Bin			Structure and Novel Functional Mechanism of Drosophila SNF in Sex-Lethal Splicing	PLOS ONE			English	Article								Sans-fille (SNF) is the Drosophila homologue of mammalian general splicing factors U1A and U2B '', and it is essential in Drosophila sex determination. We found that, besides its ability to bind U1 snRNA, SNF can also bind polyuridine RNA tracts flanking the male-specific exon of the master switch gene Sex-lethal (Sxl) pre-mRNA specifically, similar to Sex-lethal protein (SXL). The polyuridine RNA binding enables SNF directly inhibit Sxl exon 3 splicing, as the dominant negative mutant SNF(1621) binds U1 snRNA but not polyuridine RNA. Unlike U1A, both RNA recognition motifs (RRMs) of SNF can recognize polyuridine RNA tracts independently, even though SNF and U1A share very high sequence identity and overall structure similarity. As SNF RRM1 tends to self-associate on the opposite side of the RNA binding surface, it is possible for SNF to bridge the formation of super-complexes between two introns flanking Sxl exon 3 or between a intron and U1 snRNP, which serves the molecular basis for SNF to directly regulate Sxl splicing. Taken together, a new functional model for SNF in Drosophila sex determination is proposed. The key of the new model is that SXL and SNF function similarly in promoting Sxl male-specific exon skipping with SNF being an auxiliary or backup to SXL, and it is the combined dose of SXL and SNF governs Drosophila sex determination.			Hu, JC (corresponding author), Beijing Nucl Magnet Resonance Ctr, Beijing, Peoples R China.	jiwuwang@allelebiotech.com; binxia@pku.edu.cn	Xia, Bin/O-1160-2016; liu, cong/H-1103-2011; Cui, Gaofeng/A-1107-2013	Xia, Bin/0000-0002-2197-6403; Cui, Gaofeng/0000-0001-5267-9033				ALBRECHT EB, 1993, GENETICS, V134, P801; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Auweter SD, 2008, CELL MOL LIFE SCI, V65, P516, DOI 10.1007/s00018-007-7378-2; Avila FW, 2007, CURR BIOL, V17, P643, DOI 10.1016/j.cub.2007.02.038; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BERNSTEIN M, 1995, GENETICS, V139, P631; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Cline TW, 1999, P NATL ACAD SCI USA, V96, P14451, DOI 10.1073/pnas.96.25.14451; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deshpande G, 1996, MOL CELL BIOL, V16, P5036; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Erickson JW, 2007, PLOS BIOL, V5, P2821, DOI 10.1371/journal.pbio.0050332; FLICKINGER TW, 1994, GENE DEV, V8, P914, DOI 10.1101/gad.8.8.914; GANS M, 1975, GENETICS, V81, P683; Gebauer F, 1998, RNA, V4, P142; GOLLIN SM, 1981, DEV GENET, V2, P203, DOI 10.1002/dvg.1020020206; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HARPER DS, 1992, NUCLEIC ACIDS RES, V20, P3645, DOI 10.1093/nar/20.14.3645; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HORABIN JI, 1993, MOL CELL BIOL, V13, P1408, DOI 10.1128/MCB.13.3.1408; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; Katsamba PS, 2002, J BIOL CHEM, V277, P33267, DOI 10.1074/jbc.M200304200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kramer SG, 1999, DEVELOPMENT, V126, P191; Labourier E, 2001, RNA, V7, P457, DOI 10.1017/S1355838201001327; Lallena MJ, 2002, CELL, V109, P285, DOI 10.1016/S0092-8674(02)00730-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Law MJ, 2006, RNA, V12, P1168, DOI 10.1261/rna.75206; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; Lu JR, 1997, BIOCHEMISTRY-US, V36, P10393, DOI 10.1021/bi9709811; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Nagengast AA, 2003, DEVELOPMENT, V130, P463, DOI 10.1242/dev.00274; OLIVER B, 1988, GENETICS, V120, P159; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Penalva LOF, 2003, MICROBIOL MOL BIOL R, V67, P343, DOI 10.1128/MMBR.67.3.343-359.2003; PolycarpouSchwarz M, 1996, RNA, V2, P11; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SALZ HK, 1992, GENETICS, V130, P547; Salz HK, 1996, GENETICS, V144, P95; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schutt C, 2000, DEVELOPMENT, V127, P667; Sefton L, 2000, NATURE, V405, P970, DOI 10.1038/35016119; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; STEINMANNZWICKY M, 1988, EMBO J, V7, P3889, DOI 10.1002/j.1460-2075.1988.tb03275.x; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; Vaynberg J, 2006, TRENDS BIOTECHNOL, V24, P22, DOI 10.1016/j.tibtech.2005.09.006; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; Yang D, 2001, MOL CELL BIOL, V21, P1581, DOI 10.1128/MCB.21.5.1581-1592.2001	62	11	11	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6890	10.1371/journal.pone.0006890	http://dx.doi.org/10.1371/journal.pone.0006890			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727396	Green Submitted, Green Published, gold			2022-12-27	WOS:000269522900019
J	Oppegard, SC; Nam, KH; Carr, JR; Skaalure, SC; Eddington, DT				Oppegard, Shawn C.; Nam, Ki-Hwan; Carr, Janai R.; Skaalure, Stacey C.; Eddington, David T.			Modulating Temporal and Spatial Oxygenation over Adherent Cellular Cultures	PLOS ONE			English	Article								Oxygen is a key modulator of many cellular pathways, but current devices permitting in vitro oxygen modulation fail to meet the needs of biomedical research. A microfabricated insert for multiwell plates has been developed to more effectively control the temporal and spatial oxygen concentration to better model physiological phenomena found in vivo. The platform consists of a polydimethylsiloxane insert that nests into a standard multiwell plate and serves as a passive microfluidic gas network with a gas-permeable membrane aimed to modulate oxygen delivery to adherent cells. Equilibration time is on the order of minutes and a wide variety of oxygen profiles can be attained based on the device design, such as the cyclic profile achieved in this study, and even oxygen gradients to mimic those found in vivo. The proper biological consequences of the device's oxygen delivery were confirmed in cellular models via a proliferation assay and western analysis of the upregulation of hypoxia inducible transcription factor-1 alpha. These experiments serve as a demonstration for the platform as a viable tool to increase experimental throughput and permit novel experimental possibilities in any biomedical research lab.			Oppegard, SC (corresponding author), Univ Illinois, Dept Bioengn, Chicago, IL 60680 USA.	dte@uic.edu		Skaalure, Stacey/0000-0001-5746-0575; Nam, Ki-Hwan/0000-0001-9943-6792; Carr-Ascher, Janai/0000-0002-2074-4643				Allen CB, 2001, AM J PHYSIOL-LUNG C, V281, pL1021, DOI 10.1152/ajplung.2001.281.4.L1021; Allen JW, 2003, HEPATOLOGY, V38, p270A; Allen JW, 2003, BIOTECHNOL BIOENG, V82, P253, DOI 10.1002/bit.10569; Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Baumgardner JE, 2003, RESP PHYSIOL NEUROBI, V136, P131, DOI 10.1016/S1569-9048(03)00077-6; Cairns RA, 2001, CANCER RES, V61, P8903; CARRAWAY ER, 1991, ANAL CHEM, V63, P337, DOI 10.1021/ac00004a007; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; FALANGA V, 2005, J CELLULAR PHYSL, V154, P506; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harvey AJ, 2007, ANIM REPROD SCI, V98, P113, DOI 10.1016/j.anireprosci.2006.10.008; Heo YS, 2007, ANAL CHEM, V79, P1126, DOI 10.1021/ac061990v; HOLZER C, 1987, J CELL PHYSIOL, V133, P297, DOI 10.1002/jcp.1041330213; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Lee HLT, 2006, LAB CHIP, V6, P1229, DOI 10.1039/b608014f; Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081; Lin JH, 1998, CLIN PHARMACOKINET, V35, P361, DOI 10.2165/00003088-199835050-00003; Mehta G, 2007, BIOMED MICRODEVICES, V9, P123, DOI 10.1007/s10544-006-9005-7; Mukhopadhyay R, 2007, ANAL CHEM, V79, P7249, DOI 10.1021/ac071972t; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Prabhakar NR, 2002, AM J RESP CRIT CARE, V165, P859, DOI 10.1164/ajrccm.165.7.2202030c; Randall GC, 2005, P NATL ACAD SCI USA, V102, P10813, DOI 10.1073/pnas.0503287102; Roman GT, 2005, ANAL CHEM, V77, P1414, DOI 10.1021/ac048811z; ROSEN P, 1991, EXP EYE RES, V53, P597, DOI 10.1016/0014-4835(91)90218-4; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tilles AW, 2001, BIOTECHNOL BIOENG, V73, P379, DOI 10.1002/bit.1071; Uno K, 2007, DEV DYNAM, V236, P981, DOI 10.1002/dvdy.21122; Vollmer AP, 2005, LAB CHIP, V5, P1059, DOI 10.1039/b508097e; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yuan GX, 2005, J BIOL CHEM, V280, P4321, DOI 10.1074/jbc.M407706200; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; ZHONG H, 1999, CANCER RES, V60, P4693	33	63	64	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6891	10.1371/journal.pone.0006891	http://dx.doi.org/10.1371/journal.pone.0006891			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727397	Green Published, gold			2022-12-27	WOS:000269522900020
J	Pitkaniemi, J; Varvio, SL; Corander, J; Lehti, N; Partanen, J; Tuomilehto-Wolf, E; Tuomilehto, J; Thomas, A; Arjas, E				Pitkaniemi, Janne; Varvio, Sirkka-Liisa; Corander, Jukka; Lehti, Nella; Partanen, Jukka; Tuomilehto-Wolf, Eva; Tuomilehto, Jaakko; Thomas, Andrew; Arjas, Elja			Full Likelihood Analysis of Genetic Risk with Variable Age at Onset Disease-Combining Population-Based Registry Data and Demographic Information	PLOS ONE			English	Article							HLA-ASSOCIATED RISKS; FINNISH POPULATION; DIABETES-MELLITUS; HAPLOTYPE; ASCERTAINMENT; SUSCEPTIBILITY; EPIDEMIOLOGY; MODELS	Background: In genetic studies of rare complex diseases it is common to ascertain familial data from population based registries through all incident cases diagnosed during a pre-defined enrollment period. Such an ascertainment procedure is typically taken into account in the statistical analysis of the familial data by constructing either a retrospective or prospective likelihood expression, which conditions on the ascertainment event. Both of these approaches lead to a substantial loss of valuable data. Methodology and Findings: Here we consider instead the possibilities provided by a Bayesian approach to risk analysis, which also incorporates the ascertainment procedure and reference information concerning the genetic composition of the target population to the considered statistical model. Furthermore, the proposed Bayesian hierarchical survival model does not require the considered genotype or haplotype effects be expressed as functions of corresponding allelic effects. Our modeling strategy is illustrated by a risk analysis of type 1 diabetes mellitus (T1D) in the Finnish population-based on the HLA-A, HLA-B and DRB1 human leucocyte antigen (HLA) information available for both ascertained sibships and a large number of unrelated individuals from the Finnish bone marrow donor registry. The heterozygous genotype DR3/DR4 at the DRB1 locus was associated with the lowest predictive probability of T1D free survival to the age of 15, the estimate being 0.936 (0.926; 0.945 95% credible interval) compared to the average population T1D free survival probability of 0.995. Significance: The proposed statistical method can be modified to other population-based family data ascertained from a disease registry provided that the ascertainment process is well documented, and that external information concerning the sizes of birth cohorts and a suitable reference sample are available. We confirm the earlier findings from the same data concerning the HLA-DR3/4 related risks for T1D, and also provide here estimated predictive probabilities of disease free survival as a function of age.			Pitkaniemi, J (corresponding author), Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.	janne.pitkaniemi@helsinki.fi	Partanen, Jukka/B-7207-2014	Partanen, Jukka/0000-0001-6681-4734				[Anonymous], 2001, BAYESIAN SURVIVAL AN; Beaumont MA, 2004, NAT REV GENET, V5, P251, DOI 10.1038/nrg1318; Burton PR, 2003, GENET EPIDEMIOL, V24, P24, DOI 10.1002/gepi.10206; Clayton D, 2003, BIOMETRIKA, V90, P976, DOI 10.1093/biomet/90.4.976; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; GAUDERMAN WJ, 1994, GENET EPIDEMIOL, V11, P171, DOI 10.1002/gepi.1370110207; Gelman A., 2004, BAYESIAN DATA ANAL; Glickman ME, 2002, LIFETIME DATA ANAL, V8, P211, DOI 10.1023/A:1015880003274; Harkanen T, 2000, SCAND J STAT, V27, P577, DOI 10.1111/1467-9469.00209; Kraft P, 2000, AM J HUM GENET, V66, P1119, DOI 10.1086/302808; Lambert AP, 2004, J CLIN ENDOCR METAB, V89, P4037, DOI 10.1210/jc.2003-032084; LANGHOLZ B, 1995, GENET EPIDEMIOL, V12, P441, DOI 10.1002/gepi.1370120502; Marsh Steven G E, 2004, Tissue Antigens, V63, P505, DOI 10.1111/j.1399-0039.2004.00213.x; Mensah FK, 2007, GENET EPIDEMIOL, V31, P348, DOI 10.1002/gepi.20215; Pitkaniemi J, 2004, HUM HERED, V57, P69, DOI 10.1159/000077544; Seaman SR, 2002, GENET EPIDEMIOL, V22, P356, DOI 10.1002/gepi.0197; Siegmund KD, 1998, EPIDEMIOLOGY, V9, P557, DOI 10.1097/00001648-199809000-00015; Siegmund KD, 2000, HUM HERED, V50, P205, DOI 10.1159/000022916; Sobel E, 1996, AM J HUM GENET, V58, P1323; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Sun WL, 2004, LIFETIME DATA ANAL, V10, P229, DOI 10.1023/B:LIDA.0000036390.15378.5e; THOMAS D, 1995, GENET EPIDEMIOL, V12, P455, DOI 10.1002/gepi.1370120503; TIENARI PJ, 1992, DIABETOLOGIA, V35, P254, DOI 10.1007/BF00400926; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; *U HELS DEP MATH, OPENBUGS	26	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6836	10.1371/journal.pone.0006836	http://dx.doi.org/10.1371/journal.pone.0006836			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718441	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415900009
J	Halder, S; Murakami, M; Verma, SC; Kumar, P; Yi, FM; Robertson, ES				Halder, Sabyasachi; Murakami, Masanao; Verma, Subhash C.; Kumar, Pankaj; Yi, Fuming; Robertson, Erle S.			Early Events Associated with Infection of Epstein-Barr Virus Infection of Primary B-Cells	PLOS ONE			English	Article								Epstein Barr virus (EBV) is closely associated with the development of a vast number of human cancers. To develop a system for monitoring early cellular and viral events associated with EBV infection a self-recombining BAC containing 172-kb of the Epstein Barr virus genome BAC-EBV designated as MD1 BAC (Chen et al., 2005, J. Virology) was used to introduce an expression cassette of green fluorescent protein (GFP) by homologous recombination, and the resultant BAC clone, BAC-GFP-EBV was transfected into the HEK 293T epithelial cell line. The resulting recombinant GFP EBV was induced to produce progeny virus by chemical inducer from the stable HEK 293T BAC GFP EBV cell line and the virus was used to immortalize human primary B-cell as monitored by green fluorescence and outgrowth of the primary B cells. The infection, B-cell activation and cell proliferation due to GFP EBV was monitored by the expression of the B-cell surface antigens CD5, CD10, CD19, CD23, CD39, CD40, CD44 and the intercellular proliferation marker Ki-67 using Flow cytometry. The results show a dramatic increase in Ki-67 which continues to increase by 6-7 days post-infection. Likewise, CD40 signals showed a gradual increase, whereas CD23 signals were increased by 6-12 hours, maximally by 3 days and then decreased. Monitoring the viral gene expression pattern showed an early burst of lytic gene expression. This up-regulation of lytic gene expression prior to latent genes during early infection strongly suggests that EBV infects primary B-cell with an initial burst of lytic gene expression and the resulting progeny virus is competent for infecting new primary B-cells. This process may be critical for establishment of latency prior to cellular transformation. The newly infected primary B-cells can be further analyzed for investigating B cell activation due to EBV infection.			Halder, S (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.	erle@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA137894, R01CA108461, K99CA126182] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA137894-01, K99 CA126182-02, K99 CA126182, 5R01CA108461-05, R01 CA108461, R01 CA137894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; Baumforth KRN, 1999, J CLIN PATHOL-MOL PA, V52, P307; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; BROOKS LA, 1993, J VIROL, V67, P3182, DOI 10.1128/JVI.67.6.3182-3190.1993; Brune W, 2000, TRENDS GENET, V16, P254, DOI 10.1016/S0168-9525(00)02015-1; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen A, 2005, J VIROL, V79, P4506, DOI 10.1128/JVI.79.7.4506-4509.2005; CLARK EA, 1991, ANNU REV IMMUNOL, V97, P127; COLBY BM, 1980, J VIROL, V34, P560, DOI 10.1128/JVI.34.2.560-568.1980; CORDIERBUSSAT M, 1993, INT J CANCER, V53, P153, DOI 10.1002/ijc.2910530128; DALENS M, 1975, INT J CANCER, V16, P1008, DOI 10.1002/ijc.2910160614; DATTA AK, 1980, P NATL ACAD SCI-BIOL, V77, P5163, DOI 10.1073/pnas.77.9.5163; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; FARREL PJ, 2005, EPSTEIN BARR VIRUS G; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P4549, DOI 10.1128/JVI.64.9.4549-4552.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; Gagro A, 2000, IMMUNOLOGY, V101, P201, DOI 10.1046/j.1365-2567.2000.00098.x; Gerdes J, 1984, Hematol Oncol, V2, P365; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; GONG M, 1987, J VIROL, V61, P499, DOI 10.1128/JVI.61.2.499-508.1987; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; Herrold RE, 1996, J VIROL, V70, P2049, DOI 10.1128/JVI.70.3.2049-2054.1996; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; Imadome KI, 2009, MICROBES INFECT, V11, P429, DOI 10.1016/j.micinf.2009.01.007; Imadome KI, 2003, P NATL ACAD SCI USA, V100, P7836, DOI 10.1073/pnas.1231363100; ISHII Y, 1972, J RETICULOENDOTH SOC, V11, P383; JONES JF, 1988, NEW ENGL J MED, V318, P733, DOI 10.1056/NEJM198803243181203; Kanda T, 2004, J VIROL, V78, P7004, DOI 10.1128/JVI.78.13.7004-7015.2004; Kaplan D, 2001, P NATL ACAD SCI USA, V98, P13850, DOI 10.1073/pnas.241509398; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, P NATL ACAD SCI USA, V92, P5875, DOI 10.1073/pnas.92.13.5875; KENNEY S, 1989, J VIROL, V63, P1729, DOI 10.1128/JVI.63.4.1729-1736.1989; KIEFF E, 2001, FIELDS VIROLOGY, P2511; KIEFF E, 1996, FIELDS VIROLOGY, P2443; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; Klein E, 1999, IMMUNOL LETT, V68, P147, DOI 10.1016/S0165-2478(99)00044-9; Kobayashi I, 1999, J PATHOL, V189, P34, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;34::AID-PATH391&gt;3.0.CO;2-4; KRYWORUCKHO M, 1995, IMMUNOLOGY, V86, P41; Kuppers R, 2003, NAT REV IMMUNOL, V3, P801, DOI 10.1038/nri1201; Lan K, 2007, CURR PROTOC MICROBIO, DOI DOI 10.1002/9780471729259.MCL4E02S6; LEWIN N, 1987, INT J CANCER, V39, P472, DOI 10.1002/ijc.2910390411; LIN JC, 1991, J VIROL, V65, P2728, DOI 10.1128/JVI.65.5.2728-2731.1991; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MILLER RA, 1984, J IMMUNOL, V133, P3408; MOCARSKI ES, 1980, CELL, V22, P243, DOI 10.1016/0092-8674(80)90172-5; NADLER LM, 1983, J IMMUNOL, V131, P244; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; Neuhierl B, 2002, P NATL ACAD SCI USA, V99, P15036, DOI 10.1073/pnas.232381299; PEARSON GR, 1978, J VIROL, V28, P344, DOI 10.1128/JVI.28.1.344-351.1978; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6; RICKINSON AB, 1974, INT J CANCER, V14, P704, DOI 10.1002/ijc.2910140603; RICKINSON AB, 1977, INT J CANCER, V19, P775, DOI 10.1002/ijc.2910190606; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; ROSS W, 1995, J CLIN PATHOL-CL MOL, V48, pM113; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SMILEY JR, 1980, NATURE, V285, P333, DOI 10.1038/285333a0; Smith GA, 2000, P NATL ACAD SCI USA, V97, P4873, DOI 10.1073/pnas.080502497; Speck P, 1999, ARCH VIROL, V144, P1123, DOI 10.1007/s007050050574; Takada K, 2001, CURR TOP MICROBIOL, V258, P141; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; UCKUN FM, 1988, BLOOD, V71, P13; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Verma SC, 2007, CELL HOST MICROBE, V2, P106, DOI 10.1016/j.chom.2007.07.002; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1993, INTERVIROLOGY, V35, P26, DOI 10.1159/000150293; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yuan J, 2006, J VIROL, V80, P2548, DOI 10.1128/JVI.80.5.2548-2565.2006	80	71	74	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7214	10.1371/journal.pone.0007214	http://dx.doi.org/10.1371/journal.pone.0007214			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500HQ	19784370	Green Published, gold, Green Submitted			2022-12-27	WOS:000270290000015
J	Balabanova, Y; Drobniewski, F; Nikolayevskyy, V; Kruuner, A; Malomanova, N; Simak, T; Ilyina, N; Zakharova, S; Lebedeva, N; Alexander, HL; O'Brien, R; Sohn, H; Shakhmistova, A; Fedorin, I				Balabanova, Yanina; Drobniewski, Francis; Nikolayevskyy, Vladyslav; Kruuner, Annika; Malomanova, Nadezhda; Simak, Tatyana; Ilyina, Nailya; Zakharova, Svetlana; Lebedeva, Natalya; Alexander, Heather L.; O'Brien, Rick; Sohn, Hojoon; Shakhmistova, Anastasia; Fedorin, Ivan			An Integrated Approach to Rapid Diagnosis of Tuberculosis and Multidrug Resistance Using Liquid Culture and Molecular Methods in Russia	PLOS ONE			English	Article								Objective: To analyse the feasibility, cost and performance of rapid tuberculosis (TB) molecular and culture systems, in a high multidrug-resistant TB (MDR TB) middle-income region (Samara, Russia) and provide evidence for WHO policy change. Methods: Performance and cost evaluation was conducted to compare the BACTEC (TM) MGIT (TM) 960 system for culture and drug susceptibility testing (DST) and molecular systems for TB diagnosis, resistance to isoniazid and rifampin, and MDR TB identification compared to conventional Lowenstein-Jensen culture assays. Findings: 698 consecutive patients (2487 sputum samples) with risk factors for drug-resistant tuberculosis were recruited. Overall M. tuberculosis complex culture positivity rates were 31.6% (787/2487) in MGIT and 27.1% (675/2487) in LJ (90.5% and 83.2% for smear-positive specimens). In total, 809 cultures of M. tuberculosis complex were isolated by any method. Median time to detection was 14 days for MGIT and 36 days for LJ (10 and 33 days for smear positive specimens) and indirect DST in MGIT took 9 days compared to 21 days on LJ. There was good concordance between DST on LJ and MGIT (96.8% for rifampin and 95.6% for isoniazid). Both molecular hybridization assay results correlated well with MGIT DST results, although molecular assays generally yielded higher rates of resistance (by approximately 3% for both isoniazid and rifampin). Conclusion: With effective planning and logistics, the MGIT 960 and molecular based methodologies can be successfully introduced into a reference laboratory setting in a middle incidence country. High rates of MDR TB in the Russian Federation make the introduction of such assays particularly useful.			Balabanova, Y (corresponding author), Univ London, Barts & London Sch Med, Queen Mary Coll,Inst Cell & Mol Sci, Natl Mycobacterium Reference Lab, London, England.	y.balabanova@qmul.ac.uk	Sohn, Hojoon/AAL-2856-2020; Nikolayevskyy, Vladyslav/HFZ-7738-2022	Sohn, Hojoon/0000-0001-5837-3844; Nikolayevskyy, Vladyslav/0000-0002-9502-0332				Balabanova Y, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-44; Baltussen R, 2005, BMJ-BRIT MED J, V331, P1364, DOI 10.1136/bmj.38645.660093.68; Bardarov S, 2003, DIAGN MICR INFEC DIS, V45, P53, DOI 10.1016/S0732-8893(02)00478-9; Bemer P, 2002, J CLIN MICROBIOL, V40, P150, DOI 10.1128/JCM.40.1.150-154.2002; Bergmann JS, 2000, ARCH PATHOL LAB MED, V124, P82; Chien HP, 2000, INT J TUBERC LUNG D, V4, P866; Coninx R, 1998, BRIT MED J, V316, P1423, DOI 10.1136/bmj.316.7142.1423; Dewan P, 2005, INT J TUBERC LUNG D, V9, P170; Drobniewski F, 2005, JAMA-J AM MED ASSOC, V293, P2726, DOI 10.1001/jama.293.22.2726; Drobniewski F, 2002, EMERG INFECT DIS, V8, P1320, DOI 10.3201/eid0811.020507; Drobniewski FA, 2003, LANCET INFECT DIS, V3, P141, DOI 10.1016/S1473-3099(03)00544-9; Drobniewski FA, 2000, J MED MICROBIOL, V49, P271, DOI 10.1099/0022-1317-49-3-271; DROBNIEWSKI FA, 2006, EUROPE EUR RESP J; Drummond MF, 2015, METHODS EC EVALUATIO; Edejer T, 2003, MAKING CHOICES HLTH; Giampaglia CMS, 2007, INT J TUBERC LUNG D, V11, P986; Goloubeva V, 2001, J CLIN MICROBIOL, V39, P1501, DOI 10.1128/JCM.39.4.1501-1505.2001; Hanna BA, 1999, J CLIN MICROBIOL, V37, P748, DOI 10.1128/JCM.37.3.748-752.1999; Hillemann D, 2007, J CLIN MICROBIOL, V45, P2635, DOI 10.1128/JCM.00521-07; Hillemann D, 2006, J CLIN MICROBIOL, V44, P4014, DOI 10.1128/JCM.00829-06; Kent PT, 1985, GUIDE LEVEL 3 LAB; Kruuner A, 2006, J CLIN MICROBIOL, V44, P811, DOI 10.1128/JCM.44.3.811-818.2006; Kubica T, 2005, INT J TUBERC LUNG D, V9, P646; Laszlo A, 2002, INT J TUBERC LUNG D, V6, P748; Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1; Migliori GB, 2008, CLIN INFECT DIS, V46, P958, DOI 10.1086/528875; Mokrousov I, 2004, J MICROBIOL METH, V57, P323, DOI 10.1016/j.mimet.2004.02.006; Nikolayevsky V, 2004, J CLIN MICROBIOL, V42, P4498, DOI 10.1128/JCM.42.10.4498-4502.2004; Nikolayevskyy V, 2009, BMC CLIN PATHOL, V9, DOI 10.1186/1472-6890-9-2; Pfyffer GE, 1997, J CLIN MICROBIOL, V35, P364, DOI 10.1128/JCM.35.2.364-368.1997; *PRIK MIN HLTH RUS, 2003, 109 PRIK MIN HLTH RU; Ruddy M, 2005, THORAX, V60, P130, DOI 10.1136/thx.2004.026922; Rusch-Gerdes S, 1999, J CLIN MICROBIOL, V37, P45; Seagar AL, 2008, J MED MICROBIOL, V57, P605, DOI 10.1099/jmm.0.47484-0; Skenders G, 2005, EMERG INFECT DIS, V11, P1461, DOI 10.3201/eid1109.041236; Somoskovi A, 2003, J CLIN MICROBIOL, V41, P2822, DOI 10.1128/JCM.41.7.2822-2826.2003; Somoskovi A, 2006, J CLIN MICROBIOL, V44, P2314, DOI 10.1128/JCM.00712-06; Somoskovi A, 2006, J CLIN MICROBIOL, V44, P4459, DOI 10.1128/JCM.01506-06; Srisuwanvilai LO, 2008, DIAGN MICR INFEC DIS, V61, P402, DOI 10.1016/j.diagmicrobio.2008.02.015; Tortoli E, 2002, J CLIN MICROBIOL, V40, P607, DOI 10.1128/JCM.40.2.607-610.2002; Toungoussova OS, 2002, J CLIN MICROBIOL, V40, P1930, DOI 10.1128/JCM.40.6.1930-1937.2002; Watterson SA, 1998, J CLIN MICROBIOL, V36, P1969, DOI 10.1128/JCM.36.7.1969-1973.1998; *WHO, 2008, NEW WHO POL; *WHO INT UN TUB LU, 2008, 4WHOHTMTB2008394 INT; World Health Organization, 2008, MOL LIN PROB ASS RAP	45	41	44	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7129	10.1371/journal.pone.0007129	http://dx.doi.org/10.1371/journal.pone.0007129			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774085	Green Submitted, gold, Green Published			2022-12-27	WOS:000270160900013
J	Solomon, LA; Li, JR; Berube, NG; Beier, F				Solomon, Lauren A.; Li, Jennifer R.; Berube, Nathalie G.; Beier, Frank			Loss of ATRX in Chondrocytes Has Minimal Effects on Skeletal Development	PLOS ONE			English	Article							MENTAL-RETARDATION; CRE RECOMBINASE; PROTEIN ATRX; MICE LACKING; SNF2 FAMILY; MUTATIONS; DIFFERENTIATION; EXPRESSION; PROLIFERATION; OSTEOBLAST	Background: Mutations in the human ATRX gene cause developmental defects, including skeletal deformities and dwarfism. ATRX encodes a chromatin remodeling protein, however the role of ATRX in skeletal development is currently unknown. Methodology/Principal Findings: We induced Atrx deletion in mouse cartilage using the Cre-loxP system, with Cre expression driven by the collagen II (Col2a1) promoter. Growth rate, body size and weight, and long bone length did not differ in Atrx(Col2cre) mice compared to control littermates. Histological analyses of the growth plate did not reveal any differences between control and mutant mice. Expression patterns of Sox9, a transcription factor required for cartilage morphogenesis, and p57, a marker of cell cycle arrest and hypertrophic chondrocyte differentiation, was unaffected. However, loss of ATRX in cartilage led to a delay in the ossification of the hips in some mice. We also observed hindlimb polydactily in one out of 61 mutants. Conclusions/Significance: These findings indicate that ATRX is not directly required for development or growth of cartilage in the mouse, suggesting that the short stature in ATR-X patients is caused by defects in cartilage-extrinsic mechanisms.			Solomon, LA (corresponding author), Univ Western Ontario, Dept Biochem, London, ON, Canada.	nberube@uwo.ca; fbeier@uwo.ca	Beier, Frank/G-4595-2013; Berube, Nathalie G/E-3885-2015; Beier, Frank/T-4734-2019	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Badens C, 2006, CLIN GENET, V70, P57, DOI 10.1111/j.1399-0004.2006.00641.x; Ballock R. Tracy, 2003, Birth Defects Research, V69, P123, DOI 10.1002/bdrc.10014; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Berube NG, 2005, J CLIN INVEST, V115, P258, DOI 10.1172/JCI200522329; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; Bobick Brent E., 2008, Birth Defects Research, V84, P131, DOI 10.1002/bdrc.20126; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Garrick D, 2004, GENE, V326, P23, DOI 10.1016/j.gene.2003.10.026; Garrick D, 2006, PLOS GENET, V2, P438, DOI 10.1371/journal.pgen.0020058; Gibbons R, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-15; Gibbons RJ, 2008, HUM MUTAT, V29, P796, DOI 10.1002/humu.20734; GIBBONS RJ, 1995, AM J MED GENET, V55, P288, DOI 10.1002/ajmg.1320550309; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gibbons RJ, 2000, AM J MED GENET, V97, P204, DOI 10.1002/1096-8628(200023)97:3<204::AID-AJMG1038>3.0.CO;2-X; Hoffman UM, 2003, J BONE JOINT SURG AM, V85A, P124, DOI 10.2106/00004623-200300002-00017; James CG, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-205; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; Maestroni GJM, 2000, ANN NY ACAD SCI, V917, P29; Medina CF, 2009, HUM MOL GENET, V18, P966, DOI 10.1093/hmg/ddn424; Picketts DJ, 1996, HUM MOL GENET, V5, P1899, DOI 10.1093/hmg/5.12.1899; Ritchie K, 2008, J CELL BIOL, V180, P315, DOI 10.1083/jcb.200706083; Seah C, 2008, J NEUROSCI, V28, P12570, DOI 10.1523/JNEUROSCI.4048-08.2008; Takeda S, 2005, BIOCHEM BIOPH RES CO, V328, P697, DOI 10.1016/j.bbrc.2004.11.071; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Wang GY, 2007, DEV BIOL, V306, P612, DOI 10.1016/j.ydbio.2007.03.520; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	33	25	25	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7106	10.1371/journal.pone.0007106	http://dx.doi.org/10.1371/journal.pone.0007106			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774083	Green Submitted, gold, Green Published			2022-12-27	WOS:000270160900008
J	Chen, LW; Tredget, EE; Liu, CX; Wu, YJ				Chen, Liwen; Tredget, Edward E.; Liu, Chenxiong; Wu, Yaojiong			Analysis of Allogenicity of Mesenchymal Stem Cells in Engraftment and Wound Healing in Mice	PLOS ONE			English	Article							MARROW STROMAL CELLS; HUMAN BONE-MARROW; T-CELLS; DIFFERENTIATION; RESPONSES; INHIBIT; REPAIR; FIBROBLASTS; DISEASE; HOST	Studies have shown that allogeneic (allo-) bone marrow derived mesenchymal stem cells (BM-MSCs) may enhance tissue repair/regeneration. However, recent studies suggest that immune rejection may occur to allo- MSCsleading to reduced engraftment. In this study, we compared allo- BM-MSCs with syngeneic BM-MSCs or allo- fibroblasts in engraftment and effect in wound healing. Equal numbers of GFP-expressing allo- BM-MSCs, syngeneic BM-MSCs or allo- fibroblasts were implanted into excisional wounds in GFP-negative mice. Quantification of GFP-expressing cells in wounds at 7, 14 and 28 days indicated similar amounts of allogeneic or syngeneic BM-MSCs but significantly reduced amounts of allo- fibroblasts. With healing progression, decreasing amounts of allogeneic and syngeneic BM-MSCs were found in the wound; however, the reduction was more evident (2 fold) in allo- fibroblasts. Similar effects in enhancing wound closure were found in allogeneic and syngeneic BM-MSCs but not in allo- fibroblasts. Histological analysis showed that allo- fibroblasts were largely confined to the injection sites while allo- BM-MSCs had migrated into the entire wound. Quantification of inflammatory cells in wounds showed that allo-fibroblast- but not allo- BM-MSC-treated wounds had significantly increased CD45(+) leukocytes, CD3(+) lymphocytes and CD8(+) T cells. Our study suggests that allogeneic BM-MSCs exhibit ignorable immunogenicity and are equally efficient as syngeneic BM-MSCs in engraftment and in enhancing wound healing.			Chen, LW (corresponding author), S China Agr Univ, Coll Anim Sci, Guangzhou, Guangdong, Peoples R China.	wu.yaojiong@sz.tsinghua.edu.cn						Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; El-Badri NS, 2004, STEM CELLS DEV, V13, P463, DOI 10.1089/scd.2004.13.463; Eliopoulos N, 2005, BLOOD, V106, P4057, DOI 10.1182/blood-2005-03-1004; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067-1927.2004.12404.x; Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood-2004-09-3696; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f; Kern A, 2001, J INVEST DERMATOL, V117, P112, DOI 10.1046/j.0022-202x.2001.01386.x; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104; Lamme EN, 2002, WOUND REPAIR REGEN, V10, P152, DOI 10.1046/j.1524-475X.2002.10901.x; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; McFarlin K, 2006, WOUND REPAIR REGEN, V14, P471, DOI 10.1111/j.1743-6109.2006.00153.x; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Nauta AJ, 2006, BLOOD, V108, P2114, DOI 10.1182/blood-2005-11-011650; Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Smythe JA, 1999, J IMMUNOL, V163, P3239; Sudres M, 2006, J IMMUNOL, V176, P7761, DOI 10.4049/jimmunol.176.12.7761; Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	34	127	135	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7119	10.1371/journal.pone.0007119	http://dx.doi.org/10.1371/journal.pone.0007119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771171	Green Submitted, gold, Green Published			2022-12-27	WOS:000270154400012
J	Danovaro, R; Umani, SF; Pusceddu, A				Danovaro, Roberto; Umani, Serena Fonda; Pusceddu, Antonio			Climate Change and the Potential Spreading of Marine Mucilage and Microbial Pathogens in the Mediterranean Sea	PLOS ONE			English	Article								Background: Marine snow (small amorphous aggregates with colloidal properties) is present in all oceans of the world. Surface water warming and the consequent increase of water column stability can favour the coalescence of marine snow into marine mucilage, large marine aggregates representing an ephemeral and extreme habitat. Marine mucilage characterize aquatic systems with altered environmental conditions. Methodology/Principal Findings: We investigated, by means of molecular techniques, viruses and prokaryotes within the mucilage and in surrounding seawater to examine the potential of mucilage to host new microbial diversity and/or spread marine diseases. We found that marine mucilage contained a large and unexpectedly exclusive microbial biodiversity and hosted pathogenic species that were absent in surrounding seawater. We also investigated the relationship between climate change and the frequency of mucilage in the Mediterranean Sea over the last 200 years and found that the number of mucilage outbreaks increased almost exponentially in the last 20 years. The increasing frequency of mucilage outbreaks is closely associated with the temperature anomalies. Conclusions/Significance: We conclude that the spreading of mucilage in the Mediterranean Sea is linked to climate-driven sea surface warming. The mucilage can act as a controlling factor of microbial diversity across wide oceanic regions and could have the potential to act as a carrier of specific microorganisms, thereby increasing the spread of pathogenic bacteria.			Danovaro, R (corresponding author), Polytech Univ Marche, Dept Marine Sci, Ancona, Italy.	r.danovaro@univpm.it	Fonda, Serena/H-6753-2012					Aktan Y., 2008, Harmful Algae News, V36, P1; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Azam F, 2001, NATURE, V414, P495, DOI 10.1038/35107174; Azam F, 1999, Ann Ist Super Sanita, V35, P411; Baldi F, 1997, MAR ECOL PROG SER, V153, P45, DOI 10.3354/meps153045; Beaumont NJ, 2007, MAR POLLUT BULL, V54, P253, DOI 10.1016/j.marpolbul.2006.12.003; Bongiorni L, 2007, AQUAT MICROB ECOL, V49, P15, DOI 10.3354/ame01126; Carlton JT, 1998, CONSERV BIOL, V12, P1165, DOI 10.1046/j.1523-1739.1998.0120061165.x; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Corinaldesi C, 2005, APPL ENVIRON MICROB, V71, P46, DOI 10.1128/AEM.71.1.46-50.2005; Corinaldesi C, 2003, APPL ENVIRON MICROB, V69, P2664, DOI 10.1128/AEM.69.5.2664-2673.2003; Danovaro R, 2006, APPL ENVIRON MICROB, V72, P5982, DOI 10.1128/AEM.01361-06; Danovaro R, 2005, SCI TOTAL ENVIRON, V353, P189, DOI 10.1016/j.scitotenv.2005.09.029; Danovaro R, 2003, MAR POLLUT BULL, V46, P301, DOI 10.1016/S0025-326X(02)00461-7; Danovaro R, 2001, TRENDS ECOL EVOL, V16, P505, DOI 10.1016/S0169-5347(01)02215-7; Danovaro R, 2008, NATURE, V454, P1084, DOI 10.1038/nature07268; Danovaro R, 2008, ENVIRON HEALTH PERSP, V116, P441, DOI 10.1289/ehp.10966; DEGOBBIS D, 1995, SCI TOTAL ENVIRON, V165, P43, DOI 10.1016/0048-9697(95)04542-9; Del Negro P, 2005, SCI TOTAL ENVIRON, V353, P258, DOI 10.1016/j.scitotenv.2005.09.018; Flander-Putrle V, 2008, HARMFUL ALGAE, V7, P752, DOI 10.1016/j.hal.2008.02.009; FOGG GE, 1995, SCI TOTAL ENVIRON, V165, P59, DOI 10.1016/0048-9697(95)04543-A; Fonda Umani S., 1989, EPISODI MARE SPORCO, P178; GIANI M, 1992, SCIENCE OF THE TOTAL ENVIRONMENT, SUPPLEMENT 1992, P539; Heissenberger A, 1996, MAR ECOL PROG SER, V135, P299, DOI 10.3354/meps135299; HEISSENBERGER A, 1994, MARINE ECOLOGY PROGR, V111, P128; Herndl Gerhard J., 1992, Marine Microbial Food Webs, V6, P149; HERNDL GJ, 1988, PSZNI MAR ECOL, V9, P79; KALTENBOCK E, 1992, MAR ECOL PROG SER, V87, P147, DOI 10.3354/meps087147; KOKELJ F, 1994, CONTACT DERMATITIS, V31, P257, DOI 10.1111/j.1600-0536.1994.tb01999.x; LEPPARD GG, 1995, SCI TOTAL ENVIRON, V165, P103, DOI 10.1016/0048-9697(95)04546-D; Luna GM, 2007, ENVIRON MICROBIOL, V9, P1851, DOI 10.1111/j.1462-2920.2007.01287.x; MacKenzie L, 2002, HARMFUL ALGAE, V1, P295, DOI 10.1016/S1568-9883(02)00006-9; MALEJ A, 1993, MAR ECOL PROG SER, V96, P33, DOI 10.3354/meps096033; MONTI M, 1995, SCI TOTAL ENVIRON, V165, P145, DOI 10.1016/0048-9697(95)04548-F; MULLERNIKLAS G, 1994, LIMNOL OCEANOGR, V39, P58; MYKLESTAD S, 1977, J EXP MAR BIOL ECOL, V29, P161, DOI 10.1016/0022-0981(77)90046-6; OBERNOSTERER I, 1995, MAR ECOL PROG SER, V116, P247, DOI 10.3354/meps116247; Pachauri Rajendra, 2007, AR4 CLIMATE CHANGE 2; Pajdak-Stos A, 2001, AQUAT MICROB ECOL, V23, P237, DOI 10.3354/ame023237; Patz JA, 2005, NATURE, V438, P310, DOI 10.1038/nature04188; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PEDUZZI P, 1993, LIMNOL OCEANOGR, V38, P1562, DOI 10.4319/lo.1993.38.7.1562; POSEDEL N, 1991, MAR ECOL PROG SER, V77, P135, DOI 10.3354/meps077135; Precali R, 2005, SCI TOTAL ENVIRON, V353, P10, DOI 10.1016/j.scitotenv.2005.09.066; Pusceddu A, 2005, CONT SHELF RES, V25, P2491, DOI 10.1016/j.csr.2005.08.013; Rath J, 1998, AQUAT MICROB ECOL, V14, P261, DOI 10.3354/ame014261; Richardson LL, 1998, TRENDS ECOL EVOL, V13, P438, DOI 10.1016/S0169-5347(98)01460-8; RINALDI A, 1995, SCI TOTAL ENVIRON, V165, P165, DOI 10.1016/0048-9697(95)04550-K; Roether W, 1996, SCIENCE, V271, P333, DOI 10.1126/science.271.5247.333; SCHUSTER S, 1995, MAR ECOL PROG SER, V124, P227, DOI 10.3354/meps124227; Sellner KG, 1999, COAST ESTUAR STUD, V55, P173; SHIBATA A, 2007, MARINE ECOLOGY PROGR, V155, P303; Simon M, 2002, AQUAT MICROB ECOL, V28, P175, DOI 10.3354/ame028175; Umani SF, 2007, AQUAT MICROB ECOL, V46, P163; Umani SF, 2005, SCI TOTAL ENVIRON, V353, P218, DOI 10.1016/j.scitotenv.2005.09.016; WEINBAUER MG, 1995, J PLANKTON RES, V17, P1851, DOI 10.1093/plankt/17.9.1851; WEINBAUER MG, 1995, MICROBIAL ECOL, V30, P25, DOI 10.1007/BF00184511; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000	58	87	100	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7006	10.1371/journal.pone.0007006	http://dx.doi.org/10.1371/journal.pone.0007006			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19759910	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970000008
J	Stahl, AL; Sartz, L; Nelsson, A; Bekassy, ZD; Karpman, D				Stahl, Anne-lie; Sartz, Lisa; Nelsson, Anders; Bekassy, Zivile D.; Karpman, Diana			Shiga Toxin and Lipopolysaccharide Induce Platelet-Leukocyte Aggregates and Tissue Factor Release, a Thrombotic Mechanism in Hemolytic Uremic Syndrome	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; POLYMORPHONUCLEAR LEUKOCYTES; FACTOR EXPRESSION; UP-REGULATION; COAGULATION; ACTIVATION; DIARRHEA; VEROCYTOTOXIN; MONOCYTES	Background: Aggregates formed between leukocytes and platelets in the circulation lead to release of tissue factor (TF)-bearing microparticles contributing to a prothrombotic state. As enterohemorrhagic Escherichia coli (EHEC) may cause hemolytic uremic syndrome (HUS), in which microthrombi cause tissue damage, this study investigated whether the interaction between blood cells and EHEC virulence factors Shiga toxin (Stx) and lipopolysaccharide (LPS) led to release of TF. Methodology/Principal Findings: The interaction between Stx or LPS and blood cells induced platelet-leukocyte aggregate formation and tissue factor (TF) release, as detected by flow cytometry in whole blood. O157LPS was more potent than other LPS serotypes. Aggregates formed mainly between monocytes and platelets and less so between neutrophils and platelets. Stimulated blood cells in complex expressed activation markers, and microparticles were released. Microparticles originated mainly from platelets and monocytes and expressed TF. TF-expressing microparticles, and functional TF in plasma, increased when blood cells were simultaneously exposed to the EHEC virulence factors and high shear stress. Stx and LPS in combination had a more pronounced effect on platelet-monocyte aggregate formation, and TF expression on these aggregates, than each virulence factor alone. Whole blood and plasma from HUS patients (n = 4) were analyzed. All patients had an increase in leukocyte-platelet aggregates, mainly between monocytes and platelets, on which TF was expressed during the acute phase of disease. Patients also exhibited an increase in microparticles, mainly originating from platelets and monocytes, bearing surface-bound TF, and functional TF was detected in their plasma. Blood cell aggregates, microparticles, and TF decreased upon recovery. Conclusions/Significance: By triggering TF release in the circulation, Stx and LPS can induce a prothrombotic state contributing to the pathogenesis of HUS.			Stahl, AL (corresponding author), Lund Univ, Dept Pediat, Clin Sci Lund, Lund, Sweden.	diana.karpman@med.lu.se		Aradottir, Sigridur Sunna/0000-0002-6898-3256; Karpman, Diana/0000-0001-7220-7658				Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; Bancsi MJLMF, 1996, INFECT IMMUN, V64, P448, DOI 10.1128/IAI.64.2.448-451.1996; Brambilla M, 2008, ARTERIOSCL THROM VAS, V28, P947, DOI 10.1161/ATVBAHA.107.161471; Cambien B, 2004, TRENDS MOL MED, V10, P179, DOI 10.1016/j.molmed.2004.02.007; Chandler WL, 2002, NEW ENGL J MED, V346, P23, DOI 10.1056/NEJMoa011033; DAVEY MG, 1966, THROMB DIATH HAEMOST, VS, P283; EDGINGTON TS, 1992, NOUV REV FR HEMATOL, V34, pS15; Etalamy I, 2008, THROMB RES, V121, P843, DOI 10.1016/j.thromres.2007.07.016; Galli M, 1996, THROMB HAEMOSTASIS, V75, P427; Geelen JM, 2007, NEPHROL DIAL TRANSPL, V22, P749, DOI 10.1093/ndt/gfl688; Ghosh SA, 2004, J THROMB HAEMOST, V2, P499, DOI 10.1111/j.1538-7933.2004.00638.x; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HILLER E, 1977, HAEMOSTASIS, V6, P347; Inward CD, 1997, PEDIATR NEPHROL, V11, P556, DOI 10.1007/s004670050337; INZANA TJ, 1983, J INFECT DIS, V148, P492, DOI 10.1093/infdis/148.3.492; Kalsch T, 2007, BASIC RES CARDIOL, V102, P460, DOI 10.1007/s00395-007-0667-y; Kamitsuji H, 2000, CLIN NEPHROL, V53, P319; Karpman D, 1995, PEDIATR NEPHROL, V9, P694, DOI 10.1007/BF00868714; Karpman D, 2001, BLOOD, V97, P3100, DOI 10.1182/blood.V97.10.3100; Karpman D, 2002, CURR PAEDIAT, V12, P569, DOI DOI 10.1054/CUPE.2002.0346; Leguyader Alexandre, 2006, Interact Cardiovasc Thorac Surg, V5, P60; LOUISE CB, 1992, INFECT IMMUN, V60, P1536, DOI 10.1128/IAI.60.4.1536-1543.1992; LOUISE CB, 1995, J INFECT DIS, V172, P1397, DOI 10.1093/infdis/172.5.1397; Maugeri N, 2006, J THROMB HAEMOST, V4, P1323, DOI 10.1111/j.1538-7836.2006.01968.x; May AE, 2007, SEMIN THROMB HEMOST, V33, P123, DOI 10.1055/s-2007-969023; MESZAROS K, 1994, BLOOD, V83, P2516; MILFORD DV, 1991, NEPHROL DIAL TRANSPL, V6, P232, DOI 10.1093/ndt/6.4.232; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Morigi M, 2001, BLOOD, V98, P1828, DOI 10.1182/blood.V98.6.1828; Muller I, 2003, FASEB J, V17, P476, DOI 10.1096/fj.02-0574fje; Murata K, 2006, BBA-MOL BASIS DIS, V1762, P835, DOI 10.1016/j.bbadis.2006.07.004; Nestoridi E, 2008, PEDIATR NEPHROL, V23, P221, DOI 10.1007/s00467-007-0636-6; Nevard CHF, 1997, THROMB HAEMOSTASIS, V78, P1450; Nieuwland R, 2000, BLOOD, V95, P930, DOI 10.1182/blood.V95.3.930.003k46_930_935; Osterud B, 2003, DM-DIS MON, V49, P7, DOI 10.1016/S0011-5029(03)90010-1; Proulx F, 2001, PEDIATR RES, V50, P163, DOI 10.1203/00006450-200108000-00002; Siddiqui FA, 2002, PLATELETS, V13, P247, DOI 10.1080/09537100220146398; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153; Stahl AL, 2006, BLOOD, V108, P167, DOI 10.1182/blood-2005-08-3219; Sugatani J, 2000, THROMB RES, V100, P61, DOI 10.1016/S0049-3848(00)00305-4; Svenungsson B, 2000, CLIN INFECT DIS, V30, P770, DOI 10.1086/313770; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Tazzari PL, 2004, CYTOM PART B-CLIN CY, V61B, P40, DOI 10.1002/cyto.b.20022; te Loo DMWM, 2001, J AM SOC NEPHROL, V12, P800, DOI 10.1681/ASN.V124800; Tefferi A, 2007, SEMIN THROMB HEMOST, V33, P313, DOI 10.1055/s-2007-976165; Tremoli E, 1999, ATHEROSCLEROSIS, V144, P273, DOI 10.1016/S0021-9150(99)00063-5; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; vanSetten PA, 1996, BLOOD, V88, P174, DOI 10.1182/blood.V88.1.174.bloodjournal881174; Wakita Y, 1999, CLIN APPL THROMB-HEM, V5, P10, DOI 10.1177/107602969900500103; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; Yamani MH, 2002, J HEART LUNG TRANSPL, V21, P983, DOI 10.1016/S1053-2498(02)00408-4	54	97	99	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6990	10.1371/journal.pone.0006990	http://dx.doi.org/10.1371/journal.pone.0006990			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750223	Green Submitted, Green Published, gold			2022-12-27	WOS:000269696600016
J	Charles, RC; Harris, JB; Chase, MR; Lebrun, LM; Sheikh, A; LaRocque, RC; Logvinenko, T; Rollins, SM; Tarique, A; Hohmann, EL; Rosenberg, I; Krastins, B; Sarracino, DA; Qadri, F; Calderwood, SB; Ryan, ET				Charles, Richelle C.; Harris, Jason B.; Chase, Michael R.; Lebrun, Lauren M.; Sheikh, Alaullah; LaRocque, Regina C.; Logvinenko, Tanya; Rollins, Sean M.; Tarique, Abdullah; Hohmann, Elizabeth L.; Rosenberg, Ian; Krastins, Bryan; Sarracino, David A.; Qadri, Firdausi; Calderwood, Stephen B.; Ryan, Edward T.			Comparative Proteomic Analysis of the PhoP Regulon in Salmonella enterica Serovar Typhi Versus Typhimurium	PLOS ONE			English	Article								Background: S. Typhi, a human-restricted Salmonella enterica serovar, causes a systemic intracellular infection in humans (typhoid fever). In comparison, S. Typhimurium causes gastroenteritis in humans, but causes a systemic typhoidal illness in mice. The PhoP regulon is a well studied two component (PhoP/Q) coordinately regulated network of genes whose expression is required for intracellular survival of S. enterica. Methodology/Principal Findings: Using high performance liquid chromatography mass spectrometry (HPLC-MS/MS), we examined the protein expression profiles of three sequenced S. enterica strains: S. Typhimurium LT2, S. Typhi CT18, and S. Typhi Ty2 in PhoP-inducing and non-inducing conditions in vitro and compared these results to profiles of phoP(-)/Q(-) mutants derived from S. Typhimurium LT2 and S. Typhi Ty2. Our analysis identified 53 proteins in S. Typhimurium LT2 and 56 proteins in S. Typhi that were regulated in a PhoP-dependent manner. As expected, many proteins identified in S. Typhi demonstrated concordant differential expression with a homologous protein in S. Typhimurium. However, three proteins (HlyE, STY1499, and CdtB) had no homolog in S. Typhimurium. HlyE is a pore-forming toxin. STY1499 encodes a stably expressed protein of unknown function transcribed in the same operon as HlyE. CdtB is a cytolethal distending toxin associated with DNA damage, cell cycle arrest, and cellular distension. Gene expression studies confirmed up-regulation of mRNA of HlyE, STY1499, and CdtB in S. Typhi in PhoP-inducing conditions. Conclusions/Significance: This study is the first protein expression study of the PhoP virulence associated regulon using strains of Salmonella mutant in PhoP, has identified three Typhi-unique proteins (CdtB, HlyE and STY1499) that are not present in the genome of the wide host-range Typhimurium, and includes the first protein expression profiling of a live attenuated bacterial vaccine studied in humans (Ty800).			Charles, RC (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.	rccharles@partners.org	Qadri, Firdausi/AAF-4583-2019; Sheikh, Alaullah/H-3125-2019; Charles, Richelle/W-4342-2019; Tarique, Abdullah/M-2860-2013; Harris, Jason/ABF-2684-2020	Charles, Richelle/0000-0002-8881-1849; Tarique, Abdullah/0000-0003-3782-345X; Harris, Jason/0000-0003-3642-5126; Sheikh, Alaullah/0000-0002-2972-6978; Rollins, Sean/0000-0002-3724-1989	FOGARTY INTERNATIONAL CENTER [D43TW005572, K01TW007144, K01TW007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI089721, U01AI058935, R21AI072599, U54AI057159, R01AI067103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS059429] Funding Source: NIH RePORTER; FIC NIH HHS [TW05572, K01 TW007144, D43 TW005572, K01 TW07144, K01 TW007409] Funding Source: Medline; NIAID NIH HHS [AI058935, K08 AI089721, U01 AI058935, R21 AI072599, U54 AI057159, R01 AI067103, AI072599, AI67103] Funding Source: Medline; NINDS NIH HHS [NS059429, R21 NS059429] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adkins JN, 2006, MOL CELL PROTEOMICS, V5, P1450, DOI 10.1074/mcp.M600139-MCP200; Aguirre A, 2000, J BACTERIOL, V182, P3874, DOI 10.1128/JB.182.13.3874-3876.2000; Ansong C, 2008, J PROTEOME RES, V7, P546, DOI 10.1021/pr070434u; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Bijlsma JJE, 2005, MOL MICROBIOL, V57, P85, DOI 10.1111/j.1365-2958.2005.04668.x; Bjur E, 2006, INFECT IMMUN, V74, P5140, DOI 10.1128/IAI.00449-06; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Daigle F, 2001, MOL MICROBIOL, V41, P1211, DOI 10.1046/j.1365-2958.2001.02593.x; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Faucher SP, 2009, MICROBIOL-SGM, V155, P477, DOI 10.1099/mic.0.022988-0; Faucher SP, 2006, P NATL ACAD SCI USA, V103, P1906, DOI 10.1073/pnas.0509183103; Faucher SP, 2005, INFECT IMMUN, V73, P5217, DOI 10.1128/IAI.73.8.5217-5221.2005; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 2006, NAT REV MICROBIOL, V4, P705, DOI 10.1038/nrmicro1478; Haas BJ, 2004, BIOINFORMATICS, V20, P3643, DOI 10.1093/bioinformatics/bth397; Haghjoo E, 2004, P NATL ACAD SCI USA, V101, P4614, DOI 10.1073/pnas.0400932101; Haghjoo E, 2007, MOL MICROBIOL, V64, P1549, DOI 10.1111/j.1365-2958.2007.05754.x; Hautefort I, 2008, CELL MICROBIOL, V10, P958, DOI 10.1111/j.1462-5822.2007.01099.x; Hohmann EL, 1996, J INFECT DIS, V173, P1408, DOI 10.1093/infdis/173.6.1408; Kato A, 1999, J BACTERIOL, V181, P5516, DOI 10.1128/JB.181.17.5516-5520.1999; Kato A, 2008, ADV EXP MED BIOL, V631, P7; KIER LD, 1979, J BACTERIOL, V138, P155, DOI 10.1128/JB.138.1.155-161.1979; Kotton CN, 2006, VACCINE, V24, P6216, DOI 10.1016/j.vaccine.2006.05.094; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; Lai XH, 2000, INFECT IMMUN, V68, P4363, DOI 10.1128/IAI.68.7.4363-4367.2000; LaRocque RC, 2005, INFECT IMMUN, V73, P4488, DOI 10.1128/IAI.73.8.4488-4493.2005; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; Lithgow JK, 2007, MOL MICROBIOL, V66, P685, DOI 10.1111/j.1365-2958.2007.05950.x; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MILLER SI, 1993, VACCINE, V11, P122, DOI 10.1016/0264-410X(93)90006-J; Monsieurs P, 2005, J MOL EVOL, V60, P462, DOI 10.1007/s00239-004-0212-7; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; Navarre WW, 2005, MOL MICROBIOL, V56, P492, DOI 10.1111/j.1365-2958.2005.04553.x; Norte VA, 2003, J BACTERIOL, V185, P3508, DOI 10.1128/JB.185.12.3508-3514.2003; Oscarsson J, 2002, INFECT IMMUN, V70, P5759, DOI 10.1128/IAI.70.10.5759-5769.2002; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Shi L, 2006, J BIOL CHEM, V281, P29131, DOI 10.1074/jbc.M604640200; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Spano S, 2008, CELL HOST MICROBE, V3, P30, DOI 10.1016/j.chom.2007.11.001; Spory A, 2002, J BACTERIOL, V184, P3549, DOI 10.1128/JB.184.13.3549-3559.2002; Tu X, 2006, P NATL ACAD SCI USA, V103, P13503, DOI 10.1073/pnas.0606026103; VESCOVI EG, 1994, RES MICROBIOL, V145, P473, DOI 10.1016/0923-2508(94)90096-5; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; von Rhein C, 2006, INFECT IMMUN, V74, P6505, DOI 10.1128/IAI.00779-06; VONRHEIN C, 2008, INT J MED MICROBIOL; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; Wosten MMSM, 1999, J BIOL CHEM, V274, P27185, DOI 10.1074/jbc.274.38.27185; Wyborn NR, 2004, J BACTERIOL, V186, P1620, DOI 10.1128/JB.186.6.1620-1628.2004; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x; Zhang B, 2006, J PROTEOME RES, V5, P2909, DOI 10.1021/pr0600273; Zwir I, 2005, P NATL ACAD SCI USA, V102, P2862, DOI 10.1073/pnas.0408238102	60	50	53	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2009	4	9							e6994	10.1371/journal.pone.0006994	http://dx.doi.org/10.1371/journal.pone.0006994			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XR	19746165	gold, Green Submitted, Green Published			2022-12-27	WOS:000269696500007
J	Petkova, VI; Ehrsson, HH				Petkova, Valeria I.; Ehrsson, H. Henrik			When Right Feels Left: Referral of Touch and Ownership between the Hands	PLOS ONE			English	Article							VENTRAL INTRAPARIETAL AREA; PRIMARY SOMATOSENSORY CORTEX; RUBBER HAND; RECEPTIVE-FIELDS; PARIETAL CORTEX; MULTISENSORY INTEGRATION; CALLOSAL CONNECTIONS; CUTANEOUS RABBIT; INFERIOR AREA-6; BODY	Feeling touch on a body part is paradigmatically considered to require stimulation of tactile afferents from the body part in question, at least in healthy non-synaesthetic individuals. In contrast to this view, we report a perceptual illusion where people experience "phantom touches" on a right rubber hand when they see it brushed simultaneously with brushes applied to their left hand. Such illusory duplication and transfer of touch from the left to the right hand was only elicited when a homologous (i.e., left and right) pair of hands was brushed in synchrony for an extended period of time. This stimulation caused the majority of our participants to perceive the right rubber hand as their own and to sense two distinct touches - one located on the right rubber hand and the other on their left (stimulated) hand. This effect was supported by quantitative subjective reports in the form of questionnaires, behavioral data from a task in which participants pointed to the felt location of their right hand, and physiological evidence obtained by skin conductance responses when threatening the model hand. Our findings suggest that visual information augments subthreshold somatosensory responses in the ipsilateral hemisphere, thus producing a tactile experience from the non-stimulated body part. This finding is important because it reveals a new bilateral multisensory mechanism for tactile perception and limb ownership.			Petkova, VI (corresponding author), Karolinska Inst, Dept Neurosci, Stockholm, Sweden.	Valeria.Petkova@ki.se						Armel KC, 2003, P ROY SOC B-BIOL SCI, V270, P1499, DOI 10.1098/rspb.2003.2364; Avillac M, 2007, J NEUROSCI, V27, P1922, DOI 10.1523/JNEUROSCI.2646-06.2007; Blankenburg F, 2006, PLOS BIOL, V4, P459, DOI 10.1371/journal.pbio.0040069; Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; Botvinick M, 2004, SCIENCE, V305, P782, DOI 10.1126/science.1101836; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; Chen LM, 2003, SCIENCE, V302, P881, DOI 10.1126/science.1087846; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P517, DOI 10.1016/0028-3932(91)90008-V; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; Costantini M, 2007, CONSCIOUS COGN, V16, P229, DOI 10.1016/j.concog.2007.01.001; Dawson ME, 2007, HANDBOOK OF PSYCHOPHYSIOLOGY, 3RD EDITION, P159, DOI 10.1017/cbo9780511546396.007; Driver J, 2008, NEURON, V57, P11, DOI 10.1016/j.neuron.2007.12.013; Duhamel JR, 1998, J NEUROPHYSIOL, V79, P126, DOI 10.1152/jn.1998.79.1.126; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; Ehrsson HH, 2007, P NATL ACAD SCI USA, V104, P9828, DOI 10.1073/pnas.0610011104; Ehrsson HH, 2009, PERCEPTION, V38, P310, DOI 10.1068/p6304; Ehrsson HH, 2008, BRAIN, V131, P3443, DOI 10.1093/brain/awn297; Ehrsson HH, 2005, J NEUROSCI, V25, P10564, DOI 10.1523/JNEUROSCI.0800-05.2005; Ehrsson HH, 2004, SCIENCE, V305, P875, DOI 10.1126/science.1097011; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fabri M, 1999, EUR J NEUROSCI, V11, P3983, DOI 10.1046/j.1460-9568.1999.00829.x; GARDNER EP, 1980, J NEUROPHYSIOL, V43, P420, DOI 10.1152/jn.1980.43.2.420; GELDARD FA, 1972, SCIENCE, V178, P178, DOI 10.1126/science.178.4057.178; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GODSCHALK M, 1984, EXP BRAIN RES, V56, P410; Graziano MSA, 1999, P NATL ACAD SCI USA, V96, P10418, DOI 10.1073/pnas.96.18.10418; Graziano MSA, 2000, SCIENCE, V290, P1782, DOI 10.1126/science.290.5497.1782; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; Haggard P, 2007, EXP BRAIN RES, V180, P187, DOI 10.1007/s00221-007-0971-7; Halligan PW, 1996, NEUROCASE, V2, P21; Hlushchuk Y, 2006, J NEUROSCI, V26, P5819, DOI 10.1523/JNEUROSCI.5536-05.2006; HYVARINEN J, 1981, BRAIN RES, V206, P287, DOI 10.1016/0006-8993(81)90533-3; Iriki A, 1996, NEUROREPORT, V7, P2325; Iwamura Y, 2002, BEHAV BRAIN RES, V135, P185, DOI 10.1016/S0166-4328(02)00164-X; Iwamura Y, 2001, NEUROSCIENTIST, V7, P419, DOI 10.1177/107385840100700511; Iwamura Y, 2000, PHILOS T R SOC B, V355, P267, DOI 10.1098/rstb.2000.0563; IWAMURA Y, 1994, NATURE, V369, P554, DOI 10.1038/369554a0; Johnson MJ, 1996, J NEUROPHYSIOL, V75, P1444, DOI 10.1152/jn.1996.75.4.1444; JONES EG, 1978, J COMP NEUROL, V181, P291, DOI 10.1002/cne.901810206; Kennett S, 2001, CURR BIOL, V11, P1188, DOI 10.1016/S0960-9822(01)00327-X; Lakatos P, 2007, NEURON, V53, P279, DOI 10.1016/j.neuron.2006.12.011; LEDBERG A, 1995, EUR J NEUROSCI, V7, P1934, DOI 10.1111/j.1460-9568.1995.tb00716.x; LEDERMAN SJ, 1981, J EXP PSYCHOL HUMAN, V7, P902, DOI 10.1037/0096-1523.7.4.902; Lloyd DM, 2007, BRAIN COGNITION, V64, P104, DOI 10.1016/j.bandc.2006.09.013; Makin TR, 2008, BEHAV BRAIN RES, V191, P1, DOI 10.1016/j.bbr.2008.02.041; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; McCabe CS, 2005, RHEUMATOLOGY, V44, P509, DOI 10.1093/rheumatology/keh529; NEAL JW, 1987, BRAIN RES, V419, P341, DOI 10.1016/0006-8993(87)90605-6; Nihashi T, 2005, CLIN NEUROPHYSIOL, V116, P842, DOI 10.1016/j.clinph.2004.10.011; Pavani F, 2000, PSYCHOL SCI, V11, P353, DOI 10.1111/1467-9280.00270; Press C, 2004, EXP BRAIN RES, V154, P238, DOI 10.1007/s00221-003-1651-x; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058; RAMACHANDRAN VS, 1995, NATURE, V377, P489, DOI 10.1038/377489a0; Rizzolatti G, 2001, NEURON, V31, P889, DOI 10.1016/S0896-6273(01)00423-8; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P125, DOI 10.1016/0166-4328(81)90052-8; ROBINSON CJ, 1980, J COMP NEUROL, V192, P69, DOI 10.1002/cne.901920105; ROBINSON CJ, 1980, J COMP NEUROL, V192, P43, DOI 10.1002/cne.901920104; ROCK I, 1964, SCIENCE, V143, P594, DOI 10.1126/science.143.3606.594; ROSEN B, 2009, SCAND J PLA IN PRESS; Ruben J, 2001, CEREB CORTEX, V11, P463, DOI 10.1093/cercor/11.5.463; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; Sathian K, 2000, NEUROLOGY, V54, P1866, DOI 10.1212/WNL.54.9.1866; Shams L, 2000, NATURE, V408, P788, DOI 10.1038/35048669; SHERRICK CE, 1964, AM J PSYCHOL, V77, P42, DOI 10.2307/1419270; Shimojo S, 2001, CURR OPIN NEUROBIOL, V11, P505, DOI 10.1016/S0959-4388(00)00241-5; Simoes C, 1999, NEUROIMAGE, V10, P408, DOI 10.1006/nimg.1999.0476; Stein BE, 2008, NAT REV NEUROSCI, V9, P255, DOI 10.1038/nrn2331; Tipper SP, 2001, EXP BRAIN RES, V139, P160, DOI 10.1007/s002210100743; Tsakiris M, 2005, J EXP PSYCHOL HUMAN, V31, P80, DOI 10.1037/0096-1523.31.1.80; von Bekesy G, 1967, SENSORY INHIBITION; Wozny DR, 2008, J VISION, V8, DOI 10.1167/8.3.24	72	71	73	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6933	10.1371/journal.pone.0006933	http://dx.doi.org/10.1371/journal.pone.0006933			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	491ZI	19742313	Green Published, gold			2022-12-27	WOS:000269622500011
J	Evertsen, J; Alemzadeh, R; Wang, XJ				Evertsen, Jennifer; Alemzadeh, Ramin; Wang, Xujing			Increasing Incidence of Pediatric Type 1 Diabetes Mellitus in Southeastern Wisconsin: Relationship with Body Weight at Diagnosis	PLOS ONE			English	Article								Introduction: Several studies have confirmed the increasing rate of type 1 diabetes mellitus (T1DM) in children and the link with increasing BMI at diagnosis termed the 'accelerator hypothesis'. Our objective was to assess whether changing incidence of type 1 diabetes in a group of children and adolescent from the Midwest United States was associated with changes in BMI. Methods: Data from 1618 (52.1% M/47.9% F) newly-diagnosed children and adolescents (<19 years) with T1DM, admitted to Children's Hospital of Wisconsin (CHW) between January 1995 and December 2004, was analyzed in relationship to body mass index (BMI) standard deviation score (SDS). Results: An overall, 10-year cumulative incidence of 27.92 per 100,000 (19.12 to 41.72/100,000) was observed, with an average yearly cumulative incidence of 2.39%. The increase was largest in the younger age groups, 0-4, 5-9, and 10-14 having an average yearly increase of 2.4, 2.3, and 3.0%, respectively, corresponding to a relative 10-year increase of 25.3, 33.8, and 38.0%, respectively. Age at diagnosis was inversely correlated with BMI SDS (p<0.001) and remained significant for both males and females. Conclusions: Annual incidence of T1DM increased two-fold at CHW over the 10-year study period. The majority of the increase was observed in the youngest age groups, which also appeared to be the heaviest. This research adds to the growing literature supporting the hypothesis that excess weight gain during childhood may be a risk factor for early manifestation of T1DM.			Evertsen, J (corresponding author), Med Coll Wisconsin, Dept Epidemiol, Milwaukee, WI 53226 USA.	Jennifer.evertsen@aurora.org						ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Barker JM, 2004, J CLIN ENDOCR METAB, V89, P3896, DOI 10.1210/jc.2003-031887; Bessaoud K, 2006, DIABETIC MED, V23, P857, DOI 10.1111/j.1464-5491.2006.01925.x; BJORK E, 1992, J CLIN ENDOCR METAB, V75, P1574, DOI 10.1210/jc.75.6.1574; *CDCP, EP INF SOFTW; Charkaluk ML, 2002, PEDIATR RES, V52, P859, DOI 10.1203/01.PDR.0000034261.44203.26; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Cotellessa M, 2003, DIABETES CARE, V26, P1786, DOI 10.2337/diacare.26.6.1786; Dabelea D, 2006, DIABETES CARE, V29, P290, DOI 10.2337/diacare.29.02.06.dc05-1339; Dabelea D, 2007, JAMA-J AM MED ASSOC, V297, P2716; DAWSON B, 2001, BASIC  CLIN BIOSTATI; Ehehalt S, 2008, DIABETIC MED, V25, P755, DOI 10.1111/j.1464-5491.2008.02450.x; Gale EAM, 2002, DIABETES, V51, P3353, DOI 10.2337/diabetes.51.12.3353; Gardner SG, 1997, BRIT MED J, V315, P713, DOI 10.1136/bmj.315.7110.713; GIMENEZ M, DIABETES CARE, V30, P1593; Green A, 2001, DIABETOLOGIA, V44, pB3, DOI 10.1007/PL00002950; Harjutsalo V, 2008, LANCET, V371, P1777, DOI 10.1016/S0140-6736(08)60765-5; Karvonen M, 1999, DIABETES CARE, V22, P1066, DOI 10.2337/diacare.22.7.1066; KAVONEN M, 2000, DIABETES CARE, V23, P1516; Kibirige M, 2003, DIABETES CARE, V26, P2865, DOI 10.2337/diacare.26.10.2865; Knerr I, 2005, DIABETOLOGIA, V48, P2501, DOI 10.1007/s00125-005-0033-2; Kordonouri O, 2005, DIABETIC MED, V22, P1783, DOI 10.1111/j.1464-5491.2005.01792.x; KOSTRABA JN, 1992, EPIDEMIOLOGY, V3, P232, DOI 10.1097/00001648-199205000-00008; LAPORTE R, 1995, DIABETES AM, pCH3; Libman IM, 2003, DIABETES CARE, V26, P2871, DOI 10.2337/diacare.26.10.2871; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Rangasami JJ, 1997, ARCH DIS CHILD, V77, P210, DOI 10.1136/adc.77.3.210; Sabbah E, 2000, DIABETES CARE, V23, P1326, DOI 10.2337/diacare.23.9.1326; Schober E, 2008, EUR J PEDIATR, V167, P293, DOI 10.1007/s00431-007-0480-5; Schoenle EJ, 2001, DIABETOLOGIA, V44, P286, DOI 10.1007/s001250051615; *US CENS BUR, COUNT CENS DAT; Weets I, 2007, DIABETES-METAB RES, V23, P637, DOI 10.1002/dmrr.758; Wilkin TJ, 2006, ARCH DIS CHILD, V91, P456, DOI 10.1136/adc.2006.094037; Wilkin TJ, 2006, DIABETES CARE, V29, P1462, DOI 10.2337/dc06-0345; Wilkin TJ, 2001, DIABETOLOGIA, V44, P914, DOI 10.1007/s001250100548; *WISC DEP HLTH FAM, SERV GEOGR REG; *WISC DEP HLTH FAM, OB EP WISC STUD; *WISC HOSP ASS, HOSP UT REP; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	39	35	37	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6873	10.1371/journal.pone.0006873	http://dx.doi.org/10.1371/journal.pone.0006873			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727402	Green Published, Green Submitted, gold			2022-12-27	WOS:000269522900009
J	Kawakubo, Y; Kuwabara, H; Watanabe, K; Minowa, M; Someya, T; Minowa, I; Kono, T; Nishida, H; Sugiyama, T; Kato, N; Kasai, K				Kawakubo, Yuki; Kuwabara, Hitoshi; Watanabe, Kei-ichiro; Minowa, Michiko; Someya, Toshikazu; Minowa, Iwao; Kono, Toshiaki; Nishida, Hisami; Sugiyama, Toshiro; Kato, Nobumasa; Kasai, Kiyoto			Impaired Prefrontal Hemodynamic Maturation in Autism and Unaffected Siblings	PLOS ONE			English	Article							NEAR-INFRARED SPECTROSCOPY; VERBAL FLUENCY TASK; BRAIN ACTIVATION; SPECTRUM DISORDERS; ABNORMAL-DEVELOPMENT; COGNITIVE PHENOTYPE; OXYGENATION CHANGES; EXECUTIVE FUNCTION; ASPERGER-SYNDROME; CHILDHOOD AUTISM	Background: Dysfunctions of the prefrontal cortex have been previously reported in individuals with autism spectrum disorders (ASD). Previous studies reported that first-degree relatives of individuals with ASD show atypical brain activity during tasks associated with social function. However, developmental changes in prefrontal dysfunction in ASD and genetic influences on the phenomena remain unclear. In the present study, we investigated the change in hemoglobin concentration in the prefrontal cortex as measured with near-infrared spectroscopy, in children and adults with ASD during the letter fluency test. Moreover, to clarify the genetic influences on developmental changes in the prefrontal dysfunction in ASD, unaffected siblings of the ASD participants were also assessed. Methodology/Principal Findings: Study participants included 27 individuals with high-functioning ASD, age-and IQ-matched 24 healthy non-affected siblings, and 27 unrelated healthy controls aged 5 to 39 years. The relative concentration of hemoglobin ([Hb]) in the prefrontal cortex was measured during the letter fluency task. For children, neither the [oxy-Hb] change during the task nor task performances differed significantly among three groups. For adults, the [oxy-Hb] increases during the task were significantly smaller in the bilateral prefrontal cortex in ASD than those in control subjects, although task performances were similar. In the adult siblings the [oxy-Hb] change was intermediate between those in controls and ASDs. Conclusion/Significance: Although indirectly due to a cross-sectional design, the results of this study indicate altered age-related change of prefrontal activity during executive processing in ASD. This is a first near-infrared spectroscopy study that implies alteration in the age-related changes of prefrontal activity in ASD and genetic influences on the phenomena.			Kawakubo, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neuropsychiat, Tokyo, Japan.	yukik-tky@umin.ac.jp		Kasai, Kiyoto/0000-0002-4443-4535				BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Baldo JV, 2006, J INT NEUROPSYCH SOC, V12, P896, DOI 10.1017/S1355617706061078; Baron-Cohen S, 2006, BRAIN COGNITION, V61, P122, DOI 10.1016/j.bandc.2005.12.011; Boecker M, 2007, BEHAV BRAIN RES, V176, P259, DOI 10.1016/j.bbr.2006.10.009; Braver TS, 2002, NEUROIMAGE, V15, P523, DOI 10.1006/nimg.2001.1019; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Christoff K, 2003, BEHAV NEUROSCI, V117, P1161, DOI 10.1037/0735-7044.117.6.1161; Chugani HT, 1998, PREV MED, V27, P184, DOI 10.1006/pmed.1998.0274; Dalton KM, 2007, BIOL PSYCHIAT, V61, P512, DOI 10.1016/j.biopsych.2006.05.019; Dawson G, 2005, DEV PSYCHOPATHOL, V17, P679, DOI 10.1017/S0954579405050327; de Jonge MV, 2006, J AUTISM DEV DISORD, V36, P677, DOI 10.1007/s10803-006-0113-2; Delorme R, 2007, EUR PSYCHIAT, V22, P32, DOI 10.1016/j.eurpsy.2006.05.002; Dorris L, 2004, J CHILD PSYCHOL PSYC, V45, P412, DOI 10.1111/j.1469-7610.2004.00232.x; Elfgren CI, 1998, NEUROPSYCHOLOGIA, V36, P505, DOI 10.1016/S0028-3932(97)00146-2; Fallgatter AJ, 1997, COGNITIVE BRAIN RES, V6, P67, DOI 10.1016/S0926-6410(97)00016-5; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Fombonne E, 1997, J CHILD PSYCHOL PSYC, V38, P667, DOI 10.1111/j.1469-7610.1997.tb01694.x; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Happe F, 1996, NEUROREPORT, V8, P197, DOI 10.1097/00001756-199612200-00040; Happe F, 2001, J CHILD PSYCHOL PSYC, V42, P299, DOI 10.1111/1469-7610.00723; Happe F, 2006, NAT NEUROSCI, V9, P1218, DOI 10.1038/nn1770; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Hock C, 1997, BRAIN RES, V755, P293, DOI 10.1016/S0006-8993(97)00122-4; Hughes C, 1999, J CHILD PSYCHOL PSYC, V40, P705, DOI 10.1017/S0021963099004023; Hughes C, 1997, PSYCHOL MED, V27, P209, DOI 10.1017/S0033291796004308; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Kameyama M, 2006, NEUROIMAGE, V29, P172, DOI 10.1016/j.neuroimage.2005.07.025; Kennedy DP, 2006, P NATL ACAD SCI USA, V103, P8275, DOI 10.1073/pnas.0600674103; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; KURITA H, 1989, J AUTISM DEV DISORD, V19, P389, DOI 10.1007/BF02212937; Kuwabara H, 2006, BEHAV BRAIN RES, V172, P272, DOI 10.1016/j.bbr.2006.05.020; LeCouteur A, 1996, J CHILD PSYCHOL PSYC, V37, P785; Luna B, 2002, NEUROLOGY, V59, P834, DOI 10.1212/WNL.59.6.834; Mehagnoul-Schipper DJ, 2002, HUM BRAIN MAPP, V16, P14, DOI 10.1002/hbm.10026; Muller RA, 2003, AM J PSYCHIAT, V160, P1847, DOI 10.1176/appi.ajp.160.10.1847; Ofen N, 2007, NAT NEUROSCI, V10, P1198, DOI 10.1038/nn1950; Ohnishi T, 2000, BRAIN, V123, P1838, DOI 10.1093/brain/123.9.1838; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OZONOFF S, 1993, J AUTISM DEV DISORD, V23, P429, DOI 10.1007/BF01046049; Pilowsky T, 2003, J CHILD PSYCHOL PSYC, V44, P914, DOI 10.1111/1469-7610.00175; Pilowsky T, 2007, J AUTISM DEV DISORD, V37, P537, DOI 10.1007/s10803-006-0185-z; Piven J, 2001, AM J MED GENET, V105, P34, DOI 10.1002/1096-8628(20010108)105:1<34::AID-AJMG1052>3.0.CO;2-D; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Ring HA, 1999, BRAIN, V122, P1305, DOI 10.1093/brain/122.7.1305; Ronald A, 2006, SCIENCE, V311, P952, DOI 10.1126/science.311.5763.952a; Ronald A, 2005, DEVELOPMENTAL SCI, V8, P444, DOI 10.1111/j.1467-7687.2005.00433.x; Ronald A, 2006, J AM ACAD CHILD PSY, V45, P691, DOI 10.1097/01.chi.0000215325.13058.9d; Schmitz N, 2006, BIOL PSYCHIAT, V59, P7, DOI 10.1016/j.biopsych.2005.06.007; Schroeter ML, 2004, NEUROIMAGE, V23, P1317, DOI 10.1016/j.neuroimage.2004.08.001; Semendeferi K, 2001, AM J PHYS ANTHROPOL, V114, P224, DOI 10.1002/1096-8644(200103)114:3<224::AID-AJPA1022>3.3.CO;2-9; Shinba T, 2004, BIOL PSYCHIAT, V55, P154, DOI 10.1016/S0006-3223(03)00547-X; Silk TJ, 2006, AM J PSYCHIAT, V163, P1440, DOI 10.1176/appi.ajp.163.8.1440; SMALLEY SL, 1988, ARCH GEN PSYCHIAT, V45, P953; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Strangman G, 2002, NEUROIMAGE, V17, P719, DOI 10.1006/nimg.2002.1227; Suto T, 2004, BIOL PSYCHIAT, V55, P501, DOI 10.1016/j.biopsych.2003.09.008; Takizawa R, 2008, SCHIZOPHR RES, V99, P250, DOI 10.1016/j.schres.2007.10.025; Toronov V, 2001, MED PHYS, V28, P521, DOI 10.1118/1.1354627; Wilcox J, 2002, NEUROPSYCHOBIOLOGY, V46, P13, DOI 10.1159/000063570	63	37	37	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6881	10.1371/journal.pone.0006881	http://dx.doi.org/10.1371/journal.pone.0006881			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	490RX	19727389	gold, Green Submitted, Green Published			2022-12-27	WOS:000269522900011
J	Sacrey, LAR; Clark, CAM; Whishaw, IQ				Sacrey, Lori-Ann R.; Clark, Callie A. M.; Whishaw, Ian Q.			Music Attenuates Excessive Visual Guidance of Skilled Reaching in Advanced but Not Mild Parkinson's Disease	PLOS ONE			English	Article								Parkinson's disease (PD) results in movement and sensory impairments that can be reduced by familiar music. At present, it is unclear whether the beneficial effects of music are limited to lessening the bradykinesia of whole body movement or whether beneficial effects also extend to skilled movements of PD subjects. This question was addressed in the present study in which control and PD subjects were given a skilled reaching task that was performed with and without accompanying preferred musical pieces. Eye movements and limb use were monitored with biomechanical measures and limb movements were additionally assessed using a previously described movement element scoring system. Preferred musical pieces did not lessen limb and hand movement impairments as assessed with either the biomechanical measures or movement element scoring. Nevertheless, the PD patients with more severe motor symptoms as assessed by Hoehn and Yahr (HY) scores displayed enhanced visual engagement of the target and this impairment was reduced during trials performed in association with accompanying preferred musical pieces. The results are discussed in relation to the idea that preferred musical pieces, although not generally beneficial in lessening skilled reaching impairments, may normalize the balance between visual and proprioceptive guidance of skilled reaching.			Sacrey, LAR (corresponding author), Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada.	lori.sacrey@uleth.ca	Sacrey, Lori/AAB-6412-2020	Sacrey, Lori/0000-0002-4229-6933				Adamovich SV, 2001, NEUROSCIENCE, V104, P1027, DOI 10.1016/S0306-4522(01)00099-9; BAGLEY S, 1991, PHYSIOTHERAPY, V77, P415, DOI DOI 10.1016/S0031-9406(10)62035-4; BARONI A, 1984, NEUROLOGY, V34, P868, DOI 10.1212/WNL.34.7.868; Berardelli A, 2001, BRAIN, V124, P2131, DOI 10.1093/brain/124.11.2131; BurleighJacobs A, 1997, MOVEMENT DISORD, V12, P206, DOI 10.1002/mds.870120211; CAIRD FI, 1991, REHABILITATION PARKI; Castiello U, 2000, NEUROPSYCHOLOGIA, V38, P46, DOI 10.1016/S0028-3932(99)00049-4; Chomiak T, 2008, J NEUROPHYSIOL, V100, P327, DOI 10.1152/jn.90392.2008; Chuma T, 2007, J NEUROL, V254, P58, DOI 10.1007/s00415-007-4010-1; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Bruin N, 2008, J MOTOR BEHAV, V40, P337, DOI 10.3200/JMBR.40.4.337-346; Deijen JB, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-43; Dibble LE, 2004, GAIT POSTURE, V19, P215, DOI 10.1016/S0966-6362(03)00065-1; Doan J, 2006, J MOTOR BEHAV, V38, P45, DOI 10.3200/JMBR.38.1.45-59; Doan JB, 2008, BEHAV BRAIN RES, V194, P207, DOI 10.1016/j.bbr.2008.07.015; Dunnewold RJW, 1997, J NEUROSCI METH, V74, P107, DOI 10.1016/S0165-0270(97)02254-1; Eshkol N, 1958, MOVEMENT NOTATION; FLOWERS KA, 1976, BRAIN, V99, P269, DOI 10.1093/brain/99.2.269; GEORGIOU N, 1994, J NEUROL NEUROSUR PS, V57, P368, DOI 10.1136/jnnp.57.3.368; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Howe TE, 2003, CLIN REHABIL, V17, P363, DOI 10.1191/0269215503cr621oa; Hu B, 2003, EXP BRAIN RES, V153, P543, DOI 10.1007/s00221-003-1611-5; Keijsers NLW, 2005, EUR J NEUROSCI, V21, P239, DOI 10.1111/j.1460-9568.2004.03840.x; KLOCKGETHER T, 1994, MOVEMENT DISORD, V9, P48, DOI 10.1002/mds.870090108; Lehman David A, 2005, J Neurol Phys Ther, V29, P2; Ma HI, 2004, AM J PHYS MED REHAB, V83, P530, DOI 10.1097/01.PHM.0000130032.97113.E0; MARTINEZ AJ, 1973, NEUROLOGY, V23, P421; Melvin KG, 2005, BEHAV BRAIN RES, V160, P188, DOI 10.1016/j.bbr.2004.12.001; Mooney DM, 2004, P NATL ACAD SCI USA, V101, P320, DOI 10.1073/pnas.0304445101; Pacchetti C, 2000, PSYCHOSOM MED, V62, P386, DOI 10.1097/00006842-200005000-00012; Ponsen MM, 2008, PARKINSONISM RELAT D, V14, P199, DOI 10.1016/j.parkreldis.2007.07.019; Posner M. I., 1994, IMAGES MIND; Sacks O., 1982, AWAKENINGS; Siegert RJ, 2002, J CLIN EXP NEUROPSYC, V24, P146, DOI 10.1076/jcen.24.2.146.991; Slavutskaya M, 2007, SPAN J PSYCHOL, V10, P277, DOI 10.1017/S1138741600006545; Stern G M, 1980, J Neural Transm Suppl, P137; SWALLOW M, 1990, THERAPY PARKINSONS D, P109; Thaut MH, 2002, NEUROPSYCHOLOGIA, V40, P1073, DOI 10.1016/S0028-3932(01)00141-5; Thaut MH, 1996, MOVEMENT DISORD, V11, P193, DOI 10.1002/mds.870110213; Tresilian JR, 1997, BRAIN, V120, P2093, DOI 10.1093/brain/120.11.2093; Whishaw IQ, 2002, BEHAV BRAIN RES, V133, P165, DOI 10.1016/S0166-4328(01)00479-X	41	16	16	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6841	10.1371/journal.pone.0006841	http://dx.doi.org/10.1371/journal.pone.0006841			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718260	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415900014
J	Villar, J; Perez-Mendez, L; Espinosa, E; Flores, C; Blanco, J; Muriel, A; Basaldua, S; Muros, M; Blanch, L; Artigas, A; Kacmarek, RM				Villar, Jesus; Perez-Mendez, Lina; Espinosa, Elena; Flores, Carlos; Blanco, Jesus; Muriel, Arturo; Basaldua, Santiago; Muros, Mercedes; Blanch, Lluis; Artigas, Antonio; Kacmarek, Robert M.		GRECIA Grp; GEN-SEP Grp	Serum Lipopolysaccharide Binding Protein Levels Predict Severity of Lung Injury and Mortality in Patients with Severe Sepsis	PLOS ONE			English	Article								Background: There is a need for biomarkers insuring identification of septic patients at high-risk for death. We performed a prospective, multicenter, observational study to investigate the time-course of lipopolysaccharide binding protein (LBP) serum levels in patients with severe sepsis and examined whether serial serum levels of LBP could be used as a marker of outcome. Methodology/Principal Findings: LBP serum levels at study entry, at 48 hours and at day-7 were measured in 180 patients with severe sepsis. Data regarding the nature of infections, disease severity, development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) outcome were recorded. LBP serum levels were similar in survivors and non-survivors at study entry (117.4 +/- 75.7 mu g/mL vs. 129.8 +/- 71.3 mu g/mL, P = 0.249) but there were significant differences at 48 hours (77.2 +/- 57.0 vs. 121.2 +/- 73.4 mu g/mL, P < 0.0001) and at day-7 (64.7 +/- 45.8 vs. 89.7 +/- 61.1 mu g/ml, p = 0.017). At 48 hours, LBP levels were significantly higher in ARDS patients than in ALI patients (112.5 +/- 71.8 mu g/ml vs. 76.6 +/- 55.9 mu g/ml, P = 0.0001). An increase of LBP levels at 48 hours was associated with higher mortality (odds ratio 3.97; 95%CI: 1.84-8.56; P < 0.001). Conclusions/Significance: Serial LBP serum measurements may offer a clinically useful biomarker for identification of patients with severe sepsis having the worst outcomes and the highest probability of developing sepsis-induced ARDS.			Villar, J (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.	jesus.villar54@gmail.com	Villar, Jesús/R-4526-2019; Flores, Carlos/R-1159-2019	Villar, Jesús/0000-0001-5687-3562; Perez-Mendez, Lina/0000-0001-8246-333X; antonio, artigas/0000-0002-8029-1017; Tejera, Paula/0000-0002-0317-890X; Flores, Carlos/0000-0001-5352-069X				BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Blairon L, 2003, J INFECT DIS, V187, P287, DOI 10.1086/346046; Blanco J, 2008, CRIT CARE, V12, DOI 10.1186/cc7157; Bregeon F, 2005, ANESTHESIOLOGY, V102, P331; Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4; Chien JW, 2008, BLOOD, V111, P2462, DOI 10.1182/blood-2007-09-101709; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cunningham Steven C, 2006, Surg Infect (Larchmt), V7, P251, DOI 10.1089/sur.2006.7.251; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Engel C, 2007, INTENS CARE MED, V33, P606, DOI 10.1007/s00134-006-0517-7; Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Flores C, 2008, CRIT CARE, V12, DOI 10.1186/cc7098; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Gaini S, 2008, CLIN EXP IMMUNOL, V151, P423, DOI 10.1111/j.1365-2249.2007.03586.x; Gaini S, 2007, CRIT CARE, V11, DOI 10.1186/cc5967; Gaini S, 2006, CRIT CARE, V10, DOI 10.1186/cc4866; GALLAY P, 1994, J INFECT DIS, V170, P1319, DOI 10.1093/infdis/170.5.1319; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gharib SA, 2006, AM J RESP CRIT CARE, V173, P653, DOI 10.1164/rccm.200509-1473OC; Grunwald U, 1996, J IMMUNOL, V157, P4119; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Herrera MT, 2003, INTENS CARE MED, V29, P1345, DOI 10.1007/s00134-003-1756-5; Hubacek JA, 2001, CRIT CARE MED, V29, P557, DOI 10.1097/00003246-200103000-00015; Kalil AC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002291; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lee PS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003712; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Martin GS, 2005, CRIT CARE, V9, pR74, DOI 10.1186/cc3025; Martin TR, 1997, AM J RESP CRIT CARE, V155, P937, DOI 10.1164/ajrccm.155.3.9117029; McClintock D, 2008, CRIT CARE, V12, DOI 10.1186/cc6846; Minter RM, 2009, AM J PHYSIOL-GASTR L, V296, pG45, DOI 10.1152/ajpgi.00041.2008; Opal SM, 1999, J INFECT DIS, V180, P1584, DOI 10.1086/315093; Padkin A, 2003, CRIT CARE MED, V31, P2332, DOI 10.1097/01.CCM.0000085141.75513.2B; Polderman KH, 1999, LANCET, V353, P380, DOI 10.1016/S0140-6736(05)74953-9; Prucha M, 2003, CRIT CARE, V7, pR154, DOI 10.1186/cc2386; Sablotzki A, 2001, THORAC CARDIOV SURG, V49, P273, DOI 10.1055/s-2001-17803; Sakr Y, 2008, CRIT CARE MED, V36, P2014, DOI 10.1097/CCM.0b013e31817b86e3; Salluh JIF, 2008, CRIT CARE MED, V36, P2192, DOI 10.1097/CCM.0b013e31817c0cd8; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shapiro NI, 2009, CRIT CARE MED, V37, P96, DOI 10.1097/CCM.0b013e318192fd9d; Suistomaa M, 2000, INTENS CARE MED, V26, P1773, DOI 10.1007/s001340000677; Tunnell RD, 1998, ANAESTHESIA, V53, P1045, DOI 10.1046/j.1365-2044.1998.00566.x; Villar J, 2004, CRIT CARE, V8, P180, DOI 10.1186/cc2863; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vreugdenhil ACE, 1999, J IMMUNOL, V163, P2792; Wang ZX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004380; Wurfel Mark M, 2007, Proc Am Thorac Soc, V4, P77, DOI 10.1513/pats.200608-149JG; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	50	50	55	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6818	10.1371/journal.pone.0006818	http://dx.doi.org/10.1371/journal.pone.0006818			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718443	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415900002
J	Chen, F; He, YQ				Chen, Fang; He, Yongqun			Caspase-2 Mediated Apoptotic and Necrotic Murine Macrophage Cell Death Induced by Rough Brucella abortus	PLOS ONE			English	Article								Brucella species are Gram-negative, facultative intracellular bacteria that cause zoonotic brucellosis. Survival and replication inside macrophages is critical for establishment of chronic Brucella infection. Virulent smooth B. abortus strain 2308 inhibits programmed macrophage cell death and replicates inside macrophages. Cattle B. abortus vaccine strain RB51 is an attenuated rough, lipopolysaccharide O antigen-deficient mutant derived from smooth strain 2308. B. abortus rough mutant RA1 contains a single wboA gene mutation in strain 2308. Our studies demonstrated that live RB51 and RA1, but not strain 2308 or heat-killed Brucella, induced both apoptotic and necrotic cell death in murine RAW264.7 macrophages and bone marrow derived macrophages. The same phenomenon was also observed in primary mouse peritoneal macrophages from mice immunized intraperitoneally with vaccine strain RB51 using the same dose as regularly performed in protection studies. Programmed macrophage cell death induced by RB51 and RA1 was inhibited by a caspase-2 inhibitor (Z-VDVADFMK). Caspase-2 enzyme activation and cleavage were observed at the early infection stage in macrophages infected with RB51 and RA1 but not strain 2308. The inhibition of macrophage cell death promoted the survival of rough Brucella cells inside macrophages. The critical role of caspase-2 in mediating rough B. abortus induced macrophage cell death was confirmed using caspase-2 specific shRNA. The mitochondrial apoptosis pathway was activated in macrophages infected with rough B. abortus as demonstrated by increase in mitochondrial membrane permeability and the release of cytochrome c to cytoplasm in macrophages infected with rough Brucella. These results demonstrate that rough B. abortus strains RB51 and RA1 induce apoptotic and necrotic murine macrophage cell death that is mediated by caspase-2. The biological relevance of Brucella O antigen and caspase-2-mediated macrophage cell death in Brucella pathogenesis and protective Brucella immunity is discussed.			Chen, F (corresponding author), Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI 48109 USA.	yongqunh@umich.edu		He, Yongqun/0000-0001-9189-9661	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153, R21AI057875] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI057153, 1R21AI057875-01, 1-U54-AI-057153, R21 AI057875, R21 AI057875-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barquero-Calvo E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000631; Baumann S, 2006, CURR OPIN IMMUNOL, V18, P438, DOI 10.1016/j.coi.2006.05.016; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Bricker BJ, 2002, VET MICROBIOL, V90, P435, DOI 10.1016/S0378-1135(02)00228-6; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Chang K, 2006, NAT METHODS, V3, P707, DOI 10.1038/NMETH923; Chen MJ, 2006, J IMMUNOL, V176, P3707, DOI 10.4049/jimmunol.176.6.3707; Chen Y, 2008, PHARM RES-DORDR, V25, P72, DOI 10.1007/s11095-007-9504-0; Ciaramella A, 2002, J INFECT DIS, V186, P1277, DOI 10.1086/344645; Cloeckaert A, 2002, VACCINE, V20, P1820, DOI 10.1016/S0264-410X(02)00035-X; Colussi PA, 1999, IMMUNOL CELL BIOL, V77, P58, DOI 10.1046/j.1440-1711.1999.00788.x; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; de Bagues MPJ, 2004, INFECT IMMUN, V72, P2429, DOI 10.1128/IAI.72.4.2429-2433.2004; DETILLEUX PG, 1990, VET PATHOL, V27, P317, DOI 10.1177/030098589002700503; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Faderl S, 1999, CLIN CANCER RES, V5, P4041; Fernandez-Prada CM, 2003, INFECT IMMUN, V71, P2110, DOI 10.1128/IAI.71.4.2110-2119.2003; Fewell GD, 2006, DRUG DISCOV TODAY, V11, P975, DOI 10.1016/j.drudis.2006.09.008; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; FREEMAN BA, 1961, J INFECT DIS, V108, P333, DOI 10.1093/infdis/108.3.333; FREEMAN BA, 1964, J INFECT DIS, V114, P441, DOI 10.1093/infdis/114.5.441; Galdiero E, 2000, MICROBIOLOGICA, V23, P271; Gonzalez D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002760; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Gross A, 2000, INFECT IMMUN, V68, P342, DOI 10.1128/IAI.68.1.342-351.2000; He YQ, 2006, INFECT IMMUN, V74, P5035, DOI 10.1128/IAI.01998-05; He YQ, 2001, INFECT IMMUN, V69, P5502, DOI 10.1128/IAI.69.9.5502-5508.2001; Hetz CA, 2005, BIOCHEM CELL BIOL, V83, P579, DOI 10.1139/o05-065; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; Lapaque N, 2005, CURR OPIN MICROBIOL, V8, P60, DOI 10.1016/j.mib.2004.12.003; Lara-Tejero M, 2006, J EXP MED, V203, P1407, DOI 10.1084/jem.20060206; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee IK, 1999, CAN J VET RES, V63, P284; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; MAJNO G, 1995, AM J PATHOL, V146, P3; Marianelli C, 2004, J CLIN MICROBIOL, V42, P5439, DOI 10.1128/JCM.42.12.5439-5443.2004; Martin-Martin AI, 2008, MICROBES INFECT, V10, P706, DOI 10.1016/j.micinf.2008.02.013; McQuiston JR, 1999, INFECT IMMUN, V67, P3830, DOI 10.1128/IAI.67.8.3830-3835.1999; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Pappas G, 2006, LANCET INFECT DIS, V6, P91, DOI 10.1016/S1473-3099(06)70382-6; Pei JW, 2006, INFECT IMMUN, V74, P2667, DOI 10.1128/IAI.74.5.2667-2675.2006; Pei JW, 2004, INFECT IMMUN, V72, P440, DOI 10.1128/IAI.72.1.440-450.2004; Porte F, 2003, INFECT IMMUN, V71, P1481, DOI 10.1128/IAI.71.3.1481-1490.2003; Raupach B, 2006, INFECT IMMUN, V74, P4922, DOI 10.1128/IAI.00417-06; Reed WP, 2004, SURG ENDOSC, V18, P11, DOI 10.1007/s00464-003-8913-3; Rittig MG, 2003, J LEUKOCYTE BIOL, V74, P1045, DOI 10.1189/jlb.0103015; Rodriguez-Enriquez S, 2004, INT J BIOCHEM CELL B, V36, P2463, DOI 10.1016/j.biocel.2004.04.009; Roop RM, 2003, ANNU REV MICROBIOL, V57, P57, DOI 10.1146/annurev.micro.57.030502.090803; Sansonetti PJ, 2000, IMMUNITY, V12, P581, DOI 10.1016/S1074-7613(00)80209-5; Santos RL, 2001, INFECT IMMUN, V69, P2293, DOI 10.1128/IAI.69.4.2293-2301.2001; Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9; SCHURIG GG, 1991, VET MICROBIOL, V28, P171, DOI 10.1016/0378-1135(91)90091-S; Seleem MN, 2004, BIOTECHNIQUES, V37, P740, DOI 10.2144/04375BM05; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; STEVENS MG, 1995, INFECT IMMUN, V63, P3199, DOI 10.1128/IAI.63.8.3199-3205.1995; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TIMONEY JF, 1988, GENUS BRUCELLA HAGAN, P135; Tolomeo M, 2003, CLIN INFECT DIS, V36, P1533, DOI 10.1086/375223; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Vemulapalli R, 1999, CLIN DIAGN LAB IMMUN, V6, P760, DOI 10.1128/CDLI.6.5.760-764.1999; Yoo NJ, 2004, APMIS, V112, P330; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305; Zhang XN, 2005, INT J CANCER, V113, P397, DOI 10.1002/ijc.20553; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	73	58	59	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6830	10.1371/journal.pone.0006830	http://dx.doi.org/10.1371/journal.pone.0006830			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714247	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415800014
J	Gacsi, M; Gyori, B; Viranyi, Z; Kubinyi, E; Range, F; Belenyi, B; Miklosi, A				Gacsi, Marta; Gyori, Borbala; Viranyi, Zsofia; Kubinyi, Eniko; Range, Friederike; Belenyi, Beatrix; Miklosi, Adam			Explaining Dog Wolf Differences in Utilizing Human Pointing Gestures: Selection for Synergistic Shifts in the Development of Some Social Skills	PLOS ONE			English	Article							REARED WOLVES; COGNITION; ANIMALS	Background: The comparison of human related communication skills of socialized canids may help to understand the evolution and the epigenesis of gesture comprehension in humans. To reconcile previously contradicting views on the origin of dogs' outstanding performance in utilizing human gestures, we suggest that dog-wolf differences should be studied in a more complex way. Methodology/Principal Findings: We present data both on the performance and the behaviour of dogs and wolves of different ages in a two-way object choice test. Characteristic behavioural differences showed that for wolves it took longer to establish eye contact with the pointing experimenter, they struggled more with the handler, and pups also bit her more before focusing on the human's signal. The performance of similarly hand-reared 8-week-old dogs and wolves did not differ in utilizing the simpler proximal momentary pointing. However, when tested with the distal momentary pointing, 4-month-old pet dogs outperformed the same aged hand reared wolves. Thus early and intensive socialisation does not diminish differences between young dogs and wolves in behaviour and performance. Socialised adult wolves performed similarly well as dogs in this task without pretraining. The success of adult wolves was accompanied with increased willingness to cooperate. Conclusion/Significance: Thus, we provide evidence for the first time that socialised adult wolves are as successful in relying on distal momentary pointing as adult pet dogs. However, the delayed emergence of utilising human distal momentary pointing in wolves shows that these wild canines react to a lesser degree to intensive socialisation in contrast to dogs, which are able to control agonistic behaviours and inhibition of actions in a food related task early in development. We suggest a "synergistic'' hypothesis, claiming that positive feedback processes (both evolutionary and epigenetic) have increased the readiness of dogs to attend to humans, providing the basis for dog-human communication.			Gacsi, M (corresponding author), Eotvos Lorand Univ, Dept Ethol, Budapest, Hungary.	gm.art@t-online.hu	Kubinyi, Eniko/B-5824-2013; Miklosi, Adam/N-5147-2017	Kubinyi, Eniko/0000-0002-4468-9845; Gacsi, Marta/0000-0003-3080-7545; Range, Friederike/0000-0003-3127-5536; Miklosi, Adam/0000-0003-4831-8985	Austrian Science Fund FWF [P 21244] Funding Source: Medline; Austrian Science Fund (FWF) [P 21244] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Coppinger R., 2001, DOGS NEW UNDERSTANDI; Gacsi M, 2005, DEV PSYCHOBIOL, V47, P111, DOI 10.1002/dev.20082; GACSI M, 2009, BRAIN BEHAV IN PRESS; Gacsi M, 2009, ANIM COGN, V12, P471, DOI 10.1007/s10071-008-0208-6; Hare B, 2005, TRENDS COGN SCI, V9, P439, DOI 10.1016/j.tics.2005.07.003; Hare B, 2005, CURR BIOL, V15, P226, DOI 10.1016/j.cub.2005.01.040; Hare B, 2002, SCIENCE, V298, P1634, DOI 10.1126/science.1072702; Kubinyi E, 2007, COMP COGN BEHAV REV, V2, P26; Lakatos G, 2009, ANIM COGN, V12, P621, DOI 10.1007/s10071-009-0221-4; Miklosi A, 2004, ANIM BEHAV, V67, P995, DOI 10.1016/j.anbehav.2003.10.008; Miklosi A, 2003, CURR BIOL, V13, P763, DOI 10.1016/S0960-9822(03)00263-X; Miklosi A., 2007, DOG BEHAV EVOLUTION; Miklosi A, 2006, ANIM COGN, V9, P81, DOI 10.1007/s10071-005-0008-1; Packard Jane M., 2003, P35; Price EO, 1999, APPL ANIM BEHAV SCI, V65, P245, DOI 10.1016/S0168-1591(99)00087-8; RIEDEL J, 2007, ANIM BEHAV, DOI DOI 10.1016/J.ANBE-HAV.2007.08.010; Soproni K, 2002, J COMP PSYCHOL, V116, P27, DOI 10.1037//0735-7036.116.1.27; Szetei V, 2003, APPL ANIM BEHAV SCI, V83, P141, DOI 10.1016/S0168-1591(03)00114-X; Topal J, 2005, ANIM BEHAV, V70, P1367, DOI 10.1016/j.anbehav.2005.03.025; Udell MAR, 2008, ANIM BEHAV, V76, P1767, DOI 10.1016/j.anbehav.2008.07.028; Viranyi Z, 2008, ANIM COGN, V11, P373, DOI 10.1007/s10071-007-0127-y	21	140	141	2	103	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6584	10.1371/journal.pone.0006584	http://dx.doi.org/10.1371/journal.pone.0006584			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714197	Green Published, gold, Green Submitted			2022-12-27	WOS:000269415800001
J	Poongothai, S; Pradeepa, R; Ganesan, A; Mohan, V				Poongothai, Subramani; Pradeepa, Rajendra; Ganesan, Anbhazhagan; Mohan, Viswanathan			Prevalence of Depression in a Large Urban South Indian Population - The Chennai Urban Rural Epidemiology Study (Cures-70)	PLOS ONE			English	Article							COMMON MENTAL-DISORDERS; RISK-FACTORS; PRIMARY-CARE; MAJOR DEPRESSION; COMMUNITY SURVEY; SYMPTOMS; HEALTH; WOMEN; AGE; IDEATION	Background: In India there are very few population based data on prevalence of depression. The aim of the study was to determine the prevalence of depression in an urban south Indian population. Methods and Findings: Subjects were recruited from the Chennai Urban Rural Epidemiology Study (CURES), involving 26,001 subjects randomly recruited from 46 of the 155 corporation wards of Chennai (formerly Madras) city in South India. 25,455 subjects participated in this study (response rate 97.9%). Depression was assessed using a self-reported and previously validated instrument, the Patient Health Questionnaire (PHQ) - 12. Age adjustment was made according to the 2001 census of India. The overall prevalence of depression was 15.1% (age-adjusted, 15.9%) and was higher in females (females 16.3% vs. males 13.9%, p < 0.0001). The odds ratio (OR) for depression in female subjects was 1.20 [Confidence Intervals (CI): 1.12-1.28, p < 0.001] compared to male subjects. Depressed mood was the most common symptom (30.8%), followed by tiredness (30.0%) while more severe symptoms such as suicidal thoughts (12.4%) and speech and motor retardation (12.4%) were less common. There was an increasing trend in the prevalence of depression with age among both female (p < 0.001) and male subjects (p < 0.001). The prevalence of depression was higher in the low income group (19.3%) compared to the higher income group (5.9%, p < 0.001). Prevalence of depression was also higher among divorced (26.5%) and widowed (20%) compared to currently married subjects (15.4%, p < 0.001). Conclusions: This is the largest population-based study from India to report on prevalence of depression and shows that among urban south Indians, the prevalence of depression was 15.1%. Age, female gender and lower socio-economic status are some of the factors associated with depression in this population.			Poongothai, S (corresponding author), WHO, Collaborating Ctr Noncommunicable Dis Prevent &, Madras Diabet Res Fdn, Madras, Tamil Nadu, India.	drmohans@vsnl.net		Pradeepa, Rajendra/0000-0002-4909-3733				Aluoja A, 2004, J AFFECT DISORDERS, V78, P27, DOI 10.1016/S0165-0327(02)00179-9; Amin G, 1998, Indian J Psychiatry, V40, P364; Asghar S, 2007, DIABETIC MED, V24, P872, DOI 10.1111/j.1464-5491.2007.02136.x; Bebbington PE, 1998, PSYCHOL MED, V28, P9, DOI 10.1017/S0033291797006077; Berardi D, 2002, FAM PRACT, V19, P397, DOI 10.1093/fampra/19.4.397; BISWAS SS, 2009, INT PSYCHOGERIATR, V13, P1; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Chandran M, 2002, BRIT J PSYCHIAT, V181, P499, DOI 10.1192/bjp.181.6.499; Deepa M, 2003, J Assoc Physicians India, V51, P863; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; GADIT A, 1998, J COLL PHYS SURG PK, V8, P262; Gadit AAM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000209; GOLDBERG DP, 1995, MENTAL ILLNESS GEN H, P323; Harrison GG, 1988, ANTHROPOMETRIC STAND, P55; Husain N, 2000, PSYCHOL MED, V30, P395, DOI 10.1017/S0033291700001707; Isometsa E, 1997, ACTA PSYCHIAT SCAND, V96, P122, DOI 10.1111/j.1600-0447.1997.tb09916.x; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KESSLER RC, 2005, JAMA-J AM MED ASSOC, V2495, P1990; Kishore J, 1996, Indian J Psychiatry, V38, P137; Lee S, 2007, ACTA PSYCHIAT SCAND, V116, P429, DOI 10.1111/j.1600-0447.2007.01064.x; Lerer B, 1996, Int Psychogeriatr, V8, P83, DOI 10.1017/S1041610296002499; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; MIROWSKY J, 1992, J HEALTH SOC BEHAV, V33, P187, DOI 10.2307/2137349; Mirza I, 2004, BMJ-BRIT MED J, V328, P794, DOI 10.1136/bmj.328.7443.794; Nakku Juliet E M, 2006, Afr Health Sci, V6, P207; Nambi SK, 2002, NATL MED J INDIA, V15, P331; National Institute of Mental Health, 2001, NIH PUBL; Nisar N, 2004, J Pak Med Assoc, V54, P519; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Nolen-Hoeksema S., 1990, SEX DIFFERENCES DEPR; Olsen LR, 2004, ACTA PSYCHIAT SCAND, V109, P96, DOI 10.1046/j.0001-690X.2003.00231.x; Ovuga E, 2005, SOC PSYCH PSYCH EPID, V40, P439, DOI 10.1007/s00127-005-0915-0; Palsson SP, 2001, PSYCHOL MED, V31, P1159, DOI 10.1017/S0033291701004524; PARIKH RM, 2001, AM PSYCH ASS 2001 AN, P70; Patel V, 2002, AM J PSYCHIAT, V159, P43, DOI 10.1176/appi.ajp.159.1.43; Patel V, 2006, ARCH GEN PSYCHIAT, V63, P404, DOI 10.1001/archpsyc.63.4.404; Patel V, 2007, TROP MED INT HEALTH, V12, P130, DOI 10.1111/j.1365-3156.2006.01756.x; Patel V, 2006, BRIT J PSYCHIAT, V189, P547, DOI 10.1192/bjp.bp.106.022558; Poongothai S, 2009, J Assoc Physicians India, V57, P147; Pothen M, 2003, INT J SOC PSYCHIATR, V49, P119, DOI 10.1177/0020764003049002005; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; RAJALA U, 1994, SOC PSYCH PSYCH EPID, V29, P126; RUIZ P, 2001, ETHNICITY PSYCHOPHAR; Salokangas RKR, 1998, J AFFECT DISORDERS, V48, P171, DOI 10.1016/S0165-0327(97)00171-7; Stordal E, 2003, ACTA PSYCHIAT SCAND, V107, P132, DOI 10.1034/j.1600-0447.2003.02056.x; Tracy M, 2008, ANN EPIDEMIOL, V18, P447, DOI 10.1016/j.annepidem.2007.12.004; Vasiliadis HM, 2007, PSYCHIAT SERV, V58, P63, DOI 10.1176/appi.ps.58.1.63-a; Wittchen HU, 2002, HUM PSYCHOPHARM CLIN, V17, pS1, DOI 10.1002/hup.398; World Health Organization, 2001, WORLD HLTH REP; Zinn-Souza LC, 2008, REV SAUDE PUBL, V42, P34, DOI 10.1590/S0034-89102008000100005	50	129	132	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2009	4	9							e7185	10.1371/journal.pone.0007185	http://dx.doi.org/10.1371/journal.pone.0007185			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	500HQ	19784380	Green Published, gold			2022-12-27	WOS:000270290000006
J	Belin, S; Beghin, A; Solano-Gonzalez, E; Bezin, L; Brunet-Manquat, S; Textoris, J; Prats, AC; Mertani, HC; Dumontet, C; Diaz, JJ				Belin, Stephane; Beghin, Anne; Solano-Gonzalez, Eduardo; Bezin, Laurent; Brunet-Manquat, Stephanie; Textoris, Julien; Prats, Anne-Catherine; Mertani, Hichem C.; Dumontet, Charles; Diaz, Jean-Jacques			Dysregulation of Ribosome Biogenesis and Translational Capacity Is Associated with Tumor Progression of Human Breast Cancer Cells	PLOS ONE			English	Article							RNA-POLYMERASE-I; C-MYC; PROTEIN SYNTHESIS; HELA-CELLS; ENTRY SITE; EXPRESSION; PERSISTENCE; EFFICIENCY; INITIATION; INFECTION	Protein synthesis is a fundamental cell process and ribosomes - particularly through the ribosomal RNA that display ribozyme activity - are the main effectors of this process. Ribosome biogenesis is a very complex process involving transcriptional as well as many post-transcriptional steps to produce functional ribosomes. It is now well demonstrated that ribosome production is enhanced in cancer cells and that ribosome biogenesis plays a crucial role in tumor progression. However, at present there is an important lack of data to determine whether the entire process of ribosome biogenesis and ribosome assembly is modified during tumor progression and what could be the potential impact on the dysregulation of translational control that is observed in cancer cells. In breast cancer cells displaying enhanced aggressivity, both in vitro and in vivo, we have analyzed the major steps of ribosome biogenesis and the translational capacity of the resulting ribosome. We show that increased tumorigenicity was associated with modifications of nucleolar morphology and profound quantitative and qualitative alterations in ribosomal biogenesis and function. Specifically cells with enhanced tumor aggressivity displayed increased synthesis of 45S pre-rRNA, with activation of an alternative preRNA synthetic pathway containing a 43S precursor and enhanced post-transcriptional methylation of specifc sites located in the 28S rRNA. While the global translational activity was not modified, IRES-initiated translation, notably that of p53 mRNA, was less efficient and the control of translational fidelity was importantly reduced in cells with increased aggressivity. These results suggest that acquisition of enhanced tumor aggressivity can be associated with profound qualitative alterations in ribosomal control, leading to reduced quality control of translation in cancer cells.	[Beghin, Anne; Brunet-Manquat, Stephanie; Dumontet, Charles] INSERM, U590, Lyon, France; [Beghin, Anne; Brunet-Manquat, Stephanie; Dumontet, Charles] Univ Lyon 1, ISPB, Lyon, France; [Belin, Stephane; Textoris, Julien; Diaz, Jean-Jacques] Univ Lyon 1, CNRS, UMR 5534, Ctr Leon Berard, Lyon, France; [Bezin, Laurent; Mertani, Hichem C.] Univ Lyon 1, CNRS, UMR 5123, Ctr Leon Berard, Lyon, France; [Solano-Gonzalez, Eduardo; Prats, Anne-Catherine] INSERM, U858, Toulouse, France; [Solano-Gonzalez, Eduardo; Prats, Anne-Catherine] Univ Toulouse, UPS, Inst Med Mol Rangueil, IFR150, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Diaz, JJ (corresponding author), Univ Lyon 1, CNRS, UMR 5534, Ctr Leon Berard, Lyon, France.	diazjj@lyon.fnclcc.fr	MERTANI, Hichem-Claude/AAR-6415-2020; DIAZ, Jean-Jacques/H-3018-2014; Prats, Anne-Catherine/E-5051-2016; Textoris, Julien/H-3317-2019; DIAZ, Jean-Jacques/AAT-3846-2021	DIAZ, Jean-Jacques/0000-0002-7914-4319; Prats, Anne-Catherine/0000-0002-5282-3776; Textoris, Julien/0000-0002-3821-9337; DIAZ, Jean-Jacques/0000-0002-7914-4319; Dumontet, Charles/0000-0003-1875-134X; Belin, Stephane/0000-0001-7074-6885				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Baxter-Roshek JL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000174; Beghin A, 2008, CELL CYCLE, V7, P3074, DOI 10.4161/cc.7.19.6777; Behin A, 2007, EXP CELL RES, V313, P473, DOI 10.1016/j.yexcr.2006.10.024; BOISVERT FM, 2007, NAT REV MOL CELL BIO; Chaudhuri S, 2007, RNA, V13, P2224, DOI 10.1261/rna.694007; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Coute Y, 2006, MASS SPECTROM REV, V25, P215, DOI 10.1002/mas.20067; COUTE Y, 2007, MOL CELL PROTEOMICS; Decatur WA, 2002, TRENDS BIOCHEM SCI, V27, P344, DOI 10.1016/S0968-0004(02)02109-6; Derenzini M, 1998, AM J PATHOL, V152, P1291; Derenzini M, 2000, MICRON, V31, P117, DOI 10.1016/S0968-4328(99)00067-0; Diaz JJ, 2002, J CHROMATOGR B, V771, P237, DOI 10.1016/S1570-0232(02)00038-7; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Giraud S, 2001, J BIOL CHEM, V276, P5668, DOI 10.1074/jbc.M005928200; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Greco A, 1997, MOL GEN GENET, V256, P320, DOI 10.1007/s004380050575; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Lestrade L, 2006, NUCLEIC ACIDS RES, V34, pD158, DOI 10.1093/nar/gkj002; Liang XH, 2007, MOL CELL, V28, P965, DOI 10.1016/j.molcel.2007.10.012; Liu B, 2008, RNA BIOL, V5, P249, DOI 10.4161/rna.6916; Maden BEH, 2001, METHODS, V25, P374, DOI 10.1006/meth.2001.1250; MADJAR JJ, 1979, MOL GEN GENET, V171, P121, DOI 10.1007/BF00269998; MADJAR JJ, 1977, MOL BIOL REP, V3, P289, DOI 10.1007/BF00368299; Martineau Y, 2004, MOL CELL BIOL, V24, P7622, DOI 10.1128/MCB.24.17.7622-7635.2004; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Navarro FP, 2008, J NEUROCHEM, V105, P34, DOI 10.1111/j.1471-4159.2007.05116.x; Ofner D, 2000, MICRON, V31, P161, DOI 10.1016/S0968-4328(99)00073-6; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; Pich A, 2000, MICRON, V31, P133, DOI 10.1016/S0968-4328(99)00070-0; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Reichow SL, 2007, NUCLEIC ACIDS RES, V35, P1452, DOI 10.1093/nar/gkl1172; Rouquette J, 2005, EMBO J, V24, P2862, DOI 10.1038/sj.emboj.7600752; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sanchez PE, 2009, P NATL ACAD SCI USA, V106, P9848, DOI 10.1073/pnas.0901840106; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Simonin D, 1997, J GEN VIROL, V78, P435, DOI 10.1099/0022-1317-78-2-435; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Tinton SA, 2005, BIOCHEM J, V385, P155, DOI 10.1042/BJ20040963; Trere D, 2004, J HISTOCHEM CYTOCHEM, V52, P1601, DOI 10.1369/jhc.4A6454.2004; Wang SI, 2002, INT J ONCOL, V20, P1269; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835	47	159	164	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7147	10.1371/journal.pone.0007147	http://dx.doi.org/10.1371/journal.pone.0007147			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779612	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200005
J	Shaham, S				Shaham, Shai			galign: A Tool for Rapid Genome Polymorphism Discovery	PLOS ONE			English	Article								Background: Highly parallel sequencing technologies have become important tools in the analysis of sequence polymorphisms on a genomic scale. However, the development of customized software to analyze data produced by these methods has lagged behind. Methods/Principal Findings: Here I describe a tool, 'galign', designed to identify polymorphisms between sequence reads obtained using Illumina/Solexa technology and a reference genome. The 'galign' alignment tool does not use Smith-Waterman matrices for sequence comparisons. Instead, a simple algorithm comparing parsed sequence reads to parsed reference genome sequences is used. 'galign' output is geared towards immediate user application, displaying polymorphism locations, nucleotide changes, and relevant predicted amino-acid changes for ease of information processing. To do so, 'galign' requires several accessory files easily derived from an annotated reference genome. Direct sequencing as well as in silico studies demonstrate that 'galign' provides lesion predictions comparable in accuracy to available prediction programs, accompanied by greater processing speed and more user-friendly output. We demonstrate the use of 'galign' to identify mutations leading to phenotypic consequences in C. elegans. Conclusion/Significance: Our studies suggest that 'galign' is a useful tool for polymorphism discovery, and is of immediate utility for sequence mining in C. elegans.			Shaham, S (corresponding author), Rockefeller Univ, Lab Dev Genet, 1230 York Ave, New York, NY 10021 USA.	shaham@rockefeller.edu			NICHD NIH HHS [R01 HD042680, R01 HD052677] Funding Source: Medline; NINDS NIH HHS [R01 NS064273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042680, R01HD052677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064273] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Perens EA, 2005, DEV CELL, V8, P893, DOI 10.1016/j.devcel.2005.03.009; Sarin S, 2008, NAT METHODS, V5, P865, DOI 10.1038/NMETH.1249; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5	7	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2009	4	9							e7188	10.1371/journal.pone.0007188	http://dx.doi.org/10.1371/journal.pone.0007188			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WL	19779626	Green Published, Green Submitted, gold			2022-12-27	WOS:000270176200019
J	Stahl, HF; Fauti, T; Ullrich, N; Bopp, T; Kubach, J; Rust, W; Labhart, P; Alexiadis, V; Becker, C; Hafner, M; Weith, A; Lenter, MC; Jonuleit, H; Schmitt, E; Mennerich, D				Stahl, Heiko F.; Fauti, Tanja; Ullrich, Nina; Bopp, Tobias; Kubach, Jan; Rust, Werner; Labhart, Paul; Alexiadis, Vassili; Becker, Christian; Hafner, Mathias; Weith, Andreas; Lenter, Martin C.; Jonuleit, Helmut; Schmitt, Edgar; Mennerich, Detlev			miR-155 Inhibition Sensitizes CD4+Th Cells for TREG Mediated Suppression	PLOS ONE			English	Article								Background: In humans and mice naturally occurring CD4(+)CD25(+) regulatory T cells (nTregs) are a thymus-derived subset of T cells, crucial for the maintenance of peripheral tolerance by controlling not only potentially autoreactive T cells but virtually all cells of the adaptive and innate immune system. Recent work using Dicer-deficient mice irrevocably demonstrated the importance of miRNAs for nTreg cell-mediated tolerance. Principal Findings: DNA-Microarray analyses of human as well as murine conventional CD4(+) Th cells and nTregs revealed a strong up-regulation of mature miR-155 (microRNA-155) upon activation in both populations. Studying miR-155 expression in FoxP3-deficient scurfy mice and performing FoxP3 ChIP-Seq experiments using activated human T lymphocytes, we show that the expression and maturation of miR-155 seem to be not necessarily regulated by FoxP3. In order to address the functional relevance of elevated miR-155 levels, we transfected miR-155 inhibitors or mature miR-155 RNAs into freshly-isolated human and mouse primary CD4(+) Th cells and nTregs and investigated the resulting phenotype in nTreg suppression assays. Whereas miR-155 inhibition in conventional CD4(+) Th cells strengthened nTreg cell-mediated suppression, overexpression of mature miR-155 rendered these cells unresponsive to nTreg cell-mediated suppression. Conclusion: Investigation of FoxP3 downstream targets, certainly of bound and regulated miRNAs revealed the associated function between the master regulator FoxP3 and miRNAs as regulators itself. miR-155 is shown to be crucially involved in nTreg cell mediated tolerance by regulating the susceptibility of conventional human as well as murine CD4(+) Th cells to nTreg cell-mediated suppression.			Stahl, HF (corresponding author), Boehringer Ingelheim Pharma GmbH & Co KG, Genom Grp, Resp Dis Res, Biberach, Germany.	detlev.mennerich@boehringer-ingelheim.com	Becker, Christian/GLS-0862-2022; Jonuleit, Helmut/D-8059-2011; Becker, Christian/AAD-4549-2020; Bopp, Tobias/A-4328-2018; Becker, Christian/F-5384-2010	Becker, Christian/0000-0002-1716-7208; Jonuleit, Helmut/0000-0002-5672-9365; Becker, Christian/0000-0002-1716-7208; Bopp, Tobias/0000-0002-3232-8065; Becker, Christian/0000-0002-1716-7208				Becker C, 2007, EUR J IMMUNOL, V37, P1217, DOI 10.1002/eji.200636480; Bopp T, 2005, J EXP MED, V201, P181, DOI 10.1084/jem.20041538; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Cattoretti G, 2006, J IMMUNOL, V177, P6930, DOI 10.4049/jimmunol.177.10.6930; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Dorsett Y, 2008, IMMUNITY, V28, P630, DOI 10.1016/j.immuni.2008.04.002; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Gottwein E, 2007, NATURE, V450, P1096, DOI 10.1038/nature05992; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; Harada M, 2007, AM J RESP CELL MOL, V36, P491, DOI 10.1165/rcmb.2006-0090OC; Kubach J, 2007, BLOOD, V110, P1550, DOI 10.1182/blood-2007-01-069229; Labhart P, 2005, P NATL ACAD SCI USA, V102, P1339, DOI 10.1073/pnas.0409578102; Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Skalsky RL, 2007, J VIROL, V81, P12836, DOI 10.1128/JVI.01804-07; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Turner M, 2008, BIOCHEM SOC T, V36, P531, DOI 10.1042/BST0360531; van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186; Venken K, 2007, J IMMUNOL METHODS, V322, P1, DOI 10.1016/j.jim.2007.01.025; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707	30	72	89	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2009	4	9							e7158	10.1371/journal.pone.0007158	http://dx.doi.org/10.1371/journal.pone.0007158			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498SW	19777054	gold, Green Submitted, Green Published			2022-12-27	WOS:000270164600006
J	Byrne, JA; Nguyen, HN; Pera, RAR				Byrne, James A.; Nguyen, Ha Nam; Pera, Renee A. Reijo			Enhanced Generation of Induced Pluripotent Stem Cells from a Subpopulation of Human Fibroblasts	PLOS ONE			English	Article							SOMATIC-CELLS; INDUCTION; FUSION	Background: The derivation of induced pluripotent stem cells (iPSCs) provides new possibilities for basic research and novel cell-based therapies. Limitations, however, include our current lack of understanding regarding the underlying mechanisms and the inefficiency of reprogramming. Methodology/Principal Findings: Here, we report identification and isolation of a subpopulation of human dermal fibroblasts that express the pluripotency marker stage specific embryonic antigen 3 (SSEA3). Fibroblasts that expressed SSEA3 demonstrated an enhanced iPSC generation efficiency, while no iPSC derivation was obtained from the fibroblasts that did not express SSEA3. Transcriptional analysis revealed NANOG expression was significantly increased in the SSEA3 expressing fibroblasts, suggesting a possible mechanistic explanation for the differential reprogramming. Conclusions/Significance: To our knowledge, this study is the first to identify a pluripotency marker in a heterogeneous population of human dermal fibroblasts, to isolate a subpopulation of cells that have a significantly increased propensity to reprogram to pluripotency and to identify a possible mechanism to explain this differential reprogramming. This discovery provides a method to significantly increase the efficiency of reprogramming, enhancing the feasibility of the potential applications based on this technology, and a tool for basic research studies to understand the underlying reprogramming mechanisms.			Byrne, JA (corresponding author), Stanford Univ, Dept Obstet & Gynecol, Inst Stem Cell Biol & Regenerat Med, Ctr Human Embryon Stem Cell Res & Educ, Palo Alto, CA 94304 USA.	reneer@stanford.edu		Byrne, James/0000-0002-2232-292X; Reijo Pera, Renee/0000-0002-6487-1329				Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503; Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; Byrne JA, 2007, NATURE, V450, P497, DOI 10.1038/nature06357; Byrne JA, 2008, HUM MOL GENET, V17, pR37, DOI 10.1093/hmg/ddn053; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345; Gurdon JB, 2003, P NATL ACAD SCI USA, V100, P8048, DOI 10.1073/pnas.1337135100; Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Li WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014; NGUYEN HN, 2008, COLD SPRING HARB PRO, V5047; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Silva J, 2006, NATURE, V441, P997, DOI 10.1038/nature04914; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Wong CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001955; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482	23	61	65	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7118	10.1371/journal.pone.0007118	http://dx.doi.org/10.1371/journal.pone.0007118			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774082	Green Published, gold, Green Submitted			2022-12-27	WOS:000270160900009
J	Mereghetti, L; Sitkiewicz, I; Green, NM; Musser, JM				Mereghetti, Laurent; Sitkiewicz, Izabela; Green, Nicole M.; Musser, James M.			Identification of an Unusual Pattern of Global Gene Expression in Group B Streptococcus Grown in Human Blood	PLOS ONE			English	Article								Because passage of the bacterium to blood is a crucial step in the pathogenesis of many group B Streptococcus (GBS) invasive infections, we recently conducted a whole-genome transcriptome analysis during GBS incubation ex vivo with human blood. In the current work, we sought to analyze in detail the difference in GBS gene expression that occurred in one blood sample (donor A) relative to other blood samples. We incubated GBS strain NEM316 with fresh heparinized human blood obtained from healthy volunteers, and analyzed GBS genome expression and cytokine production. Principal component analysis identified extensive clustering of the transcriptome data among all samples at time 0. In striking contrast, the whole bacterial gene expression in the donor A blood sample was significantly different from the gene expression in all other blood samples studied, both after 30 and 90 min of incubation. More genes were up-regulated in donor A blood relative to the other samples, at 30 min and 90 min. Furthermore, there was significant variation in transcript levels between donor A blood and other blood samples. Notably, genes with the highest transcript levels in donor A blood were those involved in carbohydrate metabolism. We also discovered an unusual production of proinflammatory and immunomodulatory cytokines: MIF, tPAI-1 and IL-1 beta were produced at higher levels in donor A blood relative to the other blood samples, whereas GM-CSF, TNF-alpha, IFN-gamma, IL-7 and IL-10 remained at lower levels in donor A blood. Potential reasons for our observations are that the immune response of donor A significantly influenced the bacterial transcriptome, or both GBS gene expression and immune response were influenced by the metabolic status of donor A.			Mereghetti, L (corresponding author), Methodist Hosp Res Inst, Ctr Mol & Translat Human Infect Dis Res, Houston, TX USA.	JMMusser@tmhs.org	Sitkiewicz, Izabela/G-5058-2011	Sitkiewicz, Izabela/0000-0001-8228-9917				Alessi MC, 2007, CURR OPIN LIPIDOL, V18, P240, DOI 10.1097/MOL.0b013e32814e6d29; Bisharat N, 2004, J CLIN MICROBIOL, V42, P2161, DOI 10.1128/JCM.42.5.2161-2167.2004; Bohnsack JF, 2001, J INFECT DIS, V183, P1694, DOI 10.1086/320717; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, SCAND J INFECT DIS, V35, P573, DOI 10.1080/00365540310016277; Edwards MS, 2005, CLIN INFECT DIS, V41, P839, DOI 10.1086/432804; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; Herbert MA, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-31; Hery-Arnaud G, 2005, J BACTERIOL, V187, P6248, DOI 10.1128/JB.187.17.6248-6252.2005; Hery-Arnaud G, 2007, APPL ENVIRON MICROB, V73, P4668, DOI 10.1128/AEM.02604-06; Jones N, 2003, J CLIN MICROBIOL, V41, P2530, DOI 10.1128/JCM.41.6.2530-2536.2003; Katial RK, 1998, CLIN DIAGN LAB IMMUN, V5, P78, DOI 10.1128/CDLI.5.1.78-81.1998; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; Kotb M, 2003, SCAND J INFECT DIS, V35, P665, DOI 10.1080/00365540310015962; Leurs PB, 2002, DIABETES CARE, V25, P1340, DOI 10.2337/diacare.25.8.1340; Liang FT, 2004, INFECT IMMUN, V72, P5759, DOI 10.1128/IAI.72.10.5759-5767.2004; Loughman JA, 2006, EMBO J, V25, P5414, DOI 10.1038/sj.emboj.7601393; Mereghetti L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002785; Mereghetti L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003143; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; Musser JM, 2005, AM J PATHOL, V167, P1461, DOI 10.1016/S0002-9440(10)61232-1; Peleg AY, 2007, DIABETES-METAB RES, V23, P3, DOI 10.1002/dmrr.682; Phares CR, 2008, JAMA-J AM MED ASSOC, V299, P2056, DOI 10.1001/jama.299.17.2056; Rolland K, 2002, MICROBIOL-SGM, V148, P1493, DOI 10.1099/00221287-148-5-1493; Sendi P, 2009, EMERG INFECT DIS, V15, P223, DOI 10.3201/eid1502.080990; Shelburne SA, 2008, P NATL ACAD SCI USA, V105, P1698, DOI 10.1073/pnas.0711767105; Sigge A, 2008, J CLIN MICROBIOL, V46, P807, DOI 10.1128/JCM.01963-07; Toso C, 2008, DIABETOLOGIA, V51, P1937, DOI 10.1007/s00125-008-1063-3; van der Mee-Marquet N, 2008, J CLIN MICROBIOL, V46, P2906, DOI 10.1128/JCM.00421-08; Virtaneva K, 2005, P NATL ACAD SCI USA, V102, P9014, DOI 10.1073/pnas.0503671102; Wang SM, 2008, DIAGN MICR INFEC DIS, V61, P165, DOI 10.1016/j.diagmicrobio.2008.01.008; Yabunaka N, 2000, DIABETES CARE, V23, P256, DOI 10.2337/diacare.23.2.256	33	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7145	10.1371/journal.pone.0007145	http://dx.doi.org/10.1371/journal.pone.0007145			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774088	Green Published, Green Submitted, gold			2022-12-27	WOS:000270160900019
J	Rzadzinska, AK; Nevalainen, EM; Prosser, HM; Lappalainen, P; Steel, KP				Rzadzinska, Agnieszka K.; Nevalainen, Elisa M.; Prosser, Haydn M.; Lappalainen, Pekka; Steel, Karen P.			MyosinVIIa Interacts with Twinfilin-2 at the Tips of Mechanosensory Stereocilia in the Inner Ear	PLOS ONE			English	Article								In vertebrates hearing is dependent upon the microvilli-like mechanosensory stereocilia and their length gradation. The staircase-like organization of the stereocilia bundle is dynamically maintained by variable actin turnover rates. Two unconventional myosins were previously implicated in stereocilia length regulation but the mechanisms of their action remain unknown. MyosinXVa is expressed in stereocilia tips at levels proportional to stereocilia length and its absence produces staircase-like bundles of very short stereocilia. MyosinVIIa localizes to the tips of the shorter stereocilia within bundles, and when absent, the stereocilia are abnormally long. We show here that myosinVIIa interacts with twinfilin-2, an actin binding protein, which inhibits actin polymerization at the barbed end of the filament, and that twinfilin localization in stereocilia overlaps with myosinVIIa. Exogenous expression of myosinVIIa in fibroblasts results in a reduced number of filopodia and promotes accumulation of twinfilin-2 at the filopodia tips. We hypothesize that the newly described interaction between myosinVIIa and twinfilin-2 is responsible for the establishment and maintenance of slower rates of actin turnover in shorter stereocilia, and that interplay between complexes of myosinVIIa/twinfilin-2 and myosinXVa/whirlin is responsible for stereocilia length gradation within the bundle staircase.			Rzadzinska, AK (corresponding author), Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England.	akr@sanger.ac.uk		Lappalainen, Pekka/0000-0001-6227-0354	MRC [MC_qA137918, G0300212] Funding Source: UKRI; Medical Research Council [MC_qA137918] Funding Source: researchfish; Medical Research Council [G0300212] Funding Source: Medline; Wellcome Trust [79643] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Belyantseva IA, 2005, NAT CELL BIOL, V7, P148, DOI 10.1038/ncb1219; Belyantseva IA, 2003, P NATL ACAD SCI USA, V100, P13958, DOI 10.1073/pnas.2334417100; Delprat B, 2005, HUM MOL GENET, V14, P401, DOI 10.1093/hmg/ddi036; Falck S, 2004, EMBO J, V23, P3010, DOI 10.1038/sj.emboj.7600310; Goode BL, 1998, J CELL BIOL, V142, P723, DOI 10.1083/jcb.142.3.723; Hasson T, 1997, CELL MOTIL CYTOSKEL, V37, P127, DOI 10.1002/(SICI)1097-0169(1997)37:2<127::AID-CM5>3.0.CO;2-5; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Helfer E, 2006, EMBO J, V25, P1184, DOI 10.1038/sj.emboj.7601019; Holme RH, 2002, J COMP NEUROL, V450, P94, DOI 10.1002/cne.10301; Hudspeth AJ, 1997, NEURON, V19, P947, DOI 10.1016/S0896-6273(00)80385-2; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; KALTENBACH JA, 1994, J COMP NEUROL, V350, P187, DOI 10.1002/cne.903500204; Karolyi IJ, 2003, HUM MOL GENET, V12, P2797, DOI 10.1093/hmg/ddg308; Kikkawa Y, 2005, HUM MOL GENET, V14, P391, DOI 10.1093/hmg/ddi035; Mburu P, 2003, NAT GENET, V34, P421, DOI 10.1038/ng1208; Mogensen MM, 2007, CELL MOTIL CYTOSKEL, V64, P496, DOI 10.1002/cm.20199; Nevalainen EM, 2009, BIOCHEM J, V417, P593, DOI 10.1042/BJ20080608; Ojala PJ, 2002, MOL BIOL CELL, V13, P3811, DOI 10.1091/mbc.E02-03-0157; Paavilainen VO, 2007, P NATL ACAD SCI USA, V104, P3113, DOI 10.1073/pnas.0608725104; Paavilainen VO, 2004, TRENDS CELL BIOL, V14, P386, DOI 10.1016/j.tcb.2004.05.002; Paavilainen VO, 2002, J BIOL CHEM, V277, P43089, DOI 10.1074/jbc.M208225200; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Prosser HM, 2008, MOL CELL BIOL, V28, P1702, DOI 10.1128/MCB.01282-07; Rzadzinska AK, 2004, J CELL BIOL, V164, P887, DOI 10.1083/jcb.200310055; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; TILNEY LG, 1988, J CELL BIOL, V106, P355, DOI 10.1083/jcb.106.2.355; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Vartiainen MK, 2003, J BIOL CHEM, V278, P34347, DOI 10.1074/jbc.M303642200; Wahlstrom G, 2001, J CELL BIOL, V155, P787, DOI 10.1083/jcb.200108022	29	45	48	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2009	4	9							e7097	10.1371/journal.pone.0007097	http://dx.doi.org/10.1371/journal.pone.0007097			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498RP	19774077	Green Published, gold, Green Submitted			2022-12-27	WOS:000270160900006
J	Cooke, GS; Little, KE; Bland, RM; Thulare, H; Newell, ML				Cooke, Graham S.; Little, Kirsty E.; Bland, Ruth M.; Thulare, Hilary; Newell, Marie-Louise			Need for Timely Paediatric HIV Treatment within Primary Health Care in Rural South Africa	PLOS ONE			English	Article								Background: In areas where adult HIV prevalence has reached hyperendemic levels, many infants remain at risk of acquiring HIV infection. Timely access to care and treatment for HIV-infected infants and young children remains an important challenge. We explore the extent to which public sector roll-out has met the estimated need for paediatric treatment in a rural South African setting. Methods: Local facility and population-based data were used to compare the number of HIV infected children accessing HAART before 2008, with estimates of those in need of treatment from a deterministic modeling approach. The impact of programmatic improvements on estimated numbers of children in need of treatment was assessed in sensitivity analyses. Findings: In the primary health care programme of HIV treatment 346 children <16 years of age initiated HAART by 2008; 245(70.8%) were aged 10 years or younger, and only 2(<1%) under one year of age. Deterministic modeling predicted 2,561 HIV infected children aged 10 or younger to be alive within the area, of whom at least 521(20.3%) would have required immediate treatment. Were extended PMTCT uptake to reach 100% coverage, the annual number of infected infants could be reduced by 49.2%. Conclusion: Despite progress in delivering decentralized HIV services to a rural sub-district in South Africa, substantial unmet need for treatment remains. In a local setting, very few children were initiated on treatment under 1 year of age and steps have now been taken to successfully improve early diagnosis and referral of infected infants.			Cooke, GS (corresponding author), Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, Kwa Zulu, South Africa.	gcooke@africacentre.ac.za	Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Cooke, Graham/0000-0001-6475-5056; Bland, Ruth/0000-0003-1675-9268	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNIGHAUSEN T, 2007, PLOS MED, pE298, DOI DOI 10.1371/JOURNAL.PMED.0040298; Bland RM, 2007, B WORLD HEALTH ORGAN, V85, P289, DOI 10.2471/BLT.06.032441; Coovadia HM, 2007, LANCET, V369, P1107, DOI 10.1016/S0140-6736(07)60283-9; *DEP HLTH HUM SERV, 2008, PAN ANT GUID AD AD G, P1; *DEP HLTH SA, 2008, PROGR REP DECL COMM; *DEP HLTH SA, 2004, HLTH STAT B 2003 4; Department of Health SA, 2004, NAT ANT TREATM GUID; Little K, 2007, INT J EPIDEMIOL, V36, P679, DOI 10.1093/ije/dym019; MCKERROW NH, 2008, STEP BY STEP GUIDE M; Meyers T, 2007, J INFECT DIS, V196, pS474, DOI 10.1086/521116; Moultrie TA, 2008, STUD FAMILY PLANN, V39, P39, DOI 10.1111/j.1728-4465.2008.00149.x; National Department of Health (South Africa), 2008, NAT HIV SYPH PREV SU; NATIONS U, 2008, MILLENIUM DEV GOALS; ROCHAT T, 2006, 16 INT AIDS C TOR CA; Rollins N, 2007, AIDS, V21, P1341, DOI 10.1097/QAD.0b013e32814db7d4; Sherman GG, 2005, PEDIATR INFECT DIS J, V24, P993, DOI 10.1097/01.inf.0000187036.73539.8d; Tanser F, 2008, INT J EPIDEMIOL, V37, P956, DOI 10.1093/ije/dym211; Tanser F, 2006, SOC SCI MED, V63, P691, DOI 10.1016/j.socscimed.2006.01.015; UNAIDS, 2008, REP GLOB AIDS EP; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organization, 2008, ANT THER INF CHILDR	22	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7101	10.1371/journal.pone.0007101	http://dx.doi.org/10.1371/journal.pone.0007101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771168	Green Submitted, Green Accepted, Green Published, gold			2022-12-27	WOS:000270154400004
J	van der Wath, RC; Wilson, A; Laurenti, E; Trumpp, A; Lio, P				van der Wath, Richard C.; Wilson, Anne; Laurenti, Elisa; Trumpp, Andreas; Lio, Pietro			Estimating Dormant and Active Hematopoietic Stem Cell Kinetics through Extensive Modeling of Bromodeoxyuridine Label-Retaining Cell Dynamics	PLOS ONE			English	Article							TURNOVER; 5-BROMO-2'-DEOXYURIDINE; PROLIFERATION; SEGREGATION; STRANDS; CANCER; CYCLE; BRDU; DNA	Bone marrow hematopoietic stem cells (HSCs) are responsible for both lifelong daily maintenance of all blood cells and for repair after cell loss. Until recently the cellular mechanisms by which HSCs accomplish these two very different tasks remained an open question. Biological evidence has now been found for the existence of two related mouse HSC populations. First, a dormant HSC (d-HSC) population which harbors the highest self-renewal potential of all blood cells but is only induced into active self-renewal in response to hematopoietic stress. And second, an active HSC (a-HSC) subset that by and large produces the progenitors and mature cells required for maintenance of day-to-day hematopoiesis. Here we present computational analyses further supporting the d-HSC concept through extensive modeling of experimental DNA label-retaining cell (LRC) data. Our conclusion that the presence of a slowly dividing subpopulation of HSCs is the most likely explanation (amongst the various possible causes including stochastic cellular variation) of the observed long term Bromodeoxyuridine (BrdU) retention, is confirmed by the deterministic and stochastic models presented here. Moreover, modeling both HSC BrdU uptake and dilution in three stages and careful treatment of the BrdU detection sensitivity permitted improved estimates of HSC turnover rates. This analysis predicts that d-HSCs cycle about once every 149-193 days and a-HSCs about once every 28-36 days. We further predict that, using LRC assays, a 75%-92.5% purification of d-HSCs can be achieved after 59-130 days of chase. Interestingly, the d-HSC proportion is now estimated to be around 30-45% of total HSCs - more than twice that of our previous estimate.			van der Wath, RC (corresponding author), Univ Cambridge, Comp Lab, Pembroke St, Cambridge CB2 3QG, England.	rvanderwath@gmail.com	P. Lió, Pietro Lio/AAV-3358-2021; Trumpp, Andreas/Z-2141-2019	P. Lió, Pietro Lio/0000-0002-0540-5053; Trumpp, Andreas/0000-0002-6212-3466; Laurenti, Elisa/0000-0002-9917-9092				Allen L.J.S., 2010, INTRO STOCHASTIC PRO; Bonhoeffer S, 2000, J IMMUNOL, V164, P5049, DOI 10.4049/jimmunol.164.10.5049; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; De Boer RJ, 2003, P ROY SOC B-BIOL SCI, V270, P849, DOI 10.1098/rspb.2002.2316; ESSERS MAG, 2009, NATURE; Foudi A, 2009, NAT BIOTECHNOL, V27, P84, DOI 10.1038/nbt.1517; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Goss PJE, 1998, P NATL ACAD SCI USA, V95, P6750, DOI 10.1073/pnas.95.12.6750; Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115; Lansdorp PM, 2007, CELL, V129, P1244, DOI 10.1016/j.cell.2007.06.017; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; POTTEN CS, 1978, CELL, V15, P899, DOI 10.1016/0092-8674(78)90274-X; Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425; STOCKDALE F, 1964, SCIENCE, V146, P533, DOI 10.1126/science.146.3643.533; VANDERWATCH RC, 2008, LECT NOTES COMPUTER, P387; VanKampen NG, 2007, NORTH-HOLL PERS LIBR, P1; Venezia TA, 2004, PLOS BIOL, V2, P1640, DOI 10.1371/journal.pbio.0020301; Viale A, 2009, EMBO MOL MED, V1, P88, DOI 10.1002/emmm.200900019; Waghmare SK, 2008, EMBO J, V27, P1309, DOI 10.1038/emboj.2008.72; Wilkinso D.J., 2006, STOCHASTIC MODELLING; Wilson A, 2007, ANN NY ACAD SCI, V1106, P64, DOI 10.1196/annals.1392.021; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; YEN A, 1990, CANCER RES, V50, P1411	26	59	61	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e6972	10.1371/journal.pone.0006972	http://dx.doi.org/10.1371/journal.pone.0006972			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771180	Green Submitted, Green Published, gold			2022-12-27	WOS:000270154400002
J	Dridi, B; Henry, M; El Khechine, A; Raoult, D; Drancourt, M				Dridi, Bedis; Henry, Mireille; El Khechine, Amel; Raoult, Didier; Drancourt, Michel			High Prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae Detected in the Human Gut Using an Improved DNA Detection Protocol	PLOS ONE			English	Article								Background: The low and variable prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae DNA in human stool contrasts with the paramount role of these methanogenic Archaea in digestion processes. We hypothesized that this contrast is a consequence of the inefficiencies of current protocols for archaeon DNA extraction. We developed a new protocol for the extraction and PCR-based detection of M. smithii and M. stadtmanae DNA in human stool. Methodology/Principal Findings: Stool specimens collected from 700 individuals were filtered, mechanically lysed twice, and incubated overnight with proteinase K prior to DNA extraction using a commercial DNA extraction kit. Total DNA was used as a template for quantitative real-time PCR targeting M. smithii and M. stadtmanae 16S rRNA and rpoB genes. Amplification of 16S rRNA and rpoB yielded positive detection of M. smithii in 95.7% and M. stadtmanae in 29.4% of specimens. Sequencing of 16S rRNA gene PCR products from 30 randomly selected specimens ( 15 for M. smithii and 15 for M. stadtmanae) yielded a sequence similarity of 99-100% using the reference M. smithii ATCC 35061 and M. stadtmanae DSM 3091 sequences. Conclusions/Significance: In contrast to previous reports, these data indicate a high prevalence of the methanogens M. smithii and M. stadtmanae in the human gut, with the former being an almost ubiquitous inhabitant of the intestinal microbiome.			Dridi, B (corresponding author), Univ Aix Marseille 2, CNRS, UMR 6236, IRD 3R198,IFR 48,Fac Med,Unite Rech Malad Infect, Marseille, France.	Michel.Drancourt@univmed.fr	RAOULT, Didier/A-8434-2008	RAOULT, Didier/0000-0002-0633-5974				Adekambi T, 2008, INT J SYST EVOL MICR, V58, P1807, DOI 10.1099/ijs.0.65440-0; BELAY N, 1988, APPL ENVIRON MICROB, V54, P600, DOI 10.1128/AEM.54.2.600-603.1988; BELAY N, 1990, J CLIN MICROBIOL, V28, P1666, DOI 10.1128/JCM.28.7.1666-1668.1990; Carcopino X, 2006, J MED VIROL, V78, P1131, DOI 10.1002/jmv.20673; Deppenmeier U, 2002, PROG NUCLEIC ACID RE, V71, P223, DOI 10.1016/S0079-6603(02)71045-3; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; El Khechine A, 2009, MICROBIOL-SGM, V155, P2384, DOI 10.1099/mic.0.026484-0; Fricke WF, 2006, J BACTERIOL, V188, P642, DOI 10.1128/JB.188.2.642-658.2006; KLENK HP, 1994, J MOL EVOL, V38, P420, DOI 10.1007/BF00163158; Kubota K, 2008, J MICROBIOL METH, V72, P54, DOI 10.1016/j.mimet.2007.10.006; Levitt MD, 2006, CLIN GASTROENTEROL H, V4, P123, DOI 10.1016/j.cgh.2005.11.006; MACY JM, 1972, AM J CLIN NUTR, V25, P1318; MCNEIL NI, 1984, AM J CLIN NUTR, V39, P338, DOI 10.1093/ajcn/39.2.338; Mihajlovski A, 2008, RES MICROBIOL, V159, P516, DOI 10.1016/j.resmic.2008.06.007; MILLER TL, 1984, APPL ENVIRON MICROB, V48, P449, DOI 10.1128/AEM.48.2.449-450.1984; MILLER TL, 1982, ARCH MICROBIOL, V131, P14, DOI 10.1007/BF00451492; MILLER TL, 1982, APPL ENVIRON MICROB, V43, P227, DOI 10.1128/AEM.43.1.227-232.1982; MISAWA H, 1986, APPL ENVIRON MICROB, V51, P429, DOI 10.1128/AEM.51.2.429-431.1986; Nicholson MJ, 2007, MICROB ECOL, V54, P141, DOI 10.1007/s00248-006-9182-1; OVCHINNIKOV YA, 1982, NUCLEIC ACIDS RES, V10, P4035, DOI 10.1093/nar/10.13.4035; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; Saengkerdsub S, 2007, LETT APPL MICROBIOL, V45, P629, DOI 10.1111/j.1472-765X.2007.02243.x; Samuel BS, 2007, P NATL ACAD SCI USA, V104, P10643, DOI 10.1073/pnas.0704189104; Samuel BS, 2006, P NATL ACAD SCI USA, V103, P10011, DOI 10.1073/pnas.0602187103; Scanlan PD, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-79; Stewart JA, 2006, LETT APPL MICROBIOL, V43, P58, DOI 10.1111/j.1472-765X.2006.01906.x; Yu ZT, 2004, BIOTECHNIQUES, V36, P808, DOI 10.2144/04365ST04	28	235	246	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2009	4	9							e7063	10.1371/journal.pone.0007063	http://dx.doi.org/10.1371/journal.pone.0007063			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KG	19759898	Green Published, Green Submitted, gold			2022-12-27	WOS:000269970200003
J	Boyd, WA; Smith, MV; Kissling, GE; Rice, JR; Snyder, DW; Portier, CJ; Freedman, JH				Boyd, Windy A.; Smith, Marjolein V.; Kissling, Grace E.; Rice, Julie R.; Snyder, Daniel W.; Portier, Christopher J.; Freedman, Jonathan H.			Application of a Mathematical Model to Describe the Effects of Chlorpyrifos on Caenorhabditis elegans Development	PLOS ONE			English	Article							C-ELEGANS; NEMATODE; TOXICOLOGY; NEURODEVELOPMENT; SYSTEM; GROWTH; ASSAY	Background: The nematode Caenorhabditis elegans is being assessed as an alternative model organism as part of an interagency effort to develop better means to test potentially toxic substances. As part of this effort, assays that use the COPAS Biosort flow sorting technology to record optical measurements (time of flight (TOF) and extinction (EXT)) of individual nematodes under various chemical exposure conditions are being developed. A mathematical model has been created that uses Biosort data to quantitatively and qualitatively describe C. elegans growth, and link changes in growth rates to biological events. Chlorpyrifos, an organophosphate pesticide known to cause developmental delays and malformations in mammals, was used as a model toxicant to test the applicability of the growth model for in vivo toxicological testing. Methodology/Principal Findings: L1 larval nematodes were exposed to a range of sub-lethal chlorpyrifos concentrations (0-75 mu M) and measured every 12 h. In the absence of toxicant, C. elegans matured from L1s to gravid adults by 60 h. A mathematical model was used to estimate nematode size distributions at various times. Mathematical modeling of the distributions allowed the number of measured nematodes and log(EXT) and log(TOF) growth rates to be estimated. The model revealed three distinct growth phases. The points at which estimated growth rates changed (change points) were constant across the ten chlorpyrifos concentrations. Concentration response curves with respect to several model-estimated quantities (numbers of measured nematodes, mean log(TOF) and log(EXT), growth rates, and time to reach change points) showed a significant decrease in C. elegans growth with increasing chlorpyrifos concentration. Conclusions: Effects of chlorpyrifos on C. elegans growth and development were mathematically modeled. Statistical tests confirmed a significant concentration effect on several model endpoints. This confirmed that chlorpyrifos affects C. elegans development in a concentration dependent manner. The most noticeable effect on growth occurred during early larval stages: L2 and L3. This study supports the utility of the C. elegans growth assay and mathematical modeling in determining the effects of potentially toxic substances in an alternative model organism using high-throughput technologies.			Boyd, WA (corresponding author), NIEHS, Natl Toxicol Program, Biomol Screening Branch, POB 12233, Res Triangle Pk, NC 27709 USA.	freedma1@niehs.nih.gov	Portier, Christopher J/A-3160-2010	Portier, Christopher J/0000-0002-0954-0279; Boyd, Windy/0000-0003-3803-3716	Intramural NIH HHS [Z01 ES102046] Funding Source: Medline; PHS HHS [GS-00F-0003L] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES045004, ZIAES102046, Z01ES102046] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 1997, TOX PROF CHLORP, P217; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson GL, 2001, ENVIRON TOXICOL CHEM, V20, P833, DOI [10.1897/1551-5028(2001)020&lt;0833:AOSEFT&gt;2.0.CO;2, 10.1002/etc.5620200419]; Boyd W.A., 2009, NEUROTOXICOL TERATOL; Boyd WA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001259; BRENNER S, 1974, GENETICS, V77, P71; BYERLY L, 1976, DEV BIOL, V51, P23, DOI 10.1016/0012-1606(76)90119-6; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Collins FS, 2008, SCIENCE, V319, P906, DOI 10.1126/science.1154619; Connors SL, 2008, PEDIATR NEUROL, V38, P163, DOI 10.1016/j.pediatrneurol.2007.10.009; Couillault C, 2004, NAT IMMUNOL, V5, P488, DOI 10.1038/ni1060; Dix DJ, 2007, TOXICOL SCI, V95, P5, DOI 10.1093/toxsci/kfl103; Dong J, 2008, J MOL BIOL, V376, P621, DOI 10.1016/j.jmb.2007.11.094; Eaton DL, 2008, CRIT REV TOXICOL, V38, P1, DOI 10.1080/10408440802272158 ; Furlong EEM, 2001, NAT BIOTECHNOL, V19, P153, DOI 10.1038/84422; Gill MS, 2003, FREE RADICAL BIO MED, V35, P558, DOI 10.1016/S0891-5849(03)00328-9; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; Hollander M, 1973, NONPARAMETRIC STAT M, Vxviii; Jameson RR, 2006, ENVIRON HEALTH PERSP, V114, P667, DOI 10.1289/ehp.8750; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, pR18; Knight CG, 2002, EVOL DEV, V4, P16, DOI 10.1046/j.1525-142x.2002.01058.x; Leung MCK, 2008, TOXICOL SCI, V106, P5, DOI 10.1093/toxsci/kfn121; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; NGUYEN M, 1995, GENETICS, V140, P527; Peterson RT, 2008, NEUROTOXICOLOGY, V29, P546, DOI 10.1016/j.neuro.2008.04.006; Pulak Rock, 2006, V351, P275; Rand JB., 2007, ACETYLCHOLINE, V1, DOI [10.1895/wormbook.1.131.1, DOI 10.1895/WORMBOOK.1.131.1]; Rea SL, 2005, NAT GENET, V37, P894, DOI 10.1038/ng1608; Ruaud AF, 2006, DEVELOPMENT, V133, P2211, DOI 10.1242/dev.02392; Sherman JD, 1996, ARCH ENVIRON HEALTH, V51, P5, DOI 10.1080/00039896.1996.9935986; Slotkin TA, 2004, TOXICOL APPL PHARM, V198, P132, DOI 10.1016/j.taap.2003.06.001; SMITH MV, 2009, PLOS ONE, pR30; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; *US NAT RES COUNC, 2000, APP C SIGN PATHW SCI, P296; USEPA, 2000, CHLORPYRIFOS REVISED; WILLIAMS PL, 1988, TOXICOL IND HEALTH, V4, P469, DOI 10.1177/074823378800400406	37	38	39	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7024	10.1371/journal.pone.0007024	http://dx.doi.org/10.1371/journal.pone.0007024			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753116	Green Submitted, Green Published, gold			2022-12-27	WOS:000269796500012
J	Chen, HG; Han, WJ; Deng, M; Qin, JC; Yuan, D; Liu, JP; Xiao, L; Gong, LL; Liang, SP; Zhang, J; Liu, Y; Li, DWC				Chen, He-Ge; Han, Wen-Jun; Deng, Mi; Qin, Jichao; Yuan, Dan; Liu, Jin-Ping; Xiao, Ling; Gong, Lili; Liang, Songping; Zhang, Jian; Liu, Yun; Li, David Wan-Cheng			Transcriptional Regulation of PP2A-A alpha Is Mediated by Multiple Factors Including AP-2 alpha, CREB, ETS-1, and SP-1	PLOS ONE			English	Article								Protein phosphatases-2A (PP-2A) is a major serine/threonine phosphatase and accounts for more than 50% serine/threonine phosphatase activity in eukaryotes. The holoenzyme of PP-2A consists of the scaffold A subunit, the catalytic C subunit and the regulatory B subunit. The scaffold subunits, PP2A-A alpha/beta, provide a platform for both C and B subunits to bind, thus playing a crucial role in providing specific PP-2A activity. Mutation of the two genes encoding PP2A-A alpha/beta leads to carcinogenesis and likely other human diseases. Regulation of these genes by various factors, both extracellular and intracellular, remains largely unknown. In the present study, we have conducted functional dissection of the promoter of the mouse PP2A-A alpha gene. Our results demonstrate that the proximal promoter of the mouse PP2A-A alpha gene contains numerous cis-elements for the binding of CREB, ETS-1, AP-2 alpha, SP-1 besides the putative TFIIB binding site (BRE) and the downstream promoter element (DPE). Gel mobility shifting assays revealed that CREB, ETS-1, AP-2 alpha, and SP-1 all bind to PP2A-A alpha gene promoter. In vitro mutagenesis and reporter gene activity assays reveal that while SP-1 displays negative regulation, CREB, ETS-1 and AP-2A alpha all positively regulate the promoter of the PP2A-A alpha gene. ChIP assays further confirm that all the above transcription factors participate the regulation of PP2A-A alpha gene promoter. Together, our results reveal that multiple transcription factors regulate the PP2A-A alpha gene.			Chen, HG (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	dwli1688@hotmail.com	chen, hege/GYV-5810-2022; Li, David/AAN-9205-2021; Deng, Mi/K-8699-2012; Gong, Lili/F-8452-2014	Deng, Mi/0000-0003-4291-0144; Gong, Lili/0000-0002-6533-5333; Qin, Jichao/0000-0002-2961-7624	NATIONAL EYE INSTITUTE [R01EY015765, R01EY018380] Funding Source: NIH RePORTER; NEI NIH HHS [1R01EY015765, 1R01EY018380, R01 EY018380, R01 EY015765] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1998, COLD SPRING HARB SYM, V63, P75, DOI 10.1101/sqb.1998.63.75; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Chen Y, 2007, NAT STRUCT MOL BIOL, V14, P527, DOI 10.1038/nsmb1254; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Cowley DO, 2000, GENE DEV, V14, P366; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; FU H, 2009, SCI CHINA SER C, V52, P1; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kantorow M, 1998, INVEST OPHTH VIS SCI, V39, P2344; Kitange G, 1999, MODERN PATHOL, V12, P618; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010; LI WC, 1992, EUR J BIOCHEM, V205, P491, DOI 10.1111/j.1432-1033.1992.tb16805.x; Liu WB, 2008, MOL VIS, V14, P762; Ma HL, 2009, GENE REGUL SYST BIO, V3, P115; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; PALCZEWSKI K, 1991, EXP EYE RES, V53, P101, DOI 10.1016/0014-4835(91)90151-4; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Qin JC, 2008, CANCER RES, V68, P4150, DOI 10.1158/0008-5472.CAN-08-0839; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Suzuki K, 2003, INT J ONCOL, V23, P1263; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; YAN Q, 2009, ENCY NEUROSCIENCE, P3325; Yan Q, 2007, J BIOL CHEM, V282, P13954, DOI 10.1074/jbc.M611476200; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200; 郑春兵, 2009, [自然科学进展, Progress in Natural Science], V19, P272	56	24	26	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2009	4	9							e7019	10.1371/journal.pone.0007019	http://dx.doi.org/10.1371/journal.pone.0007019			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FN	19750005	Green Published, gold, Green Submitted			2022-12-27	WOS:000269796300016
J	Diaz-Ruiz, O; Zapata, A; Shan, LF; Zhang, YJ; Tomac, AC; Malik, N; de la Cruz, F; Backman, CM				Diaz-Ruiz, Oscar; Zapata, Agustin; Shan, Lufei; Zhang, YaJun; Tomac, Andreas C.; Malik, Nasir; de la Cruz, Fidel; Backman, Cristina M.			Selective Deletion of PTEN in Dopamine Neurons Leads to Trophic Effects and Adaptation of Striatal Medium Spiny Projecting Neurons	PLOS ONE			English	Article								The widespread distribution of the tumor suppressor PTEN in the nervous system suggests a role in a broad range of brain functions. PTEN negatively regulates the signaling pathways initiated by protein kinase B (Akt) thereby regulating signals for growth, proliferation and cell survival. Pten deletion in the mouse brain has revealed its role in controlling cell size and number. In this study, we used Cre-loxP technology to specifically inactivate Pten in dopamine (DA) neurons (Pten KO mice). The resulting mutant mice showed neuronal hypertrophy, and an increased number of dopaminergic neurons and fibers in the ventral mesencephalon. Interestingly, quantitative microdialysis studies in Pten KO mice revealed no alterations in basal DA extracellular levels or evoked DA release in the dorsal striatum, despite a significant increase in total DA tissue levels. Striatal dopamine receptor D1 (DRD1) and prodynorphin (PDyn) mRNA levels were significantly elevated in KO animals, suggesting an enhancement in neuronal activity associated with the striatonigral projection pathway, while dopamine receptor D2 (DRD2) and preproenkephalin (PPE) mRNA levels remained unchanged. In addition, PTEN inactivation protected DA neurons and significantly enhanced DA-dependent behavioral functions in KO mice after a progressive 6OHDA lesion. These results provide further evidence about the role of PTEN in the brain and suggest that manipulation of the PTEN/Akt signaling pathway during development may alter the basal state of dopaminergic neurotransmission and could provide a therapeutic strategy for the treatment of Parkinson's disease, and other neurodegenerative disorders.			Diaz-Ruiz, O (corresponding author), NIDA, Cellular Neurobiol Branch, Natl Inst Hlth, Baltimore, MD USA.	cbackman@mail.nih.gov	backman, cristina/C-1276-2013; Diaz-Ruiz, Oscar/F-3162-2010		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000560, Z01DA000515, ZIADA000515] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman CM, 2006, GENESIS, V44, P383, DOI 10.1002/dvg.20228; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BURKE RE, 1990, J NEUROSCI METH, V35, P63, DOI 10.1016/0165-0270(90)90095-W; BURKE RE, 1992, NEUROSCIENCE, V50, P559, DOI 10.1016/0306-4522(92)90447-A; Calhoun ME, 2000, J CHEM NEUROANAT, V20, P61, DOI 10.1016/S0891-0618(00)00074-0; Chang N, 2007, TRENDS NEUROSCI, V30, P581, DOI 10.1016/j.tins.2007.08.006; Chefer VI, 2006, J NEUROSCI METH, V155, P187, DOI 10.1016/j.jneumeth.2005.12.018; Endersby R, 2008, ONCOGENE, V27, P5416, DOI 10.1038/onc.2008.239; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; HATTORI T, 1973, EXP NEUROL, V38, P70, DOI 10.1016/0014-4886(73)90008-3; He Y, 2000, BRAIN RES, V858, P163, DOI 10.1016/S0006-8993(99)02459-2; Jackson-Lewis V, 2000, J COMP NEUROL, V424, P476, DOI 10.1002/1096-9861(20000828)424:3<476::AID-CNE6>3.0.CO;2-0; Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349; Kalueff AV, 2006, BEHAV PROCESS, V72, P104, DOI 10.1016/j.beproc.2005.12.011; Krishnan V, 2008, BIOL PSYCHIAT, V64, P691, DOI 10.1016/j.biopsych.2008.06.003; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li L, 2003, J CELL BIOCHEM, V88, P24, DOI 10.1002/jcb.10312; Li Q, 2007, EXP NEUROL, V204, P840, DOI 10.1016/j.expneurol.2007.01.005; LINDEN R, 1994, NEUROSCIENCE, V58, P671, DOI 10.1016/0306-4522(94)90447-2; LUNDBERG C, 1994, BRAIN RES, V644, P205, DOI 10.1016/0006-8993(94)91681-0; Marti MJ, 1997, J NEUROSCI, V17, P2030; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Ning K, 2004, J NEUROSCI, V24, P4052, DOI 10.1523/JNEUROSCI.5449-03.2004; O'Neill MF, 1999, PSYCHOPHARMACOLOGY, V145, P237, DOI 10.1007/s002130051055; Ram, 2004, BIOPHOTONICS INT, V11, P46; Ries V, 2006, P NATL ACAD SCI USA, V103, P18757, DOI 10.1073/pnas.0606401103; Sano T, 1999, CANCER RES, V59, P1820; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SEIGER A, 1973, Z ANAT ENTWICKLUNGS, V140, P281, DOI 10.1007/BF00525058; SMITH AD, 1994, J NEUROSCI METH, V54, P75, DOI 10.1016/0165-0270(94)90161-9; Smits SM, 2006, J NEURAL TRANSM-SUPP, P57; SWERDLOW NR, 1991, J PHARMACOL EXP THER, V256, P530; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Van Diepen MT, 2008, DEV NEUROSCI-BASEL, V30, P59, DOI 10.1159/000109852; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yoshimura T, 2006, BIOCHEM BIOPH RES CO, V340, P62, DOI 10.1016/j.bbrc.2005.11.147; Zhu Y, 2006, APOPTOSIS, V11, P197, DOI 10.1007/s10495-006-3714-5	46	39	39	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e7027	10.1371/journal.pone.0007027	http://dx.doi.org/10.1371/journal.pone.0007027			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19750226	Green Published, Green Submitted, gold			2022-12-27	WOS:000269696600019
J	Gram, GJ; Karlsson, I; Agger, EM; Andersen, P; Fomsgaard, A				Gram, Gregers Jacob; Karlsson, Ingrid; Agger, Else Marie; Andersen, Peter; Fomsgaard, Anders			A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8(+) Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice	PLOS ONE			English	Article								Background: Specific cellular cytotoxic immune responses (CTL) are important in combating viral diseases and a highly desirable feature in the development of targeted HIV vaccines. Adjuvants are key components in vaccines and may assist the HIV immunogens in inducing the desired CTL responses. In search for appropriate adjuvants for CD8(+) T cells it is important to measure the necessary immunological features e. g. functional cell killing/lysis in addition to immunological markers that can be monitored by simple immunological laboratory methods. Methodology/Principal Findings: We tested the ability of a novel two component adjuvant, CAF01, consisting of the immune stimulating synthetic glycolipid TDB (Trehalose-Dibehenate) incorporated into cationic DDA (Dimethyldioctadecylammonium bromide) liposomes to induce CD8(+) T-cell restricted cellular immune responses towards subdominant minimal HLA-A0201-restricted CTL epitopes from HIV-1 proteins in HLA-A*0201 transgenic HHD mice. CAF01 has an acceptable safety profile and is used in preclinical development of vaccines against HIV-1, malaria and tuberculosis. Conclusions/Significance: We found that CAF01 induced cellular immune responses against HIV-1 minimal CTL epitopes in HLA-A*0201 transgenic mice to levels comparable with that of incomplete Freund's adjuvant.			Gram, GJ (corresponding author), Statens Serum Inst, Dept Virol, DK-2300 Copenhagen, Denmark.	afo@ssi.dk		Andersen, Peter/0000-0002-5869-2551; Fomsgaard, Anders/0000-0003-4304-0603				ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Christensen D, 2007, EXPERT REV VACCINES, V6, P785, DOI 10.1586/14760584.6.5.785; Corbet S, 2003, J GEN VIROL, V84, P2409, DOI 10.1099/vir.0.19152-0; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kloverpris H, 2009, AIDS, V23, P1329, DOI 10.1097/QAD.0b013e32832d9b00; Korsholm KS, 2007, IMMUNOLOGY, V121, P216, DOI 10.1111/j.1365-2567.2007.02560.x; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Malhotra U, 2003, J VIROL, V77, P2663, DOI 10.1128/JVI.77.4.2663-2674.2003; Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043; Thorn M, 2007, APMIS, V115, P757, DOI 10.1111/j.1600-0463.2007.apm_595.x; Vangala A, 2006, J PHARM PHARMACOL, V58, P787, DOI 10.1211/jpp.58.6.0009; Wilson CC, 2001, J VIROL, V75, P4195, DOI 10.1128/JVI.75.9.4195-4207.2001	15	37	37	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6950	10.1371/journal.pone.0006950	http://dx.doi.org/10.1371/journal.pone.0006950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759892	gold, Green Published, Green Submitted			2022-12-27	WOS:000269696600005
J	Guruharsha, KG; Ruiz-Gomez, M; Ranganath, HA; Siddharthan, R; VijayRaghavan, K				Guruharsha, K. G.; Ruiz-Gomez, Mar; Ranganath, H. A.; Siddharthan, Rahul; VijayRaghavan, K.			The Complex Spatio-Temporal Regulation of the Drosophila Myoblast Attractant Gene duf/kirre	PLOS ONE			English	Article							INDIRECT FLIGHT MUSCLES; ROLLING-PEBBLES; BINDING-SITE; MESODERM DEVELOPMENT; WIDE PREDICTION; TRANSCRIPTION; SEQUENCE; EXPRESSION; MEF2; DNA	A key early player in the regulation of myoblast fusion is the gene dumbfounded (duf, also known as kirre). Duf must be expressed, and function, in founder cells (FCs). A fixed number of FCs are chosen from a pool of equivalent myoblasts and serve to attract fusion-competent myoblasts (FCMs) to fuse with them to form a multinucleate muscle-fibre. The spatial and temporal regulation of duf expression and function are important and play a deciding role in choice of fibre number, location and perhaps size. We have used a combination of bioinformatics and functional enhancer deletion approaches to understand the regulation of duf. By transgenic enhancer-reporter deletion analysis of the duf regulatory region, we found that several distinct enhancer modules regulate duf expression in specific muscle founders of the embryo and the adult. In addition to existing bioinformatics tools, we used a new program for analysis of regulatory sequence, PhyloGibbs-MP, whose development was largely motivated by the requirements of this work. The results complement our deletion analysis by identifying transcription factors whose predicted binding regions match with our deletion constructs. Experimental evidence for the relevance of some of these TF binding sites comes from available ChIP-on-chip from the literature, and from our analysis of localization of myogenic transcription factors with duf enhancer reporter gene expression. Our results demonstrate the complex regulation in each founder cell of a gene that is expressed in all founder cells. They provide evidence for transcriptional control-both activation and repression-as an important player in the regulation of myoblast fusion. The set of enhancer constructs generated will be valuable in identifying novel trans-acting factor-binding sites and chromatin regulation during myoblast fusion in Drosophila. Our results and the bioinformatics tools developed provide a basis for the study of the transcriptional regulation of other complex genes.	[Guruharsha, K. G.; VijayRaghavan, K.] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore, Karnataka, India; [Guruharsha, K. G.; Ranganath, H. A.] Univ Mysore, Dept Studies Zool, Mysore, Karnataka, India; [Ruiz-Gomez, Mar] CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Ruiz-Gomez, Mar] UAM, Madrid, Spain; [Siddharthan, Rahul] Inst Math Sci, Chennai, Tamil Nadu, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Mysore; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Institute of Mathematical Sciences (IMSc) India	Guruharsha, KG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	vijay@ncbs.res.in	Kuthethur, Guruharsha/Z-2605-2019; Ruiz-Gómez, Mar/K-9266-2014	Kuthethur, Guruharsha/0000-0001-7292-4868; Ruiz-Gómez, Mar/0000-0002-9024-1400	Wellcome Trust [NLO- 056727/Z/99/B] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anant S, 1998, DEVELOPMENT, V125, P1361; ANDRES V, 1995, J BIOL CHEM, V270, P23246, DOI 10.1074/jbc.270.40.23246; Bagni C, 2002, MECH DEVELOP, V117, P265, DOI 10.1016/S0925-4773(02)00176-4; Bergman CM, 2005, BIOINFORMATICS, V21, P1747, DOI 10.1093/bioinformatics/bti173; Berman BP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r61; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Blanchette M, 2002, J COMPUT BIOL, V9, P211, DOI 10.1089/10665270252935421; Blanchette M, 2002, GENOME RES, V12, P739, DOI 10.1101/gr.6902; Bour BA, 2000, GENE DEV, V14, P1498; Carmena A, 1998, GENE DEV, V12, P3910, DOI 10.1101/gad.12.24.3910; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Clark AG, 2007, NATURE, V450, P203, DOI 10.1038/nature06341; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; CURRIE DA, 1991, DEVELOPMENT, V113, P91; Dai H, 2000, DEV BIOL, V227, P373, DOI 10.1006/dbio.2000.9901; Dutta D, 2005, PLOS BIOL, V3, P1789, DOI 10.1371/journal.pbio.0030337; Dutta D, 2004, DEVELOPMENT, V131, P3761, DOI 10.1242/dev.01249; Elgar SJ, 2008, P NATL ACAD SCI USA, V105, P918, DOI 10.1073/pnas.0711255105; Estrada B, 2006, PLOS GENET, V2, P160, DOI 10.1371/journal.pgen.0020016; FERNANDES J, 1991, DEVELOPMENT, V113, P67; Frith MC, 2003, NUCLEIC ACIDS RES, V31, P3666, DOI 10.1093/nar/gkg540; Furlong EE, 2004, CURR OPIN GENET DEV, V14, P343, DOI 10.1016/j.gde.2004.06.011; Gajewski K, 1998, DEV GENES EVOL, V208, P382, DOI 10.1007/s004270050194; Georgias C, 1997, MECH DEVELOP, V69, P115, DOI 10.1016/S0925-4773(97)00169-X; Ghazi A, 2000, DEVELOPMENT, V127, P5309; Gogos JA, 1996, P NATL ACAD SCI USA, V93, P2159, DOI 10.1073/pnas.93.5.2159; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Halfon MS, 2002, GENOME RES, V12, P1019, DOI 10.1101/gr.228902; HARTENSTEIN V, 1993, ATLAS DROSOPHILA DEV, V5, P57; Jakobsen JS, 2007, GENE DEV, V21, P2448, DOI 10.1101/gad.437607; Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Klapper R, 2002, MECH DEVELOP, V110, P85, DOI 10.1016/S0925-4773(01)00567-6; LAWRENCE PA, 1982, CELL, V29, P493, DOI 10.1016/0092-8674(82)90166-0; Lee CY, 2008, MOL CELL BIOL, V28, P3290, DOI 10.1128/MCB.02224-07; Lenhard Boris, 2003, J Biol, V2, P13, DOI 10.1186/1475-4924-2-13; Ludwig MZ, 2005, PLOS BIOL, V3, P588, DOI 10.1371/journal.pbio.0030093; MAGGERT K, 1995, DEVELOPMENT, V121, P2107; Maqbool T, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000122; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Menon SD, 2005, J CELL BIOL, V169, P909, DOI 10.1083/jcb.200501126; Menon SD, 2001, DEV CELL, V1, P691, DOI 10.1016/S1534-5807(01)00075-2; Nose A, 1998, DEVELOPMENT, V125, P215; Noyes MB, 2008, NUCLEIC ACIDS RES, V36, P2547, DOI 10.1093/nar/gkn048; Noyes MB, 2008, CELL, V133, P1277, DOI 10.1016/j.cell.2008.05.023; Philippakis AA, 2006, PLOS COMPUT BIOL, V2, P439, DOI 10.1371/journal.pcbi.0020053; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rau A, 2001, DEVELOPMENT, V128, P5061; Reddy KL, 2000, DEV BIOL, V224, P401, DOI 10.1006/dbio.2000.9797; Riechmann V, 1998, DEVELOPMENT, V125, P713; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; Saller E, 2001, EMBO REP, V2, P298, DOI 10.1093/embo-reports/kve068; San Martin B, 2001, DEVELOPMENT, V128, P3331; Sandmann T, 2007, GENE DEV, V21, P436, DOI 10.1101/gad.1509007; Sandmann T, 2006, DEV CELL, V10, P797, DOI 10.1016/j.devcel.2006.04.009; Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817; Segal E, 2008, NATURE, V451, P535, DOI 10.1038/nature06496; Sharma Y, 2002, GENESIS, V34, P115, DOI 10.1002/gene.10127; SIDDHARTHAN R, 2008, PLOS COMP B IN PRESS; Siddharthan R, 2005, PLOS COMPUT BIOL, V1, P534, DOI 10.1371/journal.pcbi.0010067; Sinha S, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-129; Sinha S, 2003, BIOINFORMATICS, V19, pi292, DOI 10.1093/bioinformatics/btg1040; Soler C, 2004, DEVELOPMENT, V131, P6041, DOI 10.1242/dev.01527; Srinivas BP, 2007, NAT GENET, V39, P781, DOI 10.1038/ng2055; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; Sudarsan V, 2001, DEV CELL, V1, P829, DOI 10.1016/S1534-5807(01)00089-2; Taylor MV, 2000, CURR BIOL, V10, pR646, DOI 10.1016/S0960-9822(00)00664-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zaffran S, 2001, GENE DEV, V15, P2900; Zeitlinger J, 2007, GENE DEV, V21, P385, DOI 10.1101/gad.1509607	75	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6960	10.1371/journal.pone.0006960	http://dx.doi.org/10.1371/journal.pone.0006960			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742310	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622500021
J	Leung, G; Eisen, MB				Leung, Garmay; Eisen, Michael B.			Identifying Cis-Regulatory Sequences by Word Profile Similarity	PLOS ONE			English	Article							DROSOPHILA-MELANOGASTER; MODULES; GENOME; ELEMENTS; REGIONS; CONSERVATION; PREDICTION; CLUSTERS	Background: Recognizing regulatory sequences in genomes is a continuing challenge, despite a wealth of available genomic data and a growing number of experimentally validated examples. Methodology/Principal Findings: We discuss here a simple approach to search for regulatory sequences based on the compositional similarity of genomic regions and known cis-regulatory sequences. This method, which is not limited to searching for predefined motifs, recovers sequences known to be under similar regulatory control. The words shared by the recovered sequences often correspond to known binding sites. Furthermore, we show that although local word profile clustering is predictive for the regulatory sequences involved in blastoderm segmentation, local dissimilarity is a more universal feature of known regulatory sequences in Drosophila. Conclusions/Significance: Our method leverages sequence motifs within a known regulatory sequence to identify coregulated sequences without explicitly defining binding sites. We also show that regulatory sequences can be distinguished from surrounding sequences by local sequence dissimilarity, a novel feature in identifying regulatory sequences across a genome. Source code for WPH-finder is available for download at http://rana.lbl.gov/downloads/wph.tar.gz.			Leung, G (corresponding author), Univ Calif Berkeley, Berkeley, CA 94720 USA.	garmay@berkeley.edu		Eisen, Michael/0000-0002-7528-738X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002779] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHGRI NIH HHS [R01 HG002779, HG002779] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abnizova I, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-109; Bachtrog D, 1999, MOL BIOL EVOL, V16, P602, DOI 10.1093/oxfordjournals.molbev.a026142; Berman BP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r61; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Chan BY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-262; DAVIDSON EH, 2001, GENOME REGULATORY SY; Emberly E, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-57; Glazov EA, 2005, GENOME RES, V15, P800, DOI 10.1101/gr.3545105; Grad YH, 2004, BIOINFORMATICS, V20, P2738, DOI 10.1093/bioinformatics/bth320; Halfon MS, 2006, NAT GENET, V38, P1102, DOI 10.1038/ng1006-1102; Halligan DL, 2006, GENOME RES, V16, P875, DOI 10.1101/gr.5022906; Hare EE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000106; Ivan A, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r22; Janssens H, 2006, NAT GENET, V38, P1159, DOI 10.1038/ng1886; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kantorovitz MR, 2007, BIOINFORMATICS, V23, pI249, DOI 10.1093/bioinformatics/btm211; Klingler M, 1996, DEV BIOL, V177, P73, DOI 10.1006/dbio.1996.0146; Li L, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r101; Li XY, 2008, PLOS BIOL, V6, P365, DOI 10.1371/journal.pbio.0060027; Lifanov AP, 2003, GENOME RES, V13, P579, DOI 10.1101/gr.668403; Nasiadka A., 2002, AD DEV BIOL, V12, P155; Nazina AG, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-65; Pierstorff N, 2006, BIOINFORMATICS, V22, P2858, DOI 10.1093/bioinformatics/btl499; Poulin F, 2005, GENOMICS, V85, P774, DOI 10.1016/j.ygeno.2005.03.003; Prabhakar S, 2006, GENOME RES, V16, P855, DOI 10.1101/gr.4717506; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; Sinha S, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-129; Sosinsky A, 2007, P NATL ACAD SCI USA, V104, P6305, DOI 10.1073/pnas.0701614104; Zhang CL, 2006, NUCLEIC ACIDS RES, V34, P2238, DOI 10.1093/nar/gkl248	29	18	19	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6901	10.1371/journal.pone.0006901	http://dx.doi.org/10.1371/journal.pone.0006901			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730735	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100006
J	Kersulyte, D; Lee, W; Subramaniam, D; Anant, S; Herrera, P; Cabrera, L; Balqui, J; Barabas, O; Kalia, A; Gilman, RH; Berg, DE				Kersulyte, Dangeruta; Lee, WooKon; Subramaniam, Dharmalingam; Anant, Shrikant; Herrera, Phabiola; Cabrera, Lilia; Balqui, Jacqueline; Barabas, Orsolya; Kalia, Awdhesh; Gilman, Robert H.; Berg, Douglas E.			Helicobacter Pylori's Plasticity Zones Are Novel Transposable Elements	PLOS ONE			English	Article								Background: Genes present in only certain strains of a bacterial species can strongly affect cellular phenotypes and evolutionary potentials. One segment that seemed particularly rich in strain-specific genes was found by comparing the first two sequenced Helicobacter pylori genomes (strains 26695 and J99) and was named a "plasticity zone''. Principal Findings: We studied the nature and evolution of plasticity zones by sequencing them in five more Helicobacter strains, determining their locations in additional strains, and identifying them in recently released genome sequences. They occurred as discrete units, inserted at numerous chromosomal sites, and were usually flanked by direct repeats of 5'AAGAATG, a sequence generally also present in one copy at unoccupied sites in other strains. This showed that plasticity zones are transposable elements, to be called TnPZs. Each full length TnPZ contained a cluster of type IV protein secretion genes (tfs3), a tyrosine recombinase family gene ("xerT''), and a large (>= 2800 codon) orf encoding a protein with helicase and DNA methylase domains, plus additional orfs with no homology to genes of known function. Several TnPZ types were found that differed in gene arrangement or DNA sequence. Our analysis also indicated that the first-identified plasticity zones (in strains 26695 and J99) are complex mosaics of TnPZ remnants, formed by multiple TnPZ insertions, and spontaneous and transposable element mediated deletions. Tests using laboratory-generated deletions showed that TnPZs are not essential for viability, but identified one TnPZ that contributed quantitatively to bacterial growth during mouse infection and another that affected synthesis of proinflammatory cytokines in cell culture. Conclusions: We propose that plasticity zone genes are contained in conjugative transposons (TnPZs) or remnants of them, that TnPZ insertion is mediated by XerT recombinase, and that some TnPZ genes affect bacterial phenotypes and fitness.			Kersulyte, D (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	berg@borcim.wustl.edu	Barabas, Orsolya/F-3961-2012; Herrera, Phabiola/AAL-7992-2021; Anant, Shrikant/AAF-8020-2020	Barabas, Orsolya/0000-0002-2873-5872; Kalia, Awdhesh/0000-0001-5365-1702	FIC NIH HHS [D43 TW006581, D43TW006581] Funding Source: Medline; NIDDK NIH HHS [R01 DK063041, R01 DK63041] Funding Source: Medline; PHS HHS [T35 1007646] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW006581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063041] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akada JK, 2003, MICROBIOL-SGM, V149, P1901, DOI 10.1099/mic.0.26129-0; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Alm RA, 1999, J MOL MED, V77, P834, DOI 10.1007/s001099900067; Amieva MR, 2008, GASTROENTEROLOGY, V134, P306, DOI 10.1053/j.gastro.2007.11.009; Aspholm-Hurtig M, 2004, SCIENCE, V305, P519, DOI 10.1126/science.1098801; Atmakuri K, 2007, EMBO J, V26, P2540, DOI 10.1038/sj.emboj.7601696; AUSUBEL FM, 1994, CURRENT PROTOCOLS S, V27; Backert S, 2008, CELL MICROBIOL, V10, P1573, DOI 10.1111/j.1462-5822.2008.01156.x; Baltrus DA, 2009, J BACTERIOL, V191, P447, DOI 10.1128/JB.01416-08; Barabas O, 2008, CELL, V132, P208, DOI 10.1016/j.cell.2007.12.029; Barre F.-X., 2002, MOBILE DNA, P149; Becker EC, 2000, J MOL BIOL, V300, P1067, DOI 10.1006/jmbi.2000.3902; Berg DE, 1989, MOBILE DNA; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; BONNE L, 2009, NUCL ACIDS IN PRESS; Burrus V, 2004, RES MICROBIOL, V155, P376, DOI 10.1016/j.resmic.2004.01.012; Burrus V, 2006, PLASMID, V55, P173, DOI 10.1016/j.plasmid.2006.01.001; CARNOY C, 2009, PLOS ONE IN PRESS; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Christie PJ, 2005, ANNU REV MICROBIOL, V59, P451, DOI 10.1146/annurev.micro.58.030603.123630; CHURCHWARD G, 2002, MOBILE DNA, V2, P177; CRAIG NL, 2002, MOBILE DNA, V2; Dillehay TD, 2009, P NATL ACAD SCI USA, V106, P971, DOI 10.1073/pnas.0808424106; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; Eppinger M, 2006, PLOS GENET, V2, P1097, DOI 10.1371/journal.pgen.0020120; Forterre P, 2007, BIOCHIMIE, V89, P427, DOI 10.1016/j.biochi.2006.12.009; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; Grindley NDF, 2006, ANNU REV BIOCHEM, V75, P567, DOI 10.1146/annurev.biochem.73.011303.073908; Harper CG, 2002, J CLIN MICROBIOL, V40, P4536, DOI 10.1128/JCM.40.12.4536-4543.2002; HARTL DL, 1983, CELL, V35, P503, DOI 10.1016/0092-8674(83)90184-8; Israel DA, 2006, CURR OPIN GASTROEN, V22, P3, DOI 10.1097/01.mog.0000194790.51714.f0; JILK RA, 1993, J BACTERIOL, V175, P1264, DOI 10.1128/JB.175.5.1264-1271.1993; Karnholz A, 2006, J BACTERIOL, V188, P882, DOI 10.1128/JB.188.3.882-893.2006; Kersulyte D, 2004, J BACTERIOL, V186, P7521, DOI 10.1128/JB.186.22.7521-7528.2004; Kersulyte D, 2003, J BACTERIOL, V185, P3764, DOI 10.1128/JB.185.13.3764-3772.2003; Kersulyte D, 2002, J BACTERIOL, V184, P992, DOI 10.1128/jb.184.4.992-1002.2002; Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562; McNulty SL, 2004, J CLIN MICROBIOL, V42, P5658, DOI 10.1128/JCM.42.12.5658-5663.2004; Narra HP, 2006, CURR BIOL, V16, pR705, DOI 10.1016/j.cub.2006.08.024; NEVERS P, 1977, NATURE, V268, P109, DOI 10.1038/268109a0; Occhialini A, 2000, INFECT IMMUN, V68, P6240, DOI 10.1128/IAI.68.11.6240-6249.2000; Oh JD, 2006, P NATL ACAD SCI USA, V103, P9999, DOI 10.1073/pnas.0603784103; Oleastro M, 2008, J INFECT DIS, V198, P1379, DOI 10.1086/592166; Reznikoff WS, 2008, ANNU REV GENET, V42, P269, DOI 10.1146/annurev.genet.42.110807.091656; Rizwan M, 2008, J BACTERIOL, V190, P1146, DOI 10.1128/JB.01309-07; Romo-Gonzalez C, 2009, INFECT IMMUN, V77, P2201, DOI 10.1128/IAI.01284-08; Siguier P, 2006, CURR OPIN MICROBIOL, V9, P526, DOI 10.1016/j.mib.2006.08.005; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Surtees JA, 2003, CURR TOP DEV BIOL, V56, P145, DOI 10.1016/S0070-2153(03)01010-X; Tabassam FH, 2008, CELL MICROBIOL, V10, P1008, DOI 10.1111/j.1462-5822.2007.01104.x; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Val ME, 2005, MOL CELL, V19, P559, DOI 10.1016/j.molcel.2005.07.002; van Passel MWJ, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000059; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; WANG G, 1993, J BACTERIOL, V175, P1264; Wirth T, 2005, MOL ECOL, V14, P3289, DOI 10.1111/j.1365-294X.2005.02687.x; Yamaoka Y, 2008, J MED MICROBIOL, V57, P545, DOI 10.1099/jmm.0.2008/000570-0; Ziemienowicz A, 1999, P NATL ACAD SCI USA, V96, P3729, DOI 10.1073/pnas.96.7.3729	59	74	78	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2009	4	9							e6859	10.1371/journal.pone.0006859	http://dx.doi.org/10.1371/journal.pone.0006859			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	490RX	19727398	gold, Green Published			2022-12-27	WOS:000269522900007
J	McKellar, AE; Hendry, AP				McKellar, Ann E.; Hendry, Andrew P.			How Humans Differ from Other Animals in Their Levels of Morphological Variation	PLOS ONE			English	Article							REPRODUCTIVE SUCCESS; BODY-MASS; SOCIOECONOMIC-STATUS; FACE RECOGNITION; SOCIAL-CLASSES; HEIGHT; POPULATION; WEIGHT; EVOLUTION; SELECTION	Animal species come in many shapes and sizes, as do the individuals and populations that make up each species. To us, humans might seem to show particularly high levels of morphological variation, but perhaps this perception is simply based on enhanced recognition of individual conspecifics relative to individual heterospecifics. We here more objectively ask how humans compare to other animals in terms of body size variation. We quantitatively compare levels of variation in body length (height) and mass within and among 99 human populations and 848 animal populations (210 species). We find that humans show low levels of within-population body height variation in comparison to body length variation in other animals. Humans do not, however, show distinctive levels of within-population body mass variation, nor of among-population body height or mass variation. These results are consistent with the idea that natural and sexual selection have reduced human height variation within populations, while maintaining it among populations. We therefore hypothesize that humans have evolved on a rugged adaptive landscape with strong selection for body height optima that differ among locations.			McKellar, AE (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.	ann.mckellar@queensu.ca	Hendry, Andrew/C-5765-2008	Hendry, Andrew/0000-0002-4807-6667; McKellar, Ann/0000-0002-7032-3759				Arnold SJ, 2001, GENETICA, V112, P9, DOI 10.1023/A:1013373907708; Ball K, 2005, SOC SCI MED, V60, P1987, DOI 10.1016/j.socscimed.2004.08.056; BIELICKI T, 1992, ANN HUM BIOL, V19, P589, DOI 10.1080/03014469200002402; Blackburn Tim M., 1999, Diversity and Distributions, V5, P165, DOI 10.1046/j.1472-4642.1999.00046.x; CARMICHAEL CM, 1995, J GERONTOL A-BIOL, V50, pB237, DOI 10.1093/gerona/50A.4.B237; Darwin C., 1859, ORIGIN SPECIES NATUR; Dasgupta I, 1997, AM J HUM BIOL, V9, P7, DOI 10.1002/(SICI)1520-6300(1997)9:1<7::AID-AJHB2>3.0.CO;2-#; Donohue K, 2005, NEW PHYTOL, V166, P83, DOI 10.1111/j.1469-8137.2005.01357.x; ENDLER JA, 1973, SCIENCE, V179, P243, DOI 10.1126/science.179.4070.243; Falconer D. S., 1996, INTRO QUANTITATIVE G; Fisher RA, 1930, GENETICAL THEORY NAT; HOULE D, 1992, GENETICS, V130, P195; Katzmarzyk PT, 1998, AM J PHYS ANTHROPOL, V106, P483, DOI 10.1002/(SICI)1096-8644(199808)106:4<483::AID-AJPA4>3.0.CO;2-K; Kingsolver JG, 2004, EVOLUTION, V58, P1608; LANDE R, 1977, SYST ZOOL, V26, P214, DOI 10.2307/2412845; Lange H, 2004, BEHAV ECOL, V15, P549, DOI 10.1093/beheco/arh044; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; MASCIETAYLOR CGN, 1987, ANN HUM BIOL, V14, P59, DOI 10.1080/03014468700008841; Migliano AB, 2007, P NATL ACAD SCI USA, V104, P20216, DOI 10.1073/pnas.0708024105; Nettle D, 2002, HUM NATURE-INT BIOS, V13, P473, DOI 10.1007/s12110-002-1004-7; Nettle D, 2002, P ROY SOC B-BIOL SCI, V269, P1919, DOI 10.1098/rspb.2002.2111; Nettle D, 2008, AM NAT, V172, P658, DOI 10.1086/591690; Pascalis O, 1998, BEHAV PROCESS, V43, P87, DOI 10.1016/S0376-6357(97)00090-9; Pawlowski B, 2000, NATURE, V403, P156, DOI 10.1038/35003107; Peirce JW, 2001, BEHAV PROCESS, V55, P13, DOI 10.1016/S0376-6357(01)00158-9; Perry GH, 2009, TRENDS ECOL EVOL, V24, P218, DOI 10.1016/j.tree.2008.11.008; Polivy J, 2002, ANNU REV PSYCHOL, V53, P187, DOI 10.1146/annurev.psych.53.100901.135103; Polo V, 2002, BEHAV ECOL, V13, P696, DOI 10.1093/beheco/13.5.696; Pusey AE, 2005, INT J PRIMATOL, V26, P3, DOI 10.1007/s10764-005-0721-2; Raychaudhuri Arun, 2003, International Journal of Human Genetics, V3, P151; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; SCHUMACHER A, 1979, J HUM EVOL, V8, P809, DOI 10.1016/0047-2484(79)90013-7; Sear R, 2006, HUM NATURE-INT BIOS, V17, P405, DOI 10.1007/s12110-006-1003-1; Shriver Mark D, 2004, Hum Genomics, V1, P274; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; SPUHLER JN, 1982, SOC BIOL, V29, P53; Stephan CN, 2001, MED HYPOTHESES, V57, P633, DOI 10.1054/mehy.2001.1431; Swinburn BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585; Templeton AR, 2002, NATURE, V416, P45, DOI 10.1038/416045a	40	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6876	10.1371/journal.pone.0006876	http://dx.doi.org/10.1371/journal.pone.0006876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489XX	19721716	gold, Green Submitted, Green Published			2022-12-27	WOS:000269461100005
J	Bosgraaf, L; Van Haastert, PJM				Bosgraaf, Leonard; Van Haastert, Peter J. M.			Navigation of Chemotactic Cells by Parallel Signaling to Pseudopod Persistence and Orientation	PLOS ONE			English	Article								The mechanism of chemotaxis is one of the most interesting issues in modern cell biology. Recent work shows that shallow chemoattractant gradients do not induce the generation of pseudopods, as has been predicted in many models. This poses the question of how else cells can steer towards chemoattractants. Here we use a new computational algorithm to analyze the extension of pseudopods by Dictyostelium cells. We show that a shallow gradient of cAMP induces a small bias in the direction of pseudopod extension, without significantly affecting parameters such as pseudopod frequency or size. Persistent movement, caused by alternating left/right splitting of existing pseudopodia, amplifies the effects of this bias by up to 5-fold. Known players in chemotactic pathways play contrasting parts in this mechanism; PLA2 and cGMP signal to the cytoskeleton to regulate the splitting process, while PI 3-kinase and soluble guanylyl cyclase mediate the directional bias. The coordinated regulation of pseudopod generation, orientation and persistence by multiple signaling pathways allows eukaryotic cells to detect extremely shallow gradients.			Van Haastert, PJM (corresponding author), Univ Groningen, Dept Cell Biochem, Haren, Netherlands.	P.J.M.van.haastert@rug.nl						ALCANTARA F, 1974, J GEN MICROBIOL, V85, P321, DOI 10.1099/00221287-85-2-321; Ambrosi D, 2004, B MATH BIOL, V66, P1851, DOI 10.1016/j.bulm.2004.04.004; Andrew N, 2007, NAT CELL BIOL, V9, P193, DOI 10.1038/ncb1536; Arrieumerlou C, 2005, DEV CELL, V8, P215, DOI 10.1016/j.devcel.2004.12.007; BOSGRAAF L, 2009, QUIMP3 AUTOMAT UNPUB; Bosgraaf L, 2008, J CELL SCI, V121, P3589, DOI 10.1242/jcs.031781; Bosgraaf L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005253; Bourne HR, 2002, NATURE, V419, P21, DOI 10.1038/419021a; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Chen LF, 2003, MOL BIOL CELL, V14, P5028, DOI 10.1091/mbc.E03-05-0339; Chen LF, 2007, DEV CELL, V12, P603, DOI 10.1016/j.devcel.2007.03.005; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; CODLING EA, 2008, J R SOC INTERFACE, V15, P15; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; Dormann D, 2006, CURR OPIN GENET DEV, V16, P367, DOI 10.1016/j.gde.2006.06.003; Franca-Koh J, 2006, CURR OPIN GENET DEV, V16, P333, DOI 10.1016/j.gde.2006.06.001; GAIL MH, 1970, BIOPHYS J, V10, P980, DOI 10.1016/S0006-3495(70)86347-0; HALL RL, 1977, J MATH BIOL, V4, P327, DOI 10.1007/BF00275081; Janetopoulos C, 2004, P NATL ACAD SCI USA, V101, P8951, DOI 10.1073/pnas.0402152101; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Li L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002093; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PATLAK CLIFFORD S., 1953, BULL MATH BIOPHYS, V15, P311, DOI 10.1007/BF02476407; POTEL MJ, 1979, J CELL SCI, V36, P281; Roelofs J, 2002, J BIOL CHEM, V277, P9167, DOI 10.1074/jbc.M111437200; SWANSON JA, 1982, CELL, V28, P225, DOI 10.1016/0092-8674(82)90340-3; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; van Haastert PJM, 2007, BIOPHYS J, V93, P1787, DOI 10.1529/biophysj.107.104356; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Veltman DM, 2008, J CELL BIOL, V180, P747, DOI 10.1083/jcb.200709180; Veltman DM, 2006, MOL BIOL CELL, V17, P3921, DOI 10.1091/mbc.E06-05-0381; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	37	73	74	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6842	10.1371/journal.pone.0006842	http://dx.doi.org/10.1371/journal.pone.0006842			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718261	Green Submitted, Green Published, gold			2022-12-27	WOS:000269415900015
J	Garza-Garcia, A; Harris, R; Esposito, D; Gates, PB; Driscoll, PC				Garza-Garcia, Acely; Harris, Richard; Esposito, Diego; Gates, Phillip B.; Driscoll, Paul C.			Solution Structure and Phylogenetics of Prod1, a Member of the Three-Finger Protein Superfamily Implicated in Salamander Limb Regeneration	PLOS ONE			English	Article							MULTIPLE SEQUENCE ALIGNMENT; NMR STRUCTURE; QUALITY; VENOM; BUNGAROTOXIN; DIVERGENCE; SIMILARITY; ALGORITHM; EVOLUTION; ACCURACY	Background: Following the amputation of a limb, newts and salamanders have the capability to regenerate the lost tissues via a complex process that takes place at the site of injury. Initially these cells undergo dedifferentiation to a state competent to regenerate the missing limb structures. Crucially, dedifferentiated cells have memory of their level of origin along the proximodistal (PD) axis of the limb, a property known as positional identity. Notophthalmus viridescens Prod1 is a cell-surface molecule of the three-finger protein (TFP) superfamily involved in the specification of newt limb PD identity. The TFP superfamily is a highly diverse group of metazoan proteins that includes snake venom toxins, mammalian transmembrane receptors and miscellaneous signaling molecules. Methodology/Principal Findings: With the aim of identifying potential orthologs of Prod1, we have solved its 3D structure and compared it to other known TFPs using phylogenetic techniques. The analysis shows that TFP 3D structures group in different categories according to function. Prod1 clusters with other cell surface protein TFP domains including the complement regulator CD59 and the C-terminal domain of urokinase-type plasminogen activator. To infer orthology, a structure-based multiple sequence alignment of representative TFP family members was built and analyzed by phylogenetic methods. Prod1 has been proposed to be the salamander CD59 but our analysis fails to support this association. Prod1 is not a good match for any of the TFP families present in mammals and this result was further supported by the identification of the putative orthologs of both CD59 and N. viridescens Prod1 in sequence data for the salamander Ambystoma tigrinum. Conclusions/Significance: The available data suggest that Prod1, and thereby its role in encoding PD identity, is restricted to salamanders. The lack of comparable limb-regenerative capability in other adult vertebrates could be correlated with the absence of the Prod1 gene.			Garza-Garcia, A (corresponding author), Natl Inst Med Res, MRC, Div Mol Struct, London NW7 1AA, England.	pdrisco@nimr.mrc.ac.uk	Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950; Garza-Garcia, Acely/0000-0003-0307-0138; Harris, Richard/0000-0001-7459-1745	Medical Research Council [MC_U117574559, MC_U117533887, G0600229] Funding Source: Medline; MRC [G0600229, MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Breitling R, 2001, MOL BIOL EVOL, V18, P2154, DOI 10.1093/oxfordjournals.molbev.a003761; Brockes JR, 2008, ANNU REV CELL DEV BI, V24, P525, DOI 10.1146/annurev.cellbio.24.110707.175336; Brockes JP, 2005, SCIENCE, V310, P1919, DOI 10.1126/science.1115200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; Bujnicki JM, 2000, J MOL EVOL, V50, P39, DOI 10.1007/s002399910005; Carlson B.M, 2007, PRINCIPLES REGENERAT, P379; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Csaba G, 2008, BIOINFORMATICS, V24, pI98, DOI 10.1093/bioinformatics/btn271; Cuff AL, 2009, NUCLEIC ACIDS RES, V37, pD310, DOI 10.1093/nar/gkn877; da Silva SM, 2002, DEV CELL, V3, P547, DOI 10.1016/S1534-5807(02)00288-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Echeverri K, 2005, DEV BIOL, V279, P391, DOI 10.1016/j.ydbio.2004.12.029; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Fitch WM, 1997, J MOL EVOL, V44, pS65, DOI 10.1007/PL00000059; FLEMING TJ, 1993, J IMMUNOL, V150, P5379; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; Gascuel O, 1997, MOL BIOL EVOL, V14, P685, DOI 10.1093/oxfordjournals.molbev.a025808; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Holm Liisa, 2006, Curr Protoc Bioinformatics, VChapter 5, DOI 10.1002/0471250953.bi0505s14; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huson DH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-460; Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030; JOHNSON MS, 1990, METHOD ENZYMOL, V183, P670; Junqueira-de-Azevedo ILM, 2006, GENETICS, V173, P877, DOI 10.1534/genetics.106.056515; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198; Konagurthu AS, 2006, PROTEINS, V64, P559, DOI 10.1002/prot.20921; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; Kumar A, 2007, CR BIOL, V330, P485, DOI 10.1016/j.crvi.2007.01.006; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Moreira D, 2000, MOL MICROBIOL, V35, P1, DOI 10.1046/j.1365-2958.2000.01692.x; NARDI JB, 1983, DIFFERENTIATION, V25, P27; O'Sullivan O, 2004, J MOL BIOL, V340, P385, DOI 10.1016/j.jmb.2004.04.058; Putta S, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-54; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shiu JH, 2004, PROTEINS, V57, P839, DOI 10.1002/prot.20269; Standley DM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-116; STOCUM DL, 1984, DIFFERENTIATION, V27, P13, DOI 10.1111/j.1432-0436.1984.tb01403.x; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres AM, 2001, BIOCHEM J, V360, P539, DOI 10.1042/0264-6021:3600539; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Wagele JW, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-147; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; Ye YZ, 2004, NUCLEIC ACIDS RES, V32, pW582, DOI 10.1093/nar/gkh430	60	49	52	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2009	4	9							e7123	10.1371/journal.pone.0007123	http://dx.doi.org/10.1371/journal.pone.0007123			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498PN	19771161	gold, Green Published, Green Submitted			2022-12-27	WOS:000270154400016
J	Zhao, CY; Xu, ZW; Wang, F; Chen, JH; Ng, SK; Wong, PW; Yu, ZL; Pun, FW; Ren, LH; Lo, WS; Tsang, SY; Xue, H				Zhao, Cunyou; Xu, Zhiwen; Wang, Feng; Chen, Jianhuan; Ng, Siu-Kin; Wong, Pak-Wing; Yu, Zhiliang; Pun, Frank W.; Ren, Lihuan; Lo, Wing-Sze; Tsang, Shui-Ying; Xue, Hong			Alternative-Splicing in the Exon-10 Region of GABA(A) Receptor beta(2) Subunit Gene: Relationships between Novel Isoforms and Psychotic Disorders	PLOS ONE			English	Article							2 FORMS; SCHIZOPHRENIA; ASSOCIATION; EXPRESSION; HAPLOTYPES; SUBTYPES; TARGETS; UPDATE; FAMILY; CELL	Methods and Findings: Non-coding single nucleotide polymorphisms ( SNPs) in GABRB2, the gene for beta(2)-subunit of gamma-aminobutyric acid type A (GABA(A)) receptor, have been associated with schizophrenia (SCZ) and quantitatively correlated to mRNA expression and alternative splicing. Methods and Findings: Expression of the Exon 10 region of GABRB2 from minigene constructs revealed this region to be an "alternative splicing hotspot'' that readily gave rise to differently spliced isoforms depending on intron sequences. This led to a search in human brain cDNA libraries, and the discovery of two novel isoforms, beta(2S1) and beta(2S2), bearing variations in the neighborhood of Exon-10. Quantitative real-time PCR analysis of postmortem brain samples showed increased beta(2S1) expression and decreased beta(2S2) expression in both SCZ and bipolar disorder (BPD) compared to controls. Disease-control differences were significantly correlated with SNP rs187269 in BPD males for both beta(2S1) and beta(2S2) expressions, and significantly correlated with SNPs rs2546620 and rs187269 in SCZ males for beta(2S2) expression. Moreover, site-directed mutagenesis indicated that Thr(365), a potential phosphorylation site in Exon-10, played a key role in determining the time profile of the ATP-dependent electrophysiological current run-down. Conclusion: This study therefore provided experimental evidence for the importance of non-coding sequences in the Exon-10 region in GABRB2 with respect to beta(2)-subunit splicing diversity and the etiologies of SCZ and BPD.			Zhao, CY (corresponding author), Hong Kong Univ Sci & Technol, Fok Ying Tung Grad Sch, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.	hxue@ust.hk	ZHAO, Cunyou/Q-5076-2016; Chen, Jian-Huan/ABB-9660-2021; Chen, Jian-Huan/L-7188-2017; Lo, Cario Wing Sze/DGZ-8810-2022	ZHAO, Cunyou/0000-0001-6116-4584; Chen, Jian-Huan/0000-0001-8714-2543; Chen, Jian-Huan/0000-0001-8714-2543; Xue, Hong/0000-0002-8133-9828				CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Craddock N, 2005, J MED GENET, V42, P193, DOI 10.1136/jmg.2005.030718; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; HARVEY RJ, 1994, J NEUROCHEM, V62, P10; Harvey RJ, 1997, NEUROSCIENCE, V77, P361, DOI 10.1016/S0306-4522(96)00467-8; Jurka J, 2000, TRENDS GENET, V16, P418, DOI 10.1016/S0168-9525(00)02093-X; Korpi ER, 2006, PHARMACOL THERAPEUT, V109, P12, DOI 10.1016/j.pharmthera.2005.05.009; Liu JX, 2005, BIOCHEM BIOPH RES CO, V334, P817, DOI 10.1016/j.bbrc.2005.06.167; Lo WS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000462; Lo WS, 2007, BIOL PSYCHIAT, V61, P653, DOI 10.1016/j.biopsych.2006.05.003; Lo WS, 2004, MOL PSYCHIATR, V9, P603, DOI 10.1038/sj.mp.4001461; MCKINLEY DD, 1995, MOL BRAIN RES, V28, P175, DOI 10.1016/0169-328X(94)00228-7; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; NAGATA K, 1994, BRAIN RES, V645, P19, DOI 10.1016/0006-8993(94)91633-0; Petryshen TL, 2005, MOL PSYCHIATR, V10, P1074, DOI 10.1038/sj.mp.4001739; Torrey EF, 2000, SCHIZOPHR RES, V44, P151, DOI 10.1016/S0920-9964(99)00192-9; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Whiting PJ, 1999, NEUROCHEM INT, V34, P387, DOI 10.1016/S0197-0186(99)00048-0; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Zhao C, 2006, MOL PSYCHIATR, V11, P1092, DOI 10.1038/sj.mp.4001899	20	25	30	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2009	4	9							e6977	10.1371/journal.pone.0006977	http://dx.doi.org/10.1371/journal.pone.0006977			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KI	19763268	Green Submitted, Green Published, gold			2022-12-27	WOS:000269970400003
J	Haraguchi, S; Nakagawara, A				Haraguchi, Seiki; Nakagawara, Akira			A Simple PCR Method for Rapid Genotype Analysis of the TH-MYCN Transgenic Mouse	PLOS ONE			English	Article								Background: The TH-MYCN transgenic mouse is the most widely used murine model of human neuroblastoma, in which a human MYCN oncogene is targeted to neuroectodermal cells of developing mice under the influence of the rat tyrosine hydroxylase promoter. So far, homozygous transgenic mice have been identified by either Southern blot or quantitative real-time PCR. Principal Findings: To establish a simple and reliable genotyping method by conventional PCR, we confirmed the integration of the transgene in the TH-MYCN transgenic mouse by Southern blot and inverse PCR analyses. Our results showed that either five or six copies were found to be inserted in a head-to-tail tandem configuration at a single locus. The MYCN transgene/host DNA junction was sequenced and the integration site was identified at chromosome 18qE4. Finally, we succeeded in designing rapid, simple and reliable genotyping method by common PCR using primers flanking the integrated TH-MYCN transgene. Conclusion: We established a simple and reliable genotyping PCR method for determining the integration site of the TH-MYCN transgene that enables all possible genotypes to be distinguished within several hours. TH-MYCN mice are excellent model for human neuroblastoma study, thus our results will largely be useful for facilitating the pace of neuroblastoma study, including in the study of the tumourigenic process, and in the development of therapies to treat patients suffering from neuroblastoma.			Haraguchi, S (corresponding author), Chiba Canc Ctr, Res Inst, Lab Embryon & Dev Genet, Chuo Ku, 666-2 Nitonacho, Chiba 2608717, Japan.	akiranak@chiba-cc.jp			Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burkhart CA, 2002, J BIOCHEM BIOPH METH, V52, P145, DOI 10.1016/S0165-022X(02)00052-0; Cheng AJ, 2007, EUR J CANCER, V43, P1467, DOI 10.1016/j.ejca.2007.03.008; Hackett CS, 2003, CANCER RES, V63, P5266; HOGAN B, 1994, MANIPULATING MOUSE E, P219; Moore HC, 2008, J CLIN PATHOL, V61, P1098, DOI 10.1136/jcp.2007.054627; OCHMAN H, 1988, GENETICS, V120, P621; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985	9	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2009	4	9							e6902	10.1371/journal.pone.0006902	http://dx.doi.org/10.1371/journal.pone.0006902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZF	19730731	Green Published, gold, Green Submitted			2022-12-27	WOS:000269622100007
J	Ochoa-Ochoa, L; Urbina-Cardona, JN; Vazquez, LB; Flores-Villela, O; Bezaury-Creel, J				Ochoa-Ochoa, Leticia; Nicolas Urbina-Cardona, J.; Vazquez, Luis-Bernardo; Flores-Villela, Oscar; Bezaury-Creel, Juan			The Effects of Governmental Protected Areas and Social Initiatives for Land Protection on the Conservation of Mexican Amphibians	PLOS ONE			English	Article							BIODIVERSITY CONSERVATION; SPECIES DISTRIBUTIONS; TROPICAL FOREST; MODELS; HERPETOFAUNA; POPULATION; HABITAT; PEOPLE; CHALLENGES; PRIORITIES	Traditionally, biodiversity conservation gap analyses have been focused on governmental protected areas (PAs). However, an increasing number of social initiatives in conservation (SICs) are promoting a new perspective for analysis. SICs include all of the efforts that society implements to conserve biodiversity, such as land protection, from private reserves to community zoning plans some of which have generated community-protected areas. This is the first attempt to analyze the status of conservation in Latin America when some of these social initiatives are included. The analyses were focused on amphibians because they are one of the most threatened groups worldwide. Mexico is not an exception, where more than 60% of its amphibians are endemic. We used a niche model approach to map the potential and real geographical distribution (extracting the transformed areas) of the endemic amphibians. Based on remnant distribution, all the species have suffered some degree of loss, but 36 species have lost more than 50% of their potential distribution. For 50 micro-endemic species we could not model their potential distribution range due to the small number of records per species, therefore the analyses were performed using these records directly. We then evaluated the efficiency of the existing set of governmental protected areas and established the contribution of social initiatives (private and community) for land protection for amphibian conservation. We found that most of the species have some proportion of their potential ecological niche distribution protected, but 20% are not protected at all within governmental PAs. 73% of endemic and 26% of micro-endemic amphibians are represented within SICs. However, 30 micro-endemic species are not represented within either governmental PAs or SICs. This study shows how the role of land conservation through social initiatives is therefore becoming a crucial element for an important number of species not protected by governmental PAs.			Ochoa-Ochoa, L (corresponding author), Univ Oxford, Ctr Environm, Oxford, England.	leticia.ochoa@ouce.ox.ac.uk	Vazquez, Luis-Bernardo/A-8358-2013; Urbina-Cardona, J. Nicolas/B-5447-2008; Ochoa-Ochoa, Leticia/C-5849-2015	Vazquez, Luis-Bernardo/0000-0002-1673-2455; Urbina-Cardona, J. Nicolas/0000-0002-4174-8467; Ochoa-Ochoa, Leticia/0000-0002-9846-4596; Bezaury-Creel, Juan/0000-0001-9310-501X; Flores-Villela, Oscar/0000-0002-2849-6912				Anderson RP, 2003, ECOL MODEL, V162, P211, DOI 10.1016/S0304-3800(02)00349-6; [Anonymous], MAXIMUM ENTROPY MODE; [Anonymous], 2020, BIOL AMPHIBIANS, V28, P32; Arriaga, 2000, BIODIVERSITAS, V30, P7; Becker CG, 2007, SCIENCE, V318, P1775, DOI 10.1126/science.1149374; BEZAURYCREEL JE, 2008, HDB INT WILDERNESS L, P182; BEZAURYCREEL JE, 2007, AREAS NATURALES PROT; BEZAURYCREEL JE, 2008, BASE DATOS GEOGRAFIC; BEZAURYCREEL JE, 2007, BASE DATOS GEOGRAFIC; Botkin DB, 2007, BIOSCIENCE, V57, P227, DOI 10.1641/B570306; Brandon K, 2005, WORLD DEV, V33, P1403, DOI 10.1016/j.worlddev.2004.10.005; Brooks TM, 2004, BIOSCIENCE, V54, P1081, DOI 10.1641/0006-3568(2004)054[1081:CPBTGP]2.0.CO;2; Brown K, 2003, GLOBAL ECOL BIOGEOGR, V12, P89, DOI 10.1046/j.1466-822X.2003.00327.x; *CONABIO CCONANP T, 2007, AN VAC OM CONS BIOD; Crump Martha L., 2003, P53; DELAMAZAELVIRA R, 2005, HIST AREAS NATURALES; *DFID EC UNDPB WOR, 2003, 84824 DFID EC UNDPB; Dirzo R, 2003, ANNU REV ENV RESOUR, V28, P137, DOI 10.1146/annurev.energy.28.050302.105532; Ehrlich P.R., 1981, EXTINCTION; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; Epps CW, 2007, J APPL ECOL, V44, P714, DOI 10.1111/j.1365-2664.2007.01325.x; Ewers RM, 2007, CONSERV BIOL, V21, P926, DOI 10.1111/j.1523-1739.2007.00720.x; Fahrig L, 2003, ANNU REV ECOL EVOL S, V34, P487, DOI 10.1146/annurev.ecolsys.34.011802.132419; Fjeldsa J, 2005, AMBIO, V34, P205, DOI 10.1639/0044-7447(2005)034[0205:ICAACA]2.0.CO;2; Flores-Villela Oscar, 2004, Acta Zool. Mex, V20, P115; FLORESVILLELA O, 1991, ANALISIS DISTRIBUCIO; Fuller T, 2006, BIOL CONSERV, V133, P131, DOI 10.1016/j.biocon.2006.04.040; Gallant AL, 2007, COPEIA, P967, DOI 10.1643/0045-8511(2007)7[967:GROHLA]2.0.CO;2; Galvan DV, 2008, ANIM CONSERV, V11, P215, DOI 10.1111/j.1469-1795.2008.00171.x; Garcia A, 2006, BIOL CONSERV, V130, P25, DOI 10.1016/j.biocon.2005.11.030; Gascon C, 1999, BIOL CONSERV, V91, P223, DOI 10.1016/S0006-3207(99)00080-4; GASCON C, 2007, AMPHIBIAN CONSERVATI; Gaston KJ, 2006, BIOL CONSERV, V132, P76, DOI 10.1016/j.biocon.2006.03.013; Gibbs JP, 1998, LANDSCAPE ECOL, V13, P263, DOI 10.1023/A:1008056424692; Godown ME, 2000, BIODIVERS CONSERV, V9, P1313, DOI 10.1023/A:1008924322405; GOMEZPOMPA A, 1987, INTERCIENCIA, V12, P10; GONZALEZ MA, 2008, BASE DATOS GEOGRAFIC; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; HUTCHINSON GE, 1957, COLD SPRING HARB SYM, V22, P415, DOI 10.1101/SQB.1957.022.01.039; INEGI, 2005, CONJ DAT VECT CART U; Jetz W, 2008, CONSERV BIOL, V22, P110, DOI 10.1111/j.1523-1739.2007.00847.x; Johnson ML, 2003, EMERG INFECT DIS, V9, P922; Lehtinen RM, 2003, BIODIVERS CONSERV, V12, P1357, DOI 10.1023/A:1023673301850; Loiselle BA, 2003, CONSERV BIOL, V17, P1591, DOI 10.1111/j.1523-1739.2003.00233.x; Loucks C, 2008, J BIOGEOGR, V35, P1337, DOI 10.1111/j.1365-2699.2008.01899.x; Margules CR, 2007, ECOL BIODIVERS CONS, P1; Urbina-Cardona JN, 2008, TROP CONSERV SCI, V1, P359, DOI 10.1177/194008290800100405; Urbina-Cardona JN, 2008, TROP CONSERV SCI, V1, P417, DOI 10.1177/194008290800100408; Nygren A, 2004, SOC NATUR RESOUR, V17, P189, DOI 10.1080/08941920490270221; Ochoa- Ochoa L., 2007, ANALISIS VACIOS OMIS; Ochoa-Ochoa LM., 2006, AREAS DIVERSIDAD END; OCHOAOCHOA LM, 1991, AREAS DIVERSIDAD END; Pawar S, 2007, BIOL CONSERV, V136, P346, DOI 10.1016/j.biocon.2006.12.012; Pearce J, 2001, J ENVIRON MANAGE, V62, P171, DOI 10.1006/jema.2001.0425; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; Phillips SJ, 2008, ECOGRAPHY, V31, P161, DOI 10.1111/j.0906-7590.2008.5203.x; Pressey RL, 2003, BIOL CONSERV, V112, P99, DOI 10.1016/S0006-3207(02)00424-X; Raxworthy CJ, 2003, NATURE, V426, P837, DOI 10.1038/nature02205; REDFORD KH, 1992, BIOSCIENCE, V42, P412, DOI 10.2307/1311860; Rodrigues ASL, 2004, NATURE, V428, P640, DOI 10.1038/nature02422; Sarkar S, 2006, ANNU REV ENV RESOUR, V31, P123, DOI 10.1146/annurev.energy.31.042606.085844; Sarkar S, 2009, BIODIVERS CONSERV, V18, P1793, DOI 10.1007/s10531-008-9559-1; Sheil D, 2006, AMBIO, V35, P17, DOI 10.1579/0044-7447-35.1.17; Soberon Jorge, 2005, Biodiversity Informatics, V2, P1; Stebbins R. C., 2021, NATURAL HIST AMPHIBI; Stuart SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/science.1103538; Tsoar A, 2007, DIVERS DISTRIB, V13, P397, DOI 10.1111/j.1472-4642.2007.00346.x; Urbina-Cardona JN, 2006, BIOL CONSERV, V132, P61, DOI 10.1016/j.biocon.2006.03.014; Valenzuela-Galvan D, 2008, BIODIVERS CONSERV, V17, P539, DOI 10.1007/s10531-007-9269-0; Vazquez LB, 2006, BIODIVERS CONSERV, V15, P2397, DOI 10.1007/s10531-004-3954-z; Vermeulen S, 2007, ORYX, V41, P434, DOI 10.1017/S0030605307001056; Wake DB, 2001, HERPETOLOGICA, V57, P509; Whiles MR, 2006, FRONT ECOL ENVIRON, V4, P27, DOI 10.1890/1540-9295(2006)004[0027:TEOAPD]2.0.CO;2; Whittaker RJ, 2005, DIVERS DISTRIB, V11, P3, DOI 10.1111/j.1366-9516.2005.00143.x; Young B.E., 2004, DISAPPEARING JEWELS; Zimmerer KS, 2004, AMBIO, V33, P520, DOI 10.1639/0044-7447(2004)033[0520:GAMTIT]2.0.CO;2; HYDROIK GEOLOGICAL S	77	60	64	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2009	4	9							e6878	10.1371/journal.pone.0006878	http://dx.doi.org/10.1371/journal.pone.0006878			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489XX	19721719	Green Submitted, Green Published, gold			2022-12-27	WOS:000269461100007
J	Hack, KEA; Koopman-Esseboom, C; Derks, JB; Elias, SG; de Kleine, MJK; Baerts, W; Go, ATJI; Schaap, AHP; van der Hoeven, MAHBM; Eggink, AJ; Sollie, KM; Weisglas-Kuperus, N; Visser, GHA				Hack, Karien E. A.; Koopman-Esseboom, Corine; Derks, Jan B.; Elias, Sjoerd G.; de Kleine, Martin J. K.; Baerts, Wim; Go, Attie T. J. I.; Schaap, Arty H. P.; van der Hoeven, Mark A. H. B. M.; Eggink, Alex J.; Sollie, Krystyna M.; Weisglas-Kuperus, Nynke; Visser, Gerard H. A.			Long-Term Neurodevelopmental Outcome of Monochorionic and Matched Dichorionic Twins	PLOS ONE			English	Article								Background: Monochorionic (MC) twins are at increased risk for perinatal mortality and serious morbidity due to the presence of placental vascular anastomoses. Cerebral injury can be secondary to haemodynamic and hematological disorders during pregnancy (especially twin-to-twin transfusion syndrome (TTTS) or intrauterine co-twin death) or from postnatal injury associated with prematurity and low birth weight, common complications in twin pregnancies. We investigated neurodevelopmental outcome in MC and dichorionic (DC) twins at the age of two years. Methods: This was a prospective cohort study. Cerebral palsy (CP) was studied in 182 MC infants and 189 DC infants matched for weight and age at delivery, gender, ethnicity of the mother and study center. After losses to follow-up, 282 of the 366 infants without CP were available to be tested with the Griffiths Mental Developmental Scales at 22 months corrected age, all born between January 2005 and January 2006 in nine perinatal centers in The Netherlands. Due to phenotypic (un)alikeness in mono-or dizygosity, the principal investigator was not blinded to chorionic status; perinatal outcome, with exception of co-twin death, was not known to the examiner. Findings: Four out of 182 MC infants had CP (2.2%)-two of the four CP-cases were due to complications specific to MC twin pregnancies (TTTS and co-twin death) and the other two cases of CP were the result of cystic PVL after preterm birth compared to one sibling of a DC twin (0.5%; OR 4.2, 95% CI 0.5-38.2) of unknown origin. Follow-up rate of neurodevelopmental outcome by Griffith's test was 76%. The majority of 2-year-old twins had normal developmental status. There were no significant differences between MC and DC twins. One MC infant (0.7%) had a developmental delay compared to 6 DC infants (4.2%; OR 0.2, 95% 0.0-1.4). Birth weight discordancy did not influence long-term outcome, though the smaller twin had slightly lower developmental scores than its larger co-twin. Conclusions: There were no significant differences in occurrence of cerebral palsy as well as neurodevelopmental outcome between MC and DC twins. Outcome of MC twins seems favourable in the absence of TTTS or co-twin death.			Hack, KEA (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Obstet, Utrecht, Netherlands.	k.e.a.hack@umcutrecht.nl	van der Hoeven, Markus/M-8558-2015; Elias, Sjoerd G/E-6057-2011	van der Hoeven, Markus/0000-0002-3978-256X; Elias, Sjoerd G/0000-0003-3903-4024				Adegbite AL, 2005, EUR J OBSTET GYN R B, V119, P47, DOI 10.1016/j.ejogrb.2004.06.016; Adegbite AL, 2004, AM J OBSTET GYNECOL, V190, P156, DOI 10.1016/j.ajog.2003.07.004; Bajoria R, 1999, HUM REPROD, V14, P2124, DOI 10.1093/humrep/14.8.2124; Banek CS, 2003, AM J OBSTET GYNECOL, V188, P876, DOI 10.1067/mob.2003.202; BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2; Blickstein I, 2002, DEV MED CHILD NEUROL, V44, P352; Burguet A, 1999, BIOL NEONATE, V75, P177, DOI 10.1159/000014094; Cincotta RB, 2000, ARCH DIS CHILD-FETAL, V83, pF171, DOI 10.1136/fn.83.3.F171; De Lia JE, 1999, J PERINAT MED, V27, P61, DOI 10.1515/JPM.1999.007; Denbow ML, 2000, AM J OBSTET GYNECOL, V182, P417, DOI 10.1016/S0002-9378(00)70233-X; Dickinson JE, 2005, BJOG-INT J OBSTET GY, V112, P63, DOI 10.1111/j.1471-0528.2004.00330.x; Frusca T, 2003, EUR J OBSTET GYN R B, V107, P145, DOI 10.1016/S0301-2115(02)00341-X; Goyen TA, 2003, EARLY HUM DEV, V73, P27, DOI 10.1016/S0378-3782(03)00059-8; Graef C, 2006, AM J OBSTET GYNECOL, V194, P303, DOI 10.1016/j.ajog.2005.07.040; Gratacos E, 2004, ULTRASOUND OBST GYN, V24, P159, DOI 10.1002/uog.1105; Hack KE, 2008, BJOG-INT J OBSTET GY, V115, P58, DOI 10.1111/j.1471-0528.2007.01556.x; Haverkamp F, 2001, Eur J Paediatr Neurol, V5, P21, DOI 10.1053/ejpn.2001.0400; Hikino S, 2007, FETAL DIAGN THER, V22, P68, DOI 10.1159/000095847; Huber A, 2004, BEST PRACT RES CL OB, V18, P543, DOI 10.1016/j.bpobgyn.2004.04.006; Huntley M., 1996, GRIFFITHS MENTAL DEV; Lopriore E, 2006, AM J OBSTET GYNECOL, V194, P1215, DOI 10.1016/j.ajog.2005.12.003; Lopriore E, 2005, J PEDIATR-US, V147, P597, DOI 10.1016/j.jpeds.2005.06.004; Lopriore E, 2003, AM J OBSTET GYNECOL, V189, P1314, DOI 10.1067/S0002-9378(03)00760-9; Lopriore E, 2007, AM J OBSTET GYNECOL, V196, P231, DOI 10.1016/j.ajog.2006.10.906; Mari G, 2000, AM J OBSTET GYNECOL, V183, P211, DOI 10.1016/S0002-9378(00)66819-9; Minakami H, 1999, J REPROD MED, V44, P595; Monset-Couchard M, 2004, ARCH DIS CHILD-FETAL, V89, pF310, DOI 10.1136/adc.2002.021626; Nicolini U, 1999, ULTRASOUND OBST GYN, V14, P297, DOI 10.1046/j.1469-0705.1999.14050297.x; Ong SSC, 2006, BJOG-INT J OBSTET GY, V113, P992, DOI 10.1111/j.1471-0528.2006.01027.x; ORTIBUS E, 2009, AM J OBSTET GYNECOL, V494, pE1; Pharoah P O D, 2002, Semin Neonatol, V7, P223, DOI 10.1053/siny.2002.0109; Pharoah POD, 2001, ARCH DIS CHILD-FETAL, V84, pF111, DOI 10.1136/fn.84.2.F111; Pharoah POD, 2000, LANCET, V355, P1597, DOI 10.1016/S0140-6736(00)02215-7; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Saigal S, 2005, QUAL LIFE RES, V14, P243, DOI 10.1007/s11136-004-4228-7; Senat MV, 2004, NEW ENGL J MED, V351, P136, DOI 10.1056/NEJMoa032597; Sutcliffe AG, 2001, BRIT J OBSTET GYNAEC, V108, P1246	37	33	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6815	10.1371/journal.pone.0006815	http://dx.doi.org/10.1371/journal.pone.0006815			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714240	gold, Green Published			2022-12-27	WOS:000269415800005
J	Ji, Q; Hao, XB; Zhang, M; Tang, WH; Meng, Y; Li, L; Xiang, DB; DeSano, JT; Bommer, GT; Fan, DM; Fearon, ER; Lawrence, TS; Xu, L				Ji, Qing; Hao, Xinbao; Zhang, Min; Tang, Wenhua; Meng, Yang; Li, Ling; Xiang, Debing; DeSano, Jeffrey T.; Bommer, Guido T.; Fan, Daiming; Fearon, Eric R.; Lawrence, Theodore S.; Xu, Liang			MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells	PLOS ONE			English	Article							HUMAN PROSTATE-CANCER; STEM-CELLS; P53; SUPPRESSOR; IDENTIFICATION; EXPRESSION; APOPTOSIS; GROWTH; CONTRIBUTES; ACTIVATION	Background: MicroRNAs (miRNAs) have been implicated in cancer initiation and progression via their ability to affect expression of genes and proteins that regulate cell proliferation and/or cell death. Transcription of the three miRNA miR-34 family members was recently found to be directly regulated by p53. Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2, suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells. Methodology/Principal Findings: We examined the roles of miR-34 in p53-mutant human pancreatic cancer cell lines MiaPaCa2 and BxPC3, and the potential link to pancreatic cancer stem cells. Restoration of miR-34 expression in the pancreatic cancer cells by either transfection of miR-34 mimics or infection with lentiviral miR-34-MIF downregulated Bcl-2 and Notch1/2. miR-34 restoration significantly inhibited clonogenic cell growth and invasion, induced apoptosis and G1 and G2/M arrest in cell cycle, and sensitized the cells to chemotherapy and radiation. We identified that CD44+/CD133+ MiaPaCa2 cells are enriched with tumorsphere-forming and tumor-initiating cells or cancer stem/progenitor cells with high levels of Notch/Bcl-2 and loss of miR-34. More significantly, miR-34 restoration led to an 87% reduction of the tumor-initiating cell population, accompanied by significant inhibition of tumorsphere growth in vitro and tumor formation in vivo. Conclusions/Significance: Our results demonstrate that miR-34 may restore, at least in part, the tumor suppressing function of the p53 in p53-deficient human pancreatic cancer cells. Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal, potentially via the direct modulation of downstream targets Bcl-2 and Notch, implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination. Restoration of miR-34 may hold significant promise as a novel molecular therapy for human pancreatic cancer with loss of p53-miR34, potentially via inhibiting pancreatic cancer stem cells.			Ji, Q (corresponding author), Third Mil Med Univ, Inst Gastroenterol, Southwest Hosp, Chongqing, Peoples R China.	liangxu@umich.edu	Xin, Xiaofei/N-4518-2018; Xiang, Debing/AAZ-7727-2020; Bommer, Guido/A-8425-2011	Xin, Xiaofei/0000-0002-7618-0808; Hao, Xinbao/0000-0002-5398-8564; Bommer, Guido/0000-0001-6898-4884	NCI NIH HHS [R21 CA128220, R21 CA128220-02, P30 CA46592, R01 CA121830-04S1, R01 CA134655-01A1, CA128220-01, R01 CA121830-03, CA121830-01, R01 CA134655, R01 CA121830, P30 CA046592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592, R21CA128220, R01CA134655, R01CA121830] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bui M, 1998, CANCER METAST REV, V17, P391, DOI 10.1023/A:1006197923640; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dai Y, 2009, AM J TRANSL RES, V1, P1; Dai Y, 2008, CLIN CANCER RES, V14, P7701, DOI 10.1158/1078-0432.CCR-08-0188; Dai Y, 2009, INT J RADIAT ONCOL, V74, P1217, DOI 10.1016/j.ijrobp.2009.03.057; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Han Z, 2007, J EXP CLIN CANC RES, V26, P261; Hatfield S, 2008, CELL TISSUE RES, V331, P57, DOI 10.1007/s00441-007-0530-3; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Immervoll H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-48; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333; Nicolis SK, 2007, NEUROBIOL DIS, V25, P217, DOI 10.1016/j.nbd.2006.08.022; Papagiannakopoulos T, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-15; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Simeone DM, 2008, CLIN CANCER RES, V14, P5646, DOI 10.1158/1078-0432.CCR-08-0584; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Wang ZW, 2006, MOL CANCER THER, V5, P483, DOI 10.1158/1535-7163.MCT-05-0299; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xu L, 2005, MOL CANCER THER, V4, P197; Xu L, 2002, HUM GENE THER, V13, P469, DOI 10.1089/10430340252792594; Xu L, 2002, MOL CANCER THER, V1, P337; Xu L, 1999, TUMOR TARGET, V4, P92; Xu LN, 1997, HUM GENE THER, V8, P467, DOI 10.1089/hum.1997.8.4-467; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; ZENZ T, 2008, BLOOD; Zhang WY, 2007, AM J PATHOL, V171, P728, DOI 10.2353/ajpath.2007.070070	48	539	591	0	93	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6816	10.1371/journal.pone.0006816	http://dx.doi.org/10.1371/journal.pone.0006816			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714243	gold, Green Submitted, Green Published			2022-12-27	WOS:000269415800006
J	Caillaud, MC; Paganelli, L; Lecomte, P; Deslandes, L; Quentin, M; Pecrix, Y; Le Bris, M; Marfaing, N; Abad, P; Favery, B				Caillaud, Marie-Cecile; Paganelli, Laetitia; Lecomte, Philippe; Deslandes, Laurent; Quentin, Michael; Pecrix, Yann; Le Bris, Manuel; Marfaing, Nicolas; Abad, Pierre; Favery, Bruno			Spindle Assembly Checkpoint Protein Dynamics Reveal Conserved and Unsuspected Roles in Plant Cell Division	PLOS ONE			English	Article								Background: In eukaryotes, the spindle assembly checkpoint ( SAC) ensures that chromosomes undergoing mitosis do not segregate until they are properly attached to the microtubules of the spindle. Methodology/Principal Findings: We investigated the mechanism underlying this surveillance mechanism in plants, by characterising the orthogolous SAC proteins BUBR1, BUB3 and MAD2 from Arabidopsis. We showed that the cell cycle-regulated BUBR1, BUB3.1 and MAD2 proteins interacted physically with each other. Furthermore, BUBR1 and MAD2 interacted specifically at chromocenters. Following SAC activation by global defects in spindle assembly, these three interacting partners localised to unattached kinetochores. In addition, in cases of 'wait anaphase', plant SAC proteins were associated with both kinetochores and kinetochore microtubules. Unexpectedly, BUB3.1 was also found in the phragmoplast midline during the final step of cell division in plants. Conclusions/Significance: We conclude that plant BUBR1, BUB3.1 and MAD2 proteins may have the SAC protein functions conserved from yeast to humans. The association of BUB3.1 with both unattached kinetochore and phragmoplast suggests that in plant, BUB3.1 may have other roles beyond the spindle assembly checkpoint itself. Finally, this study of the SAC dynamics pinpoints uncharacterised roles of this surveillance mechanism in plant cell division.	[Caillaud, Marie-Cecile; Paganelli, Laetitia; Lecomte, Philippe; Quentin, Michael; Marfaing, Nicolas; Abad, Pierre; Favery, Bruno] INRA, Unite Mixte Rech 1301, Sophia Antipolis, France; [Caillaud, Marie-Cecile; Paganelli, Laetitia; Lecomte, Philippe; Quentin, Michael; Marfaing, Nicolas; Abad, Pierre; Favery, Bruno] CNRS, Unite Mixte Rech 6243, Sophia Antipolis, France; [Caillaud, Marie-Cecile; Paganelli, Laetitia; Lecomte, Philippe; Quentin, Michael; Marfaing, Nicolas; Abad, Pierre; Favery, Bruno] Univ Nice Sophia Antipolis, Unite Mixte Rech 1301, Sophia Antipolis, France; [Deslandes, Laurent] CNRS, INRA, Unite Mixte Rech 2594, Castanet Tolosan, France; [Pecrix, Yann; Le Bris, Manuel] Univ Paul Cezanne, IMEP, Unite Mixte Rech, CNRS,Inst Rech Dev 6116, Marseille, France	INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Caillaud, MC (corresponding author), INRA, Unite Mixte Rech 1301, Sophia Antipolis, France.	favery@sophia.inra.fr	Favery, Bruno/B-9062-2008; Quentin, Michaël/AFN-9766-2022; Caillaud, Marie-Cecile/G-9320-2018; Deslandes, Laurent/N-5752-2017	Favery, Bruno/0000-0003-3323-1852; Quentin, Michaël/0000-0002-8030-1203; Caillaud, Marie-Cecile/0000-0002-0348-7024; Pecrix, Yann/0000-0002-6537-3145; LECOMTE, Philippe/0000-0003-1186-6283				Abad P, 2008, NAT BIOTECHNOL, V26, P909, DOI 10.1038/nbt.1482; Austin JR, 2005, J CELL SCI, V118, P3895, DOI 10.1242/jcs.02512; Basu J, 1998, CHROMOSOMA, V107, P376, DOI 10.1007/s004120050321; Caillaud MC, 2008, PLANT CELL, V20, P423, DOI 10.1105/tpc.107.057422; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Criqui MC, 2000, PLANT J, V24, P763, DOI 10.1111/j.1365-313X.2000.t01-1-.x; Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang YD, 2005, MOL BIOL CELL, V16, P5710, DOI 10.1091/mbc.E05-08-0706; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Genschik P, 1998, PLANT CELL, V10, P2063; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Houben A, 2003, CURR OPIN PLANT BIOL, V6, P554, DOI 10.1016/j.pbi.2003.09.007; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Kimbara J, 2004, CHROMOSOME RES, V12, P703, DOI 10.1023/B:CHRO.0000045760.42880.8c; Lee YRJ, 2001, PLANT CELL, V13, P2427, DOI 10.1105/tpc.13.11.2427; Lermontova I, 2008, FRONT BIOSCI-LANDMRK, V13, P5202, DOI 10.2741/3076; Lermontova I, 2006, PLANT CELL, V18, P2443, DOI 10.1105/tpc.106.043174; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Menges M, 2005, PLANT J, V41, P546, DOI 10.1111/j.1365-313X.2004.02319.x; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Perez-Perez JM, 2008, PLANT J, V53, P78, DOI 10.1111/j.1365-313X.2007.03312.x; Pfleger CM, 2000, GENE DEV, V14, P655; Ritzenthaler C, 2002, PLANT CELL, V14, P237, DOI 10.1105/tpc.010237; Sczaniecka M, 2008, J BIOL CHEM, V283, P23039, DOI 10.1074/jbc.M803594200; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Talbert PB, 2002, PLANT CELL, V14, P1053, DOI 10.1105/tpc.010425; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; van Damme D, 2004, PLANT J, V40, P386, DOI 10.1111/j.1365-313X.2004.02222.x; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Vos JW, 2008, PLANT CELL, V20, P2783, DOI 10.1105/tpc.107.056796; Yu HG, 1999, J CELL BIOL, V145, P425, DOI 10.1083/jcb.145.3.425	43	52	56	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2009	4	8							e6757	10.1371/journal.pone.0006757	http://dx.doi.org/10.1371/journal.pone.0006757			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JE	19710914	Green Published, Green Submitted, gold			2022-12-27	WOS:000269415600002
J	Chen, GJ; Han, GC; Feng, JN; Wang, JA; Wang, RX; Xu, RN; Shen, BF; Qian, JH; Li, Y				Chen, Guojiang; Han, Gencheng; Feng, Jiannan; Wang, Jianan; Wang, Renxi; Xu, Ruonan; Shen, Beifen; Qian, Jiahua; Li, Yan			Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4(+)CD25(+) Regulatory T Cells	PLOS ONE			English	Article								Background: CD4(+)CD25(+) regulatory T cell (Treg)-based immunotherapy is considered a promising regimen for controlling the progression of autoimmune diabetes. In this study, we tested the hypothesis that the therapeutic effects of Tregs in response to the antigenic epitope stimulation depend on the structural properties of the epitopes used. Methodology/Principal Findings: Splenic lymphocytes from nonobese diabetic (NOD) mice were stimulated with different glutamic acid decarboxylase (GAD)-derived epitopes for 7-10 days and the frequency and function of Tregs was analyzed. We found that, although all expanded Tregs showed suppressive functions in vitro, only p524 (GAD524-538)-expanded CD4(+)CD25(+) T cells inhibited diabetes development in the co-transfer models, while p509 (GAD509-528)- or p530 (GAD530-543)-expanded CD4(+)CD25(+) T cells had no such effects. Using computer-guided molecular modeling and docking methods, the differences in structural characteristics of these epitopes and the interaction mode (including binding energy and identified domains in the epitopes) between the above-mentioned epitopes and MHC class II I-A(g7) were analyzed. The theoretical results showed that the epitope p524, which induced protective Tregs, possessed negative surface-electrostatic potential and bound two chains of MHC class II I-A(g7), while the epitopes p509 and p530 which had no such ability exhibited positive surface-electrostatic potential and bound one chain of I-A(g7). Furthermore, p524 bound to I-A(g7) more stably than p509 and p530. Of importance, we hypothesized and subsequently confirmed experimentally that the epitope (GAD570-585, p570), which displayed similar characteristics to p524, was a protective epitope by showing that p570-expanded CD4(+)CD25(+) T cells suppressed the onset of diabetes in NOD mice. Conclusions/Significance: These data suggest that molecular modeling-based structural analysis of epitopes may be an instrumental tool for prediction of protective epitopes to expand functional Tregs.			Chen, GJ (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Mol Immunol, Beijing 100730, Peoples R China.	liyan62033@yahoo.com.cn	Wang, Renxi/AAM-1326-2020	Wang, Renxi/0000-0003-4130-3334; Han, George/0000-0003-3302-5098; Friedman, Adam/0000-0001-8925-1620				Arneson LS, 2000, J IMMUNOL, V165, P2059, DOI 10.4049/jimmunol.165.4.2059; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Bayer AL, 2007, J IMMUNOL, V178, P4062, DOI 10.4049/jimmunol.178.7.4062; Bommireddy R, 2007, TRENDS MOL MED, V13, P492, DOI 10.1016/j.molmed.2007.08.005; Chen C, 2003, J IMMUNOL, V171, P733, DOI 10.4049/jimmunol.171.2.733; Chen ZB, 2005, P NATL ACAD SCI USA, V102, P14735, DOI 10.1073/pnas.0507014102; Corper AL, 2000, SCIENCE, V288, P505, DOI 10.1126/science.288.5465.505; Dai YD, 2008, EUR J IMMUNOL, V38, P968, DOI 10.1002/eji.200737703; Deng L, 2007, NAT IMMUNOL, V8, P398, DOI 10.1038/ni1447; Di Lorenzo TP, 2007, CLIN EXP IMMUNOL, V148, P1, DOI 10.1111/j.1365-2249.2006.03244.x; Ellis TM, 1996, NAT MED, V2, P148, DOI 10.1038/nm0296-148; Fanelli F, 1998, METHODS, V14, P302, DOI 10.1006/meth.1998.0586; Fisson S, 2006, EUR J IMMUNOL, V36, P817, DOI 10.1002/eji.200535445; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Geng LP, 1998, P NATL ACAD SCI USA, V95, P10055, DOI 10.1073/pnas.95.17.10055; Han GC, 2005, J IMMUNOL, V174, P4516, DOI 10.4049/jimmunol.174.8.4516; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Masteller EL, 2005, J IMMUNOL, V175, P3053, DOI 10.4049/jimmunol.175.5.3053; Nicholson MJ, 2005, IMMUNITY, V23, P351, DOI 10.1016/j.immuni.2005.09.009; Ochoa-Reparaz J, 2007, J IMMUNOL, V178, P1791, DOI 10.4049/jimmunol.178.3.1791; Ortiz AR, 1999, PROTEINS, P177; Pop SM, 2005, J EXP MED, V201, P1333, DOI 10.1084/jem.20042398; Quinn A, 2001, J IMMUNOL, V166, P2982, DOI 10.4049/jimmunol.166.5.2982; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Severe S, 2007, MOL IMMUNOL, V44, P2950, DOI 10.1016/j.molimm.2007.01.008; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Song L, 2004, GENE THER, V11, P1487, DOI 10.1038/sj.gt.3302327; Stockinger B, 2001, NAT IMMUNOL, V2, P757, DOI 10.1038/ni0901-757; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2007, J EXP MED, V204, P191, DOI 10.1084/jem.20061631; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Tarbell KV, 2002, J EXP MED, V196, P481, DOI 10.1084/jem.20011845; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Tisch R, 1998, DIABETES, V47, P894, DOI 10.2337/diabetes.47.6.894; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4; Yamanouchi J, 2007, NAT GENET, V39, P329, DOI 10.1038/ng1958; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878; Zhao YL, 2008, BIOCHEM BIOPH RES CO, V372, P346, DOI 10.1016/j.bbrc.2008.05.046; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455	51	31	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2009	4	9							e7034	10.1371/journal.pone.0007034	http://dx.doi.org/10.1371/journal.pone.0007034			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FM	19759824	Green Published, Green Submitted, gold			2022-12-27	WOS:000269796100001
